{
  "responseHeader":{
    "status":0,
    "QTime":540,
    "params":{
      "q":"(Doc_abstract: leukemia OR \"acute lymphoblastic leukemia\" OR \"acute myeloid leukemia\" OR \"chronic lymphocytic leukemia\" OR \"chronic myeloid leukemia\" OR Doc_title: leukemia OR \"acute lymphoblastic leukemia\" OR \"acute myeloid leukemia\" OR \"chronic lymphocytic leukemia\" OR \"chronic myeloid leukemia\") AND (Doc_abstract: ABL1 OR \"ABL\" OR \"JTK7\" OR \"p150\" OR \"c-ABL\" OR \"v-abl\" OR \"CHDSKM\" OR \"c-ABL1\" OR \"bcr/abl\" OR Doc_title: ABL1 OR \"ABL\" OR \"JTK7\" OR \"p150\" OR \"c-ABL\" OR \"v-abl\" OR \"CHDSKM\" OR \"c-ABL1\" OR \"bcr/abl\")"}},
  "response":{"numFound":5311,"start":0,"docs":[
      {
        "Doc_abstract":"Dasatinib is a kinase inhibitor that inhibits BCR-ABL, Src family kinases, c-Kit, and platelet-derived growth factor receptor kinase. It is licensed for the first- and second-line treatment of chronic myeloid leukemia and second-line treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia on the basis of BCR-ABL inhibition, but the activity of dasatinib against additional molecular targets may enable treatment of other hematologic disorders. Potential targets for dasatinib in chronic lymphocytic leukemia (CLL) include Lyn (a Src family kinase), ABL, and the associated CD40 pathway. Although dasatinib monotherapy has modest clinical activity in CLL, ongoing studies are evaluating combination treatment. In acute myeloid leukemia (AML), FLT3, Lyn, c-Kit, and BCR-ABL are expressed in a subpopulation of patients. To date, clinical responses to dasatinib in patients with unselected AML have been mixed and larger studies are needed, particularly correlating clinical response to molecular markers. Imatinib has been used successfully to treat patients with chronic eosinophilic disorders with the FIP1L1-PDGFRA fusion kinase; limited clinical data indicate that dasatinib could be active in imatinib-resistant disease. Ongoing clinical studies should further define the value of dasatinib in these disorders.",
        "Doc_title":"The potential for dasatinib in treating chronic lymphocytic leukemia, acute myeloid leukemia, and myeloproliferative neoplasms.",
        "Journal":"Leukemia & lymphoma",
        "Do_id":"21463117",
        "Doc_ChemicalList":"Protein Kinase Inhibitors;Pyrimidines;Thiazoles;Dasatinib",
        "Doc_meshdescriptors":"Dasatinib;Hematologic Neoplasms;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Leukemia, Myeloid, Acute;Myeloproliferative Disorders;Protein Kinase Inhibitors;Pyrimidines;Thiazoles",
        "Doc_meshqualifiers":"drug therapy;drug therapy;drug therapy;drug therapy;therapeutic use;therapeutic use;therapeutic use",
        "_version_":1605747050352214017},
      {
        "Doc_abstract":"Actual BCR-ABL kinase inhibition in vivo as determined by phospho-CRKL (pCRKL) monitoring has been recognized as a prognostic parameter in patients with chronic myelogenous leukemia treated with imatinib. We report a biomarker sub-study of the international phase I clinical trial of nilotinib (AMN107) using the established pCRKL assay in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia. A minimum dose (200 mg) required for effective BCR-ABL inhibition in imatinib resistant/intolerant leukemia was determined. The pre-clinical activity profile of nilotinib against mutant BCR-ABL was largely confirmed. Substantial differences between peripheral blood baseline pCRKL/CRKL ratios were observed when comparing chronic myeloid leukemia with Ph+ acute lymphoblastic leukemia. Finally, rapid BCR-ABL-reactivation shortly after starting nilotinib treatment was seen in acute lymphoblastic leukemia patients with progressive disease carrying the P-loop mutations Y253H, E255K, or mutation T315I. Monitoring the actual BCR-ABL inhibition in nilotinib treated patients using pCRKL as a surrogate is a means to establish effective dosing and to characterize resistance mechanisms against nilotinib.",
        "Doc_title":"Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib.",
        "Journal":"Haematologica",
        "Do_id":"18367481",
        "Doc_ChemicalList":"4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide;Adaptor Proteins, Signal Transducing;Antineoplastic Agents;Benzamides;CRKL protein;Nuclear Proteins;Piperazines;Pyrimidines;Imatinib Mesylate;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adaptor Proteins, Signal Transducing;Adolescent;Adult;Aged;Aged, 80 and over;Antineoplastic Agents;Benzamides;Female;Fusion Proteins, bcr-abl;Gene Expression Regulation, Leukemic;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Nuclear Proteins;Piperazines;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Pyrimidines",
        "Doc_meshqualifiers":"chemistry;pharmacology;metabolism;drug therapy;metabolism;chemistry;pharmacology;drug therapy;metabolism;pharmacology",
        "_version_":1605766382405812224},
      {
        "Doc_abstract":"Tyrosine kinase inhibitors have profoundly modified the treatment and prognosis of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia. A rapid and accurate detection of the BCR-ABL fusion protein is paramount today for an optimal management of Ph(+) acute lymphoblastic leukemia. We have utilized a recently described and commercialized immunoassay that identifies qualitatively the presence of the BCR-ABL protein in leukemic cell lysates. The BCR-ABL fusion protein is captured and detected by a cytometric bead assay and analyzed by flow cytometry. The assay was applied to 101 primary patient samples (94 acute leukemias and 7 chronic myeloid leukemia blast crisis) and the results of the immunoassay were concordant with those obtained by conventional molecular techniques. The method proved reliable, reproducible, of simple execution and it was successfully completed within four hours. This flow cytometric immunoassay has important implications for perfecting the management of Ph(+) acute lymphoblastic leukemia patients worldwide.",
        "Doc_title":"An accurate and rapid flow cytometric diagnosis of BCR-ABL positive acute lymphoblastic leukemia.",
        "Journal":"Haematologica",
        "Do_id":"19608682",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Aged, 80 and over;Child;Child, Preschool;Female;Flow Cytometry;Fusion Proteins, bcr-abl;Humans;Immunoassay;Infant;Male;Middle Aged;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Reproducibility of Results;Reverse Transcriptase Polymerase Chain Reaction;Sensitivity and Specificity;Young Adult",
        "Doc_meshqualifiers":"instrumentation;methods;analysis;genetics;instrumentation;methods;diagnosis;genetics;metabolism;methods",
        "_version_":1605741916588081153},
      {
        "Doc_abstract":"To explore the specificity of anti-phosphotyrosine monoclonal antibody PY20 in bcr-abl+ cells and its possible clinical applications.;Bcr-abl cell lines( K562, MEG-01) and bcr-abl- cells lines( Jurkat, MCF-7 )were stained with PY20. Phosphotyrosine protein of K562 and MEG-01 cells was detected by flow cytometry before and after treatment with imatinib. Phosphotyrosine protein in bone marrow cells from 49 patients with chronic myeloid leukemia (CML), Ph+ acute lymphoblastic leukemia(Ph(+) -ALL), Ph- ALL, acute myeloid leukemia (AML-M1, M2, M3, M5, FAB classification), chronic lymphocytic leukemia (CML) and 3 normal donor. Positive cells over 5% of total cells was considered positive cases for phosphotyrosine protein. The level of tyrosine phosphorylation was determined by median fluorescence intensity (MFI).;Bcr-abl cell lines and marrow cells from 10 CML patients and 8 ALL patients were all PY20-positive, while bcr-abl- cell lines and marrow cells from 18 leukemia patients and 3 normal donor were all PY20-negative. MFI decreased remarkably after blocked by imatinib in K562 cells and MEG-01 cells. The positive cell percent of marrow cells from 10 newly diagnosed CML patients and 9 imatinib-sensitive CML patients was (54.20 +/- 19.82)% and (14.84 +/- 6.17)% (P < 0.05), while that of 2 cases of imatinib-resistant was 64.3% and 57.2%. There was significant difference of MFI between imatinib-resistant patients and imatinib-sensitive patients (99.42 +/- 4.87 vs 46.41 +/- 4.67, P < 0.01).;PY20 monoclonal antibody is highly specific for bcr-abl+ cells. It might be useful in rapid detection of bcr-abl+ cells and sensitivity to imatinib of CML patients.",
        "Doc_title":"[Detection of phosphotyrosine in bcr-abl-positive cells with PY20 antibody and its clinical applications].",
        "Journal":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi",
        "Do_id":"17147244",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Phosphotyrosine;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Antibodies, Monoclonal;Bone Marrow Cells;Flow Cytometry;Fusion Proteins, bcr-abl;Humans;K562 Cells;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Leukemia, Myeloid, Acute;Phosphotyrosine",
        "Doc_meshqualifiers":"analysis;metabolism;analysis;metabolism;metabolism;analysis;immunology",
        "_version_":1605808826498416640},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) progression is characterized by occurrence of new cytogenetic and molecular abnormalities. In the previous study, we have shown the important role of GATA-2 L359 V mutation in CML progression. To further ascertain the truth of transcription factor GATA-2 in hematological malignancies, we expanded our study to GATA-2 full length by directly sequencing and applied MassARRAY assay into GATA-2 L359 V mutation analysis. Finally, no GATA-2 L359 V mutation was found in 270 acute myeloid leukemia, 30 myelodysplastic syndrome, 50 acute lymphoblastic leukemia, 12 chronic lymphocytic leukemia, 40 CML chronic phase and 286 BCR/ABL negative myeloproliferative disorders except CML blast crisis. A new variation of GATA-2 resulted in P250A change was identified, which was not found to have statistical difference between patients with hematological malignancies and healthy control. Hence, we concluded GATA-2 L359 V is exclusively associated with CML progression but not other hematological malignancies and P250A is a new single nucleotide polymorphism.",
        "Doc_title":"GATA-2 L359 V mutation is exclusively associated with CML progression but not other hematological malignancies and GATA-2 P250A is a novel single nucleotide polymorphism.",
        "Journal":"Leukemia research",
        "Do_id":"19304323",
        "Doc_ChemicalList":"GATA2 Transcription Factor;GATA2 protein, human",
        "Doc_meshdescriptors":"Amino Acid Substitution;Blast Crisis;DNA Mutational Analysis;Disease Progression;Female;GATA2 Transcription Factor;Hematologic Neoplasms;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Mutation, Missense;Polymorphism, Single Nucleotide",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism",
        "_version_":1605801368014028800},
      {
        "Doc_abstract":"The mammalian target of rapamycin (mTOR) signaling pathway plays a critical role in growth and survival of BCR-ABL transformed cells. AMPK kinase is a metabolic sensor that exhibits suppressive effects on the mTOR pathway and negatively regulates mTOR activity. We report that AMPK activators, such as metformin and 5-aminoimidazole-4-carboxamide ribonucleotide, suppress activation of the mTOR pathway in BCR-ABL-expressing cells. Treatment with these inhibitors results in potent suppression of chronic myeloid leukemia leukemic precursors and Ph(+) acute lymphoblastic leukemia cells, including cells expressing the T315I-BCR-ABL mutation. Altogether, our data suggest that AMPK is an attractive target for the treatment of BCR-ABL-expressing malignancies and raise the potential for use of AMPK activators in the treatment of refractory chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia.",
        "Doc_title":"Antileukemic effects of AMPK activators on BCR-ABL-expressing cells.",
        "Journal":"Blood",
        "Do_id":"22021366",
        "Doc_ChemicalList":"Antineoplastic Agents;Mutant Proteins;Prodrugs;Recombinant Proteins;Ribonucleotides;Aminoimidazole Carboxamide;Metformin;Protein Kinases;AMP-activated protein kinase kinase;Fusion Proteins, bcr-abl;AICA ribonucleotide",
        "Doc_meshdescriptors":"Amino Acid Substitution;Aminoimidazole Carboxamide;Antineoplastic Agents;Apoptosis;Bone Marrow Cells;Cell Line, Transformed;Cell Survival;Cell Transformation, Neoplastic;Down-Regulation;Drug Resistance, Neoplasm;Enzyme Activation;Fusion Proteins, bcr-abl;Hematopoietic Stem Cells;Humans;Leukemia, Lymphoid;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Metformin;Molecular Targeted Therapy;Mutant Proteins;Prodrugs;Protein Kinases;Recombinant Proteins;Ribonucleotides",
        "Doc_meshqualifiers":"analogs & derivatives;pharmacology;pharmacology;drug effects;drug effects;metabolism;drug effects;metabolism;drug effects;drug effects;genetics;metabolism;drug effects;metabolism;drug therapy;metabolism;blood;drug therapy;metabolism;pharmacology;metabolism;pharmacology;chemistry;metabolism;pharmacology",
        "_version_":1605901942213574656},
      {
        "Doc_abstract":"Recent improved treatments for lymphoid malignancies produce more long-term survivors, yet increase the risk for secondary malignancies. Therapy-related myelodysplasia and acute myeloid leukemia are well described, but secondary chronic myeloid leukemia (CML) has only rarely been reported. We report three patients with CML diagnosed 8, 10 and 2.5 years following Hodgkin's disease, non-Hodgkin's lymphoma and chronic lymphocytic leukemia therapy, respectively. BCR-ABL transcripts were not detected after completion of primary therapy in two cases. All three patients received imatinib therapy, with one patient subsequently undergoing allogeneic hematopoietic stem cell transplantation. All three patients have ongoing favorable responses to CML therapy.",
        "Doc_title":"Chronic myeloid leukemia after treatment of lymphoid malignancies: response to imatinib mesylate and favorable outcomes in three patients.",
        "Journal":"Leukemia research",
        "Do_id":"16330096",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Pyrimidines;Imatinib Mesylate",
        "Doc_meshdescriptors":"Adult;Antineoplastic Agents;Benzamides;Disease-Free Survival;Female;Hematopoietic Stem Cell Transplantation;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Neoplasms, Second Primary;Piperazines;Pyrimidines;Remission Induction;Time Factors;Transplantation, Homologous",
        "Doc_meshqualifiers":"administration & dosage;etiology;metabolism;therapy;etiology;metabolism;therapy;administration & dosage;administration & dosage",
        "_version_":1605742660560093185},
      {
        "Doc_abstract":"In chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) the Ph1 chromosome (22q-) is the most frequent chromosomal aberration encountered. At the molecular level the c-abl gene from chr. 9 is translocated to the bcr gene on chr. 22. As a result, a chimeric bcr-abl gene is generated, which encodes chimeric proteins. Since these proteins are only expressed in Ph1 positive cells, they are per definition tumor-specific. In this report we describe the reactivity of polyvalent antisera raised against synthetic peptides corresponding to the tumor-specific bcr-abl junctions. Native chimeric proteins were specifically recognized by these junction-specific antisera. Therefore we conclude that the bcr-abl junctions are antigenically exposed on the chimeric proteins. We discuss the relevance of these antisera for CML and ALL diagnosis.",
        "Doc_title":"Detection of tumor-specific antigens in Philadelphia chromosome positive leukemias.",
        "Journal":"Leukemia & lymphoma",
        "Do_id":"7504546",
        "Doc_ChemicalList":"Antigens, Neoplasm;Biomarkers, Tumor;Epitopes;Peptide Fragments;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Amino Acid Sequence;Antigens, Neoplasm;Biomarkers, Tumor;Epitopes;Fusion Proteins, bcr-abl;Genes, abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Molecular Sequence Data;Peptide Fragments;Philadelphia Chromosome;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Sensitivity and Specificity",
        "Doc_meshqualifiers":"analysis;genetics;immunology;analysis;genetics;immunology;immunology;analysis;genetics;immunology;diagnosis;genetics;immunology;chemical synthesis;immunology;classification;diagnosis;genetics;immunology",
        "_version_":1605746317990035457},
      {
        "Doc_abstract":"Diagnosis of chronic myeloid leukemia and acute lymphoblastic leukemia requires the investigation of the Philadelphia chromosome translocation t(9;22) or the molecular detection of BCR-ABL fusion transcripts. Determination of the type of fusion transcript is crucial for quantitative molecular monitoring the course of the disease during treatment. Histopathologists, who usually use formalin-fixed tissues, may be confronted with the need to investigate the BCR-ABL rearrangement when evaluating tumor forming infiltrates and bone marrow trephines from patients presenting with chronic myeloproliferative disorders. Therefore, we have established a one-tube multiplex RT-PCR for the detection of common BCR-ABL fusion transcripts (b2a2, b3a2, e1a2) in routinely processed tissues and bone marrow trephines with respect to the inevitable fragmentation of ribonucleic acids in these specimens. RT-PCR products allow distinct and unequivocal differentiation of the underlying fusion in either the Major- or minor-breakpoint cluster region. Detection of BCR-ABL fusion transcripts by multiplex RT-PCR in routinely processed and fixed tissues is a time- and cost-sparing tool for definite diagnosis of typical chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia.",
        "Doc_title":"Multiplex RT-PCR for the detection of common BCR-ABL fusion transcripts in paraffin-embedded tissues from patients with chronic myeloid leukemia and acute lymphoblastic leukemia.",
        "Journal":"Diagnostic molecular pathology : the American journal of surgical pathology, part B",
        "Do_id":"12960692",
        "Doc_ChemicalList":"DNA Primers;DNA, Neoplasm;RNA, Neoplasm;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Bone Marrow Cells;Cell Line, Tumor;DNA Primers;DNA, Neoplasm;Fusion Proteins, bcr-abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Paraffin Embedding;Precursor Cell Lymphoblastic Leukemia-Lymphoma;RNA, Neoplasm;Reverse Transcriptase Polymerase Chain Reaction;Sensitivity and Specificity",
        "Doc_meshqualifiers":"metabolism;chemistry;analysis;genetics;metabolism;genetics;metabolism;pathology;genetics;metabolism;pathology;analysis;methods",
        "_version_":1605903038058332160},
      {
        "Doc_abstract":"Although Bcr-Abl kinase inhibitors have proven effective in the treatment of chronic myeloid leukemia (CML), they generally fail to eradicate Bcr-Abl(+) leukemia cells. To identify genes whose inhibition sensitizes Bcr-Abl(+) leukemias to killing by Bcr-Abl inhibitors, we performed an RNAi-based synthetic lethal screen with imatinib mesylate in CML cells. This screen identified numerous components of a Wnt/Ca(2+)/NFAT signaling pathway. Antagonism of this pathway led to impaired NFAT activity, decreased cytokine production, and enhanced sensitivity to Bcr-Abl inhibition. Furthermore, NFAT inhibition with cyclosporin A facilitated leukemia cell elimination by the Bcr-Abl inhibitor dasatinib and markedly improved survival in a mouse model of Bcr-Abl(+) acute lymphoblastic leukemia (ALL). Targeting this pathway in combination with Bcr-Abl inhibition could improve treatment of Bcr-Abl(+) leukemias.",
        "Doc_title":"Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl.",
        "Journal":"Cancer cell",
        "Do_id":"20609354",
        "Doc_ChemicalList":"Benzamides;Cytokines;Immunosuppressive Agents;NFATC Transcription Factors;Piperazines;Protein Kinase Inhibitors;Pyrimidines;RNA, Messenger;RNA, Small Interfering;Thiazoles;Wnt Proteins;Cyclosporine;Imatinib Mesylate;Fusion Proteins, bcr-abl;Dasatinib;Calcium",
        "Doc_meshdescriptors":"Animals;Antineoplastic Combined Chemotherapy Protocols;Apoptosis;Benzamides;Blotting, Western;Calcium;Cell Proliferation;Cyclosporine;Cytokines;Dasatinib;Female;Flow Cytometry;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Immunosuppressive Agents;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mice;Mice, Inbred C57BL;NFATC Transcription Factors;Philadelphia Chromosome;Piperazines;Protein Kinase Inhibitors;Pyrimidines;RNA, Messenger;RNA, Small Interfering;Reverse Transcriptase Polymerase Chain Reaction;Signal Transduction;Thiazoles;Tumor Cells, Cultured;Wnt Proteins",
        "Doc_meshqualifiers":"metabolism;pharmacology;metabolism;antagonists & inhibitors;genetics;metabolism;pharmacology;metabolism;pathology;genetics;metabolism;pharmacology;pharmacology;pharmacology;genetics;pharmacology;pharmacology;genetics;metabolism",
        "_version_":1605843539476873216},
      {
        "Doc_abstract":"Dasatinib is an orally bioavailable potent inhibitor of multiple tyrosine kinases, including ABL and SRC. Preclinical studies have shown dasatinib to be a much more potent inhibitor of BCR-ABL than imatinib is, and to harbor efficacy against nearly all imatinib-resistant BCR-ABL mutants. Phase I clinical studies have been conducted in imatinib-resistant and -intolerant chronic myeloid leukemia and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. No dose-limiting toxicity was observed at doses that harbored substantial clinical efficacy. Multinational phase II studies have confirmed the phase I experience and have led to accelerated approval by the U.S. Food and Drug Administration for the treatment of imatinib-resistant and -intolerant chronic myeloid leukemia as well as its full approval for the treatment of therapy-resistant Ph+ acute lymphoblastic leukemia.",
        "Doc_title":"Dasatinib.",
        "Journal":"Drugs of today (Barcelona, Spain : 1998)",
        "Do_id":"17315048",
        "Doc_ChemicalList":"Protein Kinase Inhibitors;Pyrimidines;Thiazoles;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl;Dasatinib",
        "Doc_meshdescriptors":"Dasatinib;Drug Evaluation, Preclinical;Fusion Proteins, bcr-abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Protein Kinase Inhibitors;Protein-Tyrosine Kinases;Pyrimidines;Thiazoles",
        "Doc_meshqualifiers":"drug therapy;pharmacology;therapeutic use;antagonists & inhibitors;pharmacology;therapeutic use;pharmacology;therapeutic use",
        "_version_":1605742102300327937},
      {
        "Doc_abstract":"In chronic myeloid leukemia (CML), a chromosome translocation has fused the bcr gene to the c-abl oncogene, such that a chimeric bcr-abl polypeptide can be made. To explore the biological properties of bcr-abl and compare them with those of the Abelson virus (AMuLV) transforming gene (gag-v-abl), we have used either a synthetic bcr-v-abl gene that mimics the translocation product or, in some experiments, a bcr-c-abl cDNA. A new retroviral vector was used to introduce the genes into the factor-dependent myeloid line FDC-P1. Both bcr-abl and v-abl efficiently rendered the myeloid cells factor independent and tumorigenic. Their fully autonomous growth may be due to the myeloid growth factor interleukin-3 (IL-3) made in small amounts by the infected cells. Hence autocrine factor production may feature in CML development and Abelson virus transformation.",
        "Doc_title":"bcr-abl oncogene renders myeloid cell line factor independent: potential autocrine mechanism in chronic myeloid leukemia.",
        "Journal":"Oncogene research",
        "Do_id":"3147434",
        "Doc_ChemicalList":"Growth Substances;Interleukin-3;Neoplasm Proteins;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Animals;Cell Division;Cell Line;Cell Transformation, Neoplastic;Fusion Proteins, bcr-abl;Gene Expression Regulation;Genetic Engineering;Growth Substances;Interleukin-3;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mice;Neoplasm Proteins;Neoplasms, Experimental;Transfection",
        "Doc_meshqualifiers":"genetics;biosynthesis;biosynthesis;pathology;physiopathology;physiology;genetics;pathology",
        "_version_":1605902278069321728},
      {
        "Doc_abstract":"Advances in the molecular characterization of leukemic cells have greatly improved the precision of diagnosis and treatment assignment as well as the monitoring of residual disease in both acute lymphoblastic leukemia and acute myeloid leukemia. Currently, specific genetic rearrangements can be identified in as many as 50% of children with either acute lymphoblastic leukemia or acute myeloid leukemia. The genes p16 (or MTS1) and TEL/AML1 are now respectively recognized as the most common tumor suppressor and fusion genes in childhood acute lymphoblastic leukemia. Increasingly, contemporary protocols for the acute leukemias are relying on genetic information to guide treatment decisions. Examples include the use of allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia with the BCR-ABL fusion gene or MLL rearrangement, and for acute myeloid leukemia with monosomy 7; antimetabolite-based therapy for acute lymphoblastic leukemia cases with hyperdiploidy of more than 50 chromosomes (DNA index > or = 1.16); and retinoic acid and anthracycline-containing regimens for the acute promyelocytic acute myeloid leukemia subtype with PML-RARA fusion. Other efforts are being made to reduce the long-term sequelae of treatment. Indeed, extended intrathecal therapy and intensive systemic chemotherapy will, in all likelihood, replace cranial irradiation as subclinical central nervous system therapy for patients with intermediate-risk acute lymphoblastic leukemia, and perhaps even for those with high-risk acute lymphoblastic leukemia. The challenge now is to identify specific treatments for other genetically defined subtypes of leukemia. This goal will be realized only through protocol-based studies employing uniform criteria for defining risk status.",
        "Doc_title":"Acute leukemia in children.",
        "Journal":"Current opinion in hematology",
        "Do_id":"9372085",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Acute Disease;Child;Child, Preschool;Gene Rearrangement;Genes, Tumor Suppressor;Humans;Leukemia, Myeloid;Precursor Cell Lymphoblastic Leukemia-Lymphoma",
        "Doc_meshqualifiers":"genetics;physiopathology;therapy;genetics;physiopathology;therapy",
        "_version_":1605825366367141888},
      {
        "Doc_abstract":"We designed a novel multiplex in-cell reverse transcription-polymerase chain reaction method for the simultaneous detection and differentiation of p190 and p210 BCR-ABL mRNAs within single cells from the human chronic myeloid leukemia and Philadelphia positive acute lymphoblastic leukemia. Human K562 chronic myeloid leukemia and SUP B-15 Ph+ acute lymphoblastic leukemia cell lines were used as positive controls for p210 and p190 BCR-ABL mRNAs, respectively. HL60 cell line was used as a negative control. After the leukemia cells were fixed and permeabilized, without extracting nucleic acids, the mRNAs were reverse transcribed to cDNAs, and the cDNAs were amplified by multiplex polymerase chain reaction with fluorescent primers specific for p190 and p210 BCR-ABL mRNAs. After transfer onto glass slides by cytospin, the amplified cells were detected by fluorescence microscopy. Fluorescence microscopy after propidium iodide or 4',6-diamidino-2-phenylindone counterstaining showed that the positive K562 cells exhibited a yellow-green fluorescent cytoplasm around a red nucleus, and that the positive SUP B-15 cells exhibited an orange cytoplasm around a blue nucleus. Only the red or blue nucleus was visible in respective negative HL60 cells. The specificity of amplification was confirmed by the absence of a signal when control experiments were performed either with RNase digestion of mRNA or without reverse transcriptase/Taq polymerase. We conclude that the multiplex in-cell reverse transcription-polymerase chain reaction method is capable of simultaneously detecting and differentiating the p210 and p190 BCR-ABL mRNAs of chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia cells, and that it may be useful in quantitatively monitoring the minimal residual disease during therapy.",
        "Doc_title":"Multiplex in-cell reverse transcription-polymerase chain reaction for the simultaneous detection of p210 and p190 BCR-ABL mRNAs in chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia cell lines.",
        "Journal":"Clinical chemistry and laboratory medicine",
        "Do_id":"11097354",
        "Doc_ChemicalList":"DNA Primers;RNA, Messenger;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"DNA Primers;Flow Cytometry;Fusion Proteins, bcr-abl;Humans;K562 Cells;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Philadelphia Chromosome;Precursor Cell Lymphoblastic Leukemia-Lymphoma;RNA, Messenger;Reverse Transcriptase Polymerase Chain Reaction;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"genetics;genetics;genetics;analysis;genetics",
        "_version_":1605792106074341376},
      {
        "Doc_abstract":"To investigate GATA-2 gene expression in leukemia patients and its clinical significance.;GATA-2 gene transcripts were detected by reverse transcriptase polymerase chain reaction (RT-PCR), and bcr/abl or PML/RAR alpha transcripts were detected in patients with chronic myeloid leukemia (CML) and acute promyelocytic leukemia (APL), respectively.;The GATA-2 transcripts were revealed in 93% of acute myeloid leukemia (AML), in 70% of acute lymphoblastic leukemia (ALL), and 83% of CML patients, but not in normal bone marrow and peripheral blood cells. GATA-2 expression in remission patients was similar to newly diagnosed or relapsed patients. In post-transplantation patients, GATA-2 expression was significantly decreased. In these cases GATA-2 transcripts could be detected with bcr/abl fusion gene disappeared in 2 of 12 CML, whereas neither GATA-2 nor PML/RARalpha transcripts could be detected in APL.;GATA-2 transcripts was highly expressed in leukemia patients and had no change in remission but significantly decreased in post-transplantation patients. Detection of GATA-2 expression would give information about the residual leukemia stem cells.",
        "Doc_title":"[GATA-2 gene expression in leukemia patients and its significance].",
        "Journal":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi",
        "Do_id":"11877047",
        "Doc_ChemicalList":"GATA2 Transcription Factor",
        "Doc_meshdescriptors":"Bone Marrow Cells;Cells, Cultured;GATA2 Transcription Factor;Gene Expression Regulation, Leukemic;Humans;Leukemia;Recurrence",
        "Doc_meshqualifiers":"metabolism;genetics;metabolism;genetics;metabolism;pathology",
        "_version_":1605757240347721728},
      {
        "Doc_abstract":"Ponatinib is a bcr-abl tyrosine-kinase inhibitor (TKI) used to treat resistant and refractory chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia that express bcr-abl. Neutrophilic panniculitis has been described in rare cases of patients on other TKIs in the same class as ponatinib. We present the first case of neutrophilic panniculitis following treatment with ponatinib and summarize the other cases of panniculitis caused by TKIs.",
        "Doc_title":"Ponatinib-induced neutrophilic panniculitis.",
        "Journal":"Journal of cutaneous pathology",
        "Do_id":"24602068",
        "Doc_ChemicalList":"Imidazoles;Protein Kinase Inhibitors;Pyridazines;ponatinib;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Female;Fusion Proteins, bcr-abl;Humans;Imidazoles;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Middle Aged;Neutrophils;Panniculitis;Protein Kinase Inhibitors;Pyridazines",
        "Doc_meshqualifiers":"antagonists & inhibitors;administration & dosage;adverse effects;drug therapy;pathology;pathology;chemically induced;pathology;administration & dosage;adverse effects;administration & dosage;adverse effects",
        "_version_":1605742022627426304},
      {
        "Doc_abstract":"Chromosomal translocations generating the BCR-ABL oncogene cause chronic myeloid leukemia (CML) and a subset of acute lymphoblastic leukemia. The BCR-ABL(T315I) mutation confers drug resistance to FDA-approved targeted therapeutics imatinib mesylate, dasatinib, and nilotinib. We tested the ability of a recombinant yeast-based vaccine expressing the T315I-mutated BCR-ABL antigen to stimulate an anti-BCR-ABL(T315I) immune response. The yeast-based immunotherapy significantly reduced or eliminated BCR-ABL(T315I) leukemia cells from the peripheral blood of immunized animals and extended leukemia-free survival in a murine model of BCR-ABL(+) leukemia compared to animals receiving sham injection or yeast expressing ovalbumin. With immunization, leukemic cells harboring BCR-ABL(T315I) were selectively eliminated after challenge with a mixed population of BCR-ABL and BCR-ABL(T315I) leukemias. In summary, yeast-based immunotherapy represents a novel approach against the emergence of cancer drug resistance by the pre-emptive targeted ablation of tumor escape mutants.",
        "Doc_title":"Mutation-specific control of BCR-ABL T315I positive leukemia with a recombinant yeast-based therapeutic vaccine in a murine model.",
        "Journal":"Vaccine",
        "Do_id":"20619375",
        "Doc_ChemicalList":"Cancer Vaccines;Vaccines, Synthetic;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Amino Acid Sequence;Animals;Cancer Vaccines;Disease-Free Survival;Fusion Proteins, bcr-abl;Genes, MHC Class I;Immunotherapy;Leukemia, Experimental;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mice;Mice, Inbred BALB C;Mice, Inbred C57BL;Models, Molecular;Molecular Sequence Data;Protein Structure, Tertiary;Saccharomyces cerevisiae;Vaccines, Synthetic",
        "Doc_meshqualifiers":"immunology;immunology;immunology;therapy;immunology;therapy;immunology",
        "_version_":1605883695676260352},
      {
        "Doc_abstract":"This review summarizes the molecular genetics of childhood leukemias, with emphasis on pathogenesis and clinical applications.;We first describe the most common genetic events that occur in pediatric acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and chronic myeloid leukemia (CML). We then illustrate how these molecular alterations may be used to alter therapy.;In childhood ALL, the TEL-AML1 fusion and hyperdiploidy are both associated with excellent treatment outcomes and therefore identify patients who may be candidates for less intensive therapy. In contrast, MLL gene rearrangements and the BCR-ABL fusion confer a poor prognosis; these patients may be best treated by allogeneic bone marrow transplantation in first remission.;Although clinical features are important prognostic indicators, genetic alterations of leukemic blasts may be better predictors of outcome for acute leukemia patients. We therefore favor risk-adapted therapy based on classification schemes that incorporate both genetic and clinical features.",
        "Doc_title":"Molecular genetics of childhood leukemias.",
        "Journal":"Journal of pediatric hematology/oncology",
        "Do_id":"9482406",
        "Doc_ChemicalList":"Core Binding Factor Alpha 2 Subunit;DNA-Binding Proteins;MLL protein, human;Proto-Oncogene Proteins;RUNX1 protein, human;Transcription Factors;Myeloid-Lymphoid Leukemia Protein;Histone-Lysine N-Methyltransferase;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Child;Core Binding Factor Alpha 2 Subunit;DNA-Binding Proteins;Fusion Proteins, bcr-abl;Gene Rearrangement;Genes, Tumor Suppressor;Histone-Lysine N-Methyltransferase;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Leukemia, Myeloid, Acute;Myeloid-Lymphoid Leukemia Protein;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Proto-Oncogene Proteins;Proto-Oncogenes;Transcription Factors;Translocation, Genetic",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;genetics;genetics",
        "_version_":1605746407807909888},
      {
        "Doc_abstract":"The Philadelphia chromosome in cells of patients with chronic myeloid leukemia and acute lymphoblastic leukemia can be detected by reverse transcriptase-polymerase chain reaction (RT-PCR). We have tested two new methods for this purpose. For diagnostic purposes, three different BCR-ABL translocations (b3a2, b2a2 and ela2) can be detected in a multiprimed, one step PCR reaction. By using a competitor DNA construct and a two-step, nested PCR reaction, a quantitative measure of the number of specific BCR-ABL transcripts can be estimated. We tested five patients with chronic myeloid leukemia. All of them showed positive BCR-ABL translocations in the diagnostic test. Patients with other myeloproliferative disorders, used as controls, were all negative. Quantitative measurements of specific BCR-ABL mRNA showed that as few as ten transcripts could be quantified in the assay. The analysis showed that coefficients of variation between 15% and 30% were obtained for specific transcripts per micrograms RNA, whereas specific BCR-ABL per normal ABL showed a coefficient of variation of 10%. These new methods to detect BCR-ABL translocation by RT-PCR should provide easy and sensitive diagnosis, and possibilities of monitoring residual disease or relapse.",
        "Doc_title":"[Diagnosis and follow-up in chronic myeloid leukemia. Detection and quantification of specific transcripts with the help of reverse transcriptase-polymerase chain reaction].",
        "Journal":"Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke",
        "Do_id":"8644073",
        "Doc_ChemicalList":"RNA-Directed DNA Polymerase",
        "Doc_meshdescriptors":"Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Philadelphia Chromosome;Polymerase Chain Reaction;RNA-Directed DNA Polymerase;Translocation, Genetic",
        "Doc_meshqualifiers":"diagnosis;enzymology;genetics;methods;metabolism",
        "_version_":1605747981056737280},
      {
        "Doc_abstract":"The BCR-ABL fusion gene is the molecular expression of the Philadelphia chromosome. This cytogenetic aberration is the most frequent alteration found in leukemias, which is produced by the translocation t(9;22). Two different fusion proteins are produced depending on the break point (210 kD and 190 kD). The detection of this gene has both diagnostic and prognostic importance, associated with poor prognosis in acute lymphoblastic leukemia (ALL).;To detect BCR-ABL gene sequences in patients with leukemia from the IX Region of Chile.;We studied 58 patients: 5 chronic myeloid leukemia (CML), 35 ALL, 15 acute myeloid leukemia (AML) and 3 biphenotypic leukemia. The gene sequences were detected using reverse transcriptase polymerase chain reaction (RT-PCR).;BRC-ABL gene sequences were positive in all patients with CML, 2 of 35 ALL (one child and one adult). The remaining patients were negative. We found p210 and p190 co-expression in 2 CML and 1 ALL.;Our results are in agreement with other reports. The detection of these and other genetic alterations will allow us to have invaluable diagnostic and prognostic information from our patients with leukemia.",
        "Doc_title":"[Detection of BCR-ABL gene sequences using RT-PCR in patients with leukemia in the IX region. Chile].",
        "Journal":"Revista medica de Chile",
        "Do_id":"12194684",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Acute Disease;Adolescent;Adult;Aged;Base Sequence;Child;Child, Preschool;Chile;Female;Fusion Proteins, bcr-abl;Genes, abl;Humans;Infant;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Leukemia, Myeloid;Male;Middle Aged;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Prognosis;Reverse Transcriptase Polymerase Chain Reaction",
        "Doc_meshqualifiers":"genetics;diagnosis;genetics;diagnosis;genetics;diagnosis;genetics",
        "_version_":1605785473848967168},
      {
        "Doc_abstract":"To evaluate levels of common specific fusion transcripts M-bcr-abl, m-bcr-abl, TEL-AML1, AML1-ETO, PML-RAR alpha, CBF beta-MYH11 in untreated leukemia patients.;Specific fusion transcript levels were detected by TaqMan-based real-time quantitative RT-PCR technique in a total of 208 samples, including 195 bone marrow samples from 50 M-bcr-abl(+) chronic phase-chronic myeloid leukemia (CML-CP), 10 M-bcr-abl(+) acute lymphoblastic leukemia (ALL), 19 m-bcr-abl(+) ALL, 11 TEL-AML1(+) ALL, 30 AML1-ETO(+) acute myeloid leukemia (AML), 58 PML-RAR alpha(+) acute promyelocytic leukemia (APL) and 17 CBF beta-MYH11(+) AML patients and 13 peripheral blood samples from 13 M-bcr-abl(+) CML-CP patients. abl was chosen as internal control gene. Fusion transcript level was calculated as fusion transcript copies/abl transcript copies in percentage.;Bone marrow and peripheral blood samples of CML-CP patients had similar M-bcr-abl fusion transcript levels (median 30% vs 35%, P > 0.05). M- and m-bcr-abl (median 64% vs 54%) levels were similar in ALL patients (P > 0.05), M-bcr-abl level was significantly higher in ALL than CML-CP patients(P < 0.001). Median TEL-AML1 level was 228% in ALL patients. Among AML patients, AML1-ETO level was significantly higher than CBF beta-MYH11 and PML-RAR alpha levels (median 388% vs 145%, 388% vs 47%, all P < 0.001), CBF beta-MYH11 level was significantly higher than PML-RAR alpha level (P < 0.001). Fusion transcript levels of L-, V- and S-type PML-RAR alpha were 45%, 44% and 55%, respectively. L-type was significantly lower than S-type (P = 0.04).;Fusion transcript levels in untreated leukemia patients were different and patient-to-patient variations did exist. Detection of fusion transcript levels in untreated leukemia patients not only provides baseline for minimal residual disease monitoring and treatment evaluation but also enable the comparison in inter-laboratory data.",
        "Doc_title":"[Detection of common fusion transcript levels in untreated leukemia patients by real-time quantitative RT-PCR technique].",
        "Journal":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi",
        "Do_id":"18072623",
        "Doc_ChemicalList":"AML1-ETO fusion protein, human;CBFbeta-MYH11 fusion protein;Core Binding Factor Alpha 2 Subunit;Oncogene Proteins, Fusion;TEL-AML1 fusion protein;promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adolescent;Adult;Bone Marrow Cells;Child;Child, Preschool;Core Binding Factor Alpha 2 Subunit;Female;Fusion Proteins, bcr-abl;Humans;Leukemia;Male;Middle Aged;Oncogene Proteins, Fusion;Reverse Transcriptase Polymerase Chain Reaction;Transcription, Genetic",
        "Doc_meshqualifiers":"metabolism;genetics;genetics;genetics;genetics;methods",
        "_version_":1605751245223493632},
      {
        "Doc_abstract":"Chromosomal translocation t(9; 22)(q34; q11), found in 95% of patients with chronic myeloid leukemia(CML) and 30% of adult patients with acute lymphoblastic leukemia (ALL) generates a chimeric gene, BCR/ABL. There are three kinds BCR/ABL fusion transcripts of p210BCR-ABL found in CML and ALL, p190BCR-ABL mainly in ALL, and p230BCR-ABL in CML, either of which depends on the location of the breakpoints within the BCR gene. For the detection of t(9; 22) or BCR/ABL, karyotype analysis, Southern blot hybridization of the BCR gene, fluorescence in situ hybridization, and reverse transcription-polymerase chain reaction(RT-PCR) have been used. Especially, recent advance in RT-PCR methods have allowed refined quantitative detection of the BCR/ABL transcripts, which are useful for monitoring response status and detecting minimal residual disease.",
        "Doc_title":"[Genetic diagnosis of chronic myeloid leukemia].",
        "Journal":"Nihon rinsho. Japanese journal of clinical medicine",
        "Do_id":"11766335",
        "Doc_ChemicalList":"RNA, Messenger;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Chimera;Fusion Proteins, bcr-abl;Genes, abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Philadelphia Chromosome;RNA, Messenger;Translocation, Genetic",
        "Doc_meshqualifiers":"genetics;diagnosis;genetics;isolation & purification",
        "_version_":1605821238190538752},
      {
        "Doc_abstract":"After allogeneic stem cell transplantation (SCT), we evaluated the use of the Wilms' tumor gene (WT1) as a minimal residual disease (MRD) marker in 32 patients (28 chronic myeloid leukemia, three acute lymphoblastic leukemia and one acute myeloid leukemia). All patients expressed BCR-ABL and the kinetics of WT1 were compared with those of BCR-ABL using real-time quantitative PCR. WT1 expression was seen in the peripheral blood (PB) of healthy controls with a median expression level of 7 x 10(-5) (WT1/ABL ratio). The corresponding values for BCR-ABL-negative and BCR-ABL-positive patient samples were 1 x 10(-4) and 1.6 x 10(-4), respectively. Kinetic studies in individual patients showed that WT1 and BCR-ABL levels usually did not copy each other. In four out of six patients who relapsed, an increase in WT1 from the background level (10(-4)) was observed only at the time of or after relapse, and in two patients increasing WT1 levels were observed before the relapse. In addition, the WT1 values found at the time of relapse were only two logs higher than the background level, indicating a sensitivity of 10(-2). In conclusion, there is a constitutive low expression of WT1 in normal hematopoietic cells. The sensitivity and ability of WT1 to predict a relapse were poor in this study.",
        "Doc_title":"Poor correlation of kinetics between BCR-ABL and WT1 transcript levels after allogeneic stem cell transplantation.",
        "Journal":"Bone marrow transplantation",
        "Do_id":"14704656",
        "Doc_ChemicalList":"RNA, Neoplasm;WT1 Proteins;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adolescent;Adult;Child;Child, Preschool;Fusion Proteins, bcr-abl;Hematopoietic Stem Cell Transplantation;Humans;Kinetics;Leukemia;Middle Aged;Neoplasm, Residual;Predictive Value of Tests;RNA, Neoplasm;Recurrence;Reverse Transcriptase Polymerase Chain Reaction;Sensitivity and Specificity;Transplantation, Homologous;WT1 Proteins",
        "Doc_meshqualifiers":"genetics;standards;diagnosis;therapy;diagnosis;genetics;analysis;methods;standards;genetics",
        "_version_":1605766203166425088},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) and some acute lymphoblastic leukemias are characterized by the t(9;22) chromosome, which encodes the BCR/ABL oncogene. Multiple mouse models of CML express BCR/ABL at high levels from non-Bcr promoters, resulting in the development of leukemias. In contrast, a significant fraction of healthy humans have been found to have BCR/ABL-positive hematopoietic cells. To bridge the gap between the information derived from current mouse models and nonleukemic humans with the BCR/ABL oncogene, we generated a knockin model with BCR/ABL p210 expressed from the Bcr locus. Unlike previous models, expression of BCR/ABL from the knockin allele did not induce leukemia. BCR/ABL mutant cells did exhibit favorable bone marrow engraftment compared to control cells. These data suggest that BCR/ABL expression alone is insufficient to induce disease. This model allows for inducible spatial and temporal control of BCR/ABL expression for analysis of early steps in the pathogenesis of BCR/ABL-expressing leukemias. ",
        "Doc_title":"Expression of BCR/ABL p210 from a knockin allele enhances bone marrow engraftment without inducing neoplasia.",
        "Journal":"Cell reports",
        "Do_id":"24095735",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Alleles;Animals;Bone Marrow Transplantation;Cell Transformation, Neoplastic;Fusion Proteins, bcr-abl;Gene Expression Regulation;Gene Knock-In Techniques;Humans;Leukemia, Myeloid;Mice;Mice, Transgenic",
        "Doc_meshqualifiers":"methods;genetics;metabolism;analysis;biosynthesis;genetics;genetics;metabolism",
        "_version_":1605808891369619456},
      {
        "Doc_abstract":"In human Ph-positive leukemia there is a clear association of different forms of the BCR-ABL oncogene with distinct types of leukemia. The P190 form of BCR-ABL is rarely observed in chronic myeloid leukemia (CML) but is present in 50% of Ph-positive acute lymphoblastic leukemia (ALL). In contrast, the P210 form is observed both in CML and 50% of Ph-positive ALL. Methylation of the proximal promoter of the ABL1 gene has been shown to be a nearly universal event associated with clinical progression of CML. This raises the question of whether methylation of the ABL1 promoter is an epigenetic modification also associated with Ph-positive ALL. To study this issue, we used methylation-specific PCR and bisulfite sequencing to determine the methylation status of the ABL1 promoter in 18 Ph-positive ALL samples. We report here that gene-specific ABL1 promoter methylation is associated mainly with the P210 form of BCR-ABL and not the P190 form. While six out of the seven P210-positive ALL samples had ABL1 promoter methylation, none of the 11 P190-positive ALL samples demonstrated ABL1 promoter methylation. In addition, we estimated the extent and relative abundance of ABL1 promoter methylation in several Ph-positive ALL samples and compared it to the methylation pattern in chronic, accelerated and blastic crisis phases of CML. We put forth a model that correlates the different types of leukemias with the different levels of ABL1 promoter methylation.",
        "Doc_title":"ABL1 methylation in Ph-positive ALL is exclusively associated with the P210 form of BCR-ABL.",
        "Journal":"Leukemia",
        "Do_id":"11368359",
        "Doc_ChemicalList":"Cell Cycle Proteins;DNA-Binding Proteins;Tumor Suppressor Proteins;ATM protein, human;Ataxia Telangiectasia Mutated Proteins;Protein-Serine-Threonine Kinases",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Ataxia Telangiectasia Mutated Proteins;Cell Cycle Proteins;DNA Methylation;DNA-Binding Proteins;Genes, abl;Humans;Middle Aged;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Promoter Regions, Genetic;Protein-Serine-Threonine Kinases;Tumor Suppressor Proteins",
        "Doc_meshqualifiers":"genetics;genetics",
        "_version_":1605741926392266754},
      {
        "Doc_abstract":"c-Abl is activated by oxidative stress but its precise function in cell response to this stress is elusive. Studies of c-Abl(-/-) osteoblasts revealed that c-Abl played a negative role in the induction of peroxiredoxin I (Prx I, Prdx I), an anti-oxidant protein with tumor suppression activity. In contrast, Atm, a signaling molecule that interacts with c-Abl and is required for c-Abl activation, served a totally different function. The significance of these findings is discussed here in the context of aging and tumorigenesis and their links to reactive oxygen species. c-Abl and its derivatives BCR-ABL and v-Abl were discovered more than twenty years ago. BCR-ABL and v-Abl acquire elevated tyrosine kinase activities by fusing to BCR and gag respectively and are capable of transforming myeloid and fibroblast cells. BCR-ABL is also the underlying cause in the development of most cases of chronic myeloid leukemia (CML) in humans. In contrast, c-Abl takes on an auto-inhibiting conformation and its activation requires post-translational modifications such as phosphorylation and myristoylation. The physiological functions of c-Abl remain elusive.",
        "Doc_title":"c-Abl in oxidative stress, aging and cancer.",
        "Journal":"Cell cycle (Georgetown, Tex.)",
        "Do_id":"15655364",
        "Doc_ChemicalList":"Cell Cycle Proteins;DNA-Binding Proteins;Oncogene Proteins v-abl;Tumor Suppressor Proteins;Peroxidases;Peroxiredoxins;Fusion Proteins, bcr-abl;Proto-Oncogene Proteins c-abl;ATM protein, human;Ataxia Telangiectasia Mutated Proteins;Atm protein, mouse;Protein-Serine-Threonine Kinases;Protein Kinase C-delta",
        "Doc_meshdescriptors":"Aging;Animals;Ataxia Telangiectasia Mutated Proteins;Cell Cycle Proteins;DNA-Binding Proteins;Fusion Proteins, bcr-abl;Gene Expression Regulation;Gene Expression Regulation, Neoplastic;Genes, abl;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mice;Neoplasms;Oncogene Proteins v-abl;Oxidative Stress;Peroxidases;Peroxiredoxins;Protein Kinase C-delta;Protein Processing, Post-Translational;Protein-Serine-Threonine Kinases;Proto-Oncogene Proteins c-abl;Tumor Suppressor Proteins",
        "Doc_meshqualifiers":"physiology;genetics;physiology;genetics;physiology;genetics;physiology;physiology;etiology;physiopathology;genetics;physiopathology;genetics;physiology;physiology;genetics;physiology;physiology;genetics;physiology;genetics;physiology;genetics;physiology",
        "_version_":1605822586235650048},
      {
        "Doc_abstract":"The SET gene is a target of chromosomal translocations in acute leukemia and encodes a widely expressed multifunctional phosphoprotein. It has been shown that SET is upregulated in BCR-ABL1-positive cell lines, patient-derived chronic myeloid leukemia CD34-positive cells, and some solid tumors.;We determined the expression level of SET in 59 pediatric acute lymphoblastic leukemia patients who were BCR-ABL-negative using quantitative real-time reverse-transcriptase-polymerase chain reaction. Results. We showed that SET expression was significantly upregulated in 96.5% of B-acute lymphoblastic leukemia (28 of 29; 16.6 fold) and 93% of T-acute lymphoblastic leukemia (28 of 30; 47.6 fold) patients. This upregulation was not associated with any clinical features or overall and relapse-free survival.;Our results showed that SET is significantly overexpressed in pediatric acute lymphoblastic leukemia samples, and an increased level of SET might contribute to leukemic process.",
        "Doc_title":"SET oncogene is upregulated in pediatric acute lymphoblastic leukemia.",
        "Journal":"Tumori",
        "Do_id":"22677993",
        "Doc_ChemicalList":"Biomarkers, Tumor;Histone Chaperones;Neoplasm Proteins;SET protein, human;Transcription Factors",
        "Doc_meshdescriptors":"Adolescent;Biomarkers, Tumor;Child;Child, Preschool;Disease-Free Survival;Female;Gene Expression Regulation, Neoplastic;Histone Chaperones;Humans;Kaplan-Meier Estimate;Male;Neoplasm Proteins;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Real-Time Polymerase Chain Reaction;Reverse Transcriptase Polymerase Chain Reaction;Transcription Factors;Up-Regulation",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;metabolism;metabolism;metabolism;genetics;metabolism",
        "_version_":1605808876949602304},
      {
        "Doc_abstract":"We have previously identified NME2 (Nm23-H2) as a tumor antigen in a patient with chronic myeloid leukemia (CML). Here we investigated the association between NME2 and Bcr-Abl. NME2 protein was highly overexpressed in the cytoplasm of peripheral blood mononuclear cells from 29/30 patients with CML at diagnosis and 10/10 patients resistant to imatinib. Protein was overexpressed in the absence of increased levels of mRNA and was limited to Bcr-Abl + populations, being absent from Bcr-Abl - patient cells, normal donors and 14/15 acute myeloid leukemia (AML) samples. Furthermore, the Bcr-Abl dependent overexpression of NME2 protein was reversed specifically by tyrosine kinase inhibitor (TKI) treatment of Ba/F3 expressing wild-type and TKI-sensitive, but not TKI-resistant, mutants of Bcr-Abl. The post-transcriptional up-regulation of the tumor antigen NME2 is therefore a common and specific property of CML closely associated with Bcr-Abl activity.",
        "Doc_title":"Bcr-Abl dependent post-transcriptional activation of NME2 expression is a specific and common feature of chronic myeloid leukemia.",
        "Journal":"Leukemia & lymphoma",
        "Do_id":"22251158",
        "Doc_ChemicalList":"Antigens, Neoplasm;Benzamides;NM23 Nucleoside Diphosphate Kinases;Piperazines;Pyrimidines;Imatinib Mesylate;Fusion Proteins, bcr-abl;NME2 protein, human",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Antigens, Neoplasm;Benzamides;Cytoplasm;Drug Resistance, Neoplasm;Female;Fusion Proteins, bcr-abl;Gene Expression Regulation, Leukemic;Humans;Imatinib Mesylate;In Situ Hybridization, Fluorescence;Karyotyping;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Leukocytes, Mononuclear;Male;Middle Aged;NM23 Nucleoside Diphosphate Kinases;Piperazines;Pyrimidines;RNA Processing, Post-Transcriptional",
        "Doc_meshqualifiers":"metabolism;metabolism;metabolism;genetics;metabolism;cytology;biosynthesis;pharmacology;pharmacology",
        "_version_":1605904858126221312},
      {
        "Doc_abstract":"Tyrosine kinases are commonly mutated and activated in both acute and chronic myeloid leukemias. Here, we review the functions, signaling activities, mechanism of transformation, and therapeutic targeting of two prototypic tyrosine kinase oncogenes, BCR-ABL and FLT3, associated with chronic myeloid leukemia (CML) and acute myeloid leukemia (AML), respectively. BCR-ABL is generated by the Philadelphia chromosome translocation between chromosomes 9 and 22, creating a chimeric oncogene in which the BCR and c-ABL genes are fused. The product of this oncogene, BCR-ABL, has elevated ABL tyrosine kinase activity and transforms hematopoietic cells by exerting a wide variety of biological effects, including reduction in growth factor dependence, enhanced viability, and altered adhesion of chronic myelocytic leukemia (CML) cells. Elevated tyrosine kinase activity of BCR-ABL is critical for activating downstream signalling cascades and for all aspects of transformation, explaining the remarkable clinical efficacy of the tyrosine kinase inhibitor, imatinib mesylate (STI571). By comparison, FLT3 is mutated in about one third of all cases of AML, most often through a mechanism that involves an internal tandem duplication (ITD) of a small number of amino acid residues in the juxtamembrane domain of the receptor. As is the case for BCR-ABL, these mutations activate the kinase activity constitutively, activate multiple signaling pathways, and result in an augmentation of proliferation and viability. Transformation by FLT3-ITD can readily be observed in murine models, and FLT3 cooperates with other types of oncogenes to create a fully transformed acute leukemia. FLT3 tyrosine kinase inhibitors are currently being evaluated in clinical trials and may be very useful therapeutic agents in AML.",
        "Doc_title":"Mutated tyrosine kinases as therapeutic targets in myeloid leukemias.",
        "Journal":"Advances in experimental medicine and biology",
        "Do_id":"12908554",
        "Doc_ChemicalList":"Benzamides;Enzyme Inhibitors;Piperazines;Proto-Oncogene Proteins;Pyrimidines;Imatinib Mesylate;FLT3 protein, human;Flt3 protein, mouse;Protein-Tyrosine Kinases;Receptor Protein-Tyrosine Kinases;fms-Like Tyrosine Kinase 3;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Animals;Benzamides;Binding Sites;Clinical Trials as Topic;Enzyme Inhibitors;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Leukemia;Leukemia, Myeloid;Mice;Mutation;Piperazines;Protein Structure, Tertiary;Protein-Tyrosine Kinases;Proto-Oncogene Proteins;Pyrimidines;Receptor Protein-Tyrosine Kinases;Signal Transduction;fms-Like Tyrosine Kinase 3;src Homology Domains",
        "Doc_meshqualifiers":"pharmacology;metabolism;genetics;drug therapy;genetics;pharmacology;antagonists & inhibitors;genetics;metabolism;pharmacology;metabolism",
        "_version_":1605876258753740800},
      {
        "Doc_abstract":"The Philadelphia chromosome defines chronic myeloid leukemia, and is mostly based on a translocation t(9;22) with a typical BCR-ABL rearrangement which also occurs in so called atypical translocations. The transformation of chronic myeloid leukemia is associated with clonal evolution in 80% of cases. The appearance of an isochromosome 17q unequivocally heralds the onset of a myeloid type of blast crisis. Treatment of Ph-positive CML has still to be considered palliative except for allogeneic bone marrow transplantation. The Philadelphia chromosome is also found in about 20% of patients with acute lymphoblastic leukemia and in about 2% of patients with nonlymphoblastic leukemia. It is associated with a poor prognosis. Molecular and cytogenetic findings help differentiating between de novo acute leukemia and blast crisis of chronic myeloid leukemia.",
        "Doc_title":"[Cytogenetic and clinical features of Philadelphia chromosome positive leukemias].",
        "Journal":"Verhandlungen der Deutschen Gesellschaft fur Pathologie",
        "Do_id":"1708614",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Blast Crisis;Humans;Karyotyping;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Philadelphia Chromosome;Translocation, Genetic",
        "Doc_meshqualifiers":"genetics;pathology;classification;genetics;pathology",
        "_version_":1605783203071655936},
      {
        "Doc_abstract":"A minority of chronic myeloid leukemia (CML) cases have breakpoint in the minor cluster region (m-bcr) of the BCR-ABL fusion gene. We report a patient with Ph-positive acute lymphoblastic leukemia and m-bcr breakpoint at diagnosis. The patient was treated with chemotherapy followed by an autologous peripheral blood stem cell transplantation, achieving a clinical and hematological complete remission but with persistence of the Philadelphia chromosome. One year later, she developed leukocytosis with a blood picture consistent with CML. She was treated with hydroxyurea and interferon alpha with no response. This is the second case of m-bcr CML reported presenting with features of lymphoid blast crisis or acute lymphoblastic leukemia.",
        "Doc_title":"p190 BCR-ABL rearrangement in chronic myeloid leukemia and acute lymphoblastic leukemia.",
        "Journal":"Cancer genetics and cytogenetics",
        "Do_id":"10459357",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adult;Bone Marrow;Disease Progression;Female;Fusion Proteins, bcr-abl;Humans;Karyotyping;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Reverse Transcriptase Polymerase Chain Reaction",
        "Doc_meshqualifiers":"pathology;genetics;genetics;genetics",
        "_version_":1605756128500645888},
      {
        "Doc_abstract":"Bcr-Abl proteins are effective inducers of the leukemic phenotype in chronic myeloid leukemia (CML) and distinct variants of acute lymphoblastic leukemia (ALL). Targeting bcr-abl by treatment with the selective tyrosine kinase inhibitor imatinib has proved to be highly efficient for controlling leukemic growth. However, it is unclear whether imatinib is sufficient to eradicate the disease because of primary or secondary resistance of leukemic cells. Therefore, targeting Bcr-Abl with an alternative approach is of great interest. We demonstrate that RNA interference (RNAi) with a breakpoint-specific short-interfering RNA (siRNA) is capable of decreasing Bcr-Abl protein expression and of antagonizing Bcr-Abl-induced biochemical activities. RNAi selectively inhibited Bcr-Abl-dependent cell growth. Furthermore, bcr-abl-homologous siRNA increased sensitivity to imatinib in Bcr-Abl-overexpressing cells and in a cell line expressing the imatinib-resistant Bcr-Abl kinase domain mutation His396Pro, thereby antagonizing 2 of the major mechanisms of resistance to imatinib.",
        "Doc_title":"Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571).",
        "Journal":"Blood",
        "Do_id":"12750174",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Pyrimidines;RNA, Small Interfering;Imatinib Mesylate;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Antineoplastic Agents;Benzamides;Cell Division;Cell Survival;Drug Resistance, Neoplasm;Fusion Proteins, bcr-abl;Gene Expression Regulation, Leukemic;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Piperazines;Pyrimidines;RNA, Small Interfering;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"pharmacology;drug effects;drug effects;genetics;drug effects;drug therapy;genetics;pharmacology;pharmacology;pharmacology",
        "_version_":1605923880165179392},
      {
        "Doc_abstract":"It is generally believed that shutting down the kinase activity of BCR-ABL by imatinib will completely inhibit its functions, leading to inactivation of its downstream signaling pathways and cure of the disease. Imatinib is highly effective at treating human Philadelphia chromosome-positive (Ph(+)) chronic myeloid leukemia (CML) in chronic phase but not Ph(+) B cell acute lymphoblastic leukemia (B-ALL) and CML blast crisis. We find that SRC kinases activated by BCR-ABL remain fully active in imatinib-treated mouse leukemic cells, suggesting that imatinib does not inactivate all BCR-ABL-activated signaling pathways. This SRC pathway is essential for leukemic cells to survive imatinib treatment and for CML transition to lymphoid blast crisis. Inhibition of both SRC and BCR-ABL kinase activities by dasatinib affords complete B-ALL remission. However, curing B-ALL and CML mice requires killing leukemic stem cells insensitive to both imatinib and dasatinib. Besides BCR-ABL and SRC kinases, stem cell pathways must be targeted for curative therapy of Ph(+) leukemia.",
        "Doc_title":"Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.",
        "Journal":"Proceedings of the National Academy of Sciences of the United States of America",
        "Do_id":"17077147",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Thiazoles;Imatinib Mesylate;Fusion Proteins, bcr-abl;src-Family Kinases;Dasatinib",
        "Doc_meshdescriptors":"Animals;Antineoplastic Agents;B-Lymphocytes;Benzamides;Blast Crisis;Burkitt Lymphoma;Cell Line, Tumor;Cell Transformation, Neoplastic;Dasatinib;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mice;Mice, Inbred BALB C;Mice, Inbred C57BL;Mice, Knockout;Neoplastic Stem Cells;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Thiazoles;src-Family Kinases",
        "Doc_meshqualifiers":"therapeutic use;enzymology;enzymology;drug therapy;enzymology;metabolism;antagonists & inhibitors;drug therapy;enzymology;genetics;pathology;drug effects;enzymology;therapeutic use;therapeutic use;therapeutic use;therapeutic use;deficiency;genetics;metabolism",
        "_version_":1605742046105042944},
      {
        "Doc_abstract":"The BCR/ABL oncogene product is one of the genes associated with and possibly responsible for human leukemias. Chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia are associated with p210BCR/ABL and p185BCR/ABL, respectively. Abelson murine leukemia virus encodes the related oncogene product, v-Abl, and also causes pre-B-cell leukemia. In this article, recent advances in understanding the function of these oncogenes as well as the function of normal counterparts, c-Abl and Bcr, are discussed. Intracellular signaling events initiated from these oncogene products are emphasized. The possibilities are also discussed that inhibition of apoptosis and altered adhesive properties to the bone marrow microenvironment by BCR/ABL might contribute to disease initiation.",
        "Doc_title":"The function of BCR/ABL and related proto-oncogenes.",
        "Journal":"Current opinion in hematology",
        "Do_id":"9050373",
        "Doc_ChemicalList":"Oncogene Proteins;Proto-Oncogene Proteins;Protein-Tyrosine Kinases;BCR protein, human;Proto-Oncogene Proteins c-bcr",
        "Doc_meshdescriptors":"Animals;Gene Expression Regulation, Neoplastic;Genes, abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Oncogene Proteins;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Protein-Tyrosine Kinases;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-bcr",
        "Doc_meshqualifiers":"genetics;genetics;genetics",
        "_version_":1605812160578977792},
      {
        "Doc_abstract":"We describe a patient with a t(7;11)(p15;p15) acute myeloid leukemia who was subsequently found to harbor the Philadelphia (Ph) translocation, in addition to the t(7;11), at the second relapse. A BCR/ABL transcript was detected at the second relapse by reverse transcription-polymerase chain reaction assay; the leukemic cells had a BCR/ABL fusion gene involving the minor breakpoint cluster region (minor-BCR; situated in intron 1 of the BCR gene). Although the Ph translocation is commonly detected in de novo acute leukemia and chronic myeloid leukemia as the primary leukemia-specific chromosomal translocation, our case suggests that this cytogenetic change might occur as an additional chromosomal change in neoplastic cells. Moreover, minor-BCR/ABL rearrangements may also occur as a late appearance of Ph translocation.",
        "Doc_title":"Late appearance of a Philadelphia translocation with minor-BCR/ABL transcript in a t(7;11)(p15;p15) acute myeloid leukemia.",
        "Journal":"Leukemia",
        "Do_id":"7723398",
        "Doc_ChemicalList":"DNA Primers;RNA, Neoplasm;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Base Sequence;Chromosome Aberrations;Chromosome Disorders;Chromosomes, Human, Pair 11;Chromosomes, Human, Pair 7;DNA Primers;Female;Fusion Proteins, bcr-abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Leukemia, Myeloid, Acute;Molecular Sequence Data;RNA, Neoplasm;Time Factors",
        "Doc_meshqualifiers":"pathology;genetics;genetics;pathology;genetics;pathology;genetics",
        "_version_":1605818784588759041},
      {
        "Doc_abstract":"We herein present a case of concurrent chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL). Two different clones, a Philadelphia (Ph) clone and a CLL clone with a 13q deletion, were identified using fluorescent in situ hybridization. Dasatinib was administered to inhibit Bcr-Abl and Lyn kinase. The patient exhibited a molecular response for CML and a partial response for CLL. To our knowledge, this is the first report to describe the occurrence of a gradual increase in the Bcr-Abl transcript level prior to the diagnosis of Ph-positive CML in an individual with CLL who was successfully treated with dasatinib as the first-line therapy.",
        "Doc_title":"Dasatinib-responsive chronic lymphocytic leukemia in a patient treated for coexisting chronic myeloid leukemia.",
        "Journal":"Internal medicine (Tokyo, Japan)",
        "Do_id":"24240798",
        "Doc_ChemicalList":"Antineoplastic Agents;Protein Kinase Inhibitors;Pyrimidines;Thiazoles;Dasatinib",
        "Doc_meshdescriptors":"Aged, 80 and over;Antineoplastic Agents;Chromosome Deletion;Chromosome Disorders;Chromosomes, Human, Pair 13;Dasatinib;Female;Genes, abl;Humans;Leukemia, Lymphocytic, Chronic, B-Cell;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Neoplasms, Multiple Primary;Protein Kinase Inhibitors;Pyrimidines;Thiazoles",
        "Doc_meshqualifiers":"therapeutic use;genetics;genetics;drug therapy;genetics;drug therapy;genetics;drug therapy;genetics;therapeutic use;therapeutic use;therapeutic use",
        "_version_":1605789890753069056},
      {
        "Doc_abstract":"Ponatinib is a novel, next-generation, small-molecule tyrosine kinase inhibitor with potent activity against the BCR-ABL fusion oncogene as well as all other ABL kinase domain mutations that confer resistance to earlier generation tyrosine kinase inhibitors. Due to its unique structure, it is the only tyrosine kinase inhibitor with the capability to counter the highly resistant T315I or gate-keeper mutation in leukemic cells that express the Philadelphia chromosome. This review will focus on the preclinical pharmacology, pharmacokinetics and clinical utility of ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive adult acute lymphoblastic leukemia.",
        "Doc_title":"Ponatinib for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.",
        "Journal":"Drugs of today (Barcelona, Spain : 1998)",
        "Do_id":"23616953",
        "Doc_ChemicalList":"Antineoplastic Agents;Imidazoles;Protein Kinase Inhibitors;Pyridazines;ponatinib;Protein-Tyrosine Kinases",
        "Doc_meshdescriptors":"Animals;Antineoplastic Agents;Drug Interactions;Drug Resistance, Neoplasm;Humans;Imidazoles;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Philadelphia Chromosome;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Protein Kinase Inhibitors;Protein-Tyrosine Kinases;Pyridazines",
        "Doc_meshqualifiers":"adverse effects;pharmacology;therapeutic use;adverse effects;pharmacology;therapeutic use;drug therapy;pathology;drug therapy;pathology;administration & dosage;pharmacology;therapeutic use;antagonists & inhibitors;adverse effects;pharmacology;therapeutic use",
        "_version_":1605764785280909312},
      {
        "Doc_abstract":"Recent advances in the treatment of lymphoid leukemias have incorporated molecular targeted drugs (CD20-targeting rituximab and BCR-ABL tyrosine kinase inhibitors) into the traditional chemotherapeutic agents. This article reviews novel molecular targeted therapies for patients with lymphoid leukemias including acute lymphoblastic leukemia, chronic lymphocytic leukemia, hairly cell leukemia and HTLV-I-related adult T-cell leukemia. Investigational agents that will be discussed in this review include inotuzumab, blinatumomab, alemtuzumab, ofatumumab, ibrutinib, idelalisib, bafetinib, lenalidomide, ABT-199 and mogamulizumab. Novel approaches warrant continued research to improve outcomes for patients with lymphoid leukemias.",
        "Doc_title":"[Molecular targeted therapy in lymphoid leukemias].",
        "Journal":"Nihon rinsho. Japanese journal of clinical medicine",
        "Do_id":"25016810",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adult;Humans;Leukemia, Lymphocytic, Chronic, B-Cell;Leukemia, Lymphoid;Leukemia-Lymphoma, Adult T-Cell;Molecular Targeted Therapy;Precursor Cell Lymphoblastic Leukemia-Lymphoma",
        "Doc_meshqualifiers":"drug therapy;drug therapy;drug therapy;methods",
        "_version_":1605792077158809600},
      {
        "Doc_abstract":"The Bcr-Abl inhibitor imatinib mesylate induces complete hematologic and cytogenetic remissions in most newly diagnosed chronic myeloid leukemia (CML) patients, but relatively few of them achieve molecular remission. In addition, imatinib is much less effective in advanced phase-CML as well as in Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL), mainly due to the development of drug resistance. The challenge for the future is to improve current clinical results with kinase inhibitors in CML, developing strategies that can eradicate residual disease and overcome or prevent resistance. 'Dual' Src and Abl kinase inhibitors are an attractive class of compounds, since (a) these molecules are able to bind Bcr-Abl with less stringent conformational requirements with respect to imatinib, therefore allowing for efficient inhibition of several, resistance-associated mutant forms of Bcr-Abl; (b) Src kinases have been shown to be involved in Bcr-Abl-mediated leukemogenesis as well as upregulated in some patients resistant to imatinib. Here, we review the development, the mode of action and the preclinical or early clinical evaluation of several novel dual Src and Abl kinase inhibitors.",
        "Doc_title":"Dual tyrosine kinase inhibitors in chronic myeloid leukemia.",
        "Journal":"Leukemia",
        "Do_id":"16179913",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Enzyme Inhibitors;Piperazines;Pyrimidines;Imatinib Mesylate;Protein-Tyrosine Kinases;src-Family Kinases",
        "Doc_meshdescriptors":"Antineoplastic Agents;Benzamides;Drug Design;Drug Resistance, Neoplasm;Enzyme Inhibitors;Genes, abl;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Piperazines;Protein-Tyrosine Kinases;Pyrimidines;src-Family Kinases",
        "Doc_meshqualifiers":"pharmacology;pharmacology;genetics;physiology;drug therapy;enzymology;pharmacology;antagonists & inhibitors;pharmacology;antagonists & inhibitors",
        "_version_":1605832410148110336},
      {
        "Doc_abstract":"The BCR-ABL kinase inhibitor imatinib has shown significant efficacy in chronic myeloid leukemia (CML) and is the standard front-line therapy for patients in chronic phase. However, a substantial number of patients are either primarily refractory or acquire resistance to imatinib. While a number of mechanisms are known to confer resistance to imatinib, increasing evidence has demonstrated a role for BCR-ABL-independent pathways. The Src-family kinases (SFKs) are one such pathway and have been implicated in imatinib resistance. Additionally, these kinases are key to the progression of CML and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The dual SFK/BCR-ABL inhibitor dasatinib is now clinically available and has markedly greater potency compared with imatinib against native BCR-ABL and the majority of imatinib-resistant BCR-ABL mutants. Therefore, this agent, as well as other dual SFK/BCR-ABL inhibitors under development, could provide added therapeutic advantages by overcoming both BCR-ABL-dependent (i.e. BCR-ABL mutations) and -independent forms of imatinib resistance and delaying transition to advanced phase disease. In this review, we discuss the preclinical and clinical evidence demonstrating the involvement of SFKs in imatinib resistance and the progression of CML and Ph+ ALL, as well as the potential role of dual SFK/BCR-ABL inhibition in the management of these diseases.",
        "Doc_title":"Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia.",
        "Journal":"Leukemia & lymphoma",
        "Do_id":"18203007",
        "Doc_ChemicalList":"Benzamides;Piperazines;Pyrimidines;Imatinib Mesylate;Fusion Proteins, bcr-abl;src-Family Kinases",
        "Doc_meshdescriptors":"Benzamides;Drug Resistance, Neoplasm;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Piperazines;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Pyrimidines;Signal Transduction;src-Family Kinases",
        "Doc_meshqualifiers":"antagonists & inhibitors;drug therapy;etiology;therapeutic use;drug therapy;etiology;therapeutic use;physiology",
        "_version_":1605876651895291904},
      {
        "Doc_abstract":"Optimal function of multiple intracellular signaling pathways is essential for normal regulation of cellular transcription, translation, growth, proliferation, and survival. Dysregulation or aberrant activation of such cascades can lead to inappropriate cell survival and abnormal cell proliferation in leukemia. Successful treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors targeting the BCR-ABL fusion gene is a prime example of effectively inhibiting intracellular signaling cascades. However, even in these patients resistance can develop via emergence of mutations or feedback activation of other pathways that cause refractory disease. Constitutive activation of the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR) signaling pathway has been observed in different types of leukemia, including CML, acute myeloid leukemia, and acute lymphoblastic leukemia. Abnormal mTOR activity may contribute to chemotherapy resistance, while it may also be effectively targeted via molecular means and/or development of specific pharmacological inhibitors. This review discusses the role of PI3K/Akt/mTOR dysre-gulation in leukemia and summarizes the emergence of preliminary data for the development of novel therapeutic approaches. J. Cell. Biochem. 117: 1745-1752, 2016.  2016 Wiley Periodicals, Inc. ",
        "Doc_title":"Targeting the mTOR Pathway in Leukemia.",
        "Journal":"Journal of cellular biochemistry",
        "Do_id":"27018341",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605851582509875200},
      {
        "Doc_abstract":"Despite the clinical efficacy achieved with frontline therapies for BCR-ABL-positive disease, such as imatinib and second-generation ABL inhibitors like nilotinib or dasatinib that were originally designed to override insensitivity to imatinib, drug resistance still remains a challenge, especially for patients with advanced-stage chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia. The discovery of BCR-ABL point mutations has been a great asset to furthering our understanding of a major cause of drug resistance, as has discovery of multidrug resistance proteins, dysregulation of signaling molecules downstream of BCR-ABL, and insights into the underlying causes of stromal-mediated chemoresistance. Such elucidation of mechanisms of resistance associated with leukemic cell survival is essential for the optimization of current therapies and enhancement of patient survival via delaying or preventing disease recurrence. Here, we present an overview of the use of nilotinib in combination with other agents against BCR-ABL-positive leukemia, as well as solid tumors, for the purpose of increasing clinical efficacy and overriding drug resistance. ",
        "Doc_title":"Combination therapy with nilotinib for drug-sensitive and drug-resistant BCR-ABL-positive leukemia and other malignancies.",
        "Journal":"Archives of toxicology",
        "Do_id":"25331939",
        "Doc_ChemicalList":"4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide;Pyrimidines;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Antineoplastic Combined Chemotherapy Protocols;Drug Resistance, Neoplasm;Fusion Proteins, bcr-abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Point Mutation;Pyrimidines;Randomized Controlled Trials as Topic;Signal Transduction",
        "Doc_meshqualifiers":"administration & dosage;adverse effects;therapeutic use;drug effects;genetics;antagonists & inhibitors;genetics;drug therapy;genetics;pathology;administration & dosage;adverse effects;therapeutic use",
        "_version_":1605796516953325568},
      {
        "Doc_abstract":"The simultaneous occurrence of Philadelphia positive chronic myeloid leukemia (Ph+ CML) and B-cell chronic lymphocytic leukemia (B-CLL) is a rare event which raises the possibility that the two malignant clones derive from a common, or distinct, malignant stem cells. In this study, we used combined CD19-based cell-sorting and fluorescence in situ hybridisation (FISH) to investigate whether or not the BCR-ABL fusion gene was present in the malignant B-cells of a patient who presented a Ph+ CML/B-CLL association. The CD19+ cells lacked the BCR-ABL rearrangement whereas all CD19-cells exhibited the fusion gene. This result demonstrates that B-cell transformation occurred in a Ph-B-cell subset.",
        "Doc_title":"Chronic myeloid leukemia associated with B-cell chronic lymphocytic leukemia: evidence of two separate clones as shown by combined cell-sorting and fluorescence in situ hybridisation.",
        "Journal":"Leukemia & lymphoma",
        "Do_id":"12802927",
        "Doc_ChemicalList":"Antigens, CD19;DNA, Neoplasm;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Aged;Antigens, CD19;B-Lymphocytes;Cell Transformation, Neoplastic;Clone Cells;DNA, Neoplasm;Flow Cytometry;Fusion Proteins, bcr-abl;Humans;In Situ Hybridization, Fluorescence;Leukemia, Lymphocytic, Chronic, B-Cell;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Neoplasms, Multiple Primary;Neoplastic Cells, Circulating",
        "Doc_meshqualifiers":"analysis;pathology;pathology;analysis;analysis;genetics;diagnosis;etiology;pathology;diagnosis;etiology;pathology;diagnosis;etiology;pathology",
        "_version_":1605846295977656320},
      {
        "Doc_abstract":"Dasatinib is a highly potent Bcr-Abl inhibitor that is approved for the treatment of imatinib-resistant or -intolerant chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia. Across a series of phase 2 and 3 trials, dasatinib was associated with durable treatment responses in all phases of the disease and was well tolerated. For this article, the authors reviewed available information on specific side effects associated with the use of dasatinib. On the basis of more than 2 years' experience of dasatinib treatment during clinical trials, they provide practical recommendations for side-effect management.",
        "Doc_title":"Dasatinib treatment for Philadelphia chromosome-positive leukemias: practical considerations.",
        "Journal":"Cancer",
        "Do_id":"19195046",
        "Doc_ChemicalList":"Pyrimidines;Thiazoles;Dasatinib",
        "Doc_meshdescriptors":"Clinical Trials as Topic;Dasatinib;Drug Interactions;Gastrointestinal Tract;Heart Diseases;Hematologic Diseases;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Pleural Effusion;Pyrimidines;Thiazoles",
        "Doc_meshqualifiers":"drug effects;chemically induced;chemically induced;drug therapy;chemically induced;adverse effects;contraindications;adverse effects;contraindications",
        "_version_":1605741986101329921},
      {
        "Doc_abstract":"Omacetaxine mepesuccinate (formerly homoharringtonine) is a molecule with a mechanism of action that is different from tyrosine kinase inhibitors, and its activity in chronic myeloid leukemia (CML) seems to be independent of the BCR-ABL mutation status. Using BCR-ABL-expressing myelogenous and lymphoid cell lines and mouse models of CML and B-cell acute lymphoblastic leukemia (B-ALL) induced by wild-type BCR-ABL or T315I mutant-BCR-ABL, we evaluated the inhibitory effects of omacetaxine on CML and B-ALL. We showed that more than 90% of the leukemic stem cells were killed after treatment with omacetaxine in vitro. In contrast, less than 9 or 25% of the leukemic stem cells were killed after treating with imatinib or dasatinib, respectively. After 4 days of treatment of CML mice with omacetaxine, Gr-1(+)myeloid leukemia cells decreased in the peripheral blood of the treated CML mice. In the omacetaxine-treated B-ALL mice, only 0.8% of the B220(+)leukemia cells were found in peripheral blood, compared with 34% of the B220(+)leukemia cells in the placebo group. Treatment with omacetaxine decreased the number of leukemia stem cells and prolonged the survival of mice with BCR-ABL-induced CML or B-ALL.",
        "Doc_title":"Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice.",
        "Journal":"Leukemia",
        "Do_id":"19322212",
        "Doc_ChemicalList":"Antineoplastic Agents, Phytogenic;HSP90 Heat-Shock Proteins;Harringtonines;Recombinant Fusion Proteins;homoharringtonine;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Animals;Antineoplastic Agents, Phytogenic;Cell Line, Tumor;Fusion Proteins, bcr-abl;Gene Expression Regulation, Leukemic;HSP90 Heat-Shock Proteins;Harringtonines;Humans;K562 Cells;Leukemia, B-Cell;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mice;Mice, Inbred BALB C;Mice, Inbred C57BL;Neoplastic Stem Cells;Precursor B-Cell Lymphoblastic Leukemia-Lymphoma;Radiation Chimera;Recombinant Fusion Proteins;Transduction, Genetic",
        "Doc_meshqualifiers":"pharmacology;therapeutic use;drug effects;genetics;physiology;drug effects;biosynthesis;genetics;pharmacology;therapeutic use;drug effects;blood;drug therapy;pathology;genetics;pathology;drug effects;pathology;physiology",
        "_version_":1605751991919706112},
      {
        "Doc_abstract":"The bcr-abl translocation characteristic of chronic myeloid leukemia (CML) was detected by the polymerase chain reaction (PCR) modified to use mRNA as the starting material. Amplification of a sequence spanning the bcr-abl junction was obtained by using peripheral blood cells from all of 20 patients with classic CML, one patient with acute lymphoblastic leukemia probably secondary to CML, and two cell lines derived from patients with CML. The presence of bcr exon 3 in the mRNA was determined from the size of the amplified sequence; it was present in 14 and absent in seven patients. One leukemic cell per 1,000 nonleukemic cells could be readily detected, thus indicating the great sensitivity of the method. This technique is of routine value in CML both for diagnosis and for following the course of treatment.",
        "Doc_title":"Detection of the molecular abnormality in chronic myeloid leukemia by use of the polymerase chain reaction.",
        "Journal":"Blood",
        "Do_id":"3143430",
        "Doc_ChemicalList":"Neoplasm Proteins;RNA, Messenger;RNA, Neoplasm;Fusion Proteins, bcr-abl;Taq Polymerase;DNA-Directed DNA Polymerase",
        "Doc_meshdescriptors":"Blast Crisis;DNA-Directed DNA Polymerase;Fusion Proteins, bcr-abl;Gene Amplification;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Molecular Probe Techniques;Neoplasm Proteins;Philadelphia Chromosome;Precursor Cell Lymphoblastic Leukemia-Lymphoma;RNA, Messenger;RNA, Neoplasm;Taq Polymerase",
        "Doc_meshqualifiers":"genetics;diagnosis;genetics;genetics;genetics;genetics;genetics",
        "_version_":1605808612546969600},
      {
        "Doc_abstract":"Around 20% of patients with acute lymphoblastic leukemia are Philadelphia chromosome positive (Ph-positive acute lymphoblastic leukemia) and express the Bcr/Abl tyrosine kinase. Treatment with the tyrosine kinase inhibitor Imatinib is currently standard for chronic myelogenous leukemia, which is also caused by Bcr/Abl. However, Imatinib has shown limited efficacy for treating Ph-positive acute lymphoblastic leukemia. In our study, we have investigated the effect of Imatinib therapy on murine P190 Bcr/Abl lymphoblastic leukemia cells. Three of four cultures were very sensitive to treatment with 5 mumol/L Imatinib. Significant cell death also initially occurred when the same cultures were treated in the presence of stromal support. However, after 6 days, remaining cells started to proliferate vigorously. The Bcr/Abl tyrosine kinase present in the cells that were now able to multiply in the presence of 5 mumol/L Imatinib was still inhibited by the drug. In concordance with this, the Abl ATP-binding pocket domain of Bcr/Abl in the resistant cells did not contain point mutations which would make the protein Imatinib resistant. The effect of stroma in selecting Imatinib-resistant lymphoblasts did not require direct cell-cell contact. SDF-1alpha could substitute for the presence of stromal cells. Our results show that stroma selects Imatinib-resistant Bcr/Abl P190 lymphoblasts that are less dependent on Bcr/Abl tyrosine kinase activity. Therefore, therapy for Ph-positive acute lymphoblastic leukemia, aimed at interfering with the protective effect of stroma in combination with Imatinib, could be of benefit for the eradication of the leukemic cells.",
        "Doc_title":"Resistance to imatinib of bcr/abl p190 lymphoblastic leukemia cells.",
        "Journal":"Cancer research",
        "Do_id":"16707466",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;CXCL12 protein, human;Chemokine CXCL12;Chemokines, CXC;Cxcl12 protein, mouse;Piperazines;Pyrimidines;Imatinib Mesylate;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Animals;Antineoplastic Agents;Antineoplastic Combined Chemotherapy Protocols;Benzamides;Cell Line, Tumor;Chemokine CXCL12;Chemokines, CXC;Drug Resistance, Neoplasm;Female;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Leukemia, Lymphoid;Mice;Mice, Nude;Piperazines;Point Mutation;Protein Structure, Tertiary;Pyrimidines;Stromal Cells",
        "Doc_meshqualifiers":"pharmacology;pharmacology;administration & dosage;pharmacology;biosynthesis;genetics;drug therapy;genetics;metabolism;pathology;administration & dosage;pharmacology;administration & dosage;pharmacology;pathology",
        "_version_":1605840089498255360},
      {
        "Doc_abstract":"The BCR/ABL tyrosine kinase inhibitor imatinib mesylate produces a high rate of cytogenetic responses in patients with Philadelphia (Ph)-positive chronic myeloid leukemia (CML), but secondary clonal chromosome abnormalities may develop in Ph-negative cells, and acute myeloid leukemia (AML) has been reported in patients with secondary chromosome abnormalities. We report a patient who developed AML during imatinib treatment of Ph-positive CML despite a cytogenetic response and absence of secondary chromosome abnormalities. Thus, development of AML as a rare event in CML patients with cytogenetic responses to imatinib therapy does not depend on the development of secondary cytogenetic abnormalities.",
        "Doc_title":"Acute myeloid leukemia developing during imatinib mesylate therapy for chronic myeloid leukemia in the absence of new cytogenetic abnormalities.",
        "Journal":"Leukemia research",
        "Do_id":"17391756",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;DNA Primers;DNA, Complementary;Piperazines;Pyrimidines;Imatinib Mesylate",
        "Doc_meshdescriptors":"Adult;Antineoplastic Agents;Base Sequence;Benzamides;DNA Primers;DNA, Complementary;Female;Humans;Imatinib Mesylate;In Situ Hybridization, Fluorescence;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Leukemia, Myeloid, Acute;Piperazines;Pyrimidines",
        "Doc_meshqualifiers":"adverse effects;therapeutic use;complications;drug therapy;genetics;chemically induced;complications;genetics;adverse effects;therapeutic use;adverse effects;therapeutic use",
        "_version_":1605821303018749952},
      {
        "Doc_abstract":"The bcr-abl rearrangement has rarely been reported in T-lineage acute lymphoblastic leukemia and the clinical significance of this translocation is currently unknown. We screened 28 children with T-lineage acute lymphoblastic leukemia at diagnosis by reverse transcription polymerase chain reaction for major and minor break point regions of bcr-abl fusion gene. Four out of 28 patients (14.2%) were bcr-abl positive for the minor breakpoint transcript. One of these patients was refractory to therapy, whereas the other 3 relapsed on therapy.",
        "Doc_title":"Detection and clinical relevance of BCR-ABL fusion gene in childhood T-lineage acute lymphoblastic leukemia: a report on 4 cases.",
        "Journal":"Journal of pediatric hematology/oncology",
        "Do_id":"19816207",
        "Doc_ChemicalList":"RNA, Messenger;RNA, Neoplasm",
        "Doc_meshdescriptors":"Child;Chromosomes, Human, Pair 22;Chromosomes, Human, Pair 9;Exons;Female;Genes, abl;Humans;Male;Precursor T-Cell Lymphoblastic Leukemia-Lymphoma;Prognosis;RNA, Messenger;RNA, Neoplasm;Risk Factors;Translocation, Genetic",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;diagnosis;genetics;genetics;genetics",
        "_version_":1605800203308236800},
      {
        "Doc_abstract":"The successful introduction of the tyrosine kinase inhibitors has initiated a new era in the management of chronic myeloid leukemia.;Imatinib therapy has significantly improved prognosis of chronic myeloid leukemia. A minority of patients with chronic-phase disease (4% annually) and considerably more in advanced stages develop resistance. This is attributed, in 40-50% of cases, to the development of BCR-ABL (breakpoint cluster region/Abelson oncogene) tyrosine kinase domain mutations that impair imatinib binding. This has led to the development of more potent novel tyrosine kinase inhibitors that can overcome both BCR-ABL-dependent and BCR-ABL-independent mechanisms of resistance. Preliminary results of phase I and II trials with dasatinib and nilotinib have provided promising data that may reduce disease progression and potentially prevent acquired resistance to the tyrosine kinase inhibitors.;Novel tyrosine kinase inhibitors with more potent and selective Bcr-Abl inhibition and with multitargeted inhibition of Bcr-Abl and Src family kinases are promising and may further improve prognosis in chronic myeloid leukemia.",
        "Doc_title":"Novel tyrosine kinase inhibitors in chronic myelogenous leukemia.",
        "Journal":"Current opinion in oncology",
        "Do_id":"16988578",
        "Doc_ChemicalList":"Protein Kinase Inhibitors;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Clinical Trials as Topic;Fusion Proteins, bcr-abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Protein Kinase Inhibitors;Protein-Tyrosine Kinases",
        "Doc_meshqualifiers":"drug effects;genetics;drug therapy;genetics;pathology;therapeutic use;antagonists & inhibitors",
        "_version_":1605905160547074048},
      {
        "Doc_abstract":"T315I(+) Philadelphia chromosome-positive leukemias are inherently resistant to all licensed tyrosine kinase inhibitors, and therapeutic options remain limited. We report the outcome of allogeneic stem cell transplantation in 64 patients with documented BCR-ABL(T315I) mutations. Median follow-up was 52 months from mutation detection and 26 months from transplantation. At transplantation, 51.5% of patients with chronic myeloid leukemia were in the chronic phase and 4.5% were in advanced phases. Median overall survival after transplantation was 10.3 months (range 5.7 months to not reached [ie, still alive]) for those with chronic myeloid leukemia in the blast phase and 7.4 months (range 1.4 months to not reached [ie, still alive]) for those with Philadelphia chromosome-positive acute lymphoblastic leukemia but has not yet been reached for those in the chronic and accelerated phases of chronic myeloid leukemia. The occurrence of chronic GVHD had a positive impact on overall survival (P = .047). Transplant-related mortality rates were low. Multivariate analysis identified only blast phase at transplantation (hazard ratio 3.68, P = .0011) and unrelated stem cell donor (hazard ratio 2.98, P = .011) as unfavorable factors. We conclude that allogeneic stem cell transplantation represents a valuable therapeutic tool for eligible patients with BCR-ABL(T315I) mutation, a tool that may or may not be replaced by third-generation tyrosine kinase inhibitors.",
        "Doc_title":"Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias.",
        "Journal":"Blood",
        "Do_id":"21926354",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Drug Resistance, Neoplasm;Female;Follow-Up Studies;Fusion Proteins, bcr-abl;Graft vs Host Disease;Hematopoietic Stem Cell Transplantation;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Prognosis;Registries;Transplantation, Homologous;Young Adult",
        "Doc_meshqualifiers":"genetics;genetics;mortality;mortality;genetics;mortality;therapy;statistics & numerical data",
        "_version_":1605852628266254336},
      {
        "Doc_abstract":"In vitro studies show that BCR/ABL-expressing hematopoietic cells exhibit altered adhesion properties. No in vivo studies show whether the altered adhesion properties affect BCR/ABL leukemogenesis. Using mice with homozygous inactivation of genes encoding the 2 adhesion molecules P-selectin and intercellular adhesion molecule-1 (ICAM1), we show that the mutant mice develop BCR/ABL-induced chronic myeloid leukemia (CML)-like leukemia at a significantly faster rate than do wild-type (WT) mice. Lack of P-selectin and ICAM1 did not have a significant effect on the development of B-cell acute lymphoblastic leukemia (BALL) induced by BCR/ABL. Using mice deficient for P-selectin or ICAM1 alone, we show that P-selectin plays a major role in the acceleration of CML-like leukemia. Lack of P-selectin resulted in early release of BCR/ABL-expressing myeloid progenitors from bone marrow, appearing to alter the biologic properties of leukemic cells rather than their growth rate by increasing their homing to the lungs, causing fatal lung hemorrhages. These results indicate that adhesion of BCR/ABL-expressing myeloid progenitors to marrow stroma through P-selectin and ICAM1 play an inhibitory role in the development of CML-like disease, suggesting that improvement of adhesion between BCR/ABL-expressing myeloid progenitor cells and bone marrow stroma may be of therapeutic value for human CML.",
        "Doc_title":"Lack of the adhesion molecules P-selectin and intercellular adhesion molecule-1 accelerate the development of BCR/ABL-induced chronic myeloid leukemia-like myeloproliferative disease in mice.",
        "Journal":"Blood",
        "Do_id":"15213099",
        "Doc_ChemicalList":"DNA, Complementary;Luminescent Proteins;P-Selectin;Intercellular Adhesion Molecule-1;Green Fluorescent Proteins;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Animals;Bone Marrow Cells;Cell Adhesion;Cell Separation;DNA, Complementary;Flow Cytometry;Fusion Proteins, bcr-abl;Genetic Vectors;Green Fluorescent Proteins;Homozygote;Intercellular Adhesion Molecule-1;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Luminescent Proteins;Lung;Mice;Mice, Inbred C57BL;Mice, Mutant Strains;Mutation;Myeloproliferative Disorders;P-Selectin;Retroviridae;Stem Cells;Time Factors",
        "Doc_meshqualifiers":"cytology;metabolism;metabolism;metabolism;physiology;metabolism;metabolism;pathology;genetics;physiology;genetics;metabolism",
        "_version_":1605764083763642368},
      {
        "Doc_abstract":"Chronic myeloid leukemia is effectively treated with imatinib, but reactivation of BCR-ABL frequently occurs through acquisition of kinase domain mutations. The additional approved ABL tyrosine kinase inhibitors (TKIs) nilotinib and dasatinib, along with investigational TKIs such as ponatinib (AP24534) and DCC-2036, support the possibility that mutation-mediated resistance in chronic myeloid leukemia can be fully controlled; however, the molecular events underlying resistance in patients lacking BCR-ABL point mutations are largely unknown. We previously reported on an insertion/truncation mutant, BCR-ABL(35INS), in which structural integrity of the kinase domain is compromised and all ABL sequence beyond the kinase domain is eliminated. Although we speculated that BCR-ABL(35INS) is kinase-inactive, recent reports propose this mutant contributes to ABL TKI resistance. We present cell-based and biochemical evidence establishing that BCR-ABL(35INS) is kinase-inactive and does not contribute to TKI resistance, and we find that detection of BCR-ABL(35INS) does not consistently track with or explain resistance in clinical samples from chronic myeloid leukemia patients.",
        "Doc_title":"The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia.",
        "Journal":"Blood",
        "Do_id":"21908430",
        "Doc_ChemicalList":"Benzamides;DNA, Neoplasm;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Imatinib Mesylate;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adult;Aged;Base Sequence;Benzamides;Cell Line, Tumor;DNA, Neoplasm;Drug Resistance, Neoplasm;Female;Fusion Proteins, bcr-abl;Genes, abl;Humans;INDEL Mutation;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Piperazines;Protein Kinase Inhibitors;Protein-Tyrosine Kinases;Pyrimidines;Young Adult",
        "Doc_meshqualifiers":"genetics;genetics;antagonists & inhibitors;genetics;metabolism;drug therapy;enzymology;genetics;pharmacology;pharmacology;antagonists & inhibitors;pharmacology",
        "_version_":1605809228008652800},
      {
        "Doc_abstract":"In acute lymphoblastic leukemia, besides age and white cell count at diagnosis, the cytogenetic abnormalities t(9;22)/BCR-ABL and t(4;11)/MLL-AF4 are important prognostic markers and are often included in the treatment stratification of patients with adult acute lymphoblastic leukemia. Deletions in 9p are seen in about 9% of cases of adult acute lymphoblastic leukemia, but their prognostic impact has been controversial. Cytogenetic data from 381 patients diagnosed with B-precursor acute lymphoblastic leukemia were reviewed. Chromosomal analysis was successful in 240 cases. Of these cases, 18 (8%) had abnormalities in 9p and they were compared with patients with normal karyotypes and patients with t(9;22)/BCR-ABL. Patients with abnormalities of chromosome 9 showed significantly shorter overall survival compared with patients with normal karyotypes. In fact, overall survival was similar to that in the poor prognosis t(9;22)/BCR-ABL-positive group. Our data suggest that chromosomal abnormalities involving 9p may have a significant negative impact on survival in adult B-precursor acute lymphoblastic leukemia.",
        "Doc_title":"An investigation into whether deletions in 9p reflect prognosis in adult precursor B-cell acute lymphoblastic leukemia: a multi-center study of 381 patients.",
        "Journal":"Haematologica",
        "Do_id":"18728022",
        "Doc_ChemicalList":"Genetic Markers",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Burkitt Lymphoma;Chromosome Mapping;Chromosomes, Human, Pair 1;Chromosomes, Human, Pair 22;Chromosomes, Human, Pair 9;Genetic Markers;Humans;Karyotyping;Leukocyte Count;Middle Aged;Prognosis;Sequence Deletion;Survival Analysis;Translocation, Genetic;World Health Organization",
        "Doc_meshqualifiers":"blood;classification;drug therapy;genetics;mortality",
        "_version_":1605758826408050688},
      {
        "Doc_abstract":"Bcr-Abl, a constitutively active tyrosine kinase, is the cause of chronic myeloid leukemia (CML) and a subset of acute lymphoblastic leukemias (ALL). Bruton's tyrosine kinase (BTK), a member of the Tec family of tyrosine kinases with a crucial role in B-cell development, is consistently tyrosine phosphorylated in Bcr-Abl expressing murine pre B cells. BTK has been implicated in Bcr-Abl-mediated B-cell transformation and resistance to imatinib, implying that inhibiting BTK may be therapeutically beneficial. We decided to test whether BTK is a critical node in Bcr-Abl transformation and potential drug target in imatinib-resistant Bcr-Abl-positive cells. We depleted BTK in Ba/F3 and 32D cells expressing native and kinase domain (KD) mutant (E255K and T315I) Bcr-Abl, using shRNA. BTK levels were reduced to <10% of controls. However, no differences in viability and cell proliferation were observed and the response to imatinib was not altered. Consistent with this, proliferation and viability were unaffected by inhibition of BTK with reversible (PC-005) and irreversible (PCI-31523) small molecule inhibitors. Lastly, BTK inhibition did not affect the ability of Bcr-Abl to transform primary murine hematopoietic cells in colony forming and B-cell transformation assays. Collectively this data argues against a critical role for BTK in Bcr-Abl-mediated leukemogenesis.",
        "Doc_title":"Bruton's tyrosine kinase is not essential for Bcr-Abl-mediated transformation of lymphoid or myeloid cells.",
        "Journal":"Leukemia",
        "Do_id":"18548107",
        "Doc_ChemicalList":"Benzamides;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Imatinib Mesylate;Agammaglobulinaemia tyrosine kinase;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Animals;Benzamides;Cell Transformation, Neoplastic;Cells, Cultured;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Leukemia;Lymphocytes;Mice;Mice, Inbred BALB C;Myeloid Cells;Piperazines;Protein Kinase Inhibitors;Protein-Tyrosine Kinases;Pyrimidines",
        "Doc_meshqualifiers":"physiology;etiology;pathology;pathology;pharmacology;pharmacology;antagonists & inhibitors;physiology;pharmacology",
        "_version_":1605895788739690496},
      {
        "Doc_abstract":"This study investigated the occurrence of the p190 and p210 breakpoint cluster region-Abelson (BCR-ABL) rearrangements in adults with acute lymphoblastic leukemia and possible associations with clinical and laboratory characteristics and survival.;Forty-one over 18-year-old patients with acute lymphoblastic leukemia of both genders followed-up between January 2008 and May 2012 were included in this study. Clinical and laboratory data were obtained from the medical charts of the patients. Reverse transcription polymerase chain reaction (RT-PCR) using specific primers was employed to identify molecular rearrangements.;At diagnosis, the median age was 33 years, and there was a predominance of males (61%). The most common immunophenotype was B lineage (76%). BCR-ABL rearrangements was detected in 14 (34%) patients with the following distribution: p190 (28%), p210 (50%) and double positive (22%). Overall survival of patients with a mean/median of 331/246 days of follow up was 39%, respectively, negative BCR-ABL (44%) and positive BCR-ABL (28%).;These results confirm the high frequency of BCR-ABL rearrangements and the low survival rate of adult Brazilian patients with acute lymphoblastic leukemia.",
        "Doc_title":"Frequency of p190 and p210 BCR-ABL rearrangements and survival in Brazilian adult patients with acute lymphoblastic leukemia.",
        "Journal":"Revista brasileira de hematologia e hemoterapia",
        "Do_id":"25305168",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605751108405297152},
      {
        "Doc_abstract":"Cancer research within the last decades elucidated signaling pathways and identified genes and proteins that lead or contribute to malignant transformation of a cell. Discovery of the Bcr-Abl oncoprotein as the molecular abnormality causing chronic myeloid leukemia (CML) paved the way for the development of a targeted anticancer therapy. The substantial activity of imatinib mesylate (STI571, Glivec) in CML and Philadelphia (Ph)-chromosome positive acute lymphoblastic leukemia (Ph+ ALL) changed the therapeutic approach to Ph+ leukemia and rang the bell for a new era of anticancer treatment. However, when the phenomenon of relapse occurred despite continued imatinib treatment, we had to learn the lesson that imatinib can select for a resistant disease clone. If such a clone still depends on Bcr-Abl, it either carries a BCR-ABL point mutation that prevents binding of the drug or expresses the fusion protein at high levels. Alternatively, leukemia cells that harbor secondary genetic alterations resulting in Bcr-Abl-independent proliferation are selected for their growth advantage in the presence of imatinib. Point mutations in the BCR-ABL kinase domain prevent binding of imatinib but still allow binding of ATP, thus retaining Bcr-Abl kinase activity. Mutated BCR-ABL is frequently detected in cases of imatinib-resistant Ph+ leukemia and therefore represents the main challenge for the investigation of alternative strategies to either overcome resistance or to prevent the emergence of a resistant leukemic clone.",
        "Doc_title":"Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back.",
        "Journal":"Leukemia",
        "Do_id":"12750693",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Pyrimidines;Imatinib Mesylate;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Antineoplastic Agents;Benzamides;Drug Resistance, Neoplasm;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Piperazines;Protein-Tyrosine Kinases;Pyrimidines",
        "Doc_meshqualifiers":"therapeutic use;antagonists & inhibitors;genetics;drug therapy;therapeutic use;antagonists & inhibitors;therapeutic use",
        "_version_":1605826263682908160},
      {
        "Doc_abstract":"The reciprocal translocation between chromosome 9 and chromosome 22, as observed in chronic myeloid leukemia (CML) as well as in acute lymphoblastic leukemia (ALL), results in a 22q- chromosome, the so-called Philadelphia chromosome. The translocation event creates on the Philadelphia chromosome a fusion between two genes: bcr and abl. Depending on the localization of the breakpoint in the bcr gene different chimeric bcr-abl genes are generated, each encoding their own tumor-specific protein: e1-a2P190bcr-abl, b2-a2p210bcr-abl, or b3-a2P210bcr-abl. Especially in ALL, the presence of such a tumor-specific protein is highly associated with a poor prognosis. Detection of these proteins therefore has a strong clinical significance. In this study a polyclonal antiserum, termed BP-2, was raised against a synthetic peptide, corresponding to the tumor-specific 'fusion-point' epitope of the b3-a2P210bcr-abl protein. The specificity of BP-2 for the bcr-abl joining region in b3-a2P210bcr-abl is demonstrated by means of peptide inhibition studies in combination with immunoprecipitation. In addition we show the reactivity of BP-2 with bcr-abl proteins in leukemic cells of a Philadelphia-chromosome-positive ALL patient.",
        "Doc_title":"Antibody recognition of the tumor-specific b3-a2 junction of bcr-abl chimeric proteins in Philadelphia-chromosome-positive leukemias.",
        "Journal":"Leukemia",
        "Do_id":"1434792",
        "Doc_ChemicalList":"Peptides;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Amino Acid Sequence;Fusion Proteins, bcr-abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Molecular Sequence Data;Peptides;Precipitin Tests;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Protein-Tyrosine Kinases;Serologic Tests",
        "Doc_meshqualifiers":"immunology;diagnosis;immunology;immunology;diagnosis;immunology;metabolism",
        "_version_":1605746976567066624},
      {
        "Doc_abstract":"The BCR-ABL mutation, T315I, is a common mutation and is resistant to both imatinib and second-generation Abl kinase inhibitors. Although strategies to overcome resistance-mediated T315I mutation may improve the survival of BCR-ABL-positive leukemia patients, there is little information on cell-based studies.;We established a new human BCR-ABL-positive acute lymphoblastic leukemia (ALL) cell line, SK-9 with the T315I mutation, from the peripheral blood of a 36-year-old female patient.;Growth kinetic studies revealed an approximate population doubling time of 48 hours. The common B-cell phenotype is a feature of the SK-9 cell line. Cells have the Philadelphia chromosome (Ph) with many structural abnormalities, as well as the T315I mutation in the BCR-ABL gene. Insertion of SK-9 cells into athymic nude mice induced the formation of tumors in the lymph node that infiltrated into the spleen and bone marrow. We examined the drug sensitivity of imatinib, dasatinib, and nilotinib using a cell proliferation assay and an immunoblot assay. Cell proliferation did not decrease after imatinib, dasatinib, or nilotinib treatment as compared to the BCR-ABL-positive chronic myeloid leukemia cell line K562. Because phosphorylation of BCR-ABL and Crk-L did not decrease after imatinib and dasatinib treatment, it is suggested that SK-9 is resistant to imatinib, dasatinib, and nilotinib.;This cell line may provide a useful model for in vitro and in vivo cellular and molecular studies of BCR-ABL-positive ALL with T315I mutation.",
        "Doc_title":"Establishment of a new Philadelphia chromosome-positive acute lymphoblastic leukemia cell line (SK-9) with T315I mutation.",
        "Journal":"Experimental hematology",
        "Do_id":"20471447",
        "Doc_ChemicalList":"Antineoplastic Agents;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Amino Acid Substitution;Animals;Antineoplastic Agents;Cell Line, Tumor;Cell Proliferation;Disease Models, Animal;Female;Fusion Proteins, bcr-abl;Humans;Lymph Nodes;Mice;Mice, Nude;Mutation, Missense;Neoplasm Transplantation;Philadelphia Chromosome;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Transplantation, Heterologous",
        "Doc_meshqualifiers":"pharmacology;enzymology;pathology;drug effects;antagonists & inhibitors;genetics;metabolism;enzymology;pathology;drug therapy;enzymology;genetics;pathology",
        "_version_":1605895382229843968},
      {
        "Doc_abstract":"Mixed chimerism and presence of minimal residual disease after stem cell transplantation (SCT) usually predict leukemia recurrence. In Philadelphia chromosome positive (Ph+) leukemia tyrosine kinase inhibitors can restore remission. These agents can induce clonal cytogenetic abnormalities in the Philadelphia negative cell population (CCA/Ph-), which may rarely progress to acute myeloid leukemia. A child with Ph+ acute lymphoblastic leukemia showed mixed donor chimerism and persistent bcr-abl transcripts after a matched sibling SCT. There was no response to tyrosine kinase inhibitor (TKI) therapy, but she has remained hematologically normal for more than 5 years. CCA/Ph- was detected but resolved with hypomethylating therapy.",
        "Doc_title":"Clonal cytogenetic abnormalities after tyrosine kinase inhibitor therapy in Ph+ ALL resolution after decitabine therapy.",
        "Journal":"Pediatric blood & cancer",
        "Do_id":"21910215",
        "Doc_ChemicalList":"Benzamides;Piperazines;Protein Kinase Inhibitors;Pyrimidines;decitabine;Imatinib Mesylate;Azacitidine",
        "Doc_meshdescriptors":"Azacitidine;Benzamides;Child, Preschool;Chromosome Aberrations;Female;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Neoplasm, Residual;Philadelphia Chromosome;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Stem Cell Transplantation",
        "Doc_meshqualifiers":"analogs & derivatives;therapeutic use;genetics;therapy;therapeutic use;therapeutic use;therapeutic use",
        "_version_":1605742111342198784},
      {
        "Doc_abstract":"Rapid and accurate detection of BCR-ABL fusion proteins is vital for the diagnosis and classification of leukemias, especially chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). Recently, the cytometric bead array (CBA) system has been used to identify BCR-ABL proteins in leukemic cell lysates. To evaluate the accuracy of this new technique, we tested 70 patients with hematological diseases using the CBA system, cytogenetic analysis, fluorescence in situ hybridization (FISH) and real-time quantitative polymerase chain reaction (RQ-PCR). Most of the results obtained by the CBA system were concordant with those by cytogenetic analysis, FISH and RQ-PCR. In the CBA system, dilution experiments with positive control samples revealed sensitivities of at least 1%. The statistical analysis revealed that the mean fluorescence intensity (MFI) values of the BCR-ABL fusion proteins from mononuclear cells (MNCs) were higher than those from WBC or BM samples. The MFI values of cells were not dramatically reduced after 24 hours of storage at room temperature. The CBA technique detected all types of BCR-ABL proteins in leukemic cells with high specificity and sensitivity. Therefore, CBAs will contribute to the fast and easy diagnosis of leukemias, the classification of leukemias and the monitoring of minimal residual disease (MRD).",
        "Doc_title":"Detection of BCR-ABL fusion proteins in patients with leukemia using a cytometric bead array.",
        "Journal":"Leukemia & lymphoma",
        "Do_id":"21933042",
        "Doc_ChemicalList":"Antibodies, Immobilized;Biomarkers, Tumor;RNA, Neoplasm;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Antibodies, Immobilized;Biomarkers, Tumor;Bone Marrow Cells;Early Diagnosis;Female;Fluorescent Antibody Technique, Direct;Fusion Proteins, bcr-abl;Humans;In Situ Hybridization, Fluorescence;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Leukocytes;Male;Microspheres;Middle Aged;Monocytes;Polycythemia Vera;Precursor Cell Lymphoblastic Leukemia-Lymphoma;RNA, Neoplasm;Real-Time Polymerase Chain Reaction;Sensitivity and Specificity;Specimen Handling;Thrombocythemia, Essential;Young Adult",
        "Doc_meshqualifiers":"analysis;blood;immunology;chemistry;methods;analysis;blood;immunology;blood;diagnosis;genetics;metabolism;chemistry;chemistry;blood;genetics;metabolism;blood;diagnosis;genetics;metabolism;genetics;blood;genetics;metabolism",
        "_version_":1605846456640471040},
      {
        "Doc_abstract":"Small molecule kinase inhibitors of BCR-ABL in chronic myeloid leukemia (CML) and of FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) in acute myeloid leukemia (AML) have been successful at achieving remissions in these diseases as monotherapy, but these leukemias do not initially respond in a subset of patients (primary resistance) and they progress in an additional group of patients after an initial response (secondary resistance). Resistance to these agents can be divided into mechanisms that allow reactivation kinase activity and those that bypass reliance on oncogenic signaling mediated by the target kinase. Elucidation of clinical resistance mechanisms to targeted therapies for patients can provide important insights into disease pathogenesis and signaling. ",
        "Doc_title":"Mechanisms of resistance to targeted therapies in acute myeloid leukemia and chronic myeloid leukemia.",
        "Journal":"American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Meeting",
        "Do_id":"24451819",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605755737878822912},
      {
        "Doc_abstract":"The BCR-ABL kinase inhibitor imatinib mesylate is currently the standard therapy for patients with chronic myeloid leukemia (CML). Despite the remarkable results achieved with imatinib for the treatment of CML, the emergence of resistance to this drug has become a significant problem. Mutations within the ABL kinase domain have been identified as the main mechanism of resistance to imatinib. Other mechanisms include genomic amplification of BCR-ABL and modulation of drug efflux or influx transporters. Several strategies have been developed to overcome the problem of imatinib resistance, including dose escalation of imatinib, combination treatments, or novel targeted agents. Nilotinib is a tyrosine kinase inhibitor 30-fold more potent than imatinib, active against a wide range of mutant clones, except T315I. Phase I-II trials of nilotinib showed high activity in imatinib-resistant CML and Ph+ acute lymphoblastic leukemia. We here review the development of nilotinib and the activity of this agent in CML patients and in other forms of sensitive neoplasms.",
        "Doc_title":"Refining targeted therapies in chronic myeloid leukemia: development and application of nilotinib, a step beyond imatinib.",
        "Journal":"OncoTargets and therapy",
        "Do_id":"21127752",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605881363768016896},
      {
        "Doc_abstract":"Imatinib is an inhibitor of the BCR-ABL fusion gene product that characterizes chronic myeloid leukemia (CML), and of the related tyrosine kinases c-KIT and platelet-derived growth factor (PDGF) receptor. The drug is now included as front-line therapy for CML and Philadelphia chromosome-positive acute lymphoblastic leukemia in children and adolescents, though valid concerns about serious late sequelae remain unresolved and are important issues for further study. European and North American consortia have conducted phase I and II clinical trials of imatinib in children and adolescents with brain and other solid tumors that have provided little evidence of efficacy.",
        "Doc_title":"Imatinib mesylate in children and adolescents with cancer.",
        "Journal":"Pediatric blood & cancer",
        "Do_id":"20486169",
        "Doc_ChemicalList":"Benzamides;Piperazines;Pyrimidines;Imatinib Mesylate",
        "Doc_meshdescriptors":"Adolescent;Benzamides;Child;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Philadelphia Chromosome;Piperazines;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Pyrimidines",
        "Doc_meshqualifiers":"drug therapy;adverse effects;therapeutic use;drug therapy;adverse effects;therapeutic use",
        "_version_":1605792178469076992},
      {
        "Doc_abstract":"Imatinib mesylate is a potent, selective inhibitor of the tyrosine kinase activity of bcr-abl,which is now established as the state-of-the-art treatment for chronic, accelerated or even blastic phase of Philadelphia-positive [Ph(1)(+)] chronic myelogenous leukemia. It is also active in Ph(1)(+) acute lymphoblastic leukemia, but its role in Ph(1)(+) acute myeloid leukemia (AML) is less well investigated. We report here a patient with chemoresistant Ph(1)(+) AML, who responded promptly to one cycle of Ida-FLAG second-line chemotherapy by achieving complete morphologic, immunophenotypic, and cytogenetic remission but not a molecular one. The addition of imatinib mesylate led to a molecular remission, which is sustained for 10 months so far.",
        "Doc_title":"Ida-FLAG plus imatinib mesylate-induced molecular remission in a patient with chemoresistant Ph1+ acute myeloid leukemia.",
        "Journal":"European journal of haematology",
        "Do_id":"14962264",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Pyrimidines;Recombinant Proteins;Cytarabine;Granulocyte Colony-Stimulating Factor;Imatinib Mesylate;Vidarabine;Filgrastim;Idarubicin",
        "Doc_meshdescriptors":"Adult;Antineoplastic Agents;Antineoplastic Combined Chemotherapy Protocols;Benzamides;Cytarabine;Female;Filgrastim;Granulocyte Colony-Stimulating Factor;Humans;Idarubicin;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Piperazines;Pyrimidines;Recombinant Proteins;Salvage Therapy;Treatment Outcome;Vidarabine",
        "Doc_meshqualifiers":"therapeutic use;administration & dosage;therapeutic use;administration & dosage;administration & dosage;administration & dosage;drug therapy;therapeutic use;therapeutic use;administration & dosage;analogs & derivatives",
        "_version_":1605874131269582848},
      {
        "Doc_abstract":"Osteonecrosis is one of the most common, serious, toxicities resulting from the treatment of acute lymphoblastic leukemia. In recent years, pediatric acute lymphoblastic leukemia clinical trials have used discontinuous rather than continuous dosing of dexamethasone in an effort to reduce the incidence of osteonecrosis. However, it is not known whether discontinuous dosing would compromise antileukemic efficacy of glucocorticoids. Therefore, we tested the efficacy of discontinuous dexamethasone against continuous dexamethasone in murine models bearing human acute lymphoblastic leukemia xenografts (n = 8 patient samples) or murine BCR-ABL+ acute lymphoblastic leukemia. Plasma dexamethasone concentrations (7.9 to 212 nM) were similar to those achieved in children with acute lymphoblastic leukemia using conventional dosages. The median leukemia-free survival ranged from 16 to 59 days; dexamethasone prolonged survival from a median of 4 to 129 days in all seven dexamethasone-sensitive acute lymphoblastic leukemias. In the majority of cases (7 of 8 xenografts and the murine BCR-ABL model) we demonstrated equal efficacy of the two dexamethasone dosing regimens; whereas for one acute lymphoblastic leukemia sample, the discontinuous regimen yielded inferior antileukemic efficacy (log-rank p = 0.002). Our results support the clinical practice of using discontinuous rather than continuous dexamethasone dosing in patients with acute lymphoblastic leukemia. ",
        "Doc_title":"Antileukemic Efficacy of Continuous vs Discontinuous Dexamethasone in Murine Models of Acute Lymphoblastic Leukemia.",
        "Journal":"PloS one",
        "Do_id":"26252865",
        "Doc_ChemicalList":"Antineoplastic Agents;Dexamethasone;Fusion Proteins, bcr-abl;Corticosterone",
        "Doc_meshdescriptors":"Adolescent;Animals;Antineoplastic Agents;Antineoplastic Combined Chemotherapy Protocols;Child;Child, Preschool;Corticosterone;Dexamethasone;Disease Models, Animal;Disease-Free Survival;Drug Administration Schedule;Drug Screening Assays, Antitumor;Female;Fusion Proteins, bcr-abl;Humans;Male;Mice;Mice, Inbred C57BL;Neoplasm Transplantation;Osteonecrosis;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Time Factors",
        "Doc_meshqualifiers":"administration & dosage;therapeutic use;administration & dosage;administration & dosage;metabolism;prevention & control;drug therapy",
        "_version_":1605762715618377728},
      {
        "Doc_abstract":"Although the BCR/ABL tyrosine kinase inhibitor imatinib is highly effective for treatment of chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (ALL), relapse with emerging imatinib-resistance mutations in the BCR/ABL kinase domain poses a significant problem. Here, we demonstrate that rottlerin, a putative protein kinase C-delta (PKCdelta)-specific inhibitor, acts synergistically with imatinib to induce apoptosis of BCR/ABL-expressing K562 and Ton.B210 cells. However, rottlerin inhibited neither PKCdelta nor BCR/ABL in these cells. On the other hand, rottlerin, previously characterized also as a mitochondrial uncoupler, transiently but significantly reduced mitochondrial membrane potential and gradually induced mitochondrial membrane permeabilization. Moreover, two other mitochondrial uncouplers, FCCP and DNP, very similarly induced apoptosis of BCR/ABL-expressing cells in a synergistic manner with imatinib. Imatinib synergistically enhanced mitochondrial membrane permeabilization induced by mitochondrial uncouplers, which led to release of cytochrome c into the cytoplasm and activation of caspases-3 and -9. Rottlerin also enhanced the cytotoxic effect of imatinib in leukemic cells from patients with CML blast crisis and Ph-positive ALL or a cell line expressing the imatinib-resistant E255K BCR/ABL mutant. The present study indicates that rottlerin synergistically enhances imatinib-induced apoptosis through its mitochondrial uncoupling effect independent of PKCdelta and may contribute to the development of new treatment strategy to overcome the imatinib resistance and to cure the BCR/ABL expressing leukemias.",
        "Doc_title":"Rottlerin synergistically enhances imatinib-induced apoptosis of BCR/ABL-expressing cells through its mitochondrial uncoupling effect independent of protein kinase C-delta.",
        "Journal":"Oncogene",
        "Do_id":"17130834",
        "Doc_ChemicalList":"Acetophenones;Antineoplastic Agents;Benzamides;Benzopyrans;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Uncoupling Agents;Imatinib Mesylate;rottlerin;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl;Protein Kinase C-delta",
        "Doc_meshdescriptors":"Acetophenones;Animals;Antineoplastic Agents;Apoptosis;Benzamides;Benzopyrans;Drug Synergism;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;K562 Cells;Leukemia, Erythroblastic, Acute;Mice;Mitochondria;Piperazines;Protein Kinase C-delta;Protein Kinase Inhibitors;Protein-Tyrosine Kinases;Pyrimidines;Uncoupling Agents;Up-Regulation",
        "Doc_meshqualifiers":"chemistry;pharmacology;pharmacology;drug effects;chemistry;pharmacology;drug therapy;enzymology;drug effects;enzymology;metabolism;pharmacology;physiology;chemistry;pharmacology;biosynthesis;genetics;pharmacology;chemistry;pharmacology;drug effects",
        "_version_":1605757911229792256},
      {
        "Doc_abstract":"One hundred and forty-three patients with p210 BCR-ABL-positive leukemia were studied for coexpression of p190 BCR-ABL mRNA. p190 mRNA was detected in 14 of 16 (88%) patients with chronic-phase chronic myeloid leukemia (CML) at diagnosis, in 10 of 10 (100%) CML patients in blast crisis, in 75 of 107 (70%) CML patients receiving interferon-alpha (IFN-alpha), and 10 of 10 (100%) patients with p210 BCR-ABL-positive acute lymphoblastic leukemia (ALL). Neither p210 nor p190 BCR-ABL transcripts were detected in normal healthy adults (n = 20). The numbers of p190 transcripts determined by competitive PCR in patients with CML were low compared with the numbers of p210 transcripts. The median numbers of p210 and p190 transcripts per unit volume of cDNA in positive samples were 1.0 x 10(5) (range, 15 to 1.4 x 10(6)) and 10 (range, 10 to 2.9 x 10(3)), respectively. The numbers of p190 and p210 transcripts were significantly correlated in individual samples (r = .65, P < .001). The median number of p210 BCR-ABL transcripts was significantly lower in samples negative for p190 BCR-ABL transcripts than in samples in which p190 BCR-ABL transcripts were identified (3.1 x 10(3)[n = 73] v 1.0 x 10(5)[n = 115]; P < .0001). The median ratio of p190 to p210 BCR-ABL mRNA was not significantly different between chronic phase CML (1.9 x 10(-4)) and CML in blast crisis (1.7 x 10(-4)). The median ratio in p210 ALL was also low (1.9 x 10(-3)) but significantly higher than that of CML. We conclude that pl90 BCR-ABL transcripts are frequently present at a low level in p210 BCR-ABL-positive leukemias. p190 mRNA may arise through alternative or missplicing and its presence is probably of no pathogenetic significance.",
        "Doc_title":"p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias.",
        "Journal":"Blood",
        "Do_id":"8652835",
        "Doc_ChemicalList":"DNA, Complementary;DNA, Neoplasm;Immunologic Factors;Interferon-alpha;Neoplasm Proteins;RNA, Messenger;RNA, Neoplasm;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adult;Base Sequence;Blast Crisis;DNA, Complementary;DNA, Neoplasm;Fusion Proteins, bcr-abl;Gene Expression Regulation, Leukemic;Humans;Immunologic Factors;Interferon-alpha;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Leukemia, Myeloid, Chronic-Phase;Middle Aged;Molecular Sequence Data;Molecular Weight;Neoplasm Proteins;Precursor Cell Lymphoblastic Leukemia-Lymphoma;RNA Splicing;RNA, Messenger;RNA, Neoplasm",
        "Doc_meshqualifiers":"genetics;genetics;genetics;biosynthesis;classification;genetics;therapeutic use;therapeutic use;genetics;pathology;therapy;genetics;biosynthesis;genetics;genetics;biosynthesis;genetics;biosynthesis;genetics",
        "_version_":1605875742568087552},
      {
        "Doc_abstract":"The BCR/ABL tyrosine kinase inhibitor imatinib is highly effective for treatment of chronic myeloid leukemia (CML) and Philadelphia-chromosome positive (Ph+) acute lymphoblastic leukemia (ALL). However, relapses with emerging imatinib-resistance mutations in the BCR/ABL kinase domain pose a significant problem. Here, we demonstrate that nutlin-3, an inhibitor of Mdm2, inhibits proliferation and induces apoptosis more effectively in BCR/ABL-driven Ton.B210 cells than in those driven by IL-3. Moreover, nutlin-3 drastically enhanced imatinib-induced apoptosis in a p53-dependent manner in various BCR/ABL-expressing cells, which included primary leukemic cells from patients with CML blast crisis or Ph+ ALL and cells expressing the imatinib-resistant E255K BCR/ABL mutant. Nutlin-3 and imatinib synergistically induced Bax activation, mitochondrial membrane depolarization, and caspase-3 cleavage leading to caspase-dependent apoptosis, which was inhibited by overexpression of Bcl-XL. Imatinib did not significantly affect the nutlin-3-induced expression of p53 but abrogated that of p21. Furthermore, activation of Bax as well as caspase-3 induced by combined treatment with imatinib and nutlin-3 was observed preferentially in cells expressing p21 at reduced levels. The present study indicates that combined treatment with nutlin-3 and imatinib activates p53 without inducing p21 and synergistically activates Bax-mediated intrinsic mitochondrial pathway to induce apoptosis in BCR/ABL-expressing cells.",
        "Doc_title":"Enhancement of imatinib-induced apoptosis of BCR/ABL-expressing cells by nutlin-3 through synergistic activation of the mitochondrial apoptotic pathway.",
        "Journal":"Apoptosis : an international journal on programmed cell death",
        "Do_id":"20094798",
        "Doc_ChemicalList":"Benzamides;Imidazoles;Interleukin-3;Piperazines;Protein Kinase Inhibitors;Pyrimidines;bcl-2-Associated X Protein;nutlin 3;Imatinib Mesylate;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Animals;Apoptosis;Benzamides;Cell Proliferation;Cell Survival;Drug Resistance, Neoplasm;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Imidazoles;Interleukin-3;K562 Cells;Membrane Potential, Mitochondrial;Mitochondria;Piperazines;Protein Kinase Inhibitors;Pyrimidines;bcl-2-Associated X Protein",
        "Doc_meshqualifiers":"drug effects;physiology;drug effects;genetics;genetics;metabolism;pharmacology;genetics;metabolism;drug effects;drug effects;drug effects;metabolism;pharmacology;pharmacology;pharmacology;metabolism",
        "_version_":1605873648551329792},
      {
        "Doc_abstract":"BCR-ABL is a chimeric oncogene generated by translocation of sequences from the c-abl protein-tyrosine kinase gene on chromosome 9 into the BCR gene on chromosome 22. Alternative chimeric proteins, p210BCR-ABL and p190BCR-ABL, are produced that are characteristic of chronic myelogenous leukemia and acute lymphoblastic leukemia, respectively. Their role in the etiology of human leukemia remains to be defined. Transformed murine hematopoietic cells can be used as a model of BCR-ABL function since these cells can be made growth factor independent and tumorigenic by the action of the BCR-ABL oncogene. We show that the BCR-ABL oncogenes prevent apoptotic death in these cells by inducing a Bcl-2 expression pathway. Furthermore, BCR-ABL-expressing cells revert to factor dependence and nontumorigenicity after Bcl-2 expression is suppressed. These results help to explain the ability of BCR-ABL oncogenes to synergize with c-myc in cell transformation.",
        "Doc_title":"Tumorigenic activity of the BCR-ABL oncogenes is mediated by BCL2.",
        "Journal":"Proceedings of the National Academy of Sciences of the United States of America",
        "Do_id":"7777499",
        "Doc_ChemicalList":"Interleukin-3;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-bcl-2;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Animals;Apoptosis;Cell Line;Cell Transformation, Neoplastic;Fusion Proteins, bcr-abl;Humans;Interleukin-3;Male;Mice;Mice, Nude;Oncogenes;Oxidative Stress;Protein-Tyrosine Kinases;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-bcl-2;Transfection",
        "Doc_meshqualifiers":"genetics;genetics;genetics;pharmacology;genetics;genetics",
        "_version_":1605808970668179456},
      {
        "Doc_abstract":"BCR-ABL-positive acute myeloid leukemia (AML) is a rare subtype of AML that is now included as a provisional entity in the 2016 revised WHO classification of myeloid malignancies. Since a clear distinction between de novo BCR-ABL+ AML and chronic myeloid leukemia (CML) blast crisis is challenging in many cases, the existence of de novo BCR-ABL+ AML has been a matter of debate for a long time. However, there is increasing evidence suggesting that BCR-ABL+ AML is in fact a distinct subgroup of AML. In this study, we analyzed all published cases since 1975 as well as cases from our institution in order to present common clinical and molecular features of this rare disease. Our analysis shows that BCR-ABL predominantly occurs in AML-NOS, CBF leukemia, and AML with myelodysplasia-related changes. The most common BCR-ABL transcripts (p190 and p210) are nearly equally distributed. Based on the analysis of published data, we provide a clinical algorithm for the initial differential diagnosis of BCR-ABL+ AML. The prognosis of BCR-ABL+ AML seems to depend on the cytogenetic and/or molecular background rather than on BCR-ABL itself. A therapy with tyrosine kinase inhibitors (TKIs) such as imatinib, dasatinib, or nilotinib is reasonable, but-due to a lack of systematic clinical data-their use cannot be routinely recommended in first-line therapy. Beyond first-line treatment of AML, the use of TKI remains an individual decision, both in combination with intensive chemotherapy and/or as a bridge to allogeneic stem cell transplantation. In each single case, potential benefits have to be weighed against potential risks. ",
        "Doc_title":"BCR-ABL-positive acute myeloid leukemia: a new entity? Analysis of clinical and molecular features.",
        "Journal":"Annals of hematology",
        "Do_id":"27297971",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605762670048313344},
      {
        "Doc_abstract":"STI-571 (imatinib, Gleevec, Glivec, CGP 57148) is an inhibitor of the Abl group of protein-tyrosine kinases. One of these enzymes, the Bcr-Abl oncoprotein, results from the fusion of the BCR and ABL genes that result from the reciprocal chromosomal translocation that forms the Philadelphia chromosome. The Philadelphia chromosome occurs in 95% of people with chronic myeloid leukemia. ABL is the cellular homologue of the oncogene found in murine Abelson leukemia virus, and BCR refers to breakpoint cluster region. The Bcr-Abl oncoprotein exhibits elevated protein-tyrosine kinase activity, which is strongly implicated in the mechanism of development of chronic myeloid leukemia. STI-571 is effective in the treatment of the stable phase of chronic myeloid leukemia. The c-Abl protein kinase domain exists in an active and inactive conformation. STI-571 binds only to the inactive state of the enzyme as shown by X-ray crystallography. The drug binds to a portion of the ATP-binding site and extends from there into adjacent hydrophobic regions. STI-571 is a competitive inhibitor of Abl kinase with respect to ATP. Resistance to STI-571 is often the result of mutations in residues of the Bcr-Abl kinase that ordinarily bind to the drug. Inhibition of target protein kinases represents an emerging therapeutic strategy for the treatment of cancer.",
        "Doc_title":"STI-571: an anticancer protein-tyrosine kinase inhibitor.",
        "Journal":"Biochemical and biophysical research communications",
        "Do_id":"13679030",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Enzyme Inhibitors;Piperazines;Pyrimidines;Imatinib Mesylate;Protein-Tyrosine Kinases",
        "Doc_meshdescriptors":"Animals;Antineoplastic Agents;Benzamides;Enzyme Inhibitors;Humans;Imatinib Mesylate;Models, Molecular;Piperazines;Protein-Tyrosine Kinases;Pyrimidines",
        "Doc_meshqualifiers":"pharmacology;pharmacology;pharmacology;antagonists & inhibitors;chemistry;pharmacology",
        "_version_":1605905900261867520},
      {
        "Doc_abstract":"A 46-year-old female presented with acute myeloid leukemia during complete remission of multiple myeloma after extensive treatment with alkylating agents. Leukemic blasts expressed CD34, platelet esterase and gp IIIa. RT-PCR analyses of peripheral blood cells detected a p190 type BCR-ABL rearrangement and high levels of MDR1. The patient expired during neutropenia shortly after induction chemotherapy. Autopsy revealed persistent blasts in the bone marrow, spleen and liver. 'Secondary' acute myeloid leukemia with megakaryoblastic features and p190-type BCR-ABL rearrangement has not previously been reported. The possibility that the combination of a BCR-ABL rearrangement with overexpression of MDR1 may have contributed to the treatment-refractory course is discussed.",
        "Doc_title":"Drug resistance of secondary acute myeloid leukemia with megakaryoblastic features and p190 BCR-ABL rearrangement.",
        "Journal":"Leukemia research",
        "Do_id":"9783805",
        "Doc_ChemicalList":"P-Glycoprotein;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Drug Resistance, Neoplasm;Female;Fusion Proteins, bcr-abl;Humans;Leukemia, Megakaryoblastic, Acute;Middle Aged;Multiple Myeloma;Neoplasms, Second Primary;P-Glycoprotein;Reverse Transcriptase Polymerase Chain Reaction",
        "Doc_meshqualifiers":"analysis;drug therapy;etiology;genetics;pathology;drug therapy;pathology;analysis",
        "_version_":1605800081322147840},
      {
        "Doc_abstract":"The Philadelphia (Ph) chromosome, the main product of the (9;22)(q34;q11) translocation, is the cytogenetic hallmark of chronic myeloid leukemia (CML), a clonal myeloproliferative disorder of the hematopoietic stem cell; the Ph chromosome is also found in a sizeable portion of acute lymphoblastic leukemia (ALL) patients and in a small number of acute myeloid leukemia (AML) cases. At the molecular level, the t(9;22) leads to the fusion of the BCR gene (on chromosome 22) to the ABL gene (translocated from chromosome 9); this fusion gene BCR-ABL with its elevated tyrosine kinase activity must to be central to the pathogenesis of these disorders. Three different breakpoint cluster regions are discerned within the BCR gene on chromosome 22: M-bcr, m-bcr, and mu-bcr. Ph + leukemia cell lines are important tools in this research area. More than 20 ALL-and more than 40 CML-derived Ph + leukemia cell lines have been described. Furthermore, three Ph + B-lymphoblastoid cell lines, established from patients with Ph + ALL or CML, are available. Molecular analysis has documented BCR-ABL fusion genes in three apparently Ph chromosome-negative cell lines, all three derived from CML. Nearly all Ph + ALL cell lines have the m-bcr e1-a2 fusion gene (only two ALL cell lines have a b3-a2 fusion) whereas all CML cell lines, but one carry the M-bcr b2-a2, b3-a2 or both hybrids. The mu-bcr e19-a2 has been detected in one CML cell line. Four cell lines display a three-way translocation involving chromosomes 9, 22 and a third chromosome. Additional Ph chromosomes (up to five) have been found in four Ph + ALL cell lines and in 18 CML cell lines; though in some cell lines the extra Ph chromosome(s) might be caused by the polyploidy (tri- and tetraploidy) of the cells. Another modus to acquire additional copies of the BCR-ABL fusion gene is the formation of tandem repeats of the BCR-ABL hybrid as seen in CML cell line K-562. Both mechanisms, selective multiplication of the der(22) chromosome and tandem replication of the fusion gene BCR-ABL, presumably lead to enhanced levels of the fusion protein and its tyrosine kinase activity (genetic dosage effect). The availability of a panel of Ph + cell lines as highly informative leukemia models offers the unique opportunity to analyze the pathobiology of these malignancies and the role of the Ph chromosome in leukemogenesis.",
        "Doc_title":"Leukemia cell lines: in vitro models for the study of Philadelphia chromosome-positive leukemia.",
        "Journal":"Leukemia research",
        "Do_id":"10071072",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adult;Aged;Child;Child, Preschool;Female;Fusion Proteins, bcr-abl;Gene Amplification;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Philadelphia Chromosome;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Translocation, Genetic;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"genetics;pathology;genetics;pathology",
        "_version_":1605766087278854144},
      {
        "Doc_abstract":"Incubation of chronic myeloid leukemia cells in hypoxia inhibits growth and selects BCR/Abl-independent cells with stem cell properties which are refractory to imatinib-mesylate. This study aimed to characterize the relationship of this refractoriness with glucose availability in the environment.;K562 or primary chronic myeloid leukemia cells were cultured at 0.1% O(2), different cell densities and glucose concentrations. The stem and progenitor cell potential of these cultures at different times of incubation in relation to BCR/Abl(protein) expression and sensitivity to imatinib-mesylate was explored by transferring cells to growth-permissive secondary cultures in normoxia, according to the Culture-Repopulating Ability assay methodology.;Hypoxia-resistant cells maintained BCR/Abl(protein) expression until glucose was no longer available in primary hypoxic cultures, where glucose availability appeared to regulate cell number and the balance between the enrichment of cells with kinetic properties typical of stem or progenitor cells. Cells surviving merely hypoxic conditions were, upon transfer to secondary cultures, immediately available for numerical expansion due to the maintained BCR/Abl(protein) expression, and were consequently sensitive to imatinib-mesylate. Instead, BCR/Abl(protein)-negative cells selected in primary cultures under oxygen/glucose shortage underwent a delayed numerical expansion in secondary cultures, which was completely refractory to imatinib-mesylate. Cells with the latter properties were also found in primary chronic myeloid leukemia explants.;Glucose shortage in hypoxia was shown to represent the condition selecting BCR/Abl(protein)-negative cells refractory to imatinib-mesylate from either chronic myeloid leukemia lines or patients. These cells, exhibiting stem cell properties in vitro, are metabolically suited to home to stem cell niches in vivo and so may represent the chronic myeloid leukemia cell subset responsible for minimal residual disease.",
        "Doc_title":"Glucose availability in hypoxia regulates the selection of chronic myeloid leukemia progenitor subsets with different resistance to imatinib-mesylate.",
        "Journal":"Haematologica",
        "Do_id":"21071498",
        "Doc_ChemicalList":"Benzamides;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Sweetening Agents;Imatinib Mesylate;Fusion Proteins, bcr-abl;Glucose",
        "Doc_meshdescriptors":"Apoptosis;Benzamides;Cell Proliferation;Drug Resistance, Neoplasm;Fusion Proteins, bcr-abl;Glucose;Humans;Hypoxia;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Neoplastic Stem Cells;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Sweetening Agents;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"genetics;metabolism;metabolism;drug therapy;metabolism;metabolism;pathology;pharmacology;pharmacology;pharmacology;metabolism",
        "_version_":1605892975812935680},
      {
        "Doc_abstract":"The Philadelphia chromosome found in virtually all cases of chronic myeloid leukemia (CML) and in about one third of the cases of adult acute lymphoblastic leukemia is formed by a reciprocal translocation between chromosomes 9 and 22 that results in the fusion of BCR and ABL genetic sequences. This BCR-ABL hybrid gene codes for a fusion protein with deregulated tyrosine kinase activity that can apparently cause malignant transformation. CGP57148B, a 2-phenylaminopyrimidine derivative, has been shown to selectively inhibit the tyrosine kinase of ABL and BCR-ABL. We report here that this compound selectively suppresses the growth of colony-forming unit-granulocyte/macrophage (CFU-GM) and burst-forming unit-erythroid derived from CML over a 2-logarithmic dose range with a maximal differential effect at 1.0 micromol/L. However, almost all CML colonies that grow in the presence of 1.0 micromol/L CGP57148B are BCR-ABL-positive, which may reflect the fact that residual normal clonogenic myeloid precursors are infrequent in most patients with CML. We also studied the effects of CGP57148B on hematopoietic cell lines. Proliferation was suppressed in most of the BCR-ABL-positive lines; all five BCR-ABL-negative lines were unaffected. We conclude that this new agent may have significant therapeutic applications.",
        "Doc_title":"The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells.",
        "Journal":"Blood",
        "Do_id":"9345054",
        "Doc_ChemicalList":"Benzamides;Enzyme Inhibitors;Piperazines;Pyrimidines;Imatinib Mesylate;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adult;Benzamides;Cell Differentiation;Enzyme Inhibitors;Fusion Proteins, bcr-abl;Hematopoiesis;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Piperazines;Protein-Tyrosine Kinases;Pyrimidines;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"drug effects;pharmacology;drug effects;drug therapy;pathology;pharmacology;antagonists & inhibitors;pharmacology",
        "_version_":1605759598634991616},
      {
        "Doc_abstract":"In a significant proportion of patients with chronic myeloid leukemia, resistance to BCR-ABL tyrosine kinase inhibitors develops due to acquisition of BCR-ABL kinase domain mutations and insensitivity of leukemia stem cells to tyrosine kinase inhibitors. Omacetaxine mepesuccinate (formerly called homoharringtonine) is a natural alkaloid that inhibits protein synthesis and induces cell death. Omacetaxine mepesuccinate has been recently approved by the US Food and Drug Administration to treat patients with chronic myeloid leukemia who failed to respond to multiple tyrosine kinase inhibitors and/or acquired the BCR-ABL-T315I mutation. In this review, we discuss the use and effectiveness of omacetaxine mepesuccinate in the treatment of chronic myeloid leukemia, with coverage of its pharmacology, mode of action, and pharmacokinetics. We believe that omacetaxine mepesuccinate will be beneficial to many patients with chronic myeloid leukemia who do not respond well to tyrosine kinase inhibitors. ",
        "Doc_title":"Omacetaxine mepesuccinate in the treatment of intractable chronic myeloid leukemia.",
        "Journal":"OncoTargets and therapy",
        "Do_id":"24516334",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605853271256203264},
      {
        "Doc_abstract":"The Philadelphia (Ph) chromosome, or t(9;22), is the hallmark of chronic myelogenous leukemia (CML). It results in juxtaposition of the 5' part of the BCR gene on chromosome 22 to the 3' part of the ABL1 gene (previously ABL) on chromosome 9. CML is clinically characterized by three distinct phases: chronic, accelerated, and blast phase. Blast crisis is characterized by the rapid expansion of a population of differentiation arrested blast cells (myeloid or lymphoid cells population), with secondary chromosomal abnormalities present. We report a case of myeloid blast crisis of CML resistant to imatinib mesylate and chemotherapy. By use of cytogenetic, fluorescence in situ hybridization, and comparative genomic hybridization methods, we identified a cluster of BCR-ABL amplification on inverted duplication of the Ph chromosome with t(3;21)(q26;q22) and increased genomic levels of the RUNX1 gene (previously AML1). The t(3;21)(q26;q22) is a recurrent chromosomal abnormality in some cases of CML blast phase and in treatment-related myelodysplastic syndrome and acute myeloid leukemia. Amplification or copy number increase of RUNX1 has been reported in childhood acute lymphoblastic leukemia. Our study indicated that the progenitor of CML was BCR-ABL dependent through the amplification of Ph chromosome as a mechanism of resistance to imatinib therapy. The coexistence of BCR-ABL and t(3;21)(q26;q22) with RUNX1 rearrangement might play a pivotal role in the CML blast transformation.",
        "Doc_title":"Amplification of BCR-ABL and t(3;21) in a patient with blast crisis of chronic myelogenous leukemia.",
        "Journal":"Cancer genetics and cytogenetics",
        "Do_id":"18068536",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adult;Blast Crisis;Chromosomes, Human, Pair 21;Chromosomes, Human, Pair 3;Female;Fusion Proteins, bcr-abl;Gene Amplification;Humans;In Situ Hybridization, Fluorescence;Karyotyping;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Translocation, Genetic",
        "Doc_meshqualifiers":"genetics;genetics",
        "_version_":1605759190828056576},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) is characterized by the presence of the Philadelphia chromosome, which is associated with a balanced translocation involving chromosomes 9 and 22 to produce a fusion gene (bcr-abl) that gives rise to a constitutively activated Abl tyrosine kinase. This kinase led to the discovery of several small-molecule inhibitors, imatinib being the first and most successful of these. Resistance to imatinib results in some patients from Abl kinase point mutations. Overcoming imatinib resistance represents one of the biggest challenges facing clinicians in the modern management of CML. In this review, we discuss the current understanding of CML pathophysiology and mechanisms of imatinib resistance and how advancing this knowledge has led to the design of novel therapies in the area of blastic phase CML and Philadelphia chromosome-positive acute lymphoblastic leukemia with previous imatinib failure.",
        "Doc_title":"Novel Abl kinase inhibitors in chronic myeloid leukemia in blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia.",
        "Journal":"Clinical lymphoma & myeloma",
        "Do_id":"17382020",
        "Doc_ChemicalList":"Protein Kinase Inhibitors;Fusion Proteins, bcr-abl;Proto-Oncogene Proteins c-abl",
        "Doc_meshdescriptors":"Blast Crisis;Chromosomes, Human, Pair 22;Chromosomes, Human, Pair 9;Drug Resistance, Neoplasm;Fusion Proteins, bcr-abl;Humans;Point Mutation;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Protein Kinase Inhibitors;Proto-Oncogene Proteins c-abl;Translocation, Genetic",
        "Doc_meshqualifiers":"drug therapy;enzymology;genetics;genetics;genetics;drug effects;genetics;antagonists & inhibitors;genetics;drug therapy;enzymology;genetics;chemistry;therapeutic use;antagonists & inhibitors;genetics",
        "_version_":1605755846781829120},
      {
        "Doc_abstract":"This study was purposed to set up real-time quantitative RT-PCR technique and to measure leukemia fusion gene transcripts in patients with chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) and acute promyelocytic leukemia (APL). All plasmids containing the target gene sequences were constructed to establish the standard curves. A TaqMan based real-time quantitative RT-PCR was performed to measure aberrant fusion gene transcripts in 130 samples of peripheral blood (PB) or bone marrow (BM) from 49 patients with leukemia. The results showd that the BCR-ABL(P210) transcripts were detected in 28 (82.4%) out of 34 CML patients (the ratios of BCR-ABL(P210)/ABL varied from 0.01 to 3.19) and also in 2 (33.3%) out of 6 ALL patients. The BCR-ABL(P190) transcripts were detected in 2 (33.3%) out of 6 ALL patients. The BCR-ABL(P210) and BCR-ABL(P190) transcripts were both detected in 1 (2.9%) CML patients. The PML/RARalpha transcripts were detected in 7 (77.8%) out of 9 APL patients (the ratio of PML-RARa/ABL varied from 0.0014 to 3.199). The relative frequency of both bcr1 and bcr3 was 42.9%, while that of bcr2 was 14.3%. The transcript level of aberrant fusion gene varied from the clinical situation of patient. It is concluded that real-time quantitative PCR is a reliable, innovative and promising technology with high sensitivity and specialty. It has potential clinical value for defining diagnosis, typing tumor, selecting treatment, measuring the tumor load, monitoring fusion gene expression level and evaluating therapeutic strategies, which is worthy to be popularized.",
        "Doc_title":"[Detection and quantification of aberrant leukemia fusion gene by real-time RT-PCR].",
        "Journal":"Zhongguo shi yan xue ye xue za zhi",
        "Do_id":"19698240",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Fusion Proteins, bcr-abl;Humans;K562 Cells;Leukemia;Reverse Transcriptase Polymerase Chain Reaction;Sensitivity and Specificity",
        "Doc_meshqualifiers":"genetics;genetics;methods",
        "_version_":1605830789516230656},
      {
        "Doc_abstract":"Despite the success of imatinib mesylate (IM) in the early chronic phase of chronic myeloid leukemia (CML), patients are resistant to IM and other kinase inhibitors in the later stages of CML. Our findings indicate that inhibition of Janus kinase 2 (Jak2) in Bcr-Abl+ cells overcomes IM resistance although the precise mechanism of Jak2 action is unknown. Knocking down Jak2 in Bcr-Abl+ cells reduced levels of the Bcr-Abl protein and also the phosphorylation of Tyr177 of Bcr-Abl, and Jak2 overexpression rescued these knockdown effects. Treatment of Bcr-Abl+ cells with Jak2 inhibitors for 4-6h but not with IM also reduced Bcr-Abl protein and pTyr177 levels. In vitro kinase experiments performed with recombinant Jak2 showed that Jak2 readily phosphorylated Tyr177 of Bcr-Abl (a Jak2 consensus site, YvnV) whereas c-Abl did not. Importantly, Jak2 inhibition decreased pTyr177 Bcr-Abl in immune complexes but did not reduce levels of Bcr-Abl, suggesting that the reduction of Bcr-Abl by Jak2 inhibition is a separate event from phosphorylation of Tyr177. Jak2 inhibition by chemical inhibitors (TG101209/WP1193) and Jak2 knockdown diminished the activation of Ras, PI-3 kinase pathways and reduced levels of pTyrSTAT5. These findings suggest that Bcr-Abl stability and oncogenic signaling in CML cells are under the control of Jak2.",
        "Doc_title":"Janus kinase 2 regulates Bcr-Abl signaling in chronic myeloid leukemia.",
        "Journal":"Leukemia",
        "Do_id":"21183952",
        "Doc_ChemicalList":"Adaptor Proteins, Signal Transducing;GAB2 protein, human;Pyrimidines;STAT5 Transcription Factor;Sulfonamides;TG101209;Tyrosine;Phosphatidylinositol 3-Kinases;Fusion Proteins, bcr-abl;JAK2 protein, human;Janus Kinase 2",
        "Doc_meshdescriptors":"Adaptor Proteins, Signal Transducing;Animals;Apoptosis;Female;Fusion Proteins, bcr-abl;Hematopoietic Stem Cells;Humans;Janus Kinase 2;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mice;Phosphatidylinositol 3-Kinases;Phosphorylation;Pyrimidines;STAT5 Transcription Factor;Signal Transduction;Sulfonamides;Tyrosine",
        "Doc_meshqualifiers":"metabolism;drug effects;physiology;drug effects;antagonists & inhibitors;physiology;drug therapy;metabolism;physiology;pharmacology;physiology;physiology;pharmacology;metabolism",
        "_version_":1605831913161883648},
      {
        "Doc_abstract":"A chromosomal translocation uniquely associated with chronic myeloid leukemia leads to the formation of a chimeric gene, bcr-abl, on the Philadelphia chromosome. The BRC-ABL protein displays an uncontrolled tyrosine kinase activity similar to that seen with the transforming oncogene of the Abelson murine leukemia (ABL) virus (v-abl). An interleukin 3 dependent cell line, IC.DP, has been transfected with a gene encoding a temperature sensitive v-ABL. In the absence of interleukin 3 at the restrictive temperature for ABL tyrosine kinase activity IC.DP cells died via apoptosis. At the permissive temperature ABL tyrosine kinase activity promoted IC.DP cell survival but not proliferation. ABL therefore can specifically suppress apoptosis.",
        "Doc_title":"Activation of the Abelson tyrosine kinase activity is associated with suppression of apoptosis in hemopoietic cells.",
        "Journal":"Cancer research",
        "Do_id":"8467488",
        "Doc_ChemicalList":"Interleukin-3;Oncogene Proteins v-abl;Protein-Tyrosine Kinases",
        "Doc_meshdescriptors":"Abelson murine leukemia virus;Animals;Apoptosis;Cell Line;Enzyme Activation;Interleukin-3;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mast Cells;Mice;Oncogene Proteins v-abl;Protein-Tyrosine Kinases",
        "Doc_meshqualifiers":"genetics;pharmacology;pathology;cytology;enzymology;metabolism;metabolism",
        "_version_":1605742054082609152},
      {
        "Doc_abstract":"Mediators of PI3K/AKT signaling have been implicated in chronic myeloid leukemia (CML) and acute myeloid leukemia (AML). Studies have shown that inhibitors of PI3K/AKT signaling, such as wortmannin and LY294002, are able to inhibit CML and AML cell proliferation and synergize with targeted tyrosine kinase inhibitors. We investigated the ability of BAG956, a dual PI3K/PDK-1 inhibitor, to be used in combination with inhibitors of BCR-ABL and mutant FLT3, as well as with the mTOR inhibitor, rapamycin, and the rapamycin derivative, RAD001. BAG956 was shown to block AKT phosphorylation induced by BCR-ABL-, and induce apoptosis of BCR-ABL-expressing cell lines and patient bone marrow cells at concentrations that also inhibit PI3K signaling. Enhancement of the inhibitory effects of the tyrosine kinase inhibitors, imatinib and nilotinib, by BAG956 was demonstrated against BCR-ABL expressing cells both in vitro and in vivo. We have also shown that BAG956 is effective against mutant FLT3-expressing cell lines and AML patient bone marrow cells. Enhancement of the inhibitory effects of the tyrosine kinase inhibitor, PKC412, by BAG956 was demonstrated against mutant FLT3-expressing cells. Finally, BAG956 and rapamycin/RAD001 were shown to combine in a nonantagonistic fashion against BCR-ABL- and mutant FLT3-expressing cells both in vitro and in vivo.",
        "Doc_title":"Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells.",
        "Journal":"Blood",
        "Do_id":"18184863",
        "Doc_ChemicalList":"BAG956;Enzyme Inhibitors;Imidazoles;Quinolines;Protein Kinases;Phosphatidylinositol 3-Kinases;MTOR protein, human;TOR Serine-Threonine Kinases;mTOR protein, mouse;FLT3 protein, human;Flt3 protein, mouse;Protein-Tyrosine Kinases;fms-Like Tyrosine Kinase 3;Fusion Proteins, bcr-abl;3-Phosphoinositide-Dependent Protein Kinases;Protein-Serine-Threonine Kinases;Proto-Oncogene Proteins c-akt",
        "Doc_meshdescriptors":"3-Phosphoinositide-Dependent Protein Kinases;Animals;Apoptosis;Cell Line, Tumor;Cell Proliferation;Drug Synergism;Enzyme Activation;Enzyme Inhibitors;Fusion Proteins, bcr-abl;Gene Expression Regulation, Enzymologic;Gene Expression Regulation, Leukemic;Humans;Imidazoles;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Leukemia, Myeloid, Acute;Male;Mice;Mice, Nude;Mutation;Phosphatidylinositol 3-Kinases;Phosphorylation;Protein Kinases;Protein-Serine-Threonine Kinases;Protein-Tyrosine Kinases;Proto-Oncogene Proteins c-akt;Quinolines;Signal Transduction;TOR Serine-Threonine Kinases;fms-Like Tyrosine Kinase 3",
        "Doc_meshqualifiers":"drug effects;genetics;drug effects;drug effects;genetics;agonists;pharmacology;therapeutic use;drug effects;genetics;drug effects;genetics;pharmacology;therapeutic use;drug therapy;enzymology;genetics;drug therapy;enzymology;genetics;antagonists & inhibitors;biosynthesis;genetics;drug effects;genetics;metabolism;antagonists & inhibitors;biosynthesis;genetics;antagonists & inhibitors;biosynthesis;genetics;antagonists & inhibitors;genetics;metabolism;pharmacology;therapeutic use;drug effects;genetics;antagonists & inhibitors;biosynthesis;genetics",
        "_version_":1605757084180152320},
      {
        "Doc_abstract":"ABL2/ARG (ABL-related gene) belongs to the ABL (Abelson tyrosine-protein kinase) family of tyrosine kinases. ARG plays important roles in cell morphogenesis, motility, growth and survival, and many of these biological roles overlap with the cellular functions of the ABL kinase. Chronic myeloid leukemia (CML) is associated with constitutive ABL kinase activation resulting from fusion between parts of the breakpoint cluster region (BCR) and ABL1 genes. Similarly, fusion of the ETV6 (Tel) and ARG genes drives some forms of T-cell acute lymphoblastic leukemia (T-ALL) and acute myeloid leukemia (AML). Dasatinib is a tyrosine kinase inhibitor used for the treatment of CML by inhibiting ABL, and while it also inhibits ARG, there is currently no structure of ARG in complex with dasatinib. Here, the co-crystal structure of the mouse ARG catalytic domain with dasatinib at 2.5 resolution is reported. Dasatinib-bound ARG is found in the DFG-in conformation although it is nonphosphorylated on the activation-loop tyrosine. In this structure the glycine-rich P-loop is found in a relatively open conformation compared with other known ABL family-inhibitor complex structures. ",
        "Doc_title":"Structure of the ABL2/ARG kinase in complex with dasatinib.",
        "Journal":"Acta crystallographica. Section F, Structural biology communications",
        "Do_id":"25849507",
        "Doc_ChemicalList":"Protein Kinase Inhibitors;ARG tyrosine kinase;Protein-Tyrosine Kinases;Dasatinib",
        "Doc_meshdescriptors":"Animals;Dasatinib;Humans;Mice;Protein Kinase Inhibitors;Protein Structure, Secondary;Protein Structure, Tertiary;Protein-Tyrosine Kinases",
        "Doc_meshqualifiers":"chemistry;metabolism;chemistry;metabolism;chemistry;metabolism",
        "_version_":1605884539215806464},
      {
        "Doc_abstract":"The t(9;22)(q34;q11) translocation occurs in chronic myeloid leukemia (CML) and adult B-cell acute lymphoblastic leukemia (ALL), leading to fusion of BCR to ABL1 and constitutive activation of ABL1 tyrosine kinase activity. The main BCR-ABL1 breakpoints result in P190 BCR-ABL1 or P210 BCR-ABL1 fusion proteins. The latter is found in almost all cases of CML and in one third of the cases of t(9;22)-positive adult B-ALL. P190 BCR-ABL1 is found in the remaining two thirds of t(9;22)-positive adult B-ALL cases but only exceptionally in CML. We describe here the first case of t(9;22)(q34;q11) associated with t(10;11)(p13;q14) in acute monocytic leukemia. The recurrent t(10;11)(p13;q14) translocation, usually found in acute myeloid leukemia (AML) and T-ALL, merges PICALM to MLLT10. RT-PCR enabled identification of PICALM-MLLT10 and BCR-ABL1 e1-a2 fusion transcripts; in the context of chronic and acute myeloid leukemia, the latter usually has a monocytic presentation. We also identified overexpression of HOXA9, a gene essential to myeloid differentiation that is expressed in PICALM-MLLT10 and MLL-rearranged acute leukemias. This case fits with and extends a recently proposed multistage AML model in which constitutive activation of tyrosine kinases by mutations (BCR-ABL1) are associated with deregulation of transcription factors central to myeloid differentiation (HOXA9 secondary to PICALM-MLLT10).",
        "Doc_title":"Acute monocytic leukemia with coexpression of minor BCR-ABL1 and PICALM-MLLT10 fusion genes along with overexpression of HOXA9.",
        "Journal":"Genes, chromosomes & cancer",
        "Do_id":"16518848",
        "Doc_ChemicalList":"Homeodomain Proteins;MLLT10 protein, human;Monomeric Clathrin Assembly Proteins;Oncogene Proteins, Fusion;PICALM protein, human;PICALM-MLLT10 fusion protein, human;Transcription Factors;homeobox protein HOXA9;FLT3 protein, human;fms-Like Tyrosine Kinase 3;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adolescent;Bone Marrow;Follow-Up Studies;Fusion Proteins, bcr-abl;Gene Expression Regulation, Neoplastic;Gene Fusion;Homeodomain Proteins;Humans;In Situ Hybridization, Fluorescence;Karyotyping;Leukemia, Monocytic, Acute;Male;Metaphase;Models, Genetic;Monomeric Clathrin Assembly Proteins;Oncogene Proteins, Fusion;Phenotype;Transcription Factors;Translocation, Genetic;fms-Like Tyrosine Kinase 3",
        "Doc_meshqualifiers":"metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism",
        "_version_":1605904238480719872},
      {
        "Doc_abstract":"Several methods to model human Ph+ leukemia in laboratory mice are available, including propagation of BCR/ABL-expressing cells in mice, xenotransplantation of primary Ph+ leukemia cells into immunodeficient mice, BCR/ABL transgenic mice, and BCR/ABL retroviral bone marrow transduction and transplantation. Recent studies in these different model systems have yielded important advances in our knowledge of the pathogenesis and therapy of human chronic myeloid leukemia and Ph+ B-lymphoblastic leukemia, and are the subject of this review.",
        "Doc_title":"Pathogenesis and treatment of Ph+ leukemia: recent insights from mouse models.",
        "Journal":"Current opinion in hematology",
        "Do_id":"11561160",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Animals;Bone Marrow Transplantation;Disease Models, Animal;Fusion Proteins, bcr-abl;Humans;Leukemia, B-Cell;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mice;Mice, Transgenic;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Retroviridae;Transduction, Genetic;Transplantation, Heterologous;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"genetics;metabolism;etiology;metabolism;therapy;etiology;metabolism;therapy;etiology;metabolism;therapy;genetics",
        "_version_":1605765273453854720},
      {
        "Doc_abstract":"We report the transient response of a patient with the ETV6-ABL fusion gene to imatinib mesylate (STI571). A 38-year-old man was referred with an erroneous diagnosis of Philadelphia-positive chronic myeloid leukemia in blastic transformation for treatment with the ABL tyrosine kinase inhibitor, STI571. Further investigation indicated that the patient in fact had acute myeloid leukemia; no evidence of the Philadelphia translocation or BCR-ABL was found using fluorescence in situ hybridization (FISH) or reverse transcription-polymerase chain reaction. Detailed FISH analysis identified a cryptic t(9;12) translocation, and molecular studies confirmed the presence of the ETV6-ABL fusion transcript. Because the patient was gravely ill at presentation, treatment was commenced immediately with STI571 monotherapy, resulting in considerable initial improvement. However within 10 days the patient's condition again deteriorated, and he required conventional chemotherapy. This case has implications for the design of future studies using STI571 in leukemias involving ABL-encoded fusion proteins other than BCR-ABL.",
        "Doc_title":"Transient response to imatinib mesylate (STI571) in a patient with the ETV6-ABL t(9;12) translocation.",
        "Journal":"Blood",
        "Do_id":"11964320",
        "Doc_ChemicalList":"Benzamides;DNA-Binding Proteins;ETS translocation variant 6 protein;Oncogene Proteins, Fusion;Piperazines;Proto-Oncogene Proteins c-ets;Pyrimidines;Repressor Proteins;Imatinib Mesylate",
        "Doc_meshdescriptors":"Acute Disease;Adult;Benzamides;Chromosomes, Human, Pair 12;Chromosomes, Human, Pair 9;DNA-Binding Proteins;Genes, abl;Humans;Imatinib Mesylate;Leukemia, Myeloid;Male;Oncogene Proteins, Fusion;Piperazines;Proto-Oncogene Proteins c-ets;Pyrimidines;Recurrence;Repressor Proteins;Translocation, Genetic",
        "Doc_meshqualifiers":"genetics;genetics;diagnosis;drug therapy;genetics;genetics;administration & dosage;pharmacology;administration & dosage;pharmacology;genetics",
        "_version_":1605790396895461376},
      {
        "Doc_abstract":"Philadelphia chromosome (Ph) is a hallmark of chronic myeloid leukemia (CML), which exists in more than 90% CML and in 3% to 40% acute lymphoblastic leukemia (ALL).;A 25-year-old man was diagnosed with CML in chronic phase. He first received treatment with hydroxyurea, achieving hematological remission and following imatinib mesylate for main treatment. A year later, he began to appear unexplained high fever with ineffective antibiotic treatment and bone morrow and blood tests indicated blast crisis. Both BCR/ABL 210 and BCR/ABL 190 fusion transcript were positive. Imatinib resistance was confirmed by a screening for ABL kinase domain E255K mutations, and dasatinib was administered. After two months, the patient went on to hematological remission.;During medical treatment for CML, we experienced a relatively rare case with co-expression of the p210 and p190 encoding BCR-ABL transcripts in blastic phase. Imatinib resistance was confirmed and remission wasn't easily obtained, yet dasatinib was helpful. When resistance emerges, the treatment options include increasing the daily dose of imatinib, or combining imatinib with other agents. Of course, dasatinib, nilotinib and bone marrow transplantation are good choice as well.;The presence of p-190 transcript in CML may be related to progression of the disease. Thus monitoring the resistance of imatinib in CML patients, especially for advanced phase CML and BCR-ABL ALL, may be meaningful to guide clinical treatment and predict the prognosis.",
        "Doc_title":"Coexistence of P190 and P210 BCR/ABL transcripts in chronic myeloid leukemia blast crisis resistant to imatinib.",
        "Journal":"SpringerPlus",
        "Do_id":"25897414",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605839285375729664},
      {
        "Doc_abstract":"Targeting the tyrosine kinase activity of Bcr-Abl is an attractive therapeutic strategy in chronic myeloid leukemia (CML) and in Bcr-Abl-positive acute lymphoblastic leukemia. Whereas imatinib, a selective inhibitor of Bcr-Abl tyrosine kinase, is now used in frontline therapy for CML, second-generation inhibitors of Bcr-Abl tyrosine kinase such as nilotinib or dasatinib have been developed for the treatment of imatinib-resistant or imatinib-intolerant disease. In the current study, we generated nilotinib-resistant cell lines and investigated their mechanism of resistance. Overexpression of BCR-ABL and multidrug resistance gene (MDR-1) were found among the investigated mechanisms. We showed that nilotinib is a substrate of the multidrug resistance gene product, P-glycoprotein, using verapamil or PSC833 to block binding. Up-regulated expression of p53/56 Lyn kinase, both at the mRNA and protein level, was found in one of the resistant cell lines and Lyn silencing by small interfering RNA restored sensitivity to nilotinib. Moreover, failure of nilotinib treatment was accompanied by an increase of Lyn mRNA expression in patients with resistant CML. Two Src kinase inhibitors (PP1 and PP2) partially removed resistance but did not significantly inhibit Bcr-Abl tyrosine kinase activity. In contrast, dasatinib, a dual Bcr-Abl and Src kinase inhibitor, inhibited the phosphorylation of both BCR-ABL and Lyn, and induced apoptosis of the Bcr-Abl cell line overexpressing p53/56 Lyn. Such mechanisms of resistance are close to those observed in imatinib-resistant cell lines and emphasize the critical role of Lyn in nilotinib resistance.",
        "Doc_title":"Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression.",
        "Journal":"Cancer research",
        "Do_id":"19047160",
        "Doc_ChemicalList":"4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide;Antineoplastic Agents;P-Glycoprotein;Pyrimidines;RNA, Messenger;RNA, Small Interfering;Thiazoles;Fusion Proteins, bcr-abl;lyn protein-tyrosine kinase;src-Family Kinases;Dasatinib",
        "Doc_meshdescriptors":"Antineoplastic Agents;Dasatinib;Drug Resistance, Neoplasm;Fusion Proteins, bcr-abl;Humans;K562 Cells;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;P-Glycoprotein;Pyrimidines;RNA, Messenger;RNA, Small Interfering;Thiazoles;Transfection;src-Family Kinases",
        "Doc_meshqualifiers":"biosynthesis;genetics;metabolism;drug therapy;enzymology;genetics;metabolism;biosynthesis;metabolism;pharmacology;biosynthesis;genetics;genetics;pharmacology;antagonists & inhibitors;biosynthesis;genetics;metabolism",
        "_version_":1605746419896942592},
      {
        "Doc_abstract":"The leukemia cells of approximately 95% of patients with chronic myeloid leukemia and 30%-50% of adult patients with acute lymphoblastic leukemia express the Bcr/Abl oncoprotein, which is the product of a fusion gene created by a chromosomal translocation [(9:22) (q34;q11)]. This oncoprotein expresses a constitutive tyrosine kinase activity that is crucial for its cellular transforming activity. In this study, we evaluated the antineoplastic activity of CGP57148B, which is a competitive inhibitor of the Bcr/Abl tyrosine kinase.;Nude mice were given an injection of the Bcr/Abl-positive human leukemia cell lines KU812 or MC3. Tumor-bearing mice were treated intraperitoneally or orally with CGP57148B according to three different schedules. In vitro drug wash-out experiments and in vivo molecular pharmacokinetic experiments were performed to optimize the in vivo treatment schedule.;Treatment schedules administering CGP57148B once or twice per day produced some inhibition of tumor growth, but no tumor-bearing mouse was cured. A single administration of CGP57148B caused substantial (>50%) but short-lived (2-5 hours) inhibition of Bcr/Abl kinase activity. On the basis of the results from in vitro wash-out experiments, 20-21 hours was defined as the duration of continuous exposure needed to block cell proliferation and to induce apoptosis in these two leukemia cell lines. A treatment regimen assuring the continuous block of the Bcr/Abl phosphorylating activity that was administered over an 11-day period cured 87%-100% of treated mice.;These data indicate that the continuous block of the oncogenic tyrosine kinase of Bcr/Abl protein is needed to produce important biologic effects in vivo.",
        "Doc_title":"In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor.",
        "Journal":"Journal of the National Cancer Institute",
        "Do_id":"9923858",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Enzyme Inhibitors;Piperazines;Pyrimidines;Imatinib Mesylate;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Animals;Antineoplastic Agents;Benzamides;Enzyme Inhibitors;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Leukemia, Experimental;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mice;Piperazines;Protein-Tyrosine Kinases;Pyrimidines;Signal Transduction;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"pharmacology;pharmacology;metabolism;drug therapy;metabolism;drug therapy;metabolism;pharmacology;pharmacology;pharmacology;drug effects",
        "_version_":1605808914296733696},
      {
        "Doc_abstract":"Chronic myelogenous leukemia and one type of acute lymphoblastic leukemia are characterized by a 9;22 chronosome translocation in which 5' sequences of the bcr gene become fused to the c-abl proto-oncogene. The resulting chimeric genes encode bcr/abl fusion proteins which have deregulated tyrosine kinase activity and appear to play an important role in induction of these leukemias. A series of bcr/abl genes were constructed in which nested deletions of the bcr gene were fused to the c-abl gene. The fusion proteins encoded by these genes were assayed for autophosphorylation in vivo and for differences in subcellular localization. Our results demonstrate that bcr sequences activate two functions of c-abl; the tyrosine kinase activity and a previously undescribed microfilament-binding function. Two regions of bcr which activate these functions to different degrees have been mapped: amino acids 1 to 63 were strongly activating and amino acids 64 to 509 were weakly activating. The tyrosine kinase and microfilament-binding functions were not interdependent, as a kinase defective bcr/abl mutant still associated with actin filaments and a bcr/abl mutant lacking actin association still had deregulated kinase activity. Modification of actin filament functions by the bcr/abl tyrosine kinase may be an important event in leukemogenesis.",
        "Doc_title":"Activation of tyrosinase kinase and microfilament-binding functions of c-abl by bcr sequences in bcr/abl fusion proteins.",
        "Journal":"Molecular and cellular biology",
        "Do_id":"1705008",
        "Doc_ChemicalList":"Actins;Microfilament Proteins;Proto-Oncogene Proteins;Recombinant Fusion Proteins;Phosphotyrosine;Tyrosine;Protein-Tyrosine Kinases;Proto-Oncogene Proteins c-abl;BCR protein, human;Proto-Oncogene Proteins c-bcr",
        "Doc_meshdescriptors":"Actin Cytoskeleton;Actins;Amino Acid Sequence;Cell Compartmentation;Cloning, Molecular;DNA Mutational Analysis;Enzyme Activation;Fluorescent Antibody Technique;Humans;Microfilament Proteins;Molecular Sequence Data;Molecular Weight;Phosphotyrosine;Protein-Tyrosine Kinases;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-abl;Proto-Oncogene Proteins c-bcr;Recombinant Fusion Proteins;Restriction Mapping;Structure-Activity Relationship;Tumor Cells, Cultured;Tyrosine",
        "Doc_meshqualifiers":"metabolism;metabolism;metabolism;metabolism;metabolism;metabolism;metabolism;analogs & derivatives;metabolism",
        "_version_":1605840417207615488},
      {
        "Doc_abstract":"Philadelphia or BCR-ABL positive acute lymphoblastic leukemia (PH+ ALL) is the most common and severe of adult ALL. The only potentially curator treatment remains allogeneic hematopoietic stem cells transplantation (SCT) in first complete remission. The use of imatinib has revolutionized the treatment of chronic myeloid leukemia. Its incorporation into PH + ALL protocols also improved the prognosis of this disease giving better complete remission rates compared to chemotherapy alone. The treatment of patients not eligible for SCT remains controversial. Prolonged use of high dose tyrosine kinase inhibitors (TKI) (ie: imatinib at 600 or 800 mg/j) as maintenance therapy seems to be a reasonable approach. We present a case of prolonged molecular remission of PH+ ALL under TKI alone as maintenance therapy.",
        "Doc_title":"[Prolonged molecular response induced by imatinib in Philadelphia positive acute lymphoblastic leukemia A case report and brief review].",
        "Journal":"Annales de biologie clinique",
        "Do_id":"25847743",
        "Doc_ChemicalList":"Biomarkers, Tumor;Vincristine;Dexamethasone;Doxorubicin;Imatinib Mesylate;Cyclophosphamide",
        "Doc_meshdescriptors":"Adult;Antineoplastic Combined Chemotherapy Protocols;Biomarkers, Tumor;Cyclophosphamide;Dexamethasone;Doxorubicin;Humans;Imatinib Mesylate;Philadelphia Chromosome;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Remission Induction;Vincristine",
        "Doc_meshqualifiers":"therapeutic use;genetics;therapeutic use;therapeutic use;therapeutic use;administration & dosage;therapeutic use;drug therapy;genetics;therapeutic use",
        "_version_":1605883972304240640},
      {
        "Doc_abstract":"Chronic basophilic leukemia is a rare form in chronic myeloid leukemia patients. Only limited number of reports are available. Herein, we describe a patient who presented with fatigue, weight loss, leucocytosis, prominent basophilia, and mild eosinophilia. On biopsy, bone marrow was hypercellular with marked basophils. The immunophenotype showed abnormal expression of CD7, which is suggestive of basophilic maturation. Chromosomal analysis from GTG-banded metaphases revealed Ph positivity, and fluorescence in situ hybridization (FISH) with BCR/ABL dual color, dual fusion probe showed single fusion on the der(22) chromosome and ABL/BCR fusion was deleted on the der(9) chromosome. The deletion (ABL/BCR) on der(9) may be associated with basophilia which may be also indicative of the transformation of CML to acute myeloid leukemia.",
        "Doc_title":"Deletion of ABL/BCR on der(9) associated with severe basophilia.",
        "Journal":"Indian journal of human genetics",
        "Do_id":"22090723",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605883943854276608},
      {
        "Doc_abstract":"Myeloid sarcoma (MS) is a tumor mass of myeloblasts or immature myeloid cells occurring in an extramedullary site or in bone. The tumor mass may precede or occur concurrently with acute or chronic myeloid leukemia or with other types of myeloproliferative disorders or myelodysplastic syndromes. MS is a rare disease, estimated to comprise between 2 to approximately 14% of acute myeloid leukemia. On the other hand, 95% of cases of CML have characteristic t (9;22) cytogenetic abnormality and BCR/ABL fusion gene at diagnosis. We here report the clinical significance of FISH in a diagnosis of MS that formed tumor in femur during the chronic phase of CML.",
        "Doc_title":"[A case of myeloid sarcoma diagnosed by FISH].",
        "Journal":"Rinsho byori. The Japanese journal of clinical pathology",
        "Do_id":"18283861",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Female;Humans;In Situ Hybridization, Fluorescence;Middle Aged;Sarcoma, Myeloid",
        "Doc_meshqualifiers":"diagnosis",
        "_version_":1605754533279956992},
      {
        "Doc_abstract":"The differentiation and apoptosis-sensitizing effects of the Bcr-Abl-specific tyrosine kinase inhibitor CGP57148B, also known as STI-571, were determined in human Bcr-Abl-positive HL-60/Bcr-Abl and K562 cells. First, the results demonstrate that the ectopic expression of the p185 Bcr-Abl fusion protein induced hemoglobin in the acute myeloid leukemia (AML) HL-60 cells. Exposure to low-dose cytosine arabinoside (Ara-C; 10 nmol/L) increased hemoglobin levels in HL-60/Bcr-Abl and in the chronic myeloid leukemia (CML) blast crisis K562 cells, which express the p210 Bcr-Abl protein. As compared with HL-60/neo, HL-60/Bcr-Abl and K562 cells were resistant to apoptosis induced by Ara-C, doxorubicin, or tumor necrosis factor-alpha (TNF-alpha), which was associated with reduced processing of caspase-8 and Bid protein and decreased cytosolic accumulation of cytochrome c (cyt c). Exposure to CGP57148B alone increased hemoglobin levels and CD11b expression and induced apoptosis of HL-60/Bcr-Abl and K562 cells. CGP57148B treatment down-regulated antiapoptotic XIAP, cIAP1, and Bcl-x(L), without affecting Bcl-2, Bax, Apaf-1, Fas (CD95), Fas ligand, Abl, and Bcr-Abl levels. CGP57148B also inhibited constitutively active Akt kinase and NFkappaB in Bcr-Abl-positive cells. Attenuation of NFkappaB activity by ectopic expression of transdominant repressor of IkappaB sensitized HL-60/Bcr-Abl and K562 cells to TNF-alpha but not to apoptosis induced by Ara-C or doxorubicin. Importantly, cotreatment with CGP57148B significantly increased Ara-C- or doxorubicin-induced apoptosis of HL-60/Bcr-Abl and K562 cells. This was associated with greater cytosolic accumulation of cyt c and PARP cleavage activity of caspase-3. These in vitro data indicate that combinations of CGP57148B and antileukemic drugs such as Ara-C may have improved in vivo efficacy against Bcr-Abl-positive acute leukemia.",
        "Doc_title":"CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs.",
        "Journal":"Blood",
        "Do_id":"10979973",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Enzyme Inhibitors;Piperazines;Pyrimidines;Imatinib Mesylate;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Antineoplastic Agents;Apoptosis;Benzamides;Cell Differentiation;Drug Synergism;Enzyme Inhibitors;Fusion Proteins, bcr-abl;HL-60 Cells;Humans;Imatinib Mesylate;K562 Cells;Leukemia;Piperazines;Pyrimidines",
        "Doc_meshqualifiers":"pharmacology;therapeutic use;drug effects;drug effects;pharmacology;therapeutic use;drug therapy;pathology;pharmacology;therapeutic use;pharmacology;therapeutic use",
        "_version_":1605742034817122304},
      {
        "Doc_abstract":"Tyrosine kinase inhibitors such as imatinib mesylate have changed the clinical course of chronic myeloid leukemia; however, the observation that these inhibitors do not target the leukemia stem cell implies that patients need to maintain lifelong therapy. The mechanism of this phenomenon is unclear: the question of whether tyrosine kinase inhibitors are inactive inside leukemia stem cells or whether leukemia stem cells do not require breakpoint cluster region (Bcr)-Abl signaling is currently under debate. Herein, I propose an alternative model: perhaps the leukemia stem cell requires Bcr-Abl, but is dependent on its kinase-independent functions. Kinases such as epidermal growth factor receptor and Janus kinase 2 possess kinase-independent roles in regulation of gene expression; it is worth investigating whether Bcr-Abl has similar functions. Mechanistically, Bcr-Abl is able to activate the Ras, phosphatidylinositol 3-kinase/Akt, and/or the Src-kinase Hck/Stat5 pathways in a scaffolding-dependent manner. Whereas the scaffolding activity of Bcr-Abl with Grb2 is dependent on autophosphorylation, kinases such as Hck can use Bcr-Abl as substrate, inducing phosphorylation of Y177 to enable scaffolding ability in the absence of Bcr-Abl catalytic activity. It is worth investigating whether leukemia stem cells exclusively express kinases that are able to use Bcr-Abl as substrate. A kinase-independent role for Bcr-Abl in leukemia stem cells would imply that drugs that target Bcr-Abl's scaffolding ability or its DNA-binding ability should be used in conjunction with current therapeutic regimens to increase their efficacy and eradicate the stem cells of chronic myeloid leukemia. ",
        "Doc_title":"Kinase-independent mechanisms of resistance of leukemia stem cells to tyrosine kinase inhibitors.",
        "Journal":"Stem cells translational medicine",
        "Do_id":"24598782",
        "Doc_ChemicalList":"Neoplasm Proteins;Protein Kinase Inhibitors;Phosphatidylinositol 3-Kinases;Protein-Tyrosine Kinases",
        "Doc_meshdescriptors":"Animals;Drug Resistance, Neoplasm;Gene Expression Regulation, Leukemic;Humans;Leukemia;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Neoplasm Proteins;Neoplastic Stem Cells;Phosphatidylinositol 3-Kinases;Protein Kinase Inhibitors;Protein-Tyrosine Kinases;Signal Transduction",
        "Doc_meshqualifiers":"drug effects;genetics;drug therapy;enzymology;genetics;pathology;antagonists & inhibitors;genetics;metabolism;enzymology;pathology;genetics;metabolism;pharmacology;therapeutic use;antagonists & inhibitors;genetics;metabolism;drug effects;genetics",
        "_version_":1605818575038185472},
      {
        "Doc_abstract":"The Philadelphia chromosome (Ph+), corresponding to translocation t(9;22), is found in chronic myeloid leukemia (CML) and acute lymphoblastic leukemia. Several cases of Ph+ acute myeloid leukemia (AML) have been reported in the literature. A retrospective study of Ph+ AML between 2001 and 2012 was conducted through a review of the literature. Among 400 AML patients, two cases of Ph+ AML (0.5%) were identified and treated with conventional chemotherapy with or without tyrosine kinase inhibitors (TKIs), followed by allogeneic hematopoietic stem cell transplantation (allo-HSCT). One patient had a complex karyotype including 7 monosomy (-7) and p190 BCR-ABL fusion transcript. Both patients remain in complete molecular remission. To date, 21 Ph+ AML cases treated with TKIs have been described in the literature with a median overall survival of 18months. One-third of the patients had additional karyotypic abnormalities, and 14% had -7. Molecular analysis showed 59% p210 and 41% p190 fusion protein. Relapse rate was observed in 38% of patients with p190 compared to 10% in patients with p210. Allo-HSCT was performed in eight patients; two relapsed (25%). Cytogenetic (-7) and molecular features help to distinguish Ph+ AML from CML. Survival improved with TKIs, particularly in association with conventional chemotherapy and allo-HSCT. Further studies of Ph+ AML patients are needed to better define this entity, its prognostic value, and therapeutic strategy. ",
        "Doc_title":"Rare but authentic Philadelphia-positive acute myeloblastic leukemia: two case reports and a literature review of characteristics, treatment and outcome.",
        "Journal":"Hematology/oncology and stem cell therapy",
        "Do_id":"25300567",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adult;Female;Fusion Proteins, bcr-abl;Humans;Leukemia, Myeloid, Acute;Male;Philadelphia Chromosome",
        "Doc_meshqualifiers":"genetics;genetics",
        "_version_":1605876414370807808},
      {
        "Doc_abstract":"Dasatinib is a dual Abl/Src tyrosine kinase inhibitor (TKI) designed as a prototypic short-acting BCR-ABL-targeted TKI that inhibits BCR-ABL with greater potency compared with imatinib, nilotinib, bosutinib, and ponatinib and has been shown to have potential immunomodulatory effects. Dasatinib is approved for the treatment of all phases of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to prior imatinib treatment and first-line treatment for CML in chronic phase. In this article, the development of dasatinib as a treatment for patients with CML is reviewed.;This is a review of the relevant literature regarding dasatinib development in CML (2003-2013).;Dasatinib demonstrates efficacy against most BCR-ABL mutations arising during imatinib therapy and is effective in treating patients with imatinib resistance due to other mechanisms. Randomized trial data show that first-line dasatinib provides superior responses compared with imatinib and enables patients to achieve early, deep responses correlated with improved longer-term outcomes. Dasatinib has a generally acceptable safety profile, with most adverse events (AEs) proving manageable and reversible. Cytopenias are commonly observed with dasatinib, and some nonhematologic AEs including pleural effusion have been consistently reported.;Dasatinib is an effective treatment option for patients with CML.",
        "Doc_title":"The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients.",
        "Journal":"Journal of cancer research and clinical oncology",
        "Do_id":"23942795",
        "Doc_ChemicalList":"Antineoplastic Agents;Protein Kinase Inhibitors;Pyrimidines;Thiazoles;Fusion Proteins, bcr-abl;Dasatinib",
        "Doc_meshdescriptors":"Antineoplastic Agents;Dasatinib;Fusion Proteins, bcr-abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mutation;Neoadjuvant Therapy;Protein Kinase Inhibitors;Pyrimidines;Randomized Controlled Trials as Topic;Thiazoles",
        "Doc_meshqualifiers":"therapeutic use;genetics;drug therapy;genetics;methods;therapeutic use;therapeutic use;therapeutic use",
        "_version_":1605919904476692480},
      {
        "Doc_abstract":"The ETV6/ABL1 (TEL/ABL) fusion gene is a rare aberration in malignant disorders. Only 19 cases of ETV6/ABL1-positive hematological malignancy have been published, diagnosed with chronic myeloid leukemia, other types of chronic myeloproliferative neoplasm, acute myeloid leukemia or acute lymphoblastic leukemia (ALL). This study reports three new cases (aged 8 months, 5 years, and 33 years) of ALL with the ETV6/ABL1 fusion found by screening 392 newly diagnosed ALL patients (335 children and 57 adults). A thorough review of the literature and an analysis of all published data, including the three new cases, suggest poor prognosis of ETV6/ABL1-positive acute leukemias. The course of the disease in the two pediatric patients is characterized by minimal residual disease monitoring, using quantification of both the ETV6/ABL1 transcript and immunoreceptor gene rearrangements. Eosinophilia could not be confirmed as a hallmark of the ETV6/ABL1-positive disease. Studies of neonatal blood spots demonstrated that, in the child diagnosed at five years, the ETV6/ABL1 fusion initiating the ALL originated prenatally.",
        "Doc_title":"Acute leukemias with ETV6/ABL1 (TEL/ABL) fusion: poor prognosis and prenatal origin.",
        "Journal":"Genes, chromosomes & cancer",
        "Do_id":"20589932",
        "Doc_ChemicalList":"Oncogene Proteins, Fusion;RNA, Messenger;TEL-ABL fusion protein, human;Protein-Tyrosine Kinases",
        "Doc_meshdescriptors":"Adult;Child;Child, Preschool;Comparative Genomic Hybridization;Female;Gene Rearrangement;Humans;In Situ Hybridization, Fluorescence;Infant, Newborn;Male;Neonatal Screening;Neoplasm, Residual;Oligonucleotide Array Sequence Analysis;Oncogene Proteins, Fusion;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Prognosis;Prospective Studies;Protein-Tyrosine Kinases;RNA, Messenger;Reverse Transcriptase Polymerase Chain Reaction",
        "Doc_meshqualifiers":"diagnosis;genetics;genetics;genetics;pathology;genetics;genetics",
        "_version_":1605742727195000832},
      {
        "Doc_abstract":"Leukemia cells bearing the Philadelphia (Ph) chromosome express a Bcr-Abl fusion protein with deregulated protein tyrosine kinase (PTK) activity, which plays a central role in the malignant transformation. Many different signal transduction pathways are activated by Bcr-Abl, but little is known about their downstream targets in specific cell lineages. We show here that Ph-positive cell lines as well as primary cells derived from chronic myeloid leukemia (CML) in lymphoid blast crisis or from acute lymphoblastic leukemia (ALL) consistently express high levels of cyclin D2, whereas expression of this protein is low or absent in comparable Ph-negative lines and Ph-positive myeloid lines. Inhibition of Bcr-Abl with STI571 resulted in down-regulation of cyclin D2 and reduction of the number of cells in S phase, although complete G1 arrest was not induced. The expression of cyclin D2 in Ph-positive lymphoblasts was mediated via the phosphatidyl-inositol-3 kinase pathway. Analogous results were seen in murine BaF/3 cells transfected with a BCR-ABL expression vector. In contrast to the human cell lines, murine Baf/BCR-ABL cells exposed to STI571 inhibitor were all arrested in G1. This arrest could be abrogated by exogenous expression of cyclin D2 from a transfected cDNA construct. We conclude that a direct connection exists between Bcr-Abl PTK activity and cell cycle progression in which cyclin D2 plays a critical role. However, cell cycle progression in human Ph-positive lymphoid cells is not entirely dependent on Bcr-Abl PTK, and additional genetic lesions must be present.",
        "Doc_title":"Direct relation between BCR-ABL tyrosine kinase activity and cyclin D2 expression in lymphoblasts.",
        "Journal":"Cancer research",
        "Do_id":"11691826",
        "Doc_ChemicalList":"Benzamides;CCND2 protein, human;Cyclin D2;Cyclins;Piperazines;Pyrimidines;Imatinib Mesylate;Phosphatidylinositol 3-Kinases;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Benzamides;Blast Crisis;Cyclin D2;Cyclins;Down-Regulation;Fusion Proteins, bcr-abl;G1 Phase;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Lymphocytes;Phosphatidylinositol 3-Kinases;Piperazines;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Protein-Tyrosine Kinases;Pyrimidines;S Phase;Signal Transduction;Transfection",
        "Doc_meshqualifiers":"biosynthesis;genetics;antagonists & inhibitors;genetics;metabolism;drug effects;enzymology;genetics;metabolism;enzymology;metabolism;physiology;enzymology;genetics;metabolism;antagonists & inhibitors;genetics;metabolism;pharmacology;drug effects",
        "_version_":1605847151122841600},
      {
        "Doc_abstract":"Chronic myeloid leukemia has got an outstanding position among the other oncology diseases, particularly due to specific chromosomal abnormality called Philadelphia chromosome, its molecular consequence BCR/ABL fusion gene and its biologic product BCR/ABL tyrosinekinase, which is responsible for the leukemic transformation of the hematopoetic cells. We can see a real revolution in the treatment of the chronic myeloid leukemia in the last few years. The authors pay attention to the developement of the new drugs in the large historical consequences from the beginning in the 19th century (describing leukemia first time) to the introduction of the new small specific molecules into the clinical practice.",
        "Doc_title":"[Therapy of chronic myeloid leukemia. Uncommon view of the modern approaches].",
        "Journal":"Casopis lekaru ceskych",
        "Do_id":"18578373",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive",
        "Doc_meshqualifiers":"drug therapy;genetics",
        "_version_":1605747095636017153},
      {
        "Doc_abstract":"A specific chromosomal abnormality, the Philadelphia chromosome, is present in 90 - 95% of patients with chronic myeloid leukemia. The aberration results from a reciprocal translocation of chromosomes 9 and 22, creating a BCR-ABL fusion gene. There are two major forms of the BCR-ABL fusion gene, involving ABL exon 2, but including different exons of BCR gene. The transcript b2a2 or b3a2 codes for a p210 protein. Other fusion gene leads to the expression of an e1a2 transcript, which codes for a p190 protein. Other less common fusion genes are b3a3 or b2a3 (p203) and e19a2 (p230). The incidence of one or other rearrangement in chronic myeloid leukemia patients varies in different reports. In general, fusion transcripts are determined individually, a process which is labor- intensive in order to detect all major fusion transcripts. The objective of this study was to set up a multiplex RT-PCR assay for detection and to determine the frequency of different fusion genes in 75 Iranian patients with chronic myeloid leukemia.;Peripheral blood samples were analyzed by multiplex RT-PCR from 75 adult Iranian chronic myeloid leukemia patients to detect different types of BCR-ABL transcripts of the t(9;22).;All patients examined were positive for some type of BCR/ABL rearrangement. The majority of the patients (83%) expressed one of the p210BCR-ABL transcripts (b3a2, 62% and b2a2, 20%), while the remaining showed one of the transcripts of b3a3, b2a3, e1a2 or co-expression of b3a2 and b2a2. The rate of co-expression of the b3a2 and b2a2 was 5%.;In contrast to other reports, we did not see any co-expression of p210/p190. Co-expression may be due to alternative splicing or to phenotypic variation, with clinical course different from classic chronic myeloid leukemia.",
        "Doc_title":"Frequency of BCR-ABL fusion transcripts in Iranian patients with chronic myeloid leukemia.",
        "Journal":"Archives of Iranian medicine",
        "Do_id":"18426313",
        "Doc_ChemicalList":"RNA, Messenger;RNA, Neoplasm;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adolescent;Adult;Arabs;Child;Chromosomes, Human, Pair 22;Chromosomes, Human, Pair 9;Female;Fusion Proteins, bcr-abl;Humans;Iran;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;RNA, Messenger;RNA, Neoplasm;Reverse Transcriptase Polymerase Chain Reaction;Sensitivity and Specificity;Transcription, Genetic;Young Adult",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;genetics",
        "_version_":1605898074332332032},
      {
        "Doc_abstract":"BCR-ABL is a chimaeric oncogene generated by translocation of sequences from the c-ABL protein-tyrosine kinase gene on chromosome 9 into the BCR gene on chromosome 22. Alternative chimeric proteins, p210(BCR-ABL) and p190(BCR-ABL), are produced that are characteristic of chronic myelogenous leukemia and acute lymphoblastic leukemia, respectively. Their role in the aetiology of human leukemia remains to be defined. We have previously shown that the tumorigenic effect of BCR-ABL oncogenes is mediated by Bcl-2. In addition to Bcl-2, is a protein essential for transformation by BCR-ABL. However, it is not known how Bcl-2 and Ras fit together in cell transformation by BCR-ABL. The data presented here establish that Bcl-2 is a downstream target gene of the Ras signalling pathway in cells transformed by BCR-ABL, and that constitutive Ras activation results in constitutive expression of the gene. Conversely, a truncated form of the BCR-ABL, which lacks a critical BCR region required for activation of the Ras signalling pathway, failed to induce Bcl-2 expression. These results indicate that BCR-ABL prevents apoptosis by inducing Bcl-2 through a signalling pathway involving Ras and links constitutive Ras activation and Bcl-2 gene regulation. Hence, these results further imply that Ras is involved in both mitogenic signals and survival signals.",
        "Doc_title":"Regulation of Bcl-2 gene expression by BCR-ABL is mediated by Ras.",
        "Journal":"Journal of molecular biology",
        "Do_id":"9096220",
        "Doc_ChemicalList":"Proto-Oncogene Proteins c-bcl-2;Chloramphenicol O-Acetyltransferase;Fusion Proteins, bcr-abl;ras Proteins",
        "Doc_meshdescriptors":"Animals;Cell Line;Cell Transformation, Neoplastic;Chloramphenicol O-Acetyltransferase;Fusion Proteins, bcr-abl;Gene Expression Regulation, Neoplastic;Genes, Reporter;Genes, abl;Genes, bcl-2;Humans;Leukemia;Mice;Mice, Inbred Strains;Mutagenesis, Site-Directed;Promoter Regions, Genetic;Proto-Oncogene Proteins c-bcl-2;Signal Transduction;Transcriptional Activation;Transfection;ras Proteins",
        "Doc_meshqualifiers":"genetics;metabolism;metabolism;genetics;genetics;etiology;genetics;genetics;metabolism;genetics;metabolism",
        "_version_":1605881074315952128},
      {
        "Doc_abstract":"A novel C3G isoform, designated p87C3G, lacking the most amino terminal region of the cognate protein has been found to be overexpressed in two CML cell lines, K562 and Boff 210, both expressing Bcr-Abl p210. p87C3G expression is also highly augmented in patients diagnosed with chronic myeloid leukemia (CML) Ph+, in comparison with healthy individuals, and returns to basal levels after treatment with STI571. p87C3G co-immunoprecipitates with both CrkL and Bcr-Abl in CML cell lines and co-immunoprecipitation between p87C3G and Bcr-Abl was also detected in primary cells from CML patients. These interactions have been confirmed by in vitro pull down experiments. The interaction between p87C3G and Bcr-Abl involves the SH3-binding domain of p87C3G and the SH3 domain of Abl and depends mostly on the first polyproline region of p87C3G. Furthermore, we also demonstrated that p87C3G is phosphorylated in vitro by a Bcr-Abl-dependent mechanism. These results indicate that p87C3G overexpression is linked to CML phenotype and that p87C3G may exert productive functional interactions with Bcr-Abl signaling components suggesting the implication of this C3G isoform in the pathogenesis of chronic myeloid leukemia.",
        "Doc_title":"Characterization of p87C3G, a novel, truncated C3G isoform that is overexpressed in chronic myeloid leukemia and interacts with Bcr-Abl.",
        "Journal":"Experimental cell research",
        "Do_id":"16443220",
        "Doc_ChemicalList":"Adaptor Proteins, Signal Transducing;CRKL protein;Guanine Nucleotide-Releasing Factor 2;Nuclear Proteins;Protein Isoforms;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adaptor Proteins, Signal Transducing;Cell Line, Tumor;Cloning, Molecular;Fusion Proteins, bcr-abl;Gene Expression Regulation, Leukemic;Genes, abl;Guanine Nucleotide-Releasing Factor 2;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Leukocytes, Mononuclear;Nuclear Proteins;Phosphorylation;Protein Isoforms;Protein Structure, Tertiary;Protein-Tyrosine Kinases;src Homology Domains",
        "Doc_meshqualifiers":"metabolism;genetics;genetics;metabolism;genetics;metabolism;cytology;metabolism;metabolism;genetics;metabolism;metabolism",
        "_version_":1605819718436913152},
      {
        "Doc_abstract":"INK4A/ARF mutations are acquired in bcr/abl(+) lymphoid blast phase chronic myelogenous leukemia (CML) and bcr/abl(+) acute lymphoblastic leukemia (ALL). Donor lymphocyte infusion and graft-versus-leukemia (GVL) are generally ineffective in such ALLs, whereas GVL is highly active against bcr/abl(+) CML, which does not have a lesion in the INK4A/ARF locus. The mechanisms for the ineffectiveness of GVL are not fully known, and it is possible that intrinsic resistance of acute lymphoid leukemias to immune effectors associated with allogeneic GVL may contribute to ineffectiveness. This work tested the hypothesis that INK4A/ARF mutations that are associated with transformation of bcr/abl(+) CML to an ALL phenotype, and that are associated with increased resistance to apoptosis render ALL cells insensitive to allogeneic immune responses to minor histocompatibility antigens (mHA). Murine acute pre-B ALLs were induced by transfer of the human p210 bcr/abl gene into bone marrow of INK4A/ARF null mice. These ALL lines were then studied in a murine model of MHC-matched, mHA-mismatched allogeneic BMT. In vivo growth of these ALLs was inhibited in allogeneic transplants characterized by active allogeneic immune responses compared to their behavior in syngeneic transplants. In vitro ALLs with INK4A/ARF, p210 bcr/abl, or p190 bcr/abl mutations remained sensitive to anti-mHA cytolytic T cells. In addition, the ALLs were capable of inducing primary immune responses to mHAs in vivo. Thus, ALLs with INK4A/ARF or bcr/abl mutations are not intrinsically resistant to allogeneic T cell responses, suggesting that active immunotherapies against mHA have the potential to control such acute lymphoblastic leukemias.",
        "Doc_title":"High-risk acute lymphoblastic leukemia cells with bcr-abl and INK4A/ARF mutations retain susceptibility to alloreactive T cells.",
        "Journal":"Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation",
        "Do_id":"18489987",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Minor Histocompatibility Antigens;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Animals;Apoptosis;Bone Marrow Transplantation;Cells, Cultured;Cyclin-Dependent Kinase Inhibitor p16;Disease Progression;Fusion Proteins, bcr-abl;Genes, abl;Genes, p16;Graft vs Leukemia Effect;Humans;Killer Cells, Natural;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Mice;Mice, Inbred C57BL;Mice, Knockout;Minor Histocompatibility Antigens;Models, Immunological;Precursor B-Cell Lymphoblastic Leukemia-Lymphoma;Radiation Chimera;T-Lymphocyte Subsets;T-Lymphocytes, Cytotoxic;Transplantation, Homologous",
        "Doc_meshqualifiers":"immunology;immunology;deficiency;genetics;genetics;immunology;immunology;genetics;pathology;immunology;genetics;immunology;pathology;surgery;immunology;transplantation;immunology;transplantation;immunology",
        "_version_":1605800605272506368},
      {
        "Doc_abstract":"Dasatinib is a potent BCR-ABL inhibitor effective in chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia (ALL) resistant/intolerant to imatinib. In the GIMEMA LAL1205 protocol, patients with newly diagnosed Ph(+) ALL older than 18 years (with no upper age limit) received dasatinib induction therapy for 84 days combined with steroids for the first 32 days and intrathecal chemotherapy. Postremission therapy was free. Fifty-three patients were evaluable (median age, 53.6 years). All patients achieved a complete hematologic remission (CHR), 49 (92.5%) at day 22. At this time point, 10 patients achieved a BCR-ABL reduction to < 10(-3). At 20 months, the overall survival was 69.2% and disease-free survival was 51.1%. A significant difference in DFS was observed between patients who showed at day 22 a decrease in BCR-ABL levels to < 10(-3) compared with patients who never reached these levels during induction. In multivariate analysis, BCR-ABL levels of < 10(-3) at day 85 correlated with disease-free survival. No deaths or relapses occurred during induction. Twenty-three patients relapsed after completing induction. A T315I mutation was detected in 12 of 17 relapsed cases. Treatment was well tolerated; only 4 patients discontinued therapy during the last phase of the induction when already in CHR. In adult Ph(+) ALL, induction treatment with dasatinib plus steroids is associated with a CHR in virtually all patients, irrespective of age, good compliance, no deaths, and a very rapid debulking of the neoplastic clone.",
        "Doc_title":"Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.",
        "Journal":"Blood",
        "Do_id":"21931113",
        "Doc_ChemicalList":"Antigens, CD;Protein Kinase Inhibitors;Pyrimidines;Steroids;Thiazoles;Fusion Proteins, bcr-abl;Dasatinib",
        "Doc_meshdescriptors":"Adult;Aged;Antigens, CD;Antineoplastic Combined Chemotherapy Protocols;Dasatinib;Drug Administration Schedule;Female;Flow Cytometry;Fusion Proteins, bcr-abl;Gene Expression Regulation, Leukemic;Humans;Immunophenotyping;Kaplan-Meier Estimate;Male;Middle Aged;Multivariate Analysis;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Protein Kinase Inhibitors;Pyrimidines;Recurrence;Remission Induction;Reverse Transcriptase Polymerase Chain Reaction;Steroids;Thiazoles;Time Factors;Treatment Outcome;Young Adult",
        "Doc_meshqualifiers":"metabolism;therapeutic use;genetics;drug effects;drug therapy;genetics;metabolism;therapeutic use;administration & dosage;therapeutic use;administration & dosage;administration & dosage;therapeutic use",
        "_version_":1605880230354878464},
      {
        "Doc_abstract":"Mice deficient in the interferon consensus sequence binding protein (ICSBP) develop a disease resembling chronic myeloid leukemia (CML), which in humans is caused by the BCR/ABL oncoprotein. Interferon-alpha (IFN-alpha) induces ICSBP expression and is an effective therapy for CML. This study examined whether enforced expression of ICSBP might antagonize BCR/ABL-induced leukemia; results demonstrated that ICSBP-modified cells generated a protective CD8(+) cytotoxic T-cell response against BCR/ABL-transformed BaF3 cells in a murine leukemia model. ICSBP expression represents a novel means of stimulating a host immune response to BCR/ABL(+) leukemia cells and a potential strategy for immunotherapy of CML. (Blood. 2001;97:3491-3497)",
        "Doc_title":"Expression of interferon consensus sequence binding protein induces potent immunity against BCR/ABL-induced leukemia.",
        "Journal":"Blood",
        "Do_id":"11369642",
        "Doc_ChemicalList":"Interferon Regulatory Factors;Repressor Proteins;interferon regulatory factor-8;Interferons;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Animals;CD8-Positive T-Lymphocytes;Cell Transformation, Neoplastic;Female;Fusion Proteins, bcr-abl;Gene Expression;Immunity;Immunization;Interferon Regulatory Factors;Interferons;Leukemia;Mice;Mice, Inbred BALB C;Mice, Inbred NOD;Mice, SCID;Neoplasm Transplantation;Repressor Proteins;Reverse Transcriptase Polymerase Chain Reaction;Spleen;Transfection",
        "Doc_meshqualifiers":"immunology;analysis;genetics;physiology;physiology;immunology;prevention & control;genetics;physiology;immunology",
        "_version_":1605896172284674048},
      {
        "Doc_abstract":"Myeloid malignancies frequently harbor specific mutations in protein tyrosine kinases leading to oncogenic cell signaling. The most extensively investigated example is chronic myeloid leukemia, where the pathogenic tyrosine kinase fusion protein Bcr-Abl is a successful target for disease control by the specific inhibitor imatinib mesylate. In acute myeloid leukemia the receptor tyrosine kinase Flt3 is frequently mutated and inhibitors to impair the oncogenic signaling are in development. In this review we exemplify oncogenic signaling and how signal pathways can be unraveled with help from proteomics-based technologies. The distinction between cell extract and single cell approaches aiming at rigorous standardization and reliable quantitative aspects for future proteomics-based diagnostics is discussed.",
        "Doc_title":"Proteomics approaches to elucidate oncogenic tyrosine kinase signaling in myeloid malignancies.",
        "Journal":"Current pharmaceutical biotechnology",
        "Do_id":"16789903",
        "Doc_ChemicalList":"Benzamides;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Imatinib Mesylate;Protein-Tyrosine Kinases",
        "Doc_meshdescriptors":"Benzamides;Humans;Imatinib Mesylate;Leukemia, Myeloid;Phosphorylation;Piperazines;Protein Kinase Inhibitors;Protein-Tyrosine Kinases;Proteomics;Pyrimidines;Signal Transduction",
        "Doc_meshqualifiers":"drug therapy;enzymology;genetics;therapeutic use;therapeutic use;antagonists & inhibitors;genetics;metabolism;methods;therapeutic use",
        "_version_":1605903420604022784},
      {
        "Doc_abstract":"The BCR-ABL translocation is found in chronic myeloid leukemia (CML) and in Ph+ acute lymphoblastic leukemia (ALL) patients. Although imatinib and its analogues have been used as front-line therapy to target this mutation and control the disease for over a decade, resistance to the therapy is still observed and most patients are not cured but need to continue the therapy indefinitely. It is therefore of great importance to find new therapies, possibly as drug combinations, which can overcome drug resistance. In this study, we identified eleven candidate anti-leukemic drugs that might be combined with imatinib, using three approaches: a kinase inhibitor library screen, a gene expression correlation analysis, and literature analysis. We then used an experimental search algorithm to efficiently explore the large space of possible drug and dose combinations and identified drug combinations that selectively kill a BCR-ABL+ leukemic cell line (K562) over a normal fibroblast cell line (IMR-90). Only six iterations of the algorithm were needed to identify very selective drug combinations. The efficacy of the top forty-nine combinations was further confirmed using Ph+ and Ph- ALL patient cells, including imatinib-resistant cells. Collectively, the drug combinations and methods we describe might be a first step towards more effective interventions for leukemia patients, especially those with the BCR-ABL translocation. ",
        "Doc_title":"Identification of drug combinations containing imatinib for treatment of BCR-ABL+ leukemias.",
        "Journal":"PloS one",
        "Do_id":"25029499",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Pyrimidines;Imatinib Mesylate;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Algorithms;Antineoplastic Agents;Antineoplastic Combined Chemotherapy Protocols;Benzamides;Cell Line, Tumor;Dose-Response Relationship, Drug;Drug Discovery;Drug Resistance, Neoplasm;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Piperazines;Pyrimidines",
        "Doc_meshqualifiers":"administration & dosage;pharmacology;therapeutic use;administration & dosage;pharmacology;therapeutic use;metabolism;drug therapy;metabolism;pathology;administration & dosage;pharmacology;therapeutic use;administration & dosage;pharmacology;therapeutic use",
        "_version_":1605891698843451392},
      {
        "Doc_abstract":"Imatinib inhibits the kinase activity of Bcr-Abl and is currently the most effective drug for treatment of chronic myeloid leukemia (CML). Imatinib also blocks c-Abl, a physiological tyrosine kinase activated by a variety of stress signals including damaged DNA. We investigated the effect of pharmacological inhibition of c-Abl on the processing of irradiation-induced DNA damage in Bcr-Abl-negative cells. Cell lines and peripheral blood mononuclear cells (PBMCs) from healthy volunteers were treated with imatinib or dasatinib before gamma-irradiation. Inhibition of c-Abl caused an enhanced irradiation-induced mutation frequency and slowdown of DNA repair, whereas imatinib was ineffective in cells expressing a T315I variant of c-Abl. Mutation frequency and repair kinetics were also studied in c-Abl-/- murine embryonic fibroblasts (MEFs) retransfected with wild-type c-Abl (wt-Abl) or a kinase-defect variant of Abl (KD-Abl). Enhanced mutation frequency as well as delayed DNA repair was observed in cells expressing KD-Abl. These data indicate that pharmacological inhibition of c-Abl compromises DNA-damage response.",
        "Doc_title":"Pharmacological inhibition of c-Abl compromises genetic stability and DNA repair in Bcr-Abl-negative cells.",
        "Journal":"Oncogene",
        "Do_id":"18362889",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Pyrimidines;Thiazoles;Imatinib Mesylate;Fusion Proteins, bcr-abl;Proto-Oncogene Proteins c-abl;Dasatinib",
        "Doc_meshdescriptors":"Animals;Antineoplastic Agents;Benzamides;Chromosome Aberrations;DNA Damage;DNA Repair;Dasatinib;Fibroblasts;Fusion Proteins, bcr-abl;Gene Expression Regulation, Neoplastic;Humans;Imatinib Mesylate;Kinetics;Leukocytes, Mononuclear;Mice;Piperazines;Proto-Oncogene Proteins c-abl;Pyrimidines;Thiazoles",
        "Doc_meshqualifiers":"pharmacology;metabolism;biosynthesis;drug effects;radiation effects;pharmacology;antagonists & inhibitors;physiology;pharmacology;pharmacology",
        "_version_":1605840874941448192},
      {
        "Doc_abstract":"Bcr-Abl fusion protein activates tyrosine kinase, resulting in the proliferation of leukemia cells, especially chronic myeloid leukemia (CML) cells. Imatinib (IM) effectively targets Bcr-Abl tyrosine kinase, but development of resistance to IM occurs with varying frequency.;Elucidation of the common regulatory pathway upstream of Bcr-Abl in IM-sensitive and IM-resistant CML cells is important for developing novel therapeutics against CML.;This study demonstrated that IM preferentially inhibited the viability and Bcr-Abl expression in IM-sensitive K562 (K562) cells, but not in Bcr-Abl overexpressing IM-resistant K562 (K562R) cells. Both K562 and K562R cells expressed Shh preproprotein, cleaved Shh C-terminal and N-terminal peptides, as well as mRNA level of major Shh signaling molecules, including sonic hedgehog (Shh), patched (PTCH), smoothened (Smo) and Gli-1. Moreover, Gli-1 translocation into nucleus was evident in these two cell lines, suggesting that both K562 and K562R cells possess activated and major components of the Shh signaling pathway. Silencing of Gli-1 by interference RNA was accompanied by inhibition of Bcr-Abl protein expression. Pharmacological suppression of Bcr-Abl expression was restored by the Smo agonist purmorpharmine. Treatment of Shh peptide in both K562 and K562R cells not only increased Shh and Gli-1 expression, but also up-regulated Bcr-Abl expression. Resveratrol, a known Bcr-Abl inhibitor, reduced Gli-1 activation and inhibited the viability of CML cells.;Shh signaling may regulate Bcr-Abl expression in human chronic myeloid leukemia cells. Novel compounds inhibiting both Shh signaling and Bcr-Abl expression, such as resveratrol, may have potential to be effective agents against CML independent of IM resistance.",
        "Doc_title":"Sonic hedgehog signaling regulates Bcr-Abl expression in human chronic myeloid leukemia cells.",
        "Journal":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie",
        "Do_id":"22397755",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Hedgehog Proteins;Piperazines;Pyrimidines;RNA, Messenger;RNA, Small Interfering;SHH protein, human;Stilbenes;Imatinib Mesylate;Fusion Proteins, bcr-abl;resveratrol",
        "Doc_meshdescriptors":"Antineoplastic Agents;Benzamides;Cell Survival;Drug Resistance, Neoplasm;Fusion Proteins, bcr-abl;Hedgehog Proteins;Humans;Imatinib Mesylate;K562 Cells;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Piperazines;Pyrimidines;RNA Interference;RNA, Messenger;RNA, Small Interfering;Signal Transduction;Stilbenes;Up-Regulation",
        "Doc_meshqualifiers":"pharmacology;drug effects;genetics;genetics;metabolism;drug therapy;genetics;pathology;pharmacology;pharmacology;metabolism;administration & dosage;drug effects;pharmacology;drug effects",
        "_version_":1605825604385505280},
      {
        "Doc_abstract":"A 81-year-old man was diagnosed as multiple myeloma and had received melphalan for 6 years. After that, he developed acute myeloid leukemia (AML) with monosomy 7 and minor bcr/abl transcripts. Fluorescence in situ hybridization identified no detectable level of bcr/abl rearrangement. During chemotherapy for AML, minor bcr/abl transcripts disappeared and instead major bcr/abl transcripts emerged. He died of pneumonia 3 months later. At that time, neither minor nor major bcr/abl transcripts were seen. These observations suggest that certain therapy related leukemia may be susceptible to generate very small clones with bcr/abl rearrangements.",
        "Doc_title":"Haunting appearance of bcr/abl fusion gene products in a patient with therapy related leukaemia.",
        "Journal":"Leukemia research",
        "Do_id":"15996731",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Aged, 80 and over;Chromosomes, Human, Pair 7;Fatal Outcome;Humans;Leukemia, Myeloid, Acute;Male;Monosomy;Multiple Myeloma;Neoplasms, Second Primary;Pneumonia",
        "Doc_meshqualifiers":"metabolism;complications;drug therapy;metabolism;physiopathology;complications;drug therapy;metabolism;complications;drug therapy;metabolism;etiology;metabolism",
        "_version_":1605826841926434816},
      {
        "Doc_abstract":"BCR-ABL inhibitors for treating chronic myeloid leukemia in chronic phase have transformed a previously incurable malignancy into a manageable condition. However, suboptimal medication adherence has been observed with these agents affecting clinical outcomes and healthcare costs. In order to raise awareness of the problem of adherence, and before developing pragmatic strategies to enhance medication adherence, a deep understanding of the best approaches for measuring adherence in chronic myeloid leukemia patients and identifying non-adherence is required. A systematic literature review on the prevalence, measurement methods, consequences and risk factors for non-adherence to BCR-ABL inhibitors and adherence-enhancing interventions was performed and critically appraised. Of the 19 included articles, 9 were retrospective. Average adherence varied from 19% to almost 100% of the proportion of prescribed drug taken, but it was measured through various different methods and within different study groups. Suboptimal adherence was associated with a negative impact on both clinical and economic outcomes. There is a lack of supportive evidence demonstrating a difference in adherence across BCR-ABL inhibitors and even contradictory results between the 2(nd) generation inhibitors. Drug-related adverse events and forgetfulness were common reasons for intentional and unintentional non-adherence, respectively, but further research is required to identify additional reasons behind non-adherence or patients at risk of non-adherence. Non-adherence in chronic myeloid leukemia patients treated with BCR-ABL inhibitors is common and associated with critical outcomes. However, this review highlights important existing gaps, reveals inconsistent definitions, and a lack of standardized methods for measuring adherence in chronic myeloid leukemia. All require further investigation. ",
        "Doc_title":"Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges.",
        "Journal":"Haematologica",
        "Do_id":"24598855",
        "Doc_ChemicalList":"Antineoplastic Agents;Protein Kinase Inhibitors;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Antineoplastic Agents;Fusion Proteins, bcr-abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Medication Adherence;Patient Compliance;Protein Kinase Inhibitors",
        "Doc_meshqualifiers":"therapeutic use;antagonists & inhibitors;drug therapy;therapeutic use",
        "_version_":1605884133452546048},
      {
        "Doc_abstract":"Numerous studies indirectly implicate Rac GTPases in cancer. To investigate if Rac3 contributes to normal or malignant cell function, we generated rac3 null mutants through gene targeting. These mice were viable, fertile, and lacked an obvious external phenotype. This shows Rac3 function is dispensable for embryonic development. Bcr/Abl is a deregulated tyrosine kinase that causes chronic myelogenous leukemia and Ph-positive acute lymphoblastic leukemia in humans. Vav1, a hematopoiesis-specific exchange factor for Rac, was constitutively tyrosine phosphorylated in primary lymphomas from Bcr/Abl P190 transgenic mice, suggesting inappropriate Rac activation. rac3 is expressed in these malignant hematopoietic cells. Using lysates from BCR/ABL transgenic mice that express or lack rac3, we detected the presence of activated Rac3 but not Rac1 or Rac2 in the malignant precursor B-lineage lymphoblasts. In addition, in female P190 BCR/ABL transgenic mice, lack of rac3 was associated with a longer average survival. These data are the first to directly show a stimulatory role for Rac in leukemia in vivo. Moreover, our data suggest that interference with Rac3 activity, for example, by using geranyl-geranyltransferase inhibitors, may provide a positive clinical benefit for patients with Ph-positive acute lymphoblastic leukemia.",
        "Doc_title":"Generation of rac3 null mutant mice: role of Rac3 in Bcr/Abl-caused lymphoblastic leukemia.",
        "Journal":"Molecular and cellular biology",
        "Do_id":"15964830",
        "Doc_ChemicalList":"Rac3 protein, mouse;rac GTP-Binding Proteins",
        "Doc_meshdescriptors":"Alleles;Animals;B-Lymphocytes;Cell Culture Techniques;Cell Lineage;Cells, Cultured;Female;Flow Cytometry;Gene Expression Regulation, Leukemic;Gene Targeting;Genes, abl;Leukemia, Experimental;Lymphoma;Mice;Mice, Knockout;Mice, Transgenic;Reverse Transcriptase Polymerase Chain Reaction;rac GTP-Binding Proteins",
        "Doc_meshqualifiers":"cytology;genetics;pathology;genetics;metabolism;pathology;analysis;genetics;metabolism",
        "_version_":1605742051533520897},
      {
        "Doc_abstract":"Present studies show that LBH589, a novel cinnamic hydroxamic acid analog histone deacetylase inhibitor, induces acetylation of histone H3 and H4 and of heat shock protein 90 (hsp90), increases p21 levels, as well as induces cell-cycle G(1) phase accumulation and apoptosis of the human chronic myeloid leukemia blast crisis (CML-BC) K562 cells and acute leukemia MV4-11 cells with the activating length mutation of FLT-3. In MV4-11 cells, this was associated with marked attenuation of the protein levels of p-FLT-3, FLT-3, p-AKT, and p-ERK1/2. In K562 cells, exposure to LBH589 attenuated Bcr-Abl, p-AKT, and p-ERK1/2. Treatment with LBH589 inhibited the DNA binding activity of signal transducers and activators of transcription 5 (STAT5) in both K562 and MV4-11 cells. The hsp90 inhibitor 17-allyl-amino-demethoxy geldanamycin (17-AAG) also induced polyubiquitylation and proteasomal degradation of FLT-3 and Bcr-Abl by reducing their chaperone association with hsp90. Cotreatment with LBH589 and 17-AAG exerted synergistic apoptosis of MV4-11 and K562 cells. In the imatinib mesylate (IM)-refractory leukemia cells expressing Bcr-Abl with the T315I mutation, treatment with the combination attenuated the levels of the mutant Bcr-Abl and induced apoptosis. Finally, cotreatment with LBH589 and 17-AAG also induced more apoptosis of IM-resistant primary CML-BC and acute myeloid leukemia (AML) cells (with activating mutation of FLT-3) than treatment with either agent alone.",
        "Doc_title":"Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.",
        "Journal":"Blood",
        "Do_id":"15514006",
        "Doc_ChemicalList":"Benzamides;Benzoquinones;Drug Combinations;Enzyme Inhibitors;HSP90 Heat-Shock Proteins;Histone Deacetylase Inhibitors;Hydroxamic Acids;Indoles;Lactams, Macrocyclic;Piperazines;Proto-Oncogene Proteins;Pyrimidines;Polyubiquitin;Rifabutin;tanespimycin;Imatinib Mesylate;panobinostat;FLT3 protein, human;Receptor Protein-Tyrosine Kinases;fms-Like Tyrosine Kinase 3;Fusion Proteins, bcr-abl;Proteasome Endopeptidase Complex",
        "Doc_meshdescriptors":"Acute Disease;Apoptosis;Benzamides;Benzoquinones;Blast Crisis;Cell Line, Tumor;Drug Combinations;Drug Synergism;Enzyme Inhibitors;Fusion Proteins, bcr-abl;Gene Deletion;Gene Expression Regulation;HSP90 Heat-Shock Proteins;Histone Deacetylase Inhibitors;Humans;Hydroxamic Acids;Imatinib Mesylate;Indoles;K562 Cells;Lactams, Macrocyclic;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Leukemia, Myeloid;Piperazines;Point Mutation;Polyubiquitin;Proteasome Endopeptidase Complex;Proto-Oncogene Proteins;Pyrimidines;Receptor Protein-Tyrosine Kinases;Rifabutin;fms-Like Tyrosine Kinase 3",
        "Doc_meshqualifiers":"drug effects;drug therapy;enzymology;metabolism;pathology;pharmacology;antagonists & inhibitors;genetics;metabolism;antagonists & inhibitors;metabolism;analogs & derivatives;pharmacology;drug therapy;enzymology;metabolism;pathology;drug therapy;enzymology;metabolism;pathology;pharmacology;metabolism;metabolism;genetics;metabolism;pharmacology;genetics;metabolism;analogs & derivatives;pharmacology",
        "_version_":1605742144160530433},
      {
        "Doc_abstract":"Durable responses to imatinib monotherapy are rarely seen in aggressive forms of Philadelphia chromosome positive (Ph+) leukemias. To investigate the possible cause of treatment failure we examined the role of protein kinase C epsilon (PKCE), an oncogene highly implicated in the development of solid tumors and resistance to chemotherapy. We found high levels of PKCE transcripts in Ph+ acute lymphoblastic leukemia (ALL) cells from patients and cell lines, and imatinib resistant chronic myeloid leukemia, which were also less responsive to imatinib-induced apoptosis than Ph+ cells with lower PKCE expression. Furthermore, the siRNA-mediated knockdown or peptide inhibition of PKCE in Ph+ cells increased imatinib-induced apoptosis while overexpression of PKCE reduced imatinib-induced apoptosis, with concomitant increase in the pro-survival factor AKT. Our results suggest PKCE plays a protective role against apoptosis induced by BCR-ABL inhibition in Ph+ leukemias with high PKCE expression, such as Ph+ ALL.",
        "Doc_title":"Pro-survival role of protein kinase C epsilon in Philadelphia chromosome positive acute leukemia.",
        "Journal":"Leukemia & lymphoma",
        "Do_id":"25904380",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605818628715839490},
      {
        "Doc_abstract":"Real-time quantitative reverse transcription PCR (RQ-PCR) assay for BCR-ABL is used to monitor treatment response in chronic myeloid leukemia (CML). BCR-ABL transcript levels decline over several years of imatinib treatment, and increasing numbers of patients have BCR-ABL transcripts at or below the limit of detection. More sensitive PCR methods are required to assess whether these patients have a long-term continuing decline in residual disease.;We used random pentadecamer (R15) primers for reverse transcription in RQ-PCR and compared the results with our established method that uses random hexamers. An increase in assay sensitivity would be detected as an increase in the number of BCR-ABL transcripts.;BCR-ABL transcripts increased by 86% with R15 primers. We used R15 primers to retest 19 samples from selected CML patients who had no BCR-ABL transcripts recently detectable with hexamer primers and detected BCR-ABL transcripts in 68% of the samples. Use of R15 primers showed variable increases in the transcripts for control genes BCR (breakpoint cluster region), ABL1 (c-abl oncogene 1, receptor tyrosine kinase), and GUSB (glucuronidase, beta), depending on the gene examined. The reported BCR-ABL/control gene ratio was affected, and the estimated detection limit of the assay, which was based on increased control gene copy number, was different for each control gene.;This simple modification to the reverse transcription methodology improved the detection limit of the RQ-PCR assay for BCR-ABL transcripts. In the field of CML, these results have important implications for defining the detection limit of an assay when the BCR-ABL transcript is undetectable. Random pentadecamer primers may also be useful in other reverse transcription PCR assays for which the abundance of the target RNA is low.",
        "Doc_title":"Reverse transcription with random pentadecamer primers improves the detection limit of a quantitative PCR assay for BCR-ABL transcripts in chronic myeloid leukemia: implications for defining sensitivity in minimal residual disease.",
        "Journal":"Clinical chemistry",
        "Do_id":"18641042",
        "Doc_ChemicalList":"DNA Primers;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"DNA Primers;Fusion Proteins, bcr-abl;Humans;Leukemia, Myeloid, Chronic-Phase;Neoplasm, Residual;Reverse Transcriptase Polymerase Chain Reaction;Sensitivity and Specificity;Transcription, Genetic",
        "Doc_meshqualifiers":"analysis;genetics;analysis;genetics;diagnosis;genetics;diagnosis;genetics;methods;genetics",
        "_version_":1605792721307435008},
      {
        "Doc_abstract":"Imatinib mesylate, Abl tyrosine kinase inhibitor, has improved the treatment of Bcr-Abl-positive leukemia such as chronic myeloid leukemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukemia (Ph(+)ALL). However, resistance is often reported in patients with advanced-stage disease. Several novel tyrosine kinase inhibitors, which have been developed to override imatinib resistance mechanisms such as overexpression of Bcr-Abl and point mutations within the Abl kinase domain, are currently competing. Inhibitors of Abl tyrosine kinase are divided into two main groups, namely, ATP-competitive and ATP non-competitive inhibitors. Moreover, ATP-competitive inhibitors are fall into two subclasses, i.e. the Src/Abl inhibitors, and 2-phenylaminopyrimidin-based compounds. Dasatinib (formerly BMS-354825), AP23464, SKI-606 and PD166326 are classified as Src/Abl inhibitors while AMN107 and NS-187 (INNO-406) belong to the latter subclass of inhibitors. Among these agents, clinical studies on dasatinib and AMN107 had started earlier than the others and favorable results are accumulating. Clinical studies of other compounds including NS-187 (INNO-406) will be performed in rapid succession. Because of its strong affinity, most ATP competitive inhibitors may be effective against imatinib-resistant patients. However, to date, an ATP-competitive inhibitor that can inhibit the phosphorylation of T315I Bcr-Abl has not yet been developed. To address this problem, ATP non-competitive inhibitors such as ON012380, Aurora kinase inhibitor VX-680 and p38 MAP kinase inhibitor BIRB-796 have been developed. It may be necessary for the improvement of CML and Ph(+)ALL treatment to be taken into consideration of the combination therapy with novel ATP-competitive inhibitors and these agents.",
        "Doc_title":"New tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.",
        "Journal":"Current pharmaceutical biotechnology",
        "Do_id":"17076652",
        "Doc_ChemicalList":"Antineoplastic Agents;Neoplasm Proteins;Protein Kinase Inhibitors;Protein-Tyrosine Kinases",
        "Doc_meshdescriptors":"Antineoplastic Agents;Chronic Disease;Drug Delivery Systems;Drug Design;Humans;Leukemia, Myeloid;Neoplasm Proteins;Protein Kinase Inhibitors;Protein-Tyrosine Kinases;Treatment Outcome",
        "Doc_meshqualifiers":"administration & dosage;methods;drug therapy;metabolism;metabolism;administration & dosage;antagonists & inhibitors",
        "_version_":1605751687835811840},
      {
        "Doc_abstract":"The Philadelphia (Ph) translocation is the most common cytogenetic abnormality in adult acute lymphoblastic leukemia (ALL) and is associated with an adverse prognosis. Using polymerase chain reaction (PCR) technology we recently observed a remarkably high incidence (55%) of BCR-ABL rearrangements in adult common ALL patients. In the present study we asked whether a subset of Ph-negative cALL, similarly to Ph-negative chronic myelocytic leukemia (CML) patients, exhibit BCR-ABL transcripts. PCR analysis of 58 adult Ph-negative cALL patients, including 47 cases with a normal karyotype revealed no evidence of chimeric BCR-ABL genes. We conclude that Ph-negative BCR/ABL-positive ALL is very rare entity if existing at all.",
        "Doc_title":"Polymerase chain reaction analysis of BCR-ABL sequences in adult Philadelphia chromosome-negative acute lymphoblastic leukemia patients.",
        "Journal":"Leukemia",
        "Do_id":"1593911",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adult;Fusion Proteins, bcr-abl;Genes, abl;Humans;Middle Aged;Philadelphia Chromosome;Polymerase Chain Reaction;Precursor Cell Lymphoblastic Leukemia-Lymphoma",
        "Doc_meshqualifiers":"analysis;genetics;diagnosis;genetics;metabolism",
        "_version_":1605796142137737216},
      {
        "Doc_abstract":"Ex-vivo studies have suggested that imatinib-resistance in chronic myeloid leukemia (CML) patients occurs despite adequate suppression of BCR-ABL activity. Whether BCR-ABL phosphorylation levels differ between imatinib-sensitive and -resistant patients is not known. We compared the phosphorylation of BCR-ABL in 54 previously untreated CML patients and 62 imatinib-resistant CML patients with progressive disease. Resistant patients had significantly lower levels of BCR-ABL, CrkL and AKT phosphorylation than previously untreated patients, but STAT5 phosphorylation showed no difference. These observations suggest that imatinib- resistance is not necessarily dependent on higher activity in BCR-ABL-dependent pathways, but is likely due to the activation of other pathways.",
        "Doc_title":"Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy.",
        "Journal":"Leukemia research",
        "Do_id":"17900686",
        "Doc_ChemicalList":"Adaptor Proteins, Signal Transducing;Antineoplastic Agents;Benzamides;CRKL protein;Nuclear Proteins;Piperazines;Pyrimidines;RNA, Messenger;STAT5 Transcription Factor;Imatinib Mesylate;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl;Proto-Oncogene Proteins c-akt",
        "Doc_meshdescriptors":"Adaptor Proteins, Signal Transducing;Antineoplastic Agents;Apoptosis;Benzamides;Drug Resistance, Neoplasm;Flow Cytometry;Fusion Proteins, bcr-abl;Gene Expression Regulation, Neoplastic;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Nuclear Proteins;Phosphorylation;Piperazines;Prognosis;Protein-Tyrosine Kinases;Proto-Oncogene Proteins c-akt;Pyrimidines;RNA, Messenger;Reverse Transcriptase Polymerase Chain Reaction;STAT5 Transcription Factor;Signal Transduction;Survival Rate",
        "Doc_meshqualifiers":"metabolism;therapeutic use;drug effects;genetics;metabolism;physiology;drug therapy;metabolism;metabolism;therapeutic use;antagonists & inhibitors;metabolism;therapeutic use;genetics;metabolism;metabolism;drug effects",
        "_version_":1605904071569440768},
      {
        "Doc_abstract":"The Bcr/Abl fusion protein directly causes chronic myelogenous leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Multiple independent studies have implicated Crkl, a small adapter protein, in transduction of oncogenic signals of Bcr/Abl and Crkl tyrosine-phosphorylation is used as a diagnostic tool for Philadelphia-positive leukemia. To evaluate the contribution of Crkl to this type of leukemia, we generated mutant mice that lack Crkl expression. We found that the overall survival of P190 BCR/ABL crkl-/- mice was comparable to that of genetically matched P190 BCR/ABL crkl +/+ mice. Both genotypes developed lymphoid lineage leukemia/lymphoma. Western blot analysis of -/- and +/+ lymphomas showed that the related Crk protein was tyrosine phosphorylated and could be found complexed with Bcr-Abl P190. These data indicate that possible therapeutic approaches that target Crkl may be complicated by the presence of pathways that compensate for lack of Crkl function.",
        "Doc_title":"BCR/ABL P190 transgenic mice develop leukemia in the absence of Crkl.",
        "Journal":"Oncogene",
        "Do_id":"12082638",
        "Doc_ChemicalList":"Antineoplastic Agents;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-crk;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Animals;Antineoplastic Agents;Cell Transformation, Neoplastic;Drug Design;Female;Fusion Proteins, bcr-abl;Genotype;Humans;Leukemia, Experimental;Lymphocytes;Male;Mice;Mice, Transgenic;Neoplastic Stem Cells;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-crk;Signal Transduction",
        "Doc_meshqualifiers":"pharmacology;genetics;genetics;physiology;genetics;pathology;pathology;genetics;physiology;physiology",
        "_version_":1605880630911959040},
      {
        "Doc_abstract":"Bcr-Abl tyrosine kinase activity is essential for the pathogenesis of chronic myeloid leukemia (CML). A number of Bcr-Abl substrates have been identified, but it is not clear which of these substrates are required for Bcr-Abl to transform cells. The multifunctional protein c-Cbl is one of the most prominently tyrosine-phosphorylated proteins in Bcr-Abl-expressing cells. Using cell lines and mice with homozygous disruption of the c-CBL locus, we investigated the role of this protein for Bcr-Abl-driven transformation. We find that although c-Cbl(-/-) fibroblast cell lines show a deficit in Bcr-Abl transformation compared to wild-type (Wt) cells, this deficit was less pronounced in c-Cbl(-/-) B cells derived from murine bone marrow. Most importantly, in a transplantation model of CML, Bcr-Abl was capable of inducing fatal leukemia in mice in the absence of c-Cbl protein. Our results indicate that c-Cbl is dispensable for Bcr-Abl-induced leukemogenesis in mice.",
        "Doc_title":"c-CBL is not required for leukemia induction by Bcr-Abl in mice.",
        "Journal":"Oncogene",
        "Do_id":"14654781",
        "Doc_ChemicalList":"Proto-Oncogene Proteins;Proto-Oncogene Proteins c-cbl;Ubiquitin-Protein Ligases;Fusion Proteins, bcr-abl;Cbl protein, mouse",
        "Doc_meshdescriptors":"Animals;Cell Transformation, Neoplastic;Fusion Proteins, bcr-abl;Leukemia, Experimental;Mice;Mice, Knockout;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-cbl;Ubiquitin-Protein Ligases",
        "Doc_meshqualifiers":"metabolism;metabolism;metabolism;metabolism",
        "_version_":1605784772658855936},
      {
        "Doc_abstract":"Omacetaxine mepesuccinate is a protein synthesis inhibitor that causes apoptosis of chronic myeloid leukemia cells without binding to the BCR-ABL tyrosine kinase that is implicated in the pathogenesis of this disease. It has been approved for the treatment of chronic myeloid leukemia in patients with resistance to two or more tyrosine kinase inhibitors and is emerging as an important agent in countering the highly resistant T315I mutation. This review will focus on the preclinical pharmacology, pharmacokinetics and clinical utility of omacetaxine mepesuccinate in the current milieu of tyrosine kinase inhibitor-dominant therapy of chronic myeloid leukemia. ",
        "Doc_title":"Omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia.",
        "Journal":"Drugs of today (Barcelona, Spain : 1998)",
        "Do_id":"23914353",
        "Doc_ChemicalList":"Harringtonines;homoharringtonine",
        "Doc_meshdescriptors":"Clinical Trials as Topic;Drug Interactions;Harringtonines;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive",
        "Doc_meshqualifiers":"adverse effects;pharmacology;therapeutic use;drug therapy",
        "_version_":1605876444131491840},
      {
        "Doc_abstract":"The co-occurrence of JAK2 V617F mutation with BCR-ABL reciprocal translocation is uncommon. We report a 60-year-old man who initially presented with phenotype of polycythemia vera (PV), which evolved into chronic myeloid leukemia and back to PV once treatment with imatinib was commenced. JAK2 V617F mutation and BCR-ABL fusion transcripts were detected in the initial sample. However, JAK2 V617F alleles diminished when BCR-ABL mRNA burden increased and reappeared once the patient was commenced on imatinib. The dynamic interaction between JAK2 V617F and BCR-ABL implies that two independent clones exist with the JAK2 V617F clone only achieving clonal dominance when BCR-ABL positive clones are suppressed by imatinib.",
        "Doc_title":"A man with concomitant polycythaemia vera and chronic myeloid leukemia: the dynamics of the two disorders.",
        "Journal":"International journal of hematology",
        "Do_id":"20047097",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Pyrimidines;Imatinib Mesylate;Fusion Proteins, bcr-abl;JAK2 protein, human;Janus Kinase 2",
        "Doc_meshdescriptors":"Antineoplastic Agents;Benzamides;Disease Progression;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Janus Kinase 2;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Piperazines;Polycythemia Vera;Pyrimidines",
        "Doc_meshqualifiers":"therapeutic use;genetics;genetics;complications;drug therapy;genetics;therapeutic use;complications;genetics;therapeutic use",
        "_version_":1605764040473182208},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) is a hematopoietic stem cell disease caused by the oncoprotein BCR-ABL, which exhibits a constitutive tyrosine kinase activity. Imatinib mesylate (IM), an inhibitor of the tyrosine kinase activity of BCR-ABL, has been used as a first-line therapy for CML. However, IM is less effective in the accelerated phase and blastic phases of CML and certain patients develop IM resistance due to the mutation and amplification of the BCR-ABL gene. Fangchinoline, an important chemical constituent from the dried roots of ",
        "Doc_title":"Fangchinoline induces G0/G1 arrest by modulating the expression of CDKN1A and CCND2 in K562 human chronic myelogenous leukemia cells.",
        "Journal":"Experimental and therapeutic medicine",
        "Do_id":"23596478",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605757395226591232},
      {
        "Doc_abstract":"The BCR-ABL gene rearrangement, the initial event in the development of chronic myeloid leukemia, primarily produces clonal expansion in CML by blocking apoptosis, a genetically programmed process of autonomous cell death. The mechanism by which BCR-ABL blocks apoptosis remains unclear, although recent data are beginning to shed light on the signaling pathway. As with other antiapoptotic signals, BCR-ABL induces cellular resistance to a wide spectrum of cytotoxic antitumor agents. However, apoptosis induced by both cytotoxic T lymphocytes and natural killer or lymphokine-activated killer cells is not blocked by BCR-ABL. A substantial number of patients with chronic myeloid leukemia can now be cured, and the prognosis has improved even for those patients who are not cured. Interferon-alpha has emerged as the treatment of choice for patients who do not undergo an allogeneic bone marrow transplantation. The availability of allogeneic bone marrow transplantation has been increased by the ability to find unrelated donors, although graft-versus-host disease remains a major problem. Adoptive immunotherapy with donor lymphocyte transfusions will induce durable remissions and possibly cures in many patients who relapse after allogeneic BMT. Moreover, a number of investigational approaches, especially autologous BMT, appear promising.",
        "Doc_title":"Biology and treatment of chronic myeloid leukemia.",
        "Journal":"Current opinion in oncology",
        "Do_id":"9090488",
        "Doc_ChemicalList":"Immunologic Factors;Interferon-alpha;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Animals;Apoptosis;Bone Marrow Transplantation;Drug Resistance, Neoplasm;Fusion Proteins, bcr-abl;Humans;Immunologic Factors;Immunotherapy, Adoptive;Interferon-alpha;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Lymphocyte Transfusion;Mice;Philadelphia Chromosome",
        "Doc_meshqualifiers":"genetics;genetics;physiology;therapeutic use;therapeutic use;genetics;pathology;therapy",
        "_version_":1605751414051569664},
      {
        "Doc_abstract":"Chronic myeloid leukemia(CML) is a generic term that includes five subtypes; i.e. chronic granulocytic leukemia(CGL) (95% of all CML, 90% are Ph+, 5% are Ph-, BCR/ABL+), atypical CML(survival is worse than that of CGL), chronic myelomonocytic leukemia(a subtype of myelodysplastic syndrome), chronic neutrophilic leukemia (Ph-, BCR/ABL-) and juvenile CML(Ph-, BCR/ABL-). It is not so easy to make a diagnosis of Ph-negative CML. Also, about 25% of adult acute lymphoid leukemia(ALL) patients and some essential thrombocythemia patients have Ph chromosome. In addition, about a half of cases with Ph-positive ALL have the same size of BCR/ABL fusion protein as that in Ph-positive CML. It is necessary to distinguish them by the distinctive morphological, cytogenetical and immunological characteristics of these diseases.",
        "Doc_title":"[Differential diagnosis of chronic myeloid leukemia and the related disorders].",
        "Journal":"Nihon rinsho. Japanese journal of clinical medicine",
        "Do_id":"11766339",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Diagnosis, Differential;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Leukemia, Neutrophilic, Chronic;Myelodysplastic Syndromes;Philadelphia Chromosome;Precursor Cell Lymphoblastic Leukemia-Lymphoma",
        "Doc_meshqualifiers":"diagnosis;diagnosis;diagnosis;diagnosis;genetics",
        "_version_":1605880221557325824},
      {
        "Doc_abstract":"We sought to understand the genesis of the t(9;22) by characterizing genomic breakpoints in chronic myeloid leukemia (CML) and BCR-ABL-positive acute lymphoblastic leukemia (ALL). BCR-ABL breakpoints were identified in p190 ALL (n=25), p210 ALL (n=25) and p210 CML (n=32); reciprocal breakpoints were identified in 54 cases. No evidence for significant clustering and no association with sequence motifs was found except for a breakpoint deficit in repeat regions within BCR for p210 cases. Comparison of reciprocal breakpoints, however, showed differences in the patterns of deletion/insertions between p190 and p210. To explore the possibility that recombinase-activating gene (RAG) activity might be involved in ALL, we performed extra-chromosomal recombination assays for cases with breakpoints close to potential cryptic recombination signal sequence (cRSS) sites. Of 13 ALL cases tested, 1/10 with p190 and 1/3 with p210 precisely recapitulated the forward BCR-ABL breakpoint and 1/10 with p190 precisely recapitulated the reciprocal breakpoint. In contrast, neither of the p210 CMLs tested showed functional cRSSs. Thus, although the t(9;22) does not arise from aberrant variable (V), joining (J) and diversity (D) (V(D)J) recombination, our data suggest that in a subset of ALL cases RAG might create one of the initiating double-strand breaks.",
        "Doc_title":"Analysis of genomic breakpoints in p190 and p210 BCR-ABL indicate distinct mechanisms of formation.",
        "Journal":"Leukemia",
        "Do_id":"20703256",
        "Doc_ChemicalList":"Homeodomain Proteins;RAG-1 protein;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Base Sequence;Chromosome Breakpoints;Chromosomes, Human, Pair 22;Chromosomes, Human, Pair 9;Fusion Proteins, bcr-abl;Genome, Human;Homeodomain Proteins;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Molecular Sequence Data;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Prognosis;Sequence Homology, Nucleic Acid;Translocation, Genetic",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;genetics;genetics;pathology;genetics;pathology",
        "_version_":1605741972363935746},
      {
        "Doc_abstract":"Dasatinib, (former BMS 354825), is an orally available small-molecule multikinase inhibitor. It potently inhibits BCR-ABL and SRC-family kinases (SRC, LCK, YES, FYN), but also c-KIT, PDGFR-alpha and beta, and ephrin receptor kinase.Dasatinib is about 300 times more potent than imatinib in cells expressing unmutated BCR-ABL in vitro. The drug has demonstrated activity against clinically relevant mutations, including those associated with poor prognosis during ongoing imatinib therapy.Dasatinib is approved for the treatment of patients with BCR-ABL-positive chronic myeloid leukemia (CML), resistant or intolerant to imatinib in chronic, accelerated, and blast phase. It also is approved for the treatment of Philadelphia Chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) resistant or intolerant to imatinib.A single daily dose of 100 mg in chronic phase CML results in high hematologic and molecular remission rates and prolongation of survival. In accelerated and blastic phase as well as in ALL, 70 mg twice daily is recommended. Complete hematologic and cytogenetic remissions (CR) frequently occur even in this patient group with poor prognosis. Remissions however are very short.Side effects of dasatinib are frequent but mostly moderate and manageable and include cytopenias and pleural effusions. The role of dasatinib in other diseases, including solid tumors, has to be identified.",
        "Doc_title":"Dasatinib.",
        "Journal":"Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer",
        "Do_id":"20072833",
        "Doc_ChemicalList":"Oncogene Proteins v-abl;Protein Kinase Inhibitors;Pyrimidines;Thiazoles;Proto-Oncogene Proteins c-kit;Receptor, Platelet-Derived Growth Factor alpha;src-Family Kinases;Dasatinib",
        "Doc_meshdescriptors":"Clinical Trials as Topic;Dasatinib;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Oncogene Proteins v-abl;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Protein Kinase Inhibitors;Proto-Oncogene Proteins c-kit;Pyrimidines;Receptor, Platelet-Derived Growth Factor alpha;Thiazoles;src-Family Kinases",
        "Doc_meshqualifiers":"drug therapy;antagonists & inhibitors;drug therapy;therapeutic use;antagonists & inhibitors;adverse effects;pharmacokinetics;pharmacology;therapeutic use;antagonists & inhibitors;adverse effects;pharmacokinetics;pharmacology;therapeutic use;antagonists & inhibitors",
        "_version_":1605880958210277376},
      {
        "Doc_abstract":"Chronic myeloid leukemia is a disorder that develops when a hematopoietic stem cell acquires the Philadelphia chromosome carrying the chimeric BCR/ABL oncogene leading to a deregulated cell proliferation and a decreased apoptosis in response to mutagenic stimuli. Therefore, it has been  considered that BCR/ABL oncogene is a potential attractive target for anticancer agents. Antisense strategies aiming to suppress the expression of BCR/ABL in chronic myeloid leukemia cells have been studied by several research groups over the last decade. In the present study, the effect of  Morpholino Oligo Antisense in BCR/ABL oncogene silencing was evaluated. To examine the hypothesis, K562 was used as a BCR/ABL fusion gene positive cell line using a Jurkat cell line as a control. The capacity of Morpholino Oligo Antisense in inhibiting the translation of p210(bcr-abl)  protein by a western blotting technique, inhibition of cell proliferation, and stimulation of apoptosis by flow cytometric analysis after 24 and 48 hours was studied. Prolonged exposure of K562 cell line to Morpholino Oligo Antisense targeted against BCR-ABL showed proliferation inhibition  as the main feature. Following western blotting, we found that complete silencing of BCR-ABL had been achieved but flow cytometric analysis showed no significant apoptosis. The results indicate that Morpholino Oligo Antisense was able to inhibit p210(bcr-abl), but did not induce apoptosis  due to co-silencing of BCR.",
        "Doc_title":"Morpholino Oligo Antisense efficiently suppresses BCR/ABL and cell proliferation in CML: specific inhibition of BCR-ABL gene expression by Morpholino Oligo Antisense in BCR-ABL(+) cells.",
        "Journal":"Hematology (Amsterdam, Netherlands)",
        "Do_id":"22549445",
        "Doc_ChemicalList":"Morpholinos;Oligonucleotides, Antisense;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Apoptosis;Base Sequence;Cell Growth Processes;Cell Line, Tumor;Cell Survival;Flow Cytometry;Fusion Proteins, bcr-abl;Gene Expression;Humans;Jurkat Cells;K562 Cells;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Morpholinos;Oligonucleotides, Antisense",
        "Doc_meshqualifiers":"drug effects;genetics;drug effects;genetics;drug effects;genetics;antagonists & inhibitors;biosynthesis;genetics;genetics;metabolism;pathology;therapy;genetics;pharmacology;genetics;pharmacology",
        "_version_":1605904890143440896},
      {
        "Doc_abstract":"We report the results of BCR/ABL translocation analysis on interphase leukemic cells of 33 acute myeloid leukemia (AML) patients by fluorescence in situ hybridization. Of these, there were 13 persons exposed to ionizing radiation due to the Chernobyl accident with radiation-associated AML and 20 patients with spontaneous disease. BCR/ABL translocation which was detected in 4 and I case respectively may play an important role in radiation-induced leukemigenesis.",
        "Doc_title":"[Determination of BCR/ABL translocation in radiation-associated acute myeloid leukemia patients by fluorescence in situ hybridization].",
        "Journal":"TSitologiia i genetika",
        "Do_id":"16396321",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Fusion Proteins, bcr-abl;Humans;In Situ Hybridization, Fluorescence;Male;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Radiation, Ionizing;Radioactive Hazard Release;Translocation, Genetic;Ukraine",
        "Doc_meshqualifiers":"genetics;etiology;genetics",
        "_version_":1605928617987014656},
      {
        "Doc_abstract":"Despite the lack of long-term survival data, the impressive results obtained with imatinib mesylate (Gleevec) therapy and the lack of serious adverse events have significantly altered the management of patients with chronic myeloid leukemia. Nevertheless, a large proportion of patients with more advanced disease will develop resistance to imatinib mesylate monotherapy. To prevent the development of resistance, an understanding of the pathophysiology of chronic myeloid leukemia, including the signaling pathways that are activated by the BCR-ABL fusion protein, and the mechanisms of resistance to imatinib are required. This review summarizes the pathogenesis of chronic myeloid leukemia and the potential therapeutic impact of small molecule inhibitors that target pathways critical to the growth or survival of the leukemic cells in patients with chronic myeloid leukemia.",
        "Doc_title":"Advances in targeted therapy for chronic myeloid leukemia.",
        "Journal":"Expert review of anticancer therapy",
        "Do_id":"12820774",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Animals;Drug Delivery Systems;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Signal Transduction",
        "Doc_meshqualifiers":"methods;trends;drug therapy;metabolism;physiopathology;drug effects;physiology",
        "_version_":1605758688791887872},
      {
        "Doc_abstract":"Resistance of chronic myeloid leukemia (CML) to tyrosine kinase inhibitor imatinib mesylate (IM) is most often due to point mutations in the Bcr-Abl fusion gene. T315I mutation (resulting in substitution of Ile for a Thr residue at the \"gatekeeper\" position 315) raises particular concern, because it also provides resistance to second-generation kinase inhibitors already approved for clinical use (nilotinib and dasatinib). Much effort is therefore focused on alternative molecular-based strategies. Previous studies proved that binding to 14-3-3 scaffolding proteins leads to cytoplasmic compartmentalization and suppression of proapoptotic and antiproliferative signals associated with Bcr-Abl protein kinase, hence contributing to leukemic clone expansion. Here we investigated the effect of 14-3-3 inhibition disruption on hematopoietic cells expressing the IM-sensitive wild type Bcr-Abl and the IM-resistant T315I mutation. Using a virtual screening protocol and docking simulations, we identified a nonpeptidic inhibitor of 14-3-3, named BV02, that exhibits a remarkable cytotoxicity against both cell types. c-Abl release from 14-3-3, promoting its relocation to nuclear compartment (where it triggers transcription of p73-dependent proapoptotic genes) and to mitochondrial membranes (where it induces the loss of mitochondrial transmembrane potential) combined with c-Abl enhanced association with caspase 9 (a critical step of sequential caspase activation further contributing to c-Abl pro-apoptotic function) has a prominent role in the effect of BV02 on Bcr-Abl-expressing cells. In conclusion, BV02 may be considered as a treatment option for CML and, in particular, for more advanced phases of the disease that developed IM resistance as a consequence of Bcr-Abl point mutations.",
        "Doc_title":"A new nonpeptidic inhibitor of 14-3-3 induces apoptotic cell death in chronic myeloid leukemia sensitive or resistant to imatinib.",
        "Journal":"The Journal of pharmacology and experimental therapeutics",
        "Do_id":"21041536",
        "Doc_ChemicalList":"14-3-3 Proteins;Antineoplastic Agents;BV02 compound;Benzamides;Piperazines;Pyrazoles;Pyrimidines;Imatinib Mesylate",
        "Doc_meshdescriptors":"14-3-3 Proteins;Amino Acid Sequence;Animals;Antineoplastic Agents;Apoptosis;Benzamides;Binding Sites;Cell Death;Cell Line;Cell Line, Tumor;Crystallography, X-Ray;Drug Resistance, Neoplasm;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mice;Molecular Sequence Data;Piperazines;Pyrazoles;Pyrimidines",
        "Doc_meshqualifiers":"antagonists & inhibitors;chemistry;pharmacology;drug effects;physiology;chemistry;pharmacology;therapeutic use;drug effects;physiology;drug effects;physiology;physiology;drug therapy;metabolism;pathology;pharmacology;therapeutic use;chemistry;pharmacology;therapeutic use;pharmacology;therapeutic use",
        "_version_":1605761268633829376},
      {
        "Doc_abstract":"The tyrosine kinase inhibitor STI571 inhibits BCR/ABL and induces hematologic remission in most patients with chronic myeloid leukemia. In addition to BCR/ABL, STI571 also inhibits v-Abl, TEL/ABL, the native platelet-derived growth factor (PDGF)beta receptor, and c-KIT, but it does not inhibit SRC family kinases, c-FMS, FLT3, the epidermal growth factor receptor, or multiple other tyrosine kinases. ARG is a widely expressed tyrosine kinase that shares substantial sequence identity with c-ABL in the kinase domain and cooperates with ABL to regulate neurulation in the developing mouse embryo. As described here, ARG has recently been implicated in the pathogenesis of leukemia as a fusion partner of TEL. A TEL/ARG fusion was constructed to determine whether ARG can be inhibited by STI571. When expressed in the factor-dependent murine hematopoietic cell line Ba/F3, the TEL/ARG protein was heavily phosphorylated on tyrosine, increased tyrosine phosphorylation of multiple cellular proteins, and induced factor-independent proliferation. The effects of STI571 on Ba/F3 cells transformed with BCR/ABL, TEL/ABL, TEL/PDGFbetaR, or TEL/ARG were then compared. STI571 inhibited tyrosine phosphorylation and cell growth of Ba/F3 cells expressing BCR/ABL, TEL/ABL, TEL/PDGFbetaR, and TEL/ARG with an IC(50) of approximately 0.5 microM in each case, but it had no effect on untransformed Ba/F3 cells growing in IL-3 or on Ba/F3 cells transformed by TEL/JAK2. Culture of TEL/ARG-transfected Ba/F3 cells with IL-3 completely prevented STI571-induced apoptosis in these cells, similar to what has been observed with BCR/ABL- or TEL/ABL-transformed cells. These results indicate that ARG is a target of the small molecule, tyrosine kinase inhibitor STI571.",
        "Doc_title":"ARG tyrosine kinase activity is inhibited by STI571.",
        "Journal":"Blood",
        "Do_id":"11290609",
        "Doc_ChemicalList":"Benzamides;DNA, Complementary;Enzyme Inhibitors;Neoplasm Proteins;Oncogene Proteins, Fusion;Piperazines;Pyrimidines;Recombinant Fusion Proteins;TEL-ABL fusion protein, human;TEL-ARG fusion protein, human;TEL-PDGFRbeta fusion protein, human;Imatinib Mesylate;Adenosine Triphosphate;Protein Kinases;ARG tyrosine kinase;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adenosine Triphosphate;Amino Acid Sequence;Animals;Benzamides;Binding Sites;Cell Division;Cell Line, Transformed;Cell Transformation, Neoplastic;DNA, Complementary;Enzyme Inhibitors;Fusion Proteins, bcr-abl;Hematopoietic Stem Cells;Imatinib Mesylate;Mice;Molecular Sequence Data;Neoplasm Proteins;Oncogene Proteins, Fusion;Phosphorylation;Piperazines;Protein Kinases;Protein Processing, Post-Translational;Protein-Tyrosine Kinases;Pyrimidines;Recombinant Fusion Proteins;Sequence Alignment;Sequence Homology, Amino Acid;Transfection",
        "Doc_meshqualifiers":"metabolism;drug effects;drug effects;enzymology;drug effects;genetics;genetics;pharmacology;genetics;physiology;drug effects;genetics;metabolism;genetics;physiology;drug effects;pharmacology;chemistry;drug effects;antagonists & inhibitors;genetics;metabolism;pharmacology",
        "_version_":1605762747864186880},
      {
        "Doc_abstract":"The case of a 12 yr old female with bcr-abl positive chronic myeloid leukemia who subsequently developed a fatal AML-M6b (pure erythroleukemia) blast crisis is presented. The case is unique for its rarity of occurrence and for the striking resemblance that the circulating proerythroblasts showed to the giant cells characteristically seen in Parvovirus B19-induced acute pure red cell aplasia. This is, to the best of our knowledge, the first description of such cells in a blast crisis of chronic myeloid leukemia.",
        "Doc_title":"An acute myeloid leukemia M6b blast crisis with giant proerythroblasts in chronic myeloid leukemia.",
        "Journal":"Journal of pediatric hematology/oncology",
        "Do_id":"19262253",
        "Doc_ChemicalList":"Antineoplastic Agents;Hydroxyurea",
        "Doc_meshdescriptors":"Antineoplastic Agents;Blast Crisis;Blood Transfusion;Child;Erythroblasts;Female;Humans;Hydroxyurea;Immunohistochemistry;Leukemia, Erythroblastic, Acute;Neoplasms, Multiple Primary",
        "Doc_meshqualifiers":"therapeutic use;metabolism;pathology;therapy;pathology;therapeutic use;metabolism;pathology;therapy;metabolism;pathology;therapy",
        "_version_":1605899275934367744},
      {
        "Doc_abstract":"The Philadelphia chromosome (Ph) is found in both chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). The Ph translocation, t(9;22)(q34;q11), can disrupt the BCR gene on chromosome 22 in one to two areas called the major (Mbcr1) and minor (mbcr1) breakpoint cluster regions. In CML the breakpoint has been mapped almost exclusively to Mbcr1, whereas in Ph positive ALL both Mbcr1 and the upstream mbcr1 breakpoints have been described. In this communication we describe an unusual patient with typical chronic phase Ph positive CML and evidence of the uncharacteristic mbcr1 breakpoint, predicting expression of the ALL-type p190 fusion protein. Fluorescence in situ hybridization demonstrated BCR gene rearrangement, the reverse transcription polymerase chain reaction detected the BCR-ABL fusion mRNA characteristic of the mbcr1 breakpoint, and failed to detect BCR-ABL mRNA characteristic of the Mbcr1 breakpoint. Southern blot analysis revealed no rearrangement in Mbcr1, and direct sequencing of the PCR product confirmed it to be the ALL-type mbcr1 fusion mRNA with the first exon of the BCR gene fused to ABL exon a2. This case differs from the previously reported cases of \"p190\" CML in that the patient presented without abnormal hematopoietic features other than those found in typical CML and provides further evidence that the p190 mRNA is not sufficient to cause an acute rather than chronic leukemia.",
        "Doc_title":"Unusual expression of mRNA typical of Philadelphia positive acute lymphoblastic leukemia detected in chronic myeloid leukemia.",
        "Journal":"American journal of hematology",
        "Do_id":"8756076",
        "Doc_ChemicalList":"Molecular Probes;RNA, Messenger;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Base Sequence;Fusion Proteins, bcr-abl;Gene Rearrangement;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Molecular Probes;Molecular Sequence Data;Philadelphia Chromosome;Polymerase Chain Reaction;Precursor Cell Lymphoblastic Leukemia-Lymphoma;RNA, Messenger;Stem Cells;Transcription, Genetic",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;metabolism;physiology",
        "_version_":1605753065516826624},
      {
        "Doc_abstract":"Interphase fluorescence in situ hybridization (iFISH) is increasingly used for the identification of BCR/ABL gene rearrangements in chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). In the present study, we have explored the incidence of both typical and atypical iFISH patterns of BCR/ABL gene rearrangements in a series of 168 consecutive BCR/ABL+ patients--135 CML, 31 precursor B-ALL and two acute myeloblastic leukemia (AML) cases--and established their underlying genetic alterations through further molecular and chromosome analyses. Two different FISH probes (Vysis Inc., Downers Grove, IL, USA) were used: the LSI BCR/ABL dual color extra signal (ES) and the dual color dual fusion BCR/ABL probe (D-FISH). Our results show that most BCR/ABL+ patients (83%, including 88% of all CML, 61% of ALL and one of two AML) displayed typical iFISH patterns of either Major (M) BCR/ABL (87% of CML, 13% of ALL and one of the two AML) or minor (m) BCR/ABL gene rearrangements (1% of all CML and 48% of ALL cases) with the two probes. Further molecular and cytogenetic studies confirmed the presence of such typical rearrangements in all except one of these ALL cases who had coexistence of an MBCR/ABL and an mBCR/ABL gene rearrangement together with monosomy 9. In the remaining 29 cases (17%), up to five different atypical iFISH patterns were detected with the ES probe. Atypical iFISH patterns were most frequently due to additional numerical changes--most often supernumerary Philadelphia (Ph) chromosome (7%) but also gain or loss of chromosome 9 (1%) or 22 (1%). Deletion of 9q sequences proximal to the breakpoint were also frequently observed with the ES probe (8%). Application of the D-FISH probe showed that in most of these latter cases (5%) deletion of 22q sequences distal to the breakpoint also occurred. The remaining cases with atypical iFISH had cryptic insertion of BCR in 9q34 (1%). Exact interpretation of each iFISH pattern was supported by FISH on metaphases and molecular determination of the BCR breakpoint. In summary, our results indicate that despite the high incidence of typical iFISH patterns of BCR/ABL gene rearrangements, atypical patterns are also found in BCR/ABL+ acute leukemias; the precise definition of the alteration present in individual cases is dependent on metaphase studies and molecular definition of the breakpoint.",
        "Doc_title":"Patterns of BCR/ABL gene rearrangements by interphase fluorescence in situ hybridization (FISH) in BCR/ABL+ leukemias: incidence and underlying genetic abnormalities.",
        "Journal":"Leukemia",
        "Do_id":"12764379",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Bone Marrow;Chromosome Aberrations;Chromosomes, Human, Pair 22;Chromosomes, Human, Pair 9;Fusion Proteins, bcr-abl;Gene Deletion;Gene Rearrangement;Humans;In Situ Hybridization, Fluorescence;Incidence;Interphase;Karyotyping;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Monosomy;Precursor Cell Lymphoblastic Leukemia-Lymphoma",
        "Doc_meshqualifiers":"pathology;genetics;genetics;genetics;genetics;genetics",
        "_version_":1605748218586464256},
      {
        "Doc_abstract":"Blast cells from an unselected consecutive series of 84 adults presenting with acute lymphoblastic leukemia (ALL) to St Bartholomew's Hospital over a seven year period were tested prospectively by cytogenetic and retrospectively by RT-PCR analysis for the presence of the Ph translocation and bcr-abl mRNA. This combination gave an overall figure of 20.3% for bcr-abl-positive and/or Ph-positive ALL. The incidence of bcr-abl-positive/Ph-positive ALL was most common between the ages of 31 and 50 years, becoming less common after the age of 50. Eight out of ten bcr-abl-positive patients expressed the e1a2 mRNA transcript, the other two expressed the b3a2 and b2a3 transcripts respectively. Cells from all patients with bcr-abl mRNA transcripts expressed the appropriate p190 or p210 bcr-abl protein and all were Ph-positive.",
        "Doc_title":"Detection and significance of bcr-abl mRNA transcripts and fusion proteins in Philadelphia-positive adult acute lymphoblastic leukemia.",
        "Journal":"Leukemia",
        "Do_id":"8412311",
        "Doc_ChemicalList":"RNA, Messenger;Protein Kinases;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Base Sequence;Fusion Proteins, bcr-abl;Humans;Karyotyping;Middle Aged;Molecular Sequence Data;Philadelphia Chromosome;Polymerase Chain Reaction;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Protein Kinases;RNA, Messenger;Retrospective Studies;Transcription, Genetic",
        "Doc_meshqualifiers":"analysis;genetics;genetics;genetics;genetics",
        "_version_":1605811933253992448},
      {
        "Doc_abstract":"An atypical case of Philadelphia (Ph) negative, e1a2 BCR-ABL transcript positive chronic myeloid leukemia (CML) characterized with cyclic periodic leukocytosis and spontaneous remissions is reported. The patient was treated with imatinib and good hematology response with molecular remission was achieved. So far, only few Ph positive CML patients expressing p190 BCR-ABL protein and different clinical characteristics and treatment have been described in the literature. This is the first report of Philadelphia negative, p190 BCR-ABL positive CML with cyclic spontaneous oscillation of white blood cell count (WBC), and excellent response to imatinib treatment.",
        "Doc_title":"Molecular response to imatinib in patient with Ph negative p190 BCR-ABL transcript positive chronic myeloid leukemia with cyclic leukocytosis.",
        "Journal":"Leukemia research",
        "Do_id":"19091403",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Pyrimidines;RNA, Messenger;Imatinib Mesylate",
        "Doc_meshdescriptors":"Adult;Antineoplastic Agents;Benzamides;Electrophoresis, Agar Gel;Genes, abl;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Leukocytosis;Male;Piperazines;Pyrimidines;RNA, Messenger;Reverse Transcriptase Polymerase Chain Reaction",
        "Doc_meshqualifiers":"therapeutic use;drug therapy;genetics;therapeutic use;therapeutic use;genetics",
        "_version_":1605742783879970818},
      {
        "Doc_abstract":"Chimera gene products, the molecular hallmark of acute leukemias were detected and quantified for diagnostic purposes and for follow up of therapy and characterization of minimal residual disease. In acute lymphoid leukemia mainly the bcr-abl, and in acute myeloid leukemias, depending on the morphological classification, the aml-eto, bcr-abl, pml-rara, plzf-rara, and cbfb-myh chimeras were investigated. The determinations were based on reverse transcriptase-polymerase chain reaction. The results were used in diagnosis of 315 new leukemic patients, and in follow up of 70 ones. In the present paper the usefulness of the applied methods is illustrated by presentation of data of 38 (27, acute myeloid leukemias and 11 acute lymphoid ones) patients out of the 139 treated in the National Institute during the last years.",
        "Doc_title":"[Role of molecular genetic investigations in the diagnosis of acute leukemias and in the detection of minimal residual disease].",
        "Journal":"Orvosi hetilap",
        "Do_id":"11449838",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Acute Disease;Adult;Chimera;Female;Gene Expression Regulation, Neoplastic;Humans;Leukemia;Leukemia, Myeloid;Male;Middle Aged;Molecular Biology;Neoplasm, Residual;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Retrospective Studies;Reverse Transcriptase Polymerase Chain Reaction",
        "Doc_meshqualifiers":"genetics;diagnosis;genetics;diagnosis;genetics;diagnosis;genetics",
        "_version_":1605824035437936640},
      {
        "Doc_abstract":"In patients with Philadelphia-positive acute lymphoblastic leukemia, resistance to treatment with tyrosine kinase inhibitors is frequent and most often associated with the development of point mutations in the BCR-ABL kinase domain. We aimed to assess: (i) in how many patients BCR-ABL kinase domain mutations are already detectable at relatively low levels at the time of diagnosis, and (ii) whether mutation detection correlates with subsequent response to therapy.;We retrospectively analyzed samples collected at diagnosis from 15 patients with Philadelphia-positive acute lymphoblastic leukemia who subsequently received tyrosine kinase inhibitor therapy (dasatinib) by cloning the BCR-ABL kinase domain in a bacterial vector and sequencing 200 independent clones per sample.;Mutations at relatively low levels (2-4 clones out of 200) could be detected in all patients--eight who relapsed and seven who achieved persistent remission. Each patient had evidence of two to eight different mutations, the majority of which have never been reported in association with resistance to tyrosine kinase inhibitors. In two patients out of six who relapsed because of a mutation, the mutation (a T315I) was already detectable in a few clones at the time of diagnosis. On the other hand, a patient who was found to harbor an F317L mutation is in persistent remission on dasatinib.;Our results suggest that the BCR-ABL kinase domain is prone to randomly accumulate point mutations in Philadelphia-positive acute lymphoblastic leukemia, although the presence of these mutations in a relatively small leukemic subclone does not always preclude a primary response to tyrosine kinase inhibitors.",
        "Doc_title":"Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis.",
        "Journal":"Haematologica",
        "Do_id":"21193419",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adult;Aged;Amino Acid Substitution;Female;Fusion Proteins, bcr-abl;Gene Order;Humans;Male;Middle Aged;Mutation;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Retrospective Studies",
        "Doc_meshqualifiers":"genetics;genetics;genetics;diagnosis;genetics",
        "_version_":1605805136461955072},
      {
        "Doc_abstract":"MK-0457, an Aurora kinase and BCR-ABL inhibitor, was studied on a Phase I/II study in 77 patients with refractory hematologic malignancies. The average number of cycles per patient was 3 (range 1-21). Maximum tolerated doses for a 5-day short infusion and continuous infusion regimens were 40 mg/m(2)/h and 144 mg/m(2)/h, respectively. Drug-related adverse events (AEs) included transient mucositis and alopecia. Eight of 18 patients with BCR-ABL T315I-mutated chronic myelogenous leukemia (44%) had hematologic responses and one of three patients (33%) with Philadelphia chromosome-positive acute lymphoblastic leukemia obtained complete remission. MK-0457 has important activity in patients with leukemias expressing the highly resistant T315I BCR-ABL mutation.",
        "Doc_title":"MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia.",
        "Journal":"Leukemia",
        "Do_id":"22772060",
        "Doc_ChemicalList":"Piperazines;Protein Kinase Inhibitors;VX680;Fusion Proteins, bcr-abl;Aurora Kinases;Protein-Serine-Threonine Kinases",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Aged, 80 and over;Aurora Kinases;Drug Resistance, Neoplasm;Female;Follow-Up Studies;Fusion Proteins, bcr-abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Leukemia, Myeloid, Acute;Male;Maximum Tolerated Dose;Middle Aged;Mutation;Neoplasm Staging;Philadelphia Chromosome;Piperazines;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Prognosis;Protein Kinase Inhibitors;Protein-Serine-Threonine Kinases;Remission Induction;Young Adult",
        "Doc_meshqualifiers":"drug effects;genetics;antagonists & inhibitors;drug therapy;genetics;drug therapy;genetics;genetics;therapeutic use;drug therapy;genetics;therapeutic use;antagonists & inhibitors",
        "_version_":1605742673955651585},
      {
        "Doc_abstract":"A common problem in cell culturing is cross-contamination with other cells or misidentification of cells. An effective cell culture quality and identity control is required in order to avoid inter- and intraspecies contamination of cell lines and their further propagation and dissemination. We present evidence that supposedly unrelated cell lines that we received from the original investigators are in fact related to the chronic myeloid leukemia cell line K-562. The sister cell lines SPI-801 and SPI-802 were originally established from a patient with T-cell acute lymphoblastic leukemia and displayed T-cell associated features. However, data from morphological evaluation, immunophenotyping, bcr-abl gene rearrangement analysis, DNA fingerprinting, Northern blot analysis of globin gene expression and esterase isoenzyme analysis clearly established that the three cell lines are related. Cytogenetic examination while not proving the common identity of the cells provided further evidence for the suspected common origin of all three cell lines. Chromosome banding, DNA fingerprinting and bcr-abl genotyping suggested further evolution of these clones during long-term cultivation. Quality and identity control is an essential feature of cell culture technique. Only regular monitoring for purity and integrity of cell lines will significantly reduce the incidence of cell line contamination and misidentification.",
        "Doc_title":"Multiparameter approach in the identification of cross-contaminated leukemia cell lines.",
        "Journal":"Leukemia & lymphoma",
        "Do_id":"8220135",
        "Doc_ChemicalList":"Antigens, Neoplasm;Biomarkers, Tumor;DNA, Neoplasm;Isoenzymes;Neoplasm Proteins;Oncogene Proteins;Proto-Oncogene Proteins;Globins;Protein-Tyrosine Kinases;BCR protein, human;Proto-Oncogene Proteins c-bcr;Esterases",
        "Doc_meshdescriptors":"Antigens, Neoplasm;Artifacts;Biomarkers, Tumor;Cell Differentiation;Child;Culture Techniques;DNA Fingerprinting;DNA, Neoplasm;Esterases;Female;Gene Rearrangement;Globins;Humans;Immunophenotyping;Isoenzymes;Karyotyping;Leukemia, Erythroblastic, Acute;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Leukemia-Lymphoma, Adult T-Cell;Middle Aged;Neoplasm Proteins;Oncogene Proteins;Pleural Effusion;Precursor B-Cell Lymphoblastic Leukemia-Lymphoma;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Protein-Tyrosine Kinases;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-bcr;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"analysis;analysis;methods;analysis;analysis;genetics;analysis;pathology;pathology;pathology;analysis;genetics;pathology;pathology;pathology",
        "_version_":1605820788366114816},
      {
        "Doc_abstract":"bcr gene rearrangement and c-abl gene expression were analyzed in a patient with Philadelphia chromosome (Ph1)-positive hybrid acute leukemia with simultaneous proliferation of lymphoid and myeloid blasts. These data were compared with those from a patient with chronic myelogenous leukemia (CML) in mixed crisis. The leukemic cells of both patients showed immuno-phenotypic profiles such as non-T, non-B common ALL with some MPO-positive leukemic cells and rearranged JH genes. On analysis of molecular events associated with the Ph1 chromosome, the leukemic cells of a patient with CML in mixed crisis showed bcr rearrangement and an 8.5-kb bcr-abl chimeric mRNA, but those of a patient with Ph1-positive hybrid acute leukemia showed no 8.5-kb bcr-abl mRNA, as previously reported in a number of Ph1-positive acute lymphoblastic leukemia (ALL) cases. These results revealed that the molecular event found in Ph1-positive ALL is not only restricted to lymphoid lineage but may play an important role in the proliferation of the myeloid lineage.",
        "Doc_title":"bcr rearrangement and C-abl gene expression in Ph1-positive hybrid acute leukemia with simultaneous proliferation of lymphoid and myeloid blasts.",
        "Journal":"Blut",
        "Do_id":"2655744",
        "Doc_ChemicalList":"Proto-Oncogene Proteins;RNA, Messenger;Protein-Tyrosine Kinases;Proto-Oncogene Proteins c-abl;BCR protein, human;Proto-Oncogene Proteins c-bcr",
        "Doc_meshdescriptors":"Adult;Blotting, Southern;Bone Marrow Cells;Female;Gene Expression Regulation;Gene Rearrangement;Genes, Immunoglobulin;Humans;Leukemia, Lymphoid;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Molecular Probe Techniques;Protein-Tyrosine Kinases;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-abl;Proto-Oncogene Proteins c-bcr;RNA, Messenger",
        "Doc_meshqualifiers":"pathology;genetics;genetics;analysis",
        "_version_":1605903583049416704},
      {
        "Doc_abstract":"In lymph node (LN) proliferation centers in chronic lymphocytic leukemia (CLL), the environment protects from apoptotic and cytotoxic triggers. Here, we aimed to define the molecular basis for the increased drug resistance and searched for novel strategies to circumvent it. The situation in CLL LN could be mimicked by prolonged in vitro CD40 stimulation, which resulted in up-regulation of antiapoptotic Bcl-xL, A1/Bfl-1, and Mcl-1 proteins, and afforded resistance to various classes of drugs (fludarabine, bortezomib, roscovitine). CD40 stimulation also caused ERK-dependent reduction of Bim-EL protein, but ERK inhibition did not prevent drug resistance. Drugs combined with sublethal doses of the BH3-mimetic ABT-737 displayed partial and variable effects per individual CD40-stimulated CLL. The antiapoptotic profile of CD40-triggered CLL resembled BCR-Abl-dependent changes seen in chronic myeloid leukemia (CML), which prompted application of c-Abl inhibitors imatinib or dasatinib. Both compounds, but especially dasatinib, prevented the entire antiapoptotic CD40 program in CLL cells, and restored drug sensitivity. These effects also occurred in CLL samples with dysfunctional p53. Importantly, ex vivo CLL LN samples also displayed strong ERK activation together with high Bcl-xL and Mcl-1 but low Bim levels. These data indicate that CLL cells in chemoresistant niches may be sensitive to therapeutic strategies that include c-Abl inhibitors.",
        "Doc_title":"c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches.",
        "Journal":"Blood",
        "Do_id":"18796631",
        "Doc_ChemicalList":"Antigens, CD40;Apoptosis Regulatory Proteins;BCL2L1 protein, human;BCL2L11 protein, human;Bcl-2-Like Protein 11;Membrane Proteins;Myeloid Cell Leukemia Sequence 1 Protein;Protein Kinase Inhibitors;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-bcl-2;bcl-X Protein;Proto-Oncogene Proteins c-abl;Extracellular Signal-Regulated MAP Kinases",
        "Doc_meshdescriptors":"Antigens, CD40;Apoptosis;Apoptosis Regulatory Proteins;Bcl-2-Like Protein 11;Cells, Cultured;Drug Delivery Systems;Drug Resistance, Neoplasm;Extracellular Signal-Regulated MAP Kinases;Humans;Leukemia, Lymphocytic, Chronic, B-Cell;Lymph Nodes;Membrane Proteins;Myeloid Cell Leukemia Sequence 1 Protein;Protein Kinase Inhibitors;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-abl;Proto-Oncogene Proteins c-bcl-2;Stem Cell Niche;Up-Regulation;bcl-X Protein",
        "Doc_meshqualifiers":"metabolism;physiology;genetics;metabolism;metabolism;pathology;genetics;pharmacology;therapeutic use;genetics;antagonists & inhibitors;genetics;pathology;genetics",
        "_version_":1605820475804483584},
      {
        "Doc_abstract":"The chimeric BCR/ABL protein is characteristic of Philadelphia (Ph)+ leukemia because it is the direct product of the Ph translocation and it has been shown to play a causal role in the genesis of leukemia. The BCR/ABL protein exhibits a deregulated tyrosine-kinase activity capable of phosphorylating different cellular substrates in vivo and in vitro. CRKL, an adaptor protein consisting of SH2 and SH3 domains in the absence of a catalytic domain, is one potential in vivo substrate of BCR/ABL. Previous experiments have shown that CRKL is phosphorylated on tyrosine in the chronic myelogenous leukemia (CML) cell line K562 and that CRKL is a substrate for ABL and for BCR/ABL in COS-1 cells. In the current study, we show that in peripheral blood cells a direct correlation exists between the presence of BCR/ABL and the phosphorylation status of CRKL. In Ph- peripheral blood cells, CRKL is present only in the nonphosphorylated form. In contrast, all BCR/ABL+ CML and acute lymphoblastic leukemia patient samples examined showed clear tyrosine-phosphorylation of CRKL. This result strongly suggests that CRKL is a biologically significant substrate for BCR/ABL and is likely to play a major role in the development of Ph+ leukemia.",
        "Doc_title":"Tyrosine phosphorylation of CRKL in Philadelphia+ leukemia.",
        "Journal":"Blood",
        "Do_id":"7521685",
        "Doc_ChemicalList":"Adaptor Proteins, Signal Transducing;CRKL protein;Nuclear Proteins;Phosphotyrosine;Tyrosine;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adaptor Proteins, Signal Transducing;Blotting, Western;Fusion Proteins, bcr-abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Nuclear Proteins;Phosphorylation;Phosphotyrosine;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Tumor Cells, Cultured;Tyrosine",
        "Doc_meshqualifiers":"blood;blood;blood;genetics;blood;analogs & derivatives;blood",
        "_version_":1605766527389270016},
      {
        "Doc_abstract":"BCR/ABL (Breakpoint Cluster Region protein/Abelson tyrosine-protein kinase 1) kinase domain (KD) mutations represent the most frequently described mechanism of resistance to the treatment with tyrosine kinase inhibitors (TKI) in patients with chronic myeloid leukemia (CML). Mutations may impair TKI activity by directly or indirectly impairing the drug binding to the protein. We report the discovery of three new BCR/ABL mutations, L248R, T315V, and F317R identified in two patients with CML (L248R and T315V) and in one patient with Ph+ acute lymphoblastic leukemia (ALL) (F317R). Mutations were screened against second-generation (bosutinib, nilotinib, and dasatinib), as well as third-generation TKIs (ponatinib/AP-24534 and DCC-2036). Furthermore, the activity profile of ponatinib and DCC-2036 against a panel of 24 clinically relevant BCR/ABL mutants is presented and compared to the other TKIs. The IC50 values for each TKI against the mutants and the IC50 increase over wild type BCR/ABL (relative resistance, RR) were calculated to define four resistance levels: sensitive (RR  2), moderately resistant (2 < RR  4), resistant (4 < RR  10), or highly resistant (RR > 10). L248R and T315V showed high resistance to imatinib, bosutinib, dasatinib, and nilotinib, intermediate resistance to ponatinib, but were sensitive to DCC-2036. Interestingly, F317R showed a moderate resistance to imatinib and nilotinib, but is resistant/highly resistant to dasatinib, bosutinib, ponatinib, and DCC-2036. The availability of drugs activity profiles may become a useful tool for clinicians dealing with the treatment of drug-resistant CML patients.",
        "Doc_title":"Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.",
        "Journal":"American journal of hematology",
        "Do_id":"23044928",
        "Doc_ChemicalList":"Antineoplastic Agents;Protein Kinase Inhibitors;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Animals;Antineoplastic Agents;Cell Culture Techniques;Drug Resistance, Neoplasm;Fusion Proteins, bcr-abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mice;Mutagenesis, Site-Directed;Mutation;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Protein Kinase Inhibitors;Protein-Tyrosine Kinases;Sequence Analysis, Protein;Structure-Activity Relationship;Transfection;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"chemistry;pharmacology;therapeutic use;genetics;antagonists & inhibitors;chemistry;genetics;drug therapy;enzymology;genetics;pathology;drug therapy;enzymology;genetics;pathology;chemistry;pharmacology;therapeutic use;antagonists & inhibitors;chemistry;genetics",
        "_version_":1605766918155796480},
      {
        "Doc_abstract":"Both radiation and chemotherapeutic drugs induce autophagy in tumor cells, and whether this contributes to cell death or survival is debated. Although a prodeath role has been reported in certain contexts, treatment-induced autophagy often exerts a prosurvival function by preventing apoptosis and delaying necrosis. Interestingly, a more specific role of autophagy has been demonstrated in certain subtypes of leukemia. The fusion oncoproteins PML-RARA and BCR-ABL, the main oncogenic drivers of acute promyelocytic leukemia and chronic myeloid leukemia (CML), respectively, have recently been identified as autophagy substrates and their degradation by autophagy shown to contribute to treatment. However, this does not seem to be a general feature of leukemic fusion oncoproteins, as we recently found that AML1-ETO, the most frequently occurring acute myeloid leukemia (AML) fusion protein, is not an autophagy substrate. Rather we demonstrate a clear prosurvival role of autophagy in this AML subtype and that addition of autophagy inhibitors in the treatment regimen might be beneficial. ",
        "Doc_title":"Autophagy: friend or foe in the treatment of fusion protein-associated leukemias?",
        "Journal":"Autophagy",
        "Do_id":"24145192",
        "Doc_ChemicalList":"AML1-ETO fusion protein, human;Core Binding Factor Alpha 2 Subunit;Histone Deacetylase Inhibitors;Oncogene Proteins, Fusion;promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Antineoplastic Combined Chemotherapy Protocols;Autophagy;Cell Survival;Core Binding Factor Alpha 2 Subunit;Drug Resistance, Neoplasm;Fusion Proteins, bcr-abl;Histone Deacetylase Inhibitors;Humans;Leukemia;Oncogene Proteins, Fusion",
        "Doc_meshqualifiers":"therapeutic use;drug effects;physiology;genetics;genetics;metabolism;genetics;genetics;metabolism;administration & dosage;genetics;pathology;therapy;genetics;metabolism",
        "_version_":1605799488789676032},
      {
        "Doc_abstract":"Bcr-Abl, a constitutively activated tyrosine kinase, is a product of the Philadelphia chromosome (Ph) translocation t(9;22), present in nearly all cases of chronic myeloid leukemia (CML) and in about 20% of cases with acute lymphoblastic leukemia. CML, a myeloproliferative disorder, progresses through three phases--chronic phase, accelerated phase and blast crisis. Current therapies include drug regimens such as interferon alpha, hydroxyurea, busulfan or allogeneic bone marrow transplantation, the only curative treatment for CML, which is, however, limited to younger patients with a suitable donor. INHIBITION OF BCR-ABL AS EFFECTIVE AND SELECTIVE TREATMENT IN CML: In vitro studies and studies in animal models have shown, that Bcr-Abl is the molecular cause CML. Therefore inhibition of the Bcr-Abl tyrosine kinase is expected to be an effective and selective treatment modality for CML. STI571 was shown to be a competitive inhibitor at the ATP-binding site of the Bcr-Abl tyrosine kinase, the platelet-derived growth factor receptor and c-kit tyrosine kinases. It shows effects on proliferation and survival of Bcr-Abl-expressing cells without affecting normal cells or Ph-negative leukemic cells. DRUG RESISTANCE TO STI571: Several mechanisms of resistance have been identified from in vitro studies with Bcr-Abl-positive cell lines. Mechanisms include amplification or overexpression of Bcr-Abl or an increased expression of P-gly-coprotein. In a mouse model the binding of STI571 to acidic alpha 1 glycoprotein (AAG) has been proposed to be involved in the development of STI571 resistance. Recent studies with clinical samples from resistant patients have shown that point mutations in the kinase domain of Bcr-Abl play a role in the development of resistance to STI571.;STI571 is a promising example of a moleculary targeted therapy directed towards the molecular cause of CML. To maximize the therapeutic value and to avoid the induction of resistance, a combination of the drug with other chemotherapies should be considered. According to its pharmacological profile, STI571 could also be useful in the treatment of tumors with deregulated PDGF receptor or c-kit signaling, e.g., in chronic myelomonocytic leukemia with a t(5;12) chromosomal translocation or in cases with gastrointestinal stromal tumors (GIST). STI571 shows a new paradigm in the development of new targeted therapies for the treatment of malignant diseases.",
        "Doc_title":"[Bcr-Abl inhibition as molecular therapy approach in chronic myeloid leukemia].",
        "Journal":"Medizinische Klinik (Munich, Germany : 1983)",
        "Do_id":"11831067",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Enzyme Inhibitors;Piperazines;Pyrimidines;Imatinib Mesylate;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Animals;Antineoplastic Agents;Benzamides;Enzyme Inhibitors;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Piperazines;Protein-Tyrosine Kinases;Pyrimidines",
        "Doc_meshqualifiers":"therapeutic use;therapeutic use;drug therapy;therapeutic use;antagonists & inhibitors;therapeutic use",
        "_version_":1605806482755944448},
      {
        "Doc_abstract":"The myeloid malignancies include the myeloproliferative neoplasms (MPN) including chronic myeloid leukemia (CML), and acute myeloid leukemia (AML). A growing body of evidence documents that these diseases are caused by genetic mutations that constitutively activate tyrosine kinases. They include the BCR/ABL in CML, the V617F JAK2 in Philadelphia chromosome-negative MPN, and the Flt3 ITD and TKD mutations in AML. Trials of the ABL kinase inhibitor, imatinib, have revolutionized the treatment of CML, and there are ongoing studies with other kinase inhibitors in MPN and AML. Here we review results of recent studies with first-generation JAK2 inhibitors in the treatment of MPN and second-generation ABL and Flt3 inhibitors in CML and AML, respectively. It is becoming apparent that although these kinase mutations have similar effects in vitro, each of the diseases has unique features that alter the use of kinase inhibitors in the clinic.",
        "Doc_title":"Targeted signal transduction therapies in myeloid malignancies.",
        "Journal":"Current oncology reports",
        "Do_id":"20809224",
        "Doc_ChemicalList":"Protein Kinase Inhibitors;FLT3 protein, human;fms-Like Tyrosine Kinase 3;Janus Kinase 2",
        "Doc_meshdescriptors":"Clinical Trials as Topic;Clinical Trials, Phase III as Topic;Drug Resistance, Neoplasm;Female;Humans;Janus Kinase 2;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Leukemia, Myeloid, Acute;Male;Mutation;Protein Kinase Inhibitors;Randomized Controlled Trials as Topic;Signal Transduction;fms-Like Tyrosine Kinase 3",
        "Doc_meshqualifiers":"drug effects;genetics;antagonists & inhibitors;genetics;drug therapy;genetics;metabolism;drug therapy;genetics;metabolism;administration & dosage;chemical synthesis;drug effects;genetics;antagonists & inhibitors;genetics",
        "_version_":1605836343146971136},
      {
        "Doc_abstract":"Imatinib (glivec), formerly known as STI571) effectively blocks the ATP-binding site of the bcr/abl fusion protein thereby inactivating selectively the tyrosine kinase activity of bcr/abl. Therefore, it is a promising drug in Philadelphia chromosome positive chronic myeloid leukemia showing high hematologic and cytogenetic response rates combined with a mild toxicity profile. Here we report two cases of squamous cell carcinoma of the skin, which appeared in the photo-exposed areas in two elderly patients treated for advanced chronic myeloid leukemia with imatinib. The role of chemotherapy, chronic sun exposure and of possible additional risk factors such as human papillomavirus infection is discussed.",
        "Doc_title":"Squamous cutaneous epithelial cell carcinoma in two CML patients with progressive disease under imatinib treatment.",
        "Journal":"European journal of haematology",
        "Do_id":"12656746",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Enzyme Inhibitors;Piperazines;Pyrimidines;Imatinib Mesylate;Hydroxyurea",
        "Doc_meshdescriptors":"Age Factors;Aged;Antineoplastic Agents;Benzamides;Carcinoma, Squamous Cell;Cocarcinogenesis;Coronary Disease;Drug Eruptions;Dyspnea;Enzyme Inhibitors;Facial Neoplasms;Humans;Hydroxyurea;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Neoplasms, Radiation-Induced;Neoplasms, Second Primary;Pancytopenia;Piperazines;Pleural Effusion;Pyrimidines;Sunlight;Ultraviolet Rays",
        "Doc_meshqualifiers":"adverse effects;therapeutic use;etiology;complications;complications;etiology;chemically induced;adverse effects;therapeutic use;etiology;adverse effects;therapeutic use;complications;drug therapy;etiology;etiology;chemically induced;adverse effects;therapeutic use;etiology;adverse effects;therapeutic use;adverse effects;adverse effects",
        "_version_":1605775048702951424},
      {
        "Doc_abstract":"The t (9;22)(q34;q11) translocation is found in about 90% of the chronic myeloid leukemia patients. About 5-10% of these patients have complex variant translocations involving a third chromosome in addition to chromosomes 9 and 22. We describe five male patients in the chronic myeloid leukemia-chronic phase, with rare variant Philadelphia translocations. All of them had the BCR-ABL fusion gene and responded well to treatment with imatinib mesylate. All the patients are on regular follow-up.",
        "Doc_title":"Variant Philadelphia translocations in chronic myeloid leukemia: A report of five cases.",
        "Journal":"Journal of cancer research and therapeutics",
        "Do_id":"26458641",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Humans;In Situ Hybridization, Fluorescence;Karyotyping;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Translocation, Genetic",
        "Doc_meshqualifiers":"diagnosis;genetics;pathology",
        "_version_":1605909932970868736},
      {
        "Doc_abstract":"The advent of imatinib has been a major breakthrough in chronic myeloid leukemia (CML) treatment. A few patients treated with imatinib are either refractory to imatinib or eventually relapse. Resistance is frequently associated with mutations in the kinase domain of BCR-ABL. Over 100 point mutations coding for single amino acid substitutions in the BCR-ABL kinase domain have been isolated from CML patients resistant to imatinib treatment. Most reported mutants are rare, whereas 7 mutated residues comprise two-thirds of all mutations detected. BCR-ABL mutations affect amino acids involved in imatinib binding or in regulatory regions of the BCR-ABL kinase domain, resulting in decreased sensitivity to imatinib while retaining aberrant kinase activity. The early detection of BCR-ABL mutants during therapy may aid in risk stratification as well as molecularly based treatment decisions.",
        "Doc_title":"BCR-ABL mutations in chronic myeloid leukemia.",
        "Journal":"Hematology/oncology clinics of North America",
        "Do_id":"22054731",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Fusion Proteins, bcr-abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Point Mutation;Protein Structure, Tertiary",
        "Doc_meshqualifiers":"genetics;genetics",
        "_version_":1605809485506412544},
      {
        "Doc_abstract":"To investigate the mechanism of apoptosis of chronic myeloid leukemia (CML) cells induced by the novel p210 bcr/abl inhibitor berbamine.;Human Ph+ CML leukemia K562 cells, which express endogenous p210 bcr/abl protein, were cultured in RPMI 1640 and treated with berbamine as indicated time and dose. Flow cytometry (FCM) and Annexin-V-Fluos/PI staining kit were used to evaluate the apoptosis of leukemic cells; FCM and cytoperm/cytofix plus Caspase-3-McAb-PE were employed to measure the leukemic cells with activated Caspase-3. Phosphorylation of p210 bcr/abl protein in the leukemic cells were assessed by a combination of immunoprecipitation (IP) with c-abl antibody and Western blotting with p-Tyr (pY99) antibody. The protein levels of p210 bcr/abl, Hsp90 and Hsp70 in the leukemic cells were determined by Western blotting with antibodies to c-abl, Hsp90, and Hsp70 respectively.;After treatment with berbamine at 8 microg/ml for 48 h, the percentages of leukemic cells expressing activated caspase-3 and apoptotic cells were 45.69% and 48.43% respectively. IP and WB results showed that berbamine at low concentration markedly inhibited phosphorylation of p210 bcr/abl protein in the leukemia cells, and the amount of phosphorylated p210 bcr/abl in the leukemia cells exposed to berbamine at 8 microg/ml for 6 h were only 8.41% of that of untreated leukemia cells without the protein levels of p210 bcr/abl down-regulated. Significantly, berbamine also down-regulated chaperone Hsp90 protein, and the amount of Hsp90 protein in the leukemia cells treated with berbamine at 8 microg/ml for 48 h accounted for 18.37% of that of the untreated leukemia cells. Berbamine at 8 microg/ml had no obvious effect on chaperone Hsp70 protein expression associated with the resistance of leukemia cells to apoptosis.;(1) Berbamine induces caspase-3-mediated apoptosis of Ph+ leukemia cells through inhibiting phosphorylation of p210 bcr/abl protein and down-regulating its chaperone Hsp90 protein. (2) Unlike Hsp90 inhibitor GA that upregulates Hsp70, berbamine has no obvious effect on chaperone Hsp70 protein expression in leukemia cells, suggesting that berbamine may be a novel class of Hsp90 inhibitor, and further study is required.",
        "Doc_title":"[The mechanism of apoptosis of chronic myeloid leukemia cells induced by the novel p210 bcr/abl inhibitor berbamine].",
        "Journal":"Zhonghua yi xue za zhi",
        "Do_id":"17064567",
        "Doc_ChemicalList":"Alkaloids;Benzylisoquinolines;HSP90 Heat-Shock Proteins;Oncogene Proteins v-abl;bcl-Associated Death Protein;Caspase 3;berbamine",
        "Doc_meshdescriptors":"Alkaloids;Apoptosis;Benzylisoquinolines;Caspase 3;HSP90 Heat-Shock Proteins;Humans;K562 Cells;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Oncogene Proteins v-abl;Phytotherapy;bcl-Associated Death Protein",
        "Doc_meshqualifiers":"therapeutic use;drug effects;therapeutic use;metabolism;metabolism;metabolism;pathology;metabolism;metabolism",
        "_version_":1605847120359718912},
      {
        "Doc_abstract":"To exam the role of leukemia cells-derived microparticles in the post-complete molecular response stratification.;Blood samples from 29 patients diagnosed with chronic myeloid leukemia (CML) were collected. Microparticles (MP) were extracted from the peripheral blood. Real-time PCR was performed to measure the level of BCR-ABL mRNA.;BCR-ABL mRNA could be stably detected both in MP and peripheral blood cells; BCR-ABL in MP showed significant difference within complete molecular response, major molecular response and complete cytogenetic response (9.12.8, 25.26.9 and 62.86.3 respectively, P<0.05). BCR-ABL was detected in MP even when it was negative in peripheral blood cells (3.7-15.3). For patients with complete molecular response, BCR-ABL in MP but not cells were significantly different between imatinib and stem cell transplant recipients (3.32.1 vs 9.12.8, P<0.05).;This study indicated that MP may serves as a new target for monitoring of CML. Quantification of BCR-ABL in MP may offer a novel strategy for stratification of molecular response.",
        "Doc_title":"[Detection of leukemia-derived microparticles in the monitoring of chronic myeloid leukemia].",
        "Journal":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi",
        "Do_id":"24606656",
        "Doc_ChemicalList":"RNA, Messenger;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adolescent;Adult;Cell-Derived Microparticles;Child;Female;Fusion Proteins, bcr-abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;RNA, Messenger;Real-Time Polymerase Chain Reaction;Young Adult",
        "Doc_meshqualifiers":"genetics;genetics;therapy;genetics",
        "_version_":1605897257592291328},
      {
        "Doc_abstract":"The discovery of the Philadelphia chromosome in 1960, and of the BCR-ABL oncogene in 1984, enabled the development in subsequent years of a targeted therapy that revolutionized the treatment of chronic myeloid leukemia, thus changing its natural history. The use of imatinib resulted in a significant improvement of the prognosis and outcome of patients with chronic myeloid leukemia. However, the occurrence of mechanisms of resistance or intolerance precludes the eradication of the disease in some of the patients. Second-generation tyrosine-kinase inhibitors are efficient in most of these patients, except for those with T315I mutation. We present an overall review of chronic myeloid leukemia, with emphasis on the progress in its treatment. ",
        "Doc_title":"Chronic myeloid leukemia: past, present, future.",
        "Journal":"Einstein (Sao Paulo, Brazil)",
        "Do_id":"26760823",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605853409215250432},
      {
        "Doc_abstract":"Imatinib, a multitargeted tyrosine kinase inhibitor, exhibits potent anticancer activity against leukemia harboring the Bcr-Abl oncogene and some solid tumors overexpressing c-kit and PDGFR. However, its clinical efficacy is severely compromised by the emergence of resistance primarily due to acquired mutations in the Bcr-Abl kinase domain. In this study, we showed that combination of imatinib with platinum (Pt)-based anticancer agents, including cisplatin and oxaliplatin, exhibited synergistic cytotoxic effect specifically in Bcr-Abl+ human chronic myeloid leukemia cell line K562 but not in Bcr-Abl- RPMI8226 cells. Importantly, the synergistic effect was also found to circumvent imatinib resistance in an imatinib-selected resistant subline K562 ima1.0. The combination treatment increased apoptosis and DNA damage. Mechanistic study revealed that increased inhibition of Bcr-Abl and downstream ERK phosphorylation by the drug combination may contribute to the synergistic effect.",
        "Doc_title":"Synergistic cytotoxicity from combination of imatinib and platinum-based anticancer drugs specifically in Bcr-Abl positive leukemia cells.",
        "Journal":"Journal of pharmacological sciences",
        "Do_id":"26644081",
        "Doc_ChemicalList":"Antineoplastic Agents;DNA, Neoplasm;Enzyme Inhibitors;Organoplatinum Compounds;oxaliplatin;Imatinib Mesylate;Protein-Tyrosine Kinases;Cisplatin",
        "Doc_meshdescriptors":"Antineoplastic Agents;Antineoplastic Combined Chemotherapy Protocols;Cisplatin;DNA Damage;DNA, Neoplasm;Drug Synergism;Enzyme Inhibitors;Genes, abl;Humans;Imatinib Mesylate;K562 Cells;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;MAP Kinase Signaling System;Organoplatinum Compounds;Phosphorylation;Protein-Tyrosine Kinases",
        "Doc_meshqualifiers":"toxicity;toxicity;toxicity;drug effects;toxicity;drug effects;toxicity;genetics;pathology;drug effects;toxicity;drug effects;antagonists & inhibitors",
        "_version_":1605747555622191104},
      {
        "Doc_abstract":"BCR-ABL is a chimeric oncogene generated by translocation of sequences from the chromosomal counterpart (c-ABL gene) on chromosome 9 into the BCR gene on chromosome 22. Alternative chimeric proteins, BCR-ABL(p190) and BCR-ABL(p210), are produced that are characteristic of chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph(1)-ALL). In CML, the transformation occurs at the level of pluripotent stem cells. However, Ph(1)-ALL is thought to affect progenitor cells with lymphoid differentiation. Here we demonstrate that the cell capable of initiating human Ph(1)-ALL in non-obese diabetic mice with severe combined immunodeficiency disease (NOD/SCID), termed SCID leukemia-initiating cell (SL-IC), possesses the differentiative and proliferative capacities and the potential for self-renewal expected of a leukemic stem cell. The SL-ICs from all Ph(1)-ALL analyzed, regardless of the heterogeneity in maturation characteristics of the leukemic blasts, were exclusively CD34(+ )CD38(-), which is similar to the cell-surface phenotype of normal SCID-repopulating cells. This indicates that normal primitive cells, rather than committed progenitor cells, are the target for leukemic transformation in Ph(1)-ALL.",
        "Doc_title":"A primitive hematopoietic cell is the target for the leukemic transformation in human philadelphia-positive acute lymphoblastic leukemia.",
        "Journal":"Blood",
        "Do_id":"10648416",
        "Doc_ChemicalList":"Antigens, CD;Antigens, CD34;Antigens, Differentiation;Antigens, Neoplasm;Membrane Glycoproteins;Fusion Proteins, bcr-abl;ADP-ribosyl Cyclase;Antigens, CD38;CD38 protein, human;Cd38 protein, mouse;NAD+ Nucleosidase",
        "Doc_meshdescriptors":"ADP-ribosyl Cyclase;Animals;Antigens, CD;Antigens, CD34;Antigens, CD38;Antigens, Differentiation;Antigens, Neoplasm;Cell Differentiation;Cell Division;Cell Transformation, Neoplastic;Fusion Proteins, bcr-abl;Hematopoietic Stem Cells;Humans;Immunophenotyping;Membrane Glycoproteins;Mice;Mice, Inbred NOD;Mice, SCID;NAD+ Nucleosidase;Neoplasm Transplantation;Neoplastic Stem Cells;Philadelphia Chromosome;Precursor Cell Lymphoblastic Leukemia-Lymphoma",
        "Doc_meshqualifiers":"analysis;analysis;analysis;analysis;pathology;physiology;classification;pathology;analysis;classification;pathology;transplantation;pathology",
        "_version_":1605790220736790528},
      {
        "Doc_abstract":"Advanced-phase chronic myeloid leukemia patients treated with imatinib often relapse due to point mutations in the Abl kinase domain. We herein examine the in vitro and in vivo effects of a Bcr-Abl/Lyn dual tyrosine kinase inhibitor, NS-187, on seven mutated Bcr-Abl proteins. NS-187 inhibited both Tyr393-phosphorylated and Tyr393-unphosphorylated Abl, resulting in significant in vitro growth inhibition of cells expressing six of seven mutated Bcr-Abl kinases, though not T315I. Furthermore, NS-187 prolonged the survival of mice injected with leukemic cells expressing all mutated Bcr-Abl tested except T315I, and its efficacy correlated well with its in vitro effects.",
        "Doc_title":"In vivo antiproliferative effect of NS-187, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor, on leukemic cells harbouring Abl kinase domain mutations.",
        "Journal":"Leukemia research",
        "Do_id":"16546254",
        "Doc_ChemicalList":"Benzamides;Piperazines;Pyrimidines;bafetinib;Imatinib Mesylate;Fusion Proteins, bcr-abl;lyn protein-tyrosine kinase;src-Family Kinases",
        "Doc_meshdescriptors":"Administration, Oral;Animals;Benzamides;Cell Line, Tumor;Cell Proliferation;Disease Models, Animal;Dose-Response Relationship, Drug;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Leukemia;Mice;Mice, Inbred BALB C;Mice, Nude;Mutation;Phosphorylation;Piperazines;Pyrimidines;Structure-Activity Relationship;Survival Rate;Transplantation, Heterologous;Xenograft Model Antitumor Assays;src-Family Kinases",
        "Doc_meshqualifiers":"drug effects;drug effects;genetics;metabolism;drug therapy;genetics;metabolism;administration & dosage;pharmacology;administration & dosage;pharmacology;antagonists & inhibitors",
        "_version_":1605783499422302208},
      {
        "Doc_abstract":"BCR-ABL caused by the translocation of t(9,22) with elevated tyrosine-kinase activity could induce leukemia in mice, which established BCR-ABL as the molecular pathogenic event in CML (Chronic myeloid leukemia). In recent years, a variety of tyrosine kinase inhibitors (TKIs) targeting at BCR-ABL specifically and effectively have been developed, which has fundamentally promoted the treatment of CML. However, the efficacy of TKIs was limited by its resistance induced by the development of kinase domain mutations and other mechanisms illustrated. In this review, we summarized BCR-ABL inhibitors approved by Food and Drug Administration (FAD), with the same concerns focus on the resistant mechanisms of BCR-ABL inhibitors and therapeutic resistant strategies. ",
        "Doc_title":"Mechanisms of resistance to BCR-ABL TKIs and the therapeutic strategies: A review.",
        "Journal":"Critical reviews in oncology/hematology",
        "Do_id":"25500000",
        "Doc_ChemicalList":"Antineoplastic Agents;Protein Kinase Inhibitors;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Antineoplastic Agents;Antineoplastic Combined Chemotherapy Protocols;Drug Resistance, Neoplasm;Fusion Proteins, bcr-abl;Gene Expression Regulation, Leukemic;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mutation;Protein Kinase Inhibitors;Signal Transduction;Tumor Microenvironment",
        "Doc_meshqualifiers":"pharmacology;therapeutic use;therapeutic use;genetics;antagonists & inhibitors;genetics;metabolism;drug therapy;genetics;metabolism;pharmacology;therapeutic use;drug effects",
        "_version_":1605836197647613952},
      {
        "Doc_abstract":"This report describes a precise molecular analysis of a rare case of Philadelphia chromosome (Ph) positive acute myeloid leukemia (AML) (FAB classification M2). Phenotypic markers were positive for cells of the myeloid lineage, but negative for B cell and T cell lineage. The leukemic cells carried a Philadelphia chromosome. Major breakpoint cluster region (M-BCR) rearrangement was detected by the Southern blot analysis. Reverse transcriptase polymerase chain reaction analysis revealed the presence of b3a2 BCR/ABL mRNA transcripts. The patient achieved complete remission by conventional remission induction therapy for acute myeloid leukemia. M-BCR rearrangement could not be detected during complete remission. After hematological remission of an 8-month duration, the patient relapsed and died of respiratory distress due to pneumonia. Our case indicate Ph-positive AML with M-BCR rearrangement actually exists. Ph-positive AML carries either M-BCR rearrangement expressing the P210 BCR-ABL or minor breakpoint cluster region (m-BCR) rearrangement producing the P190 BCR-ABL. Therefore, additional other factor (s) apart from the Ph chromosome must be responsible for the acute malignant transformation.",
        "Doc_title":"Molecular analysis of a case of Philadelphia chromosome-positive acute myeloid leukemia.",
        "Journal":"Anticancer research",
        "Do_id":"9066590",
        "Doc_ChemicalList":"Biomarkers, Tumor;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Aged;Antineoplastic Combined Chemotherapy Protocols;Biomarkers, Tumor;Blotting, Southern;Fusion Proteins, bcr-abl;Humans;Karyotyping;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male",
        "Doc_meshqualifiers":"therapeutic use;analysis;analysis;drug therapy;genetics",
        "_version_":1605761994499031040},
      {
        "Doc_abstract":"The p210(bcr-abl) and p190(bcr-abl) fusion proteins, respectively responsible for chronic myelogenous leukemia and acute lymphoblastic leukemia, present deregulated tyrosine kinase activity and abnormal localization. The Dbl homology domain of Bcr, activating Rho GTPases, is present in p210(bcr-abl), but absent in p190(bcr-abl). We investigated the interaction of Bcr-Abl chimeras and Rho proteins by coimmunoprecipitation, pull-down experiments and GEF activity measurement. RhoA, Rac1 and Cdc42 interact in vivo with p210(bcr-abl) only. Moreover, the three types of GTPases are activated in vitro and in vivo by p210(bcr-abl). Nevertheless, Rac1 and Cdc42, but not RhoA, are activated by p190(bcr-abl) in vitro and in vivo. Part of this GEF activity of p190(bcr-abl) is probably attributable to p95(vav), which is complexed with both p190(bcr-abl) and p210(bcr-abl) in an activated form. p160(bcr), also in complex with Bcr-Abl, presents no GEF activity in p190(bcr-abl)-expressing cells. These results suggest that differential activation of Rho proteins should play a major role in Bcr-Abl-induced leukemogenesis.",
        "Doc_title":"Differential interaction and activation of Rho family GTPases by p210bcr-abl and p190bcr-abl.",
        "Journal":"Oncogene",
        "Do_id":"14508524",
        "Doc_ChemicalList":"Guanosine Diphosphate;Guanosine Triphosphate;Fusion Proteins, bcr-abl;rho GTP-Binding Proteins",
        "Doc_meshdescriptors":"Animals;Enzyme Activation;Fusion Proteins, bcr-abl;Guanosine Diphosphate;Guanosine Triphosphate;Mice;Precipitin Tests;rho GTP-Binding Proteins",
        "Doc_meshqualifiers":"physiology;metabolism;metabolism;metabolism;metabolism",
        "_version_":1605899097862045696},
      {
        "Doc_abstract":"The chimeric Bcr-Abl oncoprotein, which causes chronic myeloid leukemia, mainly localizes in the cytoplasm, and loses its ability to transform cells after moving into the nucleus. Here we report a new strategy to convert Bcr-Abl to be an apoptotic inducer by altering its subcellular localization. We show that a rapalog nuclear transport system (RNTS) containing six nuclear localization signals directs Bcr-Abl into the nucleus and that nuclear entrapped Bcr-Abl induces apoptosis and inhibits proliferation of CML cells by activating p73 and shutting down cytoplasmic oncogenic signals mediated by Bcr-Abl. Coupling cytoplasmic depletion with nuclear entrapment of Bcr-Abl synergistically enhances the inhibitory effect of nuclear Bcr-Abl on its oncogenicity in mice. These results provide evidence that direction of cytoplasmic Bcr-Abl to the nucleus offers an alternative CML therapy. ",
        "Doc_title":"Induction of apoptosis by directing oncogenic Bcr-Abl into the nucleus.",
        "Journal":"Oncotarget",
        "Do_id":"24158537",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Animals;Apoptosis;Cell Growth Processes;Cell Nucleus;Female;Fusion Proteins, bcr-abl;Humans;K562 Cells;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mice;Mice, Inbred C3H",
        "Doc_meshqualifiers":"physiology;physiology;metabolism;metabolism;metabolism;pathology",
        "_version_":1605821257746481152},
      {
        "Doc_abstract":"Imatinib mesylate is a BCR-ABL tyrosine kinase inhibitor used in the management of chronic myeloid leukemia. It is a safe and well-tolerated agent with a few manageable side effects. We are reporting a case of imatinib-related fatal bone marrow aplasia after complete cytogenetic response.",
        "Doc_title":"Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.",
        "Journal":"Journal of the College of Physicians and Surgeons--Pakistan : JCPSP",
        "Do_id":"18460249",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Imatinib Mesylate;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Antineoplastic Agents;Benzamides;Bone Marrow Diseases;Fatal Outcome;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Piperazines;Protein Kinase Inhibitors;Protein-Tyrosine Kinases;Pyrimidines",
        "Doc_meshqualifiers":"adverse effects;therapeutic use;chemically induced;drug therapy;adverse effects;therapeutic use;adverse effects;therapeutic use;antagonists & inhibitors;adverse effects;therapeutic use",
        "_version_":1605851710208606208},
      {
        "Doc_abstract":"Imatinib is a selective breakpoint cluster region-Abelson (BCR-ABL) tyrosine kinase inhibitor (TKI) that has significantly improved the prognosis of patients with chronic myeloid leukemia (CML). However, T315I gene mutations of the BCR-ABL kinase domain have been shown to confer resistance to imatinib. In the present study, we synthesized a novel BCR-ABL inhibitor, HS-438, and identified its anti-leukemic effects in vitro and in vivo. We found that HS-438 strongly inhibited the expression of BCR-ABL signaling pathways in wild-type BCR-ABL (BaF3/WT) cells as well as T315I-mutated BCR-ABL (BaF3/T315I) cells with resistance to imatinib. HS-438 induced cell cycle arrest, particularly during the G0/G1 cell cycle phase, and induced apoptosis. In BaF3/T315I xenograft models, HS-438 significantly delayed tumor growth, unlike imatinib. In summary, we suggest that HS-438 may be a novel drug candidate with the therapeutic potential to target BCR-ABL and overcome imatinib resistance in patients with CML.",
        "Doc_title":"HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.",
        "Journal":"Cancer letters",
        "Do_id":"24657654",
        "Doc_ChemicalList":"1-(2-hydroxyethyl)-3-(6-(2-methoxyphenyl)benzo(d)thiazol-2-yl)urea;Antineoplastic Agents;Benzamides;Benzothiazoles;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Imatinib Mesylate;Urea;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Animals;Antineoplastic Agents;Apoptosis;Benzamides;Benzothiazoles;Binding Sites;Cell Cycle Checkpoints;Cell Line, Tumor;Cell Proliferation;Cell Survival;Dose-Response Relationship, Drug;Drug Resistance, Neoplasm;Fusion Proteins, bcr-abl;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Membrane Potential, Mitochondrial;Mice;Mice, Nude;Models, Molecular;Mutation;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Time Factors;Tumor Burden;Urea",
        "Doc_meshqualifiers":"metabolism;pharmacology;drug effects;pharmacology;metabolism;pharmacology;drug effects;drug effects;drug effects;genetics;antagonists & inhibitors;genetics;metabolism;drug therapy;enzymology;genetics;pathology;drug effects;pharmacology;metabolism;pharmacology;pharmacology;drug effects;analogs & derivatives;metabolism;pharmacology",
        "_version_":1605897560784896000},
      {
        "Doc_abstract":"Beginning with imatinib a decade ago, therapy based on targeted inhibition of the BCR-ABL kinase has greatly improved the prognosis for chronic myeloid leukemia (CML) patients. The recognition that some patients experience relapse due to resistance-conferring point mutations within BCR-ABL sparked the development of the second-generation ABL kinase inhibitors nilotinib and dasatinib. Collectively, these drugs target most resistant BCR-ABL mutants, with the exception of BCR-ABL(T315I). A third wave of advances is now cresting in the form of ABL kinase inhibitors whose target profile encompasses BCR-ABL(T315I). The leading third-generation clinical candidate for treatment-refractory CML, including patients with the T315I mutation, is ponatinib (AP24534), a pan-BCR-ABL inhibitor that has entered pivotal phase 2 testing. A second inhibitor with activity against the BCR-ABL(T315I) mutant, DCC-2036, is in phase 1 clinical evaluation. We provide an up-to-date synopsis of BCR-ABL signaling pathways, highlight new findings on mechanisms underlying BCR-ABL mutation acquisition and disease progression, discuss the use of nilotinib and dasatinib in a first-line capacity, and evaluate ponatinib, DCC-2036, and other ABL kinase inhibitors with activity against BCR-ABL(T315I) in the development pipeline.",
        "Doc_title":"Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia.",
        "Journal":"Clinical cancer research : an official journal of the American Association for Cancer Research",
        "Do_id":"21098337",
        "Doc_ChemicalList":"4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide;Antineoplastic Agents;Drugs, Investigational;Imidazoles;Pyridazines;Pyrimidines;Thiazoles;ponatinib;Fusion Proteins, bcr-abl;Dasatinib",
        "Doc_meshdescriptors":"Antineoplastic Agents;Dasatinib;Drug Resistance, Neoplasm;Drugs, Investigational;Fusion Proteins, bcr-abl;Humans;Imidazoles;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Molecular Targeted Therapy;Mutation;Pyridazines;Pyrimidines;Signal Transduction;Thiazoles",
        "Doc_meshqualifiers":"therapeutic use;antagonists & inhibitors;genetics;metabolism;therapeutic use;drug therapy;therapeutic use;therapeutic use;drug effects;therapeutic use",
        "_version_":1605929161879191552},
      {
        "Doc_abstract":"Pharmacologic inhibition of the Bcr-Abl tyrosine kinase in human chronic myeloid leukemia leads to dramatic clinical responses, but relapses occur in advanced stage patients. New findings about Abl kinase domain regulation provide insight into novel strategies for targeted therapy.",
        "Doc_title":"Disabling Abl-perspectives on Abl kinase regulation and cancer therapeutics.",
        "Journal":"Cancer cell",
        "Do_id":"12086882",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Enzyme Inhibitors;Piperazines;Pyrimidines;Imatinib Mesylate;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Antineoplastic Agents;Benzamides;Binding Sites;Enzyme Inhibitors;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Piperazines;Protein Structure, Tertiary;Protein-Tyrosine Kinases;Pyrimidines",
        "Doc_meshqualifiers":"therapeutic use;therapeutic use;drug therapy;enzymology;therapeutic use;physiology;antagonists & inhibitors;therapeutic use",
        "_version_":1605747561764749312},
      {
        "Doc_abstract":"The BCR-ABL kinase inhibitor, imatinib mesylate, is the front-line treatment for chronic myeloid leukemia, but the emergence of imatinib resistance has led to the search for alternative drug treatments. There is a pressing need, therefore, to develop and test novel drugs. Natural products including plants, microorganisms, and halobios provide rich resources for discovery of anticancer drugs. In this article, we demonstrate that emodin inhibited the growth of K562 cells harboring BCR-ABL in vitro and in vivo, and induced abundant apoptosis, which was correlated with the inhibition of PETN/PI3K/Akt level and deletion of BCR-ABL. These findings suggest that emodin is a promising agent to kill K562 cells harboring BCR-ABL.",
        "Doc_title":"Emodin Exerts an Antiapoptotic Effect on Human Chronic Myelocytic Leukemia K562 Cell Lines by Targeting the PTEN/PI3K-AKT Signaling Pathway and Deleting BCR-ABL.",
        "Journal":"Integrative cancer therapies",
        "Do_id":"27698265",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605755910929514496},
      {
        "Doc_abstract":"We report a chronic myeloid leukemia patient without evidence of a Philadelphia (Ph) chromosome in whom RT-PCR analysis performed in blast crisis demonstrated the existence of both common b3a2 and b2a2 BCR/ABL fusion transcripts. In situ hybridization studies with BCR- and ABL-specific probes showed location of the BCR/ABL fusion gene on chromosome 9, band q34, instead of at chromosome 22q11, and that it resulted from an insertion of the 5' side of BCR within the ABL gene on chromosome 9. The vast majority of cells showed a BCR/ABL fusion gene on both chromosomes 9, which is equivalent to a double Ph chromosome, thus reinforcing the notion that the critical event in CML is the formation of a functional BCR/ABL fusion gene.",
        "Doc_title":"Insertion of the 5' part of BCR within the ABL gene at 9q34 in a Philadelphia-negative chronic myeloid leukemia.",
        "Journal":"Cancer genetics and cytogenetics",
        "Do_id":"10526530",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Chromosomes, Human, Pair 9;Female;Fusion Proteins, bcr-abl;Humans;In Situ Hybridization, Fluorescence;Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative;Middle Aged;Mutagenesis, Insertional;Mutation;Philadelphia Chromosome",
        "Doc_meshqualifiers":"genetics;genetics",
        "_version_":1605909327874359296},
      {
        "Doc_abstract":"Here we describe how we detected the BCR/ABL fusion gene on the short arm of der(9) combining classical GTG banding and Fluorescence In Situ Hybridization (FISH) in a case of chronic myeloid leukemia (CML). To our knowledge, variant translocations involving the short arm of chromosome 9, in literature, are almost rare in chronic myeloid leukemia. It is not clear if this complex genetic translocation represents clonal evolution or a unique, initial presentation variant of the Philadelphia chromosome (Ph).",
        "Doc_title":"Complex variant Philadelphia translocation involving the short arm of chromosome 9 in a case of chronic myeloid leukemia.",
        "Journal":"Haematologica",
        "Do_id":"15377489",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adult;Female;Humans;In Situ Hybridization, Fluorescence;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Leukemia, Myeloid, Chronic-Phase;Philadelphia Chromosome",
        "Doc_meshqualifiers":"genetics;genetics",
        "_version_":1605804793734889472},
      {
        "Doc_abstract":"Treatment of acute lymphoblastic leukemia in adults focuses on the initial assessment of prognostic relevant genetic features as well as response-guided therapy based on molecular data. In at least half of adult acute lymphoblastic leukemia patients, clonal chromosomal abnormalities can be identified that deregulate candidate oncogenes or transcription factors by introducing a heterologous promoter or enhancer. Altered cell cycle progression or upregulated tyrosine kinase activity are other important mechanisms. Most of the translocations can lead to the generation of fusion genes that are translated into chimeric oncogeneic proteins, such as BCR-ABL, providing targets for novel therapeutic agents.",
        "Doc_title":"Molecular genetic events in adult acute lymphoblastic leukemia.",
        "Journal":"Expert review of molecular diagnostics",
        "Do_id":"12779008",
        "Doc_ChemicalList":"Biomarkers, Tumor",
        "Doc_meshdescriptors":"Adult;Biomarkers, Tumor;Chromosome Aberrations;Gene Deletion;Humans;Mutation;Precursor Cell Lymphoblastic Leukemia-Lymphoma",
        "Doc_meshqualifiers":"diagnosis;genetics",
        "_version_":1605875846210387968},
      {
        "Doc_abstract":"We describe the case of a young man with therapy-naive chronic myeloid leukemia who did not initially have any peripheral blood or bone marrow excess blasts but presented with extramedullary myeloid blast crises involving the central nervous system and multiple lymph nodes. Conventional cytogenetic tests were positive for t(9;22)(q34:q11) as well as for trisomy 8, 14 and 21 and del(16q). The patient's peripheral blood and bone marrow were positive for the BCR-ABL oncogene when analyzed by fluorescence in situ hybridization and polymerase chain reaction. He achieved good clinical, radiological, cytogenetic and molecular response to acute myeloid leukemia induction chemotherapy combined with 16 doses of triple intrathecal chemotherapy and oral dasatinib (second-generation tyrosine kinase inhibitor) treatment. Due to his poor general condition, he was treated with 24 Gy of whole-brain radiation therapy, as allogeneic stem cell transplantation was not feasible. Although extramedullary CNS blast crises are usually associated with a very poor outcome, our patient remains in complete cytogenetic and molecular remission, on single-agent dasatinib, 4 years after the diagnosis with no current evidence of active extramedullary disease. This suggests that dasatinib has a role in controlling not only chronic-phase chronic myeloid leukemia, but also its CNS blast crisis.",
        "Doc_title":"An Atypical Initial Presentation of Chronic Myeloid Leukemia with Central Nervous System and Lymph Node Blast Crises.",
        "Journal":"Case reports in oncology",
        "Do_id":"27721761",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605742781061398531},
      {
        "Doc_abstract":"Aurora kinases are a family of protein kinases that have a key role in multiple stages of mitosis. Over-expression of Aurora kinases, particularly Aurora A, has been demonstrated in a number of solid tumors and hematological malignancies. Not surprisingly, these serine/threonine kinases have become attractive small molecule targets for cancer therapeutics, with several inhibitors currently in early-phase clinical trials. A small number of compounds developed to date are highly selective for either Aurora A or Aurora B, while the majority inhibit both Aurora A and Aurora B; many of these compounds exhibit 'off-target' inhibition of kinases such as ABL, JAK2 and FLT3. It is currently unclear whether the therapeutic activity of these compounds in leukemia is primarily due to selective Aurora or multi-kinase inhibition. The most promising application for Aurora kinase inhibitors to date appears to be in FLT3-mutated acute myeloid leukemia (AML) and imatinib-resistant chronic myeloid leukemia/Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia, particularly when caused by the T315I mutation. Here we review the growing body of evidence supporting the use of Aurora kinase inhibitors as effective agents for AML and Ph+ leukemias.",
        "Doc_title":"Aurora kinase inhibitors: novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemias.",
        "Journal":"Leukemia",
        "Do_id":"20147976",
        "Doc_ChemicalList":"Protein Kinase Inhibitors;AURKB protein, human;Aurora Kinase B;Aurora Kinases;Protein-Serine-Threonine Kinases",
        "Doc_meshdescriptors":"Aurora Kinase B;Aurora Kinases;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Leukemia, Myeloid, Acute;Protein Kinase Inhibitors;Protein-Serine-Threonine Kinases",
        "Doc_meshqualifiers":"drug therapy;enzymology;drug therapy;enzymology;therapeutic use;antagonists & inhibitors",
        "_version_":1605746412673302528},
      {
        "Doc_abstract":"The presence of Philadelphia chromosome t(9:22) is a hallmark of 95% of clinical cases of chronic myelogenous leukemia (CML) as well as 20% of adult acute lymphoblastic leukemia (ALL) and 5% of acute myeloid leukemia (AML). The product of t(9;22) is a fusion protein BCR-ABL. The fusion proteins of CML, ALL and AML have increased tyrosine kinase activity and show a transforming potential in vitro and in animal models. The shorter p190 protein is associated almost only with ALL and AML, while the protein p210 is present in both chronic phase and blast crisis of CML and also in 50% of Philadelphia-positive (Ph1+) ALL. In CML the transition from chronic phase to blast crisis is usually accompanied by additional genetic events, e.g. additional chromosomal abnormalities, and oncogene activation(s). The detailed understanding of molecular basis of CML, and Ph1+ ALL and AML provides highly sensitive molecular and serological methods to complement classical cytogenetics. The advantages and limitations of these techniques are described and discussed below.",
        "Doc_title":"Molecular pathology of chronic myelogenous leukemia.",
        "Journal":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine",
        "Do_id":"2247753",
        "Doc_ChemicalList":"Neoplasm Proteins",
        "Doc_meshdescriptors":"Animals;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Neoplasm Proteins;Philadelphia Chromosome;Proto-Oncogenes;Translocation, Genetic",
        "Doc_meshqualifiers":"genetics;genetics",
        "_version_":1605754669178552320},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) is characterized by a specific translocation of the c-abl oncogene on chromosome 9 to the break point cluster region (bcr) on chromosome 22, t(9;22) (q34;q11). This translocation results in the expression of a 210-kD bcr-abl protein fusion gene product. The juxtaposition of the bcr and abl genes produces a novel junctional amino acid sequence, which may be presented by antigen-presenting cells and recognized specifically by human T lymphocytes. We have generated a CD4+ T lymphocyte line (NG-1) which recognizes the peptide epitope (GFKQSSKALQR) in association with HLA-DRbeta1*0101-02. A comparison of antigen-presenting cells showed that CMRF-44+ blood dendritic cell presented a 12mer b3a2 peptide effectively. The b3a2 peptide was able to generate specific primary T-lymphocyte responses in other HLA-DR1 donors. We also show that bcr-abl, b3a2 peptide-specific T-lymphocyte lines proliferate in response to bcr-abl b3a2 containing cell lysates (K562 or CML PBMC derived) but not control (including b2a2 CML PBMC) lysates.",
        "Doc_title":"HLA-DR1-restricted bcr-abl (b3a2)-specific CD4+ T lymphocytes respond to dendritic cells pulsed with b3a2 peptide and antigen-presenting cells exposed to b3a2 containing cell lysates.",
        "Journal":"Blood",
        "Do_id":"9207464",
        "Doc_ChemicalList":"HLA-DR1 Antigen;Peptides;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Amino Acid Sequence;Antigen Presentation;CD4-Positive T-Lymphocytes;Cell Line;Dendritic Cells;Fusion Proteins, bcr-abl;HLA-DR1 Antigen;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Molecular Sequence Data;Peptides",
        "Doc_meshqualifiers":"immunology;pathology;immunology;pathology;biosynthesis;genetics;immunology;immunology;metabolism;pathology;pharmacology",
        "_version_":1605763545412141056},
      {
        "Doc_abstract":"Patients with chronic phase chronic myeloid leukemia who respond to imatinib have a rapid initial decrease in BCR-ABL transcript levels (), followed by a slow decline (). The rate of  decrease is consistent with declining leukemic stem cells and may predict which patients may safely discontinue therapy.",
        "Doc_title":"Is it downhill from here? Eliminating leukemic stem cells and curing chronic myeloid leukemia.",
        "Journal":"Clinical cancer research : an official journal of the American Association for Cancer Research",
        "Do_id":"21948230",
        "Doc_ChemicalList":"Benzamides;Piperazines;Pyrimidines;Imatinib Mesylate;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Benzamides;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Neoplastic Stem Cells;Piperazines;Pyrimidines",
        "Doc_meshqualifiers":"genetics;drug therapy;genetics;drug effects;pharmacology;pharmacology",
        "_version_":1605842351877521408},
      {
        "Doc_abstract":"The BCR-ABL inhibitor dasatinib achieves clinical remissions in chronic myeloid leukemia (CML) patients using a dosing schedule that achieves potent but transient BCR-ABL inhibition. In vitro, transient potent BCR-ABL inhibition with either dasatinib or imatinib is cytotoxic to CML cell lines, as is transient potent EGFR inhibition with erlotinib in a lung cancer cell line. Cytotoxicity correlates with the magnitude as well as the duration of kinase inhibition. Moreover, cytotoxicity with transient potent target inhibition is equivalent to prolonged target inhibition and in both cases is associated with BIM activation and rescued by BCL-2 overexpression. In CML patients receiving dasatinib once daily, response correlates with the magnitude of BCR-ABL kinase inhibition, thereby demonstrating the potential clinical utility of intermittent potent kinase inhibitor therapy.",
        "Doc_title":"Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis.",
        "Journal":"Cancer cell",
        "Do_id":"19061839",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Thiazoles;Imatinib Mesylate;Receptor, Epidermal Growth Factor;Fusion Proteins, bcr-abl;Dasatinib",
        "Doc_meshdescriptors":"Antineoplastic Agents;Apoptosis;Benzamides;Cell Line, Tumor;Cell Survival;Dasatinib;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;K562 Cells;Kinetics;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Receptor, Epidermal Growth Factor;Thiazoles",
        "Doc_meshqualifiers":"pharmacology;antagonists & inhibitors;physiology;drug therapy;metabolism;pathology;pharmacology;pharmacology;pharmacology;antagonists & inhibitors;metabolism;pharmacology",
        "_version_":1605753039843491840},
      {
        "Doc_abstract":"Imatinib mesylate treatment causes remissions in a majority of patients with chronic myeloid leukemia (CML), but relapses are an increasing problem. We hypothesized that imatinib-resistant leukemic cells emerge from CML stem cells that acquire BCR-ABL gene mutations even before exposure to BCR-ABL-targeted agents such as imatinib.;Lineage-negative (i.e., immature) CD34+ CD38- CML stem cell-enriched populations were isolated from five patients with chronic phase CML samples by fluorescence-activated cell sorting. To identify BCR-ABL gene mutations, complementary DNAs (cDNAs) prepared from purified CML stem cells were subjected to allele-specific amplification using primers corresponding to 16 kinase domain mutations, with normal bone marrow cells serving as negative controls. We also cloned and directly sequenced BCR-ABL cDNAs prepared from freshly isolated CML stem cells and from their progeny generated after 3-5 weeks of culture.;In 20%-33% of cDNA preparations from freshly isolated CML stem cell-enriched populations, both allele-specific amplification and direct sequencing methods revealed mutations in sequences corresponding to the BCR-ABL kinase domain. Mutations were not observed in cDNA sequences encoding the c-ABL kinase domain that were obtained from similar types of primitive normal cells. More than 70 different BCR-ABL mutations (including frameshift mutations and premature stop codons) were identified in the progeny of cultured CML stem cells. Analysis of individual clones derived from the cultured cells demonstrated that new BCR-ABL mutations were produced.;Primary CML stem cells display instability of the BCR-ABL fusion gene both in vivo and in vitro. Thus, patients may possess leukemic stem cells with BCR-ABL kinase mutations before initiation of BCR-ABL-targeted therapies and would likely be predisposed to develop resistance to these agents.",
        "Doc_title":"Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells.",
        "Journal":"Journal of the National Cancer Institute",
        "Do_id":"17470736",
        "Doc_ChemicalList":"Benzamides;DNA Primers;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Imatinib Mesylate",
        "Doc_meshdescriptors":"Benzamides;Colony-Forming Units Assay;DNA Mutational Analysis;DNA Primers;Genes, abl;Genomic Instability;Humans;Imatinib Mesylate;Immunomagnetic Separation;In Situ Hybridization, Fluorescence;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Leukocyte Count;Mutation;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Reverse Transcriptase Polymerase Chain Reaction;Stem Cells;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"drug effects;blood;drug therapy;genetics;pathology;therapeutic use;therapeutic use;therapeutic use;physiology",
        "_version_":1605896216061673472},
      {
        "Doc_abstract":"Musashi-2 (MSI2) expression of 116 adult B-cells acute lymphoblastic leukemia (B-ALL) patients was measured by real-time PCR. Kaplan-Meier analysis showed that patients with high MSI2 expression had inferior overall survival (OS) (P=0.004), event free survival (EFS) (P=0.001) and relapse free survival (RFS) (P=0.018) in BCR-ABL-negative B-ALL. Multivariate models revealed that, besides WBC more than 3010(9)/L and IK6 variant of IKZF1, high MSI2 expression was also an independent prognostic factor for adult BCR-ABL-negative B-ALL. Our data suggest that high MSI2 expression could indicate poor prognosis and facilitate risk and treatment stratification in adult BCR-ABL-negative B-ALL. ",
        "Doc_title":"High expression of Musashi-2 indicates poor prognosis in adult B-cell acute lymphoblastic leukemia.",
        "Journal":"Leukemia research",
        "Do_id":"23759245",
        "Doc_ChemicalList":"MSI2 protein, human;RNA-Binding Proteins;Fusion Proteins, bcr-abl;RNA-Directed DNA Polymerase",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;B-Lymphocytes;Female;Fusion Proteins, bcr-abl;Gene Expression Regulation, Leukemic;Humans;Kaplan-Meier Estimate;Male;Middle Aged;Multivariate Analysis;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Prognosis;RNA-Binding Proteins;RNA-Directed DNA Polymerase;Young Adult",
        "Doc_meshqualifiers":"metabolism;pathology;genetics;genetics;pathology;genetics",
        "_version_":1605875817536028672},
      {
        "Doc_abstract":"In order to ascertain whether p53 has a role in chronic myeloid leukemia hematopoietic progenitor response to the innovative tyrosine kinase inhibitor STI571 (Imatinib), we overexpressed a wild type (wt) p53 construct in the K562 cell line, generated from a human blast crisis and lacking endogenous p53. Wt p53 overexpression was associated with a significant reduction of bcr-abl expression levels resulting, at least in part, from post-transcriptional events affecting the stability of p210 bcr-abl fusion protein. Moreover, we demonstrated that p53 overexpression enhances the commitment to the apoptotic death fate of K562 following its in vitro exposure to 1 microM STI571. Multiple mechanisms are involved in p53 impact on K562 survival: Most importantly, we found that a greater reduction of bcr-abl transcription by STI571 was associated with the overexpression of wt p53. Further studies are required to elucidate the mechanisms involved in the transcriptional repression of bcr-abl by STI571 and p53 and in their synergic effects on the clonal hematopoiesis of chronic myeloid leukemia.",
        "Doc_title":"Tyrosine kinase inhibitor STI571 (Imatinib) cooperates with wild-type p53 on K562 cell line to enhance its proapoptotic effects.",
        "Journal":"Acta haematologica",
        "Do_id":"16227678",
        "Doc_ChemicalList":"Benzamides;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Tumor Suppressor Protein p53;Imatinib Mesylate;Protein-Tyrosine Kinases",
        "Doc_meshdescriptors":"Apoptosis;Benzamides;Gene Expression;Genes, abl;Genes, p53;Humans;Imatinib Mesylate;K562 Cells;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Neoplastic Stem Cells;Piperazines;Protein Kinase Inhibitors;Protein-Tyrosine Kinases;Pyrimidines;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"drug effects;physiology;drug therapy;genetics;pathology;drug effects;pathology;pharmacology;pharmacology;antagonists & inhibitors;pharmacology;genetics;physiology",
        "_version_":1605785418926653440},
      {
        "Doc_abstract":"BCR-ABL inhibitors administered in conjunction with chemotherapy have significantly improved outcomes in Philadelphia chromosome-positive acute lymphoblastic leukemia but, for patients diagnosed during pregnancy, data on risks to the fetus are limited. We report a woman treated with chemotherapy and imatinib mesylate who delivered a healthy baby at 30 weeks, and we discuss available data. ",
        "Doc_title":"Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in pregnancy.",
        "Journal":"Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners",
        "Do_id":"25616656",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605898080950943744},
      {
        "Doc_abstract":"BCR-ABL plays an essential role in the pathogenesis of chronic myeloid leukemia (CML) and some cases of acute lymphocytic leukemia (ALL). Although ABL kinase inhibitors have shown great promise in the treatment of CML, the persistence of residual disease and the occurrence of resistance have prompted investigations into the molecular effectors of BCR-ABL. Here, we show that BCR-ABL stimulates the proteasome-dependent degradation of members of the forkhead family of tumor suppressors in vitro, in an in vivo animal model, and in samples from patients with BCR-ABL-positive CML or ALL. As several downstream mediators of BCR-ABL are regulated by the proteasome degradation pathway, we also show that inhibition of this pathway, using bortezomib, causes regression of CML-like disease. Bortezomib treatment led to inhibition of BCR-ABL-induced suppression of FoxO proteins and their proapoptotic targets, tumor necrosis factor-related apoptosis-inducing ligand and BIM, thereby providing novel insights into the molecular effects of proteasome inhibitor therapy. We additionally show sensitivity of imatinib-resistant BCR-ABL T315I cells to bortezomib. Our data delineate the involvement of FoxO proteins in BCR-ABL-induced evasion of apoptosis and provide evidence that bortezomib is a candidate therapeutic in the treatment of BCR-ABL-induced leukemia.",
        "Doc_title":"Proteasome inhibition causes regression of leukemia and abrogates BCR-ABL-induced evasion of apoptosis in part through regulation of forkhead tumor suppressors.",
        "Journal":"Cancer research",
        "Do_id":"19654305",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Boronic Acids;Cysteine Proteinase Inhibitors;Forkhead Transcription Factors;Piperazines;Proteasome Inhibitors;Pyrazines;Pyrimidines;Tumor Suppressor Proteins;Bortezomib;Imatinib Mesylate;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Animals;Antineoplastic Agents;Apoptosis;Benzamides;Boronic Acids;Bortezomib;Cysteine Proteinase Inhibitors;Drug Resistance, Neoplasm;Female;Forkhead Transcription Factors;Fusion Proteins, bcr-abl;Gene Expression Regulation, Leukemic;Humans;Imatinib Mesylate;Leukemia;Mice;Mice, Nude;Piperazines;Proteasome Inhibitors;Pyrazines;Pyrimidines;Remission Induction;Tumor Cells, Cultured;Tumor Suppressor Proteins;Xenograft Model Antitumor Assays",
        "Doc_meshqualifiers":"pharmacology;therapeutic use;drug effects;genetics;pharmacology;therapeutic use;pharmacology;therapeutic use;drug effects;genetics;metabolism;physiology;genetics;physiology;drug effects;drug therapy;genetics;pathology;pharmacology;pharmacology;therapeutic use;pharmacology;metabolism;physiology",
        "_version_":1605784814696267776},
      {
        "Doc_abstract":"The bcr-abl oncogene is a fusion gene resulting from a reciprocal translocation which forms the hallmark of chronic myeloid leukemia (CML). Antisense oligonucleotides complementary to the two possible mRNA breakpoints were found to inhibit cell growth of CML patient cells and cell lines, but doubt exists about their specificity. In order to test the specificity, phosphorothioate and 3' phosphorothioate capped antisense BCR-ABL oligonucleotides of different length were used. Stability, cellular uptake of oligonucleotides and effect on cell growth were studied in two CML cell lines, BV173 and LAMA-84. Phosphorothioate antisense BCR-ABL oligonucleotides were most stable, showed the highest uptake and induced cell death in BV173 but not in LAMA-84 cells. We selected the most effective antisense oligonucleotide for further analysis. The BV173 and LAMA-84 cell lines do not express the normal c-abl protein, we therefore used a c-abl specific monoclonal antibody for the detection of p210bcr-abl expression by flow cytometry. Dead cells found after treatment were gated out of analysis. Although BCR-ABL antisense oligonucleotides can induce apoptosis, no reduction of p210bcr-abl levels could be detected in living cells after treatment with antisense oligonucleotides. We conclude that antisense mediated inhibition of translation of mRNA into p210bcr-abl is not the mechanism responsible for the induction of apoptosis in cell line BV173.",
        "Doc_title":"Phosphorothioate BCR-ABL antisense oligonucleotides induce cell death, but fail to reduce cellular bcr-abl protein levels.",
        "Journal":"Leukemia",
        "Do_id":"7845006",
        "Doc_ChemicalList":"Oligonucleotides, Antisense;RNA, Messenger;Thionucleotides;Fusion Proteins, bcr-abl;Proto-Oncogene Proteins c-abl",
        "Doc_meshdescriptors":"Apoptosis;Base Sequence;Cell Division;Fusion Proteins, bcr-abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Molecular Sequence Data;Oligonucleotides, Antisense;Proto-Oncogene Proteins c-abl;RNA, Messenger;Thionucleotides;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"drug effects;drug effects;analysis;genetics;physiology;metabolism;pathology;pharmacology;genetics;analysis;pharmacology",
        "_version_":1605804322334965760},
      {
        "Doc_abstract":"We report on a 67-year-old woman with acute lymphoblastic leukemia (ALL) who was supposed to have a variant Philadelphia (Ph) translocation identified by conventional cytogenetic techniques. Fluorescence in situ hybridization (FISH) analysis demonstrated the presence of an amplification of BCR-ABL rearrangement at locus 22q11. This is the first observation, to our knowledge, of a duplicated BCR-ABL chimeric gene within the derived chromosome 22 in ALL. Our observation supports the possibility of detecting a variant Ph chromosome at the single-cell level by FISH analysis.",
        "Doc_title":"Amplification of BCR-ABL rearrangement in atypical Philadelphia chromosome: a new variant detected by fluorescence in situ hybridization in one case of acute lymphoblastic leukemia.",
        "Journal":"Cancer genetics and cytogenetics",
        "Do_id":"9973946",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Aged;Antineoplastic Combined Chemotherapy Protocols;Female;Fusion Proteins, bcr-abl;Gene Rearrangement;Humans;In Situ Hybridization, Fluorescence;Karyotyping;Philadelphia Chromosome;Precursor Cell Lymphoblastic Leukemia-Lymphoma",
        "Doc_meshqualifiers":"therapeutic use;genetics;drug therapy;genetics",
        "_version_":1605818711597383680},
      {
        "Doc_abstract":"The Bcr/Abl oncoprotein is directly responsible for the development of chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia in humans. The adapter protein Crkl is one of the most prominently tyrosine-phosphorylated substrates of Bcr/Abl in cells and tissues isolated from such patients. The guanine nucleotide exchange factor for the small GTPase Rap1, C3G, binds constitutively to Crkl. Here, we report that Crkl mediates the formation of protein complexes that include C3G and Bcr/Abl. These complexes contain highly elevated levels of tyrosine-phosphorylated C3G and P130Cas, a scaffolding protein. Moreover, the presence of Rap1 further promoted tyrosine phosphorylation of C3G and Cas. Co-expression of Crkl and C3G with Bcr/Abl generated increased levels of activated Rap1. In addition, lysates from leukemic cells of P190 BCR/ABL transgenic mice and of the myelogenous leukemia cell line K562 contained tyrosine-phosphorylated C3G and activated Rap1. These data suggest a role for C3G-mediated Rap1 activation in Bcr/Abl-induced leukemia development.",
        "Doc_title":"Interaction of Bcr/Abl with C3G, an exchange factor for the small GTPase Rap1, through the adapter protein Crkl.",
        "Journal":"Biochemical and biophysical research communications",
        "Do_id":"15982636",
        "Doc_ChemicalList":"Adaptor Proteins, Signal Transducing;CRKL protein;Guanine Nucleotide-Releasing Factor 2;Nuclear Proteins;Fusion Proteins, bcr-abl;rap1 GTP-Binding Proteins",
        "Doc_meshdescriptors":"Adaptor Proteins, Signal Transducing;Animals;COS Cells;Cell Line, Tumor;Cercopithecus aethiops;Enzyme Activation;Fusion Proteins, bcr-abl;Guanine Nucleotide-Releasing Factor 2;Leukemia;Mice;Mice, Transgenic;Nuclear Proteins;rap1 GTP-Binding Proteins",
        "Doc_meshqualifiers":"metabolism;metabolism;metabolism;metabolism;metabolism;metabolism",
        "_version_":1605891149811154944},
      {
        "Doc_abstract":"Targeted therapy with the Abl kinase inhibitor imatinib has markedly improved the outlook for patients with chronic myeloid leukemia (CML). Breakpoint cluster region (Bcr)-Abl signaling is reactivated at the time of resistance, predominantly due to mutations in the kinase domain of Bcr-Abl that interfere with drug binding. This discovery prompted the development of new Abl kinase inhibitors, among which nilotinib and dasatinib have gained regulatory approval. Despite excellent results in patients with imatinib-resistant or imatinib-intolerant CML treated with nilotinib or dasatinib, early indications suggest that: the cross-resistant Bcr-Abl(T315I) mutant is disproportionately represented among patients who relapse on these therapies; each Abl inhibitor exhibits vulnerabilities to certain kinase domain mutations. We review new inhibitors of Bcr-Abl, including preliminary information on inhibitors of Bcr-Abl(T315I) and discuss the potential of combined Abl kinase inhibitor therapy to preempt resistance. Improved Abl inhibitor therapies will be useful in achieving maximum disease control but a clinical T315I inhibitor remains a high priority.",
        "Doc_title":"New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check.",
        "Journal":"Expert opinion on investigational drugs",
        "Do_id":"18491988",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;HSP90 Heat-Shock Proteins;Harringtonines;Neoplasm Proteins;Piperazines;Protein Kinase Inhibitors;Pyrimidines;homoharringtonine;Imatinib Mesylate;Fusion Proteins, bcr-abl;Proto-Oncogene Proteins c-abl",
        "Doc_meshdescriptors":"Administration, Oral;Antineoplastic Agents;Benzamides;Biological Availability;Clinical Trials as Topic;Drug Design;Drug Resistance, Neoplasm;Drug Screening Assays, Antitumor;Fusion Proteins, bcr-abl;Genes, abl;HSP90 Heat-Shock Proteins;Harringtonines;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mutation, Missense;Neoplasm Proteins;Piperazines;Point Mutation;Protein Conformation;Protein Kinase Inhibitors;Proto-Oncogene Proteins c-abl;Pyrimidines;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"pharmacokinetics;pharmacology;therapeutic use;statistics & numerical data;drug effects;genetics;antagonists & inhibitors;genetics;antagonists & inhibitors;pharmacology;therapeutic use;drug therapy;enzymology;genetics;antagonists & inhibitors;genetics;pharmacokinetics;pharmacology;therapeutic use;drug effects;pharmacokinetics;pharmacology;therapeutic use;antagonists & inhibitors;pharmacokinetics;pharmacology;therapeutic use;drug effects;enzymology",
        "_version_":1605905269444837376},
      {
        "Doc_abstract":"Imatinib inhibits Bcr-Abl, the oncogenic tyrosine kinase that causes chronic myeloid leukemia. The second-line inhibitors nilotinib and dasatinib are effective in patients with imatinib resistance resulting from Bcr-Abl kinase domain mutations. Bcr-Abl(T315I), however, is resistant to all Abl kinase inhibitors in clinical use and is emerging as the most frequent cause of salvage therapy failure. SGX393 is a potent inhibitor of native and T315I-mutant Bcr-Abl kinase that blocks the growth of leukemia cell lines and primary hematopoietic cells expressing Bcr-Abl(T315I), with minimal toxicity against Bcr-Abl-negative cell lines or normal bone marrow. A screen for Bcr-Abl mutants emerging in the presence of SGX393 revealed concentration-dependent reduction in the number and range of mutations. Combining SGX393 with nilotinib or dasatinib preempted emergence of resistant subclones, including Bcr-Abl(T315I). These findings suggest that combination of a T315I inhibitor with the current clinically used inhibitors may be useful for reduction of Bcr-Abl mutants in Philadelphia chromosome-positive leukemia.",
        "Doc_title":"SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib.",
        "Journal":"Proceedings of the National Academy of Sciences of the United States of America",
        "Do_id":"18367669",
        "Doc_ChemicalList":"4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide;Protein Kinase Inhibitors;Pyrimidines;Thiazoles;Fusion Proteins, bcr-abl;Dasatinib",
        "Doc_meshdescriptors":"Antineoplastic Combined Chemotherapy Protocols;Cell Line, Tumor;Dasatinib;Drug Resistance, Neoplasm;Fusion Proteins, bcr-abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mutation, Missense;Protein Kinase Inhibitors;Pyrimidines;Thiazoles",
        "Doc_meshqualifiers":"pharmacology;drug effects;genetics;antagonists & inhibitors;genetics;drug therapy;pharmacology;pharmacology;pharmacology",
        "_version_":1605901782886645760},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) was the first hematological malignancy to be associated with a specific genetic lesion. The Philadelphia translocation, producing a BCRABL hybrid oncogene, is the most common mechanism of CML development. However, in the present study, b3a2, b2a2 and ela2 fusion junctions of the breakpoint cluster region (BCR)-V-abl Abelson murine leukemia viral oncogene homolog 1 (ABL) gene were not detected in patients diagnosed with CML three and four years previously. RNA-Seq technology, with an average coverage of ~30fold, was used to detect gene fusion events in a patient with a 6-year history of CML, identified to be in the chronic phase of the disease. Using deFuse and TopHatfusion programs with improved filtering methods, we identified two reliable gene fusions in a blood sample obtained from the CML patient, including extremely low expression levels of the classic BCRABL1 gene fusion. In addition, a novel gene fusion involving the ring finger protein 213 (RNF213)-solute carrier family 26, member 11 (SLC26A11) was identified and validated by reverse transcription polymerase chain reaction. Further bioinformatic analysis revealed that specific domains of SLC26A11 were damaged, which may affect the function of sulfate transportation of the normal gene. The present study demonstrated that, in specific cases, alternative gene fusions, besides BCRABL, may be associated with the development of CML.",
        "Doc_title":"Identification of a novel gene fusion RNF213SLC26A11 in chronic myeloid leukemia by RNA-Seq.",
        "Journal":"Molecular medicine reports",
        "Do_id":"23151810",
        "Doc_ChemicalList":"Membrane Transport Proteins;SLC26A4 protein, human;RNF213 protein, human;Ubiquitin-Protein Ligases;Adenosine Triphosphatases",
        "Doc_meshdescriptors":"Adenosine Triphosphatases;Aged;Gene Fusion;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Membrane Transport Proteins;Reverse Transcriptase Polymerase Chain Reaction;Sequence Analysis, RNA;Ubiquitin-Protein Ligases",
        "Doc_meshqualifiers":"metabolism;pathology;genetics;metabolism;genetics;metabolism",
        "_version_":1605896386441641984},
      {
        "Doc_abstract":"BCR-ABL kinase has been observed to be potentially related to leukemic cell development. Adult patients with acute lymphoblastic leukemia (ALL) were evaluated to determine whether presence/absence of BCR-ABL induced differences in activation of Src, PI3K/Akt and NF-B or in the expression of anti-apoptotic proteins such as BCL-2 and c-IAP1. BCR-ABL positive patients showed a significantly higher activation of Src and Akt compared with BCR-ABL negative patients and healthy donors. BCR-ABL negative patients also showed a significant activation of Src and low levels of Akt activation compared with healthy donors. Both patient groups had increased NF-B activation and overexpression of BCL-2 and c-IAP1. This is the first study to evaluate concurrently in ALL patients presence/absence of BCR-ABL in relation to activation of Src, Akt and NF-B and the expression of anti-apoptotic proteins. Results suggest that these proteins may be involved in an anti-apoptotic signaling pathway.",
        "Doc_title":"Src, Akt, NF-B, BCL-2 and c-IAP1 may be involved in an anti-apoptotic effect in patients with BCR-ABL positive and BCR-ABL negative acute lymphoblastic leukemia.",
        "Journal":"Leukemia research",
        "Do_id":"22591684",
        "Doc_ChemicalList":"Apoptosis Regulatory Proteins;Inhibitor of Apoptosis Proteins;NF-kappa B;Proto-Oncogene Proteins c-bcl-2;Fusion Proteins, bcr-abl;Proto-Oncogene Proteins pp60(c-src);Proto-Oncogene Proteins c-akt",
        "Doc_meshdescriptors":"Adult;Apoptosis;Apoptosis Regulatory Proteins;Bone Marrow Examination;Case-Control Studies;Female;Fusion Proteins, bcr-abl;Gene Expression Regulation, Leukemic;Humans;Inhibitor of Apoptosis Proteins;Male;NF-kappa B;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Proto-Oncogene Proteins c-akt;Proto-Oncogene Proteins c-bcl-2;Proto-Oncogene Proteins pp60(c-src);Signal Transduction",
        "Doc_meshqualifiers":"genetics;genetics;metabolism;physiology;genetics;metabolism;genetics;metabolism;physiology;genetics;metabolism;physiology;genetics;metabolism;pathology;genetics;metabolism;physiology;genetics;metabolism;physiology;genetics;metabolism;physiology;genetics",
        "_version_":1605742135884120064},
      {
        "Doc_abstract":"Chronic myeloid leukemia is caused by the tyrosine kinase oncoprotein BCR/ABL. Using oligonucleotide arrays to assay mRNAs at different phases of the cell cycle in BCR/ABL-transformed cells, we found that cyclin D2 mRNA was constitutively expressed at high levels throughout the cell cycle, a pattern confirmed by immunoblotting of protein lysates. Bone marrow cells from cyclin D2-deficient strains of mice failed to proliferate in response to infection with a retrovirus carrying BCR/ABL and failed to generate transformed lymphoid cell lines in vitro. These results establish that BCR/ABL promotes cell cycle progression by altering expression of cyclin D2 and that cyclin D2 induction plays a critical role in proliferation of hematopoietic cells by BCR/ABL.",
        "Doc_title":"Critical role for cyclin D2 in BCR/ABL-induced proliferation of hematopoietic cells.",
        "Journal":"Cancer research",
        "Do_id":"11809706",
        "Doc_ChemicalList":"Ccnd2 protein, mouse;Cyclin D2;Cyclins;RNA, Messenger;Fusion Proteins, bcr-abl;Tetracycline",
        "Doc_meshdescriptors":"Animals;Bone Marrow Cells;Cell Division;Cell Line, Transformed;Cell Transformation, Neoplastic;Cyclin D2;Cyclins;Fusion Proteins, bcr-abl;Gene Expression Profiling;Gene Expression Regulation;Genes, abl;Hematopoietic Stem Cells;Mice;Oligonucleotide Array Sequence Analysis;RNA, Messenger;Signal Transduction;Tetracycline;Transcriptional Activation",
        "Doc_meshqualifiers":"cytology;physiology;genetics;biosynthesis;genetics;physiology;biosynthesis;genetics;physiology;drug effects;physiology;metabolism;biosynthesis;genetics;pharmacology",
        "_version_":1605874494390403072},
      {
        "Doc_abstract":"In order to investigate the features of M-bcr/abl and m-bcr/abl fusion transcripts in patients with chronic myeloid leukemia (CML) after allogeneic stem cell transplantation (SCT), M-bcr/abl and m-bcr/abl fusion transcripts were sequentially detected by RT-PCR technique in 72 CML patients after SCT. The results showed that M-bcr/abl positive rate (79.2%, 42/53) within 6 months after SCT was remarkably higher than that in 6-12 months group (34.3%, 11/32) and >or= 12 months group (35.1%, 13/37) (P < 0.001), and the clinical relapse rates in corresponding periods were 1.9% (1/53), 0% (0/32) and 16.2% (6/37) respectively. M-bcr/abl and m-bcr/abl fusion transcripts occurred in 5 of 6 clinically relapsed patients. In period of more than 6 months after transplantation, none of 17 M-bcr/abl(+) samples from 14 patients in cytogenetic remission appeared positive reaction of m-bcr/abl. It is concluded that M-bcr/abl(+) fusion transcript still existed in most patients after SCT, and usually disappeared within 6 months. Existence of M-bcr/abl is not a clinical relapse marker in CML patients. Simultaneous detection of M-bcr/abl and m-bcr/abl fusion transcripts can be helpful for monitoring residual disease.",
        "Doc_title":"[Follow-up detection of M-bcr/abl and m-bcr/abl fusion transcripts in chronic myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation].",
        "Journal":"Zhongguo shi yan xue ye xue za zhi",
        "Do_id":"12962564",
        "Doc_ChemicalList":"RNA, Messenger;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adolescent;Adult;Child;Child, Preschool;Female;Follow-Up Studies;Fusion Proteins, bcr-abl;Hematopoietic Stem Cell Transplantation;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;RNA, Messenger;Recurrence;Reverse Transcriptase Polymerase Chain Reaction;Transplantation, Homologous",
        "Doc_meshqualifiers":"genetics;metabolism;therapy;analysis",
        "_version_":1605755349395046400},
      {
        "Doc_abstract":"Tyrosine kinase inhibitors have revolutionized the treatment of several malignancies, converting lethal diseases in a manageable aspect. Imitanib, a small molecule ABL kinase inhibitor is a highly effective therapy for early phase chronic myeloid leukemia (CML), which has constitutively active ABL kinase activity owing to the over expression of the BCR-ABL fusion protein. But some patients develop imatinib resistance, particularly in the advanced phases of CML.The discovery of resistance mechanisms of imitanib; urge forward the development of second generation drugs. Nilotinib, a second generation drug is more potent inhibitor of BCR-ABL than imatinib. But nilotinib also develops dermatologic events and headache in patients. Large information about BCR-ABL structure and its inhibitors are now available. Based on the pharmacophore modeling approaches, it is possible to decipher the molecular determinants to inhibit BCR-ABL. We conducted a structure based and ligand based study to identify potent natural compounds as BCR-ABL inhibitor. First kinase inhibitors were docked with the receptor (BCR-ABL) and nilotinib was selected as a pharmacophore due its high binding efficiency. Eleven compounds were selected out of 1457 substances which have mutual pharmacopohre features with nilotinib. These eleven compounds were validated and used for docking study to find the drug like molecules. The best molecules from the final set of screening candidates can be evaluated in cell lines and may represent a novel class of BCR-ABL inhibitors.;CML - Chronic myeloid leukemia, PDGFR - Platelet derived growth factor receptor, TKI - Tyrosine kinase inhibitors.",
        "Doc_title":"Nilotinib based pharmacophore models for BCRABL.",
        "Journal":"Bioinformation",
        "Do_id":"23055606",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605840409025576960},
      {
        "Doc_abstract":"In Ph(+) chronic myeloid leukemia (CML), the constitutively active Bcr-Abl kinase leads to the up-regulation and activation of multiple genes, which may subsequently result in the expression of leukemia-associated antigens. In this study, we investigated the immunogenicity of Bcr-Abl-regulated antigens by stimulating CD8(+) T lymphocytes with autologous dendritic cells transfected with RNA coding for Bcr-Abl wild-type or a kinase-deficient mutant. Significant HLA class I-restricted T-cell responses were detected against antigens regulated by the Bcr-Abl kinase, but not toward the Bcr-Abl protein itself. The T-cell repertoire of a patient with CML in major molecular remission due to imatinib mesylate was also dominated by T cells directed against Bcr-Abl-regulated antigens. These results encourage the development of immunotherapeutic approaches against Bcr-Abl-regulated antigens for the treatment of CML patients with residual disease following therapy with Bcr-Abl kinase inhibitors.",
        "Doc_title":"The immunogenicity of Bcr-Abl expressing dendritic cells is dependent on the Bcr-Abl kinase activity and dominated by Bcr-Abl regulated antigens.",
        "Journal":"Blood",
        "Do_id":"17579186",
        "Doc_ChemicalList":"Antigens;Benzamides;HLA Antigens;Piperazines;Pyrimidines;Imatinib Mesylate;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Animals;Antigens;Benzamides;CD8-Positive T-Lymphocytes;Dendritic Cells;Enzyme Activation;Fusion Proteins, bcr-abl;Gene Expression Regulation, Neoplastic;HLA Antigens;Humans;Imatinib Mesylate;Immunogenetics;Leukemia;Lymphocyte Activation;Piperazines;Pyrimidines;Up-Regulation;Xenopus laevis",
        "Doc_meshqualifiers":"immunology;immunology;metabolism;immunology;metabolism;drug effects;antagonists & inhibitors;genetics;immunology;metabolism;metabolism;immunology;metabolism;immunology;pharmacology;pharmacology",
        "_version_":1605837548011126784},
      {
        "Doc_abstract":"Li-Fraumeni syndrome is a familial cancer syndrome characterized by different tumors and hereditary p53 mutations. Here, a chronic myeloid leukemia-like syndrome case in a Li-Fraumeni syndrome family with del (12) (p12) cytogenetic abnormality was presented. A hereditary p53 mutation (pro309ser) supported the Li-Fraumeni syndrome diagnosis in this family. This syndrome was characterized by the clonal myeloproliferative accumulation in bone marrow and peripheral blood with negative bcr/abl gene rearrangement finding. The etiology of this rare syndrome is still unclear. This is the only chronic myeloid leukemia-like syndrome case reported in a Li-Fraumeni syndrome family. Del (12)(p12) was observed in leukemias except chronic myeloid leukemia-like syndrome. The deletion in chromosome 12p12 with hereditary p53 mutation should have a critical role in chronic myeloid leukemia-like syndrome etiology in our case.",
        "Doc_title":"A chronic myeloid leukemia-like syndrome case with del (12) (p12) in a Li-Fraumeni syndrome family.",
        "Journal":"Clinical and laboratory haematology",
        "Do_id":"15784129",
        "Doc_ChemicalList":"Tumor Suppressor Protein p53",
        "Doc_meshdescriptors":"Chromosome Deletion;Chromosomes, Human, Pair 12;Diagnosis, Differential;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Li-Fraumeni Syndrome;Male;Middle Aged;Mutation;Myeloproliferative Disorders;Syndrome;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"diagnosis;genetics;diagnosis;genetics;genetics",
        "_version_":1605904050400788480},
      {
        "Doc_abstract":"The effect of mutations in the Src homology 2 (SH2) domain of the BCR/ABL oncogene on leukemogenesis was tested in a quantitative murine bone marrow transduction/transplantation assay that accurately models human Philadelphia-positive B-lymphoid leukemia and chronic myeloid leukemia (CML). The SH2 domain was not required for induction of B-lymphoid leukemia in mice by BCR/ABL. Under conditions where the p190 and p210 forms of BCR/ABL induce fatal CML-like myeloproliferative disease within 4 weeks, p210 SH2 mutants induced CML-like disease in some mice only after a significant delay, with other recipients succumbing to B-lymphoid leukemia instead. In contrast, p190 BCR/ABL SH2 point and deletion mutants rapidly induced CML-like disease. These results provide the first direct evidence of significant differences in cell signaling by the Bcr/Abl tyrosine kinase between these distinct leukemias. Contrary to previous observations, high levels of phosphatidylinositol 3-kinase (PI 3-kinase) activity in primary malignant lymphoblasts and myeloid cells from recipients of marrow transduced with the BCR/ABL SH2 mutants were found. Hence, the decreased induction of CML-like disease by the p210 BCR/ABL SH2 mutants is not due to impaired activation of PI 3-kinase.",
        "Doc_title":"The src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase.",
        "Journal":"Blood",
        "Do_id":"11133737",
        "Doc_ChemicalList":"Interleukin-3;Phosphotyrosine;Phosphatidylinositol 3-Kinases;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Animals;Bone Marrow Cells;Cell Line;Cell Transformation, Neoplastic;Disease Models, Animal;Enzyme Activation;Female;Fusion Proteins, bcr-abl;Interleukin-3;Leukemia, B-Cell;Leukemia, Experimental;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Mice;Mice, Inbred BALB C;Myeloid Cells;Phosphatidylinositol 3-Kinases;Phosphorylation;Phosphotyrosine;Point Mutation;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Protein Binding;Signal Transduction;Stem Cells;src Homology Domains",
        "Doc_meshqualifiers":"drug effects;enzymology;drug effects;drug effects;drug effects;genetics;metabolism;pharmacology;pharmacology;etiology;enzymology;etiology;enzymology;etiology;enzymology;drug effects;metabolism;metabolism;enzymology;drug effects;enzymology;genetics;physiology",
        "_version_":1605819427811491840},
      {
        "Doc_abstract":"Regulated phosphorylation by protein tyrosine kinases (PTKs), such as c-Abl, is critical to cellular homeostasis. In turn, once deregulated as in the chronic myeloid leukemia (CML) fusion protein Bcr-Abl, PTKs can promote cancer onset and progression. The dramatic success of the Bcr-Abl inhibitor imatinib as therapy for CML has inspired interest in other PTKs as targets for cancer drug discovery. Here we report a novel PTK activity and inhibition screening method using hydrogel-immobilized peptide substrates. Using acrylate crosslinkers, we tether peptides via terminal cysteines to thiol-presenting hydrogels in 96-well plates. These surfaces display low background and high reproducibility, allowing semiquantitative detection of peptide phosphorylation by recombinant c-Abl or by Bcr-Abl activity in cell extracts using traditional anti-phosphotyrosine immunodetection and chemifluorescence. The capabilities of this assay are demonstrated by performing model screens for inhibition with several commercially available PTK inhibitors and a collection of pyridopyrimidine Src/Abl dual inhibitors. This assay provides a practical method to measure the activity of a single kinase present in a whole cell lysate with high sensitivity and specificity as a valuable means for efficient small molecule screening.",
        "Doc_title":"A solid-phase Bcr-Abl kinase assay in 96-well hydrogel plates.",
        "Journal":"Analytical biochemistry",
        "Do_id":"18194660",
        "Doc_ChemicalList":"Cell Extracts;Peptides;Protein Kinase Inhibitors;Hydrogel;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Biological Assay;Cell Extracts;Drug Evaluation, Preclinical;Fusion Proteins, bcr-abl;Humans;Hydrogel;K562 Cells;Peptides;Phosphorylation;Protein Kinase Inhibitors;Structure-Activity Relationship;Time Factors",
        "Doc_meshqualifiers":"methods;antagonists & inhibitors;metabolism;metabolism;chemistry;metabolism;drug effects;analysis;chemistry;pharmacology",
        "_version_":1605757465998131200},
      {
        "Doc_abstract":"Chronic myeloid leukemia cells contain a BCR-ABL oncoprotein with an enhanced tyrosine kinase activity, which is considered to be the principal 'cause' of the leukemia. Though the precise mechanisms underlying the leukemogenesis remains enigmatic, the use of imatinib to inhibit the dysregulated kinase activity has proved remarkably successful in clinical practice. Imatinib was the first small molecule developed to inhibit BCR-ABL tyrosine kinase activity and its success introduced the current era of molecularly targeted therapies for a number of other malignancies. In patients with chronic myeloid leukaemia who develop resistance to imatinib, the Bcr-Abl signaling pathway is often re-established. This has led to the emergence of a number of alternative treatment strategies designed to target the leukemic cell which are resistant to imatinib.",
        "Doc_title":"Molecularly targeted treatment of chronic myeloid leukemia: beyond the imatinib era.",
        "Journal":"Frontiers in bioscience : a journal and virtual library",
        "Do_id":"16146726",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Cancer Vaccines;Piperazines;Pyrimidines;Imatinib Mesylate;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Animals;Antineoplastic Agents;Benzamides;Cancer Vaccines;Drug Resistance, Neoplasm;Fusion Proteins, bcr-abl;Gene Expression Regulation, Neoplastic;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Models, Biological;Models, Genetic;Philadelphia Chromosome;Piperazines;Protein-Tyrosine Kinases;Pyrimidines;Signal Transduction",
        "Doc_meshqualifiers":"pharmacology;metabolism;drug therapy;genetics;therapeutic use;metabolism;therapeutic use",
        "_version_":1605836491489017856},
      {
        "Doc_abstract":"The Bcr-Abl oncoprotein plays a major role in the development and progression of chronic myeloid leukemia and is a determinant of chemotherapy resistance occurring during the blast crisis phase of the disease. The aim of this article was to investigate the possibility of combating the resistance to apoptosis caused by Bcr-Abl by inducing an alternative cell death process. As a model of chronic myeloid leukemia, we employed Bcr-Abl-transfected mouse progenitor 32D cells with low and high Bcr-Abl expression levels corresponding to drug-sensitive and drug-resistant cells, respectively. The drug curcumin (diferuloylmethane), a known potent inducer of cell death in many cancer cells, was investigated for efficacy with Bcr-Abl-expressing cells. Curcumin strongly inhibited cell proliferation and affected cell viability by inducing apoptotic symptoms in all tested cells; however, apoptosis was a relatively late event. G(2)-M cell cycle arrest, together with increased mitotic index and cellular and nuclear morphology resembling those described for mitotic catastrophe, was observed and preceded caspase-3 activation and DNA fragmentation. Mitosis-arrested cells displayed abnormal chromatin organization, multipolar chromosome segregation, aberrant cytokinesis, and multinucleated cells-morphologic changes typical of mitotic catastrophe. We found that the mitotic cell death symptoms correlated with attenuated expression of survivin, a member of the chromosomal passenger complex, and mislocalization of Aurora B, the partner of survivin in the chromosomal passenger complex. Inhibition of survivin expression with small interfering RNA exhibited similar mitotic disturbances, thus implicating survivin as a major, albeit not the only, target for curcumin action. This study shows that curcumin can overcome the broad resistance to cell death caused by expression of Bcr-Abl and suggests that curcumin may be a promising agent for new combination regimens for drug-resistant chronic myeloid leukemia.",
        "Doc_title":"Curcumin affects components of the chromosomal passenger complex and induces mitotic catastrophe in apoptosis-resistant Bcr-Abl-expressing cells.",
        "Journal":"Molecular cancer research : MCR",
        "Do_id":"16849521",
        "Doc_ChemicalList":"Birc5 protein, mouse;Inhibitor of Apoptosis Proteins;Microtubule-Associated Proteins;Repressor Proteins;Fusion Proteins, bcr-abl;Aurkb protein, mouse;Aurora Kinase B;Aurora Kinases;Protein-Serine-Threonine Kinases;Caspases;Curcumin",
        "Doc_meshdescriptors":"Animals;Apoptosis;Aurora Kinase B;Aurora Kinases;Caspases;Cell Growth Processes;Chromosome Segregation;Curcumin;Down-Regulation;Enzyme Activation;Fusion Proteins, bcr-abl;Genes, abl;Hematopoietic Stem Cells;Inhibitor of Apoptosis Proteins;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mice;Microtubule-Associated Proteins;Mitosis;Polyploidy;Protein-Serine-Threonine Kinases;Repressor Proteins",
        "Doc_meshqualifiers":"drug effects;genetics;metabolism;drug effects;pharmacology;drug effects;biosynthesis;genetics;cytology;drug effects;physiology;drug therapy;genetics;pathology;biosynthesis;genetics;metabolism;drug effects;genetics;metabolism",
        "_version_":1605741927134658561},
      {
        "Doc_abstract":"When injected into SCID mice, the Philadelphia chromosome-positive chronic myeloid leukemia-blast crisis cell line BV173 induces a disease process closely resembling that seen in leukemia patients. At 1 and 3 weeks after injection of 10(6) BV173 cells, CD10+ cells were detected in the bone marrow of the mice, leukemic colonies grew from bone marrow and spleen cell suspensions, and BCR-ABL transcripts were detectable in bone marrow, spleen, peripheral blood, liver, and lungs. Systemic treatment of the leukemic mice with a 26-mer BCR-ABL antisense oligodeoxynucleotide (1 mg/day for 9 days) induced disappearance of CD10+ and clonogenic leukemic cells and a marked decrease in BCR-ABL mRNA in mouse tissues. Untreated mice or mice treated with a BCR-ABL sense oligodeoxynucleotide or a 6-base-mismatched antisense oligodeoxynucleotide oligodeoxynucleotide were dead 8-13 weeks after leukemia cell injection; in marked contrast, mice treated with BCR-ABL antisense oligodeoxynucleotide died of leukemia 18-23 weeks after injection of leukemic cells. These findings provide evidence for the in vivo effectiveness of an anticancer therapy based on antisense oligodeoxynucleotides targeting a tumor-specific gene.",
        "Doc_title":"Suppression of Philadelphia1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide.",
        "Journal":"Proceedings of the National Academy of Sciences of the United States of America",
        "Do_id":"8183938",
        "Doc_ChemicalList":"Oligodeoxyribonucleotides;Oligonucleotides, Antisense;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Animals;Base Sequence;Cell Division;Cell Line;Flow Cytometry;Fusion Proteins, bcr-abl;Genes, abl;Humans;Kidney;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Leukemia, Promyelocytic, Acute;Liver;Male;Mice;Mice, SCID;Molecular Sequence Data;Oligodeoxyribonucleotides;Oligonucleotides, Antisense;Spleen;Time Factors;Transcription, Genetic;Translocation, Genetic;Transplantation, Heterologous;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"drug effects;biosynthesis;genetics;pathology;drug therapy;pathology;pathology;pathology;toxicity;analysis;therapeutic use;toxicity;pathology",
        "_version_":1605831816987541504},
      {
        "Doc_abstract":"BCR-ABL(p190) oncogene is the result of a reciprocal translocation between chromosomes 9 and 22 and is associated with B-cell acute lymphoblastic leukemia (B-ALL) in humans. Current models expressing the BCR-ABL(p190) chimeric gene fail to consistently reproduce the phenotype with which the fusion gene is associated in human pathology, mainly due to the difficulty of being expressed in the appropriate cell type in vivo. We have used here homologous recombination in ES cells to create an in-frame fusion of BCR-ABL(p190) that mimics the consequences of the human chromosomal translocation by fusion of BCR-ABL coding sequences into the bcr endogenous gene. The chimeric mice generated with the mutant embryonic stem cells systematically develop B-ALL. Using these chimeric mice, we further show that BCR-ABL oncogene does not require the endogenous bcr product in leukemogenesis. Our results show that BCR-ABL(p190) chimeric mice are a new model to study the biology of the BCR-ABL oncogene and indicate the efficacy of this strategy for studying the role of specific chromosome abnormalities in tumor development.",
        "Doc_title":"A BCR-ABL(p190) fusion gene made by homologous recombination causes B-cell acute lymphoblastic leukemias in chimeric mice with independence of the endogenous bcr product.",
        "Journal":"Blood",
        "Do_id":"9310467",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Animals;Burkitt Lymphoma;Chimera;Fusion Proteins, bcr-abl;Gene Expression Regulation, Neoplastic;Gene Rearrangement, B-Lymphocyte, Heavy Chain;Immunophenotyping;Mice;Mice, Transgenic;Neoplasm Transplantation;Recombination, Genetic;Translocation, Genetic",
        "Doc_meshqualifiers":"genetics;immunology;pathology;genetics",
        "_version_":1605759235158704128},
      {
        "Doc_abstract":"Nilotinib is a potent tyrosine kinase inhibitor of breakpoint cluster region-abelson (BCR-ABL), which has been approved as front-line therapy for newly diagnosed chronic myeloid leukemia in chronic phase and as second-line therapy after imatinib failure in chronic or accelerated phase chronic myeloid leukemia. Tyrosine kinase inhibitors have been associated with myelosuppression and grade 3 or grade 4 cytopenias are not uncommon in chronic myeloid leukemia patients treated with these drugs. There are a few reports of imatinib-associated bone marrow aplasia, but to our knowledge only one reported case of bone marrow aplasia associated with nilotinib. Herein, we report a 49-year-old male patient with chronic phase chronic myeloid leukemia, who developed severe bone marrow aplasia due to nilotinib. Possible mechanisms for this significant adverse drug reaction are discussed along with a review of literature.",
        "Doc_title":"Recurrent bone marrow aplasia secondary to nilotinib in a patient with chronic myeloid leukemia: a case report.",
        "Journal":"Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners",
        "Do_id":"22399151",
        "Doc_ChemicalList":"4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide;Pyrimidines",
        "Doc_meshdescriptors":"Bone Marrow Diseases;Humans;Leukemia, Myeloid, Chronic-Phase;Male;Middle Aged;Pyrimidines",
        "Doc_meshqualifiers":"chemically induced;drug therapy;adverse effects;therapeutic use",
        "_version_":1605746442583932928},
      {
        "Doc_abstract":"Transient pancytopenia preceding acute lymphoblastic leukemia (pre-ALL) is a rare but well-known occurrence usually affecting children and adolescents. Though pre-ALL in a few adults has ever been reported, the association of this preleukemic syndrome with positive Philadelphia chromosome and P190(BCR-ABL) is extremely rare. To the best of our knowledge, this is the first report of adult B-cell type pre-ALL with positive Philadelphia chromosome and P190(BCR-ABL) published in the literature. We report the case of a 49-year-old woman who was diagnosed with B-cell type ALL associated positive Philadelphia chromosome and P190(BCR-ABL) preceded by transient pancytopenia. The clinical, morphologic, immunophenotypic and molecular features of this patient are described and the literature reviewed.",
        "Doc_title":"Transient pancytopenia preceding acute lymphoblastic leukemia with positive Philadelphia chromosome.",
        "Journal":"Leukemia research",
        "Do_id":"18291524",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Female;Fusion Proteins, bcr-abl;Humans;Immunophenotyping;Middle Aged;Pancytopenia;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Preleukemia",
        "Doc_meshqualifiers":"analysis;diagnosis;diagnosis",
        "_version_":1605746461341908992},
      {
        "Doc_abstract":"Resistance to tyrosine kinase inhibitors (TKIs) remains a challenge in management of patients with chronic myeloid leukemia (CML). A better understanding of the BCR-ABL signalling network may lead to better therapy.;Here we report the discovery of a novel downstream target of BCR-ABL signalling, PRL-3 (PTP4A3), an oncogenic tyrosine phosphatase. Analysis of CML cancer cell lines and CML patient samples reveals the upregulation of PRL-3. Inhibition of BCR-ABL signalling either by Imatinib or by RNAi silencing BCR-ABL reduces PRL-3 and increases cleavage of PARP. In contrast, the amount of PRL-3 protein remains constant or even increased in response to Imatinib treatment in drug resistant cells expressing P210 T315I. Finally, analysis with specific shRNA shows PRL-3 involvement in the proliferation and self-renewal of CML cells.;These data support a role for PRL-3 in BCR-ABL signalling and CML biology and may be a potential therapeutic target downstream of BCR-ABL in TKI resistant mutant cells.",
        "Doc_title":"The pro-metastasis tyrosine phosphatase, PRL-3 (PTP4A3), is a novel mediator of oncogenic function of BCR-ABL in human chronic myeloid leukemia.",
        "Journal":"Molecular cancer",
        "Do_id":"22995644",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Neoplasm Proteins;Piperazines;Protein Kinase Inhibitors;Pyrimidines;STAT Transcription Factors;Imatinib Mesylate;Fusion Proteins, bcr-abl;PTP4A3 protein, human;Protein Tyrosine Phosphatases",
        "Doc_meshdescriptors":"Antineoplastic Agents;Benzamides;Cell Line, Tumor;Cell Proliferation;Cell Transformation, Neoplastic;Drug Resistance, Neoplasm;Fusion Proteins, bcr-abl;Gene Expression;Gene Expression Regulation, Leukemic;Gene Silencing;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Neoplasm Metastasis;Neoplasm Proteins;Piperazines;Protein Kinase Inhibitors;Protein Tyrosine Phosphatases;Pyrimidines;STAT Transcription Factors;Signal Transduction",
        "Doc_meshqualifiers":"pharmacology;genetics;genetics;genetics;genetics;pathology;genetics;antagonists & inhibitors;genetics;pharmacology;pharmacology;antagonists & inhibitors;genetics;pharmacology;metabolism;drug effects",
        "_version_":1605746436254728192},
      {
        "Doc_abstract":"The telomerase protein is constitutively activated in malignant cells from many patients with cancer, including the chronic myeloid leukemia (CML), but whether telomerase is essential for the pathogenesis of this disease is not known. Here, we used telomerase deficient mice to determine the requirement for telomerase in CML induced by BCR-ABL in mouse models of CML. Loss of one telomerase allele or complete deletion of telomerase prevented the development of leukemia induced by BCR-ABL. However, BCR-ABL was expressed and active in telomerase heterozygous and null leukemic hematopoietic stem cells. These results demonstrate that telomerase is essential for oncogene-induced reprogramming of hematopoietic stem cells in CML development and validate telomerase and the genes it regulates as targets for therapy in CML.",
        "Doc_title":"Essential role for telomerase in chronic myeloid leukemia induced by BCR-ABL in mice.",
        "Journal":"Oncotarget",
        "Do_id":"22408137",
        "Doc_ChemicalList":"Antigens, Ly;Ly6a protein, mouse;Membrane Proteins;Fusion Proteins, bcr-abl;Telomerase",
        "Doc_meshdescriptors":"Animals;Antigens, Ly;Cell Proliferation;Cell Survival;Cell Transformation, Neoplastic;Disease Models, Animal;Fusion Proteins, bcr-abl;Hematopoietic Stem Cells;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Membrane Proteins;Mice;Mice, Transgenic;Neoplastic Stem Cells;Telomerase;Transfection",
        "Doc_meshqualifiers":"genetics;genetics;pathology;genetics;physiology;metabolism;pathology;genetics;pathology;genetics;metabolism;pathology;physiology;genetics;metabolism;physiology",
        "_version_":1605761369789956096},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) is a hemopoietic condition caused by chromosomal translocation t(9;22)(q34;q11) or bcr-abl fusion gene. The predominant variants of bcr-abl oncogene rearrangement are b3a2 and b2a2. The present study evaluated the efficacy of interferon-a therapy of CML patients and molecular prognostic factors. Cytogenetic response and complete hematological remission were more frequent in CML b3a2 treatment with interferon-a. Moreover, after therapy, chronic phase lasted in that group (p = 0.026) much longer. Overall survival in the group was significantly longer, too (p = 0.046).",
        "Doc_title":"[The effectiveness of interferon-alpha therapy in Ph-positive chronic myeloid leukemia].",
        "Journal":"Voprosy onkologii",
        "Do_id":"12785203",
        "Doc_ChemicalList":"Antineoplastic Agents;Biomarkers, Tumor;Interferon-alpha",
        "Doc_meshdescriptors":"Antineoplastic Agents;Biomarkers, Tumor;Humans;Interferon-alpha;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Survival Analysis;Treatment Outcome",
        "Doc_meshqualifiers":"therapeutic use;metabolism;therapeutic use;drug therapy;genetics",
        "_version_":1605755038868701184},
      {
        "Doc_abstract":"Human leukemia is closely associated with various genetic alterations such as chromosomal translocations and gene mutations. The use of retroviral transduction/bone marrow transplantation mouse model harboring these genetic abnormalities has been critical in understanding the molecular pathogenesis of leukemia and exploring new therapeutic target. Additional genetic events are verified to cooperate with fusion genes resulting from chromosomal translocations in acute myeloid leukemia (AML) to develop a leukemic phenotype in mice, such as C-KIT N822K with AML1-ETO, FLT3-ITD with PML-RAR, Meis1 with NUP98-HOX, and Cdx4 with MLL-AF9. Mouse model shows that BCR/ABL fusion gene induces chronic myeloid leukemia (CML), and suggests that GATA-2 L359V and high expression of Hes1 are key molecules in acute myeloid transformation of CML. Furthermore, combination therapy with Imatinib and arsenic sulfide for CML mice exerts more profound therapeutic effects than either drug as a single agent. This review focuses the recent progress and application of retroviral-mediated mouse models of myeloid leukemia, and discusses some factors influencing the mouse model establishment, including retroviral construction, retrovirus titer and hematopoietic microenvironment.",
        "Doc_title":"[Recent progress of study on retroviral mediated mouse model of myeloid leukemia --- review].",
        "Journal":"Zhongguo shi yan xue ye xue za zhi",
        "Do_id":"21867644",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Animals;Disease Models, Animal;Leukemia, Myeloid;Mice;Retroviridae",
        "Doc_meshqualifiers":"genetics;genetics",
        "_version_":1605884019384254464},
      {
        "Doc_abstract":"To explore the effects of As(2)O(3) on BCR-ABL protein level and signal transduction in chronic myeloid leukemia (CML) cells.;Immunoprecipitation, protein tyrosine kinase (PTK) activity assay, real-time Taqman quantitative PCR and Western blot were used.;As(2)O(3) downregulated BCR-ABL protein and STAT1 protein of CML mononuclear cells in the concentrations of 1.0 approximately 2.0 micro mol/L and 0.5 approximately 2.0 micro mol/L after 48 h exposure, respectively. However, p27 protein level was not affected. The PTK activity of BCR-ABL protein was also mildly decreased in CML monouclear cells at 60 h. The bcr-abl mRNA level remained unchanged.;As(2)O(3) downregulats BCR-ABL protein, STAT1 protein, BCR-ABL signal transduction and PTK activity in CML cells.",
        "Doc_title":"Effects of As(2)O(3) on BCR-ABL protein level and signal transduction in CML cells.",
        "Journal":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi",
        "Do_id":"12411053",
        "Doc_ChemicalList":"Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Fusion Proteins, bcr-abl;Humans;K562 Cells;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Phosphorylation;Protein-Tyrosine Kinases;Signal Transduction",
        "Doc_meshqualifiers":"genetics;genetics;drug effects;metabolism",
        "_version_":1605761890769698816},
      {
        "Doc_abstract":"The fusion tyrosine kinase Bcr-Abl plays a fundamental role in the pathogenesis of chronic myeloid leukemia (CML). Imatinib, a potent inhibitor of Bcr-Abl, has shown impressive clinical activity in CML patients. However, primary and acquired resistance occurs in many patients and is associated with reactivation of Bcr-Abl in primary leukemia cells. Studies reported over the past year have begun to elucidate the molecular basis of imatinib resistance, which may involve amplification of BCR-ABL or, more commonly, mutations that introduce amino acid substitutions into the Bcr-Abl kinase. Biochemical analysis and molecular modeling indicate that these mutant proteins retain kinase activity but are less sensitive to inhibition due to structural changes that perturb drug binding. These studies establish a paradigm for elucidating resistance to targeted therapeutics.",
        "Doc_title":"Resistance in the land of molecular cancer therapeutics.",
        "Journal":"Cancer cell",
        "Do_id":"12204529",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Pyrimidines;Imatinib Mesylate;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Antineoplastic Agents;Benzamides;Disease Progression;Drug Resistance, Neoplasm;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mutation;Piperazines;Pyrimidines",
        "Doc_meshqualifiers":"administration & dosage;therapeutic use;genetics;chemistry;genetics;metabolism;drug therapy;genetics;metabolism;pathology;administration & dosage;therapeutic use;administration & dosage;therapeutic use",
        "_version_":1605804822623158272},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder of a stem cell, involving myeloid, erythroid, megacaryocyte, lymphoid B-cells and \"natural killer\" cells. The hallmark of CML is the Philadelphia (Ph) chromosome which is a shortened chromosome 22 (22q-) resulting from a reciprocal translocation involving chromosome 9 and chromosome 22, designed t (9;22) (q34;q11). This translocation juxtaposes parts of two genes; ABL on chromosome 9 and BCR (breakpoint cluster region) on chromosome 22. Transcription of the BCR/ABL fusion gene results in an hybrid mRNA that is translated into a 210 kDa or 190 kDa protein, depending on the location of the breakpoint in the bcr region. This protein plays a key role in CML: its tyrosine-kinase activity, that differs from the normal ABL product, may be involved in leukemic cell growth. Nonetheless, the loss of the negative cell growth regulation by c-ABL, or BCR/ABL fusion protein interaction with other cellular genes (such as RAS or c-MYC) could also be involved in CML pathophysiology. A better understanding of the molecular mecanisms of CML could lead to specific treatment, such as tyrosine-kinase inhibitors, synthetic oligodeoxynucleotides, or site-specific DNA-binding proteins designed against BCR/ABL oncogenic fusion sequence.",
        "Doc_title":"[Chronic myeloid leukemia, biological aspects].",
        "Journal":"La Revue de medecine interne",
        "Do_id":"8734143",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Cloning, Molecular;Fusion Proteins, bcr-abl;Genes, abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Philadelphia Chromosome;Translocation, Genetic",
        "Doc_meshqualifiers":"physiology;genetics;physiopathology",
        "_version_":1605741925125586944},
      {
        "Doc_abstract":"In Philadelphia chromosome-positive human leukemias, which include chronic myelogenous leukemia and some acute lymphocytic leukemias, the c-abl proto-oncogene on chromosome 9 becomes fused to the bcr gene on chromosome 22, and Bcr-Abl fusion proteins are produced. The Bcr sequences activate the Abl tyrosine kinase which is required for the transforming function of Bcr-Abl. The Bcr sequences also enhance an F-actin-binding activity associated with c-Abl. Here, we show that binding of c-Abl and Bcr-Abl proteins to actin filaments in vivo and in vitro is mediated by an evolutionarily conserved domain at the C-terminal end of c-Abl. The c-Abl F-actin-binding domain contains a consensus motif found in several other actin-crosslinking proteins. Mutations in the consensus motif are shown to abolish binding to F-actin. Bcr-Abl proteins unable to associate with F-actin have a reduced ability to transform Rat-1 fibroblasts and to abrogate the requirement for interleukin-3 in the lymphoblastoid cell line Ba/F3. In transformed cells, Bcr-Abl induces a redistribution of F-actin into punctate, juxtanuclear aggregates. The binding to actin filaments has important implications for the pathogenic and physiological functions of the Bcr-Abl and c-Abl proteins.",
        "Doc_title":"An actin-binding function contributes to transformation by the Bcr-Abl oncoprotein of Philadelphia chromosome-positive human leukemias.",
        "Journal":"The EMBO journal",
        "Do_id":"8467803",
        "Doc_ChemicalList":"Interleukin-3;Microfilament Proteins;Proto-Oncogene Proteins;Recombinant Fusion Proteins;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl;Proto-Oncogene Proteins c-abl;BCR protein, human;Bcr protein, mouse;Proto-Oncogene Proteins c-bcr",
        "Doc_meshdescriptors":"Actin Cytoskeleton;Amino Acid Sequence;Animals;Cell Division;Cell Transformation, Neoplastic;Cells, Cultured;Cercopithecus aethiops;Consensus Sequence;DNA Mutational Analysis;Fluorescent Antibody Technique;Fusion Proteins, bcr-abl;Humans;In Vitro Techniques;Interleukin-3;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mice;Microfilament Proteins;Molecular Sequence Data;Protein-Tyrosine Kinases;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-abl;Proto-Oncogene Proteins c-bcr;Rats;Recombinant Fusion Proteins;Sequence Alignment;Structure-Activity Relationship",
        "Doc_meshqualifiers":"metabolism;ultrastructure;drug effects;genetics;metabolism;metabolism;pharmacology;genetics;metabolism;metabolism;metabolism;metabolism;metabolism",
        "_version_":1605827291783364608},
      {
        "Doc_abstract":"The tyrosine kinase inhibitor imatinib mesylate (Gleevec, Novartis Pharmaceuticals Corp, East Hanover, NJ) (formerly STI571) blocks the constitutively activated Bcr-Abl tyrosine kinase that is characteristic of chronic myeloid leukemia (CML). Molecular analysis for the presence of residual Bcr-Abl-positive cells in patients with a cytogenetic response following treatment with imatinib mesylate reveals that some patients have undetectable disease using quantitative reverse-transcriptase polymerase chain reaction (RT-PCR) assays capable of detecting 1 in 10(5) Philadelphia chromosome-positive (Ph(+)) cells. To examine whether the leukemia is still Bcr-Abl-dependent in patients who have responded to imatinib mesylate but have relapsed, a quantitative assay that directly measures enzymatic activity of Bcr-Abl toward one of its major signaling substrates has been developed. This assay allows monitoring both of the imatinib mesylate sensitivity of patient cells in vitro, and of the endogenous inhibition of Bcr-Abl kinase activity during imatinib mesylate treatment and relapse. Studies show that imatinib mesylate resistance is associated with restored activation of the Bcr-Abl signal transduction pathway in the majority of cases, indicating that Bcr-Abl remains a valid target for therapeutic intervention. Understanding resistance mechanisms of Ph(+) leukemia to imatinib mesylate will allow design of therapies to overcome such barriers to efficacy.",
        "Doc_title":"Molecular studies in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.",
        "Journal":"Seminars in hematology",
        "Do_id":"11526597",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Enzyme Inhibitors;Piperazines;Pyrimidines;Imatinib Mesylate;Protein-Tyrosine Kinases",
        "Doc_meshdescriptors":"Antineoplastic Agents;Benzamides;Drug Resistance, Neoplasm;Enzyme Inhibitors;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Piperazines;Protein-Tyrosine Kinases;Pyrimidines;Recurrence",
        "Doc_meshqualifiers":"therapeutic use;genetics;therapeutic use;drug therapy;therapeutic use;antagonists & inhibitors;therapeutic use",
        "_version_":1605877031709442048},
      {
        "Doc_abstract":"Using human acute leukemia HL-60/Bcr-Abl (with ectopic expression of p185 Bcr-Abl) and K562 cells (with endogenous expression of p210 Bcr-Abl) subjected to a continuous selection pressure of up to 1.0 micro M Gleevec (imatinib mesylate, STI-571), we have isolated Gleevec-resistant K562 R (+Bcr-Abl), K562 R (-Bcr-Abl), and HL-60/Bcr-Abl R cells, which display disparate level and activity of Bcr-Abl tyrosine kinase (TK). As compared with their sensitive counterparts, Gleevec-resistant cell types were >/=5-fold resistant to Gleevec-induced apoptosis. Bcr-Abl protein levels were significantly increased in HL-60/Bcr-Abl R and K562 R (+Bcr-Abl) cells, but K562 R (-Bcr-Abl) cells showed a marked decline in the mRNA and protein levels and activity of Bcr-Abl. Bcr-Abl TK level and activity corresponded to the signal transducers and activators of transcription-5 DNA binding activity and up-regulation of heat shock protein 70 levels. The decline in Bcr-Abl expression and TK activity in K562 R (-Bcr-Abl) cells was associated with reduced AKT kinase and signal transducers and activators of transcription-5 DNA binding activities and increased sensitivity to the death ligand Apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and 1-beta-D-arabinofuranosylcytosine-induced apoptosis. All Gleevec-resistant cell types were sensitive to 17-allylamino-17-demethoxygeldanamycin (17-AAG)- and PD180970 (a SRC and Bcr-Abl TK inhibitor)-induced apoptosis. Treatment with 17-AAG or PD180970 also induced apoptosis of CD34+ leukemic cells from three patients with chronic myeloid leukemia in blast crisis who had progressive leukemia while receiving Gleevec therapy. Taken together, these findings indicate that in addition to overexpression or mutations in Bcr-Abl, resistance to Gleevec may also develop due to a loss of Bcr-Abl expression. These findings also support the rationale to test the in vivo efficacy of 17-AAG and PD180970 against STI-571-resistant Bcr-Abl-positive acute leukemias.",
        "Doc_title":"Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin.",
        "Journal":"Cancer research",
        "Do_id":"12384536",
        "Doc_ChemicalList":"Benzamides;Benzoquinones;DNA-Binding Proteins;Enzyme Inhibitors;Lactams, Macrocyclic;Milk Proteins;PD 180970;Piperazines;Proto-Oncogene Proteins;Pyridones;Pyrimidines;STAT5 Transcription Factor;Trans-Activators;Cytarabine;Rifabutin;tanespimycin;Imatinib Mesylate;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl;src-Family Kinases;AKT1 protein, human;Protein-Serine-Threonine Kinases;Proto-Oncogene Proteins c-akt;Mitogen-Activated Protein Kinase 1;Mitogen-Activated Protein Kinase 3;Mitogen-Activated Protein Kinases",
        "Doc_meshdescriptors":"Benzamides;Benzoquinones;Blast Crisis;Cytarabine;DNA-Binding Proteins;Drug Resistance, Neoplasm;Enzyme Inhibitors;Fusion Proteins, bcr-abl;HL-60 Cells;Humans;Imatinib Mesylate;K562 Cells;Lactams, Macrocyclic;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Milk Proteins;Mitogen-Activated Protein Kinase 1;Mitogen-Activated Protein Kinase 3;Mitogen-Activated Protein Kinases;Piperazines;Protein-Serine-Threonine Kinases;Protein-Tyrosine Kinases;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-akt;Pyridones;Pyrimidines;Rifabutin;STAT5 Transcription Factor;Trans-Activators;src-Family Kinases",
        "Doc_meshqualifiers":"pharmacology;metabolism;pharmacology;biosynthesis;metabolism;drug effects;metabolism;drug effects;metabolism;drug therapy;pathology;metabolism;metabolism;pharmacology;metabolism;metabolism;pharmacology;pharmacology;analogs & derivatives;pharmacology;metabolism;antagonists & inhibitors;metabolism",
        "_version_":1605913380457021440},
      {
        "Doc_abstract":"We evaluated the in vitro activity of imatinib on BCR-ABL-positive and -negative tumor cells from patients with adult acute lymphoblastic leukemia (ALL), and investigated in vitro interactions between imatinib and conventional agents. A non-clonogenic cytotoxicity assay was used to analyze p190 BCR-ABL-positive (n = 4), p210 BCR-ABL-positive (n = 2) and BCR-ABL-negative (n = 9) tumor cells from adult ALL patients. The in vitro cytotoxic effect of imatinib was studied alone, and in combination with the cytotoxic agents cytarabine, prednisolone, vincristine, daunorubicin, asparaginase and mercaptopurine. The BCR-ABL-positive samples were significantly (p < 0.05) more sensitive to imatinib than the BCR-ABL-negative at the concentrations 0.1, 1 and 10 muM. Interestingly, the two p210 samples were somewhat less sensitive to imatinib than the p190 samples. Daunorubicin, prednisolone and cytarabine showed the largest benefit from combination with imatinib compared to the most active single agent. The study confirms that drug sensitivity to imatinib is specific for BCR-ABL-positive samples. The results also suggest that combinations between imatinib and daunorubicin, predisolone or cytarabine may be advantageous for the treatment of Philadelphia-positive ALL.",
        "Doc_title":"In vitro activity of imatinib in cells from patients with adult acute lymphoblastic leukemia.",
        "Journal":"Anti-cancer drugs",
        "Do_id":"15930891",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Immunosuppressive Agents;Piperazines;Pyrimidines;Cytarabine;Vincristine;Imatinib Mesylate;Prednisolone;6-Mercaptopurine;Fusion Proteins, bcr-abl;Asparaginase;Daunorubicin",
        "Doc_meshdescriptors":"6-Mercaptopurine;Adult;Antineoplastic Agents;Asparaginase;Benzamides;Cell Survival;Cytarabine;Daunorubicin;Drug Interactions;Drug Screening Assays, Antitumor;Fluorometry;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Immunosuppressive Agents;Philadelphia Chromosome;Piperazines;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Prednisolone;Pyrimidines;Tumor Cells, Cultured;Vincristine",
        "Doc_meshqualifiers":"pharmacology;pharmacology;pharmacology;drug effects;pharmacology;pharmacology;genetics;pharmacology;pharmacology;drug therapy;genetics;pharmacology;pharmacology;pharmacology",
        "_version_":1605844102875709440},
      {
        "Doc_abstract":"Imatinib mesylate is a novel tyrosine kinase inhibitor used for the treatment of Philadelphia chromosome positive (Ph+) leukemia and other malignancies. In previous studies, we found significant telomere shortening in Ph+ cells from patients with chronic myeloid leukemia (CML). Interestingly, imatinib treatment was found to lead to a normalization of previously shortened telomere length in CML patients. Based on recent reports demonstrating that c-ABL phosphorylates hTERT and thereby inhibits hTERT activity, a direct effect of imatinib on hTERT activity leading to telomere elongation in BCR-ABL-positive cells has been proposed by others. Such an effect could be of potential importance for telomere maintenance in Ph+ cells by facilitating clonal selection and progression of the disease to blast crisis.;We investigated the impact of imatinib on telomere length and telomerase activity of the interleukin-3 (IL-3)-dependent murine pro-B cell line BaF3 and the BCR-ABL-positive, IL-3-independent transfectant BaF3p185 in vitro.;When BaF3 and BaF3p185 cells were treated with imatinib (the latter being rescued with IL-3), no effect on either telomerase activity or telomere length was observed. These findings can be explained by the cytoplasmatic localization of BCR-ABL found in BaF3p185 as compared to the nuclear localization of telomerase (and c-ABL).;As opposed to recent reports for c-ABL, we do not see evidence for a functional interaction between BCR-ABL and hTERT in this model system arguing against imatinib-mediated upregulation of hTERT as a crucial factor for clonal selection and disease progression of CML.",
        "Doc_title":"Telomere length and telomerase activity in the BCR-ABL-transformed murine Pro-B cell line BaF3 is unaffected by treatment with imatinib.",
        "Journal":"Experimental hematology",
        "Do_id":"15850831",
        "Doc_ChemicalList":"Benzamides;Culture Media;Interleukin-3;Piperazines;Pyrimidines;Imatinib Mesylate;Fusion Proteins, bcr-abl;Telomerase",
        "Doc_meshdescriptors":"Animals;B-Lymphocytes;Benzamides;Cell Division;Cell Line, Transformed;Culture Media;Fluorescent Antibody Technique;Fusion Proteins, bcr-abl;Imatinib Mesylate;In Situ Hybridization, Fluorescence;Interleukin-3;Mice;Piperazines;Pyrimidines;Telomerase;Telomere",
        "Doc_meshqualifiers":"drug effects;enzymology;metabolism;drug effects;physiology;pharmacology;pharmacology;pharmacology;metabolism",
        "_version_":1605903536168632320},
      {
        "Doc_abstract":"Of 144 adult Eastern Cooperative Oncology Group (ECOG) patients with acute lymphoblastic leukemia (ALL) entered on study E2993 at the time of analysis, 104 had informative immunophenotypes and molecular analysis by polymerase chain reaction for BCR/ABL fusion transcripts. In 23 patients (22%), BCR/ABL transcripts were detected: the ALL-typical e1a2 alone in 12, e1a2 + b2a2/b3a2 in five, and b2a2 and/or b3a2 in six. Of BCR/ABL-positive patients, 83% had early pre-B ALL, one patient had pre-T ALL, while half of the BCR/ABL-negative patients had early pre-B ALL, 18% had CD10-negative pro-B ALL and 21% were pre-T. When antibodies to both the interleukin-2 receptor alpha (CD25) and beta chain (CD122) were tested, CD25 was expressed significantly more frequently in BCR/ABL-positive (median 23% positive blast cells, range 1-84%) than BCR/ABL-negative patients (median 3%, range 0-69%) (P = 0.00006). There was no corelation with CD122 expression. Therefore, CD25 expression may serve as a surrogate marker for BCR/ABL positivity (Philadelphia chromosome), the major poor prognostic parameter in adult ALL.",
        "Doc_title":"Expression of CD25 (interleukin-2 receptor alpha chain) in adult acute lymphoblastic leukemia predicts for the presence of BCR/ABL fusion transcripts: results of a preliminary laboratory analysis of ECOG/MRC Intergroup Study E2993. Eastern Cooperative Oncology Group/Medical Research Council.",
        "Journal":"Leukemia",
        "Do_id":"9369422",
        "Doc_ChemicalList":"Biomarkers, Tumor;Receptors, Interleukin-2;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adult;Biomarkers, Tumor;Diagnosis, Differential;Flow Cytometry;Fusion Proteins, bcr-abl;Humans;Immunophenotyping;Philadelphia Chromosome;Polymerase Chain Reaction;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Receptors, Interleukin-2",
        "Doc_meshqualifiers":"genetics;metabolism;methods;genetics;metabolism;genetics;metabolism;genetics;metabolism",
        "_version_":1605883771258667008},
      {
        "Doc_abstract":"Isolated central nervous system (CNS) relapse occurred in 5 out of 24 patients (20.8%) with chronic myeloid leukemia (CML) lymphoid blast crisis (2), Philadelphia (Ph) chromosome positive acute lymphoblastic leukemia (ALL) (2) or CML with biphenotypic markers (1) treated on imatinib mesylate (IM) protocols at our institution. CNS relapse occurred despite peripheral blood (5) and bone marrow (3) complete responses. Median time to CNS relapse was day 32 (range 23 to 100). This observation raised the possibility that IM may not penetrate into the CNS. Simultaneous plasma and cerebral spinal fluid (CSF) IM levels were determined in four subsequent patients by liquid chromatography and mass spectrophotometric assay. Levels of IM were found to be approximately two logs lower in CSF than in plasma (0.044 microg/ml (0.088 +/- 0.029 micrro) vs 3.27 microg/ml (6.54 +/- 0.93 microM)). CSF levels were substantially below the concentration required for inhibition of BCR-ABL and killing of cell lines in vitro. These results suggest that IM may not penetrate the intact blood/brain barrier and its implications are discussed.",
        "Doc_title":"Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI-571).",
        "Journal":"Leukemia & lymphoma",
        "Do_id":"15160941",
        "Doc_ChemicalList":"Benzamides;Piperazines;Pyrimidines;Imatinib Mesylate",
        "Doc_meshdescriptors":"Adult;Benzamides;Blast Crisis;Blood-Brain Barrier;Central Nervous System Neoplasms;Female;Humans;Imatinib Mesylate;Male;Middle Aged;Piperazines;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Pyrimidines;Recurrence;Remission Induction;Tissue Distribution;Treatment Outcome",
        "Doc_meshqualifiers":"drug therapy;pathology;etiology;blood;cerebrospinal fluid;pharmacokinetics;drug therapy;pathology;blood;cerebrospinal fluid;pharmacokinetics;methods",
        "_version_":1605797179744583680},
      {
        "Doc_abstract":"Protein-based cellular therapeutics have been limited by getting molecules into cells and the fact that many proteins require accurate cellular localization for function. Cytoplasmic transduction peptide (CTP) is a newly designed transduction peptide that carries molecules across the cell membrane with a preference to localize in the cytoplasmic compartment and is, therefore, applicable for cytoplasmic targeting. The Bcr-Abl fusion protein, playing major causative role in chronic myeloid leukemia (CML), is a cytoplasmic oncoprotein that contains an N-terminus oligomerization domain (OD) mediating homodimerization of Bcr-Abl proteins, and an intact OD in Bcr-Abl is required both for the activation of its transforming activity and tyrosine kinase. Therefore, disrupting Bcr-Abl oligomerization represents a potential therapeutic strategy for inhibiting Bcr-Abl oncogenicity. In this study, we explored the possible homodimerization-disrupting and tyrosine kinase inhibiting effect of the transduction of OD in Bcr-Abl positive K562 cells. By expressing in Escherichia coli a CTP-OD-HA fusion protein followed by Ni+-NTA affinity purification, immunoblot identification and enterokinase cleavage, we showed that the CTP-OD-HA protein was structurally and functionally active in that it potently transduced and primarily localized into the cytoplasmic compartment, heterodimerized with Bcr-Abl, and potently inhibited the phospho-tyrosine pathways of Bcr-Abl oncoprotein at a low concentration of 4 microM. These results delineate strategies for the expression and purification of therapeutic molecules for intracytoplasmic protein based therapeutics and the CTP-OD-HA-mediated killing strategy could be explored as a promising anti-leukemia agent or an adjuvant to the conventional therapeutic modalities in chronic myeloid leukemia, such as in vitro purging.",
        "Doc_title":"Cloning, expression, purification and functional characterization of the oligomerization domain of Bcr-Abl oncoprotein fused to the cytoplasmic transduction peptide.",
        "Journal":"Protein expression and purification",
        "Do_id":"19041400",
        "Doc_ChemicalList":"Peptides;Recombinant Proteins;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Cells, Cultured;Cloning, Molecular;Cytoplasm;Fusion Proteins, bcr-abl;Gene Expression;Humans;K562 Cells;Microscopy, Confocal;Peptides;Protein Structure, Tertiary;Recombinant Proteins",
        "Doc_meshqualifiers":"metabolism;chemistry;genetics;isolation & purification;chemistry;genetics;metabolism;chemistry;genetics;isolation & purification",
        "_version_":1605758967685840897},
      {
        "Doc_abstract":"This is the largest Latin American study of BCR-ABL mutations in chronic myeloid leukemia (CML) patients, resistant to imatinib (IM). In 195/467 (41%) patients, mutations were detected. The most frequent mutation was T315I (n = 31, 16%). Progression-free (PFS) and overall survival (OS) at 5 years were lower in patients with BCR-ABL mutations (43% vs. 65%, p = 0.07 and 47% vs. 72%, p = 0.03, respectively) and in those with the T315I mutation (p = 0.003 and p = 0.03). OS and PFS were superior in subgroup who switched to second generation inhibitors (SGIs) after IM failure (OS: 50% vs. 39% p = 0.01; PFS: 48% vs. 30% p = 0.02). BCR-ABL mutations conferred a significant poor prognosis in CML patients. ",
        "Doc_title":"BCR-ABL mutations in chronic myeloid leukemia treated with tyrosine kinase inhibitors and impact on survival.",
        "Journal":"Cancer investigation",
        "Do_id":"26288116",
        "Doc_ChemicalList":"Antineoplastic Agents;Protein Kinase Inhibitors;Imatinib Mesylate;Protein-Tyrosine Kinases",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Aged, 80 and over;Antineoplastic Agents;Child;Child, Preschool;Disease-Free Survival;Female;Genes, abl;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Mutation;Prognosis;Protein Kinase Inhibitors;Protein-Tyrosine Kinases;Retrospective Studies;Young Adult",
        "Doc_meshqualifiers":"therapeutic use;genetics;therapeutic use;genetics;mortality;pathology;genetics;therapeutic use;antagonists & inhibitors",
        "_version_":1605901753092407296},
      {
        "Doc_abstract":"Danusertib is a pan-aurora kinase inhibitor with potent activity against Abl kinase including the gatekeeper T315I mutant. A phase 1 dose escalation study of danusertib was conducted in patients with accelerated or blastic phase chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia. Two dosing schedules were studied: schedule A, in which danusertib was given by 3-hour intravenous infusion daily for 7 consecutive days (days 1-7) in a 14-day cycle, and schedule B, in which the danusertib was given by 3-hour intravenous infusion daily for 14 consecutive days (days 1-14) in a 21-day cycle. A total of 37 patients were treated, 29 with schedule A and eight with schedule B. The recommended phase 2 dose for schedule A was 180 mg/m(2). Enrollment to schedule B was stopped early because of logistical problems with the frequency of infusions. Febrile neutropenia and mucositis were dose-limiting toxicities in schedule A. Four patients with T315I ABL kinase mutation, all treated with schedule A, responded. Danusertib has an acceptable toxicity profile and is active in patients with Bcr-Abl-associated advanced hematologic malignancies. This study was registered with the European Clinical Trails Data Base (EudraCT number 2007-004070-18). ",
        "Doc_title":"A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy.",
        "Journal":"Haematologica",
        "Do_id":"25887498",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Protein Kinase Inhibitors;Pyrazoles;Imatinib Mesylate;Fusion Proteins, bcr-abl;danusertib",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Antineoplastic Agents;Benzamides;Blast Crisis;Drug Administration Schedule;Febrile Neutropenia;Female;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Leukemia, Myeloid, Accelerated Phase;Male;Middle Aged;Mucositis;Mutation;Philadelphia Chromosome;Protein Kinase Inhibitors;Pyrazoles",
        "Doc_meshqualifiers":"administration & dosage;adverse effects;pharmacokinetics;administration & dosage;adverse effects;pharmacokinetics;drug therapy;genetics;pathology;chemically induced;genetics;pathology;genetics;administration & dosage;adverse effects;pharmacokinetics;drug therapy;genetics;pathology;chemically induced;genetics;pathology;administration & dosage;adverse effects;pharmacokinetics;administration & dosage;adverse effects;pharmacokinetics",
        "_version_":1605876545445953536},
      {
        "Doc_abstract":"To study the bcr/abl fusion gene in chronic myeloid leukemia (CML) cases with Philadelphia chromosome(Ph) negative, and variant Ph translocations and other chromosome anomalies.;The status of bcr/abl fusion gene in 8 kinds of chromosome anomalies was tested with dual-color fluorescence in situ hybridization (D-FISH) technique.;The positive hybridization was demonstrated in 3 cases of variant Ph CML and other 7 cases of standard Ph, respectively. In 2 cases of Ph-negative CML, one case that had karyotype such as 46,XY,t(9;18) showed positive hybridization, the other case with 46,XY,inv(2) showed negative result.;The result demonstrates that D-FISH technique is reliable for detecting bcr/abl fusion gene. The existence of negative bcr/abl fusion gene CML implies that some other initial events inducing CML might have occurred in such cases.",
        "Doc_title":"[A molecular cytogenetic study on chromosome anomalies of chronic myeloid leukemia].",
        "Journal":"Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics",
        "Do_id":"10751535",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adult;Chromosome Aberrations;Female;Fusion Proteins, bcr-abl;Humans;In Situ Hybridization, Fluorescence;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged",
        "Doc_meshqualifiers":"genetics;genetics",
        "_version_":1605783100192718848},
      {
        "Doc_abstract":"Breakpoint cluster region-Abelson (BCR-ABL) rearrangement or Philadelphia (Ph) chromosome in Chronic Myeloid Leukemia (CML) is derived from a reciprocal chromosomal translocation between ABL gene on chromosome 9 and BCR gene on chromosome 22. This chimeric protein has various sizes and therefore different clinical behaviour. The purpose of this study was to determine the heterogeneity of BCR-ABL rearrangement in patients with Ph(+)CML in Pakistan.;The study was conducted at Civil Hospital and Baqai Institute of Hematology (BIH) Karachi. Blood samples from 25 patients with CML were collected. Multiplex reverse transcription polymerase chain reaction (RT-PCR) was performed to identify various BCR-ABL transcripts.;All 25 samples showed BCR-ABL rearrangements. Out of these, 24 (96%) patients expressed p210 BCR-ABL rearrangements i.e. 60% (n=15) had b3a2 and 32% (n=8) had b2a2 rearrangements. Co-expression of b3a2 /b2a2 rearrangement and p190 (e1a3) rearrangement was also identified in two patients.;It is apparent that majority of the patients had p210 BCR-ABL rearrangements. Frequency of co-expression and rare fusion transcripts was very low.",
        "Doc_title":"Heterogeneity of BCR-ABL rearrangement in patients with chronic myeloid leukemia in Pakistan.",
        "Journal":"Pakistan journal of medical sciences",
        "Do_id":"25097530",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605750780604710912},
      {
        "Doc_abstract":"Imatinib mesylate is currently the standard of care for chronic myeloid leukemia (CML) patients in early chronic phase. However, the emergence of resistance and intolerance has dampened the enthusiasm for this drug. To overcome this phenomenon, different strategies have been developed, including novel targeted agents. Nilotinib, formerly known as AMN107, is a second-generation tyrosine kinase inhibitor 30-fold more potent than imatinib, with high affinity and selectivity on BCR/ABL, and also active against a wide range of mutant clones, except T315I mutation. Phase II trials of nilotinib showed high activity in imatinib-resistant or intolerant CML patients, whereas front-line treatment of the disease in chronic phase demonstrated rapid and stable cytogenetic responses and increasing molecular responses. We here review the development of nilotinib and the efficacy data in phase II and front-line trials. The aim of this review is to evaluate the pharmacology, pharmacokinetic and pharmacodynamic properties of the drug and the recent results of clinical trials performed in patients with CML and Ph+ acute lymphoblastic leukemia (ALL).",
        "Doc_title":"Nilotinib: a second-generation tyrosine kinase inhibitor for chronic myeloid leukemia.",
        "Journal":"Leukemia research",
        "Do_id":"19783301",
        "Doc_ChemicalList":"4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide;Protein Kinase Inhibitors;Pyrimidines;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Clinical Trials as Topic;Drug Resistance, Neoplasm;Fusion Proteins, bcr-abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mutation;Protein Kinase Inhibitors;Pyrimidines;Treatment Outcome",
        "Doc_meshqualifiers":"genetics;genetics;drug therapy;pharmacokinetics;therapeutic use;pharmacokinetics;therapeutic use",
        "_version_":1605747008567508992},
      {
        "Doc_abstract":"Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) is diagnosed rarely in children, but constitutes the most frequent cytogenetic abnormality in adults with ALL. In contrast to chronic myeloid leukemia (CML), patients with Ph-positive ALL usually demonstrate expression of a truncated version of the BCR-ABL protein called p190bcr-abl. Irrespective of age and breakpoint location, Ph-positive ALL carries a poor prognosis. Although remission rates are identical to those of Ph-negative ALL, relapse is almost universal and long-term survival remains rare. Given the poor outcome with current chemotherapy consolidation programs, stem cell transplantation is usually recommended for these patients in first remission or as soon as feasible. Even with transplantation the impact on outcome is limited and new therapeutic concepts are urgently needed. One of the most promising developments in recent years has been the introduction of the tyrosine kinase inhibitors such as STI571. An overview of current treatment modalities in Ph-positive ALL will be provided and the rationale for new therapies will be discussed.",
        "Doc_title":"Philadelphia chromosome-positive acute lymphoblastic leukemia- current concepts and future perspectives.",
        "Journal":"Reviews in clinical and experimental hematology",
        "Do_id":"12196213",
        "Doc_ChemicalList":"Antineoplastic Agents;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Antineoplastic Agents;Fusion Proteins, bcr-abl;Hematopoietic Stem Cell Transplantation;Humans;Neoplasm, Residual;Philadelphia Chromosome;Precursor Cell Lymphoblastic Leukemia-Lymphoma",
        "Doc_meshqualifiers":"therapeutic use;analysis;genetics;physiology;diagnosis;genetics;diagnosis;genetics;therapy",
        "_version_":1605831983126020096},
      {
        "Doc_abstract":"Imatinib therapy, which targets the oncogene product BCR-ABL, has transformed chronic myeloid leukemia (CML) from a life-threatening disease into a chronic condition. Most patients, however, harbor residual leukemia cells, and disease recurrence usually occurs when imatinib is discontinued. Although various mechanisms to explain leukemia cell persistence have been proposed, the critical question from a therapeutic standpoint--whether disease persistence is BCR-ABL dependent or independent--has not been answered. Here, we report that human CML stem cells do not depend on BCR-ABL activity for survival and are thus not eliminated by imatinib therapy. Imatinib inhibited BCR-ABL activity to the same degree in all stem (CD34+CD38-, CD133+) and progenitor (CD34+CD38+) cells and in quiescent and cycling progenitors from newly diagnosed CML patients. Although short-term in vitro imatinib treatment reduced the expansion of CML stem/progenitors, cytokine support permitted growth and survival in the absence of BCR-ABL activity that was comparable to that of normal stem/progenitor counterparts. Our findings suggest that primitive CML cells are not oncogene addicted and that therapies that biochemically target BCR-ABL will not eliminate CML stem cells.",
        "Doc_title":"Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity.",
        "Journal":"The Journal of clinical investigation",
        "Do_id":"21157039",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Cytokines;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Imatinib Mesylate;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Antineoplastic Agents;Benzamides;Cell Proliferation;Cell Survival;Cytokines;Drug Resistance, Neoplasm;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;In Vitro Techniques;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Models, Biological;Neoplastic Stem Cells;Piperazines;Protein Kinase Inhibitors;Pyrimidines",
        "Doc_meshqualifiers":"pharmacology;drug effects;drug effects;pharmacology;antagonists & inhibitors;drug therapy;metabolism;pathology;drug effects;metabolism;pathology;pharmacology;pharmacology;pharmacology",
        "_version_":1605822025246441472},
      {
        "Doc_abstract":"Sustained undetectable molecular residual disease (UMRD) is obtained in a minority of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. It remains unclear whether these patients are definitively cured of their leukemia or whether leukemic stem cells (LSCs) persist in their BM. We have evaluated the presence of BCR-ABL-expressing marrow LSCs in 6 patients with chronic myeloid leukemia with sustained UMRD induced by IFN- (n = 3), imatinib mesylate after IFN- failure (n = 2), and dasatinib after imatinib intolerance (n = 1). Purified CD34(+) cells were used for clonogenic and long-term culture-initiating cell assays performed on classic or HOXB4-expressing MS-5 feeders. Using this strategy, we identified BCR-ABL-expressing LSCs in all patients. Interestingly, long-term culture-initiating cell assays with MS-5/HOXB4 stromal feeders increased detected numbers of LSCs in 3 patients. The relation between LSC persistency and a potential risk of disease relapse for patients with durable UMRD (on or off tyrosine kinase inhibitor therapy) warrants further investigation.",
        "Doc_title":"Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease.",
        "Journal":"Blood",
        "Do_id":"21791426",
        "Doc_ChemicalList":"Biomarkers, Tumor",
        "Doc_meshdescriptors":"Adult;Aged;Algorithms;Biomarkers, Tumor;Cell Survival;Female;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Limit of Detection;Male;Middle Aged;Models, Biological;Molecular Diagnostic Techniques;Neoplasm, Residual;Neoplastic Stem Cells;Remission Induction;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"analysis;genetics;metabolism;diagnosis;pathology;standards;statistics & numerical data;pathology;physiology",
        "_version_":1605813139828375552},
      {
        "Doc_abstract":"Aurora kinases play a pivotal role in the regulator of mitotic processes during cell division and Aurora kinases are overexpressed in a number of human cancers. In this study, we examined the intracellular signaling of Aurora kinases inhibitor, MK-0457 (VX-680), in BCR-ABL positive cell lines and in primary samples. MK-0457 induced apoptosis. Caspase 3 and poly (ADP-ribose) polymerase (PARP) were activated and heat shock proteins were reduced. A combination of MK-0457 and histone deacetylase inhibitor, vorinostat, increased apoptosis. Caspase 3 and PARP were activated and phosphorylation of BCR-ABL, Lyn, and Crk-L were reduced. BCR-ABL and Aurora A and B were reduced after vorinostat treatment. Moreover, combination of vorinostat and MK-0457 synergistically increased the extent of apoptosis in primary acute lymphoblastic leukemia cells with T315I mutation. Our study increases insight into how MK-0457 may mediate its effects on BCR-ABL positive leukemia cells with T315I mutation, and information of potential therapeutic relevance.",
        "Doc_title":"Efficacy of MK-0457 and in combination with vorinostat against Philadelphia chromosome positive acute lymphoblastic leukemia cells.",
        "Journal":"Annals of hematology",
        "Do_id":"20563869",
        "Doc_ChemicalList":"Antineoplastic Agents;Enzyme Inhibitors;Histone Deacetylase Inhibitors;Hydroxamic Acids;Piperazines;vorinostat;VX680;Aurora Kinases;Protein-Serine-Threonine Kinases",
        "Doc_meshdescriptors":"Adult;Antineoplastic Agents;Aurora Kinases;Cell Line, Tumor;Cell Proliferation;Drug Therapy, Combination;Enzyme Inhibitors;Histone Deacetylase Inhibitors;Humans;Hydroxamic Acids;Piperazines;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Protein-Serine-Threonine Kinases",
        "Doc_meshqualifiers":"pharmacology;therapeutic use;pharmacology;therapeutic use;pharmacology;therapeutic use;pharmacology;therapeutic use;pharmacology;therapeutic use;drug therapy;antagonists & inhibitors",
        "_version_":1605746347037687810},
      {
        "Doc_abstract":"In chronic myelogenous leukemia (CML), the Philadelphia (Ph) chromosome translocation results in the formation of BCR/ABL genes, normally transcribed in two types of hybrid transcripts with a b2a2 or b3a2 BCR/ABL junction, which give origin to 210-kD fusion proteins (P210). A third type of BCR/ABL (with e1a2 type of junction) has been identified in approximately 50% of the Ph-positive acute lymphoblastic leukemia (Ph+ALL) cases and results in the production of a BCR/ABL protein of 190 kD (P190). The presence of this transcript has been associated almost exclusively with the presence of an acute leukemia phenotype. By contrast, here we describe that in addition to transcripts with the b2a2 and b3a2 types of junction corresponding to the P210 proteins, virtually all CMLs at diagnosis bear also BCR/ABL transcripts showing the e1a2 type of junction, which correspond to the acute leukemia-associated P190 protein. With a quantitative polymerase chain reaction assay we found that the amount of the e1a2 mRNA present in CMLs in chronic phase, although in absolute amount much lower than that present in Ph+ ALLs, represents in most cases approximately 20% to 30% of the total BCR/ABL transcripts. Moreover, using a novel and very sensitive Western blot technique, we detected relevant amounts of P190 protein in addition to P210 from peripheral cells of two of the patients.",
        "Doc_title":"Consistent amounts of acute leukemia-associated P190BCR/ABL transcripts are expressed by chronic myelogenous leukemia patients at diagnosis.",
        "Journal":"Blood",
        "Do_id":"8562932",
        "Doc_ChemicalList":"RNA, Messenger;RNA, Neoplasm;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Base Sequence;Bone Marrow;Fusion Proteins, bcr-abl;Gene Expression Regulation, Leukemic;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Molecular Sequence Data;Polymerase Chain Reaction;RNA, Messenger;RNA, Neoplasm;Transcription, Genetic",
        "Doc_meshqualifiers":"pathology;biosynthesis;genetics;diagnosis;genetics;metabolism;pathology;biosynthesis;genetics;biosynthesis;genetics",
        "_version_":1605904049437147136},
      {
        "Doc_abstract":"The hallmark of chronic myeloid leukemia (CML) is the abnormal activity of p210(Bcr-Abl) kinase. Selective kinase inhibitors such as imatinib or nilotinib have been established successfully for the treatment of CML. Despite high rates of clinical response, CML patients can develop resistance to these kinase inhibitors mainly due to point mutations within the Abl kinase domain of the fusion protein. Previously, we reported that a crude extract of the mushroom Daedalea gibbosa inhibited kinase activity of Bcr-Abl kinase. Here we report on the identification of the active component of Daedalea gibbosa, oleic acid, which inhibited Bcr-Abl kinase autophosphorylation in Ba/F3 cells and exhibited anti-CML activity in a BCR/ABL-positive mouse model.",
        "Doc_title":"Oleic acid is the active component in the mushroom Daedalea gibbosa inhibiting Bcr-Abl kinase autophosphorylation activity.",
        "Journal":"Anticancer research",
        "Do_id":"21273596",
        "Doc_ChemicalList":"Antineoplastic Agents;Plant Extracts;Protein Kinase Inhibitors;Oleic Acid;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Agaricales;Animals;Antineoplastic Agents;Chromatography, High Pressure Liquid;Female;Fusion Proteins, bcr-abl;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mice;Mice, Nude;Oleic Acid;Phosphorylation;Plant Extracts;Precursor Cells, B-Lymphoid;Protein Kinase Inhibitors;Protein-Tyrosine Kinases",
        "Doc_meshqualifiers":"chemistry;therapeutic use;antagonists & inhibitors;drug therapy;enzymology;isolation & purification;therapeutic use;drug effects;therapeutic use;drug effects;therapeutic use;antagonists & inhibitors",
        "_version_":1605763464508211200},
      {
        "Doc_abstract":"The BCR-ABL oncogenic tyrosine kinase causes chronic myeloid leukemia and is the target for imatinib therapy. During imatinib treatment, cells are selected in some patients with BCR-ABL kinase domain mutations that render decreased drug sensitivity. In addition, some patients express deletion mutants of BCR-ABL, apparently due to missplicing. Most commonly these deletion mutants lack a significant portion of the kinase domain that includes the P-loop. We describe a screen for such mutations in patients with CML and demonstrate that they are not oncogenic and are catalytically inactive. We hypothesized that coexpressing BCR-ABL deletion mutants has a dominant-negative effect on the native form through heterocomplex formation. However, upon coexpression of native and deletion mutant BCR-ABL in Ba/F3 cells, growth factor independence is maintained and signaling is activated normally. Despite this, these cells have increased imatinib sensitivity compared to cells expressing only native BCR-ABL. Thus, it will be important to investigate the prognostic impact of coexpression of deletion mutants in CML patients during imatinib treatment.",
        "Doc_title":"Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemia.",
        "Journal":"Leukemia",
        "Do_id":"18354488",
        "Doc_ChemicalList":"Benzamides;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Tyrosine;Imatinib Mesylate;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adult;Aged;Benzamides;Cell Proliferation;Cells, Cultured;Drug Resistance, Neoplasm;Female;Follow-Up Studies;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Immunoblotting;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Mutation;Phosphorylation;Piperazines;Precursor Cells, B-Lymphoid;Protein Conformation;Protein Kinase Inhibitors;Protein-Tyrosine Kinases;Pyrimidines;Sequence Deletion;Tyrosine",
        "Doc_meshqualifiers":"genetics;drug therapy;genetics;pathology;genetics;therapeutic use;metabolism;pathology;therapeutic use;antagonists & inhibitors;therapeutic use;metabolism",
        "_version_":1605919471151611904},
      {
        "Doc_abstract":"By employing a new semi-quantitative assay system that includes co-culturing leukemia cells with the mouse bone marrow-derived stromal cell line MS-5, we examined the suppressive effect of a selective inhibitor of ABL tyrosine kinase, STI571, on acute lymphoblastic leukemia (ALL) cells with BCR-ABL fusion. Leukemic blast cells from eight patients with B-precursor ALL, including three patients with BCR-ABL-positive ALL, were cultured on monolayers of MS-5 cells for 3 weeks with or without addition of variable amounts of STI571. In all cases, cobblestone areas (CAs) were formed, showing clear linear cell dose-dependent curves, allowing quantitative assessment of blast cell growth. The progenitor frequencies obtained by this direct CA-forming cell (CAFC) assay were equivalent to ALL progenitor frequencies assessed by the standard limiting dilution assay. The number of CAFCs ranged from 12.3 to 140.3/10(4) cells. In BCR-ABL-positive ALL patients, CA-containing cells were examined by FISH, and all contained BCR-ABL fusion genes. STI571 inhibited CA formation of BCR-ABL-positive ALL cells virtually 100% at 0.1-1.0 micromol/l. None of the five BCR-ABL-negative ALL patients showed this growth inhibition by STI571 at 0.1-1.0 micromol/l. Our results indicate that STI571 selectively inhibits in vitro growth of BCR-ABL-positive ALL cells.",
        "Doc_title":"Effect of a selective Abl tyrosine kinase inhibitor, STI571, on in vitro growth of BCR-ABL-positive acute lymphoblastic leukemia cells.",
        "Journal":"Leukemia",
        "Do_id":"11368361",
        "Doc_ChemicalList":"Benzamides;Piperazines;Pyrimidines;Imatinib Mesylate;Proto-Oncogene Proteins c-abl",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Animals;Benzamides;Cell Division;Female;Genes, abl;Humans;Imatinib Mesylate;Male;Mice;Piperazines;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Proto-Oncogene Proteins c-abl;Pyrimidines",
        "Doc_meshqualifiers":"drug effects;pharmacology;drug therapy;pathology;antagonists & inhibitors;pharmacology",
        "_version_":1605791933435740160},
      {
        "Doc_abstract":"We present the case of a two-year-old child with an atypical presentation of chronic myeloid leukemia. At diagnosis, he showed clinical and biological features of juvenile chronic myeloid leukemia (CML). However, eosinophilia was observed in blood and bone marrow. The bone marrow karyotype did not demonstrate the Philadelphia chromosome but BCR-ABL rearrangement was shown to be present by reverse transcriptase polymerase chain reaction (RT-PCR) analysis and confirmed by fluorescent in situ hybridization (FISH) analysis. Discussion centres on the differentiation between juvenile CML and childhood chronic myelogenous Leukemia and the importance of carrying out RT PCR for all juvenile CML cases.",
        "Doc_title":"Philadelphia negative BCR-ABL positive chronic myeloid leukemia mimicking juvenile chronic myeloid leukemia in a 2-year-old child.",
        "Journal":"Leukemia & lymphoma",
        "Do_id":"9389369",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Child, Preschool;Diagnosis, Differential;Fusion Proteins, bcr-abl;Gene Rearrangement;Humans;Karyotyping;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative;Male",
        "Doc_meshqualifiers":"genetics;diagnosis;genetics;pathology;diagnosis;genetics;pathology",
        "_version_":1605837650550325248},
      {
        "Doc_abstract":"Due to high rates of response and durable remissions, imatinib (Glivec((R)), or Gleevec((R)) in the USA; Novartis Pharma AG) is the standard of care in patients with chronic myeloid leukemia. Recently, a non-authorized product which claims comparability to imatinib has become available.;This report describes the loss of response in a 36-year-old male patient with chronic-phase chronic myeloid leukemia who had previously been in full hematologic and cytogenetic remission and partial molecular remission for three years, under treatment with brand-name imatinib of 400 mg per day. Before the initiation of treatment with a copy product, imatib (CIPLA-India), the patient had negative BCR-ABL status. Within three months of initiation of treatment with the copy product, the patient's BCR-ABL status became positive, with substantial decreases noted in white blood cell counts, red blood cell counts and platelet counts. Conversion of the BCR-ABL status to negative and improvements in hematologic parameters were achieved when the brand medication, imatinib, was resumed at a dose of 600 mg per day.;In our patient, the substitution of a copy product for imatinib resulted in the rapid loss of a previously stable response, with the risk of progression to life-threatening accelerated phase or blast crisis phase of the disease. Without supportive clinical evidence of efficacy and safety of imatib (or any other copy product) caution should be used when substituting imatinib in the treatment of any patient with chronic myeloid leukemia.",
        "Doc_title":"Failure of a non-authorized copy product to maintain response achieved with imatinib in a patient with chronic phase chronic myeloid leukemia: a case report.",
        "Journal":"Journal of medical case reports",
        "Do_id":"19830137",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605747507024887810},
      {
        "Doc_abstract":"We have investigated the involvement of the p53 tumor suppressor gene and RAS family proto-oncogenes in BCR/ABL-negative chronic myeloproliferative disorders (CMPD), including nine cases of myelosclerosis with myeloid metaplasia, four polycythemia vera, 10 essential thrombocythemia, one juvenile chronic myeloid leukemia, and eight BCR/ABL-negative chronic myeloid leukemia. Twenty-five samples were studied in the chronic phase, while seven samples were analyzed in the acute accelerated or blastic phase. The presence of mutations in p53 exons 5-9, as well as in N-, K-, H-Ras exons 1 and 2 (containing codons 12, 13, and 61) was tested by the polymerase chain reaction (PCR) single strand conformation polymorphism technique and by PCR direct sequencing. In addition, restriction analysis was performed to screen for gross rearrangements within the p53 locus. Alterations of the p53 tumor suppressor gene and Ras family proto-oncogenes were detected in 2/7 and 3/7 cases of acute phase BCR/ABL-negative CMPD, respectively, while consistently negative in all the chronic phase samples analyzed. These results suggest that p53 inactivation and/or Ras activation might play a role in acute transformation of BCR/ABL-negative CMPD.",
        "Doc_title":"Mutations in the P53 and RAS family genes are associated with tumor progression of BCR/ABL negative chronic myeloproliferative disorders.",
        "Journal":"Leukemia",
        "Do_id":"8321046",
        "Doc_ChemicalList":"Oligodeoxyribonucleotides;Proto-Oncogene Proteins;Protein-Tyrosine Kinases;BCR protein, human;Proto-Oncogene Proteins c-bcr",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Base Sequence;Child, Preschool;Female;Gene Rearrangement;Genes, abl;Genes, p53;Genes, ras;Humans;Male;Middle Aged;Molecular Sequence Data;Mutation;Myeloproliferative Disorders;Oligodeoxyribonucleotides;Polymerase Chain Reaction;Prognosis;Protein-Tyrosine Kinases;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-bcr",
        "Doc_meshqualifiers":"diagnosis;genetics;chemistry;genetics",
        "_version_":1605761151461752832},
      {
        "Doc_abstract":"Cytogenetics and polymerase chain reaction (PCR) based assays provide important information regarding biologically defined and prognostically relevant subgroups in acute leukemias. We utilized karyotyping and molecular analysis by reverse transcriptase PCR for the BCR-ABL translocation, in addition to morphological study, cytochemistry and immunophenotyping, to study 24 cases of pediatric acute lymphoblastic leukemia (ALL). Our objective was to determine the frequency of the BCRABL translocation in childhood ALL from southern India. Karyotyping showed one case of hyperdiploidy, one case of t (12; 21) translocation and one case of 46, XY-21+mar. The BCR-ABL translocation was found in 8.3% of these cases. One of these was a cryptic translocation, the karyotype being normal. BCR-ABL positivity in ALL is associated with aggressive disease and has been shown to be a poor prognostic factor, especially in children.",
        "Doc_title":"BCR-ABL Translocation in Pediatric Acute Lymphoblastic Leukemia in Southern India.",
        "Journal":"Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion",
        "Do_id":"23449388",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605764890637631488},
      {
        "Doc_abstract":"Many biological and clinical features of chronic myeloid leukemia make it as a paradigm of rational drug design in human cancer. Chronic myeloid leukemia was the first malignancy to be linked to a clear genetic anomaly, the Philadelphia chromosome and, at present, it is probably the best understood of all human malignancies. Studies of the disease pathology revealed that the molecular consequence of the Philadelphia translocation is a BCR-ABL chimeric gene, which encodes a constitutively active tyrosine kinase with wholesale range of biological activities. Animal models have validated the direct role of the BCR-ABL protein in malignant transformation and subsequent research confirmed that its enhanced tyrosine kinase activity is essential and sufficient for the leukemogenesis. The very existence of a single genetic abnormality, presented in essentially all patients with the disease, made it an effective target for molecularly designed therapeutic approaches for the disease. The advent of tyrosine kinase inhibitors, designed specifically to inhibit the tyrosine kinase activity of the BCR-ABL oncoprotein, represents one of the major innovations in cancer therapy and may serve as a model for, how discoveries of disease pathogenesis may be translated into the development of successful targeted therapies in cancer medicine.",
        "Doc_title":"Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia as a model of rational drug design in cancer.",
        "Journal":"Expert review of hematology",
        "Do_id":"21082933",
        "Doc_ChemicalList":"Antineoplastic Agents;Protein Kinase Inhibitors;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Antineoplastic Agents;Chromosomes, Human;Drug Design;Fusion Proteins, bcr-abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Protein Kinase Inhibitors;Protein-Tyrosine Kinases",
        "Doc_meshqualifiers":"therapeutic use;antagonists & inhibitors;metabolism;drug therapy;therapeutic use;antagonists & inhibitors;metabolism",
        "_version_":1605909756187246592},
      {
        "Doc_abstract":"Molecular-biological approaches was applied for detection of Philadelphia chromosome in patients with chronic myeloid and acute lymphoblastic leukemias. It includes bcr-genomic probes and polymerase chain reaction with specific bcr/abl primers. The latter is more preferable for clinic use. Different diagnostic methods are compared and leukemias etiology problems are discussed.",
        "Doc_title":"[The molecular biology diagnosis of neoplastic blood diseases].",
        "Journal":"TSitologiia i genetika",
        "Do_id":"9695255",
        "Doc_ChemicalList":"DNA Primers;Genetic Markers;RNA;DNA;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adult;Base Sequence;Child;DNA;DNA Primers;Fusion Proteins, bcr-abl;Genes, abl;Genetic Markers;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Molecular Sequence Data;Philadelphia Chromosome;Precursor Cell Lymphoblastic Leukemia-Lymphoma;RNA",
        "Doc_meshqualifiers":"blood;genetics;genetics;genetics;diagnosis;genetics;diagnosis;genetics;blood;genetics",
        "_version_":1605752456662220800},
      {
        "Doc_abstract":"A case of chronic myeloid leukemia displaying an uncommon t(21;22)(q22;q11) is reported. For the first time, this translocation has been characterized by fluorescence in situ hybridization (FISH) and the reverse transcriptase polymerase chain reaction (RT-PCR). FISH, with the use of whole-chromosome painting probes and probes specific for the BCR and ABL genes, showed a three-way variant Philadelphia translocation (9;22;21)(q34;q11;q22) with a BCR/ABL fusion residing on the der(22). In addition, RT-PCR demonstrated a b2a3 BCR/ABL fusion transcript. Underlying mechanisms and prognostic implications are discussed.",
        "Doc_title":"Chronic myeloid leukemia with a rare variant Philadelphia translocation: t(9;22;21)(q34;q11;q22).",
        "Journal":"Cancer genetics and cytogenetics",
        "Do_id":"10640151",
        "Doc_ChemicalList":"Interferon-alpha;Fusion Proteins, bcr-abl;Hydroxyurea",
        "Doc_meshdescriptors":"Chromosome Banding;Chromosomes, Human, Pair 21;Female;Fusion Proteins, bcr-abl;Humans;Hydroxyurea;In Situ Hybridization, Fluorescence;Interferon-alpha;Karyotyping;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Middle Aged;Philadelphia Chromosome;Reverse Transcriptase Polymerase Chain Reaction",
        "Doc_meshqualifiers":"genetics;therapeutic use;therapeutic use;drug therapy;genetics",
        "_version_":1605759063758471168},
      {
        "Doc_abstract":"Recent reports have shown that concomitant submicroscopic deletions can occur in association with chromosomal translocations/inversions in several leukemia subtypes. Detectable by fluorescence in situ hybridization (FISH), these losses of sequence include deletion of the 5' region of the ABL gene and the 3' region of BCR in chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL), as well as the 5' region of ETO in acute myeloid leukemia (AML) French-American-British type M2 associated with t(8;21), 3'MLL in AML and ALL, and 3' core-binding factor beta (CBFbeta) in AML associated with inv(16). While it has been widely reported that submicroscopic deletions of the derivative 9 in CML have an adverse prognostic impact, the clinical significance, if any, of deletions associated with t(8;21), inv(16)/t(16;16), or MLL rearrangement is yet to be determined. We analyzed a series of 39 patients diagnosed with AML who had cytogenetically detectable inv(16)/t(16;16) by using a FISH probe for the CBFbeta region to determine the incidence of the 3'CBFbeta deletion. Deletions were detected in three patients (8%), all associated with inv(16), bringing the number of cases reported so far to seven. The prognostic significance of this finding remains unclear.",
        "Doc_title":"3'CBFbeta deletion associated with inv(16) in acute myeloid leukemia.",
        "Journal":"Cancer genetics and cytogenetics",
        "Do_id":"16213359",
        "Doc_ChemicalList":"CBFB protein, human;Core Binding Factor beta Subunit",
        "Doc_meshdescriptors":"Acute Disease;Adult;Aged;Chromosome Deletion;Chromosome Inversion;Chromosomes, Human, Pair 16;Core Binding Factor beta Subunit;Female;Humans;In Situ Hybridization, Fluorescence;Leukemia, Myeloid;Male",
        "Doc_meshqualifiers":"genetics;genetics",
        "_version_":1605844024082563072},
      {
        "Doc_abstract":"Pulmonary leukostasis is a rare but serious and often fatal complication of chronic myeloid leukemia (CML) in blast crisis and acute myeloid leukemia. Treatment options are limited for these patients. Imatinib mesylate (STI-571, Gleevec, Novartis) is a potent and selective inhibitor of the BCR-abl tyrosine kinase, the molecular abnormality that causes CML. The case of a 74-year-old man with a history of CML who presented in myeloid blast crisis with pulmonary leukostasis characterized by increasing dyspnea, hypoxemia, fever, and impending respiratory failure is reported. The patient was treated with single agent imatinib mesylate (IM) with rapid decrease in his white blood cell count (WBC) and marked improvement in his respiratory status. No electrolyte abnormalities consistent with tumor lysis syndrome were observed. IM may be an effective single agent therapy for pulmonary leukostasis in patients with CML blast crisis who are at the risk for tumor lysis.",
        "Doc_title":"Management of life-threatening pulmonary leukostasis with single agent imatinib mesylate during CML myeloid blast crisis.",
        "Journal":"Haematologica",
        "Do_id":"15377482",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Pyrimidines;Imatinib Mesylate",
        "Doc_meshdescriptors":"Aged;Antineoplastic Agents;Apoptosis;Benzamides;Blast Crisis;Dyspnea;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Leukostasis;Lung;Male;Piperazines;Pyrimidines;Remission Induction;Tomography, X-Ray Computed",
        "Doc_meshqualifiers":"therapeutic use;drug effects;complications;etiology;complications;diagnostic imaging;drug therapy;etiology;blood supply;diagnostic imaging;therapeutic use;therapeutic use",
        "_version_":1605742077940858881},
      {
        "Doc_abstract":"Expression of myeloid or T cell lymphoid in precursor B cell acute lymphoblastic leukemia (pre-B cell ALL), which is referred to as aberrant expression, is quite a common phenomenon. CD66c is a myeloid marker which has aberrant expression in pre-B cell ALL, with strong correlation with non-random genetic changes (BCR/ABL rearrangement). Another leukemia associated marker (CD25) is frequently expressed in pre-B cell ALL. The frequency of CD25-expressing lymphoblasts has been found to be significantly higher in BCR/ABL-positive vs. BCR/ABL-negative patients.;In a cohort of 103 patients diagnosed with pre-B cell ALL or biphenotypic leukemia and studied for expression of CD66c and CD25 at presentation, we evaluated the frequency of expression of either or both in BCR/ABL positive cases.;Surface CD66c was expressed by 70 cases (68%) and CD25 was expressed by 33 cases (32%) while both were expressed together on 29 cases (28%). BCR/ABL was positive in 18/103 patients. All BCR/ABL positive cases were positive for surface CD66c and CD25.;Positivity for both leukemia-associated antigens CD66c and CD25 in combination can predict the presence of BCR/ABL rearrangement in pre-B cell ALL. While this finding does not replace the detection of BCR/ABL abnormality by cytogenetic or molecular techniques, it does provide an early and handy tool for prediction and management of high-risk cases of pre-B cell ALL, especially in centers with limited laboratory facilities.",
        "Doc_title":"Expression of CD66c and CD25 in acute lymphoblastic leukemia as a predictor of the presence of BCR/ABL rearrangement.",
        "Journal":"Hematology/oncology and stem cell therapy",
        "Do_id":"20063526",
        "Doc_ChemicalList":"Antigens, CD;Biomarkers, Tumor;CEACAM6 protein, human;Cell Adhesion Molecules;GPI-Linked Proteins;Interleukin-2 Receptor alpha Subunit;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adolescent;Adult;Antigens, CD;Biomarkers, Tumor;Cell Adhesion Molecules;Child;Child, Preschool;Female;Fusion Proteins, bcr-abl;GPI-Linked Proteins;Humans;Immunophenotyping;In Situ Hybridization, Fluorescence;Interleukin-2 Receptor alpha Subunit;Male;Middle Aged;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Reverse Transcriptase Polymerase Chain Reaction;Translocation, Genetic;Young Adult",
        "Doc_meshqualifiers":"biosynthesis;analysis;biosynthesis;genetics;metabolism;biosynthesis;genetics;metabolism",
        "_version_":1605751598374453248},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder that is characterized by the presence of the fusion oncogene BCR-ABL that encodes the tyrosine kinase BCR-ABL. Constitutive expression of BCR-ABL leads to the unregulated production of mature myeloid cells in the bone marrow and their subsequent release into the blood. Untreated, CML will progress from a chronic to accelerated phase over a number of years before quickly proceeding to a terminal blast crisis phase, reminiscent of acute leukemia. The advent of tyrosine kinase inhibitors has led to much improved management of the disease, but these drugs do not provide a cure as they are unable to eradicate the most primitive, quiescent fraction of CML stem cells. This review looks at recent research into targeting CML stem cells and focuses on major signalling pathways of interest.",
        "Doc_title":"Targeting chronic myeloid leukemia stem cells.",
        "Journal":"Current hematologic malignancy reports",
        "Do_id":"23264204",
        "Doc_ChemicalList":"Antineoplastic Agents;Neoplasm Proteins",
        "Doc_meshdescriptors":"Antineoplastic Agents;Autophagy;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Neoplasm Proteins;Neoplastic Stem Cells",
        "Doc_meshqualifiers":"therapeutic use;drug effects;drug therapy;genetics;pathology;antagonists & inhibitors;genetics;metabolism;drug effects;metabolism",
        "_version_":1605818720860504064},
      {
        "Doc_abstract":"The role of BCR/ABL isoforms and their relationship to leukemia phenotype have been of major concern. Atypical BCR/ABL mRNA transcripts lacking exon a2 have been reported in 12 cases of acute lymphoblastic leukemia (ALL) to date; among them, a b3a3 type transcript has been reported only once in the childhood ALL. Reported here is the case of a patient with Philadelphia-positive (Ph(+)) ALL expressing a b3a3 type transcript, a rare type of BCR/ABL mRNA lacking ABL exon a2 sequences. Bone marrow showed a hypercellular marrow with leukemic blasts positive for CD10, CD19, CD79a, and cytoplasmic mu, which is consistent with pre-B ALL. The G-banding and fluorescence in situ hybridization analyses indicated Ph(+). After the patient was diagnosed with ALL-L2, induction chemotherapy was performed and imatinib mesylate was thereafter given as the maintenance therapy. Sequencing analysis showed deletion of ABL a2 in the polymerase chain reaction product, which corresponded to a b3a3 fusion transcript. To our knowledge, this is the second report of an aberrant BCR/ABL product lacking ABL exon a2 in childhood ALL.",
        "Doc_title":"BCR/ABL rearrangement with b3a3 fusion transcript in a case of childhood acute lymphoblastic leukemia.",
        "Journal":"Cancer genetics and cytogenetics",
        "Do_id":"19215796",
        "Doc_ChemicalList":"Protein Isoforms;RNA, Messenger;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Base Sequence;Child;Chromosomes, Human, Pair 22;Chromosomes, Human, Pair 9;Cytogenetic Analysis;DNA Mutational Analysis;Exons;Fusion Proteins, bcr-abl;Humans;Male;Molecular Sequence Data;Mutation;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Protein Isoforms;RNA, Messenger;Translocation, Genetic",
        "Doc_meshqualifiers":"genetics;genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics",
        "_version_":1605874512966975488},
      {
        "Doc_abstract":"Mutations in oncogenes and tumor suppressor genes confer a fitness advantage to cells that can lead to cancer. The tumor phenotype normally results from the interaction of many mutant genes making it difficult to estimate the fitness advantage provided by any oncogene, except when tumors depend on one oncogene only. We utilize a model of chronic myeloid leukemia (CML), to quantitate the fitness advantage conferred by expression of BCR-ABL in hematopoietic cells from in vivo patient data. We show that BCR-ABL expression provides a high fitness advantage, which explains why this single mutation drives the chronic phase of CML.",
        "Doc_title":"Reproductive fitness advantage of BCR-ABL expressing leukemia cells.",
        "Journal":"Cancer letters",
        "Do_id":"20153920",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Pyrimidines;Imatinib Mesylate;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Animals;Antineoplastic Agents;Benzamides;Cell Differentiation;Cell Division;Cell Movement;Fusion Proteins, bcr-abl;Gene Expression Regulation, Leukemic;Genetic Fitness;Hematopoiesis;Hematopoietic Stem Cells;Humans;Imatinib Mesylate;Leukemia;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Models, Genetic;Mutation;Oncogenes;Phenotype;Piperazines;Probability;Pyrimidines",
        "Doc_meshqualifiers":"therapeutic use;genetics;genetics;physiology;pathology;genetics;pathology;drug therapy;genetics;therapeutic use;therapeutic use",
        "_version_":1605818732660129793},
      {
        "Doc_abstract":"Imatinib is a selective inhibitor of the BCR/ABL tyrosine kinase. The remarkable initial results of the first phase I clinical trial published in 1999 prompted the rapid initiation of large phase II trials. They also generated intense media coverage and significant interest from patients and clinicians and demand for access to imatinib before marketing approval. In response, a worldwide expanded access program (EAP) for imatinib was implemented in May 2000.;In total, 7380 patients with chronic myeloid leukemia (CML) and acute lymphoblastic leukemia failing prior therapies were enrolled in 106 centers in 34 countries.;Time to progression and overall survival, as well as the safety profile, were similar to those observed in published phase II studies. At the end of the program, patients benefiting from treatment were continued on imatinib therapy by transferring to national health care systems or patient assistance programs.;The imatinib EAP successfully provided therapy to patients with CML before marketing approval. The program provides an efficient framework for the development of global EAPs for innovative investigational anticancer agents in patients without a satisfactory therapeutic alternative.",
        "Doc_title":"Report of an international expanded access program of imatinib in adults with Philadelphia chromosome positive leukemias.",
        "Journal":"Annals of oncology : official journal of the European Society for Medical Oncology",
        "Do_id":"18344535",
        "Doc_ChemicalList":"Benzamides;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Imatinib Mesylate",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Aged, 80 and over;Benzamides;Child;Clinical Trials, Phase I as Topic;Clinical Trials, Phase II as Topic;Disease Progression;Female;Humans;Imatinib Mesylate;International Cooperation;Kaplan-Meier Estimate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Leukemia, Myeloid, Chronic-Phase;Male;Middle Aged;Multicenter Studies as Topic;Piperazines;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Program Development;Protein Kinase Inhibitors;Pyrimidines;Survival Analysis;Time Factors",
        "Doc_meshqualifiers":"mortality;therapy;mortality;therapy;adverse effects;therapeutic use;mortality;therapy;adverse effects;therapeutic use;adverse effects;therapeutic use",
        "_version_":1605805803548180480},
      {
        "Doc_abstract":"The polymerase chain reaction (PCR) allows the detection of minimal amounts of nucleic sequences and has been successfully used to test for the chronic myeloid leukemia-specific bcr/abl transcripts. We studied blood samples from 17 patients who had undergone allogeneic bone marrow transplantation for CML, using a modified polymerase chain reaction-based assay for the detection of leukemic mRNA. This nested PCR technique was found to be highly sensitive, detecting the chimeric bcr/abl transcript in 16 of 17 patients including several long-term survivors. Cytogenetic techniques failed to detect Ph mitoses. The clinical significance of the persisting bcr/abl transcript for long periods following BMT is poorly understood and remains to be elucidated by further studies.",
        "Doc_title":"Frequent detection of minimal residual disease by use of the polymerase chain reaction in long-term survivors after bone marrow transplantation for chronic myeloid leukemia.",
        "Journal":"Leukemia",
        "Do_id":"2406520",
        "Doc_ChemicalList":"Proto-Oncogene Proteins;RNA, Messenger;Protein-Tyrosine Kinases;BCR protein, human;Proto-Oncogene Proteins c-bcr",
        "Doc_meshdescriptors":"Bone Marrow Transplantation;Gene Amplification;Gene Rearrangement;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Polymerase Chain Reaction;Protein-Tyrosine Kinases;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-bcr;RNA, Messenger",
        "Doc_meshqualifiers":"diagnosis;genetics;therapy;genetics;analysis",
        "_version_":1605873943699259392},
      {
        "Doc_abstract":"Two patients with Philadelphia chromosome-positive acute lymphoblastic leukemia showed novel variants of the chimeric bcr-abl mRNA. The bcr-abl breakpoint region on cDNA derived from the chimeric mRNA was amplified using the polymerase chain reaction (PCR). Sequence analysis of the breakpoint-containing fragment showed that in both patients exon a2 of the abl gene was deleted, giving rise to an in-frame joining at the mRNA level of 5' bcr sequences to the abl exon a3. These findings were confirmed by Southern blot analysis and cloning of chromosomal DNA. Protein studies showed a bcr-abl protein with heightened tyrosine kinase activity in blast cells of both patients: one of the P190 type, the other of the P210 type. The significance of these findings and the role of this new type of translocation in the disregulation of the abl gene are discussed.",
        "Doc_title":"A novel variant of the bcr-abl fusion product in Philadelphia chromosome-positive acute lymphoblastic leukemia.",
        "Journal":"Leukemia",
        "Do_id":"2193202",
        "Doc_ChemicalList":"RNA, Messenger;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adult;Base Sequence;Blotting, Southern;Chromosome Deletion;Cloning, Molecular;Female;Fusion Proteins, bcr-abl;Humans;Middle Aged;Molecular Sequence Data;Molecular Weight;Oncogenes;Philadelphia Chromosome;Polymerase Chain Reaction;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Protein-Tyrosine Kinases;RNA, Messenger",
        "Doc_meshqualifiers":"genetics;metabolism;enzymology;genetics;metabolism;metabolism;metabolism",
        "_version_":1605839619164733440},
      {
        "Doc_abstract":"The BCR-ABL oncogene is central in the pathogenesis of chronic myeloid leukemia (CML). Here, tandem nanospray mass spectrometry was used to demonstrate cell surface HLA-associated expression of the BCR-ABL peptide KQSSKALQR on class I-negative CML cells transfected with HLA-A*0301, and on primary CML cells from HLA-A3-positive patients. These patients mounted a cytotoxic T-lymphocyte response to KQSSKALQR that also killed autologous CML cells, and tetramer staining demonstrated the presence of circulating KQSSKALQR-specific T cells. The findings are the first demonstration that CML cells express HLA-associated leukemia-specific immunogenic peptides and provide a sound basis for immunization studies against BCR-ABL.",
        "Doc_title":"Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein.",
        "Journal":"Blood",
        "Do_id":"11698267",
        "Doc_ChemicalList":"Antigens, Neoplasm;Antigens, Surface;HLA-A3 Antigen;Neoplasm Proteins;Peptide Fragments;Recombinant Fusion Proteins;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adult;Amino Acid Sequence;Antigen Presentation;Antigens, Neoplasm;Antigens, Surface;Female;Fusion Proteins, bcr-abl;HLA-A3 Antigen;Humans;K562 Cells;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Neoplasm Proteins;Neoplastic Stem Cells;Peptide Fragments;Recombinant Fusion Proteins;Spectrometry, Mass, Electrospray Ionization;T-Lymphocytes, Cytotoxic;Transfection",
        "Doc_meshqualifiers":"chemistry;immunology;chemistry;immunology;chemistry;immunology;genetics;immunology;immunology;genetics;immunology;chemistry;immunology;immunology;chemistry;immunology;immunology;immunology",
        "_version_":1605750217422929920},
      {
        "Doc_abstract":"The study aimed to examine a rare case of Philadelphia (Ph)-negative chronic myeloid leukemia (CML) with t(9;13). Chromosome samples were prepared after culture of bone marrow cells for 24 hours, the karyotypes were analyzed by G banding technique. Chromosome painting analysis was performed by using whole chromosome paints for chromosomes 9 and 22. Fluorescence in situ hybridization (FISH) was done with dual color dual fusion LSI bcr/abl probe. Bcr/abl transcripts were detected by real time fluorescence quantitative polymerase chain reaction (RQ-PCR). As a result, G banding analysis showed a karyotype of 45, XX, der(9)t(9;13)(q34;q10), -13[20]. FISH assay using LSI bcr/abl DNA probe showed a red abl signal inserted into der(22) and a fusion signal of bcr/abl rearrangement was discovered. RQ-PCR detected high copies of bcr/abl transcripts. In conclusion, insertion of bcr/abl rearrangement was a rare variant t(9;22) and could be well detected by molecular techniques, however, regular cytogenetic banding technique and whole chromosome paintings may probably lead a misdiagnosis to such cases.",
        "Doc_title":"[Laboratory study on a rare case of chronic myeloid leukemia with ins(22;9)t(9;13) and Ph-negative].",
        "Journal":"Zhongguo shi yan xue ye xue za zhi",
        "Do_id":"20416167",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Chromosome Painting;Chromosomes, Human, Pair 13;Chromosomes, Human, Pair 22;Chromosomes, Human, Pair 9;Female;Humans;Karyotyping;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative;Middle Aged",
        "Doc_meshqualifiers":"genetics;genetics",
        "_version_":1605765635179020288},
      {
        "Doc_abstract":"A competitive mimic of the cDNA of the BCR-ABL fusion gene was constructed, and its feasibility was testified by capillary electropheresis (CE). The 4 bp-shorter mimic was obtained by PCR amplification using a newly synthesized downstream primer analogous to the former one. Mimics of both types of BCR-ABL cDNA were achieved and the validity was verified with restriction endonuclease. And the products of the coamplification PCR could be easily separated by capillary electrophorisis. The mimic can be used to quantitative detection of BCR-ABL gene through competitive RT-PCR in chronic myeloid leukemia.",
        "Doc_title":"[Constructing a Competitor of BCR-ABL cDNA by PCR Site-Directed Mutagenesis]",
        "Journal":"Zhongguo shi yan xue ye xue za zhi",
        "Do_id":"12578693",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605784067026976768},
      {
        "Doc_abstract":"Drug-mediated thrombotic microangiopathy may cause life-threatening medical emergencies. Novel targeted therapies have dramatically changed the prognosis of a number of oncological diseases. Tyrosine kinase inhibitors of the Breakpoint Cluster Region-Abelson (BCR-ABL) oncoprotein are used in patients with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia. Imatinib mesylate, which was the first anti-BCR-ABL tyrosine kinase inhibitor, has demonstrated a high tolerance profile and efficacy in these patients for many years. Good results have also been observed in patients with gastrointestinal stromal tumors. In this study, we describe two patients with Philadelphia chromosome-positive hematological malignancies who presented with secondary thrombotic microangiopathy that was most likely linked to the use of imatinib. Other potential causes of thrombotic microangiopathy were discarded, and the predisposing role of some comorbidities and potential short or long-term drug-drug interactions was assessed. The clinical and biological data were more indicative of atypical secondary hemolytic uremic syndrome in one of the cases and of secondary thrombotic microangiopathy with renal and cardiac impairment in the other, which is also categorized as secondary hemolytic uremic syndrome. The outcome was favorable after imatinib discontinuation and the treatment of severe cardiac and renal failures. ",
        "Doc_title":"Secondary thrombotic microangiopathy in two patients with Philadelphia-positive hematological malignancies treated with imatinib mesylate.",
        "Journal":"Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners",
        "Do_id":"25591869",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605748509332471808},
      {
        "Doc_abstract":"The polymerase chain reaction (PCR) has become a standard method for highly sensitive detection of the bcr/abl rearrangement in patients with chronic myelogenous leukemia (CML) or acute lymphoblastic leukemia (ALL). The exquisite sensitivity of the PCR facilitates the detection of residual leukemic cells after chemotherapy or after bone marrow transplantation. However, the detection of minimal residual disease does not yield any information on the malignant potential of the bcr/abl-rearranged cells. Qualitative PCR is therefore of limited prognostic value in the monitoring of residual leukemia. We have adapted the PCR for quantitative evaluation of cells carrying the bcr/abl rearrangement and by means of two exemplary cases of CML patients after bone marrow transplantation and under treatment with alpha-interferon, respectively, we show that this new technique is suitable for the long term follow-up of the activity of the residual bcr/abl rearranged clone. Longitudinal monitoring of residual disease by the technique presented provides a novel tool for detection of incipient relapse at a very early stage.",
        "Doc_title":"Monitoring of residual disease in chronic myelogenous leukemia by quantitative polymerase chain reaction.",
        "Journal":"Leukemia",
        "Do_id":"1602787",
        "Doc_ChemicalList":"RNA, Messenger;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adolescent;Adult;Chromosome Fragility;Female;Follow-Up Studies;Fusion Proteins, bcr-abl;Gene Rearrangement;Genes, abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Multigene Family;Polymerase Chain Reaction;RNA, Messenger",
        "Doc_meshqualifiers":"genetics;diagnosis;genetics;metabolism;analysis",
        "_version_":1605742008486330369},
      {
        "Doc_abstract":"We report on the use of dasatinib, a second-generation bcr-abl kinase inhibitor, in a child in early relapse of Philadelphia chromosome positive acute lymphoblastic leukemia after hematopoietic stem cell transplantation. This patient benefited from the use of dasatinib obtaining of a complete molecular response which allowed a second successful transplant. Moreover, dasatinib was well tolerated in this heavily pretreated patient.",
        "Doc_title":"Successful second allogeneic stem cell transplantation in second remission induced by dasatinib in a child with Philadelphia chromosome positive acute lymphoblastic leukemia.",
        "Journal":"Pediatric blood & cancer",
        "Do_id":"19202569",
        "Doc_ChemicalList":"Protein Kinase Inhibitors;Pyrimidines;Thiazoles;Fusion Proteins, bcr-abl;Dasatinib",
        "Doc_meshdescriptors":"Child, Preschool;Dasatinib;Fusion Proteins, bcr-abl;Hematopoietic Stem Cell Transplantation;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Philadelphia Chromosome;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Protein Kinase Inhibitors;Pyrimidines;Remission Induction;Salvage Therapy;Thiazoles;Transplantation, Homologous",
        "Doc_meshqualifiers":"antagonists & inhibitors;genetics;genetics;therapy;genetics;therapy;therapeutic use;therapeutic use;therapeutic use",
        "_version_":1605784450156724224},
      {
        "Doc_abstract":"We previously described a novel type of the chimeric bcr-abl mRNA transcript in a patient with a Philadelphia chromosome positive chronic myeloid leukemia. A similar bcr-abl transcript has also been described by others.;Sequence analysis of the fusion region showed a join between part of exon e8 of the bcr gene and an intronic sequence of abl intron 1b spliced on exon a2 of the abl gene, giving rise to an in-frame e8-int-a2 bcr-abl transcript, translated into a 197.5 kDa BCR-ABL protein of 1804 amino acid residues, which we named p200 BCR-ABL.;In this work, employing protein comparison analysis (pFAM) we show that these novel bcr-abl transcripts retain the DBL homology (DH) domain and the recently recognized CDC24 homology domain, but not the pleckstrin homology (PH) domain of the bcr gene.;This observation, along with the myeloid immunophenotype of the tumor and, at least in one case, the patient's correspondingly good response to alpha-interferon therapy, suggests that p200 BCR-ABL is more similar to p210 BCR-ABL, in which the DH, CDC24 and PH domains are all maintained, than to p185, in which these domains are all lost.",
        "Doc_title":"Novel types of bcr-abl transcript with breakpoints in BCR exon 8 found in Philadelphia positive patients with typical chronic myeloid leukemia retain the sequence encoding for the DBL- and CDC24 homology domains but not the pleckstrin homology one.",
        "Journal":"Haematologica",
        "Do_id":"12091118",
        "Doc_ChemicalList":"RNA, Messenger;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Amino Acid Motifs;Amino Acid Sequence;Chromosome Breakage;Exons;Fusion Proteins, bcr-abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Molecular Sequence Data;Molecular Weight;Protein Structure, Tertiary;RNA, Messenger;Sequence Analysis",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics",
        "_version_":1605789052000272384},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) is caused by the constitutively activated tyrosine kinase breakpoint cluster (BCR)-ABL. Current frontline therapy for CML is imatinib, an inhibitor of BCR-ABL. Although imatinib has a high rate of clinical success in early phase CML, treatment resistance is problematic, particularly in later stages of the disease, and is frequently mediated by mutations in BCR-ABL. Dasatinib (BMS-354825) is a multitargeted tyrosine kinase inhibitor that targets oncogenic pathways and is a more potent inhibitor than imatinib against wild-type BCR-ABL. It has also shown preclinical activity against all but one of the imatinib-resistant BCR-ABL mutants tested to date. Analysis of the crystal structure of dasatinib-bound ABL kinase suggests that the increased binding affinity of dasatinib over imatinib is at least partially due to its ability to recognize multiple states of BCR-ABL. The structure also provides an explanation for the activity of dasatinib against imatinib-resistant BCR-ABL mutants.",
        "Doc_title":"The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants.",
        "Journal":"Cancer research",
        "Do_id":"16740718",
        "Doc_ChemicalList":"Benzamides;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Thiazoles;Imatinib Mesylate;Proto-Oncogene Proteins c-abl;Dasatinib",
        "Doc_meshdescriptors":"Animals;Benzamides;Crystallography, X-Ray;Dasatinib;Drug Resistance, Neoplasm;Enzyme Activation;Humans;Imatinib Mesylate;Models, Molecular;Piperazines;Protein Conformation;Protein Kinase Inhibitors;Protein Structure, Tertiary;Proto-Oncogene Proteins c-abl;Pyrimidines;Structure-Activity Relationship;Thiazoles",
        "Doc_meshqualifiers":"chemistry;metabolism;pharmacology;chemistry;metabolism;pharmacology;antagonists & inhibitors;chemistry;metabolism;chemistry;metabolism;pharmacology;chemistry;metabolism;pharmacology",
        "_version_":1605810164141654016},
      {
        "Doc_abstract":"The chimeric oncogene BCR/ABL, which is the product of reciprocal translocation between chromosomes 9 and 22, is a known molecular marker of chronic myeloid leukemia (CML), and is related to the major factors involved in leukemogenesis. Some previous studies have also reported the presence of this oncogene in peripheral blood cells of healthy individuals. In this study, we investigated the presence of BCR/ABL transcripts in peripheral blood of individuals aged 40 years or more without symptoms of CML. The presence of BCR/ABL transcripts was observed in 2 of the 30 individuals analyzed. The genesis of BCR/ABL transcripts and its presence in healthy individuals are topics of ongoing debate. The risks and biological implications of the presence of BCR/ABL transcripts in healthy individuals are challenging issues that remain to be elucidated. ",
        "Doc_title":"Analysis of BCR/ABL transcripts in healthy individuals.",
        "Journal":"Genetics and molecular research : GMR",
        "Do_id":"24301757",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adult;Female;Fusion Proteins, bcr-abl;Healthy Volunteers;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Leukocytes, Mononuclear;Male;Middle Aged;Transcription, Genetic;Translocation, Genetic",
        "Doc_meshqualifiers":"genetics;genetics;metabolism",
        "_version_":1605785272709021696},
      {
        "Doc_abstract":"Emergence of resistance to Imatinib complicates the treatment of chronic myeloid leukemia (CML). Second-generation Bcr-Abl inhibitors are capable to overcome resistance mediated by most mutations except T315I. As this mutation is causative for approximately 20% of clinically observed resistances, the need for novel treatment strategies becomes obvious. Here, we report on a novel kinase inhibitor PHA-680626 exhibiting strong inhibitory activity on both Bcr-Abl and Aurora kinases. Significant anti-proliferative and pro-apoptotic effects were observed in human BCR-ABL positive cell lines and murine BaF3 cells ectopically expressing wt BCR-ABL or the Imatinib-resistant BCR-ABL mutants M351T, E255K and, T315I. Treatment with PHA-680626 decreased phosphorylation of CrkL and histone H3. As CrkL represents a typical downstream target of Bcr-Abl while histone H3 phosphorylation is an indicator for Aurora kinase B activity, these findings indicate that effects of PHA-680626 are mediated via inhibition of both pathways. Moreover, high anti-proliferative activity of PHA-680626 was observed in primary CD34+ cells derived from CML patients at diagnosis or in blast crisis as well as from an individual harbouring the T315I mutation. Thus, both Bcr-Abl and Aurora kinase inhibition contribute to the efficacy of PHA-680626 against Imatinib-resistant BCR-ABL positive leukemias, particularly those harbouring the T315I mutation.",
        "Doc_title":"PHA-680626 exhibits anti-proliferative and pro-apoptotic activity on Imatinib-resistant chronic myeloid leukemia cell lines and primary CD34+ cells by inhibition of both Bcr-Abl tyrosine kinase and Aurora kinases.",
        "Journal":"Leukemia research",
        "Do_id":"18514829",
        "Doc_ChemicalList":"Antigens, CD;Antigens, CD34;Antineoplastic Agents;Benzamides;PHA 680626;Piperazines;Pyrazoles;Pyrimidines;Pyrroles;Imatinib Mesylate;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl;AURKB protein, human;Aurora Kinase B;Aurora Kinases;Protein-Serine-Threonine Kinases",
        "Doc_meshdescriptors":"Antigens, CD;Antigens, CD34;Antineoplastic Agents;Apoptosis;Aurora Kinase B;Aurora Kinases;Benzamides;Cell Division;Cell Line, Tumor;Drug Resistance, Neoplasm;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Piperazines;Protein-Serine-Threonine Kinases;Protein-Tyrosine Kinases;Pyrazoles;Pyrimidines;Pyrroles",
        "Doc_meshqualifiers":"drug effects;drug effects;pharmacology;drug effects;drug effects;enzymology;pathology;pharmacology;antagonists & inhibitors;antagonists & inhibitors;pharmacology;pharmacology;pharmacology",
        "_version_":1605784010371366912},
      {
        "Doc_abstract":"Together, acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) make up approximately one-third of all pediatric cancer diagnoses. Despite remarkable improvement in the treatment outcomes of these diseases over the past several decades, the prognosis for certain high-risk groups of leukemia and for relapsed disease remains poor. However, recent insights into different types of 'driver' lesions of leukemogenesis, such as the aberrant activation of signaling pathways and various epigenetic modifications, have led to the discovery of novel agents that specifically target the mechanism of transformation. In parallel, emerging approaches in cancer immunotherapy have led to newer therapies that can exploit and harness cytotoxic immunity directed against malignant cells. This review details the rationale and implementation of recent and specifically targeted therapies in acute pediatric leukemia. Topics covered include the inhibition of critical cell signaling pathways [BCR-ABL, FMS-like tyrosine kinase 3 (FLT3), mammalian target of rapamycin (mTOR), and Janus-associated kinase (JAK)], proteasome inhibition, inhibition of epigenetic regulators of gene expression [DNA methyltransferase (DNMT) inhibitors, histone deacetylase (HDAC) inhibitors, and disruptor of telomeric signaling-1 (DOT1L) inhibitors], monoclonal antibodies and immunoconjugated toxins, bispecific T-cell engaging (BiTE) antibodies, and chimeric antigen receptor-modified (CAR) T cells. ",
        "Doc_title":"Novel agents for the treatment of childhood acute leukemia.",
        "Journal":"Therapeutic advances in hematology",
        "Do_id":"25830014",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605747510312173569},
      {
        "Doc_abstract":"bcr-abl, the oncogene causing chronic myeloid leukemia, encodes a fusion protein with constitutively active tyrosine kinase and transforming capacity in hematopoietic cells. Various intracellular signaling intermediates become activated and/or associate by/with Bcr-Abl, including the Src family kinase Hck. To elucidate some of the structural requirements and functional consequences of the association of Bcr-Abl with Hck, their interaction was investigated in transiently transfected COS7 cells. Neither the complex formation of Hck kinase with Bcr-Abl nor the activation of Hck by Bcr-Abl was dependent on the Abl kinase activity. Both inactivating point mutations of Hck and dephosphorylation of Hck enhanced its complex formation with Bcr-Abl, indicating that their physical interaction was negatively regulated by Hck (auto)phosphorylation. Finally, experiments with a series of kinase negative Bcr-Abl mutants showed that Hck phosphorylated Bcr-Abl and induced the binding of Grb2 to Tyr177 of Bcr-Abl. Taken together, our results suggest that Bcr-Abl preferentially binds inactive forms of Hck by an Abl kinase-independent mechanism. This physical interaction stimulates the Hck tyrosine kinase, which may then phosphorylate the Grb2-binding site in Bcr-Abl.",
        "Doc_title":"The Src family kinase Hck interacts with Bcr-Abl by a kinase-independent mechanism and phosphorylates the Grb2-binding site of Bcr.",
        "Journal":"The Journal of biological chemistry",
        "Do_id":"9407116",
        "Doc_ChemicalList":"Adaptor Proteins, Signal Transducing;GRB2 Adaptor Protein;GRB2 protein, human;Proteins;Proto-Oncogene Proteins;Protein-Tyrosine Kinases;Receptor, Epidermal Growth Factor;Fusion Proteins, bcr-abl;HCK protein, human;Proto-Oncogene Proteins c-hck;Proto-Oncogene Proteins pp60(c-src)",
        "Doc_meshdescriptors":"Adaptor Proteins, Signal Transducing;Animals;Binding Sites;COS Cells;Fusion Proteins, bcr-abl;GRB2 Adaptor Protein;Humans;Phosphorylation;Point Mutation;Protein-Tyrosine Kinases;Proteins;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-hck;Proto-Oncogene Proteins pp60(c-src);Receptor, Epidermal Growth Factor",
        "Doc_meshqualifiers":"metabolism;metabolism;genetics;metabolism;metabolism;metabolism;metabolism",
        "_version_":1605850637612875776},
      {
        "Doc_abstract":"The initial success of the first synthetic bcr-abl kinase inhibitor imatinib has been dampened by the emergence of imatinib-resistant disease in blast crisis chronic myeloid leukemia. Here, we report that the novel triterpenoid methyl-2-cyano-3,12-dioxooleana-1,9-diene-28-oate (CDDO-Me) potently induced cytotoxicity in imatinib-resistant KBM5 cells expressing the T315I mutation of bcr-abl (24-h EC50, 540 nmol/L). In long-term culture, CDDO-Me abrogated the growth of human parental KBM5 and KBM5-STI cells with 96-h IC50 of 205 and 221 nmol/L, respectively. In addition, CDDO-Me rapidly decreased the viability of murine lymphoid Ba/F3 cells expressing wild-type p210 as well as the imatinib-resistant E255K and T315I mutations of bcr-abl. The low-dose effects of CDDO-Me are associated with inhibition of mitochondrial oxygen consumption, whereas the cytotoxic effects appear to be mediated by a rapid and selective depletion of mitochondrial glutathione that accompanies the increased generation of reactive oxygen species and mitochondrial dysfunction. Interestingly, the mitochondriotoxic effects of CDDO-Me are followed by the rapid autophagocytosis of intracellular organelles or the externalization of phosphatidylserine in different cell types. We conclude that alterations in mitochondrial function by CDDO-Me can result in autophagy or apoptosis of chronic myeloid leukemia cells regardless of the mutational status of bcr-abl. CDDO-Me is in clinical trials and shows signs of clinical activity, with minimal side effects and complete lack of cardiotoxicity. Studies in leukemias are in preparation.",
        "Doc_title":"Inhibition of mitochondrial metabolism by methyl-2-cyano-3,12-dioxooleana-1,9-diene-28-oate induces apoptotic or autophagic cell death in chronic myeloid leukemia cells.",
        "Journal":"Molecular cancer therapeutics",
        "Do_id":"18483301",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Pyrimidines;Reactive Oxygen Species;Oleanolic Acid;Imatinib Mesylate;methyl 2-cyano-3,12-dioxoolean-1,9-dien-28-oate;Fusion Proteins, bcr-abl;Oxygen",
        "Doc_meshdescriptors":"Antineoplastic Agents;Apoptosis;Autophagy;Benzamides;Dose-Response Relationship, Drug;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mitochondria;Oleanolic Acid;Oxidation-Reduction;Oxygen;Piperazines;Pyrimidines;Reactive Oxygen Species",
        "Doc_meshqualifiers":"pharmacology;genetics;metabolism;drug therapy;metabolism;pathology;drug effects;metabolism;analogs & derivatives;pharmacology;metabolism;pharmacology;pharmacology;metabolism",
        "_version_":1605826481189027840},
      {
        "Doc_abstract":"Dasatinib is a drug for treatment of oncogene fusion protein BCR-ABL-positive chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant/intolerant to imatinib. Pleural effusion (PE) is a common adverse effect, and in this context, we present four cases seen due to this cause. One of them is a chylothorax. The PE grade is variable, and the physiopathology is not well established, although a block in T-lymphocyte function or inhibition of platelet-derived growth factor receptor- is suggested being involved. The PE is generally a lymphocyte-predominant exudate, but can also present as chylothorax. Several factors have been associated with its appearance, particularly the administration in two daily doses. Low grade (1-2) PEs usually respond well to interrupt the treatment while those of higher grade may also require therapeutic thoracentesis and corticosteroids. There are currently no firm guidelines that establish when to resort to one form of treatment or another.",
        "Doc_title":"Dasatinib-induced pleural effusion: Chylothorax, an option to consider.",
        "Journal":"Annals of thoracic medicine",
        "Do_id":"27803756",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605882678327902208},
      {
        "Doc_abstract":"To investigate the biological features of leukemic cells in bcr/abl fusion transcript-positive B-lineage acute lymphoblastic leukemia (B-ALL), 3- or 4-color flow cytometry with directly conjugated monoclonal antibodies was used to detect the immunophenotype of the cells in 26 patients with bcr/able-positive B-ALL and 32 patients with bcr/abl-negative B-ALL. bcr/abl fusion transcript was detected by RT-PCR. Immunoglobulin heavy chain (IgH) gene rearrangement was detected by PCR. The results showed that all of the B-ALL patients were positive for CD19. There was significant difference in expression of CD34 (96.2% vs 65.6%), CD10 (96.2% vs 71.8%) and CD38 (43.8% vs 95.4%) between bcr/abl-positive and -negative groups. In bcr/abl-positive B-ALL group, the co-expression rates of CD10(+)/CD19(+)/CD34(+), CD10(+)/CD34(+)/HLA-DR(+) and CD10(+)/CD34(+)/CD38(-) were 92.3% (24/26), 73.1% (19/26) and 56.2% (9/16), respectively. In bcr/abl-negative group, co-expression of CD10(+)/CD19(+)/CD34(+) and CD10(+)/CD34(+)/HLA-DR(+) were 43.8% (14/32) and 37.5% (12/32), respectively, there were significant differences (P < 0.05) between bcr/abl-positive and -negative groups, but none of the cases co-expressed CD10(+)/CD34(+)/CD38(-). The detection rate of monoclonal IgH gene rearrangement (58.8%, 10/17) was lower in bcr/abl-positive group than that (85.7%, 12/14) in bcr/able-negative group. It is concluded that the expression rates of CD34 and CD10 are higher, and CD38 and IgH gene rearrangement are lower in bcr/abl-positive B-ALL cases, CD10(+)/CD34(+)/CD38(-) is a unique feature of immunophenotype, and this phenotype of leukemia cells is closer to that of early B-lineage progenitor cells.",
        "Doc_title":"[Immunophenotypic features of bcr/abl fusion transcript-positive B-lineage acute lymphoblast leukemia].",
        "Journal":"Zhongguo shi yan xue ye xue za zhi",
        "Do_id":"12744735",
        "Doc_ChemicalList":"Antigens, CD19;Antigens, CD34;RNA, Messenger;Fusion Proteins, bcr-abl;Antigens, CD45;Neprilysin",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Antigens, CD19;Antigens, CD34;Antigens, CD45;Burkitt Lymphoma;Child;Female;Flow Cytometry;Fusion Proteins, bcr-abl;Humans;Immunophenotyping;Male;Middle Aged;Neprilysin;Polymerase Chain Reaction;RNA, Messenger",
        "Doc_meshqualifiers":"analysis;analysis;analysis;immunology;genetics;analysis;analysis",
        "_version_":1605841349497585664},
      {
        "Doc_abstract":"Formation of the hybrid BCR-ABL gene is responsible for >95% of chronic myeloid leukemia (CML). The alternative, downstream ABL promoter (Pa), which is usually retained in this chimeric oncogene, was reported to be methylated in many CML patients, but there has been controversy as to whether this methylation is a frequent change in bone marrow (BM) in early chronic phase (CP) or only past this stage. Also, the relevance of Pa promoter methylation to BCR-ABL expression in CML is unclear. We examined methylation of the ABL Pa promoter in uncultured BM samples and in colonies derived from their hematopoietic precursor cells by bisulfite and PCR-based assays (combined bisulfite restriction analysis and methylation-specific PCR). BM from seven CP CML patients at diagnosis had about 20-60% of the copies of the ABL Pa promoter methylated. No Pa methylation was detected in normal BMs or colonies derived from them. In contrast, most colonies from CP CML patients had Pa methylation. Surprisingly, 18-49% of the CML-derived colonies with this methylation reproducibly had no detectable BCR-ABL RNA on nested reverse transcription-PCR. Furthermore, the percentage of BCR-ABL RNA-positive colonies was almost same among the colonies not displaying Pa methylation as among the colonies in which this methylation was found. We conclude that ABL Pa methylation is often an early marker of CML in hematopoietic precursors and in total mononuclear BM cells but that it is not associated with an increased frequency of BCR-ABL RNA-positive cells. This methylation might be emblematic of cancer-associated hypermethylation elsewhere in the genome with the consequent silencing of tumor suppressor genes seen in many malignancies.",
        "Doc_title":"ABL1 promoter methylation can exist independently of BCR-ABL transcription in chronic myeloid leukemia hematopoietic progenitors.",
        "Journal":"Cancer research",
        "Do_id":"11559572",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adult;Aged;Base Sequence;Bone Marrow Cells;DNA Methylation;Female;Gene Expression;Genes, abl;Hematopoietic Stem Cells;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Molecular Sequence Data;Neoplastic Stem Cells;Promoter Regions, Genetic;Reverse Transcriptase Polymerase Chain Reaction;Transcription, Genetic",
        "Doc_meshqualifiers":"pathology;physiology;genetics;pathology;physiology;genetics;pathology;pathology;physiology",
        "_version_":1605741939928334339},
      {
        "Doc_abstract":"Juvenile myelomonocytic leukemia (JMML), previously known as juvenile chronic myeloid leukemia (JCML), is a rare, myelodysplastic-myeloproliferative disease typically presenting in early childhood. This disorder is difficult to distinguish from other myeloproliferative syndromes such as chronic myeloid leukemia (CML) because of the similarities in their clinical and bone marrow findings. However, because of its unique biological characteristics such as absolute monocytosis with dysplasia, absence of Philadelphia chromosome or BCR-ABL fusion protein, hypergammaglobulinemia, and raised fetal hemoglobin level, this disorder does not satisfy the criteria for inclusion in the CML or chronic myelomonocytic leukemia (CMML) group, as seen in adult patients. We describe three cases of JMML, who had very similar clinical and laboratory findings.",
        "Doc_title":"[Juvenile myelomonocytic leukemia: A three-case series].",
        "Journal":"Archives de pediatrie : organe officiel de la Societe francaise de pediatrie",
        "Do_id":"27789175",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605893487124807680},
      {
        "Doc_abstract":"We describe the cases of two patients with Philadelphia chromosome-positive chronic myeloid leukemia (CML), in whom the extramedullary blastic phase developed during disease progression. The similar clinical presentations of these patients was accompanied by gain of identical secondary chromosome abnormalities, that is, monosomies 9, 14, and 22, and by a clustered amplification of the BCR/ABL fusion gene. The additional copies of the BCR/ABL fusion gene were integrated into the short arm of structurally abnormal chromosomes 17 in both patients. The conformity of these genetic features in two patients with a rare disease manifestation leads us to the assumption that either the clustered amplification of the BCR/ABL fusion gene or the integration of this cluster into the short arm of chromosome 17 or both are associated with extramedullar disease progression in CML. Furthermore, the insertion of amplified BCR/ABL fusion genes into structurally abnormal chromosomes provides a novel mechanism of disease progression in BCR/ABL-positive CML.",
        "Doc_title":"Integration of amplified BCR/ABL fusion genes into the short arm of chromosome 17 as a novel mechanism of disease progression in chronic myeloid leukemia.",
        "Journal":"Genes, chromosomes & cancer",
        "Do_id":"11284030",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adult;Blast Crisis;Chromosome Aberrations;Chromosome Disorders;Chromosomes, Human, Pair 17;Cytogenetic Analysis;Disease Progression;Female;Fusion Proteins, bcr-abl;Gene Amplification;Genes, abl;Humans;In Situ Hybridization, Fluorescence;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Reverse Transcriptase Polymerase Chain Reaction",
        "Doc_meshqualifiers":"genetics;pathology;genetics;pathology;genetics;genetics;metabolism;genetics;genetics;methods;genetics;pathology",
        "_version_":1605845281713160192},
      {
        "Doc_abstract":"Within the past year substantial progress has been made in understanding the molecular changes underlying the development of acute leukemia. Development of molecular probes allowed substantial improvements in the detection of minimal residual disease. Pilot studies underlined the correlation between the expression of the multidrug resistance gene and the likelihood of response to chemotherapy. The expression of mdr-1 apparently correlates with the expression of certain surface antigens like CD34 and CD7, which by themselves are associated with the expression of bcl-2 and poor treatment response. The value of hematopoietic growth factors to overcome drug resistance has not yet been clearly demonstrated in clinical trials, but they seem to reduce early mortality in elderly patients with acute myeloid leukemia when given after chemotherapy. Substantial progress has been made in the understanding of molecular changes in acute promyelocytic leukemia. Combination of all-trans retinoic acid and chemotherapy is the treatment of choice in acute promyelocytic leukemia. Allogeneic bone marrow transplantation proved to be superior in certain high-risk groups of patients with acute leukemia, including those with acute lymphoblastic leukemia with the bcr-abl configuration. The value of allogeneic bone marrow transplantation from related and unrelated donors, as well as the value of autologous bone marrow transplantation, is increasingly defined in randomized trials.",
        "Doc_title":"Acute leukemia.",
        "Journal":"Current opinion in hematology",
        "Do_id":"9371290",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Acute Disease;Bone Marrow Transplantation;Clinical Trials as Topic;Humans;Leukemia, Myeloid;Leukemia, Promyelocytic, Acute;Precursor Cell Lymphoblastic Leukemia-Lymphoma",
        "Doc_meshqualifiers":"physiopathology;therapy;physiopathology;therapy;physiopathology;therapy",
        "_version_":1605909912049680384},
      {
        "Doc_abstract":"To evaluate the prognostic power of minimal residual disease (MRD) monitored by polymerase chain reaction at defined time points during early treatment in adult patients with acute lymphoblastic leukemia (ALL).;Seventy-one patients were treated according to the GMALL 07/2003 protocol and evaluated for MRD in bone marrow by specific clonal rearrangements of Ig/TCR in BCR-ABL negative ALL or fusion gene transcript in BCR-ABL positive ALL.;Three-year overall survival (OS) was 94% in patients with BCR-ABL negative ALL reaching complete molecular response (CMR) after the first course of chemotherapy (vs. 32% if MRD >10(-4) ; P = 0.001). Patients with CMR prior to the start of consolidation chemotherapy at week 11 had 3-yr OS 82% (vs. 18% if MRD >10(-4) ; P = 0.001). Patients with BCR-ABL positive ALL showed slower MRD dynamics. There was a trend to better OS in patients with  4 log reduction of BCR-ABL transcript prior to HSCT (92% vs. 50%; P = 0.065). None of the patients with detectable MRD (both BCR-ABL positive and negative) after HSCT survived 3 yr.;Early MRD kinetics is an important tool for new prognostication models with direct clinical impact irrespective of standard prognostic factors in patients with BCR-ABL negative ALL.",
        "Doc_title":"Early MRD response as a prognostic factor in adult patients with acute lymphoblastic leukemia.",
        "Journal":"European journal of haematology",
        "Do_id":"25997106",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605902872479793152},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) was the first human malignant disease to be linked to a single, acquired genetic abnormality. Identification of the BCR-ABL kinase fusion protein and its central role in the pathogenesis of CML provided new opportunities to develop rational molecular targeted therapies. This review provides an update on the underlying pathophysiologies of disease progression and imatinib mesylate resistance, leading to the development of new targeted tyrosine kinase inhibitors for managing CML. Imatinib, a selective inhibitor of BCR-ABL, represents a major success in the era of target-directed cancer chemotherapy. However, patients with advanced CML have been less sensitive to therapy and responses have been short. In addition, treatment resistance is an emerging problem at all disease stages. Insight into factors involved in imatinib resistance and disease progression has highlighted a role for such BCR-ABL-dependent factors as amplification and overexpression of the BCR-ABL gene and the emergence of mutant isoforms of BCR-ABL. However, BCR-ABL-independent factors, including leukemogenic pathways involving kinases other than BCR-ABL, also play a part. In light of the limitations of imatinib against these factors, newer tyrosine kinase inhibitors, including dasatinib (a multitargeted kinase inhibitor of BCR-ABL and Src family kinases) and nilotinib (AMN107, a selective BCR-ABL inhibitor), may provide promising treatment options for patients with CML.",
        "Doc_title":"New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance.",
        "Journal":"Annals of internal medicine",
        "Do_id":"17179059",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Pyrimidines;Imatinib Mesylate;Fusion Proteins, bcr-abl;src-Family Kinases",
        "Doc_meshdescriptors":"Antineoplastic Agents;Benzamides;Disease Progression;Drug Resistance, Neoplasm;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Piperazines;Pyrimidines;src-Family Kinases",
        "Doc_meshqualifiers":"therapeutic use;antagonists & inhibitors;physiology;drug therapy;genetics;physiopathology;therapeutic use;therapeutic use;antagonists & inhibitors",
        "_version_":1605758496858439680},
      {
        "Doc_abstract":"MicroRNA regulate the activity of protein-coding genes including those involved in hematopoietic cancers. The aim of the current study was to explore which microRNA are unique for seven different subtypes of pediatric acute lymphoblastic leukemia.;Expression levels of 397 microRNA (including novel microRNA) were measured by quantitative real-time polymerase chain reaction in 81 cases of pediatric leukemia and 17 normal hematopoietic control cases.;All major subtypes of acute lymphoblastic leukemia, i.e. T-cell, MLL-rearranged, TEL-AML1-positive, E2A-PBX1-positive and hyperdiploid acute lymphoblastic leukemia, with the exception of BCR-ABL-positive and 'B-other' acute lymphoblastic leukemias (defined as precursor B-cell acute lymphoblastic leukemia not carrying the foregoing cytogenetic aberrations), were found to have unique microRNA-signatures that differed from each other and from those of healthy hematopoietic cells. Strikingly, the microRNA signature of TEL-AML1-positive and hyperdiploid cases partly overlapped, which may suggest a common underlying biology. Moreover, aberrant down-regulation of let-7b (~70-fold) in MLL-rearranged acute lymphoblastic leukemia was linked to up-regulation of oncoprotein c-Myc (P(FDR)<0.0001). Resistance to vincristine and daunorubicin was characterized by an approximately 20-fold up-regulation of miR-125b, miR-99a and miR-100 (P(FDR)0.002). No discriminative microRNA were found for prednisolone response and only one microRNA was linked to resistance to L-asparaginase. A combined expression profile based on 14 microRNA that were individually associated with prognosis, was highly predictive of clinical outcome in pediatric acute lymphoblastic leukemia (5-year disease-free survival of 89.4%7% versus 60.812%, P=0.001).;Genetic subtypes and drug-resistant leukemic cells display characteristic microRNA signatures in pediatric acute lymphoblastic leukemia. Functional studies of discriminative and prognostically important microRNA may provide new insights into the biology of pediatric acute lymphoblastic leukemia.",
        "Doc_title":"MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia.",
        "Journal":"Haematologica",
        "Do_id":"21242186",
        "Doc_ChemicalList":"Antineoplastic Agents;MicroRNAs;Vincristine;Asparaginase;Daunorubicin",
        "Doc_meshdescriptors":"Antineoplastic Agents;Asparaginase;Child;Cluster Analysis;Daunorubicin;Drug Resistance, Neoplasm;Gene Expression Profiling;Genetic Variation;Humans;MicroRNAs;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Prognosis;Vincristine",
        "Doc_meshqualifiers":"therapeutic use;therapeutic use;therapeutic use;genetics;genetics;classification;drug therapy;genetics;therapeutic use",
        "_version_":1605760724107264000},
      {
        "Doc_abstract":"Bcr-Abl-positive leukemias include chronic myelogenous leukemia (CML), both myeloid and lymphoid blast-phase CML, and some cases of acute lymphoblastic leukemia. The chimeric bcr-abl gene codes for a tyrosine kinase that is constitutively activated in the leukemic cells and plays the central role in leukemogenesis. Hematologic malignancies, including Bcr-Abl-positive leukemias, also frequently have overactivity of the Ras signaling pathway, leading to abnormal transduction of growth and survival signals. New and investigational therapeutic options that target these specific molecular defects of leukemic cells include the tyrosine kinase inhibitor imatinib mesylate (STI571) and farnesyltransferase inhibitors (R115777, SCH66336), which block localization of Ras proteins to the cell membrane. While single-agent therapy with these new agents may produce hematologic and cytogenetic remissions in patients with Bcr-Abl-positive leukemias, molecular remissions are less common, and resistance may develop. Therefore, the development of a multifaceted therapeutic approach to these leukemias is of great interest. Arsenic trioxide (ATO), which has significant activity in patients with relapsed and refractory acute promyelocytic leukemia, is a potential addition to the therapeutic arsenal. While some of the molecular activities of ATO are specific to acute promyelocytic leukemia, arsenicals also have a broad variety of antineoplastic properties that may be useful in combination therapy with agents that target specific molecular defects of Bcr-Abl-positive leukemias.",
        "Doc_title":"Multifaceted approach to the treatment of bcr-abl-positive leukemias.",
        "Journal":"The oncologist",
        "Do_id":"11961207",
        "Doc_ChemicalList":"Antineoplastic Agents;Arsenicals;Benzamides;Enzyme Inhibitors;Interferon-alpha;Oxides;Piperazines;Pyrimidines;Imatinib Mesylate;Alkyl and Aryl Transferases;Farnesyltranstransferase;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl;arsenic trioxide",
        "Doc_meshdescriptors":"Alkyl and Aryl Transferases;Antineoplastic Agents;Antineoplastic Combined Chemotherapy Protocols;Arsenicals;Benzamides;Enzyme Inhibitors;Farnesyltranstransferase;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Interferon-alpha;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Oxides;Piperazines;Protein-Tyrosine Kinases;Pyrimidines;Survival Analysis;Treatment Outcome",
        "Doc_meshqualifiers":"antagonists & inhibitors;therapeutic use;therapeutic use;administration & dosage;therapeutic use;metabolism;administration & dosage;drug therapy;enzymology;metabolism;administration & dosage;administration & dosage;antagonists & inhibitors;administration & dosage",
        "_version_":1605756126700240896},
      {
        "Doc_abstract":"In the present study, we analyzed the involvement of the BCR-ABL protein in the induction of antigen-specific CTL in order to develop an immunotherapeutic approach in patients with chronic myelogenous leukemia (CML). To accomplish this, we generated dendritic cells (DC) in vitro and electroporated them with various sources of RNA harboring the chimeric bcr-abl transcript. These genetically engineered DCs were used as antigen-presenting cells for the induction of CTLs. By applying this approach, we found that the CTLs induced by DCs transfected with RNA extracted from bcr-abl-positive K-562 cells or CML blasts lysed DCs transfected with the corresponding RNA, but failed to recognize epitopes derived from the chimeric BCR-ABL fusion protein in (51)Cr-release assays. In contrast, they were able to lyse autologous DCs electroporated with RNA isolated from patients with acute myeloid leukemia, indicating that antigens shared among these malignant cells are involved and recognized by these CTLs. In patients with CML in complete cytogenetic remission during IFN-alpha treatment, we detected some reactivity of CD8(+) T cells against BCR-ABL in IFN-gamma ELISPOT assays, which was weaker as compared with proteinase 3 (PR3)- or prame-directed responses, suggesting that the BCR-ABL protein is less immunogenic as compared with other CML-derived antigens.",
        "Doc_title":"BCR-ABL is not an immunodominant antigen in chronic myelogenous leukemia.",
        "Journal":"Cancer research",
        "Do_id":"16740729",
        "Doc_ChemicalList":"Immunodominant Epitopes;RNA, Neoplasm;Interferon-gamma;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"CD4-Positive T-Lymphocytes;CD8-Positive T-Lymphocytes;Dendritic Cells;Fusion Proteins, bcr-abl;Humans;Immunodominant Epitopes;Interferon-gamma;K562 Cells;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;RNA, Neoplasm;T-Lymphocytes, Cytotoxic;Transfection",
        "Doc_meshqualifiers":"immunology;physiology;immunology;secretion;immunology;physiology;genetics;immunology;genetics;immunology;secretion;genetics;immunology;genetics;immunology;immunology",
        "_version_":1605852517558648832},
      {
        "Doc_abstract":"To investigate the expression and regulation mechanism of mismatch repair (MMR) genes in chronic myeloid leukemia (CML).;Expression of MMR genes hMSH2, hMSH3, hMSH6, hMLH1 and hPMS2 mRNAs in 62 CML patients and K562 cell line were detected by semi-quantitative reverse transcription polymerase chain reaction (RT-PCR). Expression of bcr-abl mRNA and MMR genes mRNA were detected by RT-PCR in 26 CML patients with allogeneic peripheral blood stem cell transplantation (allo-PBSCT) and 4 CML patients on imatinib treatment. Expression of bcr-abl mRNA was detected by RT-PCR and tyrosine phosphorylation of BCR-ABL fusion protein by Western blot.;Expression of hMSH2, hMSH3 and hMLH1 mRNA was significantly lower in CML and K562 cells than in normal control (P < 0.05). In 26 CML with allo-PBSCT and 4 CML patients on imatinib treatment, expressions of hMSH2, hMSH3 and hMLH1 mRNA was enhanced while expression of bcr-abl mRNA decreased. In CML MNC after imatinib treatment and in K562 cells, expression of hMSH2, hMSH3 and hMLH1 mRNA was enhanced while tyrosine phosphorylation of BCR-ABL fusion protein decreased.;Expressions of hMSH2, hMSH3 and hMLH1 mRNA were down-regulated by bcr-abl fusion gene.",
        "Doc_title":"[Study on mismatch repair genes of chronic myeloid leukemia].",
        "Journal":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi",
        "Do_id":"16732964",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Pyrimidines;RNA, Messenger;Imatinib Mesylate;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adult;Aged;Antineoplastic Agents;Benzamides;DNA Mismatch Repair;Female;Fusion Proteins, bcr-abl;Gene Expression;Gene Expression Regulation, Neoplastic;Humans;Imatinib Mesylate;K562 Cells;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Piperazines;Pyrimidines;RNA, Messenger;Reverse Transcriptase Polymerase Chain Reaction",
        "Doc_meshqualifiers":"pharmacology;genetics;metabolism;genetics;pharmacology;pharmacology;genetics",
        "_version_":1605874518972170240},
      {
        "Doc_abstract":"In this chapter, we describe model systems to study leukemia driven by the Abelson oncogene. In people, the Abelson oncogene results from the chromosomal translocation t(9;22)(q34;q11) that is found in more than 90 % of all human chronic myeloid leukemia (CML) patients and in 20-25 % of patients suffering from acute lymphoid leukemia (ALL). This translocation is also called Philadelphia chromosome and encodes the BCR/ABL oncogene, a constitutive active tyrosine kinase. BCR/ABL renders hematopoietic cells independent from exogenous growth-stimulatory signals by continuously engaging signaling pathways including JAK-STAT signaling and the MAPK pathway. The enforced expression of BCR/ABL suffices to transform hematopoietic cells which made it to one of the best studied model systems in the field. Here we present methods to study BCR/ABL-triggered leukemia and solid lymphoid tumor formation. ",
        "Doc_title":"Modeling BCR/ABL-driven malignancies in the mouse.",
        "Journal":"Methods in molecular biology (Clifton, N.J.)",
        "Do_id":"25636473",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Animals;Animals, Newborn;Bone Marrow Transplantation;Cell Line, Tumor;Coculture Techniques;Disease Models, Animal;Female;Fusion Proteins, bcr-abl;Gene Deletion;Hematopoiesis;Humans;Leukemia, Lymphoid;Male;Mice;Pregnancy;Retroviridae;Species Specificity",
        "Doc_meshqualifiers":"genetics;genetics;pathology;surgery;genetics",
        "_version_":1605830851777527808},
      {
        "Doc_abstract":"Interphase fluorescence in situ hybridization (FISH) and real-time quantitative reverse transcription PCR (RQ-PCR) are the common methods for monitoring minimal residual disease (MRD) in chronic myeloid leukemia (CML) patients. This study was to assess the value of monitoring BCR-ABL fusion gene level in CML patients after allogeneic hematopoietic stem cell transplantation (allo-HSCT) using FISH and RQ-PCR.;BCR-ABL fusion gene levels were detected in the bone marrow of 31 patients with CML before and 3-48 months after allo-HSCT using FISH and RQ-PCR.;BCR-ABL positive cells detected by FISH were decreased 3-30 months after allo-HSCT and BCR-ABL/ABL mRNA was reduced by 2 logarithmic units in RQ-PCR (P < 0.05). While no BCR-ABL positive cell was detected by FISH 30 months after allo-HSCT, BCR-ABL/ABL mRNA was detected by RQ-PCR and declined by more than 3 logarithmic units, (P < 0.05).;Dynamic monitoring of BCR-ABL gene on molecular level in CML patients after allo-HSCT is useful in the early prediction of susceptibility to recurrence in the patients and in designing intervention, and is thus helpful in improving the overall survival rate after transplantation.",
        "Doc_title":"Minimal residual disease monitoring in chronic myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation using interphase fluorescence in situ hybridization and real-time quantitative reverse transcription PCR.",
        "Journal":"Chinese journal of cancer",
        "Do_id":"20109350",
        "Doc_ChemicalList":"RNA, Messenger;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adolescent;Adult;Child;Female;Fusion Proteins, bcr-abl;Hematopoietic Stem Cell Transplantation;Humans;In Situ Hybridization, Fluorescence;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Neoplasm, Residual;RNA, Messenger;Reverse Transcriptase Polymerase Chain Reaction;Young Adult",
        "Doc_meshqualifiers":"genetics;metabolism;metabolism;pathology;therapy;metabolism",
        "_version_":1605827173739921408},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) is a clonal disorder originating in the pluripotent hematopoietic stem cell (HSC), the hallmark of which is the constitutively activated p210-type of Bcr-Abl tyrosine kinase protein. Studies in recent years have helped us to understand the molecular processes involved in the initiation and progression of CML. Although a great amount of knowledge has been accumulated, the effect of Bcr-Abl on the HSC is still unclear. We have developed an in vitro system that mirrors the chronic phase of CML with a combination of in vitro embryonic stem cell differentiation and tetracycline-inducible Bcr-Abl expression. Enforced Bcr-Abl expression was sufficient to increase the number of both multilineage progenitors and myeloid progenitors. The current system is powerful for analyzing the genetic changes in hematopoietic development. This review focuses on how Bcr-Abl affects HSCs and how Bcr-Abl expression alters the properties of HSCs.",
        "Doc_title":"Bcr-Abl is a \"molecular switch\" for the decision for growth and differentiation in hematopoietic stem cells.",
        "Journal":"International journal of hematology",
        "Do_id":"12138893",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl;Tetracycline",
        "Doc_meshdescriptors":"Animals;Cell Differentiation;Cell Division;Fusion Proteins, bcr-abl;Gene Expression Regulation;Hematopoietic Stem Cells;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Tetracycline",
        "Doc_meshqualifiers":"drug effects;genetics;drug effects;genetics;biosynthesis;drug effects;cytology;metabolism;genetics;pharmacology",
        "_version_":1605836653101842432},
      {
        "Doc_abstract":"The human BCR-ABL oncogenes encoded by the Philadelphia chromosome (Ph) affect the pathogenesis of diverse types of leukemia and yet are rarely associated with T-lymphoid leukemia. To determine whether BCR-ABL kinases are inefficient in transforming T lymphocytes, BCR-ABL-expressing retroviruses were injected intrathymically into mice. Thymomas that expressed BCR-ABL kinase developed after a relatively long latent period. In most thymomas, deletion of 3' proviral sequences resulted in loss of tk-neo and occasionally caused expression of kinase-active carboxy-terminally truncated BCR-ABL oncoprotein. In contrast, deletion of 3' proviral sequences was not observed in thymomas induced with Abelson murine leukemia virus (A-MuLV). BCR-ABL viruses induced distinct patterns of disease and involved different thymocyte subsets than A-MuLV and Moloney murine leukemia virus (Mo-MuLV). While Mo-MuLV only induced Thy-1+ thymomas, v-abl- and BCR-ABL-induced thymomas often contained mixed populations of B220+ and Thy-1+ lymphocytes in the same tumor. In most v-abl and BCR-ABL tumors, Thy-1+ lymphoid cells expressed CD8 and a continuum of CD4 ranging from negative to positive. Conversely, Mo-MuLV thymomas contained distinct populations of CD4+ cells that were either CD8+ or CD8-. A-MuLV-transformed T-lymphoid cells did not express the CD3/T-cell receptor complex, while BCR-ABL tumors were CD3+. Thus, BCR-ABL viruses preferentially induce somewhat more differentiated T lymphocytes than are transformed by A-MuLV. Furthermore, rare B220+ lymphocytes may represent preferred v-abl and BCR-ABL transformation targets in the thymus.",
        "Doc_title":"BCR-ABL and v-abl oncogenes induce distinct patterns of thymic lymphoma involving different lymphocyte subsets.",
        "Journal":"Journal of virology",
        "Do_id":"8396667",
        "Doc_ChemicalList":"Antigens, CD;Antigens, CD3;Antigens, CD4;Antigens, CD8;Receptors, Antigen, T-Cell;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Animals;Antigens, CD;Antigens, CD3;Antigens, CD4;Antigens, CD8;Cell Transformation, Neoplastic;Flow Cytometry;Fusion Proteins, bcr-abl;Gene Deletion;Genes, Immunoglobulin;Genes, abl;Humans;Leukemia Virus, Murine;Mice;Oncogenes;Philadelphia Chromosome;Proviruses;Receptors, Antigen, T-Cell;Repetitive Sequences, Nucleic Acid;Restriction Mapping;Retroviridae;T-Lymphocyte Subsets;Thymoma;Thymus Neoplasms;Transcription, Genetic",
        "Doc_meshqualifiers":"analysis;analysis;analysis;analysis;genetics;genetics;genetics;genetics;genetics;immunology;physiology;genetics;microbiology;genetics;microbiology",
        "_version_":1605798054161547264},
      {
        "Doc_abstract":"Mutations within the ABL kinase domain and overexpression of SRC family kinases have been identified among the known mechanisms of resistance to imatinib in chronic myeloid leukemia (CML). The development of agents with dual inhibitory activity against SRC and ABL kinases is one approach to overcome imatinib resistance. One such agent, dasatinib (formerly BMS-354825), is approximately 300-fold more potent against BCR-ABL than imatinib, and is active against all tested ABL mutant isoforms, except for T315I. Dasatinib has demonstrated high efficacy in Phase I and II studies in patients with CML following failure of imatinib therapy. Studies exploring the efficacy of dasatinib as front-line therapy in patients with BCR-ABL-expressing hematologic malignancies are underway.",
        "Doc_title":"Targeting ABL and SRC kinases in chronic myeloid leukemia: experience with dasatinib.",
        "Journal":"Future oncology (London, England)",
        "Do_id":"17155893",
        "Doc_ChemicalList":"Benzamides;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Thiazoles;Imatinib Mesylate;Fusion Proteins, bcr-abl;src-Family Kinases;Dasatinib",
        "Doc_meshdescriptors":"Benzamides;Dasatinib;Drug Resistance, Neoplasm;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Thiazoles;src-Family Kinases",
        "Doc_meshqualifiers":"drug effects;drug therapy;pharmacology;pharmacology;therapeutic use;pharmacology;therapeutic use;pharmacology;therapeutic use;drug effects",
        "_version_":1605746386505039872},
      {
        "Doc_abstract":"The Philadelphia (Ph1) chromosome, the cytogenetic hallmark of chronic myeloid leukemia (CML), has also been detected in a significant number of acute lymphoblastic leukemias (ALL). Using in situ hybridization, we demonstrate that in accordance with observations in CML the Ph1 chromosome in ALL patients is the result of a consistent translocation of the c-abl oncogene to the Ph1 chromosome. Southern blot analysis using bcr probes, however, suggests that Ph1-positive ALL includes heterogeneous leukemic subtypes: six ALL patients showed bcr rearrangements as observed in CML; in three other patients recombination involving 5' bcr sequences could be demonstrated, but the corresponding translocated 3' bcr sequences were not detectable. A third group of five patients did not show any bcr rearrangements at all. Northern blot analysis using RNA from three Ph1-positive ALL patients revealed that in the leukemic cells of two patients larger c-abl mRNA transcripts were present, as in CML. In the RNA of one patient without a detectable bcr rearrangement, only the normal c-abl mRNA transcripts are present. The observed heterogeneity in bcr rearrangements of this group of Ph1-positive ALL patients is in contrast with the consistent results obtained in more than 50 Ph1-positive CML patients investigated in chronic and acute states.",
        "Doc_title":"bcr rearrangement and translocation of the c-abl oncogene in Philadelphia positive acute lymphoblastic leukemia.",
        "Journal":"Blood",
        "Do_id":"3465378",
        "Doc_ChemicalList":"DNA, Neoplasm;RNA, Messenger;RNA, Neoplasm",
        "Doc_meshdescriptors":"Chromosome Deletion;Chromosome Mapping;Chromosomes, Human, Pair 22;Chromosomes, Human, Pair 9;DNA, Neoplasm;Genes;Humans;Leukemia, Lymphoid;Philadelphia Chromosome;Proto-Oncogenes;RNA, Messenger;RNA, Neoplasm;Transcription, Genetic;Translocation, Genetic",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics",
        "_version_":1605797977098551296},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) is caused by Bcr-Abl, an activated tyrosine kinase. The amounts of Bcr-Abl mRNA and protein in cells from patients in blast crisis (BC) are higher than in those chronic phase (CP), indicating that their expression rises with disease progression. In order to study this phenomenon on cells with the same genetic background, we transfected the 32D cell line with the BCR-ABL transgene and selected clones with graded expression of Bcr-Abl within the range found in cells from CP to BC. In vitro, we found that Bcr-Abl exerted dose-dependent effects upon growth factor dependence, clonogenicity and migration. However, the relationship between Bcr-Abl expression and cellular adhesion to fibronectin was more complex: rather than a direct positive correlation, clones that expressed low, but not high, levels of Bcr-Abl were less adhesive than growth factor stimulated, parental BCR-ABL-negative 32D cells. This finding parallels the situation with normal and CML-CP progenitors where the latter exhibit defective adhesion to fibronectin. Treatment with the tyrosine kinase inhibitor imatinib mesylate reversed the adhesion deficient phenotype of clones expressing low levels of Bcr-Abl. When injected subcutaneously into syngeneic mice, cell lines expressing high levels of Bcr-Abl rapidly induced tumors, whereas low-expressing clones led to tumor formation only after a prolonged latency. These findings suggest that the level of Bcr-Abl may be essential in determining the phenotype of the leukemic clone at different stages of the disease.",
        "Doc_title":"Dose-dependent effects of Bcr-Abl in cell line models of different stages of chronic myeloid leukemia.",
        "Journal":"Oncogene",
        "Do_id":"16007188",
        "Doc_ChemicalList":"RNA, Messenger",
        "Doc_meshdescriptors":"Animals;Cell Line, Tumor;Dose-Response Relationship, Drug;Female;Genes, abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Mice;Mice, Inbred C3H;Models, Biological;RNA, Messenger",
        "Doc_meshqualifiers":"genetics;genetics;pathology;genetics",
        "_version_":1605876289318682624},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) is characterized by a genomic translocation generating a permanently active BCR-ABL oncogene with a complex pattern of atypically tyrosine-phosphorylated proteins that drive the malignant phenotype of CML. Recently, the LIM and SH3 domain protein 1 (LASP1) was identified as a component of a six gene signature that is strongly predictive for disease progression and relapse in CML patients. However, the underlying mechanisms why LASP1 expression correlates with dismal outcome remained unresolved. Here, we identified LASP1 as a novel and overexpressed direct substrate of BCR-ABL in CML. We demonstrate that LASP1 is specifically phosphorylated by BCR-ABL at tyrosine-171 in CML patients, which is abolished by tyrosine kinase inhibitor therapy. Further studies revealed that LASP1 phosphorylation results in an association with CRKL - another specific BCR-ABL substrate and bona fide biomarker for BCR-ABL activity. pLASP1-Y171 binds to non-phosphorylated CRKL at its SH2 domain. Accordingly, the BCR-ABL-mediated pathophysiological hyper-phosphorylation of LASP1 in CML disrupts normal regulation of CRKL and LASP1, which likely has implications on downstream BCR-ABL signaling. Collectively, our results suggest that LASP1 phosphorylation might serve as an additional candidate biomarker for assessment of BCR-ABL activity and provide a first step toward a molecular understanding of LASP1 function in CML.",
        "Doc_title":"LASP1 is a novel BCR-ABL substrate and a phosphorylation-dependent binding partner of CRKL in chronic myeloid leukemia.",
        "Journal":"Oncotarget",
        "Do_id":"24913448",
        "Doc_ChemicalList":"Adaptor Proteins, Signal Transducing;CRKL protein;Cytoskeletal Proteins;LASP1 protein, human;LIM Domain Proteins;Nuclear Proteins;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adaptor Proteins, Signal Transducing;Adult;Cytoskeletal Proteins;Female;Fusion Proteins, bcr-abl;Humans;LIM Domain Proteins;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Neoplasm Recurrence, Local;Nuclear Proteins;Phosphorylation;Signal Transduction;Tumor Cells, Cultured;Young Adult",
        "Doc_meshqualifiers":"metabolism;metabolism;metabolism;metabolism;metabolism;metabolism;metabolism",
        "_version_":1605761752603033600},
      {
        "Doc_abstract":"Residual leukemia was evaluated in autologous bone marrow grafts harvested in first (n = 11) or second (n = 3) complete remission from 14 patients with BCR-ABL-positive acute lymphoblastic leukemia after treatment according to the German multicenter ALL protocols. The intervals from diagnosis to BM harvest were median 159 (range 78-463) and from preceding chemotherapy to BM harvest median 39 (range 26-69) days, respectively. A limiting log(10)-dilution RT-PCR was used to semiquantify BCR-ABL-positive cells. All autografts appeared to be significantly contaminated with residual leukemic cells. The BCR-ABL-specific titers ranged from 1:10(3) to 1:10(6) (median 1:10(4)) above the limit of detection. This was the rationale to purge the grafts using two cycles of IgM anti-CD10, CD19, and AB4 MoAbs-coated immunomagnetic beads (IMB). Purging depleted median 3 (range 2-4) logs of residual leukemia, resulting in a median 1:10(1) (range 1:10(0) to 1:10(3)) postpurge BCR-ABL-specific titer. The second purging cycle accounted for 1 log of depletion. The mean +/- s.e.m. post-purge recoveries of MNC and CFU-GM were 59 +/- 4%, and 61 +/- 9%, respectively. We conclude that all BCR-ABL-positive ALL patients achieving CR by cytological criteria have critically high levels of residual leukemia in their bone marrow, which can be reduced by median 3 log using immunomagnetic bead purging.",
        "Doc_title":"Residual leukemia and immunomagnetic bead purging in patients with BCR-ABL-positive acute lymphoblastic leukemia.",
        "Journal":"Bone marrow transplantation",
        "Do_id":"8879615",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adolescent;Adult;Bone Marrow Purging;Bone Marrow Transplantation;Child;Female;Fusion Proteins, bcr-abl;Humans;Immunomagnetic Separation;Male;Middle Aged;Neoplasm, Residual;Polymerase Chain Reaction;Precursor Cell Lymphoblastic Leukemia-Lymphoma",
        "Doc_meshqualifiers":"analysis;therapy",
        "_version_":1605746475984224257},
      {
        "Doc_abstract":"MK-0457 (VX-680) is a small-molecule aurora kinase (AK) inhibitor with preclinical antileukemia activity. The T315I BCR-ABL mutation mediates resistance to imatinib, nilotinib, and dasatinib. MK-0457 has in vitro activity against cells expressing wild-type or mutated BCR-ABL, including the T315I BCR-ABL mutation. Three patients with T315I abl-mutated chronic myeloid leukemia (CML) or Philadelphia chromosome (Ph)-positive acute lymphocytic leukemia (ALL) have achieved clinical responses to doses of MK-04547 that are not associated with adverse events. Higher MK-0457 dose levels were associated with clinical responses and down-regulation of CrkL phosphorylation in leukemia cells. The possible role of AK inhibition in these clinical responses requires further investigation. The currently reported cases are the first observed clinical activity of a kinase inhibitor against the T315I phenotype. The observation of responses in 3 patients with T315I phenotype-refractory CML or Ph-positive ALL, at doses of MK-0457 associated with no significant extramedullary toxicity, is very encouraging.",
        "Doc_title":"MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation.",
        "Journal":"Blood",
        "Do_id":"16990603",
        "Doc_ChemicalList":"Adaptor Proteins, Signal Transducing;CRKL protein;Nuclear Proteins;Piperazines;Protein Kinase Inhibitors;VX680;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adaptor Proteins, Signal Transducing;Adult;Dose-Response Relationship, Drug;Down-Regulation;Female;Fusion Proteins, bcr-abl;Humans;Infusions, Intravenous;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Maximum Tolerated Dose;Middle Aged;Mutation;Nuclear Proteins;Phenotype;Phosphorylation;Piperazines;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Protein Kinase Inhibitors;Treatment Outcome",
        "Doc_meshqualifiers":"drug effects;metabolism;drug effects;drug effects;genetics;diagnosis;drug therapy;genetics;drug effects;metabolism;administration & dosage;adverse effects;therapeutic use;diagnosis;drug therapy;genetics;administration & dosage;adverse effects;therapeutic use",
        "_version_":1605799764766490624},
      {
        "Doc_abstract":"Previous studies have shown that patients with Bcr-Abl-positive acute lymphoblastic leukemia (ALL) either have primary disease that is refractory to imatinib mesylate or develop disease recurrence after an initial response.;The authors investigated the effects of a newly designed Bcr-Abl inhibitor, AMN107, by comparing its in vitro inhibitory potency on p190 Bcr-Abl ALL cell lines with that of imatinib.;In two Philadelphia (Ph)-positive ALL cell lines, AMN107 was found to be 30-40 times more potent than imatinib in inhibiting cellular proliferation. AMN107 was also more effective than imatinib in inhibiting phosphorylation of p190 Bcr-Abl tyrosine kinase in cell lines and primary ALL cells. The inhibition of cellular proliferation was associated with the induction of apoptosis in only one of the cell lines. No activity was observed in cell lines lacking the BCR-ABL genotype.;The results of the current study suggest the superior potency of AMN107 compared with imatinib in Ph-positive ALL and support clinical trials of AMN107 in patients with Ph-positive ALL.",
        "Doc_title":"AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells.",
        "Journal":"Cancer",
        "Do_id":"16078266",
        "Doc_ChemicalList":"4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide;Antineoplastic Agents;Benzamides;Piperazines;Pyrimidines;Imatinib Mesylate;Fusion Proteins, bcr-abl;CASP3 protein, human;Caspase 3;Caspases",
        "Doc_meshdescriptors":"Antineoplastic Agents;Apoptosis;Benzamides;Caspase 3;Caspases;Cell Cycle;Cell Line, Tumor;Cell Proliferation;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Phosphorylation;Piperazines;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Pyrimidines",
        "Doc_meshqualifiers":"pharmacology;drug effects;metabolism;drug effects;drug effects;antagonists & inhibitors;metabolism;pharmacology;drug therapy;pathology;pharmacology",
        "_version_":1605924430141194240},
      {
        "Doc_abstract":"Resistance to the ABL kinase inhibitor imatinib (STI571 or Gleevec) in chronic myeloid leukemia (CML) occurs through selection for tumor cells harboring BCR-ABL kinase domain point mutations that interfere with drug binding. Crystallographic studies predict that most imatinib-resistant mutants should remain sensitive to inhibitors that bind ABL with less stringent conformational requirements. BMS-354825 is an orally bioavailable ABL kinase inhibitor with two-log increased potency relative to imatinib that retains activity against 14 of 15 imatinib-resistant BCR-ABL mutants. BMS-354825 prolongs survival of mice with BCR-ABL-driven disease and inhibits proliferation of BCR-ABL-positive bone marrow progenitor cells from patients with imatinib-sensitive and imatinib-resistant CML. These data illustrate how molecular insight into kinase inhibitor resistance can guide the design of second-generation targeted therapies.",
        "Doc_title":"Overriding imatinib resistance with a novel ABL kinase inhibitor.",
        "Journal":"Science (New York, N.Y.)",
        "Do_id":"15256671",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Enzyme Inhibitors;Piperazines;Pyrimidines;Thiazoles;abl-bcr fusion protein, human;Imatinib Mesylate;Fusion Proteins, bcr-abl;Dasatinib",
        "Doc_meshdescriptors":"Amino Acid Substitution;Animals;Antineoplastic Agents;Benzamides;Binding Sites;Cell Division;Cell Line;Clinical Trials, Phase I as Topic;Dasatinib;Drug Resistance, Neoplasm;Enzyme Inhibitors;Fusion Proteins, bcr-abl;Hematopoietic Stem Cells;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mice;Mice, SCID;Mutation;Piperazines;Protein Conformation;Pyrimidines;Thiazoles;Transfection",
        "Doc_meshqualifiers":"metabolism;pharmacology;therapeutic use;drug effects;metabolism;pharmacology;therapeutic use;antagonists & inhibitors;chemistry;genetics;metabolism;drug effects;drug therapy;pharmacology;therapeutic use;metabolism;pharmacology;therapeutic use;metabolism;pharmacology;therapeutic use",
        "_version_":1605758613744254976},
      {
        "Doc_abstract":"The evidence that the bcr-abl gene product (P210) of the Philadelphia chromosome plays a crucial role in the pathogenesis of chronic myeloid leukemia (CML), and the absence of the bcr-abl fused transcript in non-malignant cells makes this messenger RNA an ideal candidate for antisense strategies in CML. To inhibit the expression of the bcr-abl gene, and to try to eradicate Philadelphia-positive cells, different methods can be used: 1) the introduction into the cells of antisense oligonucleotides, 2) the use of specific ribozymes, or 3) the transduction, using retroviral vectors, of stably integrated sequences coding for antisense RNA. Each of these approaches has potential advantages and drawbacks that are discussed below. Although many data emerge that support the use of anti-bcr-abl antisense molecules in CML, numerous questions remain to be completely answered before the most efficient strategy can be designed, either for in vitro or in vivo purposes.",
        "Doc_title":"Antisense inhibition of P210 bcr-abl in chronic myeloid leukemia.",
        "Journal":"Stem cells (Dayton, Ohio)",
        "Do_id":"8298481",
        "Doc_ChemicalList":"Oligonucleotides, Antisense;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Animals;Fusion Proteins, bcr-abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Oligonucleotides, Antisense",
        "Doc_meshqualifiers":"antagonists & inhibitors;genetics;physiology;etiology;genetics;pharmacology",
        "_version_":1605883955096059904},
      {
        "Doc_abstract":"The BCR-ABL K247R change is based on a rare single nucleotide polymorphism occurring likewise in healthy controls and non-hematologic cell types. Despite its juxtaposition to the P-loop, functional analysis showed no alteration compared to non-mutated BCR-ABL. We sought to investigate if other changes in the BCR-ABL kinase domain should be considered as single nucleotide polymorphisms rather than acquired mutations. A total of 911 chronic myeloid leukemia patients after failure or suboptimal response to imatinib were screened for BCR-ABL kinase domain mutations. Single nucleotide polymorphism analysis was based on the search for nucleotide changes in corresponding normal, non-translocated ABL alleles by ABL allele-specific PCR following mutation analysis. In addition to the K247R polymorphism we uncovered five new single nucleotide polymorphisms within the BCR-ABL kinase domain; two of them led to amino acid changes. Single nucleotide polymorphisms could theoretically contribute to primary but not to secondary resistance to tyrosine kinase inhibitors and must therefore be distinguished from acquired mutations. Novel point mutations should be confirmed by analyzing the normal ABL alleles to exclude polymorphisms.",
        "Doc_title":"ABL single nucleotide polymorphisms may masquerade as BCR-ABL mutations associated with resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia.",
        "Journal":"Haematologica",
        "Do_id":"18603549",
        "Doc_ChemicalList":"Protein Kinase Inhibitors;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Aged, 80 and over;Alleles;Base Sequence;Chronic Disease;Drug Resistance, Neoplasm;Female;Fusion Proteins, bcr-abl;Humans;Leukemia, Myeloid;Male;Middle Aged;Mutation;Polymorphism, Single Nucleotide;Protein Kinase Inhibitors;Protein-Tyrosine Kinases;Sequence Analysis",
        "Doc_meshqualifiers":"drug effects;genetics;drug therapy;genetics;genetics;genetics;therapeutic use;antagonists & inhibitors;metabolism",
        "_version_":1605851161590497281},
      {
        "Doc_abstract":"Chromosomal abnormalities of bone marrow cells in dynamic chronic myeloid leukemia (CML) with bcr-abl-tyrosinkinase inhibitor (400 mg/m2) in 34 children and adolescent were estimated. Appearence of additional chromosomal abnormalities such as del(16)(q22), del(11)(q23), del(6) (q23), del(21)(q12), trisomy chromosome 8, additional neartetraploid clones were evidence about tumor cells resistence to therapy in children and adolescent.",
        "Doc_title":"[Additional chromosomal abnormalities in dynamic of target therapy for chronic myeloid leukemia in children and adolescents].",
        "Journal":"Likars'ka sprava",
        "Do_id":"24908961",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Pyrimidines;Imatinib Mesylate;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adolescent;Antineoplastic Agents;Benzamides;Bone Marrow Cells;Child;Child, Preschool;Chromosome Aberrations;Cytogenetic Analysis;Drug Resistance, Neoplasm;Female;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Infant;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Piperazines;Predictive Value of Tests;Prognosis;Pyrimidines",
        "Doc_meshqualifiers":"administration & dosage;adverse effects;therapeutic use;administration & dosage;adverse effects;therapeutic use;drug effects;enzymology;chemically induced;statistics & numerical data;genetics;antagonists & inhibitors;genetics;drug therapy;enzymology;epidemiology;administration & dosage;adverse effects;therapeutic use;administration & dosage;adverse effects;therapeutic use",
        "_version_":1605804305172922368},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) is characterized by a constitutive activation of Bcr-Abl tyrosine kinase. Bcr-Abl/T315I is the predominant mutation that causes resistance to Imatinib. In the present study, we synthesized a novel Bcr-Abl inhibitor, HS-543, and investigated its effect on cell survival or apoptosis in CML cells bearing Bcr-Abl/T315I (BaF3/T315I) or wild-type Bcr-Abl (BaF3/WT). HS-543 showed anti-proliferative effects in the BaF3/WT cells as well as the BaF3/T315I cells with resistance to Imatinib and strongly inhibited the Bcr-Abl signaling pathway in a dose-dependent manner. Furthermore, it significantly increased the sub G1 phase associated with early apoptosis, with increased levels of cleaved PARP and cleaved caspase-3, as well as the TUNEL-positive apoptotic cells. In addition, we found that HS-543 induced apoptosis with the loss of mitochondrial membrane potential by decreasing the expression of Mcl-1 and survivin, together with increasing that of Bax. In BaF3/T315I xenograft models, HS-543 significantly delayed tumor growth, unlike Imatinib. Our results demonstrate that HS-543 exhibits the induction of apoptosis and anti-proliferative effect by blocking the Bcr-Abl signaling pathway in the T315I-mutated Bcr-Abl cells with resistance to Imatinib. We suggest that HS-543 may be a novel promising agent to target Bcr-Abl and overcome Imatinib resistance in CML patients. ",
        "Doc_title":"HS-543 induces apoptosis of Imatinib-resistant chronic myelogenous leukemia with T315I mutation.",
        "Journal":"Oncotarget",
        "Do_id":"25483100",
        "Doc_ChemicalList":"Antineoplastic Agents;BCR-ABL1 fusion protein, human;Piperazines;Imatinib Mesylate;Urea;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Animals;Antineoplastic Agents;Apoptosis;Cell Line, Tumor;Cell Proliferation;Drug Resistance, Neoplasm;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Mice;Mice, Inbred BALB C;Mice, Nude;Models, Molecular;Mutation;Piperazines;Random Allocation;Signal Transduction;Urea;Xenograft Model Antitumor Assays",
        "Doc_meshqualifiers":"pharmacology;drug effects;drug effects;antagonists & inhibitors;genetics;metabolism;pharmacology;drug therapy;genetics;metabolism;pathology;pharmacology;analogs & derivatives;pharmacology",
        "_version_":1605749444330913792},
      {
        "Doc_abstract":"Resistance to the BCR-ABL inhibitor imatinib mesylate (IM) poses a major problem for the treatment of chronic myeloid leukemia (CML). IM resistance often results from a secondary mutation in BCR-ABL that interferes with drug binding. However, in many instances, there is no mutation in BCR-ABL, and the basis of such BCR-ABL-independent IM resistance remains to be elucidated. To gain insight into BCR-ABL-independent IM resistance mechanisms, we performed a large-scale RNA interference screen and identified IM-sensitizing genes (IMSGs) whose knockdown renders BCR-ABL(+) cells IM-resistant. In these IMSG knockdown cells, RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) signaling is sustained after IM treatment because of up-regulation of PRKCH, which encodes the protein kinase C (PKC) family member PKC, an activator of CRAF. PRKCH is also up-regulated in samples from CML patients with BCR-ABL-independent IM resistance. Combined treatment with IM and trametinib, a U.S. Food and Drug Administration-approved MEK inhibitor, synergistically kills BCR-ABL(+) IMSG knockdown cells and prolongs survival in mouse models of BCR-ABL-independent IM-resistant CML. Finally, we showed that CML stem cells contain high levels of PRKCH, and this contributes to their intrinsic IM resistance. Combined treatment with IM and trametinib synergistically kills CML stem cells with negligible effect on normal hematopoietic stem cells. Collectively, our results identify a therapeutically targetable mechanism of BCR-ABL-independent IM resistance in CML and CML stem cells. ",
        "Doc_title":"A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia.",
        "Journal":"Science translational medicine",
        "Do_id":"25186176",
        "Doc_ChemicalList":"Benzamides;Piperazines;Protein Kinase Inhibitors;Pyrimidines;RNA, Small Interfering;Imatinib Mesylate;protein kinase C eta;Fusion Proteins, bcr-abl;raf Kinases;Protein Kinase C;Extracellular Signal-Regulated MAP Kinases;Mitogen-Activated Protein Kinase Kinases",
        "Doc_meshdescriptors":"Animals;Benzamides;Cell Line, Tumor;Cell Proliferation;Disease Models, Animal;Disease Progression;Drug Resistance, Neoplasm;Extracellular Signal-Regulated MAP Kinases;Fusion Proteins, bcr-abl;Gene Knockdown Techniques;Genes, Neoplasm;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mice;Mitogen-Activated Protein Kinase Kinases;Molecular Targeted Therapy;Neoplastic Stem Cells;Phosphorylation;Piperazines;Protein Kinase C;Protein Kinase Inhibitors;Pyrimidines;RNA, Small Interfering;Survival Analysis;Up-Regulation;raf Kinases",
        "Doc_meshqualifiers":"pharmacology;therapeutic use;drug effects;drug effects;metabolism;metabolism;drug therapy;genetics;metabolism;drug effects;pathology;drug effects;pharmacology;therapeutic use;metabolism;pharmacology;pharmacology;therapeutic use;metabolism;drug effects;metabolism",
        "_version_":1605802355637354496},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) is characterized by a reciprocal chromosomal translocation between chromosomes 9 and 22 t(9;22)(q34;q11) that causes fusion of the bcr and abl genes. Transcription and splicing of the fusion gene generate two major splice variants of the bcr/abl transcript that encode an oncoprotein with tyrosine kinase activity. We have taken advantage of lentiviral vectormediated delivery of anti-bcr/abl short hairpin RNAs (shRNA) to downregulate the bcr/abl transcript in Philadelphia chromosome-positive (Ph+) K562 leukemia cells. This downregulation caused complete inhibition of proliferation of these cells and was accompanied by >90% inhibition of the bcr/abl transcript and p210 protein. These results demonstrate the feasibility of using a lentiviral vector to stably transduce therapeutic shRNAs into leukemia cells for the potential ex vivo purging of Ph+ cells in an autologous hematopoietic cell transplant setting. Furthermore, the robust expression of the shRNAs from our lentiviral vector suggests that this system could be generally useful for the expression of other shRNAs.",
        "Doc_title":"Specific killing of Ph+ chronic myeloid leukemia cells by a lentiviral vector-delivered anti-bcr/abl small hairpin RNA.",
        "Journal":"Oligonucleotides",
        "Do_id":"15000831",
        "Doc_ChemicalList":"RNA, Messenger;RNA, Small Interfering;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Base Sequence;Cell Division;Fusion Proteins, bcr-abl;Gene Expression Regulation, Neoplastic;Gene Silencing;Genetic Vectors;Humans;K562 Cells;Lentivirus;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Philadelphia Chromosome;Plasmids;RNA, Messenger;RNA, Small Interfering;Reverse Transcriptase Polymerase Chain Reaction",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;pathology;genetics;genetics;genetics",
        "_version_":1605746437550768128},
      {
        "Doc_abstract":"Imatinib mesylate (IM) is a tyrosine kinase inhibitor selective for BCR-ABL and indicated for the treatment of chronic myeloid leukemia. It has recently been demonstrated that IM also targets other cellular components. Considering the significant role of telomerase in malignant transformation, we studied the effect of IM on telomerase activity (TA) and regulation in BCR-ABL-positive and -negative cells, sensitive and resistant to IM.;Through combining telomeric repeat amplification protocol for detecting TA, reverse transcription polymerase chain reaction and Western blots for detecting RNA and protein levels of telomerase regulating proteins and fluorescence-activated cell sorting analysis, we showed that IM targets telomerase and the signal transduction cascade upstream of it.;IM significantly inhibited TA in BCR-ABL-positive and -negative cells and in chronic myeloid leukemia patients. TA inhibition was also observed in BCR-ABL positive cells resistant to IM at drug concentrations that did not lead to a reduction in BCR-ABL expression. In addition, a reduction in phosphorylated AKT and phosphorylated PDK-1 was also detected following IM incubation.;We demonstrate an inhibitory effect of IM on TA and on the AKT/PDK pathway. Because this effect was observed in cell expressing the BCR-ABL protein as well as cells not expressing it, and in cells sensitive as well as resistant to IM, it is reasonable to assume that the inhibitory effect of IM on TA is not mediated through known IM targets. The results of this study show that cells resistant to IM with regard to its effect on BCR-ABL could still be sensitive to IM treatment regarding other cellular components.",
        "Doc_title":"Effect of imatinib on the signal transduction cascade regulating telomerase activity in K562 (BCR-ABL-positive) cells sensitive and resistant to imatinib.",
        "Journal":"Experimental hematology",
        "Do_id":"19837126",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;DNA Primers;Piperazines;Pyrimidines;Imatinib Mesylate;Phosphatidylinositol 3-Kinases;Telomerase",
        "Doc_meshdescriptors":"Antineoplastic Agents;Base Sequence;Benzamides;Blotting, Western;Cell Cycle;Cell Division;DNA Primers;Genes, abl;Humans;Imatinib Mesylate;K562 Cells;Leukemia, Erythroblastic, Acute;Phosphatidylinositol 3-Kinases;Piperazines;Pyrimidines;Reverse Transcriptase Polymerase Chain Reaction;Signal Transduction;Telomerase",
        "Doc_meshqualifiers":"pharmacology;drug effects;drug effects;enzymology;pathology;metabolism;pharmacology;pharmacology;drug effects;antagonists & inhibitors",
        "_version_":1605762376681914368},
      {
        "Doc_abstract":"Inhibition of BCR-ABL tyrosine kinase with imatinib represents a major breakthrough in the treatment of patients with chronic myeloid leukemia (CML). However, resistance to imatinib develops frequently, particularly in late-stage disease. To identify new cellular BCR-ABL downstream targets, we analyzed differences in global protein expression in BCR-ABL-positive K562 cells treated with or without imatinib in vitro. Among the 19 proteins found to be differentially expressed, we detected the down-regulation of eukaryotic initiation factor 5A (eIF5A), a protein essential for cell proliferation. eIF5A represents the only known eukaryotic protein activated by posttranslational hypusination. Hypusination inhibitors (HIs) alone exerted an antiproliferative effect on BCR-ABL-positive and -negative leukemia cell lines in vitro. However, the synergistic dose-response relationship found for the combination of imatinib and HI was restricted to Bcr-Abl-positive cells. Furthermore, this synergistic effect was confirmed by cytotoxicity assays, cell-cycle analysis, and CFSE labeling of primary CD34+ CML cells. Specificity of this effect could be demonstrated by cotreatment of K562 cells with imatinib and siRNA against eIF5. In conclusion, through a comparative proteomics approach and further functional analysis, we identified the inhibition of eIF5A hypusination as a promising new approach for combination therapy in BCR-ABL-positive leukemias.",
        "Doc_title":"Hypusination of eukaryotic initiation factor 5A (eIF5A): a novel therapeutic target in BCR-ABL-positive leukemias identified by a proteomics approach.",
        "Journal":"Blood",
        "Do_id":"17008552",
        "Doc_ChemicalList":"Benzamides;Peptide Initiation Factors;Piperazines;Pyrimidines;RNA-Binding Proteins;eukaryotic translation initiation factor 5A;hypusine;Imatinib Mesylate;Fusion Proteins, bcr-abl;Lysine",
        "Doc_meshdescriptors":"Antineoplastic Combined Chemotherapy Protocols;Benzamides;Cell Proliferation;Down-Regulation;Drug Delivery Systems;Drug Synergism;Fusion Proteins, bcr-abl;Gene Expression Regulation, Leukemic;Humans;Imatinib Mesylate;K562 Cells;Leukemia;Lysine;Peptide Initiation Factors;Piperazines;Protein Processing, Post-Translational;Proteomics;Pyrimidines;RNA-Binding Proteins",
        "Doc_meshqualifiers":"pharmacology;drug effects;genetics;drug therapy;pathology;analogs & derivatives;antagonists & inhibitors;metabolism;genetics;metabolism;pharmacology;methods;pharmacology;genetics;metabolism",
        "_version_":1605774988771590144},
      {
        "Doc_abstract":"Detailed information on the crystal structure of the pharmacologically targeted domains of the BCR-ABL molecule and on its intracellular signaling, which are potentially involved in growth, anti-apoptosis, metabolism and stemness, has made the study of chronic myeloid leukemia the most successful field in tumor biology. However, we now face the issue of drug resistance due to deregulation in the quality control of both DNA and protein. BCR-ABL is basically a misfolded protein with intrinsically disordered regions, which not only produces endoplasmic reticulum stress followed by unfolded protein response in some settings, but also conformational plasticity that may affect the structure of the whole molecule. The intercellular signaling derived from the leukemic cell microenvironment may influence the intracellular responses that take place in a manner both dependent on and independent of BCR-ABL tyrosine kinase activity.",
        "Doc_title":"Molecular biology of chronic myeloid leukemia.",
        "Journal":"Cancer science",
        "Do_id":"22632137",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Animals;Fusion Proteins, bcr-abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mutation;Neoplastic Stem Cells;Phenotype;Protein Conformation;Protein Processing, Post-Translational;Signal Transduction;Tumor Microenvironment",
        "Doc_meshqualifiers":"chemistry;genetics;metabolism;genetics;metabolism;metabolism",
        "_version_":1605747549864460289},
      {
        "Doc_abstract":"Breakpoint cluster region Abelson (Bcr-Abl) tyrosine kinase (TK) is a constitutively activated cytoplasmic TK and is the underlying cause of chronic myeloid leukemia (CML). To date, imatinib represents the frontline treatment for CML therapy. The development of resistance has prompted the search for novel Bcr-Abl inhibitors.;This review presents a short overview of drugs already approved for CML therapy and of the compounds that are in clinical trials. The body of the article deals with Bcr-Abl inhibitors patented since 2008, focusing on their chemical features.;The search for Bcr-Abl inhibitors is very active. We believe that a number of patented compounds could enter clinical trials and some could be approved for CML therapy in the next few years. Overall, Bcr-Abl inhibitors constitute a very appealing research field that can be expected to expand further.",
        "Doc_title":"Bcr-Abl tyrosine kinase inhibitors: a patent review.",
        "Journal":"Expert opinion on therapeutic patents",
        "Do_id":"25656651",
        "Doc_ChemicalList":"Antineoplastic Agents;Protein Kinase Inhibitors;Imatinib Mesylate;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Animals;Antineoplastic Agents;Drug Design;Drug Resistance, Neoplasm;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Patents as Topic;Protein Kinase Inhibitors",
        "Doc_meshqualifiers":"pharmacology;antagonists & inhibitors;metabolism;drug therapy;enzymology;pharmacology",
        "_version_":1605742666093428738},
      {
        "Doc_abstract":"Real-time quantitative polymerase chain reaction (RQ-PCR) has been widely used for molecular monitoring for patients with chronic myeloid leukemia (CML). Currently, RQ-PCR is not based on the concept of international scale (IS) in Japan; mainly because none of the domestic laboratories have obtained their own conversion factor (CF) which makes it possible to convert locally scaled BCR-ABL (BCR-ABL (L)) value to the IS (BCR-ABL (IS)). To join the global trend of molecular assessment of BCR-ABL in CML patients, we have tried to obtain a CF in Japan.;Samples from 55 patients were exchanged between the Japanese laboratory and the reference laboratory in Adelaide, and BCR-ABL and internal control gene transcripts of the samples were measured using RQ-PCR. The patient bias conversion method was used to determine the CF for the IS using the Bland and Altman method.;The local CF in the Japanese laboratory was determined to be 0.87. Based on this CF, 0.1% BCR-ABL (IS), defined as major molecular response, becomes equivalent to 731 copy/g RNA BCR-ABL (L).;This study is the first to introduce a laboratory-specific CF for harmonizing RQ-PCR methodology for detecting BCR-ABL transcripts to Japan, which may open new windows for molecular assessment of CML patients in Japan.",
        "Doc_title":"Harmonization of molecular monitoring of chronic myeloid leukemia therapy in Japan.",
        "Journal":"International journal of clinical oncology",
        "Do_id":"21986632",
        "Doc_ChemicalList":"RNA, Messenger;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Fusion Proteins, bcr-abl;Humans;Japan;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;RNA, Messenger;Real-Time Polymerase Chain Reaction;Reverse Transcriptase Polymerase Chain Reaction",
        "Doc_meshqualifiers":"analysis;genetics;diagnosis;genetics;therapy;analysis",
        "_version_":1605764253041557504},
      {
        "Doc_abstract":"The tyrosine kinase activity of BCR-ABL fusion proteins plays an important role in the pathogenesis of leukemia that is for the Philadelphia chromosome (Ph1). Because nuclear c-ABL is regulated during the cell cycle through a specific interaction with the retinoblastoma protein (pRB), the possible interaction of BCR-ABL with pRB in Ph1-positive cell lines was investigated. P145 c-ABL as well as P190 and P210 BCR-ABL proteins interacted with pRB. Furthermore, c-ABL and BCR-ABL associated with both phosphorylated and nonphosphorylated forms of pRB. These findings suggest that BCR-ABL interferes with pRB function and thereby regulates cell growth.",
        "Doc_title":"Interaction of BCR-ABL with the retinoblastoma protein in Philadelphia chromosome-positive cell lines.",
        "Journal":"International journal of hematology",
        "Do_id":"9071815",
        "Doc_ChemicalList":"Retinoblastoma Protein;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Animals;Fusion Proteins, bcr-abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mice;Phosphorylation;Protein Binding;Retinoblastoma Protein;Signal Transduction;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"metabolism;metabolism;metabolism",
        "_version_":1605807044237983744},
      {
        "Doc_abstract":"Deregulated BCR-ABL oncogenic activity leads to transformation, oncogene addiction and drives disease progression in chronic myeloid leukemia (CML). Inhibition of BCR-ABL using Abl-specific kinase inhibitors (TKI) such as imatinib induces remarkable clinical responses. However, approximately only less than 15% of all chronic-phase CML patients will remain relapse-free after discontinuation of imatinib in deep molecular remission. It is not well understood why persisting CML cells survive under TKI therapy without developing clonal evolution and frank TKI resistance. BCR-ABL expression level may be critically involved. Whereas higher BCR-ABL expression has been described as a pre-requisite for malignant CML stem cell transformation and CML progression to blast crisis, recent evidence suggests that during persistence TKI select for CML precursors with low BCR-ABL expression. Genetic, translational and clinical evidence is discussed to suggest that TKI-induced maintenance of low BCR-ABL signaling output may be potently tumor suppressive, because it abrogates oncogenic addiction. ",
        "Doc_title":"Maintaining low BCR-ABL signaling output to restrict CML progression and enable persistence.",
        "Journal":"Current hematologic malignancy reports",
        "Do_id":"24500518",
        "Doc_ChemicalList":"Antineoplastic Agents;Protein Kinase Inhibitors;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Antineoplastic Agents;Cell Transformation, Neoplastic;Disease Progression;Fusion Proteins, bcr-abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Neoplastic Stem Cells;Protein Kinase Inhibitors;Signal Transduction",
        "Doc_meshqualifiers":"therapeutic use;metabolism;genetics;metabolism;drug therapy;metabolism;cytology;therapeutic use;physiology",
        "_version_":1605742015430000640},
      {
        "Doc_abstract":"In order to investigate the safety and efficacy of stem cell mobilization in chronic myeloid leukemia patients under imatinib therapy we treated 10 such patients with granulocyte colony-stimulating factor. We observed that none of the patients developed progressive disease under this treatment. Instead, sufficient CD34+ apheresis could be performed in 7 patients and, as assessed by nested reverse transcriptase polymerase chain reaction (RT-PCR), bcr/abl-negative stem cell products could be generated in 3 patients. Interestingly, in 3 other patients with bcr/abl-positivity in 1st round RT-PCR of peripheral leukocytes, bcr/abl transcripts in stem cell products could only be detected by nested RT-PCR.",
        "Doc_title":"Safety and efficacy of stem cell mobilization under imatinib therapy.",
        "Journal":"Haematologica",
        "Do_id":"14555323",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Pyrimidines;Imatinib Mesylate",
        "Doc_meshdescriptors":"Antineoplastic Agents;Benzamides;Hematopoietic Stem Cell Mobilization;Humans;Imatinib Mesylate;Piperazines;Pyrimidines;Treatment Outcome",
        "Doc_meshqualifiers":"adverse effects;therapeutic use;methods;adverse effects;therapeutic use;adverse effects;therapeutic use",
        "_version_":1605742075708440576},
      {
        "Doc_abstract":"In the treatment of chronic myeloid leukemia (CML) with Bcr-Abl kinase inhibitors, the T315I gatekeeper mutant has emerged as resistant to all currently approved agents, such as imatinib, nilotinib and dasatinib, by discrupting important contact interactions between the inhibitors and the enzyme. To overcome this particular resistance, several different strategies have been explored and many molecules have been investigated as capable of potently inhibiting Bcr-Abl T315I. Herein, this review reports on some predominant examples of third generation inhibitors of Bcr-Abl active against the T315I mutation, and special attentions are paid to the \"hybrid-design\" strategy for creating type-II class ATP-competitive inhibitors.",
        "Doc_title":"Recent developments in the third generation inhibitors of Bcr-Abl for overriding T315I mutation.",
        "Journal":"Current medicinal chemistry",
        "Do_id":"21517764",
        "Doc_ChemicalList":"Antineoplastic Agents;Protein Kinase Inhibitors;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Animals;Antineoplastic Agents;Fusion Proteins, bcr-abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Models, Molecular;Mutation;Protein Kinase Inhibitors",
        "Doc_meshqualifiers":"chemistry;pharmacology;therapeutic use;genetics;drug therapy;enzymology;genetics;drug effects;chemistry;pharmacology;therapeutic use",
        "_version_":1605802668910968832},
      {
        "Doc_abstract":"Philadelphia-chromosome positive chronic myeloid leukemia cells in chronic phase (CML-CP) or blast crisis (CML-BC) and normal bone marrow cells (NBMC) were incubated in vitro with antisense oligonucleotide specific against the BCR/ABL breakpoint junction to examine the possibility of selective inhibition of leukemia growth. Growth capability was determined in vitro by colony assay in semisolid medium in the presence of interleukin 3 (IL-3) and granulocyte-macrophage colony stimulating factor (GM-CSF). The 18-mer antisense directed against the specific BCR/ABL mRNA breakpoint region diminished the colony formation by CML-CP and CML-BC cells, but not by NBMC. Scrambled oligomer did not affect significantly the growth of leukemic and normal cells. If CML-BC cells were mixed with NMBC and incubated with specific BCR/ABL antisense oligomer, leukemic colonies were selectively inhibited, as was shown by reverse, transcriptase-polymerase chain reaction (RT-PCR) performed to detect BCR/ABL mRNA in single colonies. These results confirm the possibility of selective inhibition of leukemia cells by antisense treatment.",
        "Doc_title":"Gene-targeted specific inhibition of chronic myeloid leukemia cell growth by BCR-ABL antisense oligodeoxynucleotides.",
        "Journal":"Folia histochemica et cytobiologica",
        "Do_id":"1794439",
        "Doc_ChemicalList":"Interleukin-3;Oligonucleotides, Antisense;RNA, Messenger;Granulocyte-Macrophage Colony-Stimulating Factor;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Base Sequence;Blast Crisis;Bone Marrow;Cell Transformation, Neoplastic;Cells, Cultured;Fusion Proteins, bcr-abl;Genes, abl;Granulocyte-Macrophage Colony-Stimulating Factor;Humans;Interleukin-3;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Leukemia, Myeloid, Chronic-Phase;Molecular Sequence Data;Oligonucleotides, Antisense;Polymerase Chain Reaction;RNA, Messenger;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"pathology;chemistry;pathology;drug effects;pathology;genetics;genetics;pharmacology;pharmacology;genetics;pathology;genetics;pathology;genetics;pharmacology;analysis;genetics;chemistry;drug effects;pathology",
        "_version_":1605821805624295424},
      {
        "Doc_abstract":"We present two patients with Ph-negative chronic myeloid leukemia (CML) and fusion signal BCR/ABL on both chromosomes 9, located in region 9q34. The first case was a 27 years old man with CML. Molecular studies (RT-PCR) revealed the rearrangement in the major-BCR region and expression of chimeric BCR/ABL mRNA of b3a2 configuration. By classical cytogenetic studies (G-banding) karyotype 46,XY was found in short-term cultivated bone marrow cells and phytohemagglutinin (PHA) stimulated peripheral lymphocytes. FISH studies revealed the BCR/ABL fusion signals on both chromosomes 9 and green BCR signals on both chromosomes 22 in all mitoses studied. Detection of the alleles of ABL1 intragenic STR locus by fluorescence PCR followed by fragmentation analysis in the patient and his parents provided no information about transmission of the ABL gene. Quantitative assessment of BCR/ABL transcript level by RT-PCR showed 60 and 70% BCR/ABL positivity in two peripheral blood samples at 6,5 and 10,5 months after diagnosis, respectively, which does not correspond to the expression from two identical BCR/ABL hybrid genes. Therefore, the possible mechanism of the origin of two BCR/ABL fusion signals present on both chromosomes 9 could not be resolved and remains speculative. The second case was a 53 years old male with diagnosis of chronic phase of CML, with first sign of acceleration one month after diagnosis and death because of sepsis in blastic phase within four months. The cytogenetic findings were identical to those in case No. 1., i.e. karyotype 46, XY by G-banding, two BCR/ABL fusion signals on both chromosomes 9 and RT-PCR molecular studies proved b3a2 breakpoints. It is generally accepted that prognosis of the patients with fused BCR/ABL gene located on chromosome 9 is poor. The presence of two fused genes could be anticipated as two Ph chromosomes in accelerated and blastic phases of the disease. However, in our study, quantitative findings of BCR/ABL transcripts did not corresponded to the expression of two BCR/ABL genes originating from duplication. If this assumption is correct then the expression of both fused genes BCR/ABL was in case No. 1 equally suppressed and total expression reached about the level of one BCR/ABL gene.",
        "Doc_title":"Location of the BCR/ABL fusion genes on both chromosomes 9q34 in Ph negative chronic myeloid leukemia.",
        "Journal":"Leukemia & lymphoma",
        "Do_id":"12400616",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adult;Chromosomes, Human, Pair 9;Fusion Proteins, bcr-abl;Humans;In Situ Hybridization, Fluorescence;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative;Male;Reverse Transcriptase Polymerase Chain Reaction",
        "Doc_meshqualifiers":"genetics;genetics;genetics",
        "_version_":1605822873607340032},
      {
        "Doc_abstract":"Persistence of bcr-abl transcripts after marrow grafting is thought to convey a high risk for relapse in patients with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL). Donor leukocyte infusion (DLI) is closely associated with development of graft-versus-host disease (GVHD) and has well-defined activity against relapsed chronic myelogenous leukemia (CML) but not ALL. We report two patients with Ph-positive ALL who remained bcr-abl positive by reverse transcriptase polymerase chain reaction (RT-PCR) after marrow grafting. Residual bcr-abl transcripts in both patients were eliminated following acute GVHD, which was induced by either DLI or rapid reduction of immunosuppression. Both patients have continued in complete molecular remission for 18 months and 8 months following transplantation, respectively. Our observation suggests that induction of GVHD may eliminate minimal residual disease, thereby preventing leukemia relapse in patients transplanted for Ph-positive ALL.",
        "Doc_title":"Eradication of residual bcr-abl-positive clones by inducing graft-versus-host disease after allogeneic stem cell transplantation in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.",
        "Journal":"Bone marrow transplantation",
        "Do_id":"11840146",
        "Doc_ChemicalList":"RNA, Messenger;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Clone Cells;Female;Fusion Proteins, bcr-abl;Graft vs Host Disease;Graft vs Leukemia Effect;Humans;Immunosuppression;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Leukocyte Transfusion;Male;Middle Aged;Neoplasm, Residual;Precursor Cell Lymphoblastic Leukemia-Lymphoma;RNA, Messenger;Stem Cell Transplantation;Transplantation, Homologous",
        "Doc_meshqualifiers":"pathology;analysis;genetics;etiology;diagnosis;pathology;therapy;pathology;therapy;diagnosis;pathology;therapy;analysis",
        "_version_":1605893650746703872},
      {
        "Doc_abstract":"A 12-year-old male with pre-B-cell acute lymphoblastic leukemia with cryptic BCR/ABL rearrangement underwent sex-mismatched allogeneic bone marrow transplantation (allo-BMT). Contradictory results were provided by various chimerism analyses 3 months later. Y-chromosome-specific quantitative polymerase chain reaction and sex chromosome-specific interphase fluorescence in situ hybridization (i-FISH) showed complete donor chimerism. Analysis of autosomal short tandem repeats (A-STR), BCR/ABL i-FISH test, and X-STR haplotype indicated relapse. Metaphase-FISH and combined BCR/ABL and sex chromosome-specific i-FISH patterns revealed loss of the Y-chromosome and duplication of the X-chromosome in the host cells. Sex chromosome changes after allo-BMT can cause significant difficulties in chimerism analysis.",
        "Doc_title":"Sex chromosome changes after sex-mismatched allogeneic bone marrow transplantation can mislead the chimerism analysis.",
        "Journal":"Pediatric blood & cancer",
        "Do_id":"20979181",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Bone Marrow Transplantation;Child;Chimera;Chromosomes, Human, X;Chromosomes, Human, Y;Fusion Proteins, bcr-abl;Humans;In Situ Hybridization, Fluorescence;Male;Polymerase Chain Reaction;Precursor B-Cell Lymphoblastic Leukemia-Lymphoma;Sex Determination Analysis;Tandem Repeat Sequences;Transplantation, Homologous;Treatment Outcome",
        "Doc_meshqualifiers":"genetics;genetics;genetics;diagnosis;genetics;therapy;genetics",
        "_version_":1605785010926780416},
      {
        "Doc_abstract":"The Philadelphia chromosome is present in a heterogeneous group of leukemias. It is most commonly associated with chronic myelogenous leukemia (CML) and B-lineage acute lymphoblastic leukemia (ALL) being found in more than 95% and 15-25% of cases respectively. We undertook a study to determine the morphologic, phenotypic and molecular diversity of Philadelphia positive de novo acute leukemia patients seen at our institution over the past 3 1/2 years. Twenty-one patients with de novo acute leukemia were found to have the Philadelphia chromosome by cytogenetic studies. They consisted of 3 patients with acute myelogenous leukemia (AML), 1 biphenotypic leukemia and 17 ALL patients. Of the patients with ALL, 16 were of B-lineage while 1 had a T-cell phenotype. Ten patients expressed the p210 BCR-ABL transcript alone and 10 expressed only the p190 BCR-ABL transcript. One patient had co-expression of p190 and p210 b3a2 BCR-ABL transcripts. Thus the Philadelphia chromosome can be found in a diverse cohort of morphologic and immunologic subtypes of de novo acute leukemia reflecting the heterogeneity of lineage involvement in this disease.",
        "Doc_title":"Molecular and phenotypic spectrum of de novo Philadelphia positive acute leukemia.",
        "Journal":"International journal of molecular medicine",
        "Do_id":"10567681",
        "Doc_ChemicalList":"Antigens, CD;Antigens, Neoplasm;Biomarkers, Tumor;Protein Isoforms;RNA, Messenger;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Acute Disease;Adolescent;Adult;Aged;Antigens, CD;Antigens, Neoplasm;Biomarkers, Tumor;Chromosome Banding;Female;Fusion Proteins, bcr-abl;Humans;Immunophenotyping;Leukemia, Myeloid;Leukemia-Lymphoma, Adult T-Cell;Male;Middle Aged;Neoplastic Stem Cells;Phenotype;Precursor B-Cell Lymphoblastic Leukemia-Lymphoma;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Protein Isoforms;RNA, Messenger",
        "Doc_meshqualifiers":"analysis;analysis;analysis;genetics;analysis;genetics;genetics;pathology;genetics;pathology;immunology;pathology;genetics;pathology;genetics;pathology;analysis;genetics;biosynthesis;genetics",
        "_version_":1605895488951812096},
      {
        "Doc_abstract":"BCR-ABL-targeting tyrosine kinase inhibitors (TKIs) constitute the cornerstone of treatment for chronic myeloid leukemia. Although these agents are normally safe and effective, they can cause side effects that lead to intolerance and necessitate switching to an alternative treatment. In this review, we describe side effects that occur during treatment with imatinib, nilotinib or dasatinib-the currently approved TKI treatments for chronic myeloid leukemia-including class effects and key differences in safety profiles. We also describe how common side effects can be effectively managed and offer a working definition of intolerance that may be useful to clinicians when they consider switching between TKIs.",
        "Doc_title":"Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.",
        "Journal":"Leukemia",
        "Do_id":"20861918",
        "Doc_ChemicalList":"4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide;Benzamides;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Thiazoles;Imatinib Mesylate;Protein-Tyrosine Kinases;Dasatinib",
        "Doc_meshdescriptors":"Benzamides;Dasatinib;Disease Management;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Piperazines;Protein Kinase Inhibitors;Protein-Tyrosine Kinases;Pyrimidines;Thiazoles",
        "Doc_meshqualifiers":"complications;drug therapy;adverse effects;adverse effects;antagonists & inhibitors;adverse effects;adverse effects",
        "_version_":1605789808757571584},
      {
        "Doc_abstract":"Oncogene inactivation in both clinical targeted therapies and conditional transgenic mouse cancer models can induce significant tumor regression associated with the robust induction of apoptosis. Here we report that in MYC-, RAS-, and BCR-ABL-induced acute lymphoblastic leukemia (ALL), apoptosis upon oncogene inactivation is mediated by the same pro-apoptotic protein, BIM. The induction of BIMin the MYC- and RAS-driven leukemia is mediated by the downregulation of miR-17-92. Overexpression of miR-17-92 blocked the induction of apoptosis upon oncogene inactivation in the MYC and RAS-driven but not in the BCR-ABL-driven ALL leukemia. Hence, our results provide novel insight into the mechanism of apoptosis upon oncogene inactivation and suggest that induction of BIM-mediated apoptosis may be an important therapeutic approach for ALL. ",
        "Doc_title":"BIM mediates oncogene inactivation-induced apoptosis in multiple transgenic mouse models of acute lymphoblastic leukemia.",
        "Journal":"Oncotarget",
        "Do_id":"27095570",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605906628164452352},
      {
        "Doc_abstract":"The t(9;22) translocation leads to the formation of the chimeric breakpoint cluster region/c-abl oncogene 1 (BCR/ABL) fusion gene on der22, the Philadelphia chromosome. The p185(BCR/ABL) or the p210(BCR/ABL) fusion proteins are encoded as a result of the translocation, depending on whether a \"minor\" or \"major\" breakpoint occurs, respectively. Both p185(BCR/ABL) and p210(BCR/ABL) exhibit constitutively activated ABL kinase activity. Through fusion to BCR the ABL kinase in p185(BCR/ABL) and p210(BCR/ABL) \"escapes\" the auto-inhibition mechanisms of c-ABL, such as allosteric inhibition. A novel class of compounds including GNF-2 restores allosteric inhibition of the kinase activity and the transformation potential of BCR/ABL. Here we investigated whether there are differences between p185(BCR/ABL) and p210(BCR/ABL) regarding their sensitivity towards allosteric inhibition by GNF-2 in models of Philadelphia chromosome-positive acute lymphatic leukemia.;We investigated the anti-proliferative activity of GNF-2 in different Philadelphia chromosome-positive acute lymphatic leukemia models, such as cell lines, patient-derived long-term cultures and factor-dependent lymphatic Ba/F3 cells expressing either p185(BCR/ABL) or p210(BCR/ABL) and their resistance mutants.;The inhibitory effects of GNF-2 differed constantly between p185(BCR/ABL) and p210(BCR/ABL) expressing cells. In all three Philadelphia chromosome-positive acute lymphatic leukemia models, p210(BCR/ABL)-transformed cells were more sensitive to GNF-2 than were p185BCR/ABL-positive cells. Similar results were obtained for p185(BCR/ABL) and the p210(BCR/ABL) harboring resistance mutations.;Our data provide the first evidence of a differential response of p185(BCR/ABL)- and p210(BCR/ABL)- transformed cells to allosteric inhibition by GNF-2, which is of importance for the treatment of patients with Philadelphia chromosome-positive acute lymphatic leukemia.",
        "Doc_title":"p185(BCR/ABL) has a lower sensitivity than p210(BCR/ABL) to the allosteric inhibitor GNF-2 in Philadelphia chromosome-positive acute lymphatic leukemia.",
        "Journal":"Haematologica",
        "Do_id":"22058195",
        "Doc_ChemicalList":"GNF-2 compound;Pyrimidines;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Allosteric Regulation;Cell Line, Tumor;Fusion Proteins, bcr-abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Pyrimidines",
        "Doc_meshqualifiers":"drug effects;physiology;antagonists & inhibitors;genetics;drug therapy;genetics;pharmacology;therapeutic use",
        "_version_":1605746405460148225},
      {
        "Doc_abstract":"The most immediate issues that will have a major impact on the long-term survival of patients with chronic myeloid leukemia is the optimal use of imatinib mesylate (Gleevec, Novartis) and the development of effective therapies for those patients who are intolerant of, or become resistant to, optimal doses of this agent. Of the multiple new agents that are currently being developed for patients with chronic myeloid leukemia, most are being investigated in patients who have developed resistance to imatinib, which is a confounding factor in itself. The mechanisms of action of novel agents are diverse and they may have a variably synergistic therapeutic relationship with imatinib. The complete blockade of the intracellular pathways that are triggered by Bcr-Abl, combined with successful reversal of apoptotic and/or angiogenic abnormalities in chronic myeloid leukemia, may well lead to a cure for the majority of patients.",
        "Doc_title":"Novel therapies for patients with chronic myeloid leukemia.",
        "Journal":"Expert review of anticancer therapy",
        "Do_id":"15056057",
        "Doc_ChemicalList":"Antineoplastic Agents;Enzyme Inhibitors",
        "Doc_meshdescriptors":"Animals;Antineoplastic Agents;Enzyme Inhibitors;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Signal Transduction",
        "Doc_meshqualifiers":"therapeutic use;therapeutic use;drug therapy;metabolism;drug effects",
        "_version_":1605747514256916480},
      {
        "Doc_abstract":"ABL kinase domain mutations have been implicated in the resistance to the BCR-ABL inhibitor imatinib mesylate of Philadelphia-positive (Ph+) leukemia patients.;Using denaturing high-performance liquid chromatography and sequencing, we screened for ABL kinase domain mutations in 370 Ph+ patients with evidence of hematologic or cytogenetic resistance to imatinib.;Mutations were found in 127 of 297 (43%) evaluable patients. Mutations were found in 27% of chronic-phase patients (14% treated with imatinib frontline; 31% treated with imatinib post-IFN failure), 52% of accelerated-phase patients, 75% of myeloid blast crisis patients, and 83% of lymphoid blast crisis/Ph+ acute lymphoblastic leukemia (ALL) patients. Mutations were associated in 30% of patients with primary resistance (44% hematologic and 28% cytogenetic) and in 57% of patients with acquired resistance (23% patients who lost cytogenetic response; 55% patients who lost hematologic response; and 87% patients who progressed to accelerated phase/blast crisis). P-loop and T315I mutations were particularly frequent in advanced-phase chronic myeloid leukemia and Ph+ ALL patients, and often accompanied progression from chronic phase to accelerated phase/blast crisis.;We conclude that (a) amino acid substitutions at seven residues (M244V, G250E, Y253F/H, E255K/V, T315I, M351T, and F359V) account for 85% of all resistance-associated mutations; (b) the search for mutations is important both in case of imatinib failure and in case of loss of response at the hematologic or cytogenetic level; (c) advanced-phase chronic myeloid leukemia and Ph+ ALL patients have a higher likelihood of developing imatinib-resistant mutations; and (d) the presence of either P-loop or T315I mutations in imatinib-treated patients should warn the clinician to reconsider the therapeutic strategy.",
        "Doc_title":"Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.",
        "Journal":"Clinical cancer research : an official journal of the American Association for Cancer Research",
        "Do_id":"17189410",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Pyrimidines;Imatinib Mesylate;Protein Kinases",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Antineoplastic Agents;Benzamides;Chromatography, High Pressure Liquid;DNA Mutational Analysis;Drug Resistance, Neoplasm;Gene Frequency;Genes, abl;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Middle Aged;Mutation;Neoplasm Staging;Piperazines;Protein Kinases;Protein Structure, Tertiary;Pyrimidines",
        "Doc_meshqualifiers":"therapeutic use;methods;genetics;physiology;drug therapy;genetics;pathology;physiology;therapeutic use;genetics;genetics;therapeutic use",
        "_version_":1605910266644529152},
      {
        "Doc_abstract":"The mechanism leading to the expanding population of maturing myeloid cells which characterises chronic myeloid leukemia (CML) remains obscure. Because of its ability to mimic the proliferative and cell survival functions of hematopoietic growth factors, we hypothesized that the oncogene activated in CML, BCR-ABL, might also influence differentiation. To test this hypothesis, we examined the effects of expressing BCR-ABL on the myeloid differentiation of murine M1 leukemic cells, which cease dividing and differentiate into macrophages in the presence of the cytokines leukemia inhibitory factor (LIF) or interleukin (IL)-6. We found that BCR-ABL induced macrophage differentiation in M1 cells, accompanied by increased expression of macrophage cell surface markers and the acquisition of phagocytic ability. interestingly, clones of M1 cells which expressed BCR-ABL remained in cell cycle and were refractory to the growth inhibition and apoptosis induced by IL-6 or LIF in parental M1 cells. These cells also expressed inappropriately high levels of c-MYC mRNA for their degree of differentiation, which may have been important in maintaining cellular proliferation. These data suggest that BCR-ABL can stimulate both differentiation and proliferation and that these characteristics may contribute to the phenotype observed in CML.",
        "Doc_title":"Expression of BCR - ABL in M1 myeloid leukemia cells induces differentiation without arresting proliferation.",
        "Journal":"Oncogene",
        "Do_id":"9927191",
        "Doc_ChemicalList":"Growth Inhibitors;Interleukin-6;Leukemia Inhibitory Factor;Lif protein, mouse;Lymphokines;Proto-Oncogene Proteins c-myc;RNA, Messenger;Dexamethasone;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Animals;Cell Cycle;Cell Differentiation;Cell Division;Clone Cells;Dexamethasone;Fusion Proteins, bcr-abl;Growth Inhibitors;Interleukin-6;Leukemia Inhibitory Factor;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Lymphokines;Macrophages;Mice;Phenotype;Proto-Oncogene Proteins c-myc;RNA, Messenger;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"genetics;genetics;drug effects;pharmacology;genetics;pharmacology;pharmacology;metabolism;pathology;pharmacology;cytology;genetics;genetics",
        "_version_":1605904010672340992},
      {
        "Doc_abstract":"Self-renewal of Bcr-Abl(+) chronic myeloid leukemia (CML) cells is sustained by a nuclear activated serine/threonine-(S/T) unphosphorylated beta-catenin. Although beta-catenin can be tyrosine (Y)-phosphorylated, the occurrence and biological relevance of this covalent modification in Bcr-Abl-associated leukemogenesis is unknown. Here we show that Bcr-Abl levels control the degree of beta-catenin protein stabilization by affecting its Y/S/T-phospho content in CML cells. Bcr-Abl physically interacts with beta-catenin, and its oncogenic tyrosine kinase activity is required to phosphorylate beta-catenin at Y86 and Y654 residues. This Y-phospho beta-catenin binds to the TCF4 transcription factor, thus representing a transcriptionally active pool. Imatinib, a Bcr-Abl antagonist, impairs the beta-catenin/TCF-related transcription causing a rapid cytosolic retention of Y-unphosphorylated beta-catenin, which presents an increased binding affinity for the Axin/GSK3beta complex. Although Bcr-Abl does not affect GSK3beta autophosphorylation, it prevents, through its effect on beta-catenin Y phosphorylation, Axin/GSK3beta binding to beta-catenin and its subsequent S/T phosphorylation. Silencing of beta-catenin by small interfering RNA inhibited proliferation and clonogenicity of Bcr-Abl(+) CML cells, in synergism with Imatinib. These findings indicate the Bcr-Abl triggered Y phosphorylation of beta-catenin as a new mechanism responsible for its protein stabilization and nuclear signalling activation in CML.",
        "Doc_title":"Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation.",
        "Journal":"The EMBO journal",
        "Do_id":"17318191",
        "Doc_ChemicalList":"Benzamides;Piperazines;Pyrimidines;RNA, Small Interfering;beta Catenin;Tyrosine;Imatinib Mesylate;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl;Glycogen Synthase Kinase 3",
        "Doc_meshdescriptors":"Apoptosis;Benzamides;Blotting, Western;Cell Line;Cell Line, Tumor;Cell Proliferation;Fusion Proteins, bcr-abl;Glycogen Synthase Kinase 3;Humans;Imatinib Mesylate;Immunoprecipitation;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Models, Biological;Phosphorylation;Piperazines;Protein Binding;Protein-Tyrosine Kinases;Pyrimidines;RNA, Small Interfering;Signal Transduction;Transcription, Genetic;Tyrosine;beta Catenin",
        "Doc_meshqualifiers":"genetics;metabolism;physiology;antagonists & inhibitors;genetics;metabolism;genetics;metabolism;pathology;drug effects;pharmacology;genetics;metabolism;pharmacology;genetics;drug effects;drug effects;metabolism;chemistry;genetics;metabolism",
        "_version_":1605898828099092480},
      {
        "Doc_abstract":"In Ph-positive leukemia, imatinib brought marked clinical improvement; however, further improvement is needed to prevent relapse. Cancer cells efficiently use limited energy sources, and drugs targeting cellular metabolism improve the efficacy of therapy. In this study, we characterized the effects of novel anti-cancer fatty-acid derivative AIC-47 and imatinib, focusing on cancer-specific energy metabolism in chronic myeloid leukemia cells. AIC-47 and imatinib in combination exhibited a significant synergic cytotoxicity. Imatinib inhibited only the phosphorylation of BCR-ABL; whereas AIC-47 suppressed the expression of the protein itself. Both AIC-47 and imatinib modulated the expression of pyruvate kinase M (PKM) isoforms from PKM2 to PKM1 through the down-regulation of polypyrimidine tract-binding protein 1 (PTBP1). PTBP1 functions as alternative splicing repressor of PKM1, resulting in expression of PKM2, which is an inactive form of pyruvate kinase for the last step of glycolysis. Although inactivation of BCR-ABL by imatinib strongly suppressed glycolysis, compensatory fatty-acid oxidation (FAO) activation supported glucose-independent cell survival by up-regulating CPT1C, the rate-limiting FAO enzyme. In contrast, AIC-47 inhibited the expression of CPT1C and directly fatty-acid metabolism. These findings were also observed in the CD34(+) fraction of Ph-positive acute lymphoblastic leukemia cells. These results suggest that AIC-47 in combination with imatinib strengthened the attack on cancer energy metabolism, in terms of both glycolysis and compensatory activation of FAO. ",
        "Doc_title":"Perturbation of energy metabolism by fatty-acid derivative AIC-47 and imatinib in BCR-ABL-harboring leukemic cells.",
        "Journal":"Cancer letters",
        "Do_id":"26607903",
        "Doc_ChemicalList":"1-(azocan-1-yl)dec-3-en-1one;Antigens, CD34;BCR-ABL1 fusion protein, human;Fatty Acids;Heterocyclic Compounds, 1-Ring;Heterogeneous-Nuclear Ribonucleoproteins;Ketones;MIRN124 microRNA, human;MicroRNAs;PTBP1 protein, human;Protein Kinase Inhibitors;Polypyrimidine Tract-Binding Protein;Imatinib Mesylate;Pyruvate Kinase;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Antigens, CD34;Antineoplastic Combined Chemotherapy Protocols;Dose-Response Relationship, Drug;Drug Synergism;Energy Metabolism;Fatty Acids;Fusion Proteins, bcr-abl;Glycolysis;Heterocyclic Compounds, 1-Ring;Heterogeneous-Nuclear Ribonucleoproteins;Humans;Imatinib Mesylate;K562 Cells;Ketones;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;MicroRNAs;Neoplastic Stem Cells;Oxidation-Reduction;Polypyrimidine Tract-Binding Protein;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Protein Kinase Inhibitors;Pyruvate Kinase;RNA Interference;Transfection",
        "Doc_meshqualifiers":"metabolism;pharmacology;drug effects;pharmacology;genetics;metabolism;drug effects;pharmacology;genetics;metabolism;pharmacology;pharmacology;drug therapy;genetics;metabolism;genetics;metabolism;drug effects;metabolism;genetics;metabolism;drug therapy;genetics;metabolism;pharmacology;genetics;metabolism",
        "_version_":1605893439688278016},
      {
        "Doc_abstract":"Inhibition of BCR-ABL with kinase inhibitors in the treatment of Philadelphia-positive (Ph(+)) chronic myeloid leukemia (CML) is highly effective in controlling but not curing the disease. This is largely due to the inability of these kinase inhibitors to kill leukemia stem cells (LSCs) responsible for disease relapse. This stem cell resistance is not associated with the BCR-ABL kinase domain mutations resistant to kinase inhibitors. Development of curative therapies for CML requires the identification of crucial molecular pathways responsible for the survival and self-renewal of LSCs. In this review, we will discuss our current understanding of these crucial molecular pathways in LSCs and the available therapeutic strategies for targeting these stem cells in CML.",
        "Doc_title":"Critical molecular pathways in cancer stem cells of chronic myeloid leukemia.",
        "Journal":"Leukemia",
        "Do_id":"20574455",
        "Doc_ChemicalList":"Antineoplastic Agents;Protein Kinase Inhibitors",
        "Doc_meshdescriptors":"Animals;Antineoplastic Agents;Disease Models, Animal;Genes, abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mice;Mice, Transgenic;Mutation;Neoplastic Stem Cells;Protein Kinase Inhibitors",
        "Doc_meshqualifiers":"therapeutic use;drug therapy;pathology;therapeutic use",
        "_version_":1605875728964911104},
      {
        "Doc_abstract":"CRKL (CRK-like) is an adapter protein predominantly phosphorylated in cells that express the tyrosine kinase p210(BCR-ABL), the fusion product of a (9;22) chromosomal translocation causative for chronic myeloid leukemia. It has been unclear, however, whether CRKL plays a functional role in p210(BCR-ABL) transformation. Here, we show that CRKL is required for p210(BCR-ABL) to support interleukin-3-independent growth of myeloid progenitor cells and long-term outgrowth of B-lymphoid cells from fetal liver-derived hematopoietic progenitor cells. Furthermore, a synthetic phosphotyrosyl peptide that binds to the CRKL SH2 domain with high affinity blocks association of endogenous CRKL with the p210(BCR-ABL) complex and reduces c-MYC levels in K562 human leukemic cells as well as in mouse hematopoietic cells transformed by p210(BCR-ABL) or the imatinib-resistant mutant T315I. These results indicate that the function of CRKL as an adapter protein is essential for p210(BCR-ABL)-induced transformation.",
        "Doc_title":"A specific need for CRKL in p210BCR-ABL-induced transformation of mouse hematopoietic progenitors.",
        "Journal":"Cancer research",
        "Do_id":"20807813",
        "Doc_ChemicalList":"Adaptor Proteins, Signal Transducing;CRKL protein;Interleukin-3;Nuclear Proteins;Proto-Oncogene Proteins c-myc;STAT5 Transcription Factor;bcl-X Protein;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adaptor Proteins, Signal Transducing;Amino Acid Sequence;Animals;Cell Growth Processes;Cell Transformation, Neoplastic;Fusion Proteins, bcr-abl;Hematopoietic Stem Cells;Humans;Interleukin-3;K562 Cells;Mice;Mice, Transgenic;Molecular Sequence Data;Nuclear Proteins;Phosphorylation;Proto-Oncogene Proteins c-myc;STAT5 Transcription Factor;bcl-X Protein",
        "Doc_meshqualifiers":"metabolism;physiology;metabolism;pathology;metabolism;metabolism;pathology;pharmacology;metabolism;genetics;metabolism;metabolism;metabolism",
        "_version_":1605752121797378048},
      {
        "Doc_abstract":"Bcr-Abl contributes prominently to the development of most chronic myeloid leukemias (CMLs). Prior work has identified the adapter protein CRKL as a major substrate of the Bcr-Abl tyrosine kinase. CRKL can also bind via its first SH3 domain [SH3(1)] to specific sequences in Bcr-Abl. Cell-penetrating peptides were developed that bind with high affinity and selectivity to the SH3(1) domain of CRKL. They disrupt Bcr-Abl-CRKL complexes and strongly reduce the proliferation of primary CML blast cells and cell lines established from Bcr-Abl-positive patients. Activation-specific antibodies against phosphorylated MAP kinase (MAPK) showed that MAPK activity is down-regulated in blast cells treated with the CRKLSH3(1) blocker peptides. We conclude that the Bcr-Abl-CRKL complexes are largely dependent on the CRKLSH3(1) domain, that the central mitogenic cascade is down-regulated as a consequence of the disruption of CRKLSH3(1) interactions, and that CRKL therefore contributes to the proliferation of CML blast cells.",
        "Doc_title":"Cell-penetrating SH3 domain blocker peptides inhibit proliferation of primary blast cells from CML patients.",
        "Journal":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology",
        "Do_id":"10928987",
        "Doc_ChemicalList":"Adaptor Proteins, Signal Transducing;CRKL protein;Calcium-Binding Proteins;Calreticulin;Nuclear Proteins;Peptides;Recombinant Fusion Proteins;Ribonucleoproteins;Fusion Proteins, bcr-abl;Mitogen-Activated Protein Kinases",
        "Doc_meshdescriptors":"Adaptor Proteins, Signal Transducing;Amino Acid Sequence;Animals;Binding Sites;Calcium-Binding Proteins;Calreticulin;Cell Division;Cell Membrane;Cell Membrane Permeability;Fluorescent Antibody Technique;Fusion Proteins, bcr-abl;Half-Life;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Lymphocyte Activation;Mitogen-Activated Protein Kinases;Molecular Sequence Data;Nuclear Proteins;Peptides;Protein Binding;Rats;Recombinant Fusion Proteins;Ribonucleoproteins;Spectrometry, Fluorescence;Tumor Cells, Cultured;src Homology Domains",
        "Doc_meshqualifiers":"metabolism;pharmacology;drug effects;metabolism;antagonists & inhibitors;metabolism;enzymology;metabolism;pathology;drug effects;antagonists & inhibitors;metabolism;antagonists & inhibitors;chemistry;metabolism;chemistry;metabolism;pharmacokinetics;pharmacology;drug effects;chemistry;metabolism;pharmacokinetics;pharmacology;metabolism;pharmacology",
        "_version_":1605798377486811136},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) is caused by the Bcr-Abl oncoprotein,the product of the t(9;22) chromosomal translocation that generates the Philadelphia chromosome. Different disease phenotypes are associated with each of the three Bcr-Abl isoforms: p190Bcr-Abl, p210Bcr-Abl, and p230Bcr-Abl all of which have a constitutively activated tyrosine kinase. Mechanisms associated with malignant transformation include altered cellular adhesion, activation of mitogenic signaling pathways, inhibition of apoptosis, and proteasomal degradation of physiologically important cellular proteins.CML is subject to an inexorable progression from an \"indolent\" chronic phase to a terminal blast crisis. Disease progression is presumed to be associated with the phenomenon of genomic instability.",
        "Doc_title":"Biology of chronic myelogenous leukemia--signaling pathways of initiation and transformation.",
        "Journal":"Hematology/oncology clinics of North America",
        "Do_id":"15271392",
        "Doc_ChemicalList":"Oncogene Proteins;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Cell Transformation, Neoplastic;Fusion Proteins, bcr-abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Oncogene Proteins;Signal Transduction;Translocation, Genetic",
        "Doc_meshqualifiers":"genetics;genetics;metabolism;physiology;etiology;genetics;metabolism;physiology;genetics",
        "_version_":1605852772721229824},
      {
        "Doc_abstract":"Recent advances in molecular genetics impact the health care and outcome of patients with acute lymphoblastic leukemia (ALL). BCR-ABL, a common molecular defect in adult ALL, is a valuable tumor marker whose detection influences prognosis and clinical management decisions. Molecular methods such as fluorescence in situ hybridization (FISH), reverse-transcriptase polymerase chain reaction (rtPCR), and real-time quantitative rtPCR can be used to detect the chimeric BCR-ABL gene or its transcripts. These molecular assays improve our ability to measure residual disease and to estimate risk of relapse. On the horizon are gene expression profiles that will likely provide additional information beyond what is obtainable with current clinical and laboratory approaches.",
        "Doc_title":"Clinical applications of BCR-ABL molecular testing in acute leukemia.",
        "Journal":"The Journal of molecular diagnostics : JMD",
        "Do_id":"12707370",
        "Doc_ChemicalList":"Benzamides;Piperazines;Pyrimidines;RNA, Messenger;Imatinib Mesylate;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Benzamides;Blotting, Southern;Chromosomes, Human, Pair 22;Chromosomes, Human, Pair 9;Fusion Proteins, bcr-abl;Gene Expression Regulation, Neoplastic;Humans;Imatinib Mesylate;In Situ Hybridization, Fluorescence;Karyotyping;Models, Genetic;Oligonucleotide Array Sequence Analysis;Piperazines;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Prognosis;Pyrimidines;RNA, Messenger;Reverse Transcriptase Polymerase Chain Reaction;Time Factors",
        "Doc_meshqualifiers":"ultrastructure;ultrastructure;analysis;methods;methods;therapeutic use;diagnosis;genetics;therapeutic use;metabolism",
        "_version_":1605742794930913281},
      {
        "Doc_abstract":"Analysis of v-abl-homologous transcripts in peripheral blood leukocytes from 20 leukemia patients revealed a 5-kb species as the major abl-mRNA present. Elevated levels of this 5-kb transcript, together with detectable levels of 2- and 10-kb abl-homologous species, were observed in mRNA samples from two patients, one with Philadelphia chromosome (Ph')-positive chronic myeloid leukemia (CML) in lymphoid blast crisis, and the other with childhood Burkitt-type B-lymphoblastic leukemia. These abl-homologous transcripts differed from the aberrant 8-kb abl-mRNA reported by others in Ph'-positive CML patients in both size and extent of v-abl-homology. No alteration in the organization of v-abl-homologous sequences was detected in the genomic DNA of the Ph'-positive CML patient. Karyotypic analysis of the Burkitt-type B-lymphoblastic leukemia patient revealed the presence of an 8,14 translocation together with a number of other chromosomal aberrations. However, no abnormality of chromosome 9 could be detected. Hence, the observed increase in c-abl transcription is not consistently associated with either gross gene rearrangement or presence of the Ph'. The high levels of c-abl mRNA may be a function of the cell type involved (early lymphoid blast), suggesting that failure to down-regulate c-abl may be a factor in the onset of pre- or early B-lymphoid leukemias.",
        "Doc_title":"Elevation of c-abl-mRNA in human leukemic B lymphoblasts.",
        "Journal":"Leukemia research",
        "Do_id":"3491935",
        "Doc_ChemicalList":"RNA, Messenger",
        "Doc_meshdescriptors":"B-Lymphocytes;Base Sequence;Humans;Karyotyping;Leukemia;Philadelphia Chromosome;Proto-Oncogenes;RNA, Messenger;Transcription, Genetic",
        "Doc_meshqualifiers":"analysis;genetics;analysis",
        "_version_":1605881148893822976},
      {
        "Doc_abstract":"In 2006, most newly diagnosed patients with chronic myeloid leukemia (CML) underwent first-line, molecular-targeted therapy with the Bcr-Abl tyrosine kinase inhibitor, imatinib. The expectation was that the vast majority of these patients would exhibit a complete cytogenetic response on imatinib alone. Studies of patients with acquired imatinib resistance revealed that Bcr-Abl signaling is reactivated at the time of resistance, predominantly because of mutations that interfere with drug binding in the kinase domain of Bcr-Abl. The knowledge that Bcr-Abl remains the optimal target for treating imatinib-refractory CML has driven an already highly successful search for alternative approaches to restore target inhibition. Here, we review the current state of affairs in the realm of controlling drug resistance in CML, including cutting-edge strategies to reign in Bcr-AblT315I, which is cross resistant to imatinib, as well as the \"next generation\" Bcr-Abl inhibitors, nilotinib and dasatinib. We also critically assess the role of combined Abl kinase inhibitor therapy in overcoming resistance and provide recommendations for monitoring patients for kinase domain mutations.",
        "Doc_title":"Bcr-Abl kinase domain mutations and the unsettled problem of Bcr-AblT315I: looking into the future of controlling drug resistance in chronic myeloid leukemia.",
        "Journal":"Clinical lymphoma & myeloma",
        "Do_id":"17382021",
        "Doc_ChemicalList":"Benzamides;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Imatinib Mesylate;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Benzamides;Drug Resistance, Neoplasm;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Piperazines;Protein Kinase Inhibitors;Protein Structure, Tertiary;Pyrimidines;Signal Transduction",
        "Doc_meshqualifiers":"drug effects;genetics;antagonists & inhibitors;genetics;drug therapy;enzymology;genetics;therapeutic use;therapeutic use;genetics;therapeutic use;drug effects;genetics",
        "_version_":1605843930976354304},
      {
        "Doc_abstract":"We obtained a global view of gene expression in both cell lines and pediatric acute lymphoblastic leukemia (ALL) samples that harbor one of several selected chromosomal abnormalities. When the cell lines were studied alone, we found that these chromosomal abnormalities were associated with the predominant variation in transcriptional programs across the set of cell lines studied. When cell lines and clinical samples were studied together, we found that each chromosomal abnormality (TEL/AML1, BCR/ABL, or MLL abnormalities) was associated with a characteristic gene expression signature that was shared by both cell lines and clinical samples. However, BCR/ABL was associated with a much more heterogeneous pattern of expression than were TEL/AML1 and MLL abnormalities. This observation has important implications for the study of BCR/ABL ALL. In addition, we systematically identified genes whose expression was associated with TEL/AML1, BCR/ABL, or MLL abnormalities in both clinical samples and cell lines. Although some of these genes have previously been described, many have not previously been reported to be associated with one of these chromosomal abnormalities. Notably, we found that the erythropoietin receptor (EPOR) is consistently highly expressed in TEL/AML1 ALL compared with BCR/ABL or MLL.",
        "Doc_title":"Gene expression patterns associated with recurrent chromosomal translocations in acute lymphoblastic leukemia.",
        "Journal":"Blood",
        "Do_id":"14525776",
        "Doc_ChemicalList":"Core Binding Factor Alpha 2 Subunit;DNA, Neoplasm;DNA-Binding Proteins;MLL protein, human;Oncogene Proteins, Fusion;Receptors, Erythropoietin;TEL-AML1 fusion protein;Transcription Factors;Myeloid-Lymphoid Leukemia Protein;Histone-Lysine N-Methyltransferase",
        "Doc_meshdescriptors":"Adolescent;Base Sequence;Cell Line, Tumor;Child;Child, Preschool;Core Binding Factor Alpha 2 Subunit;DNA, Neoplasm;DNA-Binding Proteins;Female;Gene Expression;Gene Expression Profiling;Genes, abl;Histone-Lysine N-Methyltransferase;Humans;Infant;Infant, Newborn;Male;Myeloid-Lymphoid Leukemia Protein;Oncogene Proteins, Fusion;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Proto-Oncogenes;Receptors, Erythropoietin;Reverse Transcriptase Polymerase Chain Reaction;Transcription Factors;Translocation, Genetic",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;genetics",
        "_version_":1605845935586279424},
      {
        "Doc_abstract":"It has been suggested that the BCR-ABL gene of chronic myeloid leukemia (CML) is not uniformly expressed in Philadelphia (Ph)-positive cells, and that BCR-ABL gene expression precludes transcription of the normal BCR or ABL genes. Therefore, we have analyzed granulocyte-macrophage colony-forming unit (CFU-GM) colonies derived from peripheral blood of 11 CML patients by cytogenetic and by reverse transcriptase-polymerase chain reaction (PCR) amplification of BCR-ABL, ABL-BCR, BCR, and ABL. All CFU-GM colonies with analyzable metaphases were found to contain a Ph chromosome. In 2 patients, the initial PCR screening failed to detect BCR-ABL transcripts in 2 of 11 and 1 of 7 Ph-positive colonies. However, when amplification for BCR-ABL was repeated in quintuplicate, all but 1 colony from a single patient showed one or more positive results. Amplifications of the four genes in each colony showed that BCR-ABL, ABL-BCR, and the normal BCR and ABL were simultaneously expressed in the majority of CFU-GM colonies. Replicate PCR tests for BCR and for ABL in colonies initially scored as negative also uncovered previously undetected positive amplifications. We conclude that BCR-ABL expression does not suppress transcription from the normal BCR and ABL genes, and that Ph-positive, BCR-ABL-negative colonies derived from peripheral blood CFU-GM are rare or nonexistent.",
        "Doc_title":"BCR-ABL, ABL-BCR, BCR, and ABL genes are all expressed in individual granulocyte-macrophage colony-forming unit colonies derived from blood of patients with chronic myeloid leukemia.",
        "Journal":"Blood",
        "Do_id":"7718887",
        "Doc_ChemicalList":"Biomarkers, Tumor;Neoplasm Proteins;Oncogene Proteins;Proto-Oncogene Proteins;RNA, Messenger;RNA, Neoplasm;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl;Proto-Oncogene Proteins c-abl;BCR protein, human;Proto-Oncogene Proteins c-bcr",
        "Doc_meshdescriptors":"Base Sequence;Biomarkers, Tumor;Clone Cells;Fusion Proteins, bcr-abl;Gene Expression Regulation, Leukemic;Granulocytes;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative;Leukemia, Myeloid, Chronic-Phase;Macrophages;Molecular Sequence Data;Neoplasm Proteins;Neoplastic Stem Cells;Oncogene Proteins;Philadelphia Chromosome;Polymerase Chain Reaction;Protein-Tyrosine Kinases;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-abl;Proto-Oncogene Proteins c-bcr;RNA, Messenger;RNA, Neoplasm;Tumor Stem Cell Assay",
        "Doc_meshqualifiers":"biosynthesis;genetics;metabolism;pathology;biosynthesis;genetics;metabolism;pathology;blood;pathology;blood;pathology;blood;pathology;metabolism;pathology;biosynthesis;genetics;metabolism;biosynthesis;genetics;biosynthesis;genetics;analysis;genetics;analysis;genetics",
        "_version_":1605899052915884032},
      {
        "Doc_abstract":"Dasatinib is a BCR-ABL inhibitor with 325-fold higher potency than imatinib against unmutated BCR-ABL in vitro. Imatinib failure is commonly caused by BCR-ABL mutations. Here, dasatinib efficacy was analyzed in patients recruited to phase 2/3 trials with chronic-phase chronic myeloid leukemia with or without BCR-ABL mutations after prior imatinib. Among 1043 patients, 39% had a preexisting BCR-ABL mutation, including 48% of 805 patients with imatinib resistance or suboptimal response. Sixty-threedifferent BCR-ABL mutations affecting 49 amino acids were detected at baseline, with G250, M351, M244, and F359 most frequently affected. After 2 years of follow-up, dasatinib treatment of imatinib-resistant patients with or without a mutation resulted in notable response rates (complete cytogenetic response: 43% vs 47%) and durable progression-free survival (70% vs 80%). High response rates were achieved with different mutations except T315I, including highly imatinib-resistant mutations in the P-loop region. Impaired responses were observed with some mutations with a dasatinib median inhibitory concentration (IC(50)) greater than 3nM; among patients with mutations with lower or unknown IC(50), efficacy was comparable with those with no mutation. Overall, dasatinib has durable efficacy in patients with or without BCR-ABL mutations. All trials were registered at http://www.clinicaltrials.gov as NCT00123474, NCT00101660, and NCT00103844.",
        "Doc_title":"Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations.",
        "Journal":"Blood",
        "Do_id":"19779040",
        "Doc_ChemicalList":"Protein Kinase Inhibitors;Pyrimidines;Thiazoles;Fusion Proteins, bcr-abl;Dasatinib",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Aged, 80 and over;Clinical Trials, Phase II as Topic;Clinical Trials, Phase III as Topic;DNA Mutational Analysis;Dasatinib;Female;Fusion Proteins, bcr-abl;Humans;Kaplan-Meier Estimate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Mutation;Protein Kinase Inhibitors;Pyrimidines;Randomized Controlled Trials as Topic;Thiazoles;Treatment Outcome;Young Adult",
        "Doc_meshqualifiers":"genetics;drug therapy;genetics;mortality;therapeutic use;therapeutic use;therapeutic use",
        "_version_":1605892488285913088},
      {
        "Doc_abstract":"We recently developed an Invader assay combined with reverse transcriptase polymerase-chain-reaction in order to quantify T315I bcr-abl transcripts. Using this assay, we serially monitored T315I bcr-abl transcripts in chronic myeloid leukemia (CML) patients whose bcr-abl transcripts were still detectable at 6 months after starting imatinib therapy. Although, we continued to monitor bcr-abl transcripts in 14 CML patients (13 chronic phases and 1 accelerated phase) for up to 12 months, there were no patients who were apparently resistant to imatinib due to the T315I mutation. In contrast, in a case of Philadelphia chromosome-positive acute lymphoid leukemia being treated with chemotherapy including imatinib, we monitored both wild-type and T315I bcr-abl transcripts, and found increased levels of T315I transcripts during relapse (0% at the time of diagnosis and 54.8% at relapse). Thus, our new approach could be a useful tool to study the kinetics of mutant clones and the pharmacokinetics of drug resistance with regard to the T315I mutation.",
        "Doc_title":"Serial monitoring of T315I BCR-ABL mutation by Invader assay combined with RT-PCR.",
        "Journal":"International journal of hematology",
        "Do_id":"19343480",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adult;Aged;Female;Fusion Proteins, bcr-abl;Genetic Techniques;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Mutation",
        "Doc_meshqualifiers":"analysis;genetics;genetics;genetics",
        "_version_":1605796358473646080},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) is a hematological malignancy that arises due to reciprocal translocation of 3' sequences from c-Abelson (ABL) protooncogene of chromosome 9 with 5' sequence of truncated break point cluster region (BCR) on chromosome 22. BCR-ABL is a functional oncoprotein p210 that exhibits constitutively activated tyrosine kinase causing genomic alteration of hematopoietic stem cells. BCR-ABL specific tyrosine kinase inhibitors (TKIs) successfully block CML progression. However, drug resistance owing to BCR-ABL mutations and overexpression is still an issue. Heat-shock proteins (Hsps) function as molecular chaperones facilitating proper folding of nascent polypeptides. Their increased expression under stressful conditions protects cells by stabilizing unfolded or misfolded peptides. Hsp90 is the major mammalian protein and is required by BCR-ABL for stabilization and maturation. Hsp90 inhibitors destabilize the binding of BCR-ABL protein thus leading to the formation of heteroprotein complex that is eventually degraded by the ubiquitin-proteasome pathway. Results of many novel Hsp90 inhibitors that have entered into various clinical trials are encouraging. The present review targets the current development in the CML treatment by availing Hsp90 specific inhibitors. ",
        "Doc_title":"Hsp90 Inhibitors for the Treatment of Chronic Myeloid Leukemia.",
        "Journal":"Leukemia research and treatment",
        "Do_id":"26770832",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605795529964388352},
      {
        "Doc_abstract":"Abnormal expression of microRNAs (miRNAs) has been implicated in carcinogenesis. Here we report a novel BCR (breakpoint cluster region)-ABL (c-abl oncogene 1, non-receptor tyrosine kinase)/GATA1/microRNA-138 (miR-138) circuitry in chronic myeloid leukemia (CML). miR-138 expression is downregulated in K562 cells and primary CML samples, which is restored after imatinib treatment. The tumor suppressor activity of miR-138 is demonstrated by the induction of cell cycle arrest at G0/G1, inhibition of cell proliferation and colony forming unit granulocyte-macrophage colony formation and enhanced imatinib-induced apoptosis in K562 and Ku812 cells overexpressing miR-138. Moreover, overexpression of miR-138 led to the downregulation of BCR-ABL. Based on luciferase assay, ABL and BCR-ABL are shown to be the target genes regulated by miR-138. Furthermore, miR-138 binding to ABL was shown to localize to the coding region instead of 3'-untranslated regions (3'-UTR) of ABL mRNA. In addition, CCND3 is another target of miR-138, which represses CCND3 expression by binding to its 3'-UTR. Finally, upregulation of miR-138 upon imatinib treatment is associated with the enhancement of GATA1 activity, which binds to the miR-138 promoter. In conclusion, miR-138 is a tumor suppressor miRNA underexpressed in CML. miR-138 represses expression of both BCR-ABL and CCND3 via binding to the coding region and 3'-UTR, respectively. miR-138 expression is activated by GATA1, which in turn is repressed by BCR-ABL. Therefore, miR-138, by virtue of a BCR-ABL/GATA1/miR-138 circuitry, is a tumor suppressor miRNA implicated in the pathogenesis of CML and its clinical response to imatinib. ",
        "Doc_title":"BCR-ABL/GATA1/miR-138 mini circuitry contributes to the leukemogenesis of chronic myeloid leukemia.",
        "Journal":"Oncogene",
        "Do_id":"23208504",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;GATA1 Transcription Factor;GATA1 protein, human;MIRN138 microRNA, human;MicroRNAs;Piperazines;Pyrimidines;Imatinib Mesylate;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Antineoplastic Agents;Apoptosis;Base Sequence;Benzamides;Binding Sites;Carcinogenesis;Cell Proliferation;Down-Regulation;Fusion Proteins, bcr-abl;G1 Phase Cell Cycle Checkpoints;GATA1 Transcription Factor;Gene Expression;Gene Expression Regulation, Neoplastic;HEK293 Cells;Humans;Imatinib Mesylate;K562 Cells;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;MicroRNAs;Open Reading Frames;Piperazines;Promoter Regions, Genetic;Pyrimidines;RNA Interference",
        "Doc_meshqualifiers":"pharmacology;pharmacology;genetics;metabolism;genetics;metabolism;metabolism;genetics;metabolism;pharmacology;pharmacology",
        "_version_":1605902878495473664},
      {
        "Doc_abstract":"The fusion oncoprotein bcr-abl that characterizes chronic myeloid leukemia (CML) is a leukemia-specific antigen, which may be immunogenic in vivo. KQSSKALQR and GFKQSSKAL, peptide sequences spanning the b3a2 bcr-abl junction, have affinity for HLA-A3 and HLA-B8, respectively, and we have shown the presence of KQSSKALQR on the surface of CML cells. We analyzed the existence of bcr-abl-specific T cells in vivo and correlated their presence to contemporary disease burden.;We investigated circulating CD8+ T lymphocytes directed against the bcr-abl junction, using fluorochrome-labeled tetramers of HLA-A3 with KQSSKALQR and of HLA-B8 with GFKQSSKAL, and flow cytometry analysis. Using chromium-release assays and interferon-g ELISPOT assays, we also studied the functionality of these expanded T cells.;Eight of 12 b3a2+ HLA-A3+ and/or HLA-B8+ CML patients studied serially on at least three occasions had bcr-abl junction-specific CD8+ T cells. Specific T cells were more likely to be found in patients with a low leukemic burden (p=0.03). Three of 18 HLA-A3+ and/or HLA-B8+ healthy donors had bcr-abl junction-specific T cells, though these were not detected in any of 13 subjects who were HLA-A3- and HLA-B8-. Bcr-abl-specific T cells were expandable in vitro in three of seven healthy donors and five of seven CML patients.;Bcr-abl-specific T cells are detectable in CML patients, and might contribute to leukemic control. The occurrence of specific CD8+ T cells in some healthy donors might represent an immune response to occult BCR-ABL rearrangements.",
        "Doc_title":"Circulating bcr-abl-specific CD8+ T cells in chronic myeloid leukemia patients and healthy subjects.",
        "Journal":"Haematologica",
        "Do_id":"16219567",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;CD8-Positive T-Lymphocytes;Female;Fusion Proteins, bcr-abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Neoplastic Cells, Circulating",
        "Doc_meshqualifiers":"chemistry;metabolism;blood;blood;immunology;metabolism",
        "_version_":1605891803803811840},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) is a hematopoietic stem cell disease with distinct biological and clinical features. The Philadelphia (Ph) chromosome and BCR/ABL fusion gene is the major cytogenetic and molecular marker of CML chronic phase. However, the molecular mechanisms of disease progression are not well known. Recent studies have shown that a several of transcription factors such as AML1, C/EBPalpha, HOX and GATA family play important role in hematopoiesis. In addition, the aberrations of these transcription factors including mutations or translocations have also been found to contribute the disease progression. Hence, BCR/ABL and aberrant transcription factors may result in the phenotype of CML blast crisis together.",
        "Doc_title":"The role of aberrant transcription factor in the progression of chronic myeloid leukemia.",
        "Journal":"Leukemia & lymphoma",
        "Do_id":"18766960",
        "Doc_ChemicalList":"Transcription Factors",
        "Doc_meshdescriptors":"Disease Progression;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mutation;Transcription Factors;Translocation, Genetic",
        "Doc_meshqualifiers":"etiology;genetics;genetics",
        "_version_":1605896418213494784},
      {
        "Doc_abstract":"To evaluate follow-up after -interferon (IFN) discontinuation, 23 patients with chronic myeloid leukemia (CML) in stable complete molecular response (CMolR) with IFN were revisited. After a median IFN treatment of 105.8 months (IR 56.1 - 127.3), all patients discontinued IFN for prolonged CMolR (12), intolerance (8) or planned ABMT (3). After 12.5 months, one patient developed an extramedullar blast crisis. Four patients needed to start imatinib, all achieving again molecular response. Eighteen patients are still off-therapy (median time from IFN discontinuation 125.5 months, IR 86.9-205.3); among these, five are BCR-ABL negative, six present with a sporadic positivity (BCR-ABL ratio < 0.1) and seven show a stable and long-lasting mild positivity (BCR-ABL ratio < 0.5). Patients in prolonged CMolR with IFN have low risk of recurrence after discontinuation; the reappearance of a BCR-ABL positivity < 0.5 did not always precede a relapse, suggesting mechanisms of immunological control induced by IFN. ",
        "Doc_title":"Discontinuation of alpha-interferon treatment in patients with chronic myeloid leukemia in long-lasting complete molecular response.",
        "Journal":"Leukemia & lymphoma",
        "Do_id":"25997497",
        "Doc_ChemicalList":"Antineoplastic Agents;Biomarkers;Interferon-alpha",
        "Doc_meshdescriptors":"Adult;Antineoplastic Agents;Biomarkers;Combined Modality Therapy;Female;Hematopoietic Stem Cell Transplantation;Humans;Interferon-alpha;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Remission Induction;Treatment Outcome",
        "Doc_meshqualifiers":"therapeutic use;therapeutic use;diagnosis;drug therapy;genetics;mortality",
        "_version_":1605881572801642496},
      {
        "Doc_abstract":"Previous studies demonstrated selective inhibition of the BCR-ABL (breakpoint cluster region-Abelson murine leukemia oncogene) tyrosine kinase by RNA interference in leukemic cells. In this study, we evaluated the effect of BCR-ABL small interfering RNA (siRNA) and GFI1B siRNA silencing on chronic myeloid leukemia (CML) cells in myeloid blast crises. The GFI1B gene was mapped to chromosome 9 and is, therefore, located downstream of the BCR-ABL translocation in CML cells. Co-transfection of BCR-ABL siRNA and GFI1B siRNA dramatically decreased cell viability and significantly induced apoptosis and inhibited proliferation in K562 cells (P<0.0001) and primary advanced phase CML cells (P<0.0001) versus controls. Furthermore, combining of BCR-ABL siRNA and GFI1B siRNA significantly modified the expression of several relevant genes including Myc, MDR1, MRP1 and tyrosyl-phosphoproteins in primary CML cells. Our data suggest that silencing of both BCR-ABL siRNA and GFI1B siRNA is associated with an additive antileukemic effect against K562 cells and primary advanced CML cells, further validating these genes as attractive therapeutic targets. ",
        "Doc_title":"Additive antileukemia effects by GFI1B- and BCR-ABL-specific siRNA in advanced phase chronic myeloid leukemic cells.",
        "Journal":"Cancer gene therapy",
        "Do_id":"23788109",
        "Doc_ChemicalList":"GFI1B protein, human;Proto-Oncogene Proteins;RNA, Small Interfering;Repressor Proteins;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Apoptosis;Cell Proliferation;Fusion Proteins, bcr-abl;Gene Expression;Gene Knockdown Techniques;Hematopoietic Stem Cells;Humans;K562 Cells;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Proto-Oncogene Proteins;RNA Interference;RNA, Small Interfering;Real-Time Polymerase Chain Reaction;Repressor Proteins",
        "Doc_meshqualifiers":"genetics;metabolism;metabolism;genetics;metabolism;genetics;genetics;metabolism",
        "_version_":1605891786975215616},
      {
        "Doc_abstract":"We describe the fourth case of e6a2 BCR-ABL transcript in a patient with chronic myeloid leukemia (CML), using reverse transcriptase polymerase chain reaction (RT-PCR) and sequencing analysis. The clinical and hematologic features and the aggressive course of disease in our patient and in the others reported in literature lead us to hypothesize that this atypical rearrangement may be associated with a worse prognosis.",
        "Doc_title":"e6a2 BCR-ABL transcript in chronic myeloid leukemia: is it associated with aggressive disease?",
        "Journal":"Haematologica",
        "Do_id":"15136228",
        "Doc_ChemicalList":"Interferon-alpha;Fusion Proteins, bcr-abl;Hydroxyurea",
        "Doc_meshdescriptors":"Adult;Aged;Antineoplastic Combined Chemotherapy Protocols;Disease Progression;Fusion Proteins, bcr-abl;Humans;Hydroxyurea;Interferon-alpha;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Prognosis",
        "Doc_meshqualifiers":"therapeutic use;genetics;therapeutic use;therapeutic use;diagnosis;drug therapy;genetics",
        "_version_":1605898152979726336},
      {
        "Doc_abstract":"Philadelphia chromosome-positive acute lymphoblastic leukemia occurs in two molecular forms, those with and those without rearrangement of the breakpoint cluster region on chromosome 22. The molecular abnormality in the former group is similar to that found in chronic myelogenous leukemia. To characterize the abnormality in the breakpoint cluster region-unrearranged form, we have mapped a 9;22 translocation from the Philadelphia chromosome-positive acute lymphoblastic leukemia cell line SUP-B13 by using pulsed-field gel electrophoresis and have cloned the DNA at the translocation junctions. We demonstrate a BCR-ABL fusion gene on the Philadelphia chromosome. The breakpoint on chromosome 9 is within ABL between exons Ia and II, and the breakpoint on chromosome 22 is approximately equal to 50 kilobases upstream of a breakpoint cluster region in an intron of the BCR gene. This upstream BCR breakpoint leads to inclusion of fewer BCR sequences in the fusion gene, compared with the BCR-ABL fusion gene of chronic myelogenous leukemia. Consequently, the associated mRNA and protein are smaller. The exons from ABL are the same. Analysis of leukemic cells from four other patients with breakpoint cluster region-unrearranged Philadelphia chromosome-positive acute lymphoblastic leukemia revealed a rearrangement on chromosome 22 close to the breakpoint in SUP-B13 in only one patient. These data indicate that breakpoints do not cluster tightly in this region but are scattered, possibly in a large intron. Given the large size of BCR and the heterogeneity in breakpoint location, detection of BCR rearrangement by standard Southern blot analysis is difficult. Pulsed-field gel electrophoresis should allow detection at the DNA level in every patient and thus will permit clinical correlation of the breakpoint location with prognosis.",
        "Doc_title":"Heterogeneity of genomic fusion of BCR and ABL in Philadelphia chromosome-positive acute lymphoblastic leukemia.",
        "Journal":"Proceedings of the National Academy of Sciences of the United States of America",
        "Do_id":"2833755",
        "Doc_ChemicalList":"Proto-Oncogene Proteins;DNA Restriction Enzymes",
        "Doc_meshdescriptors":"Chromosome Mapping;Chromosomes, Human, Pair 22;Chromosomes, Human, Pair 9;Cloning, Molecular;DNA Restriction Enzymes;Humans;Leukemia, Lymphoid;Oncogenes;Philadelphia Chromosome;Proto-Oncogene Proteins;Translocation, Genetic;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"genetics;genetics",
        "_version_":1605799564036538368},
      {
        "Doc_abstract":"A 32-yr-old man with the chronic phase of chronic myeloid leukemia (CML-CP) was treated with imatinib mesylate for 6 mo. The real-time quantitative reverse transcription PCR ratio for BCR/ABL in blood mRNA (BCR/ABL RT-QPCR) decreased from an initial value of 0.0159 to a low value of 0.0012 after 3 mo, indicating complete hematologic response. During the next 3 mo, the patient progressed to a promyelocytic blast crisis, displaying leukemic cells containing both BCR/ABL and PML/RARalpha chimeric mRNAs. Complete remission was achieved by therapy with all-trans retinoic acid (ATRA) and high-dose imatinib mesylate. Using retrospective PML/RARalpha RT-QPCR with a bone marrow specimen obtained at the initial diagnosis of CML-CP, we quantified the mRNA ratio as 0.000321, suggesting that the clonal evolution of PML/RARalpha translocation occurred early in the CML-CP.",
        "Doc_title":"Promyelocytic blast crisis of chronic myeloid leukemia during imatinib treatment.",
        "Journal":"Annals of clinical and laboratory science",
        "Do_id":"18715859",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Pyrimidines;Tretinoin;Imatinib Mesylate",
        "Doc_meshdescriptors":"Adult;Antineoplastic Agents;Benzamides;Blast Crisis;Humans;Imatinib Mesylate;Karyotyping;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Piperazines;Pyrimidines;Treatment Outcome;Tretinoin",
        "Doc_meshqualifiers":"therapeutic use;drug therapy;drug therapy;pathology;therapeutic use;therapeutic use;therapeutic use",
        "_version_":1605826743098146816},
      {
        "Doc_abstract":"Although BCR-ABL+ stem cells in chronic myeloid leukemia (CML) resist elimination by targeted pharmacotherapy in most patients, immunological graft-versus-leukemia effects can cure the disease. Besides cytotoxic T cells, natural killer (NK) cells may have a role in immune control of CML. Here, we explored the functionality of NK cells in CML patients and in a transgenic inducible BCR-ABL mouse model. Compared with controls, NK-cell proportions among lymphocytes were decreased at diagnosis of CML and did not recover during imatinib-induced remission for 10-34 months. Functional experiments revealed limited in vitro expansion of NK cells from CML patients and a reduced degranulation response to K562 target cells both at diagnosis and during imatinib therapy. Consistent with the results in human CML, relative numbers of NK1.1+ NK cells were reduced following induction of BCR-ABL expression in mice, and the defects persisted after BCR-ABL reversion. Moreover, target-induced degranulation by expanded BCR-ABL+ NK cells was compromised. We conclude that CML is associated with quantitative and functional defects within the NK-cell compartment, which is reproduced by induced BCR-ABL expression in mice. Further work will aim at identifying the mechanisms of NK-cell deficiency in CML and at developing strategies to exploit NK cells for immunotherapy.",
        "Doc_title":"NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR-ABL-positive mice.",
        "Journal":"Leukemia",
        "Do_id":"21904381",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Imatinib Mesylate;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Animals;Antineoplastic Agents;Benzamides;Cell Degranulation;Child;Disease Models, Animal;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;K562 Cells;Killer Cells, Natural;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mice;Mice, Transgenic;Middle Aged;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Young Adult",
        "Doc_meshqualifiers":"pharmacology;therapeutic use;genetics;immunology;genetics;drug effects;immunology;metabolism;drug therapy;genetics;immunology;pharmacology;therapeutic use;pharmacology;therapeutic use;pharmacology;therapeutic use",
        "_version_":1605774249821208576},
      {
        "Doc_abstract":"Adult B-cell acute lymphoblastic leukemia remains a major therapeutic challenge, requiring a better characterization of the molecular determinants underlying disease progression and resistance to treatment. Here, using a phospho-flow cytometry approach we show that adult diagnostic B-cell acute lymphoblastic leukemia specimens display PI3K/Akt pathway hyperactivation, irrespective of their BCR-ABL status and despite paradoxically high basal expression of PTEN, the major negative regulator of the pathway. Protein kinase CK2 is known to phosphorylate PTEN thereby driving PTEN protein stabilization and concomitant PTEN functional inactivation. In agreement, we found that adult B-cell acute lymphoblastic leukemia samples show significantly higher CK2 kinase activity and lower PTEN lipid phosphatase activity than healthy controls. Moreover, the clinical-grade CK2 inhibitor CX-4945 (Silmitasertib) reversed PTEN levels in leukemia cells to those observed in healthy controls, and promoted leukemia cell death without significantly affecting normal bone marrow cells. Our studies indicate that CK2-mediated PTEN posttranslational inactivation, associated with PI3K/Akt pathway hyperactivation, are a common event in adult B-cell acute lymphoblastic leukemia and suggest that CK2 inhibition may constitute a valid, novel therapeutic tool in this malignancy. ",
        "Doc_title":"Adult B-cell acute lymphoblastic leukemia cells display decreased PTEN activity and constitutive hyperactivation of PI3K/Akt pathway despite high PTEN protein levels.",
        "Journal":"Haematologica",
        "Do_id":"24561792",
        "Doc_ChemicalList":"Protein Kinase Inhibitors;STAT Transcription Factors;Phosphatidylinositol 3-Kinases;Janus Kinases;Casein Kinase II;Proto-Oncogene Proteins c-akt;PTEN Phosphohydrolase;PTEN protein, human",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Case-Control Studies;Casein Kinase II;Cell Line;Chromosome Aberrations;Enzyme Activation;Female;Gene Expression;Humans;Immunohistochemistry;Janus Kinases;Male;Middle Aged;PTEN Phosphohydrolase;Phosphatidylinositol 3-Kinases;Precursor B-Cell Lymphoblastic Leukemia-Lymphoma;Protein Kinase Inhibitors;Proto-Oncogene Proteins c-akt;STAT Transcription Factors;Signal Transduction;Young Adult",
        "Doc_meshqualifiers":"antagonists & inhibitors;metabolism;metabolism;genetics;metabolism;antagonists & inhibitors;metabolism;genetics;metabolism;pharmacology;metabolism;metabolism;drug effects",
        "_version_":1605795225089867776},
      {
        "Doc_abstract":"Although imatinib mesylate (IM) has revolutionized the treatment of chronic myeloid leukemia (CML), some patients develop resistance with progression of leukemia. Alternative or additional targeting of signaling pathways deregulated in bcr-abl-driven CML cells may provide a feasible option for improving clinical response and overcoming resistance. In this study, we show that carboxyamidotriazole (CAI), an orally bioavailable calcium influx and signal transduction inhibitor, is equally effective in inhibiting the proliferation and bcr-abl dependent- and independent-signaling pathways in imatinib-resistant CML cells. CAI inhibits phosphorylation of cellular proteins including STAT5 and CrkL at concentrations that induce apoptosis in IM-resistant CML cells. The combination of imatinib and CAI also down-regulated bcr-abl protein levels. Since CAI is already available for clinical use, these results suggest that it may be an effective addition to the armamentarium of drugs for the treatment of CML.",
        "Doc_title":"Effects of carboxyamidotriazole on in vitro models of imatinib-resistant chronic myeloid leukemia.",
        "Journal":"Journal of cellular physiology",
        "Do_id":"17924401",
        "Doc_ChemicalList":"Benzamides;Enzyme Inhibitors;Molecular Probes;Piperazines;Pyrimidines;Triazoles;Phosphotyrosine;Imatinib Mesylate;carboxyamido-triazole;Fusion Proteins, bcr-abl;ras Proteins",
        "Doc_meshdescriptors":"Apoptosis;Benzamides;Cell Line, Tumor;Cell Proliferation;Down-Regulation;Drug Resistance, Neoplasm;Enzyme Activation;Enzyme Inhibitors;Fusion Proteins, bcr-abl;Gene Expression Regulation, Neoplastic;Humans;Imatinib Mesylate;In Situ Hybridization, Fluorescence;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;MAP Kinase Signaling System;Molecular Probes;Phosphotyrosine;Piperazines;Pyrimidines;Triazoles;ras Proteins",
        "Doc_meshqualifiers":"drug effects;drug effects;drug effects;drug effects;pharmacology;genetics;metabolism;drug effects;enzymology;pathology;drug effects;metabolism;metabolism;pharmacology;pharmacology;pharmacology;metabolism",
        "_version_":1605751549892493312},
      {
        "Doc_abstract":"Expression of c-Myb is required for normal hematopoiesis and for proliferation of myeloid leukemia blasts and a subset of T-cell leukemia, but its role in B-cell leukemogenesis is unknown. We tested the role of c-Myb in p190(BCR/ABL)-dependent B-cell leukemia in mice transplanted with p190(BCR/ABL)-transduced marrow cells with a c-Myb allele (Myb(f/d)) and in double transgenic p190(BCR/ABL)/Myb(w/d) mice. In both models, loss of a c-Myb allele caused a less aggressive B-cell leukemia. In p190(BCR/ABL)-expressing human B-cell leukemia lines, knockdown of c-Myb expression suppressed proliferation and colony formation. Compared with c-Myb(w/f) cells, expression of Bmi1, a regulator of stem cell proliferation and maintenance, was decreased in pre-B cells from Myb(w/d) p190(BCR/ABL) transgenic mice. Ectopic expression of a mutant c-Myb or Bmi1 enhanced the proliferation and colony formation of Myb(w/d) p190(BCR/ABL) B-cells; by contrast, Bmi1 downregulation inhibited colony formation of p190(BCR/ABL)-expressing murine B cells and human B-cell leukemia lines. Moreover, c-Myb interacted with a segment of the human Bmi1 promoter and enhanced its activity. In blasts from 19 Ph(1) adult acute lymphoblastic leukemia patients, levels of c-Myb and Bmi1 showed a positive correlation. Together, these findings support the existence of a c-Myb-Bmi1 transcription-regulatory pathway required for p190(BCR/ABL) leukemogenesis.",
        "Doc_title":"c-Myb and its target Bmi1 are required for p190BCR/ABL leukemogenesis in mouse and human cells.",
        "Journal":"Leukemia",
        "Do_id":"21960247",
        "Doc_ChemicalList":"Bmi1 protein, mouse;Nuclear Proteins;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-myb;Repressor Proteins;Polycomb Repressive Complex 1;Fusion Proteins, bcr-abl;MAPK7 protein, human;Mitogen-Activated Protein Kinase 7",
        "Doc_meshdescriptors":"Animals;Cell Proliferation;Cell Transformation, Neoplastic;Fusion Proteins, bcr-abl;Humans;Leukemia, B-Cell;Mice;Mice, Inbred C57BL;Mitogen-Activated Protein Kinase 7;Nuclear Proteins;Polycomb Repressive Complex 1;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-myb;Repressor Proteins",
        "Doc_meshqualifiers":"pathology;physiology;etiology;pathology;physiology;physiology;physiology;physiology;physiology",
        "_version_":1605906495969427456},
      {
        "Doc_abstract":"The objective of this study was to analyze the level of bcr-abl mRNA in peripheral blood (PB) after allogeneic stem cell transplantation (allo-SCT) in chronic myeloid leukemia patients, providing a experimental basis for diagnosing early relapse. bcr-abl mRNA levels in 78 PB and bone marrow (BM) samples from 15 CML patients after allo-SCT were detected by using real-time quantitative PCR. The results indicated that levels of bcr-abl mRNA before transplantation were high (median 29.303%) and decreased greatly (median 0) at the first month after allo-SCT. During the first year after allo-SCT, the patterns of serial bcr-abl transcripts varied in number, but the overall bcr-abl transcript levels significantly decreased at 6 months after allo-SCT. Majority of patients with undetectable or very low levels of bcr-abl mRNA were monitored after 1 year following transplantation. The hematological features of BM and PB in all detected patients remained normal. PB and BM bcr-abl values were not different significantly and had the similar trend of changes. It is concluded that the bcr-abl mRNA levels in CML patients change greatly early after allograft. Serial monitoring measurements for bcr-abl mRNA contribute to understanding the trend of change and effect of transplantation, also can be a guidance for starting therapy. But detectable levels of bcr-abl mRNA during the first 6 months do not indicate relapse. Measurements of bcr-abl mRNA of PB may be more suitable for routine monitoring long-term disease status in CML after allo-HSCT.",
        "Doc_title":"[Significance of quantitative detection of bcr-abl mRNA in chronic myeloid leukemia patients after allogeneic hematopoietic stem cell transplant].",
        "Journal":"Zhongguo shi yan xue ye xue za zhi",
        "Do_id":"17956677",
        "Doc_ChemicalList":"RNA, Messenger;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adolescent;Adult;Bone Marrow;Fusion Proteins, bcr-abl;Hematopoietic Stem Cell Transplantation;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Neoplasm, Residual;RNA, Messenger;Reverse Transcriptase Polymerase Chain Reaction;Young Adult",
        "Doc_meshqualifiers":"metabolism;blood;metabolism;metabolism;therapy;diagnosis;blood;metabolism",
        "_version_":1605746423640358912},
      {
        "Doc_abstract":"The use of a DNA vaccine encoding the BCR/ABL fusion gene is thought to be a promising approach for patients with chronic myeloid leukemia (CML) to eradicate minimal residual disease after treatment with chemotherapy or targeted therapy. In this study, our strategy employs genetic technology to create a DNA vaccine encoding the BCR/ABL fusion and human interleukin-2 (hIL-2) genes. The successfully constructed plasmids BCR/ABL-pIRES-hIL-2, BCR/ABL-pIRES, and pIRES-hIL-2 were delivered intramuscularly to BALB/c mice at 14-day intervals for three cycles. The transcription and expression of the BCR/ABL and hIL-2 genes were found in the injected muscle tissues. The interferon-  (IFN-  ) serum levels were increased, and the splenic CD4(+)/CD8(+) T cell ratio was significantly decreased in the BCR/ABL-pIRES-hIL-2-injected mice. Furthermore, specific antibodies against K562 cells could be detected by indirect immunofluorescence. These results indicate that a DNA vaccine containing BCR/ABL and hIL-2 together may elicit increased in vivo humoral and cellular immune responses in BALB/c mice. ",
        "Doc_title":"A BCR/ABL-hIL-2 DNA vaccine enhances the immune responses in BALB/c mice.",
        "Journal":"BioMed research international",
        "Do_id":"23841051",
        "Doc_ChemicalList":"Cancer Vaccines;Interleukin-2;Recombinant Fusion Proteins;Vaccines, DNA;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Animals;Cancer Vaccines;Fusion Proteins, bcr-abl;Humans;Immunity, Cellular;Interleukin-2;K562 Cells;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mice;Recombinant Fusion Proteins;Vaccines, DNA",
        "Doc_meshqualifiers":"administration & dosage;genetics;administration & dosage;genetics;immunology;genetics;genetics;genetics;therapy;administration & dosage;genetics;administration & dosage",
        "_version_":1605893104145006592},
      {
        "Doc_abstract":"The BCR-ABL tyrosine kinase is the defining feature of chronic myeloid leukemia (CML) and its kinase activity is required for induction of this disease. Current thinking holds that BCR-ABL forms a multi-protein complex that incorporates several substrates and adaptor proteins and is stabilized by multiple direct and indirect interactions. Signaling output from this highly redundant network leads to cellular transformation. Proteins known to be associated with BCR-ABL in this complex include: GRB2, c-CBL, p62(DOK), and CRKL. These proteins in turn, link BCR-ABL to various signaling pathways indicated in cellular transformation. In this study we show that a triple mutant of BCR-ABL with mutations of the direct binding sites for GRB2, CBL, p62(DOK) and CRKL, is defective for transformation of primary hematopoietic cells in vitro and in a murine CML model, while it retains the capacity to induce IL-3 independence in 32D cells. Compared to BCR-ABL, the triple mutant's ability to activate the MAP kinase and PI3-kinase pathways is severely compromised, while STAT5 phosphorylation is maintained, suggesting that the former are crucial for the transformation of primary cells, but dispensable for transformation of factor dependent cell lines. Our data suggest that inhibition of BCR-ABL-induced leukemia by disrupting protein interactions could be possible, but would require blocking of multiple sites.",
        "Doc_title":"A BCR-ABL mutant lacking direct binding sites for the GRB2, CBL and CRKL adapter proteins fails to induce leukemia in mice.",
        "Journal":"PloS one",
        "Do_id":"19823681",
        "Doc_ChemicalList":"Adaptor Proteins, Signal Transducing;CRKL protein;GRB2 Adaptor Protein;Grb2 protein, mouse;Interleukin-3;Nuclear Proteins;STAT5 Transcription Factor;Proto-Oncogene Proteins c-cbl;Phosphatidylinositol 3-Kinases;Fusion Proteins, bcr-abl;Cbl protein, mouse",
        "Doc_meshdescriptors":"Adaptor Proteins, Signal Transducing;Animals;Binding Sites;Cell Transformation, Neoplastic;Female;Fusion Proteins, bcr-abl;GRB2 Adaptor Protein;Interleukin-3;Leukemia;Mice;Mice, Inbred BALB C;Neoplasms, Experimental;Nuclear Proteins;Phosphatidylinositol 3-Kinases;Phosphorylation;Proto-Oncogene Proteins c-cbl;STAT5 Transcription Factor;Signal Transduction",
        "Doc_meshqualifiers":"metabolism;genetics;metabolism;metabolism;genetics;metabolism;genetics;metabolism;metabolism;metabolism;metabolism",
        "_version_":1605895475891798016},
      {
        "Doc_abstract":"The Philadelphia (Ph) chromosome was the first chromosomal abnormality associated with a specific leukemia, chronic myeloid leukemia (CML). This chromosome arises from the t(9;22)(q34;q11) translocation which results in the juxtaposition of the bcr gene and the abl proto-oncogene. This BCR/ABL fusion gene encodes for a hybrid protein with the capacity of oncogenic transformation of hematopoietic cells. Nonetheless, very few myeloproliferative disorders (about 10%) included under the generic term of CML have no Ph chromosome. Half of these Ph-negative CML have the BCR/ABL fusion gene (BCR-positive) and are considered equivalent to Ph-positive CML. In contrast, the patients without detectable BCR/ABL fusion (BCR-negative) fulfil the criteria for atypical CML (aCML) of the French-American-British (FAB) classification, despite considerable variability at the individual level. Due to the very small number of patients with precise cytological descriptions already published, cooperative studies focused on aCML are warranted to draw definitive conclusions and to provide some pointers on physiopathology.",
        "Doc_title":"Clinical and biological aspects of Philadelphia-negative/BCR-negative chronic myeloid leukemia.",
        "Journal":"Leukemia & lymphoma",
        "Do_id":"9168433",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adult;Female;Fusion Proteins, bcr-abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative;Male;Middle Aged;Philadelphia Chromosome",
        "Doc_meshqualifiers":"genetics;diagnosis;etiology;genetics;diagnosis;etiology;genetics",
        "_version_":1605874959241969664},
      {
        "Doc_abstract":"We report two cases of chronic myeloid leukemia (CML) in childhood presenting with monocytosis. History, physical examination and laboratory findings were in favor of juvenile myelomonocytic leukemia in both the cases, but reverse transcriptase polymerase chain reaction (RT-PCR) detected b2a2 and b3a2 transcript of p210 bcr-abl protein characteristic of major BCR breakpoint. Presence of monocytosis in early childhood suggests a viral infection or JMML but a possibility of CML with monocytosis needs to be considered.",
        "Doc_title":"Childhood chronic myeloid leukemia with monocytosis.",
        "Journal":"Indian journal of pediatrics",
        "Do_id":"20882436",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Cytogenetic Analysis;Fusion Proteins, bcr-abl;Humans;Infant;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Monocytes",
        "Doc_meshqualifiers":"genetics;blood;diagnosis;genetics;metabolism",
        "_version_":1605843578379042816},
      {
        "Doc_abstract":"We have previously identified a tyrosine kinase-independent, guanine nucleotide exchange factor (GEF) activity, which is contained within the region of p210 no expansion BCR/ABL that distinguishes it from p190 BCR/ABL. In the current study, we have compared the transforming activity of p190 BCR/ABL, p210 BCR/ABL and a mutant that lacks GEF activity (p210 BCR/ABL(S509A)). In cell-based, ex vivo, and murine bone marrow transplantation (BMT) assays the transforming activity of p210 BCR/ABL(S509A) mimics p190 BCR/ABL, and is distinct from p210 BCR/ABL. Thus, in the BMT assay, the p190 BCR/ABL- and p210 BCR/ABL(S509A)-transplanted mice exhibit a more rapid onset of disease than mice transplanted with p210 BCR/ABL. The reduced disease latency is associated with erythroid hyperplasia in the absence of anemia, and expansion of the megakaryocyte-erythrocyte progenitor (MEP), common myeloid progenitor (CMP) and granulocyte-macrophage progenitor (GMP) populations, producing a phenotype that is similar to acute myeloid leukemia (AML-M6). The disease phenotype is readily transplantable into secondary recipients. This is consistent with ex vivo clonogenicity assays, where p210 BCR/ABL preferentially supports the growth of colony forming unit (CFU)-granulocyte-macrophage (GM), whereas p190 BCR/ABL and the mutant preferentially support the growth of burst forming unit-erythroid (BFU-E). These results suggest that the GEF activity that distinguishes p210 BCR/ABL from p190 BCR/ABL actively regulates disease progression.",
        "Doc_title":"Contributions of the RhoGEF activity of p210 BCR/ABL to disease progression.",
        "Journal":"Leukemia",
        "Do_id":"23207522",
        "Doc_ChemicalList":"Guanine Nucleotide Exchange Factors;Interleukin-3;Rho Guanine Nucleotide Exchange Factors;Fusion Proteins, bcr-abl;rhoA GTP-Binding Protein",
        "Doc_meshdescriptors":"Animals;Bone Marrow Transplantation;Cells, Cultured;Disease Progression;Fusion Proteins, bcr-abl;Guanine Nucleotide Exchange Factors;Humans;Interleukin-3;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mice;Mice, Inbred BALB C;Rho Guanine Nucleotide Exchange Factors;Signal Transduction;rhoA GTP-Binding Protein",
        "Doc_meshqualifiers":"physiology;physiology;pharmacology;etiology;physiology",
        "_version_":1605746277488787457},
      {
        "Doc_abstract":"We have analyzed the M-bcr breakpoint position in 133 Philadelphia-positive chronic myeloid leukemia patients and correlated the findings with clinical, hematologic, and cytogenetic data. We also investigated the splicing pattern of the BCR-ABL mRNA in 30 patients, using reverse transcriptase PCR. No statistically significant differences were found between breakpoint position within M-bcr and clinical parameters at diagnosis, the karyotypic evolution pattern, or the leukemic phenotype during blast crisis. Furthermore, the breakpoint position within M-bcr did not correlate with the duration of chronic phase or survival time. When the splicing pattern of the BCR-ABL mRNA was compared with the results of the genomic breakpoint mapping, it was found that approximately 60% (8/14) of the patients with a 5' break expressed b2a2 fusion mRNA, whereas all patients (10/10) with a 3' break expressed b3a2 BCR-ABL mRNA.",
        "Doc_title":"Clinical impact of breakpoint position within M-bcr in chronic myeloid leukemia.",
        "Journal":"Leukemia",
        "Do_id":"8350622",
        "Doc_ChemicalList":"Proto-Oncogene Proteins;RNA, Messenger;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl;BCR protein, human;Proto-Oncogene Proteins c-bcr",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Analysis of Variance;Chi-Square Distribution;Child;Chromosome Fragility;Chromosome Mapping;Chromosomes, Human, Pair 22;Female;Fusion Proteins, bcr-abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Multigene Family;Polymerase Chain Reaction;Prognosis;Protein-Tyrosine Kinases;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-bcr;RNA Splicing;RNA, Messenger;Survival Rate",
        "Doc_meshqualifiers":"genetics;genetics;mortality;genetics;genetics",
        "_version_":1605809303441113088},
      {
        "Doc_abstract":"Approximately 2-5% of children with newly diagnosed acute lymphoblastic leukemia (ALL) have a Philadelphia (Ph) chromosome detectable on cytogenetic analysis, which is associated with a poor prognosis. In rare ALL cases the Ph chromosome may appear in leukemic cells during the course of the disease. We report here the case of a 5.5-year-old male patient with T-ALL who was found to have the b2a2 BCR-ABL mRNA transcript by reverse transcriptase-polymerase chain reaction (RT-PCR) at first marrow relapse. At the time of initial diagnosis, no BCR-ABL transcripts had been detected by PCR in the patient's blood and marrow samples. Further studies were performed using a competitive PCR titration assay and the fluorescence in situ hybridization (FISH) method to monitor the leukemic clone. Progression of the disease was associated with a higher BCR-ABL transcript level and an increasing proportion of BCR-ABL-positive cells. Metaphase FISH analysis identified the presence of the BCR-ABL fusion gene on a normal chromosome 22. This study shows that a late-appearing Ph translocation in ALL may be cytogenetically invisible. Quantitative RT-PCR and FISH techniques are appropriate and efficient methods for detecting these rare ALL variants expressing the BCR-ABL fusion gene and for estimating the level of residual disease following treatment.",
        "Doc_title":"Molecular detection of a late-appearing BCR-ABL gene in a child with T-cell acute lymphoblastic leukemia.",
        "Journal":"Annals of hematology",
        "Do_id":"9760154",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Child;Cytogenetics;Fusion Proteins, bcr-abl;Genes, Neoplasm;Humans;Karyotyping;Leukemia-Lymphoma, Adult T-Cell;Male",
        "Doc_meshqualifiers":"genetics;genetics",
        "_version_":1605807051528732672},
      {
        "Doc_abstract":"This study aimed to verify the association between human leukocyte antigens and the bcr-abl fusion protein resulting from t(9;22)(q34;q11) in chronic leukemia myeloid and acute lymphoblastic leukemia patients.;Forty-seven bcr-abl positive individuals were evaluated. Typing was performed bymicrolymphocytotoxicity and molecular biological methods (human leukocyte antigens Class I and Class II). A control group was obtained from the data of potential bone marrow donors registered in the Brazilian Bone Marrow Donor Registry (REDOME).;Positive associations with HLA-A25 and HLA-B18 were found for the b2a2 transcript, as well as a tendency towards a positive association with HLA-B40 and a negative association with HLA-A68. The b3a2 transcript showed positive associations with HLA-B40 and HLA-DRB1*3.;The negative association between human leukocyte antigens and the BCR-ABL transcript suggests that binding and presentation of peptides derived from the chimeric protein are effective to increase a cytotoxic T lymphocyte response appropriate for the destruction of leukemic cells.",
        "Doc_title":"Association of HLA antigens and BCR-ABL transcripts in leukemia patients with the Philadelphia chromosome.",
        "Journal":"Revista brasileira de hematologia e hemoterapia",
        "Do_id":"23049441",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605883682027995136},
      {
        "Doc_abstract":"Inactivation of glycogen synthase kinase (GSK)-3 has been implicated in cancer progression. Previously, we showed an abundance of inactive GSK-3 in the human chronic myeloid leukemia (CML) cell line. CML is a hematopoietic malignancy caused by an oncogenic Bcr-Abl tyrosine kinase. In Bcr-Abl signaling, the role of GSK-3 is not well defined. Here, we report that enforced expression of constitutively active GSK-3 reduced proliferation and increased Bcr-Abl inhibition-induced apoptosis by nearly 1-fold. Bcr-Abl inhibition activated GSK-3 and GSK-3-dependent apoptosis. Inactivation of GSK-3 by Bcr-Abl activity is, therefore, confirmed. To reactivate GSK-3, we used glucosylceramide synthase (GCS) inhibitor PDMP to accumulate endogenous ceramide, a tumor-suppressor sphingolipid and a potent GSK-3 activator. We found that either PDMP or silence of GCS increased Bcr-Abl inhibition-induced GSK-3 activation and apoptosis. Furthermore, PDMP sensitized the most clinical problematic drug-resistant CML T315I mutant to Bcr-Abl inhibitor GNF-2-, imatinib-, or nilotinib-induced apoptosis by >5-fold. Combining PDMP and GNF-2 eliminated transplanted-CML-T315I-mutants in vivo and dose dependently sensitized primary cells from CML T315I patients to GNF-2-induced proliferation inhibition and apoptosis. The synergistic efficacy was Bcr-Abl restricted and correlated to increased intracellular ceramide levels and acted through GSK-3-mediated apoptosis. This study suggests a feasible novel anti-CML strategy by accumulating endogenous ceramide to reactivate GSK-3 and abrogate drug resistance.",
        "Doc_title":"Glucosylceramide synthase inhibitor PDMP sensitizes chronic myeloid leukemia T315I mutant to Bcr-Abl inhibitor and cooperatively induces glycogen synthase kinase-3-regulated apoptosis.",
        "Journal":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology",
        "Do_id":"21705667",
        "Doc_ChemicalList":"Ceramides;Enzyme Inhibitors;GNF-2 compound;Immunoglobulin G;Morpholines;Pyrimidines;antineoplastic agent K 18;1-Deoxynojirimycin;RV 538;miglustat;Glucosyltransferases;ceramide glucosyltransferase;Glycogen Synthase Kinase 3;Melphalan",
        "Doc_meshdescriptors":"1-Deoxynojirimycin;Animals;Apoptosis;Cell Line, Tumor;Ceramides;Dose-Response Relationship, Drug;Drug Resistance, Neoplasm;Enzyme Inhibitors;Female;Genes, abl;Glucosyltransferases;Glycogen Synthase Kinase 3;Humans;Immunoglobulin G;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Melphalan;Mice;Mice, SCID;Morpholines;Mutation;Neoplasms, Experimental;Pyrimidines;Transplantation, Heterologous",
        "Doc_meshqualifiers":"analogs & derivatives;pharmacology;drug effects;physiology;metabolism;pharmacology;drug effects;physiology;antagonists & inhibitors;metabolism;drug therapy;pharmacology",
        "_version_":1605742753121042432},
      {
        "Doc_abstract":"Peptides were immobilized onto superparamagnetic beads via photocleavable linkers. This enabled simple, rapid, and label-free protein kinase assays via MALDI-TOF MS detection of substrate peptide phosphorylation. Abltide, a model substrate for the Abl protein tyrosine kinase model, was coupled onto amine-terminated beads, incubated with ATP and recombinant c-Abl kinase, and released and further detected to determine phosphorylation. Abltide phosphorylation was found to depend significantly on the length and composition of linkers to the bead surface. Inserting a diblock spacer of poly(glycine) and poly(ethylene glycol) segments markedly enhanced phosphorylation. To validate the assay, the activity of two small-molecule kinase inhibitors, imatinib and dasatinib, which target the oncogenic mutant tyrosine kinase Bcr-Abl to treat chronic myeloid leukemia (CML), was tested. Examining inhibition of the purified c-Abl or Bcr-Abl in K562 CML cell extracts, IC(50) values were determined to be consistent with the literature. This simple, label-free, MALDI-based protein kinase assay can be readily adapted to allow multiplexed assays of multiple peptide substrates and/or analysis of alternative post-translational modifications as a tool for drug discovery and clinical testing.",
        "Doc_title":"Photocleavable peptide-conjugated magnetic beads for protein kinase assays by MALDI-TOF MS.",
        "Journal":"Bioconjugate chemistry",
        "Do_id":"20860375",
        "Doc_ChemicalList":"9-fluorenylmethoxycarbonyl;Fluorenes;Peptides;Protein Kinase Inhibitors;Protein Kinases",
        "Doc_meshdescriptors":"Amino Acid Sequence;Enzyme Assays;Fluorenes;Humans;K562 Cells;Magnetics;Microspheres;Molecular Sequence Data;Peptides;Photochemical Processes;Protein Kinase Inhibitors;Protein Kinases;Reproducibility of Results;Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization",
        "Doc_meshqualifiers":"methods;chemistry;chemistry;pharmacology;metabolism;methods",
        "_version_":1605881123894722560},
      {
        "Doc_abstract":"Distinct clinicopathologic acute lymphoblastic leukemia (ALL) entities have been identified, resulting in the adoption of risk-oriented treatment approaches. In Philadelphia chromosome-positive (Ph(+)) ALL, the optimal treatment requires the addition of BCR-ABL tyrosine kinase inhibitors, as imatinib. However, the outcome remains poor in absence of allogeneic stem cell transplantation, and novel agents are desperately required. Resistance attributable to kinase domain mutations can lead to relapse despite the development of second-generation compounds, including dasatinib and nilotinib. Despite these therapeutic options, the cross-resistant BCR-ABL (T315I) mutation remains a major clinical challenge. The first evaluations of AP24534 present this drug as a potent multi-targeted kinase inhibitor active against T315I and all other BCR-ABL mutants. AP24534 could be the next treatment of choice in hematological malignancies with Philadelphia-positive chromosome, particularly Ph(+) ALL known for its frequent occurrence of T315I mutation.",
        "Doc_title":"[Is AP24534 (Ponatinib) the next treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia?].",
        "Journal":"Bulletin du cancer",
        "Do_id":"21700550",
        "Doc_ChemicalList":"Antineoplastic Agents;Imidazoles;Protein Kinase Inhibitors;Pyridazines;ponatinib;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Acute Disease;Antineoplastic Agents;Clinical Trials, Phase I as Topic;Fusion Proteins, bcr-abl;Humans;Imidazoles;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Point Mutation;Protein Kinase Inhibitors;Protein-Tyrosine Kinases;Pyridazines",
        "Doc_meshqualifiers":"therapeutic use;antagonists & inhibitors;genetics;therapeutic use;drug therapy;genetics;therapeutic use;antagonists & inhibitors;genetics;therapeutic use",
        "_version_":1605874748846243840},
      {
        "Doc_abstract":"The study of the minimum residual disease in a series of patients diagnosed with chronic myeloid leukemia (CML) treated with non manipulated allogeneic bone marrow transplantation (BMT) reporting a survival longer than 6 months is presented.;The positivity of the chimeric transcription bcr-abl was studied in 18 long surviving BMT patients. The complementary DNA (cDNA) corresponding to this transcription was amplified by the polymerase chain reaction (PCR) technique. Double internal PCR (PCR nested) was performed to increase the sensitivity of the determination.;The first determination was performed in different post BMT stages with a median of 27 months (4-97). Fourteen out the 18 patients were positive for the bcr-abl transcription. On the second determination carried out in 11 cases with a sample obtained 24 months after the first 7 out of the 10 positive cases evaluated presented an identical pattern while the patient who originally was negative, remained so. The original transcription became negative in three patients. Only one of the positive cases developed hematologic relapse during the study period.;Aggressive chemo-radiotherapy does not eradicate the leukemic clone in all patients with chronic myeloid leukemia. The persistence of positive results in a high number of patients with chronic myeloid leukemia in remission for over 6 months after bone marrow transplantation is not predictive of imminent relapse.",
        "Doc_title":"[Minimal residual disease in chronic myeloid leukemia in patients with long survival after allogeneic bone marrow transplantation].",
        "Journal":"Medicina clinica",
        "Do_id":"7715257",
        "Doc_ChemicalList":"DNA, Complementary",
        "Doc_meshdescriptors":"Adult;Bone Marrow Transplantation;Child;DNA, Complementary;Electrophoresis, Agar Gel;Female;Genes, abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Neoplasm, Residual;Polymerase Chain Reaction;Time Factors;Transcription, Genetic",
        "Doc_meshqualifiers":"genetics;genetics;mortality;therapy",
        "_version_":1605819328922386432},
      {
        "Doc_abstract":"The Nuclear Factor-kappa B (NF-B) family of transcription factors plays a key role in cancer pathogenesis due to the ability to promote cellular proliferation and survival, to induce resistance to chemotherapy and to mediate invasion and metastasis. NF-B is recruited through different mechanisms involving either canonical (RelA/p50) or non-canonical pathways (RelB/p50 or RelB/p52), which transduce the signals originated from growth-factors, cytokines, oncogenic stress and DNA damage, bacterial and viral products or other stimuli. The pharmacological inhibition of the NF-B pathway has clearly been associated with significant clinical activity in different cancers. Almost 20 years ago, NF-B was described as an essential modulator of BCR-ABL signaling in Chronic Myeloid Leukemia and Philadelphia-positive Acute Lymphoblastic Leukemia. This review summarizes the role of NF-B in BCR-ABL-mediated leukemogenesis and provides new insights on the long lasting BCR-ABL/NF-B connection.",
        "Doc_title":"The BCR-ABL/NF-B signal transduction network: a long lasting relationship in Philadelphia positive Leukemias.",
        "Journal":"Oncotarget",
        "Do_id":"27563822",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605818652846718978},
      {
        "Doc_abstract":"Despite the excellent responses to imatinib therapy observed in patients with chronic phase chronic myeloid leukemia, approximately 25% of patients display primary resistance or suboptimal response. The OCT-1 activity in mononuclear cells reflects the efficiency of active influx of imatinib. OCT-1 activity in mononuclear cells is highly variable between patients and significantly correlates with a patient's molecular response to imatinib treatment and overall survival. The present study examined whether cell lineage and BCR-ABL expression influenced OCT-1 activity.;The OCT-1 activity and OCT-1 mRNA expression was assessed in pure populations of neutrophils, monocytes and lymphocytes recovered from chronic myeloid leukemia patients at diagnosis, in cytogenetic remission and normal individuals. The role of BCR-ABL on OCT-1 activity and differentiation was examined in a cell line model of ectopic BCR-ABL expression.;The OCT-1 activity and OCT-1 mRNA expression was highest in the neutrophil population and lowest in lymphocytes (P<0.05). This was observed for patients at diagnosis, in cytogenetic remission and normal individuals. Interestingly, neutrophil OCT-1 activity was not significantly different between patients at diagnosis, in remission and normal donors. This was also observed for monocytes and lymphocytes. Furthermore, OCT-1 activity in mononuclear cells was significantly correlated with the OCT-1 activity in neutrophils (P=0.001). In a cell line model in which BCR-ABL was ectopically expressed, we found no evidence that BCR-ABL directly affected OCT-1 expression and function. However, BCR-ABL stimulated granulocyte differentiation which, in turn, led to significantly increased OCT-1 activity (P=0.024).;These studies suggest that the predictive OCT-1 activity in patient mononuclear cells is strongly related to cell lineage, particularly the presence of neutrophils in the peripheral blood. Furthermore, BCR-ABL expression is unlikely to directly influence OCT-1 activity but may have an indirect role by enhancing granulocyte differentiation.",
        "Doc_title":"OCT-1 function varies with cell lineage but is not influenced by BCR-ABL.",
        "Journal":"Haematologica",
        "Do_id":"20971815",
        "Doc_ChemicalList":"Organic Cation Transporter 1;RNA, Messenger;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Blotting, Western;Case-Control Studies;Cell Cycle;Cell Differentiation;Cell Lineage;Fusion Proteins, bcr-abl;Humans;Immunophenotyping;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Lymphocytes;Monocytes;Neutrophils;Organic Cation Transporter 1;RNA, Messenger;Reverse Transcriptase Polymerase Chain Reaction",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;metabolism;pathology;metabolism;metabolism;metabolism;genetics;metabolism;genetics",
        "_version_":1605783712056737792},
      {
        "Doc_abstract":"Despite dramatic advances in the treatment of chronic myeloid leukemia (CML), resistance to therapeutic agents has emerged as a significant treatment dilemma. Mutations of the BCR-ABL kinase domain, a common mechanism of resistance to imatinib in CML, are discussed.;Several new targeted kinase inhibitors have reached clinical trials and have proved to be efficacious in halting the oncogenic activity of most BCR-ABL mutants. Dasatinib is 300 times more potent than imatinib at BCR-ABL inhibition, has few side effects, and inhibits the SRC family kinases. Nilotinib inhibits BCR-ABL at 20-50 times more potency than imatinib. Both agents were highly effective in treating chronic phase CML but were less effective at treating accelerated phase CML in early phase clinical trials. In addition to these specific kinase inhibitors, farnesyl transferase inhibitors are actively being investigated. Vaccination strategies are undergoing clinical investigation transitioning from animal models to human clinical trials.;The new kinase inhibitors, dasatinib and nilotinib, are emerging as plausible therapeutic options for the treatment of imatinib-refractory CML.",
        "Doc_title":"Novel treatment strategies for chronic myeloid leukemia.",
        "Journal":"American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists",
        "Do_id":"17106016",
        "Doc_ChemicalList":"Protein Kinase Inhibitors",
        "Doc_meshdescriptors":"Drug Therapy;Humans;Immunotherapy, Active;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Molecular Structure;Protein Kinase Inhibitors",
        "Doc_meshqualifiers":"methods;trends;methods;trends;diagnosis;immunology;therapy;chemistry;therapeutic use",
        "_version_":1605906697098887168},
      {
        "Doc_abstract":"An elderly woman with chronic myeloid leukemia-chronic phase (CML-CP) aged at 67 underwent imatinib therapy. Ph chromosomes gradually decreased, but imatinib was discontinued after 10 months because of aggravated skin eruptions. Three months later, myeloid blast crisis (MBC) occurred. DXR+VCR+PSL chemotherapy and imatinib therapy was administered, and return to CP (RTC) was achieved with the disappearance of Ph chromosomes and a marked decrease of BCR/ABL (FISH). Although imatinib therapy was continued, a second MBC was diagnosed, 13 months after RTC. Chemotherapy, using mainly VCR+PSL was performed and imatinib was discontinued. RTC was achieved, and Ph chromosomes and BCR/ABL again disappeared. One year later, a 3rd MBC developed, and chemotherapy using Ara-C+DNR was performed. A 3rd RTC was achieved, and BCR/ABL decreased. This CML case was resistant to imatinib, but chemotherapy was effective in all 3 episodes of MBC, and BCR/ABL decreased or disappeared.",
        "Doc_title":"[An elderly case of chronic myeloid leukemia in which BCR/ABL decreased or disappeared, following imatinib therapy after each episode of blast crisis].",
        "Journal":"Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics",
        "Do_id":"20339212",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Pyrimidines;Imatinib Mesylate",
        "Doc_meshdescriptors":"Aged;Antineoplastic Agents;Benzamides;Female;Genes, abl;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Piperazines;Pyrimidines",
        "Doc_meshqualifiers":"therapeutic use;drug therapy;genetics;therapeutic use;therapeutic use",
        "_version_":1605774846552178688},
      {
        "Doc_abstract":"Philadelphia (Ph) chromosome is the cytogenetic hallmark of chronic myeloid leukemia (CML). The translocation forms a chimeric gene, bcr-abl, which generates BCR-ABL. This fusion protein constitutively activate ABL tyrosine kinase and causes CML. Imatinib mesylate is a selective tyrosine kinase inhibitor on ABL, c-Kit and PGDF-receptor, and functions through competitive inhibition at the ATP-binding site of the enzyme, which leads to growth arrest or apoptosis in cells that express BCR-ABL. Imatinib has revolutionized the management of patients with CML, and at a dose of 400 mg daily has become the current standard therapy for newly diagnosed patients with CML even when they have HLA-matched family donors. Although imatinib therapy has only a 5-year history, it is hoped that CML will be cured with this drug and with forthcoming second-generation tyrosine kinase inhibitors as well as by allogeneic stem cell transplantation in patients who have become resistant to these drugs.",
        "Doc_title":"Treatment of chronic myeloid leukemia with imatinib mesylate.",
        "Journal":"International journal of clinical oncology",
        "Do_id":"16850123",
        "Doc_ChemicalList":"Benzamides;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Imatinib Mesylate;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Benzamides;Combined Modality Therapy;Drug Resistance;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Stem Cell Transplantation;Transplantation, Homologous",
        "Doc_meshqualifiers":"drug effects;drug therapy;therapy;pharmacology;therapeutic use;pharmacology;therapeutic use;pharmacology;therapeutic use",
        "_version_":1605845306633617408},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) is characterized by the presence of the constitutively active BCR-ABL protein tyrosine kinase. Using a multipotent hemopoietic cell line, FDCP-Mix, expressing BCR-ABL tyrosine kinase, we investigated the initial effects of this kinase in primitive hematopoietic stem cells. We identified down-regulation of a novel gene, CCN3, as a direct consequence of BCR-ABL kinase activity. CCN3 has been reported to function as a tumor suppressor gene in solid tumors. Northern and Western blotting plus immunocytochemical analysis confirmed CCN3 expression is decreased and is tyrosine-phosphorylated in BCR-ABL kinase active FDCP-Mix cells. Decreased cellular CCN3 correlated with increased CCN3 secretion in BCR-ABL kinase active cells. In vitro treatment of human CML cell lines with imatinib or siRNA directed against BCR-ABL significantly reduced BCR-ABL while increasing CCN3 expression. Cells from patients responding to imatinib showed a similar decrease in BCR-ABL and increase in CCN3. CML CD34+ cells treated with imatinib in vitro demonstrated increased CCN3 protein. Transfecting CCN3 into BCR-ABL+ cells inhibited proliferation and decreased clonogenic potential. CCN3 plays an important role in internal and external cell-signaling pathways. Thus, BCR-ABL can regulate protein levels by governing secretion, a novel mechanism for this tyrosine kinase.",
        "Doc_title":"A novel mechanism for BCR-ABL action: stimulated secretion of CCN3 is involved in growth and differentiation regulation.",
        "Journal":"Blood",
        "Do_id":"16670264",
        "Doc_ChemicalList":"CTGF protein, human;DNA Primers;Immediate-Early Proteins;Intercellular Signaling Peptides and Proteins;NOV protein, human;Nephroblastoma Overexpressed Protein;RNA, Small Interfering;Connective Tissue Growth Factor;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Base Sequence;Blotting, Northern;Cell Differentiation;Cell Division;Connective Tissue Growth Factor;DNA Primers;Fusion Proteins, bcr-abl;Gene Expression Regulation, Neoplastic;Humans;Immediate-Early Proteins;Intercellular Signaling Peptides and Proteins;K562 Cells;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Nephroblastoma Overexpressed Protein;Oligonucleotide Array Sequence Analysis;RNA, Small Interfering;Reference Values;Transfection",
        "Doc_meshqualifiers":"genetics;genetics;metabolism;genetics;metabolism;genetics;genetics",
        "_version_":1605792765815291904},
      {
        "Doc_abstract":"Resistance of Bcr-Abl-positive leukemic stem cells (LSCs) to imatinib treatment in patients with chronic myeloid leukemia (CML) can cause relapse of disease and might be the origin for emerging drug-resistant clones. In this study, we identified Smo as a drug target in Bcr-Abl-positive LSCs. We show that Hedgehog signaling is activated in LSCs through upregulation of Smo. While Smo(-/-) does not impact long-term reconstitution of regular hematopoiesis, the development of retransplantable Bcr-Abl-positive leukemias was abolished in the absence of Smo expression. Pharmacological Smo inhibition reduced LSCs in vivo and enhanced time to relapse after end of treatment. Our results indicate that Smo inhibition might be an effective treatment strategy to reduce the LSC pool in CML.",
        "Doc_title":"Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation.",
        "Journal":"Cancer cell",
        "Do_id":"18772113",
        "Doc_ChemicalList":"4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide;Gli protein, mouse;Hedgehog Proteins;Kruppel-Like Transcription Factors;Patched Receptors;Pyrimidines;Receptors, Cell Surface;Receptors, G-Protein-Coupled;Smo protein, mouse;Smoothened Receptor;Veratrum Alkaloids;Zinc Finger Protein GLI1;Fusion Proteins, bcr-abl;cyclopamine",
        "Doc_meshdescriptors":"Animals;Apoptosis;Bone Marrow Cells;Bone Marrow Transplantation;Cell Proliferation;Drug Therapy, Combination;Fetal Stem Cells;Fusion Proteins, bcr-abl;Gene Expression;Hedgehog Proteins;Hematopoiesis;Humans;Kruppel-Like Transcription Factors;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mice;Mice, Inbred C57BL;Mice, Knockout;Mice, Transgenic;Neoplastic Stem Cells;Patched Receptors;Pyrimidines;Receptors, Cell Surface;Receptors, G-Protein-Coupled;Signal Transduction;Smoothened Receptor;Survival Analysis;Veratrum Alkaloids;Zinc Finger Protein GLI1",
        "Doc_meshqualifiers":"drug effects;drug effects;metabolism;pathology;cytology;metabolism;transplantation;genetics;metabolism;drug effects;physiology;drug effects;physiology;genetics;metabolism;drug therapy;metabolism;pathology;drug effects;metabolism;pathology;pharmacology;therapeutic use;genetics;metabolism;genetics;metabolism;drug effects;physiology;pharmacology;therapeutic use",
        "_version_":1605746822852116480},
      {
        "Doc_abstract":"The vast majority of chronic myeloid leukemia (CML) patients express the BCR-ABL transcript with the b2a2 (e13a2) and/or b3a2 (e14a2) junctions. However, some rare cases have atypical breakpoints.;We identified a CML patient with a unique e8a2 BCR-ABL transcript variant. It contained the first 114 nucleotides of BCR exon 8, with an insertion of 16 nucleotides from the 3' end of ABL intron 1a, followed by ABL exon 2. Due to her uncontrolled thrombocytosis after 3 years of interferon-alpha treatment, the patient received imatinib at a dosage of 400 mg/day. Though achieving a sustained and complete hematological response after 3 months, she was resistant to imatinib during the entire 65-month imatinib treatment. That is, she failed to achieve major cytogenetic response and there was no significant decrease in her BCR-ABL transcript levels. Meanwhile, an M351T mutant was detected at 18 months after the start of imatinib treatment.;ABL point mutation is also a mechanism of imatinib resistance for CML patients with the BCR-ABL transcript variant.",
        "Doc_title":"Imatinib mesylate resistance in a chronic myeloid leukemia patient with a novel e8a2 BCR-ABL transcript variant.",
        "Journal":"Acta haematologica",
        "Do_id":"19039205",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Immunologic Factors;Interferon-alpha;Piperazines;Pyrimidines;Imatinib Mesylate;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adult;Antineoplastic Agents;Benzamides;Drug Resistance, Neoplasm;Female;Fusion Proteins, bcr-abl;Gene Expression Regulation, Leukemic;Humans;Imatinib Mesylate;Immunologic Factors;Interferon-alpha;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Piperazines;Point Mutation;Pyrimidines;Transcription, Genetic",
        "Doc_meshqualifiers":"administration & dosage;genetics;biosynthesis;genetics;drug effects;genetics;administration & dosage;administration & dosage;drug therapy;genetics;metabolism;administration & dosage;administration & dosage;drug effects",
        "_version_":1605822455271653376},
      {
        "Doc_abstract":"A patient with BCR/ABL negative myeloproliferative syndrome with a 46,XY,del(3)(q21), t(4;15)(p16;q24) karyotype is described. Fluorescence in situ hybridization performed with chromosomes 4 and 15 painting probes confirmed a novel reciprocal (4;15) translocation. The absence of crkl tyrosine phosphorylation, no activation of the abl kinase as measured by autophosphorylation, and a normal-size abl transcript suggest an alternative mechanism for leukemogenesis to that operative in Ph positive BCR/ABL positive chronic myeloid leukemia. A number of genes potentially relevant to tumorigenesis, some involving the ras signaling pathway, map to the 4p16 and 15q24 chromosome regions.",
        "Doc_title":"Translocation (4;15)(p16;q24): a novel reciprocal translocation in a patient with BCR/ABL negative myeloproliferative syndrome progressing to blastic phase.",
        "Journal":"Cancer genetics and cytogenetics",
        "Do_id":"10326585",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Acute-Phase Reaction;Blotting, Western;Chromosome Painting;Chromosomes, Human, Pair 15;Chromosomes, Human, Pair 4;Disease Progression;Fusion Proteins, bcr-abl;Humans;Male;Middle Aged;Myeloproliferative Disorders;Phosphorylation;Translocation, Genetic",
        "Doc_meshqualifiers":"genetics;genetics",
        "_version_":1605742687355404289},
      {
        "Doc_abstract":"Patients with chronic myeloid leukemia (CML) are commonly treated with a specific inhibitor of BCR-ABL tyrosine kinase, imatinib mesylate (IM). Unfortunately, CML patients develop IM-resistance, which has emerged as a significant clinical problem. Somatic mutations, especially T315I mutation, in BCR-ABL kinase domain represent the most common mechanism underlying drug resistance to tyrosine kinase inhibitors (TKI), including imatinib. Thus, it is urgent to develop novel therapeutic strategies to overcome TKI-resistance. The anti-rheumatic gold (I) compound Auranofin (AF), was recently approved by US Food and Drug Administration for Phase II clinical trials to treat leukemia. In a recent study, we discovered that AF can selectively inhibit 19S proteasome-associated deubiquitinases (UCHL5 and USP14), which mediates its anticancer effects. More recently studies we have shown that AF inhibits the growth of both Bcr-Abl wild-type cells and IM-resistant Bcr-Abl-T315I mutation cells ",
        "Doc_title":"Novel use of old drug: Anti-rheumatic agent auranofin overcomes imatinib-resistance of chronic myeloid leukemia cells.",
        "Journal":"Cancer cell & microenvironment",
        "Do_id":"25995993",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605879841816576000},
      {
        "Doc_abstract":"The Bcr protein was originally identified because of its fusion to Abl as a consequence of the Philadelphia chromosome translocation found in chronic myelogenous and acute lymphoblastic leukemias. The Bcr moiety is essential for the transforming activity of the Bcr/Abl oncogene. In search of physiologically relevant Bcr and Bcr/Abl-interacting proteins, we performed an interaction screen in yeast using the entire Bcr protein as bait. We here report that the alpha catalytic subunit of protein kinase CKII strongly and specifically forms a complex with Bcr in yeast in mouse lysates. The region in Bcr responsible for CKIIalpha binding was localized to residues 242-413. CKIIalpha was previously shown to be involved in leukemogenesis and tumorigenesis using different experimental approaches including mouse models. Inhibition of Bcr/Abl P190 in lymphoma cells from Bcr/Abl transgenic mice using imatinib reduced CKIIalpha activity. A highly selective inhibitor of CKIIalpha, 4,5,6,7-tetrabromo-2-benzotriazole, inhibited the growth of murine lymphoid cells with induced P210 Bcr/Abl expression and of P190 lymphoma cells. Our results demonstrate that CKIIalpha plays an important role in the proliferation of Bcr/Abl expressing cells, and suggests that inhibitors of CKIIalpha may have therapeutic potential in the treatment of Bcr/Abl-positive leukemia patients.",
        "Doc_title":"Protein kinase CKIIalpha interacts with the Bcr moiety of Bcr/Abl and mediates proliferation of Bcr/Abl-expressing cells.",
        "Journal":"Oncogene",
        "Do_id":"14614449",
        "Doc_ChemicalList":"Enzyme Inhibitors;Fusion Proteins, bcr-abl;Casein Kinase II;Protein-Serine-Threonine Kinases",
        "Doc_meshdescriptors":"Animals;CHO Cells;Casein Kinase II;Cell Division;Cricetinae;Enzyme Inhibitors;Exons;Fusion Proteins, bcr-abl;Mice;Mice, Transgenic;Protein Binding;Protein-Serine-Threonine Kinases;Two-Hybrid System Techniques",
        "Doc_meshqualifiers":"drug effects;physiology;pharmacology;metabolism;antagonists & inhibitors;metabolism;physiology",
        "_version_":1605808082436227072},
      {
        "Doc_abstract":"STI571 selectively inhibits the ABL-tyrosine kinase, the activity of which is activated by the formation of chimeric BCR/ABL. A phase I study in the USA showed STI571 to be remarkably effective in cases of interferon-refractory chronic myeloid leukemia, with almost no adverse effects. STI571 may become the first choice drug prior to stem cell transplantation and interferon treatment.",
        "Doc_title":"[Tyrosine kinase inhibitor--hematological malignancies].",
        "Journal":"Gan to kagaku ryoho. Cancer & chemotherapy",
        "Do_id":"11383207",
        "Doc_ChemicalList":"Antineoplastic Agents;Enzyme Inhibitors;Styrenes;ST 271;Tretinoin;Genistein;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Antineoplastic Agents;Clinical Trials, Phase I as Topic;Enzyme Inhibitors;Fusion Proteins, bcr-abl;Genistein;Hematopoietic Stem Cell Transplantation;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Protein-Tyrosine Kinases;Styrenes;Tretinoin",
        "Doc_meshqualifiers":"therapeutic use;pharmacology;therapeutic use;genetics;therapeutic use;drug therapy;antagonists & inhibitors;pharmacology;therapeutic use;therapeutic use",
        "_version_":1605764080461676544},
      {
        "Doc_abstract":"Nilotinib is a novel BCR-ABL inhibitor with significantly improved potency and selectivity over imatinib. In Phase I and Phase II clinical studies of nilotinib in patients with a variety of leukemias, infrequent instances of reversible, benign elevation of bilirubin were observed. Uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) glucuronidates bilirubin in humans, and a polymorphism in the promoter of the gene that encodes it has been associated with hyperbilirubinemia during treatment with a number of drugs. Pharmacogenetic analysis of that TA-repeat polymorphism found an association between the (TA)7/(TA)7 genotype and risk of hyperbilirubinemia in Phase I patients with imatinib-resistant/intolerant chronic myeloid leukemia (CML) or relapsed/refractory Ph+ acute lymphoblastic leukemia (ALL); this result was replicated in two separate analyses of the chronic phase (CP) and accelerated phase (AP) CML arms of a Phase II study. As nilotinib is not known to be glucuronidated by UGT1A1, the combined impact of inhibition of UGT1A1 activity by nilotinib and genetic polymorphism is the most likely cause of the increased rate of hyperbilirubinemia.",
        "Doc_title":"UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia.",
        "Journal":"Leukemia",
        "Do_id":"17611564",
        "Doc_ChemicalList":"4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide;Pyrimidines;UGT1A1 enzyme;Glucuronosyltransferase;Bilirubin",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Bilirubin;Drug Resistance, Neoplasm;Genetic Predisposition to Disease;Genotype;Glucuronosyltransferase;Humans;Hyperbilirubinemia;Middle Aged;Polymorphism, Genetic;Pyrimidines;Recurrence;Risk",
        "Doc_meshqualifiers":"metabolism;genetics;chemically induced;genetics;pharmacology",
        "_version_":1605757266425806848},
      {
        "Doc_abstract":"Important advances in the understanding of the molecular basis of chronic myeloid leukemia have resulted in the development of new therapies and changed the paradigm for managing this myeloproliferative disease. Translocation of chromosomes 9 and 22 (known as the Philadelphia chromosome) results in a fusion BCR-ABL gene that produces a dysregulated BCR-ABL tyrosine kinase protein and triggers events leading to malignant transformation. The tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib block the BCR-ABL protein and prevent activation of the transformation pathways. Molecular monitoring, the most sensitive approach currently available to assess treatment response, measures BCR-ABL messenger RNA levels and serves as a surrogate marker of disease. Further, molecular responses are predictive of patient outcomes. It is important for advanced practitioners to become familiar with the technology and interpretation of molecular monitoring results as well as efforts to standardize this type of testing so they can educate their patients and aid their understanding of test results. Undetectable BCR-ABL levels can bring feelings of relief, whereas an increasing level can lead to anxiety. Advanced practitioners, therefore, are an important resource for interpreting results for patients, answering questions, alleviating concerns, and encouraging continued adherence to treatment. ",
        "Doc_title":"Interpreting molecular monitoring results and international standardization in chronic myeloid leukemia.",
        "Journal":"Journal of the advanced practitioner in oncology",
        "Do_id":"25031941",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605752772778524672},
      {
        "Doc_abstract":"Protein kinase inhibitors can be effective in treating selected cancers, but most suppress several kinases. Imatinib mesylate has been useful in the treatment of Philadelphia chromosome-positive chronic myelogenous leukemia and B cell acute lymphoblastic leukemia through the inhibition of BCR-ABL tyrosine kinase activity. Imatinib mesylate has also been shown to inhibit KIT, ARG, and platelet-derived growth factor receptors alpha and beta, and potentially other tyrosine kinases. We have produced a mutant allele of BCR-ABL (T315A) that is uniquely inhibitable by the small molecule 4-amino-1-tert-butyl-3-(1-naphthyl)pyrazolo[3,4-d]pyrimidine and used it to demonstrate that sole suppression of BCR-ABL activity was insufficient to eliminate BCR-ABL(+) KIT(+)-expressing immature murine myeloid leukemic cells. In contrast, imatinib mesylate effectively eliminated BCR-ABL(+) KIT(+)-expressing leukemic cells. In the cellular context of mature myeloid cells and Pro/Pre B cells that do not express KIT, monospecific BCR-ABL inhibition was quantitatively as effective as imatinib mesylate in suppressing cell growth and inducing apoptosis. These results suggest that the therapeutic effectiveness of small molecule drugs such as imatinib mesylate could be due to the inhibitor's ability to suppress protein kinases in addition to the dominant target.",
        "Doc_title":"Sole BCR-ABL inhibition is insufficient to eliminate all myeloproliferative disorder cell populations.",
        "Journal":"Proceedings of the National Academy of Sciences of the United States of America",
        "Do_id":"15505216",
        "Doc_ChemicalList":"Benzamides;Enzyme Inhibitors;Piperazines;Pyrimidines;Phosphotyrosine;Tyrosine;Imatinib Mesylate;Protein-Tyrosine Kinases;Proto-Oncogene Proteins c-kit;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Apoptosis;B-Lymphocytes;Benzamides;Cell Cycle;Cell Line;Cell Proliferation;Drug Synergism;Enzyme Inhibitors;Fusion Proteins, bcr-abl;Gene Expression Regulation, Enzymologic;Humans;Imatinib Mesylate;Mutation;Myeloproliferative Disorders;Phosphotyrosine;Piperazines;Protein-Tyrosine Kinases;Proto-Oncogene Proteins c-kit;Pyrimidines;Tyrosine",
        "Doc_meshqualifiers":"drug effects;drug effects;pathology;drug effects;drug effects;pharmacology;genetics;enzymology;genetics;pathology;metabolism;pharmacology;antagonists & inhibitors;genetics;metabolism;metabolism;pharmacology;genetics;metabolism",
        "_version_":1605783728865411072},
      {
        "Doc_abstract":"In Philadelphia chromosome (Ph1)-positive acute lymphoblastic leukemia (ALL), some cytogenetic studies have suggested clonal derivation from a multipotential stem cell. The role of the product of the chimeric gene, P190, is not, however, well understood. We examined the expression of P190-type bcr/abl in single hematopoietic colonies obtained at various clinical stages of a patient with Ph1-positive ALL, using the polymerase chain reaction (PCR). Seven out of 58 colonies examined expressed P190-type bcr/abl. Five out of seven colonies were granulocyte/macrophage (GM) colonies and two were erythroid colonies. The cell lineages of these colonies were confirmed by testing for the expressions of the myeloperoxidase (MPO) gene in the GM colonies and the beta-globin gene in the erythroid colonies. These results suggest transformation of multipotential stem cell in this patient and confirm that expression of the P190-type bcr/abl fusion gene permits stem cell differentiation leading to Ph1-positive ALL.",
        "Doc_title":"P190-type bcr/abl expressed in myeloid colonies in a patient with Ph1-positive acute lymphoblastic leukemia.",
        "Journal":"Leukemia",
        "Do_id":"1640730",
        "Doc_ChemicalList":"RNA, Messenger;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adult;Base Sequence;Bone Marrow;Fusion Proteins, bcr-abl;Gene Expression;Humans;Male;Molecular Sequence Data;Philadelphia Chromosome;Polymerase Chain Reaction;Precursor Cell Lymphoblastic Leukemia-Lymphoma;RNA, Messenger",
        "Doc_meshqualifiers":"metabolism;pathology;genetics;genetics;pathology;biosynthesis",
        "_version_":1605840159287279616},
      {
        "Doc_abstract":"The so-called Philadelphia (Ph) chromosome is present in more than 90% of chronic myeloid leukemia (CML) cases. Amplification or duplication of the BCR-ABL gene has been found to be one of the key factors leading to drug resistance to imatinib mesylate (IM). In the present study, we identified the presence of isodicentric Ph chromosomes [idic(Ph)] in an IM-resistant patient. Fluorescence ",
        "Doc_title":"Multiple copies of BCR-ABL fusion gene on two isodicentric Philadelphia chromosomes in an imatinib mesylate-resistant chronic myeloid leukemia patient.",
        "Journal":"Oncology letters",
        "Do_id":"23761821",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605827197923229696},
      {
        "Doc_abstract":"Recent evidence suggests chronic myeloid leukemia (CML) stem cells are insensitive to kinase inhibitors and responsible for minimal residual disease in treated patients. We investigated whether CML stem cells, in a transgenic mouse model of CML-like disease or derived from patients, are dependent on Bcr-Abl. In the transgenic model, after retransplantation, donor-derived CML stem cells in which Bcr-Abl expression had been induced and subsequently shut off were able to persist in vivo and reinitiate leukemia in secondary recipients on Bcr-Abl reexpression. Bcr-Abl knockdown in human CD34(+) CML cells cultured for 12 days in physiologic growth factors achieved partial inhibition of Bcr-Abl and downstream targets p-CrkL and p-STAT5, inhibition of proliferation and colony forming cells, but no reduction of input cells. The addition of dasatinib further inhibited p-CrkL and p-STAT5, yet only reduced input cells by 50%. Complete growth factor withdrawal plus dasatinib further reduced input cells to 10%; however, the surviving fraction was enriched for primitive leukemic cells capable of growth in a long-term culture-initiating cell assay and expansion on removal of dasatinib and addition of growth factors. Together, these data suggest that CML stem cell survival is Bcr-Abl kinase independent and suggest curative approaches in CML must focus on kinase-independent mechanisms of resistance.",
        "Doc_title":"Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival.",
        "Journal":"Blood",
        "Do_id":"22184410",
        "Doc_ChemicalList":"Adaptor Proteins, Signal Transducing;Antigens, CD34;CRKL protein;Nuclear Proteins;Protein Kinase Inhibitors;Pyrimidines;STAT5 Transcription Factor;Thiazoles;Fusion Proteins, bcr-abl;Dasatinib",
        "Doc_meshdescriptors":"Adaptor Proteins, Signal Transducing;Animals;Antigens, CD34;Apoptosis;Blotting, Western;Cell Line, Tumor;Cell Proliferation;Cell Survival;Dasatinib;Dose-Response Relationship, Drug;Flow Cytometry;Fusion Proteins, bcr-abl;Gene Expression Regulation, Leukemic;Gene Knockout Techniques;HEK293 Cells;Humans;K562 Cells;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mice;Mice, Transgenic;Neoplastic Stem Cells;Nuclear Proteins;Protein Kinase Inhibitors;Pyrimidines;Reverse Transcriptase Polymerase Chain Reaction;STAT5 Transcription Factor;Thiazoles",
        "Doc_meshqualifiers":"metabolism;metabolism;drug effects;drug effects;drug effects;antagonists & inhibitors;genetics;metabolism;genetics;metabolism;pathology;metabolism;pathology;metabolism;pharmacology;pharmacology;metabolism;pharmacology",
        "_version_":1605809248661405696},
      {
        "Doc_abstract":"We have established 2 Philadelphia chromosome (Ph1)-positive acute lymphoblastic leukemia (ALL) cell lines, designated PALL-1 and PALL-2, from distinct adult Ph1-positive ALL patients. PALL-1 was established in nude mice, and PALL-2 was established in culture. Both retained the Ph1 chromosome and expressed the ALL type bcr/abl chimeric mRNA containing the junction of the first exon of BCR gene (e1) and second exon of c-abl gene (a2). PALL-1 and PALL-2 expressed CD34 surface antigen which is characteristic of early hematopoietic progenitor cells. PALL-2 expressed antigens for both pre-B and early myeloid cells and had rearrangements of both the heavy chain of immunoglobulin gene and the beta chain of T-cell-receptor gene. Both PALL-1 and PALL-2 expressed detectable levels of p53 gene RNA. Polymerase-chain-reaction-single-strand conformation polymorphism (PCR-SSCP) analysis of the p53 gene showed a normal pattern of mobility in both cell lines. Taken together, the 2 cell lines had features of Ph1-positive ALL: (i) hematopoietic progenitor cells with pre-B-cell phenotype and, (ii) activation of e1-a2 type bcr/abl oncogene without alterations of p53 gene. These unique lines should provide a valuable tool for studying the pathogenesis of Ph1-positive ALL.",
        "Doc_title":"Phenotypic and molecular analysis of Ph1-chromosome-positive acute lymphoblastic leukemia cell lines.",
        "Journal":"International journal of cancer",
        "Do_id":"8428799",
        "Doc_ChemicalList":"Oligodeoxyribonucleotides;Proto-Oncogene Proteins;Receptors, Antigen, T-Cell, alpha-beta;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl;BCR protein, human;Bcr protein, mouse;Proto-Oncogene Proteins c-bcr",
        "Doc_meshdescriptors":"Adult;Animals;Base Sequence;Fusion Proteins, bcr-abl;Gene Rearrangement, B-Lymphocyte, Heavy Chain;Genes, abl;Genes, p53;Humans;Male;Mice;Mice, Nude;Neoplasm Transplantation;Oligodeoxyribonucleotides;Philadelphia Chromosome;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Protein-Tyrosine Kinases;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-bcr;Receptors, Antigen, T-Cell, alpha-beta;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"chemistry;pathology;genetics;genetics;pathology",
        "_version_":1605762581790720000},
      {
        "Doc_abstract":"The purpose of this study was to determine whether histone deacetylase (HDAC) inhibitors (HDACI) such as vorinostat or entinostat (SNDX-275) could increase the lethality of the dual Bcr/Abl-Aurora kinase inhibitor KW-2449 in various Bcr/Abl(+) human leukemia cells, including those resistant to imatinib mesylate (IM).;Bcr/Abl(+) chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL) cells, including those resistant to IM (T315I, E255K), were exposed to KW-2449 in the presence or absence of vorinostat or SNDX-275, after which apoptosis and effects on signaling pathways were examined. In vivo studies combining HDACIs and KW2449 were carried out by using a systemic IM-resistant ALL xenograft model.;Coadministration of HDACIs synergistically increased KW-2449 lethality in vitro in multiple CML and Ph(+) ALL cell types including human IM resistant cells (e.g., BV-173/E255K and Adult/T315I). Combined treatment resulted in inactivation of Bcr/Abl and downstream targets (e.g., STAT5 and CRKL), as well as increased reactive oxygen species (ROS) generation and DNA damage (H2A.X). The latter events and cell death were significantly attenuated by free radical scavengers (TBAP). Increased lethality was also observed in primary CD34(+) cells from patients with CML, but not in normal CD34(+) cells. Finally, minimally active vorinostat or SNDX275 doses markedly increased KW2449 antitumor effects and significantly prolonged the survival of murine xenografts bearing IM-resistant ALL cells (BV173/E255K).;HDACIs increase KW-2449 lethality in Bcr/Abl(+) cells in association with inhibition of Bcr/Abl, generation of ROS, and induction of DNA damage. This strategy preferentially targets primary Bcr/Abl(+) hematopoietic cells and exhibits enhanced in vivo activity. Combining KW-2449 with HDACIs warrants attention in IM-resistant Bcr/Abl(+) leukemias.",
        "Doc_title":"HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo.",
        "Journal":"Clinical cancer research : an official journal of the American Association for Cancer Research",
        "Do_id":"21474579",
        "Doc_ChemicalList":"Benzamides;Histone Deacetylase Inhibitors;Indazoles;KW 2449;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Imatinib Mesylate;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adult;Animals;Antineoplastic Combined Chemotherapy Protocols;Benzamides;Cell Line, Tumor;Drug Resistance, Neoplasm;Drug Synergism;Fusion Proteins, bcr-abl;Histone Deacetylase Inhibitors;Humans;Imatinib Mesylate;Indazoles;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mice;Mice, Inbred BALB C;Mice, SCID;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Xenograft Model Antitumor Assays",
        "Doc_meshqualifiers":"pharmacology;therapeutic use;drug effects;antagonists & inhibitors;metabolism;administration & dosage;pharmacology;administration & dosage;pharmacology;drug therapy;pathology;administration & dosage;pharmacology;therapeutic use;administration & dosage;pharmacology;therapeutic use",
        "_version_":1605791333182603264},
      {
        "Doc_abstract":"Twenty-four adult Chinese patients with de novo acute lymphoblastic leukemia (ALL) were studied for the BCR/ABL translocation using both conventional cytogenetics and fluorescence in situ hybridization (FISH). Eight (33%) patients had the translocation as shown by FISH and all were B-lineage ALL (8/19, 42%). Conventional cytogenetics revealed a t(9;22)(q34;q11) in six of them, but was either unsuccessful, or not done in the other two. Seven of the eight positive cases (88%) showed a breakpoint at the minor breakpoint cluster region (m-BCR), which was confirmed by reverse transcriptase polymerase chain reaction (RT-PCR). To conclude, the frequency of BCR/ABL translocation in Chinese patients with de novo ALL is comparable to patients in the Western hemisphere, in contrast to a previous report. The predominance of m-BCR/ABL fusion among these Chinese patients with BCR/ABL translocation is also similar to patients in the Western population. Fluorescence in situ hybridization is a sensitive, specific and relatively simple technique for demonstrating this important unfavorable prognostic marker in ALL, even in a routine service laboratory setting.",
        "Doc_title":"BCR/ABL translocation in adult acute lymphoblastic leukemia: a comparison of conventional and interphase cytogenetic studies.",
        "Journal":"Cancer genetics and cytogenetics",
        "Do_id":"10198617",
        "Doc_ChemicalList":"Oncogene Proteins;Proto-Oncogene Proteins;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl;BCR protein, human;Proto-Oncogene Proteins c-bcr",
        "Doc_meshdescriptors":"Adult;Aged;Female;Fusion Proteins, bcr-abl;Genes, abl;Humans;Interphase;Male;Middle Aged;Oncogene Proteins;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Protein-Tyrosine Kinases;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-bcr;Translocation, Genetic",
        "Doc_meshqualifiers":"genetics;genetics;genetics",
        "_version_":1605819601216602112},
      {
        "Doc_abstract":"Activation of the oncogenic potential of c-abl proto-oncogene has been correlated with the activation of its tyrosine kinase activity. The oncogenes derived from c-abl, e.g., gag/v-abl in Abelson murine leukemia virus or bcr/abl in chronic myelogenous leukemia, lack N-terminal coding sequences of the normal c-abl gene. In mouse and human cells, two sets of N-terminal amino acids encoded by 5'-variable exons are found in c-abl proteins. To assess the importance of N-terminal deletion in the activation of c-abl tyrosine kinase, a full length or an N-terminal deleted c-abl protein was expressed in bacteria and in monkey COS cells. Measurements of the autokinase activity of these two c-abl proteins showed that deletion of the N-terminal amino acids led to a three to five fold increase of the c-abl tyrosine kinase activity. Thus, the N-terminal deletion is important in the activation of c-abl proto-oncogene.",
        "Doc_title":"Negative regulation of c-abl tyrosine kinase by its variable N-terminal amino acids.",
        "Journal":"Oncogene research",
        "Do_id":"3144698",
        "Doc_ChemicalList":"Gene Products, gag;Proto-Oncogene Proteins;Recombinant Proteins;Retroviridae Proteins;Viral Proteins;Protein-Tyrosine Kinases;Proto-Oncogene Proteins c-abl",
        "Doc_meshdescriptors":"Amino Acid Sequence;Animals;Cell Line;Enzyme Induction;Escherichia coli;Gene Products, gag;Haplorhini;Humans;Mice;Phosphorylation;Protein-Tyrosine Kinases;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-abl;Recombinant Proteins;Regulatory Sequences, Nucleic Acid;Retroviridae Proteins;Viral Proteins",
        "Doc_meshqualifiers":"biosynthesis;genetics;biosynthesis;genetics;biosynthesis;biosynthesis;biosynthesis",
        "_version_":1605824812856377344},
      {
        "Doc_abstract":"To assess the impact of BCR-ABL kinase domain mutations on dasatinib response in elderly chronic myeloid leukemia (CML) patients, we analyzed the outcome of 76 individuals aged >60 affected by imatinib-resistant chronic-phase CML. We found that 36 cases (47%) displayed mutations before dasatinib. Compared to non-mutated patients, subjects with point mutations had a worse response to dasatinib, with significantly lower rates of complete cytogenetic response (57 vs 32%), higher percentage of primary resistance (16/36 vs 6/40) and a trend towards a shorter median event-free survival. Our data suggest that, in elderly patients, detection of BCR-ABL mutations negatively affects response to dasatinib.",
        "Doc_title":"Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia.",
        "Journal":"Annals of hematology",
        "Do_id":"23053188",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Thiazoles;Imatinib Mesylate;Fusion Proteins, bcr-abl;Dasatinib",
        "Doc_meshdescriptors":"Aged;Antineoplastic Agents;Benzamides;DNA Mutational Analysis;Dasatinib;Disease-Free Survival;Drug Resistance, Neoplasm;Female;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Italy;Kaplan-Meier Estimate;Leukemia, Myeloid, Chronic-Phase;Male;Middle Aged;Mutation, Missense;Piperazines;Point Mutation;Protein Kinase Inhibitors;Pyrimidines;Retrospective Studies;Thiazoles",
        "Doc_meshqualifiers":"adverse effects;pharmacology;therapeutic use;genetics;genetics;physiology;epidemiology;drug therapy;enzymology;genetics;mortality;adverse effects;pharmacology;adverse effects;pharmacology;therapeutic use;adverse effects;pharmacology;therapeutic use;adverse effects;pharmacology;therapeutic use",
        "_version_":1605791148949897216},
      {
        "Doc_abstract":"Identification of Philadelphia chromosome or BCR/ABL gene rearrangement in chronic myeloid leukemia is important at diagnosis as well as after treatment.;To compare the results of karyotyping using fluorescent in-situ hybridization (FISH) upon diagnosis and 1 year after bone marrow transplantation in 12 patients.;Diagnostic test and residual disease detection.;Hematology and Hemotherapy Department, Federal University of So Paulo/Escola Paulista de Medicina, So Paulo, Brazil.;12 patients with chronic myeloid leukemia at diagnosis and 1 year after bone marrow transplantation.;Karyotyping was done in the usual way and the BCR/ABL gene-specific probe was used for FISH.;Disease at diagnosis and residual.;At diagnosis, 10 patients presented t(9;22)(q34.1;q11) as well as positive FISH. Two cases did not have metaphases but FISH was positive. After bone marrow transplantation, 8 patients presented normal karyotype, 1 had persistence of identifiable Philadelphia chromosome and 3 had no metaphases. Two cases showed complete chimera and 2 had donor and host cells simultaneously. FISH was possible in all cases after bone marrow transplantation and confirmed the persistence of identifiable Philadelphia chromosome clone in one patient, and identified another that did not present metaphases for analysis. Cases that showed mixed chimera in karyotype were negative for BCR/ABL by FISH.;The applicability of FISH is clear, particularly for residual disease detection. Classical and molecular cytogenetics are complementary methods.",
        "Doc_title":"Fluorescent in-situ hybridization (FISH) for BCR/ABL in chronic myeloid leukemia after bone marrow transplantation.",
        "Journal":"Sao Paulo medical journal = Revista paulista de medicina",
        "Do_id":"11175620",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adolescent;Adult;Bone Marrow Transplantation;Female;Fusion Proteins, bcr-abl;Humans;In Situ Hybridization, Fluorescence;Karyotyping;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Neoplasm, Residual;Philadelphia Chromosome",
        "Doc_meshqualifiers":"genetics;genetics;pathology;therapy;genetics;pathology",
        "_version_":1605775042678882304},
      {
        "Doc_abstract":"Ph-positive leukemias are caused by the aberrant fusion of the BCR and ABL genes. Nilotinib is a selective Bcr/Abl tyrosine kinase inhibitor related to imatinib, which is widely used to treat chronic myelogenous leukemia. Because Ph-positive acute lymphoblastic leukemia only responds transiently to imatinib therapy, we have used mouse models to test the efficacy of nilotinib against lymphoblastic leukemia caused by the P190 form of Bcr/Abl.;After transplant of 10,000 highly malignant leukemic cells into compatible recipients, untreated mice succumbed to leukemia within 21 days, whereas mice treated with 75 mg/kg nilotinib survived significantly longer. We examined cells from mice that developed leukemia while under treatment for Bcr/Abl kinase domain point mutations but these were not detected. In addition, culture of such cells ex vivo showed that they were as sensitive as the parental cell line to nilotinib but that the presence of stromal support allowed resistant cells to grow out. Nilotinib also exhibited impressive anti-leukemia activity in P190 Bcr/Abl transgenic mice that had developed overt leukemia/lymphoma masses and that otherwise would have been expected to die within 7 days. Visible lymphoma masses disappeared within six days of treatment and leukemic cell numbers in peripheral blood were significantly reduced. Treated mice survived more than 30 days.;These results show that nilotinib has very impressive anti-leukemia activity but that lymphoblastic leukemia cells can become unresponsive to it both in vitro and in vivo through mechanisms that appear to be Bcr/Abl independent.",
        "Doc_title":"Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia.",
        "Journal":"Molecular cancer",
        "Do_id":"17958915",
        "Doc_ChemicalList":"4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide;Antineoplastic Agents;Pyrimidines;Fusion Proteins, bcr-abl;Janus Kinase 2",
        "Doc_meshdescriptors":"Animals;Antineoplastic Agents;Blotting, Western;Cell Line, Tumor;Disease Models, Animal;Flow Cytometry;Fusion Proteins, bcr-abl;Janus Kinase 2;Leukemia, Experimental;Mice;Mice, Inbred C57BL;Mice, Transgenic;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Pyrimidines;Stromal Cells",
        "Doc_meshqualifiers":"therapeutic use;drug effects;metabolism;drug therapy;drug therapy;therapeutic use;drug effects;metabolism",
        "_version_":1605852434362531840},
      {
        "Doc_abstract":"The concomitant occurrence of JAK2617F mutation and BCR/ABL translocation is a rare event. It is unclear if this is a result of the clonal evolution or a separately emergence of two clones and if it could lead to the progression to a more aggressive phase of the disease. We present the case of a 61-year-old man diagnosed and treated for polycythaemia vera for 7 years, which evolved into chronic myeloid leukemia BCR/ABL positive and with JAK2617F mutated clone, that became dominant after an effective treatment with Imatinib.",
        "Doc_title":"The concomitant occurrence of JAK2V617F mutation and BCR/ABL transcript with phenotypic expression - an overlapping myeloproliferative disorder or two distinct diseases? - case report.",
        "Journal":"Journal of medicine and life",
        "Do_id":"23599815",
        "Doc_ChemicalList":"RNA, Messenger;Fusion Proteins, bcr-abl;JAK2 protein, human;Janus Kinase 2",
        "Doc_meshdescriptors":"Fusion Proteins, bcr-abl;Humans;In Situ Hybridization, Fluorescence;Janus Kinase 2;Karyotyping;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Mutation;Myeloproliferative Disorders;Phenotype;Polycythemia Vera;RNA, Messenger;Treatment Outcome",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;diagnosis;genetics;genetics;enzymology;genetics;genetics;genetics;metabolism",
        "_version_":1605874109816766464},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) is a stem cell disorder caused by a constitutively activated tyrosine kinase, the Bcr-Abl oncoprotein. An inhibitor of this tyrosine kinase, imatinib mesylate, is rapidly becoming the first-line therapy for CML. However, the development of resistance to this drug is a frequent setback, particularly in patients in advanced phases of the disease. Several mechanisms of resistance have been described, the most frequent of which are amplification and/or mutations of the BCR-ABL gene. To overcome resistance, several approaches have been studied in vitro and in vivo. They include dose escalation of imatinib, combination of imatinib with chemotherapeutic drugs, alternative Bcr-Abl inhibitors, inhibitors of kinases downstream of Bcr-Abl, farnesyl and geranylgeranyl transferase inhibitors, histone deacetylase, proteasome and cyclin-dependent kinase inhibitors, arsenic trioxide, hypomethylating agents, troxacitabine, targeting Bcr-Abl messenger RNA, and immunomodulatory strategies. It is important to understand that these approaches differ in efficiency, which is often dependent on the mechanisms of resistance. Further investigations into the molecular mechanisms of disease and how to specifically target the abnormal processes will guide the design of new treatment modalities in future clinical trials.",
        "Doc_title":"Biology of chronic myeloid leukemia and possible therapeutic approaches to imatinib-resistant disease.",
        "Journal":"International journal of hematology",
        "Do_id":"15239391",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Pyrimidines;Imatinib Mesylate",
        "Doc_meshdescriptors":"Antineoplastic Agents;Antineoplastic Combined Chemotherapy Protocols;Benzamides;Dose-Response Relationship, Drug;Drug Administration Schedule;Drug Resistance, Neoplasm;Genes, abl;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Piperazines;Pyrimidines",
        "Doc_meshqualifiers":"pharmacology;therapeutic use;genetics;physiology;drug therapy;genetics;physiopathology;pharmacology;pharmacology",
        "_version_":1605746386199904257},
      {
        "Doc_abstract":"The advent of imatinib has considerably changed the treatment of chronic myeloid leukemia (CML). Early studies demonstrated high rates of hematologic and cytogenetic responses in all phases of the disease after limited observation periods.;The authors evaluated long-term outcome, rates of response, and resistance in 300 patients with BCR-ABL-positive leukemias (CML in chronic phase after failure to respond to interferon-alpha [CP], n = 139; accelerated phase [AP], n = 80; myeloid blast crisis [BC], n = 76; lymphoid BC and Philadelphia chromosome-positive acute lymphoblastic leukemia, n = 5) who entered clinical trials with imatinib in a single center after an observation time of 4.5 years.;In CP, hematologic remission was achieved in 97% and major (MCR) and complete cytogenetic remission (CCR) in 61% and 49% of patients, respectively. The chance to achieve MCR was higher in patients commencing imatinib earlier in the course of CML. In AP, the median survival period after the start of imatinib was 44 months, and MCR and CCR were observed in 31% and 26% of patients, respectively. In myeloid BC, the median survival period after the start of imatinib and after diagnosis of BC was 6 and 9 months, respectively. Hematologic resistance occurred in 25%, 41%, and 92% of patients in CP, AP, and myeloid BC, respectively, and was associated with BCR-ABL mutations in 45% of patients and with clonal evolution in 58% of patients.;The data emphasized the need for a prolonged follow-up of patients treated with imatinib to define the clinical potential of the drug and to establish methods to optimize therapy.",
        "Doc_title":"Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.",
        "Journal":"Cancer",
        "Do_id":"15747376",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Interferon-alpha;Piperazines;Pyrimidines;Imatinib Mesylate;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Antineoplastic Agents;Benzamides;Blast Crisis;Cytogenetic Analysis;Drug Resistance, Neoplasm;Female;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Interferon-alpha;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Mutation;Neoplasm Recurrence, Local;Piperazines;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Protein-Tyrosine Kinases;Pyrimidines;Remission Induction;Salvage Therapy;Survival Rate;Treatment Outcome",
        "Doc_meshqualifiers":"therapeutic use;genetics;metabolism;adverse effects;drug therapy;genetics;pathology;drug therapy;genetics;pathology;therapeutic use;drug therapy;genetics;pathology;antagonists & inhibitors;therapeutic use",
        "_version_":1605873886600101888},
      {
        "Doc_abstract":"Arsenic trioxide (As2O3) and the proteasome inhibitor bortezomib (BTZ) have been used successfully to treat acute promyelocytic leukemia and multiple myeloma. Their synergistic effects with other anticancer drugs have been widely studied. In this study, interactions between As2O3 and BTZ were examined in imatinibresistant Bcr/Abl+ (K562r) cells. Cotreatment of K562r cells with subtoxic concentrations of As2O3 (2 M) and BTZ (24 nM) resulted in a synergistic enhancement in growth inhibition and apoptosis, as demonstrated by increased annexin V staining. These events were associated with activation of protein kinase C, poly ADPribose polymerase cleavage and caspase3 activation, along with downregulation of Bcr/Abl mRNA and Bcr/Abl protein expression levels during apoptosis. In addition, reactive oxygen species were downregulated during combined treatment in K562r cells. Collectively, these findings suggest that BTZ and As2O3 act synergistically to induce apoptosis in K562r cells. Therefore, further studies are required to assess the potential of BTZ and As2O3 combinatory treatment of chronic myeloid leukemia, particularly using imatinibresistant Bcr/Abl+ clones.",
        "Doc_title":"Arsenic trioxide and bortezomib interact synergistically to induce apoptosis in chronic myelogenous leukemia cells resistant to imatinib mesylate through Bcr/Abldependent mechanisms.",
        "Journal":"Molecular medicine reports",
        "Do_id":"24939418",
        "Doc_ChemicalList":"Arsenicals;Benzamides;Boronic Acids;Oxides;Piperazines;Pyrazines;Pyrimidines;RNA, Messenger;Reactive Oxygen Species;Bortezomib;Imatinib Mesylate;Poly(ADP-ribose) Polymerases;Fusion Proteins, bcr-abl;CASP3 protein, human;Caspase 3;arsenic trioxide",
        "Doc_meshdescriptors":"Apoptosis;Arsenicals;Benzamides;Boronic Acids;Bortezomib;Caspase 3;Cell Line, Tumor;Down-Regulation;Drug Resistance, Neoplasm;Drug Synergism;Fusion Proteins, bcr-abl;Gene Expression Regulation, Leukemic;Humans;Imatinib Mesylate;K562 Cells;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Oxides;Piperazines;Poly(ADP-ribose) Polymerases;Pyrazines;Pyrimidines;RNA, Messenger;Reactive Oxygen Species",
        "Doc_meshqualifiers":"drug effects;pharmacology;pharmacology;pharmacology;genetics;metabolism;genetics;metabolism;drug therapy;pharmacology;pharmacology;genetics;metabolism;pharmacology;pharmacology;genetics;metabolism;metabolism",
        "_version_":1605807073369522176},
      {
        "Doc_abstract":"This report describes a patient with Philadelphia chromosome-negative (Ph-) but bcr/abl fusion gene-positive chronic myeloid leukemia (CML) and a molecular analysis of the mechanisms behind the Ph status. Spectral karyotyping-fluorescent in situ hybridization (SKY-FISH) analysis showed no abnormal translocation; however, a bcr/abl fusion gene was detected by reverse transcriptase-polymerase chain reaction analysis. FISH analysis showed that signals from the 9q and 22q subtelomere probes were detected on the der(9) and der(22) chromosomes, respectively. On the other hand, FISH analysis of the abl and bcr genes with dual fusion probes, which can detect the bcr/abl fusion gene on both the der(9) and der(22) chromosomes, showed the signal for bcr/abl fusion on the der(22) chromosome but not on the der(9) chromosome. These results indicate that insertion of the abl gene into the bcr region on the der(22) chromosome or retranslocation between the der(9) chromosome and the der(22) chromosome may have caused the Ph CML in this case.",
        "Doc_title":"Fluorescent in situ hybridization analysis of Philadelphia chromosome-negative chronic myeloid leukemia with the bcr/abl fusion gene.",
        "Journal":"International journal of hematology",
        "Do_id":"15481444",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adult;Female;Genes, abl;Humans;In Situ Hybridization, Fluorescence;Karyotyping;Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative;Metaphase;Reverse Transcriptase Polymerase Chain Reaction",
        "Doc_meshqualifiers":"genetics;genetics",
        "_version_":1605775244385058816},
      {
        "Doc_abstract":"Although the BCR/ABL tyrosine kinase inhibitor imatinib is highly effective for treatment of chronic myelogenous leukemia and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia, relapse with emerging imatinib resistance mutations in the BCR/ABL kinase domain poses a significant problem. Here, we show that the multikinase inhibitor sorafenib inhibits proliferation and induces apoptosis at much lower concentrations in Ton.B210 cells when driven by inducibly expressed BCR/ABL than when driven by interleukin-3. The increased sensitivity to sorafenib was also observed in cells inducibly expressing BCR/ABL with the imatinib-resistant E255K or T315I mutation. Sorafenib-induced apoptosis in these cells and Ph+ leukemic cells was synergistically enhanced by rottlerin, bortezomib, or ABT-737 and inhibited by the pan-caspase inhibitor BOC-d-fmk or the overexpression of Bcl-XL. It was further revealed that sorafenib activates Bax and caspase-3 and reduces mitochondrial membrane potential specifically in BCR/ABL-driven cells. Sorafenib also inhibited BCR/ABL-induced tyrosine phosphorylation of its cellular substrates and its autophosphorylation in Ton.B210. It was finally shown that sorafenib inhibits the kinase activity of BCR/ABL as well as its E255K and T315I mutants in in vitro kinase assays. These results indicate that sorafenib induces apoptosis of BCR/ABL-expressing cells, at least partly, by inhibiting BCR/ABL to activate the mitochondria-mediated apoptotic pathway. Thus, sorafenib may provide an effective therapeutic measure to treat Ph+ leukemias, particularly those expressing the T315I mutant, which is totally resistant to imatinib and the second generation BCR/ABL inhibitors.",
        "Doc_title":"Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.",
        "Journal":"Cancer research",
        "Do_id":"19366808",
        "Doc_ChemicalList":"ABT-737;Acetophenones;Benzamides;Benzenesulfonates;Benzopyrans;Biphenyl Compounds;Boronic Acids;Interleukin-3;Nitrophenols;Phenylurea Compounds;Piperazines;Protein Kinase Inhibitors;Pyrazines;Pyridines;Pyrimidines;Sulfonamides;Niacinamide;Bortezomib;Imatinib Mesylate;sorafenib;rottlerin;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl;Caspases",
        "Doc_meshdescriptors":"Acetophenones;Antineoplastic Combined Chemotherapy Protocols;Apoptosis;Benzamides;Benzenesulfonates;Benzopyrans;Biphenyl Compounds;Boronic Acids;Bortezomib;Caspases;Drug Resistance, Neoplasm;Drug Synergism;Enzyme Activation;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Interleukin-3;K562 Cells;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mitochondria;Mutation;Niacinamide;Nitrophenols;Phenylurea Compounds;Piperazines;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Protein Kinase Inhibitors;Protein-Tyrosine Kinases;Pyrazines;Pyridines;Pyrimidines;Sulfonamides",
        "Doc_meshqualifiers":"administration & dosage;pharmacology;drug effects;physiology;administration & dosage;pharmacology;administration & dosage;administration & dosage;administration & dosage;metabolism;drug effects;antagonists & inhibitors;biosynthesis;genetics;pharmacology;drug therapy;genetics;metabolism;pathology;drug effects;physiology;analogs & derivatives;administration & dosage;administration & dosage;pharmacology;drug therapy;genetics;metabolism;pathology;administration & dosage;pharmacology;antagonists & inhibitors;biosynthesis;administration & dosage;administration & dosage;pharmacology;pharmacology;administration & dosage",
        "_version_":1605839863372840960},
      {
        "Doc_abstract":"Despite central nervous system (CNS) prophylactic programs limit leptomeningeal involvement in acute lymphoblastic leukemia (ALL), it can still occur in a restricted percentage of cases. The exact risk rate remains still unknown, and several factors are associated with an increased probability to develop CNS involvement. Among them, Philadelphia (Ph)-positive genotype seems to play a relevant role. Recently, a flow cytometric assay to detect BCR-ABL protein has been developed, but little is known about its possible employment in leptomeningeal disease. Here, we show the miniaturized application of the original assay for BCR-ABL oncoprotein detection in cerebrospinal fluid (CSF) samples.",
        "Doc_title":"Miniaturized flow cytometry-based BCR-ABL immunoassay in detecting leptomeningeal disease.",
        "Journal":"Leukemia research",
        "Do_id":"21658767",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Diagnosis, Differential;Flow Cytometry;Fusion Proteins, bcr-abl;Humans;Immunoassay;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Meningeal Neoplasms;Philadelphia Chromosome;Polymerase Chain Reaction;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Sensitivity and Specificity",
        "Doc_meshqualifiers":"methods;cerebrospinal fluid;genetics;cerebrospinal fluid;complications;diagnosis;genetics;cerebrospinal fluid;complications;diagnosis;genetics;cerebrospinal fluid;complications;diagnosis;genetics",
        "_version_":1605818659138174977},
      {
        "Doc_abstract":"Cytotoxic T-lymphocytes (CTL) have been generated in vitro against chronic myeloid leukemia (CML)-associated BCR/ABL-specific peptides. We analyzed the existence of high-avidity T cells recognizing endogenously processed BCR/ABL-specific proteins.;We performed binding studies of BCR/ABL-specific peptides, proteosomal digestion of BCR/ABL breakpoint overlapping protein, mass spectrometry of eluates from HLA-*0301-transduced K562 cells, and tried to isolate peptide-specific T-cells using tetramers.;We confirmed the binding of the BCR/ABL-specific peptides KQSSKALQR to HLA-A*0301 and GFKQSSKAL to HLA-B*0801. Proteasomal digestion showed cleavage sites leading to KQSSKALQR but not to GFKQSSKAL. Using mass spectrometry KQSSKALQR could not be detected in the eluates from HLA-A*0301-transduced K562 cells. We attempted to induce BCR/ABL-specific CTL lines from 4 healthy donors using dendritic cells pulsed with KQSSKALQR and performed single cell sorting to isolate tetramer-positive T cells. None of 31 generated clones showed BCR/ABL-specific cytotoxicity. Isolation of tetramer-positive cells from peripheral blood of relapsed CML patients after allogeneic transplantation treated with donor lymphocyte infusion resulted in 38 T-cell clones which did not show peptide-specific cytotoxicity.;We provide evidence that BCR/ABL protein processing can lead to KQSSKALQR peptide binding to HLA-A*0301. However, KQSSKALQR could not be detected in HLA-A*0301-transduced K562 cells, and KQSSKALQR could not be demonstrated to induce high-avidity BCR/ABL-specific CTL.",
        "Doc_title":"Proteosomal degradation of BCR/ABL protein can generate an HLA-A*0301-restricted peptide, but high-avidity T cells recognizing this leukemia-specific antigen were not demonstrated.",
        "Journal":"Haematologica",
        "Do_id":"15377467",
        "Doc_ChemicalList":"Antigens, Neoplasm;HLA-A Antigens;HLA-A*03:01 antigen;HLA-A3 Antigen;HLA-B Antigens;HLA-B*08:01 antigen;HLA-B8 Antigen;Peptide Fragments;Fusion Proteins, bcr-abl;Proteasome Endopeptidase Complex",
        "Doc_meshdescriptors":"Amino Acid Sequence;Antigen Presentation;Antigens, Neoplasm;Clone Cells;Dendritic Cells;Fusion Proteins, bcr-abl;HLA-A Antigens;HLA-A3 Antigen;HLA-B Antigens;HLA-B8 Antigen;Humans;K562 Cells;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mass Spectrometry;Molecular Sequence Data;Peptide Fragments;Proteasome Endopeptidase Complex;Protein Binding;Protein Interaction Mapping;T-Cell Antigen Receptor Specificity",
        "Doc_meshqualifiers":"immunology;metabolism;immunology;immunology;immunology;metabolism;immunology;immunology;immunology;chemical synthesis;immunology;metabolism;metabolism",
        "_version_":1605800980624965632},
      {
        "Doc_abstract":"The transcription factor Sox4 plays an indispensable role in the development of early progenitor B cells from hematopoietic stem cells. However, its role in B-cell acute lymphoblastic leukemia, a malignant counterpart of normal progenitor B cells, is not fully understood. Here we show that SOX4 is highly expressed in human acute lymphoblastic leukemia cells. To systematically study the function of Sox4 in acute lymphoblastic leukemia, we established a genetically defined mouse leukemia model by transforming progenitor B cells carrying a floxed Sox4 allele and inducing deletion of the allele by the self-excising Cre recombinase. This model allowed us to work with two groups of leukemic cells that had either one copy or both copies of Sox4 deleted. We found that depletion of Sox4 in transformed cells in vitro reduced cell growth in vitro and the progression of leukemia in vivo. Moreover, depletion of Sox4 in leukemic cells in vivo prolonged the survival of the mice, suggesting that it could be a potential target in acute lymphoblastic leukemia therapy. Our microarray and bioChIP studies revealed that Tcf7l1 was the key gene directly regulated by Sox4. Knockdown of Tcf7l1 reduced cell proliferation, just as did knockout of Sox4, and ectopic expression of Tcf7l1 could reverse the effect of Sox4 knockout on cell proliferation. These data suggest that Sox4 and Tcf7l1 form a functional axis that promotes the progression of BCR-ABL-positive acute lymphoblastic leukemia. ",
        "Doc_title":"The Sox4/Tcf7l1 axis promotes progression of BCR-ABL-positive acute lymphoblastic leukemia.",
        "Journal":"Haematologica",
        "Do_id":"24997151",
        "Doc_ChemicalList":"RNA, Messenger;SOXC Transcription Factors;Transcription Factor 7-Like 1 Protein;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Animals;Cell Line, Tumor;Cell Transformation, Neoplastic;Cluster Analysis;Disease Progression;Fusion Proteins, bcr-abl;Gene Expression Profiling;Gene Expression Regulation, Leukemic;Humans;Mice;Mice, Transgenic;Precursor Cell Lymphoblastic Leukemia-Lymphoma;RNA Interference;RNA, Messenger;SOXC Transcription Factors;Transcription Factor 7-Like 1 Protein;Tumor Burden",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;genetics;metabolism;mortality;pathology;genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics",
        "_version_":1605840754027003904},
      {
        "Doc_abstract":"JAK2V617F, a somatic gain-of-function mutation involving the JAK2 tyrosine kinase gene, occurs in nearly all patients with polycythemia vera (PV) but also in a variable proportion of patients with other myeloid disorders; mutational frequency is estimated at approximately 50% in both essential thrombocythemia (ET) and myelofibrosis (MF), up to 20% in certain subcategories of atypical myeloproliferative disorder (atypical MPD), less than 3% in de novo myelodysplastic syndrome (MDS) or acute myeloid leukemia, and 0% in chronic myeloid leukemia (CML). Accordingly, there is now molecular justification for grouping PV, ET, and MF together in a distinct MPD category (i.e., classic, BCR-ABL(-) MPD) that is separate from chronic myeloid leukemia (CML), MDS, and atypical MPD. To date, JAK2V617F has not been described in patients with reactive myeloproliferation, lymphoid disorders, or solid tumor. Therefore, the presence of JAK2V617F strongly suggests an underlying MPD and it is therefore reasonable to consider JAK2V617F-based laboratory tests for the evaluation of polycythemia, primary thrombocytosis, unexplained leukocytosis, bone marrow fibrosis, or abdominal vein thrombosis. Current information on disease-specific prognostic relevance of JAK2V617F is inconclusive and confounded by inter-study differences in the performance of mutation screening assays. Regardless, the discovery of JAK2V617F has reinforced the pathogenetic contribution of JAK-STAT signaling in MPD and identifies JAK2 as a valid drug target.",
        "Doc_title":"Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era.",
        "Journal":"Hematology. American Society of Hematology. Education Program",
        "Do_id":"17124067",
        "Doc_ChemicalList":"Janus Kinase 2",
        "Doc_meshdescriptors":"Disease Management;Humans;Janus Kinase 2;Mutation, Missense;Myeloproliferative Disorders",
        "Doc_meshqualifiers":"genetics;classification;diagnosis;etiology;genetics",
        "_version_":1605830556645326848},
      {
        "Doc_abstract":"Expression of BCR-ABL oncoprotein in chronic myeloid leukemia (CML) promotes neoplastic transformation of hematopoietic stem cells through modulation of diverse pathways. CML is a multistep disease, which evolves as a chronic phase and progresses to blast crisis. This progression has been associated with the appearance and accumulation of new cytogenetic anomalies and mutations. The mechanisms underlying the genomic instability promoted by BCR-ABL remain obscure. Through comparative analysis of different DNA double-strand break (DSB) repair mechanisms as a function of the BCR-ABL status in human megakaryocytic and CML cell lines, we found that BCR-ABL upregulates error-prone DSB repair pathways [single-strand annealing (SSA) and non-homologous end joining] rather than the high-fidelity mechanism of homologous recombination. Intriguingly, expression analysis of DSB repair pathway choice determining factors revealed increased levels of the protein CtIP in BCR-ABL-positive cells, particularly in response to irradiation. Moreover, treatment with the BCR-ABL kinase inhibitor, Imatinib Mesylate, abolished CtIP accumulation. When we silenced CtIP expression in cells with functional BCR-ABL, SSA enhancement by BCR-ABL was completely abrogated. Importantly, we also provide evidence that BCR-ABL stimulates DSB end resection, which is mediated by CtIP. Briefly, BCR-ABL promotes mutagenic DSB repair with the DSB end-processing protein CtIP acting as the key mediator downstream of BCR-ABL.",
        "Doc_title":"BCR-ABL stimulates mutagenic homologous DNA double-strand break repair via the DNA-end-processing factor CtIP.",
        "Journal":"Carcinogenesis",
        "Do_id":"20974687",
        "Doc_ChemicalList":"Carrier Proteins;Nuclear Proteins;RBBP8 protein, human;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Carrier Proteins;Cell Line;Cell Transformation, Neoplastic;DNA Breaks, Double-Stranded;DNA Repair;Fluorescent Antibody Technique;Fusion Proteins, bcr-abl;Humans;Immunoblotting;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Nuclear Proteins",
        "Doc_meshqualifiers":"metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism;metabolism",
        "_version_":1605910195943243776},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) is currently considered incurable in most patients. Stem cell transplantation, an accepted curative option for which extensive experience has been gained, is limited by high morbidity and mortality rates, particularly in older patients. Tyrosine kinase inhibitors targeting BCR-ABL are widely used and induce remission in a high proportion of patients, but resistance and incomplete response to these agents portends eventual relapse and disease progression. Although BCR-ABL inhibitors eradicate most CML cells, they are largely ineffective against the reservoir of quiescent leukemic stem cells (LSCs). Thus a strong medical need exists for therapies that effectively eradicate LSCs and is currently a focus of extensive research. To date, evidence obtained from in vitro studies, animal models, and clinical CML specimens suggests that an effective approach may be to partner existing BCR-ABL inhibitors with compounds targeting key stem cell molecular effectors, including Wnt/-catenin, hedgehog pathway components, histone deacetylase (HDAC), transforming growth factor- (TGF-), Janus kinase 2, promyelocytic leukemia protein, and arachidonate 5-lipoxygenase (ALOX5). Novel combinations may sensitize LSCs to BCR-ABL inhibitors, thereby overcoming resistance and creating the possibility of improving disease outcome beyond the current standard of care.",
        "Doc_title":"Novel combination treatments targeting chronic myeloid leukemia stem cells.",
        "Journal":"Clinical lymphoma, myeloma & leukemia",
        "Do_id":"22178144",
        "Doc_ChemicalList":"Antineoplastic Agents;Protein Kinase Inhibitors;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Antineoplastic Agents;Antineoplastic Combined Chemotherapy Protocols;Fusion Proteins, bcr-abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Molecular Targeted Therapy;Neoplastic Stem Cells;Protein Kinase Inhibitors;Signal Transduction",
        "Doc_meshqualifiers":"administration & dosage;pharmacology;therapeutic use;antagonists & inhibitors;drug therapy;metabolism;drug effects;metabolism;administration & dosage;drug effects",
        "_version_":1605784748332941312},
      {
        "Doc_abstract":"Until recently, it was impossible to identify leukemia cells making up less than 1% of a bone marrow sample, which is designated as minimal residual disease (MRD). Owing to the development of the polymerase chain reaction (PCR) MRD can be detected at the 10(-5) level by amplifying the leukemia-specific DNA rearrangement (BCR/ABL, PML/RARA etc.) or clone-specific DNA sequences (IgH chain CDR-III etc.). Here, our studies on MRD of acute lymphoblastic leukemia and acute promyelocytic leukemia are presented, and their technical problems and clinical significance are discussed.",
        "Doc_title":"[Detection of minimal residual leukemia using polymerase chain reaction method].",
        "Journal":"Rinsho byori. The Japanese journal of clinical pathology",
        "Do_id":"8752731",
        "Doc_ChemicalList":"DNA, Neoplasm",
        "Doc_meshdescriptors":"DNA, Neoplasm;Humans;Leukemia;Neoplasm, Residual;Polymerase Chain Reaction",
        "Doc_meshqualifiers":"analysis;diagnosis;diagnosis",
        "_version_":1605891661170212865},
      {
        "Doc_abstract":"We report a new case of Ph positive chronic myeloid leukemia (CML) without the classical rearrangement in Mbcr. By Southern blot analysis the molecular breakpoint was mapped 3 to 8 kb upstream of Mbcr. This region has not been shown to be rearranged in any other described case of CML. We did not detect any specific abnormal BCR-ABL transcript even with the use of the very sensitive RNA-PCR technique.",
        "Doc_title":"A new chromosomal breakpoint in Ph positive, bcr negative chronic myelogenous leukemia. Report of a case.",
        "Journal":"Cancer genetics and cytogenetics",
        "Do_id":"1353407",
        "Doc_ChemicalList":"Proto-Oncogene Proteins;Protein-Tyrosine Kinases;BCR protein, human;Proto-Oncogene Proteins c-bcr",
        "Doc_meshdescriptors":"Base Sequence;Blood Cell Count;Blotting, Southern;Chromosome Mapping;Chromosomes, Human, Pair 22;Chromosomes, Human, Pair 9;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Molecular Sequence Data;Nucleic Acid Hybridization;Polymorphism, Restriction Fragment Length;Protein-Tyrosine Kinases;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-bcr;Translocation, Genetic",
        "Doc_meshqualifiers":"genetics;genetics",
        "_version_":1605760946553225216},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by the t(9;22) translocation coding for the chimeric protein p210 BCR-ABL. The tumor suppressor phosphatase and tensin homolog (PTEN) has recently been shown to have a critical role in the pathogenesis of CML. Nuclear localization and proper nuclear-cytoplasmic shuttling are crucial for PTEN's tumor suppressive function. In this study, we show that BCR-ABL enhances HAUSP-induced de-ubiquitination of PTEN in turn favoring its nuclear exclusion. We further demonstrate that BCR-ABL physically interacts with and phosphorylates HAUSP on tyrosine residues to trigger its activity. Importantly, we also find that PTEN delocalization induced by BCR-ABL does not occur in the leukemic stem cell compartment due to high levels of PML, a potent inhibitor of HAUSP activity toward PTEN. We therefore identify a new proto-oncogenic mechanism whereby BCR-ABL antagonizes the nuclear function of the PTEN tumor suppressor, with important therapeutic implications for the eradication of CML minimal residual disease. ",
        "Doc_title":"BCR-ABL disrupts PTEN nuclear-cytoplasmic shuttling through phosphorylation-dependent activation of HAUSP.",
        "Journal":"Leukemia",
        "Do_id":"24317448",
        "Doc_ChemicalList":"Nuclear Proteins;Promyelocytic Leukemia Protein;Transcription Factors;Tumor Suppressor Proteins;PML protein, human;Fusion Proteins, bcr-abl;USP7 protein, human;PTEN Phosphohydrolase;PTEN protein, human;Ubiquitin Thiolesterase",
        "Doc_meshdescriptors":"Animals;Blotting, Western;Cell Nucleus;Cells, Cultured;Cytoplasm;Flow Cytometry;Fluorescent Antibody Technique;Fusion Proteins, bcr-abl;Humans;Immunoenzyme Techniques;Immunoprecipitation;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mice;Nuclear Proteins;PTEN Phosphohydrolase;Phosphorylation;Promyelocytic Leukemia Protein;Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization;Transcription Factors;Tumor Suppressor Proteins;Ubiquitin Thiolesterase;Ubiquitination",
        "Doc_meshqualifiers":"metabolism;metabolism;metabolism;metabolism;pathology;metabolism;metabolism;metabolism;metabolism;metabolism",
        "_version_":1605747014754107392},
      {
        "Doc_abstract":"Occurrence of the BCR-ABL(T315I) gatekeeper mutation is among the most pressing challenges in the therapy of chronic myeloid leukemia (CML). Several BCR-ABL inhibitors have multiple targets and pleiotropic effects that could be exploited for their synergistic potential. Testing combinations of such kinase inhibitors identified a strong synergy between danusertib and bosutinib that exclusively affected CML cells harboring BCR-ABL(T315I). To elucidate the underlying mechanisms, we applied a systems-level approach comprising phosphoproteomics, transcriptomics and chemical proteomics. Data integration revealed that both compounds targeted Mapk pathways downstream of BCR-ABL, resulting in impaired activity of c-Myc. Using pharmacological validation, we assessed that the relative contributions of danusertib and bosutinib could be mimicked individually by Mapk inhibitors and collectively by downregulation of c-Myc through Brd4 inhibition. Thus, integration of genome- and proteome-wide technologies enabled the elucidation of the mechanism by which a new drug synergy targets the dependency of BCR-ABL(T315I) CML cells on c-Myc through nonobvious off targets.",
        "Doc_title":"Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML.",
        "Journal":"Nature chemical biology",
        "Do_id":"23023260",
        "Doc_ChemicalList":"Aniline Compounds;Benzamides;Nitriles;Piperazines;Protein Kinase Inhibitors;Proto-Oncogene Proteins c-myc;Pyrazoles;Pyrimidines;Quinolines;bosutinib;Imatinib Mesylate;Fusion Proteins, bcr-abl;danusertib",
        "Doc_meshdescriptors":"Aniline Compounds;Animals;Antineoplastic Combined Chemotherapy Protocols;Apoptosis;Benzamides;Cell Line, Tumor;Cell Survival;Dose-Response Relationship, Drug;Down-Regulation;Drug Resistance, Neoplasm;Drug Synergism;Fusion Proteins, bcr-abl;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mice;Nitriles;Piperazines;Protein Kinase Inhibitors;Proteomics;Proto-Oncogene Proteins c-myc;Pyrazoles;Pyrimidines;Quinolines;Structure-Activity Relationship;Systems Biology",
        "Doc_meshqualifiers":"pharmacology;pharmacology;drug effects;pharmacology;drug effects;drug effects;drug effects;antagonists & inhibitors;genetics;drug therapy;metabolism;pathology;pharmacology;pharmacology;pharmacology;antagonists & inhibitors;metabolism;pharmacology;pharmacology;pharmacology",
        "_version_":1605766044793700352},
      {
        "Doc_abstract":"The examination of the presence of Ph chromosome and of the fused gene BCR-ABL in patients with chronic myeloid leukemia (CML) is significant for the precise diagnosis and in some cases for the prognosis of the disease. We examined peripheral blood for the presence of BCR-ABL fused gene by polymerase chain reaction (PCR) in eight patients with CML consecutively cytogenetically studied before and after the bone marrow transplantation and in two patients treated with interferon. Southern blot analysis was performed before BMT in two patients and the molecular rearrangement of Ph chromosome was found. In all cases our results have proved that cytogenetic and recombinant DNA evaluations confirm each other. Due to the high sensitivity of PCR technique the minimal residual leukemia can be detected.",
        "Doc_title":"[Use of cytogenetic and molecular biology in the detection of chronic myeloid leukemia].",
        "Journal":"Casopis lekaru ceskych",
        "Do_id":"1288873",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Blotting, Southern;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Philadelphia Chromosome;Polymerase Chain Reaction",
        "Doc_meshqualifiers":"diagnosis;genetics",
        "_version_":1605818655349669891},
      {
        "Doc_abstract":"To describe three methods used to screen for frameshift mutations in exon 9 of the CALR gene.;Genomic DNA from 47 patients was extracted from peripheral blood and bone marrow using the EZ1 DNA Blood Kit (Qiagen, Valencia, CA) and quantified by the Quant-iT PicoGreen dsDNA Assay Kit (Invitrogen, San Diego, CA). After clinical history, cytogenetics, and molecular tests, patients were diagnosed with either clonal or nonclonal hematologic diseases. CALR screening was primarily performed using fragment analysis polymerase chain reaction, then next-generation sequencing and Sanger sequencing.;Among the 18 patients diagnosed with clonal diseases, one had acute myeloid leukemia (positive for trisomy 8), and 17 had myeloproliferative neoplasms (MPNs), including chronic myeloid leukemia (CML), essential thrombocythemia (ET), primary myelofibrosis (PMF), and polycythemia vera (PV). Patients with CML were positive for the BCR-ABL1 fusion. Ten patients were positive for JAK2 (PMF, n=1; ET, n=2; PV, n=7), and three were CALR positive (ET, n=1; PMF, n=2). Patients diagnosed with a nonclonal disease were negative for JAK2, BCR-ABL, and CALR mutations.;Screening for CALR mutations is essential in BCR-ABL-negative MPNs since it not only provides valuable diagnostic and prognostic information but also identifies potential treatment targets. Since this study describes the importance of screening for known and novel biomarkers, we described in detail three methods that could be easily integrated into a clinical laboratory.",
        "Doc_title":"Detection of CALR Mutation in Clonal and Nonclonal Hematologic Diseases Using Fragment Analysis and Next-Generation Sequencing.",
        "Journal":"American journal of clinical pathology",
        "Do_id":"27686171",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605826381927677952},
      {
        "Doc_abstract":"A 51-year-old man was diagnosed as having Philadelpha (Ph) chromosome-positive acute myeloid leukemia (AML) with major-BCR/ABL mRNA. He achieved complete remission after induction chemotherapy. Five months later, he was again positive for the Ph chromosome despite additional chemotherapy. He was therefore treated with imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, at a dose of 600 mg/day. However, the treatment was interrupted because of thrombocytopenia, skin eruption and face edema. After the patient recovered from these side effects, imatinib was readministered at a dose of 400 mg/day and a complete cytogenetic response was achieved. Imatinib is expected to be an effective drug for Ph chromosome-positive AML.",
        "Doc_title":"[Successful treatment with imatinib mesylate for Philadelphia chromosome-positive refractory acute myeloid leukemia].",
        "Journal":"[Rinsho ketsueki] The Japanese journal of clinical hematology",
        "Do_id":"12784659",
        "Doc_ChemicalList":"Benzamides;Enzyme Inhibitors;Piperazines;Pyrimidines;RNA, Messenger;Imatinib Mesylate;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Benzamides;Enzyme Inhibitors;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Piperazines;Protein-Tyrosine Kinases;Pyrimidines;RNA, Messenger;Treatment Outcome",
        "Doc_meshqualifiers":"administration & dosage;adverse effects;drug therapy;genetics;administration & dosage;adverse effects;antagonists & inhibitors;administration & dosage;adverse effects;genetics",
        "_version_":1605906924243517440},
      {
        "Doc_abstract":"Selective inhibition of the BCR-ABL tyrosine kinase by imatinib (Gleevec) (formerly STI571) is a promising new therapeutic strategy in patients with chronic myelogenous leukemia (CML). Despite significant hematologic and cytogenetic responses, resistance occurs in patients with chronic phase (CP) and advanced disease. A cohort of 72 patients with CML in myeloid blast crisis (BC) (n = 34), lymphoid BC (n = 2), accelerated phase (AP) (n = 16), CP (n = 18), and BCR-ABL(+) acute lymphoblastic leukemia (ALL) (n = 2) resistant to imatinib were investigated. Median levels of BCR-ABL transcripts, determined by quantitative reverse-transcriptase polymerase chain reaction (RT-PCR), were not significantly changed at the time of resistance, but seven of 55 patients showed a greater than 10-fold increase in BCR-ABL levels. Genomic amplification of BCR-ABL was found in two of 32 patients evaluated by fluorescence in situ hybridization (FISH). Additional chromosomal aberrations were observed in 19 of 36 patients and point mutations of the ABL tyrosine kinase domain resulting in reactivation of the BCR-ABL tyrosine kinase were detected in 29 of 72 patients. Resistance may be caused by BCR-ABL-independent or BCR-ABL-dependent mechanisms. A thorough evaluation of resistant cases is required to suggest therapeutic measures in the individual case. Clonal selection of resistant cells harboring a BCR-ABL mutation might be reversed by stopping imatinib therapy and switching to chemotherapy. Combination therapy from the start of treatment to reduce the frequency of resistance is currently being evaluated with several drugs.",
        "Doc_title":"Cytogenetic and molecular mechanisms of resistance to imatinib.",
        "Journal":"Seminars in hematology",
        "Do_id":"12783379",
        "Doc_ChemicalList":"Benzamides;Piperazines;Pyrimidines;RNA, Neoplasm;Imatinib Mesylate;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Benzamides;Chromosome Aberrations;Clone Cells;Cytogenetic Analysis;DNA Mutational Analysis;Disease Progression;Drug Resistance, Neoplasm;Fusion Proteins, bcr-abl;Genes, abl;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Piperazines;Point Mutation;Pyrimidines;RNA, Neoplasm;Treatment Outcome",
        "Doc_meshqualifiers":"pathology;genetics;genetics;genetics;drug therapy;genetics;pathology;pharmacology;therapeutic use;pharmacology;therapeutic use;analysis",
        "_version_":1605742648214159362},
      {
        "Doc_abstract":"The BCR-ABL fusion gene is directly involved in the pathogenesis of chronic myeloid leukemia (CML). Specific inhibition of the BCR-ABL gene expression with antisense oligodeoxynucleotides has been shown to have profound effects on cell growth in vitro. We examined antisense phosphodiester oligonucleotides (16-mers at a concentration of 60 micrograms/ml) spanning the two possible junction sites K28 (b3a2) and L6 (b2a2) in a clonogenic assay. Single colonies from 9 patients with CML and from patients with normal bone marrow were screened for BCR-ABL expression with a new 'single-tube nested PCR' method. There was a marked reduction in colony number in the CML group and a lesser growth inhibition in the control group. The number and percentage of BCR-ABL-positive colonies, however, was not reduced in the CML group. This indicates a nonspecific growth inhibition only.",
        "Doc_title":"Unmodified phosphodiester antisense oligodeoxynucleotides to the BCR-ABL junction do not suppress Philadelphia-positive clonogenic cells.",
        "Journal":"Acta haematologica",
        "Do_id":"7701917",
        "Doc_ChemicalList":"DNA Primers;Oligonucleotides, Antisense;RNA, Neoplasm;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Base Sequence;Clone Cells;DNA Primers;Fusion Proteins, bcr-abl;Hematopoiesis;Humans;In Vitro Techniques;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Molecular Sequence Data;Oligonucleotides, Antisense;RNA, Neoplasm;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"chemistry;genetics;drug effects;pathology;therapy;chemistry;genetics",
        "_version_":1605831377172824064},
      {
        "Doc_abstract":"P210(bcr/abl) fusion gene is indispensable for generation and progression of chronic myeloid leukemia (CML). Small molecule inhibitors, such as imatinib, are effective for P210(bcr/abl) gene mediated CML, but drug resistance may occur. The unique fusion junction of P210(bcr/abl) gene is an attractive target for therapeutic intervention using RNA interference (RNAi). This study was purposed to constructed the BaF3 cell line by viral vector which can stably express P210(bcr/abl) shRNA and P210(bcr/abl) mRNA at the same time, and investigate the effect of lentiviral-victor-delivered shRNA on P210(bcr/abl) gene expression. The infective rate of lentiviral vector on BaF3 cells with P210(bcr/abl) gene was assayed by fluorescent microscopy; the cell proliferation ability was determined by trypan blue exclusion; the P210(bcr/abl) mRNA and protein expressions were detected by RT-PCR and Western blot respectively. The results found that stable expression of the P210(bcr/abl) shRNA resulted in obvious inhibition of P210(bcr/abl) mRNA and protein expression and increased sensitivity of these P210(bcr/abl) gene transformed Ba/F3 cells to imatinib. The IC(50) to imatinib in these cells decreased < 50% as compared with Ba/F3-P210(bcr/abl) cells which did not express P210(bcr/abl) mRNA. The survival time of the lethal dose irradiated mice induced by intravenous injection of these Ba/F3 cells was longer than the other group induced by Ba/F3-P210(bcr/abl). It is concluded that stable expression of shRNA targeting the P210(bcr/abl) gene fusion junction may potentiate the effects of conventional therapy for CML.",
        "Doc_title":"[Stable interference on P210(bcr/abl) gene expression by lentiviral vector-delivered shRNA in vitro and in vivo].",
        "Journal":"Zhongguo shi yan xue ye xue za zhi",
        "Do_id":"23114125",
        "Doc_ChemicalList":"RNA, Small Interfering;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Animals;Fusion Proteins, bcr-abl;Gene Expression;Genetic Vectors;Lentivirus;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mice;NIH 3T3 Cells;RNA, Small Interfering",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;genetics;metabolism;genetics",
        "_version_":1605844893809246208},
      {
        "Doc_abstract":"Imatinib mesylate (IM) and other BCR-ABL tyrosine kinase inhibitors (TKIs) have improved chronic myeloid leukemia (CML) patient survival markedly but fail to eradicate quiescent CML leukemia stem cells (LSCs). Thus, strategies targeting LSCs are required to induce long-term remission and achieve cure. Here, we investigated the ability of topoisomerase II (Top II) inhibitor etoposide (Eto) to target CML LSCs. Treatment with Eto combined with IM markedly induced apoptosis in primitive CML CD34",
        "Doc_title":"Selective and effective targeting of chronic myeloid leukemia stem cells by topoisomerase II inhibitor etoposide in combination with imatinib mesylate in vitro.",
        "Journal":"Cell biology international",
        "Do_id":"27677634",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605837336654905344},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) is a hematopoietic disease characterized by expansion of myeloid blood cells. It is caused by the t(9;22) chromosomal translocation that results in the expression of the fusion tyrosine kinase BCR-ABL. Tyrosine kinase inhibitor (TKI) therapy has led to long-term remissions, but patients remain BCR-ABL+. There is agreement that TKIs do not kill CML stem cells; however, it is controversial whether this is because of a lack of BCR-ABL kinase inhibition in CML stem cells or because CML stem cells do not require BCR-ABL for survival. In this issue of the JCI, Corbin and colleagues provide definitive evidence that BCR-ABL is kinase active in CML stem cells and that TKIs inhibit this kinase activity without affecting CML stem cell survival. Rather, CML stem cells revert to a normal dependence on cytokines for survival and proliferation. These results demonstrate that the CML stem cell is not BCR-ABL addicted and have important implications for developing curative therapeutic approaches to CML.",
        "Doc_title":"BCR-ABL kinase is dead; long live the CML stem cell.",
        "Journal":"The Journal of clinical investigation",
        "Do_id":"21157035",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Imatinib Mesylate;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Antineoplastic Agents;Benzamides;Cell Proliferation;Cell Survival;Drug Resistance, Neoplasm;Enzyme Activation;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Models, Biological;Neoplastic Stem Cells;Piperazines;Protein Kinase Inhibitors;Protein-Tyrosine Kinases;Pyrimidines",
        "Doc_meshqualifiers":"therapeutic use;drug effects;drug effects;antagonists & inhibitors;metabolism;drug therapy;enzymology;pathology;drug effects;enzymology;pathology;therapeutic use;therapeutic use;antagonists & inhibitors;metabolism;therapeutic use",
        "_version_":1605760753166450688},
      {
        "Doc_abstract":"The tyrosine kinase Bcr-Abl causes chronic myeloid leukemia and is the cognate target of tyrosine kinase inhibitors like imatinib. We have charted the protein-protein interaction network of Bcr-Abl by a 2-pronged approach. Using a monoclonal antibody we have first purified endogenous Bcr-Abl protein complexes from the CML K562 cell line and characterized the set of most tightly-associated interactors by MS. Nine interactors were subsequently subjected to tandem affinity purifications/MS analysis to obtain a molecular interaction network of some hundred cellular proteins. The resulting network revealed a high degree of interconnection of 7 \"core\" components around Bcr-Abl (Grb2, Shc1, Crk-I, c-Cbl, p85, Sts-1, and SHIP-2), and their links to different signaling pathways. Quantitative proteomics analysis showed that tyrosine kinase inhibitors lead to a disruption of this network. Certain components still appear to interact with Bcr-Abl in a phosphotyrosine-independent manner. We propose that Bcr-Abl and other drug targets, rather than being considered as single polypeptides, can be considered as complex protein assemblies that remodel upon drug action.",
        "Doc_title":"Charting the molecular network of the drug target Bcr-Abl.",
        "Journal":"Proceedings of the National Academy of Sciences of the United States of America",
        "Do_id":"19380743",
        "Doc_ChemicalList":"Multienzyme Complexes;Protein Kinase Inhibitors;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Cell Line;Fusion Proteins, bcr-abl;Humans;Multienzyme Complexes;Protein Interaction Mapping;Protein Kinase Inhibitors;Proteomics",
        "Doc_meshqualifiers":"antagonists & inhibitors;metabolism;antagonists & inhibitors;metabolism;pharmacology",
        "_version_":1605801969608294400},
      {
        "Doc_abstract":"With an annual incidence of about ten in 1,000,000 people, chronic myeloid leukemia (CML) accounts for most cases of myeloproliferative disease and for 20% of all leukemias. While novel therapies such as treatment with interferon-alpha or bone marrow transplantation have successively improved the outcome of CML treatment, hope for future progress in the therapy of CML lies in an almost unique feature of this hematological malignancy. In contrast to many other forms or subforms of leukemias which display a great diversity in chromosomal alterations, most cases (>95%) of CML seem to be caused by an almost invariably found cytogenetic aberration, the so-called Philadelphia chromosome (Ph), resulting in the bcr-abl fusion gene. Its gene product, p210bcr-abl (Bcr-Abl), is believed to be essential for hematopoietic cell transformation and seems to exert its effects by interfering with cellular signal transduction pathways, normally involved in the control of cell death and proliferation. Several partially interacting pathways have been shown to be induced by Bcr-Abl. The role of most of them is still unclear and, as understanding their biological functions should lead to novel therapeutic strategies on a molecular basis, much effort is spent on identifying their precise roles in CML. This review focuses on our current understanding of Bcr-Abl-induced signal transduction and outlines its importance for the biological effects of Bcr-Abl.",
        "Doc_title":"Molecular pathogenesis of chronic myeloid leukemia: implications for new therapeutic strategies.",
        "Journal":"Annals of hematology",
        "Do_id":"10089019",
        "Doc_ChemicalList":"Adaptor Proteins, Signal Transducing;CRKL protein;Cytokines;Growth Substances;Guanine Nucleotides;Nuclear Proteins;Phosphoproteins;Proteins;Receptors, Cytokine;Receptors, Growth Factor;Retinoblastoma-Like Protein p130;Transcription Factors;Phosphatidylinositol 3-Kinases;Fusion Proteins, bcr-abl;src-Family Kinases;Calcium-Calmodulin-Dependent Protein Kinases;ras Proteins",
        "Doc_meshdescriptors":"Adaptor Proteins, Signal Transducing;Animals;Apoptosis;Blast Crisis;Calcium-Calmodulin-Dependent Protein Kinases;Cell Adhesion;Cell Division;Cell Transformation, Neoplastic;Cytokines;Fibroblasts;Fusion Proteins, bcr-abl;Gene Expression Regulation, Leukemic;Genes, abl;Growth Substances;Guanine Nucleotides;Hematopoietic Stem Cells;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mice;Mice, SCID;Mice, Transgenic;Models, Biological;Nuclear Proteins;Philadelphia Chromosome;Phosphatidylinositol 3-Kinases;Phosphoproteins;Proteins;Rats;Receptors, Cytokine;Receptors, Growth Factor;Retinoblastoma-Like Protein p130;Signal Transduction;Structure-Activity Relationship;Transcription Factors;ras Proteins;src-Family Kinases",
        "Doc_meshqualifiers":"genetics;genetics;pathology;physiology;drug effects;genetics;physiology;pathology;chemistry;genetics;physiology;physiology;physiology;pathology;genetics;metabolism;pathology;therapy;physiology;physiology;physiology;physiology;physiology;physiology;physiology;physiology",
        "_version_":1605819736918065152},
      {
        "Doc_abstract":"As the first clinically successful tyrosine kinase inhibitor (TKI), imatinib pioneered a new approach to treating patients with cancer. Dramatic results from chronic myeloid leukemia (CML) clinical trials spurred the development of TKIs for other malignancies such as acute myeloid leukemia as well as kidney and lung cancer. In CML, imatinib resistance led to the rapid development of dasatinib and nilotinib, more potent second-generation ABL kinase inhibitors that can often overcome imatinib resistance. While the clinical efficacy of TKIs in CML is well established, a number of important questions remain about the optimal dose and duration of therapy. Even the best initial dose for imatinib is still under investigation. Although laboratory and clinical studies had led to the prevailing view that continual inhibition of the BCR-ABL kinase was required for optimal efficacy, recent data on dasatinib have upended this notion and have led to a change in the recommended dosing schedule. The availability of dasatinib and nilotinib also begs the question of whether they might be superior to imatinib as first-line agents. Finally, the question of whether it may be possible to stop TKI therapy at least in some patients with CML has attracted considerable attention. More than 10 years after the introduction of imatinib, optimization of TKI therapy for CML continues.",
        "Doc_title":"How much and how long: tyrosine kinase inhibitor therapy in chronic myeloid leukemia.",
        "Journal":"Clinical lymphoma, myeloma & leukemia",
        "Do_id":"20529804",
        "Doc_ChemicalList":"Benzamides;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Thiazoles;Imatinib Mesylate;Dasatinib",
        "Doc_meshdescriptors":"Benzamides;Dasatinib;Dose-Response Relationship, Drug;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Thiazoles",
        "Doc_meshqualifiers":"drug therapy;administration & dosage;administration & dosage;pharmacology;administration & dosage;administration & dosage",
        "_version_":1605850618112507904},
      {
        "Doc_abstract":"Acquired point mutations within the BCR-ABL kinase domain represent a common mechanism of resistance to ABL inhibitor therapy in patients with chronic myeloid leukemia (CML). The BCR-ABL(T315I) mutant is highly resistant to imatinib, nilotinib, and dasatinib, and is frequently detected in relapsed patients. This critical gap in resistance coverage drove development of DCC-2036, an ABL inhibitor that binds the switch control pocket involved in conformational regulation of the kinase domain. We evaluated the efficacy of DCC-2036 against BCR-ABL(T315I) and other mutants in cellular and biochemical assays and conducted cell-based mutagenesis screens. DCC-2036 inhibited autophosphorylation of ABL and ABL(T315I) enzymes, and this activity was consistent with selective efficacy against Ba/F3 cells expressing BCR-ABL (IC(50): 19 nmol/L), BCR-ABL(T315I) (IC(50): 63 nmol/L), and most kinase domain mutants. Ex vivo exposure of CML cells from patients harboring BCR-ABL or BCR-ABL(T315I) to DCC-2036 revealed marked inhibition of colony formation and reduced phosphorylation of the direct BCR-ABL target CrkL. Cell-based mutagenesis screens identified a resistance profile for DCC-2036 centered around select P-loop mutations (G250E, Q252H, Y253H, E255K/V), although a concentration of 750 nmol/L DCC-2036 suppressed the emergence of all resistant clones. A decreased concentration of DCC-2036 (160 nmol/L) in dual combination with either nilotinib or dasatinib achieved the same zero outgrowth result. Further screens for resistance due to BCR-ABL compound mutations (two mutations in the same clone) identified BCR-ABL(E255V / T315I) as the most resistant mutant. Taken together, these findings support continued evaluation of DCC-2036 as an important new agent for treatment-refractory CML.",
        "Doc_title":"The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile.",
        "Journal":"Cancer research",
        "Do_id":"21505103",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;DCC-2036;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Quinolines;abl-bcr fusion protein, human;Imatinib Mesylate;Fusion Proteins, bcr-abl;Proto-Oncogene Proteins c-abl",
        "Doc_meshdescriptors":"Antineoplastic Agents;Benzamides;Cell Line, Tumor;Drug Resistance, Neoplasm;Fusion Proteins, bcr-abl;Genes, abl;Humans;Imatinib Mesylate;K562 Cells;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Phosphorylation;Piperazines;Point Mutation;Protein Kinase Inhibitors;Proto-Oncogene Proteins c-abl;Pyrimidines;Quinolines",
        "Doc_meshqualifiers":"pharmacology;genetics;drug therapy;enzymology;genetics;pharmacology;pharmacology;antagonists & inhibitors;pharmacology;pharmacology",
        "_version_":1605797587823099904},
      {
        "Doc_abstract":"The sensitive detection of minimal residual disease by the polymerase chain reaction (PCR) has revolutionized our ability to follow treatment response and predict relapse. Examples of how the detection of minimal residual disease can drive clinical research are best found in chronic myeloid leukemia (CML). The use of PCR to detect the BCR-ABL chimeric transcript in CML has been found to predict relapse in the transplant setting, and more recently, has been found in trials of imatinib to be a strong measure in predicting progression-free survival. In addition, clinical trials are now under way using the quantitative assessment of BCR-ABL as a surrogate outcome marker, potentially reducing the time and cost of clinical trials.",
        "Doc_title":"Monitoring BCR-ABL in the treatment of chronic myeloid leukemia by polymerase chain reaction.",
        "Journal":"Current hematologic malignancy reports",
        "Do_id":"20425346",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Biomarkers, Tumor;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Imatinib Mesylate;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adult;Antineoplastic Agents;Antineoplastic Combined Chemotherapy Protocols;Benzamides;Biomarkers, Tumor;Bone Marrow Transplantation;Child;Clinical Trials as Topic;Combined Modality Therapy;Disease-Free Survival;Drug Monitoring;Drug Resistance, Neoplasm;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Multicenter Studies as Topic;Neoplasm, Residual;Piperazines;Polymerase Chain Reaction;Protein Kinase Inhibitors;Pyrimidines;Recurrence;Sensitivity and Specificity",
        "Doc_meshqualifiers":"therapeutic use;therapeutic use;blood;methods;genetics;antagonists & inhibitors;blood;genetics;blood;drug therapy;genetics;pathology;surgery;administration & dosage;therapeutic use;methods;administration & dosage;therapeutic use;administration & dosage;therapeutic use",
        "_version_":1605765894658588672},
      {
        "Doc_abstract":"The Philadelphia (Ph(1)) chromosome arising from the reciprocal t(9;22) translocation is found in more than 90% of chronic myeloid leukemia (CML) patients and results in the formation of the chimeric fusion gene BCR-ABL. However, a small proportion of patients with CML have simple or complex variants of this translocation, involving various breakpoints in addition to 9q34 and 22q11. We report five CML cases carrying variant Ph translocations involving both chromosomes 9 and 22 as well as chromosomes 3, 5, 7, 8, or 10. G-banding showed a reciprocal three-way translocation involving 3q21, 5q31, 7q32, 8q24, and 10q22 bands. BCR-ABL fusion signal on der(22) was found in all of the cases by FISH.",
        "Doc_title":"Complex Variant t(9;22) Chromosome Translocations in Five Cases of Chronic Myeloid Leukemia.",
        "Journal":"Advances in hematology",
        "Do_id":"19946422",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605824952720687104},
      {
        "Doc_abstract":"PTEN plays an essential role in the pathogenesis of chronic myeloid leukemia. Recently, we have shown that BCR-ABL promotes PTEN nuclear exclusion, through the modulation of HAUSP activity.;Here, we investigate HAUSP cellular compartmentalization in primary CML samples.;While in normal CD34 positive cells HAUSP is expressed mostly in the nucleus, in CML CD34 cells HAUSP is expressed both in the nuclear bodies and in the cytoplasm.;This observation suggests that HAUSP behaves as a shuttling protein in CML. It can bind to BCR-ABL in the cytosol, where it is phosphorylated on tyrosine residues, and it maintains the proper compartmentalization in the nuclear bodies, where it acts as part of a PML network to regulate PTEN de-ubiquitination.",
        "Doc_title":"HAUSP compartmentalization in chronic myeloid leukemia.",
        "Journal":"European journal of haematology",
        "Do_id":"25082234",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl;USP7 protein, human;PTEN Phosphohydrolase;PTEN protein, human;Ubiquitin Thiolesterase",
        "Doc_meshdescriptors":"Cell Line;Fusion Proteins, bcr-abl;Gene Expression;Humans;Intracellular Space;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;PTEN Phosphohydrolase;Protein Binding;Protein Transport;Ubiquitin Thiolesterase",
        "Doc_meshqualifiers":"genetics;metabolism;metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism",
        "_version_":1605757089431420928},
      {
        "Doc_abstract":"The constitutively activated tyrosine kinase activity of the p210(bcr-abl) fusion protein, generated by a t(9;22)(q34;q11) chromosomal translocation, is pathogenetically associated with chronic myeloid leukemia (CML). However, mechanisms contributing to the expansion of a BCR-ABL positive clone are largely obscure. In the presence of an impaired immune surveillance, cells carrying any of these alterations may become phenotypically relevant. Therefore, immunosuppressed solid organ recipients represent an optimal population to investigate the frequency of mRNA products of this translocation. Blood leukocytes were studied in 201 individuals (100 organ recipients and 101 control individuals) for the presence of BCR-ABL transcripts by a nested-reverse transcriptase-polymerase chain reaction assay, routinely used in our institution. In 5/100 immunosuppressed patients, at least one out of two RT-PCR products was bcr-abl positive while all controls were negative. These findings were extended by four CML cases of organ transplant recipients (three renal and one liver transplants). Three of these cases developed CML in a total of 2088 transplantations in 9 yr, suggesting a higher incidence of CML in these patients.",
        "Doc_title":"BCR-ABL positive cells and chronic myeloid leukemia in immune suppressed organ transplant recipients.",
        "Journal":"European journal of haematology",
        "Do_id":"19799626",
        "Doc_ChemicalList":"Immunosuppressive Agents;RNA, Messenger;RNA, Neoplasm;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adolescent;Adult;Child;Clone Cells;Female;Fusion Proteins, bcr-abl;Humans;Immunologic Surveillance;Immunosuppressive Agents;Incidence;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Leukocytes;Male;Middle Aged;Organ Transplantation;Philadelphia Chromosome;Postoperative Complications;RNA, Messenger;RNA, Neoplasm;Reverse Transcriptase Polymerase Chain Reaction;Young Adult",
        "Doc_meshqualifiers":"enzymology;blood;adverse effects;blood;epidemiology;etiology;genetics;enzymology;pathology;blood;epidemiology;etiology;biosynthesis;blood;biosynthesis;blood",
        "_version_":1605742774157574147},
      {
        "Doc_abstract":"Chronic myeloproliferative disease (CMPD) is a group of malignant blood disorders including polycythemia vera, essential thrombocythemia, primary myelofibrosis, chronic myeloid leukemia, and so on. CMPD is characterized by proliferation of one or several lineages in hematopoietic system. The pathogenesis of CMPD is not clear except chronic myeloid leukemia associated with the bcr/abl fusion gene. In recent years, more studies demonstrated that CMPD have a higher mutation rate of gene jak2. In this review, the association of jak2 gene mutation with clinical diagnosis, clinical feature and molecular target therapy in CMPD and other hematological disease were summarized.",
        "Doc_title":"[Research progress on gene mutation of jak2].",
        "Journal":"Zhongguo shi yan xue ye xue za zhi",
        "Do_id":"20030962",
        "Doc_ChemicalList":"JAK2 protein, human;Janus Kinase 2",
        "Doc_meshdescriptors":"Chronic Disease;Humans;Janus Kinase 2;Mutation;Myelodysplastic-Myeloproliferative Diseases",
        "Doc_meshqualifiers":"genetics;genetics",
        "_version_":1605810529740259328},
      {
        "Doc_abstract":"The ability to detect the BCR-ABL fusion gene in precursor B-cell acute lymphoblastic leukemia (pB-ALL) is essential for making accurate treatment decisions.;We used a new flow cytometric immunobead assay for BCR-ABL fusion protein detection in peripheral blood and/or bone marrow samples from 38 adult pB-ALL patients and the results were compared with polymerase chain reaction (PCR) detection of BCR-ABL transcript.;The fusion protein was detected in peripheral blood and bone marrow samples from seven of the 38 (18%) patients, and results for both the p190 and p210 were confirmed by PCR. One case, which was positive by cytogenetics and fluorescence in situ hybridization (FISH), was negative by PCR but positive by flow cytometry. Another case, which was positive by PCR and negative by flow cytometry, was from a patient on steroid treatment.;The cytometric immunobead assay for BCR-ABL fusion protein detection was found to be suitable for the investigation of pB-ALL patients. This assay is reliable, rapid and simple to use for peripheral blood and bone marrow samples.",
        "Doc_title":"BCR-ABL fusion protein detection in peripheral blood and bone marrow samples of adult precursor B-cell acute lymphoblastic leukemia patients using the flow cytometric immunobead assay.",
        "Journal":"Clinical chemistry and laboratory medicine",
        "Do_id":"22962228",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Aged, 80 and over;Bone Marrow;Female;Flow Cytometry;Fusion Proteins, bcr-abl;Humans;Immunoassay;In Situ Hybridization, Fluorescence;Male;Middle Aged;Polymerase Chain Reaction;Precursor Cell Lymphoblastic Leukemia-Lymphoma;ROC Curve;Young Adult",
        "Doc_meshqualifiers":"metabolism;analysis;blood;metabolism;pathology",
        "_version_":1605906775217799168},
      {
        "Doc_abstract":"We report the successful purging of leukemia cells bearing the Philadelphia chromosome and BCR/ABL transcripts by long-term marrow culture (LTC), and subsequent grafting of the purged marrow in a case of refractory acute lymphoblastic leukemia. The efficiency of the purge was evaluated by polymerase chain reaction (PCR) for BCR/ABL transcripts. In two LTCs initiated in the blastic stage, we demonstrated the selective effect of three culture media (serum dependent, serum-free (SF) supplemented or not with IL3 and GM-CSF) on the proliferative potential of normal hematopoietic (CFU-GM/BFU-E) and leukemic progenitors (CFU-ALL). BCR/ABL positive cells disappeared after 3 to 4 weeks of culture. The addition of IL3 and GM-CSF to the SF medium enhanced the growth of CFU-GM/BFU-E and shortened the purging period. We therefore carried out a LTC in the presence of IL3 and GM-CSF with marrow harvested in morphological remission. BCR/ABL positivity was detected at the outset, although no leukemia cells could be identified. The BCR/ABL was no longer found by PCR in the 7 and 14 day LTCs. The patient, consolidated by high dose polychemotherapy and total body irradiation, was infused with the 14 day LTC. This study indicates that PCR is a useful and sensitive technique for monitoring tumor cell reduction after LTC prior to autografting.",
        "Doc_title":"Polymerase chain reaction: a method for monitoring tumor cell purge by long-term culture in BCR/ABL positive acute lymphoblastic leukemia.",
        "Journal":"Bone marrow transplantation",
        "Do_id":"8435666",
        "Doc_ChemicalList":"Culture Media, Serum-Free;Neoplasm Proteins;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Bone Marrow Purging;Bone Marrow Transplantation;Culture Media, Serum-Free;Fusion Proteins, bcr-abl;Neoplasm Proteins;Neoplastic Stem Cells;Polymerase Chain Reaction;Precursor B-Cell Lymphoblastic Leukemia-Lymphoma;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Transplantation, Autologous",
        "Doc_meshqualifiers":"analysis;genetics;analysis;genetics;chemistry;genetics;pathology;surgery;genetics;pathology;surgery",
        "_version_":1605755303578566656},
      {
        "Doc_abstract":"Point mutations of the BCR-ABL tyrosine kinase domain are considered the predominant cause of imatinib resistance in chronic myeloid leukemia. The expansion of mutant BCR-ABL-positive clones under selective pressure of tyrosine kinase inhibition is referred to as clonal selection; there are few data on the reversibility of this phenomenon.;The changes of expression of mutant BCR-ABL-positive alleles after cessation of tyrosine kinase inhibitor treatment were examined in 19 patients with chronic myeloid leukemia harboring different mutations in a longitudinal follow-up. The proportion of mutant alleles was quantified by amplification of rearranged ABL sequences followed by mutation-specific restriction digestion, electrophoresis and densitometry. The size of mutant clones was established as a measure of the absolute amount of mutant cells considering the proportion of mutant BCR-ABL transcripts and the total level of BCR-ABL obtained by quantitative reverse transcriptase polymerase chain reaction.;The median proportion of mutant transcripts was 97% before and 8% after cessation of tyrosine kinase inhibitor treatment indicating a relative decline of 88% within a median of 6 months. The relative decrease in the size of the mutant clones was 86%. Repeated selection and deselection of the mutant clone after resumption and second cessation of tyrosine kinase inhibitor treatment was observed in individual patients.;Deselection of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor treatment might be a common, rapid and reproducible phenomenon, although some patients harboring the T315I mutation showed no deselection. Cessation of tyrosine kinase inhibitor treatment may lead to the regression of T315I mutant clones to a level under the limit of detection, offering the therapeutic option of resumed tyrosine kinase inhibitor treatment under close surveillance of the mutation status.",
        "Doc_title":"Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapy.",
        "Journal":"Haematologica",
        "Do_id":"21134983",
        "Doc_ChemicalList":"4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide;Benzamides;Piperazines;Pyrimidines;RNA, Messenger;Thiazoles;Imatinib Mesylate;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl;Dasatinib",
        "Doc_meshdescriptors":"Antineoplastic Protocols;Benzamides;Clone Cells;Dasatinib;Drug Resistance, Neoplasm;Female;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Longitudinal Studies;Male;Middle Aged;Piperazines;Point Mutation;Polymerase Chain Reaction;Protein-Tyrosine Kinases;Pyrimidines;RNA, Messenger;Thiazoles;Withholding Treatment",
        "Doc_meshqualifiers":"pathology;drug effects;genetics;genetics;metabolism;drug therapy;genetics;physiopathology;administration & dosage;therapeutic use;genetics;metabolism;administration & dosage;therapeutic use;analysis;administration & dosage;therapeutic use",
        "_version_":1605804531314065408},
      {
        "Doc_abstract":"This review article describes the identification of the tyrosine kinase BCR/ABL as the hallmark of chronic myeloid leukemias (CML) as well as the development of a specific inhibitor of this tyrosine kinase, the STI571 (Glivec, imatinib mesylate). The authors discuss the results of a phase I and three phase II trials reporting the efficacy of STI571 as treatment for CML patients and propose two simplified algorithms that may help to guide decision-making for the individual patient.",
        "Doc_title":"[How I treat...chronic myeloid leukemia].",
        "Journal":"Revue medicale de Liege",
        "Do_id":"12647591",
        "Doc_ChemicalList":"Antimetabolites, Antineoplastic;Antineoplastic Agents;Benzamides;Enzyme Inhibitors;Interferon-alpha;Piperazines;Pyrimidines;Cytarabine;Imatinib Mesylate;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Algorithms;Antimetabolites, Antineoplastic;Antineoplastic Agents;Benzamides;Clinical Trials, Phase I as Topic;Clinical Trials, Phase II as Topic;Cytarabine;Enzyme Inhibitors;Fusion Proteins, bcr-abl;Hematopoietic Stem Cell Transplantation;Humans;Imatinib Mesylate;Interferon-alpha;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Piperazines;Protein-Tyrosine Kinases;Pyrimidines",
        "Doc_meshqualifiers":"therapeutic use;therapeutic use;therapeutic use;therapeutic use;antagonists & inhibitors;therapeutic use;therapy;therapeutic use;antagonists & inhibitors;therapeutic use",
        "_version_":1605754905516048384},
      {
        "Doc_abstract":"Chronic myelocytic leukemia (CML) is caused by the constitutively active tyrosine kinase Bcr-Abl. Inhibitors ofBcr-Abl have significantly improved the treatment of CML. Most notable is the inhibitor imatinib, which produces remissions in all phases of CML and is the current standard of care. However, imatinib resistance occurs in a significant proportion of patients, mainly through the development of mutations in the Bcr-Abl tyrosine kinase domain that impair imatinib binding. Attempts to circumvent resistance to imatinib led to the discovery of nilotinib (Tasigna; Novartis AG), a novel, potent and selective oral Bcr-Abl kinase inhibitor. Preclinical and clinical investigations have demonstrated that nilotinib effectively overcomes imatinib resistance. Efficacy has been observed in models of CML and other myeloproliferative disorders that are driven by Bcr-Abl and related kinases. In a phase II clinical trial in CML, major cytogenetic response rates were 52 and 33% for chronic- and accelerated-phase disease, respectively. Nilotinib has been filed for approval in the US and EU for use in Philadelphia-positive leukemias in patients who are resistant or intolerant to imatinib. Nilotinib is undergoing clinical trials in patients with newly diagnosed CML, acute lymphoblastic leukemia and gastrointestinal stromal tumors, among other indications.",
        "Doc_title":"Drug evaluation: Nilotinib - a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond.",
        "Journal":"IDrugs : the investigational drugs journal",
        "Do_id":"17642017",
        "Doc_ChemicalList":"4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide;Antineoplastic Agents;Protein Kinase Inhibitors;Pyrimidines;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Animals;Antineoplastic Agents;Clinical Trials as Topic;Drug Evaluation, Preclinical;Fusion Proteins, bcr-abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Molecular Structure;Protein Kinase Inhibitors;Protein-Tyrosine Kinases;Pyrimidines;Structure-Activity Relationship",
        "Doc_meshqualifiers":"adverse effects;chemistry;pharmacokinetics;therapeutic use;drug therapy;enzymology;adverse effects;chemistry;pharmacokinetics;therapeutic use;antagonists & inhibitors;adverse effects;chemistry;pharmacokinetics;therapeutic use",
        "_version_":1605750855074578432},
      {
        "Doc_abstract":"Philadelphia chromosome positive chronic myeloid leukemia has a progressive course starting in a benign phase and terminating in a blastic phase. In this study, we show that human homolog double minute 2 (HDM2) inhibition, with MI-219-a novel compound, and consequently p53 stabilization induce chronic myeloid leukemia (CML) blast crisis cells to undergo apoptosis regardless of the presence of the T315I mutation in the BCR-ABL kinase domain. The response to MI-219 is associated with the downregulation of c-Myc and the induction of p21(WAF1). The p53 target and pro-apoptotic proteins PUMA, Noxa and Bax are induced, whereas full length Bid protein decreases with increased activity of pro-apoptotic cleaved Bid, and decrease of Mcl-1 is observed by increased caspase activity. CD95/FAS (FAS antigen) receptor is also induced by MI-219, indicating that both intrinsic and extrinsic apoptotic responses are transcriptionally induced. In addition, p53 protein accumulates in the mitochondrial fraction of treated cells involved in transcription-independent induction of apoptosis. We conclude that HDM-2 inhibition with MI-219 effectively induces p53-dependent apoptosis in most blast crisis CML cells, with or without BCR-ABL mutation(s).",
        "Doc_title":"p53 stabilization induces apoptosis in chronic myeloid leukemia blast crisis cells.",
        "Journal":"Leukemia",
        "Do_id":"21350558",
        "Doc_ChemicalList":"Apoptosis Regulatory Proteins;BAX protein, human;BBC3 protein, human;Indoles;MI-291;PMAIP1 protein, human;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-bcl-2;Spiro Compounds;TP53 protein, human;Tumor Suppressor Protein p53;bcl-2-Associated X Protein;MDM2 protein, human;Proto-Oncogene Proteins c-mdm2",
        "Doc_meshdescriptors":"Adult;Aged;Apoptosis;Apoptosis Regulatory Proteins;Blast Crisis;Blotting, Western;Female;Flow Cytometry;Genes, abl;Humans;Indoles;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Mutation;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-bcl-2;Proto-Oncogene Proteins c-mdm2;Spiro Compounds;Tumor Cells, Cultured;Tumor Suppressor Protein p53;bcl-2-Associated X Protein",
        "Doc_meshqualifiers":"metabolism;drug therapy;metabolism;pathology;pharmacology;drug therapy;metabolism;pathology;genetics;metabolism;metabolism;antagonists & inhibitors;metabolism;pharmacology;chemistry;genetics;metabolism;metabolism",
        "_version_":1605746348722749441},
      {
        "Doc_abstract":"Dasatinib is a highly potent BCR-ABL kinase inhibitor with established efficacy and safety in imatinib-resistant or -intolerant patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia. In the global phase III DASISION trial in patients with newly diagnosed chronic phase CML (CML-CP), dasatinib was found to have an acceptable safety profile and demonstrated significantly faster and higher rates of complete cytogenetic response (CCyR) and major molecular response (MMR) compared with imatinib. Here, we report the results of a subset analysis of Japanese patients enrolled in the DASISION trial, showing safety and efficacy profiles generally consistent with patients enrolled worldwide, including higher response rates (CCyR, MMR) with dasatinib compared with imatinib and similar high rates of progression-free and overall survival with both therapies. However, the small sample size of the present study limits the strength of these conclusions, and further exploration is needed to confirm any differences observed in Japanese patients compared with the total treated population. These findings support the use of dasatinib 100mg QD as a first-line treatment in Japanese patients with newly diagnosed CML-CP. ",
        "Doc_title":"Efficacy and safety of dasatinib versus imatinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): Subset analysis of the DASISION trial with 2-year follow-up.",
        "Journal":"International journal of hematology",
        "Do_id":"24357015",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Thiazoles;Imatinib Mesylate;Fusion Proteins, bcr-abl;Dasatinib",
        "Doc_meshdescriptors":"Adult;Aged;Antineoplastic Agents;Benzamides;Dasatinib;Drug Resistance, Neoplasm;Female;Follow-Up Studies;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Japan;Leukemia, Myeloid, Chronic-Phase;Male;Middle Aged;Mutation;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Survival Analysis;Thiazoles;Young Adult",
        "Doc_meshqualifiers":"adverse effects;therapeutic use;adverse effects;therapeutic use;antagonists & inhibitors;blood;genetics;metabolism;blood;drug therapy;genetics;metabolism;adverse effects;therapeutic use;adverse effects;therapeutic use;adverse effects;therapeutic use;adverse effects;therapeutic use",
        "_version_":1605917665329676288},
      {
        "Doc_abstract":"The fusion gene bcr-abl develops chronic myeloid leukemia (CML), and stimulates PI3K/Akt/mTOR signaling, leading to impaired autophagy. PI3K/Akt/mTOR signaling also plays an important role in cell metabolism. The Warburg effect is a well-recognized hallmark of cancer energy metabolism, and is regulated by the mTOR/c-Myc/hnRNP/PKM signaling cascade. To develop a new strategy for the treatment of CML, we investigated the associations among bcr-abl, the cascade related to cancer energy metabolism, and autophagy induced by a fatty-acid derivative that we had previously reported as being an autophagy inducer. Here we report that a fatty-acid derivative, AIC-47, induced transcriptional repression of the bcr-abl gene and modulated the expression profile of PKM isoforms, resulting in autophagic cell death. We show that c-Myc functioned as a transcriptional activator of bcr-abl, and regulated the hnRNP/PKM cascade. AIC-47, acting through the PPAR/-catenin pathway, induced down-regulation of c-Myc, leading to the disruption of the bcr-abl/mTOR/hnRNP signaling pathway, and switching of the expression of PKM2 to PKM1. This switching caused autophagic cell death through an increase in the ROS level. Our findings suggest that AIC-47 induced autophagic cell death through the PPAR/-catenin/bcr-abl/mTOR/hnRNP/PKM cascade. ",
        "Doc_title":"Anti-cancer fatty-acid derivative induces autophagic cell death through modulation of PKM isoform expression profile mediated by bcr-abl in chronic myeloid leukemia.",
        "Journal":"Cancer letters",
        "Do_id":"25644089",
        "Doc_ChemicalList":"Antineoplastic Agents;CTNNB1 protein, human;Carrier Proteins;Fatty Acids;Heterogeneous-Nuclear Ribonucleoproteins;Isoenzymes;MYC protein, human;Membrane Proteins;PPAR gamma;Proto-Oncogene Proteins c-myc;Thyroid Hormones;abl-bcr fusion protein, human;beta Catenin;thyroid hormone-binding proteins;MTOR protein, human;TOR Serine-Threonine Kinases;Pyruvate Kinase;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Antineoplastic Agents;Autophagy;Carrier Proteins;Dose-Response Relationship, Drug;Energy Metabolism;Fatty Acids;Fusion Proteins, bcr-abl;Gene Expression Regulation, Neoplastic;Heterogeneous-Nuclear Ribonucleoproteins;Humans;Isoenzymes;K562 Cells;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Membrane Proteins;PPAR gamma;Proto-Oncogene Proteins c-myc;Pyruvate Kinase;RNA Interference;Signal Transduction;TOR Serine-Threonine Kinases;Thyroid Hormones;Transcription, Genetic;Transfection;beta Catenin",
        "Doc_meshqualifiers":"pharmacology;drug effects;genetics;metabolism;drug effects;pharmacology;genetics;metabolism;metabolism;enzymology;genetics;pathology;genetics;metabolism;metabolism;genetics;metabolism;genetics;metabolism;drug effects;metabolism;genetics;metabolism;genetics;metabolism",
        "_version_":1605806814406901760},
      {
        "Doc_abstract":"BCR-ABL kinase domain inhibition can be used to treat chronic myeloid leukemia. The inhibitors such as imatinib, dasatinib and nilotinib are effective drugs but are resistant to some BCR-ABL mutations. The pan-BCR-ABL kinase inhibitor ponatinib exhibits potent activity against native, T315I, and all other clinically relevant mutants, and showed better inhibition than the previously known inhibitors. We have studied the molecular dynamics simulations and calculated solvated interaction energies of native and fourteen mutant BCR-ABL kinases (M244V, G250E, Q252H, Y253F, Y253H, E255K, E255V, T315A, T315I, F317L, F317V, M351T, F359V and H396P) complexed with ponatinib. These studies revealed that the interactions between ponatinib and individual residues in BCR-ABL kinase are also affected due to the remote residue mutations. We report that some residues, Met244, Lys245, Gln252, Gly254, Leu370 and Leu298 do not undergo any conformational changes, while the fluctuations in residues from P-loop, 3-, 5- strands and C- helix are mainly responsible for ponatinib binding to native and all mutant BCR-ABL kinases. Our work provides the molecular mechanisms of native and mutant BCR-ABL kinases inhibition by ponatinib at atomic level that has not been studied before. ",
        "Doc_title":"Ponatinib is a pan-BCR-ABL kinase inhibitor: MD simulations and SIE study.",
        "Journal":"PloS one",
        "Do_id":"24236021",
        "Doc_ChemicalList":"Antineoplastic Agents;Imidazoles;Pyridazines;Solvents;Water;ponatinib;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Antineoplastic Agents;Catalytic Domain;Fusion Proteins, bcr-abl;Humans;Hydrogen Bonding;Imidazoles;Molecular Dynamics Simulation;Mutation, Missense;Protein Binding;Protein Structure, Secondary;Pyridazines;Solvents;Thermodynamics;Water",
        "Doc_meshqualifiers":"chemistry;antagonists & inhibitors;chemistry;genetics;chemistry;chemistry;chemistry;chemistry",
        "_version_":1605760092026699776},
      {
        "Doc_abstract":"Dasatinib is a second-generation BCR-ABL inhibitor approved for the treatment of patients with chronic myeloid leukemia, both in the frontline and in the imatinib-resistant/intolerant settings. The high affinity of dasatinib for the protein is currently assumed to result from its ability to bind both the active and inactive conformations of the BCR-ABL kinase. In the present work, using state of the art molecular simulation techniques we prove that dasatinib exhibits a highly selective preference for the active (open) BCR-ABL conformation. By using three different BCR-ABL conformations (active, inactive, and intermediate inactive) we show that, from a thermodynamic standpoint, the affinity of dasatinib for BCR-ABL drastically decreases in the order: active > alternative inactive > inactive, as a result of differential contributions from the single residues lining the kinase binding pocket and the concomitant stabilization/destabilization of the kinase hydrophobic spine. Molecule-pulling experiments also corroborate this trend as significantly lower forces and smaller times are required to extract dasatinib from its inactive BCR-ABL complexes with respect to the active complex counterparts. Importantly, our results support recent NMR solution results demonstrating no evidence of dasatinib bound to the inactive form of BCR-ABL.",
        "Doc_title":"Through the open door: Preferential binding of dasatinib to the active form of BCR-ABL unveiled by in silico experiments.",
        "Journal":"Molecular oncology",
        "Do_id":"23816609",
        "Doc_ChemicalList":"Pyrimidines;Thiazoles;Fusion Proteins, bcr-abl;Dasatinib",
        "Doc_meshdescriptors":"Dasatinib;Drug Resistance, Neoplasm;Fusion Proteins, bcr-abl;Humans;Hydrophobic and Hydrophilic Interactions;Inhibitory Concentration 50;Molecular Dynamics Simulation;Protein Structure, Secondary;Pyrimidines;Thiazoles",
        "Doc_meshqualifiers":"chemistry;metabolism;chemistry;metabolism;chemistry;metabolism",
        "_version_":1605844881705533440},
      {
        "Doc_abstract":"The molecular analysis of chromosomal abnormalities associated with hematological malignancies allowed the identification of genes involved in theses rearrangements as well as of some recurrent mechanisms. Polymerase chain reaction (PCR) tools are now available to detect these rearrangements, allowing a better follow-up of these diseases. Chronic myeloid leukemia is a myeloproliferative disorder characterized by a reciprocal translocation t(9;22)(q34;q11) which results in a bcr-abl fusion gene. Retro-transcription polymerase chain reaction (RT-PCR) is used to detect bcr-abl to establish diagnosis and to monitor patients. We report here the results of 30 patients samples tested in the hematology laboratory at Pasteur Institute, diagnosed as chronic myeloid leukemia and monitored with RT-PCR. Our results highlight the interest of molecular tools to diagnose and monitor patients mainly when cytogenetic techniques are irrelevant such as cases with complex chromosomal rearrangements or when patients achieve Philadelphia negativity after treatment.",
        "Doc_title":"[RT-PCR use for the diagnostic of chronic myeloid leukaemia].",
        "Journal":"Archives de l'Institut Pasteur de Tunis",
        "Do_id":"19388595",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adolescent;Adult;Bone Marrow Examination;Chromosomes, Human, Pair 22;Cytogenetic Analysis;Electrophoresis, Agar Gel;Female;Fusion Proteins, bcr-abl;Humans;Karyotyping;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Reverse Transcriptase Polymerase Chain Reaction;Sensitivity and Specificity;Translocation, Genetic;Tunisia",
        "Doc_meshqualifiers":"genetics;genetics;diagnosis;genetics;methods;standards;genetics",
        "_version_":1605875339339235328},
      {
        "Doc_abstract":"To investigate the inhibitory effect of RNA interference on chronic myeloid leukemia (CML) bcr/abl oncogene expression.;The small interference RNAs (siRNAs) were synthesized in vitro. K562 cells stably expressing bcr/abl gene were transfected with the siRNA by electroporation, both the non-transfected cells and non-specific siRNAs transfected cells were taken as controls. The enhanced green fluorescent protein (EGFP) plasmid was used as positive control and the transfection efficiency was detected by flow cytometry. Inhibitory effect of siRNAs was demonstrated by real-time quantitative RT-PCR and Western blots. Cell proliferation was measured by MTT assay and apoptosis by Annexin V-FITC assay.;The transfection efficiency was about 70%. The synthesized siRNAs inhibited CML bcr/abl oncogene expression at both mRNA and protein levels. siRNAs could inhibit K562 cell proliferation to 47% and 56% at 24 h and 48 h after transfection, respectively, and induce cell apoptosis from 1.00% in control group to 15.05% and 19.4% at 24 h and 48 h respectively.;At the cell level, inhibition of CML bcr/abl oncogene expression by chemically synthesized siRNAs provides the new method for anti-leukemia study.",
        "Doc_title":"[Inhibitory effect of RNA interference on chronic myeloid leukemia bcr/abl oncogene expression].",
        "Journal":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi",
        "Do_id":"16185484",
        "Doc_ChemicalList":"RNA, Small Interfering;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Apoptosis;Cell Proliferation;Fusion Proteins, bcr-abl;Humans;K562 Cells;RNA, Small Interfering;Transfection",
        "Doc_meshqualifiers":"genetics;genetics",
        "_version_":1605800636557819904},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) is characterized by the presence of BCR-ABL fusion gene resulting from the reciprocal chromosome translocation t(9;22)(q34;q 11), karyotypically detected as Ph chromosome. BCR-ABL gene was proved to play the principal role in CML pathogenesis. It is a hallmark of CML used in diagnostics and monitoring of the response to the therapy. The most sensitive method of detecting BCR-ABL aberration is RT-PCR which is able to find a single in leukemic cell between 10(6) normal leukocytes. Monitoring of BCR-ABL transcript level by quantitative RT-PCR is of the high prognostic value. High or increasing BCR-ABL transcript number signalizes bad response to treatment and a bad prognosis. On the contrary RT-PCR negativity, low level, or decreasing BCR-ABL transcript number denotes good response to treatment and good prognosis. Q-RT-PCR can detect changes in disease status several weeks or even months earlier than other methods. In 1994 the Q-RT-PCR was introduced at the Institute of Hematology and Blood Transfusion in Prague and was used for early detection of relapse after transplantation. At present it is used in all patients with CML for monitoring of response to the treatment. We have confirmed that this precise, sensitive and non-invasive method is of the principal importance for monitoring of disease status in CML patients.",
        "Doc_title":"[Ten years of molecular monitoring of chronic myeloid leukemia by quantitative RT-PCR].",
        "Journal":"Casopis lekaru ceskych",
        "Do_id":"15789779",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Fusion Proteins, bcr-abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Prognosis;Reverse Transcriptase Polymerase Chain Reaction;Transcription, Genetic",
        "Doc_meshqualifiers":"genetics;diagnosis;genetics;therapy",
        "_version_":1605764800139231232},
      {
        "Doc_abstract":"To develop murine models of leukemogenesis, a series of transgenic mice expressing BCR-ABL in different hematopoietic cell subsets was generated. Here we describe targeted expression of P210 BCR-ABL in stem and progenitor cells of murine bone marrow using the tet-off system. The transactivator protein tTA was placed under the control of the murine stem cell leukemia (SCL) gene 3' enhancer. Induction of BCR-ABL resulted in neutrophilia and leukocytosis, and the mice became moribund within 29 to 122 days. Autopsy of sick mice demonstrated splenomegaly, myeloid bone marrow hyperplasia, and extramedullary myeloid cell infiltration of multiple organs. BCR-ABL mRNA and protein were detectable in the affected organs. Fluorescence-activated cell sorter (FACS) analysis demonstrated a significant increase in mature and immature myeloid cells in bone marrow and spleen, together with increased bilineal B220+/Mac-1+ cells in the bone marrow. tTA mRNA was expressed in FACS-sorted hematopoietic stem cells expanded 26-fold after BCR-ABL induction. Thirty-one percent of the animals demonstrated a biphasic phenotype, consisting of neutrophilia and subsequent B-cell lymphoblastic disease, reminiscent of blast crisis. In summary, this mouse model recapitulates many characteristics of human chronic myeloid leukemia (CML) and may help elucidate basic leukemogenic mechanisms in CML stem cells during disease initiation and progression.",
        "Doc_title":"Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis.",
        "Journal":"Blood",
        "Do_id":"15331442",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Animals;Bone Marrow;Cell Transformation, Neoplastic;Disease Models, Animal;Disease Progression;Fusion Proteins, bcr-abl;Hematopoietic Stem Cells;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Leukocytosis;Mice;Mice, Inbred NOD;Mice, SCID;Mice, Transgenic;Myeloid Cells;Neoplasm Invasiveness;Neutrophils;Phenotype;Spleen;Stem Cell Transplantation;Survival Rate;Transcriptional Activation",
        "Doc_meshqualifiers":"metabolism;pathology;genetics;genetics;metabolism;metabolism;pathology;genetics;pathology;therapy;metabolism;metabolism;pathology;metabolism;pathology;metabolism;pathology;genetics",
        "_version_":1605818670667268097},
      {
        "Doc_abstract":"In patients with chronic myeloid leukemia (CML) resistant to imatinib, resistance is commonly associated with mutations in the BCR-ABL protein. Approximately 85% to 90% of resistance-associated mutations occur within the ABL kinase domain, and confer resistance either directly, by blocking imatinib binding, or indirectly, by altering the conformation of BCR-ABL. The degree of resistance depends on the mutation, with some remaining sensitive to imatinib. Imatinib dose escalation may overcome resistance in some of these patients or therapy can be switched to the second-generation tyrosine kinase inhibitors (TKIs) nilotinib or dasatinib. The long-term efficacy of second-generation TKIs may also be related to specific BCR-ABL mutations, with the T315I mutant remaining resistant to all currently available TKIs. Other treatments, including investigational agents, may be options for patients with this mutation. The choice of therapy should be guided by multiple factors, including mutational analysis, disease phase, patient characteristics, and the safety profile of the agents.",
        "Doc_title":"Understanding the role of mutations in therapeutic decision making for chronic myeloid leukemia.",
        "Journal":"Seminars in hematology",
        "Do_id":"19621546",
        "Doc_ChemicalList":"4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide;Antineoplastic Agents;Protein Kinase Inhibitors;Pyrimidines;Thiazoles;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl;Dasatinib",
        "Doc_meshdescriptors":"Antineoplastic Agents;Dasatinib;Drug Resistance, Neoplasm;Fusion Proteins, bcr-abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mutation;Protein Kinase Inhibitors;Protein-Tyrosine Kinases;Pyrimidines;Thiazoles",
        "Doc_meshqualifiers":"therapeutic use;genetics;drug effects;genetics;drug therapy;genetics;therapeutic use;antagonists & inhibitors;therapeutic use;therapeutic use",
        "_version_":1605746474008707075},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by overproduction of myeloid white blood cells. Philadelphia chromosome is an essential finding for CML diagnosis. Generally, a clinical diagnosis of essential thrombocythemia (ET) can be established from isolated marked thrombocytosis in peripheral blood. However, Philadelphia chromosome-positivity or bcr/abl rearrangement with isolated thrombocytosis should be diagnosed as CML, not ET, according to World Health Organization diagnostic criteria. Therefore, CML should not be excluded before confirming the presence of the Philadelphia chromosome or bcr/abl rearrangement in cases of isolated thrombocytosis in peripheral blood. We report a case of CML with clinical features of ET in a patient successfully treated with imatinib. ",
        "Doc_title":"A case of chronic myeloid leukemia with features of essential thrombocythemia in peripheral blood and bone marrow.",
        "Journal":"Blood research",
        "Do_id":"25025015",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605927902312923136},
      {
        "Doc_abstract":"Activation of the c-abl protooncogene occurs in Abelson murine leukemia virus, in Hardy-Zuckerman 2 feline sarcoma virus, and during the chromosomal translocations that generate BCR-ABL gene fusion products. To study the molecular mechanism involved in the c-abl activation, we have created a series of modifications in murine c-abl and assayed these constructs for oncogenic activity using the NIH 3T3 cell transformation assay. Our results show that amino-terminal deletions are sufficient for oncogenic activation of c-abl and high levels of oncogenic activities were generated by a deletion of 114 codons from the 5' end that deleted the SH3 region. A deletion of 53 codons from the 5' end (inclusive of deletions seen in Hardy-Zuckerman 2 feline sarcoma virus and BCR-ABL gene products) that retains the SH3 region of c-abl resulted in the generation of low levels of transforming activity. This transforming potential was substantially increased with the introduction of a G----A point mutation in codon 832 that is present in v-abl. The point mutation was found to affect the secondary structure and the tyrosine kinase activity of the mutant gene products.",
        "Doc_title":"Activation of murine c-abl protooncogene: effect of a point mutation on oncogenic activation.",
        "Journal":"Proceedings of the National Academy of Sciences of the United States of America",
        "Do_id":"2168550",
        "Doc_ChemicalList":"Proto-Oncogene Proteins;Protein-Tyrosine Kinases;Proto-Oncogene Proteins c-abl",
        "Doc_meshdescriptors":"Abelson murine leukemia virus;Animals;Cell Line;Cell Transformation, Neoplastic;Chromosome Deletion;Gene Expression Regulation;Genetic Vectors;Leukemia Virus, Murine;Mice;Mutation;Plasmids;Protein-Tyrosine Kinases;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-abl;Proto-Oncogenes;Transfection",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics",
        "_version_":1605746420935032832},
      {
        "Doc_abstract":"To monitor the gene expression of BCR/ABL in chronic myeloid leukemia patients after allogeneic hematopoietic stem cells transplantation with real-time RT-PCR for evaluating therapeutic efficacy and guiding further treatment.;Taqman real-time RT-PCR technique was performed to monitor peripheral blood BCR/ABL transcript levels in 10 patients at the time of diagnosis and serially at intervals in 25 patients after allogeneic hematopoietic stem cells transplantation. beta-actin mRNA was used as an endogenous reference.;The sensitivity of real-time RT-PCR was 10 copies/microl. In 15 patients receiving transplantation, the median of N(BCR/ABL) (%) before transplantation, 1 month after transplantation and 2 months after transplantation was respectively: 6.57 (0.14 - 38.83), 0.10 (0 - 1.71) and 0 (0 - 0.52). 3 months later N(BCR/ABL) (%) all turned to 0. BCR/ABL transcripts after transplantation were detected to decrease gradually. N(BCR/ABL) (%) 1 month after transplantation and 2 months after transplantation was both lower than that before transplantation (chi(2) both = 13.07, P < 0.01). N(BCR/ABL) (%) at 2 months after transplantation was lower than that at 1 month after transplantation (chi(2) = 8.10, P < 0.01). In 10 other patients, N(BCR/ABL) (%) was 0 in consecutive tests from 3 to 43 months after transplantation.;Real-time RT-PCR is sensitive, reliable and reproducible for monitoring CML relapse after transplantation. It is of help in detecting minimal residual disease, predicting the prognosis of the disease and providing practical indications for further treatment.",
        "Doc_title":"[Real-time reverse-transcriptase polymerase chain reaction in monitoring BCR/ABL transcript levels in chronic myeloid leukemia patients after allogeneic hematopoietic stem cells transplantation].",
        "Journal":"Zhonghua nei ke za zhi",
        "Do_id":"17547807",
        "Doc_ChemicalList":"RNA, Messenger;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adolescent;Adult;Child;Female;Fusion Proteins, bcr-abl;Hematopoietic Stem Cell Transplantation;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;RNA, Messenger;Reverse Transcriptase Polymerase Chain Reaction",
        "Doc_meshqualifiers":"biosynthesis;genetics;genetics;metabolism;surgery;genetics",
        "_version_":1605762136642945024},
      {
        "Doc_abstract":"For immunotherapy of residual disease in patients with Philadelphia-positive leukemias, the BCR-ABL fusion regions are attractive disease-specific T-cell targets. We analyzed these regions for the prevalence of cytotoxic T lymphocyte (CTL) epitopes by an advanced reverse immunology procedure. Seventeen novel BCR-ABL fusion peptides were identified to bind efficiently to the human lymphocyte antigen (HLA)-A68, HLA-B51, HLA-B61 or HLA-Cw4 HLA class I molecules. Comprehensive enzymatic digestion analysis showed that 10 out of the 28 HLA class I binding fusion peptides were efficiently excised after their C-terminus by the proteasome, which is an essential requirement for efficient cell surface expression. Therefore, these peptides are prime vaccine candidates. The other peptides either completely lacked C-terminal liberation or were only inefficiently excised by the proteasome, rendering them inappropriate or less suitable for inclusion in a vaccine. CTL raised against the properly processed HLA-B61 epitope AEALQRPVA from the BCR-ABL e1a2 fusion region, expressed in acute lymphoblastic leukemia (ALL), specifically recognized ALL tumor cells, proving cell surface presentation of this epitope, its applicability for immunotherapy and underlining the accuracy of our epitope identification strategy. Our study provides a reliable basis for the selection of optimal peptides to be included in immunotherapeutic BCR-ABL vaccines against leukemia.",
        "Doc_title":"BCR-ABL fusion regions as a source of multiple leukemia-specific CD8+ T-cell epitopes.",
        "Journal":"Leukemia",
        "Do_id":"16932347",
        "Doc_ChemicalList":"Cancer Vaccines;Epitopes, T-Lymphocyte;HLA-A Antigens;HLA-A*02:01 antigen;HLA-A*68 antigen;HLA-A2 Antigen;HLA-B Antigens;HLA-B51 Antigen;HLA-B61 antigen;HLA-C Antigens;HLA-C*04 antigen;Peptide Fragments;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Amino Acid Sequence;CD8-Positive T-Lymphocytes;Cancer Vaccines;Cell Line, Tumor;Epitope Mapping;Epitopes, T-Lymphocyte;Fusion Proteins, bcr-abl;HLA-A Antigens;HLA-A2 Antigen;HLA-B Antigens;HLA-B51 Antigen;HLA-C Antigens;Humans;Immunotherapy;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Molecular Sequence Data;Peptide Fragments;Protein Binding",
        "Doc_meshqualifiers":"immunology;immunology;methods;immunology;genetics;immunology;metabolism;immunology;metabolism;immunology;metabolism;immunology;metabolism;methods;immunology;therapy;genetics;immunology;metabolism;immunology",
        "_version_":1605794961195794432},
      {
        "Doc_abstract":"We report a case of pre-B-cell acute lymphoblastic leukemia (ALL) with the Ph1-chromosome, t(9;22) translocation and P190 associated BCR/ABL rearrangement. One cell with the Ph1-chromosome and t(9;22) also had del(5q). Interestingly, another diploid cell with iso(17q) lacked the Ph1-chromosome and t(9;22). This finding, similar to one reported in chronic myelogenous leukemia, is consistent with the possibility that abnormality manifest as chromosome instability antedates the Ph1-chromosome and t(9;22) in some cases of Ph1-chromosome positive acute leukemia.",
        "Doc_title":"Ph1-chromosome positive acute lymphoblastic leukemia: is t(9;22) the initial abnormality?",
        "Journal":"American journal of hematology",
        "Do_id":"8317466",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Chromosome Aberrations;Chromosome Disorders;Chromosomes, Human, Pair 22;Chromosomes, Human, Pair 9;Female;Humans;Middle Aged;Philadelphia Chromosome;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Translocation, Genetic",
        "Doc_meshqualifiers":"genetics",
        "_version_":1605893676760825856},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) is a myeloproliferative disorder caused by the Philadelphia-positive chromosome deriving from a translocation between chromosomes 22 and 9. The oncogenic product of this aberrant chromosome is the constitutively active tyrosine kinase BCR-ABL that is responsible for leukemic cell growth, proliferation and survival driven by the dysregulation of a large array of signal transduction pathways. Inhibition of BCR-ABL with tyrosine kinase inhibitors proved to be an efficient therapy of CML in the chronic phase. Unfortunately, the impressive success of BCR-ABL inhibitors as front-line therapy in CML has been tempered by problems of disease persistence or relapse arising from different mechanisms, including mutations in the kinase domain of the enzyme BCRABL and mechanisms independent from BCR-ABL activity. Growing evidence has also suggested a pivotal role of persistent leukemic cancer stem cells, characterized by high self-renewal and pluripotency, in CML maintenance and/or relapse. The present review deals with the most recent advances in this challenging field and focuses on the development of new drugs and therapeutic approaches to eradicate the subtle and dangerous leukemic stem cells responsible for maintaining and sustaining tumor growth.",
        "Doc_title":"New strategies in the chemotherapy of leukemia: eradicating cancer stem cells in chronic myeloid leukemia.",
        "Journal":"Current cancer drug targets",
        "Do_id":"22414010",
        "Doc_ChemicalList":"Antineoplastic Agents",
        "Doc_meshdescriptors":"Animals;Antineoplastic Agents;Clinical Trials as Topic;Drug Evaluation, Preclinical;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Neoplastic Stem Cells;Randomized Controlled Trials as Topic",
        "Doc_meshqualifiers":"pharmacology;therapeutic use;drug therapy;pathology;drug effects;metabolism;pathology",
        "_version_":1605811472686907392},
      {
        "Doc_abstract":"There are very few disease-specific studies focusing on outcomes of umbilical cord blood transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. We report the outcome of 45 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who underwent myeloablative single unit cord blood transplantation from unrelated donors within the GETH/GITMO cooperative group. Conditioning regimens were based on combinations of thiotepa, busulfan, cyclophospamide or fludarabine, and antithymocyte globulin. At the time of transplantation, 35 patients (78%) were in first complete remission, four (8%) in second complete remission and six (14%) in third or subsequent response. The cumulative incidence of myeloid engraftment was 96% at a median time of 20 days and significantly better for patients receiving higher doses of CD34(+) cells. The incidence of acute grade II-IV graft-versus-host disease was 31%, while that of overall chronic graft-versus-host disease was 53%. Treatment-related mortality was 17% at day +100 and 31% at 5 years. The 5-year relapse, event-free survival and overall survival rates were 31%, 36% and 44%, respectively. Although the event-free and overall survival rates in patients without BCR/ABL transcripts detectable at time of transplant were better than those in whom BCR/ABL transcripts were detected (46% versus 24% and 60% versus 30%, respectively) these differences were not statistically significant in the univariate analysis (P=0.07). These results demonstrate that umbilical cord blood transplantation from unrelated donors can be a curative treatment for a substantial number of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. ",
        "Doc_title":"Umbilical cord blood transplantation from unrelated donors in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.",
        "Journal":"Haematologica",
        "Do_id":"24097633",
        "Doc_ChemicalList":"Myeloablative Agonists",
        "Doc_meshdescriptors":"Adolescent;Adult;Allografts;Child;Child, Preschool;Chronic Disease;Cord Blood Stem Cell Transplantation;Disease-Free Survival;Female;Follow-Up Studies;Graft vs Host Disease;Humans;Male;Middle Aged;Myeloablative Agonists;Philadelphia Chromosome;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Retrospective Studies;Survival Rate;Transplantation Conditioning",
        "Doc_meshqualifiers":"mortality;pathology;prevention & control;administration & dosage;mortality;pathology;therapy",
        "_version_":1605805356611534848},
      {
        "Doc_abstract":"Herbimycin A, a benzoquinoid ansamycin antibiotic, was demonstrated to decrease intracellular phosphorylation by protein tyrosine kinase (PTK). In Philadelphia chromosome (Ph1)-positive leukemias such as chronic myelogenous leukemia (CML) and Ph1-positive acute lymphoblastic leukemia (ALL), both of which express bcr-abl fused gene products (P210bcr-abl or P190bcr-abl protein kinase) with augmented tyrosine kinase activities, herbimycin A markedly inhibited the in vitro growth of the Ph1-positive ALL cells and the leukemic cells derived from CML blast crisis. However, the same dose of herbimycin A did not inhibit in vitro growth of a broad spectrum of Ph1-negative human leukemia cells, and several other protein kinase antagonists also displayed no preferential inhibition. Furthermore, we demonstrated that herbimycin A has an antagonizing effect on the growth of transformed cells by a transfection of retroviral amphotrophic vector expressing P210bcr/abl into a murine interleukin (IL)-3-dependent myeloid FDC-P2 cell line. This inhibition was abrogated by the addition of sulfhydryl compounds, similar to the reaction previously described for Rous sarcoma virus transformation. The inhibitory effect of herbimycin A on the growth of Ph1-positive cells was associated with decreased bcr/abl tyrosine kinase activity, but no decrease of bcr-abl mRNA and protein, suggesting that the inactivation of bcr-abl tyrosine kinase activity by herbimycin A may be induced by its binding to the bcr-abl protein portion that is rich with sulfhydryl groups. The present study indicates that herbimycin A is a beneficial agent for the investigation of the role of the bcr-abl gene in Ph1-positive leukemias and further suggests that the development of agents inhibiting the bcr-abl gene product may offer a new therapeutic potential for Ph1-positive leukemias.",
        "Doc_title":"Effect of herbimycin A, an antagonist of tyrosine kinase, on bcr/abl oncoprotein-associated cell proliferations: abrogative effect on the transformation of murine hematopoietic cells by transfection of a retroviral vector expressing oncoprotein P210bcr/abl and preferential inhibition on Ph1-positive leukemia cell growth.",
        "Journal":"Blood",
        "Do_id":"1515646",
        "Doc_ChemicalList":"Benzoquinones;Lactams, Macrocyclic;Quinones;Sulfhydryl Compounds;Rifabutin;herbimycin;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Benzoquinones;Cell Division;Cell Transformation, Neoplastic;Fusion Proteins, bcr-abl;Genetic Vectors;Humans;Lactams, Macrocyclic;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Protein-Tyrosine Kinases;Quinones;Retroviridae;Rifabutin;Sulfhydryl Compounds;Transfection",
        "Doc_meshqualifiers":"drug effects;drug effects;antagonists & inhibitors;genetics;drug therapy;pathology;antagonists & inhibitors;pharmacology;genetics;analogs & derivatives;pharmacology",
        "_version_":1605762607548989440},
      {
        "Doc_abstract":"To investigate the expression of the CDH13 gene and BCR/ABL fusion gene in chronic myeloid leukemia(CML) patients at different stages and explore their relationship.;RNA was isolated from peripheral blood in 30 healthy adults, 22 primary CML patients and 25 blastic crisis of CML patients. We examined the expression of the CDH13 gene and BCR/ABL fusion gene using EVA Green real-time reverse transcriptase-polymerase chain reaction (RT-PCR).;The expression of the BCR/ABL fusion gene in the patients with blastic crisis CML was 4.72 folds as that of the patients with primary CML. The expression of the CDH13 gene in the primary and blastic crisis CML patients was significantly reduced to 36% and 25% of that in healthy controls, respectively. Moreover, negative correlation was found between the expressions of these two genes.;The study showed that the reduction of the CDH13 expression at different clinical stage of CML may account for the defective cell adhesion in CML, and the expression of the CDH13 gene was probably down-regulated by the BCR/ABL fusion gene.",
        "Doc_title":"[Expression of the CDH13 gene and BCR/ABL fusion gene in chronic myeloid leukemia patients and their relationship].",
        "Journal":"Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics",
        "Do_id":"19199263",
        "Doc_ChemicalList":"Cadherins;H-cadherin;abl-bcr fusion protein, human;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Cadherins;Case-Control Studies;Female;Fusion Proteins, bcr-abl;Gene Expression Regulation, Neoplastic;Humans;Leukemia, Myeloid;Male;Middle Aged;Polymerase Chain Reaction",
        "Doc_meshqualifiers":"genetics;genetics;genetics;pathology",
        "_version_":1605883895569448960},
      {
        "Doc_abstract":"A 65-year-old woman presented with clinical features of primary thrombocythemia (PT), and absence of the BCR/ABL fusion gene. She responded to hydroxyurea treatment, although after 1 year she required progressive increases in the dose. Six years later, she maintained a high platelet count despite hydroxyurea at 2 g/day and treatment was changed to anagrelide. After 3 weeks, both platelet and leukocyte counts increased. A karyotype study detected the Philadelphia chromosome in all of the 24 metaphases studied. Fluorescent in situ hybridization (FISH) analysis revealed the BCR/ABL rearrangement. The patient was treated with imatinib mesylate and achieved a normal platelet and leukocyte count in 3 weeks. Patients presenting clinical features of PT expressing the Ph chromosome or the BCR/ABL fusion gene have been well documented but, to our knowledge, this is the first report of evolution from typical PT to chronic myeloid leukemia.",
        "Doc_title":"Emergence of chronic myelogenous leukemia in a patient with primary thrombocythemia and absence of BCR/ABL rearrangement.",
        "Journal":"Cancer genetics and cytogenetics",
        "Do_id":"16682291",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Fibrinolytic Agents;Piperazines;Pyrimidines;Quinazolines;Imatinib Mesylate;Fusion Proteins, bcr-abl;anagrelide;Hydroxyurea",
        "Doc_meshdescriptors":"Aged;Antineoplastic Agents;Benzamides;Blood Platelets;Bone Marrow Cells;Cells, Cultured;Chromosomes, Human, Pair 22;Chromosomes, Human, Pair 9;Chronic Disease;Dose-Response Relationship, Drug;Female;Fibrinolytic Agents;Fusion Proteins, bcr-abl;Humans;Hydroxyurea;Imatinib Mesylate;In Situ Hybridization, Fluorescence;Karyotyping;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Leukocytes;Piperazines;Pyrimidines;Quinazolines;Thrombocythemia, Essential;Time Factors;Translocation, Genetic;Treatment Outcome",
        "Doc_meshqualifiers":"therapeutic use;drug effects;cytology;therapeutic use;analysis;therapeutic use;complications;diagnosis;genetics;therapy;drug effects;therapeutic use;therapeutic use;therapeutic use;complications;diagnosis;drug therapy",
        "_version_":1605760889592479744},
      {
        "Doc_abstract":"The cytosolic 185 and 210 kDa Bcr-Abl protein tyrosine kinases play important roles in the development of Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (Ph+ ALL). p185 and p210 Bcr-Abl contain identical abl-encoded sequences juxtaposed to a variable number of bcr-derived amino acids. As the mitogenic and transforming activities of tyrosine kinases involve stimulation of the Ras pathway, we analyzed Bcr-Abl oncoproteins for interactions with cytoplasmic proteins that mediate Ras activation. Such polypeptides include Grb2, which comprises a single Src homology 2 (SH2) domain flanked by two SH3 domains, and the 66, 52 and 46 kDa Shc proteins which possess an SH2 domain in their carboxy-terminus. Grb2 associates with tyrosine phosphorylated proteins through its SH2 domain, and with the Ras guanine nucleotide releasing protein mSos1 through its SH3 domains. mSos1 stimulates conversion of the inactive GDP-bound form of Ras to the active GTP-bound state. In bcr-abl-transformed cells, Grb2 and mSos1 formed a physical complex with Bcr-Abl. In vitro, the Grb2 SH2 domain bound Bcr-Abl through recognition of a tyrosine phosphorylation site within the amino-terminal bcr-encoded sequence (p.Tyr177-Val-Asn-Val), that is common to both Bcr-Abl proteins. These results suggest that autophosphorylation within the Bcr element of Bcr-Abl creates a direct physical link to Grb2-mSos1, and potentially to the Ras pathway, and thereby modifies the target specificity of the Abl tyrosine kinase.(ABSTRACT TRUNCATED AT 250 WORDS)",
        "Doc_title":"Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway.",
        "Journal":"The EMBO journal",
        "Do_id":"8112292",
        "Doc_ChemicalList":"Adaptor Proteins, Signal Transducing;GRB2 Adaptor Protein;Grb2 protein, mouse;Proteins;Tyrosine;Fusion Proteins, bcr-abl;Oncogene Protein p21(ras)",
        "Doc_meshdescriptors":"Adaptor Proteins, Signal Transducing;Amino Acid Sequence;Animals;Binding Sites;Cell Line, Transformed;Cell Transformation, Neoplastic;Fusion Proteins, bcr-abl;GRB2 Adaptor Protein;Mice;Molecular Sequence Data;Oncogene Protein p21(ras);Phosphorylation;Proteins;Signal Transduction;Tyrosine",
        "Doc_meshqualifiers":"metabolism;metabolism;metabolism;physiology;metabolism",
        "_version_":1605753109371420672},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) is characterized by the formation of the Philadelphia chromosome and oncogenic signaling by the resulting Bcr-Abl fusion protein. Understanding the molecular basis of CML has led to the development of highly effective targeted therapies that block Bcr-Abl tyrosine kinase activity. Imatinib, the current first-line therapy for CML, induces durable treatment responses in most patients. However, patients may develop imatinib resistance, which is often due to BCR-ABL mutations. With the availability of second generation tyrosine kinase inhibitors, an effective therapeutic option other than stem cell transplantation is available following imatinib failure. Randomized trial data suggest that dasatinib treatment is superior to imatinib dose escalation in patients with imatinib resistance. Nilotinib, a recently approved analogue of imatinib, has also demonstrated encouraging treatment responses in patients with imatinib-resistant CML. Other agents (including bosutinib and INNO-406) are in clinical development. With the potential availability of multiple treatment options for patients with CML, it may be possible to tailor treatment according to individual patient or disease characteristics, for example, BCR-ABL mutations. Future CML treatment may involve combination strategies. Overall, targeted agents have significantly improved the prognosis of patients diagnosed with CML.",
        "Doc_title":"Targeted therapy in chronic myeloid leukemia.",
        "Journal":"Expert review of anticancer therapy",
        "Do_id":"18095887",
        "Doc_ChemicalList":"Antineoplastic Agents",
        "Doc_meshdescriptors":"Antineoplastic Agents;Clinical Trials as Topic;Hematopoietic Stem Cell Transplantation;Humans;Leukemia, Myeloid, Chronic-Phase",
        "Doc_meshqualifiers":"therapeutic use;genetics;therapy",
        "_version_":1605881238166437888},
      {
        "Doc_abstract":"Using a real-time RT-PCR method, we analyzed the expression of e1a2 BCR-ABL mRNA in bone marrow samples from 13 patients with e1a2 BCR-ABL-positive acute lymphoblastic leukemia (ALL) at different time points during chemotherapy and after bone marrow transplantation (BMT). The detection limit of the method, assessed using serial dilutions of ALL/MIK cells, was found to be 1:10(5), similar to what is observed for the conventional RT-nested PCR method. The e1a2 BCR-ABL values were normalized with respect to those of the housekeeping gene GAPDH. The decrease in the e1a2 BCR-ABL/GAPDH ratio after remission induction chemotherapy reflects well the response to chemotherapy and consequently correlates with the prognosis. Although molecular remission was achieved by chemotherapy alone, some patients relapsed, and the e1a2 BCR-ABL/GAPDH ratios in these cases progressively increased to the levels seen prior to hematological relapse. Long-term hematological complete remission (more than 30 months) could be achieved in cases in which a more than 4.0 log decrease in the e1a2 BCR-ABL/GAPDH ratio was obtained by chemotherapy alone, and BMT was then performed. In conclusion, real-time RT-PCR allows for an evaluation of the kinetics of e1a2 BCR-ABL/GAPDH expression during the various phases of chemotherapy or after BMT and may be effective for the indication and control of disease relapse in Ph-positive ALL patients.",
        "Doc_title":"Quantification of minimal residual disease in patients with e1a2 BCR-ABL-positive acute lymphoblastic leukemia using a real-time RT-PCR assay.",
        "Journal":"Leukemia",
        "Do_id":"12040449",
        "Doc_ChemicalList":"RNA, Neoplasm;Glyceraldehyde-3-Phosphate Dehydrogenases;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adult;Aged;Bone Marrow Transplantation;Combined Modality Therapy;Female;Fusion Proteins, bcr-abl;Glyceraldehyde-3-Phosphate Dehydrogenases;HL-60 Cells;Humans;Kinetics;Male;Middle Aged;Neoplasm, Residual;Precursor Cell Lymphoblastic Leukemia-Lymphoma;RNA, Neoplasm;Reference Standards;Remission Induction;Reproducibility of Results;Retrospective Studies;Reverse Transcriptase Polymerase Chain Reaction;Sensitivity and Specificity;Time Factors;Treatment Outcome;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"analysis;biosynthesis;genetics;biosynthesis;genetics;diagnosis;genetics;therapy;biosynthesis;standards",
        "_version_":1605875095315677184},
      {
        "Doc_abstract":"BCR/ABL-transformed chronic myeloid leukemia (CML) cells accumulate numerous DNA double-strand breaks (DSB) induced by reactive oxygen species (ROS) and genotoxic agents. To repair these lesions BCR/ABL stimulate unfaithful DSB repair pathways, homologous recombination repair (HRR), nonhomologous end-joining (NHEJ), and single-strand annealing (SSA). Here, we show that BCR/ABL enhances the expression and increase nuclear localization of WRN (mutated in Werner syndrome), which is required for processing DSB ends during the repair. Other fusion tyrosine kinases (FTK), such as TEL/ABL, TEL/JAK2, TEL/PDGFR, and NPM/ALK also elevate WRN. BCR/ABL induces WRN mRNA and protein expression in part by c-MYC-mediated activation of transcription and Bcl-xL-dependent inhibition of caspase-dependent cleavage, respectively. WRN is in complex with BCR/ABL resulting in WRN tyrosine phosphorylation and stimulation of its helicase and exonuclease activities. Activated WRN protects BCR/ABL-positive cells from the lethal effect of oxidative and genotoxic stresses, which causes DSBs. In addition, WRN promotes unfaithful recombination-dependent repair mechanisms HRR and SSA, and enhances the loss of DNA bases during NHEJ in leukemia cells. In summary, we postulate that BCR/ABL-mediated stimulation of WRN modulates the efficiency and fidelity of major DSB repair mechanisms to protect leukemia cells from apoptosis and to facilitate genomic instability.",
        "Doc_title":"BCR/ABL stimulates WRN to promote survival and genomic instability.",
        "Journal":"Cancer research",
        "Do_id":"21123451",
        "Doc_ChemicalList":"DNA, Neoplasm;Recombinant Fusion Proteins;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl;Exodeoxyribonucleases;RecQ Helicases;WRN protein, human;Werner Syndrome Helicase;Wrn protein, mouse",
        "Doc_meshdescriptors":"Animals;Cell Line, Tumor;Chromosome Aberrations;DNA Breaks, Double-Stranded;DNA Repair;DNA, Neoplasm;Disease Progression;Exodeoxyribonucleases;Fusion Proteins, bcr-abl;Genomic Instability;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mice;Oxidative Stress;Phosphorylation;Protein-Tyrosine Kinases;RecQ Helicases;Recombinant Fusion Proteins;Werner Syndrome Helicase",
        "Doc_meshqualifiers":"genetics;genetics;metabolism;genetics;metabolism;genetics;metabolism;pathology;genetics;genetics;metabolism;genetics;metabolism;genetics;metabolism",
        "_version_":1605836564872560640},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) represents the first human malignancy successfully treated with a tyrosine kinase inhibitor (TKI; imatinib). However, early relapses and the emergence of imatinib-resistant disease are problematic. Evidence suggests that imatinib and other inhibitors may not effectively eradicate leukemic stem/progenitor cells, and that combination therapy directed to complimentary targets may improve treatment. Abelson helper integration site 1 (Ahi-1)/AHI-1 is a novel oncogene that is highly deregulated in CML stem/progenitor cells where levels of BCR-ABL transcripts are also elevated. Here, we demonstrate that overexpression of Ahi-1/AHI-1 in murine and human hematopoietic cells confer growth advantages in vitro and induce leukemia in vivo, enhancing effects of BCR-ABL. Conversely, RNAi-mediated suppression of AHI-1 in BCR-ABL-transduced lin(-)CD34(+) human cord blood cells and primary CML stem/progenitor cells reduces their growth autonomy in vitro. Interestingly, coexpression of Ahi-1 in BCR-ABL-inducible cells reverses growth deficiencies exhibited by BCR-ABL down-regulation and is associated with sustained phosphorylation of BCR-ABL and enhanced activation of JAK2-STAT5. Moreover, we identified an AHI-1-BCR-ABL-JAK2 interaction complex and found that modulation of AHI-1 expression regulates phosphorylation of BCR-ABL and JAK2-STAT5 in CML cells. Importantly, this complex mediates TKI response/resistance of CML stem/progenitor cells. These studies implicate AHI-1 as a potential therapeutic target downstream of BCR-ABL in CML.",
        "Doc_title":"AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells.",
        "Journal":"The Journal of experimental medicine",
        "Do_id":"18936234",
        "Doc_ChemicalList":"Ahi1 protein, mouse;Benzamides;DNA Primers;Piperazines;Proto-Oncogene Proteins;Pyrimidines;Imatinib Mesylate;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl;Janus Kinase 2",
        "Doc_meshdescriptors":"Animals;Benzamides;Blotting, Western;Cell Line;Cell Transformation, Neoplastic;DNA Primers;Flow Cytometry;Fusion Proteins, bcr-abl;Gene Expression Regulation, Neoplastic;Hematopoietic Stem Cells;Humans;Imatinib Mesylate;Immunoprecipitation;Janus Kinase 2;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mice;Phosphorylation;Piperazines;Protein-Tyrosine Kinases;Proto-Oncogene Proteins;Pyrimidines;RNA Interference;Reverse Transcriptase Polymerase Chain Reaction",
        "Doc_meshqualifiers":"metabolism;genetics;metabolism;physiology;drug effects;metabolism;metabolism;metabolism;antagonists & inhibitors;genetics;metabolism",
        "_version_":1605798991681814528},
      {
        "Doc_abstract":"Chronic myeloid leukemia is one of the commonest hematological malignancies seen in clinical practice. It is the result of abnormal and excess cell proliferation due to de-regulated bcr-abl tyrosine kinase activity as a result of Philadelphia chromosome. The present article discusses the various options available to treat the disorder. Allogeneic stem cell transplant remains the gold standard and the only curative option. Hydroxyurea and Busulfan helps in controlling the total leukocyte count but fail to impact on survival. Interferon especially when combined with cytarabine is curative in minority of patients though a substantial number of patients achieve functional cure. Imatinib, a molecular targeted oral therapy, against bcr-abl tyrosine kinase is the latest addition to various treatment options. Early results appear very promising and can be considered as non- transplant standard of care.",
        "Doc_title":"Chronic myeloid leukemia.",
        "Journal":"The Journal of the Association of Physicians of India",
        "Do_id":"15656033",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Pyrimidines;Imatinib Mesylate;Interferons;Busulfan;Hydroxyurea",
        "Doc_meshdescriptors":"Antineoplastic Agents;Benzamides;Busulfan;Humans;Hydroxyurea;Imatinib Mesylate;Interferons;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Piperazines;Pyrimidines;Stem Cell Transplantation",
        "Doc_meshqualifiers":"therapeutic use;therapeutic use;therapeutic use;therapeutic use;therapy;therapeutic use;therapeutic use;methods",
        "_version_":1605802365464608768},
      {
        "Doc_abstract":"This study was conducted to determine the frequency of the most common fusion genes in Mexican pediatric patients with acute lymphoblastic leukemia (ALL). Molecular analysis using RT-PCR was carried out in 53-blood samples: 52 patients with de novo ALL and one with relapsed ALL. The ETV6-RUNX1 fusion was found in 7 cases (13.5%), BCR-ABL fusion was detected in 2 cases (3.8%), and 6 patients (11.5%) expressed the chimeric gene E2A-PBX1. The prevalence of E2A-PBX1 is one of the highest that has been described thus far in childhood ALL. Furthermore, we detected both the BCR-ABL, and E2A-PBX1 fusion in the relapsed patient. With regards to the immunophenotype, ETV6-RUNX1 was expressed in both pre-B and T-cell cases, while the presence of E2A-PBX1 and BCR-ABL was associated with the pre-B ALL phenotype. The prevalence of E2A-PBX1 in Mexican pediatric cases supports the existence of ethnic differences in the frequency of molecular markers of ALL.",
        "Doc_title":"BCR-ABL, ETV6-RUNX1 and E2A-PBX1: prevalence of the most common acute lymphoblastic leukemia fusion genes in Mexican patients.",
        "Journal":"Leukemia research",
        "Do_id":"18455790",
        "Doc_ChemicalList":"Core Binding Factor Alpha 2 Subunit;ETS translocation variant 6 protein;Homeodomain Proteins;Oncogene Proteins, Fusion;Proto-Oncogene Proteins c-ets;RUNX1 protein, human;Repressor Proteins;E2A-Pbx1 fusion protein;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adolescent;Child;Child, Preschool;Core Binding Factor Alpha 2 Subunit;Female;Fusion Proteins, bcr-abl;Gene Frequency;Homeodomain Proteins;Humans;Infant;Male;Mexico;Oncogene Proteins, Fusion;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Proto-Oncogene Proteins c-ets;Repressor Proteins",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;ethnology;genetics;genetics;genetics",
        "_version_":1605747529464414209},
      {
        "Doc_abstract":"Bone marrow cells of 325 adults with acute leukemia were immunophenotyped using a panel of monoclonal antibodies proposed by the European Group for the Immunological Characterization of Leukemias (EGIL). Of these, 97.2% could be assigned clearly to myeloid or lymphoid lineage (254 acute myeloid leukemias [AMLs], 48 B-cell lineage acute lymphoblastic leukemias [ALLs], 14 T-cell lineage ALLs), 1.8% as biphenotypic, and less than 1% as undifferentiated. Immunologic subtyping of ALLs revealed an association between early precursor phenotypes and coexpression of myeloid antigens, particularly CD15/CD65s coexpression and pre-pre-B cell-specific phenotypes and genotypes. The common ALL phenotype was associated with BCR-ABL translocation. Among AMLs, CD2 coexpression was almost exclusively restricted to French-American-British subtypes M3 variant and M4Eo and related molecular aberrations. The most valuable markers to differentiate between myeloperoxidase-negative AML subtypes M0 and ALLs were CD13, CD33, and CD117, typical of M0, and intracytoplasmic CD79a, intracytoplasmic CD3, CD10, and CD2, typical of B cell- or T cell-lineage ALL. Our results confirm excellent practicability of the EGIL proposalfor immunologic classification of acute leukemias. For myeloperoxidase-negative AMLs, we suggest a scoring system based on markers most valuable to distinguish between AML-M0 and ALLs.",
        "Doc_title":"The immunophenotype of 325 adult acute leukemias: relationship to morphologic and molecular classification and proposal for a minimal screening program highly predictive for lineage discrimination.",
        "Journal":"American journal of clinical pathology",
        "Do_id":"11888077",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antigens, CD;Biomarkers, Tumor",
        "Doc_meshdescriptors":"Acute Disease;Adolescent;Adult;Aged;Aged, 80 and over;Antibodies, Monoclonal;Antigens, CD;Biomarkers, Tumor;Bone Marrow Cells;Burkitt Lymphoma;Female;Humans;Immunophenotyping;Leukemia;Leukemia, Myeloid, Acute;Leukemia-Lymphoma, Adult T-Cell;Male;Middle Aged",
        "Doc_meshqualifiers":"analysis;analysis;immunology;immunology;classification;immunology;immunology;immunology",
        "_version_":1605811836159000576},
      {
        "Doc_abstract":"Patients with advanced stages of chronic myeloid leukemia (CML) often manifest imatinib mesylate resistance associated with point mutations in BCR-ABL. AMN107 is a new higher-potency inhibitor of BCR-ABL. To identify mutations in BCR-ABL that could result in resistance to AMN107, a cDNA library of BCR-ABL mutants was introduced into Ba/F3 cells followed by selection in AMN107 (0.125-0.5 microM). A total of 86 individual, drug-resistant colonies were recovered, and the SH3, SH2, and kinase domains of BCR-ABL were sequenced. A total of 46 colonies had single point mutations in BCR-ABL, with a total of 17 different mutations, all within the kinase domain. The other 40 colonies had multiple point mutations and were not analyzed further. Each of the 17 single point mutants were reconstructed by site-directed mutagenesis of native BCR-ABL and found to be approximately 2.5- to 800-fold more resistant to AMN107 than native BCR-ABL. The mutations included 6 known imatinib mesylate-resistant mutations, including T315I, which showed complete resistance to AMN107. Interestingly, most AMN107-resistant mutants were also resistant to imatinib mesylate. These results may predict some of the resistance mutations that will be detected in clinical trials with this kinase inhibitor.",
        "Doc_title":"Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study.",
        "Journal":"Blood",
        "Do_id":"17303698",
        "Doc_ChemicalList":"4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide;Antineoplastic Agents;Pyrimidines;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Animals;Antineoplastic Agents;Cell Line, Tumor;Drug Resistance, Neoplasm;Fusion Proteins, bcr-abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mice;Models, Molecular;Mutagenesis;Mutation;Point Mutation;Protein Conformation;Protein Structure, Tertiary;Pyrimidines",
        "Doc_meshqualifiers":"pharmacology;genetics;drug therapy;genetics;pharmacology",
        "_version_":1605876068341776384},
      {
        "Doc_abstract":"The aim of this study was to investigate the role and mechanism of miR-23a in the regulation of BCR/ABL and to provide a new prognostic biomarker for chronic myeloid leukemia (CML). The expression levels of miR-23a and BCR/ABL were assessed in 42 newly diagnosed CML patients, 37 CML patients in first complete remission and 25 healthy controls. Quantitative real-time PCR, western blot analysis and colony formation assay were used to evaluate changes induced by overexpression or inhibition of miR-23a or BCR/ABL. MiR-23a mimic or negative control mimic was transfected into a CML cell line (K562) and two lung cancer cell lines (H157 and SKMES1) using Lipofectamine 2000, and the cells were used for real-time reverse transcription-PCR (RT-PCR) and western blot analysis. We found that the downregulation of miR-23a expression was a frequent event in both leukemia cell lines and primary leukemic cells from patients with de novo CML. The microarray results showed that most of the CML patients expressed high levels of BCR/ABL and low levels of miR-23a. Real-time RT-PCR and western blot analysis showed that the BCR/ABL levels in miR-23a-transfected cells were lower than those in the control groups. Ectopic expression of miR-23a in K562 cells led to cellular senescence. Moreover, when K562 cells were treated with 5-aza-2'-deoxycytidine, a DNA methylation inhibitor, BCR/ABL expression was upregulated, which indicates epigenetic silencing of miR-23a in leukemic cells. BCR/ABL and miR-23a expressions were inversely related to CML, and BCR/ABL expression was regulated by miR-23a in leukemic cells. The epigenetic silencing of miR-23a led to derepression of BCR/ABL expression, and consequently contributes to CML development and progression. ",
        "Doc_title":"The malignancy suppression role of miR-23a by targeting the BCR/ABL oncogene in chromic myeloid leukemia.",
        "Journal":"Cancer gene therapy",
        "Do_id":"25213664",
        "Doc_ChemicalList":"3' Untranslated Regions;MIRN23 microRNA, human;MicroRNAs;Phosphatidylinositol 3-Kinases;Fusion Proteins, bcr-abl;Proto-Oncogene Proteins c-akt;Matrix Metalloproteinase 9;Azacitidine",
        "Doc_meshdescriptors":"3' Untranslated Regions;Adolescent;Adult;Aged;Azacitidine;Bone Marrow;Bone Marrow Cells;Cell Aging;Cell Line, Tumor;Female;Fusion Proteins, bcr-abl;Gene Expression Regulation, Leukemic;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Matrix Metalloproteinase 9;MicroRNAs;Middle Aged;Phosphatidylinositol 3-Kinases;Proto-Oncogene Proteins c-akt;RNA Interference;Signal Transduction;Young Adult",
        "Doc_meshqualifiers":"pharmacology;metabolism;pathology;metabolism;pathology;genetics;genetics;drug effects;genetics;metabolism;pathology;metabolism;genetics;metabolism",
        "_version_":1605774250050846720},
      {
        "Doc_abstract":"Lineage switch from acute lymphoblastic leukemia (ALL) to acute myeloid leukemia (AML) is very rare. We report a case of a 9 yr-old ALL patient relapsed as acute myelomonocytic leukemia. At the initial diagnosis, the blast cell morphology and immunophenotype were consistent with the diagnosis of typical ALL (L1 subtype according to FAB classification). The BCR-ABL fusion gene was not found by reverse transcription-PCR. Complete remission (CR) was achieved after induction and consolidation chemotherapy (Children's Cancer Study Group 1891 protocol, CCG1891). Nine months, which is a very short time compared with other cases in the literatures, after the diagnosis of ALL, she relapsed with completely different blasts (typical AML, M4 according to FAB classification) in morphology, cytochemistry, and immunophenotyping. The karyotype has changed from 56,XY,+X,+Y,+Y,+4,+8,+10, +14,+17,-20,+21,+21,+21[6]/57,idem,+Y[19] to 46,XY,t(8;16)(p11.2;p13.1)[19]/46,XY[1], showing unrelated chromosomal abnormality to the karyotype at the initial diagnosis. Moreover, both findings were quite specific for each common cell ALL and acute myelomonocytic leukemia. These findings support that this case is completely different leukemic clones occurred at each leukemic expression. The treatment with AML 2000 protocol chemotherapy failed, and he underwent the chemotherapy with the combination of high dose cytarabine and mitoxantrone and has been in CR state for 21 months, until now.",
        "Doc_title":"A case of lineage switch from acute lymphoblastic leukemia to acute myeloid leukemia.",
        "Journal":"The Korean journal of laboratory medicine",
        "Do_id":"18094559",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Cell Lineage;Cell Transformation, Neoplastic;Child;Humans;Karyotyping;Leukemia, Myeloid, Acute;Male;Precursor Cell Lymphoblastic Leukemia-Lymphoma",
        "Doc_meshqualifiers":"diagnosis;pathology;diagnosis;pathology",
        "_version_":1605752518787203072},
      {
        "Doc_abstract":"Treatment of chronic myeloid leukemia with BCR-ABL tyrosine kinase inhibitors requires full adherence in order to maximize the likelihood of achieving optimal responses, and to minimize healthcare costs. In this article, we review some of the methods available for assessing compliance, the main consequences of nonadherence on treatment outcomes, major factors commonly associated with poor compliance, a few successful measures for improving adherence and the most accepted recommendations for proactively managing adverse events. ",
        "Doc_title":"Importance of adherence to BCR-ABL tyrosine-kinase inhibitors in the treatment of chronic myeloid leukemia.",
        "Journal":"Revista brasileira de hematologia e hemoterapia",
        "Do_id":"24624037",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605742059837194242},
      {
        "Doc_abstract":"Primitive subsets of leukemic cells isolated by using fluorescence-activated cell sorting from patients with newly diagnosed Ph(+)/BCR-ABL(+) chronic myeloid leukemia display an abnormal ability to proliferate in vitro in the absence of added growth factors. We now show from analyses of growth-factor gene expression, protein production, and antibody inhibition studies that this deregulated growth can be explained, at least in part, by a novel differentiation-controlled autocrine mechanism. This mechanism involves the consistent and selective activation of IL-3 and granulocyte colony-stimulating factor (G-CSF) production and a stimulation of STAT5 phosphorylation in CD34(+) leukemic cells. When these cells differentiate into CD34(-) cells in vivo, IL-3 and G-CSF production declines, and the cells concomitantly lose their capacity for autonomous growth in vitro despite their continued expression of BCR-ABL. Based on previous studies of normal cells, excessive exposure of the most primitive chronic myeloid leukemia cells to IL-3 and G-CSF through an autocrine mechanism could explain their paradoxically decreased self-renewal in vitro and slow accumulation in vivo, in spite of an increased cycling activity and selective expansion of later compartments.",
        "Doc_title":"Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia.",
        "Journal":"Proceedings of the National Academy of Sciences of the United States of America",
        "Do_id":"10536003",
        "Doc_ChemicalList":"DNA Primers;Interleukin-3;RNA, Messenger;Granulocyte Colony-Stimulating Factor",
        "Doc_meshdescriptors":"Base Sequence;Cell Division;DNA Primers;Granulocyte Colony-Stimulating Factor;Humans;Interleukin-3;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;RNA, Messenger;Reverse Transcriptase Polymerase Chain Reaction;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"biosynthesis;genetics;physiology;biosynthesis;genetics;physiology;metabolism;pathology;genetics",
        "_version_":1605748725144092672},
      {
        "Doc_abstract":"In the first years of imatinib treatment, BCR-ABL remained detectable in all but a small minority of patients with chronic myeloid leukemia. We determined whether BCR-ABL continues to decline with longer imatinib exposure and the incidence and consequence of undetectable BCR-ABL.;BCR-ABL levels were measured in a subset of 53 imatinib-treated IRIS trial patients for up to 7 years (29 first-line, 24 second-line). Levels were deemed undetectable using strict PCR sensitivity criteria.;By 18 months, the majority achieved a 3-log reduction [major molecular response (MMR)]. BCR-ABL continued to decline but at a slower rate (median time to 4-log reduction and undetectable BCR-ABL of 45 and 66 months for first-line). The probability of undetectable BCR-ABL increased considerably from 36 to 81 months of first-line imatinib {7% [95% confidence interval (95% CI), 0-17%] versus 52% (95% CI, 32-72%)}. Undetectable BCR-ABL was achieved in 18 of 53 patients and none of these 18 lost MMR after a median follow-up of 33 months. Conversely, MMR was lost in 6 of 22 (27%) patients with sustained detectable BCR-ABL and was associated with BCR-ABL mutations in 3 of 6. Loss of MMR was recently defined as suboptimal imatinib response. There was no difference in the probability of achieving molecular responses between first- and second-line patients but first-line had a significantly higher probability of maintaining MMR [P = 0.03; 96% (95% CI, 88-100%) versus 71% (95% CI, 48-93%)].;With prolonged therapy, BCR-ABL continued to decline in most patients and undetectable BCR-ABL was no longer a rare event. Loss of MMR was only observed in patients with sustained detectable BCR-ABL.",
        "Doc_title":"BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria.",
        "Journal":"Clinical cancer research : an official journal of the American Association for Cancer Research",
        "Do_id":"18056186",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Pyrimidines;RNA, Messenger;Imatinib Mesylate;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Antineoplastic Agents;Benzamides;Clinical Trials as Topic;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Leukemia, Myeloid, Chronic-Phase;Mutation;Piperazines;Polymerase Chain Reaction;Pyrimidines;RNA, Messenger;Remission Induction;Sensitivity and Specificity",
        "Doc_meshqualifiers":"therapeutic use;biosynthesis;genetics;metabolism;drug therapy;genetics;metabolism;drug therapy;genetics;metabolism;therapeutic use;methods;therapeutic use;metabolism",
        "_version_":1605847194589462528},
      {
        "Doc_abstract":"Activating NOTCH1 mutations are common in T-cell acute lymphoblastic leukemia. Inhibition of NOTCH1 signaling with gamma-secretase inhibitors causes cell cycle block, but only after treatment for several days. We further documented the effects of gamma-secretase inhibitor treatment on T-cell acute lymphoblastic leukemia cell lines and tested whether combining gamma-secretase inhibitors with other anti-cancer drugs offers a therapeutic advantage.;The effect of gamma-secretase inhibitor treatment and combinations of gamma-secretase inhibitors with chemotherapy or glucocorticoids was assessed on T-cell acute lymphoblastic leukemia cell lines. We sequenced NOTCH1 in T-cell acute lymphoblastic leukemia cases with ABL1 fusions and tested combinations of gamma-secretase inhibitors and the ABL1 inhibitor imatinib in a T-cell acute lymphoblastic leukemia cell line.;gamma-secretase inhibitor treatment for 5-7 days reversibly inhibited cell proliferation, caused cell cycle block in sensitive T-cell acute lymphoblastic leukemia cell lines, and caused differentiation of some T-cell acute lymphoblastic leukemia cell lines. Treatment for 14 days or longer was required to induce significant apoptosis. The cytotoxic effects of the chemotherapeutic agent vincristine were not significantly enhanced by addition of gamma-secretase inhibitors to T-cell acute lymphoblastic leukemia cell lines, but gamma-secretase inhibitor treatment sensitized cells to the effect of dexamethasone. NOTCH1 mutations were identified in all T-cell acute lymphoblastic leukemia patients with ABL1 fusions and in a T-cell acute lymphoblastic leukemia cell line expressing NUP214-ABL1. In this cell line, the anti-proliferative effect of imatinib was increased by pre-treatment with gamma-secretase inhibitors.;Short-term treatment of T-cell acute lymphoblastic leukemia cell lines with gamma-secretase inhibitors had limited effects on cell proliferation and survival. Combinations of gamma-secretase inhibitors with other drugs may be required to obtain efficient therapeutic effects in T-cell acute lymphoblastic leukemia, and not all combinations may be useful.",
        "Doc_title":"In vitro validation of gamma-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia.",
        "Journal":"Haematologica",
        "Do_id":"18322257",
        "Doc_ChemicalList":"2-(((3,5-difluorophenyl)acetyl)amino)-N-(1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)propanamide;Antineoplastic Agents;Benzamides;Benzodiazepinones;Carbamates;DNA, Neoplasm;Dipeptides;Enzyme Inhibitors;L 685458;NOTCH1 protein, human;NUP214-ABL1 fusion protein, human;Neoplasm Proteins;Oncogene Proteins, Fusion;Piperazines;Pyrimidines;Receptor, Notch1;Vincristine;Dexamethasone;Imatinib Mesylate;Amyloid Precursor Protein Secretases;Daunorubicin",
        "Doc_meshdescriptors":"Amyloid Precursor Protein Secretases;Antineoplastic Agents;Apoptosis;Benzamides;Benzodiazepinones;Carbamates;Cell Cycle;Cell Division;Cell Line, Tumor;DNA, Neoplasm;Daunorubicin;Dexamethasone;Dipeptides;Drug Screening Assays, Antitumor;Drug Synergism;Enzyme Inhibitors;Humans;Imatinib Mesylate;In Vitro Techniques;Leukemia-Lymphoma, Adult T-Cell;Mutation;Neoplasm Proteins;Oncogene Proteins, Fusion;Piperazines;Pyrimidines;Receptor, Notch1;Sequence Analysis, DNA;Vincristine",
        "Doc_meshqualifiers":"antagonists & inhibitors;administration & dosage;pharmacology;drug effects;pharmacology;administration & dosage;pharmacology;drug effects;drug effects;drug effects;enzymology;genetics;administration & dosage;pharmacology;administration & dosage;pharmacology;administration & dosage;pharmacology;administration & dosage;pharmacology;drug therapy;genetics;pathology;antagonists & inhibitors;genetics;antagonists & inhibitors;genetics;administration & dosage;pharmacology;administration & dosage;pharmacology;antagonists & inhibitors;genetics;administration & dosage;pharmacology",
        "_version_":1605818574701592578},
      {
        "Doc_abstract":"Fusion protein RUNX1-ETO (AML1-ETO, RUNX1-RUNX1T1) is expressed as the result of the 8q22;21q22 translocation [t(8;21)], which is one of the most common chromosomal abnormalities found in acute myeloid leukemia. RUNX1-ETO is thought to promote leukemia development through the aberrant regulation of RUNX1 (AML1) target genes. Repression of these genes occurs via the recruitment of the corepressors N-COR and SMRT due to their interaction with ETO. Mechanisms of RUNX1-ETO target gene upregulation remain less well understood. Here we show that RUNX1-ETO9a, the leukemogenic alternatively spliced transcript expressed from t(8;21), upregulates target gene Alox5, which is a gene critically required for the promotion of chronic myeloid leukemia development by BCR-ABL. Loss of Alox5 expression reduces activity of RUNX1-ETO9a, MLL-AF9 and PML-RAR in vitro. However, Alox5 is not essential for the induction of leukemia by RUNX1-ETO9a in vivo. Finally, we demonstrate that the upregulation of Alox5 by RUNX1-ETO9a occurs via the CH zinc finger transcription factor KLF6, a protein required for early hematopoiesis and yolk sac development. Furthermore, KLF6 is specifically upregulated by RUNX1-ETO in human leukemia cells. This identifies KLF6 as a novel mediator of t(8;21) target gene regulation, providing a new mechanism for RUNX1-ETO transcriptional control.",
        "Doc_title":"Cooperation between RUNX1-ETO9a and novel transcriptional partner KLF6 in upregulation of Alox5 in acute myeloid leukemia.",
        "Journal":"PLoS genetics",
        "Do_id":"24130502",
        "Doc_ChemicalList":"Core Binding Factor Alpha 2 Subunit;KLF6 protein, human;Kruppel-Like Transcription Factors;Oncogene Proteins, Fusion;Proto-Oncogene Proteins;RUNX1 protein, human;RUNX1T1 protein, human;Transcription Factors;Arachidonate 5-Lipoxygenase;ALOX5 protein, human",
        "Doc_meshdescriptors":"Alternative Splicing;Animals;Arachidonate 5-Lipoxygenase;Cell Line, Tumor;Chromosome Aberrations;Core Binding Factor Alpha 2 Subunit;Gene Expression Regulation, Leukemic;Humans;Kruppel-Like Transcription Factors;Leukemia, Myeloid, Acute;Mice;Oncogene Proteins, Fusion;Proto-Oncogene Proteins;Transcription Factors",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;pathology;genetics;genetics;genetics",
        "_version_":1605792694844522496},
      {
        "Doc_abstract":"ider(9)(q10)t(9;22)(q34;q11.2) is an isochromosome for the long arm of a derivative chromosome 9 generated by a t(9;22), resulting from the deletion of the short arm of chromosome 9. It is known to be rarely observed in acute lymphoblastic leukemia (ALL) or lymphoblastic crisis transformed from chronic myelogenous leukemia. We herein describe a 26-year-old female patient with precursor B-cell ALL, cytogenetically characterized by ider(9)(q10)t(9;22). Fluorescence in situ hybridization analysis showed two ABL-BCR fusion signals on the derivative chromosome 9 and one BCR-ABL fusion signal on the derivative chromosome 22. Although a t(9;22) and a deletion of the short arm of chromosome 9 are known to be associated with a poor prognostic factor in acute lymphoblastic leukemia, a larger study is needed to determine the prognosis of ider(9)(q10)t(9;22) cases.",
        "Doc_title":"[A Case of Acute Lymphoblastic Leukemia with ider(9)(q10)t(9;22)(q34;q11.2).].",
        "Journal":"The Korean journal of laboratory medicine",
        "Do_id":"18156729",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605757266652299264},
      {
        "Doc_abstract":"Monitoring for residual leukemic burden is an integral part of ongoing evaluation in chronic myeloid leukemia. With high rates of complete cytogenetic response induced by imatinib and other tyrosine kinase inhibitors, exploring refinements in current methods of minimal residual disease monitoring is relevant.;Estimation of leukemic burden can influence treatment decisions. Real-time RT-PCR has become the method of choice for quantifying bcr-abl transcripts in patients undergoing therapy. Efforts are in progress to standardize this technique. The numbers of bcr-abl transcripts can vary in serial specimens, and it is important that changes in treatment (e.g. referral for transplantation, imatinib dose increase, or switch to a new tyrosine kinase inhibitor) be based on consistent rises in transcript number over time rather than on a single change.;Prognosis in newly diagnosed patients with chronic myeloid leukemia in chronic phase has dramatically improved with the availability of imatinib and other tyrosine kinase inhibitors. In parallel, methods of monitoring minimal residual disease are evolving. Although real-time RT-PCR is now a standard monitoring method, the clinical significance of frequent and more precise follow up in patients achieving a complete cytogenetic response requires better definition.",
        "Doc_title":"Monitoring minimal residual disease in patients with chronic myeloid leukemia after treatment with tyrosine kinase inhibitors.",
        "Journal":"Current opinion in hematology",
        "Do_id":"18300760",
        "Doc_ChemicalList":"Protein Kinase Inhibitors;Protein-Tyrosine Kinases",
        "Doc_meshdescriptors":"Drug Resistance, Neoplasm;Genes, abl;Humans;Karyotyping;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Neoplasm, Residual;Prognosis;Protein Kinase Inhibitors;Protein-Tyrosine Kinases",
        "Doc_meshqualifiers":"drug effects;genetics;drug effects;drug therapy;physiopathology;physiopathology;therapeutic use;antagonists & inhibitors",
        "_version_":1605754952959918080},
      {
        "Doc_abstract":"K562 cell line, established from a patient in the blast crisis of chronic myeloid leukemia, expresses high levels of c-myc and bcr/abl gene products. Exposure of K562 cells to 5-fluorouracil (5-FU) resulted in a marked benzidine-positive erythroid differentiation with concomitant reduction in cell proliferation. No change in c-myc mRNA or protein levels occurred during 96 h of drug treatment. In contrast, a biphasic change of p210bcr/abl and the abl-associated kinase activities was observed upon treatment with 5-FU. The change in p210bcr/abl expression may be mediated at the translational level, since the steady-state level and the enzymatic activity of p210bcr/abl are reduced, whereas bcr/abl mRNA levels are unaltered. The results are consistent with the existence of pleiotropic differentiation pathways in K562 cells.",
        "Doc_title":"Induction of erythroid differentiation by 5-fluorouracil in K562 leukemia cells.",
        "Journal":"Japanese journal of cancer research : Gann",
        "Do_id":"7493914",
        "Doc_ChemicalList":"RNA, Messenger;Fusion Proteins, bcr-abl;Fluorouracil",
        "Doc_meshdescriptors":"Cell Differentiation;Cell Division;Erythropoiesis;Fluorouracil;Fusion Proteins, bcr-abl;Gene Expression;Genes, abl;Genes, myc;Humans;Leukemia, Erythroblastic, Acute;RNA, Messenger;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"drug effects;drug effects;drug effects;pharmacology;metabolism;drug effects;pathology;genetics",
        "_version_":1605840096277299200},
      {
        "Doc_abstract":"Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) is triggered by BCR/ABL and SRC family tyrosine kinases. They interact with each other and subsequently activate downstream growth-signaling pathways, including Raf/MEK/ERK, Akt/mTOR, and STAT5 pathways. Although imatinib is the standard treatment for Ph+ leukemia, response rate of Ph+ ALL to imatinib is low, relapse is frequent and quick. Studies have documented the potential anti-tumor activities of curcumin. However, whether curcumin can be used in the therapy for Ph+ ALL remains obscure. Here, we reported that curcumin induced apoptosis by inhibition of AKT/mTOR and ABL/STAT5 signaling, down-regulation of BCR/ABL expression, and induction of the BCL2/BAX imbalance. Curcumin exerted synergetic anti-leukemia effects with imatinib by inhibition of the imatinib-mediated overactivation of AKT/mTOR signaling and down-regulation of BCR/ABL gene expression. In primary samples from Ph+ ALL patients, curcumin inhibited cellular proliferation and down-regulated constitutive activation of growth-signaling pathways not only in newly diagnosed patients but also in imatinib-resistant patients. In Ph+ ALL mouse models, curcumin exhibited synergetic anti-leukemia effects with imatinib. These results demonstrated that curcumin might be a promising agent for Ph+ ALL patients. ",
        "Doc_title":"Curcumin potentiates the anti-leukemia effects of imatinib by downregulation of the AKT/mTOR pathway and BCR/ABL gene expression in Ph+ acute lymphoblastic leukemia.",
        "Journal":"The international journal of biochemistry & cell biology",
        "Do_id":"25979368",
        "Doc_ChemicalList":"Imatinib Mesylate;MTOR protein, human;TOR Serine-Threonine Kinases;Fusion Proteins, bcr-abl;Curcumin",
        "Doc_meshdescriptors":"Animals;Antineoplastic Combined Chemotherapy Protocols;Cell Line, Tumor;Curcumin;Down-Regulation;Drug Synergism;Female;Fusion Proteins, bcr-abl;Gene Expression;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mice;Mice, Inbred BALB C;Signal Transduction;TOR Serine-Threonine Kinases;Xenograft Model Antitumor Assays",
        "Doc_meshqualifiers":"pharmacology;administration & dosage;pharmacology;drug effects;biosynthesis;genetics;drug effects;administration & dosage;pharmacology;drug therapy;genetics;metabolism;pathology;metabolism",
        "_version_":1605760732950953984},
      {
        "Doc_abstract":"Landmark clinical studies of new drugs developed to target specific forms of cancer were reported in 2001. Herceptin, a monoclonal antibody against the Her2/neu receptor tyrosine kinase, prolonged the survival of women with Her-2/neu positive metastatic breast cancer, when combined with chemotherapy. STI-571, a small molecule inhibitor of the Bcr-Abl, c-kit and platelet derived growth factor receptor tyrosine kinases, produced dramatic clinical responses in patients with Bcr-Abl positive chronic myeloid leukemia and c-kit positive gastrointestinal stromal tumors. These examples have galvanized the cancer research community to extend kinase-inhibitor therapy to other cancers.",
        "Doc_title":"Rational therapeutic intervention in cancer: kinases as drug targets.",
        "Journal":"Current opinion in genetics & development",
        "Do_id":"11790564",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antineoplastic Agents;Enzyme Inhibitors;Protein-Tyrosine Kinases;Receptor, ErbB-2",
        "Doc_meshdescriptors":"Animals;Antibodies, Monoclonal;Antineoplastic Agents;Breast Neoplasms;Clinical Trials as Topic;Drug Delivery Systems;Enzyme Inhibitors;Female;Humans;Mutation;Neoplasms;Protein-Tyrosine Kinases;Receptor, ErbB-2",
        "Doc_meshqualifiers":"therapeutic use;therapeutic use;drug therapy;therapeutic use;drug therapy;enzymology;genetics;antagonists & inhibitors;antagonists & inhibitors",
        "_version_":1605785072392208384},
      {
        "Doc_abstract":"We report a 44-yr-old female with Philadelphia chromosome positive chronic myeloid leukemia who was initially treated with busulfan, and clinical remission has been achieved. After 4 yr, low-dose busulfan therapy was started again and induced bone marrow aplasia. The patient spontaneously has recovered from aplasia, and complete cytogenetic remission with loss of Ph+ chromosome in bone marrow has been achieved. However, reverse-transcription-polymerase chain reaction analysis showed presence of the bcr-abl transcript in bone marrow.",
        "Doc_title":"Busulfan-induced loss of Ph chromosome in chronic myeloid leukemia.",
        "Journal":"Medical oncology (Northwood, London, England)",
        "Do_id":"11917947",
        "Doc_ChemicalList":"Antineoplastic Agents, Alkylating;DNA, Neoplasm;Busulfan",
        "Doc_meshdescriptors":"Adult;Antineoplastic Agents, Alkylating;Bone Marrow;Busulfan;DNA, Neoplasm;Female;Genes, abl;Humans;In Situ Hybridization, Fluorescence;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Philadelphia Chromosome;Reverse Transcriptase Polymerase Chain Reaction",
        "Doc_meshqualifiers":"pharmacology;pharmacology;genetics;drug therapy;genetics",
        "_version_":1605818567157088258},
      {
        "Doc_abstract":"The oncogenic BCR/ABL tyrosine kinase induces constitutive enhanced \"spontaneous\" DNA damage and unfaithful repair in Philadelphia chromosome positive leukemia cells. Here, we investigated the changes of protein profile in H2O2-induced DNA damage/repair in BaF3-MIGR1 and BaF3-BCR/ABL cells through a proteomic strategy consisting of two-dimensional gel electrophoresis (2-DE) coupled with MALDI-TOF mass spectrometry. In total, 41 spots were differentially expressed and 13 proteins were identified with further MS analysis. Two essential proteins, Proto-oncogene tyrosine-protein kinase ABL1 (c-ABL) and Heat shock 70kDa protein 4 (Apg-2), were confirmed by Western blot and showed consistent changes with proteomic results. Moreover, functional analysis demonstrated that inhibition of Apg-2 not only decreased cell proliferation, but also induced cell apoptosis in BCR/ABL positive cells (BaF3-BCR/ABL, BaF3-BCR/ABL(T315I)). We also proved that Apg-2 inhibition aggravated H2O2 induced damage in BCR/ABL positive cells, and enhanced the sensitivity of BaF3-BCR/ABL(T315I) to STI571. Taken together, the findings in this work provide us with some clues to a better understanding of the molecular mechanisms underlying BCR/ABL in the DNA damage/repair processes and demonstrated that Apg-2 would be a valid target for anti-leukemia drug development. ",
        "Doc_title":"Proteomic-based identification of Apg-2 as a therapeutic target for chronic myeloid leukemia.",
        "Journal":"Cellular signalling",
        "Do_id":"24012954",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;HSP110 Heat-Shock Proteins;Hspa4 protein, mouse;Piperazines;Proteome;Pyrimidines;RNA, Small Interfering;Imatinib Mesylate;Hydrogen Peroxide",
        "Doc_meshdescriptors":"Animals;Antineoplastic Agents;Benzamides;Cell Cycle;Cell Line, Tumor;Cell Proliferation;Drug Resistance, Neoplasm;Gene Expression Regulation, Neoplastic;HSP110 Heat-Shock Proteins;Hydrogen Peroxide;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mice;Molecular Targeted Therapy;Piperazines;Proteome;Proteomics;Pyrimidines;RNA Interference;RNA, Small Interfering",
        "Doc_meshqualifiers":"pharmacology;pharmacology;genetics;metabolism;metabolism;drug therapy;genetics;metabolism;pathology;pharmacology;metabolism;pharmacology;genetics",
        "_version_":1605764389877579776},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) is a pluripotent hematopoietic stem cell disorder almost always characterized by the presence of the Philadelphia chromosome (Ph), usually due to t(9;22)(q34;q11). The presence of Ph results in the formation of the BCR/ABL fusion gene, which is a constitutively activated tyrosine kinase. Approximately 1% of CML patients appear to have a Ph-negative karyotype but carry a cryptic BCR/ABL fusion that can be located by fluorescence in situ hybridization (FISH) at chromosome 22q11, 9q34 or a third chromosome. This study investigated a rare Ph-negative CML case with insertion of the 3' ABL region into the long arm of derivative chromosome 1 but lacking the 5' BCR region on der(22).",
        "Doc_title":"Insertion of the 3' ABL region into the long arm of chromosome 1 in a Philadelphia chromosome-negative chronic myeloid leukemia case.",
        "Journal":"Oncology letters",
        "Do_id":"22870093",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605795798594879488},
      {
        "Doc_abstract":"Treatment options for chronic myeloid leukemia (CML) have changed dramatically during the last decades. Interferon-alpha treatment and stem cell transplantation (SCT) clearly improved survival over conventional chemotherapy and offered the possibility of complete and durable responses. With the advent of the small molecule inhibitor imatinib mesylate (Glivec((R)), Gleevectrade mark) targeting the causative Bcr-Abl oncoprotein, the era of molecular cancer therapy began with remarkable success especially in chronic phase patients. Today, imatinib is the first-line treatment for CML. However, imatinib does not appear to be capable to eliminate all leukemia cells in the patients and pre-existing as well as acquired resistance to the drug has been increasingly recognized. To overcome these problems, several strategies involving dose escalation, combinations with other agents, and novel Bcr-Abl inhibitors have been developed.",
        "Doc_title":"Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark).",
        "Journal":"Therapeutics and clinical risk management",
        "Do_id":"18728706",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605902629741789184},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) appears an ideal and exciting immunological target. Novel and rational immunotherapy may therefore play an important adjuvant role in the treatment of CML patients. Peptides derived from the BCR-ABL fusion region have been shown to be immunogenic and are able to stimulate the production of BCR-ABL-specific T cell lines and clones. In this study, A 280 bp multiple epitope region of BCR-ABL fusion antigen was designed and synthesized. This region contains three BCR-ABL antigen epitopes which can bind to HLA-A2, HLA-A3 and HLA-DR11 molecules, respectively, and epitopes of cholera toxin B (CTB) and tetanus toxoid (TT) which are able to elicit vigorous T cell responses. The fusion antigen gene has highly been expressed in E. coli and the purified fusion protein reserved satisfied activity and antigenicity. The results of this investigation provided a basis for further research on the developing specific T cell immunotherapy of CML.",
        "Doc_title":"[Synthesis, Cloning and Expression of a Multiple Epitope Antigen of BCR-ABL Fusion Gene]",
        "Journal":"Zhongguo shi yan xue ye xue za zhi",
        "Do_id":"12578695",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605818762988093441},
      {
        "Doc_abstract":"Immunocompetent alloreactive donor lymphocytes directed against minor histocompatibility antigens are supposed to be responsible for graft-versus-host disease (GvHD) and graft-versus-leukemia (GvL) activity after allogeneic stem cell transplantation. The authors describe the detection of HA-1-specific T cells by peptide-loaded dimers and flow cytometry in the peripheral blood of a patient in complete remission but without GvHD after donor lymphocyte infusion for chemotherapy-resistant Philadelphia chromosome-positive acute lymphoblastic leukemia. The HA-1-specific T cells were sorted and an alloreactive, polyclonal T-cell line with specific lytic activity against HA-1-positive target cells, including leukemic cells, was established. Although P190 bcr/abl peptide-specific CD8positive T cells were detected in the peripheral blood at the same time, these T cells could not be expanded. Furthermore, no P190 bcr/abl peptide-specific T-cell response could be induced in vitro, even when peptide-loaded dendritic cells were used as stimulator cells. The authors conclude that in the absence of GvHD, HA-1-specific rather than P190 bcr/abl-specific T cells are responsible for ongoing GvL activity.",
        "Doc_title":"Hematopoietic lineage-restricted minor histocompatibility antigen HA-1 in graft-versus-leukemia activity after donor lymphocyte infusion.",
        "Journal":"Journal of immunotherapy (Hagerstown, Md. : 1997)",
        "Do_id":"14770087",
        "Doc_ChemicalList":"HA-1 antigen;HLA-A Antigens;HLA-A*02:01 antigen;HLA-A2 Antigen;Minor Histocompatibility Antigens;Oligopeptides;Peptides",
        "Doc_meshdescriptors":"Cell Division;Cell Lineage;Cell Transplantation;Dendritic Cells;Dimerization;Flow Cytometry;Graft vs Leukemia Effect;HLA-A Antigens;HLA-A2 Antigen;Hematopoietic Stem Cells;Humans;Immunotherapy;Leukemia;Lymphocytes;Minor Histocompatibility Antigens;Oligopeptides;Peptides;Phenotype;Protein Binding;T-Lymphocytes",
        "Doc_meshqualifiers":"cytology;chemistry;cytology;methods;therapy;cytology;immunology;chemistry;metabolism",
        "_version_":1605760892768616448},
      {
        "Doc_abstract":"Over the past decade the clinical introduction of agents that directionally blocks the activity of BCR-ABL tumor tyrosine kinase (TK) has changed the prognosis of chronic myeloid leukemia. A significant malignant Ph'-positive clone inhibition and durable remissions have made it possible to increase overall and relapse-free survival. Due to their higher life expectancy, the number of patients is on the increase and their quality of life and working capacity remain good. According to the All-Russian Register of Chronic Myeloid Leukemia, there were more than 6500 cases in the Russian Federation in 2012. Of them, 93.1% were diagnosed with the chronic phase of the disease, 6.4 and 0.4% with its accelerated phase and blast crisis, respectively. Among the BCR-ABL TK inhibitors (TKI) registered in the Russian Federation and recommended for the treatment of chronic myeloid leukemia, there are 3 medications: imatinib, nilotinib, and dasatinib. The efficiency and safety of TKI therapy have been well studied. The most important principle of treatment is to permanently affect the Ph'-positive tumor cell clone by the long-term daily use of TKls. Regular cytogenetic and molecular genetic monitoring allows adequate estimation of the leukemic clone volume and it is essential in evaluating the therapeutic effectiveness. To choose a TKI for each specific patient with regard for its best tolerability and maximum efficiency permits individualized treatment. The prospect of therapy discontinuation can be discussed only in individual patients with a durable and stable complete molecular response and only within clinical trials.",
        "Doc_title":"[Therapeutic strategy for chronic myeloid leukemia: possibilities and prospects].",
        "Journal":"Terapevticheskii arkhiv",
        "Do_id":"24137941",
        "Doc_ChemicalList":"Antineoplastic Agents;Protein Kinase Inhibitors;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Antineoplastic Agents;Fusion Proteins, bcr-abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Protein Kinase Inhibitors;Treatment Outcome",
        "Doc_meshqualifiers":"administration & dosage;adverse effects;therapeutic use;antagonists & inhibitors;drug therapy;enzymology;administration & dosage;adverse effects;therapeutic use",
        "_version_":1605796340094205952},
      {
        "Doc_abstract":"Mouse polyomavirus-like particles (MPyV-VLPs) carrying inside a fragment of the Bcr-Abl hybrid protein containing the epitope of chronic myeloid leukemia fusion region were prepared. A sequence encoding 171 amino acids covering Bcr-Abl breakpoint was fused to the C-terminal part of VP3 minor protein connecting it to the VP1 capsomeres. Chimeric particles, the Bcr-Abl VLPs, were tested for their ability to induce Bcr-Abl specific immune response in mice after their intranasal (i.n.) or intraperitoneal (i.p.) administration without any other adjuvants. Bcr-Abl VLPs induced strong anti-VP1 immune response in both i.n. and i.p. immunized mice. As expected, neither IgG nor IgM anti-Bcr-Abl specific antibodies were detected in the sera of immunized animals. Surprisingly, no specific CTL (cytotoxic T-lymphocyte) activity was proved using two different methods (in vitro cytotoxicity assay with CFSE-labeled target cells and highly sensitive cytotoxicity assay using MHC class I Bcr-Abl specific pentamers). In addition, no proliferative response of T-cells of i.n. immunized mice after in vitro restimulation with antigen-pulsed bone marrow-derived dendritic cells was observed. Taken together, Bcr-Abl breakpoint epitopes appeared to be weak immunogens and even MPyV-VLPs did not provide sufficient adjuvant ability to support induction of immune responses specific to Bcr-Abl fusion zone epitope.",
        "Doc_title":"Bcr-Abl fusion sequences do not induce immune responses in mice when administered in mouse polyomavirus based virus-like particles.",
        "Journal":"International journal of oncology",
        "Do_id":"19885546",
        "Doc_ChemicalList":"Antigens, Viral;Epitopes;Recombinant Proteins;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Animals;Antigens, Viral;Blotting, Western;Cytotoxicity, Immunologic;Epitopes;Fluorescent Antibody Technique;Fusion Proteins, bcr-abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mice;Microscopy, Immunoelectron;Polyomavirus;Recombinant Proteins",
        "Doc_meshqualifiers":"immunology;immunology;immunology;immunology;immunology;immunology",
        "_version_":1605812228358930432},
      {
        "Doc_abstract":"The Philadelphia chromosome is present in more than 95% of chronic myeloid leukemia patients and 13% of acute lymphocytic leukemia patients. The Philadelphia translocation, t(9;22), fuses the BCR and ABL genes resulting in the expression of leukemia-specific, chimeric BCR-ABL messenger RNAs. To facilitate diagnosis of these leukemias, we have developed a method of amplifying and detecting only the unique mRNA sequences, using an extension of the polymerase chain reaction technique. Diagnosis of chronic myeloid and acute lymphocytic leukemias by this procedure is rapid, much more sensitive than existing protocols, and independent of the presence or absence of an identifiable Philadelphia chromosome.",
        "Doc_title":"Diagnosis of chronic myeloid and acute lymphocytic leukemias by detection of leukemia-specific mRNA sequences amplified in vitro.",
        "Journal":"Proceedings of the National Academy of Sciences of the United States of America",
        "Do_id":"3165197",
        "Doc_ChemicalList":"RNA, Messenger;RNA, Neoplasm",
        "Doc_meshdescriptors":"Cell Line;Gene Amplification;Humans;Immunoassay;Karyotyping;Leukemia, Lymphoid;Leukemia, Myeloid;Nucleic Acid Hybridization;Philadelphia Chromosome;RNA, Messenger;RNA, Neoplasm",
        "Doc_meshqualifiers":"diagnosis;genetics;diagnosis;genetics;analysis;immunology;analysis",
        "_version_":1605805317643304960},
      {
        "Doc_abstract":"In chronic myeloid leukemia (CML), the best characterized imatinib resistance mechanisms are BCR-ABL tyrosine kinase domain mutations and clonal evolution, but recently alternative splicing of BCR-ABL was also proposed as a mechanism for imatinib resistance. Among recently reported BCR-ABL splice variants, exon 7 deletion (exon7) was characterized in this study. The frequency of exon7 was investigated in 30 healthy controls and in 76 CML patients at different time points of the disease course by four different molecular genetic methods (direct sequencing, fragment analysis, allele-specific and quantitative PCR). The functionality and viability of the variant protein was tested by bioinformatic prediction. The exon7 was abundantly detected with similar frequency in healthy controls, in imatinib naive and resistant CML patients on BCR-ABL and also on the nontranslocated ABL. The detection rate of exon7 (varying between 17 and 100%) was highly dependent on the expression levels of BCR-ABL or ABL and the sensitivity of detection method. According to secondary structure prediction by bioinformatic methods, the exon 7 deleted mRNA is a target for nonsense-mediated decay, and the translated protein is likely to be nonfunctional and unstable. Taken together all the above observations, we concluded that exon7 is a common splice variant not associating with imatinib resistance.",
        "Doc_title":"Characterization of ABL exon 7 deletion by molecular genetic and bioinformatic methods reveals no association with imatinib resistance in chronic myeloid leukemia.",
        "Journal":"Medical oncology (Northwood, London, England)",
        "Do_id":"22038725",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Protein Isoforms;Pyrimidines;Imatinib Mesylate;Proto-Oncogene Proteins c-abl",
        "Doc_meshdescriptors":"Amino Acid Sequence;Antineoplastic Agents;Benzamides;Computational Biology;Drug Resistance, Neoplasm;Exons;Gene Deletion;Genes, abl;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Molecular Biology;Molecular Sequence Data;Piperazines;Polymerase Chain Reaction;Protein Isoforms;Protein Structure, Secondary;Proto-Oncogene Proteins c-abl;Pyrimidines;Sequence Deletion",
        "Doc_meshqualifiers":"therapeutic use;therapeutic use;genetics;genetics;genetics;drug therapy;genetics;therapeutic use;chemistry;genetics;therapeutic use",
        "_version_":1605790134589980672},
      {
        "Doc_abstract":"Imatinib mesylate (Gleevec) was developed as the first molecularly targeted therapy that specifically inhibits the BCR-ABL tyrosine kinase activity in patients with Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML). Due to its excellent hematologic and cytogenetic responses, particularly in patients with chronic phase CML, imatinib has moved towards first-line treatment for newly diagnosed CML. Nevertheless, resistance to the drug has been frequently reported and is attributed to the fact that transformation of hematopoietic stem cells by BCR-ABL is associated with genomic instability. Point mutations within the ABL tyrosine kinase of the BCR-ABL oncoprotein are the major cause of resistance, though overexpression of the BCR-ABL protein and novel acquired cytogenetic aberrations have also been reported. A variety of strategies derived from structural studies of the ABL-imatinib complex have been developed, resulting in the design of novel ABL inhibitors, including AMN107, BMS-354825, ON012380 and others. The major goal of these efforts is to create new drugs that are more potent than imatinib and/or more effective against imatinib-resistant BCR-ABL clones. Some of these drugs have already been successfully tested in preclinical studies where they show promising results. Additional approaches are geared towards targeting the expression or stability of the BCR-ABL kinase itself or targeting signaling pathways that are chronically activated and required for transformation. In this review, we will discuss the underlying mechanisms of resistance to imatinib and novel targeted approaches to overcome imatinib resistance in CML.",
        "Doc_title":"Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).",
        "Journal":"Critical reviews in oncology/hematology",
        "Do_id":"16213151",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Imatinib Mesylate;Protein-Tyrosine Kinases",
        "Doc_meshdescriptors":"Antineoplastic Agents;Benzamides;Drug Resistance, Neoplasm;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Piperazines;Protein Kinase Inhibitors;Protein-Tyrosine Kinases;Pyrimidines",
        "Doc_meshqualifiers":"pharmacology;therapeutic use;drug therapy;metabolism;metabolism;therapeutic use;pharmacology;therapeutic use;antagonists & inhibitors;metabolism;therapeutic use",
        "_version_":1605892695427907584},
      {
        "Doc_abstract":"Calcium-dependent protein kinases (PKCs) function in a myriad of cellular processes, including cell-cycle regulation, proliferation, hematopoietic stem cell differentiation, apoptosis, and malignant transformation. PKC inhibitors, when targeted to these pathways, have demonstrated efficacy against several types of solid tumors as well as leukemia. Chronic myeloid leukemia (CML) represents 20% of all adult leukemia. The aberrant Philadelphia chromosome has been reported as the main cause of CML development in hematopoietic stem cells, due to the formation of the BCR-ABL oncogene. PKCs and BCR-ABL coordinate several signaling pathways that are crucial to cellular malignant transformation. Experimental and clinical evidence suggests that pharmacological approaches using PKC inhibitors may be effective in the treatment of CML. This mini review summarizes articles from the National Center for Biotechnology Information website that have shown evidence of the involvement of PKC in CML. ",
        "Doc_title":"Role of calcium-dependent protein kinases in chronic myeloid leukemia: combined effects of PKC and BCR-ABL signaling on cellular alterations during leukemia development.",
        "Journal":"OncoTargets and therapy",
        "Do_id":"25045273",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605843532710412288},
      {
        "Doc_abstract":"Constitutive activation of protein tyrosine kinases plays a central role in the pathogenesis of myeloproliferative disorders, including BCR-ABL-negative chronic myeloid leukemia. Current research is focused on elucidating the full spectrum of causative mutations in this rare, heterogeneous disease. Activated tyrosine kinases are excellent targets for signal transduction therapy, and an accurate diagnosis including morphology, karyotyping, and molecular genetics will become increasingly important to direct individualized treatment. In addition, new molecular findings need to be incorporated into disease classification systems.",
        "Doc_title":"BCR-ABL-negative chronic myeloid leukemia.",
        "Journal":"Current hematologic malignancy reports",
        "Do_id":"20425354",
        "Doc_ChemicalList":"Oncogene Proteins, Fusion;Protein Kinases",
        "Doc_meshdescriptors":"Aged;Aneuploidy;Enzyme Activation;Humans;Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative;Middle Aged;Mutation;Oncogene Proteins, Fusion;Protein Kinases;Risk Factors;Signal Transduction;Translocation, Genetic",
        "Doc_meshqualifiers":"classification;diagnosis;enzymology;genetics;pathology;genetics;physiology;genetics;physiology;genetics",
        "_version_":1605801812987740160},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) is a myeloproliferative disease originating from a constitutively active tyrosine kinase, called BCR-ABL, expressed by an oncogene resulting from a reciprocal translocation between chromosome 9 and chromosome 22, coded as (t[9,22][q34;q11]). Inhibition of BCR-ABL with tyrosine kinase inhibitors (TKI) proved to be an efficient targeted therapy of Philadelphia-positive (Ph+) CML in the chronic phase. This review mainly addresses the synthetic pathways and process chemistry leading to the large scale preparation for pre-clinical demands and clinical supply of the three TKIs approved for Ph+ CML, i.e., imatinib, dasatinib and nilotinib and three more investigational drugs, i.e., bosutinib, ponatinib and bafetinib. Recent progress on the biochemical profiling of the six examined TKIs has been also reported.",
        "Doc_title":"BCR-ABL inhibitors in chronic myeloid leukemia: process chemistry and biochemical profile.",
        "Journal":"Current medicinal chemistry",
        "Do_id":"21651486",
        "Doc_ChemicalList":"Antineoplastic Agents;Protein Kinase Inhibitors;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Animals;Antineoplastic Agents;Fusion Proteins, bcr-abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Models, Molecular;Protein Kinase Inhibitors",
        "Doc_meshqualifiers":"chemical synthesis;chemistry;therapeutic use;antagonists & inhibitors;metabolism;drug therapy;enzymology;chemical synthesis;chemistry;therapeutic use",
        "_version_":1605810761832071168},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) is a myeloproliferative disease characterized by the presence of Philadelphia chromosome (Ph) leading to expression of a BCR-ABL1 fusion oncogene. The BCR-ABL protein has a constitutive tyrosine kinase activity which is responsible for CML pathogenesis by promoting cell apoptosis resistance; however, the cellular and molecular mechanisms associated with BCR-ABL expression and apoptosis impairment in CML leukemic cells have not been fully elucidated.;This study evaluated apoptomiRs and their predicted apoptotic genes in BCR-ABL(+) cells from patients in different phases of CML treated with tyrosine kinase inhibitor (TKI) according to their imatinib (IM) response by qPCR. Phosphotyrosine and c-ABL expressions in HL-60.BCR-ABL cells treated with TKI were done by Western blot.;We found that dasatinib (DAS) modulated miR-let-7d, miR-let-7e, miR-15a, miR-16, miR-21, miR-130a and miR-142-3p expressions while IM modulated miR-15a and miR-130a levels. miR-16, miR-130a and miR-145 expressions were modulated by nilotinib (NIL). We observed higher miR-15a, miR-130b and miR-145; and lower miR-16, miR-26a and miR-146a expressions in CML-CP in comparison with controls. CML-AP patients showed low miR-let-7d, miR-15a, miR-16, miR-29c, miR-142-3p, miR-145, and miR-146a levels in comparison with CML-CP. We noted that the miR-26a, miR-29c, miR-130b and miR-146a expressions were downregulated in IM resistant patients in comparison with IM responsive patients.;This study showed the modulation of apoptomiRs by BCR-ABL kinase activity and the deregulation of apoptomiRs and their predicted apoptotic target genes in different CML phases and after treatment with TK inhibitors. ApoptomiRs may be involved in the BCR-ABL(+) cell apoptosis regulation.",
        "Doc_title":"ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.",
        "Journal":"Blood cells, molecules & diseases",
        "Do_id":"24629639",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;MicroRNAs;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Imatinib Mesylate;Fusion Proteins, bcr-abl;Proto-Oncogene Proteins c-abl",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Antineoplastic Agents;Apoptosis;Benzamides;Case-Control Studies;Cell Line, Tumor;Disease Progression;Drug Resistance, Neoplasm;Female;Fusion Proteins, bcr-abl;Gene Expression Regulation, Leukemic;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;MicroRNAs;Middle Aged;Neoplasm Staging;Phosphorylation;Piperazines;Protein Kinase Inhibitors;Proto-Oncogene Proteins c-abl;Pyrimidines;Treatment Outcome;Young Adult",
        "Doc_meshqualifiers":"pharmacology;therapeutic use;genetics;pharmacology;therapeutic use;genetics;genetics;metabolism;drug effects;drug therapy;genetics;pathology;genetics;drug effects;pharmacology;therapeutic use;pharmacology;therapeutic use;genetics;metabolism;pharmacology;therapeutic use",
        "_version_":1605742637495615488},
      {
        "Doc_abstract":"The BCR-ABL transcript level ( 10%) at 3 months after tyrosine kinase inhibitors can predict long term outcome in the patients with chronic myeloid leukemia in chronic phase (CML-CP). However, the significance of transcript level was still not determined in different risk groups of patients. A total of 299 patients with CML-CP were enrolled and stratified according to prior interferon- (IFN) treatment, age, and interval time between diagnosis and imatinib treatment to investigate the prediction value of BCR-ABL transcript level for overall survival (OS), event-free survival (EFS), progression-free survival (PFS). Univariate and multivariate analysis proved that BCR-ABL transcript level at 3 months were associated with the treatment outcome. However, in the patients with prior IFN treatment, younger age, and longer interval between diagnosis and IM treatment, the predictive value of transcript value remain obscure in terms of EFS, PFS and OS, respectively, as well as cumulative incidence of PCyR, CCR, MMR and CMR. In conclusion, the transcript level of BCR-ABL at 3 months could serve as a predictive parameter, but should be used with caution.",
        "Doc_title":"Outcome prediction by the transcript level of BCR-ABL at 3 months in patients with chronic myeloid leukemia treated with imatinib--a single institution historical experience.",
        "Journal":"Leukemia research",
        "Do_id":"25115808",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Pyrimidines;Imatinib Mesylate;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Antineoplastic Agents;Benzamides;Child;Female;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Kaplan-Meier Estimate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Piperazines;Proportional Hazards Models;Pyrimidines;Retrospective Studies;Treatment Outcome;Young Adult",
        "Doc_meshqualifiers":"therapeutic use;therapeutic use;genetics;drug therapy;genetics;mortality;therapeutic use;therapeutic use",
        "_version_":1605820966560071680},
      {
        "Doc_abstract":"In chronic myeloid leukemia (CML) the proto-oncogene c-abl from chromosome 9 q34 is translocated to the breakpoint cluster region (bcr) gene on chromosome 22 q11. This translocation results in a BCR-ABL fusion gene, which encodes chimeric fusion oncoproteins p210BCR-ABL. Here we demonstrate that a peptide with joining region sequence ATGFKQSSKALQRPVAS (eight amino acids (aa) encoded by BCR exon 3; one novel lysine, encoded by the fusion codon; eight aa encoded by ABL exon 2) is immunogenic to human T cells. Primary immune response induction with this peptide resulted in a HLA DR2(DRB1*1501) restricted CD4+ BCR-ABL peptide specific T cell line P1. Responses of P1 were negatively affected by individual aa replacement by alanine at eight aa positions within the 17mer peptide (F4, K5, Q6, K9, L11, Q12, R13, P14). These findings were supported by experiments with a panel of overlapping 11mer b3a2 peptides. Only two of these peptides with an aa sequence encompassing all residues which could not be replaced by alanine induced P1 proliferation. Since presentation of cytosolic oncoproteins as peptides by DR molecules has been observed, the present findings provide a possible explanation for post interferon-alpha persisting remissions in spite of the presence of BCR-ABL PCR positive progenitors.",
        "Doc_title":"Recognition of peptides corresponding to the joining region of p210BCR-ABL protein by human T cells.",
        "Journal":"Leukemia",
        "Do_id":"7643623",
        "Doc_ChemicalList":"HLA-DR Antigens;Peptides;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Amino Acid Sequence;Antigen-Presenting Cells;Epitope Mapping;Fusion Proteins, bcr-abl;HLA-DR Antigens;Humans;Lymphocyte Activation;Major Histocompatibility Complex;Molecular Sequence Data;Peptides;Sequence Alignment;Structure-Activity Relationship;T-Lymphocytes",
        "Doc_meshqualifiers":"immunology;immunology;immunology;chemistry;immunology;immunology",
        "_version_":1605903240831959040},
      {
        "Doc_abstract":"Several tyrosine kinase inhibitors have been developed to target the BCR-ABL fusion gene, a pathognomonic genetic change in chronic myeloid leukemia (CML), and have dramatically improved the outcomes of CML patients. BCR-ABL-expressing CML cells compete with normal hematopoietic cells over the limited space in the bone marrow to proliferate. Moreover, CML cells can gain resistance to tyrosine kinase inhibitors by utilizing bone marrow microenvironments. Thus, in order to develop a novel treatment strategy for CML, it is necessary to elucidate the cellular and molecular basis underlying the interactions between CML and normal hematopoietic cells. Herein, we discuss the roles of chemokines, particularly CXCL12 and CCL3, in reconstruction processes of bone marrow microenvironments by CML cells and the possibility of novel treatment modalities against CML, based on targeting these chemokines. ",
        "Doc_title":"[Chemokines in chronic myeloid leukemia].",
        "Journal":"[Rinsho ketsueki] The Japanese journal of clinical hematology",
        "Do_id":"26935630",
        "Doc_ChemicalList":"Chemokines;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Bone Marrow;Cellular Microenvironment;Chemokines;Fusion Proteins, bcr-abl;Hematopoietic Stem Cells;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive",
        "Doc_meshqualifiers":"metabolism;metabolism;metabolism;cytology;metabolism",
        "_version_":1605818574873559041},
      {
        "Doc_abstract":"During a 4-year period (December 1990-December 1994), among other diagnoses one hundred cases of chronic myeloid leukemia (CML) were analyzed in our department. We focused our attention on two cases with a variant form of Philadelphia translocation. Cytogenetic and molecular genetic studies were performed to resolve the status of BCR and ABL in the bone marrow or peripheral blood cells of the two CML patients with complex translocations involving chromosomes 3, 9, 22 and 9, 12, 22 respectively. In the first case the presence of Ph chromosome was detected cytogenetically, BCR-ABL translocation was detected by Southern hybridization. In the second case, only the PCR method showed BCR-ABL rearrangement. The second case, with a random variant form of Ph translocation, could be detected using different methods of clinical molecular genetics.",
        "Doc_title":"Variant forms of Philadelphia translocation in two patients with chronic myeloid leukemia.",
        "Journal":"Neoplasma",
        "Do_id":"8931748",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adult;Humans;Karyotyping;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Metaphase;Middle Aged;Philadelphia Chromosome;Translocation, Genetic",
        "Doc_meshqualifiers":"genetics;physiology",
        "_version_":1605818776437129217},
      {
        "Doc_abstract":"Bcr-Abl is the predominant therapeutic target in chronic myeloid leukemia (CML), and tyrosine kinase inhibitors (TKIs) that inhibit Bcr-Abl have been successful in treating CML. With progression of CML disease especially in blast crisis stage, cells from CML patients become resistant to imatinib mesylate (IM) and other TKIs, resulting in relapse. Because Bcr-Abl is known to drive multiple signaling pathways, the study of the regulation of stability of Bcr-Abl in IM-resistant CML cells is a critical issue as a possible therapeutic strategy. Here, we report that a new dual-kinase chemical inhibitor, ON044580, induced apoptosis of Bcr-Abl+ IM-sensitive, IM-resistant cells, including the gatekeeper Bcr-Abl mutant, T315I, and also cells from blast crisis patients. In addition, IM-resistant K562-R cells, cells from blast crisis CML patients, and all IM-resistant cell lines tested had reduced ability to form colonies in soft agar in the presence of 0.5 M ON044580. In in vitro kinase assays, ON044580 inhibited the recombinant Jak2 and Abl kinase activities when the respective Jak2 and Abl peptides were used as substrates. Incubation of the Bcr-Abl+ cells with ON044580 rapidly reduced the levels of the Bcr-Abl protein and also reduced the expression of HSP90 and its client protein levels. Lysates of Bcr-Abl+ cell lines were found to contain a large signaling network complex composed of Bcr-Abl, Jak2, HSP90, and its client proteins as detected by a gel filtration column chromatography, which was rapidly disrupted by ON044580. Therefore, targeting Jak2 and Bcr-Abl kinases is an effective way to destabilize Bcr-Abl and its network complex, which leads to the onset of apoptosis in IM-sensitive and IM-resistant Bcr-Abl+ cells. This inhibitory strategy has potential to manage all types of drug-resistant CML cells, especially at the terminal blast crisis stage of CML, where TKIs are not clinically useful.",
        "Doc_title":"Destabilization of Bcr-Abl/Jak2 Network by a Jak2/Abl Kinase Inhibitor ON044580 Overcomes Drug Resistance in Blast Crisis Chronic Myelogenous Leukemia (CML).",
        "Journal":"Genes & cancer",
        "Do_id":"20798787",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605818698290954241},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) is caused by the BCR-ABL oncogene. The Philadelphia chromosome (Ph) from a reciprocal translocation, t(9;22) (q34;q11) causes a fusion gene, BCR-ABL, that encodes a constitutively active tyrosine kinase. Treatment of CML by imatinib is effective to control the tyrosyl phosphorylation of the protein related to the cell signaling. BCR-ABL mRNA is overexpressed in the minimal residual disease (MRD), known as an early sign of relapse. Between December 2005 and June 2008, we measured BCR-ABL mRNA levels in the bone marrow (BM) from patients by quantitative real-time polymerase chain reaction (RQ-PCR) in Aomori Prefectural Central Hospital. Eighty-six samples from 26 patients were collected. Among the 26 CML patients, 11 patients (42%) were in the pretreatment group. Seven (64%) of the 11 patients achieved complete molecular response (CMR). In the post-treatment group consisting of the remaining 15 patients, 9 (60%) patients achieved CMR. The patients receiving imatinib at a dose over 300 mg per day required 13 (6-77) months [median (range)] to achieve CMR. On the other hand, the patients receiving a dose below 300 mg per day required 29.5 (11-84) months [median (range)]. When BCR-ABL mRNA was detected during the treatment course of patients with CMR, careful observation of BCR-ABL mRNA was useful for tracking the clinical course of patients. In conclusion, the BCR-ABL mRNA level was useful for monitoring the clinical course in 26 patients with CML.",
        "Doc_title":"Monitoring twenty-six chronic myeloid leukemia patients by BCR-ABL mRNA level in bone marrow:a single hospital experience.",
        "Journal":"Acta medica Okayama",
        "Do_id":"22037271",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Protein Kinase Inhibitors;Pyrimidines;RNA, Messenger;Imatinib Mesylate;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Antineoplastic Agents;Benzamides;Bone Marrow;Female;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Piperazines;Protein Kinase Inhibitors;Pyrimidines;RNA, Messenger",
        "Doc_meshqualifiers":"therapeutic use;chemistry;genetics;metabolism;drug therapy;genetics;physiopathology;therapeutic use;therapeutic use;therapeutic use;analysis",
        "_version_":1605899471205433344},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) is a clonal hematopoietic stem cell disorder characterized by Philadelphia chromosome and resultant production of the constitutively activated BCR-ABL tyrosine kinase. Imatinib (STI571), selective inhibitor of the ABL-tyrosine kinase, inhibits the activity of BCR-ABL tyrosine kinase. A phase I and II study of STI571 showed remarkable cytogenetic effect in patients with interferon-refractory CML, offering new hope for therapy for CML. It will, however, require long-term follow-up data from phase II and III clinical studies to validate the effect of STI571 on survival. As therapy for CML improves, monitoring minimal residual disease will be important.",
        "Doc_title":"[Antileukemic drug--a selective inhibitor of BCR-ABL tyrosine kynase, imatinib(STI571)].",
        "Journal":"Nihon rinsho. Japanese journal of clinical medicine",
        "Do_id":"11808344",
        "Doc_ChemicalList":"Benzamides;Piperazines;Pyrimidines;Imatinib Mesylate;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Animals;Benzamides;Blast Crisis;Clinical Trials, Phase I as Topic;Clinical Trials, Phase II as Topic;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Philadelphia Chromosome;Piperazines;Protein-Tyrosine Kinases;Pyrimidines",
        "Doc_meshqualifiers":"drug therapy;genetics;pharmacology;therapeutic use;antagonists & inhibitors;genetics;pharmacology;therapeutic use",
        "_version_":1605842350507032576},
      {
        "Doc_abstract":"The Bcr-abl tyrosine kinase inhibitor imatinib mesylate is the frontline therapy for chronic myeloid leukemia. Imatinib has been reported to cause congestive heart failure and left ventricular contractile dysfunction in patients and cardiomyopathy in rodents, findings proposed to be associated with its pharmacological activity. To investigate the specific role of Abelson oncogene 1 (c-Abl) in imatinib-induced cardiac toxicity, we performed targeted gene inhibition of c-Abl by RNA interference in neonatal cardiomyocytes (NCMs). Suppression of c-Abl did not lead to cytotoxicity or induction of endoplasmic reticulum (ER) stress. To further dis associate c-Abl from imatinib-induced cardiac toxicity, we designed imatinib structural analogs that do not have appreciable c-Abl inhibition in NCMs. The c-Abl inactive analogs induced cytotoxicity and ER stress, at similar or greater potencies and magnitudes as imatinib. Furthermore, combining c-Abl gene silencing with imatinib and analogs treatment did not significantly shift the cytotoxicity dose response curves. Imatinib and analogs were shown to accumulate in lysosomes, likely due to their physicochemical properties, and disrupt autophagy. The toxicity induced by imatinib and analogs can be rescued by bafilomycin A pretreatment, demonstrating the involvement of lysosomal accumulation in cardiac toxicity. The results from our studies strongly suggest that imatinib induces cardiomyocyte dysfunction through disruption of autophagy and induction of ER stress, independent of c-Abl inhibition.",
        "Doc_title":"Mechanistic investigation of imatinib-induced cardiac toxicity and the involvement of c-Abl kinase.",
        "Journal":"Toxicological sciences : an official journal of the Society of Toxicology",
        "Do_id":"22641616",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;DNA Primers;Piperazines;Pyrimidines;Imatinib Mesylate;Protein Kinases",
        "Doc_meshdescriptors":"Animals;Antineoplastic Agents;Base Sequence;Benzamides;DNA Primers;Heart;Imatinib Mesylate;Piperazines;Protein Kinases;Pyrimidines;RNA Interference;Rats;Reverse Transcriptase Polymerase Chain Reaction",
        "Doc_meshqualifiers":"toxicity;drug effects;toxicity;metabolism;toxicity",
        "_version_":1605746990212186112},
      {
        "Doc_abstract":"The (9;22) translocation which produces the Philadelphia (Ph1) chromosome activates the abl oncogene from chromosome 9 by recombination with the bcr gene from chromosome 22. This fusion gene is transcribed into a new 8.5-kilobase chimeric mRNA which is translated into a novel Mr 210,000 fusion protein which has a protein tyrosine kinase activity that is greatly increased in comparison to the activity of the normal abl protein. Studies from this laboratory and others have shown that virtually all patients with chronic myelogenous leukemia have this new bcr/abl fusion gene. In contrast to these findings in chronic myelogenous leukemia, a small number of patients with Ph1(+) acute lymphoblastic leukemia (ALL) have been studied and were found to lack the bcr/abl fusion gene [bcr(-)], but to have a new activation of abl, by recombination with an as yet undetermined region on chromosome 22. In this study, nine adults with Ph1(+)-ALL have been examined for evidence of a bcr/abl fusion gene. Of the nine patients, five have a bcr/abl recombination, whereas the remaining four patients do not. In contrast, the children studied to date have all been bcr(-). These data suggest that adults with Ph1(+)-ALL are a more heterogeneous group on a molecular level than are children, and that further studies will be required to determine the spectrum of molecular defects in patients with Ph1(+)-ALL, and the relationship of these various molecular defects to the clinical disease state of the individuals.",
        "Doc_title":"Molecular heterogeneity of adult Philadelphia chromosome-positive acute lymphoblastic leukemia.",
        "Journal":"Cancer research",
        "Do_id":"2827888",
        "Doc_ChemicalList":"DNA Restriction Enzymes",
        "Doc_meshdescriptors":"Adult;Chromosomes, Human, Pair 22;Chromosomes, Human, Pair 9;DNA Restriction Enzymes;Female;Humans;Leukemia, Lymphoid;Male;Middle Aged;Nucleic Acid Hybridization;Philadelphia Chromosome;Recombination, Genetic;Translocation, Genetic",
        "Doc_meshqualifiers":"genetics",
        "_version_":1605763386839138304},
      {
        "Doc_abstract":"Inhibition of Bcr-Abl kinase activity by imatinib for the treatment of chronic myeloid leukemia (CML) currently serves as the paradigm for targeting dominant oncogenes with small molecules. We recently reported the discovery of GNF-2 (1) and GNF-5 (2) as selective non-ATP competitive inhibitors of cellular Bcr-Abl kinase activity that target the myristate binding site. Here, we used cell-based structure-activity relationships to guide the optimization and diversification of ligands that are capable of binding to the myristate binding site and rationalize the findings based upon an Abl-compound 1 cocrystal. We elucidate the structure-activity relationships required to obtain potent antiproliferative activity against Bcr-Abl transformed cells and report the discovery of new compounds (5g, 5h, 6a, 14d, and 21j-I) that display improved potency or pharmacological properties. This work demonstrates that a variety of structures can effectively target the Bcr-Abl myristate binding site and provides new leads for developing drugs that can target this binding site.",
        "Doc_title":"Expanding the diversity of allosteric bcr-abl inhibitors.",
        "Journal":"Journal of medicinal chemistry",
        "Do_id":"20828158",
        "Doc_ChemicalList":"Antineoplastic Agents;Protein Kinase Inhibitors;Pyrimidines;Thiazoles;Fusion Proteins, bcr-abl;Dasatinib",
        "Doc_meshdescriptors":"Allosteric Regulation;Animals;Antineoplastic Agents;Binding Sites;Cell Line, Transformed;Dasatinib;Drug Synergism;Fusion Proteins, bcr-abl;Mice;Models, Molecular;Mutation;Protein Kinase Inhibitors;Pyrimidines;Structure-Activity Relationship;Thiazoles",
        "Doc_meshqualifiers":"chemical synthesis;chemistry;pharmacology;antagonists & inhibitors;genetics;chemical synthesis;chemistry;pharmacology;chemical synthesis;chemistry;pharmacology;pharmacology",
        "_version_":1605819672160108544},
      {
        "Doc_abstract":"Imatinib mesylate is a selective tyrosine kinase inhibitor of c-abl, bcr/abl, c-kit, and platelet-derived growth factor-receptor (PDGF-R). c-kit is expressed in most patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) and PDGF has been implicated in the pathogenesis of myeloproliferative disorders (MPD).;The authors investigated the efficacy of imatinib in patients with these disorders. Forty-eight patients with AML (n = 10), MDS (n = 8), myelofibrosis (n = 18), atypical chronic myeloid leukemia (CML; n = 7), chronic myelomonocytic leukemia (CMML; n = 3), or polycythemia vera (n = 2) were treated with imatinib 400 mg daily.;None of the patients with AML or MDS responded. Among patients with myelofibrosis, 10 of 14 patients with splenomegaly (71%) had a 30% or greater reduction in spleen size, 1 patient had trilineage hematologic improvement, 2 had erythroid hematologic improvement, and 1 had improvement in platelet count. One patient with atypical CML had erythroid hematologic improvement. Both patients with polycythemia vera needed fewer phlebotomies (from 2-3 per year to none during the 8 months of therapy and from 3-6 per year to 1 during 9 months of therapy). None of the three patients with CMML responded. Treatment was well tolerated. The side effects were similar to those observed in patients with CML.;Within these small subgroups of disease types, single-agent imatinib did not achieve a significant clinical response among patients with AML, MDS, atypical CML, or CMML without PDGF-R fusion genes. Preliminary data on polycythemia vera are promising and deserve further investigation. Responses among myelofibrosis patients were minor. Therefore, a combination treatment regimen including imatinib may be more effective.",
        "Doc_title":"Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.",
        "Journal":"Cancer",
        "Do_id":"12767088",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Pyrimidines;Imatinib Mesylate",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Antineoplastic Agents;Benzamides;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Leukemia, Myeloid, Acute;Leukemia, Myelomonocytic, Chronic;Middle Aged;Myelodysplastic Syndromes;Myeloproliferative Disorders;Piperazines;Polycythemia Vera;Primary Myelofibrosis;Pyrimidines;Recurrence",
        "Doc_meshqualifiers":"therapeutic use;toxicity;drug therapy;drug therapy;drug therapy;drug therapy;drug therapy;therapeutic use;toxicity;drug therapy;drug therapy;therapeutic use;toxicity",
        "_version_":1605762742086533120},
      {
        "Doc_abstract":"A 72-year-old female was diagnosed with chronic phase chronic myeloid leukemia (CML) in 2001. After a short course of treatment with hydroxycarbamide, imatinib (IM) 400 mg was started. A major molecular response was presumably acquired 10 months later. IM was discontinued after treatment for 47 months in November 2005. At the same time, BCR-ABL transcript was undetectable by nested RT-PCR assay, which was equivalent to <0.00138% BCR-ABL according to the international scale. The patient is still under observation with no additional therapy, and BCR-ABL has remained negative for 102 months, to date. Furthermore, interferon was never used in this patient. IM has dramatically improved the prognosis of CML. Since no cure has yet been established, patients are recommended to continue treatment even after achieving deep molecular responses. There are several ongoing clinical trials challenging the discontinuation of IM, but long-term observation is still lacking. The sustained deep molecular response, exceeding eight years, experienced in this patient is potentially encouraging. ",
        "Doc_title":"[Sustained deep molecular response over eight years after discontinuation of imatinib for chronic myeloid leukemia].",
        "Journal":"[Rinsho ketsueki] The Japanese journal of clinical hematology",
        "Do_id":"25744042",
        "Doc_ChemicalList":"Benzamides;Piperazines;Pyrimidines;RNA, Messenger;Imatinib Mesylate;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Aged;Benzamides;Female;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Piperazines;Prognosis;Pyrimidines;RNA, Messenger;Remission Induction;Time Factors",
        "Doc_meshqualifiers":"therapeutic use;genetics;diagnosis;drug therapy;genetics;therapeutic use;therapeutic use;analysis",
        "_version_":1605746343677001728},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) is a clonal hematopoietic disorder characterized by the presence of the Philadelphia chromosome which resulted from the reciprocal translocation between chromosomes 9 and 22. The pathogenesis of CML involves the constitutive activation of the BCR-ABL tyrosine kinase, which governs malignant disease by activating multiple signal transduction pathways. The BCR-ABL kinase inhibitor, imatinib, is the front-line treatment for CML, but the emergence of imatinib resistance and other tyrosine kinase inhibitors (TKIs) has called attention for additional resistance mechanisms and has led to the search for alternative drug treatments. In this paper, we discuss our current understanding of mechanisms, related or unrelated to BCR-ABL, which have been shown to account for chemoresistance and treatment failure. We focus on the potential role of the influx and efflux transporters, the inhibitor of apoptosis proteins, and transcription factor-mediated signals as feasible molecular targets to overcome the development of TKIs resistance in CML.",
        "Doc_title":"The Interface between BCR-ABL-Dependent and -Independent Resistance Signaling Pathways in Chronic Myeloid Leukemia.",
        "Journal":"Leukemia research and treatment",
        "Do_id":"23259070",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605880989840572416},
      {
        "Doc_abstract":"Co-existence of myeloproliferative disorders (MPD) and Janus associated kinase 2 mutation (JAK2 V617F) is a well-established fact. Only few case reports are available showing presence of JAK2 V617F mutation in chronic myeloid leukemia (CML). Purpose of this study was to determine the frequency of JAK2 V617F mutation in Philadelphia Chromosome positive (Ph (+)) CML patients in Pakistan.;The study was conducted from August 2009 to July 2010 at Civil Hospital and Baqai Institute of Hematology (BIH) Karachi. Blood samples from 25 patients with CML were collected. Multiplex reverse transcription polymerase chain reaction (RT-PCR) was performed for Breakpoint Cluster Region - Abelson (BCR-ABL) rearrangement. Conventional PCR was performed for JAK2 V617F mutation on BCR-ABL positive samples.;All 25 samples showed BCR-ABL rearrangement. Out of these 11 samples (44%) had JAK2 V617F mutation; the remaining 14 (56%) cases showed JAK2 617V wild type.;It is concluded that the co-existence of Ph (+)CML and JAK2 V617F mutation is possible.",
        "Doc_title":"Frequency of JAK2 V617F mutation in patients with Philadelphia positive Chronic Myeloid Leukemia in Pakistan.",
        "Journal":"Pakistan journal of medical sciences",
        "Do_id":"24639858",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605880217788743680},
      {
        "Doc_abstract":"The deregulated, oncogenic tyrosine kinase Bcr-Abl causes chronic myeloid leukemia (CML). Imatinib mesylate (Gleevec, STI571), a Bcr-Abl kinase inhibitor, selectively inhibits proliferation and promotes apoptosis of CML cells. Despite the success of imatinib mesylate in the treatment of CML, resistance is observed, particularly in advanced disease. The most common imatinib mesylate resistance mechanism involves Bcr-Abl kinase domain mutations that impart varying degrees of drug insensitivity. AP23464, a potent adenosine 5'-triphosphate (ATP)-based inhibitor of Src and Abl kinases, displays antiproliferative activity against a human CML cell line and Bcr-Abl-transduced Ba/F3 cells (IC(50) = 14 nM; imatinib mesylate IC(50) = 350 nM). AP23464 ablates Bcr-Abl tyrosine phosphorylation, blocks cell cycle progression, and promotes apoptosis of Bcr-Abl-expressing cells. Biochemical assays with purified glutathione S transferase (GST)-Abl kinase domain confirmed that AP23464 directly inhibits Abl activity. Importantly, the low nanomolar cellular and biochemical inhibitory properties of AP23464 extend to frequently observed imatinib mesylate-resistant Bcr-Abl mutants, including nucleotide binding P-loop mutants Q252H, Y253F, E255K, C-terminal loop mutant M351T, and activation loop mutant H396P. AP23464 was ineffective against mutant T315I, an imatinib mesylate contact residue. The potency of AP23464 against imatinib mesylate-refractory Bcr-Abl and its distinct binding mode relative to imatinib mesylate warrant further investigation of AP23464 for the treatment of CML.",
        "Doc_title":"Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.",
        "Journal":"Blood",
        "Do_id":"15256422",
        "Doc_ChemicalList":"AP23464;Adaptor Proteins, Signal Transducing;Amino Acids;Benzamides;CRKL protein;DNA-Binding Proteins;Enzyme Inhibitors;Milk Proteins;Nuclear Proteins;PD 173955;Piperazines;Pyridones;Pyrimidines;STAT5 Transcription Factor;Trans-Activators;Phosphotyrosine;Imatinib Mesylate;Adenosine Triphosphate;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adaptor Proteins, Signal Transducing;Adenosine Triphosphate;Amino Acids;Apoptosis;Benzamides;Cell Cycle;Cell Division;DNA-Binding Proteins;Enzyme Inhibitors;Fusion Proteins, bcr-abl;Gene Expression Regulation, Neoplastic;HL-60 Cells;Humans;Imatinib Mesylate;Inhibitory Concentration 50;K562 Cells;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Milk Proteins;Models, Molecular;Mutation;Nuclear Proteins;Phosphorylation;Phosphotyrosine;Piperazines;Protein Structure, Tertiary;Pyridones;Pyrimidines;STAT5 Transcription Factor;Trans-Activators",
        "Doc_meshqualifiers":"metabolism;analogs & derivatives;chemistry;pharmacology;genetics;metabolism;drug effects;drug effects;drug effects;metabolism;chemistry;pharmacology;antagonists & inhibitors;chemistry;genetics;metabolism;enzymology;genetics;pathology;metabolism;genetics;metabolism;drug effects;metabolism;chemistry;pharmacology;chemistry;pharmacology;chemistry;pharmacology;metabolism",
        "_version_":1605801059470540800},
      {
        "Doc_abstract":"The tyrosine kinase (TK) inhibitor, imatinib, has revolutionized therapy of malignancies that are addicted to one of its target kinases, c-abl, c-kit and PDGF-R. This addiction is generally dependent on the acquisition of an activating kinase mutation, e.g., the bcr-abl fusion gene in chronic myeloid leukemia, or point mutations of KIT or PDGFRA in gastrointestinal stroma tumors (GIST). Other types of sarcomas are generally considered to be insensitive to imatinib. We have observed a striking and durable remission of an advanced angiosarcoma to imatinib that can only be explained by TK addiction. Unexpectedly, GIST-type KIT and PDGFRA mutations were absent in this case. This case illustrates the diagnostic challenges in identifying individual candidate patients for TK inhibitor therapy.",
        "Doc_title":"Dramatic and durable efficacy of imatinib in an advanced angiosarcoma without detectable KIT and PDGFRA mutations.",
        "Journal":"Cancer biology & therapy",
        "Do_id":"19182535",
        "Doc_ChemicalList":"Antigens, CD31;Antigens, CD34;Benzamides;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Imatinib Mesylate;Proto-Oncogene Proteins c-kit;Receptor, Platelet-Derived Growth Factor alpha",
        "Doc_meshdescriptors":"Administration, Oral;Antigens, CD31;Antigens, CD34;Benzamides;Hemangiosarcoma;Humans;Imatinib Mesylate;Male;Middle Aged;Mutation;Peritoneal Neoplasms;Piperazines;Protein Kinase Inhibitors;Proto-Oncogene Proteins c-kit;Pyrimidines;Receptor, Platelet-Derived Growth Factor alpha;Sequence Analysis, DNA",
        "Doc_meshqualifiers":"biosynthesis;biosynthesis;drug therapy;genetics;metabolism;drug effects;drug therapy;genetics;metabolism;administration & dosage;administration & dosage;biosynthesis;genetics;administration & dosage;genetics",
        "_version_":1605797967246131200},
      {
        "Doc_abstract":"The BCR-ABL fusion, the molecular equivalent of the Philadelphia translocation, gains importance for treatment stratification in adult acute lymphoblastic leukemia (ALL). In this prospective study, samples from 478 patients with CD10(+) B-cell precursor ALL (c-ALL and pre-B ALL) underwent BCR-ABL reverse transcription-polymerase chain reaction (RT-PCR) analysis with double testing of positive samples. Patients were stratified according to the PCR result and treated in 2 German Multicenter Trials of Adult ALL. The outcome was followed and the prognostic impact of BCR-ABL was compared to clinical risk features. Of the 478 samples, 432 had an evaluable BCR-ABL result. Thirty-seven percent of the c-ALL and pre-B ALL patients were BCR-ABL(+) (p190, 77%; p210, 20%; simultaneous p190/p210, 3%). BCR-ABL positivity was associated with the high-risk features of older age (45 years versus 30 years median age; P =.0001) and higher white blood cell counts (23 500/microL versus 11 550/microL; P =.0001). Univariate and multivariate analyses revealed BCR-ABL as the leading factor for a poor prognosis (P =.0001) in comparison to clinical risk criteria. Irrespective of the breakpoint, presence of any BCR-ABL transcript predicted a lower chance of initial treatment response (68.4% versus 84.6%; P =.001) and a lower probability of disease-free survival at 3 years (0.13 versus 0.47; P =.0001). This bad outcome was not influenced by postinduction high-dose treatment stratifications. The results show a high prevalence of BCR-ABL fusion transcripts with predominance of p190. BCR-ABL RT-PCR is confirmed as a sensitive, rapid method to diagnose t(9;22), and p190 and p210 are unequivocally demonstrated as the most important predictors of poor long-term survival despite intensified chemotherapy.",
        "Doc_title":"Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis.",
        "Journal":"Blood",
        "Do_id":"11861265",
        "Doc_ChemicalList":"DNA Primers;RNA, Messenger;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Burkitt Lymphoma;Cytogenetic Analysis;DNA Primers;Female;Fusion Proteins, bcr-abl;Humans;Male;Middle Aged;Polymerase Chain Reaction;Precursor B-Cell Lymphoblastic Leukemia-Lymphoma;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Prognosis;Prospective Studies;RNA, Messenger;Survival Rate;Translocation, Genetic;Treatment Outcome",
        "Doc_meshqualifiers":"genetics;mortality;pathology;genetics;genetics;mortality;pathology;genetics;mortality;pathology;analysis;genetics",
        "_version_":1605844321010974720},
      {
        "Doc_abstract":"Resistance and intolerance to imatinib are of particular clinical relevance to Asian patients because of their lower body surface area. Dasatinib is 325-fold more potent than imatinib in inhibiting BCR-ABL in vitro and is indicated for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib. Data from a series of phase I/II research trials were analyzed to compare the efficacy, safety and pharmacokinetic profile of dasatinib 70 mg twice daily in Asian and non-Asian patients. Results from 55 Asian and 615 non-Asian patients demonstrated that the efficacy and safety of dasatinib was comparable. Dasatinib was well tolerated, with no observed toxicities exclusive to Asian patients. A higher incidence of adverse events and lower rate of response observed among Asian patients with myeloid blast phase CML reflected the aggressive nature of the disease. Analyses of noncompartmental pharmacokinetics (5 Asian and 49 non-Asian patients) and population pharmacokinetics (17 Asian and 382 non-Asian patients) were also comparable. The efficacy, safety and pharmacokinetic profile of dasatinib 70 mg twice daily is similar in Asian and non-Asian patients with CML. Dasatinib is therefore an important therapeutic option for this patient population.",
        "Doc_title":"Clinical profile of dasatinib in Asian and non-Asian patients with chronic myeloid leukemia.",
        "Journal":"International journal of hematology",
        "Do_id":"19455391",
        "Doc_ChemicalList":"Pyrimidines;Thiazoles;Dasatinib",
        "Doc_meshdescriptors":"Asian Continental Ancestry Group;Clinical Trials as Topic;Dasatinib;Data Interpretation, Statistical;Drug Evaluation;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Pyrimidines;Thiazoles;Treatment Outcome",
        "Doc_meshqualifiers":"statistics & numerical data;statistics & numerical data;drug therapy;adverse effects;pharmacokinetics;therapeutic use;adverse effects;pharmacokinetics;therapeutic use",
        "_version_":1605797743047999488},
      {
        "Doc_abstract":"Dasatinib is a small-molecule inhibitor of multiple tyrosine kinases, including BCR-ABL, SRC, c-KIT, ephrin A receptor and platelet-derived growth factor-beta receptor kinases, at nanomolar concentrations. In vitro, dasatinib is 325-fold more potent than imatinib against cells expressing wild-type BCR-ABL. The efficacy and tolerability of oral dasatinib has been established in the START phase II trials in adults with chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-positive ALL) who were intolerant or resistant to imatinib, and optimal dasatinib dosage regimens were identified in phase III randomized trials. In patients with chronic phase CML, the major cytogenetic response rate in the START-C trial (median follow-up 15.2 months) was 59% with dasatinib, and in the randomized START-R trial (median follow-up 15 months), was greater with dasatinib than with high-dose imatinib (52% vs 33%). Major hematologic response rates with dasatinib were 63% in patients with accelerated phase CML (follow-up > or =9 months; START-A trial), 34% in patients with myeloid blast phase CML and 35% in those with lymphoid blast phase CML (follow-up > or =12 months; START-B and START-L trials), and 41% in patients with Ph-positive ALL (follow-up > or =12 months; START-L trial). Based on phase III results, a once-daily dasatinib regimen is considered optimal in chronic phase CML (starting dosage 100 mg once daily), while a twice-daily regimen continues to be recommended in accelerated phase, myeloid blast phase or lymphoid blast phase CML and Ph-positive ALL (starting dosage 70 mg twice daily). Adverse events were frequent in patients treated with dasatinib, but most were mild to moderate in severity. Grade 3/4 adverse events were uncommon and were clinically manageable.",
        "Doc_title":"Dasatinib: in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.",
        "Journal":"BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy",
        "Do_id":"18215092",
        "Doc_ChemicalList":"Protein Kinase Inhibitors;Pyrimidines;Thiazoles;Dasatinib",
        "Doc_meshdescriptors":"Animals;Controlled Clinical Trials as Topic;Dasatinib;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Protein Kinase Inhibitors;Pyrimidines;Thiazoles",
        "Doc_meshqualifiers":"drug therapy;drug therapy;administration & dosage;adverse effects;pharmacokinetics;administration & dosage;adverse effects;pharmacokinetics;administration & dosage;adverse effects;pharmacokinetics",
        "_version_":1605804790072213504},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) starts with the acquisition of a BCR-ABL fusion gene in a single hematopoietic stem cell, but the time to progression is unpredictable. Although the tyrosine kinase inhibitor imatinib mesylate is highly effective in the treatment of CML, its continuous administration is associated with development of resistance, particularly in advanced phase or blast crisis. We investigate here whether a feature of disease progression (i.e., elevated expression of Bcr-Abl in CD34+ progenitor cells from CML patients in blast crisis) has any bearing on the kinetics of resistance to imatinib. By studying cell lines that exogenously express Bcr-Abl over the range found from chronic phase to blast crisis of CML, we show that cells expressing high amounts of Bcr-Abl, as in blast crisis, are much less sensitive to imatinib and, more significantly, take a substantially shorter time for yielding a mutant subclone resistant to the inhibitor than cells with low expression levels, as in chronic phase. Our data suggest that the differential levels of the Bcr-Abl oncoprotein expressed by CD34+ CML cells may reflect the extent and duration of their response to imatinib; the relatively high levels of oncoprotein in advanced-phase disease may underlie the observed rapid development of resistance.",
        "Doc_title":"Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.",
        "Journal":"Cancer research",
        "Do_id":"16204063",
        "Doc_ChemicalList":"Adaptor Proteins, Signal Transducing;Antineoplastic Agents;Benzamides;CRKL protein;Nuclear Proteins;Piperazines;Pyrimidines;STAT5 Transcription Factor;Imatinib Mesylate;Fusion Proteins, bcr-abl;Proto-Oncogene Proteins c-abl",
        "Doc_meshdescriptors":"Adaptor Proteins, Signal Transducing;Antineoplastic Agents;Benzamides;Blast Crisis;Cell Line, Tumor;Drug Resistance, Neoplasm;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Nuclear Proteins;Phosphorylation;Piperazines;Protein Structure, Tertiary;Proto-Oncogene Proteins c-abl;Pyrimidines;STAT5 Transcription Factor;Stem Cells",
        "Doc_meshqualifiers":"metabolism;pharmacology;genetics;metabolism;biosynthesis;genetics;drug therapy;genetics;metabolism;pathology;metabolism;pharmacology;biosynthesis;genetics;metabolism;pharmacology;metabolism;metabolism;pathology",
        "_version_":1605789582366867456},
      {
        "Doc_abstract":"Although differentiation of leukemic blasts to dendritic cells (DC) has promise in vaccine strategies, the mechanisms underlying this differentiation and the differences between leukemia and normal progenitor-derived DC are largely undescribed. In the case of chronic myeloid leukemia (CML), understanding the relationship between the induction of DC differentiation and the expression of the BCR-ABL oncogene has direct relevance to CML biology as well as the development of new therapeutic approaches. We now report that direct activation of protein kinase C (PKC) by the phorbol ester PMA in the BCR-ABL(+) CML cell line K562 and primary CML blasts induced nonterminal differentiation into cells with typical DC morphology (cytoplasmic dendrites), characteristic surface markers (MHC class I, MHC class II, CD86, CD40), chemokine and transcription factor expression, and ability to stimulate T cell proliferation (equivalent to normal monocyte-derived DC). PKC-induced differentiation was associated with down-regulation of BCR-ABL mRNA expression, protein levels, and kinase activity. This down-regulation appeared to be signaled through the mitogen-activated protein kinase pathway. Therefore, PKC-driven differentiation of CML blasts into DC-like cells suggests a potentially novel strategy to down-regulate BCR-ABL activity, yet raises the possibility that CML-derived DC vaccines will be less effective in presenting leukemia-specific Ags.",
        "Doc_title":"Induced dendritic cell differentiation of chronic myeloid leukemia blasts is associated with down-regulation of BCR-ABL.",
        "Journal":"Journal of immunology (Baltimore, Md. : 1950)",
        "Do_id":"12902478",
        "Doc_ChemicalList":"Cytokines;Proto-Oncogene Proteins;Tumor Necrosis Factor-alpha;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl;BCR protein, human;Proto-Oncogene Proteins c-bcr;Protein Kinase C;Tetradecanoylphorbol Acetate;Calcium",
        "Doc_meshdescriptors":"Blast Crisis;Calcium;Cell Differentiation;Cell Division;Cell Lineage;Cells, Cultured;Cytokines;Dendritic Cells;Down-Regulation;Enzyme Activation;Fusion Proteins, bcr-abl;Gene Expression Regulation, Neoplastic;Genes, abl;Humans;Intracellular Fluid;K562 Cells;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Protein Kinase C;Protein-Tyrosine Kinases;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-bcr;Signal Transduction;Tetradecanoylphorbol Acetate;Tumor Cells, Cultured;Tumor Necrosis Factor-alpha",
        "Doc_meshqualifiers":"genetics;immunology;pathology;metabolism;physiology;drug effects;genetics;immunology;drug effects;immunology;genetics;immunology;pharmacology;enzymology;pathology;genetics;drug effects;genetics;antagonists & inhibitors;biosynthesis;genetics;drug effects;immunology;immunology;metabolism;genetics;immunology;pathology;metabolism;physiology;antagonists & inhibitors;biosynthesis;genetics;genetics;immunology;pharmacology;pharmacology",
        "_version_":1605881381532991488},
      {
        "Doc_abstract":"Mutations within the BCR-ABL kinase domain in imatinib-treated chronic myeloid leukemia (CML) are the main mechanism of acquired resistance. The early detection of mutations should provide clinical benefit by allowing early intervention. Quantitative polymerase chain reaction (RQ-PCR) results of BCR-ABL mRNA were correlated with mutation analysis in 214 patients treated with imatinib. We determined whether there was a difference in the incidence of mutations between the patients with a more than 2-fold rise in BCR-ABL and patients with stable or decreasing levels. Of the 56 patients with a more than 2-fold rise, 34 (61%) had detectable mutations (median rise, 3.0-fold; 25th-75th percentiles, 2.3-5.2). In 31 (91%) of these 34 patients, the mutation was present at the time of the rise and became detectable within 3 months in the remaining patients. Only 1 (0.6%) of 158 patients with stable or decreasing BCR-ABL levels had a detectable mutation, P less than .0001. Thus, a more than 2-fold rise identified 34 (97%) of 35 patients with a mutation. We conclude that a rise in BCR-ABL of more than 2-fold can be used as a primary indicator to test patients for BCR-ABL kinase domain mutations.",
        "Doc_title":"Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations.",
        "Journal":"Blood",
        "Do_id":"15256429",
        "Doc_ChemicalList":"Benzamides;Piperazines;Pyrimidines;RNA, Messenger;Imatinib Mesylate;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Benzamides;DNA Mutational Analysis;Drug Monitoring;Drug Resistance, Neoplasm;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Piperazines;Polymerase Chain Reaction;Predictive Value of Tests;Protein Structure, Tertiary;Pyrimidines;RNA, Messenger",
        "Doc_meshqualifiers":"methods;methods;genetics;blood;genetics;drug therapy;genetics;pathology;therapeutic use;methods;genetics;therapeutic use;blood",
        "_version_":1605759316151762944},
      {
        "Doc_abstract":"Although Imatinib has transformed the treatment of chronic myeloid leukemia (CML), it is not curative due to the persistence of resistant cells that can regenerate the disease. We have examined how Bcr-Abl-expressing cells respond to two mechanistically different therapeutic agents, etoposide and Imatinib. We also examined Bcr-Abl expression at low and high levels as elevated expression has been associated with treatment failure. Cells expressing low levels of Bcr-Abl undergo apoptosis in response to the DNA-targeting agent (etoposide), whereas high-Bcr-Abl-expressing cells primarily induce autophagy. Autophagic populations engage a delayed nonapoptotic death; however, sufficient cells evade this and repopulate following the withdrawal of the drug. Non-Bcr-Abl-expressing 32D or Ba/F3 cells induce both apoptosis and autophagy in response to etoposide and can recover. Imatinib treatment induces both apoptosis and autophagy in all Bcr-Abl-expressing cells and populations rapidly recover. Inhibition of autophagy with ATG7 and Beclin1 siRNA significantly reduced the recovery of Imatinib-treated K562 cells, indicating the importance of autophagy for the recovery of treated cells. Combination regimes incorporating agents that disrupt Imatinib-induced autophagy would remain primarily targeted and may improve response to the treatment in CML.",
        "Doc_title":"Autophagy induction by Bcr-Abl-expressing cells facilitates their recovery from a targeted or nontargeted treatment.",
        "Journal":"American journal of hematology",
        "Do_id":"21132731",
        "Doc_ChemicalList":"Benzamides;Piperazines;Pyrimidines;RNA, Small Interfering;Etoposide;Doxorubicin;Imatinib Mesylate;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Animals;Autophagy;Benzamides;Cell Line, Tumor;DNA Damage;Doxorubicin;Etoposide;Fusion Proteins, bcr-abl;Gene Knockdown Techniques;Humans;Imatinib Mesylate;K562 Cells;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mice;Molecular Targeted Therapy;Piperazines;Pyrimidines;RNA, Small Interfering;Transfection",
        "Doc_meshqualifiers":"drug effects;genetics;pharmacology;pharmacology;biosynthesis;genetics;drug therapy;genetics;metabolism;methods;pharmacology;pharmacology;administration & dosage;genetics",
        "_version_":1605903886775746560},
      {
        "Doc_abstract":"Imatinib mesylate is a small molecule drug that in vitro inhibits the Abelson (Abl), Arg (abl-related gene), stem cell factor receptor (Kit), and platelet-derived growth factor receptor A and B (PDGFRA and PDGFRB) tyrosine kinases. The drug has acquired therapeutic relevance because of similar inhibitory activity against certain activating mutations of these molecular targets. The archetypical disease in this regard is chronic myeloid leukemia, where abl is constitutively activated by fusion with the bcr gene (bcr/abl). Similarly, the drug has now been shown to display equally impressive therapeutic activity in eosinophilia-associated chronic myeloproliferative disorders that are characterized by activating mutations of either the PDGFRB or the PDGFRA gene. The former usually results from translocations involving chromosome 5q31-33, and the latter usually results from an interstitial deletion involving chromosome 4q12 (FIP1L1-PDGFRA). In contrast, imatinib is ineffective, in vitro and in vivo, against the mastocytosis-associated c-kit D816V mutation. However, wild-type and other c-kit mutations might be vulnerable to the drug, as has been the case in gastrointestinal stomal cell tumors. Imatinib is considered investigational for the treatment of hematologic malignancies without a defined molecular drug target, such as polycythemia vera, myelofibrosis with myeloid metaplasia, and acute myeloid leukemia.",
        "Doc_title":"Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders.",
        "Journal":"Blood",
        "Do_id":"15166033",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Pyrimidines;Imatinib Mesylate;Protein-Tyrosine Kinases;Receptor, Platelet-Derived Growth Factor beta;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Antineoplastic Agents;Benzamides;Chromosomes, Human, Pair 5;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Mastocytosis;Metaplasia;Mutation;Myeloproliferative Disorders;Piperazines;Protein Structure, Tertiary;Protein-Tyrosine Kinases;Pyrimidines;Receptor, Platelet-Derived Growth Factor beta;Translocation, Genetic",
        "Doc_meshqualifiers":"pharmacology;metabolism;pathology;drug therapy;genetics;pharmacology;metabolism;pharmacology;metabolism",
        "_version_":1605903485798187008},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) is genetically characterized by the occurrence of a reciprocal translocation t(9;22)(q34;q11), resulting in a BCR/ABL gene fusion on the derivative chromosome 22, i.e. the Philadelphia (Ph) chromosome. During CML progression 60-80% of the cases acquire additional genetic changes. Even though hyperdiploidy is not a rare finding in advanced phase-CML, hyperdiploidy together with a T315I kinase domain (KD) mutation in the BCR-ABL gene has not yet been reported.;A complete cytogenetic and molecular cytogenetic analysis; molecular biology methods such as quantitative reverse transcription polymerase chain reaction (RQ-PCR) and allele-specific oligonucleotide (ASO)-PCR; and immunophenotypically confirmed CML in acceleration phase (AP). Our case revealed the presence of hyperdiploidy including multiple copies of the Ph chromosome, presence of b3a2 fusion transcript,T315I mutation in BCR-ABL KD in pre imatinib mesylate (IM) treatment. The ratio of BCR-ABL/ABL expression in post nilotinib treatment was 0.07% on international scale.;The patient demonstrated a good response to nilotinib after imatinib failure; while the hyperdiploid clone disappeared the T315I mutation remained during follow-up. The underlying mechanisms and prognostic implications of these cytogenetic abnormalities are discussed.",
        "Doc_title":"Hyperdiploidy associated with T315I mutation in BCR-ABL kinase domain in an accelerated phase-chronic myeloid leukemia case.",
        "Journal":"Molecular cytogenetics",
        "Do_id":"25621010",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605810424898387968},
      {
        "Doc_abstract":"Cytokine-provided survival signals are known to suppress apoptosis through inhibition of mitochondrial pathways that involve Bcl-2 family members. Here we show that in hematopoietic cells, cytokines also regulate death receptor-mediated pathways. We demonstrate that hematopoietic cytokines such as IL-3 and erythropoietin in normal cells, as well as BCR-ABL oncoprotein in transformed cells, inhibit transcription of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Using small interfering RNAs, we show that the inhibition of TRAIL function is sufficient to partially rescue cytokine-deprived cells from apoptosis. Finally, we demonstrate that cytokine and BCR-ABL suppression of TRAIL transcription is mediated through phosphorylation and inhibition of the forkhead FOXO3a transcription factor. BCR-ABL-induced inhibition of TRAIL transcription in hematopoietic cells may provide a novel mechanism for tumorigenicity in chronic myeloid leukemia.",
        "Doc_title":"Cytokines and BCR-ABL mediate suppression of TRAIL-induced apoptosis through inhibition of forkhead FOXO3a transcription factor.",
        "Journal":"Proceedings of the National Academy of Sciences of the United States of America",
        "Do_id":"12750477",
        "Doc_ChemicalList":"Apoptosis Regulatory Proteins;Cytokines;DNA Primers;DNA-Binding Proteins;Membrane Glycoproteins;TNF-Related Apoptosis-Inducing Ligand;Transcription Factors;Tumor Necrosis Factor-alpha;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Apoptosis;Apoptosis Regulatory Proteins;Base Sequence;Cell Line;Cytokines;DNA Primers;DNA-Binding Proteins;Electrophoretic Mobility Shift Assay;Fusion Proteins, bcr-abl;Membrane Glycoproteins;Reverse Transcriptase Polymerase Chain Reaction;TNF-Related Apoptosis-Inducing Ligand;Transcription Factors;Tumor Necrosis Factor-alpha",
        "Doc_meshqualifiers":"physiology;physiology;antagonists & inhibitors;physiology;physiology;antagonists & inhibitors;physiology",
        "_version_":1605891478225158144},
      {
        "Doc_abstract":"The Bcr-Abl fusion protein arising through the t(9;22)(q34;q11) reciprocal translocation is the causative agent in chronic myeloid leukemia and a subset of acute lymphocytic leukemia. Imatinib mesylate is a specific inhibitor of the Bcr-Abl kinase and has shown promising results in clinical studies. The structural relation between the Bcr-Abl oncogene and the tyrosine kinase inhibitor imatinib has recently been elucidated by an elegant crystal structure analysis, emphasizing the importance of dephosphorylated tyrosine 393 (Tyr393) in Bcr-Abl for access of the inhibitor to the kinase domain. By mutating this tyrosine to phenylalanine and thereby mimicking a constitutively dephosphorylated state, we now show that Ba/F3 cells transformed by this mutant demonstrate an increased sensitivity towards imatinib in vivo. This effect is not due to an impaired kinase activity of Bcr-Abl Y393F, since a synthetic substrate is phosphorylated with similar kinetics. Treatment of Ba/F3 cells transfected with Bcr-Abl wild type with a phosphatase inhibitor diminished the effect of imatinib, but did not influence the growth of Ba/F3 cells transfected with Bcr-AblY393F. The results support the findings of the crystal structure and indicate that Tyr393 indeed plays a significant role for the sensitivity of Bcr-Abl towards imatinib in vivo. These data implicate the regulation of Tyr393 phosphorylation as a potential mechanism of imatinib resistance.",
        "Doc_title":"Phosphorylation of tyrosine 393 in the kinase domain of Bcr-Abl influences the sensitivity towards imatinib in vivo.",
        "Journal":"Leukemia",
        "Do_id":"12970766",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;DNA-Binding Proteins;Milk Proteins;Piperazines;Pyrimidines;STAT5 Transcription Factor;Trans-Activators;Tyrosine;Imatinib Mesylate;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Antineoplastic Agents;Benzamides;Cell Division;Cell Line;DNA-Binding Proteins;Fusion Proteins, bcr-abl;Gene Expression Regulation, Neoplastic;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Milk Proteins;Mutagenesis, Site-Directed;Mutation;Phosphorylation;Piperazines;Pyrimidines;STAT5 Transcription Factor;Trans-Activators;Transfection;Tyrosine",
        "Doc_meshqualifiers":"therapeutic use;drug effects;drug effects;metabolism;metabolism;drug therapy;metabolism;genetics;therapeutic use;therapeutic use;metabolism;metabolism",
        "_version_":1605821870340308992},
      {
        "Doc_abstract":"Previous studies have shown that leukemogenic chromosomal translocations, including fusions between Break point Cluster Region (BCR) and Abelson (ABL) are present in the peripheral blood of healthy individuals. The aim of this study was to gain insights into the genetic alterations other than BCR-Abl translocation in molecular level, which cause chronic myeloid leukemia (CML).;We performed whole-exome sequencing on four cases representative of BCR-ABL positive CML in chronic phase of the disease.;We did not identify any pathogenic mutation in all known genes involved in CML or other cancers in our subjects. Nevertheless, we identified polymorphisms in related genes.;It is the first report of exome sequencing in Philadelphia chromosome positive CML patients. We did not identify any pathogenic mutation in known cancer genes in our patients who can be due to CML pathogenesis or technical limitations.",
        "Doc_title":"Whole Exome Sequencing of Chronic Myeloid Leukemia Patients.",
        "Journal":"Iranian journal of public health",
        "Do_id":"27141497",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605810343505821696},
      {
        "Doc_abstract":"Chronic myeloid leukemia is a neoplasia resulting from a translocation between chromosomes 9 and 22 producing the BCR-ABL hybrid known as the Philadelphia chromosome (Ph). In chronic myeloid leukemia a proliferation of malignant myeloid cells occurs in the bone marrow due to excessive tyrosine kinase activity. In order to maintain homeostasis, natural killer cells, by means of receptors, identify the major histocompatibility complex on the surface of tumor cells and subsequently induce apoptosis. The NKG2D receptor in the natural killer cells recognizes the transmembrane proteins related to major histocompatibility complex class I chain-related genes A and B (MICA and MICB), and it is by the interaction between NKG2D and MICA that natural killer cells exert cytotoxic activity against chronic myeloid leukemia tumor cells. However, in the case of chronic exposure of the NKG2D receptor, the MICA ligand releases soluble proteins called sMICA from the tumor cell surface, which negatively modulate NKG2D and enable the tumor cells to avoid lysis mediated by the natural killer cells. Blocking the formation of sMICA may be an important antitumor strategy. Treatment using tyrosine kinase inhibitors induces modulation of NKG2DL expression, which could favor the activity of the natural killer cells. However this mechanism has not been fully described in chronic myeloid leukemia. In the present study, we analyze the role of natural killer cells to reduce proliferation and in the cellular death of tumor cells in chronic myeloid leukemia.",
        "Doc_title":"The role of natural killer cells in chronic myeloid leukemia.",
        "Journal":"Revista brasileira de hematologia e hemoterapia",
        "Do_id":"23049299",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605884036726652928},
      {
        "Doc_abstract":"In patients with Chronic Myeloid Leukemia (CML), the neoplastic (Bcr-Abl+) progenitors are characterised by an increased proliferative activity. These cells appear to become resistant to apoptosis following growth factor withdraw. We demonstrate that despite this property, Bcr-Abl transformed cells (primitive hematopoietic progenitors or cell lines) remains sensitive to apoptosis induced by Ceramides analogues. This effect is dose dependent and occurs faster in transformed cells as compared to their normal counterparts. In addition to the classical features of apoptosis, we observed that Ceramide-treated CML cells display a rapid and sequential activation of the Bcr-Abl and PI3 kinases. We then demonstrated the role of the Bcr-Abl kinase activity in the accelerated response observed in CML cells treated by Ceramide. The PI3 kinase seems to be partly involved in the accelerated Phosphatidyl-Serine exposure observed in Bcr-Abl transformed cells. Finally, we observed that Ceramide-induced apoptosis does not seem to implicate a Bcl2 protein modulation. Taken together these results support the hypothesis of at least two independent signaling pathways initiating programmed cell death: one will be involved in apoptosis mediated by signals such as cytokine-starving is blocked by the Bcr-Abl fusion protein while the other one initiated by Ceramide is accelerated by the Bcr-Abl protein.",
        "Doc_title":"CML and apoptosis: the ceramide pathway.",
        "Journal":"Hematology and cell therapy",
        "Do_id":"9844818",
        "Doc_ChemicalList":"Ceramides;Growth Substances;Proto-Oncogene Proteins c-bcl-2;Phosphatidylinositol 3-Kinases;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Apoptosis;Cell Division;Cell Survival;Cell Transformation, Neoplastic;Ceramides;Fusion Proteins, bcr-abl;Growth Substances;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Phosphatidylinositol 3-Kinases;Phosphorylation;Proto-Oncogene Proteins c-bcl-2;Signal Transduction",
        "Doc_meshqualifiers":"drug effects;drug effects;drug effects;therapeutic use;physiology;pharmacology;drug therapy;pathology;metabolism;physiology;drug effects",
        "_version_":1605742069998944257},
      {
        "Doc_abstract":"The recent success in treating chronic myeloid leukemia (CML) with tyrosine kinase inhibitors (TKI), such as imatinib mesylate (IM), has created a demand for reproducible methods to accurately assess inhibition of BCR-ABL activity within CML cells, including rare stem and progenitor cells, either in vitro or in vivo. The purpose of this study was to develop an enzyme-linked immunosorbent (ELISA) method to measure total tyrosine phosphorylation (P-Tyr) in small samples of cells that express BCR-ABL and to compare to more established methods.;The assay was first validated in BCR-ABL wild-type and mutant vs BCR-ABL-negative cell lines. P-Tyr levels were then measured by ELISA in primary CD34(+) CML cells treated with IM.;In vitro exposure to TKI resulted in decreases in the level of P-Tyr, in both BCR-ABL-positive cell lines and primary CD34(+) CML samples, which were comparable to the reduction in P-Tyr by flow cytometry and phosphorylation of CrkL by either Western blot or flow cytometry.;We have developed an accurate ELISA method to measure BCR-ABL activity within Ph(+) cells, which is comparable to other in vitro BCR-ABL assessment techniques in terms of sensitivity and could be adapted for high throughput.",
        "Doc_title":"Optimization of methods for the detection of BCR-ABL activity in Philadelphia-positive cells.",
        "Journal":"Experimental hematology",
        "Do_id":"19135772",
        "Doc_ChemicalList":"Tyrosine;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Enzyme-Linked Immunosorbent Assay;Fusion Proteins, bcr-abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Methods;Phosphorylation;Research Design;Tyrosine",
        "Doc_meshqualifiers":"methods;standards;analysis;pathology;analysis",
        "_version_":1605765433037684736},
      {
        "Doc_abstract":"Resistance toward imatinib and other BCR/ABL tyrosine kinase inhibitors remains an increasing clinical problem in the treatment of advanced stages of chronic myeloid leukemia (CML). We recently have identified the heat shock protein 32 (Hsp32)/heme oxygenase-1 (HO-1) as a BCR/ABL-dependent survival molecule in CML cells. We here show that silencing Hsp32/HO-1 in CML cells by an siRNA approach results in induction of apoptosis. Moreover, targeting Hsp32/HO-1 by either pegylated zinc protoporphyrine (PEG-ZnPP) or styrene maleic acid-micelle-encapsulated ZnPP (SMA-ZnPP) resulted in growth inhibition of BCR/ABL-transformed cells. The effects of PEG-ZnPP and SMA-ZnPP were demonstrable in Ba/F3 cells carrying various imatinib-resistant mutants of BCR/ABL, including the T315I mutant, which exhibits resistance against all clinically available BCR/ABL tyrosine kinase inhibitors. Growth-inhibitory effects of PEG-ZnPP and SMA-ZnPP also were observed in the CML-derived human cell lines K562 and KU812 as well as in primary leukemic cells obtained from patients with freshly diagnosed CML or imatinib-resistant CML. Finally, Hsp32/HO-1-targeting compounds were found to synergize with either imatinib or nilotinib in producing growth inhibition in imatinib-resistant K562 cells and in Ba/F3 cells harboring the T315I mutant of BCR/ABL. In summary, these data show that HO-1 is a promising novel target in imatinib-resistant CML.",
        "Doc_title":"Targeting of heat shock protein 32 (Hsp32)/heme oxygenase-1 (HO-1) in leukemic cells in chronic myeloid leukemia: a novel approach to overcome resistance against imatinib.",
        "Journal":"Blood",
        "Do_id":"18024796",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Pyrimidines;Imatinib Mesylate;HMOX1 protein, human;Heme Oxygenase-1",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Aged, 80 and over;Antineoplastic Agents;Benzamides;Bone Marrow Cells;Cell Division;Drug Resistance, Neoplasm;Female;Heme Oxygenase-1;Humans;Imatinib Mesylate;K562 Cells;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Piperazines;Pyrimidines;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"therapeutic use;drug effects;pathology;drug effects;drug effects;drug therapy;enzymology;therapeutic use;therapeutic use",
        "_version_":1605784808823193600},
      {
        "Doc_abstract":"Pulmonary hypertension (PHT) is a pathological condition determined as an increase in mean pulmonary arterial pressure 25 mmHg. Pulmonary arterial hypertension (PAH) is precapillary PHT and a life-threatening disease group which consists of different etiologies with the same pathological and clinical findings, and which is characterized by elevated pulmonary vascular resistance. Dasatinib is a dual Src/Abl kinase inhibitor associated with higher affinity for BCR/ABL kinase than imatinib, and is used in the treatment of chronic myelocytic leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia (ALL). We describe a case with ALL, in whom dasatinib treatment induced PAH, and who recovered with bosentan treatment. ",
        "Doc_title":"Dasatinib-induced pulmonary hypertension in acute lymphoblastic leukemia: case report.",
        "Journal":"Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir",
        "Do_id":"25655855",
        "Doc_ChemicalList":"Antineoplastic Agents;Pyrimidines;Thiazoles;Dasatinib",
        "Doc_meshdescriptors":"Antineoplastic Agents;Dasatinib;Humans;Hypertension, Pulmonary;Male;Middle Aged;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Pyrimidines;Thiazoles",
        "Doc_meshqualifiers":"adverse effects;therapeutic use;chemically induced;drug therapy;adverse effects;therapeutic use;adverse effects;therapeutic use",
        "_version_":1605809527717888000},
      {
        "Doc_abstract":"Chronic myeloid leukemia is a stem cell-initiated but progenitor-driven disease induced by the BCR-ABL oncogene. Tyrosine kinase inhibitors (TKIs) were introduced in the late 1990s and have revolutionized the management of chronic myeloid leukemia in chronic phase. The majority of patients can now expect to live a normal life as long as they continue to comply with TKI treatment. However, in a significant proportion of cases TKI resistance develops over time, requiring a switch of therapy. The most frequent mechanism for drug resistance is the development of kinase domain mutations that reduce or completely ablate drug efficacy. Fortunately, the last 10 years have seen an impressive array of new drugs, some modeled on the mechanism of action of imatinib, others employing more novel approaches, for these patients.",
        "Doc_title":"Mechanisms and novel approaches in overriding tyrosine kinase inhibitor resistance in chronic myeloid leukemia.",
        "Journal":"Expert review of anticancer therapy",
        "Do_id":"22369329",
        "Doc_ChemicalList":"Benzamides;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Imatinib Mesylate;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Benzamides;Clinical Trials as Topic;Disease Management;Drug Resistance, Neoplasm;Fusion Proteins, bcr-abl;Genomic Instability;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Myeloid Cells;Piperazines;Pluripotent Stem Cells;Protein Kinase Inhibitors;Pyrimidines;Therapies, Investigational;Treatment Outcome",
        "Doc_meshqualifiers":"genetics;antagonists & inhibitors;genetics;drug therapy;genetics;metabolism;metabolism;administration & dosage;adverse effects;metabolism;administration & dosage;adverse effects;administration & dosage;adverse effects",
        "_version_":1605801936368435200},
      {
        "Doc_abstract":"Earlier reports have suggested that the BCR/ABL oncogene, associated with chronic myeloid leukemia, induces a mutator phenotype; however, it is unclear whether this leads to long-term changes in chromosomes and whether the phenotype is found in primary chronic myelogeneous leukemia (CML) cells. We have addressed both these issues. BCR/ABL-expressing cell lines show an increase in DNA breaks after treatment with etoposide as compared to control cells. However, although BCR/ABL-expressing cell lines have an equivalent cell survival, they have an increase in chromosomal translocations after DNA repair as compared to control cells. This demonstrates that BCR/ABL expression decreases the fidelity of DNA repair. To see whether this is true in primary CML samples, normal CD34+ progenitor cells and CML progenitor cells were treated with etoposide. CML progenitor cells have equivalent survival but have an increase in DNA double-strand breaks (DSBs). Spectral karyotyping demonstrates new chromosomal translocations in CML cells, but not normal progenitor cells, consistent with error-prone DNA repair. Taken together, these data demonstrate that BCR/ABL enhances the accumulation of DSBs and alters the apoptotic threshold in CML leading to error-prone DNA repair.",
        "Doc_title":"BCR/ABL induces chromosomal instability after genotoxic stress and alters the cell death threshold.",
        "Journal":"Leukemia",
        "Do_id":"19020542",
        "Doc_ChemicalList":"Etoposide;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Cell Death;Cell Survival;Chromosomal Instability;DNA Breaks, Double-Stranded;DNA Damage;DNA Repair;Etoposide;Fusion Proteins, bcr-abl;Hematopoietic Stem Cells;Humans;Translocation, Genetic;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"genetics;genetics;genetics;pharmacology;pathology",
        "_version_":1605842383798272000},
      {
        "Doc_abstract":"To determine the functional importance of Ras in transformation by Abl oncogenes, we used a genetic approach to measure the effect of impaired Ras activity on the ability of Bcr-Abl or v-Abl to transform cells. Expression of the catalytic domain of the GTPase activating protein for Ras (Gap C terminus) impaired soft agar colony formation by fibroblasts expressing v-Abl or Bcr-Abl by 70-80%. To test Ras function in a model that more closely resembles clinical diseases involving Bcr-Abl, double gene retroviruses expressing Bcr-Abl paired with the Gap C terminus or dominant negative Ras were introduced into naive mouse bone marrow cells. Transformation by Bcr-Abl was completely blocked in both situations. Coexpression of normal c-H-Ras accelerated the transforming activity of Bcr-Abl. These findings show that Ras activation is essential for the leukemogenic activity of Abl oncogenes in two distinct model systems. The results genetically define a connection between the Bcr-Abl cytoplasmic tyrosine kinase and Ras and add to the accumulating evidence that deregulation of Ras is a central event in the genesis of a number of molecularly distinct forms of human myeloid leukemia.",
        "Doc_title":"Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene.",
        "Journal":"The Journal of experimental medicine",
        "Do_id":"7807010",
        "Doc_ChemicalList":"GTPase-Activating Proteins;Proteins;ras GTPase-Activating Proteins;Fusion Proteins, bcr-abl;Proto-Oncogene Proteins p21(ras)",
        "Doc_meshdescriptors":"Animals;Bone Marrow Cells;Cells, Cultured;Fibroblasts;Fusion Proteins, bcr-abl;GTPase-Activating Proteins;Genes, Dominant;Genes, abl;Hematopoietic Stem Cells;In Vitro Techniques;Mice;Mice, Inbred BALB C;Oncogenes;Proteins;Proto-Oncogene Proteins p21(ras);Rats;Signal Transduction;ras GTPase-Activating Proteins",
        "Doc_meshqualifiers":"cytology;metabolism;physiology",
        "_version_":1605820504256544768},
      {
        "Doc_abstract":"A 45-year-old male patient with Ph-negative chronic myeloid leukemia (CML) had rearranged bcr-3' and bcr-5' gene regions in Southern blot studies when leukemia was diagnosed. During development of terminal blast crisis, successive blood samples showed a progressive decrease in the amount of germline bcr DNA and its complete loss by full blast crisis. There were also increased amounts of rearranged bcr DNA consistent with acquired homozygosity. A similar result was obtained with an IgV lambda probe and indicated homozygosity of a significant part of chromosome 22. The bcr-abl gene complex behaves as a somatic dominant in CML, and we suggest that its acquired homozygosity is a mechanism of bcr-abl amplification similar to duplication of the Ph chromosome commonly found in the blast crisis of CML.",
        "Doc_title":"Acquired homozygosity of the rearranged bcr allele during the acute leukemic phase of a patient with Ph-negative chronic myeloid leukemia.",
        "Journal":"Blood",
        "Do_id":"3164635",
        "Doc_ChemicalList":"DNA",
        "Doc_meshdescriptors":"Alleles;Blast Crisis;DNA;Homozygote;Humans;Karyotyping;Leukemia, Myeloid;Male;Middle Aged;Nucleic Acid Hybridization;Philadelphia Chromosome;Proto-Oncogenes;Translocation, Genetic",
        "Doc_meshqualifiers":"blood;genetics;blood;blood;genetics",
        "_version_":1605891779901521920},
      {
        "Doc_abstract":"The development of imatinib has resulted in sustained hematologic and cytogenetic remissions in all phases of chronic myeloid leukemia (CML). Despite the high efficacy, relapses have been observed and are much more prevalent in patients with advanced disease. The most common mechanism of acquired resistance has been traced to Bcr-Abl kinase domain mutations. Several strategies have been developed to overcome the problem of imatinib resistance, including imatinib dose escalation, novel targeted agents and combination treatments. A second generation of tyrosine kinase inhibitors was developed, which displays increased potency towards Bcr-Abl and is able to target the majority of CML mutant clones. Nilotinib (Tasigna, AMN107, Novartis) is a close analog of imatinib with approximately 20-fold higher potency for BCR-ABL kinase inhibition. Preclinical and clinical investigations demonstrate that nilotinib effectively overcomes imatinib resistance, and has induced high rates of hematologic and cytogenetic responses in CML post imatinib failure, with a good tolerance. Nilotinib has been approved for CML patients in chronic and accelerated phases, post imatinib failure.",
        "Doc_title":"Development and targeted use of nilotinib in chronic myeloid leukemia.",
        "Journal":"Drug design, development and therapy",
        "Do_id":"19920910",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605818746793885697},
      {
        "Doc_abstract":"The existence of drug resistance caused by mutations in the break-point cluster region-Abelson tyrosine kinase (Bcr-Abl) kinase domain remains a clinical challenge due to limited effective treatment options for chronic myeloid leukemia (CML). Herein we report a novel series of benzothiazole-based inhibitors that are effective against wild-type and T315I mutant Bcr-Abl kinases. The original hit compound, nocodazole, was extensively modified through a structure-based drug design strategy, especially by varying the groups at the C2 and C6 positions of the scaffold. In addition, the introduction of water-solubilizing groups at the terminal ethyl group resulted in enhanced physicochemical properties and potency in cellular inhibition. Several compounds inhibited the kinase activity of both wild-type Bcr-Abl and the T315I mutant with IC50 values in the picomolar range and exhibited good antiproliferative effects on Ba/F3 cell lines transformed with either wild-type or T315I mutant Bcr-Abl.",
        "Doc_title":"Discovery of new benzothiazole-based inhibitors of breakpoint cluster region-Abelson kinase including the T315I mutant.",
        "Journal":"Journal of medicinal chemistry",
        "Do_id":"23600806",
        "Doc_ChemicalList":"Benzothiazoles;Protein Kinase Inhibitors;Fusion Proteins, bcr-abl;benzothiazole;Nocodazole",
        "Doc_meshdescriptors":"Animals;Benzothiazoles;Cell Line;Cell Proliferation;Drug Design;Fusion Proteins, bcr-abl;Mice;Molecular Docking Simulation;Mutation;Nocodazole;Protein Kinase Inhibitors;Protein Structure, Tertiary;Signal Transduction",
        "Doc_meshqualifiers":"chemistry;metabolism;pharmacology;drug effects;antagonists & inhibitors;chemistry;genetics;metabolism;chemistry;metabolism;pharmacology;chemistry;metabolism;pharmacology;drug effects",
        "_version_":1605809023537381376},
      {
        "Doc_abstract":"The cytogenetic characteristic of Chronic Myeloid Leukemia (CML) is the formation of the Philadelphia chromosome gene product, BCR-ABL. Given that BCR-ABL is the specific target of Gleevec in CML treatment, we investigated the regulation of the catalytic component of telomerase, hTERT, by BCR-ABL at multiple levels in K562 cells.;Molecular techniques such as over expression, knockdown, real-time PCR, immunoprecipitation, western blotting, reporter assay, confocal microscopy, telomerase assays and microarray were used to suggest that hTERT expression and activity is modulated by BCR-ABL at multiple levels.;Our results suggest that BCR-ABL plays an important role in regulating hTERT in K562 (BCR-ABL positive human leukemia) cells. When Gleevec inhibited the tyrosine kinase activity of BCR-ABL, phosphorylation of hTERT was downregulated, therefore suggesting a positive correlation between BCR-ABL and hTERT. Gleevec treatment inhibited hTERT at mRNA level and significantly reduced telomerase activity (TA) in K562 cells, but not in HL60 or Jurkat cells (BCR-ABL negative cells). We also demonstrated that the transcription factor STAT5a plays a critical role in hTERT gene regulation in K562 cells. Knockdown of STAT5a, but not STAT5b, resulted in a marked downregulation of hTERT mRNA level, TA and hTERT protein level in K562 cells. Furthermore, translocation of hTERT from nucleoli to nucleoplasm was observed in K562 cells induced by Gleevec.;Our data reveal that BCR-ABL can regulate TA at multiple levels, including transcription, post-translational level, and proper localization. Thus, suppression of cell growth and induction of apoptosis by Gleevec treatment may be partially due to TA inhibition. Additionally, we have identified STAT5a as critical mediator of the hTERT gene expression in BCR-ABL positive CML cells, suggesting that targeting STAT5a may be a promising therapeutic strategy for BCR-ABL positive CML patients.",
        "Doc_title":"Regulation of hTERT by BCR-ABL at multiple levels in K562 cells.",
        "Journal":"BMC cancer",
        "Do_id":"22151181",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Protein Kinase Inhibitors;Pyrimidines;RNA, Messenger;Imatinib Mesylate;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl;Telomerase",
        "Doc_meshdescriptors":"Antineoplastic Agents;Benzamides;Down-Regulation;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;K562 Cells;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Microarray Analysis;Piperazines;Polymerase Chain Reaction;Protein Kinase Inhibitors;Protein-Tyrosine Kinases;Pyrimidines;RNA, Messenger;Telomerase;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"pharmacology;physiology;drug therapy;metabolism;pharmacology;methods;pharmacology;drug effects;metabolism;pharmacology;metabolism;metabolism",
        "_version_":1605810750390009856},
      {
        "Doc_abstract":"Although targeting the BCR-ABL tyrosine kinase activity by imatinib mesylate has rapidly become first-line therapy in chronic myeloid leukemia (CML), drug resistance suggests that combination therapy directed to a complementing target may significantly improve treatment results. To identify such potential targets, we used lentivirus-mediated RNA interference (RNAi) as a tool for functional genomics in cell lines as well as primary normal and CML CD34+ cells. In a conditional cell culture model, we demonstrate that RNAi-mediated reduction of SHP2, STAT5, and Gab2 protein expression inhibits BCR-ABL-dependent but not cytokine-dependent proliferation in a dose-dependent manner. Similarly, colony formation of purified primary CML but not of normal CD34+ colony-forming cells is specifically reduced by inhibition of SHP2, STAT5, and Gab2 expression, respectively. In addition, coexpression of both anti-BCR-ABL and anti-SHP2 shRNAs from a single lentiviral vector induces stronger inhibition of colony formation as compared to either shRNA alone. The data indicate that BCR-ABL expression may affect the function of normal signaling molecules. Targeting these molecules may harbor significant therapeutic potential for the treatment of patients with CML.",
        "Doc_title":"Enhanced sensitivity to inhibition of SHP2, STAT5, and Gab2 expression in chronic myeloid leukemia (CML).",
        "Journal":"Blood",
        "Do_id":"16278304",
        "Doc_ChemicalList":"Adaptor Proteins, Signal Transducing;Antigens, CD34;Benzamides;GAB2 protein, human;Intracellular Signaling Peptides and Proteins;Phosphoproteins;Piperazines;Protein Kinase Inhibitors;Pyrimidines;RNA, Small Interfering;STAT5 Transcription Factor;Imatinib Mesylate;Fusion Proteins, bcr-abl;PTPN11 protein, human;Protein Tyrosine Phosphatase, Non-Receptor Type 11;Protein Tyrosine Phosphatases",
        "Doc_meshdescriptors":"Adaptor Proteins, Signal Transducing;Antigens, CD34;Benzamides;Combined Modality Therapy;Dose-Response Relationship, Drug;Drug Resistance, Neoplasm;Fusion Proteins, bcr-abl;Gene Expression Regulation, Leukemic;Genetic Therapy;Genetic Vectors;Humans;Imatinib Mesylate;Intracellular Signaling Peptides and Proteins;K562 Cells;Lentivirus;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Neoplastic Stem Cells;Phosphoproteins;Piperazines;Protein Kinase Inhibitors;Protein Tyrosine Phosphatase, Non-Receptor Type 11;Protein Tyrosine Phosphatases;Pyrimidines;RNA Interference;RNA, Small Interfering;STAT5 Transcription Factor;Signal Transduction",
        "Doc_meshqualifiers":"metabolism;methods;drug effects;genetics;antagonists & inhibitors;metabolism;drug effects;genetics;methods;genetics;therapeutic use;genetics;metabolism;genetics;metabolism;therapy;drug effects;metabolism;genetics;metabolism;therapeutic use;therapeutic use;genetics;metabolism;therapeutic use;genetics;pharmacology;genetics;metabolism;genetics",
        "_version_":1605813149006561280},
      {
        "Doc_abstract":"Improved laboratory techniques now allow a more sensitive detection of leukemia cells at designated intervals throughout therapy. Using flow cytometry and polymerase chain reaction, it is possible to detect 1 leukemic cell among 10(4) normal cells (1 leukemia cell in 10,000 normal cells), representing a 100-fold greater sensitivity than morphological examination in acute lymphoblastic leukemia (ALL). Recently, it has been shown that the molecular presence of persistent acute lymphoblastic leukemia at the end of remission therapy is a poor indicator of clinical outcome. Now similar studies are being performed in acute myeloid leukemia (AML). While the sensitivity using flow cytometry is less in AML than in ALL (able to detect 1 leukemic cell among 1000 normal cells in AML), persistent or minimal residual AML provides the clinician guidance with future treatment recommendations. Minimal residual disease (MRD) is now considered an important indicator response of disease response to treatment. As such, MRD once considered a research variable is now influencing treatment decisions. Therefore, it is imperative that the nurse have an understanding of the newer techniques to study residual leukemia and their clinical implications for patients and their families.",
        "Doc_title":"Understanding the clinical implications of minimal residual disease in childhood leukemia.",
        "Journal":"Journal of pediatric oncology nursing : official journal of the Association of Pediatric Oncology Nurses",
        "Do_id":"16689404",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Child;Flow Cytometry;Humans;Leukemia, Myeloid;Neoplasm, Residual;Polymerase Chain Reaction;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Prognosis",
        "Doc_meshqualifiers":"pathology;pathology;pathology",
        "_version_":1605824067611394048},
      {
        "Doc_abstract":"Effective inhibition of BCR-ABL tyrosine kinase activity with Imatinib represents a breakthrough in the treatment of patients with chronic myeloid leukemia (CML). However, more than 30 % of patients with CML in chronic phase do not respond adequately to Imatinib and the drug seems not to affect the quiescent pool of BCR-ABL positive leukemic stem and progenitor cells. Therefore, despite encouraging clinical results, Imatinib can still not be considered a curative treatment option in CML. We recently reported downregulation of eukaryotic initiation factor 5A (eIF5A) in Imatinib treated K562 cells. Furthermore, the inhibition of eIF5A by siRNA in combination with Imatinib has been shown to exert synergistic cytotoxic effects on BCR-ABL positive cell lines. Based on the structure of known deoxyhypusine synthase (DHS) inhibitors such as CNI-1493, a drug design approach was applied to develop potential compounds targeting DHS. Here we report the biological evaluation of selected novel (DHSI-15) as compared to established (CNI-1493, deoxyspergualin) DHS inhibitors. We show that upon the compounds tested, DHSI-15 and deoxyspergualin exert strongest antiproliferative effects on BCR-ABL cells including Imatinib resistant mutants. However, this effect did not seem to be restricted to BCR-ABL positive cell lines or primary cells. Both compounds are able to induce apoptosis/necrosis during long term incubation of BCR-ABL positive BA/F3 derivates. Pharmacological synergism can be observed for deoxyspergualin and Imatinib, but not for DHSI-15 and Imatinib. Finally we show that deoxyspergualin is able to inhibit proliferation of CD34+ progenitor cells from CML patients. We conclude that inhibition of deoxyhypusine synthase (DHS) can be supportive for the anti-proliferative treatment of leukemia and merits further investigation including other cancers.",
        "Doc_title":"Evaluation of deoxyhypusine synthase inhibitors targeting BCR-ABL positive leukemias.",
        "Journal":"Investigational new drugs",
        "Do_id":"22415796",
        "Doc_ChemicalList":"Antigens, CD34;Antineoplastic Agents;Enzyme Inhibitors;Guanidines;Hydrazones;semapimod;Oxidoreductases Acting on CH-NH Group Donors;deoxyhypusine synthase;gusperimus",
        "Doc_meshdescriptors":"Animals;Antigens, CD34;Antineoplastic Agents;Apoptosis;Cell Line, Tumor;Cell Proliferation;Enzyme Inhibitors;Guanidines;Humans;Hydrazones;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mice;Oxidoreductases Acting on CH-NH Group Donors",
        "Doc_meshqualifiers":"pharmacology;drug effects;drug effects;pharmacology;pharmacology;pharmacology;drug therapy;antagonists & inhibitors",
        "_version_":1605852942124974080},
      {
        "Doc_abstract":"Dasatinib is a highly potent Bcr-Abl inhibitor that is approved for the treatment of imatinib-resistant or -intolerant chronic myeloid leukemia (CML). The potential effects of dasatinib on sperm counts, sperm function, and fertility have not been studied yet. There is only one report in the medical literature of successful pregnancies while patients were taking dasatinib, thus making our case the second report. Here, we present the case of a 38-year-old man who conceived a healthy baby while on dasatinib therapy.",
        "Doc_title":"Successful pregnancy involving a man with chronic myeloid leukemia on dasatinib.",
        "Journal":"Archives of gynecology and obstetrics",
        "Do_id":"20473616",
        "Doc_ChemicalList":"Antineoplastic Agents;Protein Kinase Inhibitors;Pyrimidines;Thiazoles;Dasatinib",
        "Doc_meshdescriptors":"Adult;Antineoplastic Agents;Dasatinib;Female;Fertilization;Humans;Infant;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Pregnancy;Protein Kinase Inhibitors;Pyrimidines;Thiazoles",
        "Doc_meshqualifiers":"adverse effects;therapeutic use;drug effects;drug therapy;adverse effects;therapeutic use;adverse effects;therapeutic use;adverse effects;therapeutic use",
        "_version_":1605882783987662848},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) is characterized by constitutively active fusion protein tyrosine kinase BCR-ABL. Although the tyrosine kinase inhibitor (TKI) against BCR-ABL, imatinib, is the first-line therapy for CML, acquired resistance almost inevitably emerges. The underlying mechanism are point mutations within the BCR-ABL gene, among which T315I is notorious because it resists to almost all currently available inhibitors. Here we took use of a previously generated chimeric ubiquitin ligase, SH2-U-box, in which SH2 from the adaptor protein Grb2 acts as a binding domain for activated BCR-ABL, while U-box from CHIP functions as an E3 ubiquitin ligase domain, so as to target the ubiquitination and degradation of both native and T315I-mutant BCR-ABL. As such, SH2-U-box significantly inhibited proliferation and induced apoptosis in CML cells harboring either the wild-type or T315I-mutant BCR-ABL (K562 or K562R), with BCR-ABL-dependent signaling pathways being repressed. Moreover, SH2-U-box worked in concert with imatinib in K562 cells. Importantly, SH2-U-box-carrying lentivirus could markedly suppress the growth of K562-xenografts in nude mice or K562R-xenografts in SCID mice, as well as that of primary CML cells. Collectively, by degrading the native and T315I-mutant BCR-ABL, the chimeric ubiquitin ligase SH2-U-box may serve as a potential therapy for both imatinib-sensitive and resistant CML. ",
        "Doc_title":"The chimeric ubiquitin ligase SH2-U-box inhibits the growth of imatinib-sensitive and resistant CML by targeting the native and T315I-mutant BCR-ABL.",
        "Journal":"Scientific reports",
        "Do_id":"27329306",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605761145090605057},
      {
        "Doc_abstract":"BCR-ABL fusion protein, a t(9;22) translocation product is indispensable for generation, maintenance and progression of chronic myeloid leukemia. RNA interference is an approach to silence gene at post-transcriptional level. We show that dsRNA targeted against the translocation region leads to more than 90% inhibition of BCR-ABL mRNA and protein expression levels using K562 as a model. Lack of BCR-ABL leads to cell cycle arrest in G1 phase as observed by decrease in cyclin D1 and increase in p21 and p27 cdk inhibitors mRNA. Apoptosis resistance imparted by BCR-ABL is lost in these cells in caspase-dependent or independent manner. Decrease in Bcl-XL is observed along with decrease in mitochondrial membrane integrity. Transient removal of BCR-ABL expression has a profound effect on proliferation and clonogenic capacity also confirmed by long-term silencing using lentiviral vectors. Interestingly, low level of BCR-ABL message leads to enhanced erythroid differentiation and reduced expression of megakaryocytic markers. Importantly, in six CML patient samples studied, silencing BCR-ABL in the lineage depleted enriched stem cell population leads to a decrease in colony-forming capacity. Thus, long-term silencing of BCR-ABL might prove to be a promising alternative approach in CML patients especially for those who do not respond to any other drug treatment.",
        "Doc_title":"Transient or long-term silencing of BCR-ABL alone induces cell cycle and proliferation arrest, apoptosis and differentiation.",
        "Journal":"Leukemia",
        "Do_id":"16281073",
        "Doc_ChemicalList":"RNA, Double-Stranded;RNA, Messenger;abl-bcr fusion protein, human;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Apoptosis;Cell Cycle;Cell Differentiation;Cell Line;Cell Proliferation;Cells, Cultured;Fusion Proteins, bcr-abl;Gene Silencing;Genetic Vectors;HeLa Cells;Humans;K562 Cells;Kinetics;Lentivirus;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;RNA, Double-Stranded;RNA, Messenger;Tumor Stem Cell Assay",
        "Doc_meshqualifiers":"drug effects;physiology;drug effects;drug effects;drug effects;genetics;metabolism;pharmacology;genetics;genetics;genetics;metabolism;pharmacology;antagonists & inhibitors;genetics;metabolism;methods",
        "_version_":1605841954816393216},
      {
        "Doc_abstract":"We previously demonstrated that the Bcr-Abl oncogene, p210(bcr-abl), through its unique GEF domain, specifically activates RhoA and induces spontaneous amoeboid motility. We intend to study the pathways downstream RhoA controlling amoeboid motility. Mouse prolymphoblastic cells (Ba/F3 cell line) expressing different forms of Bcr-Abl were embedded in 3-dimensional (3D) Matrigel to study motility and explore the effects of inhibiting Rho pathway (inhibitors and siRNAs). The phosphorylation levels of cofilin-1 and destrin were analyzed by 2-dimensional electrophoresis. Composition of Bcr-Abl signalplex in different conditions was determined by coimmunoprecipitation. Ba/F3p190 and Ba/F3 expressing a mutant form of p210(bcr-abl) (unable to activate RhoA) cells presented a spontaneous motility, but not an amoeboid type. p210(bcr-abl)-induced amoeboid motility in a 3D matrix requires isoform-specific RhoA/ROCK-1/destrin signaling. Next to the conventional Rho/ROCK/MLC/myosin pathway, this pathway is a crucial determinant for amoeboid motility, specific for the destrin isoform (and not its coexpressed homologue cofilin-1). Also, the presence of destrin (and not cofilin-1) in the p210(bcr-abl) complex is dependent on ROCK1, and this signalplex is required for amoeboid motility. This underscores isoform-specific function within the ADF/cofilin family and provides new insight into Bcr-Abl signaling to amoeboid motility and possible impact on understanding chronic myeloid leukemia progression.",
        "Doc_title":"p210bcr-abl induces amoeboid motility by recruiting ADF/destrin through RhoA/ROCK1.",
        "Journal":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology",
        "Do_id":"23047898",
        "Doc_ChemicalList":"Cytokines;DNA Primers;Destrin;Neoplasm Proteins;adult T cell leukemia-derived factor;Fusion Proteins, bcr-abl;Rock1 protein, mouse;rho-Associated Kinases;rhoA GTP-Binding Protein",
        "Doc_meshdescriptors":"Amoeba;Animals;Base Sequence;Cell Line;Cytokines;DNA Primers;Destrin;Fusion Proteins, bcr-abl;Mice;Microscopy, Fluorescence;Neoplasm Proteins;rho-Associated Kinases;rhoA GTP-Binding Protein",
        "Doc_meshqualifiers":"physiology;metabolism;metabolism;physiology;metabolism;metabolism;metabolism",
        "_version_":1605819615372378112},
      {
        "Doc_abstract":"We identified 243 patients with Philadelphia (Ph) chromosome-positive chronic myeloid leukemia (CML) who had BCR-ABL transcripts monitored by quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) after allogeneic stem cell transplantation for a median of 84.3 months. Individual patients were regarded as having achieved molecular relapse (MR) if the BCR-ABL/ABL ratio exceeded 0.02% on 3 occasions or reached 0.05% on 2 occasions. Patients were allocated to 1 of 4 categories: (1) 36 patients were \"persistently negative\" or had a single low-level positive result; (2) 51 patients, \"fluctuating positive, low level,\" had more than 1 positive result but never more than 2 consecutive positive results; (3) 27 patients, \"persistently positive, low level,\" had persisting low levels of BCR-ABL transcripts but never more than 3 consecutive positive results; and (4) 129 patients relapsed. In 107 of these, relapse was based initially only on molecular criteria; in 72 (67.3%) patients the leukemia progressed to cytogenetic or hematologic relapse either prior to or during treatment with donor lymphocyte infusions. We conclude that the pattern of BCR-ABL transcript levels after allograft is variable; only a minority of patients with fluctuating or persistent low levels of BCR-ABL transcripts satisfied our definitions of MR, whereas the majority of patients who did so were likely to progress further.",
        "Doc_title":"Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy.",
        "Journal":"Blood",
        "Do_id":"16449534",
        "Doc_ChemicalList":"Biomarkers;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adult;Biomarkers;Disease Progression;Female;Fusion Proteins, bcr-abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Stem Cell Transplantation;Survivors;Transcription, Genetic;Transplantation, Homologous;Treatment Outcome",
        "Doc_meshqualifiers":"blood;blood;genetics;blood;genetics;therapy;physiology",
        "_version_":1605845166104510464},
      {
        "Doc_abstract":"To verify the potential clinical and prognostic value of BCR/ABL isoforms, we analyzed 101 consecutive adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia enrolled in the GIMEMA 0496 trial between October 1996 and December 1999. A p190 or p210 with or without p190 BCR/ABL transcript was documented in 59 (58.5%) and 42 cases (41.5%), respectively. At diagnosis, a white cell count <16 x 10(9)/L and a higher level of CD34 and CD33 expression were associated with the p190 BCR/ABL transcript (p<0.05, p=0.009 and p=0.03, respectively). A complete remission was achieved in 62/92 (67.4%) patients, while 16/92 (17.4%) were resistant and 14/92 (15.2%) died of therapy-related complications. Fifty-two patients underwent intensive re-induction treatment, which was followed by stem cell transplant consolidation in the 36 in persistent complete remission (allogeneic = 20 patients; autologous = 16 patients). Response rates to induction therapies were similar in the two BCR/ABL isoform groups. By contrast, the p190 emerged as the only independent prognostic factor favorably affecting the 5-year overall survival and disease-free survival rates (p=0.008 and p=0.02, respectively).",
        "Doc_title":"The role of BCR/ABL isoforms in the presentation and outcome of patients with Philadelphia-positive acute lymphoblastic leukemia: a seven-year update of the GIMEMA 0496 trial.",
        "Journal":"Haematologica",
        "Do_id":"16531262",
        "Doc_ChemicalList":"Genetic Markers;Protein Isoforms;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adult;Follow-Up Studies;Fusion Proteins, bcr-abl;Genetic Markers;Humans;Multicenter Studies as Topic;Multivariate Analysis;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Proportional Hazards Models;Protein Isoforms;Randomized Controlled Trials as Topic;Treatment Outcome",
        "Doc_meshqualifiers":"genetics;physiology;genetics;physiology;genetics;physiopathology;therapy;genetics;physiology",
        "_version_":1605929061637423104},
      {
        "Doc_abstract":"Patients with chronic myeloid leukemia harbor the chromosomal translocation t(9;22), which corresponds to fusion of the BCR and ABL genes at the DNA level. The translated fusion product is an oncogenic protein with increased ABL tyrosine kinase activity causing cell transformation. To date, reverse transcriptase-polymerase chain reaction is considered the most sensitive method available for detecting low copy numbers of the BCR-ABL gene fusion. Recently, Cepheid introduced its GeneXpert-based assay for the identification of the BCR-ABL gene fusion in cells from blood samples. This system comprises a walk-away self-contained instrument that combines cartridge-based microfluidic sample preparation with reverse transcriptase-polymerase chain reaction-based fluorescent signal detection and BCR-ABL and ABL Ct (threshold cycle) determination. The difference between the BCR-ABL Ct and ABL Ct (DeltaCt) is expected to represent the ratio of the two populations of mRNAs and ultimately the percentage of neoplastic cells present. We tested whether this BCR-ABL fusion detection system could be used as a clinical diagnostic tool for monitoring patients with minimal residual disease of chronic myelogenous leukemia. We report similar performance characteristics, including limit of detection, specificity, sensitivity, and precision, of this automated BCR-ABL fusion detection system to those of a manual TaqMan reverse transcriptase-polymerase chain reaction-based test.",
        "Doc_title":"Evaluation of the Cepheid GeneXpert BCR-ABL assay.",
        "Journal":"The Journal of molecular diagnostics : JMD",
        "Do_id":"17384214",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Blood;Fusion Proteins, bcr-abl;Gene Dosage;Genetic Testing;Humans;K562 Cells;Plasmids;Reference Standards;Sensitivity and Specificity",
        "Doc_meshqualifiers":"genetics;methods;genetics",
        "_version_":1605883126424272896},
      {
        "Doc_abstract":"To evaluate the effects of tetrandrine citrate, a novel tetrandrine salt with high water solubility, on the growth of imatinib (IM)-resistant chronic myeloid leukemia (CML) in vitro and in vivo, and reveal action molecular mechanisms.;Cell viability in vitro was measured using methyl thiazolyl tetrazolium (MTT) assay. CML cell growth in vivo was assessed using a xenograft model in nude mice. Bcr-Abl and -catenin protein levels were determined using Western blotting. Bcr-Abl messenger RNA (mRNA) was measured by reverse transcription polymerase chain reaction (RT-PCR). Flow cytometry (FCM) was used to determine cell cycle status.;Tetrandrine citrate inhibited the growth of IM-resistant K562 cells, primary leukemia cells, and primitive CD34(+) leukemia cells, and their inhibition concentration that inhibited 50% of target cells (IC(50)) ranged from 1.20 to 2.97 g/ml. In contrast, tetrandrine citrate did not affect normal blood cells under the same conditions, and IC(50) values were about 10.12-13.11 g/ml. Oral administration of tetrandrine citrate caused complete regression of IM-resistant K562 xenografts in nude mice without overt toxicity. Western blot results revealed that treatment of IM-resistant K562 cells with tetrandrine citrate resulted in a significant decrease of both p210(Bcr-Abl) and -catenin proteins, but IM did not affect the Bcr-Abl protein levels. Proteasome inhibitor, MG132, did not prevent tetrandrine-mediated decrease of the p210(Bcr-Abl) protein. RT-PCR results showed that tetrandrine treatment caused a decrease of Bcr-Abl mRNA. FCM analysis indicated that tetrandrine induced gap 1 (G(1)) arrest in CML cells.;Tetrandrine citrate is a novel orally active tetrandrine salt with potent anti-tumor activity against IM-resistant K562 cells and CML cells. Tetrandrine citrate-induced growth inhibition of leukemia cells may be involved in the depletion of p210(Bcr-Abl) mRNA and -catenin protein.",
        "Doc_title":"Tetrandrine citrate eliminates imatinib-resistant chronic myeloid leukemia cells in vitro and in vivo by inhibiting Bcr-Abl/-catenin axis.",
        "Journal":"Journal of Zhejiang University. Science. B",
        "Do_id":"23125079",
        "Doc_ChemicalList":"Benzamides;Benzylisoquinolines;Citrates;Piperazines;Pyrimidines;RNA, Messenger;beta Catenin;tetrandrine;Imatinib Mesylate;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Administration, Oral;Animals;Benzamides;Benzylisoquinolines;Cell Growth Processes;Citrates;Down-Regulation;Drug Interactions;Drug Resistance, Neoplasm;Drug Screening Assays, Antitumor;Female;Flow Cytometry;Fusion Proteins, bcr-abl;G1 Phase Cell Cycle Checkpoints;Humans;Imatinib Mesylate;K562 Cells;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mice;Mice, Nude;Neoplastic Stem Cells;Piperazines;Pyrimidines;RNA, Messenger;Random Allocation;Reverse Transcriptase Polymerase Chain Reaction;Xenograft Model Antitumor Assays;beta Catenin",
        "Doc_meshqualifiers":"pharmacology;chemistry;pharmacology;drug effects;chemistry;pharmacology;drug effects;antagonists & inhibitors;genetics;metabolism;drug effects;drug therapy;genetics;metabolism;pathology;drug effects;pathology;pharmacology;pharmacology;chemistry;genetics;antagonists & inhibitors;metabolism",
        "_version_":1605883114333143040},
      {
        "Doc_abstract":"Aberrant expression of long noncoding RNAs (lncRNAs) is associated with various human cancers. However, the role of lncRNAs in Bcr-Abl-mediated chronic myeloid leukemia (CML) is unknown. In this study, we performed a comprehensive analysis of lncRNAs in human CML cells using an lncRNA cDNA microarray and identified an lncRNA termed lncRNA-BGL3 that acted as a key regulator of Bcr-Abl-mediated cellular transformation. Notably, we observed that lncRNA-BGL3 was highly induced in response to disruption of Bcr-Abl expression or by inhibiting Bcr-Abl kinase activity in K562 cells and leukemic cells derived from CML patients. Ectopic expression of lncRNA-BGL3 sensitized leukemic cells to undergo apoptosis and inhibited Bcr-Abl-induced tumorigenesis. Furthermore, transgenic (TG) mice expressing lncRNA-BGL3 were generated. We found that TG expression of lncRNA-BGL3 alone in mice was sufficient to impair primary bone marrow transformation by Bcr-Abl. Interestingly, we identified that lncRNA-BGL3 was a target of miR-17, miR-93, miR-20a, miR-20b, miR-106a and miR-106b, microRNAs that repress mRNA of phosphatase and tensin homolog (PTEN). Further experiments demonstrated that lncRNA-BGL3 functioned as a competitive endogenous RNA for binding these microRNAs to cross-regulate PTEN expression. Additionally, our experiments have begun to address the mechanism of how lncRNA-BGL3 is regulated in the leukemic cells and showed that Bcr-Abl repressed lncRNA-BGL3 expression through c-Myc-dependent DNA methylation. Taken together, these results reveal that Bcr-Abl-mediated cellular transformation critically requires silence of tumor-suppressor lncRNA-BGL3 and suggest a potential strategy for the treatment of Bcr-Abl-positive leukemia.",
        "Doc_title":"A long noncoding RNA critically regulates Bcr-Abl-mediated cellular transformation by acting as a competitive endogenous RNA.",
        "Journal":"Oncogene",
        "Do_id":"24837367",
        "Doc_ChemicalList":"Benzamides;MYC protein, human;MicroRNAs;Piperazines;Protein Kinase Inhibitors;Proto-Oncogene Proteins c-myc;Pyrimidines;RNA, Long Noncoding;RNA, Messenger;Imatinib Mesylate;Fusion Proteins, bcr-abl;PTEN Phosphohydrolase;PTEN protein, human",
        "Doc_meshdescriptors":"Animals;Apoptosis;Benzamides;Cell Line, Tumor;Cell Transformation, Neoplastic;DNA Methylation;Fusion Proteins, bcr-abl;Gene Expression Regulation, Leukemic;HEK293 Cells;Hep G2 Cells;Humans;Imatinib Mesylate;Jurkat Cells;K562 Cells;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;MCF-7 Cells;Mice;Mice, Nude;Mice, Transgenic;MicroRNAs;Neoplasm Transplantation;Oligonucleotide Array Sequence Analysis;PTEN Phosphohydrolase;Piperazines;Protein Kinase Inhibitors;Proto-Oncogene Proteins c-myc;Pyrimidines;RNA, Long Noncoding;RNA, Messenger;Transplantation, Heterologous",
        "Doc_meshqualifiers":"drug effects;pharmacology;genetics;antagonists & inhibitors;biosynthesis;genetics;drug effects;genetics;genetics;antagonists & inhibitors;genetics;pharmacology;pharmacology;genetics;pharmacology;biosynthesis;genetics;genetics",
        "_version_":1605746324095893505},
      {
        "Doc_abstract":"Tumors expressing the ABL oncoproteins (BCR/ABL, TEL/ABL, v-ABL) can avoid apoptosis triggered by DNA damaging agents. The tumor suppressor protein p53 is an important activator of apoptosis in normal cells; conversely its functional loss may cause drug resistance. The ABL oncoprotein-p53 paradigm represents the relationship between an oncogenic tyrosine kinase and a tumor suppressor gene. Here we show that BCR/ABL oncoproteins employ p53 to induce resistance to DNA damage in myeloid leukemia cells. Cells transformed by the ABL oncoproteins displayed accumulation of p53 upon DNA damage. In contrast, only a modest increase of p53 expression followed by activation of caspase-3 were detected in normal cells expressing endogenous c-ABL. Phosphatidylinositol-3 kinase-like protein kinases (ATR and also ATM) -dependent phosphorylation of p53-Ser15 residue was associated with the accumulation of p53, and stimulation of p21(Waf-1) and GADD45, resulting in G(2)/M delay in BCR/ABL cells after genotoxic treatment. Inhibition of p53 by siRNA or by the temperature-sensitive mutation reduced G(2)/M accumulation and drug resistance of BCR/ABL cells. In conclusion, accumulation of the p53 protein contributed to prolonged G(2)/M checkpoint activation and drug resistance in myeloid cells expressing the BCR/ABL oncoproteins.",
        "Doc_title":"BCR/ABL recruits p53 tumor suppressor protein to induce drug resistance.",
        "Journal":"Cell cycle (Georgetown, Tex.)",
        "Do_id":"15492510",
        "Doc_ChemicalList":"Mutagens;Oncogene Proteins v-abl;Tumor Suppressor Protein p53;Methylnitronitrosoguanidine;DNA;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Animals;Cell Cycle;Cell Line, Transformed;Cell Survival;DNA;DNA Damage;Drug Resistance, Neoplasm;Fusion Proteins, bcr-abl;Humans;Leukemia, Myeloid;Methylnitronitrosoguanidine;Mice;Models, Genetic;Mutagens;Oncogene Proteins v-abl;Phosphorylation;Protein Processing, Post-Translational;RNA Interference;Transfection;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"drug effects;drug effects;drug effects;genetics;metabolism;genetics;metabolism;pathology;toxicity;toxicity;genetics;metabolism;genetics;metabolism",
        "_version_":1605841888031539200},
      {
        "Doc_abstract":"Chronic Myeloid Leukemia (CML) is a clonal disease characterized by the presence of the Philadelphia (Ph+) chromosome and its oncogenic product, BCR-ABL, a constitutively active tyrosine kinase, that is present in >90% of the patients. Epidemiologic data indicates that almost 5000 new cases are reported every year and 10% of these patients eventually succumb to the disease. The treatment of CML was revolutionized by the introduction of imatinib mesylate (IM, Gleevec), a BCR-ABL tyrosine kinase inhibitor (TKI). The clinical use of specific BCR-ABL inhibitors has resulted in a significantly improved prognosis, response rate, overall survival, and patient outcome in CML patients compared to previous therapeutic regimens. However, the complete eradication of CML in patients receiving imatinib was limited by the emergence of resistance mostly due to mutations in the ABL kinase domain and to a lesser extent by molecular residual disease after treatment. The second-generation BCR-ABL TKIs nilotinib (Tasigna) and dasatinib (Sprycel), showed significant activity in clinical trials in patients intolerant or resistant to imatinib therapy, except in those patients with the T315I BCR-ABL mutation. Identifying key components involved in the CML pathogenesis may lead to the exploration of new approaches that might eventually overcome resistance mediated to the BCR-ABL TKIs. Here, we present an overview about the current treatment of Ph+ CML patients with the TKIs and the obstacles to successful treatment with these drugs.",
        "Doc_title":"BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.",
        "Journal":"Leukemia research",
        "Do_id":"20537386",
        "Doc_ChemicalList":"Benzamides;Piperazines;Protein Kinase Inhibitors;Pyrimidines;RNA, Messenger;Imatinib Mesylate;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Benzamides;Clinical Trials as Topic;Drug Resistance, Neoplasm;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Piperazines;Point Mutation;Protein Kinase Inhibitors;Pyrimidines;RNA, Messenger",
        "Doc_meshqualifiers":"antagonists & inhibitors;genetics;drug therapy;adverse effects;pharmacokinetics;therapeutic use;adverse effects;pharmacology;therapeutic use;adverse effects;pharmacokinetics;therapeutic use;analysis",
        "_version_":1605902010162348032},
      {
        "Doc_abstract":"Radotinib, developed as a BCR/ABL tyrosine kinase inhibitor (TKI), is approved for the second-line treatment of chronic myeloid leukemia (CML) in South Korea. However, therapeutic effects of radotinib in acute myeloid leukemia (AML) are unknown. In the present study, we demonstrate that radotinib significantly decreases the viability of AML cells in a dose-dependent manner. Kasumi-1 cells were more sensitive to radotinib than NB4, HL60, or THP-1 cell lines. Furthermore, radotinib induced CD11b expression in NB4, THP-1, and Kasumi-1 cells either in presence or absence of all trans-retinoic acid (ATRA). We found that radotinib promoted differentiation and induced CD11b expression in AML cells by downregulating LYN. However, CD11b expression induced by ATRA in HL60 cells was decreased by radotinib through upregulation of LYN. Furthermore, radotinib mainly induced apoptosis of CD11b+ cells in the total population of AML cells. Radotinib also increased apoptosis of CD11b+ HL60 cells when they were differentiated by ATRA/dasatinib treatment. We show that radotinib induced apoptosis via caspase-3 activation and the loss of mitochondrial membrane potential (m) in CD11b+ cells differentiated from AML cells. Our results suggest that radotinib may be used as a candidate drug in AML or a chemosensitizer for treatment of AML by other therapeutics. ",
        "Doc_title":"Radotinib Induces Apoptosis of CD11b+ Cells Differentiated from Acute Myeloid Leukemia Cells.",
        "Journal":"PloS one",
        "Do_id":"26065685",
        "Doc_ChemicalList":"4-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide;Antigens, CD11b;Antineoplastic Agents;Benzamides;Protein Kinase Inhibitors;Pyrazines;Tretinoin;lyn protein-tyrosine kinase;src-Family Kinases",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Antigens, CD11b;Antineoplastic Agents;Apoptosis;Benzamides;Cell Line, Tumor;Female;Humans;Leukemia, Myeloid, Acute;Leukocytes;Male;Middle Aged;Protein Kinase Inhibitors;Pyrazines;Tretinoin;src-Family Kinases",
        "Doc_meshqualifiers":"genetics;metabolism;pharmacology;pharmacology;therapeutic use;metabolism;drug effects;metabolism;pharmacology;pharmacology;therapeutic use;pharmacology;genetics;metabolism",
        "_version_":1605799694810742784},
      {
        "Doc_abstract":"Imatinib mesylate (IM) therapy is effective in patients with chronic myeloid leukemia (CML). However, whether it should be discontinued in patients who achieve sustained molecular response is debated. We describe 4 patients with undetectable levels of BCR-ABL transcripts in whom IM therapy was discontinued. Two patients relapsed after 7 and 10 months and promptly responded after restarting therapy; 2 patients are off therapy at the last follow-up visit after 14 and 15 months and are still in complete molecular remission.",
        "Doc_title":"Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation.",
        "Journal":"Haematologica",
        "Do_id":"15996937",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Pyrimidines;Imatinib Mesylate;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Antineoplastic Agents;Benzamides;Female;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Piperazines;Pyrimidines;Recurrence;Remission Induction;Reverse Transcriptase Polymerase Chain Reaction;Time Factors;Treatment Outcome",
        "Doc_meshqualifiers":"therapeutic use;genetics;genetics;therapeutic use;therapeutic use",
        "_version_":1605811076603052032},
      {
        "Doc_abstract":"The well-known typical fusion gene BCR/ABL is observed in connection with a complex translocation event in 5-8% of cases of chronic myeloid leukemia (CML). The present study described an exceptional CML case with complex chromosomal aberrations not previously observed. Aberrations included a translocated BCR to the derivative chromosome 2 [der(2)] that also involved a four-chromosome translocation, implying chromosomal regions 1p32 and 2q21, besides 9q34 and 22q11.2, which were characterized by molecular cytogenetics.",
        "Doc_title":"BCR translocation to derivative chromosome 2: a new case of chronic myeloid leukemia with a complex variant translocation and Philadelphia chromosome.",
        "Journal":"Oncology letters",
        "Do_id":"22966323",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605831784716566528},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) was the first human malignancy to be associated with a single genetic abnormality, characterized by a reciprocal translocation involving chromosomes 9 and 22 (the Philadelphia chromosome). The fusion gene that results (BCR-ABL) produces a constitutively activated tyrosine kinase that exists in different isoforms depending on BCR break-points. Imatinib mesylate is a highly selective inhibitor of this kinase, producing normal blood-counts in 98% of patients in chronic phase CML and disappearance of the Philadelphia chromosome in 86%. However, 17% of patients in the chronic phase will either relapse or develop resistance resulting mainly from one or more point mutations affecting at least 30 amino acids within the Abl kinase protein. This review focuses on the relevant biology of CML, imatinib mesylate resistance mechanisms, and the current status of the next generation of Bcr-Abl inhibitors.",
        "Doc_title":"Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid leukemia.",
        "Journal":"Current hematologic malignancy reports",
        "Do_id":"20425355",
        "Doc_ChemicalList":"4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide;Benzamides;Drugs, Investigational;Piperazines;Protein Isoforms;Protein Kinase Inhibitors;Pyrimidines;Thiazoles;Imatinib Mesylate;Fusion Proteins, bcr-abl;Dasatinib",
        "Doc_meshdescriptors":"Animals;Benzamides;Clinical Trials as Topic;Dasatinib;Drug Delivery Systems;Drug Design;Drug Resistance, Neoplasm;Drug Screening Assays, Antitumor;Drugs, Investigational;Fusion Proteins, bcr-abl;Genes, abl;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Leukemia, Myeloid, Chronic-Phase;Mice;Multicenter Studies as Topic;Mutation;Piperazines;Protein Isoforms;Protein Kinase Inhibitors;Pyrimidines;Signal Transduction;Thiazoles",
        "Doc_meshqualifiers":"genetics;pharmacology;antagonists & inhibitors;genetics;drug therapy;enzymology;genetics;drug therapy;enzymology;genetics;pharmacology;therapeutic use;antagonists & inhibitors;genetics;pharmacology;therapeutic use;pharmacology;therapeutic use;drug effects;genetics;pharmacology;therapeutic use",
        "_version_":1605790365996023808},
      {
        "Doc_abstract":"Treatment of chronic myelogenous leukemia with a specific inhibitor of the Bcr/Abl tyrosine kinase, imatinib, has shown great promise. However, acute lymphoblastic leukemias that express Bcr/Abl only transiently respond to imatinib. Therefore, alternative treatments for this type of leukemia are urgently needed. Here, we examined the activity of the farnesyltransferase inhibitor SCH66336 as a single chemotherapeutic agent in a nude mouse model representative of very advanced stage Bcr/Abl P190-positive lymphoblastic leukemia/lymphoma. Our results show that oral administration of the inhibitor was able to significantly increase the survival of these mice compared to controls treated with vehicle (P<0.005), and caused marked regression of the tumor burden in the treated mice. Upon prolonged treatment, lymphomas re-emerged and a subset of cells from two of such lymphomas tested was able to survive in the presence of increased concentrations of SCH66336. The same cells, however, remained sensitive towards imatinib. A combination of the two drugs, preceded by a therapy to reduce the initial tumor burden, could be very effective in the treatment of Ph-positive ALL. We conclude that SCH66336, on its own, is remarkably effective in eradicating large numbers of lymphoblastic lymphoma cells and causing visible reduction in tumor size, with minimal toxicity.",
        "Doc_title":"A farnesyltransferase inhibitor increases survival of mice with very advanced stage acute lymphoblastic leukemia/lymphoma caused by P190 Bcr/Abl.",
        "Journal":"Leukemia",
        "Do_id":"14603339",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Piperidines;Pyridines;Pyrimidines;Imatinib Mesylate;Alkyl and Aryl Transferases;Farnesyltranstransferase;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl;lonafarnib",
        "Doc_meshdescriptors":"Administration, Oral;Alkyl and Aryl Transferases;Animals;Antineoplastic Agents;Benzamides;Disease Models, Animal;Farnesyltranstransferase;Female;Fusion Proteins, bcr-abl;Imatinib Mesylate;Leukemia, Experimental;Lymphoma;Mice;Mice, Inbred C57BL;Mice, Inbred CBA;Mice, Nude;Mice, Transgenic;Piperazines;Piperidines;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Protein-Tyrosine Kinases;Pyridines;Pyrimidines;Survival Rate;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"antagonists & inhibitors;administration & dosage;adverse effects;therapeutic use;genetics;metabolism;drug therapy;genetics;pathology;drug therapy;genetics;pathology;therapeutic use;administration & dosage;adverse effects;therapeutic use;drug therapy;genetics;pathology;antagonists & inhibitors;administration & dosage;adverse effects;therapeutic use;therapeutic use;transplantation",
        "_version_":1605915434700242944},
      {
        "Doc_abstract":"Tumor-specific alterations in oncogenes are thought to play a central role in the development of cancer. An example is the consistent fusion of the bcr gene to the c-abl oncogene on the Ph chromosome in CML. The Ph chromosome can also be observed in ALL. About 50% of Ph+ ALL cases, in contrast to CML, do not exhibit chromosomal breakpoints in the major cluster region or mcr (Ph+ mcr- ALL). These cases may have a novel bcr-abl fusion gene instead. We tested this hypothesis in eight Ph+ mcr- ALL patients by amplifying the putative hybrid part of the bcr-abl cDNA, using the polymerase chain reaction method. All cases examined showed the same joining of the first exon of the bcr gene to the c-abl oncogene. Thus, the novel bcr-abl fusion in Ph+ mcr- ALL is the result of a molecularly distinct Ph chromosome. This allows the definition of Ph+ leukemias by their respective bcr-abl oncogene activation. Moreover, the cDNA amplification method we use is a clinically useful tool to screen for bcr-abl oncogene activations in leukemia patients.",
        "Doc_title":"bcr-abl oncogene activation in Philadelphia chromosome-positive acute lymphoblastic leukemia.",
        "Journal":"Leukemia",
        "Do_id":"3172839",
        "Doc_ChemicalList":"DNA, Neoplasm;RNA, Messenger;RNA, Neoplasm",
        "Doc_meshdescriptors":"DNA, Neoplasm;Humans;Nucleic Acid Amplification Techniques;Oncogenes;Philadelphia Chromosome;Precursor Cell Lymphoblastic Leukemia-Lymphoma;RNA, Messenger;RNA, Neoplasm;Recombination, Genetic",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics",
        "_version_":1605789009036967936},
      {
        "Doc_abstract":"Manipulation of autologous bone marrow cells (BM) for transplantation in chronic myeloid leukemia (CML) to enrich for normal cells is a novel approach that may improve survival for patients not suitable for allogeneic transplantation. Limitations of this technique include the reported low frequency of normal stem cells in CML and the difficulties in obtaining sufficient BM for manipulation. To address these problems we compared the apheresis product with the diagnostic bone marrow at diagnosis as a source of primitive BCR/ABL-negative progenitors. We analyzed the CD34+ HLA-DR- and CD34+CD38(-) populations in five CML patients to evaluate the frequency of BCR-ABL-negative progenitors and pre-progenitors in these populations. Progenitor analysis was performed by RT-PCR of individual hemopoietic colonies from a standard CFU-GM assay. Analysis of pre-progenitors involved RT-PCR of secondary colonies derived from a stroma-free pre-CFU assay. Our results show variable levels of BCR-ABL-negative progenitors in the 34+DR- population but very low levels of BCR-ABL-negative progenitors in the 34+38- population in blood. Analysis of pre-progenitors from the 34+DR- fraction of peripheral blood (PB) and BM showed 80-100% and 85-100% of colonies were BCR-ABL negative at days 14 and 28, respectively. Analysis of pre-progenitors from the 34+38- fraction of PB and BM showed 23-100% and 42-100% of colonies were BCR-ABL negative at days 14 and 28, respectively. In summary, pre-progenitors from the 34+DR- and 34+38- populations are predominantly BCR-ABL negative in both marrow and blood at diagnosis. Apheresis product collected at diagnosis is a more abundant sources of BCR-ABL-negative pre-progenitors than BM. Thus, apheresis product could potentially be utilized as a source of BCR-ABL-negative stem cells in CML.",
        "Doc_title":"Peripheral blood is a source of BCR-ABL-negative pre-progenitors in early chronic phase chronic myeloid leukemia.",
        "Journal":"Leukemia",
        "Do_id":"9096699",
        "Doc_ChemicalList":"Antigens, CD;Antigens, CD34;Antigens, Differentiation;HLA-DR Antigens;Membrane Glycoproteins;N-Glycosyl Hydrolases;ADP-ribosyl Cyclase;Antigens, CD38;CD38 protein, human",
        "Doc_meshdescriptors":"ADP-ribosyl Cyclase;Adult;Antigens, CD;Antigens, CD34;Antigens, CD38;Antigens, Differentiation;Blood Component Removal;Bone Marrow;Cell Count;Cell Separation;Female;Flow Cytometry;HLA-DR Antigens;Hematopoietic Stem Cells;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Membrane Glycoproteins;Middle Aged;N-Glycosyl Hydrolases;Phenotype",
        "Doc_meshqualifiers":"analysis;analysis;immunology;ultrastructure;analysis;immunology;ultrastructure;blood;analysis",
        "_version_":1605809302107324416},
      {
        "Doc_abstract":"The Philadelphia (Ph1) chromosome results in a fusion of portions of the BCR gene from chromosome 22 and the ABL gene from chromosome 9, producing a chimeric BCR-ABL mRNA and protein. In lymphoblastic leukemias, there are two molecular subtypes of the Ph1 chromosome, one with a rearrangement of the breakpoint cluster region (bcr) of the BCR gene, producing the same 8.5-kilobase BCR-ABL fusion mRNA seen in chronic myelogenous leukemia (CML), and the other, without a bcr rearrangement, producing a 7.0-kilobase BCR-ABL fusion mRNA that is seen only in acute lymphoblastic leukemia (ALL). We studied the molecular subtype of the Ph1 chromosome in 11 cases of Ph1-positive ALL, including 2 with a previous diagnosis of CML, using a sensitive method to analyze the mRNA species based on the polymerase chain reaction (PCR). We observed unexpected heterogeneity in BCR-ABL mRNA in this population; in particular, 1 of 6 bcr-rearranged cases and 1 of 5 bcr-unrearranged cases contained none of the known fusion mRNA species, while 1 of the bcr-rearranged cases contained both. This latter case is particularly interesting because it suggests that the acquisition of an additional BCR-ABL fusion species may be a mechanism of disease progression. We conclude that the PCR gives additional information about the Ph1 chromosome gene products that cannot be obtained by genomic analysis, but that it cannot be used as the sole means of detection of this chromosomal abnormality in ALL because of the high incidence of false negative results.",
        "Doc_title":"Unexpected heterogeneity of BCR-ABL fusion mRNA detected by polymerase chain reaction in Philadelphia chromosome-positive acute lymphoblastic leukemia.",
        "Journal":"Proceedings of the National Academy of Sciences of the United States of America",
        "Do_id":"2498881",
        "Doc_ChemicalList":"Neoplasm Proteins;RNA, Messenger;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl;DNA-Directed DNA Polymerase",
        "Doc_meshdescriptors":"Blotting, Southern;Chromosomes, Human, Pair 9;DNA-Directed DNA Polymerase;Fusion Proteins, bcr-abl;Gene Amplification;Genes;Humans;Karyotyping;Neoplasm Proteins;Philadelphia Chromosome;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Protein-Tyrosine Kinases;RNA, Messenger;Reference Values",
        "Doc_meshqualifiers":"genetics;enzymology;genetics;genetics;analysis;genetics",
        "_version_":1605852604669100032},
      {
        "Doc_abstract":"The patient was a 62-year-old man. His hematological data in April 2000 had shown no abnormalities, but he was referred to our hospital because of a fever and leukocytosis in June 2000. The peripheral blood showed 29.8 x 10(9)/L white blood cells, with 68.0% blasts. A bone marrow aspirate showed hypercellularity with a proliferation of large leukemic blasts. The leukemic cells were positive for CD13 (91%), CD33 (54.8%), CD34 (94.5%), and HLA-DR (97.9%). Some leukemic cells (15.6%) also expressed CD14. Cytogenetic analysis revealed 92,XXYY,t(9;22)(q34;q11)x2 in all 20 metaphase cells. Reverse transcriptase polymerase chain reaction analysis detected the minor BCR/ABL messenger RNA (mRNA) but failed to detect the major BCR/ABL mRNA. The patient achieved complete remission after induction chemotherapy, with no evidence of Philadelphia chromosome (Ph) or minor BCR/ABL mRNA. Ph-positive acute myeloid leukemia (Ph-AML) has rarely been reported. Herein, we report a case of Ph-AML with tetraploidy and review the previously reported Ph-AML cases.",
        "Doc_title":"Philadelphia chromosome-positive acute myeloid leukemia with tetraploidy.",
        "Journal":"International journal of hematology",
        "Do_id":"11843293",
        "Doc_ChemicalList":"Biomarkers, Tumor;RNA, Messenger;RNA, Neoplasm;Cytarabine;Prednisolone;enocitabine;Mitoxantrone;6-Mercaptopurine;Fusion Proteins, bcr-abl;Daunorubicin",
        "Doc_meshdescriptors":"6-Mercaptopurine;Acute Disease;Antineoplastic Combined Chemotherapy Protocols;Biomarkers, Tumor;Cytarabine;Daunorubicin;Fusion Proteins, bcr-abl;Humans;Karyotyping;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Mitoxantrone;Polyploidy;Prednisolone;RNA, Messenger;RNA, Neoplasm;Remission Induction",
        "Doc_meshqualifiers":"administration & dosage;therapeutic use;genetics;administration & dosage;analogs & derivatives;administration & dosage;genetics;genetics;administration & dosage;administration & dosage;genetics;genetics",
        "_version_":1605852575464161280},
      {
        "Doc_abstract":"The expression of c-abl, c-sis, c-myc and N-ras oncogenes was examined in 2 lymphoblastoid cell lines, one with Ph1 (PB-1049) and the other without Ph1 (LN-1049), both established from a patient with chronic myelogenous leukemia (CML), and in a Ph1-positive cell line (PB-1049-T) derived from a tumor formed after transplantation of PB-1049 cells in a nude mouse with reference to their tumorigenic potential in nude mice. The normal transcripts of c-abl were detected in all 3 lymphoblastoid cell lines. Although in situ hybridization of v-abl proved, and restriction endonuclease analyses of the bcr region strongly indicated the occurrence of bcr-abl rearrangement in PB-1049 and PB-1049-T, we could not obtain any evidence for the expression of the hybrid bcr-abl mRNA. These results indicate that the Ph1 translocation does not ensure the production of the hybrid bcr-abl mRNA, and that the expression of hybrid bcr-abl gene is not essential for the maintenance of tumorigenicity of these cell lines. Expression of c-sis was not detected in any of the cell lines examined, whereas the expression of c-myc was uniformly higher in the 3 cell lines than in normal control cells. The levels of N-ras expression varied considerably, probably in parallel with the changes in tumorigenicity of the cell lines. N-ras expression in the PB-1049 and PB-1049-T cell lines was higher than that in the LN-1049 line when they retained tumorigenic potential, but it fell to the level of LN-1049 with loss or decline of tumorigenicity.",
        "Doc_title":"Absence of the hybrid bcr-abl mRNA in Ph1-positive B lymphoblastoid cell lines established from a patient with chronic myelogenous leukemia.",
        "Journal":"International journal of cancer",
        "Do_id":"3121521",
        "Doc_ChemicalList":"RNA, Neoplasm;Recombinant Fusion Proteins;Recombinant Proteins;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Fusion Proteins, bcr-abl;Humans;Leukemia, Myeloid;Lymphocytes;Male;Philadelphia Chromosome;RNA, Neoplasm;Recombinant Fusion Proteins;Recombinant Proteins;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"genetics;analysis;analysis;genetics;analysis;genetics;analysis;analysis",
        "_version_":1605784837904400384},
      {
        "Doc_abstract":"Gene amplification is a relatively rare event in hematologic malignancies. The ABL gene on chromosome band 9q34 is a proto-oncogene and is the well-known translocation partner of the BCR gene on 22q11 giving rise to t(9;22)(q34;q11), which is the hallmark of chronic myeloid leukemia and is the most common chromosomal abnormality in adult acute lymphoblastic leukemia (ALL). Amplification of ABL is an exceedingly rare event, with only less than 5 cases reported in the literature. The p16(INK4a) (or CDKN2A) gene on 9p21 is a tumor suppressor gene, and deletion thereof is recently recognized as one of the most common genetic abnormalities in ALL. The authors herein describe an 8-year-old male patient with precursor T-cell ALL harboring both ABL gene amplification and p16(INK4a) gene deletion. Fluorescence in situ hybridization (FISH) analysis using BCR/ABL probes revealed five or more ABL signals, indicating amplification in 51.5% of interphase nuclei. FISH using p16(INK4a) gene probes showed heterozygous p16(INK4a) deletion in 71.0%. On conventional cytogenetic analysis, however, only 10 metaphases were available, which showed the normal karyotype, 46,XY[10], serving no evidence for the findings on FISH. This is the first report of an ALL case with ABL amplification, and the authors speculate that both ABL proto-oncogene amplification and the p16(INK4a) tumor suppressor gene deletion have been implicated in leukemogenesis in the present case, although whether the ABL amplification truly contributes to the leukemogenesis or merely an epiphenomenon representing underlying genomic instability remains to be determined.",
        "Doc_title":"ABL oncogene amplification with p16(INK4a) gene deletion in precursor T-cell acute lymphoblastic leukemia/lymphoma: report of the first case.",
        "Journal":"American journal of hematology",
        "Do_id":"15282669",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Child;Chromosomes, Human, Pair 9;Gene Amplification;Gene Deletion;Genes, abl;Genes, p16;Humans;In Situ Hybridization, Fluorescence;Karyotyping;Male;Precursor T-Cell Lymphoblastic Leukemia-Lymphoma",
        "Doc_meshqualifiers":"genetics;ultrastructure;genetics",
        "_version_":1605882713863094272},
      {
        "Doc_abstract":"Chronic myeloid leukemia is a malignant clonal alteration of the pluripotent hemopoietic stem cell. The genetic hallmarks of the disease are the t(9,22) (Philadelphia chromosome), registered by conventional cytogenetics in more than 90% of all chronic myeloid leukemia cases and the active tyrosine kinase protein encoded by bcr-abl fusion gene. The constitutively active tyrosine kinase is currently accepted to be the cause of chronic myeloid leukemia. The introduction of imatinib has considerably changed the treatment of chronic myeloid leukemia. Prior studies demonstrated high rates of cytogenetic responses in all phases of the disease.;The authors evaluated the cytogenetic and molecular responses of 21 chronic phase chronic myeloid leukemia patients who were consecutively admitted to their center. 13 of them were primarily treated with imatinib, and the other 7 were heavily pretreated with interferon alpha, cytarabine, all-trans-retinoic acid. Hydroxyurea pretreatment was routinely introduced in all patients until complete hematologic remission. Peripheral blood sample in every 3 months were collected for quantitative real-time polymerase chain reaction, and bone marrow aspirate in every 6 months for conventional cytogenetics.;Hematologic remission could have been achieved with hydroxyurea pretreatment in each patient. Complete cytogenetic remission at the 6th month and major molecular response at the 12th month were observed in each patient.;Imatinib treatment caused complete cytogenetic response and major molecular response in each chronic phase chronic myeloid leukaemia patient in our group. Hydroxyurea might have some effect on the rapid and deep cytogenetic and molecular responses, observed in the primary imatinib-treated group.",
        "Doc_title":"[Imatinib therapy in chronic myeloid leukemia].",
        "Journal":"Orvosi hetilap",
        "Do_id":"18672441",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Nucleic Acid Synthesis Inhibitors;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Imatinib Mesylate;Hydroxyurea",
        "Doc_meshdescriptors":"Antineoplastic Agents;Benzamides;Drug Administration Schedule;Female;Humans;Hydroxyurea;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Nucleic Acid Synthesis Inhibitors;Piperazines;Polymerase Chain Reaction;Protein Kinase Inhibitors;Pyrimidines;Remission Induction;Treatment Outcome",
        "Doc_meshqualifiers":"administration & dosage;therapeutic use;administration & dosage;therapeutic use;drug therapy;pathology;administration & dosage;therapeutic use;therapeutic use;administration & dosage;therapeutic use;therapeutic use",
        "_version_":1605839411800440832},
      {
        "Doc_abstract":"BCR/ABL expression, which is the molecular equivalent of the Philadelphia chromosome, is an independent poor risk factor in acute lymphoblastic leukemia (ALL). We used a two-step (nested) reverse transcriptase polimerase chain reaction (RT-PCR) assay to examine BCR/ABL expression in the diagnostic bone marrow specimen of children with ALL, prospectively. Among 75 de novo ALL patients, 4 (%5.3) were found to be BCR/ABL- ositive, whereas 4 of 17 relapsed patients (23.5%) were positive. This preliminary study in Turkish children showed an incidence similar to reports from Europe and the U.S.A. More intensive chemotherapies and allogeneic bone marrow transplantations (BMT) uring the first remission were planned if a donor was available. Out of 8 BCR/ABL-positive patients, complete remission (CR) was achieved in 7 patients and partial remission (PR) was achieved in 1 patient. Three patients underwent allogeneic BMT during the first CR and 1 under went autologous BMT during the first PR. The Kaplan-Meier estimate of vent-free survival (EFS) of BCR/ABL negative de novo ALL patients was 78.36% at 3 years, whereas the EFS of positive patients was 31.25% at 26  6.4 months. Molecular screening for the Philadelphia chromosome should become a part of the routine diagnostic panel in ALL patients in order to predict which patients have a poor prognosis and need tailored therapy. ",
        "Doc_title":"Detection of BCR/ABL transcripts by reverse transcriptase polimerase chain reaction in pediatric acute Lymphoblastic Leukemia: ncidence and clinical eatures.",
        "Journal":"Turkish journal of haematology : official journal of Turkish Society of Haematology",
        "Do_id":"27263637",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605903607938416640},
      {
        "Doc_abstract":"BCR-ABL tyrosine kinase, generated from the reciprocal chromosomal translocation t(9;22), causes chronic myeloid leukemia (CML). BCR-ABL is inhibited by imatinib; however, several mechanisms of imatinib resistance have been proposed that account for loss of imatinib efficacy in patients with CML. Previously, we showed that overexpression of the efflux drug transporter P-glycoprotein partially contributed to imatinib resistance in imatinib-resistant K562 CML cells having no BCR-ABL mutations. To explain an additional mechanism of drug resistance, we established a subclone (K562/R) of the cells and examined the BCR-ABL signaling pathway in these and wild-type K562 (K562/W) cells. We found the K562/R cells were 15 times more resistant to imatinib than their wild-type counterparts. In both cell lines, BCR-ABL and its downstream signaling molecules, such as ERK1/2, ERK5, STAT5, and AKT, were phosphorylated in the absence of imatinib. In both cell lines, imatinib effectively reduced the phosphorylation of all the above, except ERK1/2, whose phosphorylation was, interestingly, only inhibited in the wild-type cells. We then observed that phospho-ERK1/2 levels decreased in the presence of siRNA targeting BCR-ABL, again, only in the K562/W cells. However, using an ERK1/2 inhibitor, U0126, we found that we could reduce phospho-ERK1/2 levels in K562/R cells and restore their sensitivity to imatinib. Taken together, we conclude that the BCR-ABL-independent activation of ERK1/2 contributes to imatinib resistance in K562/R cells, and that ERK1/2 could be a target for the treatment of CML patients whose imatinib resistance is due to this mechanism.",
        "Doc_title":"Contribution of BCR-ABL-independent activation of ERK1/2 to acquired imatinib resistance in K562 chronic myeloid leukemia cells.",
        "Journal":"Cancer science",
        "Do_id":"19843070",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Imatinib Mesylate;Fusion Proteins, bcr-abl;Mitogen-Activated Protein Kinase 1;Mitogen-Activated Protein Kinase 3",
        "Doc_meshdescriptors":"Antineoplastic Agents;Benzamides;Drug Resistance, Neoplasm;Enzyme Activation;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;K562 Cells;Mitogen-Activated Protein Kinase 1;Mitogen-Activated Protein Kinase 3;Piperazines;Protein Kinase Inhibitors;Pyrimidines",
        "Doc_meshqualifiers":"pharmacology;physiology;antagonists & inhibitors;metabolism;antagonists & inhibitors;metabolism;pharmacology;pharmacology;pharmacology",
        "_version_":1605784032552943616},
      {
        "Doc_abstract":"A 13-year-old boy without any previous illness was diagnosed as suffering from acute lymphoblastic leukemia (ALL). After a period of apparent complete remission until 17 years of age, the presence of Ph1 positive cells in bone marrow was demonstrated by karyotype analysis. This finding suggested chronic myelogenous leukemia (CML) because of the absence of blastic changes in bone marrow but mild leukocytosis with basophilia at that time. Six months later he had a relapse (blast crisis) with the appearance of peroxidase negative lymphoid blasts and myeloid surface markers. To make differential diagnosis, leukemia blasts at onset and relapse were examined for rearrangement of immunoglobulin JH gene and bcr/abl fusion mRNA, and were found to have the same JH gene rearrangement pattern and the same bcr/abl mRNA of bcr exon 2/abl exon 2. These results indicate an unusual case of CML which appeared in blast crisis at onset, followed by a long-term remission.",
        "Doc_title":"bcr/abl mRNA in leukemic blasts of an unusual patient with acute lymphoblastic leukemia followed after 5-year remission by chronic myelogenous leukemia in blast crisis.",
        "Journal":"Leukemia",
        "Do_id":"8090037",
        "Doc_ChemicalList":"RNA, Messenger;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adolescent;Blast Crisis;Fusion Proteins, bcr-abl;Gene Rearrangement, B-Lymphocyte, Heavy Chain;Humans;Immunophenotyping;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Philadelphia Chromosome;Polymerase Chain Reaction;Precursor Cell Lymphoblastic Leukemia-Lymphoma;RNA, Messenger;Remission Induction",
        "Doc_meshqualifiers":"genetics;metabolism;pathology;genetics;genetics;metabolism;pathology;genetics;metabolism;pathology;metabolism",
        "_version_":1605884056505942016},
      {
        "Doc_abstract":"The BCR/ABL kinase has been targeted for the treatment of chronic myelogenous leukemia (CML) by imatinib mesylate. While imatinib has been extremely effective for chronic phase CML, blast crisis CML and Ph+ acute lymphoblastic leukemia (ALL) are often resistant. In particular, mutation of the T315 residue in the bcr/abl activation loop renders cells highly resistant to imatinib and to second-generation kinase inhibitors such as BMS-354825 or AMN107. Adaphostin is a tyrphostin that was originally intended to inhibit the BCR/ABL kinase by competing with its peptide substrates. Recent findings have in addition implicated reactive oxygen species (ROS) in the cytotoxic mechanism of adaphostin. In view of this unique mode of action, we examined the effects of adaphostin on numerous imatinib-resistant leukemia models, including imatinib-resistant CML and Ph+ ALL cell lines, cells harboring point mutations in BCR/ABL, and specimens from imatinib-resistant CML patients, using assays for intracellular ROS, apoptosis, and clonogenicity. Every model of imatinib resistance examined remained fully sensitive to adaphostin-induced cell death. Collectively, these data suggest that ROS generation by adaphostin overcomes even the most potent imatinib resistance in CML and Ph+ ALL.",
        "Doc_title":"Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance.",
        "Journal":"Blood",
        "Do_id":"16291594",
        "Doc_ChemicalList":"Benzamides;Hydroquinones;NSC 680410;Piperazines;Pyrimidines;Reactive Oxygen Species;Imatinib Mesylate;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl;Adamantane",
        "Doc_meshdescriptors":"Adamantane;Apoptosis;Benzamides;Cell Line, Tumor;Clone Cells;Drug Resistance, Neoplasm;Fusion Proteins, bcr-abl;Humans;Hydroquinones;Imatinib Mesylate;Leukemia;Mutation;Oxidative Stress;Piperazines;Protein-Tyrosine Kinases;Pyrimidines;Reactive Oxygen Species",
        "Doc_meshqualifiers":"analogs & derivatives;pharmacology;genetics;pharmacology;drug therapy;genetics;pathology;drug effects;pharmacology;antagonists & inhibitors;genetics;pharmacology",
        "_version_":1605877179195850752},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by clonal expansion of cells in the myeloid line, expressing the BCR-ABL fusion protein responsible for the oncogenic effect of CML. The current frontline therapy in CML is the BCR-ABL tyrosine kinase inhibitor, Imatinib. Although this drug has been shown to improve survival in CML patients, its role in the context of a transplant setting has not been widely described in the literature. We report on the long term molecular remission of CML in a 55 year old man with a second renal transplant who is hepatitis C virus positive, and has associated cardiovascular and immunological risk factors.",
        "Doc_title":"[Molecular remission of chronic myeloid leukaemia in a patient with hepatitis and a second kidney transplant].",
        "Journal":"Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia",
        "Do_id":"19936007",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Hepatitis C;Humans;Kidney Transplantation;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Remission Induction;Reoperation",
        "Doc_meshqualifiers":"complications;complications;surgery",
        "_version_":1605811507400015872},
      {
        "Doc_abstract":"The introduction of targeted therapy has revolutionized the treatment of chronic myeloid leukemia (CML). The pivotal role of the Philadelphia chromosome, resulting from the breakpoint cluster region-Abelson (BCR-ABL) translocation, led to the development of imatinib mesylate, a tyrosine kinase inhibitor with significant activity against the BCR-ABL oncoprotein. Unprecedented clinical activity in CML led to rapid approval and established first-line therapy with imatinib mesylate as the standard of care in most patients. However, the occurrence of imatinib resistance or intolerance has sparked the development of newer drugs with increased activity or specificity. Nilotinib is a second-generation tyrosine kinase inhibitor that has been rationally designed on the basis of imatinib. An overview is given on clinical results in imatinib-resistant or -intolerant patients that led to its current approval as second-line therapy for the chronic and accelerated phases of CML. Future studies will address the role of nilotinib as first-line therapy, in combination strategies and in the context of specific BCR-ABL mutations.",
        "Doc_title":"Nilotinib for the treatment of chronic myeloid leukemia.",
        "Journal":"Expert review of hematology",
        "Do_id":"21083005",
        "Doc_ChemicalList":"4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide;Antineoplastic Agents;Benzamides;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Imatinib Mesylate;Protein-Tyrosine Kinases",
        "Doc_meshdescriptors":"Antineoplastic Agents;Benzamides;Clinical Trials as Topic;Drug Evaluation, Preclinical;Drug Resistance, Neoplasm;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Piperazines;Protein Kinase Inhibitors;Protein-Tyrosine Kinases;Pyrimidines",
        "Doc_meshqualifiers":"chemistry;pharmacokinetics;therapeutic use;drug therapy;economics;economics;therapeutic use;chemistry;pharmacokinetics;therapeutic use;antagonists & inhibitors;metabolism;chemistry;economics;pharmacokinetics;therapeutic use",
        "_version_":1605808295819345920},
      {
        "Doc_abstract":"Imatinib mesylate (IM), a selective tyrosine kinase inhibitor of the oncoprotein BCR-ABL, is the 'gold standard' for patients with chronic myeloid leukemia (CML) but the drug does not eliminate CML stem cells, leading to disease relapse on drug discontinuation. At present, much effort is focused on delivery carriers that can increase the intracellular retention and antileukemic impact of IM. We previously validated IM-loaded polyelectrolyte microcapsules as effective purging agents to eradicate BCR-ABL(+) cells from CML patient autografts. The aim is to develop controlled release carriers that can increase the intracellular retention and functionality of IM in leukemia cells.;Herein, novel polyelectrolyte complexes were used as model carriers for IM in a CML cell line (KU812) and CD34(+) cells freshly isolated from patients.;Polyelectrolyte complexes promoted a long-acting BCR-ABL kinase inactivation that was necessary to promote apoptosis at approximately twofold lower intracellular IM dose compared with the microscale formulation polyelectrolyte microcapsules.;IM-loaded polyelectrolyte complexes can be used as more efficient delivery devices for overcoming drug resistance of BCR-ABL(+) leukemic cells.",
        "Doc_title":"Uptake of imatinib-loaded polyelectrolyte complexes by BCR-ABL(+) cells: a long-acting drug-delivery strategy for targeting oncoprotein activity.",
        "Journal":"Nanomedicine (London, England)",
        "Do_id":"24364873",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Electrolytes;Oncogene Proteins;Piperazines;Pyrimidines;Imatinib Mesylate;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Antineoplastic Agents;Benzamides;Drug Delivery Systems;Electrolytes;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Oncogene Proteins;Piperazines;Pyrimidines",
        "Doc_meshqualifiers":"administration & dosage;administration & dosage;administration & dosage;drug therapy;genetics;metabolism;administration & dosage;administration & dosage",
        "_version_":1605757456788488192},
      {
        "Doc_abstract":"Micro-RNAs (miRNAs) control gene expression by destabilizing targeted transcripts and inhibiting their translation. Aberrant expression of miRNAs has been described in many human cancers, including chronic myeloid leukemia. Current first-line therapy for newly diagnosed chronic myeloid leukemia is imatinib mesylate, which typically produces a rapid hematologic response. However the effect of imatinib on miRNA expression in vivo has not been thoroughly examined.;Using a TaqMan Low-Density Array system, we analyzed miRNA expression in blood samples from newly diagnosed chronic myeloid leukemia patients before and within the first two weeks of imatinib therapy. Quantitative real-time PCR was used to validate imatinib-modulated miRNAs in sequential primary chronic myeloid leukemia samples (n=11, plus 12 additional validation patients). Bioinformatic target gene prediction analysis was performed based on changes in miRNA expression.;We observed increased expression of miR-150 and miR-146a, and reduced expression of miR-142-3p and miR-199b-5p (3-fold median change) after two weeks of imatinib therapy. A significant correlation (P<0.05) between the Sokal score and pre-treatment miR-142-3p levels was noted. Expression changes in the same miRNAs were consistently found in an additional cohort of chronic myeloid leukemia patients, as compared to healthy subjects. Peripheral blood cells from chronic phase and blast crisis patients displayed a 30-fold lower expression of miR-150 compared to normal samples, which is of particular interest since c-Myb, a known target of miR-150, was recently shown to be necessary for Bcr-Abl-mediated transformation.;We found that imatinib treatment of chronic myeloid leukemia patients rapidly normalizes the characteristic miRNA expression profile, suggesting that miRNAs may serve as a novel clinically useful biomarker in this disease.",
        "Doc_title":"Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia.",
        "Journal":"Haematologica",
        "Do_id":"20460641",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;MIRN150 microRNA, human;MicroRNAs;Piperazines;Pyrimidines;Imatinib Mesylate",
        "Doc_meshdescriptors":"Aged;Antineoplastic Agents;Benzamides;Cells, Cultured;Female;Gene Expression Profiling;Gene Expression Regulation, Leukemic;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;MicroRNAs;Middle Aged;Oligonucleotide Array Sequence Analysis;Piperazines;Pyrimidines;Reverse Transcriptase Polymerase Chain Reaction;Time Factors",
        "Doc_meshqualifiers":"therapeutic use;drug effects;drug therapy;genetics;pathology;genetics;therapeutic use;therapeutic use",
        "_version_":1605763070831886336},
      {
        "Doc_abstract":"Imatinib mesylate induces a complete cytogenetic response (CCR) in many patients with chronic myeloid leukemia (CML). However, the ultimate goal of therapy for CML is complete elimination of Philadelphia chromosome positive cells or BCR-ABL rearrangements. We studied molecular responses in CML patients in CCR after imatinib treatment.;Real-time quantitative reverse transcriptase polymerase chain reaction analysis were used to monitor BCR-ABL levels in 59 CCR patients. Negative results were confirmed by two different techniques performed in two different laboratories. Patients were considered in complete molecular remission if they had four undetectable analyses from two separate samples taken three months apart.;The median follow-up was 41 months (17-53). The median BCR-ABL/ABL ratio at the time of CCR was 0.3 % (0-9.88). Patients were split into two groups: group A (n=43) comprised patients with a detectable BCR-ABL/ABL ratio throughout the follow-up and group B (n=16) included those with an undetectable level of BCR-ABL/ABL (< 10(-5)) i.e. in complete molecular remission. No relapses were observed in group B, while 13 group A patients lost their CCR. The probability of losing CCR in this group was 33.2 % >+/-18.0. By Cox regression analysis the best factor for predicting the probability of achieving molecular remission was having a CCR at 6 months (p=0.038) or at 3 months (p=0.024).;Molecular remission after imatinib treatment, i.e. BCR-ABL/ABL< 10-5 in peripheral blood, is not a rare event, particularly in patients achieving CCR at 6 months.",
        "Doc_title":"Molecular remission in chronic myeloid leukemia patients with sustained complete cytogenetic remission after imatinib mesylate treatment.",
        "Journal":"Haematologica",
        "Do_id":"16461299",
        "Doc_ChemicalList":"Benzamides;Piperazines;Pyrimidines;Imatinib Mesylate;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Benzamides;Cytogenetic Analysis;Female;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Piperazines;Polymerase Chain Reaction;Pyrimidines;Remission Induction",
        "Doc_meshqualifiers":"analysis;diagnosis;drug therapy;administration & dosage;administration & dosage;methods",
        "_version_":1605749644669747200},
      {
        "Doc_abstract":"We evaluated bone marrow pathologic features and cytogenetic and molecular genetic status of 13 patients with interferon-resistant, chronic-phase chronic myeloid leukemia (CML), treated with imatinib mesylate (Gleevec). All had morphologic evidence of CML in the blood and bone marrow and were positive for bcr-abl by reverse transcriptase-polymerase chain reaction, fluorescence in situ hybridization (FISH), or both. Follow-up marrow biopsies, interphase FISH for bcr-abl, and conventional cytogenetics were performed at 3-month intervals (up to 24 months) after therapy initiation. All patients exhibited a reduction in bone marrow cellularity with decreases in myeloid/erythroid ratios at 3 to 6 months after therapy. The percentage of bcr-abl-positive cells by FISH decreased in all patients (pretherapy median, 73%; 3 months median, 47%). Cytogenetic and FISH data defined 2 groups after 6 months of follow-up: 5 patients became negative for bcr-abl by FISH; 8 remained positive, 4 of whom developed signs of clonal cytogenetic evolution. Patients who became negative for bcr-abl had no morphologic evidence of CML at 15 to 24 months of follow-up, whereas patients who remained positive redeveloped morphologic features of CML as cellularity increased. Some bcr-abl-positive patients showed signs of progression, including 2 patients who developed myeloid blast phase. Although all patients demonstrated an initial decrease in bone marrow cellularity after imatinib mesylate therapy, continued follow-up showed that histopathologic findings correlated with genetic response.",
        "Doc_title":"Chronic myeloid leukemia following therapy with imatinib mesylate (Gleevec). Bone marrow histopathology and correlation with genetic status.",
        "Journal":"American journal of clinical pathology",
        "Do_id":"12817431",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Pyrimidines;Reticulin;Imatinib Mesylate;Interferons;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Antineoplastic Agents;Benzamides;Biopsy;Bone Marrow;Cytogenetic Analysis;Drug Resistance;Fibrosis;Fusion Proteins, bcr-abl;Histiocytes;Humans;Hyperplasia;Imatinib Mesylate;In Situ Hybridization, Fluorescence;Interferons;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Leukocyte Count;Megakaryocytes;Piperazines;Pyrimidines;Reticulin;Reverse Transcriptase Polymerase Chain Reaction",
        "Doc_meshqualifiers":"therapeutic use;pathology;genetics;pathology;drug therapy;genetics;pathology;pathology;therapeutic use;therapeutic use;analysis",
        "_version_":1605794710156214272},
      {
        "Doc_abstract":"The BCR/ABL fusion protein transforms myeloid stem cells. Both chronic myelogenous leukemias (CML) and a subset of acute lymphoblastic leukemias (ALL) are associated with the expression of BCR/ABL proteins. This knowledge has not yet been translated into any specific tool to control ABL driven neoplastic cells growth. CGP57148B is an ATP-competitive inhibitor of the ABL protein kinase; it has been shown to inhibit the kinase activity of ABL both in vitro and in vivo and to inhibit the growth of v-abl and bcr/abl transfectants, as well as the in vitro formation of bone marrow (BM)-derived colonies in the presence of growth factors in some CML patients. These studies were performed to investigate the activity of CGP57148B on the spontaneous proliferation of both fresh and cultured, leukemic and normal, BCR/ABL positive and negative cells, and to study its mechanism of action. Six cell lines derived from BCR/ABL+ leukemias (K562, BV173, KCL22, KU812, MC3, LAMA84), thirteen BCR/ABL negative lines, both neoplastic (KG1, SU-DHL-1, U937, Daudi, NB4, NB4.306) and derived from normal cells (PHA blasts, LAK, fibroblasts, LCL, renal epithelial cells, endothelial cells, CD34(+) cells), and 14 fresh leukemic samples were tested using a tritiated thymidine uptake assay. The in vivo phosphorylation of the BCR/ABL protein was evaluated by western blot, while apoptosis was detected by the annexin V/propidium binding test. The induction of differentiation was assayed by immunofluorescence using multiple antibodies. All six BCR/ABL+ lines showed a dose dependent inhibition of their spontaneous proliferative rate, which was not accompanied by differentiation. The treatment caused, within minutes, dephosphorylation of the BCR/ABL protein, followed in 16-24 hours by a decrease in cycling cells and induction of apoptosis. No significant inhibition of DNA synthesis was observed in any BCR/ABL negative normal or neoplastic line at concentrations </=3 microM, with the exception of fibroblasts and CD34 cells. Proliferation inhibition was observed also when using fresh samples obtained from two Ph+ ALL and 12 consecutive CML patients. Induction of apoptosis was observed in these samples too. The activity of CGP57148B can be monitored in ex vivo isolated or cultured cells using a simple and reproducible assay, without the need for exogenously added growth factors. This molecule possibly exerts its effects through the inhibition of the kinase activity of BCR/ABL and the subsequent initiation of apoptosis, without inducing cell differentiation. Some normal cells are also affected. These data support the use of CGP57148B in initial clinical studies; possible toxic effects on BM and fibroblast-derived cells will have to be closely monitored. The in vivo monitoring of patients will have to be focused on the induction of apoptosis in leukemic cells.",
        "Doc_title":"Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis.",
        "Journal":"Blood cells, molecules & diseases",
        "Do_id":"9446752",
        "Doc_ChemicalList":"Benzamides;Piperazines;Pyrimidines;Imatinib Mesylate;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Apoptosis;Benzamides;Cell Differentiation;Cell Division;Cell Line;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Leukemia, Myeloid;Phosphorylation;Piperazines;Protein-Tyrosine Kinases;Pyrimidines;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"drug effects;drug effects;drug effects;antagonists & inhibitors;classification;metabolism;enzymology;pathology;drug effects;pharmacology;antagonists & inhibitors;pharmacology",
        "_version_":1605799632544202752},
      {
        "Doc_abstract":"Imatinib mesylate is considered the standard first-line systemic treatment for patients with chronic myeloid leukemia (CML) and functions by targeting BCR-ABL tyrosine kinases. Imatinib has substantially changed the clinical management and improved the prognosis of CML and Philadelphia chromosome-positive acute lymphocytic leukemia (Ph(+) ALL). Here, we review the pharmacology, mode of action, and pharmacokinetics of imatinib; Chinese efficacy studies in CML and Ph(+) ALL; safety and tolerability; patient-focused perspectives, such as quality of life, patient satisfaction, acceptability, and adherence; and uptake of imatinib. ",
        "Doc_title":"Clinical efficacy and safety of imatinib in the management of Ph(+) chronic myeloid or acute lymphoblastic leukemia in Chinese patients.",
        "Journal":"OncoTargets and therapy",
        "Do_id":"24623982",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605821834492641280},
      {
        "Doc_abstract":"Chronic Myeloid Leukemia (CML), a myeloproliferative disease of stem cell origin, is characterized by the presence of the Philadelphia (Ph) chromosome and the bcr-abl oncogene. The BCR-ABL fusion gene product, thought to be causative in CML, has multiple effects on diverse cell functions such as growth, differentiation and turnover as well as adhesion and apoptosis. Persistent Ph-negative progenitors co-exist with leukemic cells, both in the marrow and blood of patients, in the early chronic phase of the disease. Despite accumulating knowledge of hemopoiesis and the disease process, CML remains incurable with conventional chemotherapy. Nonetheless, with the efficacy of the ABL tyrosine kinase inhibitor STI-571 (signal transduction inhibitor 571) as a novel therapy in CML recently being realized in clinical trials, it is therefore timely to review our current understanding of the cell biology of this fascinating disease.",
        "Doc_title":"A comparison of normal and leukemic stem cell biology in Chronic Myeloid Leukemia.",
        "Journal":"Hematological oncology",
        "Do_id":"11574931",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Animals;Fusion Proteins, bcr-abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Neoplastic Stem Cells;Philadelphia Chromosome;Signal Transduction;Stem Cells;Telomere",
        "Doc_meshqualifiers":"pharmacology;physiology;etiology;genetics;pathology;metabolism;pathology;physiology;drug effects;cytology;metabolism;physiology;metabolism",
        "_version_":1605813054095753216},
      {
        "Doc_abstract":"We studied lineage-specific chimerism and minimal residual disease (MRD) in sequential posttransplant samples from 55 patients who underwent unmanipulated (n = 44) or partially T-cell-depleted (n = 11) allogeneic bone marrow transplantation (BMT) for chronic myeloid leukemia (CML). Chimerism was assessed by polymerase chain reaction (VNTR [variable number of tandem repeats]-PCR) analysis in highly purified CD19+, CD3+, CD15+, and CD56+ cell fractions, whereas MRD was investigated in whole blood by reverse transcriptase-PCR (RT-PCR) of both p210(BCR-ABL) and p190(BCR-ABL) hybrid transcripts. Of 55 patients, 14 (including 6 T-cell-depleted patients) had cytogenetic relapse at 5-80 months and progressed to hematologic relapse, while 41 patients remained in prolonged cytogenetic remission 12-107 months post-BMT. Before leukemia recurrence, patients in the relapse group showed a consistent evolution pattern sequentially featured by persistent p210(BCR-ABL) positivity, increasing mixed chimerism (MC) in myeloid cells, p190(BCR-ABL) positivity, and, finally, cytogenetic relapse. Myeloid MC preceded cytogenetic relapse by 2-12 months, whereas p190(BCR/ABL) was detected 1-6 months prior to cytogenetic relapse in 11 patients and concomitant with cytogenetic relapse in 3 patients. In the remission group, all patients invariably tested negative for p190(BCR-ABL); 10 patients tested positive for p210(BCR-ABL) at variable time-points but showed persistent full donor chimerism (DC), whereas 31 patients tested p210(BCR-ABL) negative and displayed full DC or transient MC due to the persistence of recipient T cells. Two patients in the relapse group were successfully reinduced into molecular remission with donor lymphocyte infusion. Sequential molecular analysis after such treatment showed the inverse pattern to that observed prior to relapse, ie, progressive disappearance of p190(BCR-ABL) transcripts, conversion of myeloid chimerism to donor type, and, finally, p210(BCR-ABL) negativity. We conclude that lineage-specific chimerism and p190(BCR-ABL) messenger RNA (mRNA) analyses contribute a better characterization of CML evolution after BMT and enable early identification of patients at the highest risk of relapse. (Blood. 2000;95:2659-2665)",
        "Doc_title":"Molecular analysis of lineage-specific chimerism and minimal residual disease by RT-PCR of p210(BCR-ABL) and p190(BCR-ABL) after allogeneic bone marrow transplantation for chronic myeloid leukemia: increasing mixed myeloid chimerism and p190(BCR-ABL) detection precede cytogenetic relapse.",
        "Journal":"Blood",
        "Do_id":"10753848",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adolescent;Adult;Bone Marrow Transplantation;Cell Lineage;Child;Female;Fusion Proteins, bcr-abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Neoplasm, Residual;Predictive Value of Tests;Recurrence;Reverse Transcriptase Polymerase Chain Reaction;Transplantation Chimera;Transplantation, Homologous",
        "Doc_meshqualifiers":"genetics;genetics;genetics;pathology;therapy;diagnosis;genetics;genetics",
        "_version_":1605747556096147456},
      {
        "Doc_abstract":"STI571 (imatinib; Gleevec) was developed to specifically target the tyrosine kinase activity of the Bcr-Abl protein in Philadelphia chromosome-positive chronic myeloid leukemia (CML). It also inhibits the activity of c-Kit and PDGFR. It is the first-line drug for newly diagnosed CML, with remarkable efficacy to patients in the chronic phase of this cancer. However, CML patients in the accelerated phase or blast crisis often relapse due to drug resistance. STI571 fails to eradicate leukemic stem cells, and BCR-ABL(+). cells remain detectable in the majority of patients. The necessity for alternative or additional treatment for STI571-resistant leukemia resulted in the development of a second generation of drugs for targeted therapies. In this review a literature overview of the alternative inhibitors which were designed to override STI571 resistance and decrease the aberrant kinase activity of Bcr-Abl protein with higher efficiency is presented.",
        "Doc_title":"[Novel inhibitors of Bcr-Abl].",
        "Journal":"Postepy higieny i medycyny doswiadczalnej (Online)",
        "Do_id":"17245319",
        "Doc_ChemicalList":"4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide;AP23464;Antineoplastic Agents;Benzamides;Hydroxamic Acids;Indoles;PD 166326;PD 180970;Piperazines;Protein Kinase Inhibitors;Pyridines;Pyridones;Pyrimidines;Thiazoles;bafetinib;Imatinib Mesylate;Adenosine Triphosphate;panobinostat;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl;Dasatinib",
        "Doc_meshdescriptors":"Adenosine Triphosphate;Animals;Antineoplastic Agents;Benzamides;Dasatinib;Drug Resistance, Neoplasm;Fusion Proteins, bcr-abl;Humans;Hydroxamic Acids;Imatinib Mesylate;Indoles;Inhibitory Concentration 50;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mice;Molecular Structure;Mutation;Piperazines;Protein Kinase Inhibitors;Protein-Tyrosine Kinases;Pyridines;Pyridones;Pyrimidines;Thiazoles",
        "Doc_meshqualifiers":"analogs & derivatives;chemistry;pharmacology;therapeutic use;antagonists & inhibitors;drug effects;drug therapy;metabolism;chemistry;pharmacology;therapeutic use;antagonists & inhibitors",
        "_version_":1605763343268708352},
      {
        "Doc_abstract":"LMO2 is highly expressed at the most immature stages of lymphopoiesis. In T-lymphocytes, aberrant LMO2 expression beyond those stages leads to T-cell acute lymphoblastic leukemia, while in B cells LMO2 is also expressed in germinal center lymphocytes and diffuse large B-cell lymphomas, where it predicts better clinical outcome. The implication of LMO2 in B-cell acute lymphoblastic leukemia must still be explored.;We measured LMO2 expression by real time RT-PCR in 247 acute lymphoblastic leukemia patient samples with cytogenetic data (144 of them also with survival and immunophenotypical data) and in normal hematopoietic and lymphoid cells.;B-cell acute lymphoblastic leukemia cases expressed variable levels of LMO2 depending on immunophenotypical and cytogenetic features. Thus, the most immature subtype, pro-B cells, displayed three-fold higher LMO2 expression than pre-B cells, common-CD10+ or mature subtypes. Additionally, cases with TEL-AML1 or MLL rearrangements exhibited two-fold higher LMO2 expression compared to cases with BCR-ABL rearrangements or hyperdyploid karyotype. Clinically, high LMO2 expression correlated with better overall survival in adult patients (5-year survival rate 64.8% (42.5%-87.1%) vs. 25.8% (10.9%-40.7%), P= 0.001) and constituted a favorable independent prognostic factor in B-ALL with normal karyotype: 5-year survival rate 80.3% (66.4%-94.2%) vs. 63.0% (46.1%-79.9%) (P= 0.043).;Our data indicate that LMO2 expression depends on the molecular features and the differentiation stage of B-cell acute lymphoblastic leukemia cells. Furthermore, assessment of LMO2 expression in adult patients with a normal karyotype, a group which lacks molecular prognostic factors, could be of clinical relevance.",
        "Doc_title":"LMO2 expression reflects the different stages of blast maturation and genetic features in B-cell acute lymphoblastic leukemia and predicts clinical outcome.",
        "Journal":"Haematologica",
        "Do_id":"21459790",
        "Doc_ChemicalList":"Adaptor Proteins, Signal Transducing;DNA-Binding Proteins;LIM Domain Proteins;LMO2 protein, human;Metalloproteins;Proto-Oncogene Proteins",
        "Doc_meshdescriptors":"Adaptor Proteins, Signal Transducing;Adolescent;Adult;Age Factors;Aged;Aged, 80 and over;B-Lymphocyte Subsets;Cell Differentiation;Cell Line, Tumor;Child;Child, Preschool;DNA-Binding Proteins;Gene Expression Regulation, Leukemic;Humans;Immunophenotyping;Infant;Karyotyping;LIM Domain Proteins;Metalloproteins;Middle Aged;Precursor B-Cell Lymphoblastic Leukemia-Lymphoma;Precursor T-Cell Lymphoblastic Leukemia-Lymphoma;Prognosis;Proto-Oncogene Proteins;Survival Analysis;Treatment Outcome;Young Adult",
        "Doc_meshqualifiers":"metabolism;genetics;genetics;genetics;diagnosis;genetics;metabolism;mortality;genetics",
        "_version_":1605904825656016896},
      {
        "Doc_abstract":"Our previous study demonstrates that Bcr-Abl fusion oncogene frequently found in chronic myeloid leukemia (CML) cells can up-regulate Skp2 expression via transcriptional activation. However, Bcr-Abl also modulates Skp2 protein stability in these cells. Treatment of Bcr-Abl kinase inhibitor imatinib led to G1 growth arrest accompanied with reduced Skp2 expression. Interestingly, reduction of Skp2 protein occurred prior to down-regulation of Skp2 mRNA suggesting a post-translational control. The half-life of Skp2 protein was significantly attenuated in imatinib-treated cells. These effects are not cell line specific because similar results were also found in CML cells obtained from patients. Knockdown of Bcr-Abl similarly caused Skp2 protein instability. The decrease of Skp2 was induced by increased protein degradation through the ubiquitin/proteasome pathway. Imatinib treatment or Bcr-Abl knockdown reduced Emi1, an endogenous inhibitor of the E3 ligase APC/Cdh1 which mediated Skp2 degradation. We found that Emi1 stability was regulated by phosphorylation and mutation of tyrosine 142 reduced the stability. Our data suggested Bcr-Abl-induced Emi1 phosphorylation might be mediated by Src kinase. Firstly, Src inhibitor SU6656 inhibited Emi1 tyrosine phosphorylation in K562 cells. Secondly, transfection of v-Src rescued the reduction of Emi1 by imatinib. Thirdly, mutation of tyrosine 142 to phenylalanine (Y142F) abolished the phosphorylation of Emi1 by recombinant Src kinase. In addition, ectopic expression of wild type but not Y142F mutant Emi1 counteracted imatinib-caused growth arrest. Collectively, our results suggest that Bcr-Abl increases Emi1 phosphorylation and stability to prevent Skp2 protein degradation via APC/Cdh1-induced ubiquitination and to enhance proliferation of CML cells.",
        "Doc_title":"Bcr-Abl-induced tyrosine phosphorylation of Emi1 to stabilize Skp2 protein via inhibition of ubiquitination in chronic myeloid leukemia cells.",
        "Journal":"Journal of cellular physiology",
        "Do_id":"20717963",
        "Doc_ChemicalList":"CDH1 protein, human;Cadherins;Cell Cycle Proteins;F-Box Proteins;FBXO5 protein, human;S-Phase Kinase-Associated Proteins;Tyrosine;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Cadherins;Cell Cycle Proteins;F-Box Proteins;Fusion Proteins, bcr-abl;Humans;K562 Cells;Mutagenesis, Site-Directed;Phosphorylation;S-Phase Kinase-Associated Proteins;Tyrosine;Ubiquitination",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;metabolism;genetics;metabolism;antagonists & inhibitors;genetics;metabolism;genetics;metabolism;metabolism",
        "_version_":1605891985559781376},
      {
        "Doc_abstract":"We carried out fluorescence in situ hybridization (FISH) studies on 18 Ph+ chronic myeloid leukemia (CML) cases with chromosome 22 genomic deletions with the Vysis BCR-ABL dual-color/dual-fusion probe (BCR-ABL DC/DF) to compare the hybridization patterns obtained with this approach to those obtained with the \"home brew\" BAC/PAC system. Our results are the following: chromosome 22 microdeletions less than 400 kilobases (Kb) were not detected by the BCR DC/DF probe; FISH analysis with the BCR DC/DF probe in cases bearing chromosome 22 microdeletions ranging from 400 to 700 Kb produced a faint signal on the der(9); and the BCR-ABL DC/DF FISH pattern was comparable to the one obtained by the home brew probe in the presence of a 900-Kb chromosome 22 microdeletion. Our home-brew FISH system represents an accurate method for revealing a subset of CML patients with der(9) microdeletions.",
        "Doc_title":"\"Home-brew\" FISH assay shows higher efficiency than BCR-ABL dual color, dual fusion probe in detecting microdeletions and complex rearrangements associated with t(9;22) in chronic myeloid leukemia.",
        "Journal":"Cancer genetics and cytogenetics",
        "Do_id":"17452253",
        "Doc_ChemicalList":"DNA Probes;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Chromosome Deletion;Chromosomes, Human, Pair 22;Chromosomes, Human, Pair 9;DNA Probes;Fusion Proteins, bcr-abl;Gene Rearrangement;Humans;In Situ Hybridization, Fluorescence;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Reproducibility of Results;Translocation, Genetic",
        "Doc_meshqualifiers":"genetics;genetics;methods;genetics",
        "_version_":1605832020043235328},
      {
        "Doc_abstract":"Treatments for chronic myeloid leukemia (CML) represent a success story in molecular medicine. The development of imatinib, a tyrosine kinase inhibitor (TKI) targeted against the causative Bcr-Abl oncoprotein in CML, has resulted in hematologic and cytogenetic remissions in all phases of CML. A significant proportion of patients are resistant to imatinib or develop resistance during treatment. This is often a result of mutated forms of the Bcr-Abl oncoprotein to which imatinib is unable to bind. Several strategies have been developed to overcome the problem of imatinib resistance, including high-dose imatinib, novel targeted agents, and combination treatments. Novel agents include dasatinib, a potent TKI that inhibits several critical oncogenic proteins and which has recently been approved for patients with CML who are resistant or intolerant to imatinib; and nilotinib, a potent selective Bcr-Abl kinase inhibitor currently in clinical development. Other agents in development include SKI-606 and INNO-406. Stem cell transplantation remains a useful option, although it is not generally used as first-line treatment. Overall, there are an increasing number of treatment options available for patients with CML.",
        "Doc_title":"Current and emerging treatment options in chronic myeloid leukemia.",
        "Journal":"Cancer",
        "Do_id":"17431887",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Imatinib Mesylate",
        "Doc_meshdescriptors":"Antineoplastic Agents;Benzamides;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Piperazines;Protein Kinase Inhibitors;Pyrimidines",
        "Doc_meshqualifiers":"therapeutic use;drug therapy;metabolism;therapeutic use;therapeutic use;therapeutic use",
        "_version_":1605852071415775232},
      {
        "Doc_abstract":"The targeting of BCR-ABL, a hybrid oncogenic tyrosine (Y) kinase, does not eradicate chronic myeloid leukemia (CML)-initiating cells. Activation of -catenin was linked to CML leukemogenesis and drug resistance through its BCR-ABL-dependent Y phosphorylation and impaired binding to GSK3 (glycogen synthase kinase 3). Herein, we show that GSK3 is constitutively Y(216) phospho-activated and predominantly relocated to the cytoplasm in primary CML stem/progenitor cells compared with its balanced active/inactive levels and cytosolic/nuclear distribution in normal cells. Under cytokine support, persistent GSK3 activity and its altered subcellular localization were correlated with BCR-ABL-dependent and -independent activation of MAPK and p60-SRC/GSK3 complex formation. Specifically, GSK3 activity and nuclear import were increased by imatinib mesylate (IM), a selective ABL inhibitor, but prevented by dasatinib that targets both BCR-ABL- and cytokine-dependent MAPK/p60-SRC activity. SB216763, a specific GSK3 inhibitor, promoted an almost complete suppression of primary CML stem/progenitor cells when combined with IM, but not dasatinib, while sparing bcr-abl-negative cells. Our data indicate that GSK3 inhibition acts to prime a pro-differentiative/apoptotic transcription program in the nucleus of IM-treated CML cells by affecting the -catenin, cyclinD1, C-EBP, ATF5, mTOR, and p27 levels. In conclusion, our data gain new insight in CML biology, indicating that GSK3 inhibitors may be of therapeutic value in selectively targeting leukemia-initiating cells in combination with IM but not dasatinib.",
        "Doc_title":"Targeting of GSK3 promotes imatinib-mediated apoptosis in quiescent CD34+ chronic myeloid leukemia progenitors, preserving normal stem cells.",
        "Journal":"Blood",
        "Do_id":"22262776",
        "Doc_ChemicalList":"Antigens, CD34;Benzamides;Cytokines;Indoles;Maleimides;Piperazines;Protein Kinase Inhibitors;Pyrimidines;SB 216763;Thiazoles;beta Catenin;Cyclin D1;Imatinib Mesylate;Fusion Proteins, bcr-abl;Proto-Oncogene Proteins pp60(c-src);GSK3B protein, human;Glycogen Synthase Kinase 3 beta;Mitogen-Activated Protein Kinases;Glycogen Synthase Kinase 3;Dasatinib",
        "Doc_meshdescriptors":"Antigens, CD34;Apoptosis;Benzamides;Blotting, Western;Cell Nucleus;Cells, Cultured;Cyclin D1;Cytokines;Dasatinib;Drug Synergism;Fusion Proteins, bcr-abl;Glycogen Synthase Kinase 3;Glycogen Synthase Kinase 3 beta;Hematopoietic Stem Cells;Humans;Imatinib Mesylate;Indoles;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Maleimides;Microscopy, Confocal;Mitogen-Activated Protein Kinases;Neoplastic Stem Cells;Phosphorylation;Piperazines;Protein Kinase Inhibitors;Protein Transport;Proto-Oncogene Proteins pp60(c-src);Pyrimidines;Signal Transduction;Thiazoles;beta Catenin",
        "Doc_meshqualifiers":"metabolism;drug effects;metabolism;metabolism;pharmacology;antagonists & inhibitors;genetics;metabolism;antagonists & inhibitors;metabolism;drug effects;metabolism;pharmacology;genetics;metabolism;pathology;pharmacology;metabolism;drug effects;metabolism;pathology;drug effects;pharmacology;pharmacology;drug effects;metabolism;pharmacology;drug effects;pharmacology;metabolism",
        "_version_":1605818567405600771},
      {
        "Doc_abstract":"Allogeneic stem cell transplantation is the only curative therapy for chronic myeloid leukemia. There have been several recent advances in this field. Early data suggest that blood-derived stem cells are an effective substitute for bone marrow. Allografting can be performed using progenitor cells from other family members, unrelated donors, and umbilical cord blood. Evidence of early relapse can be detected by assays for the fusion gene, BCR-ABL, using the polymerase chain reaction. Most patients who relapse following allogeneic stem cell transplantation can be treated effectively by transfusion of lymphocytes from their original donors.",
        "Doc_title":"Allografting for chronic myeloid leukemia.",
        "Journal":"Current opinion in hematology",
        "Do_id":"9358991",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Blood Donors;Hematopoietic Stem Cell Transplantation;Histocompatibility Testing;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Prognosis;Splenectomy;Transplantation Conditioning;Transplantation, Homologous",
        "Doc_meshqualifiers":"therapy",
        "_version_":1605805989379964928},
      {
        "Doc_abstract":"PCR for the BCR/ABL fusion transcript provides a highly sensitive and specific method for detecting minimal residual disease in patients with chronic myeloid leukemia (CML). We sought to determine if quantitative PCR measurement of peripheral blood BCR/ABL transcript can be used to monitor response in CML patients with clinically evident disease while receiving the protein tyrosine kinase inhibitor STI-571. Serial bone marrow cytogenetics and peripheral blood BCR/ABL mRNA levels were measured in 17 patients [9 with chronic phase (CP) and 8 with accelerated phase or blast crisis (AP/BC)] during 1 year of treatment. Overall, quantitative PCR BCR/ABL transcript level decreased by a median of 0.9 log during the first 3 months, and by 1.6 logs by 12 months. Among cytogenetic responders (6 CP and 2 AP/BC), median BCR/ABL copy number was 0.9 and 2.1 logs lower than baseline after 3 and 12 months of treatment, respectively. No patient became PCR-negative for BCR/ABL. Among cytogenetic non-responders, BCR/ABL transcript level decreased by 0.4 logs after 3 months, with no subsequent reductions. At study entry, BCR/ABL expression in cytogenetic responders and non-responders was similar. However, BCR/ABL expression became significantly different 3 months after treatment (p = 0.02), and increasingly different with continued therapy (p = 0.04, 0.005, 0.0008 at 6, 9 and 12 months, respectively). Our results demonstrate that PBMC BCR/ABL mRNA levels correlate well with response to STI-571. This non-invasive, rapid and sensitive PCR-based assay can be used to monitor response to STI-571.",
        "Doc_title":"Quantitative monitoring of BCR/ABL transcript during STI-571 therapy.",
        "Journal":"Leukemia & lymphoma",
        "Do_id":"12613514",
        "Doc_ChemicalList":"Benzamides;Piperazines;Pyrimidines;RNA, Messenger;Imatinib Mesylate;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adult;Aged;Benzamides;Bone Marrow Examination;Cytogenetic Analysis;Drug Monitoring;Female;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Leukocytes, Mononuclear;Male;Middle Aged;Piperazines;Pyrimidines;RNA, Messenger;Reverse Transcriptase Polymerase Chain Reaction;Sensitivity and Specificity",
        "Doc_meshqualifiers":"methods;standards;analysis;genetics;drug therapy;pathology;therapeutic use;therapeutic use;analysis;standards",
        "_version_":1605882941632675840},
      {
        "Doc_abstract":"Leukemia cells from adults with Philadelphia (Ph1)-chromosome positive chronic myelogenous leukemia (CML) have a characteristic molecular rearrangement between the BCR and ABL genes whereby major breakpoint cluster region (Mbcr) exons 2 or 3 are joined to ABL exon II. Ph1-chromosome positive CML is uncommon in children and it is unknown whether these children have similar rearrangements. We studied 17 children with Ph1-chromosome positive CML. Five were studied for Mbcr rearrangement using Southern blotting, nine for the presence of chimeric BCR-ABL mRNA using reverse transcription and polymerase chain reaction, and three for both. All eight children studied by Southern blotting had BCR rearrangement. Of 12 children in whom BCR-ABL mRNA was studied, 10 had Mbcr exon 2 joined to ABL exon II, one had Mbcr exon 3 joined to ABL II, and one had both Mbcr-ABL junctions. These data indicate a similarity to adult CML. However, mRNA processing in children may preferentially splice Mbcr exon 2 to ABL exon II. No child had BCR exon 1 joined to ABL exon II, the rearrangement typical of childhood Ph1-chromosome positive acute lymphoblastic leukemia.",
        "Doc_title":"BCR-ABL rearrangements in children with Philadelphia chromosome-positive chronic myelogenous leukemia.",
        "Journal":"Blood",
        "Do_id":"1932752",
        "Doc_ChemicalList":"RNA, Messenger;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adolescent;Blotting, Southern;Child;Child, Preschool;Exons;Female;Fusion Proteins, bcr-abl;Gene Rearrangement;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Philadelphia Chromosome;Polymerase Chain Reaction;RNA Splicing;RNA, Messenger",
        "Doc_meshqualifiers":"genetics;genetics;analysis;genetics",
        "_version_":1605756855814979584},
      {
        "Doc_abstract":"In order to clarify the action of the bcr-abl, a growth factor dependent human leukemic cell line (HSM-911) was transfected with p210bcr-abl or bcr-v-abl by electroporation. The cells transfected with bcr-v-abl, but not the cells transfected with p210bcr-abl, became growth factor independent. Some clones of the cells transfected with p210bcr-abl demonstrated cellular maturation (nuclear segmentation, becoming positive for naphthol ASD chloroacetate esterase, the disappearance of CD34 expression and the appearance of glycophorin A and CD10 expression). Moreover, these clones transfected with p210bcr-abl demonstrated apoptosis (increased expression of Fas and DNA ladder formation suggesting apoptotic DNA fragmentation). These findings demonstrated the different actions of p210 bcr-abl and bcr-v-abl, the former of which gave the cells the characteristics of maturation like the cells from chronic myelogenous leukemia, and the latter of which rendered the cells grow autonomously.",
        "Doc_title":"Effects of transfection of p210bcr-abl and bcr-v-abl into the factor-dependent human leukemia cell line HSM-911.",
        "Journal":"Leukemia research",
        "Do_id":"9444946",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Apoptosis;Cell Division;Fusion Proteins, bcr-abl;Humans;Leukemia, Biphenotypic, Acute;Transfection;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"physiology;physiology;genetics;pharmacology;genetics;pathology",
        "_version_":1605784542743887872},
      {
        "Doc_abstract":"Bcr-Abl is an oncogene that arises from fusion of the Bcr gene with the c-Abl proto-oncogene. Three different Bcr-Abl variants can be formed, depending on the amount of Bcr gene included: p185, p210, and p230. The three variants are associated with distinct types of human leukemias. Examination of the signaling pathways differentially regulated by the Bcr-Abl proteins will help us gain better insight into Bcr-Abl mediated leukemogenesis.",
        "Doc_title":"Bcr-Abl variants: biological and clinical aspects.",
        "Journal":"Leukemia research",
        "Do_id":"12191565",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Genes, abl;Genetic Variation;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Philadelphia Chromosome",
        "Doc_meshqualifiers":"genetics;diagnosis;genetics",
        "_version_":1605898485197963264},
      {
        "Doc_abstract":"To investigate the methylation, expression and clinical significance of miR-203 in pediatric acute leukemia.;The methylation status of miR-203 promoter CpG islands was detected with methylation-specific polymerase chain reaction. The expression of miR-203 was detected by Taqman real- time quantitative polymerase chain reaction. And the clinical significance of miR-203 in pediatric acute leukemia (ALL) was also analyzed.;The promoter of miR-203 was unmethylated in all of 31 pediatric acute lymphoblastic leukemia, all of 15 pediatric acute myeloid leukemia (AML) and all of 23 controls. The relative expression levels of miR-203 in controls, pediatric acute leukemia, ALL and AML were 16.936.31, 48.9710.38, 55.8812.91, 24.289.10 respectively. The results indicated that miR-203 was significantly up- regulated in pediatric acute leukemia (P=0.011) and ALL (P=0.009), not in pediatric AML (P=0.514) compared with control. The expression of miR-203 was significantly related with the gender, immunophenotype, chromosome, fusion gene, BCR-ABL, SIL-TAL1 and prednisone experiment in pediatric ALL and the gender, chromosome, fusion gene, SIL-TAL1 in pediatric acute leukemia (P<0.05). And in risk stratification pairwise comparisons, the expression of miR-203 in the medium-risk and high-risk groups appeared significantly different (P=0.022).;miR-203 may not be regulated with methylation mechanism in pediatric acute leukemia. miR- 203 may be a protooncogene involved in the formation of pediatric acute leukemia and ALL. Further analyses indicated that high expression of miR-203 may be associated with poor prognosis of pediatric ALL and acute leukemia.",
        "Doc_title":"[The expression and clinical significance of miR-203 in pediatric acute leukemia].",
        "Journal":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi",
        "Do_id":"24103876",
        "Doc_ChemicalList":"MIRN203 microRNA, human;MicroRNAs",
        "Doc_meshdescriptors":"Acute Disease;Adolescent;Case-Control Studies;Child;Child, Preschool;CpG Islands;DNA Methylation;Female;Gene Expression Regulation, Leukemic;Humans;Infant;Leukemia;Leukemia, Myeloid;Male;MicroRNAs;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Promoter Regions, Genetic",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;genetics;metabolism",
        "_version_":1605831285265137664},
      {
        "Doc_abstract":"Many unique features of chronic myelogenous leukemia (CML) make it as a model for studying the development of leukemia in humans. Chronic myeloid leukemia is a disease of the hematopoietic stem cell that progress in a multistep fashion. The biphasic or triphasic clinical course of the disease exemplies the multistep process of tumor progression from the indolent chronic phase to a more aggressive and terminal blast crisis. CML was the first neoplastic disease shown to be associated with consistent karyotypic abnormality now known as the Philadelphia (Ph) chromosome. The result of the Philadelphia chromosome translocation t(9;22)(q34:q11) is the transposition of the c-abl oncogene from chromosome 9 to chromosome 22, where it is fused with part of the her gene. The translocation generates a new hybrid bcr-abl gene which plays a crucial role in the pathogenesis of CML. Presently, CML is perhaps the best understood cancer in humans and the model of oncogenesis mediated by the Ph chromosome translocation is one of the best-characterized example of gene activation in leukemia.",
        "Doc_title":"Chronic myelogenous leukemia as gene activation model in oncology minireview.",
        "Journal":"Neoplasma",
        "Do_id":"11130241",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Chromosome Mapping;Chromosomes, Human, Pair 22;Chromosomes, Human, Pair 9;Gene Expression Regulation, Neoplastic;Hematopoietic Stem Cells;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Models, Genetic;Transcriptional Activation;Translocation, Genetic",
        "Doc_meshqualifiers":"pathology;genetics;pathology",
        "_version_":1605811024221437952},
      {
        "Doc_abstract":"The BCR-ABL tyrosine kinase inhibitor imatinib is effective in Philadelphia chromosome-positive (Ph-positive) leukemias, but relapse occurs, mainly as a result of the outgrowth of leukemic subclones with imatinib-resistant BCR-ABL mutations. We evaluated dasatinib, a BCR-ABL inhibitor that targets most imatinib-resistant BCR-ABL mutations, in patients with chronic myelogenous leukemia (CML) or Ph-positive acute lymphoblastic leukemia (ALL).;Patients with various phases of CML or with Ph-positive ALL who could not tolerate or were resistant to imatinib were enrolled in a phase 1 dose-escalation study. Dasatinib (15 to 240 mg per day) was administered orally in four-week treatment cycles, once or twice daily.;A complete hematologic response was achieved in 37 of 40 patients with chronic-phase CML, and major hematologic responses were seen in 31 of 44 patients with accelerated-phase CML, CML with blast crisis, or Ph-positive ALL. In these two phases, the rates of major cytogenetic response were 45 percent and 25 percent, respectively. Responses were maintained in 95 percent of patients with chronic-phase disease and in 82 percent of patients with accelerated-phase disease, with a median follow-up more than 12 months and 5 months, respectively. Nearly all patients with lymphoid blast crisis and Ph-positive ALL had a relapse within six months. Responses occurred among all BCR-ABL genotypes, with the exception of the T315I mutation, which confers resistance to both dasatinib and imatinib in vitro. Myelosuppression was common but not dose-limiting.;Dasatinib induces hematologic and cytogenetic responses in patients with CML or Ph-positive ALL who cannot tolerate or are resistant to imatinib. (ClinicalTrials.gov number, NCT00064233 [ClinicalTrials.gov].).",
        "Doc_title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.",
        "Journal":"The New England journal of medicine",
        "Do_id":"16775234",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Thiazoles;abl-bcr fusion protein, human;Imatinib Mesylate;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl;Dasatinib",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Antineoplastic Agents;Benzamides;Dasatinib;Drug Resistance, Neoplasm;Female;Fusion Proteins, bcr-abl;Genotype;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Mutation;Neutropenia;Piperazines;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Protein Kinase Inhibitors;Protein-Tyrosine Kinases;Pyrimidines;Thiazoles",
        "Doc_meshqualifiers":"administration & dosage;adverse effects;genetics;antagonists & inhibitors;genetics;drug therapy;genetics;chemically induced;drug therapy;genetics;administration & dosage;adverse effects;antagonists & inhibitors;administration & dosage;adverse effects;administration & dosage;adverse effects",
        "_version_":1605904039709507584},
      {
        "Doc_abstract":"Early molecular response (MR) defined by BCR-ABL(IS) levels has prognostic impact in chronic myeloid leukemia (CML). MR was evaluated at 3 and 6 months after switching to nilotinib or dasatinib in 115 patients with resistance to imatinib. Three groups were delineated at 3 months (< 1%, 1-10% or > 10% BCR-ABL(IS) levels) with different outcomes at 3 years regarding major molecular response (MMR, 91%, 47%, 22%, p < 0.001), failure-free survival (FFS), progression-free survival (PFS, 96%, 89% and 78%, p = 0.05) and overall survival (OS). After 6 months, patients with MR < 1% had higher 3-year MMR (83% vs. 16%, p < 0.001), FFS, PFS (94% vs. 84%, p = 0.05) and OS. Four patients had 3-month and 6-month MR > 10% and < 1%, respectively (3-year FFS 50%). Thirteen had 3-month and 6-month MR < 10% and  1%, respectively (3-year FFS 38%). These findings confirm the strong predictive value of 3-month and 6-month BCR-ABL(IS) levels in imatinib-resistant patients. ",
        "Doc_title":"Molecular responses at 3 and 6 months after switching to a second-generation tyrosine kinase inhibitor are complementary and predictive of long-term outcomes in patients with chronic myeloid leukemia who fail imatinib.",
        "Journal":"Leukemia & lymphoma",
        "Do_id":"25311496",
        "Doc_ChemicalList":"4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide;Protein Kinase Inhibitors;Pyrimidines;Imatinib Mesylate;Fusion Proteins, bcr-abl;Dasatinib",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Aged, 80 and over;Dasatinib;Female;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Multivariate Analysis;Prognosis;Protein Kinase Inhibitors;Pyrimidines;Survival Analysis;Time Factors;Transcription, Genetic;Treatment Failure;Treatment Outcome;Young Adult",
        "Doc_meshqualifiers":"therapeutic use;antagonists & inhibitors;genetics;therapeutic use;drug therapy;genetics;therapeutic use;therapeutic use;drug effects",
        "_version_":1605884559938813952},
      {
        "Doc_abstract":"Wilms' tumor gene 1 (WT1) gene expression was analyzed in 32 patient with acute myeloid leukemia (AML) and 18 with acute lymphoblastic leukemia (ALL) to investigate whether it could serve as a MRD marker. Ninety-four percent of patients with acute leukemia showed high WT1 expression at presentation. WT1 expression as a MRD marker was evaluated in 36 patients. The rise of WT1 expression preceded the hematological relapse by approximately 4 months (mean time 129 days; range 6-298). The prognostic significance of WT1 expression was analyzed in 30 patients with AML. WT1 expression higher than 20 WT1 copies /10(4)ABL copies after induction and consolidation chemotherapy was associated with shorter OS. WT1 expression analysis could be a useful tool for MRD monitoring in acute leukemia.",
        "Doc_title":"Wilms' tumor gene 1 expression analysis by real-time quantitative polymerase chain reaction for monitoring of minimal residual disease in acute leukemia.",
        "Journal":"Leukemia & lymphoma",
        "Do_id":"19811333",
        "Doc_ChemicalList":"Neoplasm Proteins;WT1 Proteins",
        "Doc_meshdescriptors":"Acute Disease;Adolescent;Adult;Aged;Computer Systems;Disease-Free Survival;Female;Gene Expression Regulation, Leukemic;Genes, Wilms Tumor;Humans;Kaplan-Meier Estimate;Leukemia, Myeloid;Male;Middle Aged;Neoplasm Proteins;Neoplasm, Residual;Polymerase Chain Reaction;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Prognosis;Proportional Hazards Models;WT1 Proteins;Young Adult",
        "Doc_meshqualifiers":"genetics;mortality;pathology;biosynthesis;chemistry;diagnosis;methods;genetics;mortality;pathology;biosynthesis",
        "_version_":1605806362159218688},
      {
        "Doc_abstract":"In patients with chronic myeloid leukemia (CML), disease in the initial chronic phase (CP) and subsequent progression are driven by the oncogenic activity of the BCR-ABL fusion kinase. Imatinib, a tyrosine kinase inhibitor of BCR-ABL, has been the mainstay of first-line therapy for CML for 10 years. Although patients with CML-CP respond well to imatinib, those who have delayed reductions in leukemic burden during imatinib therapy, such as not achieving a complete cytogenetic response (CCyR) by 12 months, have an increased risk of disease progression. It has been recognized, with 8 years of observation, that patients who achieve an early major molecular response (MMR) on imatinib have a very low probability of disease progression. Recent randomized phase 3 trials have shown that first-line treatment with dasatinib or nilotinib-more potent BCR-ABL inhibitors-results in significantly higher rates and more rapid achievement of CCyR and MMR in comparison with standard-dose imatinib. These trials suggest that CML treatment can be improved with more potent BCR-ABL inhibition during initial therapy, but further follow-up is needed to confirm that the improved response rates with dasatinib and nilotinib are maintained long term.",
        "Doc_title":"Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR-ABL inhibitors as first-line therapy.",
        "Journal":"Leukemia",
        "Do_id":"21844872",
        "Doc_ChemicalList":"Antineoplastic Agents;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Antineoplastic Agents;Fusion Proteins, bcr-abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive",
        "Doc_meshqualifiers":"pharmacology;therapeutic use;antagonists & inhibitors;drug therapy",
        "_version_":1605850652313911296},
      {
        "Doc_abstract":"Clinical presentation of chronic myeloid leukemia (CML) requires not only the deregulated tyrosine kinase BCR-ABL, but also the failure of an immune response against BCR-ABL-expressing cells. T-cell responses against BCR-ABL and other antigens are well-described, but their relevance to the in vivo control of CML is unclear. The suppressive role of naturally occurring T regulatory (T-reg) cells in antitumor immunity is well-established, although little is known about their role in modulating the T-cell response to BCR-ABL.;Naturally occurring T-reg cells were characterized and quantified by flow cytometry in 39 CML patients and 10 healthy donors. Their function was studied by observing their effect on responses to purified protein derivative, a recall antigen, and on the response of an autologous T-cell line recognizing BCR-ABL.;T-reg cells were CD4(+), CD25(+), FOXP3(+), CD127(low), and CD62L(high). T-reg numbers in patients in complete cytogenetic remission were significantly lower than in patients not in complete cytogenetic remission (p < 0.01). T-reg cell depletion using anti-CD25 selection enhanced proliferative responses to purified protein derivative. Furthermore, the interferon- and/or granzyme-B production of effector cells specific for viral peptides or a BCR-ABL HLA-A3-restricted peptide was inhibited when autologous T-reg cells were present.;Taken together, these data suggest a role for T-reg cells in limiting immune responses in CML patients and this may include immune responses to BCR-ABL. The increased frequency of T-reg cells in patients with high levels of BCR-ABL transcripts indicates that an immune mechanism may be important in the control of CML.",
        "Doc_title":"Naturally occurring CD4+ CD25+ FOXP3+ T-regulatory cells are increased in chronic myeloid leukemia patients not in complete cytogenetic remission and can be immunosuppressive.",
        "Journal":"Experimental hematology",
        "Do_id":"20854875",
        "Doc_ChemicalList":"FOXP3 protein, human;Forkhead Transcription Factors;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adult;Aged;Female;Forkhead Transcription Factors;Fusion Proteins, bcr-abl;Humans;Immune Tolerance;Immunologic Memory;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;T-Lymphocytes, Regulatory",
        "Doc_meshqualifiers":"analysis;genetics;genetics;immunology;immunology",
        "_version_":1605891863033675776},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) is the consequence of a single balanced translocation that produces the BCR-ABL fusion oncogene which is detectable in over 90% of patients at presentation. The BCR-ABL inhibitor imatinib mesylate (IM) has improved survival in all phases of CML and is the standard of care for newly diagnosed patients in chronic phase. Despite the very significant therapeutic benefits of IM, a small minority of patients with early stage disease do not benefit optimally while IM therapy in patients with advanced disease is of modest benefit in many. Diverse mechanisms may be responsible for IM failures, with point mutations within the Bcr-Abl kinase domain being amongst the most common resistance mechanisms described in patients with advanced CML. The development of novel agents designed to overcome IM resistance, while still primarily targeted on BCR-ABL, led to the creation of the high affinity aminopyrimidine inhibitor, nilotinib. Nilotinib is much more potent as a BCR-ABL inhibitor than IM and inhibits both wild type and IM-resistant BCR-ABL with significant clinical activity across the entire spectrum of BCR-ABL mutants with the exception of T315I. The selection of a second generation tyrosine kinase inhibitor to rescue patients with imatinib failure will be based on several factors including age, co-morbid medical problems and ABL kinase mutational profile. It should be noted that while the use of targeted BCR-ABL kinase inhibitors in CML represents a paradigm shift in CML management these agents are not likely to have activity against the quiescent CML stem cell pool. The purpose of this review is to summarize the pre-clinical and clinical data on nilotinib in patients with CML who have failed prior therapy with IM or dasatinib.",
        "Doc_title":"Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib.",
        "Journal":"Drug design, development and therapy",
        "Do_id":"19920925",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605818569574055936},
      {
        "Doc_abstract":"Compare the correlation and the concordance of simultaneous bone marrow cytogenetic and peripheral blood molecular responses in patients with chronic myeloid leukemia (CML) during tyrosine kinase inhibitor (TKI) treatment.;A total of 1 030 pairs of simultaneous bone marrow and peripheral blood samples from 419 patients with CML during TKI treatment were analyzed with standard G-banding techniques and real-time quantitative reverse transcriptase PCR (Q-PCR).;The Spearman correlation coefficient for the paired analysis of the percentage of Ph- positive metaphases versus Q-PCR (BCR-ABL/ABL) values was 0.655 (n=1 030, P<0.01). There was a significant difference in terms of BCR-ABL values among all three cytogenetic response groups of no partial cytogenetic (no PCyR), partial cytogenetic (PCyR) and complete cytogenetic responses(CCyR) (P<0.01). 93.8% of the patients in CCyR had BCR-ABL1% [International Scale (IS)], and 97.5% of those with BCR-ABL0.1% (IS) were in CCyR. There was good concordance of 86.2% (888 of 1 030 samples) when BCR-ABL values according to cutoffs of BCR-ABL>10%(IS), 10%->1%(IS)and 1%(IS) were coupled with cytogenetic responses including no PCyR, PCyR and CCyR. Furthermore, 497 pairs of samples from 279 patients with newly diagnosed CML in chronic phase during the first year on TKI as first-line therapy were analyzed. Concordances between major cytogenetic response and BCR-ABL10%(IS) at 3 months, CCyR and BCR-ABL1%(IS) at 6 months and 12 months were 89%, 83.5% and 92.1%, respectively.;There were significant correlation and concordance between cytogenetic and molecular responses, and some differences in assessment of early responses between using cytogenetic and molecular analyses in CML patients during TKI treatment.",
        "Doc_title":"[Comparison of simultaneous bone marrow cytogenetic and peripheral blood molecular responses in chronic myeloid leukemia].",
        "Journal":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi",
        "Do_id":"24606648",
        "Doc_ChemicalList":"Protein Kinase Inhibitors;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Aged, 80 and over;Bone Marrow Cells;Child;Cytogenetic Analysis;Female;Fusion Proteins, bcr-abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Philadelphia Chromosome;Protein Kinase Inhibitors;Treatment Outcome;Young Adult",
        "Doc_meshqualifiers":"cytology;drug effects;antagonists & inhibitors;drug therapy;genetics;therapeutic use",
        "_version_":1605811402237280256},
      {
        "Doc_abstract":"Interferon alfa has been used in the treatment of myeloproliferative disorders, particularly chronic myeloid leukemia, polycythemia vera, and idiopathic thrombocythemia. The effectiveness of interferon alfa in agnogenic myeloid metaplasia needs additional evaluation, although preliminary evidence suggests that it may be more efficacious when used in the cellular (ie, proliferative) phase than when the marrow is fibrotic or osteosclerotic. Cytogenetic and molecular changes after interferon alfa therapy are apparent in patients with chronic myeloid leukemia, as manifested by change in the Philadelphia chromosome and BCR-ABL gene, respectively. The exact role of interferon in prolonging the life of chronic myeloid leukemia patients, however, remains to be determined in larger studies of longer duration. Interferon treatment seems to be well tolerated, and the frequency of treatment-limiting toxicity is low. Data to date suggest that interferon alfa may be a new and effective drug for the treatment of the myeloproliferative disorders.",
        "Doc_title":"Interferon in the treatment of myeloproliferative diseases.",
        "Journal":"Seminars in hematology",
        "Do_id":"2115694",
        "Doc_ChemicalList":"Interferon Type I;Recombinant Proteins;Interferon-gamma",
        "Doc_meshdescriptors":"Humans;Interferon Type I;Interferon-gamma;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Myeloproliferative Disorders;Polycythemia Vera;Primary Myelofibrosis;Recombinant Proteins;Thrombocythemia, Essential",
        "Doc_meshqualifiers":"therapeutic use;therapeutic use;drug therapy;drug therapy;drug therapy;drug therapy;drug therapy",
        "_version_":1605782934870032384},
      {
        "Doc_abstract":"This study was aimed to investigate the effects and the mechanism of mangiferin on chronic myeloid leukemia cell lines K562 cells in vitro. The antiproliferation effects of mangiferin on K562 leukemia cells were tested by tetrazolium salt (MTT) method; the apoptosis induced by mangiferin on K562 cell line was explored by means of cell morphology, DNA gel electrophoresis and flow cytometry. The changes in bcr/abl gene expression was detected by using reverse transcriptase (RT)-PCR. The results showed that five different concentrations of mangiferin (25 - 200 micromol/L) dose-dependently and time-dependently inhibited the proliferation of K562 cells, and induced apoptosis in K562 cell line. RT-PCR revealed that bcr/abl gene expression was down-regulated when K562 cells had been treated with different concentrations of mangiferin. In conclusion, mangiferin remarkably inhibits the proliferation of K562 leukemia cells in vitro, and induces apoptosis in K562 cell line probably through down-regulation of bcr/abl gene expression.",
        "Doc_title":"[CML cell line K562 cell apoptosis induced by mangiferin].",
        "Journal":"Zhongguo shi yan xue ye xue za zhi",
        "Do_id":"15498116",
        "Doc_ChemicalList":"Xanthones;mangiferin",
        "Doc_meshdescriptors":"Apoptosis;Cell Proliferation;DNA Fragmentation;Flow Cytometry;Genes, abl;Humans;K562 Cells;Xanthones",
        "Doc_meshqualifiers":"drug effects;drug effects;drug effects;pharmacology",
        "_version_":1605918191113994240},
      {
        "Doc_abstract":"Interferon-alfa (IFN-alpha) is one of the most effective drugs in the treatment of chronic myeloid leukemia (CML). Recently, IFN-alpha has also been tried in the treatment of Ph-positive acute lymphoid leukemia (ALL), a disease in part sharing the same molecular genetic lesion as CML, namely a BCR/ABL fusion gene. In the present study we analyzed the effect of IFN-alpha (rHuIFN-alphaA/D) on a mouse model for Ph-positive ALL - mice transgenic for the P190 BCR/ABL fusion gene. IFN-alpha treatment was started in the early leukemic phase and continued throughout the course of the disease in eight transgenic animals. No prolonged survival or altered disease pattern with regard to the development of leukemia and/or lymphoma was observed. We conclude that IFN-alpha, at least in a transgenic setting, does not interfere with the leukemogenic process induced by the P190 BCR/ABL fusion gene.",
        "Doc_title":"IFN-alpha treatment of p190 bcr abl transgenic mice.",
        "Journal":"International journal of oncology",
        "Do_id":"21559556",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605928353409269760},
      {
        "Doc_abstract":"The Abl kinase inhibitor imatinib mesylate (STI571) has significant and rapid antileukemic activity in Philadelphia chromosome/Bcr-Abl-positive acute lymphoblastic leukemia (Ph(+) ALL) but such activity is usually of short duration except for a small proportion of patients. To determine the prognostic significance of early Bcr-Abl levels and changes in peripheral blood (PB) and bone marrow (BM), serial samples of 56 patients with relapsed or refractory Ph(+) ALL treated in phase 2 trials of imatinib were analyzed by quantitative polymerase chain reaction (PCR). Imatinib induced a complete hematologic response (CHR) or complete marrow response (marrow-CR) in 40 patients (good responders) and a partial (n = 2) or no (n = 14) remission in the remaining patients (poor responders). Compared with baseline, the median Bcr-Abl/glyceraldehyde-3-phosphate dehydrogenase (GAPDH) ratios decreased significantly in PB by 2.65, 2.64, and 3.11 log steps after 2 weeks, 4 weeks, and at the time of best response, respectively. In BM, the decline of median Bcr-Abl/GAPDH was 0.75, 1.37, and 2.78 logs, respectively. Thus, Bcr-Abl levels decreased more rapidly in PB than in BM (median time to best level 31 vs 39 days). Low Bcr-Abl/GAPDH ratios below 10(-4) in PB and below 10(-2) in BM after 2 weeks were significantly associated with good responses after 4 weeks. Moreover, Bcr-Abl levels (< 10(-2)) in BM of good responders after 4 weeks discriminated between 2 groups of patients with significantly different median time to progression (139 vs 22 days). The data show that Bcr-Abl levels in PB and BM after 2 weeks of imatinib treatment and in BM after 4 weeks have predictive relevance and may guide the application of additional therapies.",
        "Doc_title":"Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl-positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571).",
        "Journal":"Blood",
        "Do_id":"12393581",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Pyrimidines;Imatinib Mesylate;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Antineoplastic Agents;Benzamides;Bone Marrow;Disease-Free Survival;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Neoplasm, Residual;Piperazines;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Prognosis;Pyrimidines;Remission Induction;Salvage Therapy",
        "Doc_meshqualifiers":"administration & dosage;chemistry;analysis;blood;diagnosis;mortality;administration & dosage;diagnosis;drug therapy;metabolism;administration & dosage;methods",
        "_version_":1605896336751722496},
      {
        "Doc_abstract":"Imatinib mesylate was designed as an inhibitor targeting the BCR-ABL tyrosine kinase, the molecular counterpart of the Philadelphia translocation t(9;22)(q34;q11). We report on a patient with chronic myeloid leukemia (CML) undergoing acceleration during imatinib treatment. Cytogenetic analysis revealed four different cell populations: 46,XX,t(9;22)(q34;q11),der(18)t(2;18)(p11;p11)[1]/47,idem,i(17)(q10),-der(18)t(2;18),+der(22)t(9;22)[1]/46,idem,-t(9;22),der(9)t(9;22),ider(22)t(9;22)[12]/ 47,idem,-t(9;22),der(9)t(9;22),+22,ider(22)t(9;22)x2[1]. FISH analysis confirmed the presence of these four clones. Moreover, 49% of the interphase nuclei contained either one or two clustered fusion signals, indicating a low-level amplification of the BCR-ABL fusion gene. With quantitative real-time RT-PCR, a BCR-ABL/G6PDH ratio of 0.8 was determined, which is comparable to that measured in the K562 cell line with a known BCR-ABL amplification and which is increased by more than about 60-fold compared to a CML at diagnosis with >80% Philadelphia-positive cells. We give further evidence that the genomic BCR-ABL amplification results in an increased level of BCR-ABL transcript linking two potent mechanisms of resistance against imatinib treatment.",
        "Doc_title":"BCR-ABL gene amplification and overexpression in a patient with chronic myeloid leukemia treated with imatinib.",
        "Journal":"Cancer genetics and cytogenetics",
        "Do_id":"15899391",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Intracellular Signaling Peptides and Proteins;Piperazines;Pyrimidines;protein kinase modulator;Imatinib Mesylate;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Aged;Antineoplastic Agents;Benzamides;Chromosome Aberrations;Drug Resistance, Neoplasm;Female;Fusion Proteins, bcr-abl;Gene Amplification;Humans;Imatinib Mesylate;In Situ Hybridization, Fluorescence;Intracellular Signaling Peptides and Proteins;Karyotyping;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Piperazines;Pyrimidines;Translocation, Genetic",
        "Doc_meshqualifiers":"therapeutic use;genetics;metabolism;therapeutic use;drug therapy;genetics;therapeutic use;therapeutic use",
        "_version_":1605801726342856704},
      {
        "Doc_abstract":"Aberrant methylation of tumor-suppressor gene promoter regions may play a causal role in the pre-neoplastic stage of cancer progression. In chronic myeloid leukemia, changes in the methylation status of the CpG-rich islands at several sites in the proximal ABL1 promoter (Pa) on the Philadelphia (Ph)-chromosome have been observed. It remains unclear if the Pa methylation precedes the translocation event (t9;22) that generates the Ph-chromosome or if Pa methylation is a stochastic event in a progenitor cell which will later acquire other mutations, namely t9;22. The present study was conducted to answer two questions: What is the methylation status of Pa in patients with Ph-negative myeloproliferative disorders (MPD)? Can the study of methylation in patients with Ph-negative MPD shed light on the initial events associated with the translocation? To probe CpG methylation, we used two methodologies; site-methylation-sensitive restriction enzyme assay and methylation-specific PCR analysis following modification of genomic DNA by bisulfite. Results showed that 22 of the 97 patients with Ph-negative MPD expressed BCR-ABL transcripts. Seven of the 97 patients possessed methylated Pa, but only 2 of them expressed BCR-ABL transcripts. In some of the patients, Pa methylation was a dynamic event. In conclusion, aberrant methylation in Ph-negative MPD could be an initial event triggering the occurrence of the t9;22 translocation and its clinical expression. These findings may shed light on the pathogenesis and progression of MPD.",
        "Doc_title":"Detection of methylated ABL1 promoter in philadelphia-negative myeloproliferative disorders.",
        "Journal":"Blood cells, molecules & diseases",
        "Do_id":"12667992",
        "Doc_ChemicalList":"DNA;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Alleles;CpG Islands;DNA;DNA Methylation;Follow-Up Studies;Fusion Proteins, bcr-abl;Genes, abl;Humans;Myeloproliferative Disorders;Philadelphia Chromosome;Polymerase Chain Reaction;Promoter Regions, Genetic;Restriction Mapping;Sensitivity and Specificity",
        "Doc_meshqualifiers":"genetics;genetics;metabolism;genetics;genetics;genetics;pathology;methods;methods",
        "_version_":1605764036641685504},
      {
        "Doc_abstract":"This case report highlights the relevance of quantifying the BCR-ABL gene in cerebrospinal fluid of patients with suspected relapse of chronic myeloid leukemia in the central nervous system.;We report on a female patient with isolated central nervous system relapse of chronic myeloid leukemia (CML) during peripheral remission after allogeneic hematopoietic stem cell transplantation. The patient showed a progressive cognitive decline as the main symptom. MRI revealed a hydrocephalus and an increase in cell count in the cerebrospinal fluid (CSF) with around 50% immature blasts in the differential count. A highly elevated BCR-ABL/ ABL ratio was detected in the CSF, whilst the ratio for peripheral blood and bone marrow was not altered. On treatment of the malresorptive hydrocephalus with shunt surgery, the patient showed an initial cognitive improvement, followed by a secondary deterioration. At this time, the cranial MRI showed leukemic infiltration of lateral ventricles walls. Hence, intrathecal administration of cytarabine, methotrexate, and dexamethasone was initiated, which caused a significant decrease of cells in the CSF. Soon after, the patient demonstrated significant cognitive improvement with a good participation in daily activities. At a later time point, after the patient had lost the major molecular response of CML, therapy with dasatinib was initiated. In a further follow-up, the patient was neurologically and hematologically stable.;In patients with treated CML, the rare case of an isolated CNS blast crisis has to be taken into account if neurological symptoms evolve. The analysis of BCR-ABL in the CSF is a further option for the reliable detection of primary isolated relapse of CML in these patients.",
        "Doc_title":"Isolated central nervous system relapse of chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation.",
        "Journal":"BMC blood disorders",
        "Do_id":"22871019",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605784358545784832},
      {
        "Doc_abstract":"Development of drug resistance to imatinib mesylate in chronic myeloid leukemia (CML) patients is often accompanied by selection of point mutations in the kinase domain (KD) of the Bcr-Abl oncoprotein, where imatinib binds. Several second-generation tyrosine kinase inhibitors (TKIs) have been designed rationally so as to enhance potency and retain the ability to bind mutated forms of Bcr-Abl. Since the preclinical phase of their development, most of these inhibitors have been tested in in vitro studies to assess their half maximal inhibitory concentration (IC) for unmutated and mutated Bcr-Abl-that is, the drug concentration required to inhibit the cell proliferation or the phosphorylation processes driven by either the unmutated or the mutated forms of the kinase. A number of such studies have been published, and now that two inhibitors-dasatinib and nilotinib-are available for the treatment of imatinib-resistant cases, it is tempting for clinicians to reason on the IC values to guess, case by case, which one will work best in patients harboring specific Bcr-Abl KD mutations. Here, we discuss the pros and cons of using this approach in TKI selection.",
        "Doc_title":"Choosing the best second-line tyrosine kinase inhibitor in imatinib-resistant chronic myeloid leukemia patients harboring Bcr-Abl kinase domain mutations: how reliable is the IC?",
        "Journal":"The oncologist",
        "Do_id":"21632458",
        "Doc_ChemicalList":"4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide;Antineoplastic Agents;Benzamides;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Thiazoles;Imatinib Mesylate;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl;Dasatinib",
        "Doc_meshdescriptors":"Antineoplastic Agents;Benzamides;Clinical Trials as Topic;Dasatinib;Drug Resistance, Neoplasm;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Inhibitory Concentration 50;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Phosphorylation;Piperazines;Point Mutation;Protein Kinase Inhibitors;Protein-Tyrosine Kinases;Pyrimidines;Thiazoles",
        "Doc_meshqualifiers":"therapeutic use;genetics;drug therapy;therapeutic use;drug effects;therapeutic use;genetics;therapeutic use;therapeutic use",
        "_version_":1605891381985804288},
      {
        "Doc_abstract":"Imatinib mesylate, a specific inhibitor of the BCR-ABL tyrosine kinase, has been very effective in the treatment of chronic myeloid leukemia (CML) in chronic phase with high rates of hematological and cytogenetic remissions. Resistance to therapy can develop and transformation to blast crisis may occur, particularly in patients without a cytogenetic response. We report a case of a patient with CML treated in chronic phase who developed blast crisis; withdrawal of imatinib mesylate resulted in spontaneous reversion to chronic phase.",
        "Doc_title":"Spontaneous reversion from blast to chronic phase after withdrawal of imatinib mesylate in a patient with chronic myelogenous leukemia.",
        "Journal":"Leukemia & lymphoma",
        "Do_id":"12613534",
        "Doc_ChemicalList":"Benzamides;Piperazines;Pyrimidines;Imatinib Mesylate;Hydroxyurea",
        "Doc_meshdescriptors":"Aged;Benzamides;Blast Crisis;Cytogenetic Analysis;Drug Resistance, Neoplasm;Female;Humans;Hydroxyurea;Imatinib Mesylate;Immunophenotyping;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Piperazines;Pyrimidines",
        "Doc_meshqualifiers":"chemically induced;pathology;therapeutic use;drug therapy;pathology;adverse effects;adverse effects",
        "_version_":1605899059980140544},
      {
        "Doc_abstract":"To identify gene expression patterns and interaction networks related to BCR-ABL status and clinical outcome in adults with acute lymphoblastic leukemia (ALL).;DNA microarrays were used to profile a set of 54 adult ALL specimens from the Medical Research Council UKALL XII/Eastern Cooperative Oncology Group E2993 trial (21 p185BCR-ABL-positive, 16 p210BCR-ABL-positive and 17 BCR-ABL-negative specimens).;Using supervised and unsupervised analysis tools, we detected significant transcriptomic changes in BCR-ABL-positive versus -negative specimens, and assessed their validity in an independent cohort of 128 adult ALL specimens. This set of 271 differentially expressed genes (including GAB1, CIITA, XBP1, CD83, SERPINB9, PTP4A3, NOV, LOX, CTNND1, BAALC, and RAB21) is enriched for genes involved in cell death, cellular growth and proliferation, and hematologic system development and function. Network analysis demonstrated complex interaction patterns of these genes, and identified FYN and IL15 as the hubs of the top-scoring network. Within the BCR-ABL-positive subgroups, we identified genes overexpressed (PILRB, STS-1, SPRY1) or underexpressed (TSPAN16, ADAMTSL4) in p185BCR-ABL-positive ALL relative to p210BCR-ABL-positive ALL. Finally, we constructed a gene expression- and interaction-based outcome predictor consisting of 27 genes (including GRB2, GAB1, GLI1, IRS1, RUNX2, and SPP1), which correlated with overall survival in BCR-ABL-positive adult ALL (P = .0001), independent of age (P = .25) and WBC count at presentation (P = .003).;We identified prominent molecular features of BCR-ABL-positive adult ALL, which may be useful for developing novel therapeutic targets and prognostic markers in this disease.",
        "Doc_title":"Differential gene expression patterns and interaction networks in BCR-ABL-positive and -negative adult acute lymphoblastic leukemias.",
        "Journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
        "Do_id":"17312329",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adult;Fusion Proteins, bcr-abl;Gene Expression Profiling;Gene Expression Regulation, Leukemic;Humans;Oligonucleotide Array Sequence Analysis;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Proportional Hazards Models;Reverse Transcriptase Polymerase Chain Reaction;Statistics, Nonparametric;Survival Analysis",
        "Doc_meshqualifiers":"genetics;genetics;pathology",
        "_version_":1605746387600801792},
      {
        "Doc_abstract":"Imatinib is a cornerstone of treatment of chronic myeloid leukemia. It remains unclear whether transient treatment discontinuation or dose changes affect outcome and this approach has not yet been approved for use outside clinical trials.;We conducted a retrospective single-institution observational study to evaluate factors affecting response in 'real-life' clinical practice in 138 chronic myeloid leukemia patients in chronic phase treated with imatinib. We used a novel longitudinal data analytical model, with a generalized estimating equation model, to study BCR-ABL variation according to continuous standard dose, change in dose or discontinuation; BCR-ABL transcript levels were recorded. Treatment history was subdivided into time periods for which treatment was given at constant dosage (total 483 time periods). Molecular and cytogenetic complete response was observed after 154 (32%) and 358 (74%) time periods, respectively.;After adjusting for length of time period, no association between dose and cytogenetic complete response rate was observed. There was a significantly lower molecular complete response rate after time periods at a high imatinib dosage.;This statistical approach can identify individual patient variation in longitudinal data collected over time and suggests that changes in dose or discontinuation of therapy could be considered in patients with appropriate biological characteristics.",
        "Doc_title":"'Real-life' study of imatinib therapy in chronic phase-chronic myeloid leukemia: A novel retrospective observational longitudinal analysis.",
        "Journal":"Hematology (Amsterdam, Netherlands)",
        "Do_id":"27320082",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605837510824427520},
      {
        "Doc_abstract":"The hallmarks of chronic myelogenous leukemia (CML) include the Philadelphia chromosome (Ph) translocation [t (9;22)(q34;q11)] and consistent molecular genetic aberrations: a break within a restricted 5.8 kb DNA segment, bcr, on chromosome 22q11; transposition of the c-abl protooncogene from chromosome 9q34 to 22q11; and formation of a hybrid bar-abl gene encoding an abnormal 210 Kd bcr-abl protein with augmented tyrosine kinase enzymatic activity. These molecular phenomena may occur even in the absence of cytogenetic evidence of the Ph translocation. They are highly specific and sensitive markers for CML, and are presumed to play a significant role in the pathogenesis of this malignancy. Surprisingly, we have encountered 11 patients who lacked the Ph translocation, bcr rearrangement, and (in the four patients with available mRNA) a bcr-abl message, and yet had a disease phenotype at diagnosis that was a morphologic facsimile of classic chronic phase CML. These patients presented with high white blood cell counts, neutrophilia, occasional basophilia, splenomegaly, and a hypercellular bone marrow with granulocytic hyperplasia and a left shift in myeloid maturation. Despite the striking resemblance between the early stages of bcr-negative and bcr-positive CML, disease progression manifests distinctly in these two disorders. In contrast to the blastic transformation that inevitably complicates bcr-positive CML, the natural history of our 11 Ph-negative, bcr-negative CML patients was characterized by increasing leukemia burden with leukocytosis, pronounced organomegaly, extramedullary infiltrates, and eventual bone marrow failure (anemia and thrombocytopenia) without marked increases in blast cells. Our current observations suggest that a chronic myeloid leukemia process can develop without associated changes in the bcr or c-abl genes. Although the initial phase of this disease is indistinguishable from CML, the presence or absence of molecular markers may aid in the prediction of the clinical course of Ph-negative CML.",
        "Doc_title":"Philadelphia chromosome-negative chronic myelogenous leukemia without breakpoint cluster region rearrangement: a chronic myeloid leukemia with a distinct clinical course.",
        "Journal":"Blood",
        "Do_id":"2403827",
        "Doc_ChemicalList":"DNA Probes;RNA, Messenger;RNA, Neoplasm;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Aged;Blotting, Northern;Bone Marrow;DNA Probes;Fusion Proteins, bcr-abl;Gene Rearrangement;Humans;Karyotyping;Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative;Middle Aged;Prognosis;RNA, Messenger;RNA, Neoplasm;Restriction Mapping",
        "Doc_meshqualifiers":"pathology;genetics;genetics;physiopathology;genetics;genetics",
        "_version_":1605906039164633088},
      {
        "Doc_abstract":"The chimeric oncoprotein BCR-Abl exhibits deregulated protein tyrosine kinase activity and is responsible for the pathogenesis of certain human leukemias, such as chronic myelogenous leukemia. The activities of cellular Abl (c-Abl) and BCR-Abl are stringently regulated and the cellular mechanisms involved in their inactivation are poorly understood. Protein tyrosine phosphatases can negatively regulate Abl mediated signaling by dephosphorylating the kinase and/or its substrates. This study investigated the ability of the intracellular T cell protein tyrosine phosphatase (TCPTP/PTPN2) to dephosphorylate and regulate the functions of BCR-Abl and c-Abl. TCPTP is expressed as two alternately spliced isoforms - TC48 and TC45, which differ in their C-termini and localize to the cytoplasm and nucleus respectively. We show that TC48 dephosphorylates BCR-Abl but not c-Abl and inhibits its activity towards its substrate, CrkII. Y1127 and Y1294 residues whose phosphorylation corresponds with BCR-Abl activation status were the primary sites targeted by TC48. Co-localization and immunoprecipitation experiments showed that TC48 interacted with BCR-Abl but not with c-Abl, and BCR domain was sufficient for interaction. TC48 expression resulted in the stabilization of Bcr-Abl protein dependent on its phosphatase activity. Inactivation of cellular TC48 in K562 cells by stable expression of a dominant negative catalytically inactive mutant TC48, enhanced proliferation. TC48 expressing K562 clones showed reduced proliferation and enhanced sensitivity to STI571 compared to control clones suggesting that TC48 can repress the growth of CML cells. This study identifies a novel cellular regulator that specifically inhibits the activity of oncogenic BCR-Abl but not that of the cellular Abl kinase.",
        "Doc_title":"The tyrosine phosphatase TC48 interacts with and inactivates the oncogenic fusion protein BCR-Abl but not cellular Abl.",
        "Journal":"Biochimica et biophysica acta",
        "Do_id":"23124138",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl;Proto-Oncogene Proteins c-abl;Proto-Oncogene Proteins c-bcr;Protein Tyrosine Phosphatase, Non-Receptor Type 2",
        "Doc_meshdescriptors":"Fusion Proteins, bcr-abl;Humans;K562 Cells;Phosphorylation;Protein Binding;Protein Tyrosine Phosphatase, Non-Receptor Type 2;Proto-Oncogene Proteins c-abl;Proto-Oncogene Proteins c-bcr",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism",
        "_version_":1605795575510335488},
      {
        "Doc_abstract":"An isochromosome of the long arm of chromosome 17, i(17q), is the most frequent genetic abnormality observed during the disease progression of Philadelphia chromosome-positive chronic myeloid leukemia (CML), and has been described as the sole anomaly in various other hematologic malignancies. The i(17q) hence plays a presumably important pathogenetic role both in leukemia development and progression. This notwithstanding, the molecular consequences of this abnormality have not been investigated in detail. We have analyzed 21 hematologic malignancies (8 CML in blast crisis, 8 myelodysplastic syndromes [MDS], 2 acute myeloid leukemias, 2 chronic lymphocytic leukemias, and 1 acute lymphoblastic leukemia) with i(17q) by fluorescence in situ hybridization (FISH). Using a yeast artificial chromosome (YAC) contig, derived from the short arm of chromosome 17, all cases were shown to have a breakpoint in 17p. In 12 cases, the breaks occurred within the Smith-Magenis Syndrome (SMS) common deletion region in 17p11, a gene-rich region which is genetically unstable. In 10 of these 12 cases, we were able to further map the breakpoints to specific markers localized within a single YAC clone. Six other cases showed breakpoints located proximally to the SMS common deletion region, but still within 17p11, and yet another case had a breakpoint distal to this region. Furthermore, using chromosome 17 centromere-specific probes, it could be shown that the majority of the i(17q) chromosomes (11 of 15 investigated cases) were dicentric, ie, they contained two centromeres, strongly suggesting that i(17q) is formed through an intrachromosomal recombination event, and also implicating that the i(17q), in a formal sense, should be designated idic(17)(p11). Because i(17q) formation results in loss of 17p material, potentially uncovering the effect of a tumor suppressor on the remaining 17p, the occurrence of TP53 mutations was studied in 17 cases by sequencing the entire coding region. In 16 cases, no TP53 mutations were found, whereas one MDS displayed a homozygous deletion of TP53. Thus, our data suggest that there is no association between i(17q) and coding TP53 mutations, and that another tumor suppressor gene(s), located in proximity of the SMS common deletion region, or in a more distal location, is of pathogenetic importance in i(17q)-associated leukemia.",
        "Doc_title":"Isochromosome 17q in blast crisis of chronic myeloid leukemia and in other hematologic malignancies is the result of clustered breakpoints in 17p11 and is not associated with coding TP53 mutations.",
        "Journal":"Blood",
        "Do_id":"10381517",
        "Doc_ChemicalList":"Tumor Suppressor Protein p53",
        "Doc_meshdescriptors":"Adolescent;Aged;Aged, 80 and over;Child, Preschool;Chromosomes, Human, Pair 17;Female;Genes, Tumor Suppressor;Hematologic Neoplasms;Humans;Isochromosomes;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Mutation;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"genetics;genetics;genetics",
        "_version_":1605883496891416576},
      {
        "Doc_abstract":"Although it has been well-established that hemangioblasts are present in chronic myeloid leukemia (CML) and contribute to both malignant hematopoiesis and endotheliopoiesis, the real contribution of CML-derived endothelial cells to endotheliopoiesis in CML patients has never been evaluated. The current study sought to determine CML-derived endotheliopoiesis in patients with CML.;Endothelial cells were isolated from the bone marrow or peripheral blood of six newly diagnosed CML patients using an immunomagnetic approach. The resulting endothelial cells were immediately subjected to fluorescence in situ hybridization analysis to determine BCR-ABL-positive endothelial cells.;The purity of isolated endothelial cells was 94.47% +/- 2.37%. In bone marrow, the BCR-ABL-positive endothelial cells accounted for 70.8% +/- 10.7% of total freshly isolated endothelial cells. In peripheral blood, however, the BCR-ABL-positive endothelial cells accounted for only 20.8% +/- 9.8% of isolated endothelial cells.;The present data demonstrate a dominant contribution of CML-derived endothelial cells to endotheliopoiesis in newly diagnosed CML, and provide the rationale for targeting hemangioblasts and angiogenesis in management of CML.",
        "Doc_title":"Dominant contribution of malignant endothelial cells to endotheliopoiesis in chronic myeloid leukemia.",
        "Journal":"Experimental hematology",
        "Do_id":"18951692",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adult;Cell Separation;Endothelial Cells;Female;Genes, abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged",
        "Doc_meshqualifiers":"methods;metabolism;pathology;metabolism;pathology",
        "_version_":1605801282024505344},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) is characterized by the Philadelphia translocation that fuses BCR sequences from chromosome 22 upstream of the ABL gene on chromosome 9. The chimerical Bcr-Abl protein expressed by CML cells has constitutive tyrosine kinase activity, which is essential for the pathogenesis of the disease. Imatinib, an ATP-competitive selective inhibitor of Bcr-Abl, has unprecedented efficacy for the treatment of CML. Most patients with early stage disease achieve durable complete hematological and complete cytogenetic remissions, with minimal toxicity. In contrast, responses are less stable in patients with advanced CML. This review highlights the pathogenesis of CML, its clinical features, and the development of imatinib as a specific molecularly targeted therapy. Aspects of disease monitoring and side effects are covered as well as resistance to imatinib and strategies to overcome resistance, such as alternative signal transduction inhibitors and drug combinations. Perspectives for further development are also discussed.",
        "Doc_title":"Specific targeted therapy of chronic myelogenous leukemia with imatinib.",
        "Journal":"Pharmacological reviews",
        "Do_id":"12869662",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Interferon-alpha;Piperazines;Pyrimidines;Imatinib Mesylate;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Animals;Antineoplastic Agents;Antineoplastic Combined Chemotherapy Protocols;Benzamides;Clinical Trials as Topic;Drug Resistance, Neoplasm;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Interferon-alpha;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Piperazines;Protein-Tyrosine Kinases;Pyrimidines;Stem Cells;Transplantation, Homologous",
        "Doc_meshqualifiers":"administration & dosage;adverse effects;therapeutic use;antagonists & inhibitors;genetics;therapeutic use;drug therapy;genetics;administration & dosage;adverse effects;antagonists & inhibitors;administration & dosage;adverse effects",
        "_version_":1605825525512667136},
      {
        "Doc_abstract":"We studied nine patients affected by chronic myeloid leukemia (CML Ph+ and bcr-abl positive) and treated with alpha-interferon (alpha-INF) in order to: first, to evaluate the feasibility of a mobilization of peripheral blood stem cells induced by granulocyte-colony-stimulating factor (G-CSF) and the contamination by Ph+ cells and second, to quantify the amount of bcr-abl leukemia associated transcript by a quantitative assay during mobilization procedures, and post mobilization follow-up. Eight achieved a complete karyotypic remission before mobilization obtained with discontinuation of alpha-INF for few days and G-CSF at a dosage of 15 microg/kg/day for 5-7 consecutive days. By quantitative-competitive polymerase chain reaction (QC-PCR) assay, all the leukaphereses and bone marrow samples during post mobilization follow up were studied to determine the amount of bcr-abl transcript. Karyotypic and molecular analysis on evaluable leukapheresis showed that all the harvests were Ph negative and bcr-abl positive: in seven cases the levels of bcr-abl transcript were higher or equal to the pre-apheresis status. In three out of four patients, who underwent more than one leukapheresis procedure, we noticed a decreasing amount of bcr-abl contamination from the first to the last apheresis. Our results suggest that in patients who achieved a complete or major cytogenetic conversion with alpha-INF, it is possible to obtain a sufficient amount of PBSC for autografting by leukapheresis following priming G-CSF therapy and that the amount of neoplastic transcript does not seem to increase.",
        "Doc_title":"Quantitative evaluation of BCR-ABL amount of transcript post mobilization with G-CSF of peripheral blood stem cells from chronic myeloid leukemia patients in cytogenetic response.",
        "Journal":"Leukemia & lymphoma",
        "Do_id":"10975389",
        "Doc_ChemicalList":"RNA, Neoplasm;Granulocyte Colony-Stimulating Factor;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adolescent;Adult;Blood Component Removal;Cytogenetic Analysis;Female;Follow-Up Studies;Fusion Proteins, bcr-abl;Granulocyte Colony-Stimulating Factor;Hematopoietic Stem Cell Mobilization;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Philadelphia Chromosome;RNA, Neoplasm",
        "Doc_meshqualifiers":"genetics;administration & dosage;pharmacology;drug therapy;genetics;blood",
        "_version_":1605881521206460416},
      {
        "Doc_abstract":"Although a tyrosine kinase inhibitor (TKI) targeted for BCR/ABL administered in combination with chemotherapy has been established as the current first-line strategy for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), relapse remains common, even among allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients. Recently, preclinical and preliminary clinical studies suggested a potential therapeutic role of nilotinib, a second-generation TKI, in Ph+ ALL, including patients who have undergone prior allo-HSCT. This report presents the case of a patient with a post-transplant persistent positive BCR/ABL value, who was treated with imatinib and dasatinib before a second allo-HSCT. The patient started taking nilotinib due to a persistent BCR/ABL value and residual mass in her ovaries after a second allo-HSCT. Nine months after introducing nilotinib, the patient achieved complete molecular remission, and despite the continued existence of the residual ovary mass, no hot spot was found in her positron emission tomography scan. The present paper also reviews existing literature on the pre-emptive use of nilotinib for Ph+ ALL patients who received all-HSCT.",
        "Doc_title":"Pre-emptive treatment with nilotinib after second allogeneic transplantation in a Philadelphia chromosome-positive acute lymphoblastic leukemia patient with high risk of relapse.",
        "Journal":"Acta haematologica",
        "Do_id":"20460883",
        "Doc_ChemicalList":"4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide;Pyrimidines",
        "Doc_meshdescriptors":"Adult;Female;Hematopoietic Stem Cell Transplantation;Humans;Philadelphia Chromosome;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Pyrimidines;Recurrence;Remission Induction;Transplantation, Homologous",
        "Doc_meshqualifiers":"prevention & control;administration & dosage",
        "_version_":1605807547831287808},
      {
        "Doc_abstract":"Several patients with clinical features of chronic myeloid leukemia (CML) have fusion of the TEL (ETV6) gene on 12p13 with ABL on 9q34 and express a chimeric Tel-Abl protein that contains the same portion of the Abl tyrosine kinase fused to Tel, an Ets family transcription factor, rather than Bcr. In a murine retroviral bone marrow transduction-transplantation model, a Tel (exon 1-5)-Abl fusion protein induced 2 distinct illnesses: a CML-like myeloproliferative disease very similar to that induced by Bcr-Abl but with increased latency and a novel syndrome characterized by small-bowel myeloid cell infiltration and necrosis, increased circulating endotoxin and tumor necrosis factor alpha levels, and fulminant hepatic and renal failure. Induction of both diseases required the Tel pointed homology oligomerization domain and Abl tyrosine kinase activity. Myeloid cells from mice with both diseases expressed Tel-Abl protein. CML-like disease induced by Tel-Abl and Bcr-Abl was polyclonal and originated from cells with multilineage (myeloid, erythroid, and B- and T-lymphoid) repopulating ability and the capacity to generate day-12 spleen colonies in secondary transplantations. In contrast to findings with Bcr-Abl, however, neither Tel-Abl-induced disease could be adoptively transferred to irradiated secondary recipient syngeneic mice. These results show that Tel-Abl has leukemogenic properties from distinct from those of Bcr-Abl and may act in a different bone marrow progenitor.",
        "Doc_title":"The Tel-Abl (ETV6-Abl) tyrosine kinase, product of complex (9;12) translocations in human leukemia, induces distinct myeloproliferative disease in mice.",
        "Journal":"Blood",
        "Do_id":"12036890",
        "Doc_ChemicalList":"Oncogene Proteins, Fusion;TEL-ABL fusion protein, human;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Animals;Bone Marrow Cells;Bone Marrow Transplantation;Chromosomes, Human, Pair 12;Chromosomes, Human, Pair 9;Female;Fusion Proteins, bcr-abl;Humans;Intestinal Diseases;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mice;Mice, Inbred BALB C;Myeloproliferative Disorders;Neoplasm Transplantation;Oncogene Proteins, Fusion;Protein-Tyrosine Kinases;Survival Rate;Transduction, Genetic;Translocation, Genetic",
        "Doc_meshqualifiers":"metabolism;pathology;adverse effects;genetics;etiology;mortality;etiology;pathology;etiology;mortality;pathology;adverse effects;mortality;pathology;adverse effects;genetics;adverse effects;genetics",
        "_version_":1605892270464172032},
      {
        "Doc_abstract":"The natural history of the chronic phase (CP) of chronic myeloid leukemia (CML) and the high response rates achieved with BCR-ABL inhibitor therapy necessitate long-term evaluation of survival-based outcome measures. Prior to the availability of long-term BCR-ABL inhibitor data, short-term surrogate end points predictive of longer-term outcomes have been identified using data from clinical trials of patients with CML-CP treated with interferon--based therapy and approved BCR-ABL inhibitors. In patients with newly diagnosed CML-CP treated with imatinib, achieving a complete cytogenetic response (CCyR) by 12 months has been associated with more favorable outcomes, and both CCyR and major cytogenetic response have been used as surrogate end points for regulatory approval. Following approval of second-generation BCR-ABL inhibitors in the first-line setting (nilotinib, dasatinib), which have significantly faster and deeper response rates than imatinib, molecular-based surrogate markers at earlier time points of 3 and 6 months are also being explored, although longer follow-up is needed. As patients who achieve early responses show the greatest long-term benefit, these end points may help to identify patients with suboptimal responses early in treatment who might benefit from switching to a different, more effective therapy.",
        "Doc_title":"Surrogate end points for long-term outcomes in chronic myeloid leukemia.",
        "Journal":"Leukemia & lymphoma",
        "Do_id":"23383600",
        "Doc_ChemicalList":"Antineoplastic Agents;Biomarkers, Tumor;Protein Kinase Inhibitors;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Antineoplastic Agents;Biomarkers, Tumor;Fusion Proteins, bcr-abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Philadelphia Chromosome;Protein Kinase Inhibitors;Treatment Outcome",
        "Doc_meshqualifiers":"therapeutic use;genetics;antagonists & inhibitors;drug therapy;genetics;mortality;therapeutic use",
        "_version_":1605830636069715968},
      {
        "Doc_abstract":"Chronic myeloid leukemia is a hematopoietic stem cell cancer, originated by the perpetually \"switched on\" activity of the tyrosine kinase Bcr-Abl, leading to uncontrolled proliferation and insensitivity to apoptotic stimuli. The genetic phenotype of myeloid leukemic K562 cells includes the suppression of cytosolic sialidase Neu2. Neu2 transfection in K562 cells induced a marked decrease (-30% and -80%) of the mRNA of the anti-apoptotic factors Bcl-XL and Bcl-2, respectively, and an almost total disappearance of Bcl-2 protein. In addition, gene expression and activity of Bcr-Abl underwent a 35% diminution, together with a marked decrease of Bcr-Abl-dependent Src and Lyn kinase activity. Thus, the antiapoptotic axis Bcr-Abl, Src, and Lyn, which stimulates the formation of Bcl-XL and Bcl-2, was remarkably weakened. The ultimate consequences of these modifications were an increased susceptibility to apoptosis of K562 cells and a marked reduction of their proliferation rate. The molecular link between Neu2 activity and Bcr-Abl signaling pathway may rely on the desialylation of some cytosolic glycoproteins. In fact, three cytosolic glycoproteins, in the range 45-66 kDa, showed a 50-70% decrease of their sialic acid content upon Neu2 expression, supporting their possible role as modulators of the Bcr-Abl complex.",
        "Doc_title":"Expression of sialidase Neu2 in leukemic K562 cells induces apoptosis by impairing Bcr-Abl/Src kinases signaling.",
        "Journal":"The Journal of biological chemistry",
        "Do_id":"17374613",
        "Doc_ChemicalList":"Glycoproteins;Proto-Oncogene Proteins c-bcl-2;RNA, Messenger;Sphingolipids;bcl-X Protein;Tyrosine;Fusion Proteins, bcr-abl;Proto-Oncogene Proteins pp60(c-src);lyn protein-tyrosine kinase;src-Family Kinases;NEU2 protein, human;Neuraminidase",
        "Doc_meshdescriptors":"Apoptosis;Blotting, Western;Cell Proliferation;Down-Regulation;Fluorescent Antibody Technique;Fusion Proteins, bcr-abl;Gene Expression Regulation, Neoplastic;Glycoproteins;Humans;K562 Cells;Neuraminidase;Phosphorylation;Proto-Oncogene Proteins c-bcl-2;Proto-Oncogene Proteins pp60(c-src);RNA, Messenger;Reverse Transcriptase Polymerase Chain Reaction;Signal Transduction;Sphingolipids;Tyrosine;bcl-X Protein;src-Family Kinases",
        "Doc_meshqualifiers":"metabolism;enzymology;metabolism;metabolism;metabolism;genetics;metabolism;metabolism;metabolism;metabolism",
        "_version_":1605742116442472448},
      {
        "Doc_abstract":"This study was aimed to verify the efficacy of home-made LSI bcr/abl ES probe for detection of bcr/abl fusion gene and derivative chromosome 9 deletions in chronic myeloid leukemia (CML). Fluorescence in situ hybridization (FISH) was carried out with dual color bcr/abl extra signal (ES) probe in 97 cases of CML based on morphology and cytogenetic karyotype and 129 cases of non-hematological malignancies/non-myeloproliferative diseases with normal cytogenetic karyotype. For the patients with signals of 1R1G1F indicating der(9) deletions, FISH were done using ASS DNA probe. The results showed that 91 cases with standard t(9;22) and 6 cases with variant translocation of t(9;22) were detected by conventional G banding technique. All of the 97 patients displayed bcr/abl fusion gene by ES-FISH, including 16 cases with signal patterns of 1R1G1F showing der(9) deletions. Among the 16 cases with der(9) deletions, 13 cases were detected to have deletions of ASS gene. Meanwhile, none of the 129 cases of negative control showed bcr/abl fusion gene by ES-FISH. It is concluded that home-made LSI bcr/abl ES probe is effective to identify the bcr/abl fusion gene and der(9) deletions in CML, and the ES-FISH results are consistent with conventional cytogenetic karyotype.",
        "Doc_title":"[Detection of bcr/abl fusion gene and its derivative chromosome 9 deletions in CML by using home-made bcr/abl extra-signal probe].",
        "Journal":"Zhongguo shi yan xue ye xue za zhi",
        "Do_id":"20137147",
        "Doc_ChemicalList":"DNA Probes;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Aged, 80 and over;Child;Child, Preschool;Chromosome Aberrations;Chromosomes, Human, Pair 9;DNA Probes;Female;Fusion Proteins, bcr-abl;Gene Deletion;Humans;In Situ Hybridization, Fluorescence;Karyotyping;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Sequence Deletion;Young Adult",
        "Doc_meshqualifiers":"genetics;analysis;genetics;methods;diagnosis;genetics",
        "_version_":1605790510232895488},
      {
        "Doc_abstract":"Nucleotide-excision repair (NER) is the most versatile mechanism of DNA repair, recognizing and dealing with a variety of helix-distorting lesions, such as the UV-induced photoproducts cyclobutane pyrimidine dimers (CPDs) and pyrimidine (6-4) photoproducts. We investigated the influence of an anticancer drug, STI571, on the efficacy of NER in removing UV-induced DNA damage. STI571 is used mostly in the treatment of chronic myeloid leukemia and inhibits activity of the BCR/ABL oncogenic tyrosine kinase, which is a hallmark of this disease. NER activity was examined in the BCR/ABL-expressing cell lines K562 and BV173 of myeloid and lymphoid origin, respectively, as well as in CCRF-CEM cells, which do not express BCR/ABL. A murine myeloid parental 32D cell line and its counterpart transfected with the BCR/ABL gene were also tested. NER activity was assessed in the cell extracts by use of an UV-irradiated plasmid as a substrate and by a modified single-cell gel electrophoresis (comet) assay on UV-treated nucleoids. Additionally, quantitative PCR was performed to evaluate the efficacy of the removal of UV-induced lesions from the p53 gene by intact cells. Results obtained from these experiments indicate that STI571 decreases the efficacy of NER in leukemic cells expressing BCR/ABL. Therefore, STI571 may overcome the drug resistance associated with increased DNA repair in BCR/ABL-positive leukemias.",
        "Doc_title":"STI571 reduces NER activity in BCR/ABL-expressing cells.",
        "Journal":"Mutation research",
        "Do_id":"18602021",
        "Doc_ChemicalList":"Benzamides;Piperazines;Pyrimidines;Imatinib Mesylate",
        "Doc_meshdescriptors":"Animals;Benzamides;Cell Line, Tumor;Cell Survival;Comet Assay;DNA Repair;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mice;Piperazines;Polymerase Chain Reaction;Pyrimidines",
        "Doc_meshqualifiers":"drug effects;radiation effects;genetics;pharmacology;pharmacology",
        "_version_":1605762926705115136},
      {
        "Doc_abstract":"Chronic myeloid leukemia, the most common adult leukemia, is characterized by the Ph+ chromosome produced by the fusion of the BCR gene from chromosome 22 and the ABL gene from chromosome 9. Inhibition of the deleterious effects of this potent oncogene by the tyrosine kinase inhibitor (TKI) imatinib has revolutionized care of this disease, but intolerance and resistance does occur.;The authors have reviewed both the preclinical and the clinical data concerning second-generation TKIs intended to circumvent or ameliorate issues with imatinib intolerance or resistance.;Two second-generation TKIs, dasatinib and nilotinib, are currently approved by the US Food and Drug Administration. Both have shown significant clinical activity in patients with chronic myeloid leukemia (CML) and Ph+ acute lymphoblastic leukemia (ALL) who are resistant or intolerant to imatinib or other therapies.;The TKIs are a superb example of an effective targeted approach for a malignant disease. As more clinical data become available and additional novel agents are developed, specific therapy and dosing strategies for individuals with CML will depend on the status of their disease, the anticipated side effects, and concurrent drug therapy.",
        "Doc_title":"Chronic myeloid leukemia therapy: focus on second-generation tyrosine kinase inhibitors.",
        "Journal":"Cancer control : journal of the Moffitt Cancer Center",
        "Do_id":"19337199",
        "Doc_ChemicalList":"4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide;Antineoplastic Agents;Protein Kinase Inhibitors;Pyrimidines;Thiazoles;Protein-Tyrosine Kinases;Dasatinib",
        "Doc_meshdescriptors":"Animals;Antineoplastic Agents;Clinical Trials as Topic;Dasatinib;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Protein Kinase Inhibitors;Protein-Tyrosine Kinases;Pyrimidines;Thiazoles",
        "Doc_meshqualifiers":"therapeutic use;drug therapy;therapeutic use;antagonists & inhibitors;therapeutic use;therapeutic use",
        "_version_":1605906099644399616},
      {
        "Doc_abstract":"To investigate the characteristics of immunophenotype of B-lineage acute lymphoblastic leukemia (B-ALL) cells in Chinese cases, B-ALL cells from 181 patients were analyzed by 4-color flow cytometry with CD45/SSC gating. The results demonstrated that the antigen expression frequencies were as follows: CD19 (100%), HLA-DR (98.9%), CD38 (88.5%), CD10 (76.8%) and CD34 (76.8%). CD117 and T antigens (CD2 and CD7) were rarely expressed. Childhood group (<or= 14 years) had the highest frequency of CD10. Adolescent (15 - 18 years) and adult groups (>or= 19 years) had a higher expression rate of myeloid antigens (CD13 and/or CD33). Subtype CD10(+)/CD34(+) took the highest percentage in three age groups. Percentages of CD10(-)/CD34(+) group increased by age. Subtype CD10(-)/CD34(+) had the highest myeloid antigen co-expression. Comparing with CD45-positive cases, those with CD45-negative or CD45(+/-) always had higher CD10 expression. Bcr/abl mRNA was evaluated in 43 samples from patients with B-ALL. Myeloid antigen co-expression was not different in bcr/abl(+) and bcr/abl(-) groups, and m-bcr/abl(+) was mainly observed in subtype CD10(+)/CD34(+). In conclusion, typical B-ALL cells expressed CD19(+), HLA-DR(+), and CD117(-). CD34, CD10 and CD45 expression varied in different maturation stages. The immunophenotypic subtype of B-ALL in adolescents was similar to that in the adults. Blasts with CD45(+) were mostly seen in CD10(-) cases. CD13 and/or CD33 co-expression was fewer in children patients. m-bcr/abl(+) was mainly seen in subtype CD10(+)/CD34(+).",
        "Doc_title":"[Analysis of immunophenotype of B-lineage acute lymphoblastic leukemia cells by 4-color flow cytometry].",
        "Journal":"Zhongguo shi yan xue ye xue za zhi",
        "Do_id":"12744734",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl;Antigens, CD45;Neprilysin",
        "Doc_meshdescriptors":"Adolescent;Adult;Age Factors;Aged;Aged, 80 and over;Antigens, CD45;Burkitt Lymphoma;Child;Child, Preschool;Female;Flow Cytometry;Fusion Proteins, bcr-abl;Humans;Immunophenotyping;Male;Middle Aged;Neprilysin",
        "Doc_meshqualifiers":"analysis;immunology;methods;genetics;analysis",
        "_version_":1605806567551139840},
      {
        "Doc_abstract":"To revalidate the conversion factorCFfor the conversion of BCR-ABL P210transcript levels to the international scaleBCR- ABLISin chronic myeloid leukemiaCML which validated before.;Peking University People's HospitalPKUPHprepared the exchange samples for revalidation of CFs of 15 laboratories which validated nine or eighteen months ago. The fresh BCR-ABLP210+bone morrow or peripheral blood nucleated cells were diluted with BCR-ABL P210-cells to achieve different BCR- ABL levels, totally 16 sets and 24 samples per set were prepared. TRIzol reagent was added in each tube. Each laboratory tested BCR-ABL transcript levels of one set of samples. Agreement between BCR-ABLIS of each laboratory and PKUPH was assessed by the Bland- Altman method. For laboratories which did not meet the criteria of revalidation, linear regression equation was derived after the samples with maximum BCR-ABL deviation were removed until R>0.98, then new CF was calculated.;10 laboratories met the revalidation criteria with both bias within 1.4 fold and 95% limits of agreement within 6 folds, and their CFs still could be used for accurately conversion of BCR-ABLIS. New CFs were recalculated as of 1.8-6.3 folds of their previous CFs in 5 laboratories not met the criteria.;Revalidation of CF by sample exchange among laboratories was necessary for accurate and continuous application of BCR-ABLIS, which not only tested the validity of CF acquired before but also calculated new available CFs for those with invalid CFs.",
        "Doc_title":"[A multicenter study on the revalidation of validated conversion factor for the conversion of BCRABLP210transcript levels to the international scale in chronic myeloid leukemia].",
        "Journal":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi",
        "Do_id":"26477757",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Bone Marrow Cells;Fusion Proteins, bcr-abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive",
        "Doc_meshqualifiers":"genetics;diagnosis;genetics",
        "_version_":1605880794029490176},
      {
        "Doc_abstract":"The Bcr-Abl inhibitor imatinib is the current first-line therapy for all newly diagnosed chronic myeloid leukemia (CML). Nevertheless, resistance to imatinib emerges as CML progresses to an acute deadly phase implying that physiopathologically relevant cellular targets should be validated to develop alternative therapeutic strategies. The NF-kappaB transcription factor that exerts pro-survival actions is found abnormally active in numerous hematologic malignancies. In the present study, using Bcr-Abl-transfected BaF murine cells, LAMA84 human CML cell line and primary CML, we show that NF-kappaB is active downstream of Bcr-Abl. Pharmacological blockade of NF-kappaB by the IKK2 inhibitor AS602868 prevented survival of BaF cells expressing either wild-type, M351T or T315I imatinib-resistant mutant forms of Bcr-Abl both in vitro and in vivo using a mouse xenograft model. AS602868 also affected the survival of LAMA84 cells and of an imatinib-resistant variant. Importantly, the IKK2 inhibitor strongly decreased in vitro survival and ability to form hematopoietic colonies of primary imatinib resistant CML cells including T315I cells. Our data strongly support the targeting of NF-kappaB as a promising new therapeutic opportunity for the treatment of imatinib resistant CML patients in particular in the case of T315I patients. The T315I mutation escapes all currently used Bcr-Abl inhibitors and is likely to become a major clinical problem as it is associated with a poor clinical outcome.",
        "Doc_title":"NF-kappaB inhibition triggers death of imatinib-sensitive and imatinib-resistant chronic myeloid leukemia cells including T315I Bcr-Abl mutants.",
        "Journal":"International journal of cancer",
        "Do_id":"19378338",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;NF-kappa B;Piperazines;Pyrimidines;Imatinib Mesylate",
        "Doc_meshdescriptors":"Animals;Antineoplastic Agents;Apoptosis;Benzamides;Cell Line, Tumor;Fluorescent Antibody Technique;Genes, abl;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mice;Mice, Nude;Mutation;NF-kappa B;Piperazines;Pyrimidines",
        "Doc_meshqualifiers":"pharmacology;drug effects;genetics;genetics;pathology;antagonists & inhibitors;pharmacology;pharmacology",
        "_version_":1605928646539739136},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) is a progressive and often fatal myeloproliferative disorder. The introduction of imatinib, a tyrosine kinase inhibitor (TKI) specific for BCR-ABL, was a major breakthrough in CML therapy. Although most patients respond to first-line imatinib therapy, some experience a loss of response (resistance) or require treatment discontinuation due to toxicity (intolerance). For patients who fail with standard-dose imatinib therapy, imatinib dose escalation is a second-line option. However, high-dose imatinib is not an appropriate approach for patients experiencing drug toxicity, and there remain questions over the durability of responses achieved with this strategy. Alternative second-line options include the newer TKIs dasatinib and nilotinib. A substantial amount of long-term data for these agents is available. Although both are potent and specific BCR-ABL TKIs, dasatinib and nilotinib exhibit unique pharmacological profiles and response patterns relative to different patient characteristics, such as disease stage and BCR-ABL mutational status. To optimize therapeutic benefit, clinicians should select treatment based on each patient's historical response, adverse-event tolerance level, and risk factors.",
        "Doc_title":"Chronic myeloid leukemia and second-generation tyrosine kinase inhibitors: when, how, and which one?",
        "Journal":"Seminars in hematology",
        "Do_id":"20875551",
        "Doc_ChemicalList":"4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide;Antineoplastic Agents;Benzamides;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Thiazoles;Imatinib Mesylate;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl;Dasatinib",
        "Doc_meshdescriptors":"Antineoplastic Agents;Benzamides;Dasatinib;Drug Resistance, Neoplasm;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Piperazines;Protein Kinase Inhibitors;Protein-Tyrosine Kinases;Pyrimidines;Thiazoles",
        "Doc_meshqualifiers":"adverse effects;pharmacology;therapeutic use;antagonists & inhibitors;genetics;drug therapy;enzymology;adverse effects;pharmacology;therapeutic use;adverse effects;pharmacology;therapeutic use;antagonists & inhibitors;adverse effects;pharmacology;therapeutic use;adverse effects;pharmacology;therapeutic use",
        "_version_":1605818577455153154},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm resulting from the fusion of the BCR-ABL genes, forming the Philadelphia chromosome. The diagnosis is often suspected when there is leukocytosis with left shift and basophilia. Confirmation of the diagnosis requires a demonstration of BCR-ABL by polymerase chain reaction. Using data from the William Beaumont laboratory data registry, we conducted a retrospective review of all the orders for BCR-ABL tests sent to the clinical pathology laboratory between March 11, 2014 and September 12, 2014. We concluded that the presence of concurrent neutrophilia and basophilia has a sensitivity of 100% (95% CI, 69.15% to 100%) and specificity of 100% (95% CI, 93.15% to 100%) in the initial diagnosis of CML. Our results suggest that the presence of both neutrophilia and basophilia should be used as a threshold for the placement of orders for BCR-ABL in the initial diagnosis of CML in patients with leukocytosis with left shift and provide a basis for a reduction in health care spending. Restricting BCR-ABL tests to this population would save approximately $198 million annually in national health care spending.",
        "Doc_title":"BCR-ABL Testing by Polymerase Chain Reaction in Patients With Neutrophilia: The William Beaumont Hospital Experience and the Case for Rational Laboratory Test Requests.",
        "Journal":"Journal of oncology practice",
        "Do_id":"27624943",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605759562813538304},
      {
        "Doc_abstract":"The bcr-abl chimeric gene is found in 95% of chronic myeloid leukemia (CML) patients and is thought to be seminal to the etiology of the disease. The possibility of using ribozymes to suppress bcr-abl gene expression and subsequently alter the malignant phenotype of hematopoietic cells may provide an alternative therapeutic approach to current regimens. A series of hammerhead ribozymes targeted to a b3a2 bcr-abl transcript has been developed and previously shown to be capable of cleaving the desired sequence with varying degrees of specificity. This study investigated the ex vivo effects of endogenous expression of these ribozymes in a CML cell line, K562. We demonstrated a 53% decrease in bcr-abl mRNA levels in a clone induced to express Rz8, compared with its uninduced control. Phenotypic analysis of this clone also revealed a 63% decrease in colony-forming ability and a 43% inhibition of cell proliferation following ribozyme expression. Morphologic analysis of cells showed there was a slight increase (2.5% to 15%) in the number of cells undergoing apoptosis. These results suggest that Rz8 was effective in suppressing bcr-abl gene expression within a cellular environment and altering the leukemic nature of a CML cell line.",
        "Doc_title":"Ex vivo effects associated with the expression of a bcr-abl-specific ribozyme in a CML cell line.",
        "Journal":"Antisense & nucleic acid drug development",
        "Do_id":"9512092",
        "Doc_ChemicalList":"RNA, Catalytic;RNA, Messenger;RNA, recombinant;RNA;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Fusion Proteins, bcr-abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Phenotype;RNA;RNA, Catalytic;RNA, Messenger;Transfection;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"biosynthesis;genetics;genetics;metabolism;genetics;metabolism;metabolism",
        "_version_":1605904073575366656},
      {
        "Doc_abstract":"The expression of the fusion protein BCR/ABL is a hallmark of chronic myeloid leukemia. BCR/ABL is a constitutively active tyrosine kinase influencing cell proliferation, apoptosis, and differentiation. To what extent and by which mechanism BCR/ABL affects the adhesion of leukemic cells to bone marrow stromal cells (BMSC) is controversial. To characterize adhesion of BCR/ABL-transformed 32D cells (32D-BCR/ABL) to the BMSC line M2-10B4, we used washing assays and single-cell force spectroscopy (SCFS). Compared to control 32D cells (32D-V), 32D-BCR/ABL developed threefold higher adhesion forces. This enhanced cell adhesion could be reduced to control levels after specifically inhibiting the activity of the tyrosine kinase BCR/ABL using imatinib mesylate (IM). SCFS showed that the adhesion forces of 32D-BCR/ABL were strongest to fibronectin and collagen type I, suggesting that beta1-integrin has a major role in mediating the adhesion of leukemic cells to BMSC. Indeed, the beta1-integrin blocking antibody Ha2/5 abrogated the attachment of 32D-V and 32D-BCR/ABL cells to BMSC. Although 32D-BCR/ABL cells show significantly increased beta1-integrin expression, no significant difference of beta1-integrin mRNA levels could be detected, indicating a post-transcriptional regulation of beta1-comprising integrin heterodimers by BCR/ABL. The data presented here argue that the interaction of beta1-integrin and extracellular matrix components is functionally important in leukemic cells expressing high-levels of BCR/ABL, and could provide a rationale for the development of optimized targeted therapies.",
        "Doc_title":"BCR/ABL expression of myeloid progenitors increases beta1-integrin mediated adhesion to stromal cells.",
        "Journal":"Journal of molecular biology",
        "Do_id":"18313694",
        "Doc_ChemicalList":"Antigens, CD29;Antineoplastic Agents;Benzamides;Collagen Type I;Fibronectins;Piperazines;Pyrimidines;Imatinib Mesylate;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Animals;Antigens, CD29;Antineoplastic Agents;Benzamides;Cell Adhesion;Cell Culture Techniques;Cells, Cultured;Collagen Type I;Fibronectins;Fusion Proteins, bcr-abl;Imatinib Mesylate;Mice;Myeloid Progenitor Cells;Piperazines;Pyrimidines;Stromal Cells;Time Factors;Transfection",
        "Doc_meshqualifiers":"metabolism;physiology;pharmacology;drug effects;genetics;metabolism;metabolism;genetics;physiology;drug effects;metabolism;physiology;pharmacology;pharmacology;drug effects;metabolism;physiology",
        "_version_":1605810421110931456},
      {
        "Doc_abstract":"The tyrosine kinase inhibitor imatinib (STI571, Glivec) blocks the activity of the BCR/ABL oncogene and induces hematologic remissions in the majority of patients with chronic myeloid leukemia (CML). Glivec is an aminopyrimidine derivative that interacts with the ATP-binding site within the kinase domain of ABL and several other tyrosine kinases, including c-KIT, PDGF beta receptor, and ARG. The compound is currently in phase III clinical trials. Although patients with chronic phase CML have been found to develop drug resistance only rarely so far, patients in more advanced phases of the leukemia develop resistance frequently. The available information on Glivec resistance will be reviewed.",
        "Doc_title":"Mechanisms of resistance imatinib (STI571) in preclinical models and in leukemia patients.",
        "Journal":"Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy",
        "Do_id":"11512149",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Pyrimidines;Imatinib Mesylate;Protein-Tyrosine Kinases",
        "Doc_meshdescriptors":"Animals;Antineoplastic Agents;Benzamides;Clinical Trials as Topic;Dose-Response Relationship, Drug;Drug Resistance, Neoplasm;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Models, Biological;Piperazines;Protein-Tyrosine Kinases;Pyrimidines;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"therapeutic use;genetics;drug therapy;therapeutic use;antagonists & inhibitors;therapeutic use",
        "_version_":1605760047562883072},
      {
        "Doc_abstract":"Investigation of the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in chronic myeloid leukemia patients is essential to predict prognosis and survival. In 20 patients treated at the Bone Marrow Transplantation Unit of So Jos do Rio Preto (So Paulo, Brazil), we used fluorescence in situ hybridization (FISH) to investigate the frequency of cells with BCR/ABL rearrangement at diagnosis and at distinct intervals after allo-HSCT until complete cytogenetic remission (CCR). We investigated the disease-free survival, overall survival in 3 years and transplant-related mortality rates, too. Bone marrow samples were collected at 1, 2, 3, 4, 6, 12, and 24 months after transplantation and additional intervals as necessary. Success rate of the FISH analyses was 100%. CCR was achieved in 75% of the patients, within on average of 3.9 months; 45% patients showed CCR within 60 days after HSCT. After 3 years of the allo-HSCT, overall survival rate was 60%, disease-free survival was 50% and the transplant-related mortality rate was 40%. The study demonstrated that the BCR-ABL FISH assay is useful for follow-up of chronic myeloid leukemia patients after HSCT and that the clinical outcome parameters in our patient cohort were similar to those described for other bone marrow transplantation units.",
        "Doc_title":"Clinical outcome in chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation: the experience of the Bone Marrow Transplantation Unit of FUNFARME/BRAZIL using FISH.",
        "Journal":"Genetics and molecular research : GMR",
        "Do_id":"18551408",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adolescent;Adult;Bone Marrow Transplantation;Brazil;Disease-Free Survival;Hematopoietic Stem Cell Transplantation;Hospital Departments;Humans;In Situ Hybridization, Fluorescence;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Middle Aged;Prognosis;Survival Rate;Transplantation, Homologous;Treatment Outcome",
        "Doc_meshqualifiers":"methods;methods;genetics;mortality;surgery",
        "_version_":1605846652314189824},
      {
        "Doc_abstract":"Chronic myeloid leukemia(CML)is a clonal disease of the hematopoietic stem cells that is characterized by excessive proliferation, but retains of the capacity for differentiation duringthe chronic phase of the disease. This phase is followed after 4-6 years by rapid progression, an accelerated phase, and consequently a fatal acute leukemia a blast crisis. The hallmark abnormality of CML is the Philadelphia chromosome that generates a BCR-ABL fusion gene, resulting in the expression of a leukemia-specific oncoprotein, Bcr-Abl. Bcr-Abl is a potent tyrosine kinase and plays a central role in CML pathogenesis. Recently, the treatment of CML has been revolutionized by the introduction of imatinib mesylate(IM). With daily IM treatment, more than 80% of chronic-phase CML patients achieve a complete cytogenetic response. Nevertheless, a small percentage of CML patients are primarily refractory or acquire secondary resistance against IM. Nilotinib is a highly selective Abl kinase inhibitor that possesses greater potency and selectivity for Abl kinase than IM. In addition to being more potent than IM against wild-type BCR-ABL, nilotinib is significantly active against many IM-resistant BCR-ABL mutants. In preclinical studies, nilotinib has produced hematologic and cytogenetic responses in CML patients, with either IM resistance or IM intolerance. As second-line treatment, both nilotinib and dasatinib may be used in case of suboptimal response or failure, which is defined in the efficacy criteria of the European Leukemia Net Consensus. The choice of second-generation tyrosine kinase inhibitors may be made after the mutation analyses of the kinase domain. It is recommended that nilotinib or dasatinib whichever was shown to be active against the specific mutation, should be chosen for treatment. For patients with no mutations or patients with IM intolerance, it is recommended that either second-generation tyrosine kinase inhibitor be chosen, based on the patient's disease history.",
        "Doc_title":"[Nilotinib as a second-line treatment for chronic myeloid leukemia].",
        "Journal":"Gan to kagaku ryoho. Cancer & chemotherapy",
        "Do_id":"21677481",
        "Doc_ChemicalList":"4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide;Protein Kinase Inhibitors;Pyrimidines;Protein-Tyrosine Kinases",
        "Doc_meshdescriptors":"Chronic Disease;Clinical Trials as Topic;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Protein Kinase Inhibitors;Protein-Tyrosine Kinases;Pyrimidines;Salvage Therapy",
        "Doc_meshqualifiers":"drug therapy;drug therapy;enzymology;therapeutic use;antagonists & inhibitors;chemistry;therapeutic use",
        "_version_":1605844965397626880},
      {
        "Doc_abstract":"To understand the prognostic value of early monitoring BCR-ABL transcripts in patients with chronic myeloid leukemia (CML) after treatment with imatinib, and to provide the information for early assessment of prognosis and treatment options.;The clinical data of 251 patients with CML in chronic phase (CML-CP) who received imatinib as first-line therapy were retrospectively analyzed, the progression-free survival (PFS)and overall survival (OS) between different BCR-ABL transcriptional level at 3 and 6 month after imatinib treatment were compared. Meanwhile, Chi-square test and logistic regression were used to analyze the risk factors for disease progression.;At 3 months after imatinib treatment BCR-ABL transcriptional levels>10%, >1%- 10% and  1% were found in 92, 94 and 64 patients, their PFS were 53.3%, 71.3% and 86.2%, respectively. The results showed that the PFS of patients with low BCR-ABL transcriptional levels was significantly superior to that with high BCR-ABL transcriptional levels for CML at 3 months treatment (P<0.05). The OS of three group did not reach statistical significance (92.4% vs 96.8% vs 93.8%, P> 0.05). When 182 patients received imatinib treatment at 6 months, 22 patients with BCR-ABL transcriptional levels>10%, 50>1% - 10% and 110  1%, their PFS were 27.3% vs 66.0% vs 82.7% (P<0.05), the OS of three groups were 86.4% vs 94.0% vs 100%. There were significant differences among the three groups (P<0.05). Logistic regression confirmed that the level of BCR-ABL transcriptional level at 3 and 6 months after imatinib treatment was independent factor to influence the progress of disease.;It is important for the prognosis evaluation of CML patients to monitor BCR-ABL transcriptional level at 3 and 6 months after imatinib treatment.",
        "Doc_title":"[The prognostic value of early BCR-ABL transcripts level in 251 patients with chronic myeloid leukemia after treatment with imatinib].",
        "Journal":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi",
        "Do_id":"26304076",
        "Doc_ChemicalList":"Antineoplastic Agents;Imatinib Mesylate;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Antineoplastic Agents;Disease-Free Survival;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Prognosis;Retrospective Studies;Risk Factors",
        "Doc_meshqualifiers":"therapeutic use;metabolism;therapeutic use;diagnosis;drug therapy",
        "_version_":1605749164955664384},
      {
        "Doc_abstract":"Grb2-associated binder 2 (Gab2) serves as a critical amplifier in the signaling network of Bcr-Abl, the driver of chronic myeloid leukemia (CML). Despite the success of tyrosine kinase inhibitors (TKIs) in CML treatment, TKI resistance, caused by mutations in Bcr-Abl or aberrant activity of its network partners, remains a clinical problem. Using inducible expression and knockdown systems, we analyzed the role of Gab2 in Bcr-Abl signaling in human CML cells, especially with respect to TKI sensitivity. We show for the first time that Gab2 signaling protects CML cells from various Bcr-Abl inhibitors (imatinib, nilotinib, dasatinib and GNF-2), whereas Gab2 knockdown or haploinsufficiency leads to increased TKI sensitivity. We dissected the underlying molecular mechanism using various Gab2 mutants and kinase inhibitors and identified the Shp2/Ras/ERK and the PI3K/AKT/mTOR axes as the two critical signaling pathways. Gab2-mediated TKI resistance was associated with persistent phosphorylation of Gab2 Y452, a PI3K recruitment site, and consistent with this finding, the protective effect of Gab2 was completely abolished by the combination of dasatinib with the dual PI3K/mTOR inhibitor NVP-BEZ235. The identification of Gab2 as a novel modulator of TKI sensitivity in CML suggests that Gab2 could be exploited as a biomarker and therapeutic target in TKI-resistant disease.",
        "Doc_title":"Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors.",
        "Journal":"Leukemia",
        "Do_id":"22858987",
        "Doc_ChemicalList":"14-3-3 Proteins;Adaptor Proteins, Signal Transducing;Benzamides;GAB2 protein, human;Imidazoles;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Quinolines;RNA, Small Interfering;Thiazoles;Imatinib Mesylate;Phosphatidylinositol 3-Kinases;MTOR protein, human;TOR Serine-Threonine Kinases;Fusion Proteins, bcr-abl;Proto-Oncogene Proteins c-akt;Protein Tyrosine Phosphatase, Non-Receptor Type 11;Dasatinib;dactolisib",
        "Doc_meshdescriptors":"14-3-3 Proteins;Adaptor Proteins, Signal Transducing;Adult;Aged;Antineoplastic Combined Chemotherapy Protocols;Benzamides;Blotting, Western;Dasatinib;Drug Resistance, Neoplasm;Female;Follow-Up Studies;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Imidazoles;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;MAP Kinase Signaling System;Male;Middle Aged;Phosphatidylinositol 3-Kinases;Phosphorylation;Piperazines;Prognosis;Protein Kinase Inhibitors;Protein Tyrosine Phosphatase, Non-Receptor Type 11;Proto-Oncogene Proteins c-akt;Pyrimidines;Quinolines;RNA, Small Interfering;TOR Serine-Threonine Kinases;Thiazoles;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"metabolism;antagonists & inhibitors;genetics;metabolism;antagonists & inhibitors;pharmacology;drug therapy;metabolism;drug effects;antagonists & inhibitors;metabolism;drug effects;pharmacology;pharmacology;metabolism;metabolism;pharmacology;pharmacology;genetics;antagonists & inhibitors;metabolism;pharmacology",
        "_version_":1605784330965090304},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) is a progressive and often fatal myeloproliferative disorder. The hallmark of CML is an acquired chromosomal translocation known as the Philadelphia chromosome (Ph) that results in the synthesis of the BCR-ABL fusion protein, a constitutively active tyrosine kinase (TK). The introduction of imatinib, a TK inhibitor (TKI) specific for BCR-ABL, was a major breakthrough in CML therapy. Although most patients respond to first-line imatinib therapy, some experience a loss of response (resistance) or require treatment discontinuation because of toxicity (intolerance). In patients for whom standard-dose imatinib therapy (400 mg/day) fails, imatinib dose escalation (600-800 mg/day) is a second-line option. However, high-dose imatinib is not an appropriate approach for patients experiencing drug toxicity, and there remain questions over the durability of responses achieved with this strategy. Alternative second-line options include the newer TKIs dasatinib and nilotinib. A substantial amount of long-term data for these agents is available. Although both are potent and specific BCR-ABL TKIs, dasatinib and nilotinib exhibit unique pharmacologic profiles and response patterns relative to different patient characteristics, such as disease stage and BCR-ABL mutational status. To optimize therapeutic benefit, clinicians should select treatment based on each patient's historical response, adverse event tolerance level, and risk factors.",
        "Doc_title":"Clinical algorithms for the treatment of patients with chronic myeloid leukemia: the 2010 perspective.",
        "Journal":"Clinical lymphoma, myeloma & leukemia",
        "Do_id":"20529808",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Pyrimidines;Thiazoles;Imatinib Mesylate;Dasatinib",
        "Doc_meshdescriptors":"Algorithms;Antineoplastic Agents;Benzamides;Dasatinib;Female;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Piperazines;Pyrimidines;Thiazoles",
        "Doc_meshqualifiers":"administration & dosage;therapeutic use;drug therapy;administration & dosage;therapeutic use;administration & dosage;therapeutic use;administration & dosage;therapeutic use",
        "_version_":1605891623699349504},
      {
        "Doc_abstract":"A variety of oncogenes are activated by specific chromosomal translocations, which are associated with distinct subtypes of leukemia. The identification of these rearrangements provides critical diagnostic and prognostic information, which may contribute to the selection of specific anti-leukemic therapy. The translocation t(9;22), the equivalent of the BCR/ABL rearrangement, is associated with a poor prognosis. We therefore used RT-PCR to detect this molecular event in a prospective study including 890 children. 673 of them suffered from acute lymphoblastic leukemia (ALL) at primary diagnosis and a transcription of the chimeric gene was detected in 21 of 648 with a successful analysis (3.2%). All children were treated by one of the two German multicenter childhood ALL therapy studies ALL-BFM-90 or COALL-05-92, respectively. Comparison of clinical features between BCR/ABL-positive and -negative children showed no significant differences regarding WBC, percentage of blasts, splenomegaly, hepatomegaly and age. Immunophenotypic studies at diagnosis in 21 BCR/ABL-positive children identified common ALL in 16 patients (76.2%), pre-B-ALL in four (19.0%), and an early T-lineage ALL in one (4.8%). Coexpression of myeloid antigens (CD13 and/or CD33) was observed in six of 16 common ALL patients as well as in the one child with early T-lineage ALL phenotype. The type of breakpoint (m-BCR/ABL: n = 14; M-BCR/ABL: n = 7) showed no correlation with clinical parameters. A comparison of cytogenetic and molecular data was performed in 16 positive patients and was concordant in all of them. We analyzed the response to the prednisone pretreatment and found a higher incidence of poor responders among the BCR/ABL-positive children. Regarding the event-free survival (EFS) of BCR/ABL-positive (0.53) and -negative patients (0.79) after a follow-up of 2 years, significant differences (P < 0.05) between both groups could be demonstrated.",
        "Doc_title":"Incidence and clinical outcome of children with BCR/ABL-positive acute lymphoblastic leukemia (ALL). A prospective RT-PCR study based on 673 patients enrolled in the German pediatric multicenter therapy trials ALL-BFM-90 and CoALL-05-92.",
        "Journal":"Leukemia",
        "Do_id":"8667652",
        "Doc_ChemicalList":"Cytarabine;Vincristine;Cyclophosphamide;6-Mercaptopurine;Fusion Proteins, bcr-abl;Asparaginase;Prednisone;Methotrexate;Daunorubicin",
        "Doc_meshdescriptors":"6-Mercaptopurine;Adolescent;Antineoplastic Combined Chemotherapy Protocols;Asparaginase;Base Sequence;Child;Child, Preschool;Chromosomes, Human, Pair 22;Chromosomes, Human, Pair 9;Cyclophosphamide;Cytarabine;Daunorubicin;Disease-Free Survival;Female;Fusion Proteins, bcr-abl;Germany;Humans;Incidence;Infant;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Methotrexate;Molecular Sequence Data;Polymerase Chain Reaction;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Prednisone;Prognosis;Prospective Studies;Transcription, Genetic;Translocation, Genetic;Vincristine",
        "Doc_meshqualifiers":"administration & dosage;therapeutic use;administration & dosage;administration & dosage;administration & dosage;administration & dosage;genetics;drug therapy;epidemiology;genetics;administration & dosage;drug therapy;epidemiology;genetics;administration & dosage;administration & dosage",
        "_version_":1605812410306789376},
      {
        "Doc_abstract":"Optimum sample quality is a crucial requirement for molecular monitoring of patients with chronic myeloid leukemia (CML) on therapy. Bedside RNA stabilization systems (e.g., PAXgene) have been developed to inhibit RNA degradation during shipment of samples from the clinical site to the specialized laboratory. In CML, blood but not bone marrow samples have been examined using RNA stabilization in previous studies. Therefore, we sought to investigate the applicability of the PAXgene system for bone marrow samples in CML.;Simultaneously stabilized blood and bone marrow samples were obtained from 55 imatinib-resistant CML patients to compare RNA yield and purity, expression of two housekeeping genes (total ABL and beta-glucuronidase; GUS) by quantitative reverse-transcriptase polymerase chain reaction, BCR-ABL expression (ratios BCR-ABL/ABL and BCR-ABL/GUS), and BCR-ABL kinase domain mutations analyzed by denaturing high-performance liquid chromatography and direct sequencing.;RNA extraction revealed high-quality RNA derived from both stabilized blood and bone marrow samples. RNA yield was significantly higher in bone marrow (median 9.9 microg RNA/mL bone marrow) than in blood (median 4.3 microg RNA/mL blood) (p=0.0005). The number of housekeeping gene transcripts was comparable in blood and bone marrow (median ABL copies/2 microL cDNA 13,260 vs. 25,590; median GUS copies/2 microL cDNA 35,490 vs. 60,200; n.s.). Further, ratios BCR-ABL/ABL (blood vs. bone marrow, median 47% vs. 57%) and ratios BCR-ABL/GUS (blood vs. bone marrow, median 26% vs. 21%) were not significantly different. Results of mutation analysis corresponded in 51 out of 55 patients (93%), whereas moderate differences were observed in four patients.;We conclude that bone marrow can be effectively stabilized using the PAXgene system and shows concordance with blood in terms of BCR-ABL mRNA quantification and mutation analysis in imatinib-resistant CML patients.",
        "Doc_title":"Suitability of the PAXgene system to stabilize bone marrow RNA in imatinib-resistant patients with chronic myeloid leukemia.",
        "Journal":"Clinical chemistry and laboratory medicine",
        "Do_id":"18303987",
        "Doc_ChemicalList":"Benzamides;Piperazines;Pyrimidines;RNA, Neoplasm;Imatinib Mesylate;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl;Glucuronidase",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Benzamides;Bone Marrow;DNA Mutational Analysis;Drug Resistance, Neoplasm;Female;Fusion Proteins, bcr-abl;Gene Expression Regulation, Neoplastic;Glucuronidase;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Mutation;Piperazines;Protein Structure, Tertiary;Protein-Tyrosine Kinases;Pyrimidines;RNA Stability;RNA, Neoplasm;Reference Standards",
        "Doc_meshqualifiers":"metabolism;methods;genetics;genetics;metabolism;blood;drug therapy;genetics;genetics;pharmacology;therapeutic use;chemistry;genetics;metabolism;pharmacology;therapeutic use;blood;metabolism",
        "_version_":1605820028556410880},
      {
        "Doc_abstract":"Neutrophilic-chronic myeloid leukemia (CML-N) has been described as a CML variant associated both with a distinctive molecular defect of the Philadelphia chromosome and with a more benign clinical course than classic CML. The translocation (9;22) in CML-N results in the transcription of an e19/a2 type BCR/ABL mRNA that codes for a 230-kD BCR/ABL protein (p230). The indolence of the clinical course of patients with CML-N has been disputed.;The objectives of this study were to quantify and correlate with clinical outcome the p230 mRNA and protein in patients with CML-N, to describe six new patients and the follow-up (with molecular analysis) of five previously reported patients with CML-N, and to review characteristics of all patients with CML-N and p230 BCR/ABL reported to date in the literature.;Quantitative polymerase chain reaction assays on specimens from the great majority of patients with CML-N revealed minimal numbers of molecules of p230 BCR/ABL transcripts per total RNA. This also was associated with a lack of detectable p230 BCR/ABL protein in patient specimens, even in one patient who was followed for 16 years after diagnosis. This may explain the milder leukemic phenotype in most patients with CML-N. A review of all 23 patients who had an e19/a2 type BCR/ABL translocation suggested that the low level of p230 BCR/ABL mRNA and the lack of detectable p230 BCR/ABL protein in patients with no additional cytogenetic abnormalities may predict their indolent clinical course.;Patients with p230 positive CML-N have indolent course, probably as a result of low p230 mRNA and protein levels. This supports the need to conduct additional molecular studies, even if cytogenetic studies have revealed t(9;22), because of the prognostic importance of the molecular findings.",
        "Doc_title":"Neutrophilic-chronic myeloid leukemia: low levels of p230 BCR/ABL mRNA and undetectable BCR/ABL protein may predict an indolent course.",
        "Journal":"Cancer",
        "Do_id":"12015767",
        "Doc_ChemicalList":"Peptides;RNA, Messenger;p 230;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adult;Aged;Blotting, Western;Cell Line;Female;Follow-Up Studies;Fusion Proteins, bcr-abl;Humans;Leukemia, Neutrophilic, Chronic;Male;Middle Aged;Peptides;Philadelphia Chromosome;Polymerase Chain Reaction;RNA, Messenger;Translocation, Genetic",
        "Doc_meshqualifiers":"genetics;genetics;physiopathology;genetics;analysis",
        "_version_":1605818790542573569},
      {
        "Doc_abstract":"We describe the development of an array-based assay for the molecular level detection of tyrosine kinase activity directly from cellular extracts. Glutathione S-transferase-Crkl (GST-Crkl) fusion proteins are covalently immobilized into polyacrylamide gel pads via copolymerization of acrylic monomer and acrylic-functionalized GST-Crkl protein constructs on a polyacrylamide surface. The resulting hydrogels resist nonspecific protein adsorption, permitting quantitative and reproducible determination of Abl tyrosine kinase activity and inhibition, even in the presence of a complex cell lysate mixture. Half-maximal inhibition (IC50) values for imatinib mesylate inhibition of GST-Crkl (SH3) phosphorylation by v-Abl in a purified system and Bcr-Abl within a K562 cell lysate were determined to be 1.5 and 20 microM, respectively. Additionally, the protein-acrylamide copolymer arrays detected CML cell levels as low as 15% in a background of Bcr-Abl- leukemic cells and provided the framework for the parallel evaluation of six tyrosine kinase inhibitors. Such a system may have direct application to the detection and treatment of cancers resulting from upregulated tyrosine kinase activity, such as chronic myeloid leukemia (CML). These findings also establish a basis for screening tyrosine kinase inhibitors and provide a framework on which protein-protein interactions in other complex systems can be studied.",
        "Doc_title":"Protein-acrylamide copolymer hydrogels for array-based detection of tyrosine kinase activity from cell lysates.",
        "Journal":"Biomacromolecules",
        "Do_id":"16153117",
        "Doc_ChemicalList":"Acrylamides;Acrylic Resins;Benzamides;Biocompatible Materials;Biopolymers;Enzyme Inhibitors;Hydrogels;Piperazines;Polymers;Proteins;Pyrimidines;Recombinant Fusion Proteins;Polylysine;Imatinib Mesylate;polyacrylamide;Glutathione Transferase;Protein-Tyrosine Kinases;Proto-Oncogene Proteins c-abl",
        "Doc_meshdescriptors":"Acrylamides;Acrylic Resins;Adsorption;Benzamides;Biocompatible Materials;Biopolymers;Enzyme Inhibitors;Glutathione Transferase;HL-60 Cells;Humans;Hydrogels;Imatinib Mesylate;Inhibitory Concentration 50;K562 Cells;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Models, Chemical;Phosphorylation;Piperazines;Polylysine;Polymers;Protein Binding;Protein Structure, Tertiary;Protein-Tyrosine Kinases;Proteins;Proto-Oncogene Proteins c-abl;Pyrimidines;Recombinant Fusion Proteins",
        "Doc_meshqualifiers":"chemistry;chemistry;chemistry;chemistry;pharmacology;metabolism;chemistry;drug therapy;pharmacology;chemistry;chemistry;antagonists & inhibitors;metabolism;chemistry;metabolism;pharmacology;metabolism",
        "_version_":1605880899102048256},
      {
        "Doc_abstract":"The molecular signature of BCR-ABL fusion in chronic myeloid leukemia (CML) provides a unique tool for diagnosis and monitoring of tumor burden during therapy. The gold standard in this regard is conventional bone marrow cytogenetics. Peripheral blood fluorescent in situ hybridization (FISH) offers the possibility of a less invasive, more practical alternative method in terms of both cost and turnaround time. In the present study, we examined 296 paired samples from 65 patients with CML and demonstrate a tight correlation, in quantifying BCR-ABL burden between bone marrow cytogenetics, bone marrow dual color, double fusion (D-FISH), and peripheral blood D-FISH (P < 0.0001 for each). Furthermore, we demonstrate that peripheral blood D-FISH can be used as a surrogate for cytogenetic studies in monitoring cytogenetic remission status.",
        "Doc_title":"Utility of peripheral blood dual color, double fusion fluorescent in situ hybridization for BCR/ABL fusion to assess cytogenetic remission status in chronic myeloid leukemia.",
        "Journal":"Leukemia & lymphoma",
        "Do_id":"17071476",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Cohort Studies;Cytogenetics;Fusion Proteins, bcr-abl;Humans;In Situ Hybridization, Fluorescence;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Middle Aged;Philadelphia Chromosome;Regression Analysis;Remission Induction",
        "Doc_meshqualifiers":"genetics;instrumentation;methods;diagnosis;genetics;pathology",
        "_version_":1605842193498505216},
      {
        "Doc_abstract":"In acute lymphoblastic leukemia (ALL), the Philadelphia chromosome (Ph) is associated with a poor prognosis. For these patients, hematopoietic stem cell transplantation (HSCT) and BCR/ABL tyrosine kinase inhibitors (TKIs) are considered standard of therapy. However, it remains unclear whether BCR/ABL TKIs should be administered lifelong as maintenance post-HSCT, and whether the presence of minimal residual disease (MRD) is invariably associated with relapse. We report on two patients with Ph+ ALL who were successfully treated with polychemotherapy and consecutive autologous HSCT. Both patients are in continuous hematologic remission after an observation period of 12 years and 18 years, respectively, despite measurable MRD and although no maintenance therapy was initiated. BCR/ABL transcript-levels ranged between 0.1 and 3% in patient 1, and 0.01 and 0.1% in patient 2 during the observation time. Collectively, these data suggest that not all Ph+ subclones even those that persist after HSCT in Ph+ ALL, may have the potential to cause a hematologic relapse. We hypothesize that these small-sized clones are derived from neoplastic stem cells that have not (yet) accumulated a sufficient number of pro-oncogenic hits required for full transformation to ALL-initiating (stem) cells and thus overt leukemia.",
        "Doc_title":"Stable non-transforming minimal residual disease in Philadelphia chromosome positive acute lymphoblastic leukemia after autologous transplantation: origin from neoplastic yet 'pre-leukemic' stem cells?",
        "Journal":"Leukemia & lymphoma",
        "Do_id":"21463112",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Female;Follow-Up Studies;Hematopoietic Stem Cell Transplantation;Humans;Male;Middle Aged;Neoplasm, Residual;Neoplastic Stem Cells;Philadelphia Chromosome;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Remission Induction;Transplantation, Autologous",
        "Doc_meshqualifiers":"pathology;pathology;pathology;therapy",
        "_version_":1605801591521148928},
      {
        "Doc_abstract":"The sensitivity and clinical utility of the polymerase chain reaction (PCR) assay for the detection of BCR-ABL gene rearrangement was compared to conventional cytogenetics for the Philadelphia chromosome (Ph1) in adult acute lymphoblastic leukemia (ALL) patients entered onto a single clinical trial. Ninety-three patients had evaluable PCR assays for both the p190bcr-abl and p210bcr-abl type of BCR-ABL gene rearrangements. Twenty-one of 93 patients (23%) were positive for the BCR-ABL rearrangement by the PCR assay. Fourteen of these patients had the p210brc-abl BCR-ABL rearrangement characteristically seen in CML patients, while seven had the p190bcr-abl rearrangement seen in ALL alone. Of 61 patients analyzed, both with conventional cytogenetics and PCR, eight (13%) were positive for the Ph1, while 14 (23%) were positive for the BCR-ABL rearrangement by the PCR assay. Discordance between the PCR assay and cytogenetics occurred in eight cases where the PCR assay was positive and the cytogenetics negative, and two cases where the PCR assay was negative and cytogenetics positive. PCR positivity did not correlate with treatment response, survival, or relapse-free survival, but there was a higher percentage of L2 FAB morphology in the PCR+ cases compared to the PCR-cases (67 vs. 28%, p = 0.003). In addition, the data suggested that patients with a p190bcr-abl rearrangement have a better response to induction therapy, but a worse relapse-free survival compared to patients with a p210bcr-abl breakpoint, but these differences were not statistically significant. These data suggest that PCR and conventional cytogenetics may provide complementary information, since there appear to be a subset of patients who are Ph1-negative yet BCR-ABL positive by PCR. Further studies will be required to determine the prognostic significance of the detailed information about BCR-ABL breakpoints that is available from the PCR assay.",
        "Doc_title":"Detection of BCR-ABL fusion genes in adult acute lymphoblastic leukemia by the polymerase chain reaction.",
        "Journal":"Leukemia",
        "Do_id":"7934164",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Chromosome Fragility;Disease-Free Survival;Female;Fusion Proteins, bcr-abl;Gene Rearrangement;Genes, abl;Humans;Karyotyping;Logistic Models;Male;Middle Aged;Philadelphia Chromosome;Polymerase Chain Reaction;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Prognosis;Proportional Hazards Models;Remission Induction;Sensitivity and Specificity",
        "Doc_meshqualifiers":"genetics;drug therapy;genetics",
        "_version_":1605903484595470336},
      {
        "Doc_abstract":"Transformation by tyrosine kinase oncogenes (TKOs) in myeloid malignancies, including BCR-ABL in chronic myeloid leukemia, FLT3ITD in acute myeloid leukemia or JAK2V617F in myeloproliferative neoplasms, is associated with increased growth and cytoskeletal abnormalities. Using targeted approaches against components of the superoxide-producing NADPH-oxidases, including NADPH oxidase 2 (NOX2), NOX4 and the common p22(phox) subunit of NOX1-4, myeloid cells were found to display reduced cell growth and spontaneous migration. Consistent with a role of NOXs as regulators of membrane proximal signaling events in nonphagocytic cells, NOX2 and NOX4 were not involved in the excess production of intracellular reactive oxygen species and did not significantly increase oxygen consumption. All NOX family members are controlled in part through levels of the rate-limiting substrate NADPH, which was found to be significantly elevated in TKO-transformed cells. Also, reduced phosphorylation of the actin filament crosslinking protein myristoylated alanine-rich C-kinase substrate (MARCKS) in response to suppression of p22(phox) hints at a novel effector of NOX signaling. MARCKS was also found to be required for increased migration. Overall, these data suggest a model whereby NOX links metabolic NADPH production to cellular events that directly contribute to transformation.",
        "Doc_title":"NADPH oxidases regulate cell growth and migration in myeloid cells transformed by oncogenic tyrosine kinases.",
        "Journal":"Leukemia",
        "Do_id":"21072051",
        "Doc_ChemicalList":"NADP;NADPH Oxidase;Protein-Tyrosine Kinases",
        "Doc_meshdescriptors":"Animals;Cell Line;Cell Movement;Cell Proliferation;Cell Transformation, Neoplastic;Humans;Leukemia, Myeloid;Mice;Myeloid Cells;NADP;NADPH Oxidase;Oncogenes;Protein-Tyrosine Kinases",
        "Doc_meshqualifiers":"etiology;pathology;pathology;biosynthesis;physiology;genetics",
        "_version_":1605844111623979008},
      {
        "Doc_abstract":"The limited value of qualitative reverse transcription polymerase chain-reaction (RT-PCR) for monitoring chronic myeloid leukemia (CML) patients has prompted the development of quantitative assays. We have developed a quantitative real-time PCR (QC-PCR) method in the LightCycler, based on the use of fluorescently labeled probes (HybProbes), to estimate BCR-ABL fusion gene transcripts in samples from CML patients.;Fifty-two samples (45 peripheral blood, five bone marrow, and two apheresis product samples) from nine patients with CML were analyzed. Seven patients were studied at diagnosis and during follow-up after hematopoietic stem cell transplantation (HSCT), whereas two were evaluated only after HSCT. The PCR reaction was carried out in capillary tubes in a final volume of 10 microL, using 2 microL cDNA, the Mensik et al. primers, and two HybProbes. The results for BCR-ABL were normalized with reference to ABL. The PCR program is completed in only 45 min.;The sensitivity attained allowed the detection of rearrangements at dilutions of between 5-10(-4) and 10(-5) K562 cDNA. The within-assay coefficient of variation was 11% for BCR-ABL, and 9% for ABL. A greater than 2 log reduction in the BCR-ABL/ABL ratio was evident shortly after transplantation in all allografted patients.;We may conclude that the TaqMan probe technology can be easily adapted to HybProbes with equivalent results. Besides, the results of BCR-ABL quantification in the follow-up of patients clearly confirm that real-time PCR with HybProbes is a reliable and sensitive method for monitoring minimal residual leukemia after HSCT in CML patients.",
        "Doc_title":"Rapid quantitative detection of BCR-ABL transcripts in chronic myeloid leukemia patients by real-time reverse transcriptase polymerase-chain reaction using fluorescently labeled probes.",
        "Journal":"Haematologica",
        "Do_id":"11114130",
        "Doc_ChemicalList":"Fluorescent Dyes;RNA, Messenger;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adolescent;Adult;Bone Marrow;Female;Fluorescent Dyes;Follow-Up Studies;Fusion Proteins, bcr-abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;RNA, Messenger;Reverse Transcriptase Polymerase Chain Reaction",
        "Doc_meshqualifiers":"metabolism;genetics;diagnosis;genetics;blood;metabolism;standards",
        "_version_":1605891256122081280},
      {
        "Doc_abstract":"The outcome of children and adults with acute lymphoblastic leukemia is markedly different. Since there is limited information on the distribution of clinico-biological variables in different age cohorts, we analyzed 5202 patients with acute lymphoblastic leukemia enrolled in the Italian multicenter AIEOP and GIMEMA protocols and stratified them in nine age cohorts. The highest prevalence of acute lymphoblastic leukemia was observed in children, although a second peak was recorded from the 4(th) decade onwards. Interestingly, the lowest incidence was found in females between 14-40 years. Immunophenotypic characterization showed a B-lineage in 85.8% of patients: a pro-B stage, associated with MLL/AF4 positivity, was more frequent in patients between 10-50 years. T-lineage leukemia (14.2%) was rare among small children and increased in patients aged 10-40 years. The prevalence of the BCR/ABL1 rearrangement increased progressively with age starting from the cohort of patients 10-14 years old and was present in 52.7% of cases in the 6th decade. Similarly, the MLL/AF4 rearrangement constantly increased up to the 5(th) decade, while the ETV6/RUNX1 rearrangement disappeared from the age of 30 onwards. This study shows that acute lymphoblastic leukemia in adolescents and young adults is characterized by a male prevalence, higher percentage of T-lineage cases, an increase of poor prognostic molecular markers with aging compared to cases in children, and conclusively quantified the progressive increase of BCR/ABL(+) cases with age, which are potentially manageable by targeted therapies. ",
        "Doc_title":"Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts.",
        "Journal":"Haematologica",
        "Do_id":"23716539",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adolescent;Adult;Age Factors;Child;Child, Preschool;Cohort Studies;Female;Humans;Infant;Italy;Male;Middle Aged;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Retrospective Studies;Young Adult",
        "Doc_meshqualifiers":"epidemiology;diagnosis;epidemiology;genetics",
        "_version_":1605883108430708736},
      {
        "Doc_abstract":"We investigated parental origin of rearranged chromosomes 9 and 22 (9q + and 22q -) in five patients with Ph-positive chronic myeloid leukemia (CML) using the C-banding and silver-staining methods of nucleolus organizer regions, respectively; of rearranged chromosome 21 (21q +) in seven patients with t(8;21)-positive acute myeloid leukemia (AML); and of rearranged chromosome 15 (15q +) in six patients with t(15;17)-positive AML. It was found that these rearranged chromosomes can be of either paternal or maternal origin. Although the number of patients examined was small, these results indicate that the genes rearranged as a result of these chromosome translocations (ABL, BCR, AML-1 and PML) are not genomically imprinted.",
        "Doc_title":"No parental origin bias for the rearranged chromosomes in myeloid leukemias associated with t(9;22), t(8;21) and t(15;17).",
        "Journal":"Leukemia research",
        "Do_id":"9716010",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adolescent;Adult;Child;Chromosome Banding;Chromosomes, Human, Pair 15;Chromosomes, Human, Pair 17;Chromosomes, Human, Pair 21;Chromosomes, Human, Pair 22;Chromosomes, Human, Pair 8;Chromosomes, Human, Pair 9;Female;Genomic Imprinting;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Translocation, Genetic",
        "Doc_meshqualifiers":"genetics",
        "_version_":1605741945785679872},
      {
        "Doc_abstract":"The chimeric bcr-abl gene encodes a constitutively active tyrosine kinase that leads to abnormal transduction of growth and survival signals leading to chronic myeloid leukemia (CML). According to our previous observations, in vitro differentiation of several erythroid cell lines is accompanied by the downregulation of extracellular signal-regulated kinases (ERK)1/2 mitogen-activated protein kinase (MAPK) activities. In this work we investigated whether ERKs have a decisive role in either the erythroid differentiation process or apoptosis of bcr-abl+ K562 cells by means of direct (MEK1/2 inhibitor UO126) and indirect (reduced Bcr-Abl function) inhibition of their activities. We found that both Gleevec and UO126 induced hemoglobin expression. Gleevec treatment reduced the phosphorylation of Bcr-Abl, ERK and STAT-5 for up to 24 h, decreased Bcl-XL levels, and induced caspase-3-dependent apoptosis. In contrast, UO126 treatment resulted in only a transient decrease of ERK activity and did not induce cell death. For studying the effect of reduced Bcr-Abl function on erythroid differentiation at the level of the bcr-abl transcript, we applied the siRNA approach. Stable degradation of bcr-abl mRNA was achieved by using a retroviral vector with enhanced green fluorescent protein (EGFP) reporter. Despite a high (>90%) transduction efficiency we detected only a transient decrease in Bcr-Abl protein and in phosphorylated ERK1/2 levels. This transient change in Bcr-Abl signaling was sufficient to induce hemoglobin expression without significant cell death. These results suggest that by transiently reducing Bcr-Abl function it is possible to overcome the differentiation blockade without evoking apoptosis in CML cells and that reduced ERK activity may have a crucial role in this process.",
        "Doc_title":"Reduction of Bcr-Abl function leads to erythroid differentiation of K562 cells via downregulation of ERK.",
        "Journal":"Annals of the New York Academy of Sciences",
        "Do_id":"17384279",
        "Doc_ChemicalList":"DNA Primers;RNA, Small Interfering;Fusion Proteins, bcr-abl;Extracellular Signal-Regulated MAP Kinases",
        "Doc_meshdescriptors":"Base Sequence;Cell Differentiation;DNA Primers;Down-Regulation;Erythrocytes;Extracellular Signal-Regulated MAP Kinases;Fusion Proteins, bcr-abl;Gene Silencing;Humans;K562 Cells;RNA, Small Interfering;Reverse Transcriptase Polymerase Chain Reaction",
        "Doc_meshqualifiers":"physiology;cytology;metabolism;physiology",
        "_version_":1605766146594701312},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by the translocation t(9;22), coding for the chimeric protein BCR-ABL. The development of BCR-ABL tyrosine kinase inhibitors (TKIs) has dramatically revolutionized and improved CML therapy. However, TKI-based therapy faces a major challenge: the insensitivity of CML leukemic stem cells (LSCs) to TKIs. In particular, while CML progenitor cells and differentiated cells are oncogene addicted, BCR-ABL tyrosine kinase is dispensable for CML LSC survival and maintenance. Notably, in CML, additional cellular mechanisms promote LSC survival and maintenance, rendering these cells able to survive even in the presence of TKI and to eventually promote relapse.;This review will focus on the mechanisms of LSC insensitivity to TKI and on the strategies to obtain synthetic lethality with combination therapies.;Several pathways have been proposed to promote LSC maintenance and described as ideal targets to induce CML LSC exhaustion in combination with TKI. Ongoing clinical trials designed to target some of these pathways will assess which molecular target is relevant for in vivo human LSC survival in a new 'stem-cell targeting' perspective.",
        "Doc_title":"Kinase-inhibitor-insensitive cancer stem cells in chronic myeloid leukemia.",
        "Journal":"Expert opinion on biological therapy",
        "Do_id":"24387320",
        "Doc_ChemicalList":"Protein Kinase Inhibitors",
        "Doc_meshdescriptors":"Animals;Clinical Trials as Topic;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Neoplastic Stem Cells;Protein Kinase Inhibitors",
        "Doc_meshqualifiers":"methods;drug therapy;enzymology;drug effects;enzymology;pharmacology;therapeutic use",
        "_version_":1605755982274625536},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm, characterized by the unrestrained expansion of pluripotent hematopoietic stem cells. CML was the first malignancy in which a unique chromosomal abnormality was identified and a pathophysiologic association was suggested. The hallmark of CML is a reciprocal chromosomal translocation between the long arms of chromosomes 9 and 22, t(9; 22)(q34; q11), creating a derivative 9q+ and a shortened 22q-. The latter, known as the Philadelphia (Ph) chromosome, harbors the breakpoint cluster region-abelson (BCR-ABL) fusion gene, encoding the constitutively active BCR-ABL tyrosine kinase that is necessary and sufficient for initiating CML. The successful implementation of tyrosine kinase inhibitors (TKIs) for the treatment of CML remains a flagship for molecularly targeted therapy in cancer. TKIs have changed the clinical course of CML; however, some patients nonetheless demonstrate primary or secondary resistance to such therapy and require an alternative therapeutic strategy. Therefore, the assessment of early response to treatment with TKIs has become an important tool in the clinical monitoring of CML patients. Although mutations in the BCR-ABL have proven to be the most prominent mechanism of resistance to TKIs, other mechanisms-either rendering the leukemic cells still dependent on BCR-ABL activity or supporting oncogenic properties of the leukemic cells independent of BCR-ABL signaling-have been identified. This article provides an overview of the current understanding of CML pathogenesis; recommendations for diagnostic tools, treatment strategies, and management guidelines; and highlights the BCR-ABL-dependent and -independent mechanisms that contribute to the development of resistance to TKIs. ",
        "Doc_title":"Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.",
        "Journal":"Molecular diagnosis & therapy",
        "Do_id":"27220498",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605807281892491264},
      {
        "Doc_abstract":"This study was purposed to explore the application value of fluorescence in situ hybridization (FISH) detection in differential diagnosis of chronic myeloproliferative disorders (CMPD) and Ph(+) acute lymphoblastic leukemia (Ph(+) ALL), as well as in dynamic monitoring of minimal residual disease (MRD) after treatment. The BCR/ABL fusion gene of newly diagnosed and treated cases was detected by using BCR/ABL (ES) probe and BCR/ABL (DF) probe respectively. The results showed that among 49 newly diagnosed cases considered as CMPD, 28 cases met the criterion of CML morphologically, out of them 23 cases were eventually diagnosed to be CML and with morphological consistent rate 82.1% (23/28), the sensitivity and specificity all were 100% (23/23). The BCR/ABL positive rate of eventually diagnosed cases was 81.3%  17.7%. Among 13 cases received allogeneic haemopoietic stem cell transplantation (allo-HSCT), 9 cases achieved long-term disease-free survival and 4 cases relapsed, the several monitoring for whom after donor lymphocyte infusion (DLI) and imatinib treatment or allo-HSCT showed BCR/ABL negative. Among 16 cases treated with imatinib, 11 cases remained BCR/ABL negative after 1 year; 5 cases showed BCR/ABL positive during 6, 7 and 10 years after treatment, respectively, but out of them BCR/ABL positive in 1 case turned negative after allo-HSCT. It is concluded that the FISH is sensitive and specific diagnostic technique, the detection of BCR/ABL fusion gene in newly diagnosed and treated cases by using 2 different probes can help to fast and accurately determine the differential diagnosis for CML and Ph(+) ALL, and dynamically monitor the MRD after treatment with imatinib and allo-HSCT.",
        "Doc_title":"[Clinical application of BCR/ABL probes in myeloproliferative disorders].",
        "Journal":"Zhongguo shi yan xue ye xue za zhi",
        "Do_id":"23998593",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Aged, 80 and over;Child;Child, Preschool;Diagnosis, Differential;Female;Fusion Proteins, bcr-abl;Humans;In Situ Hybridization, Fluorescence;Male;Middle Aged;Myeloproliferative Disorders;Neoplasm, Residual;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Retrospective Studies;Sensitivity and Specificity;Young Adult",
        "Doc_meshqualifiers":"genetics;diagnosis;pathology;pathology;diagnosis;pathology",
        "_version_":1605799013129388032},
      {
        "Doc_abstract":"Most chronic myeloid leukemia (CML) patients show the Philadelphia chromosome (Ph) arising from the reciprocal t(9;22), but 5-10% present variants of this translocation involving different breakpoints besides 9q34 and 22q11. WE REPORT THE NON SIMULTANEOUS OCCURRENCE OF TWO DIFFERENT TYPES OF PH TRANSLOCATION IN A CML PATIENT: a t(9;22)(q34;q11) standard and a three-way variant t(9;11;22)(q34;p15;q11). Bone marrow cells with standard translocation did not have BCR/ABL kinase domain (KD) mutations and were sensitive to imatinib therapy. In contrast, bone marrow cells with the variant translocation showed two BCR/ABL KD mutations and were resistant to imatinib, thus inducing transformation to the blast phase and karyotype evolution. ",
        "Doc_title":"Standard and variant Philadelphia translocation in a CML patient with different sensitivity to imatinib therapy.",
        "Journal":"Leukemia research reports",
        "Do_id":"24371787",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605746316034441217},
      {
        "Doc_abstract":"Therapy with imatinib mesylate is a standard of care for most patients with Philadelphia chromosome-positive chronic myeloid leukemia (CML). However, resistance or intolerance to imatinib develops in a considerable number of patients leading to relapse or discontinuation of treatment. Nilotinib is a rationally designed second-generation tyrosine kinase inhibitor (TKI) with improved affinity and specificity against the BCR-ABL kinase, when compared with imatinib. Considerable efficacy after imatinib failure has been demonstrated in clinical trials leading to nilotinib's current approval as second-line therapy for CML in chronic and accelerated phase (AP). The role of nilotinib as first-line treatment for CML, in combinatorial strategies and in the context of specific BCR-ABL mutations, requires future studies.",
        "Doc_title":"Nilotinib.",
        "Journal":"Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer",
        "Do_id":"20072834",
        "Doc_ChemicalList":"4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide;Antineoplastic Agents;Pyrimidines",
        "Doc_meshdescriptors":"Animals;Antineoplastic Agents;Clinical Trials as Topic;Drug Resistance, Neoplasm;Humans;Neoplasms;Pyrimidines",
        "Doc_meshqualifiers":"therapeutic use;drug therapy;adverse effects;pharmacokinetics;pharmacology;therapeutic use",
        "_version_":1605775269988139008},
      {
        "Doc_abstract":"BCR-ABL tyrosine kinase inhibitors (TKIs) are effective in controlling Philadelphia-positive (Ph+) chronic myeloid leukemia (CML) are unlikely to cure the disease because TKIs are unable to eradicate leukemia stem cells (LSCs) responsible for the disease relapse even after tyrosine kinase inhibition. In addition, the TKI resistance of LSCs is not associated with the BCR-ABL kinase domain mutations. These observations indicate that TKI-insensitive LSCs and TKI-sensitive leukemic progenitor cells are biologically different, which leads us to believe that LSCs and more differentiated leukemic cells have different genetic mechanisms. Further study of LSCs to identify the novel gene signatures and mechanisms that control the function and molecular phenotype of LSCs is critical. In this mini-review, we will discuss our current understanding of the biology of LSCs and novel genes that could serve as a molecular signature of LSCs in CML. These novel genes could also serve as potential targets for eradicating LSCs in CML. ",
        "Doc_title":"Molecular signatures of chronic myeloid leukemia stem cells.",
        "Journal":"Biomarker research",
        "Do_id":"24252550",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605759456149241856},
      {
        "Doc_abstract":"Persistence of BCR-ABL rearrangements was demonstrated by D-FISH technique in chronic myeloid leukemia (CML) patients in complete cytogenetic response (CCR) after allogeneic bone marrow transplantation (BMT) or interferon-alpha therapy (IFN-alpha). Samples from bone marrow aspirate or peripheral blood or both were analyzed by conventional cytogenetics, Southern blot, fluorescent interphase in situ hybridization (FISH), and quantitative reverse transcription polymerase chain reaction (Q-RT-PCR). In all patients, FISH detected 1% to 12% nuclei with a BCR-ABL fusion gene, whereas Q-RT-PCR were negative or weakly positive. Based on these results, we hypothesize that the BCR-ABL genomic rearrangement remains unexpressed in a small percentage of cells whatever the treatment (IFN-alpha or BMT), and this in spite of the negativity of the RT-PCR-based classical molecular remission criterion. These data corroborate those obtained by other investigators and point to the need for follow-up of CML patients in CCR over an extensive period, at the DNA level to evaluate the residual disease and at the RNA level (Q-RT-PCR) to estimate the risk of relapse and guide the therapeutic decision. Experimental models suggesting the persistence of positive BCR-ABL cells are discussed and tentative explanations of tumor \"dormancy\" are proposed.",
        "Doc_title":"Persistence of transcriptionally silent BCR-ABL rearrangements in chronic myeloid leukemia patients in sustained complete cytogenetic remission.",
        "Journal":"Leukemia & lymphoma",
        "Do_id":"11697648",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Chromosomes, Human, Pair 22;Chromosomes, Human, Pair 9;Cytogenetic Analysis;Fusion Proteins, bcr-abl;Gene Rearrangement;Gene Silencing;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Neoplasm, Residual;Translocation, Genetic",
        "Doc_meshqualifiers":"genetics;diagnosis;genetics;diagnosis;genetics",
        "_version_":1605825906853543936},
      {
        "Doc_abstract":"To investigate the significance of duel-color fluorescence in situ hybridization (D-FISH) in monitoring the response to interferon alpha (IFN-alpha) therapy in patients with chronic myeloid leukemia (CML), the D-FISH method was employed to detect the proportion of the interphase nuclei cells with bcr/abl fusion gene in the bone marrow of patients with CML before and after IFN-alpha therapy, and the results were compared with those of bcr/abl fusion mRNA by RT-PCR and Philadephia chromosome (Ph) by conventional cytogenetic analysis. The results showed that the mean detectable rate of bcr/abl fusion gene before and after IFN-alpha therapy was 96.4% and 58.6% respectively, in 22 patients who were bcr/abl-positive before IFN-alpha therapy by D-FISH method, was 94.0% and 70.1% respectively, in 2 patients of Ph-negative before treatment. Major, minor and no responses were seen respectively in 4, 4 and 14 cases from 22 patients by D-FISH method. The results also showed a good correlation with the analysis of RT-PCR and conventional cytogenetics. In conclusion, D-FISH method could directly detect the bcr/abl fusion gene of the interphase cells in bone marrow of patients with CML. It can overcome the defect of conventional cytogenetic methods which analyze only the cells in metaphase and the drawback of RT-PCR unable to quantify the bcr/abl fusion gene. D-FISH provides a more convenient and reliable method for evaluating the degree of clone remission to patients with CML after IFN-alpha therapy.",
        "Doc_title":"[Monitoring of the therapeutic response of interferon to chronic myeloid leukemia by duel-color fluorescence in situ hybridization].",
        "Journal":"Zhongguo shi yan xue ye xue za zhi",
        "Do_id":"12667287",
        "Doc_ChemicalList":"Antineoplastic Agents;Interferon-alpha;RNA, Messenger;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Antineoplastic Agents;Bone Marrow Cells;Female;Fusion Proteins, bcr-abl;Humans;In Situ Hybridization, Fluorescence;Interferon-alpha;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Philadelphia Chromosome;RNA, Messenger;Reproducibility of Results;Reverse Transcriptase Polymerase Chain Reaction;Treatment Outcome",
        "Doc_meshqualifiers":"therapeutic use;drug effects;metabolism;pathology;genetics;methods;therapeutic use;drug therapy;genetics;pathology;genetics;metabolism",
        "_version_":1605852323549020160},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) was the first human malignancy shown to be associated with a specific cytogenetic lesion, the Philadelphia chromosomal translocation. Forty years on, many biological and biochemical properties have been ascribed to its molecular product, the BCR-ABL tyrosine kinase fusion protein. However, it has been difficult to establish their precise contribution to the deregulation of normal survival, proliferative and differentiative control in chronic phase CML and the degree to which the involvement of stem cells extends beyond their role as the aetiological target. This review will focus on our current understanding of the pathogenesis of CML from the perspective of stem cell involvement, and how the biological and biochemical properties ascribed to BCR-ABL from studies of in vitro transformation and in vivo leukemogenesis systems relate to the abnormalities manifest in the human disease.",
        "Doc_title":"Consequences of BCR-ABL expression within the hematopoietic stem cell in chronic myeloid leukemia.",
        "Journal":"Stem cells (Dayton, Ohio)",
        "Do_id":"11072027",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Animals;Disease Models, Animal;Fusion Proteins, bcr-abl;Hematopoietic Stem Cells;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive",
        "Doc_meshqualifiers":"biosynthesis;metabolism;metabolism",
        "_version_":1605741939556089859},
      {
        "Doc_abstract":"Bone marrow BCR-ABL transcript levels were monitored serially by real-time quantitative PCR in 46 imatinib-treated chronic myeloid leukemia patients after achieving complete cytogenetic response (CCyR) for a median of 42 months (range: 9-53). Of 41 patients in continuous CCyR, 32 and nine could achieve a >/=3-log (MMoR group) or 2- to 3-log reduction (non-MMoR group), respectively. The MMoR group had a significantly lower recurrence rate of Ph+ metaphase than the non-MMoR group (6/32 vs. 7/9, P = 0.002), which was not significantly different between patients first achieving CCyR within or after 12 months of imatinib treatment (7/27 vs. 6/14, P = 0.086). Five patients suffered cytogenetic or hematological relapse. For all 46 patients, a >2-log reduction but not time when CCyR was first achieved was related to a lower relapse rate (1/42 vs. 4/4, P < 0.001). We concluded that the depth of BCR-ABL reduction after CCyR is more critical than when CCyR is first achieved. The kinetic pattern of BCR-ABL transcript is a good predictor of disease stability.",
        "Doc_title":"Different kinetic patterns of BCR-ABL transcript levels in imatinib-treated chronic myeloid leukemia patients after achieving complete cytogenetic response.",
        "Journal":"International journal of laboratory hematology",
        "Do_id":"18665830",
        "Doc_ChemicalList":"Benzamides;Piperazines;Protein Kinase Inhibitors;Pyrimidines;RNA, Messenger;Imatinib Mesylate;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Benzamides;Cytogenetic Analysis;Female;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Neoplasm, Residual;Piperazines;Prognosis;Protein Kinase Inhibitors;Pyrimidines;RNA, Messenger;Remission Induction;Transcription, Genetic",
        "Doc_meshqualifiers":"genetics;metabolism;drug therapy;genetics;diagnosis;genetics;therapeutic use;therapeutic use;therapeutic use;analysis;metabolism",
        "_version_":1605766216764358656},
      {
        "Doc_abstract":"In chronic myeloid leukemia following therapy with Imatinib (STI571) hematologic and cytogenetic response is associated with conspicuous changes of bone marrow morphology. However, it is not known to which extent these alterations are accompanied by a loss of the bcr/abl translocation. To study regression of the leukemic cell population we recruited 14 patients lacking pretreatment. Therapy resulted in a reduction of CD61(+) megakaryopoiesis. Dwarf megakaryocytes characteristic for this disorder were replaced by large, normally appearing cells of this lineage. Morphometric analysis confirmed the significant decrease in the number of micromegakaryocytes and yielded planimetric parameters in keeping with normalization. Moreover, a fluorescence in-situ hybridization study in five patients of this cohort revealed that before therapy 70% of all myeloid cells exhibited the bcr/abl gene. Regarding megakaryopoiesis about 65% of the micromegakaryocytes displayed positive signals. Following treatment these bcr/abl(+) cell populations decreased significantly while the emerging large megakaryocytes lacked a proper labeling. Because cytogenetic response and reduction of atypical micromegakaryocytes are linked, this feature may be useful to monitor therapeutic efficacy.",
        "Doc_title":"[Regression of the Philadelphia chromosome (bcr/abl)-positive myelo- and megakaryopoiesis after Imatinib (STI571) therapy in chronic myelogenous leukemia (CML)].",
        "Journal":"Der Pathologe",
        "Do_id":"15179523",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Biopsy;Bone Marrow;Genes, abl;Humans;In Situ Hybridization;In Situ Hybridization, Fluorescence;Leukemia, Myelogenous, Chronic, BCR-ABL Positive",
        "Doc_meshqualifiers":"pathology;genetics;genetics;pathology",
        "_version_":1605785466867548160},
      {
        "Doc_abstract":"Recent reports support a possible future application of gene expression profiling for the diagnosis of leukemias. However, the robustness of subtype-specific gene expression signatures has to be proven on independent patient samples. Here, we present gene expression data of 34 adult acute lymphoblastic leukemia (ALL) patients (Affymetrix U133A microarrays). Support Vector Machines (SVMs) were applied to stratify our samples based on given gene lists reported to predict MLL, BCR-ABL, and T-ALL, as well as MLL and non-MLL gene rearrangement positive pediatric ALL. In addition, seven other B-precursor ALL cases not bearing t(9;22) or t(11q23)/MLL chromosomal aberrations were analyzed. Using top differentially expressed genes, hierarchical cluster and principal component analyses demonstrate that the genetically more heterogeneous B-precursor ALL samples intercalate with BCR-ABL-positive cases, but were clearly distinct from T-ALL and MLL profiles. Similar expression signatures were observed for both heterogeneous B-precursor ALL and for BCR-ABL-positive cases. As an unrelated laboratory, we demonstrate that gene signatures defined for childhood ALL were also capable of stratifying distinct subtypes in our cohort of adult ALL patients. As such, previously reported gene expression patterns identified by microarray technology are validated and confirmed on truly independent leukemia patient samples.",
        "Doc_title":"Pediatric acute lymphoblastic leukemia (ALL) gene expression signatures classify an independent cohort of adult ALL patients.",
        "Journal":"Leukemia",
        "Do_id":"14603332",
        "Doc_ChemicalList":"Neoplasm Proteins;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adult;Bone Marrow Cells;Chromosome Aberrations;Cohort Studies;Fusion Proteins, bcr-abl;Gene Expression Profiling;Gene Expression Regulation, Leukemic;Gene Rearrangement;Humans;Neoplasm Proteins;Oligonucleotide Array Sequence Analysis;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Prognosis;Translocation, Genetic",
        "Doc_meshqualifiers":"chemistry;pathology;metabolism;methods;genetics;genetics",
        "_version_":1605802584858165248},
      {
        "Doc_abstract":"Donor leukocyte infusion (DLI) can induce graft-versus-leukemia (GvL) reactions in patients with chronic myeloid leukemia (CML) relapsing after allogeneic bone marrow transplantation (BMT), but the mechanisms of the antileukemic effect of DLI are unknown, and the procedure is complicated by graft-versus-host disease (GvHD) and graft failure. Here, we adapted a murine retroviral BMT model of Philadelphia(+) leukemia by combining allogeneic bone marrow (BM) from C57Bl/6 (H-2(b)) mice with BCR-ABL-transduced Balb/c (H-2(d)) BM, inducing mixed chimerism and myeloproliferative disease in recipients resembling relapse of CML following allogeneic BMT. Infusions of allogeneic splenocytes eliminated BCR-ABL-induced CML-like disease in the majority of mixed chimeras, with significant GvL effects mediated by both CD4(+) and CD4(-) cells. BCR-ABL-induced acute B-lymphoblastic leukemia was also eradicated by DLI in major histocompatibility complex (MHC)-mismatched chimeras. Most DLI-treated mice converted to full allogeneic chimerism but succumbed frequently to GvHD or graft failure. When MHC-matched B10.D2 (H-2(d)) mice were the allogeneic donors, CML-like disease was more resistant to DLI. These results suggest that depletion of CD8(+) cells from DLI could impair GvL against CML, while increased MHC disparity between donor and recipient may improve the responsiveness of Philadelphia(+) B-lymphoblastic leukemia to DLI.",
        "Doc_title":"Adoptive immunotherapy of BCR-ABL-induced chronic myeloid leukemia-like myeloproliferative disease in a murine model.",
        "Journal":"Blood",
        "Do_id":"15308567",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Animals;Bone Marrow Transplantation;Disease Models, Animal;Fusion Proteins, bcr-abl;Histocompatibility Testing;Immunotherapy, Adoptive;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Major Histocompatibility Complex;Mice;Mice, Inbred BALB C;Mice, Inbred Strains;Myeloproliferative Disorders;Transplantation Chimera",
        "Doc_meshqualifiers":"immunology;therapy;immunology;therapy",
        "_version_":1605899154625658880},
      {
        "Doc_abstract":"Progression and disease relapse of chronic myeloid leukemia (CML) depends on leukemia-initiating cells (LIC) that resist treatment. Using mouse genetics and a BCR-ABL model of CML, we observed cross talk between Wnt/-catenin signaling and the interferon-regulatory factor 8 (Irf8). In normal hematopoiesis, activation of -catenin results in up-regulation of Irf8, which in turn limits oncogenic -catenin functions. Self-renewal and myeloproliferation become dependent on -catenin in Irf8-deficient animals that develop a CML-like disease. Combined Irf8 deletion and constitutive -catenin activation result in progression of CML into fatal blast crisis, elevated leukemic potential of BCR-ABL-induced LICs, and Imatinib resistance. Interestingly, activated -catenin enhances a preexisting Irf8-deficient gene signature, identifying -catenin as an amplifier of progression-specific gene regulation in the shift of CML to blast crisis. Collectively, our data uncover Irf8 as a roadblock for -catenin-driven leukemia and imply both factors as targets in combinatorial therapy. ",
        "Doc_title":"Cross talk between Wnt/-catenin and Irf8 in leukemia progression and drug resistance.",
        "Journal":"The Journal of experimental medicine",
        "Do_id":"24101380",
        "Doc_ChemicalList":"Benzamides;Interferon Regulatory Factors;Piperazines;Pyrimidines;interferon regulatory factor-8;Imatinib Mesylate",
        "Doc_meshdescriptors":"Animals;Benzamides;Blast Crisis;Disease Progression;Drug Resistance, Neoplasm;Gene Expression Profiling;Gene Expression Regulation, Neoplastic;Hematopoietic Stem Cells;Humans;Imatinib Mesylate;Immunophenotyping;Interferon Regulatory Factors;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mice;Myeloid Cells;Neoplastic Stem Cells;Piperazines;Pyrimidines;Side-Population Cells;Wnt Signaling Pathway",
        "Doc_meshqualifiers":"pharmacology;genetics;pathology;drug effects;drug effects;metabolism;pathology;deficiency;metabolism;genetics;pathology;drug effects;metabolism;metabolism;pathology;pharmacology;pharmacology;drug effects;metabolism;pathology",
        "_version_":1605757097420521472},
      {
        "Doc_abstract":"Complementary inhibition of tyrosine and SRC kinases implement dual SRC/ABL inhibitor effects in chronic myeloid leukemia (CML). Here, we show that one such inhibitor, SKI-606, induces persistent Cdk2 inactivation leading to growth arrest of BCR-ABL-expressing cells either IM-sensitive or driven to IM-resistance by other events than gene overexpression and point mutations. Inhibition of Akt serine/threonine kinase, a phosphatidylinositol 3 kinase (PI-3k) target that integrates p210 TK signaling with membrane-associated SRC kinases, is a central component of restored expression and subcellular redistribution of Cdk2 regulatory signals (p21 and p27 and Cdc25A phosphatase) in response to SKI-606. The putative roles of growth factor (namely IL-3) autocrine loop in BCR-ABL-expressing progenitor progression towards a drug-resistant phenotype are discussed.",
        "Doc_title":"Persistent Cdk2 inactivation drives growth arrest of BCR-ABL-expressing cells in response to dual inhibitor of SRC and ABL kinases SKI606.",
        "Journal":"Leukemia research",
        "Do_id":"17129604",
        "Doc_ChemicalList":"Aniline Compounds;CDKN1A protein, human;Cyclin-Dependent Kinase Inhibitor p21;Enzyme Inhibitors;Interleukin-3;Nitriles;Quinolines;Cyclin-Dependent Kinase Inhibitor p27;bosutinib;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl;Proto-Oncogene Proteins c-abl;src-Family Kinases;Proto-Oncogene Proteins c-akt;CDK2 protein, human;Cyclin-Dependent Kinase 2;CDC25A protein, human;cdc25 Phosphatases",
        "Doc_meshdescriptors":"Aniline Compounds;Apoptosis;Cell Cycle;Cyclin-Dependent Kinase 2;Cyclin-Dependent Kinase Inhibitor p21;Cyclin-Dependent Kinase Inhibitor p27;Drug Resistance, Neoplasm;Enzyme Inhibitors;Fusion Proteins, bcr-abl;Humans;Interleukin-3;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Nitriles;Phosphorylation;Protein-Tyrosine Kinases;Proto-Oncogene Proteins c-abl;Proto-Oncogene Proteins c-akt;Quinolines;Tumor Cells, Cultured;cdc25 Phosphatases;src-Family Kinases",
        "Doc_meshqualifiers":"pharmacology;drug effects;drug effects;antagonists & inhibitors;metabolism;metabolism;metabolism;pharmacology;metabolism;metabolism;pathology;pharmacology;metabolism;antagonists & inhibitors;metabolism;pharmacology;drug effects;metabolism;antagonists & inhibitors",
        "_version_":1605742705988599808},
      {
        "Doc_abstract":"Chronic Myeloid Leukemia (CML) is a myeloproliferative neoplasm with an incidence of 1-2 cases per 100,000 adults, and accounts for 15% of newly diagnosed cases of leukemia in adults.;CML is characterized by a balanced genetic translocation, t(9;22)(q34;q11.2), involving a fusion of the Abelson oncogene (ABL) from chromosome 9q34 with the breakpoint cluster region (BCR) gene on chromosome 22q11.2. This rearrangement is known as the Philadelphia chromosome. The molecular consequence of this translocation is the generation of a BCR-ABL fusion oncogene, which in turn translates into a Bcr-Abl oncoprotein.;Three tyrosine kinase inhibitors (TKIs), imatinib, nilotinib, and dasatinib have been approved by the US Food and Drug Administration for the first-line treatment of patients with newly diagnosed CML in chronic phase (CML-CP). Clinical trials with second generation TKIs reported significantly deeper and faster responses; their impact on long-term survival remains to be determined.;For patients who fail frontline therapy, second-line options include second and third generation TKIs. Although second and third generation TKIs are potent and specific BCR-ABL TKIs, they exhibit unique pharmacological profiles and response patterns relative to different patient characteristics, such as patients comorbidities, disease stage, and BCR-ABL mutational status. Patients who develop the T315I \"gatekeeper\" mutation display resistance to all currently available TKIs except ponatinib. Allogeneic transplantation remains an important therapeutic option for CML-CP who have failed at least 2 TKIs, and for all patients in advanced phase disease.",
        "Doc_title":"Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management.",
        "Journal":"American journal of hematology",
        "Do_id":"24729196",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive",
        "Doc_meshqualifiers":"diagnosis;therapy",
        "_version_":1605746310820921346},
      {
        "Doc_abstract":"to elucidate the pattern of molecular response assessed by logarithmic reduction in BCR-ABL transcription levels based on Sokal prognostic score in chronic phase chronic myeloid leukemia (CML) patients receiving Imatinib treatment.;cross-sectional study was conducted in the Hematologic Outpatient Clinic, Dr. Soetomo Hospital Surabaya in all chronic phase CML patients from June 2008 to June 2012. Data on subject characteristics (age and sex), complete blood count with differential and spleen size were collected. Patients were stratified according to Sokal score at diagnosis. Real-time quantitative PCR (RT-qPCR) were used to monitor BCR-ABL levels in patients who fulfilled study. Proportion difference of complete molecular response (MR) was analyzed by chi-square test, while differences of BCR-ABL transcript level among Sokal prognostic scole subgroups was analyzed by Kruskal-Wallis test.;40 subjects finished the study. After 18 months of Imatinib treatment, the undetected BCR-ABL transcript level (complete MR) were 7(70%), 8(66.7%), and 9(50%) in low-, intermediate-, and high risk group patients, respectively (p=0.417). Although proportion of subjects with complete MR is higher in sokal low risk group compared to in sokal high risk groups (70% v.s. 50%), but this difference is not statistically significant (p=0.557). Kruskal-Wallis test showed that there was no significant difference of BCR-ABL transcript level among Sokal prognostic score subgroup (p=0.734).;there was no difference of BCR-ABL transcript level among sokal prognostic score risk groups in chronic phase CML patients treated with Imatinib.",
        "Doc_title":"Profile of BCR-ABL transcript levels based on Sokal prognostic score in chronic myeloid leukemia patients treated with imatinib.",
        "Journal":"Acta medica Indonesiana",
        "Do_id":"23770790",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Biomarkers, Tumor;Piperazines;Pyrimidines;Imatinib Mesylate;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Administration, Oral;Adult;Antineoplastic Agents;Benzamides;Biomarkers, Tumor;Cross-Sectional Studies;Drug Administration Schedule;Drug Monitoring;Female;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Leukemia, Myeloid, Chronic-Phase;Male;Middle Aged;Piperazines;Prognosis;Pyrimidines;Real-Time Polymerase Chain Reaction;Reverse Transcriptase Polymerase Chain Reaction;Severity of Illness Index;Treatment Outcome",
        "Doc_meshqualifiers":"therapeutic use;therapeutic use;blood;blood;blood;diagnosis;drug therapy;therapeutic use;therapeutic use",
        "_version_":1605783595444600832},
      {
        "Doc_abstract":"Constitutive activation of the Abelson (Abl) protein tyrosine kinase (PTK) is a causative event in chronic myeloid leukemia, where intense chemotherapy currently fails to eradicate the leukemic clone. Using a mouse mast cell line (IC.DP), we previously showed that v-Abl PTK induced resistance to the anti-cancer drugs melphalan and hydroxyurea by the suppression of apoptosis. Here, using this cell line, we demonstrate by alkaline elution that v-Abl PTK did not affect the levels of DNA damage induced by either drug. This confirms that v-Abl PTK acts downstream of the drug-target interaction to prevent the coupling of drug-induced damage to the apoptotic pathway. Although Abl PTK- and interleukin-3 (IL-3)-stimulated signaling events share common signaling pathways, a similar level of drug resistance was not provided by IL-3, implying that Abl PTK does not merely mimic an IL-3 survival signaling pathway. Previously we demonstrated translocation of protein kinase C-beta II stimulated by activation of Abl PTK. Drug sensitivity was restored in cells with active v-Abl PTK by simultaneous addition of calphostin C, an inhibitor of protein kinase C, suggesting a role for protein kinase C in the suppression of drug-induced apoptosis by v-Abl PTK. One novel strategy for the treatment of chronic myeloid leukemia could therefore include the use of a downstream modifier of the Abl PTK-mediated survival signaling pathway to render leukemic cells more sensitive to a second drug, such as a cytotoxic agent.",
        "Doc_title":"Characterization of drug resistance mediated via the suppression of apoptosis by Abelson protein tyrosine kinase.",
        "Journal":"Molecular pharmacology",
        "Do_id":"7651367",
        "Doc_ChemicalList":"Interleukin-3;Naphthalenes;DNA;Protein-Tyrosine Kinases;Protein Kinase C;calphostin C;Melphalan;Hydroxyurea",
        "Doc_meshdescriptors":"Abelson murine leukemia virus;Animals;Apoptosis;Cell Cycle;Cell Line;DNA;DNA Damage;Drug Resistance;Hydroxyurea;Interleukin-3;Melphalan;Mice;Naphthalenes;Protein Kinase C;Protein-Tyrosine Kinases",
        "Doc_meshqualifiers":"enzymology;drug effects;pharmacology;pharmacology;pharmacology;pharmacology;antagonists & inhibitors;metabolism",
        "_version_":1605755166084038656},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) is a stem cell disorder characterized by unrestricted proliferation of the myeloid series that occurs due to the BCR-ABL fusion oncogene as a result of reciprocal translocation t(9;22) (q34;q11). This discovery has made this particular domain a target for future efforts to cure CML. Imatinib revolutionized the treatment options for CML and gave encouraging results both in case of safety as well as tolerability profile as compared to agents such as hydroxyurea or busulfan given before Imatinib. However, about 2-4% of patients show resistance and mutations have been found to be one of the reasons for its development. European Leukemianet gives recommendations for BCR-ABL mutational analysis along with other tyrosine kinase inhibitors (TKIs) that should be administered according to the mutations harbored in a patient. The following overview gives recommendations for monitoring patients on the basis of their mutational status. ",
        "Doc_title":"Chronic Myeloid Leukemia--Prognostic Value of Mutations.",
        "Journal":"Asian Pacific journal of cancer prevention : APJCP",
        "Do_id":"26625737",
        "Doc_ChemicalList":"Antineoplastic Agents;Protein Kinase Inhibitors;Imatinib Mesylate;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Antineoplastic Agents;DNA Mutational Analysis;Drug Resistance, Neoplasm;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mutation;Prognosis;Protein Kinase Inhibitors",
        "Doc_meshqualifiers":"therapeutic use;genetics;genetics;therapeutic use;drug therapy;genetics;mortality;genetics;therapeutic use",
        "_version_":1605875806562680832},
      {
        "Doc_abstract":"Within the recent years, RNA interference (RNAi) has become an almost-standard method for in vitro knockdown of any target gene of interest. Now, one major focus is to further explore its potential in vivo, including the development of novel therapeutic strategies. From the mechanism, it becomes clear that small interfering RNAs (siRNAs) play a pivotal role in triggering RNAi. Thus, the efficient delivery of target gene-specific siRNAs is one major challenge in the establishment of therapeutic RNAi. Here we show that in vivo application of targeted nonvirally delivered synthetic bcr-abl siRNA in a female patient with recurrent Philadelphia chromosome positive chronic myeloid leukemia (CML) resistant to imatinib (Y253F mutation) and chemotherapy after allogeneic hematopoietic stem cell transplantation can silence the expression of bcr-abl gene. We found a remarkable inhibition of the overexpressed bcr-abl oncogene resulting in increased apoptosis of CML cells. In vivo siRNA application was well tolerated without any clinically adverse events. Our findings imply that the clinical application of synthetic siRNA is feasible, safe and has real potential for genetic-based therapies using synthetic nonviral carriers.",
        "Doc_title":"Therapeutic targeting of gene expression by siRNAs directed against BCR-ABL transcripts in a patient with imatinib-resistant chronic myeloid leukemia.",
        "Journal":"Methods in molecular biology (Clifton, N.J.)",
        "Do_id":"19301661",
        "Doc_ChemicalList":"Benzamides;Piperazines;Protein Kinase Inhibitors;Pyrimidines;RNA, Small Interfering;Imatinib Mesylate;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Benzamides;Drug Resistance, Neoplasm;Female;Fusion Proteins, bcr-abl;Gene Expression Regulation, Leukemic;Genetic Therapy;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Middle Aged;Philadelphia Chromosome;Piperazines;Protein Kinase Inhibitors;Protein-Tyrosine Kinases;Pyrimidines;RNA, Small Interfering",
        "Doc_meshqualifiers":"genetics;metabolism;drug effects;methods;genetics;metabolism;therapy;therapeutic use;therapeutic use;antagonists & inhibitors;therapeutic use;therapeutic use",
        "_version_":1605766120992669696},
      {
        "Doc_abstract":"The bcr/abl fusion in chronic myelogenous leukemia (CML) creates a chimeric tyrosine kinase with dramatically different properties than intact c-abl. In P210 bcr/abl, the bcr portion includes a coiled-coil oligomerization domain (amino acids 1-63) and a grb2-binding site at tyrosine 177 (Tyr177) that are critical for fibroblast transformation, but give variable results in other cell lines. To investigate the role of the coiled-coil domain and Tyr177 in promoting CML, 4 P210 bcr/abl-derived mutants containing different bcr domains fused to abl were constructed. All 4 mutants, Delta(1-63) bcr/abl, (1-63) bcr/abl, Tyr177Phe bcr/abl, and (1-210) bcr/abl exhibited elevated tyrosine kinase activity and conferred factor-independent growth in cell lines. In contrast, differences in the transforming potential of the 4 mutants occurred in our mouse model, in which all mice receiving P210 bcr/abl-expressing bone marrow cells exclusively develop a myeloproliferative disease (MPD) resembling human CML. Of the 4 mutants assayed, only 1-210 bcr/abl, containing both the coiled-coil domain and Tyr177, induced MPD. Unlike full-length P210, this mutant also caused a simultaneous B-cell acute lymphocytic leukemia (ALL). The other 3 mutants, (1-63) bcr/abl, Tyr177Phe bcr/abl, and Delta(1-63) bcr/abl, failed to induce an MPD but instead caused T-cell ALL. These results show that both the bcr coiled-coil domain and Tyr177 are required for MPD induction by bcr/abl and provide the basis for investigating downstream signaling pathways that lead to CML.",
        "Doc_title":"The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr/abl.",
        "Journal":"Blood",
        "Do_id":"11929787",
        "Doc_ChemicalList":"Oncogene Proteins;Peptide Fragments;Proto-Oncogene Proteins;Tyrosine;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl;Bcr protein, mouse;Proto-Oncogene Proteins c-bcr",
        "Doc_meshdescriptors":"Animals;Base Sequence;Binding Sites;Bone Marrow Cells;Bone Marrow Transplantation;Cell Transformation, Neoplastic;Fusion Proteins, bcr-abl;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mice;Models, Animal;Mutation;Neoplasms, Experimental;Oncogene Proteins;Peptide Fragments;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Protein Structure, Tertiary;Protein-Tyrosine Kinases;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-bcr;Survival Analysis;Transduction, Genetic;Tumor Cells, Cultured;Tyrosine",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;administration & dosage;genetics;pharmacology;etiology;genetics;etiology;genetics;genetics;pharmacology;administration & dosage;pharmacology;etiology;genetics;metabolism",
        "_version_":1605742792173158400},
      {
        "Doc_abstract":"A 73-year-old woman with chronic myeloid leukemia was treated with interferon-alpha, hydroxyurea, and busulfan before imatinib mesylate treatment. The leukocyte count was 8,400/; hemoglobin concentration, 12.0 g/; and platelet count, 19.7 x 10(4)/. She received 400 mg of imatinib mesylate for 17 days before the agent was discontinued because of pancytopenia. A bone marrow biopsy on the 87th day after the last imatinib mesylate administration demonstrated severe hypocellularity. She needed many RBC and Plt transfusions and filgrastim administration. Grade 4 neutropenia continued for 35 days and Grade 3 thrombocytopenia continued for over 122 days. Imatinib mesylate, an agent targeting BCR-ABL, is expected to be useful as an effective therapeutic agent for chronic myeloid leukemia. However the present case suggests that its appropriate dose is individually variable and we should carefully consider the former treatment, and the clinical stage of the disease before initiating imatinib treatment.",
        "Doc_title":"[Chronic myeloid leukemia associated with sustained severe pancytopenia after imatinib mesylate therapy].",
        "Journal":"[Rinsho ketsueki] The Japanese journal of clinical hematology",
        "Do_id":"12412295",
        "Doc_ChemicalList":"Benzamides;Piperazines;Pyrimidines;Imatinib Mesylate;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Aged;Benzamides;Female;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Pancytopenia;Piperazines;Protein-Tyrosine Kinases;Pyrimidines;Severity of Illness Index",
        "Doc_meshqualifiers":"drug therapy;chemically induced;administration & dosage;adverse effects;antagonists & inhibitors;administration & dosage;adverse effects",
        "_version_":1605812862029135872},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) is a clonal myeloproliferative disease characterized by a reciprocal translocation between long arms of chromosomes 9 and 22 t(9;22) that generates the BCR-ABL fusion gene. If left untreated, newly diagnosed chronic phase CML patients finally progress to accelerated and blastic phase. After the introduction of tyrosine kinase inhibitors (TKIs), treatment strategies of CML changed dramatically. However, the development of resistance to TKIs started to create problems over time. In this review, the current information about CML biology before and after imatinib mesylate treatment is summarized. ",
        "Doc_title":"Changes in molecular biology of chronic myeloid leukemia in tyrosine kinase inhibitor era.",
        "Journal":"American journal of blood research",
        "Do_id":"23997982",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605801229413253120},
      {
        "Doc_abstract":"Leukemia due to a chromosomal translocation offers an attractive model for the design and testing of antisense agents because the sequence at the translocation junction is unique to the leukemic cell population. Chronic myeloid leukemia is the most common such translocation-induced leukemia. We have found antisense phosphodiester oligonucleotides directed at the bcr-abl junction to be ineffective in inhibiting the growth of CML cell lines. Therefore, we have investigated the effects produced by certain structural modifications of bcr-abl antisense oligonucleotides. For assay purposes we used K562 cells which have the bcr exon 3/abl exon 2 junction and BV173 cells which have the bcr exon 2/abl exon 2 junction. We have found that 5'-capping with a dimethoxytrityl group and 3'-capping with an amino-2-hydroxypropyl group confer antiproliferative activity. The enhancement of activity by capping appears at least partly attributable to exonuclease resistance since stability in serum-containing medium is increased.",
        "Doc_title":"Capping of bcr-abl antisense oligonucleotides enhances antiproliferative activity against chronic myeloid leukemia cell lines.",
        "Journal":"Leukemia research",
        "Do_id":"8207957",
        "Doc_ChemicalList":"Culture Media;Culture Media, Serum-Free;Oligonucleotides, Antisense;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Base Sequence;Cell Division;Cell Line;Culture Media;Culture Media, Serum-Free;Exons;Fusion Proteins, bcr-abl;Genes, abl;Humans;Kinetics;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Molecular Sequence Data;Oligonucleotides, Antisense;Oncogenes;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"drug effects;biosynthesis;pharmacology",
        "_version_":1605897874440192000},
      {
        "Doc_abstract":"Imatinib mesylate (imatinib) is highly effective in the treatment of chronic myeloid leukemia (CML) but is less effective in eliminating CML stem cells. We investigated whether SKI-606, a potent Bcr-Abl and Src kinase inhibitor without anti-PDGF or c-Kit activity, could effectively target primitive CML progenitors. CML and normal progenitors were cultured with SKI-606 or imatinib. SKI-606 effectively inhibited Bcr-Abl kinase activity in CML CD34(+) cells and inhibited Src phosphorylation more potently than imatinib. However, SKI-606 and imatinib resulted in similar suppression of CML primitive and committed progenitor proliferation and growth in CFC and LTC-IC assays. Exposure to either agent alone or in combination resulted in only modest increase in apoptosis. Evaluation of downstream signaling pathways indicated that Akt and STAT5 activity was not changed, but a delayed increase in MAPK activity was seen at high concentrations of SKI-606. SKI-606 inhibited normal progenitor proliferation to a lesser extent than imatinib. SKI-606 effectively inhibits Bcr-Abl and Src kinase activity and inhibits CML progenitor growth with relatively little effect on normal progenitors. However, SKI-606 does not demonstrate increased ability to eliminate primitive CML progenitors by apoptosis compared with imatinib, emphasizing the need for additional strategies besides Bcr-Abl kinase inhibition for curative therapy of CML.",
        "Doc_title":"Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606.",
        "Journal":"Blood",
        "Do_id":"18056843",
        "Doc_ChemicalList":"Aniline Compounds;Antineoplastic Agents;Benzamides;Nitriles;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Quinolines;bosutinib;Imatinib Mesylate;Proto-Oncogene Proteins c-abl;src-Family Kinases",
        "Doc_meshdescriptors":"Aniline Compounds;Antineoplastic Agents;Benzamides;Fetal Blood;Hematopoietic Stem Cells;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Nitriles;Piperazines;Protein Kinase Inhibitors;Proto-Oncogene Proteins c-abl;Pyrimidines;Quinolines;src-Family Kinases",
        "Doc_meshqualifiers":"pharmacology;therapeutic use;cytology;drug effects;drug effects;pathology;drug therapy;pathology;pharmacology;therapeutic use;pharmacology;antagonists & inhibitors;therapeutic use;pharmacology;antagonists & inhibitors",
        "_version_":1605882970833420288},
      {
        "Doc_abstract":"To address whether mutations and single nucleotide polymorphisms (SNPs) in perforin gene (PRF1) are correlated with acute lymphoblastic leukemia (ALL) in Chinese, we screened mutations in codon region of PRF1 in 111 ALL patients, and correlated the results with patients' immunophenotype, karyotype and fusion genes. Four novel monoallelic missense and two novel monoallelic synonymous mutations (G198R, R225Q, D486G, R509K, S388S and Q540Q) were identified in 9 B-ALL, of whom 7 cases carried BCR-ABL gene, one carried MLL-AF4 fusion gene, and one lost two chromosomes. Our results suggest that mutations in PRF1 may play a role in the pathogenesis of B-ALL.",
        "Doc_title":"Mutations of perforin gene in Chinese patients with acute lymphoblastic leukemia.",
        "Journal":"Leukemia research",
        "Do_id":"20638125",
        "Doc_ChemicalList":"Perforin",
        "Doc_meshdescriptors":"Asian Continental Ancestry Group;Female;Genes, abl;Humans;Immunophenotyping;Karyotyping;Male;Mutation;Perforin;Polymerase Chain Reaction;Polymorphism, Single Nucleotide;Precursor Cell Lymphoblastic Leukemia-Lymphoma",
        "Doc_meshqualifiers":"genetics;genetics;genetics",
        "_version_":1605904851455180800},
      {
        "Doc_abstract":"Despite the great success in using tyrosine kinase inhibitors (TKIs) to treat chronic myeloid leukemia (CML), the frequent development of multi-drug resistance, particularly the T315I mutation of BCR-ABL, remains a challenging issue. Enhancement of protein phosphatase 2A (PP2A) activity by dissociating its endogenous inhibitor SET is an effective approach to combat TKI-based resistance. Here, we report the identification of a novel 2-phenyloxypyrimidine compound TGI1002 to specifically disrupt SET-PP2A interaction. By binding to SET, TGI1002 inhibits SET-PP2A interaction and increases PP2A activity. In addition, knocking-down SET expression decreases tumor cell sensitivity to TGI1002. TGI1002 treatments also markedly increase dephosphorylation of BCR-ABL. Moreover, TGI1002 significantly inhibits tumor growth and prolongs survival of xenografted mice implanted with BaF3-p210T315I cells. These findings demonstrate that TGI1002 is a novel SET inhibitor with important therapeutic potential for the treatment of drug-resistant CML. ",
        "Doc_title":"Discovery of a small molecule targeting SET-PP2A interaction to overcome BCR-ABLT315I mutation of chronic myeloid leukemia.",
        "Journal":"Oncotarget",
        "Do_id":"25900240",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl;Protein Phosphatase 2",
        "Doc_meshdescriptors":"Animals;Apoptosis;Cell Culture Techniques;Cell Line, Tumor;Cell Proliferation;Fusion Proteins, bcr-abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mice, Inbred BALB C;Mutation;Protein Phosphatase 2;Signal Transduction;Survival Analysis;Transfection",
        "Doc_meshqualifiers":"drug therapy;genetics",
        "_version_":1605774067654197248},
      {
        "Doc_abstract":"Point mutations within the ABL kinase domain of the BCR-ABL gene are associated with clinical resistance to imatinib mesylate in chronic myeloid leukemia (CML). To obtain more information about the association between BCR-ABL mutations and type of imatinib resistance, we studied 30 early chronic phase (CP) CML patients, commencing imatinib therapy, using a conventional sequencing technique. Seven patients treated in late CP and three patients treated in the accelerated phase were included for comparison. Blood samples were collected before and every third month during imatinib therapy. Mutations were not seen in any blood sample collected before start of therapy. During imatinib treatment, 2 of the 30 early CP patients acquired point mutations and both of them had other signs of imatinib resistance. None of the five early CP patients with a complete hematologic response (HR), but no cytogenetic response at 12 months, displayed any missense mutation. Likewise, none of 12 early CP patients with detectable BCR-ABL transcripts but in complete hematologic and cytogenetic remission at 12 months displayed any mutation. We conclude that screening early CP patients for BCR-ABL mutations before start of imatinib therapy is not cost-effective. BCR-ABL kinase domain mutations do not appear to explain cytogenetic or molecular (detectable BCR-ABL transcripts by polymerase chain reaction) disease persistence in patients otherwise in stable disease. However, in patients with signs of expanding disease burden, a search for BCR-ABL mutations is warranted.",
        "Doc_title":"Not all imatinib resistance in CML are BCR-ABL kinase domain mutations.",
        "Journal":"Annals of hematology",
        "Do_id":"17006667",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Pyrimidines;Imatinib Mesylate;Protein Kinases;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Antineoplastic Agents;Benzamides;Drug Resistance, Neoplasm;Female;Fusion Proteins, bcr-abl;Gene Frequency;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Mutation;Neoplasm Staging;Piperazines;Prognosis;Protein Kinases;Protein Structure, Tertiary;Pyrimidines;Treatment Outcome",
        "Doc_meshqualifiers":"therapeutic use;genetics;genetics;diagnosis;drug therapy;genetics;pathology;therapeutic use;genetics;genetics;therapeutic use",
        "_version_":1605758638119452672},
      {
        "Doc_abstract":"BCR-ABL oncoprotein is the cause of chronic myeloid leukemia. The homologous oligomerization of BCR-ABL protein mediated by BCR coiled-coil (CC) domain plays an important role in ABL kinase activation. The HIV-1 TAT peptide has been used extensively for the introduction of proteins into cells. We recombinated a TAT-CC-HA protein to interrupt the homologous oligomerization of BCR-ABL. The expression conditions for TAT-CC-HA were optimized. The TAT-CC-HA fusion protein was purified with Ni+-NTA resin. TAT-CC-HA fusion protein was added into the cultures of Ba/F3-p210, 32D-p210, K562, KU812, Ba/F3, 32D, and HL-60 cells. It was found that TAT-CC-HA could transduce into these cells. It was confirmed that TAT-CC-HA fusion protein was internalized by Ba/F3-p210, K562, and Ba/F3 cells and located in the cytoplasm observed by confocal laser scanning fluorescence microscope. The transduction of TAT-CC-HA fusion protein into K562 cells was in a dose-dependent and time-dependent manner. The result of coimmunoprecipitation assay indicated that TAT-CC-HA could interact with BCR-ABL in K562 cells. The effects of TAT-CC-HA fusion protein on cell growth and apoptosis were detected by MTT test and flow cytometry. Our findings suggested that TAT-CC-HA fusion protein could specifically inhibit the growth of BCR-ABL positive cells, and specifically induce apoptosis of BCR-ABL positive cells, while not affect the growth and apoptosis of BCR-ABL negative cells.",
        "Doc_title":"Purification of TAT-CC-HA protein under native condition, and its transduction analysis and biological effects on BCR-ABL positive cells.",
        "Journal":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie",
        "Do_id":"21641753",
        "Doc_ChemicalList":"Recombinant Fusion Proteins;tat Gene Products, Human Immunodeficiency Virus;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Apoptosis;Cell Division;Cytoplasm;Fusion Proteins, bcr-abl;HL-60 Cells;Humans;K562 Cells;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Protein Structure, Tertiary;Recombinant Fusion Proteins;Transduction, Genetic;tat Gene Products, Human Immunodeficiency Virus",
        "Doc_meshqualifiers":"genetics;genetics;genetics;metabolism;chemistry;genetics;isolation & purification;metabolism;genetics;metabolism;pathology;chemistry;genetics;isolation & purification;metabolism;methods;chemistry;genetics;isolation & purification;metabolism",
        "_version_":1605825884874342400},
      {
        "Doc_abstract":"Information about fusion transcripts in acute lymphoblastic leukemia (ALL) is used to risk-stratify patients, decide on the treatment and to detect minimal residual disease. This study was conducted to determine the frequency of common fusion transcripts BCR-ABL, TEL-AML1, MLL-AF4 and E2A-PBX1 for B-ALL and SIL-TAL1 for T-ALL as seen at a tertiary care center in India.;Up to 304 new cases of ALL (271 B-ALL and 33 T-ALL) diagnosed on morphology, cytochemistry and immunophenotyping were studied. All were screened for the common fusion transcripts by RT-PCR.;Both our B- (218/271; 80.4%) and T-ALL (26/33; 78.8%) patients were largely children. In the B-ALL children, BCR-ABL was detected in 26/218 (11.9%), E2A-PBX1 in 13/218 (5.9%), TEL-AML1 in 16/218 (7.3%) and MLL-AF4 in 3/218 (1.4%) patients. Adult B-ALL cases had BCR-ABL in 15/53 (28.3%) and E2A-PBX in 2/53 (3.8%); however, no other fusion transcript was detected. SIL-TAL1 was found in four of 26 pediatric (15%) and zero of 7 adult T-ALL cases.;The higher incidence of BCR-ABL and lower incidence of TEL-AML1 in our ALL patients, both in children and adults as compared with the West, suggests that patients in India may be biologically different. This difference may explain at least in part the higher relapse rate and poorer outcome in our B-ALL cases.",
        "Doc_title":"Prevalence of common fusion transcripts in acute lymphoblastic leukemia: A report of 304 cases.",
        "Journal":"Asia-Pacific journal of clinical oncology",
        "Do_id":"26264145",
        "Doc_ChemicalList":"Core Binding Factor Alpha 2 Subunit;Oncogene Proteins, Fusion;TEL-AML1 fusion protein;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Child;Child, Preschool;Core Binding Factor Alpha 2 Subunit;Female;Fusion Proteins, bcr-abl;Humans;Immunophenotyping;India;Infant;Infant, Newborn;Male;Middle Aged;Neoplasm, Residual;Oncogene Proteins, Fusion;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Prevalence;Retrospective Studies;Young Adult",
        "Doc_meshqualifiers":"genetics;genetics;epidemiology;epidemiology;genetics;pathology;genetics;epidemiology;genetics;pathology",
        "_version_":1605831172436262912},
      {
        "Doc_abstract":"BCR-ABL induces an intrinsic genetic instability in chronic myeloid leukemia (CML). The protein breast cancer 1, early onset (BRCA1)-associated protein 1 (BAP1) is a deubiquitinase interacting with the DNA repair regulator BRCA1 and is frequently inactivated in many cancers. Here, we report that BAP1 mRNA and protein levels are downregulated in a BCR-ABL1-expressing hematopoietic cell line (UT-7/11). A decrease of BAP1 transcripts is also observed in newly diagnosed CML patients. Moreover, BAP1 protein levels are low or undetectable in CD34(+) cells from CML patients at diagnosis as compared with CD34(+) cells from normal donors. In addition, BRCA1 protein level is reduced in BCR-ABL1-expressing UT-7/11 cells. Finally, the enforced expression of BAP1 is associated with BRCA1 protein deubiquitination and restoration. These results demonstrate BAP1 as a major link with the BCR-ABL-induced downregulation of BRCA1 in CML.",
        "Doc_title":"The downregulation of BAP1 expression by BCR-ABL reduces the stability of BRCA1 in chronic myeloid leukemia.",
        "Journal":"Experimental hematology",
        "Do_id":"26118501",
        "Doc_ChemicalList":"BRCA1 Protein;BRCA1 protein, human;Tumor Suppressor Proteins;Fusion Proteins, bcr-abl;BAP1 protein, human;Ubiquitin Thiolesterase",
        "Doc_meshdescriptors":"BRCA1 Protein;Cell Line;Down-Regulation;Fusion Proteins, bcr-abl;Gene Expression Regulation, Leukemic;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Protein Stability;Tumor Suppressor Proteins;Ubiquitin Thiolesterase",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;metabolism;genetics;metabolism;pathology;biosynthesis;genetics;biosynthesis;genetics",
        "_version_":1605818642445893633},
      {
        "Doc_abstract":"There is remarkable recent progress in our understanding of the biology of chronic myelogenous leukemia (CML). First, the BCR/ABL rearrangement was identified as the molecular basis of the disease. Second, animal models support the notion that the BCR/ABL gene product causes a syndrome similar to CML. Third, recent advances in understanding the functions of the normal ABL protein have given clues to the mechanism(s) of ABL-induced leukemias and approaches to blocking this process. Extrapolating these findings to humans seems reasonable. The challenge now is to determine how the BCR/ABL gene product causes chronic phase CML. Also unresolved is whether BCR/ABL also plays a role in the acute phase of the disease. Finally, the relationship between the two common forms of BCR/ABL, the P190 and P210 configurations, and different disease phenotypes, like CML and Philadelphia (Ph1)-chromosome positive acute lymphoblastic leukemia (ALL), needs to be clarified. There is also substantial progress in treating CML. Bone marrow transplants have emerged as the preferred therapy. These result in long-term leukemia-free survival in more than one-half of appropriately selected subjects. How transplants cure CML is complex and controversial. Some data suggest high-dose treatment is the dominant factor whereas other data implicate antileukemia effects of the immune system. Interferon treatment has also proven effective in CML. Whether it prolongs survival of persons with CML remains to be determined, as does its mechanism of action. Certainly the most important and difficult challenge in CML therapy is determining how to use knowledge about the causes CML to treat the disease. These and other issues in the biology and therapy of CML were the subject of a recent meeting of basic and clinical scientists. The meeting, third in a series begun in 1987, was held on Martha's Vineyard, Cape Cod, Massachusetts, USA from 4-7 April, 1992. Four major topics were considered in five sessions: molecular biology, cell biology, Ph1-chromosome positive ALL, and therapy of CML. This report summarizes meeting highlights.",
        "Doc_title":"Chronic myelogenous leukemia: biology and therapy.",
        "Journal":"Leukemia",
        "Do_id":"8464245",
        "Doc_ChemicalList":"Proto-Oncogene Proteins c-abl",
        "Doc_meshdescriptors":"Animals;Bone Marrow Transplantation;Disease Models, Animal;Gene Expression Regulation, Neoplastic;Genes, abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mice;Proto-Oncogene Proteins c-abl;Signal Transduction",
        "Doc_meshqualifiers":"etiology;genetics;therapy;genetics",
        "_version_":1605784906892312576},
      {
        "Doc_abstract":"Imatinib mesylate (IM), a potent inhibitor of the BCR/ABL tyrosine kinase, has become standard first-line therapy for patients with chronic myeloid leukemia (CML), but the frequency of resistance increases in advancing stages of disease. Elimination of BCR/ABL-dependent intracellular signals triggers apoptosis, but it is unclear whether this activates additional cell survival and/or death pathways. We have shown here that IM induces autophagy in CML blast crisis cell lines, CML primary cells, and p210BCR/ABL-expressing myeloid precursor cells. IM-induced autophagy did not involve c-Abl or Bcl-2 activity but was associated with ER stress and was suppressed by depletion of intracellular Ca2+, suggesting it is mechanistically nonoverlapping with IM-induced apoptosis. We further demonstrated that suppression of autophagy using either pharmacological inhibitors or RNA interference of essential autophagy genes enhanced cell death induced by IM in cell lines and primary CML cells. Critically, the combination of a tyrosine kinase inhibitor (TKI), i.e., IM, nilotinib, or dasatinib, with inhibitors of autophagy resulted in near complete elimination of phenotypically and functionally defined CML stem cells. Together, these findings suggest that autophagy inhibitors may enhance the therapeutic effects of TKIs in the treatment of CML.",
        "Doc_title":"Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells.",
        "Journal":"The Journal of clinical investigation",
        "Do_id":"19363292",
        "Doc_ChemicalList":"4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide;Antineoplastic Agents;Benzamides;DDIT3 protein, human;Macrolides;Microtubule-Associated Proteins;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Thiazoles;light chain 3, human;Transcription Factor CHOP;Chloroquine;bafilomycin A1;Imatinib Mesylate;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl;Dasatinib;Calcium",
        "Doc_meshdescriptors":"Animals;Antineoplastic Agents;Autophagy;Benzamides;Calcium;Cell Death;Cell Line, Tumor;Chloroquine;Dasatinib;Endoplasmic Reticulum;Fusion Proteins, bcr-abl;Gene Expression;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Macrolides;Mice;Mice, Inbred C3H;Microtubule-Associated Proteins;Neoplastic Stem Cells;Piperazines;Protein Kinase Inhibitors;Protein-Tyrosine Kinases;Pyrimidines;RNA Interference;Thiazoles;Transcription Factor CHOP;Xenograft Model Antitumor Assays",
        "Doc_meshqualifiers":"pharmacology;therapeutic use;drug effects;physiology;metabolism;drug effects;physiology;pharmacology;therapeutic use;drug effects;metabolism;antagonists & inhibitors;genetics;drug effects;genetics;drug therapy;metabolism;pathology;pharmacology;therapeutic use;metabolism;cytology;drug effects;metabolism;pharmacology;therapeutic use;pharmacology;therapeutic use;antagonists & inhibitors;pharmacology;therapeutic use;pharmacology;therapeutic use;genetics",
        "_version_":1605822219675500544},
      {
        "Doc_abstract":"The recent introduction of imatinib mesylate has deeply changed the treatment of chronic myeloid leukemia. This first physiopathology-based therapy, which targets the molecular anomaly that gives rise to the disease (the abnormal tyrosine kinase activity generated by the fusion protein P210 Bcr-Abl) has demonstrated an impressive activity. However, its long-term efficacy remains unknown. On the other hand, other treatment modalities, such as stem cell transplantation or experimental ones (immunotherapy) are also profoundly evolving. In this review, the authors have tried to synthesize the current knowledge of this disease and suggest a therapeutic strategy based on the currently available data.",
        "Doc_title":"[Chronic myeloid leukemia in 2003].",
        "Journal":"Revue medicale de Bruxelles",
        "Do_id":"14650319",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Pyrimidines;Imatinib Mesylate",
        "Doc_meshdescriptors":"Antineoplastic Agents;Benzamides;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Piperazines;Prognosis;Pyrimidines",
        "Doc_meshqualifiers":"therapeutic use;classification;etiology;therapy;therapeutic use;therapeutic use",
        "_version_":1605904724666613760},
      {
        "Doc_abstract":"Oligodeoxynucleic acid (21-mer) containing both negatively charged phosphate and positively charged ribonucleic guanidine linkages (RNG/DNA chimera) have been synthesized. DNA binding characteristics and nuclease resistance of RNG/DNA chimeras have been evaluated. Using the bcr-abl oncogene (cause of chronic myeloid leukemia) as a target, the binding of a 21-mer RNG/DNA chimera that includes six RNG's is more than 103.5 stronger than the binding of 21-mer composed solely of DNA.",
        "Doc_title":"Incorporation of positively charged ribonucleic guanidine linkages into oligodeoxyribonucleotides: Development of potent antisense agents.",
        "Journal":"Bioorganic & medicinal chemistry letters",
        "Do_id":"18353646",
        "Doc_ChemicalList":"Oligodeoxyribonucleotides;Oligonucleotides, Antisense;Phosphates;RNA;DNA;Guanidine",
        "Doc_meshdescriptors":"Base Sequence;Binding Sites;DNA;Guanidine;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Nucleic Acid Conformation;Nucleic Acid Denaturation;Oligodeoxyribonucleotides;Oligonucleotides, Antisense;Phosphates;RNA",
        "Doc_meshqualifiers":"chemistry;metabolism;chemistry;genetics;pathology;chemical synthesis;pharmacology;chemical synthesis;pharmacology;chemistry;chemistry;metabolism",
        "_version_":1605749594126286848},
      {
        "Doc_abstract":"Dasatinib (BMS-354825) is a novel, oral, potent, multi-targeted kinase inhibitor of Bcr-Abl and Src family kinases (SFK) and is a promising cancer therapeutic agent. Preclinical data indicate that dasatinib is 325-fold more potent than imatinib against cells expressing wild-type Bcr-Abl, and that dasatinib is active against 18 of 19 Bcr-Abl mutations known to cause imatinib resistance. Phase I clinical data show that dasatinib is well tolerated and highly effective for the treatment of imatinib-resistant/imatinib-intolerant chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia. However, the molecular mechanism of action of dasatinib is not fully understood. In this study, we confirm that dasatinib inhibits tyrosine phosphorylation of SFKs, including Src, Hck, and Lyn, in K562 human CML cells. Significantly, downstream signal transducer and activator of transcription 5 (Stat5) signaling is also blocked by dasatinib as shown by decreases in levels of phosphorylated Stat5 and Stat5 DNA-binding activities. In addition, dasatinib down-regulates expression of Stat5 target genes, including Bcl-x, Mcl-1, and cyclin D1. Consistent with these results, blockade of Stat5 signaling by dasatinib is accompanied by inhibition of cell proliferation and induction of apoptosis. Surprisingly, Stat5 DNA-binding activities are enhanced with increasing cell density, which is associated with resistance to apoptosis by dasatinib. Our findings indicate that inhibition of Stat5 signaling downstream of Bcr-Abl/SFKs contributes to the action of dasatinib, and, conversely, that increasing cell density up-regulates Stat5 activation and confers resistance to dasatinib. Moreover, the level of phosphorylated Stat5 in CML cells represents a mechanistically relevant biomarker for monitoring inhibition of Bcr-Abl signaling by dasatinib in CML patients using convenient immunocytochemical assays.",
        "Doc_title":"Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells.",
        "Journal":"Molecular cancer therapeutics",
        "Do_id":"17431118",
        "Doc_ChemicalList":"DNA, Neoplasm;Myeloid Cell Leukemia Sequence 1 Protein;Neoplasm Proteins;Protein Kinase Inhibitors;Proto-Oncogene Proteins c-bcl-2;Pyrimidines;STAT5 Transcription Factor;Thiazoles;bcl-X Protein;Cyclin D1;Phosphotyrosine;src-Family Kinases;Dasatinib",
        "Doc_meshdescriptors":"Apoptosis;Cell Count;Cell Survival;Cyclin D1;DNA, Neoplasm;Dasatinib;Down-Regulation;Drug Resistance, Neoplasm;HL-60 Cells;Humans;K562 Cells;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Myeloid Cell Leukemia Sequence 1 Protein;Neoplasm Proteins;Phosphotyrosine;Protein Binding;Protein Kinase Inhibitors;Proto-Oncogene Proteins c-bcl-2;Pyrimidines;STAT5 Transcription Factor;Signal Transduction;Thiazoles;bcl-X Protein;src-Family Kinases",
        "Doc_meshqualifiers":"drug effects;drug effects;genetics;metabolism;metabolism;drug effects;drug therapy;pathology;genetics;metabolism;metabolism;drug effects;pharmacology;genetics;metabolism;pharmacology;therapeutic use;metabolism;drug effects;pharmacology;therapeutic use;genetics;metabolism;metabolism",
        "_version_":1605795264577142784},
      {
        "Doc_abstract":"In order to evaluate relapse predication ability of STR-PCR combining with qualitative RT-PCR for the bar/abl transcripts to the patient with chronic myeloid leukemia (CML) fulfilled allogeneic stem cell transplantation (allo-HSCT), 24 patients with CML after allo-HSCT were dynamically investigated for MRD, quantitative analysis of donor chimerism was performed by multiplex PCR amplification of STR markers and capillary electrophoresis with fluorescence detection, qualitative detection of bcr/abl transcripts was detected by nested RT-PCR. The results showed that persistent full donor chimerism (DC >/= 95%) was associated with an absence of MRD. All patients with stable MC (90% </= DC < 95%) and bcr/abl negative had a probability of long-term survival with molecular remission, however the result of bcr/abl positivity was not always associated with leukemia relapse, only the patient with decreasing values of donor chimerism as well as bcr/abl positive proved to be in a higher risk of relapse or graft failure. Decrease of donor chimerism in correlation with MRD positive was detected in 5 patients. Three out of five patients had been proved to have a molecular relapse, one out of five patients had developed to cytogenetic relapse and another patient experienced graft failure. It is concluded that the results of STR-PCR in the range of its sensitivity fully correspond with bcr/abl tests in patients. The combination of STR-PCR with RT-PCR will provide a highly sensitive and valuable tool for MRD detection in CML and can identify these high risk patients with molecular or cytogenetic relapse after allo-HSCT.",
        "Doc_title":"[Detection of minimal residual disease of chronic myeloid leukemia patients after allogeneic stem cell transplantation by combination of STR-PCR with RT-PCR].",
        "Journal":"Zhongguo shi yan xue ye xue za zhi",
        "Do_id":"15363137",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Genes, abl;Hematopoietic Stem Cell Transplantation;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Neoplasm, Residual;Polymerase Chain Reaction;Transplantation, Homologous",
        "Doc_meshqualifiers":"diagnosis;therapy;methods",
        "_version_":1605826170921680896},
      {
        "Doc_abstract":"Data demonstrating the superiority of nilotinib over imatinib in the frontline treatment of chronic myeloid leukemia (CML) and ongoing studies with dasatinib and bosutinib are rapidly changing the treatment landscape for CML. In this review, the authors discuss currently available therapies for CML, focusing on mechanisms of resistance to imatinib and treatment strategies to overcome resistance. Relevant articles were identified through searches of PubMed and abstracts from international hematology/oncology congresses. Additional information sources were identified from the bibliographies of these references and from the authors' own libraries and expertise. In vitro 50% inhibitory concentration (IC(50) ) data alone are not sufficient to guide the choice of a tyrosine kinase inhibitor (TKI) in the presence of a mutant breakpoint cluster region-v-abl Abelson murine leukemia viral oncogene homolog (BCR-ABL) clone, because there is a lack of data regarding how well such IC(50) values correlate with clinical response. A small subset of BCR-ABL mutant clones have been associated with impaired responses to second-generation TKIs (tyrosine to histidine mutation at codon 253 [Y253H], glutamic acid to lysine or valine mutation at codon 255 [E255K/V], and phenylalanine to cysteine or valine mutation at codon 359 [F359C/V] for nilotinib; valine to leucine mutation at codon 299 [V299L] and F317L for dasatinib); neither nilotinib nor dasatinib is active against the threonine to isoleucine mutation at codon 315 (T315I). For each second-generation TKI, the detection of 1 of a small subset of mutations at the time of resistance may be helpful in the selection of second-line therapy [corrected]. For the majority of patients, comorbidities and drug safety profiles should be the basis for choosing a second-line agent. Clinical trial data from an evaluation of the response of specific mutant BCR-ABL clones to TKIs is needed to establish the role of mutation testing in the management of CML.",
        "Doc_title":"Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.",
        "Journal":"Cancer",
        "Do_id":"21509757",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Imatinib Mesylate;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Algorithms;Antineoplastic Agents;Benzamides;DNA Mutational Analysis;Drug Resistance, Neoplasm;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mutation;Piperazines;Protein Kinase Inhibitors;Protein-Tyrosine Kinases;Pyrimidines;Retreatment",
        "Doc_meshqualifiers":"therapeutic use;genetics;drug therapy;genetics;therapeutic use;therapeutic use;antagonists & inhibitors;therapeutic use",
        "_version_":1605827146652057600},
      {
        "Doc_abstract":"Myeloid malignancies are frequently associated with translocations and mutations of tyrosine kinase genes. Fusion genes involving ABL, ARG, PDGFRs, JAK2, SYK, TRKC, and FGFRs, and gain-of-function mutations of FLT3, KIT and JAK2 have been detected at various rates in myeloproliferative disease and acute myeloid leukemia. Furthermore, abnormal overexpression of tyrosine kinases such as FLT3 has also been reported. These gene products are constitutively activated and potentially transform hematopoietic cells by augmentation of proliferation and enhanced viability. Since the fusion or mutation of tyrosine kinase is a primary and central event in chronic myeloproliferative diseases, targeting the kinase activity has been thought to be an ideal intervention to treat these diseases. The clinical success of imatinib for chronic myeloid leukemia has made this idea a reality, and has accelerated the development of new tyrosine kinase inhibitors (TKIs). Challenging studies with TKIs have also been reported for acute myeloid leukemia. This review will focus on recent trials of TKIs against oncogenic tyrosine kinases (ABL, PDGFRs, FLT3 and KIT) in myeloid malignancies.",
        "Doc_title":"Developing target therapy against oncogenic tyrosine kinase in myeloid maliganacies.",
        "Journal":"Current pharmaceutical biotechnology",
        "Do_id":"17076649",
        "Doc_ChemicalList":"Antineoplastic Agents;Neoplasm Proteins;Protein Kinase Inhibitors;Protein-Tyrosine Kinases",
        "Doc_meshdescriptors":"Antineoplastic Agents;Drug Delivery Systems;Drug Design;Humans;Leukemia, Myeloid;Neoplasm Proteins;Protein Kinase Inhibitors;Protein-Tyrosine Kinases;Treatment Outcome",
        "Doc_meshqualifiers":"administration & dosage;methods;drug therapy;metabolism;metabolism;administration & dosage;antagonists & inhibitors",
        "_version_":1605893050258685952},
      {
        "Doc_abstract":"Chronic myelogenous leukemia (CML) is defined by the presence of the constitutively active tyrosine kinase breakpoint cluster region/Abelson (Bcr-Abl), which activates numerous signal transduction pathways leading to uncontrolled cell proliferation. The development of the Bcr-Abl-targeted imatinib represents a paradigm shift in the treatment of CML, because treatment with imatinib resulted in significantly better patient outcome, response rates, and overall survival compared with previous standards. Despite this advance, not all patients benefit from imatinib because of resistance and intolerance. Resistance to imatinib can develop from a number of mechanisms that can be defined as Bcr-Abl-dependent (e.g., most commonly resulting from point mutations in the Abl kinase domain) and Bcr-Abl-independent mechanisms (including the constitutive activation of downstream signaling molecules, e.g., Src family kinases), which could result in the activation of the pathway regardless of Bcr-Abl inhibition. Clearly, new treatment approaches are required for patients resistant to or intolerant of imatinib, which can be dose escalated in patients who demonstrate resistance. This does not result in long-term responses. Hematopoietic stem cell transplantation is limited by the availability of matched donors and the potential for morbidity. Dasatinib, a dual Bcr-Abl/Src kinase inhibitor, has shown efficacy against all imatinib-resistant Bcr-Abl mutations except for T315I. A large trial program showed that dasatinib is effective in patients previously exposed to imatinib and has a manageable safety profile in all phases of CML and Philadelphia chromosome-positive acute lymphoblastic leukemia, resulting in its approval. Nilotinib, an analogue of imatinib, also has demonstrated activity in a similar patient population. These agents and less clinically advanced strategies are discussed in this review.",
        "Doc_title":"Therapy options in imatinib failures.",
        "Journal":"The oncologist",
        "Do_id":"18448557",
        "Doc_ChemicalList":"4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide;Antineoplastic Agents;Benzamides;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Thiazoles;Imatinib Mesylate;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl;Dasatinib",
        "Doc_meshdescriptors":"Antineoplastic Agents;Benzamides;Dasatinib;Drug Resistance, Neoplasm;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mutation;Piperazines;Prognosis;Protein Kinase Inhibitors;Protein-Tyrosine Kinases;Pyrimidines;Thiazoles;Treatment Failure;Treatment Outcome",
        "Doc_meshqualifiers":"therapeutic use;drug effects;drug therapy;physiopathology;therapeutic use;therapeutic use;antagonists & inhibitors;therapeutic use;therapeutic use",
        "_version_":1605784252530556928},
      {
        "Doc_abstract":"To explore dynamic status of bcr-abl transcript levels in chronic myeloid leukemia (CML) patients after allogeneic HSCT and to define low relapse patients who may not require further therapeutic intervention.;One hundred and forty-nine CML cases received allo-HSCT at our Institute between Nov. 2004 and Nov. 2006. Bcr-abl transcripts levels were monitored from bone marrow samples by Q-RT-PCR in all cases pre-HSCT and at 1, 2, 3, 4, 5, 6 months post HSCT. The median value of bcr-abl at these time points were calculated and compared by Mann-Whitney U test. The relapse rate, overall survival (OS) and incidence of graft versus host disease (GVHD) were calculated by Kaplan-Meier curve.;All cases engrafted. 2-year OS rate was 86.0% (CI: 82.9% -89.1%), 2-year accumulated hematological relapse rate (RI) was 3.5% (CI: 1.7% -5.3%). 102 cases were not received any further intervention and none of them relapsed. The median value of bcr-abl transcripts was 25.800% (CI: 0.067% - 96.100%) pre-HSCT and 0.025% (CI: 0 - 3.583%) at +30 d, 0.011% (CI: 0-0.425%) at +60 d, 0.002% (CI: 0 - 0.610%) at +90 d, 0 (CI: 0 - 0.056%) at +120 d post HSCT. The bcr-abl mRNA levels decreased to undetectable level at +3 m, +4 m, and +5 m in recipients from HLA-mismatched related donor, identical sibling donor and unrelated donor respectively.;Serial monitoring of bcr-abl transcript levels by real-time quantitative PCR after allo-HSCT is helpful for screening CML patients with low risk of relapse.",
        "Doc_title":"[The significance of serial monitoring of bcr-abl transcripts levels after allogeneic hematopoietic stem cell transplantation in screening chronic myeloid leukemia patients with low relapse].",
        "Journal":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi",
        "Do_id":"19112914",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adolescent;Adult;Child;Female;Follow-Up Studies;Fusion Proteins, bcr-abl;Hematopoietic Stem Cell Transplantation;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Postoperative Period;Reverse Transcriptase Polymerase Chain Reaction;Young Adult",
        "Doc_meshqualifiers":"metabolism;metabolism;therapy",
        "_version_":1605846093038354432},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) is triggered by the BCR-ABL oncogene. Imatinib is the first-line treatment of CML; however imatinib resistance and intolerance have been detected in many patients. Therefore, new therapeutic approaches are required. The present work aimed at the development and application of transferrin receptor (TrfR) targeted liposomes co-encapsulating anti-BCR-ABL siRNA and imatinib at different molar ratios. The encapsulation yields and drug loading of each molecule was evaluated. Anti-leukemia activity of the developed formulations co-encapsulating siRNA and imatinib and of the combination of Trf-liposomes carrying siRNA and free imatinib under two different treatment schedules of pre-sensitization was assessed. The results obtained demonstrate that the presence of imatinib significantly decreases the encapsulation yields of siRNA, whereas imatinib encapsulation yields are increased by the presence of siRNA. Cytotoxicity assays demonstrate that the formulations co-encapsulating siRNA and imatinib promote a 3.84-fold reduction on the imatinib IC(50) (from 3.49 to 0.91M), whereas a 8.71-fold reduction was observed for the pre-sensitization protocols (from 42.7 to 4.9 nM). It was also observed that the formulations with higher siRNA to imatinib molar ratios promote higher cell toxicity. Thus, the present work describes a novel triple targeting strategy with one single system: cellular targeting (through the targeting ligand, transferrin) and molecular targeting at the BCR-ABL mRNA and Bcr-Abl protein level.",
        "Doc_title":"Co-encapsulation of anti-BCR-ABL siRNA and imatinib mesylate in transferrin receptor-targeted sterically stabilized liposomes for chronic myeloid leukemia treatment.",
        "Journal":"Biotechnology and bioengineering",
        "Do_id":"20632368",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Drug Carriers;Liposomes;Oncogene Proteins v-abl;Piperazines;Pyrimidines;RNA, Small Interfering;Transferrin;Imatinib Mesylate;BCR protein, human;Proto-Oncogene Proteins c-bcr",
        "Doc_meshdescriptors":"Antineoplastic Agents;Benzamides;Cell Line, Tumor;Drug Carriers;Humans;Imatinib Mesylate;Inhibitory Concentration 50;Liposomes;Oncogene Proteins v-abl;Piperazines;Proto-Oncogene Proteins c-bcr;Pyrimidines;RNA, Small Interfering;Transferrin",
        "Doc_meshqualifiers":"metabolism;metabolism;pharmacokinetics;metabolism;pharmacokinetics;analysis;genetics;metabolism;pharmacokinetics;analysis;genetics;metabolism;pharmacokinetics;metabolism;pharmacokinetics;metabolism",
        "_version_":1605818703142715392},
      {
        "Doc_abstract":"Molecular cytogenetics is becoming one of the most useful tools targeting some genes which are generally considered to lead to leukemic transformation (as well as for numerical abnormalities). A fraction of acute lymphoblastic leukemia (ALL) cases carry the translocation t(9;22) (q34;q11.2) which juxtaposes the ABL proto-oncogene to the BCR gene generating a chimeric gene, BCR/ABL. This aberration is more frequent in adult ALL (20%-40%) than in pediatric ALL (<5%), and predicts poor clinical outcome. AIM OF OUR WORK: Is to study BCR/ABL fusion gene in ALL cases using fluorescent in situ hybridization.;Twenty newly diagnosed ALL patients, 16 adult and 4 paediatric cases, were included in the study, 11 cases (55%) were of precursor B phenotype, 8 cases (40%) belonged to T lineage, while one case was biphenotypic expressing mainly precursor B cell markers tether with CD13, CD33, CD117, Detection of BCR/ABL fusion gene was done using interphase FISH technique and was confirmed molecularly using the RT-PCR technique.;BCR/ABL fusion gene was negative in all the examined cases, yet abnormality involving 9q34, ABL gene, either by addition or deletion was detected in three cases (15%). Two of these cases were associated with BCR gene extra copies (three and four copies, respectively).;This may reflect the frequency of association of ABL gene and BCR gene abnormality in our cases, and that absence of fusion gene BCR/ABL does not exclude their role in the leukomogenic process, yet a larger study is required to confirm and detect the prevalence of these gene disturbances in ALL and their association.",
        "Doc_title":"Molecular detection of BCR/ABL fusion gene in Saudi acute lymphoblastic leukemia patients.",
        "Journal":"Journal of the Egyptian National Cancer Institute",
        "Do_id":"17496935",
        "Doc_ChemicalList":"Antigens, Differentiation, B-Lymphocyte;RNA, Messenger;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adolescent;Antigens, Differentiation, B-Lymphocyte;Female;Fusion Proteins, bcr-abl;Humans;In Situ Hybridization, Fluorescence;Male;Precursor Cell Lymphoblastic Leukemia-Lymphoma;RNA, Messenger;Reverse Transcriptase Polymerase Chain Reaction",
        "Doc_meshqualifiers":"analysis;genetics;diagnosis;analysis",
        "_version_":1605880552500494336},
      {
        "Doc_abstract":"Although the tyrosine kinase inhibitor (TKI) imatinib is often used as first-line therapy for newly diagnosed chronic myelogenous leukemia (CML), some patients fail to respond, or become intolerant to imatinib. Nilotinib is a potent and selective second-generation TKI, with confirmed efficacy and tolerability in patients with imatinib-resistant or -intolerant CML. A phase I/II study was conducted in Japanese patients with imatinib-resistant or -intolerant CML or relapsed/refractory Ph+ acute lymphoblastic leukemia. Thirty-four patients were treated with nilotinib for up to 36 months. Major cytogenetic response was achieved in 15/16 patients (93.8%) with chronic-phase CML within a median of approximately 3 months. Major molecular response was achieved in 13/16 patients (81.3%). These responses were sustained at the time of the most recent evaluation in 13 patients and 11 patients, respectively. Hematologic and cytogenetic responses were also observed in patients with advanced CML. The BCR-ABL mutation associated with the most resistance to available TKIs, T315I, was observed in three patients. Common adverse events included rash, nasopharyngitis, leukopenia, neutropenia, thrombocytopenia, nausea, headache and vomiting. Most adverse events resolved following nilotinib dose interruptions/reductions. These results support the favorable long-term efficacy and tolerability of nilotinib in Japanese patients with imatinib-resistant or -intolerant chronic-phase chronic myeloid leukemia.",
        "Doc_title":"Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL: a 36-month analysis of a phase I and II study.",
        "Journal":"International journal of hematology",
        "Do_id":"22359103",
        "Doc_ChemicalList":"4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide;Protein Kinase Inhibitors;Pyrimidines;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Asian Continental Ancestry Group;Cytogenetic Analysis;Female;Fusion Proteins, bcr-abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Mutation;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Protein Kinase Inhibitors;Protein-Tyrosine Kinases;Pyrimidines;Young Adult",
        "Doc_meshqualifiers":"genetics;genetics;drug therapy;genetics;drug effects;drug therapy;genetics;adverse effects;therapeutic use;antagonists & inhibitors;adverse effects;therapeutic use",
        "_version_":1605895852678709248},
      {
        "Doc_abstract":"The Philadelphia (Ph) chromosome, the product of t(9:22), is the cytogenetic hallmark of chronic myelogenous leukemia. The c-abl oncogene on chromosome 9 is translocated to the Ph chromosome and linked to a breakpoint cluster region (bcr), which is part of a large bcr gene. This results in the formation of a bcr-c-abl fusion gene, which is transcribed into an 8.5 kb chimeric mRNA encoding a 210 kd bcr-c-abl fusion protein. The Ph chromosome is also found in acute lymphoblastic leukemia (Ph+ ALL). Although the c-abl is translocated and a new 190 kd c-abl protein has been identified, no breakpoints are observed in the bcr (Ph+bcr- ALL). Here we show that in Ph+bcr- ALL, breakpoints in chromosome 22 occur within the same bcr gene, but more 5' of the bcr. Cloning of a chimeric bcr-c-abl cDNA demonstrates that the fusion gene is transcribed into a 7 kb mRNA, encoding a novel fusion protein.",
        "Doc_title":"Unique fusion of bcr and c-abl genes in Philadelphia chromosome positive acute lymphoblastic leukemia.",
        "Journal":"Cell",
        "Do_id":"2820585",
        "Doc_ChemicalList":"DNA, Neoplasm;RNA, Messenger;DNA;DNA Restriction Enzymes",
        "Doc_meshdescriptors":"Base Sequence;Chromosomes, Human, Pair 22;Chromosomes, Human, Pair 9;Cloning, Molecular;DNA;DNA Restriction Enzymes;DNA, Neoplasm;Humans;Introns;Leukemia, Lymphoid;Leukemia, Myeloid;Molecular Sequence Data;Nucleic Acid Hybridization;Oncogenes;Philadelphia Chromosome;RNA, Messenger;Transcription, Genetic;Translocation, Genetic",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;genetics",
        "_version_":1605784453437718528},
      {
        "Doc_abstract":"Accumulating knowledge about the molecular mechanisms causing human diseases can support the development of targeted therapies such as imatinib, a BCR-ABL-specific tyrosine kinase inhibitor to treat chronic myeloid leukemia (CML). Here, we use lentivirus-mediated RNA interference (RNAi) targeting BCR-ABL and the downstream signaling molecules SHP2, STAT5, and Gab2 to compare the efficacy and specificity of molecularly defined therapeutics with that of conventional cytotoxic drugs (cytarabine, doxorubicin, etoposide) in a conditional BCR-ABL cell culture model. IC(50) values were determined for each drug in TonB cells cultured either with interleukin-3 (IL-3) or BCR-ABL, and molecularly defined therapies were studied using lentivirally expressed shRNAs. We demonstrate that conventional anti-leukemic drugs have small or no differential effects under different cell culture conditions, whereas both imatinib and specific RNAi significantly inhibit proliferation of TonB cells in the presence of BCR-ABL but not IL-3. To study molecularly defined combination therapy, we evaluated either imatinib in TonB cells with target-specific RNAi or we used lentiviral vectors to induce combinatorial RNAi through simultaneous expression of two shRNAs. These combination therapies result in increased efficacy without loss in specificity. Interestingly, combinatorial RNAi can specifically deplete TonB cell cultures in the presence of BCR-ABL, even without targeting the oncogene itself. This model provides a tool to evaluate potential therapeutic targets and to quantify efficacy and specificity preclinically of new combination therapies in BCR-ABL-positive cells.",
        "Doc_title":"Comparison between molecularly defined and conventional therapeutics in a conditional BCR-ABL cell culture model.",
        "Journal":"Oligonucleotides",
        "Do_id":"17461760",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Gab2 protein, mouse;Interleukin-3;Intracellular Signaling Peptides and Proteins;Phosphoproteins;Piperazines;Pyrimidines;RNA, Small Interfering;STAT5 Transcription Factor;Imatinib Mesylate;Fusion Proteins, bcr-abl;PTPN11 protein, human;Protein Tyrosine Phosphatase, Non-Receptor Type 11;Protein Tyrosine Phosphatases;Ptpn11 protein, mouse",
        "Doc_meshdescriptors":"Animals;Antineoplastic Agents;Benzamides;Fusion Proteins, bcr-abl;Genetic Therapy;Imatinib Mesylate;Inhibitory Concentration 50;Interleukin-3;Intracellular Signaling Peptides and Proteins;Lentivirus;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mice;Models, Biological;Phosphoproteins;Piperazines;Protein Tyrosine Phosphatase, Non-Receptor Type 11;Protein Tyrosine Phosphatases;Pyrimidines;RNA Interference;RNA, Small Interfering;STAT5 Transcription Factor;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"therapeutic use;antagonists & inhibitors;genetics;pharmacology;antagonists & inhibitors;genetics;genetics;drug therapy;therapy;antagonists & inhibitors;genetics;therapeutic use;antagonists & inhibitors;genetics;therapeutic use;genetics;antagonists & inhibitors;genetics",
        "_version_":1605742132909309954},
      {
        "Doc_abstract":"The \"gate-keeper\" mutations T674I platelet-derived growth factor receptor  (PDGFR) in hypereosinophilic syndrome (HES) and T315I Bcr-Abl in chronic myeloid leukemia (CML) are resistant to imatinib and the second-generation small-molecule tyrosine kinase inhibitors (TKI). However, to combat acquired resistance to imatinib, an alternative approach is to decrease the expression of the addicted gene to efficiently kill resistant malignant hematologic cells. The purpose of this study was to evaluate the strategy of shutting down the transcription and expression of FIP1-like-1 (FIP1L1)-PDGFR and Bcr-Abl with SNS-032, an inhibitor of cyclin-dependent kinase 7 (CDK7) and CDK9 in phase I clinical trials.;The effects of SNS-032 on PDGFR and Bcr-Abl signaling pathways, apoptosis, and cell cycling were analyzed in TKI-resistant cells of HES and CML. The in vivo antitumor activity of SNS-032 was assessed with xenografted BaF3-T674I FIP1L1-PDGFR and KBM5-T315I Bcr-Abl cells in nude mouse models.;SNS-032 inhibited the phosphorylation on Ser5 and Ser2 of RNA polymerase II. SNS-032 decreased both the mRNA and protein levels of FIP1L1-PDGFR and Bcr-Abl and inhibited the proliferation of malignant cells expressing FIP1L1-PDGFR or Bcr-Abl. It also decreased the phosphorylation of downstream molecules. It induced apoptosis by triggering both the mitochondrial pathway and the death receptor pathway.;This CDK7/9 inhibitor potently inhibits FIP1L1-PDGFR-positive HES cells and Bcr-Abl-positive CML cells regardless of their sensitivity to imatinib. SNS-032 may have potential in treating hematologic malignancy by abrogating oncogene addiction.",
        "Doc_title":"Cyclin-dependent kinase 7/9 inhibitor SNS-032 abrogates FIP1-like-1 platelet-derived growth factor receptor  and bcr-abl oncogene addiction in malignant hematologic cells.",
        "Journal":"Clinical cancer research : an official journal of the American Association for Cancer Research",
        "Do_id":"22447844",
        "Doc_ChemicalList":"N-(5-(((5-(1,1-dimethylethyl)-2-oxazolyl)methyl)thio)-2-thiazolyl)-4-piperidinecarboxamide;Oncogene Proteins, Fusion;Oxazoles;Thiazoles;mRNA Cleavage and Polyadenylation Factors;FIP1L1-PDGFRA fusion protein, human;Receptor, Platelet-Derived Growth Factor alpha;Fusion Proteins, bcr-abl;Cyclin-Dependent Kinase 9;Cyclin-Dependent Kinases;cyclin-dependent kinase-activating kinase",
        "Doc_meshdescriptors":"Animals;Apoptosis;Blotting, Western;Cell Cycle;Cell Line;Cell Line, Tumor;Cell Proliferation;Cyclin-Dependent Kinase 9;Cyclin-Dependent Kinases;Female;Fusion Proteins, bcr-abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Mice;Mice, Inbred BALB C;Mice, Nude;Oncogene Proteins, Fusion;Oxazoles;Phosphorylation;Receptor, Platelet-Derived Growth Factor alpha;Reverse Transcriptase Polymerase Chain Reaction;Signal Transduction;Thiazoles;Xenograft Model Antitumor Assays;mRNA Cleavage and Polyadenylation Factors",
        "Doc_meshqualifiers":"drug effects;drug effects;drug effects;antagonists & inhibitors;metabolism;antagonists & inhibitors;metabolism;antagonists & inhibitors;genetics;metabolism;drug therapy;genetics;metabolism;antagonists & inhibitors;genetics;metabolism;pharmacology;drug effects;antagonists & inhibitors;genetics;metabolism;drug effects;pharmacology;antagonists & inhibitors;genetics;metabolism",
        "_version_":1605882544103882752},
      {
        "Doc_abstract":"The case of an 11-year-old child with adult-type chronic myeloid leukemia, Philadelphia (BCR-ABL) positive, reverse transcription-polymerase chain reaction negative for the major, minor, and micro breakpoints is presented. In the course of 3 years, the child failed to respond to treatment with hydroxyurea, refused all therapy for 6 months, was intolerant to alpha-interferon and progressed, while on imatinib, to acute basophilic leukemia. Subsequently he underwent successful bone marrow transplantation. A secondary cytogenetic clonal evolution, i(17q), developed during hydroxyurea treatment and a tertiary clonal evolution, +8, was detected during imatinib treatment. It is not clear to what extent the several factors (undefined BCR-ABL breakpoint, treatment avoidance, and initial treatment choices, alone or in combination) played a role in the imatinib relapse and resistance and in the disease progression. We conclude that close follow-up with frequent bone marrow sampling is crucial in order to monitor such patients for early relapse and prompt referral for bone marrow transplant.",
        "Doc_title":"Imatinib resistant chronic myelogenous leukemia, BCR-ABL positive by chromosome and FISH analyses but negative by PCR, in a child progressing to acute basophilic leukemia: cytogenetic follow-up.",
        "Journal":"Cancer genetics and cytogenetics",
        "Do_id":"16965955",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Pyrimidines;Imatinib Mesylate",
        "Doc_meshdescriptors":"Antineoplastic Agents;Benzamides;Bone Marrow Transplantation;Child;Disease Progression;Drug Resistance, Neoplasm;Genes, abl;Humans;Imatinib Mesylate;Immunophenotyping;In Situ Hybridization, Fluorescence;Leukemia, Basophilic, Acute;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Piperazines;Pyrimidines;Reverse Transcriptase Polymerase Chain Reaction",
        "Doc_meshqualifiers":"therapeutic use;immunology;pathology;surgery;drug therapy;genetics;immunology;pathology;therapeutic use;therapeutic use",
        "_version_":1605806649750061056},
      {
        "Doc_abstract":"Imatinib induces a durable response in most patients with Philadelphia chromosome-positive chronic myeloid leukemia, but it is currently unclear whether imatinib reduces the leukemic stem cell (LSC) burden, which may be an important step toward enabling safe discontinuation of therapy. In this article, we use mathematical models of BCR-ABL levels to make inferences on the dynamics of LSCs.;Patients with at least 1 BCR-ABL transcript measurement on imatinib were included (N = 477). Maximum likelihood methods were used to test 3 potential hypotheses of the dynamics of BCR-ABL transcripts on imatinib therapy: (i) monoexponential, in which there is little, if any, decline in BCR-ABL transcripts; (ii) biexponential, in which patients have a rapid initial decrease in BCR-ABL transcripts followed by a more gradual response; and (iii) triexponential, in which patients first exhibit a biphasic decline but then have a third phase when BCR-ABL transcripts increase rapidly.;We found that most patients treated with imatinib exhibit a biphasic decrease in BCR-ABL transcript levels, with a rapid decrease during the first few months of treatment, followed by a more gradual decrease that often continues over many years.;We show that the only hypothesis consistent with current data on progenitor cell turnover and with the long-term, gradual decrease in the BCR-ABL levels seen in most patients is that these patients exhibit a continual, gradual reduction of the LSCs. This observation may explain the ability to discontinue imatinib therapy without relapse in some cases.",
        "Doc_title":"BCR-ABL transcript dynamics support the hypothesis that leukemic stem cells are reduced during imatinib treatment.",
        "Journal":"Clinical cancer research : an official journal of the American Association for Cancer Research",
        "Do_id":"21903771",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Protein Kinase Inhibitors;Pyrimidines;RNA, Messenger;Imatinib Mesylate;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Antineoplastic Agents;Benzamides;Fusion Proteins, bcr-abl;Hematopoiesis;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Neoplastic Stem Cells;Piperazines;Protein Kinase Inhibitors;Protein-Tyrosine Kinases;Pyrimidines;RNA, Messenger;Real-Time Polymerase Chain Reaction",
        "Doc_meshqualifiers":"pharmacology;biosynthesis;genetics;drug effects;drug therapy;genetics;metabolism;pathology;drug effects;metabolism;pathology;pharmacology;pharmacology;antagonists & inhibitors;pharmacology;biosynthesis;genetics",
        "_version_":1605796402563121152},
      {
        "Doc_abstract":"Recent findings showed that BRCA1, in addition to its role in DNA damage response, acts as an upstream regulator of genes involved in the mitotic checkpoint regulation, thus protecting against promotion of aberrant divisions and aneuploidy. Moreover, there is also an indication that the BRCA1 protein is downregulated in chronic myeloid leukemia (CML) patients. We have investigated a possible functional relationship between BRCA1 and mitotic checkpoint competence in cells with the same genetic background expressing different levels of Bcr-Abl, an oncogene responsible for CML. Herein, we show that Bcr-Abl strongly downregulates the BRCA1 protein level, which is partially reversed on treatment with imatinib, an inhibitor of Bcr-Abl tyrosine kinase. Bcr-Abl leads to decreased expression of genes involved in the mitotic checkpoint activation--Mad2, Bub1, Bub3, and BubR1, resulting in mitosis perturbances, weakened mitotic checkpoint function, and mitotic slippage after nocodazole treatment. Furthermore, high Bcr-Abl-expressing cells showed also postmitotic checkpoint dysfunctions and inability to effectively arrest in the 4NG1 phase of the cell cycle, which was associated with limited p21 induction. These observations had significant biological consequences, as we found a high level of improper divisions, chromosomal missegregation, and generation of polyploid cells on mitotic checkpoint prolonged activation. Additionally, Bcr-Abl-expressing cells showed resistance to death activated by spindle defects, reversed by imatinib. Our study presents new facts and supports the hypothesis concerning the mutator nature of Bcr-Abl itself. The functional interaction between Bcr-Abl and mitosis dysfunctions, due to compromised mitotic checkpoints, may have important implications for the generation of aneuploidy and CML progression.",
        "Doc_title":"Expression of oncogenic kinase Bcr-Abl impairs mitotic checkpoint and promotes aberrant divisions and resistance to microtubule-targeting agents.",
        "Journal":"Molecular cancer therapeutics",
        "Do_id":"20442314",
        "Doc_ChemicalList":"Tubulin Modulators;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Aneuploidy;Animals;Cell Division;Cells, Cultured;Disease Progression;Drug Delivery Systems;Drug Resistance, Neoplasm;Fusion Proteins, bcr-abl;Gene Expression Regulation, Leukemic;Genes, cdc;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mice;Microtubules;Mitosis;Protein-Tyrosine Kinases;Tubulin Modulators",
        "Doc_meshqualifiers":"genetics;genetics;genetics;physiology;physiology;physiology;drug therapy;genetics;pathology;drug effects;genetics;genetics;physiology;administration & dosage;pharmacology;therapeutic use",
        "_version_":1605907505233264640},
      {
        "Doc_abstract":"The BCR-ABL tyrosine kinase inhibitor imatinib has dramatically improved the prognosis for most patients with chronic myeloid leukemia (CML). Efforts to optimize therapy in CML have resulted in new and revised treatment guidelines or algorithms, which are reviewed here.;Data were identified by searches of MEDLINE, PubMed, and references from relevant articles using the terms \"chronic myeloid leukemia,\" \"imatinib,\" and \"tyrosine kinase inhibitors.\" Articles published in English between 1996 and 2006 were included.;In this article we review consensus criteria for a therapeutic response and current expectations for CML therapy with imatinib, as well as the evidence supporting these recommendations. In addition, novel approaches to CML treatment are considered in light of the availability of second-generation tyrosine kinase inhibitors.;With the advent of novel agents capable of treating imatinib-resistant or imatinib-intolerant CML, it should be possible in the future to further refine treatment algorithms.",
        "Doc_title":"Current perspectives on the treatment of patients with chronic myeloid leukemia: an individualized approach to treatment.",
        "Journal":"Cancer journal (Sudbury, Mass.)",
        "Do_id":"18032972",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Pyrimidines;Imatinib Mesylate",
        "Doc_meshdescriptors":"Antineoplastic Agents;Benzamides;Dose-Response Relationship, Drug;Drug Monitoring;Genes, abl;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Piperazines;Prognosis;Pyrimidines",
        "Doc_meshqualifiers":"therapeutic use;drug therapy;genetics;therapeutic use;therapeutic use",
        "_version_":1605752754550079488},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) is characterized by a 9:22 translocation resulting in production of a chimeric BCR-ABL fusion protein that has constitutive tyrosine kinase activity and drives leukemic transformation. Imatinib mesylate, a selective inhibitor of BCR-ABL, has been introduced into clinical trials with favorable toxicity and impressive activity at all disease stages. In a phase III study of diagnosed chronic phase CML, imatinib mesylate was superior to interferon plus cytarabine in cytogenetic response, freedom from disease progression, and tolerability. Hematopoietic stem cell transplantation remains the only established cure for CML. Recent reports show continued improvements with survivals after matched sibling grafts greater than 80% at 3 to 5 years. Therefore, recent advances in conventional and transplant therapy have improved treatment options for newly diagnosed patients. Sensitive and specific monitoring techniques developed for CML may help further refine treatment with regard to using these and other emerging therapies.",
        "Doc_title":"Treatment options for newly diagnosed patients with chronic myeloid leukemia.",
        "Journal":"Current hematology reports",
        "Do_id":"14695851",
        "Doc_ChemicalList":"Antineoplastic Agents;Antineoplastic Agents, Alkylating;Benzamides;Enzyme Inhibitors;Piperazines;Pyrimidines;Imatinib Mesylate;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Antineoplastic Agents;Antineoplastic Agents, Alkylating;Benzamides;Bone Marrow Transplantation;Clinical Trials as Topic;Combined Modality Therapy;Dose-Response Relationship, Drug;Drug Resistance, Neoplasm;Enzyme Inhibitors;Fusion Proteins, bcr-abl;Hematopoietic Stem Cell Transplantation;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Multicenter Studies as Topic;Piperazines;Prognosis;Pyrimidines;Survival Rate;Treatment Outcome",
        "Doc_meshqualifiers":"administration & dosage;therapeutic use;therapeutic use;administration & dosage;therapeutic use;antagonists & inhibitors;blood;blood;drug therapy;therapy;administration & dosage;therapeutic use;administration & dosage;therapeutic use",
        "_version_":1605818726652837890},
      {
        "Doc_abstract":"The BCR/ABL hybrid gene plays a central role in the pathogenesis of the chronic phase of chronic myeloid leukemia (CML). We used a very sensitive quantitative reverse transcriptase-polymerase chain reaction to investigate the levels of hybrid BCR/ABL mRNA in bone marrow cells of 20 patients with Philadelphia positive (Ph(+)) CML treated with interferon-alpha (IFN-alpha) as a single agent. Bone marrow samples were collected at diagnosis and at hematologic remission induced by IFN-alpha, or by hydroxyurea in case of resistance to IFN-alpha. The mean levels of BCR/ABL transcripts in bone marrow mononuclear cells of patients who showed a complete hematologic response to IFN-alpha were significantly reduced with respect to those at diagnosis (48 x 10(3) v 168 x 10(3); P <.001), whereas no difference was detected between the values at diagnosis and at hematologic remission in patients resistant to IFN-alpha. In cell culture experiments, IFN-alpha priming significantly reduced the levels of BCR/ABL hybrid transcripts in a dose-dependent manner in Ph+ bone marrow precursors obtained at diagnosis from patients who subsequently responded to IFN-alpha treatment (P < .005). No downmodulation was observed in bone marrow precursors from patients who subsequently proved to be IFN-resistant. These results indicate that downmodulation of BCR/ABL gene expression could be one of the mechanisms involved in the response of CML patients to IFN-alpha treatment.",
        "Doc_title":"BCR/ABL mRNA and the P210(BCR/ABL) protein are downmodulated by interferon-alpha in chronic myeloid leukemia patients.",
        "Journal":"Blood",
        "Do_id":"10498589",
        "Doc_ChemicalList":"Antineoplastic Agents;Interferon-alpha;RNA, Messenger;Fusion Proteins, bcr-abl;Hydroxyurea",
        "Doc_meshdescriptors":"Antineoplastic Agents;Bone Marrow Cells;Cells, Cultured;Dose-Response Relationship, Drug;Fusion Proteins, bcr-abl;Gene Expression Regulation, Neoplastic;Humans;Hydroxyurea;Interferon-alpha;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Leukocyte Count;Monocytes;Philadelphia Chromosome;Platelet Count;RNA, Messenger;Reverse Transcriptase Polymerase Chain Reaction;Transcription, Genetic",
        "Doc_meshqualifiers":"therapeutic use;metabolism;pathology;genetics;drug effects;immunology;therapeutic use;therapeutic use;drug therapy;genetics;metabolism;pathology;genetics",
        "_version_":1605755294599610368},
      {
        "Doc_abstract":"The introduction in 1998 of imatinib mesylate (IM) revolutionized management of patients with chronic myeloid leukemia (CML) and the second generation of tyrosine kinase inhibitors may prove superior to IM. Real-time quantitative polymerase chain reaction (RQ-PCR) provides an accurate measure of the total leukemiacell mass and the degree to which BCR-ABL transcripts are reduced by therapy correlates with progression-free survival. Because a rising level of BCR-ABL is an early indication of loss of response and thus the need to reassess therapeutic strategy, regular molecular monitoring of individual patients is clearly desirable. Here we summarize the results of a consensus meeting that took place at the National Institutes of Health (NIH) in Bethesda in October 2005. We make suggestions for (1) harmonizing the differing methodologies for measuring BCR-ABL transcripts in patients with CML undergoing treatment and using a conversion factor whereby individual laboratories can express BCR-ABL transcript levels on an internationally agreed scale; (2) using serial RQ-PCR results rather than bone marrow cytogenetics or fluorescence in situ hybridization (FISH) for the BCR-ABL gene to monitor individual patients responding to treatment; and (3) detecting and reporting Philadelphia (Ph) chromosome-positive subpopulations bearing BCR-ABL kinase domain mutations. We recognize that our recommendations are provisional and will require revision as new evidence emerges.",
        "Doc_title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.",
        "Journal":"Blood",
        "Do_id":"16522812",
        "Doc_ChemicalList":"Protein Kinase Inhibitors;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Drug Monitoring;Fusion Proteins, bcr-abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mutation;Protein Kinase Inhibitors;Protein Structure, Tertiary;Protein-Tyrosine Kinases;Reverse Transcriptase Polymerase Chain Reaction;Sensitivity and Specificity",
        "Doc_meshqualifiers":"methods;genetics;diagnosis;drug therapy;genetics;therapeutic use;genetics;antagonists & inhibitors;genetics;methods;standards",
        "_version_":1605883155190906880},
      {
        "Doc_abstract":"Vav is a guanine nucleotide exchange factor for the Rho/Rac family predominantly expressed in hematopoietic cells and implicated in cell proliferation and cytoskeletal organization. The oncogenic tyrosine kinase Bcr-Abl has been shown to activate Rac-1, which is important for Bcr-Abl induced leukemogenesis. Previous studies by Matsuguchi et al. (Matsuguchi, T., Inhorn, R. C., Carlesso, N., Xu, G., Druker, B., and Griffin, J. D. (1995) EMBO J. 14, 257-265) describe enhanced phosphorylation of Vav in Bcr-Abl-expressing Mo7e cells yet fail to demonstrate association of the two proteins. Here, we report the identification of a direct complex between Vav and Bcr-Abl in yeast, in vitro and in vivo. Furthermore, we show tyrosine phosphorylation of Vav by Bcr-Abl. Mutational analysis revealed that the SH2 domain and the C-terminal SH3 domain as well as a tetraproline motif directly adjacent to the N-terminal SH3 domain of Vav are important for establishing this phosphotyrosine dependent interaction. Activation of Rac-1 by Bcr-Abl was abrogated by co-expression of the Vav C terminus encoding the SH3-SH2-SH3 domains as a dominant negative construct. Bcr-Abl transduced primary bone marrow from Vav knock-out mice showed reduced proliferation in a culture cell transformation assay compared with wild-type bone marrow. These results suggest, that Bcr-Abl utilizes Vav as a guanine nucleotide exchange factor to activate Rac-1 in a process that involves a folding mechanism of the Vav C terminus. Given the importance of Rac-1 activation for Bcr-Abl-mediated leukemogenesis, this mechanism may be crucial for the molecular pathogenesis of chronic myeloid leukemia and of importance for other signal transduction pathways leading to the activation of Rac-1.",
        "Doc_title":"Association of Bcr-Abl with the proto-oncogene Vav is implicated in activation of the Rac-1 pathway.",
        "Journal":"The Journal of biological chemistry",
        "Do_id":"11790798",
        "Doc_ChemicalList":"Cell Cycle Proteins;DNA, Complementary;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-vav;Recombinant Fusion Proteins;VAV1 protein, human;Vav1 protein, mouse;Tyrosine;Proline;Glutathione Transferase;Fusion Proteins, bcr-abl;rac1 GTP-Binding Protein",
        "Doc_meshdescriptors":"3T3 Cells;Animals;Bone Marrow Cells;Cell Cycle Proteins;Cell Line;DNA, Complementary;Electrophoresis, Polyacrylamide Gel;Enzyme Activation;Fusion Proteins, bcr-abl;Genes, Dominant;Glutathione Transferase;Humans;Immunoblotting;Mice;Mice, Knockout;Phosphorylation;Plasmids;Precipitin Tests;Proline;Protein Binding;Protein Structure, Tertiary;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-vav;Recombinant Fusion Proteins;Retroviridae;Signal Transduction;Temperature;Transfection;Two-Hybrid System Techniques;Tyrosine;rac1 GTP-Binding Protein;src Homology Domains",
        "Doc_meshqualifiers":"metabolism;metabolism;chemistry;metabolism;metabolism;metabolism;chemistry;metabolism;metabolism;genetics;metabolism;metabolism",
        "_version_":1605794586524909568},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) is initially driven by the bcr-abl fusion oncoprotein. The identification of bcr-abl led to the discovery and rapid translation into the clinic of bcr-abl kinase inhibitors. Although, bcr-abl inhibitors are efficacious, experimental evidence indicates that targeting bcr-abl is not sufficient for elimination of minimal residual disease found within the bone marrow (BM). Experimental evidence indicates that the failure to eliminate the leukemic stem cell contributes to persistent minimal residual disease. Thus curative strategies will likely need to focus on strategies where bcr-abl inhibitors are given in combination with agents that specifically target the leukemic stem cell or the leukemic stem cell niche. One potential target to be exploited is the Janus kinase (JAK)/signal transducers and activators of transcription 3 (STAT3) pathway. Recently using STAT3 conditional knock-out mice it was shown that STAT3 is critical for initiating the disease. Interestingly, in the absence of treatment, STAT3 was not shown to be required for maintenance of the disease, suggesting that STAT3 is required only in the tumor initiating stem cell population (Hoelbl et al., 2010). In the context of the BM microenvironment, STAT3 is activated in a bcr-abl independent manner by the cytokine milieu. Activation of JAK/STAT3 was shown to contribute to cell survival even in the event of complete inhibition of bcr-abl activity within the BM compartment. Taken together, these studies suggest that JAK/STAT3 is an attractive therapeutic target for developing strategies for targeting the JAK-STAT3 pathway in combination with bcr-abl kinase inhibitors and may represent a viable strategy for eliminating or reducing minimal residual disease located in the BM in CML.",
        "Doc_title":"Role of STAT3 in Transformation and Drug Resistance in CML.",
        "Journal":"Frontiers in oncology",
        "Do_id":"22649784",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605881000801337344},
      {
        "Doc_abstract":"The Philadelphia chromosome (Ph) translocation generates a chimeric tyrosine kinase oncogene, BCR/ABL, which causes chronic myelogenous leukemia (CML) and a type of acute lymphoblastic leukemia (ALL). In primary samples from virtually all patients with CML or Ph+ALL, the CRKL adapter protein is tyrosine phosphorylated and physically associated with p210(BCR/ABL). CRKL has one SH2 domain and two SH3 domains and is structurally related to c-CRK-II (CRK) and the v-Crk oncoprotein. We have previously shown that CRKL, but not the related adapter protein c-CRK, is tyrosine phosphorylated in cell lines transformed by BCR/ABL, and that CRKL binds to BCR/ABL through the CRKL-SH3 domains. Furthermore, the CRKL-SH2 domain has been shown to bind one or more cellular proteins, one of which is p120(CBL). Here we demonstrate that another cellular protein linked to BCR/ABL through the CRKL-SH2 domain is p130(CAS). p130(CAS) was found to be tyrosine phosphorylated and associated with CRKL in BCR/ABL expressing cell lines and in samples obtained from CML and ALL patients, but not in samples from controls. In both normal and BCR/ABL transformed cells, p130(CAS) was detected in focal adhesion-like structures, as was BCR/ABL. In normal cells, the focal adhesion proteins tensin, p125(FAK), and paxillin constitutively associated with p130(CAS). However, in BCR/ABL transformed cells, the interaction between p130(CAS) and tensin was disrupted, while the associations between p130(CAS), p125(FAK), and paxillin were unaffected. These results suggest that the BCR/ABL oncogene could alter the function of p130(CAS) in at least three ways: tyrosine phosphorylation, inducing constitutive binding of CRKL to a domain in p130(CAS) containing Tyr-X-X-Pro motifs (substrate domain), and disrupting the normal interaction of p130(CAS) with the focal adhesion protein tensin. These alterations in the structure of signaling proteins in focal adhesion like structures could contribute to the known adhesion abnormalities in CML cells.",
        "Doc_title":"p130CAS forms a signaling complex with the adapter protein CRKL in hematopoietic cells transformed by the BCR/ABL oncogene.",
        "Journal":"The Journal of biological chemistry",
        "Do_id":"8810278",
        "Doc_ChemicalList":"Adaptor Proteins, Signal Transducing;BCAR1 protein, human;Bcar1 protein, mouse;CRKL protein;Crk-Associated Substrate Protein;Nuclear Proteins;Phosphoproteins;Proteins;Recombinant Fusion Proteins;Retinoblastoma Protein;Retinoblastoma-Like Protein p130;Phosphotyrosine;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adaptor Proteins, Signal Transducing;Amino Acid Sequence;Animals;Binding Sites;Blood Cells;Cell Line;Cell Line, Transformed;Cell Transformation, Neoplastic;Crk-Associated Substrate Protein;Fusion Proteins, bcr-abl;Humans;Mice;Nuclear Proteins;Oncogenes;Phosphoproteins;Phosphotyrosine;Proteins;Recombinant Fusion Proteins;Retinoblastoma Protein;Retinoblastoma-Like Protein p130;Signal Transduction;Tumor Cells, Cultured;src Homology Domains",
        "Doc_meshqualifiers":"biosynthesis;metabolism;metabolism;metabolism;metabolism",
        "_version_":1605830806739091456},
      {
        "Doc_abstract":"To screen phosphopeptide specific for acute leukemia.;Mononuclear cells from bone marrow were collected from 16 newly diagnosed acute lymphoblastic leukemia (ALL) and 20 acute myeloid leukemia (AML) patients. Peptides were extracted and purified, analyzed by immunoprecipitation and liquid chromatography coupled with tandem mass spectrometry (LC-MS).;(1) Non-receptor tyrosine kinase family members Fyn, Yes, Src widely expressed in acute leukemia; (2) Some phosphopeptides, including non-receptor tyrosine kinase family members Abl/iso1 and Abl, non-receptor Ser/Thr protein kinase family members Bcr, JNK2, JNK2 iso2, Adaptor/scaffold members Cas-L, Cbl, CrkL CENTD1 (Centaurin delta1) ZO2, transcriptor GFR-1 and phosphatase SHIP-2 were detected in Ph positive ALL, but not in other kinds of ALL. (3) Hck, Lyn and Fgr selectively expressed in AML (except AML-M(3)).;Some phosphopeptides were specific for ALL and AML, and may be useful for diagnosis and therapy of acute leukemia.",
        "Doc_title":"[Screen of phosphopeptide specific for acute leukemia].",
        "Journal":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi",
        "Do_id":"22781597",
        "Doc_ChemicalList":"Neoplasm Proteins;Phosphopeptides",
        "Doc_meshdescriptors":"Chromatography, High Pressure Liquid;Humans;Immunoprecipitation;Leukemia, Myeloid, Acute;Neoplasm Proteins;Phosphopeptides;Phosphorylation;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Proteomics;Tandem Mass Spectrometry",
        "Doc_meshqualifiers":"genetics;metabolism;analysis;analysis;genetics;metabolism",
        "_version_":1605818792203517955},
      {
        "Doc_abstract":"A 16-year-old female was diagnosed incedentally with chronic myeloid leukemia (CML) in the chronic phase. She showed complete remission after 3 months of nilotinib treatment. CML is a rare malignant neoplasm in pediatric age. It is characterized by a Philadelphia chromosome, which comes from a genetic translocation between chromosomes 9 and 22. This translocation results in an abnormal fusion called BCR-ABL oncogene which encodes a chimeric BCR-ABL protein. This protein is the underlying cause of CML. Nilotinib is a newly licensed drug for CML in adults. Structurally, it is similar to imatinib (the older tyrosine kinase inhibitor), but it is much more potent in inhibiting BCR-ABL due to its much increased affinity for its binding site. Specific guidelines for CML treatment in children have yet to be determined. In our patient, nilotinib was used as an off-label drug because it is not licensed for children. According to the pharmacokinetic response to drugs, children cannot be considered small adults irrespective of their weight. Off-label drug use based on evidence that it is the best treatment available is an important tool in the hands of expert treating physicians. ",
        "Doc_title":"Successful nilotinib treatment in a child with chronic myeloid leukemia.",
        "Journal":"Case reports in oncology",
        "Do_id":"25873877",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605907589926748160},
      {
        "Doc_abstract":"In the initiation process of chronic myeloid leukemia (CML), a small number of transformed leukemia-initiating cells (LICs) coexist with a large number of normal hematopoietic cells, gradually increasing thereafter and eventually predominating in the hematopoietic space. However, the interaction between LICs and normal hematopoietic cells at the early phase has not been clearly delineated because of the lack of a suitable experimental model. In this study, we succeeded in causing a marked leukocytosis resembling CML from restricted foci of LICs in the normal hematopoietic system by direct transplantation of BCR-ABL gene-transduced LICs into the bone marrow (BM) cavity of nonirradiated mice. Herein, we observed that BCR-ABL(+)lineage(-)c-kit(-) immature leukemia cells produced high levels of an inflammatory chemokine, MIP-1/CCL3, which promoted the development of CML. Conversely, ablation of the CCL3 gene in LICs dramatically inhibited the development of CML and concomitantly reduced recurrence after the cessation of a short-term tyrosine kinase inhibitor treatment. Finally, normal hematopoietic stem/progenitor cells can directly impede the maintenance of LICs in BM in the absence of CCL3 signal. ",
        "Doc_title":"MIP-1/CCL3-mediated maintenance of leukemia-initiating cells in the initiation process of chronic myeloid leukemia.",
        "Journal":"The Journal of experimental medicine",
        "Do_id":"24166712",
        "Doc_ChemicalList":"Ccl3 protein, mouse;Ccr1 protein, mouse;Chemokine CCL3;Receptors, CCR1;Receptors, CCR5;Protein-Tyrosine Kinases;Proto-Oncogene Proteins c-kit",
        "Doc_meshdescriptors":"Animals;Bone Marrow Transplantation;Chemokine CCL3;Disease Models, Animal;Genes, abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Mice;Mice, Inbred BALB C;Mice, Knockout;Mice, Nude;Neoplastic Stem Cells;Protein-Tyrosine Kinases;Proto-Oncogene Proteins c-kit;Receptors, CCR1;Receptors, CCR5;Signal Transduction",
        "Doc_meshqualifiers":"deficiency;genetics;metabolism;etiology;metabolism;pathology;metabolism;pathology;transplantation;antagonists & inhibitors;metabolism;deficiency;genetics;metabolism;deficiency;genetics;metabolism",
        "_version_":1605813034280812544},
      {
        "Doc_abstract":"We studied 36 DNA samples of 18 patients affected with chronic myeloid leukemia (CML) for the presence of mutations in the first exon of the BCR gene was divided into four regions amplified by polymerase chain reaction (PCR). By single strand conformation polymorphism analysis (SSCP) and direct sequencing of amplified fragments, we found different banding profiles in 9 out of 18 patients in the PCR fragment spanning nucleotide 506-826. In one patient, sequence analysis revealed the presence of a point mutation at nucleotide 669 (A-T; Gln-Leu). No difference was found between DNA samples collected during the chronic phase and the blastic transformation. No different mobility shifts of single stranded PCR products were found in the other amplified fragments. The activation of BCR-ABL involves direct interaction between BCR first exon sequences and the tyrosine kinase regulatory domains of ABL. In the first BCR exon, and around the mutated sequences two SH-2-binding sites, are retained. These domains are essential for BCR-ABL-mediated transformation. Our results demonstrate the presence of point mutation in this regulatory region, which may suggest a role for the altered BCR sequence in activation of the BCR-ABL oncogene.",
        "Doc_title":"Structural organization of BCR-ABL gene in chronic phase and blast transformation in chronic myeloid leukemia patients.",
        "Journal":"Leukemia & lymphoma",
        "Do_id":"8251917",
        "Doc_ChemicalList":"DNA, Neoplasm;Fusion Proteins, bcr-abl;Protein-Serine-Threonine Kinases",
        "Doc_meshdescriptors":"Base Sequence;Binding Sites;Blast Crisis;Cell Transformation, Neoplastic;DNA Mutational Analysis;DNA, Neoplasm;Exons;Fusion Proteins, bcr-abl;Gene Expression Regulation, Leukemic;Genes;Genes, abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Leukemia, Myeloid, Chronic-Phase;Molecular Sequence Data;Polymerase Chain Reaction;Polymorphism, Genetic;Protein-Serine-Threonine Kinases",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;genetics;pathology;genetics;genetics",
        "_version_":1605761210529087488},
      {
        "Doc_abstract":"The product of the Philadelphia chromosome (Ph) translocation, the BCR/ABL oncogene, exists in three principal forms (P190, P210, and P230 BCR/ABL) that are found in distinct forms of Ph-positive leukemia, suggesting the three proteins have different leukemogenic activity. We have directly compared the tyrosine kinase activity, in vitro transformation properties, and in vivo leukemogenic activity of the P190, P210, and P230 forms of BCR/ABL. P230 exhibited lower intrinsic tyrosine kinase activity than P210 and P190. Although all three oncogenes transformed both myeloid (32D cl3) and lymphoid (Ba/F3) interleukin (IL)-3-dependent cell lines to become independent of IL-3 for survival and growth, their ability to stimulate proliferation of Ba/F3 lymphoid cells differed and correlated directly with tyrosine kinase activity. In a murine bone marrow transduction/transplantation model, the three forms of BCR/ABL were equally potent in the induction of a chronic myeloid leukemia (CML)-like myeloproliferative syndrome in recipient mice when 5-fluorouracil (5-FU)-treated donors were used. Analysis of proviral integration showed the CML-like disease to be polyclonal and to involve multiple myeloid and B lymphoid lineages, implicating a primitive multipotential target cell. Secondary transplantation revealed that only certain minor clones gave rise to day 12 spleen colonies and induced disease in secondary recipients, suggesting heterogeneity among the target cell population. In contrast, when marrow from non- 5-FU-treated donors was used, a mixture of CML-like disease, B lymphoid acute leukemia, and macrophage tumors was observed in recipients. P190 BCR/ABL induced lymphoid leukemia with shorter latency than P210 or P230. The lymphoid leukemias and macrophage tumors had provirus integration patterns that were oligo- or monoclonal and limited to the tumor cells, suggesting a lineage-restricted target cell with a requirement for additional events in addition to BCR/ABL transduction for full malignant transformation. These results do not support the hypothesis that P230 BCR/ABL induces a distinct and less aggressive form of CML in humans, and suggest that the rarity of P190 BCR/ABL in human CML may reflect infrequent BCR intron 1 breakpoints during the genesis of the Ph chromosome in stem cells, rather than intrinsic differences in myeloid leukemogenicity between P190 and P210.",
        "Doc_title":"The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity.",
        "Journal":"The Journal of experimental medicine",
        "Do_id":"10224280",
        "Doc_ChemicalList":"Protein Isoforms;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Animals;Cell Division;Cell Line, Transformed;Disease Models, Animal;Fusion Proteins, bcr-abl;Humans;Leukemia, Lymphoid;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Lymphocytes;Mice;Mice, Inbred BALB C;Oncogenes;Protein Isoforms;Protein-Tyrosine Kinases;Syndrome",
        "Doc_meshqualifiers":"genetics;metabolism;physiology;physiopathology;etiology;cytology;metabolism",
        "_version_":1605883892046233600},
      {
        "Doc_abstract":"21-year-old male was diagnosed as having acute lymphoblastic leukemia (ALL) in March 2001. Standard G-banding analysis revealed normal karyotype. He achieved complete remission after the first course of induction therapy and underwent allogeneic PBSCT in August 2001. However, leukemic cells appeared in the peripheral blood demonstrating complex chromosomal abnormalities with Philadelphia chromosome (Ph1) and expressing minor BCR/ABL transcripts. We thus retrospectively examined the bone marrow sample at presentation with both interphase FISH and RT-PCR methods. Surprisingly, almost all leukemic blasts at presentation turned out to possess the minor type of BCR/ABL fusion gene. In spite of the second allogeneic PBSCT, the patient died of pneumonia and graft-versus-host disease in the liver in September 2002. This case is rare in that cytogenetic analysis failed to detect Ph1 due to leukemic cells dormancy. The application of both FISH and RT-PCR studies would appear to be essential to avoid overlooking Ph1-positive ALL.",
        "Doc_title":"[Philadelphia chromosome-positive acute lymphoblastic leukemia showing normal karyotype at presentation].",
        "Journal":"[Rinsho ketsueki] The Japanese journal of clinical hematology",
        "Do_id":"14689877",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adult;Humans;Karyotyping;Male;Philadelphia Chromosome;Precursor Cell Lymphoblastic Leukemia-Lymphoma",
        "Doc_meshqualifiers":"genetics",
        "_version_":1605832206916255744},
      {
        "Doc_abstract":"We describe a patient with leukocytosis with all the stages of neutrophilic series, peripheral dominant myeloblast proliferation, marked dysplasia of myeloid and erythroid series, and extramedullary hematopoiesis of the lymph nodes. A cytogenetic study of the bone marrow cells showed normal karyotype, and molecular analysis of the leukemic cells showed negative for BCR-ABL by RT-PCR. After chemotherapy, the patient went into complete remission with a normal blood and bone marrow profile with no dysplasia. On relapse, the hematological findings showed a typical bone marrow dominant acute myeloid leukemia, with the leukemic cells having a chromosomal abnormality. The patient exhibited the combined features of myeloproliferative disorder, myelodysplastic syndrome, peripheral dominant myeloblast proliferation (so-called peripheral leukemia) and typical acute myeloid leukemia throughout the clinical course. This is thought to be a rare overlapping disease involving these distinct hematological conditions that do not usually occur in the same patient.",
        "Doc_title":"A rare atypical myeloproliferative-disorder-like hemopathy with marked dysplasia, peripheral dominant myeloblast proliferation and extramedullary hematopoiesis was converted into typical acute myeloid leukemia with an interval of complete hematological remission.",
        "Journal":"International journal of hematology",
        "Do_id":"9695415",
        "Doc_ChemicalList":"Cytarabine;Prednisolone;6-Mercaptopurine;Daunorubicin",
        "Doc_meshdescriptors":"6-Mercaptopurine;Acute Disease;Antineoplastic Combined Chemotherapy Protocols;Bone Marrow;Cytarabine;Daunorubicin;Disease Progression;Hematopoiesis, Extramedullary;Humans;Leukemia, Myeloid;Male;Middle Aged;Myelodysplastic Syndromes;Myeloproliferative Disorders;Prednisolone;Preleukemia;Remission Induction",
        "Doc_meshqualifiers":"administration & dosage;therapeutic use;pathology;administration & dosage;analogs & derivatives;administration & dosage;pathology;drug therapy;pathology;drug therapy;pathology;administration & dosage;pathology",
        "_version_":1605916970663804928},
      {
        "Doc_abstract":"Chronic myeloid leukemia cells contain a Bcr-Abl oncoprotein with an enhanced tyrosine kinase activity, which is considered to be the principal cause of the leukemia. The use of the first-generation tyrosine kinase inhibitor imatinib to inhibit the dysregulated kinase activity has proved remarkably successful, and imatinib as a single-agent is now considered to be the best initial treatment for the majority of adult patients in chronic phase. For patients who develop resistance to imatinib, the Bcr-Abl signaling pathway is often re-activated, second generation tyrosine kinase inhibitors, such as dasatinib or nilotinib, might restore the kinase inhibition. Allogeneic stem cell transplantation is now generally offered to older patients in whom imatinib therapy, and perhaps dasatinib or nilotinib also, have failed; efforts to establish firm criteria for the selection of second-line therapies after imatinib failure continue. At this time, children and younger adults should probably be considered for transplantation as first-line treatment.",
        "Doc_title":"Optimal management of patients with newly diagnosed chronic phase chronic myeloid leukemia in 2007.",
        "Journal":"Clinical lymphoma & myeloma",
        "Do_id":"17382023",
        "Doc_ChemicalList":"Protein Kinase Inhibitors;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adolescent;Adult;Child;Child, Preschool;Drug Resistance, Neoplasm;Fusion Proteins, bcr-abl;History, 21st Century;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Protein Kinase Inhibitors;Stem Cell Transplantation;Transplantation, Homologous",
        "Doc_meshqualifiers":"drug effects;antagonists & inhibitors;chemistry;metabolism;diagnosis;enzymology;history;therapy;chemistry;therapeutic use",
        "_version_":1605746390268379138},
      {
        "Doc_abstract":"The monitoring of BCR-ABL transcript levels by real-time quantitative polymerase chain reaction (RT-qPCR) has become important to assess minimal residual disease (MRD) and standard of care in the treatment of chronic myeloid leukemia (CML). In this study, we performed a prospective, sequential analysis using RT-qPCR monitoring of BCR-ABL gene rearrangements in blood samples from 91 CML patients in chronic phase (CP) who achieved complete cytogenetic remission (CCyR) and major molecular remission (MMR) throughout imatinib treatment.;The absolute level of BCR-ABL transcript from peripheral blood was serially measured every 4 to 12 weeks by RT-qPCR. Only level variations > 0.5%, according to the international scale, was considered positive. Sequential cytogenetic analysis was also performed in bone marrow samples from all patients using standard protocols.;Based on sequential analysis of BCR-ABL transcripts, the 91 patients were divided into three categories: (A) 57 (62.6%) had no variation on sequential analysis; (B) 30 (32.9%) had a single positive variation result obtained in a single sample; and (C) 4 (4.39%) had variations of BCR-ABL transcripts in at least two consecutive samples. Of the 34 patients who had elevated levels of transcripts (group B and C), 19 (55.8%) had a < 1% of BCR-ABL/BCR ratio, 13 (38.2%) patients had a 1% to 10% increase and 2 patients had a >10% increase of RT-qPCR. The last two patients had lost a CCyR, and none of them showed mutations in the ABL gene. Transient cytogenetic alterations in Ph-negative cells were observed in five (5.5%) patients, and none of whom lost CCyR.;Despite an increase levels of BCR-ABL/BCR ratio variations by RT-qPCR, the majority of CML patients with MMR remained in CCyR. Thus, such single variations should neither be considered predictive of subsequent failure and nor an indication for altering imatinib dose or switching to second generation therapy. Changing of imatinib on the basis of BCR-ABL/BCR% sustained increase and mutational studies is a prudent approach for preserving other therapeutic options in imatinib-resistant patients.",
        "Doc_title":"Molecular measurement of BCR-ABL transcript variations in chronic myeloid leukemia patients in cytogenetic remission.",
        "Journal":"BMC blood disorders",
        "Do_id":"21087500",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605742102117875714},
      {
        "Doc_abstract":"The correlation between the detection of the Philadelphia chromosome by conventional cytogenetics and the identification of Mbcr/abl translocation by fluorescence in situ hybridization (FISH) in both metaphase and interphase cells is prospectively analyzed in a group of 21 chronic myeloid leukemia (CML) patients. To gain insight into the sensitivity and specificity of the detection of the bcr/abl translocation by FISH, a group of 10 healthy volunteers was also studied. Our results show that for the detection of bcr/abl translocation in CML patients, FISH is more sensitive than conventional cytogenetics because it detects significantly higher proportions of cells carrying the translocation both in metaphase (P < .0002) and interphase nuclei (P < .003). Moreover, in the metaphases of the controls analyzed, no bcr/abl+ chromosome was detected that makes the colocalization of bcr and abl signals in the CML patients highly specific. Conversely, in control interphase nuclei, a small proportion of cells (ranging between 0% and 3%, mean value of 1.7% +/- 0.9%) displaying colocalization of both signals is usually detected. This limits, at least for the moment, the routine use of FISH for the detection of minimal residual disease in CML patients at levels lower than 10(-1).",
        "Doc_title":"Detection of the Mbcr/abl translocation in chronic myeloid leukemia by fluorescence in situ hybridization: comparison with conventional cytogenetics and implications for minimal residual disease detection.",
        "Journal":"Human pathology",
        "Do_id":"9023395",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adult;Cell Count;Chromosomes, Human, Pair 22;Chromosomes, Human, Pair 9;Cytogenetics;Female;Fusion Proteins, bcr-abl;Genes, abl;Humans;In Situ Hybridization, Fluorescence;Interphase;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Philadelphia Chromosome;Translocation, Genetic",
        "Doc_meshqualifiers":"genetics;genetics;diagnosis",
        "_version_":1605746404185079810},
      {
        "Doc_abstract":"Philadelphia (Ph) or BCR/ABL-negative cells with immature phenotype (CD34-positive, DR-negative) can be recovered from patients with chronic myeloid leukemia (CML) in chronic phase. We used the technique described by Berardi et al (Science 1995; 267: 104-108) to select stem cells from marrow or blood of CML patients at diagnosis or during treatment with alpha-interferon. Mononuclear cells (MNC), and in some experiments CD34+ cells, were maintained for 7 days in the presence of 5-fluorouracil (5-FU), stem cell factor and interleukin-3. The number of viable cells recovered after culture was between 7.4 and 70.2 for 10(6) cells plated. These cells exhibited the following phenotype: CD34+, CD117+, CD38-, lineage-, and were able to generate cobblestone areas and secondary colonies in long-term culture (LTC), with a frequency similar to that of cells selected from normal marrow. Study by fluorescence in situ hybridization of LTC cells or secondary colonies showed no evidence of BCR/ABL rearrangement. Reverse transcriptase polymerase chain reaction studies on pooled LTC cells or secondary colonies were also negative. By contrast, LTC cells or secondary colonies obtained from CML CD34+ cells without culture in the presence of 5-FU were always positive for BCR/ABL rearrangement. Finally, 5-FU selected cells were able to engraft NOD/SCID mouse, as human cells were detected in blood and marrow 10 weeks post transplantation, which were BCR/ABL negative by RT-PCR. This method of culture makes it possible to select constantly BCR/ABL-negative cells with capacities of development in LTC assay and of NOD/SCID mouse engraftment.",
        "Doc_title":"Selection of BCR/ABL-negative stem cells from marrow or blood of patients with chronic myeloid leukemia.",
        "Journal":"Leukemia",
        "Do_id":"10400413",
        "Doc_ChemicalList":"Interleukin-3;Stem Cell Factor;Fusion Proteins, bcr-abl;Fluorouracil",
        "Doc_meshdescriptors":"Animals;Cell Culture Techniques;Cell Separation;Fluorouracil;Fusion Proteins, bcr-abl;Hematopoietic Stem Cells;Humans;Immunophenotyping;In Situ Hybridization, Fluorescence;Interleukin-3;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mice;Mice, Inbred NOD;Mice, SCID;Polymerase Chain Reaction;Stem Cell Factor;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"methods;therapeutic use;analysis;chemistry;therapeutic use;metabolism;pathology;therapeutic use",
        "_version_":1605752961456144384},
      {
        "Doc_abstract":"Dasatinib is a compound developed for chronic myeloid leukemia as a multi-targeted kinase inhibitor against wild-type BCR-ABL and SRC family kinases. Valproic acid (VPA) is an anti-epileptic drug that also acts as a class I histone deacetylase inhibitor. The aim of this research was to determine the anti-leukemic effects of dasatinib and VPA in combination and to identify their mechanism of action in acute myeloid leukemia (AML) cells. Dasatinib was found to exert potent synergistic inhibitory effects on VPA-treated AML cells in association with G1 phase cell cycle arrest and apoptosis induction involving the cleavage of poly (ADP-ribose) polymerase and caspase-3, -7 and -9. Dasatinib/VPA-induced cell death thus occurred via caspase-dependent apoptosis. Moreover, MEK/ERK and p38 MAPK inhibitors efficiently inhibited dasatinib/VPA-induced apoptosis. The combined effect of dasatinib and VPA on the differentiation capacity of AML cells was more powerful than the effect of each drug alone, being sufficiently strong to promote AML cell death through G1 cell cycle arrest and caspase-dependent apoptosis. MEK/ERK and p38 MAPK were found to control dasatinib/VPA-induced apoptosis as upstream regulators, and co-treatment with dasatinib and VPA to contribute to AML cell death through the regulation of differentiation capacity. Taken together, these results indicate that combined dasatinib and VPA treatment has a potential role in anti-leukemic therapy. ",
        "Doc_title":"Dasatinib accelerates valproic acid-induced acute myeloid leukemia cell death by regulation of differentiation capacity.",
        "Journal":"PloS one",
        "Do_id":"24918603",
        "Doc_ChemicalList":"Anticonvulsants;Pyrimidines;Thiazoles;Valproic Acid;Protein-Tyrosine Kinases;Dasatinib",
        "Doc_meshdescriptors":"Aged;Anticonvulsants;Cell Death;Cell Differentiation;Cell Line, Tumor;Dasatinib;Drug Synergism;Female;G1 Phase Cell Cycle Checkpoints;Humans;Leukemia, Myeloid, Acute;Middle Aged;Protein-Tyrosine Kinases;Pyrimidines;Thiazoles;Valproic Acid",
        "Doc_meshqualifiers":"pharmacology;drug effects;drug effects;drug effects;drug therapy;pathology;pharmacology;pharmacology;pharmacology;pharmacology",
        "_version_":1605841384663678976},
      {
        "Doc_abstract":"Although imatinib mesylate therapy is effective for chronic myeloid leukemia (CML) patients, there are still some unanswered questions. It is unclear whether imatinib can actually cure CML and whether this therapy can be safely discontinued in patients showing complete cytogenetic and molecular responses. This report describes the clinical outcome of a patient with chronic phase CML who discontinued imatinib therapy after achieving molecular remission. This patient has shown a relapse based on transcription-mediated amplification-hybridization protection assay (TMA-HPA) to monitor BCR-ABL transcripts, highlighting the uncertainty of discontinuing imatinib therapy for five months.",
        "Doc_title":"[Molecular relapse of chronic myeloid leukemia after discontinuation of imatinib mesylate for maintaining complete molecular response for more than 2 years].",
        "Journal":"[Rinsho ketsueki] The Japanese journal of clinical hematology",
        "Do_id":"19225231",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Biomarkers, Tumor;Piperazines;Pyrimidines;RNA, Messenger;Imatinib Mesylate",
        "Doc_meshdescriptors":"Antineoplastic Agents;Benzamides;Biomarkers, Tumor;Genes, abl;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Nucleic Acid Amplification Techniques;Piperazines;Pyrimidines;RNA, Messenger;Recurrence;Remission Induction;Reverse Transcriptase Polymerase Chain Reaction;Time Factors",
        "Doc_meshqualifiers":"administration & dosage;analysis;genetics;diagnosis;drug therapy;genetics;administration & dosage;administration & dosage;analysis",
        "_version_":1605905345566212096},
      {
        "Doc_abstract":"We show that common heterochromatin antigenic protein markers [HP1alpha, -beta, -gamma and mono-, di-, and trimethylated histone H3 lysine 9 (H3K9)], although present in human blood progenitor CD34+ cells, differentiated lymphocytes, and monocytes, are absent in neutrophil granulocytes and to large extent, in eosinophils. Monomethylated and in particular, dimethylated H3K9 are present to variable degrees in the granulocytes of chronic myeloid leukemia (CML) patients, without being accompanied by HP1 proteins. In patients with an acute phase of CML and in acute myeloid leukemia patients, strong methylation of H3K9 and all isoforms of HP1 are detected. In chronic forms of CML, no strong correlations among the level of histone methylation, disease progression, and modality of treatment were observed. Histone methylation was found even in \"cured\" patients without Philadelphia chromosome (Ph) resulting from +(9;22)(q34;q11) BCR/ABL translocation, suggesting an incomplete process of developmentally regulated chromatin remodeling in the granulocytes of these patients. Similarly, reprogramming of leukemia HL-60 cells to terminal differentiation by retinoic acid does not eliminate H3K9 methylation and the presence of HP1 isoforms from differentiated granulocytes. Thus, our study shows for the first time that histone H3 methylation may be changed dramatically during normal cell differentiation. The residual histone H3 methylation in myeloid leukemia cells suggests an incomplete chromatin condensation that may be linked to the leukemia cell proliferation and may be important for the prognosis of disease treatment and relapse.",
        "Doc_title":"Methylation of histones in myeloid leukemias as a potential marker of granulocyte abnormalities.",
        "Journal":"Journal of leukocyte biology",
        "Do_id":"15507473",
        "Doc_ChemicalList":"Antineoplastic Agents;Biomarkers, Tumor;Chromatin;Histones;Tretinoin",
        "Doc_meshdescriptors":"Acute Disease;Adult;Aged;Antineoplastic Agents;Biomarkers, Tumor;Cell Differentiation;Cell Proliferation;Chromatin;Disease Progression;Granulocytes;HL-60 Cells;Histones;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Leukemia, Myeloid;Methylation;Middle Aged;Tretinoin",
        "Doc_meshqualifiers":"pharmacology;metabolism;drug effects;metabolism;metabolism;pathology;genetics;metabolism;diagnosis;genetics;metabolism;diagnosis;genetics;metabolism;pharmacology",
        "_version_":1605850801398349824},
      {
        "Doc_abstract":"Malignant stem cells have been identified in acute myelogenous leukemia, chronic myeloid leukemia, and some types of acute lymphoblastic leukemia. Like normal stem cells, these leukemic stem cells (LSCs) are able to self-renew, differentiate, and proliferate extensively. Evidence suggests that LSCs are critical for the initiation and perpetuation of leukemic disease.;We reviewed the literature describing the characteristic features of LSCs in various leukemias and the novel molecular approaches being used to specifically ablate the LSC population.;Studies have demonstrated the potential importance of ablating LSCs when treating leukemia. The unique characteristics of LSCs that differentiate them from their normal counterparts can be exploited to specifically target the malignant population.;Current therapeutic strategies may not effectively ablate the LSC, leaving the potential for disease progression or relapse. A better understanding of LSC cell and molecular biology will allow the design of more effective therapies.",
        "Doc_title":"Considerations for targeting malignant stem cells in leukemia.",
        "Journal":"Cancer control : journal of the Moffitt Cancer Center",
        "Do_id":"15024346",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antineoplastic Agents;Enzyme Inhibitors",
        "Doc_meshdescriptors":"Antibodies, Monoclonal;Antineoplastic Agents;Drug Evaluation;Enzyme Inhibitors;Humans;Leukemia;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Leukemia, Myeloid, Acute;Neoplastic Stem Cells;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Treatment Outcome",
        "Doc_meshqualifiers":"therapeutic use;therapeutic use;therapeutic use;drug therapy;pathology;pathology;therapy;pathology;therapy;drug effects;pathology;pathology;therapy",
        "_version_":1605798358511779840},
      {
        "Doc_abstract":"The t(9;22) translocation resulting in the fusion of BCR and ABL genes is pathognomonic in chronic myeloid leukemia (CML) and may be investigated at the molecular level using fluorescence in situ hybridization (FISH). Two-color BCR-ABL probes visualizing one fusion signal (1F FISH) have high false positive rates (FPR) and false negative rates (FNR). The FPR is a result of the random spatial association of probe signals within normal interphase cells so that some cells appear to contain the BCR-ABL fusion gene. The FNR of 1F FISH probes depends on the distance between the BCR and ABL probes hybridized to the BCR-ABL fusion gene (< or =368 kb); the \"gap\" between the signals causing the cell to be interpreted as normal. To overcome these difficulties, a two-color probe was used, employing four yeast artificial chromosome (YAC) sequences that span the breakpoint regions of the BCR and ABL genes and that visualize the two fusion signals BCR-ABL and ABL-BCR in CML cells (2F FISH). The FNR for the 2F FISH probes was assessed on clonal Ph+ granulocyte-macrophage-colony-forming cell (CFU-GM) derived colonies and was reduced to 0.4% (2/450), compared with an FNR of 13.5% (111/823) with 1F FISH. The FPR in normal mononuclear cells for the 2F FISH was 0. 19 +/- 0.12% (3/1,700), whereas the FPR using 1F FISH was 4.5 +/- 2.3% (63/1,294). The 2F FISH can thus be used to evaluate very small frequencies of BCR-ABL-positive and -negative interphase cells and may be of use in the clinical monitoring of CML.",
        "Doc_title":"A two-color BCR-ABL probe that greatly reduces the false positive and false negative rates for fluorescence in situ hybridization in chronic myeloid leukemia.",
        "Journal":"Genes, chromosomes & cancer",
        "Do_id":"9739013",
        "Doc_ChemicalList":"DNA Probes;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adult;Aged;Chromosomes, Artificial, Yeast;DNA Probes;False Negative Reactions;False Positive Reactions;Female;Fusion Proteins, bcr-abl;Humans;In Situ Hybridization, Fluorescence;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Leukocyte Count;Leukocytes, Mononuclear;Male;Middle Aged;Sensitivity and Specificity",
        "Doc_meshqualifiers":"genetics;genetics;genetics;methods;genetics;chemistry",
        "_version_":1605749687405510656},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) is characterized by Philadelphia chromosome (Ph) and BCR-ABL fusion genes. This study retrospectively analyzed 2381 CML patients with Ph chromosome confirmed by cytogenetics, Fluorescence in situ hybridization (FISH) or real-time quantitative polymerase chain reaction (Q-PCR). Among them, five CML patients without e13a2, e14a2 or e1a2 transcripts detected by Q-PCR were identified. DNA sequencing confirmed the fusion of BCR exon 14 and ABL exon 3. Case 1 reponded poorly to imatinib and achieved complete cytogenetic response (CCyR) after converting from imatinib to dasatinib. BCR-ABL transcripts were undetectable in cases after 2, 3 and 4 treated with imatinib after 6, 6 and 3 months, respectively, and in one patient who had undergone allogeneic hematopoietic stem cell transplantation after 4 months. Q-PCR may miss the detection of rare cases that are not covered by the primers used in Q-PCR, unless the proper primers are used. ",
        "Doc_title":"Chronic myeloid leukemia with e14a3 BCR-ABL transcript: analysis of characteristics and prognostic significance.",
        "Journal":"Leukemia & lymphoma",
        "Do_id":"25962435",
        "Doc_ChemicalList":"Antineoplastic Agents;Protein Kinase Inhibitors;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adult;Antineoplastic Agents;Exons;Female;Fusion Proteins, bcr-abl;Humans;In Situ Hybridization, Fluorescence;Karyotype;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Mutation;Neoplasm Staging;Prognosis;Protein Kinase Inhibitors;Retreatment;Transcription, Genetic;Treatment Outcome",
        "Doc_meshqualifiers":"administration & dosage;therapeutic use;genetics;diagnosis;drug therapy;genetics;mortality;administration & dosage;therapeutic use",
        "_version_":1605746801098358786},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by the presence of the Bcr-Abl tyrosine kinase protein, which confers resistance to apoptosis in leukemic cells. Tyrosine kinase inhibitors (TKIs) are effectively used to treat CML; however, CML patients in the advanced (CML-AP) and chronic (CML-CP) phases of the disease are usually resistant to TKI therapy. Thus, it is necessary to seek for novel agents to treat CML, such as the enzyme l-amino acid oxidase from Calloselasma rhodostoma (CR-LAAO) snake venom. We examined the antitumor effect of CR-LAAO in Bcr-Abl(+) cell lines and peripheral blood mononuclear cells (PBMC) from healthy subjects and CML patients. CR-LAAO was more cytotoxic towards Bcr-Abl(+) cell lines than towards healthy subjects' PBMC. The H2O2 produced during the enzymatic action of CR-LAAO mediated its cytotoxic effect. The CR-LAAO induced apoptosis in Bcr-Abl(+) cells, as detected by caspases 3, 8, and 9 activation, loss of mitochondrial membrane potential, and DNA damage. CR-LAAO elicited apoptosis in PBMC from CML-CP patients without TKI treatment more strongly than in PBMC from healthy subjects and TKI-treated CML-CP and CML-AP patients. The antitumor effect of CR-LAAO against Bcr-Abl(+) cells makes this toxin a promising candidate to CML therapy. ",
        "Doc_title":"CR-LAAO antileukemic effect against Bcr-Abl(+) cells is mediated by apoptosis and hydrogen peroxide.",
        "Journal":"International journal of biological macromolecules",
        "Do_id":"26812110",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605765276554493952},
      {
        "Doc_abstract":"BCR-ABL tyrosine kinase plays a major role in the pathogenesis of chronic myeloid leukemia (CML) and is a proven target for drug development. Currently available drugs in the market are effective against CML; however, side-effects and drug-resistant mutations in BCR-ABL limit their full potential. Using high throughput virtual screening approach, we have screened several small molecule databases and docked against wild-type and drug resistant T315I mutant BCR-ABL. Drugs that are currently available, such as imatinib and ponatinib, were also docked against BCR-ABL protein to set a cutoff value for our screening. Selected lead compounds were further evaluated for chemical reactivity employing density functional theory approach, all selected ligands shows HLG value > 0.09900 and the binding free energy between protein-ligand complex interactions obtained was rescored using MM-GBSA. The selected compounds showed least G score -71.53KJ/mol to maximum -126.71KJ/mol in both wild type and drug resistant T315I mutant BCR-ABL. Following which, the stability of the docking complexes were evaluated by molecular dynamics simulation (MD) using GROMACS4.5.5. Results uncovered seven lead molecules, designated with Drug-Bank and PubChem ids as DB07107, DB06977, ST013616, DB04200, ST007180 ST019342, and DB01172, which shows docking scores higher than imatinib and ponatinib.",
        "Doc_title":"Identification of novel tyrosine kinase inhibitors for drug resistant T315I mutant BCR-ABL: a virtual screening and molecular dynamics simulations study.",
        "Journal":"Scientific reports",
        "Do_id":"25382104",
        "Doc_ChemicalList":"Ligands;Protein Kinase Inhibitors;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Drug Discovery;Drug Resistance, Neoplasm;Fusion Proteins, bcr-abl;Humans;Hydrogen Bonding;Ligands;Molecular Conformation;Molecular Docking Simulation;Molecular Dynamics Simulation;Mutation;Protein Binding;Protein Kinase Inhibitors;Quantitative Structure-Activity Relationship",
        "Doc_meshqualifiers":"genetics;chemistry;genetics;metabolism;chemistry;pharmacology",
        "_version_":1605790348277186560},
      {
        "Doc_abstract":"BCR-ABL induces chronic myeloid leukemia (CML) through the aberrant regulation of multiple signaling substrates. Previous research has shown that BCR-ABL mediates down-modulation of CBL-B protein levels. A murine bone marrow transplantation (BMT) study was performed to assess the contribution of Cbl-b to BCR-ABL-induced disease. The predominant phenotype in the Cbl-b(-/-) recipients was a CML-like myeloproliferative disease (MPD) similar to that observed in the wild-type animals, but with a longer latency, diminished circulating leukocyte numbers and reduced spleen weights. Despite the decreased leukemic burden in comparison to their wild-type counterparts, the Cbl-b(-/-) animals displayed enhanced numbers of Gr-1(+)/Mac-1(+) spleen cells and neutrophilia. On the basis of prior evidence of CBL-B-dependent motility toward SDF-1, we hypothesized that Cbl-b deficiency might impair bone marrow localization during transplantation. Homing experiments showed reduced migration of Cbl-b(-/-) cells to the bone marrow. Intrafemoral transplantation of BCR-ABL-transduced Cbl-b(-/-) cells revealed equivalent latency of disease development to the wild-type transplants, supporting the conclusion that Cbl-b deficiency diminishes homing of leukemic cells to the bone marrow, and perturbs the proliferation of BCR-ABL-expressing malignant clones during CML development.",
        "Doc_title":"CBL-B is required for leukemogenesis mediated by BCR-ABL through negative regulation of bone marrow homing.",
        "Journal":"Leukemia",
        "Do_id":"23160449",
        "Doc_ChemicalList":"Gr-1 protein, mouse;Receptors, Chemokine;Proto-Oncogene Proteins c-cbl;Fusion Proteins, bcr-abl;Cbl protein, mouse",
        "Doc_meshdescriptors":"Animals;Bone Marrow Cells;Bone Marrow Transplantation;Cell Movement;Cells, Cultured;Fusion Proteins, bcr-abl;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mice;Mice, Inbred BALB C;Proto-Oncogene Proteins c-cbl;Receptors, Chemokine",
        "Doc_meshqualifiers":"physiology;physiology;etiology;physiology;analysis",
        "_version_":1605875332967038976},
      {
        "Doc_abstract":"Current therapies for treatment of myeloid leukemia do not eliminate leukemia stem cells (LSC), leading to disease relapse. In this study, we supplemented mice with eicosapentaenoic acid (EPA, C20:5), a polyunsaturated omega-3 fatty acid, at pharmacologic levels, to examine whether the endogenous metabolite, cyclopentenone prostaglandin delta-12 PGJ3 ((12)-PGJ3), was effective in targeting LSCs in experimental leukemia. EPA supplementation for 8 weeks resulted in enhanced endogenous production of (12)-PGJ3 that was blocked by indomethacin, a cyclooxygenase (COX) inhibitor. Using a murine model of chronic myelogenous leukemia (CML) induced by bone marrow transplantation of BCR-ABL-expressing hematopoietic stem cells, mice supplemented with EPA showed a decrease in the LSC population, and reduced splenomegaly and leukocytosis, when compared with mice on an oleic acid diet. Supplementation of CML mice carrying the T315I mutation (in BCR-ABL) with EPA resulted in a similar effect. Indomethacin blocked the EPA effect and increased the severity of BCR-ABL-induced CML and decreased apoptosis. (12)-PGJ3 rescued indomethacin-treated BCR-ABL mice and decreased LSCs. Inhibition of hematopoietic-prostaglandin D synthase (H-PGDS) by HQL-79 in EPA-supplemented CML mice also blocked the effect of EPA. In addition, EPA supplementation was effective in a murine model of acute myeloid leukemia. EPA-supplemented mice exhibited a decrease in leukemia burden and a decrease in the LSC colony-forming unit (LSC-CFU). The decrease in LSCs was confirmed through serial transplantation assays in all disease models. The results support a chemopreventive role for EPA in myeloid leukemia, which is dependent on the ability to efficiently convert EPA to endogenous COX-derived prostanoids, including (12)-PGJ3.",
        "Doc_title":"Chemopreventive Effects of Dietary Eicosapentaenoic Acid Supplementation in Experimental Myeloid Leukemia.",
        "Journal":"Cancer prevention research (Philadelphia, Pa.)",
        "Do_id":"26290393",
        "Doc_ChemicalList":"Anticarcinogenic Agents;Eicosapentaenoic Acid",
        "Doc_meshdescriptors":"Animals;Anticarcinogenic Agents;Chromatography, Liquid;Dietary Supplements;Eicosapentaenoic Acid;Flow Cytometry;HEK293 Cells;Humans;In Situ Nick-End Labeling;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mice;Mice, Inbred C57BL;Neoplastic Stem Cells;Tandem Mass Spectrometry;Transduction, Genetic;Xenograft Model Antitumor Assays",
        "Doc_meshqualifiers":"pharmacology;pharmacology;pathology;drug effects",
        "_version_":1605742052201463809},
      {
        "Doc_abstract":"We describe a rare case of sudden blast crisis of chronic myeloid leukemia that occurred after a 13-year durable remission, following allogeneic bone marrow transplantation and donor lymphocyte infusion. A 55-year-old Japanese man was diagnosed with chronic-phase chronic myeloid leukemia 24 years previously. He underwent allogeneic bone marrow transplantation 2 years after diagnosis. Although the disease recurred 6 years after transplantation, the patient achieved remission again by a donor lymphocyte infusion. Despite a 13-year durable remission, the disease later relapsed into a sudden blast crisis. Prednisolone and vincristine combined with imatinib mesylate effectively achieved a major molecular response. However, the disease relapsed repeatedly with central nervous system infiltration. Dasatinib and intrathecal methotrexate, cytarabine, and dexamethasone administration via the Ommaya reservoir controlled disease progression. Nevertheless, the disease became refractory to treatment with the emergence of a T315I Bcr-Abl gene mutation. The patient eventually died 43 months post crisis.",
        "Doc_title":"[Sudden blast crisis of chronic myeloid leukemia after a 13-year durable remission following allogeneic bone marrow transplantation and donor lymphocyte infusion].",
        "Journal":"Gan to kagaku ryoho. Cancer & chemotherapy",
        "Do_id":"24743212",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Blast Crisis;Bone Marrow Transplantation;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Lymphocyte Transfusion;Lymphocytes;Male;Middle Aged;Recurrence;Remission Induction;Time Factors;Transplantation, Homologous",
        "Doc_meshqualifiers":"therapy;therapy",
        "_version_":1605897700123869184},
      {
        "Doc_abstract":"Imatinib mesylate is currently the drug of choice for all phases of chronic myeloid leukemia (CML). Despite the initial high rates of hematological and cytogenetic responses, many patients develop resistance. We prospectively studied 40 patients with CML with primary cytogenetic resistance to imatinib mesylate. A semi-nested reverse transcriptase-PCR approach was used for amplification of the ABL kinase domain, which was then subjected to direct sequencing for the detection of point mutations. Expression of BCR-ABL transcripts was quantified using the real-time Taqman assay, and BCR-ABL gene amplification was detected using fluorescence in situ hybridization. Twelve different point mutations were detected in 18/40 (45%) patients. Five patients had mutations in the P-loop region and 13 had mutations in other regions of the BCR-ABL kinase domain. Progression-free survival at 2 years was inferior for patients with mutations compared to those without mutations (72% vs. 95%, p < 0.0045). The BCR-ABL fusion gene was over-expressed in five patients (5/18); the mean BCR-ABL/ABL ratio was 75.38 vs. 28.72 for imatinib responders, p < 0.001. Amplification of the BCR-ABL fusion gene was detected in 4/40 (10%) patients. Point mutation was the major mechanism of primary cytogenetic resistance to imatinib mesylate in the present study. Patients with mutations had inferior progression-free survival compared to those without mutations. Regular monitoring for the presence of point mutations in the ABL kinase region may identify such patients early, with an opportunity to intervene.",
        "Doc_title":"Mutations in ABL kinase domain are associated with inferior progression-free survival.",
        "Journal":"Leukemia & lymphoma",
        "Do_id":"20367437",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Pyrimidines;Imatinib Mesylate;Fusion Proteins, bcr-abl;Proto-Oncogene Proteins c-abl",
        "Doc_meshdescriptors":"Adolescent;Adult;Antineoplastic Agents;Benzamides;Binding Sites;DNA Mutational Analysis;Disease-Free Survival;Drug Resistance, Neoplasm;Female;Fusion Proteins, bcr-abl;Gene Expression Regulation, Neoplastic;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Mutation;Piperazines;Proto-Oncogene Proteins c-abl;Pyrimidines;Reverse Transcriptase Polymerase Chain Reaction;Treatment Outcome;Young Adult",
        "Doc_meshqualifiers":"therapeutic use;genetics;genetics;genetics;drug therapy;genetics;pathology;therapeutic use;genetics;therapeutic use",
        "_version_":1605749756713238528},
      {
        "Doc_abstract":"The introduction of cultured p185(BCR-ABL)-expressing (p185+) Arf (-/-) pre-B cells into healthy syngeneic mice induces aggressive acute lymphoblastic leukemia (ALL) that genetically and phenotypically mimics the human disease. We adapted this high-throughput Philadelphia chromosome-positive (Ph(+)) ALL animal model for in vivo luminescent imaging to investigate disease progression, targeted therapeutic response, and ALL relapse in living mice. Mice bearing high leukemic burdens (simulating human Ph(+) ALL at diagnosis) entered remission on maximally intensive, twice-daily dasatinib therapy, but invariably relapsed with disseminated and/or central nervous system disease. Although relapse was frequently accompanied by the eventual appearance of leukemic clones harboring BCR-ABL kinase domain (KD) mutations that confer drug resistance, their clonal emergence required prolonged dasatinib exposure. KD P-loop mutations predominated in mice receiving less intensive therapy, whereas high-dose treatment selected for T315I \"gatekeeper\" mutations resistant to all 3 Food and Drug Administration-approved BCR-ABL kinase inhibitors. The addition of dexamethasone and/or L-asparaginase to reduced-intensity dasatinib therapy improved long-term survival of the majority of mice that received all 3 drugs. Although non-tumor-cell-autonomous mechanisms can prevent full eradication of dasatinib-refractory ALL in this clinically relevant model, the emergence of resistance to BCR-ABL kinase inhibitors can be effectively circumvented by the addition of \"conventional\" chemotherapeutic agents with alternate antileukemic mechanisms of action.",
        "Doc_title":"Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia.",
        "Journal":"Blood",
        "Do_id":"21263154",
        "Doc_ChemicalList":"Antineoplastic Agents;Cdkn2a protein, mouse;Cyclin-Dependent Kinase Inhibitor p16;Pyrimidines;Thiazoles;Fusion Proteins, bcr-abl;Dasatinib",
        "Doc_meshdescriptors":"Animals;Antineoplastic Agents;Cyclin-Dependent Kinase Inhibitor p16;Dasatinib;Disease Models, Animal;Drug Evaluation, Preclinical;Drug Resistance, Neoplasm;Fusion Proteins, bcr-abl;Humans;Male;Mice;Mice, Inbred C57BL;Mice, Knockout;Mutagenesis;Mutation, Missense;Philadelphia Chromosome;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Pyrimidines;Thiazoles;Transplantation, Isogeneic",
        "Doc_meshqualifiers":"pharmacology;therapeutic use;genetics;drug effects;genetics;genetics;drug effects;drug effects;drug effects;drug therapy;genetics;therapeutic use;therapeutic use",
        "_version_":1605874420653490176},
      {
        "Doc_abstract":"Myeloproliferative disorders (MPDs), typified by robust marrow and extramedullary hematopoiesis, have a propensity to progress to acute leukemia. Although the hematopoietic stem cell (HSC) origin of MPDs was suggested over 30 years ago, only recently the HSC-specific effects of MPD molecular mutations have been investigated. The pivotal role of BCR-ABL in chronic myeloid leukemia (CML) development provided the rationale for targeted therapy, which greatly reduced mortality rates. However, BCR-ABL inhibitor-resistant CML HSCs persist that may be a reservoir for relapse. This has provided the impetus for investigating molecular mechanisms governing the production of recalcitrant HSC. Comparatively little was known about the molecular events driving BCR-ABL-negative MPDs until seminal studies revealed that a large proportion of MPD patients harbor a JAK2-activating point mutation, JAK2V617F. Although JAK2 activation appears to be central to BCR-ABL-negative MPD pathogenesis, its effects may be cell type and context specific. Recent evidence suggests that acquired mutations misdirect differentiation and survival of the MPD-initiating stem cell resulting in the production of aberrant self-renewing progenitors that subvert the microenvironment leading to leukemia stem cell generation and leukemic transformation. Thus, combined therapies targeting aberrant molecular pathways may be required to redirect miscreant MPD stem cells.",
        "Doc_title":"Miscreant myeloproliferative disorder stem cells.",
        "Journal":"Leukemia",
        "Do_id":"18923436",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Cell Differentiation;Fusion Proteins, bcr-abl;Humans;Myeloid Progenitor Cells;Myeloproliferative Disorders;Neoplastic Stem Cells",
        "Doc_meshqualifiers":"genetics;metabolism;pathology;etiology;pathology;metabolism;pathology",
        "_version_":1605822669444349952},
      {
        "Doc_abstract":"Treatment for chronic myeloid leukemia (CML) has improved substantially in the past 20 years, especially since the introduction of oral BCR-ABL inhibitors a decade ago. However, for patients to reap the benefits of BCR-ABL inhibitors, they must likely receive therapy for the remainder of their lives. In this situation, adherence to medication becomes a concern. Adherence to therapy for chronic health conditions, including CML, has been demonstrated to be poor. Studies have shown nonadherence in CML to be common in one-third or more of patients, and 100% adherence is rare. Furthermore, evidence suggests that reduced adherence to BCR-ABL inhibitors is associated with reduced efficacy and increased healthcare costs. Factors that can cause nonadherence, including dose, toxicity, time from diagnosis to prescription, and the number of concomitant medications, should be addressed and monitored by the physician. To maximize adherence, CML treatment should be individualized to the patient and simplified as appropriate.",
        "Doc_title":"Adherence to BCR-ABL inhibitors: issues for CML therapy.",
        "Journal":"Clinical lymphoma, myeloma & leukemia",
        "Do_id":"22633166",
        "Doc_ChemicalList":"Protein Kinase Inhibitors;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Fusion Proteins, bcr-abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Medication Adherence;Protein Kinase Inhibitors",
        "Doc_meshqualifiers":"antagonists & inhibitors;drug therapy;therapeutic use",
        "_version_":1605899453501276160},
      {
        "Doc_abstract":"The development of Bcr-Abl tyrosine kinase inhibitors has dramatically changed the prognosis of patients with newly diagnosed chronic myeloid leukemia (CML). Standard-dose imatinib (400 mg/day in chronic phase, 600 mg/day in advanced CML) now dominates the management of this disease, producing considerably higher hematologic, cytogenetic, and molecular response rates than seen with previous drug therapies. However, although many patients respond well to standard-dose imatinib initially, some patients do not achieve adequate levels of response or discontinue therapy because of resistance. One approach to improving treatment response with first-line imatinib may be to increase the imatinib dose (800 mg/day), although recent trial data indicate that overall increases in response rates may be modest. Newer Bcr-Abl tyrosine kinase inhibitors can induce responses in patients with all phases of imatinib-resistant CML, even those with imatinib-resistant mutations in the BCR-ABL gene. Furthermore, in initial studies, first-line dasatinib or nilotinib treatment has produced response rates that compare favorably with historical controls treated with imatinib, although confirmation is required from head-to-head clinical trials. Future clinical approaches may include drug combinations, which may allow quiescent leukemia stem cells to be eradicated. Further improvements in drug treatment for first-line CML are expected during the next few years.",
        "Doc_title":"First-line therapy for chronic myeloid leukemia: Past, present, and future.",
        "Journal":"American journal of hematology",
        "Do_id":"19306355",
        "Doc_ChemicalList":"4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide;Benzamides;Interferon-alpha;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Thiazoles;Imatinib Mesylate;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl;Dasatinib",
        "Doc_meshdescriptors":"Antineoplastic Combined Chemotherapy Protocols;Benzamides;Clinical Trials as Topic;Dasatinib;Fusion Proteins, bcr-abl;Genes, abl;Humans;Imatinib Mesylate;Interferon-alpha;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Piperazines;Protein Kinase Inhibitors;Protein-Tyrosine Kinases;Pyrimidines;Thiazoles;Treatment Outcome",
        "Doc_meshqualifiers":"standards;trends;therapeutic use;drug therapy;administration & dosage;adverse effects;therapeutic use;pharmacology;therapeutic use;antagonists & inhibitors;administration & dosage;adverse effects;pharmacology;therapeutic use;administration & dosage;adverse effects;therapeutic use",
        "_version_":1605758815842598912},
      {
        "Doc_abstract":"In a case of Philadelphia chromosome (Ph1)-negative chronic myeloid leukemia (CML) without the Y chromosome, we investigated the differences, at the molecular level, from Ph1-positive CML. Using Southern blot analysis and in situ hybridization studies, we could demonstrate a rearrangement within the breakpoint cluster region (bcr), and the location of a bcr-abl fusion gene on chromosome 22. To our knowledge, this is the first case of Ph1-negative CML with a loss of the Y chromosome in which the molecular abnormalities are shown to be identical with those in Ph1-positive CML.",
        "Doc_title":"Missing Y chromosome in Ph1-negative chronic myeloid leukemia with bcr rearrangement. Evidence for a bcr-abl recombination on chromosome 22 by in situ hybridization.",
        "Journal":"Acta haematologica",
        "Do_id":"2011934",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Chromosome Aberrations;Chromosome Disorders;Fusion Proteins, bcr-abl;Gene Rearrangement;Humans;Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative;Male;Middle Aged;Nucleic Acid Hybridization;Y Chromosome",
        "Doc_meshqualifiers":"genetics;genetics",
        "_version_":1605785283651960832},
      {
        "Doc_abstract":"A 48-year-old man, on imatinib therapy for chronic myeloid leukemia, developed bilateral retino-choroiditis. Visual acuity was 20/100 and counting fingers at 2 m in both the right and left eye. Vitreous biopsy (left eye) revealed Toxoplasma gondii genome by polymerase chain reaction. Serum anti-toxoplasma IgG levels were significantly elevated. Blood counts were normal. Bcr-Abl/Abl transcript ratio was 0.016%. He was treated with oral co-trimoxazole, to which corticosteroids in tapering doses were added later. Imatinib therapy was continued. After 6 weeks of therapy, all retinal lesions regressed and vision improved to 20/30 and 20/40 in right and left eyes, respectively.",
        "Doc_title":"Bilateral toxoplasma retinochoroiditis in a patient with chronic myeloid leukemia treated with imatinib mesylate.",
        "Journal":"Ocular immunology and inflammation",
        "Do_id":"20128654",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Immunoglobulin G;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Trimethoprim, Sulfamethoxazole Drug Combination;Imatinib Mesylate;DNA",
        "Doc_meshdescriptors":"Antineoplastic Agents;Benzamides;Chorioretinitis;DNA;Genome;Humans;Imatinib Mesylate;Immune Tolerance;Immunoglobulin G;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Toxoplasma;Toxoplasmosis, Ocular;Treatment Outcome;Trimethoprim, Sulfamethoxazole Drug Combination;Visual Acuity",
        "Doc_meshqualifiers":"adverse effects;therapeutic use;diagnosis;drug therapy;parasitology;isolation & purification;blood;drug therapy;adverse effects;therapeutic use;adverse effects;therapeutic use;adverse effects;therapeutic use;genetics;isolation & purification;diagnosis;drug therapy;immunology;therapeutic use",
        "_version_":1605818679616864258},
      {
        "Doc_abstract":"Benzoporphyrin derivative (BPD) and light is a potent photosensitizer. We investigated this modality as a means to selectively eliminate clonogenic Ph(+) chronic myeloid leukemia (CML) cells. BPD at 10 ng/ml and 10.8 J/cm2 broad spectrum light eliminates from 5 to 6 logs of Ph(+) EM-2 cells. Long-term marrow culture studies of treated mixtures of normal and CML cells indicate that multipotent progenitor cell viability is retained while cells transcribing BCR-ABL are not detected. We conclude that BPD and light may offer a means of providing CML autografts potentially free of Ph(+) clonogenic cells.",
        "Doc_title":"Photodynamic elimination of clonogenic Ph+ chronic myeloid leukemia cells.",
        "Journal":"Leukemia & lymphoma",
        "Do_id":"8251908",
        "Doc_ChemicalList":"Biomarkers, Tumor;Porphyrins;Radiation-Sensitizing Agents;benzoporphyrin D;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adult;Base Sequence;Biomarkers, Tumor;Clone Cells;Fusion Proteins, bcr-abl;Hematopoietic Stem Cells;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Molecular Sequence Data;Neoplastic Stem Cells;Photochemotherapy;Polymerase Chain Reaction;Porphyrins;Radiation Tolerance;Radiation-Sensitizing Agents;Tumor Cells, Cultured;Tumor Stem Cell Assay",
        "Doc_meshqualifiers":"biosynthesis;drug effects;radiation effects;biosynthesis;drug effects;radiation effects;drug therapy;pathology;drug effects;metabolism;radiation effects;pharmacology;pharmacology;drug effects;radiation effects",
        "_version_":1605898301510516736},
      {
        "Doc_abstract":"The BCR-ABL chimeric protein is thought to play a central role in the pathogenesis of Philadelphia (Ph) chromosome-positive leukemias, notably chronic myeloid leukemia (CML). There is compelling evidence that malignant transformation by BCR-ABL is critically dependent on its protein tyrosine kinase (PTK) activity. As a result, multiple signaling pathways are activated in a kinase-dependent manner, and thus the activation of such pathways may affect the expression of genes that confer the malignant phenotype. In this study, we used differential display to investigate the alterations of gene expression in BV173, a CML cell line derived from lymphoid blast crisis, after exposure to ST1571, which selectively inhibits ABL PTK activity. We show that the expression of a set of 12 genes is correlated with the kinase activity and that the profile of these genes reflects mechanisms implicated in the pathogenesis of CML. Several of the genes show a consistent pattern of altered regulation in all Ph-positive lymphoid cell lines, whereas others appear to be unique to BV173 cells. We conclude that BCR-ABL PTK activity drives the expression of specific target genes that contribute to the malignant transformation of Ph-positive cells. The identification of downstream molecules with a consistent regulation pattern may provide suitable targets for therapeutic intervention in the future.",
        "Doc_title":"BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia.",
        "Journal":"Cancer research",
        "Do_id":"10766197",
        "Doc_ChemicalList":"Antineoplastic Agents;Pyrimidines;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Antineoplastic Agents;Blast Crisis;Fusion Proteins, bcr-abl;Gene Expression Regulation, Neoplastic;Humans;Jurkat Cells;Kinetics;Leukemia;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Philadelphia Chromosome;Protein-Tyrosine Kinases;Pyrimidines;Reverse Transcriptase Polymerase Chain Reaction;Signal Transduction;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"toxicity;genetics;metabolism;drug effects;genetics;pathology;antagonists & inhibitors;metabolism;toxicity",
        "_version_":1605791481108365312},
      {
        "Doc_abstract":"Plasmacytoid dendritic cells (PDCs) are crucial effectors in innate immunity. In this study, we show that imatinib, a potent inhibitor of BCR/ABL tyrosine kinase activity, in the presence of Flt3-Ligand, could induce CD34+ progenitors from chronic myeloid leukemia (CML) to give rise in vitro to typical BDCA-2+ type I interferon-producing PDCs. The effect of imatinib on PDC generation was related to up-regulation of Flt3 on leukemic CD34+ progenitors. Moreover, patients with chronic myeloid leukemia (CML) who were in complete cytogenetic or molecular response after imatinib treatment restored their blood PDCs both quantitatively and functionally comparable to healthy donors, in contrast to patients not responding to imatinib, further confirming that disease response to imatinib is accompanied by restoration of PDC function in vivo. These findings provide evidence that response to imatinib is capable to restore some DC-related immune functions in CML that might be beneficial for long-term disease control.",
        "Doc_title":"Imatinib and plasmacytoid dendritic cell function in patients with chronic myeloid leukemia.",
        "Journal":"Blood",
        "Do_id":"14715630",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Pyrimidines;Imatinib Mesylate",
        "Doc_meshdescriptors":"Antineoplastic Agents;Benzamides;Dendritic Cells;Flow Cytometry;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Piperazines;Pyrimidines",
        "Doc_meshqualifiers":"therapeutic use;drug effects;physiology;blood;drug therapy;immunology;pathology;therapeutic use;therapeutic use",
        "_version_":1605792093474652160},
      {
        "Doc_abstract":"Resistance to imatinib mesylate monotherapy is clearly a barrier to successful treatment of chronic myeloid leukemia (CML) patients. In some patients, resistance arises due to powerful selective pressure on rare cells that carry amplified copies of the BCR-ABL fusion oncogene or point mutations in the Bcr-Abl tyrosine kinase domain that affect binding of the drug to the oncoprotein. However, in a proportion of patients neither mechanism operates, and resistance appears to be a priori, existing prior to exposure to the drug. These mechanisms of imatinib resistance are poorly understood and may be heterogeneous.;We have previously described such innate resistance to imatinib in subclones of a myeloid leukemia cell line, KCL22, in which imatinib exposure inhibits the activity of Bcr-Abl and yet fails to induce apoptosis. We describe here whole-genome expression analysis of imatinib-sensitive and -resistant cells derived from the original KCL22 line, using Affymetrix microarray analysis.;We detected differential expression of 39 genes that correlate with the imatinib-resistant phenotype. The resistant cells overexpress several genes associated with the suppression of apoptosis or with conferral of a transformed phenotype.;Amongst the differentially-expressed genes correlating with imatinib resistance, several suggest the activation of alternative pathway(s) that maintain viability and growth independently of Bcr-Abl kinase activity. Given the high rate of primary imatinib resistance in blast crisis, the potential of activating such alternative pathways appears to correlate with disease progression.",
        "Doc_title":"Comparative gene expression profile of chronic myeloid leukemia cells innately resistant to imatinib mesylate.",
        "Journal":"Experimental hematology",
        "Do_id":"14585372",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Pyrimidines;Imatinib Mesylate",
        "Doc_meshdescriptors":"Antineoplastic Agents;Benzamides;Cell Line, Tumor;Drug Resistance, Neoplasm;Gene Expression Profiling;Gene Expression Regulation;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Piperazines;Pyrimidines",
        "Doc_meshqualifiers":"therapeutic use;drug effects;drug therapy;genetics;therapeutic use;therapeutic use",
        "_version_":1605808878847524864},
      {
        "Doc_abstract":"The Interferon Regulatory Factor (IRF) family consists of multiple transcription factors involved in the regulation of a variety of biological processes. Originally identified as transcriptional regulators of the type I interferon system, IRFs play a pivotal role in adaptive immunity, cell growth, differentiation and tumorigenesis. Hence, understanding IRF biology has important implications in the host response to cancer development and progression. Many lines of evidence suggest that different IRFs are involved in the pathogenesis of Chronic Myeloid Leukemia (CML), a myeloproliferative disorder caused by the BCR-ABL oncoprotein. BCR-ABL displays constitutive tyrosine kinase activity that favors cell proliferation, inhibits apoptosis and allows cell survival even in the absence of proper adhesion to the extracellular matrix. Different BCR-ABL tyrosine kinase inhibitors are currently available for CML treatment. These drugs are able to generate eight year CML-specific overall survival rates >90%, only a minority of patients will achieve molecular responses compatible with drug discontinuation. Thus, there is an unmet need for additional therapeutic targets that may lead to the cure of most patients diagnosed with CML. A growing body of evidence has suggested a role for both IRF4 and IRF8 in the pathogenesis of CML. Furthermore, IRF1 is consistently deleted at one or both alleles in patients with leukemia and myelodysplasia. Finally, we have recently demonstrated that IRF5 is a target of BCR-ABL kinase activity and reduces CML cell proliferation. In this article, we provide an update on the current knowledge of the role of the IRFs in CML. ",
        "Doc_title":"Roles of Interferon Regulatory Factors in Chronic Myeloid Leukemia.",
        "Journal":"Current cancer drug targets",
        "Do_id":"26728039",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605790501994233856},
      {
        "Doc_abstract":"Imatinib mesylate has become an effective agent for the treatment of chronic myeloid leukemia (CML). However, the development of drug resistance has led to examination of combination therapies. In this study, we investigated the effects of combining imatinib with immunotherapy against a murine bcr-abl(+) leukemia, 12B1. We have previously shown that multiple chaperone proteins may be enriched into a vaccine form from tumor cell lysates by a free-solution isoelectric focusing method. We refer to these vaccines as chaperone-rich cell lysates (CRCLs) and have found that they are potent immunologic agents against a variety of murine tumors, including 12B1. We now demonstrate that the combination of imatinib with dendritic cells loaded with 12B1-derived CRCL yields high activation of anti-12B1-specific T cells and potent antitumor activity, resulting in tumor-free survival in up to 63% of mice with bcr-abl(+) 12B1 tumors. Our data suggest that immunotherapy can be effectively combined with imatinib for the treatment of CML.",
        "Doc_title":"Imatinib mesylate effectively combines with chaperone-rich cell lysate-loaded dendritic cells to treat bcr-abl+ murine leukemia.",
        "Journal":"International journal of cancer",
        "Do_id":"15069690",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Cancer Vaccines;Molecular Chaperones;Piperazines;Pyrimidines;Interferon-gamma;Imatinib Mesylate;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Animals;Antineoplastic Agents;Benzamides;Cancer Vaccines;Combined Modality Therapy;Dendritic Cells;Female;Fusion Proteins, bcr-abl;Imatinib Mesylate;Interferon-gamma;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mice;Mice, Inbred BALB C;Molecular Chaperones;Phosphorylation;Piperazines;Pyrimidines;T-Lymphocytes, Cytotoxic",
        "Doc_meshqualifiers":"therapeutic use;immunology;immunology;analysis;biosynthesis;metabolism;therapy;physiology;therapeutic use;therapeutic use;immunology",
        "_version_":1605806948446371840},
      {
        "Doc_abstract":"Inhibition of the cell mitotic pathway may provide a novel means for therapeutic intervention in chronic myeloid leukemia (CML). Kinesin spindle protein (KSP), a microtubule-associated motor protein which is essential for cell cycle progression, is overexpressed in bcr-abl+ CML cells. Retrovirus mediated bcr-abl transduction increases KSP expression in cord blood CD34 + cells. SB743921 is a selective KSP inhibitor which is being investigated in ongoing clinical trials for treatment of myeloma, leukemia and solid tumors. Treatment of CML cells with SB743921 resulted in reduced proliferation and colony forming cell (CFC) formation ability. SB743921 also actively blocked cell cycle progression, leading to apoptosis in both primary CML cells and cell lines. KSP inhibition sensitized CML cells to imatinib-induced apoptosis. Importantly, SB743921 inhibited the proliferation of various CML cells including T315I mutation-harboring cells. Furthermore, we demonstrated that SB743921 treatment suppressed ERK and AKT activity in CML cells. These data indicate that SB743921 may become a novel treatment agent for patients with CML. ",
        "Doc_title":"Kinesin spindle protein inhibitor SB743921 induces mitotic arrest and apoptosis and overcomes imatinib resistance of chronic myeloid leukemia cells.",
        "Journal":"Leukemia & lymphoma",
        "Do_id":"25146433",
        "Doc_ChemicalList":"Benzamides;Chromones;KIF11 protein, human;SB 743921;Imatinib Mesylate;Fusion Proteins, bcr-abl;Proto-Oncogene Proteins c-akt;Extracellular Signal-Regulated MAP Kinases;Kinesin",
        "Doc_meshdescriptors":"Apoptosis;Benzamides;Blotting, Western;Cell Cycle Checkpoints;Cell Line, Tumor;Cell Proliferation;Cells, Cultured;Chromones;Drug Resistance, Neoplasm;Extracellular Signal-Regulated MAP Kinases;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;K562 Cells;Kinesin;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mitosis;Proto-Oncogene Proteins c-akt;Reverse Transcriptase Polymerase Chain Reaction;Signal Transduction;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"drug effects;pharmacology;drug effects;drug effects;pharmacology;drug effects;metabolism;genetics;pharmacology;antagonists & inhibitors;genetics;metabolism;drug therapy;genetics;pathology;drug effects;metabolism;drug effects",
        "_version_":1605896678313820160},
      {
        "Doc_abstract":"The t(9;22)(q34;q11) translocation is present in 90-95% of patients with chronic myeloid leukemia (CML). Variant complex translocations have been observed in 5-8% of CML patients, in which a third chromosome other than (9;22) is involved. Imatinib mesylate is the first line breakpoint cluster region-Abelson gene (BCR/ABL)-targeted oral therapy for CML, and may produce a complete response in 70-80% of CML patients in the chronic phase. In the present study, a bone marrow sample was used for conventional cytogenetic analysis, and the fluorescence ",
        "Doc_title":"A rare case of a three way complex variant positive Philadelphia translocation involving chromosome (9;11;22)(q34;p15;q11) in chronic myeloid leukemia: A case report.",
        "Journal":"Oncology letters",
        "Do_id":"27602125",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605880600921636864},
      {
        "Doc_abstract":"Dasatinib is an oral, potent adenosine triphosphate-competitive inhibitor of multiple tyrosine kinases including BCR-ABL, c-KIT, platelet-derived growth factor receptor, and Src family kinases (SFKs). It has gained much attention for its use in chronic myeloid leukemia and for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia. However, dasatinib is also being explored in solid tumors in ongoing Phase I and II clinical trials.;The clinical efficacy of dasatinib in a wide variety of solid tumors and important Phase I/II studies utilizing dasatinib and the optimal dosage used in solid tumors. A literature search was conducted using PubMed/MEDLINE, www.clinicaltrials.gov , and the American Society of Clinical Oncology websites to find relevant Phase I/II clinical trials during 1987-2009.;The understanding that the biology and mechanism of Src activation in tumors are not well understood and finding the optimal use of SFK inhibitors in the clinical setting requires further investigation.;In reviewing the clinical safety data of dasatinib in its current use as a Src inhibitor in a wide variety of solid malignancies, dasatinib appears to be safe and is a promising agent for the treatment of metastatic solid tumors refractory to standard therapies.",
        "Doc_title":"Dasatinib in solid tumors.",
        "Journal":"Expert opinion on investigational drugs",
        "Do_id":"20113198",
        "Doc_ChemicalList":"Protein Kinase Inhibitors;Pyrimidines;Thiazoles;src-Family Kinases;Dasatinib",
        "Doc_meshdescriptors":"Adult;Clinical Trials, Phase I as Topic;Clinical Trials, Phase II as Topic;Dasatinib;Humans;Neoplasm Metastasis;Neoplasms;Protein Kinase Inhibitors;Pyrimidines;Thiazoles;src-Family Kinases",
        "Doc_meshqualifiers":"drug therapy;physiopathology;adverse effects;pharmacology;therapeutic use;adverse effects;pharmacology;therapeutic use;adverse effects;pharmacology;therapeutic use;antagonists & inhibitors;metabolism",
        "_version_":1605850523026587648},
      {
        "Doc_abstract":"Ponatinib is a BCR-ABL tyrosine kinase inhibitor (TKI) approved for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia in patients resistant or intolerant to prior TKIs. In vitro studies suggested that metabolism of ponatinib is partially mediated by CYP3A4. The effects of CYP3A4 inhibition on the pharmacokinetics of ponatinib and its CYP3A4-mediated metabolite, AP24567, were evaluated in a single-center, randomized, two-period, two-sequence crossover study in healthy volunteers. Subjects (N = 22) received two single doses (orally) of ponatinib 15 mg, once given alone and once coadministered with daily (5 days) ketoconazole 400 mg, a CYP3A4 inhibitor. Ponatinib plus ketoconazole increased ponatinib maximum plasma concentration (C(max)) and area under the concentration-time curve (AUC) compared with ponatinib alone. The estimated mean ratios for AUC0-, AUC0-t, and C(max) indicated increased exposures to ponatinib of 78%, 70%, and 47%, respectively; exposure to AP24567 decreased by 71%. Exposure to AP24567 was marginal after ponatinib alone (no more than 4% of the exposure to ponatinib). These results suggest that caution should be exercised with the concurrent use of ponatinib and strong CYP3A4 inhibitors and that a ponatinib dose decrease to 30 mg daily, from the 45 mg daily starting dose, could be considered.",
        "Doc_title":"Effects of ketoconazole on the pharmacokinetics of ponatinib in healthy subjects.",
        "Journal":"Journal of clinical pharmacology",
        "Do_id":"23801357",
        "Doc_ChemicalList":"Cytochrome P-450 CYP3A Inhibitors;Enzyme Inhibitors;Imidazoles;Pyridazines;ponatinib;CYP3A4 protein, human;Cytochrome P-450 CYP3A;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl;Ketoconazole",
        "Doc_meshdescriptors":"Adult;Area Under Curve;Biological Availability;Cross-Over Studies;Cytochrome P-450 CYP3A;Cytochrome P-450 CYP3A Inhibitors;Drug Interactions;Enzyme Inhibitors;Fusion Proteins, bcr-abl;Humans;Imidazoles;Ketoconazole;Male;Middle Aged;Protein-Tyrosine Kinases;Pyridazines;Young Adult",
        "Doc_meshqualifiers":"administration & dosage;blood;pharmacokinetics;antagonists & inhibitors;administration & dosage;blood;pharmacokinetics;administration & dosage;antagonists & inhibitors;administration & dosage;blood;pharmacokinetics",
        "_version_":1605902926367162368},
      {
        "Doc_abstract":"The gene encoding c-ABL, a nonreceptor protein tyrosine kinase, is involved in a chromosomal translocation resulting in expression of a BCR-Abl fusion protein that causes most chronic myelogenous and some acute lymphocytic leukemias (CML and ALL) in humans. The Abelson murine leukemia virus (A-MuLV) expresses an alternative form of c-Abl, v-Abl, that transforms murine pro-B cells, resulting in acute leukemia and providing an experimental model for human disease. Gleevec (STI571) inhibits the Abl kinase and has shown great utility against CML and ALL in humans, although its usefulness is limited by acquired resistance. Since STI571 is active against A-MuLV-transformed cells in vitro, we performed a retroviral cDNA library screen for genes that confer resistance to apoptosis induced by STI571. We found that forced expression of Cdk6 promotes continued cell division and decreased apoptosis of leukemic cells. We then determined that the transcription factor E2A negatively regulates Cdk6 transcription in leukemic pro-B cells and that the v-Abl kinase stimulates Cdk6 expression via an extracellular signal-regulated kinase 1-dependent pathway. Finally, we show that the cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor PD0332991 can act synergistically with STI571 to enhance leukemic cell death, suggesting a potential role for CDK6 inhibitors in the treatment of STI571-resistant CML or ALL.",
        "Doc_title":"Forced expression of cyclin-dependent kinase 6 confers resistance of pro-B acute lymphocytic leukemia to Gleevec treatment.",
        "Journal":"Molecular and cellular biology",
        "Do_id":"21536647",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Protein Kinase Inhibitors;Pyridines;Pyrimidines;Imatinib Mesylate;CDK6 protein, human;Cyclin-Dependent Kinase 6;palbociclib",
        "Doc_meshdescriptors":"Antineoplastic Agents;Benzamides;Cell Cycle;Cell Line, Tumor;Cyclin-Dependent Kinase 6;Drug Resistance, Neoplasm;Gene Library;Humans;Imatinib Mesylate;Piperazines;Precursor B-Cell Lymphoblastic Leukemia-Lymphoma;Protein Kinase Inhibitors;Pyridines;Pyrimidines;Transcription, Genetic",
        "Doc_meshqualifiers":"therapeutic use;antagonists & inhibitors;genetics;genetics;pharmacology;therapeutic use;drug therapy;enzymology;therapeutic use;pharmacology;therapeutic use",
        "_version_":1605798346530750464},
      {
        "Doc_abstract":"Recent reports have shown that upon expression of appropriate oncogenes, both stem cells and more differentiated progenitor populations can serve as leukemia-initiating cells. These studies suggest that oncogenic mutations subvert normal development and induce reacquisition of stem-like features. However, no study has described how specific mutations influence the ability of differentiating cell subsets to serve as leukemia-initiating cells and if varying such cellular origins confers a functional difference. We have examined the role of the tumor suppressor gene p19(ARF) in a murine model of acute lymphoblastic leukemia and found that loss of p19(ARF) changes the spectrum of cells capable of tumor initiation. With intact p19(ARF), only hematopoietic stem cells (HSCs) can be directly transformed by BCR/ABL expression. In a p19(ARF)-null genetic background expression of the BCR/ABL fusion protein renders functionally defined HSCs, common lymphoid progenitors (CLP), and precursor B-lymphocytes competent to generate leukemia stem cells. Furthermore, we show that leukemias arising from p19(ARF)-null HSC versus pro-B cells differ biologically, including relative response to drug insult. Our observations elucidate a unique mechanism by which heterogeneity arises in tumor populations harboring identical genetic lesions and show that activity of p19(ARF) profoundly influences the nature of tumor-initiating cells during BCR/ABL-mediated leukemogenesis.",
        "Doc_title":"The biologic properties of leukemias arising from BCR/ABL-mediated transformation vary as a function of developmental origin and activity of the p19ARF gene.",
        "Journal":"Blood",
        "Do_id":"18755985",
        "Doc_ChemicalList":"Cdkn2a protein, mouse;Cyclin-Dependent Kinase Inhibitor p16;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Animals;Cell Transformation, Neoplastic;Cyclin-Dependent Kinase Inhibitor p16;Disease Models, Animal;Fusion Proteins, bcr-abl;Lymphoid Progenitor Cells;Mice;Mice, Transgenic;Precursor Cell Lymphoblastic Leukemia-Lymphoma",
        "Doc_meshqualifiers":"genetics;metabolism;pathology;genetics;metabolism;genetics;metabolism;metabolism;pathology;genetics;metabolism;pathology",
        "_version_":1605820248452235264},
      {
        "Doc_abstract":"Various clinical observations have implicated T cells in the control of chronic myeloid leukemia (CML). These observations have in recent years been supported by laboratory results indicating the presence of CML-specific T cells in the lymphocyte repertoire of both normal healthy individuals and disease-bearing patients. Both MHC-unrestricted and MHC-restricted immune effector mechanisms are involved. Donor lymphocyte infusion has produced encouraging GvL effects. However, future adoptive immunotherapy may depend on the isolation and generation of leukemia-specific T cells. Although many proteins may potentially act as leukemia antigens in CML for MHC-restricted cytotoxicity, the bcr-abl fusion protein has been most extensively investigated. There is now much evidence to suggest that the bcr-abl junctional peptides are capable of eliciting both CD4 and CD8 responses in normal healthy donors and CML patients. Furthermore, the T-cell lines generated react with autologous or HLA-matched fresh CML cells, suggesting that the bcr-abl fusion protein can be processed in vivo so that the joining segment is bound to HLA molecules in a configuration and concentration similar to those of the immunizing peptide for antigen recognition by the antigen-specific T-cell receptor. These results also indicate that the bcr-abl junctional peptides may be used for immunotherapy of CML. Other strategies available for immunotherapy of CML include immunologically or genetically manipulated donor T-cell infusion, the use of cytokines, adoptive immunotherapy with leukemia-reactive T-cells expanded ex vivo, and immune gene therapy. Novel and rational immunotherapy may therefore play an important adjuvant role in future in the management of patients with CML.",
        "Doc_title":"Chronic myeloid leukemia as an immunological target.",
        "Journal":"American journal of hematology",
        "Do_id":"8980262",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"CD4-Positive T-Lymphocytes;CD8-Positive T-Lymphocytes;Cytotoxicity, Immunologic;Fusion Proteins, bcr-abl;Humans;Immunity, Cellular;Immunotherapy;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Major Histocompatibility Complex;T-Lymphocytes",
        "Doc_meshqualifiers":"immunology;immunology;immunology;immunology;therapy;immunology",
        "_version_":1605820291528785920},
      {
        "Doc_abstract":"Treatment options for chronic myeloid leukemia (CML) are discussed.;In the 1980s busulfan and hydroxyurea were the standards of care. These were subsequently replaced by interferon alpha (IFN alpha) based therapy. Currently, bone marrow transplant survival has improved, making this also a viable option. Five-year progression-free survival averaged above 70% for chemotherapeutic options. Transplant survival at 56 months was approximately 60%; however, these survivors were generally cured of disease. The recognition of the role for BCR-ABL in CML has led to the development of specific kinase inhibitors such as imatinib. Clinical trial evidence has demonstrated a clear superiority of imatinib over interferon plus cytarabine, making this the new standard of care in first-line treatment of CML. Resistance to imatinib has been observed, in addition to relapse. The data suggest that the probability of response may be estimated as early as six months after initiation of imatinib therapy. Although combinations of imatinib with IFN alpha show small improvements compared to imatinib therapy alone, the biggest improvements were seen when imatinib doses were doubled. Unfortunately, not all patients can tolerate this increase in dose. The most common mechanism for imatinib resistance is the presence of a mutated BCR-ABL kinase. Several of these mutants have been cloned and characterized.;Molecular-targeted BCR-ABL kinase inhibitors, such as imatinib, are now first-line treatment for CML. Allogeneic stem cell transplant is still the only proven curable treatment for CML in patients with an appropriate donor. Next generation BCR-ABL kinase inhibitors hold promise for patients with mutated BCR-ABL kinase that confer resistance to imatinib.",
        "Doc_title":"Chronic myeloid leukemia: standard treatment options.",
        "Journal":"American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists",
        "Do_id":"17106015",
        "Doc_ChemicalList":"Interferon-alpha;Protein Kinase Inhibitors;Hydroxyurea",
        "Doc_meshdescriptors":"Drug Therapy;Humans;Hydroxyurea;Interferon-alpha;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Protein Kinase Inhibitors;Stem Cell Transplantation;Survival Analysis",
        "Doc_meshqualifiers":"methods;trends;therapeutic use;therapeutic use;diagnosis;therapy;therapeutic use;methods;trends",
        "_version_":1605762173677600768},
      {
        "Doc_abstract":"Chromosomal rearrangements in childhood acute lymphoblastic leukemia (ALL) play an important role in the identification of clinical relevant subgroups. For rapid and easy detection of the clinically most important gene rearrangements, a nested multiplex reverse transcriptase polymerase chain reaction (multiplex PCR) was developed. This multiplex PCR enables the detection of M-BCR/ABL, m-BCR/ABL, TEL/ AML1, and MLL/AF4 fusion transcripts in one PCR reaction. However, the existence of splicing variants and different breakpoints on the DNA level hampers the discrimination of the rearrangements by their fragment size on an agarose gel. Therefore, one of the internal primers of each translocation (ABL-2, TEL-2, AF4-2) was labeled with a characteristic fluorescent dye, and an automatic fluorescence-based DNA fragment analysis was performed. The sensitivity of this multiplex PCR is in the same range as that of the corresponding single PCR reaction and allows a fast screening for the detection of therapy-relevant rearrangements, with a high turnover of samples.",
        "Doc_title":"Multiplex PCR--a rapid screening method for detection of gene rearrangements in childhood acute lymphoblastic leukemia.",
        "Journal":"Annals of hematology",
        "Do_id":"10348146",
        "Doc_ChemicalList":"DNA Primers",
        "Doc_meshdescriptors":"Base Sequence;Child;Child, Preschool;DNA Primers;Humans;K562 Cells;Polymerase Chain Reaction;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Reverse Transcriptase Polymerase Chain Reaction",
        "Doc_meshqualifiers":"methods;genetics",
        "_version_":1605807475670384640},
      {
        "Doc_abstract":"Acute megakaryoblastic leukemia (AMKL) is a type of acute myeloid leukemia (AML), in which majority of the blasts are megakaryoblastic. De novo AMKL in adulthood is rare, and carries very poor prognosis. We here report a 45-year-old woman with de novo AMKL with BCR/ABL rearrangement and der(16)t(1;16)(q21;q23) translocation but negative for t(9;22) Ph chromosome. Upon induction chemotherapy consisting of homoharringtonine, cytarabine and daunorubicin, the patient achieved partial hematological remission. The patient was then switched to imatinib plus one cycle of CAG regimen (low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor), and achieved complete remission (CR). The disease recurred after 40 days and the patient eventually died of infection. To the best of our knowledge, this is the first report of de novo AMKL with p210 BCR/ABL and der(16)t(1;16)(q21;q23) translocation but not t(9;22) Ph chromosome.",
        "Doc_title":"De novo acute megakaryoblastic leukemia with p210 BCR/ABL and t(1;16) translocation but not t(9;22) Ph chromosome.",
        "Journal":"Journal of hematology & oncology",
        "Do_id":"22075327",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Antineoplastic Combined Chemotherapy Protocols;Chromosomes, Human, Pair 1;Chromosomes, Human, Pair 16;Chromosomes, Human, Pair 22;Chromosomes, Human, Pair 9;Female;Fusion Proteins, bcr-abl;Humans;Leukemia, Megakaryoblastic, Acute;Middle Aged;Translocation, Genetic",
        "Doc_meshqualifiers":"therapeutic use;genetics;drug therapy;genetics",
        "_version_":1605893861113069568},
      {
        "Doc_abstract":"Chronic myeloid leukemia is a clonal myeloproliferative expansion of transformed primitive hematopoietic progenitor cells characterized by high-level expression of BCR-ABL chimeric gene, which induces growth factor independence. However, the influence of BCR-ABL expression on cell-mediated cytotoxicity is poorly understood. In the present study, we asked whether BCR-ABL expression interferes with leukemic target sensitivity to natural killer (NK) cell cytolysis. Our approach was based on the use of 2 BCR-ABL transfectants of the pluripotent hematopoietic cell line UT-7 expressing low (UT-7/E8, UT-7/G6) and high (UT-7/9) levels of BCR-ABL. As effector cells, we used CD56(bright), CD16-, CD2- NK cells differentiated in vitro from CD34 cord blood progenitors. We demonstrated that BCR-ABL transfectants UT-7/9 were lysed by NK cells with a higher efficiency than parental and low UT-7/E8.1 and UT-7/G6 transfectants. This enhanced susceptibility to lysis correlated with an increase in expression of intercellular adhesion molecule 1 (ICAM-1) by target cells. Treatment of UT-7/9 cells by STI571 (a specific inhibitor of the abl kinase) resulted in a decrease in NK susceptibility to lysis and ICAM-1 down-regulation in target cells. Furthermore, the constitutive activation of nuclear factor-kappaB (NF-kappaB) detected in BCR-ABL transfectant UT-7/9, was significantly attenuated when cells were treated by STI571. Interestingly, inhibition of NF-kappaB activation by BAY11-67082 (a specific NF-kappaB inhibitor) resulted in down-regulation of ICAM-1 expression and a subsequent decrease in NK-induced killing of UT-7/9 transfectants. Our results show that oncogenic transformation by BCR-ABL may increase susceptibility of leukemic progenitors to NK cell cytotoxicity by a mechanism involving overexpression of ICAM-1 as a consequence of NF-kappaB activation.",
        "Doc_title":"Leukemic target susceptibility to natural killer cytotoxicity: relationship with BCR-ABL expression.",
        "Journal":"Blood",
        "Do_id":"11877286",
        "Doc_ChemicalList":"Antigens, CD34;NF-kappa B;Intercellular Adhesion Molecule-1;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Antigens, CD34;Cell Differentiation;Cytotoxicity, Immunologic;Fetal Blood;Fusion Proteins, bcr-abl;Hematopoietic Stem Cells;Humans;Intercellular Adhesion Molecule-1;Killer Cells, Natural;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;NF-kappa B;Transfection;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"drug effects;immunology;cytology;genetics;metabolism;pharmacology;cytology;drug effects;immunology;metabolism;cytology;immunology;immunology;pathology;immunology;metabolism;pharmacology",
        "_version_":1605746824806662146},
      {
        "Doc_abstract":"The role of T lymphocytes in the control of chronic myeloid leukemia (CML) after bone marrow transplantations has been clearly shown. This effect closely correlates with graft-versus-host disease (GVHD). A specific graft-versus-leukemia (GVL) effect separate from GVHD has been postulated but has been difficult to show. One possible target for specific GVL activity is the bcr-abl fusion protein characteristic of CML. We have investigated the use of normal peptide-pulsed dendritic cells for the generation of cytotoxic, bcr-abl-specific T cells from normal donors. T cells (CD3+, CD8+, TCR alpha beta+, and NK receptor-negative) generated from a normal donor (HLA A24, B52, B59, Cw1) after stimulation with autologous dendritic cells, primed with a 16 mer peptide spanning the b3a2 breakpoint of bcr-abl, lysed CML cells from the peripheral blood of seven patients with CML with the b3a2 breakpoint. CML cells from four patients with only the b2a2 breakpoint were not lysed. Phytohemagglutinin (PHA) blasts derived from peripheral blood of patients with CML were not lysed, suggesting that cytotoxicity was not due to alloreactivity. Blocking experiments with anti-HLA-A,B,C indicated that cytotoxicity was dependent on recognition of major histocompatibility complex (MHC) class I molecules, although cytotoxicity was not MHC-restricted because not all patients shared HLA types with the T-cell donor. Specificity for bcr-abl and absence of alloreactivity was confirmed by the presence of lytic activity against autologous and allogeneic class I HLA-A matched monocytes pulsed with the 16 mer bcr-abl fusion peptide, but not against unpulsed monocytes or monocytes pulsed with other peptides. These results show that bcr-abl-specific T cells with marked cytotoxic activity against CML cells can be generated and amplified from normal donor peripheral blood. Recognition of HLA molecules is essential for cytotoxicity but strict HLA identity is not required.",
        "Doc_title":"Dendritic cells stimulate the expansion of bcr-abl specific CD8+ T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia.",
        "Journal":"Blood",
        "Do_id":"9446659",
        "Doc_ChemicalList":"Antigens;HLA-A Antigens;Histocompatibility Antigens Class I;Phytohemagglutinins;Interferon-gamma;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Antigens;CD8-Positive T-Lymphocytes;Cytotoxicity, Immunologic;Dendritic Cells;Fusion Proteins, bcr-abl;Graft vs Host Reaction;HLA-A Antigens;Histocompatibility Antigens Class I;Humans;Interferon-gamma;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Phytohemagglutinins",
        "Doc_meshqualifiers":"immunology;immunology;immunology;immunology;immunology;immunology;immunology;pharmacology;immunology;pharmacology",
        "_version_":1605796721873387520},
      {
        "Doc_abstract":"Upon analyzing 696 childhood B-cell precursor acute lymphoblastic leukemia (BCP-ALL) cases, we identified the characteristics of CD66c expression. In addition to the confirmation of strong correlation with BCR-ABL positivity and hyperdiploid, we further observed that CD66c is frequently expressed in CRLF2-positive (11/15, p<0.01 against chimeric gene-negative) as well as hypodiploid cases (3/4), whereas it is never expressed in ETV6-RUNX1, MLL-AF4, MLL-AF9, MLL-ENL, and E2A-PBX1-positive cases. Although the expression of CD66c itself is not directly linked to the prognosis, the accompanying genetic abnormalities are important prognostic factors for BCP-ALL, indicating the importance of CD66c expression in the initial diagnosis of BCP-ALL. ",
        "Doc_title":"Significance of CD66c expression in childhood acute lymphoblastic leukemia.",
        "Journal":"Leukemia research",
        "Do_id":"24231528",
        "Doc_ChemicalList":"Antigens, CD;CEACAM6 protein, human;CRLF2 protein, human;Cell Adhesion Molecules;Core Binding Factor Alpha 2 Subunit;GPI-Linked Proteins;Homeodomain Proteins;MLL-AF4 fusion protein, human;MLL-AF9 fusion protein, human;MLL-ENL oncoprotein, human;Oncogene Proteins, Fusion;Receptors, Cytokine;TEL-AML1 fusion protein;E2A-Pbx1 fusion protein;Myeloid-Lymphoid Leukemia Protein;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adolescent;Antigens, CD;Cell Adhesion Molecules;Child;Child, Preschool;Core Binding Factor Alpha 2 Subunit;Female;Flow Cytometry;Fusion Proteins, bcr-abl;GPI-Linked Proteins;Gene Expression Regulation, Neoplastic;Homeodomain Proteins;Humans;Infant;Infant, Newborn;Male;Myeloid-Lymphoid Leukemia Protein;Oncogene Proteins, Fusion;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Prognosis;Receptors, Cytokine;Reverse Transcriptase Polymerase Chain Reaction",
        "Doc_meshqualifiers":"metabolism;metabolism;genetics;genetics;metabolism;genetics;genetics;genetics;genetics;metabolism;pathology;metabolism",
        "_version_":1605808957837803520},
      {
        "Doc_abstract":"Chronic myeloid leukemia is a clonal multilineage myeloproliferative disease of stem cell origin characterized by the presence of the Bcr/Abl oncoprotein, a constitutively active tyrosine kinase. In previous studies, we have provided evidence that Bcr/Abl overexpression in leukemic cells increased their susceptibility to NK-mediated lysis by different mechanisms. In the present study, using UT-7/9 cells, a high level Bcr/Abl transfectant of UT-7 cells, we show that the treatment of Bcr/Abl target by imatinib mesylate (IM), a specific Abl tyrosine kinase inhibitor, hampers the formation of the NK/target immunological synapse. The main effect of IM involves an induction of surface GM1 ganglioside on Bcr/Abl transfectants that prevents the redistribution of MHC-related Ag molecules in lipid rafts upon interaction with NK cells. IM also affects cell surface glycosylation of targets, as assessed by binding of specific lectins resulting in the subsequent modulation of their binding to lectin type NK receptor, particularly NKG2D. In addition, we demonstrate that the tyrosine kinase activity repression results in a decrease of MHC-related Ags-A/B and UL-16-binding protein expression on Bcr/Abl transfectants UT-7/9. We show that NKG2D controls the NK-mediated lysis of UT-7/9 cells, and IM treatment inhibits this activating pathway. Taken together, our results show that the high expression of Bcr/Abl in leukemic cells controls the expression of NKG2D receptor ligands and membrane GM1 via a tyrosine kinase-dependent mechanism and that the modulation of these molecules by IM interferes with NK cell recognition and cytolysis of the transfectants.",
        "Doc_title":"The decreased susceptibility of Bcr/Abl targets to NK cell-mediated lysis in response to imatinib mesylate involves modulation of NKG2D ligands, GM1 expression, and synapse formation.",
        "Journal":"Journal of immunology (Baltimore, Md. : 1950)",
        "Do_id":"16393970",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Histocompatibility Antigens Class I;KLRK1 protein, human;MHC class I-related chain A;MICB antigen;NK Cell Lectin-Like Receptor Subfamily K;Piperazines;Pyrimidines;Receptors, Immunologic;Receptors, Natural Killer Cell;G(M1) Ganglioside;Imatinib Mesylate;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Antineoplastic Agents;Benzamides;Cell Line, Tumor;Cytotoxicity, Immunologic;Fusion Proteins, bcr-abl;G(M1) Ganglioside;Genes, abl;Histocompatibility Antigens Class I;Humans;Imatinib Mesylate;In Vitro Techniques;Killer Cells, Natural;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Membrane Microdomains;NK Cell Lectin-Like Receptor Subfamily K;Piperazines;Pyrimidines;Receptors, Immunologic;Receptors, Natural Killer Cell;Transfection",
        "Doc_meshqualifiers":"pharmacology;antagonists & inhibitors;metabolism;metabolism;genetics;metabolism;immunology;metabolism;drug therapy;enzymology;genetics;immunology;drug effects;metabolism;pharmacology;pharmacology;metabolism",
        "_version_":1605892825436651520},
      {
        "Doc_abstract":"A novel Philadelphia (Ph) variant translocation, t(Y;9;22)(q12;q34;q11), was detected in a 63-year-old man with a newly diagnosed chronic myeloid leukemia (CML). Reverse transcription polymerase chain reaction (RT-PCR) analysis revealed a b3a2 fusion transcript. Fluorescence in situ hybridization (FISH) utilizing library probes, subtelomeric cosmid probes, and probes hybridizing to the ABL and BCR genes showed a reciprocal three-way translocation involving Yq12, 9q34, and 22q11, and a BCR-ABL fusion signal on der(22). The subtelomeric Yq probe hybridizing centromerically to the IL9 receptor gene and covering the centromeric portion of the SYBL1 gene was found to be translocated to der(9).",
        "Doc_title":"Novel Philadelphia variant t(Y;9;22)(q12;q34;q11) in a case of chronic myeloid leukemia.",
        "Journal":"Cancer genetics and cytogenetics",
        "Do_id":"10549273",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adult;Aged;Bone Marrow Cells;Child, Preschool;Chromosomes, Human, Pair 22;Chromosomes, Human, Pair 9;Fusion Proteins, bcr-abl;Genetic Variation;Humans;In Situ Hybridization, Fluorescence;Karyotyping;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Philadelphia Chromosome;Y Chromosome",
        "Doc_meshqualifiers":"metabolism;pathology;genetics;genetics;genetics;genetics;genetics;pathology;genetics",
        "_version_":1605785417045508096},
      {
        "Doc_abstract":"The study was purposed to explore the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) combined with Imatinib for treatment of Philadelphia chromosome positive acute lymphoblastic leukemia (Ph(+)ALL) patients. From 2007 to 2008, 3 patients with Ph(+)ALL were treated with allogeneic hematopoietic stem cell transplantation and Imatinib, and the follow-up ended at Oct 21(st) 2009. 1 patient received HSCT from matched sibling donor and 2 patients from haploidentical related donors. All 3 patients achieved complete remission before transplantation and were treated with Imatinib for distinct time at different periods before and/or after transplantation. The level of bcr/abl mRNA was monitored using real-time PCR. The results showed that all 3 patients achieved stable engraftments without severe transplantation related complications. The level of bcr/abl mRNA declined and achieved zero level finally. In conclusion, the allo-HSCT combined with Imatinib is an effective therapy regimen for Ph(+)ALL patients.",
        "Doc_title":"[Allogeneic hematopoietic stem cell transplantation combined with imatinib for treatment of Philadelphia chromosome positive acute lymphoblastic leukemia].",
        "Journal":"Zhongguo shi yan xue ye xue za zhi",
        "Do_id":"20137141",
        "Doc_ChemicalList":"Benzamides;Piperazines;Pyrimidines;Imatinib Mesylate",
        "Doc_meshdescriptors":"Adolescent;Adult;Benzamides;Combined Modality Therapy;Hematopoietic Stem Cell Transplantation;Humans;Imatinib Mesylate;Male;Piperazines;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Pyrimidines;Transplantation, Homologous;Treatment Outcome",
        "Doc_meshqualifiers":"therapeutic use;therapy;therapeutic use",
        "_version_":1605759176974270464},
      {
        "Doc_abstract":"A multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) assay for both major forms of BCR-ABL was compared with fluorescence in situ hybridization (FISH), karyotyping, and Southern blotting for disease monitoring in 37 follow-up bone marrow samples from 32 patients with Ph1-positive leukemia. Of these 37 samples, 33 were from patients with chronic myeloid leukemia (CML) (26 post allogeneic bone marrow transplantation [AlloBMT] and seven during interferon-alpha therapy) and 4 from Ph1-positive acute lymphoblastic leukemia (ALL) patients (1 post AlloBMT and 3 post high dose chemotherapy). For the 27 samples studied after AlloBMT (26 CML and 1 Ph1-positive ALL) the time after transplantation ranged from 1 to 107 months (median 47.5 months). In 8 (22%) of the 37 samples there were discrepant results among methods. The discrepancy rates relative to other techniques were: karyotyping 17% (5 of 29), Southern blotting 18% (6 of 33), multiplex RT-PCR 8% (3 of 37), and FISH 8% (3 of 37). Therefore, the relative accuracy of each method for disease monitoring in Ph1-positive leukemia was: 83% (24 of 29) for karyotyping, 82% (27 of 33) for Southern blotting, 92% (34 of 37) for FISH, and 92% (34 of 37) for multiplex RT-PCR. This multiplex RT-PCR assay appears equivalent to FISH in terms of accuracy, simplicity, and turnaround time and both are superior to Southern blot and conventional cytogenetics in the laboratory monitoring of Ph1-positive leukemias.",
        "Doc_title":"Comparison of a multiplex reverse transcriptase-polymerase chain reaction for BCR-ABL to fluorescence in situ hybridization, Southern blotting, and conventional cytogenetics in the monitoring of patients with Ph1-positive leukemias.",
        "Journal":"Diagnostic molecular pathology : the American journal of surgical pathology, part B",
        "Do_id":"11129444",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adolescent;Adult;Blotting, Southern;Child;Cytogenetic Analysis;Female;Genes, abl;Humans;In Situ Hybridization, Fluorescence;K562 Cells;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Reverse Transcriptase Polymerase Chain Reaction;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"genetics;genetics",
        "_version_":1605796260910989312},
      {
        "Doc_abstract":"The potency of Abelson (ABL) tyrosine kinase inhibitors (TKIs) against chronic myeloid leukemia (CML) has been demonstrated. However, ABL TKI resistance can develop. In this study, we investigated the efficacy of a combination therapy including rigosertib (ON 01910.Na), a polo-like kinase (PLK) and phosphoinositide 3-kinase (PI3K) inhibitor, and ABL TKIs. A 72-h rigosertib treatment was found to inhibit cell growth, induce apoptosis, reduce phosphorylation of the breakpoint cluster region-c (BCR)-ABL and its substrate Crk-L, and increase the activities of caspase 3 and poly (ADP-ribose) polymerase (PARP). This combination therapy also exerted a synergistic inhibitory effect on Philadelphia chromosome (Ph)-positive cell proliferation and reduced the phosphorylation of BCR-ABL and Crk-L while increasing that of cleaved PARP and the H2A.X histone. Rigosertib also potently inhibited the growth of ABL TKI-resistant cells, and cotreatment with ABL TKIs and rigosertib induced higher cytotoxicity. These results indicate that rigosertib treatment may be a powerful strategy against ABL TKI-resistant cells and could enhance the cytotoxic effects of ABL TKIs.",
        "Doc_title":"Efficacy of the polo-like kinase inhibitor rigosertib, alone or in combination with Abelson tyrosine kinase inhibitors, against break point cluster region-c-Abelson-positive leukemia cells.",
        "Journal":"Oncotarget",
        "Do_id":"26008977",
        "Doc_ChemicalList":"ON 01910;Protein Kinase Inhibitors;Sulfones;Glycine",
        "Doc_meshdescriptors":"Apoptosis;Cell Line, Tumor;Cell Proliferation;Glycine;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Protein Kinase Inhibitors;Sulfones;Transfection",
        "Doc_meshqualifiers":"administration & dosage;analogs & derivatives;therapeutic use;drug therapy;administration & dosage;therapeutic use;administration & dosage;therapeutic use",
        "_version_":1605789622454976512},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML), a hematopoietic stem cell disorder, which sometimes presents with fatigue, hepato-splenomegaly, and weight loss but is sometimes asymptomatic, is discussed.;Diagnosis is suspected on the observation of an increased white blood cell count and is confirmed by the presence of the Philadelphia (Ph) chromosome. CML progresses through a series of three defined stages with survival times of 3-5 years if untreated. The chromosomal translocation creating the Ph chromosome creates the BCR-ABL fusion protein, which is the initiating factor for CML. BCR-ABL is a constitutively active tyrosine kinase, which transforms hematopoietic stem cells through dysregulation of proliferation, apoptosis, differentiation, and cell adhesion. The transformation process is then accelerated by the accumulation of additional translocations. This fusion protein has been used clinically as a therapeutic target and a sensitive marker for measuring residual disease. Techniques, such as cytogenetic analysis of chromosomes, allow for the visualization of the Ph chromosome and additional translocations and abnormalities. The more sensitive fluorescent in situ hybridization assay can directly visualize the bcr-abl translocation through merged fluorescent tags. Polymerase chain reaction, the most sensitive of the assays, can be used to detect minute amounts of bcr-abl mRNA and this has made it possible to monitor and detect minimal residual disease recurrence and disease progression, thus greatly enhancing patient care.;A variety of monitoring techniques can be employed during CML therapy, providing degrees of quantifying disease burden or absence of disease.",
        "Doc_title":"Monitoring your patients with chronic myeloid leukemia.",
        "Journal":"American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists",
        "Do_id":"17106019",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Bone Marrow Examination;Cytogenetic Analysis;Disease Progression;Fusion Proteins, bcr-abl;Humans;In Situ Hybridization, Fluorescence;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Monitoring, Physiologic;Reverse Transcriptase Polymerase Chain Reaction",
        "Doc_meshqualifiers":"methods;genetics;blood;diagnosis;genetics;methods",
        "_version_":1605853475539779584},
      {
        "Doc_abstract":"Bcrabl fusion transcripts, resulting from translocation t(9;22), are hallmarks of Philadelphia chromosome positive (Ph+) leukemias. This translocation is detected in >90% of patients with chronic myelogenous leukemia and ~20% of acute lymphoblastic leukemia patients, which predominantly express the p210 and p190 proteins, respectively. Although the occurrence of t(9;22) in healthy individuals has been previously demonstrated, the number of studies is limited and the results are inconsistent. The present study screened for the presence of bcrabl transcripts in the blood of a group of healthy individuals using a sensitivenested reverse transcription polymerase chain reaction (RTPCR) assay. Samples were collected from 189 healthy volunteers (145 adults and 44 children). RNA was reverse transcribed and amplified by two rounds of PCR, amplifying the two common variants of bcrabl transcripts, p190 and p210. While the bcrabl p190 transcript was not detected, the p210 transcript was detected in ~10% of samples. Notably, the incidence of p210 translocation was higher in males (12.2%) compared with females (7.7%) and males were 2.4 times more likely to have the translocation. A significant incidence was also observed in adults compared with children, where adults were 6 times more likely to have the translocation. The presence of bcrabl transcripts in the blood of a significant proportion of healthy individuals should be considered in longterm investigations to establish its exact association with the risk of developing leukemia. Furthermore, the current assays should be revised to consider the proportion of normal samples carrying the p210 transcripts when making a differential diagnosis.",
        "Doc_title":"Incidence of bcrabl fusion transcripts in healthy individuals.",
        "Journal":"Molecular medicine reports",
        "Do_id":"24535287",
        "Doc_ChemicalList":"RNA, Messenger;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adolescent;Adult;Age Distribution;Aged;Aged, 80 and over;Child;Child, Preschool;Female;Fusion Proteins, bcr-abl;Health;Humans;Male;Middle Aged;Polymerase Chain Reaction;RNA, Messenger;Young Adult",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;metabolism",
        "_version_":1605807389441785856},
      {
        "Doc_abstract":"Increased angiogenesis in bone marrow (BM) is one of the characteristics of chronic myeloid leukemia (CML), a clonal myeloproliferative disorder that expresses a chimeric Bcr/Abl protein. Recently, the therapeutic strategy in CML has been totally modified with the development of a new drug: imatinib mesylate (STI571), a specific inhibitor of Bcr/Abl tyrosine kinase activity. The aim of our study was to determine, in patients with CML, the capacity of imatinib mesylate to modulate one of the most potent regulators of angiogenesis, the vascular endothelial growth factor (VEGF). In newly diagnosed CML, we observed significantly increased VEGF secretion by CML BM cells and significantly increased VEGF plasma concentrations. We showed that low plasma VEGF concentrations could be one of the characteristics of complete cytogenetic remission. To understand the molecular mechanisms leading to the inhibition of VEGF production by imatinib, we focused our experiments on the human cell line K562, which is Bcr/Abl positive. We demonstrated that imatinib inhibits VEGF gene transcription by targeting the Sp1 and Sp3 transcription factors. Taken together, our results highlight the potential prognostic value of VEGF concentrations in evaluating the evolution of CML patients treated with imatinib.",
        "Doc_title":"Imatinib mesylate (STI571) decreases the vascular endothelial growth factor plasma concentration in patients with chronic myeloid leukemia.",
        "Journal":"Blood",
        "Do_id":"14976047",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;DNA-Binding Proteins;Piperazines;Pyrimidines;RNA, Messenger;SP3 protein, human;Sp1 Transcription Factor;Transcription Factors;Vascular Endothelial Growth Factor A;Sp3 Transcription Factor;Imatinib Mesylate;Phosphatidylinositol 3-Kinases;Mitogen-Activated Protein Kinase 1;Mitogen-Activated Protein Kinase 3;Mitogen-Activated Protein Kinases",
        "Doc_meshdescriptors":"Antineoplastic Agents;Benzamides;Bone Marrow Cells;DNA-Binding Proteins;Gene Expression;Humans;Imatinib Mesylate;K562 Cells;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mitogen-Activated Protein Kinase 1;Mitogen-Activated Protein Kinase 3;Mitogen-Activated Protein Kinases;Phosphatidylinositol 3-Kinases;Piperazines;Promoter Regions, Genetic;Pyrimidines;RNA, Messenger;Sp1 Transcription Factor;Sp3 Transcription Factor;Transcription Factors;Transcriptional Activation;Vascular Endothelial Growth Factor A",
        "Doc_meshqualifiers":"administration & dosage;pharmacology;cytology;drug effects;secretion;metabolism;drug effects;blood;drug therapy;antagonists & inhibitors;antagonists & inhibitors;antagonists & inhibitors;administration & dosage;pharmacology;administration & dosage;pharmacology;analysis;metabolism;metabolism;drug effects;blood;genetics;secretion",
        "_version_":1605818620337717251},
      {
        "Doc_abstract":"Imatinib is a specific and potent inhibitor of the BCR-ABL tyrosine kinase. Several clinical trials have demonstrated the efficacy of imatinib in chronic myeloid leukemia. Adverse cutaneous reactions induced by imatinib are frequent and may be dose related. We report a case of an unusual pustular eruption in a patient with chronic myeloid leukemia, who received high doses imatinib for blast crisis and later voriconazole for invasive pulmonary aspergillosis. At the time of his skin eruption, elevated plasma levels of imatinib were recorded. Imatinib is primarily metabolized by the cytochrome CYP3A4. Voriconazole is a cytochrome CYP3A4 inhibitor and can lead to high plasma levels of imatinib. This case suggests that severe drug reactions to imatinib may be related not only to imatinib doses, but also to elevated plasma drug levels resulting from pharmacokinetic interactions. The monitoring of imatinib plasma levels may be of help for identifying patients at risk for severe toxicity.",
        "Doc_title":"Severe pustular eruption associated with imatinib and voriconazole in a patient with chronic myeloid leukemia.",
        "Journal":"Dermatology (Basel, Switzerland)",
        "Do_id":"16286749",
        "Doc_ChemicalList":"Antifungal Agents;Antineoplastic Agents;Benzamides;Cytochrome P-450 Enzyme Inhibitors;Enzyme Inhibitors;Irritants;Piperazines;Pyrimidines;Triazoles;Imatinib Mesylate;CYP3A4 protein, human;CYP3A protein, human;Cytochrome P-450 CYP3A;Protein-Tyrosine Kinases;Voriconazole",
        "Doc_meshdescriptors":"Adult;Antifungal Agents;Antineoplastic Agents;Aspergillosis;Benzamides;Cytochrome P-450 CYP3A;Cytochrome P-450 Enzyme Inhibitors;Drug Eruptions;Drug Interactions;Enzyme Inhibitors;Exanthema;Humans;Imatinib Mesylate;Irritants;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Lung Diseases, Fungal;Male;Piperazines;Protein-Tyrosine Kinases;Pyrimidines;Triazoles;Voriconazole",
        "Doc_meshqualifiers":"adverse effects;adverse effects;blood;drug therapy;etiology;adverse effects;chemically induced;adverse effects;drug therapy;drug therapy;adverse effects;blood;antagonists & inhibitors;adverse effects;blood;adverse effects",
        "_version_":1605875667323322368},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) is generally diagnosed in the chronic phase. We have recently encountered two CML-blastic phase (BP) cases, a 71-year-old woman and a 74-year-old man, who resembled de novo acute leukemia. The complete blood count was normal at least 11 and 13 months before the presentation, respectively. The leukemic cells showed predominant lymphoid phenotype. The blasts and granulocytes were positive for BCR-ABL, indicative of CML-BP. Both patients were successfully treated with prednisone and vincristine, followed by Imatinib. Our cases indicate rare presentations of CML-BP with an extremely short chronic phase. Ph-positive de novo acute leukemia should be carefully distinguished from CML-BP.",
        "Doc_title":"Blast phase of chronic myeloid leukemia presenting lymphoid phenotype with a chronic phase of extremely short duration.",
        "Journal":"Internal medicine (Tokyo, Japan)",
        "Do_id":"20606363",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Aged;Diagnosis, Differential;Female;Fusion Proteins, bcr-abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Lymphocytes;Male;Phenotype;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Time Factors",
        "Doc_meshqualifiers":"metabolism;diagnosis;metabolism;pathology;pathology;diagnosis;metabolism;pathology",
        "_version_":1605784363326242816},
      {
        "Doc_abstract":"A human Philadelphia-chromosome positive chronic myeloid leukemia-blast crisis (CML-BC) cell line BV173 proliferated in the hematopoietic tissues, infiltrated various organs and caused the death of immunodeficient SCID mice. Leukemia spreading was assessed with diminished number of bone marrow cells and caused splenomegaly. The leukemic colonies grew from single cell suspension of bone marrow, spleen and peripheral blood. Bcr-abl m-RNA was detectable in bone marrow, spleen, peripheral blood, liver, lungs and brain. Dying mice demonstrated severely hypoplastic bone marrow, splenomegaly and massive metastases in the liver and kidneys. The survival time of animals was dependent on the number of inoculated leukemia cells.",
        "Doc_title":"A model of Ph' positive chronic myeloid leukemia-blast crisis cell line growth in immunodeficient SCID mice.",
        "Journal":"Folia histochemica et cytobiologica",
        "Do_id":"1286728",
        "Doc_ChemicalList":"Neprilysin",
        "Doc_meshdescriptors":"Animals;Blast Crisis;Bone Marrow;Cell Division;Immunologic Deficiency Syndromes;Kidney;Kidney Neoplasms;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Lung Neoplasms;Mice;Mice, SCID;Neprilysin;Spleen;Splenomegaly;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"pathology;pathology;pathology;pathology;pathology;secondary;pathology;pathology;secondary;analysis;pathology",
        "_version_":1605844304450813952},
      {
        "Doc_abstract":"This study was aimed to investigate the expression and regulation mechanism of DNA-dependent protein kinase catalylic subunit (DNA-PKcs) in chronic myeloid leukemia (CML) and its role in blast crisis of CML. Expression of DNA-PKcs mRNA was detected by semi-quantitative reverse transcription polymerase chain reaction (RT-PCR) and DNA-PKcs protein by Western blot in 62 CML patients and K562, as compared to those of 23 normal individual controls. In 26 CML patients received allogeneic peripheral blood stem cell transplantation (allo-PBSCT) and 4 CML patients treated with imatinib, the expression of bcr-abl mRNA and DNA-PKcs protein was detected by RT-PCR and Western blot, respectively. After treatment with imatinib in mononuclear cell (MNC) of CML patients and K562 in vitro, expression of DNA-PKcs mRNA was detected by RT-PCR and DNA-PKcs protein level, tyrosine phosphorylation of bcr-abl fusion protein were detected by Western blot. The results showed that the expression of DNA-PKcs protein was significantly lower in CML and K562 than those in normal control (P<0.05). In 26 CML patients received allo-PBSCT and 4 CML patients treated with imatinib, the expression of DNA-PKcs protein was enhanced while the expression of bcr-abl mRNA decreased. After treatment of MNC of CML and K562 with imatinib in vitro, the expression of DNA-PKcs protein was enhanced while tyrosine phosphorylation of bcr-abl fusion protein decreased. It is concluded that the expression of DNA-PKcs protein is down-regulate by bcr-abl fusion gene, and the bcr-abl fusion gene down-regulate the expression of DNA-PKcs protein by post-transcriptional mechanism; the decrease of DNA-PKcs protein expression may be one of mechanisms underlying the acute transformation of CML.",
        "Doc_title":"[Gene of DNA-dependent protein kinase catalylic subunit in chronic myeloid leukemia].",
        "Journal":"Zhongguo shi yan xue ye xue za zhi",
        "Do_id":"17493325",
        "Doc_ChemicalList":"Benzamides;Piperazines;Pyrimidines;RNA, Messenger;Imatinib Mesylate;Fusion Proteins, bcr-abl;DNA-Activated Protein Kinase",
        "Doc_meshdescriptors":"Adult;Aged;Benzamides;Bone Marrow Cells;DNA-Activated Protein Kinase;Female;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Peripheral Blood Stem Cell Transplantation;Piperazines;Pyrimidines;RNA, Messenger",
        "Doc_meshqualifiers":"metabolism;biosynthesis;genetics;biosynthesis;genetics;genetics;therapy;therapeutic use;therapeutic use;biosynthesis;genetics",
        "_version_":1605742678410002432},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) is a disease of the hematopoietic system, characterized by the presence of the Bcr-Abl oncoprotein. The main characteristics of this disease include adhesion independence, growth factor independence, and resistance to apoptosis. Loss or mutation of the tumor suppressor gene, p53, is one of the most frequent secondary mutations in CML blast crisis. The transition between chronic phase and blast crisis is associated with increased resistance to apoptosis correlating with poor prognosis. This review focuses on the involvement of these two oncoproteins in the development and progression of the apoptotic-resistant phenotype in CML.",
        "Doc_title":"Molecular abnormalities in chronic myeloid leukemia: deregulation of cell growth and apoptosis.",
        "Journal":"The oncologist",
        "Do_id":"11040277",
        "Doc_ChemicalList":"Growth Substances;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Apoptosis;Cell Cycle;Chromosome Aberrations;Disease Progression;Fusion Proteins, bcr-abl;Genes, abl;Genes, p53;Growth Substances;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Signal Transduction",
        "Doc_meshqualifiers":"genetics;pathology",
        "_version_":1605831566952497152},
      {
        "Doc_abstract":"Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of chronic myeloid leukemia (CML). However, resistance is occasionally observed, mainly due to mutations within the BCR-ABL kinase domain. The T315I substitution confers complete resistance to all TKIs commonly used in clinical practice. To date, the hierarchical level of stem cells in which this mutation initially appears has not been studied. The aim of this study was to evaluate the behavior of T315I mutated cells and to study the presence of potential additional mutations in progenitors and stem cells from a patient with CML. A comprehensive analysis of BCR-ABL(315I) mRNA expressing cells in mononuclear cells, in CD34+cell populations, and in their primitive long-term culture-initiating cell (LTC-IC) derived progenitors was performed. We show that the T315I substitution arises in primitive Ph1 stem cells without altering their myeloid and erythroid terminal differentiation potential. Leukemic cells expressing a T315I mutated BCR-ABL display a progressive decline in LTC-IC assays as described for non-mutated CML cells at diagnosis. Finally, in our experiments, additional non-315 ABL mutations were identified in hematopoietic stem cell colonies. This observation is suggestive of genetic instability affecting CML progenitors.",
        "Doc_title":"Extensive analysis of the T315I substitution and detection of additional ABL mutations in progenitors and primitive stem cell compartment in a patient with tyrosine kinase inhibitor-resistant chronic myeloid leukemia.",
        "Journal":"Leukemia & lymphoma",
        "Do_id":"20929330",
        "Doc_ChemicalList":"Antineoplastic Agents;Protein Kinase Inhibitors;Isoleucine;Threonine;Protein-Tyrosine Kinases",
        "Doc_meshdescriptors":"Aged;Amino Acid Substitution;Antineoplastic Agents;DNA Mutational Analysis;Drug Resistance, Neoplasm;Genes, abl;Humans;Isoleucine;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Mutation, Missense;Myeloid Progenitor Cells;Neoplastic Stem Cells;Polymorphism, Single Nucleotide;Protein Kinase Inhibitors;Protein-Tyrosine Kinases;Threonine",
        "Doc_meshqualifiers":"genetics;physiology;therapeutic use;methods;genetics;genetics;drug therapy;genetics;metabolism;pathology;metabolism;pathology;therapeutic use;antagonists & inhibitors;genetics",
        "_version_":1605811462484262912},
      {
        "Doc_abstract":"The BCR-ABL-fusion gene is critical for the development of chronic myeloid leukemia (CML) and BCR-ABL positive acute lymphatic leukemia (Ph+ ALL). Blocking BCR-ABL by the ABL tyrosine kinase inhibitor imatinib mesylate (IM, Gleevec) is clinically highly efficient. Treatment response is unfortunately compromised by the emergence of IM resistance, which is regularly seen in accelerated and blastic phase of CML (CML-AP/BP) and in Ph+ ALL. BCR-ABL kinase domain mutations are then considered the causative mechanism of IM resistance, because 50-60% of the IM resistant patients harbour such mutations. In contrast, IM resistance arises very rarely in patients that are treated with IM in early chronic phase of CML. This implies that BCR-ABL independent factors such as the cellular context of BCR-ABL expression and stage of disease decisively control the evolution of IM resistance. In line with this, novel Abl-kinase inhibitors such as dasatinib (DA) or nilotinib (NI) - although capable of inhibiting most of the BCR/-BL kinase mutants - still often fail to overcome resistance and do mostly not induce durable cytogenetic responses in IM resistant CML-AP/BC and Ph+ ALL patients. On the basis of available evidence it is proposed here that alternative genetic aberrations, which synergize with BCR-ABL to enable leukemic self-renewal are of causal importance for the evolution of clinical kinase inhibitor resistance. Kinase mutations may in turn reflect clonal variants of cells that emerge on the basis of an already existing IM resistant and self-renewing leukemic cell population. This model has clinical implications as it implies that even highly potent Abl-kinase inhibition can not target the genetic basis of IM resistance and will also not resolve the problem of Abl-kinase inhibitor resistance.",
        "Doc_title":"Roots of imatinib resistance: a question of self-renewal?",
        "Journal":"Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy",
        "Do_id":"17683977",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Pyrimidines;Imatinib Mesylate;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Antineoplastic Agents;Benzamides;Drug Resistance, Neoplasm;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Models, Biological;Mutation;Piperazines;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Protein-Tyrosine Kinases;Pyrimidines",
        "Doc_meshqualifiers":"pharmacology;therapeutic use;genetics;pharmacology;therapeutic use;drug therapy;enzymology;genetics;antagonists & inhibitors;genetics;metabolism;pharmacology;therapeutic use",
        "_version_":1605741935821062144},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) is caused by reciprocal translocation between chromosomes 9 and 22, forming BCR-ABL, a constitutively activated tyrosine kinase. Imatinib mesylate, a selective inhibitor of BCR-ABL, represents current frontline therapy for CML; however, emerging evidence suggests that drug resistance to imatinib may limit its long-term success. To improve treatment options, dasatinib (BMS-354825) was developed as a novel, oral, multi-targeted kinase inhibitor of BCR-ABL and SRC family kinases. To date, dasatinib has shown promising anti-leukemic activity in preclinical models of CML and in phase I/II clinical studies in patients with imatinib-resistant or imatinib-intolerant disease.;The pharmacokinetic and pharmacodynamic biomarkers of dasatinib were investigated in K562 human CML xenografts grown s.c. in severe combined immunodeficient mice. Tumoral levels of phospho-BCR-ABL/phospho-CrkL were determined by Western blot.;Following a single oral administration of dasatinib at a preclinical efficacious dose of 1.25 or 2.5 mg/kg, tumoral phospho-BCR-ABL/phospho-CrkL were maximally inhibited at approximately 3 hours and recovered to basal levels by 24 hours. The time course and extent of the inhibition correlated with the plasma levels of dasatinib in mice. Pharmacokinetic/biomarker modeling predicted that the plasma concentration of dasatinib required to inhibit 90% of phospho-BCR-ABL in vivo was 10.9 ng/mL in mice and 14.6 ng/mL in humans, which is within the range of concentrations achieved in CML patients who responded to dasatinib treatment in the clinic.;Phospho-BCR-ABL/phospho-CrkL are likely to be useful clinical biomarkers for the assessment of BCR-ABL kinase inhibition by dasatinib.",
        "Doc_title":"Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure.",
        "Journal":"Clinical cancer research : an official journal of the American Association for Cancer Research",
        "Do_id":"17145844",
        "Doc_ChemicalList":"Adaptor Proteins, Signal Transducing;Antineoplastic Agents;Biomarkers, Tumor;CRKL protein;Nuclear Proteins;Pyrimidines;Thiazoles;Fusion Proteins, bcr-abl;Dasatinib",
        "Doc_meshdescriptors":"Adaptor Proteins, Signal Transducing;Administration, Oral;Animals;Antineoplastic Agents;Biomarkers, Tumor;Blotting, Western;Cell Line, Tumor;Dasatinib;Disease Models, Animal;Dose-Response Relationship, Drug;Female;Fusion Proteins, bcr-abl;Humans;Injections, Intravenous;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mice;Mice, SCID;Nuclear Proteins;Predictive Value of Tests;Pyrimidines;Structure-Activity Relationship;Thiazoles;Time Factors;Transplantation, Heterologous;Xenograft Model Antitumor Assays",
        "Doc_meshqualifiers":"analysis;antagonists & inhibitors;administration & dosage;blood;pharmacokinetics;analysis;antagonists & inhibitors;analysis;antagonists & inhibitors;drug therapy;analysis;antagonists & inhibitors;administration & dosage;blood;pharmacokinetics;administration & dosage;blood;pharmacokinetics",
        "_version_":1605846824083521536},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) develops when a hematopoietic stem cell acquires the Philadelphia chromosome carrying the BCR/ABL fusion gene. This gives the transformed cells a proliferative advantage over normal hematopoietic cells. Silencing the BCR/ABL oncogene by treatment with specific drugs remains an important therapeutic goal. In this work, we used locked nucleic acid (LNA)-modified oligonucleotides to silence BCR/ABL and reduce CML cell proliferation, as these oligonucleotides are resistant to nucleases and exhibit an exceptional affinity for cognate RNA. The anti-BCR/ABL oligonucleotides were designed as LNA-DNA gapmers, consisting of end blocks of 3/4 LNA monomers and a central DNA stretch of 13/14 deoxyribonucleotides. The gapmers were complementary to the b2a2 and b3a2 mRNA junctions with which they form hybrid duplexes that have melting temperatures of 79 degrees C and 75 degrees C, respectively, in a 20 mmol/L NaCl-buffered (pH 7.4) solution. Like DNA, the designed LNA-DNA gapmers were capable of activating RNase H and promote cleavage of the target b2a2 and b3a2 BCR/ABL mRNAs. The treatment of CML cells with junction-specific antisense gapmers resulted in a strong and specific reduction of the levels of BCR/ABL transcripts ( approximately 20% of control) and protein p210(BCR/ABL) ( approximately 30% of control). Moreover, the antisense oligonucleotides suppressed cell growth up to 40% of control and induced apoptosis, as indicated by the increase of caspase-3/7 activity in the treated cells. Finally, the b2a2-specific antisense gapmer used in combination with STI571 (imatinib mesylate), a tyrosine kinase inhibitor of p210(BCR/ABL), produced an enhanced antiproliferative effect in KYO-1 cells, which compared with K562 cells are refractory to STI571. The data of this study support the application of BCR/ABL antisense LNA-DNA gapmers, used either alone or in combination with STI571, as potential antileukemic agents.",
        "Doc_title":"Antisense locked nucleic acids efficiently suppress BCR/ABL and induce cell growth decline and apoptosis in leukemic cells.",
        "Journal":"Molecular cancer therapeutics",
        "Do_id":"16891454",
        "Doc_ChemicalList":"Benzamides;Oligonucleotides;Oligonucleotides, Antisense;Piperazines;Protein Kinase Inhibitors;Pyrimidines;RNA, Messenger;locked nucleic acid;Imatinib Mesylate;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl;Ribonuclease H",
        "Doc_meshdescriptors":"Antineoplastic Combined Chemotherapy Protocols;Apoptosis;Benzamides;Cell Proliferation;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Oligonucleotides;Oligonucleotides, Antisense;Piperazines;Protein Kinase Inhibitors;Protein-Tyrosine Kinases;Pyrimidines;RNA, Messenger;Ribonuclease H;Transcription, Genetic;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"chemistry;therapeutic use;genetics;drug effects;analysis;antagonists & inhibitors;genetics;drug therapy;genetics;chemistry;therapeutic use;therapeutic use;therapeutic use;antagonists & inhibitors;therapeutic use;antagonists & inhibitors;drug effects;drug effects",
        "_version_":1605875947361271808},
      {
        "Doc_abstract":"BCR gene fused ABL kinase is the critical driving force for the Philadelphia Chromosome positive (Ph+) Chronic Myeloid Leukemia (CML) and has been extensively explored as a drug target. With a structure-based drug design approach we have discovered a novel inhibitor CHMFL-074, that potently inhibits both the native and a variety of clinically emerged mutants of BCR-ABL kinase. The X-ray crystal structure of CHMFL-074 in complex with ABL1 kinase (PDB ID: 5HU9) revealed a typical type II binding mode (DFG-out) but relatively rare hinge binding. Kinome wide selectivity profiling demonstrated that CHMFL-074 bore a high selectivity (S score(1) = 0.03) and potently inhibited ABL1 kinase (IC50: 24 nM) and PDGFR / (IC50: 71 nM and 88 nM). CHMFL-074 displayed strong anti-proliferative efficacy against BCR-ABL-driven CML cell lines such as K562 (GI50: 56 nM), MEG-01 (GI50: 18 nM) and KU812 (GI50: 57 nM). CHMFL-074 arrested cell cycle into the G0/G1 phase and induced apoptosis in the Ph+ CML cell lines. In addition, it potently inhibited the CML patient primary cell's proliferation but did not affect the normal bone marrow cells. In the CML cell K562 inoculated xenograft mouse model, oral administration of 100 mg/kg/d of CHMFL-074 achieved a tumor growth inhibition (TGI) of 65% without exhibiting apparent toxicity. As a potential drug candidate for fighting CML, CHMFL-074 is under extensive preclinical safety evaluation now.",
        "Doc_title":"Discovery and characterization of a novel potent type II native and mutant BCR-ABL inhibitor (CHMFL-074) for Chronic Myeloid Leukemia (CML).",
        "Journal":"Oncotarget",
        "Do_id":"27322145",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605799448110170112},
      {
        "Doc_abstract":"Solid tumors may occur in 3% of the patients with chronic myeloid leukemia (CML). In this paper, we presented a case of CML following treatment of colon cancer.;A 25 year old man was diagnosed of adenocarcinoma of rectosigmoid treated with fluorouracil-based chemotherapy. Following relapse, he received florouracil, oxaliplatin and irinotecan during the next year. Then he developed BCR-ABL positive CML. With Imatinib 400 mg/day, he achieved hematologic response but died because of progressive colon cancer.;This article emphasizes that there is a possibility for etiologic correlation between CML and chemotherapeutic agents in solid cancers.",
        "Doc_title":"Chronic myeloid leukemia following colon cancer treatment: A case report and literature review.",
        "Journal":"Caspian journal of internal medicine",
        "Do_id":"24009972",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605763775890194432},
      {
        "Doc_abstract":"It was previously shown that patients with chronic myeloid leukemia (CML) have a rare but consistently detectable population of quiescent (G0) leukemic (Philadelphia chromosome-positive and BCR-ABL-positive [BCR-ABL+]) CD34+ cells. In the study described here, most such cells expressed a primitive phenotype (CD38-, CD45RA-, CD71-, and HLA-DR(lo)) and cultures of these cells containing growth factors produced ultimately larger, but initially more slowly growing clones than do cultures of initially cycling CD34+ leukemic cells. Initially quiescent leukemic cells expressing BCR-ABL proliferated in single-cell cultures in the absence of added growth factors, thereby demonstrating their ability to spontaneously exit G0 and enter a continuously cycling state. Interestingly, on isolation, few of these quiescent BCR-ABL+ cells contained either interleukin-3 (IL-3) or granulocyte colony-stimulating factor (G-CSF) transcripts, whereas both were present in most cycling BCR-ABL+ CD34+ cells. However, after 4 days of culture in the absence of added growth factors and in association with their entry into the cell cycle (as indicated by up-regulation of Ki-67 and cdc25 transcripts), IL-3 transcripts became detectable. These findings show that entry of leukemic (BCR-ABL-expressing) progenitors into a quiescent (G0) state in vivo is highest among the most primitive leukemic cell populations, associated with a down-regulation of IL-3 and G-CSF gene expression, and spontaneously reversible in association with up-regulation of IL-3 expression. These results highlight the potential physiologic relevance of quiescent CML progenitors, even in treated patients, in whom these cells would be predicted to have a proliferative advantage over their quiescent normal counterparts when cytokine concentrations are low.",
        "Doc_title":"Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3.",
        "Journal":"Blood",
        "Do_id":"11157490",
        "Doc_ChemicalList":"Antigens, CD;Antigens, CD34;Antigens, Differentiation;Culture Media, Serum-Free;Interleukin-3;Membrane Glycoproteins;Granulocyte Colony-Stimulating Factor;Fusion Proteins, bcr-abl;ADP-ribosyl Cyclase;Antigens, CD38;CD38 protein, human;NAD+ Nucleosidase",
        "Doc_meshdescriptors":"ADP-ribosyl Cyclase;Antigens, CD;Antigens, CD34;Antigens, CD38;Antigens, Differentiation;Cell Cycle;Cell Division;Culture Media, Serum-Free;Fusion Proteins, bcr-abl;Granulocyte Colony-Stimulating Factor;Hematopoietic Stem Cells;Humans;Interleukin-3;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Membrane Glycoproteins;NAD+ Nucleosidase;Phenotype;Transcriptional Activation;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"analysis;analysis;pharmacology;metabolism;metabolism;cytology;metabolism;genetics;metabolism;metabolism;pathology;analysis",
        "_version_":1605801017582026752},
      {
        "Doc_abstract":"A patient who was diagnosed with chronic myeloid leukemia remained in chronic phase for 14 years before progressing into a lymphoid blast crisis in 1983. The acute phase was successfully treated, and the patient has remained in an indolent chronic phase to date. Cytogenetic and molecular analysis during this second chronic phase confirm the presence of the Philadelphia chromosome and its transcribed BCR-ABL mRNA. The breakpoint within M-bcr occurred in the 3' portion of the region and expressed a hybrid joining the b3 exon of BCR to the a2 exon of ABL.",
        "Doc_title":"Molecular analysis of a CML patient with a long duration of chronic phase before and after lymphoid blast crisis.",
        "Journal":"Leukemia",
        "Do_id":"2359347",
        "Doc_ChemicalList":"RNA, Messenger;RNA, Neoplasm",
        "Doc_meshdescriptors":"Blast Crisis;Female;Follow-Up Studies;Gene Rearrangement;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Leukemia, Myeloid, Chronic-Phase;Middle Aged;Oncogenes;Polymerase Chain Reaction;Precursor Cell Lymphoblastic Leukemia-Lymphoma;RNA, Messenger;RNA, Neoplasm",
        "Doc_meshqualifiers":"genetics;pathology;genetics;pathology;genetics;pathology;genetics;pathology;analysis;analysis",
        "_version_":1605746463724273666},
      {
        "Doc_abstract":"In chronic myeloid leukemia, accurate determination of Ph(-) Hemopoietic stem cells (HSC) in peripheral blood (PB), bone marrow (BM) and leukapheresis products is important for the selection of patients for whom mobilization, collection, and autografting of Ph(-) HSC are envisaged. To this effect, the BCR/ABL fusion was assessed at the single cell level in 25 sets of PB and BM samples using dual-color I-FISH in immunophenotyped CD34(+) cells and RT-PCR of individual CFU-GM colonies. In 15 cases found to be 100% Ph(+), the respective BCR/ABL gene was absent in 30% of CD34(+) cells, while the respective transcripts could not be identified in 17% of CFU-GM. The mean percentage of BCR/ABL(-) CD34(+) cells and CFU-GM cells was higher (38% and 29%, respectively) in untreated patients than in treated patients (24% and 7%, respectively). In eight cases with cytogenetic response (CgR), the percentage of Ph(-) metaphases correlated with the level of BCR/ABL(-) colonies in BM and PB and with the proportion of BCR/ABL(-) CD34(+) cells in the BM. Immunophenotyping and FISH was fast, easy, always informative, and quantitative for the BCR/ABL(-) CD34(+) cells. Our results show that (a) at early diagnosis a high frequency of BCR/ABL(-) HSC circulate in the PB and that Ph(-) hematopoiesis is not completely suppressed; (b) although normal clonogenic cells decline rapidly within a few months after diagnosis, appreciable numbers of normal CD34(+) cells survive in chronic phase, especially in patients with CgR.",
        "Doc_title":"Evaluation at single cell level of residual Philadelphia negative hemopoietic stem cells in chronic phase CML patients.",
        "Journal":"Cancer genetics and cytogenetics",
        "Do_id":"11106818",
        "Doc_ChemicalList":"Antigens, CD34;RNA, Messenger;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Antigens, CD34;Cell Count;Fusion Proteins, bcr-abl;Hematopoietic Stem Cells;Humans;Immunophenotyping;In Situ Hybridization, Fluorescence;Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative;Leukemia, Myeloid, Chronic-Phase;Middle Aged;Philadelphia Chromosome;RNA, Messenger;Reverse Transcriptase Polymerase Chain Reaction",
        "Doc_meshqualifiers":"analysis;genetics;cytology;metabolism;genetics;genetics;pathology;genetics;metabolism",
        "_version_":1605907370061332480},
      {
        "Doc_abstract":"To study the incidence and prognostic significance of derivative chromosome 9 [der (9)] deletions in chronic myeloid leukemia (CMA).;Dual-color dual-fusion BCR-ABL probe and fluorescence in situ hybridization (FISH) were use to detect chromosome preparations from 48 randomly selected CML patients in blast crisis (CML-BC). If only one fusion signal was detected in interphase cells with FISH, metaphase cells were simultaneously observed to determine if there were deletions on der (9). Chromosome preparations made at diagnosis from those with der (9) deletions in CML-BC were also assayed to determine if der (9) deletions occurred at the time of Philadelphia translocation. Patients in chronic phase were treated with hydroxyurea.;Of the 48 CML-BC cases, 8 (16.7%) showed der (9) deletions and the deletions also existed in chromosome preparations made at diagnosis. The group with der (9) deletions had significantly shorter duration of chronic phase and overall survival than the group without (P < 0.05). There was no difference in the probability of the der (9) deletions between the cases transformed to acute lymphoid leukemia and those to acute myeloid leukemia (P > 0.05).;FISH technique can effectively detect der (9) deletions. Der (9) deletions occur at the time of Philadelphia translocation. CML patients with der (9) deletions have more rapid process and poor prognosis. Hydroxyurea could not reverse the poor prognosis of der (9) deletions in CML. Der (9) deletions might not lead to transformation to specific type in CML.",
        "Doc_title":"[The prognostic significance of derivative chromosome 9 deletions in chronic myeloid leukemia].",
        "Journal":"Zhonghua nei ke za zhi",
        "Do_id":"17637307",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Case-Control Studies;Chromosome Deletion;Chromosomes, Human, Pair 9;Female;Humans;In Situ Hybridization, Fluorescence;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Prognosis",
        "Doc_meshqualifiers":"diagnosis;genetics",
        "_version_":1605837389775765504},
      {
        "Doc_abstract":"This study was aimed to explore fgfr3 gene expression in leukemic cells and its clinical significance. The expression levels of fgfr3 mRNA in 4 leukemic cell lines and bone marrow samples from 96 patients with leukemia and 14 controls were assayed by RT-PCR. 96 patients with leukemia included 36 cases of acute myeloid leukemia (AML), 29 cases of acute lymphoblastic leukemia (ALL), 31 cases of chronic myelogenous leukemia (CML). The results indicated that fgfr3 gene could be detected in both K562 and U937 cell lines, but not in HL-60 and SHI-1 cell lines. The positive expression rates of fgfr3 mRNA in AL and CML were 46.15% and 51.61% respectively, and were higher than that in control (14.29%, p < 0.05). The positive expression rates of fgfr3 mRNA in AML and ALL were 44.44% and 48.28% respectively, and were higher than that in control (p < 0.05). The increased level of fgfr3 mRNA had a positive correlation with high white blood cell count of > or = 20 x 10(9)/L (p < 0.05). Higher fgfr3 mRNA expression positively correlated with fuse genes of bcr/abl in ALL (r = 0.151, p < 0.05). The expression of fgfr3 gene in AL was not related with chromosome abnormality. In conclusion, the over expression of fgfr3 gene exists in AL and CML patients, it suggests that fgfr3 gene may be partially involved in leukemogenesis.",
        "Doc_title":"[Expression of a tumor related gene fgfr3 mRNA in leukemic cells and its clinical significance].",
        "Journal":"Zhongguo shi yan xue ye xue za zhi",
        "Do_id":"18718050",
        "Doc_ChemicalList":"RNA, Messenger;FGFR3 protein, human;Receptor, Fibroblast Growth Factor, Type 3",
        "Doc_meshdescriptors":"Acute Disease;Humans;K562 Cells;Leukemia;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;RNA, Messenger;Receptor, Fibroblast Growth Factor, Type 3;U937 Cells",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism",
        "_version_":1605748509632364544},
      {
        "Doc_abstract":"The first event in origination of many childhood leukemias is likely the presence of preleukemic clone (transformed hematopoietic stem/progenitor cells with preleukemic gene fusions (PGF)) in newborn. Thus, the screening of umbilical cord blood (UCB) for PGF may be of high importance for developing strategies for childhood leukemia prevention and treatment. However, the data on incidence of PGF in UCB are contradictive. We have compared multiplex polymerase chain reaction (PCR) and real-time quantitative PCR (RT qPCR) in neonates from Slovak National Birth Cohort. According to multiplex PCR, all 135 screened samples were negative for the most frequent PGF of B-lineage acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). To explore the prevalence of prognostically important TEL-AML1, MLL-AF4 and BCR-ABL (p190), 200 UCB were screened using RT qPCR. The initial screening showed an unexpectedly high incidence of studied PGF. The validation of selected samples in two laboratories confirmed approximately  of UCB positive, resulting in 4% incidence of TEL-AML1, 6.25% incidence of BCR-ABL1 p190, and 0.75% frequency of MLL-AF4. In most cases, the PGF presented at very low level, about 1-5 copies per 105 cells. We hypothesize that low PGF numbers reflect their relatively late origin and are likely to be eliminated in further development while higher number of PGF reflects earlier origination and may represent higher risk for leukemia. ",
        "Doc_title":"Incidence of common preleukemic gene fusions in umbilical cord blood in Slovak population.",
        "Journal":"PloS one",
        "Do_id":"24621554",
        "Doc_ChemicalList":"Core Binding Factor Alpha 2 Subunit;MLL-AF4 fusion protein, human;Oncogene Proteins, Fusion;TEL-AML1 fusion protein;Myeloid-Lymphoid Leukemia Protein;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Cohort Studies;Core Binding Factor Alpha 2 Subunit;Fetal Blood;Fusion Proteins, bcr-abl;Gene Fusion;Humans;Leukemia;Leukemia, Myeloid, Acute;Myeloid-Lymphoid Leukemia Protein;Oncogene Proteins, Fusion;Precancerous Conditions;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Prognosis;Real-Time Polymerase Chain Reaction;Slovakia",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;genetics;diagnosis;genetics;diagnosis;genetics;genetics;genetics;genetics;diagnosis;genetics",
        "_version_":1605809973836644352},
      {
        "Doc_abstract":"Deletions of the 5'ABL region adjacent to the t(9;22)(q34;q11) have recently been reported in 8-32.7% of patients with chronic myeloid leukemia (CML). The deletions were visualized with fluorescence in situ hybridization using, in the majority of the cases, the Vysis LSI BCR/ABL ES (extra signal) probe. In our series, 10 of 99 CML patients (10.1%) were characterized by a 5'ABL deletion. We show that 3'BCR losses are observed in nearly all the cases with 5'ABL deletions. Moreover, the different genetic events (Philadelphia chromosome formation; 5'ABL and 3'BCR deletions) occur simultaneously in a one-step process without any evidence for genetic instability in the target bone marrow cells.",
        "Doc_title":"Deletions of the 3'BCR and 5'ABL regions in patients with Philadelphia-positive chronic myeloid leukemia: a one-step process occurring in about 10% of the cases without any evidence of genetic instability in the target cells.",
        "Journal":"Cancer genetics and cytogenetics",
        "Do_id":"15993277",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Female;Fusion Proteins, bcr-abl;Genomic Instability;Humans;In Situ Hybridization, Fluorescence;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Sequence Deletion",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics",
        "_version_":1605924962117353472},
      {
        "Doc_abstract":"This is a review (by no means comprehensive) of how the stem cell niche evolved from an abstract concept to a complex system, implemented with a number of experimental data at the cellular and molecular levels, including metabolic cues, on which we focused in particular. The concept was introduced in 1978 to model bone marrow sites suited to host hematopoietic stem cells (HSCs) and favor their self-renewal, while restraining clonal expansion and commitment to differentiation. Studies of the effects of low oxygen tension on HSC maintenance in vitro led us to hypothesize niches were located within bone marrow areas where oxygen tension is lower than elsewhere. We named these areas hypoxic stem cell niches, although a low oxygen tension is to be considered physiological for the environment where HSCs are maintained. HSCs were later shown to have the option of cycling in low oxygen, which steers this cycling to the maintenance of stem cell potential. Cell subsets capable of withstanding incubation in very low oxygen were also detected within leukemia cell populations, including chronic myeloid leukemia (CML). The oncogenetic Bcr/Abl protein is completely suppressed in these subsets, whereas Bcr/Abl messenger ribonucleic acid is not, indicating that CML cells resistant to low oxygen are independent of Bcr/Abl for persistence in culture but remain genetically leukemic. Accordingly, leukemia stem cells of CML selected in low oxygen are refractory to the Bcr/Abl inhibitor imatinib mesylate. Bcr/Abl protein suppression turned out to be actually determined when glucose shortage complicated the effects of low oxygen, indicating that ischemia-like conditions are the driving force of leukemia stem cell refractoriness to imatinib mesylate. These studies pointed to \"ischemic\" stem cell niches as a novel scenario for the maintenance of minimal residual disease of CML. A possible functional relationship of the \"ischemic\" with the \"hypoxic\" stem cell niche is discussed.",
        "Doc_title":"One more stem cell niche: how the sensitivity of chronic myeloid leukemia cells to imatinib mesylate is modulated within a \"hypoxic\" environment.",
        "Journal":"Hypoxia (Auckland, N.Z.)",
        "Do_id":"27774462",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605795181303431168},
      {
        "Doc_abstract":"To define the relationship between Ph chromosome and BCR/ABL mRNA expression in chronic myeloid leukemia (CML) patients, and compare cytogenetic analysis and PCR method.;Marrow or peripheral blood samples from 33 CML patients were analyzed by R banding technique and PCR method. Eleven patients who received allogeneic BMT or alpha-IFN + low dose HU were followed up.;In 33 patients, 29 were Ph(+), 30 expressed BCR/ABL mRNA. In 6 patients who received BMT, 4 were Ph(-), 2 were Ph(+). However, 2 patients were (-), 4 were (+) by PCR method. In 5 patients who received alpha-IFN, the percentage of Ph(+) cells reduced after 6 and 12 months treatment than before treatment in 2 cases respectively. In 41 samples, 34 cases were consistent by 2 methods.;Each method, Cytogenetic analysis or PCR has its advantage and defect. The better method are integration of 2 methods in diagnosis and treatment monitoring of CML patients, so that provide real and beneficial information for clinic.",
        "Doc_title":"[Cytogenetic analysis and bcr/abl mRNA detection in chronic myeloid leukemia].",
        "Journal":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi",
        "Do_id":"11601240",
        "Doc_ChemicalList":"Antineoplastic Agents;Interferon-alpha;RNA, Messenger;Fusion Proteins, bcr-abl;Hydroxyurea",
        "Doc_meshdescriptors":"Adolescent;Adult;Antineoplastic Agents;Bone Marrow Transplantation;Female;Fusion Proteins, bcr-abl;Humans;Hydroxyurea;Interferon-alpha;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Philadelphia Chromosome;Polymerase Chain Reaction;RNA, Messenger",
        "Doc_meshqualifiers":"therapeutic use;biosynthesis;genetics;therapeutic use;therapeutic use;genetics;therapy;biosynthesis;genetics",
        "_version_":1605747033147179008},
      {
        "Doc_abstract":"The therapy of chronic myeloid leukemia, characterized by the presence of the Philadelphia chromosome in the clonal hematopoietic stem cells, has changed dramatically in the last years with the development of a specific inhibitor of the BCR-ABL tyrosine kinase: tyrosine kinase inhibitor imatinib mesylate (formerly STI571, [Glivec]). Glivec selectively blocks cellular proliferation and induces apoptosis in Philadelphia chromosome-positive (Ph+) cells harbouring the Bcr-Abl tyrosine kinase. Clinical development of imatinib mesylate began with 3 large, multicenter, phase II trials. The majority (88%) of interferon-alpha-resistant or intolerant patients in chronic-phase CML, achieved a complete hematologic response to imatinib mesylate. More importantly, approximately half of the patients achieved a major cytogenetic response, a result historically associated with improved survival. Furthermore, 21% of patients in accelerated-phase CML and 13.5% of patients in blastic-phase CML (patient populations with typically poor prognosis before the advent of imatinib mesylate) achieved major cytogenetic responses.",
        "Doc_title":"[A new drug in the therapy of chronic myeloid leukemia: ST1571].",
        "Journal":"Minerva medica",
        "Do_id":"12858155",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Enzyme Inhibitors;Piperazines;Pyrimidines;Imatinib Mesylate",
        "Doc_meshdescriptors":"Antineoplastic Agents;Benzamides;Blast Crisis;Clinical Trials, Phase I as Topic;Enzyme Inhibitors;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Piperazines;Pyrimidines",
        "Doc_meshqualifiers":"therapeutic use;drug therapy;therapeutic use;drug therapy;genetics;therapeutic use;therapeutic use",
        "_version_":1605898570441949184},
      {
        "Doc_abstract":"The anti-epileptic drug valproic acid harbors anti-tumoral activity in solid and leukemic tumor cell models and is currently evaluated in clinical trials. However, the plasma trough concentrations obtained in patients by common anti-epileptic dose regimens are below concentrations required for exerting anti-tumor effects in vitro. Here, we describe the identification of three novel valproic acid derivatives with superior differentiation-inducing and anti-proliferative activities in K562 bcr/abl-positive chronic myeloid leukemia cells and HL60 promyelocytic leukemia cells at achievable therapeutic VPA concentrations. These compounds reveal potent inhibition of histone deacetylase activity, induction of p21Cip/Waf expression as well as low toxicity on CD34+ bone marrow cells.",
        "Doc_title":"Novel valproic acid derivatives with potent differentiation-inducing activity in myeloid leukemia cells.",
        "Journal":"Leukemia research",
        "Do_id":"16510182",
        "Doc_ChemicalList":"Anticonvulsants;Antigens, CD34;Antineoplastic Agents;CDKN1A protein, human;Cyclin-Dependent Kinase Inhibitor p21;Valproic Acid;Fusion Proteins, bcr-abl;Histone Deacetylases",
        "Doc_meshdescriptors":"Anticonvulsants;Antigens, CD34;Antineoplastic Agents;Bone Marrow Cells;Cell Differentiation;Cell Proliferation;Cyclin-Dependent Kinase Inhibitor p21;Dose-Response Relationship, Drug;Drug Screening Assays, Antitumor;Fusion Proteins, bcr-abl;Gene Expression Regulation, Enzymologic;Gene Expression Regulation, Leukemic;HL-60 Cells;Histone Deacetylases;Humans;K562 Cells;Leukemia, Myeloid;Valproic Acid",
        "Doc_meshqualifiers":"pharmacology;toxicity;pharmacology;toxicity;enzymology;pathology;drug effects;drug effects;biosynthesis;biosynthesis;drug effects;drug effects;biosynthesis;drug therapy;enzymology;pathology;analogs & derivatives;pharmacology;toxicity",
        "_version_":1605800270985428992},
      {
        "Doc_abstract":"To describe a patient with Bcr-abl(+) acute lymphoblastic leukemia who developed the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) while being treated with high-dose imatinib.;A 29-year-old woman was diagnosed with Bcr-abl(+) acute lymphoblastic leukemia, and treatment was initiated with chemotherapy and imatinib 800 mg daily. Following imatinib initiation, a gradual decrease in serum sodium level was noticed. Prolonged aplasia and neutropenic fever prompted discontinuation of therapy for 4 weeks. Following the patient's recovery, complete remission was achieved and monotherapy with imatinib 800 mg daily was restarted; however, hyponatremia recurred a few days later. The clinical findings and laboratory workup were compatible with the diagnosis of SIADH, which was attributed to high-dose imatinib. Fluid restriction and imatinib dosage reduction (to 600 mg/day) restored sodium levels. According to the Naranjo probability scale, this adverse reaction was probably associated with imatinib.;Imatinib emerged as the first tyrosine kinase inhibitor to enter everyday clinical practice for the treatment of Ph(+) leukemias. Due to its molecular specificity, imatinib lacks the broad cytotoxicity of conventional chemotherapy. Inhibition of kinases in normal tissues accounts for many of imatinib's adverse reactions. To our knowledge, this is the first reported case of imatinib-induced SIADH.;We recommend monitoring for SIADH if a patient receiving high-dose imatinib develops hyponatremia.",
        "Doc_title":"Syndrome of inappropriate secretion of antidiuretic hormone associated with imatinib.",
        "Journal":"The Annals of pharmacotherapy",
        "Do_id":"19017824",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Imatinib Mesylate",
        "Doc_meshdescriptors":"Adult;Antineoplastic Agents;Benzamides;Dose-Response Relationship, Drug;Drug Monitoring;Female;Humans;Hyponatremia;Imatinib Mesylate;Inappropriate ADH Syndrome;Piperazines;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Protein Kinase Inhibitors;Pyrimidines",
        "Doc_meshqualifiers":"administration & dosage;adverse effects;chemically induced;chemically induced;administration & dosage;adverse effects;drug therapy;administration & dosage;adverse effects;administration & dosage;adverse effects",
        "_version_":1605751550083334144},
      {
        "Doc_abstract":"Omacetaxine mepesuccinate is approved by the Food and Drug Administration in the United States for the treatment of chronic myeloid leukemia in chronic or accelerated phase resistant to two or more tyrosine kinase inhibitors. This review summarizes the mode of action, pharmacokinetics, efficacy and safety of omacetaxine mepesuccinate. Omacetaxine mepesuccinate has activity in chronic myeloid leukemia, especially in the chronic phase, regardless of the presence of ABL1 kinase domain mutations. Omacetaxine mepesuccinate has distinct but manageable adverse events profile. Omacetaxine mepesuccinate is a treatment option for a subset of patients with refractory chronic myeloid leukemia. ",
        "Doc_title":"Omacetaxine Mepesuccinate for Chronic Myeloid Leukemia.",
        "Journal":"Expert review of hematology",
        "Do_id":"26853281",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605791707636432896},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) is a hematopoietic stem cell disorder that is characterized by splenomegaly and marked elevation of the blood leukocyte count with granulocyte in maturity. Ph chromosome was identified in CML in 1960 and was found to clearly result from reciprocal translocation between chromosome 9 and chromosome 22 (t(q;22)) (q34;q11). CML arises from a single pluripotent hematopoietic stem cell with the Ph chromosome and demonstration of the Ph chromosome in blood or marrow cells establishes and unequivocal diagnosis of CML. The Ph chromosome is recognized as the cytogenetic result of a rearrangement of the ABL gene on chromosome 9 and the BCL gene on chromosome 22, which leads to the creation of a BCR/ABL fusion gene on chromosome 22. Abnormal ABL-related protein with increased tyrosine kinase activity suggested a molecular mechanism of CML. The BCR/ABL fusion gene can be found not only in the chromosome but in interphase nuclei by fluorescence in situ hybridization (FISH). We employed both fluorescence activated cell sorter (FACS) and FISH to study the lineage involvement of individual stem cells and progenitor cells in patients with CML. Evidence of BCR/ABL fusion was found in pluripotent stem cells (CD34+, Thy1+), myeloid cells, B progenitor cells (CD34+, CD19+) and T/NK progenitor cells (CD34+, CD7+, CD5+) but not mature T cells (CD3+) or natural killer cells (CD3-, CD56+). These data suggested that BCR/ABL gene fusion occurs in pluripotent stem cells and that Ph+ T cells and natural killer cells are eliminated during differentiation.",
        "Doc_title":"[Progress in laboratory medicine in chronic myeloid leukemia].",
        "Journal":"Rinsho byori. The Japanese journal of clinical pathology",
        "Do_id":"9916508",
        "Doc_ChemicalList":"Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Artificial Gene Fusion;Cell Differentiation;Chromosomes, Human, Pair 22;Chromosomes, Human, Pair 9;Fusion Proteins, bcr-abl;Gene Rearrangement;Hematopoietic Stem Cells;Humans;In Situ Hybridization, Fluorescence;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Philadelphia Chromosome;Protein-Tyrosine Kinases;Translocation, Genetic",
        "Doc_meshqualifiers":"genetics;cytology;diagnosis;genetics;metabolism",
        "_version_":1605800925704749056},
      {
        "Doc_abstract":"Interferon regulatory factor 5 (IRF5) modulates the expression of genes controlling cell growth and apoptosis. Previous findings have suggested a lack of IRF5 transcripts in both acute and chronic leukemias. However, to date, IRF5 expression and function have not been investigated in chronic myeloid leukemia (CML). We report that IRF5 is expressed in CML cells, where it interacts with the BCR-ABL kinase that modulates its expression and induces its tyrosine phosphorylation. Tyrosine-phosphorylated IRF5 displayed reduced transcriptional activity that was partially restored by imatinib mesylate (IM). Interestingly, a mutant devoid of a BCR-ABL consensus site (IRF5(Y104F)) still presented significant tyrosine phosphorylation. This finding suggests that the oncoprotein phosphorylates additional tyrosine residues or induces downstream signaling pathways leading to further IRF5 phosphorylation. We also found that ectopic expression of IRF5 decreases the proliferation of CML cell lines by slowing their S-G2 transition, increasing the inhibition of BCR-ABL signaling and enhancing the lethality effect observed after treatment with IM, -2-interferon and a DNA-damaging agent. Furthermore, IRF5 overexpression successfully reduced the clonogenic ability of CML CD34-positive progenitors before and after exposure to the above-indicated cytotoxic stimuli. Our data identify IRF5 as a downstream target of the BCR-ABL kinase, suggesting that its biological inactivation contributes to leukemic transformation. ",
        "Doc_title":"IRF5 is a target of BCR-ABL kinase activity and reduces CML cell proliferation.",
        "Journal":"Carcinogenesis",
        "Do_id":"24445143",
        "Doc_ChemicalList":"Benzamides;IRF5 protein, human;Interferon Regulatory Factors;Interferon-alpha;Piperazines;Pyrimidines;Etoposide;Imatinib Mesylate;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl;Proto-Oncogene Proteins c-akt;Extracellular Signal-Regulated MAP Kinases",
        "Doc_meshdescriptors":"Benzamides;Catalysis;Cell Line, Tumor;Cell Proliferation;Etoposide;Extracellular Signal-Regulated MAP Kinases;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Interferon Regulatory Factors;Interferon-alpha;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Phosphorylation;Piperazines;Protein Binding;Protein-Tyrosine Kinases;Proto-Oncogene Proteins c-akt;Pyrimidines;Signal Transduction;Transcriptional Activation;Tumor Stem Cell Assay",
        "Doc_meshqualifiers":"pharmacology;toxicity;pharmacology;toxicity;metabolism;metabolism;metabolism;pharmacology;genetics;metabolism;pharmacology;toxicity;metabolism;metabolism;pharmacology;toxicity;drug effects",
        "_version_":1605879645194944512},
      {
        "Doc_abstract":"B cell acute lymphoblastic leukemia (B-ALL) exhibits phenotypes reminiscent of normal stages of B-cell development. As demonstrated by flow cytometry, the immunophenotypes are able to determine the stages of B cell development. Multicolor flow cytometry (MFC) is more accurate at identifying cell populations. In this study, 9-color panels, including CD10, CD19, CD20, CD22, CD34, CD79a, CD179a, and IgM, which are sequentially expressed during B cell development, were designed to detect the leukemia cell subpopulations in adult B-ALL patients. In 23 patients at diagnosis, 192 heterogeneous subpopulations of leukemia cells were detected. Compared with their counterparts at diagnosis and after the 1st course of induction therapy, the responses of the subpopulations were also heterogeneous. In the CD10 population, the residual B cell subpopulations in the BCR/ABL patients were obviously reduced compared to those in the BCR/ABL patients. New subpopulations were detected in 22 of 23 patients and were primarily located in the CD34CD10 populations. Subpopulations of clonal evolution were heterogeneous after induction therapy. Our results suggest that the subpopulations in B-ALL patients should be dynamically monitored by development-associated immunophenotyping before, during, and after induction therapy and to predict the prognosis of the disease. ",
        "Doc_title":"Development-associated immunophenotypes reveal the heterogeneous and individualized early responses of adult B-acute lymphoblastic leukemia.",
        "Journal":"Medicine",
        "Do_id":"27559941",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605841533735534592},
      {
        "Doc_abstract":"Cells from patients with acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) can be grown and their properties analyzed in agar gel cultures. Levels of the glycoprotein regulator colony stimulating factor (CSF) were found to be elevated in 19-66% of plasmas tested from patients with various types of granulocytic leukemia, and the growth of AML and CML cells in vitro was observed to be dependent on, and responsive to, stimulation by CSF-containing material. In both diseases, the leukemic cells appear to be in a responsive state with respect to normal growth regulators, and potentially alterations in regulator levels may therefore be able to achieve sustained arrest of the growth of leukemic populations.",
        "Doc_title":"Growth and responsiveness of human granulocytic leukemic cells in vitro.",
        "Journal":"Bibliotheca haematologica",
        "Do_id":"1057945",
        "Doc_ChemicalList":"Glycoproteins",
        "Doc_meshdescriptors":"Bone Marrow;Bone Marrow Cells;Cell Division;Clone Cells;Glycoproteins;Granulocytes;Humans;In Vitro Techniques;Leukemia, Myeloid;Leukemia, Myeloid, Acute;Leukocytes",
        "Doc_meshqualifiers":"pathology;blood;pathology;blood;blood;pathology",
        "_version_":1605795718640959488},
      {
        "Doc_abstract":"The occurrence of T315I mutation during the course of targeted therapies of chronic myeloid leukemia is a major concern because it confers resistance to all currently approved tyrosine kinase inhibitors. The exact phenotype of the hematopoietic stem cell and the hierarchical level of the occurrence of this mutation in leukemic hematopoiesis has not been determined. To study the effects of T315I-mutated breakpoint cluster region-abelson (BCR-ABL) in a primitive hematopoietic stem cell, we have used the murine embryonic stem cell (mESC)-derived hematopoiesis model. Native and T315I-mutated BCR-ABL were introduced retrovirally in mESC-derived embryonic bodies followed by induction of hematopoiesis. In several experiments, T315I-mutated and nonmutated BCR-ABL-transduced embryonic bodies rapidly generated hematopoietic cells on OP-9 feeders, with evidence of hematopoietic stem cell markers. After injection into NOD/SCID mice, these cells induced myeloid and lymphoid leukemias, whereas transplantation of control (nontransduced) hematopoietic cells failed to produce any hematopoietic reconstitution invivo. Moreover, the expression of native and T315I-mutated BCR-ABL conferred to mESC-derived hematopoietic cells a self-renewal capacity demonstrated by the generation of leukemias after secondary transplantations. Secondary leukemias were more aggressive with evidence of extramedullary tumors. The expression of stem cell regulator Musashi-2 was found to be increased in bone marrow of leukemic mice. These data show that T315I-mutated BCR-ABL is functional at the stem cell level, conferring to mESC-derived leukemic cells a long-term hematopoietic repopulation ability. This model could be of interest to test the efficiency of drugs at the stem cell level in leukemias with T315I mutation.",
        "Doc_title":"Biological effects of T315I-mutated BCR-ABL in an embryonic stem cell-derived hematopoiesis model.",
        "Journal":"Experimental hematology",
        "Do_id":"23287417",
        "Doc_ChemicalList":"Msi2h protein, mouse;RNA-Binding Proteins;Green Fluorescent Proteins;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Amino Acid Substitution;Animals;Cell Differentiation;Cell Line;Cell Lineage;Cell Proliferation;Embryoid Bodies;Embryonic Stem Cells;Feeder Cells;Flow Cytometry;Fusion Proteins, bcr-abl;Green Fluorescent Proteins;Hematopoiesis;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mice;Mice, Inbred NOD;Mice, SCID;Mutation;RNA-Binding Proteins;Retroviridae;Stem Cell Transplantation;Time Factors;Transduction, Genetic",
        "Doc_meshqualifiers":"genetics;genetics;cytology;metabolism;transplantation;cytology;metabolism;transplantation;cytology;genetics;metabolism;genetics;metabolism;genetics;genetics;metabolism;pathology;genetics;metabolism;genetics;methods",
        "_version_":1605809209702612992},
      {
        "Doc_abstract":"The standard t(9;22)(q34;q11) found in Philadelphia (Ph) chromosome positive chronic myeloid leukemia (CML) involves a highly restricted (5.8 kb) chromosome 22 breakpoint cluster region (bcr), which results in the formation of a chimeric gene comprising exons from the 5' end of bcr and protooncogene c-abl coding sequences from chromosome 9. In a survey of 21 patients with hematologic and clinical features of CML we detected rearrangement of the chromosome 22 bcr by gene probe analysis in all cases, including 16 with a standard t(9;22), two with variant Ph translocations [t(10;22)(q26;q11);t(11;22)(p15;q11)], one with a complex Ph translocation [t(9;11;22)(q34;q13;q11)], one with a complex translocation and a masked Ph[t(9;14;22) (q34;q24;q11)], and one Ph-negative case with a t(1;9)(p32;q34). These observations further substantiate the suggestion that, despite karyotypic heterogeneity, a common underlying molecular lesion, the bcr-abl gene chimera, is involved in the disease pathogenesis of CML.",
        "Doc_title":"Chromosome 22 breakpoints in variant Philadelphia translocations and Philadelphia-negative chronic myeloid leukemia.",
        "Journal":"Cancer genetics and cytogenetics",
        "Do_id":"2649233",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adult;Aged;Bone Marrow Transplantation;Child;Chromosomes, Human, Pair 22;Female;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Philadelphia Chromosome;Proto-Oncogenes",
        "Doc_meshqualifiers":"genetics",
        "_version_":1605897937885331456},
      {
        "Doc_abstract":"Tyrosine kinase inhibitors (TKIs) have demonstrated success in the treatment of acute lymphoblastic leukemia (ALL) in patients that express BCR-ABL rearrangements (Philadelphia chromosome [Ph]). The current study aimed to assess the efficacy of TKIs and prognostic factors in the treatment of adults with Ph+-ALL.;In this multicenter retrospective study, the relationship between Ph+-ALL and treatment outcomes among Chinese patients receiving TKI-containing induction/consolidation chemotherapy was examined. A total of 86 Ph+-ALL patients were included and followed for 3.85 (0.43-9.30) years. Overall survival (OS) and event-free survival (EFS) were analyzed.;A total of 86 Ph+-ALL patients (40 females and 46 males; median age: 34.0 years) were enrolled, including those with BCR/ABL transcripts 190 (n = 52), 210 (n = 25), and 230 (n = 2); BCR/ABL isoform determination was not available for 7 patients. Mortality was influenced by variable BCR/ABL transcripts and TKI administration, and BCR/ABL transcripts, hematopoietic stem cell transplantation (HSCT), and TKI administration were associated with the occurrence of events. The OS rate in the TKI administration group during steady state was significantly higher compared with those patients who did not receive TKI administration (P = 0.008), the EFS rate in the TKI administration group during steady state was significantly higher compared with those patients who did not receive TKIs (P = 0.012), and also higher than those with TKI salvage administration (P = 0.004). BCR/ABL transcripts 210 showed preferable OS and EFS compared with BCR/ABL transcripts 190 and 230 (P<0.05 for each).;The susceptibility of Ph+-ALL to TKI associated with the patterns of BCR-ABL rearrangement is demonstrated for the first time, thus adding another risk-stratifying molecular prognostic tool for the management of patients with Ph+-ALL.",
        "Doc_title":"Susceptibility of Ph-positive all to TKI therapy associated with Bcr-Abl rearrangement patterns: a retrospective analysis.",
        "Journal":"PloS one",
        "Do_id":"25415187",
        "Doc_ChemicalList":"DNA Primers;Protein Kinase Inhibitors;RNA, Messenger;Protein-Tyrosine Kinases",
        "Doc_meshdescriptors":"Adult;Base Sequence;DNA Primers;Female;Gene Rearrangement;Genes, abl;Humans;Male;Philadelphia Chromosome;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Protein Kinase Inhibitors;Protein-Tyrosine Kinases;RNA, Messenger;Retrospective Studies;Survival Analysis;Young Adult",
        "Doc_meshqualifiers":"drug therapy;genetics;therapeutic use;antagonists & inhibitors;genetics",
        "_version_":1605754888197767168},
      {
        "Doc_abstract":"Chronic myeloid leukemia is an incurable white blood cell disease with slow progression which affects myeloid stem cells. In the course of chromosome 22 shortening a fusion oncogene arises whose product, a Bcr-Abl oncoprotein, is a continuously expressed tyrosine kinase protein. Beside the opportunity of chemotherapy, stem cell therapy and interferon-a therapy, the application of tyrosine kinase inhibitors also became widespread in the treatment of the disease. Patients bearing the T315I point mutation, however, show resistance against all tyrosine kinase inhibitors, which can be managed by dose escalation or the combination of therapies. The discovery of RNA interference or gene silencing put the therapeutic opportunity of CML in new light. The in vitro application of anti-bcr-abl siRNA showed promising results in the causal treatment of the disease, feasible for identification of new genes associated to the disease, but we do not have sufficient evidence for the safety and efficacy of this method in human therapy.",
        "Doc_title":"[New perspective in the treatment of chronic myeloid leukemia? gene silencing therapy].",
        "Journal":"Magyar onkologia",
        "Do_id":"22403758",
        "Doc_ChemicalList":"Protein Kinase Inhibitors;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Animals;Cell Line, Tumor;Drug Resistance, Neoplasm;Fusion Proteins, bcr-abl;Gene Silencing;Genetic Therapy;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Protein Kinase Inhibitors;Protein-Tyrosine Kinases",
        "Doc_meshqualifiers":"genetics;antagonists & inhibitors;genetics;drug effects;methods;genetics;therapy;pharmacology;therapeutic use;antagonists & inhibitors;genetics",
        "_version_":1605840855622483968},
      {
        "Doc_abstract":"We analyzed molecular responses in 55 newly diagnosed chronic-phase chronic myeloid leukemia (CML) patients enrolled in a phase 3 study (the IRIS trial) comparing imatinib to interferon-alfa plus cytarabine (IFN+AraC). BCR-ABL/BCR% levels were measured by real-time quantitative RT-PCR and were significantly lower for the imatinib-treated patients at all time points up to 18 months, P<0.0001. The median levels for imatinib-treated patients continued to decrease and had not reached a plateau by 24 months. A total of 24 IFN+AraC-treated patients crossed over to imatinib. Once imatinib commenced, the median BCR-ABL/BCR% levels in these patients were not significantly different to those on first-line imatinib for the equivalent number of months. The incidence of progression in imatinib-treated patients, defined by hematologic, cytogenetic or quantitative PCR criteria, was significantly higher in the patients who failed to achieve a 1 log reduction by 3 months or a 2 log reduction by 6 months, P=0.002. A total of 49 patients were screened for BCR-ABL kinase domain mutations. Mutations were detected in two imatinib-treated patients who crossed over from IFN+AraC and both lost their imatinib response. In conclusion, first-line imatinib-treated patients had profound reductions in BCR-ABL/BCR%, which significantly exceeded those of IFN+AraC-treated patients and early measurements were predictive of subsequent response.",
        "Doc_title":"Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase.",
        "Journal":"Leukemia",
        "Do_id":"14523461",
        "Doc_ChemicalList":"Antimetabolites, Antineoplastic;Antineoplastic Agents;Benzamides;Interferon-alpha;Piperazines;Pyrimidines;Cytarabine;Imatinib Mesylate;Phosphotransferases;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Antimetabolites, Antineoplastic;Antineoplastic Agents;Benzamides;Bone Marrow;Cross-Over Studies;Cytarabine;Cytogenetics;DNA Mutational Analysis;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Interferon-alpha;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Phosphotransferases;Piperazines;Prognosis;Protein Structure, Tertiary;Pyrimidines;Treatment Outcome",
        "Doc_meshqualifiers":"administration & dosage;administration & dosage;metabolism;administration & dosage;blood;chemistry;genetics;administration & dosage;diagnosis;drug therapy;genetics;chemistry;genetics;administration & dosage;administration & dosage",
        "_version_":1605818568042086402},
      {
        "Doc_abstract":"This study was aimed to quantitatively detect the expression level of beta-catenin and bcr/abl in different phases of chronic myeloid leukemia (CML) and to analyze their potential relationship and significance in the progression of CML. First, the total RNA isolated from BMMNC of patients with CML and donors was reversely transcribed into cDNA. The real-time quantitative PCR method was used to analyze the expression level of beta-catenin and bcr/abl. The expression level of beta-catenin and bcr/abl in different phases of CML was compared and the correlation was analyzed between the two genes. The results showed that the beta-catenin gene in BMMNC of blast crisis of CML patients was expressed significantly higher than that in chronic phase (p < 0.001) and accelerated phase (p = 0.016) of CML patients and in normal donors (p = 0.004). The expression of bcr/abl in blast crisis of CML was statistically higher than that in chronic phase of CML (p = 0.001). The expression levels of beta-catenin and bcr/abl were correlated with each other in CML patients (r = 0.620, p < 0.001). It is concluded that the beta-catenin gene in blast crisis of CML patients express higher than that in chronic phase and accelerated phase of CML, and its expression level is correlated with the level of bcr/abl expression. The increased expression of beta-catenin may be account partly for the blast crisis of CML.",
        "Doc_title":"[Expression of beta-Catenin Gene in CML and its relationship with bcr/abl].",
        "Journal":"Zhongguo shi yan xue ye xue za zhi",
        "Do_id":"17956664",
        "Doc_ChemicalList":"beta Catenin;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adult;Aged;Bone Marrow Cells;Female;Fusion Proteins, bcr-abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Tumor Cells, Cultured;Young Adult;beta Catenin",
        "Doc_meshqualifiers":"metabolism;pathology;metabolism;genetics;pathology;metabolism",
        "_version_":1605791121964793856},
      {
        "Doc_abstract":"BCR-ABL antisense oligonucleotides can specifically reduce colony formation of early hematopoietic progenitor cells from chronic myeloid leukemia (CML) patients. Little is known about the mechanism of this inhibition. We studied the inhibition of the bcr-abl oncogene using fluorescein-labeled phosphorothioate oligonucleotides in the Philadelphia chromosome-positive cell line BV173. Oligonucleotide stability, uptake, bcr-abl mRNA degradation, inhibition of cell proliferation, and cell death were studied. The oligonucleotide uptake was directly dependent on the extracellular concentration and was constant over the first 18 h of incubation. After that the uptake rate decreased. We detected a decrease in bcr-abl mRNA after 3 days of treatment with antisense oligonucleotides, but much less in controls. The controls used in the experiments were the sense oligonucleotide, equimolar amounts of sense and antisense, and an untreated control. Antisense oligonucleotides completely inhibited cell growth of BV173 cells and did not inhibit growth of HL-60 cells, whereas control oligonucleotides had no such effect on either cell line. An oligonucleotide specific for the other CML breakpoint was also effective in reducing cell growth of BV173. By the use of a DNA double staining technique to discriminate between necrotic and apoptotic cells, we detected a large number of apoptotic cells in antisense treated BV173 cultures after 5 days of treatment as compared to controls. We conclude that antisense BCR-ABL oligonucleotides reduce bcr-abl mRNA expression in BV173 cells mainly in a sequence-specific manner and induce apoptosis.",
        "Doc_title":"Antisense BCR-ABL oligonucleotides induce apoptosis in the Philadelphia chromosome-positive cell line BV173.",
        "Journal":"Leukemia",
        "Do_id":"8289478",
        "Doc_ChemicalList":"Fluoresceins;Oligonucleotides, Antisense;RNA, Messenger;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Apoptosis;Base Sequence;Cell Death;Cell Division;DNA Damage;Fluoresceins;Fusion Proteins, bcr-abl;Humans;Kinetics;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Molecular Sequence Data;Oligonucleotides, Antisense;RNA, Messenger;Sensitivity and Specificity;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"drug effects;physiology;drug effects;genetics;drug therapy;metabolism;pathology;metabolism;pharmacokinetics;pharmacology;genetics;metabolism",
        "_version_":1605808176239738880},
      {
        "Doc_abstract":"The major bcr-abl fusion gene is presently seen as the hallmark of chronic myeloid leukemia (CML) and presumably as the cause of its development. Accordingly, long-term disappearance of bcr-abl after intensive therapy is considered to be a probable cure of CML. The nested reverse transcriptase-polymerase chain reaction (RT-PCR) provides a powerful tool for minimal residual CML detection. The RT-PCR was optimized by (1) increasing the amount of total RNA involved in the reverse transcription reaction to correspond to total RNA extracted from 10(8) cells, (2) using a specific abl primer in this reverse reaction, and (3) reamplifying 10% of the RT-PCR product in nested amplification. This optimized RT-PCR permitted us to detect up to 1 copy of RNA bcr-abl synthesised in vitro, mixed with yeast RNA in an equivalent quantity to 10(8) white blood cells (WBCs). Using this highly sensitive RT-PCR during the follow-up of CML patients, a signal was unexpectedly found in healthy controls. Therefore, a systematic study of the possible expression of bcr-abl RNA in the WBCs of healthy adults and children and in umbilical cord blood was undertaken. It showed the presence of bcr-abl transcript in the blood of 22 of 73 healthy adults and in the blood of 1 of 22 children but not in 22 samples of umbilical cord blood.",
        "Doc_title":"Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals.",
        "Journal":"Blood",
        "Do_id":"7579406",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adolescent;Adult;Age Factors;Aged;Aged, 80 and over;Base Sequence;Child;Child, Preschool;Fetal Blood;Fusion Proteins, bcr-abl;Gene Expression Regulation;Genes, abl;Humans;Infant;Leukocytes;Middle Aged;Molecular Sequence Data;Polymerase Chain Reaction;Reference Values;Sensitivity and Specificity",
        "Doc_meshqualifiers":"metabolism;blood;genetics;metabolism",
        "_version_":1605806686065393664},
      {
        "Doc_abstract":"Genetic examination of childhood leukemia has not been available in Iraq. We here report the frequency of TEL-AML1, E2A-PBX1, MLL-AF4, and BCR-ABL chimeric transcripts in 264 Iraqi children newly diagnosed with acute lymphoblastic leukemia (ALL), using FTA cards impregnated with bone marrow aspirate or whole blood.;The diagnosis of ALL was made according to standard French-American-British morphologic criteria. Based on the results of storage temperature and duration, most of the FTA samples were preserved at 4C for up to 6 weeks in five Iraqi hospitals and then transferred to Japan for molecular analysis. Nested reverse transcription-polymerase chain reaction was adopted for the analysis.;TEL-AML1 chimeric transcript product was found in 32 (12.1%) of 264 ALL patients. Eleven (4.2%) patients, 4 (1.5%) patients, and 11 (4.2%) patients had E2A-PBX1 mRNA, MLL-AF4 mRNA, and BCR-ABL mRNA, respectively. One patient had both TEL-AML1 and E2A-PBX1 fusion genes. The incidence of TEL-AML1 in Iraqi ALL children appears to be similar to or slightly higher than those of Jordan (12%) and Kuwait (7%). The prevalence and clinical findings of ALL patients with either E2A-PBX1 or BCR-ABL were comparable to the data reported elsewhere.;International collaboration via FTA cards may be helpful to improve diagnosis and management of patients with hematological malignancies in low-income and underdeveloped countries.",
        "Doc_title":"Genetic evaluation of childhood acute lymphoblastic leukemia in Iraq using FTA cards.",
        "Journal":"Pediatric blood & cancer",
        "Do_id":"22238115",
        "Doc_ChemicalList":"Core Binding Factor Alpha 2 Subunit;Homeodomain Proteins;MLL-AF4 fusion protein, human;Oncogene Proteins, Fusion;RNA, Messenger;TEL-AML1 fusion protein;E2A-Pbx1 fusion protein;Myeloid-Lymphoid Leukemia Protein;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Child;Child, Preschool;Core Binding Factor Alpha 2 Subunit;Female;Fusion Proteins, bcr-abl;Homeodomain Proteins;Humans;Infant;Iraq;Male;Myeloid-Lymphoid Leukemia Protein;Oncogene Proteins, Fusion;Precursor Cell Lymphoblastic Leukemia-Lymphoma;RNA, Messenger;Translocation, Genetic",
        "Doc_meshqualifiers":"analysis;analysis;analysis;analysis;analysis;diagnosis;genetics",
        "_version_":1605820300500402176},
      {
        "Doc_abstract":"Survival of patients with chronic myeloid leukemia (CML) has dramatically improved with the introduction of the BCR-ABL-specific tyrosine kinase inhibitor imatinib. As a rule patients on therapy with imatinib achieve permanent complete cytogenetic and molecular remission. Patients who are primarily refractive to imatinib or lose remission achieved using imatinib are in the minority. This group has a poor prognosis. This article gives a transparent review of the diagnostics necessary when CML is primarily diagnosed and for assessment of the response during the course of the therapy. The guidelines developed for this procedure by the European leukemia network on the type and frequency of surveillance controls as well as the diagnostic criteria for imatinib resistance or suboptimal response will be presented. The indications for allogenic stem cell transplantation and the administration of second generation BCR-ABL inhibitors will be discussed as therapeutic alternatives in cases of imatinib failure in a stage-specific manner. Finally a view on therapy targets and forms of future first-line therapy of CML will be given.",
        "Doc_title":"[Chronic myeloid leukemia. Diagnostics, therapy and future strategy].",
        "Journal":"Der Internist",
        "Do_id":"21253680",
        "Doc_ChemicalList":"4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide;Antineoplastic Agents;Benzamides;Interferon-alpha;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Thiazoles;Imatinib Mesylate;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl;Dasatinib",
        "Doc_meshdescriptors":"Antineoplastic Agents;Antineoplastic Combined Chemotherapy Protocols;Benzamides;Bone Marrow;Dasatinib;Drug Resistance, Neoplasm;Fusion Proteins, bcr-abl;Hematopoietic Stem Cell Transplantation;Humans;Imatinib Mesylate;Interferon-alpha;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Piperazines;Prognosis;Protein Kinase Inhibitors;Protein-Tyrosine Kinases;Pyrimidines;Survival Rate;Thiazoles",
        "Doc_meshqualifiers":"adverse effects;therapeutic use;adverse effects;therapeutic use;pathology;adverse effects;therapeutic use;adverse effects;therapeutic use;diagnosis;drug therapy;mortality;pathology;adverse effects;therapeutic use;adverse effects;therapeutic use;adverse effects;antagonists & inhibitors;therapeutic use;adverse effects;therapeutic use;adverse effects;therapeutic use",
        "_version_":1605764351194562560},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) is a bi- or triphasic disease. Molecular markers distinct for the phase evolution would be clinically helpful. For signaling transformation and proliferation activities in CML, Bcr-Abl is the pivotal protein. As downstream signals of Bcr-Abl , RAS, PI3-K, and Stat 5 may lead to cell cycle progression mediated by increased expression of cyclin Ds. We analyzed copy numbers of bcr-abl and cyclin D1 transcripts by reverse transcription (RT) and competitive PCR titration in bone marrow cells of 20 patients with CML, 10 in chronic phase (CP) and the other 10 in accelerated phase (AP). The level of bcr-abl transcripts in the AP was not significantly higher than that in the CP; in contrast, the level of cyclin D1 transcripts in the AP was significantly higher than that in the CP (p <0.001). Cyclin D1 RNA expression in the CP of CML was also found to have clinical relevance to time to AP transformation. The median time to AP transformation for the CP patients with cyclin D1 transcripts of 1.50 x 10(4)/microg RNA was significantly shorter than that for those with cyclin D1 transcripts < 1.50 x 10(4)/microg RNA (15 vs. 67 months, p=0.0354) although confirmation to conduct in a larger patient group is required. These results suggest that the expression level of cyclin D1 RNA in bone marrow cells is predictive of the phase evolution in CML and may be helpful in treatment decision-making.",
        "Doc_title":"Overexpression of cyclin D1 in accelerated-phase chronic myeloid leukemia.",
        "Journal":"Leukemia & lymphoma",
        "Do_id":"15621754",
        "Doc_ChemicalList":"RNA, Messenger;Cyclin D1",
        "Doc_meshdescriptors":"Adult;Aged;Bone Marrow Cells;Cell Line, Tumor;Cyclin D1;Gene Expression Regulation, Neoplastic;Genes, abl;Humans;Leukemia, Myeloid, Accelerated Phase;Middle Aged;RNA, Messenger;Survival Rate;Time Factors;Transcription, Genetic",
        "Doc_meshqualifiers":"metabolism;genetics;genetics;genetics;pathology;genetics;metabolism;genetics",
        "_version_":1605742027292540929},
      {
        "Doc_abstract":"To investigate the characteristics and clinical outcome of T315I mutation in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph(+) ALL) and chronic myeloid leukemia (CML).;The clinical data of 118 tyrosine kinase inhibitors (TKIs) resistant Ph(+) ALL and CML cases who were detected ABL kinase domain mutation in Affiliated Tumor Hospital of Zhengzhou University from March 2014 to June 2015 were collected. Karyotypes and BCR-ABL fusion gene were analyzed respectively by R-banding, real-time quantitative polymerase chain reaction (PCR). Total RNA was extracted by TRIzol reagent and ABL kinase domain mutation was detected by direct sequencing.;In 23 TKIs resistant Ph(+) ALL and 95 CML cases, the rate of ABL kinase domain mutation was 60.9% (14/23) and 41.1% (39/95), respectively, and the rate of T315I mutation was respectively 34. 8% vs 5.3%, the difference was significant ((2)=13.586, P<0.01). The rate of mutations in chronic phase/accelerate phase /blast crisis CML patients was 38.8% (19/49), 47.1% (8/17) and 41.4% (12/29), respectively, and there was no significant difference ((2)=0.360, P=0.835). In Ph (+) ALL and CML patients, the median time from the beginning of TKI therapy to appearance of T315I mutation was 10 months and 19 months, the median time from the appearance of T315I to death/deadline was 2 months and 3 months, the median time of persistent hematologic response was 10 months and 16 months and the median time of overall survival (OS) was 13 months and 42 months.;T315I mutation was more easily occurred in Ph(+) ALL than CML, but two diseases are similar in the median time from the beginning of TKI therapy to appearance of T315I, the median time of persistent hematologic response and OS.",
        "Doc_title":"[Characteristics and clinical outcome of T315I mutation in Philadelphia chromosome-positive acute lymphoblastic leukemia and chronic myeloid leukemia].",
        "Journal":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi",
        "Do_id":"27014979",
        "Doc_ChemicalList":"Protein Kinase Inhibitors;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Acute Disease;Blast Crisis;Drug Resistance, Neoplasm;Fusion Proteins, bcr-abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mutation;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Protein Kinase Inhibitors",
        "Doc_meshqualifiers":"genetics;drug therapy;genetics;drug therapy;genetics;therapeutic use",
        "_version_":1605747043128573953},
      {
        "Doc_abstract":"Leukemia dissemination (the spread of leukemia cells from the bone marrow) and relapse are associated with poor prognosis. Often, relapse occurs in peripheral organs, such as the CNS, which acts as a sanctuary site for leukemia cells to escape anti-cancer treatments. Similar to normal leukocyte migration, leukemia dissemination entails migration of cells from the blood circulation into tissues by extravasation. To extravasate, leukemia cells cross through vascular endothelial walls via a process called transendothelial migration, which requires cytoskeletal remodeling. However, the specific molecular players in leukemia extravasation are not fully known. We examined the role of myosin-IIA a cytoskeletal class II myosin motor protein, in leukemia progression and dissemination into the CNS by use of a mouse model of Bcr-Abl-driven B cell acute lymphoblastic leukemia. Small hairpin RNA-mediated depletion of myosin-IIA did not affect apoptosis or the growth rate of B cell acute lymphoblastic leukemia cells. However, in an in vivo leukemia transfer model, myosin-IIA depletion slowed leukemia progression and prolonged survival, in part, by reducing the ability of B cell acute lymphoblastic leukemia cells to engraft efficiently. Finally, myosin-IIA inhibition, either by small hairpin RNA depletion or chemical inhibition by blebbistatin, drastically reduced CNS infiltration of leukemia cells. The effects on leukemia cell entry into tissues were mostly a result of the requirement for myosin-IIA to enable leukemia cells to complete the transendothelial migration process during extravasation. Overall, our data implicate myosin-IIA as a key mediator of leukemia cell migration, making it a promising target to inhibit leukemia dissemination in vivo and potentially reduce leukemia relapses. ",
        "Doc_title":"Myosin-IIA regulates leukemia engraftment and brain infiltration in a mouse model of acute lymphoblastic leukemia.",
        "Journal":"Journal of leukocyte biology",
        "Do_id":"26792819",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605801144782684160},
      {
        "Doc_abstract":"The kinase inhibitor imatinib mesylate targeting the oncoprotein Bcr-Abl has revolutionized the treatment of chronic myeloid leukemia (CML). However, even though imatinib successfully controls the leukemia in chronic phase, it seems not to be able to cure the disease, potentially necessitating lifelong treatment with the inhibitor under constant risk of relapse. On a molecular level, the cause of disease persistence is not well understood. Initial studies implied that innate features of primitive progenitor cancer stem cells may be responsible for the phenomenon. Here, we describe an assay using retroviral insertional mutagenesis (RIM) to identify genes contributing to disease persistence in vivo. We transplanted mice with bone marrow cells retrovirally infected with the Bcr-Abl oncogene and subsequently treated the animals with imatinib to select for leukemic cells in which the proviral integration had affected genes modulating the imatinib response. Southern blot analysis demonstrated clonal outgrowth of cells carrying similar integration sites. Candidate genes located near the proviral insertion sites were identified, among them the transcription factor RUNX3. Proviral integration near the RUNX3 promoter induced RUNX3 expression, and Bcr-Abl-positive cell lines with stable or inducible expression of RUNX1 or RUNX3 were protected from imatinib-induced apoptosis. Furthermore, imatinib treatment selected for RUNX1-expressing cells in vitro and in vivo after infection of primary bone marrow cells with Bcr-Abl and RUNX1. Our results demonstrate the utility of RIM for probing molecular modulators of targeted therapies and suggest a role for members of the RUNX transcription factor family in disease persistence in CML patients.",
        "Doc_title":"Retroviral insertional mutagenesis identifies RUNX genes involved in chronic myeloid leukemia disease persistence under imatinib treatment.",
        "Journal":"Proceedings of the National Academy of Sciences of the United States of America",
        "Do_id":"17360569",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Core Binding Factor Alpha 2 Subunit;Core Binding Factor Alpha 3 Subunit;Piperazines;Pyrimidines;Imatinib Mesylate",
        "Doc_meshdescriptors":"Animals;Antineoplastic Agents;Benzamides;Cell Line;Core Binding Factor Alpha 2 Subunit;Core Binding Factor Alpha 3 Subunit;Drug Resistance, Neoplasm;Genetic Techniques;Imatinib Mesylate;In Situ Hybridization, Fluorescence;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Mice;Mutagenesis;Mutagenesis, Site-Directed;Piperazines;Pyrimidines;Retroviridae",
        "Doc_meshqualifiers":"pharmacology;genetics;physiology;genetics;physiology;drug therapy;therapy;pharmacology;pharmacology;genetics",
        "_version_":1605874458048856064},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) is a myeloproliferative disease. Imatinib (IM), the first line treatment for CML, is excessively expensive and induces various side effects in CML patients. Therefore, it is essential to investigate a new strategy for improving CML therapy. Our immunoblot data revealed that RanGTPase activating protein 1 (RanGAP1) protein levels increased by approximately 30-fold in K562 cells compared with those in normal cells. RanGAP1 is one of the important components of RanGTPase system, which regulates the export of nuclear protein. However, whether RanGAP1 level variation influences BCR-ABL nuclear export is still unknown. In this report, using shRNA to downregulate RanGAP1 expression level augmented K562 cell apoptosis by approximately 40% after treatment with 250 nM IM. Immunofluorescence assay also indicated that three-fold of nuclear BCR-ABL was detected. These data suggest that BCR-ABL nuclear entrapment induced by RanGAP1 downregulation can be used to improve IM efficacy. Moreover, our qRT-PCR data indicated a trend of inverse correlation between the RanGAP1 and microRNA (miR)-1301 levels in CML patients. MiR-1301, targeting the RanGAP1 3' untranslated region, decreased by approximately 100-fold in K562 cells compared with that in normal cells. RanGAP1 downregulation by miR-1301 transfection impairs BCR-ABL nuclear export to increase approximately 60% of cell death after treatment of 250 nM IM. This result was almost the same as treatment with 1000 nM IM alone. Furthermore, immunofluorescence assay demonstrated that Tyr-99 of nuclear P73 was phosphorylated accompanied with nuclear entrapment of BCR-ABL after transfection with RanGAP1 shRNA or miR-1301 in IM-treated K562 cells. Altogether, we demonstrated that RanGAP1 downregulation can mediate BCR-ABL nuclear entrapment to activate P73-dependent apoptosis pathway which is a novel strategy for improving current IM treatment for CML. ",
        "Doc_title":"MicroRNA-1301-Mediated RanGAP1 Downregulation Induces BCR-ABL Nuclear Entrapment to Enhance Imatinib Efficacy in Chronic Myeloid Leukemia Cells.",
        "Journal":"PloS one",
        "Do_id":"27228340",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605896617556180992},
      {
        "Doc_abstract":"Bcr-Abl tyrosine kinase inhibitors (TKIs) have been a remarkable success for the treatment of Ph(+) chronic myeloid leukemia (CML). However, a significant proportion of patients treated with TKIs develop resistance because of leukemia stem cells (LSCs) and T315I mutant Bcr-Abl. Here we describe the unknown activity of the natural product berbamine that efficiently eradicates LSCs and T315I mutant Bcr-Abl clones. Unexpectedly, we identify CaMKII  as a specific and critical target of berbamine for its antileukemia activity. Berbamine specifically binds to the ATP-binding pocket of CaMKII , inhibits its phosphorylation and triggers apoptosis of leukemia cells. More importantly, CaMKII  is highly activated in LSCs but not in normal hematopoietic stem cells and coactivates LSC-related -catenin and Stat3 signaling networks. The identification of CaMKII  as a specific target of berbamine and as a critical molecular switch regulating multiple LSC-related signaling pathways can explain the unique antileukemia activity of berbamine. These findings also suggest that berbamine may be the first ATP-competitive inhibitor of CaMKII , and potentially, can serve as a new type of molecular targeted agent through inhibition of the CaMKII  activity for treatment of leukemia.",
        "Doc_title":"CaMKII , a critical regulator of CML stem/progenitor cells, is a target of the natural product berbamine.",
        "Journal":"Blood",
        "Do_id":"23074277",
        "Doc_ChemicalList":"Benzamides;Benzylisoquinolines;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Imatinib Mesylate;Adenosine Triphosphate;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl;CAMK1G protein, human;Calcium-Calmodulin-Dependent Protein Kinase Type 1;berbamine",
        "Doc_meshdescriptors":"Adenosine Triphosphate;Animals;Apoptosis;Benzamides;Benzylisoquinolines;Blotting, Western;Calcium-Calmodulin-Dependent Protein Kinase Type 1;Cell Line, Tumor;Dose-Response Relationship, Drug;Drug Resistance, Neoplasm;Fusion Proteins, bcr-abl;HEK293 Cells;Humans;Imatinib Mesylate;K562 Cells;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mice;Mice, Inbred NOD;Mice, SCID;Models, Molecular;Mutation;Neoplastic Stem Cells;Piperazines;Protein Binding;Protein Kinase Inhibitors;Protein-Tyrosine Kinases;Pyrimidines;Tumor Cells, Cultured;Xenograft Model Antitumor Assays",
        "Doc_meshqualifiers":"chemistry;metabolism;drug effects;chemistry;metabolism;pharmacology;chemistry;genetics;metabolism;drug effects;genetics;antagonists & inhibitors;genetics;metabolism;drug therapy;genetics;pathology;drug effects;metabolism;pharmacology;pharmacology;antagonists & inhibitors;genetics;metabolism;pharmacology",
        "_version_":1605785154194767872},
      {
        "Doc_abstract":"S-phase progression of the cell cycle is accelerated in tumors through various genetic abnormalities, and, thus, pharmacologic inhibition of altered cell-cycle progression would be an effective strategy to control tumors. In the current study, we analyzed the antileukemic activity of three available small molecules targeting CDK4/CDK6 against lymphoid crisis of chronic myeloid leukemia (CML-LC) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph(+) ALL), and found that all three molecules showed specific activities against leukemic cell lines derived from CML-LC and Ph(+) ALL. In particular, PD0332991 exhibited extremely high antileukemic activity against CML-LC and Ph(+) ALL cell lines in the nanomolar range by the induction of G0-G1 arrest and partially cell death through dephosphorylation of pRb and downregulation of the genes that are involved in S-phase transition. As an underlying mechanism for favorable sensitivity to the small molecules targeting CDK4/CDK6, cell-cycle progression of Ph(+) lymphoid leukemia cells was regulated by transcriptional and posttranscriptional modulation of CDK4 as well as Cyclin D2 gene expression under the control of BCR-ABL probably through the PI3K pathway. Consistently, the gene expression level of Cyclin D2 in Ph(+) lymphoid leukemia cells was significantly higher than that in Ph(-) lymphoid leukemia cells. Of note, three Ph(+) ALL cell lines having the T315I mutation also showed sensitivity to PD0332991. In a xenograft model, PD0332991, but not imatinib, suppressed dissemination of Ph(+) ALL having the T315I mutation and prolonged survival, demonstrating that this reagent would be a new therapeutic modality for relapsed CML-LC and Ph(+) ALL patients after treatment with tyrosine kinase inhibitors.",
        "Doc_title":"Specific Antileukemic Activity of PD0332991, a CDK4/6 Inhibitor, against Philadelphia Chromosome-Positive Lymphoid Leukemia.",
        "Journal":"Molecular cancer therapeutics",
        "Do_id":"26637365",
        "Doc_ChemicalList":"Antineoplastic Agents;Cyclin D2;Cyclin-Dependent Kinase Inhibitor p16;Piperazines;Protein Kinase Inhibitors;Pyridines;Fusion Proteins, bcr-abl;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinase 6;palbociclib",
        "Doc_meshdescriptors":"Animals;Antineoplastic Agents;Apoptosis;Cell Cycle Checkpoints;Cell Line, Tumor;Cell Proliferation;Cyclin D2;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinase 6;Cyclin-Dependent Kinase Inhibitor p16;Disease Models, Animal;Dose-Response Relationship, Drug;Fusion Proteins, bcr-abl;Humans;Mice;Mutation;Piperazines;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Protein Kinase Inhibitors;Pyridines;Xenograft Model Antitumor Assays",
        "Doc_meshqualifiers":"pharmacology;drug effects;drug effects;drug effects;genetics;metabolism;antagonists & inhibitors;antagonists & inhibitors;metabolism;genetics;pharmacology;drug therapy;genetics;metabolism;mortality;pathology;pharmacology;pharmacology",
        "_version_":1605841937742430208},
      {
        "Doc_abstract":"Resistance toward imatinib (IM) and other BCR/ABL tyrosine kinase inhibitors remains troublesome in the treatment of advanced stage chronic myeloid leukemia (CML). The aim of this study was to estimate the reversal effects of down-regulation of Na(+)/H(+) exchanger 1 (NHE1) on the chemoresistance of BCR-ABL-positive leukemia patients' cells and cell lines. After treatment with the specific NHE1 inhibitor cariporide to decrease intracellular pH (pHi), the heme oxygenase-1 (HO-1) levels of the K562R cell line and cells from IM-insensitive CML patients decreased. HO-1, as a Bcr/Abl-dependent survival molecule in CML cells, is important for the resistance to tyrosine kinase inhibitors in patients with newly diagnosed CML or IM-resistant CML. Silencing PKC- and Nrf-2 or treatment with inhibitors of p38 pathways obviously blocked NHE1-induced HO-1 expression. Furthermore, treatment with HO-1 or p38 inhibitor plus IM increased the apoptosis of the K562R cell line and IM-insensitive CML patients' cells. Inhibiting HO-1 enhanced the activation of caspase-3 and poly(ADP-ribose) polymerase-1. Hence, the results support the anti-apoptotic role of HO-1 induced by NHE1 in the K562R cell line and IM-insensitive CML patients and provide a mechanism by which inducing HO-1 expression via the PKC-/p38-MAPK pathway may promote tumor resistance to oxidative stress. ",
        "Doc_title":"Induction of heme oxygenase-1 by Na+-H+ exchanger 1 protein plays a crucial role in imatinib-resistant chronic myeloid leukemia cells.",
        "Journal":"The Journal of biological chemistry",
        "Do_id":"25802333",
        "Doc_ChemicalList":"Benzamides;Cation Transport Proteins;NF-E2-Related Factor 2;NFE2L2 protein, human;Neoplasm Proteins;Piperazines;Protein Kinase Inhibitors;Pyrimidines;SLC9A1 protein, human;Sodium-Hydrogen Antiporter;Imatinib Mesylate;HMOX1 protein, human;Heme Oxygenase-1;PRKCB protein, human;Protein Kinase C beta",
        "Doc_meshdescriptors":"Adult;Aged;Apoptosis;Benzamides;Cation Transport Proteins;Drug Resistance, Neoplasm;Enzyme Induction;Female;Gene Expression Regulation, Leukemic;Heme Oxygenase-1;Humans;Imatinib Mesylate;K562 Cells;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;MAP Kinase Signaling System;Male;Middle Aged;NF-E2-Related Factor 2;Neoplasm Proteins;Oxidative Stress;Piperazines;Protein Kinase C beta;Protein Kinase Inhibitors;Pyrimidines;Sodium-Hydrogen Antiporter",
        "Doc_meshqualifiers":"drug effects;genetics;pharmacology;genetics;metabolism;drug effects;genetics;drug effects;genetics;biosynthesis;genetics;drug therapy;genetics;metabolism;pathology;drug effects;genetics;genetics;metabolism;antagonists & inhibitors;genetics;metabolism;drug effects;genetics;pharmacology;antagonists & inhibitors;genetics;metabolism;pharmacology;pharmacology;genetics;metabolism",
        "_version_":1605850982337478656},
      {
        "Doc_abstract":"Disease progression in myeloid malignancies results from the accumulation of \"mutations\" in genes that control cellular growth and differentiation. Many types of genetic alterations have been identified in myeloid diseases. However, the mechanism(s) by which these cells acquire genetic alterations or \"Genomic instability\", is less well understood. Increasing evidence suggests that the genetic changes in myeloid malignancies lead to increased production of endogenous sources of DNA damage, such as, reactive oxygen species (ROS). The fusion gene BCR-ABL in chronic myeloid leukemia (CML), FLT3/ITD in acute myeloid leukemia (AML), and RAS mutations in myelodysplastic syndromes (MDS)/myeloproliferative diseases (MPD) result in ROS production. Increased ROS can drive a cycle of genomic instability leading to DNA double strand breaks (DSBs) and altered repair that can lead to acquisition of genomic changes. Evidence is coming to light that defects in a main repair pathway for DSBs, non-homologous end-joining (NHEJ), lead to up-regulation of alternative or \"back-up\" repair that can create chromosomal deletions and translocations. This article will review evidence for activation of RAS/PI3K/STAT pathways, that lead to increased ROS, DNA damage and defective repair in myeloid diseases, a mechanism for acquisition of additional mutations that can drive disease progression.",
        "Doc_title":"Genomic instability in myeloid malignancies: increased reactive oxygen species (ROS), DNA double strand breaks (DSBs) and error-prone repair.",
        "Journal":"Cancer letters",
        "Do_id":"18467025",
        "Doc_ChemicalList":"Reactive Oxygen Species;STAT Transcription Factors;Phosphatidylinositol 3-Kinases;FLT3 protein, human;fms-Like Tyrosine Kinase 3",
        "Doc_meshdescriptors":"DNA Breaks, Double-Stranded;DNA Repair;Genes, abl;Genomic Instability;Humans;Leukemia, Myeloid;MAP Kinase Signaling System;Phosphatidylinositol 3-Kinases;Reactive Oxygen Species;STAT Transcription Factors;fms-Like Tyrosine Kinase 3",
        "Doc_meshqualifiers":"physiology;genetics;metabolism;physiology;physiology;metabolism;physiology;physiology",
        "_version_":1605746298414170112},
      {
        "Doc_abstract":"Secondary point mutations in the Fms-like tyrosine kinase 3 (FLT3) tyrosine kinase domain (KD) are common causes of acquired clinical resistance to the FLT3 inhibitors AC220 (quizartinib) and sorafenib. Ponatinib (AP24534) is a multikinase inhibitor with in vitro and clinical activity in tyrosine kinase inhibitor (TKI)-resistant chronic myeloid leukemia, irrespective of BCR-ABL KD mutation. Ponatinib has demonstrated early clinical efficacy in chemotherapy-resistant acute myeloid leukemia (AML) patients with internal tandem duplication (ITD) mutations in FLT3. We assessed the in vitro activity of ponatinib against clinically relevant FLT3-ITD mutant isoforms that confer resistance to AC220 or sorafenib. Substitution of the FLT3 \"gatekeeper\" phenylalanine with leucine (F691L) conferred mild resistance to ponatinib, but substitutions at the FLT3 activation loop (AL) residue D835 conferred a high degree of resistance. Saturation mutagenesis of FLT3-ITD exclusively identified FLT3 AL mutations at positions D835, D839, and Y842. The switch control inhibitor DCC-2036 was similarly inactive against FLT3 AL mutations. On the basis of its in vitro activity against FLT3 TKI-resistant F691 substitutions, further clinical evaluation of ponatinib in TKI-nave and select TKI-resistant FLT3-ITD+ AML patients is warranted. Alternative strategies will be required for patients with TKI-resistant FLT3-ITD D835 mutations.",
        "Doc_title":"Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD.",
        "Journal":"Blood",
        "Do_id":"23430109",
        "Doc_ChemicalList":"Benzothiazoles;DCC-2036;Imidazoles;Phenylurea Compounds;Protein Kinase Inhibitors;Pyridazines;Quinolines;Niacinamide;ponatinib;quizartinib;sorafenib;FLT3 protein, human;fms-Like Tyrosine Kinase 3",
        "Doc_meshdescriptors":"Amino Acid Sequence;Amino Acid Substitution;Benzothiazoles;Cell Line, Tumor;Drug Resistance, Neoplasm;Gene Duplication;Humans;Imidazoles;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Leukemia, Myeloid, Acute;Molecular Docking Simulation;Molecular Sequence Data;Niacinamide;Phenylurea Compounds;Protein Kinase Inhibitors;Protein Structure, Tertiary;Pyridazines;Quinolines;fms-Like Tyrosine Kinase 3",
        "Doc_meshqualifiers":"pharmacology;pharmacology;drug therapy;genetics;drug therapy;genetics;analogs & derivatives;pharmacology;pharmacology;pharmacology;pharmacology;pharmacology;antagonists & inhibitors;chemistry;genetics",
        "_version_":1605764314833092608},
      {
        "Doc_abstract":"The primary structure of normal abl protein was determined by sequencing the coding region of its cDNA. abl contains two alternative 5' exons spliced to a common set of 3' exons to yield the two major abl RNA transcripts. These transcripts initiate in different promoter regions and give rise to proteins that vary in their N-termini. In the human cell line K562, abl is translocated from chromosome 9 to within the bcr gene on chromosome 22. Within the fused bcr-abl gene, abl exon II alternatively splices to two adjacent bcr exons. This phenomenon is seen in many patients with chronic myeloid leukemia.",
        "Doc_title":"Alternative splicing of RNAs transcribed from the human abl gene and from the bcr-abl fused gene.",
        "Journal":"Cell",
        "Do_id":"3021337",
        "Doc_ChemicalList":"Proto-Oncogene Proteins;DNA",
        "Doc_meshdescriptors":"Abelson murine leukemia virus;Amino Acid Sequence;Chromosomes, Human, Pair 22;Chromosomes, Human, Pair 9;DNA;Exons;Gene Expression Regulation;Humans;Leukemia Virus, Murine;Leukemia, Myeloid;Philadelphia Chromosome;Promoter Regions, Genetic;Proto-Oncogene Proteins;Proto-Oncogenes;RNA Splicing;Translocation, Genetic",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;genetics",
        "_version_":1605759881226223616},
      {
        "Doc_abstract":"This study was purposed to investigate the sensitivity and specificity of conventional cytogenetics (CC), nested-reverse transcriptase polymerase chain reaction (nested-RT-PCR) and dual-color/dual-fusion fluorescence in situ hybridization (D-FISH) technique in monitoring the tumor load of chronic myeloid leukemia (CML) during treatment with transplantation. CC, nested-RT-PCR and interphase D-FISH were simultaneously carried out to detect the tumor load of 7 CML patients during treatment with non-myeloablative allogeneic stem cell transplantation (allo-NSCT). 40 specimens from 7 CML patients before and after allo-NSCT were analyzed. The results showed that 29 specimens were Ph (+) with different positive ratio and 3 specimens with lower cells were not analyzed by CC. 36 specimens were bcr/abl mRNA (+) by RT-PCR. 4 specimens from case 1 at 12, 18, 26 and 38 months after allo-NSCT were Ph (-) and bcr/abl mRNA (-), 4 Ph (-) bcr/abl (+) specimens containing 2 from case 1 at 9 and 10 months after allo-NSCT, 1 from case 2 at 15 months after allo-NSCT, 1 from case 3 at 12 months after allo-NSCT showed 5.4%, 0%, 16.5% and 1.5% bcr/abl (+) cells by FISH. 3 specimens with lower cells containing 2 from case 5 at 20 and 60 days after allo-NSCT and 1 from case 7 at 40 days after allo-NSCT were analyzed by FISH and showed 55.0%, 27.5% and 73.5% bcr/abl (+) cells. The Ph (-) bcr/abl (-) specimen from case 1 at 12 months post-allo-NSCT showed 0% bcr/abl (+) cells by FISH. It is concluded that CC can be used as a basic tool to monitor the change of tumor load in CML during treatment. When specimen with lower cells can not be analyzed by CC in early period after allo-NSCT, or result of CC can not evaluate precisely dynamic change of tumor load and when tumor load in treated patient are lower to Ph (-) by CC while bcr/abl mRNA (+) by RT-PCR, FISH must be used to detect precisely tumor load and monitor dynamic change of it. More sensitive RT-PCR is used to monitor tumor load when it is lower to bcr/abl (-) by FISH during treatment.",
        "Doc_title":"[Detection of tumor load in chronic myeloid leukemia during treatment with transplantation by conventional cytogenetics, nested-RT-PCR and FISH].",
        "Journal":"Zhongguo shi yan xue ye xue za zhi",
        "Do_id":"17493323",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adult;Cytogenetic Analysis;Female;Humans;In Situ Hybridization, Fluorescence;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Reverse Transcriptase Polymerase Chain Reaction;Stem Cell Transplantation;Tumor Burden",
        "Doc_meshqualifiers":"methods;pathology;therapy;methods",
        "_version_":1605928284352151552},
      {
        "Doc_abstract":"The effect of imatinib mesylate (imatinib) therapy on angiogenesis and myelofibrosis was investigated and compared with interferon (IFN) and hydroxyurea (HU) in 98 patients with newly diagnosed Philadelphia chromosome-positive/BCR-ABL(+) (Ph(+)/BCR-ABL(+)) chronic myeloid leukemia in first chronic phase and no other pretreatment. By means of immunostaining (CD34) and morphometry, a relationship between microvessel frequency and fiber density was detectable in initial bone marrow (BM) biopsies and sequential examinations after at least 8 months of therapy. First-line monotherapy with imatinib induced a significant reduction (normalization in comparison with controls) of microvessels and reticulin fibers. In most patients, decrease in BM vascularity was associated with a complete cytogenetic response. A significant anti-angiogenic effect was also observed after HU treatment, contrasting with IFN administration or combination regimens (IFN plus HU). In conclusion, our data support the anti-angiogenic capacity of imatinib by normalization of vascularity. In contrast, hematologic response following IFN treatment is independent from BM angiogenesis.",
        "Doc_title":"Reversal of bone marrow angiogenesis in chronic myeloid leukemia following imatinib mesylate (STI571) therapy.",
        "Journal":"Blood",
        "Do_id":"14726401",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Interferon-alpha;Piperazines;Pyrimidines;Recombinant Proteins;interferon alfa-2b;Imatinib Mesylate;Hydroxyurea",
        "Doc_meshdescriptors":"Adult;Antineoplastic Agents;Benzamides;Bone Marrow;Bone Marrow Examination;Drug Evaluation;Humans;Hydroxyurea;Imatinib Mesylate;Interferon-alpha;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Microcirculation;Neovascularization, Pathologic;Piperazines;Pyrimidines;Recombinant Proteins;Remission Induction;Retrospective Studies",
        "Doc_meshqualifiers":"therapeutic use;blood supply;therapeutic use;therapeutic use;drug therapy;pathology;drug therapy;therapeutic use;therapeutic use",
        "_version_":1605836474026033152},
      {
        "Doc_abstract":"A therapeutic strategy for treating cancer is to target and eradicate cancer stem cells (CSCs) without harming their normal stem cell counterparts. The success of this approach relies on the identification of molecular pathways that selectively regulate CSC function. Using BCR-ABL-induced chronic myeloid leukemia (CML) as a disease model for CSCs, we show that BCR-ABL downregulates the Blk gene (encoding B-lymphoid kinase) through c-Myc in leukemic stem cells (LSCs) in CML mice and that Blk functions as a tumor suppressor in LSCs but does not affect normal hematopoietic stem cells (HSCs) or hematopoiesis. Blk suppresses LSC function through a pathway involving an upstream regulator, Pax5, and a downstream effector, p27. Inhibition of this Blk pathway accelerates CML development, whereas increased activity of the Blk pathway delays CML development. Blk also suppresses the proliferation of human CML stem cells. Our results show the feasibility of selectively targeting LSCs, an approach that should be applicable to other cancers.",
        "Doc_title":"The Blk pathway functions as a tumor suppressor in chronic myeloid leukemia stem cells.",
        "Journal":"Nature genetics",
        "Do_id":"22797726",
        "Doc_ChemicalList":"Ebf1 protein, mouse;Myc protein, mouse;PAX5 Transcription Factor;Pax5 protein, mouse;Proto-Oncogene Proteins c-myc;Trans-Activators;Tumor Suppressor Proteins;Cyclin-Dependent Kinase Inhibitor p27;protein-tyrosine kinase p55(blk);src-Family Kinases",
        "Doc_meshdescriptors":"Animals;Cyclin-Dependent Kinase Inhibitor p27;Genes, abl;Hematopoietic Stem Cells;Humans;K562 Cells;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mice;Mice, Inbred C57BL;Mice, Knockout;Neoplastic Stem Cells;PAX5 Transcription Factor;Proto-Oncogene Proteins c-myc;Signal Transduction;Trans-Activators;Tumor Stem Cell Assay;Tumor Suppressor Proteins;src-Family Kinases",
        "Doc_meshqualifiers":"genetics;metabolism;metabolism;pathology;genetics;metabolism;pathology;metabolism;pathology;genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism",
        "_version_":1605891979840847872},
      {
        "Doc_abstract":"Tumor necrosis factor-related apoptosis-inducing ligand-TNFSF10 (TRAIL), a member of the TNF- family and a death receptor ligand, was shown to selectively kill tumor cells. Not surprisingly, TRAIL is downregulated in a variety of tumor cells, including BCR-ABL-positive leukemia. Although we know much about the molecular basis of TRAIL-mediated cell killing, the mechanism responsible for TRAIL inhibition in tumors remains elusive because (a) TRAIL can be regulated by retinoic acid (RA); (b) the tumor antigen preferentially expressed antigen of melanoma (PRAME) was shown to inhibit transcription of RA receptor target genes through the polycomb protein, enhancer of zeste homolog 2 (EZH2); and (c) we have found that TRAIL is inversely correlated with BCR-ABL in chronic myeloid leukemia (CML) patients. Thus, we decided to investigate the association of PRAME, EZH2 and TRAIL in BCR-ABL-positive leukemia. Here, we demonstrate that PRAME, but not EZH2, is upregulated in BCR-ABL cells and is associated with the progression of disease in CML patients. There is a positive correlation between PRAME and BCR-ABL and an inverse correlation between PRAME and TRAIL in these patients. Importantly, knocking down PRAME or EZH2 by RNA interference in a BCR-ABL-positive cell line restores TRAIL expression. Moreover, there is an enrichment of EZH2 binding on the promoter region of TRAIL in a CML cell line. This binding is lost after PRAME knockdown. Finally, knocking down PRAME or EZH2, and consequently induction of TRAIL expression, enhances Imatinib sensibility. Taken together, our data reveal a novel regulatory mechanism responsible for lowering TRAIL expression and provide the basis of alternative targets for combined therapeutic strategies for CML.",
        "Doc_title":"BCR-ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patients.",
        "Journal":"Oncogene",
        "Do_id":"20838376",
        "Doc_ChemicalList":"Antigens, Neoplasm;Antineoplastic Agents;Benzamides;DNA-Binding Proteins;PRAME protein, human;Piperazines;Pyrimidines;TNF-Related Apoptosis-Inducing Ligand;TNFSF10 protein, human;Transcription Factors;Imatinib Mesylate;EZH2 protein, human;Enhancer of Zeste Homolog 2 Protein;Polycomb Repressive Complex 2;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adenocarcinoma;Antigens, Neoplasm;Antineoplastic Agents;Benzamides;Breast Neoplasms;Carcinoma;Cell Line;DNA-Binding Proteins;Disease Progression;Enhancer of Zeste Homolog 2 Protein;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Lung Neoplasms;Melanoma;Piperazines;Polycomb Repressive Complex 2;Promoter Regions, Genetic;Pyrimidines;RNA Interference;TNF-Related Apoptosis-Inducing Ligand;Transcription Factors;Tumor Cells, Cultured;Up-Regulation",
        "Doc_meshqualifiers":"drug therapy;genetics;metabolism;analysis;metabolism;therapeutic use;drug therapy;genetics;metabolism;drug therapy;genetics;metabolism;analysis;metabolism;analysis;metabolism;drug therapy;genetics;metabolism;drug therapy;genetics;metabolism;drug therapy;genetics;metabolism;therapeutic use;therapeutic use;analysis;genetics;metabolism;analysis;metabolism",
        "_version_":1605891632182329344},
      {
        "Doc_abstract":"In most patients with chronic myeloid leukemia (CML), the disease can be kept under control using the BCR/ABL kinase inhibitor imatinib. Nevertheless, resistance or intolerance to imatinib and other BCR/ABL inhibitors may occur during therapy. Therefore, CML research is focusing on novel targets and targeted drugs. Polo-like kinase 1 (Plk1) is a serine/threonine kinase that plays an essential role in mitosis. In this study, we examined the expression of Plk1 in CML cells and its potential role as a therapeutic target. Plk1 was found to be expressed in phosphorylated form in the CML cell line K562 as well as in primary CML cells in all patients tested. Inhibition of BCR/ABL by imatinib or nilotinib (AMN107) led to decreased expression of the Plk1 protein in CML cells, suggesting that BCR/ABL promotes Plk1 generation. Silencing of Plk1 in CML cells by a small interfering RNA approach was followed by cell cycle arrest and apoptosis. Furthermore, the Plk1-targeting drug BI 2536 was found to inhibit proliferation of imatinib-sensitive and imatinib-resistant CML cells, including leukemic cells, carrying the T315 mutation of BCR/ABL with reasonable IC(50) values (1-50 nmol/L). The growth-inhibitory effects of BI 2536 on CML cells were found to be associated with cell cycle arrest and apoptosis. Moreover, BI 2536 was found to synergize with imatinib and nilotinib in producing growth inhibition in CML cells. In conclusion, Plk1 is expressed in CML cells and may represent a novel, interesting target in imatinib-sensitive and imatinib-resistant CML.",
        "Doc_title":"Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.",
        "Journal":"Cancer research",
        "Do_id":"20145140",
        "Doc_ChemicalList":"BI 2536;Benzamides;Cell Cycle Proteins;Piperazines;Protein Kinase Inhibitors;Proto-Oncogene Proteins;Pteridines;Pyrimidines;Imatinib Mesylate;Fusion Proteins, bcr-abl;Protein-Serine-Threonine Kinases;polo-like kinase 1",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Antineoplastic Combined Chemotherapy Protocols;Benzamides;Cell Cycle Proteins;Drug Delivery Systems;Drug Evaluation, Preclinical;Drug Resistance, Neoplasm;Female;Fusion Proteins, bcr-abl;Gene Expression Regulation, Enzymologic;Gene Expression Regulation, Leukemic;Humans;Imatinib Mesylate;K562 Cells;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Piperazines;Protein Kinase Inhibitors;Protein-Serine-Threonine Kinases;Proto-Oncogene Proteins;Pteridines;Pyrimidines",
        "Doc_meshqualifiers":"administration & dosage;therapeutic use;antagonists & inhibitors;genetics;physiology;methods;drug effects;genetics;physiology;blood;drug therapy;genetics;therapeutic use;therapeutic use;antagonists & inhibitors;genetics;physiology;antagonists & inhibitors;genetics;physiology;administration & dosage;therapeutic use;therapeutic use",
        "_version_":1605836948650328064},
      {
        "Doc_abstract":"A Phase I/II study was designed to show whether the addition of semisynthetic homoharringtonine (sHHT) would reduce the level of residual disease in patients with Ph-positive chronic myeloid leukemia who appeared to have achieved a suboptimal response to imatinib alone.;Patients with CML who had achieved >/= 35% Ph-negativity on imatinib were included. All patients had been treated with imatinib at >/= 400 mg/day for at least 2 years and had achieved a plateau in BCR-ABL transcripts defined by measuring BCR-ABL transcripts on at least 4 occasions over a minimum period of 1 year with the latest value not lower than the previous minimum value. Initially sHHT was given subcutaneously at a dose of 1.25 mg/m(2) twice daily for 1 day. Courses were repeated every 28 days. The dosage of sHHT was escalated by adding one day of treatment every two days. Efficacy was assessed by serial monitoring of blood levels of BCR-ABL transcripts.;Of 10 evaluable patients, 7 had an appreciable decline in BCR-ABL transcript levels; in 5 cases the reduction was greater than 1 log. Asthenia (n = 10) and cytopenias (n = 3) were prominent side-effects, but the drug was generally well tolerated. Mutations in the P-loop of the BCR-ABL kinase domain were found in 2 of the patients who responded to the addition of sHHT.;The addition of sHHT should be considered for patients on imatinib who fail to obtain low levels of minimal residual disease.",
        "Doc_title":"Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib.",
        "Journal":"Cancer",
        "Do_id":"15786422",
        "Doc_ChemicalList":"Benzamides;Harringtonines;Piperazines;Protein Kinase Inhibitors;Pyrimidines;homoharringtonine;Imatinib Mesylate;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adult;Aged;Antineoplastic Combined Chemotherapy Protocols;Benzamides;Cytogenetic Analysis;Drug Resistance, Neoplasm;Female;Fusion Proteins, bcr-abl;Harringtonines;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Mutation;Neoplasm, Residual;Piperazines;Protein Kinase Inhibitors;Protein-Tyrosine Kinases;Pyrimidines",
        "Doc_meshqualifiers":"therapeutic use;antagonists & inhibitors;genetics;administration & dosage;diagnosis;drug therapy;genetics;diagnosis;drug therapy;administration & dosage;adverse effects;antagonists & inhibitors;administration & dosage",
        "_version_":1605798160819552256},
      {
        "Doc_abstract":"We studied the immunomodulating effect of withdrawal of immunosuppression with cyclosporin A (CsA) in 42 patients with leukemic relapse of chronic myelogenous leukemia (CML) (n = 24), acute myeloid leukemia (AML) (n = 13) and acute lymphoblastic leukemia (ALL) (n = 5) after allogeneic unmanipulated bone marrow (BMT) or peripheral blood stem cell transplantation (PBSCT). Response to CsA withdrawal was monitored molecularly by the polymerase chain reaction for elimination of CML cells containing the bcr-abl messenger RNA (mRNA) transcript (n = 24), or mll-af4 mRNA transcript characteristic of leukemic cells with a 11q23 chromosomal abnormality (n = 1). Rapid tapering of CsA resulted in subsequent achievement of cytogenetic remission in 11 of 14 CML patients (79%) who relapsed in early disease phase (n = 9 cytogenetic relapse, n = 2 hematological relapse) after a median of 57 days. Three of 13 AML patients and one of five ALL patients achieved complete remission. CsA withdrawal was accompanied by the development of acute graft-versus-host disease (GVHD) grade II in most of the 24 patients with CML. Two patients who achieved remission of AML or ALL died from severe GVHD grade III-IV. We calculated a probability of 84% for achieving and remaining in remission with early relapse of CML 4 years after relapse post BMT, whereas patients with AML have only a probability of about 10% of achieving and remaining in remission after 3 years. Patients with advanced CML and ALL had no chance of achieving and remaining in remission in the same time period.",
        "Doc_title":"Induction of a graft-versus-leukemia reaction by cyclosporin A withdrawal as immunotherapy for leukemia relapsing after allogeneic bone marrow transplantation.",
        "Journal":"Bone marrow transplantation",
        "Do_id":"10231138",
        "Doc_ChemicalList":"Immunosuppressive Agents;Cyclosporine",
        "Doc_meshdescriptors":"Adolescent;Adult;Bone Marrow Transplantation;Cyclosporine;Female;Graft vs Host Disease;Graft vs Tumor Effect;Humans;Immunosuppressive Agents;Immunotherapy;Leukemia;Male;Middle Aged;Recurrence;Retrospective Studies;Transplantation, Homologous",
        "Doc_meshqualifiers":"pharmacology;etiology;drug effects;pharmacology;therapy",
        "_version_":1605763074530213888},
      {
        "Doc_abstract":"Chronic lymphocytic leukemia is an incurable B-cell malignancy that is associated with tumor cell-mediated T-cell dysfunction. It therefore represents a challenging disease for T-cell immunotherapeutics. The CD19/CD3 bi-specific antibody construct blinatumomab (AMG103 or MT103) has been tested clinically in non-Hodgkin's lymphoma and acute lymphoblastic leukemia but has not been assessed in chronic lymphocytic leukemia. We investigated whether blinatumomab could overcome T-cell dysfunction in chronic lymphocytic leukemia in vitro. Blinatumomab was tested on peripheral blood mononuclear cells from 28 patients (treatment nave and previously treated). T-cell activation and function, as well as cytotoxicity against leukemic tumor cells were measured. Blinatumomab induced T-cell activation, proliferation, cytokine secretion and granzyme B release in a manner similar to that occurring with stimulation with anti-CD3/anti-CD28 beads. However, only blinatumomab was able to induce tumor cell death and this was found to require blinatumomab-mediated conjugate formation between T cells and tumor cells. Cytotoxicity of tumor cells was observed at very low T-cell:tumor cell ratios. A three-dimensional model based on confocal microscopy suggested that up to 11 tumor cells could cluster round each T cell. Importantly, blinatumomab induced cytotoxicity against tumor cells in samples from both treatment-nave and treated patients, and in the presence of co-culture pro-survival signals. The potent cytotoxic action of blinatumomab on tumor cells appears to involve conjugation of T cells with tumor cells at both the activation and effector stages. The efficacy of blinatumomab in vitro suggests that the bi-specific antibody approach may be a powerful immunotherapeutic strategy in chronic lymphocytic leukemia. ",
        "Doc_title":"Blinatumomab induces autologous T-cell killing of chronic lymphocytic leukemia cells.",
        "Journal":"Haematologica",
        "Do_id":"23812940",
        "Doc_ChemicalList":"Antibodies, Bispecific;blinatumomab",
        "Doc_meshdescriptors":"Aged;Aged, 80 and over;Antibodies, Bispecific;Cells, Cultured;Coculture Techniques;Female;Humans;Leukemia, Lymphocytic, Chronic, B-Cell;Male;Middle Aged;T-Lymphocytes",
        "Doc_meshqualifiers":"pharmacology;therapeutic use;diagnosis;drug therapy;drug effects;pathology",
        "_version_":1605837180935077888},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) is characterized by the accumulation of Philadelphia chromosome-positive (Ph+) myeloid cells. Ph+ cells occur via a reciprocal translocation between the long arms of chromosomes 9 and 22 resulting in constitutively active BCR-ABL fusion protein. Tyrosine kinase inhibitors (TKIs) are used against the kinase activity of BCR-ABL protein for the effective treatment of CML. However, the development of drug resistance, caused by different genetic mechanisms, is the major issue in the clinical application of TKIs. These mechanisms include changes in expression levels of microRNAs (miRNAs). miRNAs are short non-coding regulatory RNAs that control gene expression and play an important role in cancer development and progression. In the present review, we highlight the roles of miRNAs both in the progression and chemotherapy-resistance of CML. Our understanding of these mechanisms may lead to the use of this knowledge not only in the treatment of patients with CML, but also in other type of cancers.",
        "Doc_title":"The roles of microRNAs in the pathogenesis and drug resistance of chronic myelogenous leukemia (Review).",
        "Journal":"Oncology reports",
        "Do_id":"26718125",
        "Doc_ChemicalList":"MicroRNAs",
        "Doc_meshdescriptors":"Drug Resistance, Neoplasm;Gene Expression Regulation, Neoplastic;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;MicroRNAs",
        "Doc_meshqualifiers":"genetics;genetics;drug therapy;genetics;genetics",
        "_version_":1605812888536088576},
      {
        "Doc_abstract":"Imatinib mesylate, an inhibitor of BCR/ABL tyrosine kinase, has remarkable activity in chronic myeloid leukemia resulting in an 87% major cytogenetic response. We describe a woman who failed to achieve any cytogenetic response after 2.5 years of imatinib, 400mg daily. When daily sargramostim (GM-CSF) 100 microg/m2 was added, cytogenetic studies revealed a gradual increase in percentage of normal cells from start, 4, 9, and 15 months at 0%, 10%, 55%, and 85%, respectively. She became transfusion independent after starting GM-CSF. The addition of GM-CSF to imatinib resulted in a clinical benefit and a major cytogenetic response in this patient.",
        "Doc_title":"Addition of sargramostim (GM-CSF) to imatinib results in major cytogenetic response in a patient with chronic myeloid leukemia.",
        "Journal":"Leukemia research",
        "Do_id":"16580068",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Pyrimidines;Recombinant Proteins;sargramostim;Granulocyte-Macrophage Colony-Stimulating Factor;Imatinib Mesylate;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Antineoplastic Agents;Benzamides;Biopsy;Bone Marrow;Female;Fusion Proteins, bcr-abl;Granulocyte-Macrophage Colony-Stimulating Factor;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Philadelphia Chromosome;Piperazines;Pyrimidines;Recombinant Proteins",
        "Doc_meshqualifiers":"pathology;antagonists & inhibitors;therapeutic use;drug therapy;genetics;therapeutic use;therapeutic use",
        "_version_":1605785192885125120},
      {
        "Doc_abstract":"Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) is initiated and driven by the oncogenic fusion protein BCR-ABL, a constitutively active tyrosine kinase. Despite major advances in the treatment of this highly aggressive disease with potent inhibitors of the BCR-ABL kinase such as dasatinib, patients in remission frequently relapse due to persistent minimal residual disease possibly supported, at least in part, by salutary cytokine-driven signaling within the hematopoietic microenvironment. Using a mouse model of Ph+ ALL that accurately mimics the genetics, clinical behavior, and therapeutic response of the human disease, we show that a combination of 2 agents approved by the US Food and Drug Administration (dasatinib and ruxolitinib, which inhibit BCR-ABL and Janus kinases, respectively), significantly extends survival by targeting parallel signaling pathways. Although the BCR-ABL kinase cancels the cytokine requirement of immature leukemic B cells, dasatinib therapy restores cytokine dependency and sensitizes leukemic cells to ruxolitinib. As predicted, ruxolitinib alone had no significant antileukemic effect in this model, but it prevented relapse when administered with dasatinib. The combination of dasatinib, ruxolitinib, and the corticosteroid dexamethasone yielded more durable remissions, in some cases after completion of therapy, avoiding the potential toxicity of other cytotoxic chemotherapeutic agents. ",
        "Doc_title":"Janus kinase inhibition by ruxolitinib extends dasatinib- and dexamethasone-induced remissions in a mouse model of Ph+ ALL.",
        "Journal":"Blood",
        "Do_id":"25499760",
        "Doc_ChemicalList":"INCB018424;Interleukin-7;Pyrazoles;Pyrimidines;RNA, Messenger;STAT3 Transcription Factor;Stat3 protein, mouse;Thiazoles;Dexamethasone;Fusion Proteins, bcr-abl;Janus Kinases;ADP-Ribosylation Factor 1;Dasatinib",
        "Doc_meshdescriptors":"ADP-Ribosylation Factor 1;Animals;Antineoplastic Combined Chemotherapy Protocols;Blotting, Western;Dasatinib;Dexamethasone;Disease Models, Animal;Drug Resistance, Neoplasm;Female;Fusion Proteins, bcr-abl;Humans;Interleukin-7;Janus Kinases;Male;Mice;Mice, Inbred C57BL;Mutation;Neoplasm Recurrence, Local;Philadelphia Chromosome;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Pyrazoles;Pyrimidines;RNA, Messenger;Real-Time Polymerase Chain Reaction;Remission Induction;Reverse Transcriptase Polymerase Chain Reaction;STAT3 Transcription Factor;Signal Transduction;Survival Rate;Thiazoles;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"physiology;therapeutic use;administration & dosage;drug effects;genetics;genetics;metabolism;antagonists & inhibitors;genetics;drug therapy;metabolism;mortality;pathology;drug therapy;metabolism;mortality;pathology;administration & dosage;administration & dosage;genetics;genetics;metabolism;administration & dosage",
        "_version_":1605882695479459840},
      {
        "Doc_abstract":"Imatinib mesylate (IM) induces clinical remissions in chronic-phase chronic myeloid leukemia (CML) patients but IM resistance remains a problem. We recently identified several features of CML CD34(+) stem/progenitor cells expected to confer resistance to BCR-ABL-targeted therapeutics. From a study of 25 initially chronic-phase patients, we now demonstrate that some, but not all, of these parameters correlate with subsequent clinical response to IM therapy. CD34(+) cells from the 14 IM nonresponders demonstrated greater resistance to IM than the 11 IM responders in colony-forming cell assays in vitro (P < .001) and direct sequencing of cloned transcripts from CD34(+) cells further revealed a higher incidence of BCR-ABL kinase domain mutations in the IM nonresponders (10%-40% vs 0%-20% in IM responders, P < .003). In contrast, CD34(+) cells from IM nonresponders and IM responders were not distinguished by differences in BCR-ABL or transporter gene expression. Interestingly, one BCR-ABL mutation (V304D), predicted to destabilize the interaction between p210(BCR-ABL) and IM, was detectable in 14 of 20 patients. T315I mutant CD34(+) cells found before IM treatment in 2 of 20 patients examined were preferentially amplified after IM treatment. Thus, 2 properties of pretreatment CML stem/progenitor cells correlate with subsequent response to IM therapy. Prospective assessment of these properties may allow improved patient management.",
        "Doc_title":"Properties of CD34+ CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylate.",
        "Journal":"Blood",
        "Do_id":"20574046",
        "Doc_ChemicalList":"Antigens, CD34;Benzamides;Piperazines;Pyrimidines;Imatinib Mesylate",
        "Doc_meshdescriptors":"Adult;Aged;Antigens, CD34;Benzamides;Cells, Cultured;Drug Resistance, Neoplasm;Female;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Neoplastic Stem Cells;Piperazines;Prognosis;Pyrimidines;Stem Cells;Young Adult",
        "Doc_meshqualifiers":"drug therapy;pathology;drug effects;pathology;pharmacology;therapeutic use;pharmacology;therapeutic use;drug effects",
        "_version_":1605753192982773760},
      {
        "Doc_abstract":"Aberrant expression of tumor suppressor genes WT 1, RB 1, p53, homozygous deletion of p16 gene and their relationship with expression of oncogenes BCR-ABL, TEL-AML 1, MLL-AF 4, E2A-PBX 1, SIL-TAL 1 were determined in bone marrow samples of children with de novo B-lineage (n=170) and T-lineage (n=25) acute lymphoblastic leukemia (ALL). In contrast to expression of chimeric oncogenes alterations in p16, WT 1, RB 1 and p53 expression were T/B-lineage-unrestricted. Significant association between expression of MLL-AF 4 and WT 1, E2A-PBX 1 and p53; SIL-TAL 1 and homozygous deletion of p16 has been demonstrated.",
        "Doc_title":"Aberrant expression of tumor suppressor genes and their association with chimeric oncogenes in pediatric acute lymphoblastic leukemia.",
        "Journal":"Leukemia research",
        "Do_id":"15878620",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Adolescent;Cell Line, Tumor;Child;Child, Preschool;Cyclin-Dependent Kinase Inhibitor p16;Female;Gene Deletion;Gene Expression Regulation, Neoplastic;Genes, Retinoblastoma;Genes, Tumor Suppressor;Genes, Wilms Tumor;Genes, p53;Humans;Infant;Male;Oncogenes;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Prognosis",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;diagnosis;genetics",
        "_version_":1605756703281774592},
      {
        "Doc_abstract":"Imatinib is one of the most recent medications used for the treatment of chronic myeloid leukemia (CML) and gastrointestinal stromal tumor (GIST). It is an orally administered protein-tyrosine kinase inhibitor, an enzyme which is produced by BCR-ABL fusion which results from translocation of 9:22 chromosome (Philadelphia chromosome). Imatinib blocks proliferation and induces apoptosis of BCR-ABL-expression in CML. Many side effects produced by imatinib have been documented but its induction of hepatotoxcity has been rarely reported. Only a few cases so far have been reported in the literature and almost all were in females. We describe another case of hepatotoxicity due to imatinib in a 17-year old female with clinical, laboratory and histopathological changes. The case described here suggests that imatinib may also induce immune hepatitis, in some patients.",
        "Doc_title":"Imatinib-induced immune hepatitis: case report and literature review.",
        "Journal":"Hematology (Amsterdam, Netherlands)",
        "Do_id":"17364993",
        "Doc_ChemicalList":"Antibodies, Antinuclear;Antineoplastic Agents;Autoantibodies;Autoantigens;Benzamides;Immunosuppressive Agents;Piperazines;Pyrimidines;Imatinib Mesylate;DNA;Prednisolone;Aspartate Aminotransferases;Alanine Transaminase",
        "Doc_meshdescriptors":"Adolescent;Alanine Transaminase;Antibodies, Antinuclear;Antibody Specificity;Antineoplastic Agents;Aspartate Aminotransferases;Autoantibodies;Autoantigens;Benzamides;DNA;Female;Hepatitis, Autoimmune;Humans;Imatinib Mesylate;Immunosuppressive Agents;Jaundice, Obstructive;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Leukemia, Myeloid, Chronic-Phase;Muscle, Smooth;Piperazines;Prednisolone;Pyrimidines",
        "Doc_meshqualifiers":"blood;blood;adverse effects;immunology;therapeutic use;blood;blood;immunology;immunology;drug therapy;etiology;immunology;pathology;therapeutic use;chemically induced;complications;drug therapy;complications;drug therapy;immunology;adverse effects;immunology;therapeutic use;therapeutic use;adverse effects;immunology;therapeutic use",
        "_version_":1605824106183262208},
      {
        "Doc_abstract":"Although leukemic stem cells (LSCs) show a symbiotic relationship with bone marrow microenvironmental niches, the mechanism by which the marrow microenvironment contributes to self-renewal and proliferation of LSCs remains elusive. In the present study, we identified a unique subpopulation of Philadelphia chromosome-positive (Ph(+)) acute lymphoblastic leukemia (ALL) cells coexpressing markers of endothelial cells (including VE-cadherin, PECAM-1, and Flk-1) and committed B-lineage progenitors. After long-term coculture with bone marrow stromal cells, tumor cells formed hematopoietic colonies and cords, expressed early stem- cell markers, and showed endothelial sprouting. Gene expression profiles of LSCs were altered in the presence of stromal cell contact. Stromal cell contact promoted leukemic cell VE-cadherin expression, stabilized beta-catenin, and up-regulated Bcr-abl fusion gene expression. Our study indicates that these specific tumor cells are uniquely positioned to respond to microenvironment-derived self-renewing and proliferative cues. Ph(+)/VE-cadherin(+) tumor subpopulation circumvents the requirement of exogenous Wnt signaling for self-renewal through stromal cell support of leukemic cell VE-cadherin expression and up-regulated Bcr-abl tyrosine kinase activity. These data suggest that strategies targeting signals in the marrow microenvironment that amplify the Bcr-abl/VE-cadherin/beta-catenin axis may have utility in sensitizing drug-resistant leukemic stem cells.",
        "Doc_title":"Ph+/VE-cadherin+ identifies a stem cell like population of acute lymphoblastic leukemia sustained by bone marrow niche cells.",
        "Journal":"Blood",
        "Do_id":"17638851",
        "Doc_ChemicalList":"Antigens, CD;Biomarkers;Cadherins;Wnt Proteins;beta Catenin;cadherin 5;Proteasome Endopeptidase Complex",
        "Doc_meshdescriptors":"Antigens, CD;Biomarkers;Bone Marrow Cells;Cadherins;Cell Proliferation;Cells, Cultured;Coculture Techniques;Drug Resistance, Neoplasm;Endothelial Cells;HL-60 Cells;Humans;Jurkat Cells;K562 Cells;Neoplastic Stem Cells;Philadelphia Chromosome;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Proteasome Endopeptidase Complex;Protein Processing, Post-Translational;Signal Transduction;Transfection;Wnt Proteins;beta Catenin",
        "Doc_meshqualifiers":"genetics;metabolism;metabolism;cytology;metabolism;physiology;genetics;metabolism;genetics;metabolism;cytology;metabolism;metabolism;pathology;metabolism;physiology;physiology;metabolism;physiology",
        "_version_":1605746841757941761},
      {
        "Doc_abstract":"The Philadelphia chromosome is formed from a translocation of genetic material involving human chromosomes 9 and 22. The resulting gene product, BCR-ABL, encodes for an abnormal tyrosine kinase (TK) that is a factor in the pathology of chronic myelogenous leukemia (CML). Use of targeted therapy that inhibits BCR-ABL kinase activity may lead to hematologic and cytogenetic responses in affected individuals. The oral TK inhibitor dasatinib was approved in 2006 for use in patients with CML or Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL) who are unable to tolerate or have not responded to other treatments.;This paper reviews the available data on dasatinib, including its pharmacokinetic and pharmacodynamic properties, findings of in vitro and in vivo studies, adverse effects, and potential place in therapy.;Pertinent information was identified through searches of MEDLINE (1966-May 2007), EMBASE (1980-first quarter 2007), and International Pharmaceutical Abstracts (1970-May 2007) using the terms dasatinib, BMS-354825, chronic myelogenous leukemia, Sprycel, Philadelphia chromosome, and acute lymphoblastic leukemia. All clinical studies and case reports published at the time of the search were included in this review.;Observed mutations in the amino acid sequence of BCR-ABL cause the failure of treatment with existing TK inhibitors. Dasatinib has shown in vitro and in vivo activity against BCR-ABL, including mutations that are resistant to other available TK inhibitors. Preliminary results are available from several noncomparative studies of dasatinib in patients who were unable to tolerate or were resistant to previous therapies. The 5 phases of START (SRC/ABL Tyrosine kinase inhibition Activity Research Trials of dasatinib) represent the largest and most comprehensive evaluation of dasatinib in the treatment of patients in all stages of CML or Philadelphia chromosome-positive ALL who had undergone previous treatment for leukemia. Dasatanib had the greatest benefit in patients in the chronic phase of CML, with complete hematologic responses in 90% of patients, 52% of whom achieved a major hematologic response. Compared with those in the chronic phase, patients in the accelerated phase or blast crisis of CML, or with Philadelphia chromosome-positive ALL had lower responses. In the START-R trial, which compared the response to dasatinib and high-dose imatinib (800 mg/d), both regimens had comparable ability to induce a complete hematologic response (95% and 93%, respectively), although more patients achieved a major cytogenetic response with dasatinib (32% vs 7%). Adverse effects include significant myelosuppression. Dasatinib may have the potential for use in the management of nonleukemic malignancies.;Dasatinib has a wider spectrum of activity against a broader range of BCR-ABL forms than existing TK inhibitors. It has shown clinical benefit and tolerability in patients in all phases of CML, as well as in those with Philadelphia chromosome-positive ALL. Dasatinib illustrates the potential for targeted drug development based on an understanding of the genetic alterations leading to CML and the development of resistance to treatment.",
        "Doc_title":"Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.",
        "Journal":"Clinical therapeutics",
        "Do_id":"18158072",
        "Doc_ChemicalList":"Benzamides;Enzyme Inhibitors;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Receptors, Purinergic P2;Thiazoles;Imatinib Mesylate;Protein-Tyrosine Kinases;Proto-Oncogene Proteins c-bcr;Dasatinib",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Benzamides;Clinical Trials as Topic;Clinical Trials, Phase I as Topic;Clinical Trials, Phase II as Topic;Dasatinib;Drug Resistance, Neoplasm;Enzyme Inhibitors;Female;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Models, Chemical;Mutation;Philadelphia Chromosome;Piperazines;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Protein Kinase Inhibitors;Protein-Tyrosine Kinases;Proto-Oncogene Proteins c-bcr;Pyrimidines;Randomized Controlled Trials as Topic;Receptors, Purinergic P2;Thiazoles",
        "Doc_meshqualifiers":"adverse effects;chemistry;pharmacokinetics;therapeutic use;drug therapy;therapeutic use;drug therapy;adverse effects;contraindications;pharmacokinetics;therapeutic use;antagonists & inhibitors;genetics;adverse effects;chemistry;pharmacokinetics;therapeutic use;genetics;adverse effects;chemistry;pharmacokinetics;therapeutic use",
        "_version_":1605751324615376896},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) is a hematopoietic stem cell disorder characterized by a specific hybrid gene BCR-ABL (formed as a result of t(9;22)). This leads to two possible mRNA usually present in leukemic cells, either B2A2 or B3A2. Targeting these mRNA by antisense oligonucleotides (AS) might offer the opportunity to decrease leukemic growth. We have tested the ability of AS to inhibit the in vitro proliferation of CD34 positive (CD34+) blood cells from 16 patients with newly diagnosed CML. CD34+ cells were isolated by an immunomagnetic technique and incubated for 16 to 18 hours with an 18 mer AS (0.25 mM). Sense oligonucleotides served as controls. The effects of AS were evaluated by clonogenic test (production of CFU-GM). Moreover, colonies were picked out and studied by RT-PCR to analyse the presence of BCR-ABL transcript. For nine patients with B3A2 transcript, the median inhibition of CFU-GM formation at day 14 was 64.0 +/- 11.2% (68.0 +/- 11.4% at day 21) and for the seven patients with a B2A2 transcript: 59.0 +/- 11.4% (72.5 +/- 12.0% at day 21). AS showed no effect on CD34+ cells from three normal volunteer donor cells. However, for every patient studied, colonies picked out remained BCR-ABL positive with the RT-PCR technique.",
        "Doc_title":"Effect of antisense oligonucleotides on CD34+ cells from chronic myeloid leukemia.",
        "Journal":"Leukemia & lymphoma",
        "Do_id":"10784402",
        "Doc_ChemicalList":"Antigens, CD34;Oligonucleotides, Antisense;RNA, Messenger;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Antigens, CD34;Cell Division;Fusion Proteins, bcr-abl;Gene Targeting;Hematopoietic Stem Cells;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Oligonucleotides, Antisense;RNA, Messenger;Reverse Transcriptase Polymerase Chain Reaction",
        "Doc_meshqualifiers":"genetics;genetics;pathology;drug therapy;genetics;pathology;genetics;therapeutic use;antagonists & inhibitors;genetics",
        "_version_":1605764529155735552},
      {
        "Doc_abstract":"We report the occurrence of a BCR-JAK2 fusion gene in a case of acute myeloid leukemia (AML) resulting from a t(9;22)(p24;q11) translocation as the sole cytogenetic abnormality. The BCR-JAK2 fusion gene has the same breakpoint in BCR as is found in the BCR/ABL p210. The chimeric gene is the result of a reciprocal translocation between chromosomes 9 and 22, which implies a double break on chromosome 9; this has allowed generating an in-frame fusion transcript. Previously, BCR-JAK2 rearrangement was observed in a single case with atypical chronic myelogenous leukemia (CML), but in that case the breakpoint in the BCR was different.",
        "Doc_title":"A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11) in a patient with acute myeloid leukemia.",
        "Journal":"Cancer genetics and cytogenetics",
        "Do_id":"18503828",
        "Doc_ChemicalList":"DNA Primers;JAK2 protein, human;Janus Kinase 2;Proto-Oncogene Proteins c-bcr",
        "Doc_meshdescriptors":"Aged;Base Sequence;Chromosomes, Human, Pair 22;Chromosomes, Human, Pair 9;DNA Primers;Female;Humans;In Situ Hybridization, Fluorescence;Janus Kinase 2;Leukemia, Myeloid, Acute;Proto-Oncogene Proteins c-bcr;Reverse Transcriptase Polymerase Chain Reaction;Translocation, Genetic",
        "Doc_meshqualifiers":"genetics;genetics;genetics",
        "_version_":1605759471613640704},
      {
        "Doc_abstract":"BCR/ABL tyrosine kinase generated from the chromosomal translocation t(9;22) causes chronic myelogenous leukemia and acute lymphoblastic leukemia. To examine the roles of BCR/ABL-activated individual signaling molecules and their cooperation in leukemogenesis, we inducibly expressed a dominant negative (DN) form of Ras, phosphatidylinositol 3-kinase, and STAT5 alone or in combination in p210 BCR/ABL-positive K562 cells. The inducibly expressed DN Ras (N17), STAT5 (694F), and DN phosphatidylinositol 3-kinase (Delta p85) inhibited the growth by 90, 55, and 40%, respectively. During the growth inhibition, the expression of cyclin D2 and cyclin D3 was suppressed by N17, 694F, or Delta p85; that of cyclin E by N17; and that of cyclin A by Delta p85. In addition, N17 induced apoptosis in a small proportion of K562, whereas 694F and Delta p85 were hardly effective. In contrast, coexpression of two DN mutants in any combinations induced severe apoptosis. During these cultures, the expression of Bcl-2 was suppressed by N17, 694F, or Delta p85, and that of Bcl-XL by N17. Furthermore, although K562 was resistant to interferon-alpha- and dexamethasone-induced apoptosis, disruption of one pathway by N17, 694F, or Delta p85 sensitized K562 to these reagents. These results suggested that cooperation among these molecules is required for full leukemogenic activities of BCR/ABL.",
        "Doc_title":"Functional cooperation among Ras, STAT5, and phosphatidylinositol 3-kinase is required for full oncogenic activities of BCR/ABL in K562 cells.",
        "Journal":"The Journal of biological chemistry",
        "Do_id":"11779872",
        "Doc_ChemicalList":"Annexin A5;BCL2L1 protein, human;CCND2 protein, human;CCND3 protein, human;Coloring Agents;Cyclin A;Cyclin D2;Cyclin D3;Cyclins;DNA, Complementary;DNA-Binding Proteins;Glucocorticoids;Interferon-alpha;Milk Proteins;Proto-Oncogene Proteins c-bcl-2;STAT5 Transcription Factor;STAT5A protein, human;Trans-Activators;Tumor Suppressor Proteins;bcl-X Protein;Dexamethasone;DNA;Luciferases;Phosphatidylinositol 3-Kinases;Fusion Proteins, bcr-abl;CASP3 protein, human;Caspase 3;Caspases;ras Proteins",
        "Doc_meshdescriptors":"Annexin A5;Apoptosis;Blotting, Northern;Blotting, Western;Caspase 3;Caspases;Cell Cycle;Cell Division;Coloring Agents;Cyclin A;Cyclin D2;Cyclin D3;Cyclins;DNA;DNA, Complementary;DNA-Binding Proteins;Dexamethasone;Fusion Proteins, bcr-abl;Genes, Dominant;Glucocorticoids;Humans;In Situ Nick-End Labeling;Interferon-alpha;K562 Cells;Luciferases;Milk Proteins;Mutation;Phosphatidylinositol 3-Kinases;Plasmids;Protein Binding;Proto-Oncogene Proteins c-bcl-2;STAT5 Transcription Factor;Signal Transduction;Time Factors;Trans-Activators;Tumor Suppressor Proteins;bcl-X Protein;ras Proteins",
        "Doc_meshqualifiers":"pharmacology;metabolism;pharmacology;biosynthesis;biosynthesis;metabolism;metabolism;metabolism;pharmacology;metabolism;pharmacology;pharmacology;metabolism;metabolism;metabolism;metabolism;metabolism;metabolism",
        "_version_":1605746812083240962},
      {
        "Doc_abstract":"To investigate the signal patterns of dual color dual fusion (DCDF) probe and extra signal (ES) probe in the detection of BCR/ABL fusion gene, and illustrate the relation between the fluorescence in situ hybridization (FISH) pattern and the karyotype.;Sixty-five cases of chronic myelocytic leukemia (CML) and 50 cases of acute lymphoblastic leukemia (ALL) were detected by FISH with DCDF probe, the BCR/ABL positive samples were detected by FISH with ES probe. Among these cases, 47 cases of CML and 40 cases of ALL perform conventional cytogenetics simultaneously.;All 65 cases of CML were all BCR/ABL positive by FISH. 17 cases showed the atypical pattern by DCDF-FISH, and 12 cases showed the atypical pattern by ES-FISH. There were 7 cases of BCR/ABL positive in 50 cases of ALL by FISH. By ES-FISH, there were 5 cases in which the break-point of BCR gene was located in m-bcr, 2 cases in which the break-point of BCR gene was located in M-bcr. Conventional cytogenetics demonstrated that 43/44(98%) cases of CML and 7/32(22%) cases of ALL were Ph positive.;The features of DCDF-FISH, ES-FISH and conventional cytogenetic are different from each other. According to the features of these method, it can increase the precision of the adjustment of genetic feature to analyze these results comprehensively.",
        "Doc_title":"[Comparison and significance of DCDF probe and ES probe in the detection of BCR/ABL fusion gene].",
        "Journal":"Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics",
        "Do_id":"21462140",
        "Doc_ChemicalList":"DNA Probes;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adult;Cytogenetics;DNA Probes;Female;Fusion Proteins, bcr-abl;Humans;In Situ Hybridization, Fluorescence;Karyotyping;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Precursor Cell Lymphoblastic Leukemia-Lymphoma",
        "Doc_meshqualifiers":"methods;genetics;methods;methods;genetics;genetics",
        "_version_":1605897838397489152},
      {
        "Doc_abstract":"Philadelphia-chromosome positive acute myeloid leukemia (Ph+ AML) is a rare entity and patient prognosis is poor, with short median survival. Biphenotypic acute leukemia (BAL) is a rare disorder that is difficult to diagnose and it displays features of both myeloid and lymphoid lineage. The aim of this study was to highlight the incidence of Philadelphia chromosome and its presence in cases of acute myeloid and biphenotypic leukemia and determine its role in the outcome of these leukemias.;This study examined 464 subjects with newly diagnosed acute myeloid leukemia: 312 were males and 152 were females. All individuals were subjected to immunophenotyping and conventional karyotyping. FISH was used in failed cases of conventional cytogenetics analysis to quantify disease and to prove positive BCR-ABL fusion gene.;the incidence of Ph+ chromosome was found to be higher in BAL (38.4%) than in AML (1.99%). There was statistically significant difference according to the age and the median survival time between the two groups.;Detection of specific chimeric transcripts in AML and BAL at the time of diagnosis was crucial since it plays an important role for accurate risk stratification and treatment management.",
        "Doc_title":"Incidence of Philadelphia-chromosome in acute myelogenous leukemia and biphenotypic acute leukemia patients: And its role in their outcome.",
        "Journal":"Leukemia research",
        "Do_id":"21612824",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adult;Age Factors;Aged;Egypt;Female;Genes, abl;Humans;Immunophenotyping;In Situ Hybridization, Fluorescence;Incidence;Karyotyping;Leukemia, Biphenotypic, Acute;Leukemia, Myeloid, Acute;Male;Middle Aged;Philadelphia Chromosome;Prognosis;Risk Factors;Survival Rate",
        "Doc_meshqualifiers":"genetics;diagnosis;epidemiology;genetics;mortality;pathology;diagnosis;epidemiology;genetics;mortality;pathology",
        "_version_":1605907964953100288},
      {
        "Doc_abstract":"Within the recent years, RNA interference (RNAi) has become an almost standard method for in vitro knockdown of any target gene of interest. Now, one major focus is to further explore its potential therapeutic use. From the mechanism, it becomes clear that small interfering RNAs (siRNAs) play a pivotal role in triggering RNAi. This chapter describes the in vivo application of targeted non-virally delivered synthetic bcr-abl siRNA in a female patient with recurrent Philadelphia chromosome positive chronic myeloid leukemia (CML) resistant to imatinib (Y253F mutation) and chemotherapy after allogeneic hematopoietic stem cell transplantation. A remarkable inhibition of the overexpressed bcr-abl oncogene resulting in increased apoptosis of CML cells was found. In vivo siRNA application was well tolerated without any clinically adverse events. The current findings imply that the clinical application of synthetic siRNA is feasible and safe and has real potential for genetic-based therapies using synthetic non-viral carriers. ",
        "Doc_title":"Targeting bcr-abl transcripts with siRNAs in an imatinib-resistant chronic myeloid leukemia patient: challenges and future directions.",
        "Journal":"Methods in molecular biology (Clifton, N.J.)",
        "Do_id":"25319658",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Fatty Acids, Monounsaturated;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Quaternary Ammonium Compounds;RNA, Messenger;RNA, Small Interfering;Imatinib Mesylate;Fusion Proteins, bcr-abl;1,2-dioleoyloxy-3-(trimethylammonium)propane",
        "Doc_meshdescriptors":"Antineoplastic Agents;Apoptosis;Benzamides;Drug Resistance, Neoplasm;Fatty Acids, Monounsaturated;Female;Fusion Proteins, bcr-abl;Gene Expression Regulation, Leukemic;Genetic Therapy;Hematopoietic Stem Cell Transplantation;Humans;Imatinib Mesylate;K562 Cells;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Middle Aged;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Quaternary Ammonium Compounds;RNA Interference;RNA, Messenger;RNA, Small Interfering;Treatment Outcome",
        "Doc_meshqualifiers":"administration & dosage;administration & dosage;chemistry;metabolism;antagonists & inhibitors;genetics;metabolism;methods;genetics;metabolism;pathology;therapy;administration & dosage;administration & dosage;administration & dosage;chemistry;metabolism;antagonists & inhibitors;genetics;metabolism;genetics;metabolism",
        "_version_":1605818565562204160},
      {
        "Doc_abstract":"We further characterized a novel type of chimeric BCR-ABL mRNA transcript detected in a patient with Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML).;We used reverse-transcription polymerase chain reaction (RT-PCR) and sequence analysis of the fusion region of the amplified cDNA fragment. Western analysis was performed on total protein.;Part of exon e8 of the BCR gene was joined to an intronic sequence of ABL intron Ib spliced on exon a2 of the ABL gene, giving rise to an in-frame e8-int-a2 BCR-ABL transcript. Only part of exon 8 of the BCR gene (e8) (intra-exonic break) was retained. The consequent BCR-int-ABL transcript was translated into a BCR-ABL protein of 1804 amino acid residues with a molecular mass of 197.5 kilodaltons (kDa) called p200 BCR-ABL. The 3' part of bcr exon 8 recombined within or alongside Alu elements at the additional sites. Sequence motifs similar to consensus binding sites of the lymphoid-associated TRAX and translisin proteins were present on both participating strands at 22q11 and 9q34 recombination sites, respectively. No differences in clinical or laboratory findings at diagnosis were found between this patient and CML patients with bcr-abl fusion.;The presence of Alu sequences and of the translisin binding motif on both sides of the breaks in this novel translocation suggests a possible general mechanism of molecular recombination in CML patients.",
        "Doc_title":"Alu and translisin recognition site sequences flanking translocation sites in a novel type of chimeric bcr-abl transcript suggest a possible general mechanism for bcr-abl breakpoints.",
        "Journal":"Haematologica",
        "Do_id":"10629590",
        "Doc_ChemicalList":"Neoplasm Proteins;RNA, Messenger;Recombinant Fusion Proteins;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Alu Elements;Blotting, Western;Chromosome Breakage;Exons;Female;Fusion Proteins, bcr-abl;Humans;Introns;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Middle Aged;Neoplasm Proteins;RNA, Messenger;Recombinant Fusion Proteins;Repetitive Sequences, Nucleic Acid;Reverse Transcriptase Polymerase Chain Reaction;Sequence Analysis, DNA;Translocation, Genetic",
        "Doc_meshqualifiers":"genetics;genetics;chemistry;genetics;genetics;chemistry;genetics;chemistry;genetics;genetics;genetics",
        "_version_":1605796189920296960},
      {
        "Doc_abstract":"Little evidence exists regarding the prognostic impact of the major BCR-ABL gene variants (e13a2 and e14a2) in chronic myeloid leukemia (CML) patients diagnosed and treated in the developing Asian countries. In this study, 139 Thai CML patients were followed for a median period of 3 years (range 18-43 months). Clinical presentations of both BCR-ABL gene variant groups (73% e14a2+ and 27% e13a2+) were similar, although e14a2+ patients tended to be older (42 vs. 37 years) and had higher white blood cell counts than e13a2+ patients. The majority of patients in both groups presented with Sokal stage 2-3 (score >0.8) and were categorized as Hasford's intermediate- to high-risk groups (score >780). All patients received oral chemotherapy and 13% underwent allogeneic stem cell transplantation. None received oral tyrosine kinase inhibitors. In the conventional chemotherapy group, the overall survival (OS) rate was slightly better in e14a2+ than in e13a2+ patients (p = n.s.). The median survival in e14a2+ and e13a2+ patients who did not receive stem cell transplantation was 49 and 33 months, respectively (p = n.s.). The type of blastic crisis in e14a2+ and e13a2+ patients was similar, being predominantly myeloid. In conclusion, CML patients in Thailand, despite being much younger, had a comparable OS with those in the Western countries, with no different OS between e14a2+ and e13a2+ patients. Future studies should focus on the impact of novel oral BCR-ABL tyrosine kinase inhibitors on the outcome of Thai CML patients with different BCR-ABL gene variants.",
        "Doc_title":"Natural history of Southeast Asian chronic myeloid leukemia patients with different BCR-ABL gene variants.",
        "Journal":"Acta haematologica",
        "Do_id":"16914906",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adolescent;Adult;Antineoplastic Combined Chemotherapy Protocols;Female;Fusion Proteins, bcr-abl;Genes, abl;Genetic Variation;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Neoplasm Staging;Retrospective Studies;Stem Cell Transplantation;Thailand;Transplantation, Homologous",
        "Doc_meshqualifiers":"administration & dosage;genetics;drug therapy;genetics;pathology;therapy",
        "_version_":1605830826606460928},
      {
        "Doc_abstract":"Imatinib mesylate has proven to be the most effective treatment in chronic myeloid leukemia. Nevertheless, imatinib resistance has raised concern and prompted interest in additional strategies to achieve disease eradication. Resistance to imatinib is mainly associated with three mechanisms: acquired mutations in the kinase domain of BCR-ABL protein, genetic amplification, and transcript overexpression of BCR-ABL rearrangement. Therefore an accurate assessment of resistance mechanism is particularly important to improve strategies to overcome resistance. In order to determine overexpression of BCR-ABL, we propose a method that correlates quantitative real time PCR and fluorescence in situ hybridization data from the same peripheral blood sample. The ratio between both methodologies permits to calculate the expression index (EI) for each patient. EI estimates the rate of BCR-ABL transcription per rearrangement. The median EI value, including all cases (n = 123), was 0.288; those cases (n = 13) included in percentile 90 showed an increment of EI above 1 Log (>2.88) with respect to the median value and were considered as cases with overexpression. We also evaluated the EIs using receiver operating characteristics curve; choosing an EI cutoff of 1.836 we obtained a sensitivity of 95% and a specificity of 61%. Using this EI cutoff value, more patients (n = 17) were included in the overexpression group. Patients within this group were resistant to imatinib and also showed a worse overall survival if compared with the remaining.",
        "Doc_title":"Specific assessment of BCR-ABL transcript overexpression and imatinib resistance in chronic myeloid leukemia patients.",
        "Journal":"European journal of haematology",
        "Do_id":"19191867",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Pyrimidines;Imatinib Mesylate;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Antineoplastic Agents;Benzamides;Chromosomes, Human, Pair 22;Chromosomes, Human, Pair 9;Drug Resistance, Neoplasm;Female;Fusion Proteins, bcr-abl;Gene Amplification;Gene Expression Regulation, Neoplastic;Gene Rearrangement;Humans;Imatinib Mesylate;In Situ Hybridization, Fluorescence;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Piperazines;Polymerase Chain Reaction;Pyrimidines;Reverse Transcriptase Polymerase Chain Reaction",
        "Doc_meshqualifiers":"therapeutic use;drug effects;genetics;drug effects;drug therapy;genetics;therapeutic use;therapeutic use",
        "_version_":1605810977580777472},
      {
        "Doc_abstract":"Thirty-six patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) were studied for the presence of the bcr-abl fusion mRNA transcript after an allogeneic matched related (N = 12), partially matched related (N = 4), matched unrelated (N = 14), autologous (N = 5), or syngeneic (N = 1) bone marrow transplant (BMT). Seventeen were transplanted in relapse, and 19 were transplanted in remission. Twenty-three patients had at least one positive bcr-abl polymerase chain reaction (PCR) assay after BMT either before a relapse or without subsequent relapse. Ten of these 23 relapsed after a positive assay at a median time from first positive PCR assay of 94 days (range, 28 to 416 days). By comparison, only 2 relapses occurred in the 13 patients with no prior positive PCR assays; both patients had missed at least one scheduled follow-up assay and were not tested 2 months and 26 months before their relapse. The unadjusted relative risk (RR) of relapse associated with a positive PCR assay compared with a negative assay was 5.7 (95% confidence interval 1.2 to 26.0, P = .025). In addition, the data suggest that the type of bcr-abl chimeric mRNA detected posttransplant was associated with the risk of relapse: 7 of 10 patients expressing the p190 bcr-abl relapsed, compared with 1 of 8 who expressed only the p210 bcr-abl mRNA (P = .02, log-rank test). The RR of p190 bcr-abl positivity compared to PCR-negative patients was 11.2 (confidence interval 2.3-54.8, P = 0.003), whereas a positive test for p210 bcr-abl was apparently not associated with an increased relative risk. In separate multivariable models, PCR positivity remained a statistically significant risk factor for relapse after separately adjusting for donor (unrelated and partially matched v matched, autologous, and syngeneic), remission status at the time of transplant, the presence of acute graft-versus-host disease (GVHD), and type of conditioning regimen (total body irradiation dose of < or = 1,200 cGy v > 1,200 cGy). The PCR assay appears to be a useful test for predicting patients at high risk of relapse after BMT and may identify patients who might benefit from therapeutic interventions. The finding that the expression of p190 bcr-abl may portend an especially high risk of relapse suggests a different clinical and biologic behavior between p190 and p210 bcr-abl.",
        "Doc_title":"Detection of bcr-abl transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after marrow transplantation.",
        "Journal":"Blood",
        "Do_id":"9116308",
        "Doc_ChemicalList":"Biomarkers, Tumor;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Acute Disease;Adolescent;Adult;Biomarkers, Tumor;Bone Marrow Transplantation;Child;Child, Preschool;Disease-Free Survival;Female;Fusion Proteins, bcr-abl;Graft vs Host Disease;Humans;Infant;Male;Middle Aged;Neoplasm, Residual;Philadelphia Chromosome;Polymerase Chain Reaction;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Recurrence;Risk;Treatment Failure",
        "Doc_meshqualifiers":"analysis;genetics;analysis;genetics;epidemiology;diagnosis;mortality;pathology;therapy",
        "_version_":1605747004861841410},
      {
        "Doc_abstract":"Monotherapy of chronic myeloid leukemia (CML) with imatinib mesylate has been cast into shadow by the evolution of clinical resistance during therapy. Resistance to imatinib can arise by multiple mechanisms including amplification or mutation of Bcr-Abl, and continuity of imatinib therapy is probably a poor option for either of these patient groups. Recently, however, a structurally distinct new class of drugs, the pyrido[2,3-d]pyrimidines, has been described, and these compounds are predicted to make different molecular contacts in the Abl kinase domain. These drugs potently target both the Bcr-Abl and Src-family kinase activities, both of which are thought to be relevant to survival of the leukemic cell. We asked whether these drugs could selectively induce cell death in murine cell line models of CML cells sensitive and resistant to imatinib by different mechanisms. We show that whereas the pyrido[2,3-d] pyrimidines are indeed highly potent in suppressing proliferation of Bcr-Abl-overexpressing imatinib-resistant cells, they are almost completely ineffective against cells expressing the T315I mutant. This implies that despite structural differences from imatinib, these drugs are unlikely to be useful in patients expressing this mutant Bcr-Abl protein, but may be effective in cases where selection of cells overexpressing the oncoprotein leads to refractoriness to imatinib.",
        "Doc_title":"Efficacy of dual-specific Bcr-Abl and Src-family kinase inhibitors in cells sensitive and resistant to imatinib mesylate.",
        "Journal":"Leukemia",
        "Do_id":"15201856",
        "Doc_ChemicalList":"Benzamides;Enzyme Inhibitors;Piperazines;Pyrimidines;Imatinib Mesylate;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl;src-Family Kinases",
        "Doc_meshdescriptors":"Animals;Benzamides;Cell Division;Cell Line, Tumor;Dose-Response Relationship, Drug;Drug Delivery Systems;Drug Resistance, Neoplasm;Enzyme Inhibitors;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mice;Piperazines;Protein-Tyrosine Kinases;Pyrimidines;Treatment Outcome;src-Family Kinases",
        "Doc_meshqualifiers":"drug effects;pharmacology;therapeutic use;analysis;antagonists & inhibitors;drug therapy;pathology;pharmacology;antagonists & inhibitors;pharmacology;therapeutic use;antagonists & inhibitors",
        "_version_":1605796906318954496},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder of hematopoietic stem cells. It is characterized at the cytogenetic level by Philadelphia (ph) chromosome and at the molecular level by the BCR/ABL gene rearrangement. Bone marrow derived mesenchymal stem cells (MSCs) are pluripotent stem cells that can differentiate into several mesenchymal tissues.;To observe the biological characteristics of MSCS from CML patients and to determine whether MSCs harbor the abnormal BCR/ABL translocation similar to CML bone marrow cells.;Characterized MSCs were isolated from 12 newly diagnosed Philadelphia positive untreated CML patients.;MSCs can be readily isolated from CML marrow and exhibit major expansion. Flow cytometry analysis revealed the typical MSC phenotype. Moreover; MSCs do not harbor the BCR/ABL translocation confirmed by karyotype and real time PCR.;MSCs from CML patients express the typical MSC phenotype; and do not express the BCR/ABL gene. Since; MSCs are able to support engraftment of hematopoietic stem cells in stem cell transplantation(SCT) as well as suppress alloreactive T cells causing graft versus -host disease, this current study provides evidence that in a SCT setting of CML patients, autologous MSCs could be a source of stem cell support in future cell therapy applications.",
        "Doc_title":"Detection of BCR/ABL Translocation in Bone Marrow Derived Mesenchymal Stem Cells in Egyptian CML Patients.",
        "Journal":"Open access Macedonian journal of medical sciences",
        "Do_id":"27275226",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605928170364600320},
      {
        "Doc_abstract":"The cytogenetic finding of the Ph1+ chromosome and its molecular biologic marker bcr/abl gene rearrangement in cells from patients with chronic myeloid leukemia are associated with a proliferative advantage of the Ph1+ clone in vivo. Although the transition to the acute terminal phase or blastic crisis is often associated with additional cytogenetic abnormalities, the molecular events which correlate the initial cytogenetic lesion with the terminal phase are poorly understood. Defective cellular DNA repair capacity is often associated with chromosomal instability, increased mutation frequency, and biologic alterations.;We, therefore, tested whether the protein product of the bcr/abl translocation (p210) could alter DNA repair after gamma-irradiation of murine cell lines expressing the bcr/abl cDNA.;The 32D cl 3 parent, 32D cl 3 pYN (containing the control vector plasmid) and each of two sources of 32D cl 3 cells expressing p210 bcr/abl cDNA (32D-PC1 cell line and 32D-LG7 subclone) showed a D0 of 1.62, 1.57, 1.16, and 1.27 Gy, respectively. Thus, expression of the p210 bcr/abl product induced a significant (p < 0.05) increase in radiosensitivity at the clinically relevant radiation therapy dose-rate (1.16 Gy/min). The increased radiosensitivity of p210 bcr/abl expressing cells persisted if cells were held before plating in a density-inhibited state for 8 hr after gamma-irradiation, indicating little effect on the repair of potentially lethal gamma-irradiation damage. The IL-3 dependent parent 32D cl 3 cells demonstrated programmed cell death in the absence of growth factor or following gamma-irradiation to 200 cGy. Expression of bcr/abl cDNA in the 32D-PC1 and 32D-LG7 sub clones abrogated IL-3 requirement of these cell lines and inhibited gamma-irradiation induced programmed cell death.;These data suggest a role for bcr/abl p210 in amplifying gamma-irradiation DNA damage or broadly inhibiting DNA repair, conditions that may stimulate further cytogenetic alterations in hematopoietic cells.",
        "Doc_title":"Expression of p210 bcr/abl increases hematopoietic progenitor cell radiosensitivity.",
        "Journal":"International journal of radiation oncology, biology, physics",
        "Do_id":"8344852",
        "Doc_ChemicalList":"Biomarkers;Proto-Oncogene Proteins",
        "Doc_meshdescriptors":"Biomarkers;DNA Repair;Gene Expression;Hematopoietic Stem Cells;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Philadelphia Chromosome;Proto-Oncogene Proteins;Radiation Genetics;Radiation Tolerance;Translocation, Genetic",
        "Doc_meshqualifiers":"radiation effects;genetics;pathology",
        "_version_":1605852620219482112},
      {
        "Doc_abstract":"The mouse c-abl gene, part of the sequence of which was captured in Moloney murine leukemia virus to generate the transforming gene (v-abl) of the Abelson murine leukemia virus, has been isolated and characterized. The c-abl locus spans 40 kb in the mouse genome with the v-abl homologies distributed in no less than ten clusters along 25 kb of the cloned DNA. Partial sequence of the v-abl homologous regions indicates that v-abl derived from c-abl mainly by splicing of multiple exons of the c-abl gene. The c-abl sequences can be subdivided into two regions: a tyrosine kinase coding sequence distributed among eight small clusters on the 5' end of the gene and a C-terminal portion consisting of one small and one large cluster, which are needed neither for the tyrosine kinase activity nor for the transforming ability of v-abl. Apparent exon/intron boundaries in the homologous kinase-coding regions of c-abl and c-src are at different locations.",
        "Doc_title":"The mouse c-abl locus: molecular cloning and characterization.",
        "Journal":"Cell",
        "Do_id":"6319018",
        "Doc_ChemicalList":"Protein Kinases;Protein-Tyrosine Kinases;DNA Restriction Enzymes",
        "Doc_meshdescriptors":"Amino Acid Sequence;Animals;Bacteriophage lambda;Base Sequence;Cloning, Molecular;DNA Restriction Enzymes;Genes, Viral;Leukemia, Experimental;Mice;Moloney murine leukemia virus;Nucleic Acid Hybridization;Oncogenes;Protein Kinases;Protein-Tyrosine Kinases",
        "Doc_meshqualifiers":"genetics;genetics;microbiology;genetics;genetics",
        "_version_":1605742069485142018},
      {
        "Doc_abstract":"We have explored the RNA oncogene expression by three human acute lymphoblastic leukemia lines, NALM-6, MOLT-3, and REH. We compared such expression with that of normal human lymphocytes. Marked differences in the RNA expression of the third exon of c-myc, v-myb, v-Hras, N-ras, v-fes, and v-fos were found. We noted minimal or no differences in the RNA expression of v-abl, B-lym, v-erb-B, c-ets, v-fms, v-kras, v-mos, v-raf, and v-sis.",
        "Doc_title":"Oncogene RNA expression in three human lymphoblastic leukemia cell lines lymphocytes.",
        "Journal":"Pediatric hematology and oncology",
        "Do_id":"1373069",
        "Doc_ChemicalList":"RNA",
        "Doc_meshdescriptors":"Cell Line;Humans;Lymphocytes;Oncogenes;Precursor Cell Lymphoblastic Leukemia-Lymphoma;RNA;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"chemistry;genetics;analysis",
        "_version_":1605908223109365760},
      {
        "Doc_abstract":"Philadelphia chromosome positive (Ph(+)) acute lymphoblastic leukemia (ALL) includes at least one-quarter of all adults with ALL. Until recently, conventional chemotherapy programs that have been effective in other precursor B-cell ALL cases have been unable to cure patients with this diagnosis. Allogeneic stem cell transplantation early in first remission has been the recommended therapy. The availability of imatinib mesylate and other tyrosine kinase inhibitors and small molecules that affect the BCR/ABL signaling pathways may be changing the treatment paradigm and the prognosis for these patients. The results from clinical trials using imatinib in the frontline setting and in relapsed patients as well as preliminary experience treating imatinib-resistant Ph(+) ALL will be described.",
        "Doc_title":"Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.",
        "Journal":"Hematology. American Society of Hematology. Education Program",
        "Do_id":"16304368",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Pyrimidines;Imatinib Mesylate;Fusion Proteins, bcr-abl;Prednisone",
        "Doc_meshdescriptors":"Adult;Antineoplastic Agents;Benzamides;Chromosomes, Human, Pair 22;Chromosomes, Human, Pair 9;Clinical Trials as Topic;Drug Resistance, Neoplasm;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Neoplasm, Residual;Philadelphia Chromosome;Piperazines;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Prednisone;Prognosis;Pyrimidines;Stem Cell Transplantation;Survival Rate",
        "Doc_meshqualifiers":"therapeutic use;genetics;physiology;diagnosis;therapeutic use;drug therapy;genetics;mortality;surgery;therapeutic use;therapeutic use",
        "_version_":1605824261050597376},
      {
        "Doc_abstract":"Reactivation of hepatitis B virus (HBV) following immunosuppressive therapy or hematopoietic stem cell transplantation is a potentially fatal complication that may occur even in patients with prior resolution of HBV infection. Dasatinib is a small-molecule inhibitor of the tyrosine kinases SRC and ABL that has been approved for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia. Here, we report the first case of reactivation of resolved infection with the HBV immune escape mutant G145R in a CML patient receiving dasatinib. Although dasatinib is not recognized as an immunosuppressant, our observations suggest that dasatinib may enhance HBV replication and induce its reactivation in immunocompetent patients, that HBV escape mutants may contribute to the pathogenesis of HBV reactivation, and that close monitoring of HBV status is advisable in patients with current or resolved HBV infection. ",
        "Doc_title":"Reactivation of resolved infection with the hepatitis B virus immune escape mutant G145R during dasatinib treatment for chronic myeloid leukemia.",
        "Journal":"International journal of hematology",
        "Do_id":"25842192",
        "Doc_ChemicalList":"Dasatinib",
        "Doc_meshdescriptors":"Aged;Amino Acid Substitution;Dasatinib;Female;Hepatitis B;Hepatitis B virus;Humans;Immune Evasion;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mutation, Missense;Virus Activation",
        "Doc_meshqualifiers":"administration & dosage;adverse effects;genetics;immunology;physiology;drug effects;genetics;drug therapy;immunology;virology;drug effects;genetics;immunology",
        "_version_":1605908273218715648},
      {
        "Doc_abstract":"To analyze the clinical efficacy of imatinib mesylate (IM) for Ph-positive or BCR-ABL positive chronic myeloid leukemia (CML) to couple the trough plasma concentrations (C mins) of IM with clinical responses and adverse events (AEs).;One hundred and one CML patients received IM therapy, and Cmins of IM were determined in 30 patients.;(1) Cumulative complete hematological response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR) and negative BCR/ABL fusion gene rates were 96.6%, 86.5%, 77.5% and 47.2%, respectively, in CML-CP patients. In accelerated and blastic phases (AP and BC) patients, CHR, MCyR, CCyR and negative BCR-ABL fusion gene rates were 58.3%, 25.0%, 25.0%, 8.3%, respectively. (2) Mean Cmins of IM was significantly higher in the CCyR at 1 year [(1472 +/- 482) microg/L] group than in the non-CCyR at 1 years group [(1067 +/- 373) microg/L] (P < 0.05), and higher in the MMR at 1 year group than in the non-MMR at 1 years group [(1624 +/- 468) microg/L vs (1137 +/- 404) microg/L, P < 0.05].;IM significantly improves cytogenetic and molecular response, event-free survival, and overall survival for patients with Ph-positive CML. The Cmins of IM exerts a significant impact on clinical response (CCyR and MMR at 1 year).",
        "Doc_title":"[Monitoring of plasma concentration of imatinib mesylate in patients with chronic myeloid leukemia].",
        "Journal":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi",
        "Do_id":"22213863",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Pyrimidines;Imatinib Mesylate",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Antineoplastic Agents;Benzamides;Female;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Piperazines;Pyrimidines;Treatment Outcome;Young Adult",
        "Doc_meshqualifiers":"blood;therapeutic use;blood;drug therapy;blood;therapeutic use;blood;therapeutic use",
        "_version_":1605746451749535746},
      {
        "Doc_abstract":"In recent years, a few cases of chronic myeloid leukemia (CML) have been reported with both BCR-ABL and JAK2V617F mutations. Moreover, mutations in the additional sex comb-like 1 (ASXL1) gene were recently shown in various myeloid malignancies.There were no previous studies investigating the incidence of the ASXL1 and JAK2V617F mutations in Iranian patients with CML. Consequently, this study focuses on the analysis of these mutations in patients with CML.;In total, 66 patients with a clinical diagnosis of CML were examined at the time of diagnosis. Thirty healthy subjects were checked as controls. Exon 12 of ASXL1 was amplified from genomic DNA and bidirectionally sequenced. We also performed JAK2V617F screening by amplification refractory mutation system-polymerase chain reaction and sequencing.;Mutations in the ASXL1 gene were found in five out of 66 CML patients (7.6%). We identified a novel variant (c.1968G > A, p.Asp656Asn) in one of the patients that has not been reported before. We also identified BCR-ABL and JAK2V617F mutations simultaneously in four patients (6%).;Our demonstration of ASXL1 mutation, a putative tumor suppressor gene, represents an important molecular abnormality in CML. We also showed that concomitant detection of BCR-ABL and JAK2V617F mutations has a relatively high incidence in Iranian patients.",
        "Doc_title":"ASXL1 and JAK2V617F gene mutation screening in Iranian patients with chronic myeloid leukemia.",
        "Journal":"Asia-Pacific journal of clinical oncology",
        "Do_id":"27640403",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605798154073014272},
      {
        "Doc_abstract":"The objective of this study was to evaluate the ability of the clinically available histone deacetylase (HDAC) inhibitor valproate to enhance the cytotoxicity of the Bcr-Abl inhibitor imatinib in imatinib-resistant cell lines.;Interactions between imatinib, and valproate have been examined in imatinib-sensitive and -resistant chronic myeloid leukemia (CML)cell lines (K562, KCL-22, CML-T1) and in bone marrow mononuclear cells (MNCs) derived from imatinib-resistant CML patients.;In imatinib-sensitive cell lines, cotreatment with imatinib 0.5 muM and valproate 5 microM for 48 hours potently enhanced imatinib-induced growth arrest and apoptosis. In resistant cell lines and in primary MNCs derived from imatinib-rsistant patients, valproate restored sensitivity to the cytotoxic effects of imatinib. Coexposure of cells to valproate and imatinib was associated with repression of several genes involved in Bcr-Abl transformation. In particular, the combination valproate-imatinib downregulated the expression of Bcr-Abl and the antiapoptotic protein Bcl-2, which is particularly overexpressed in imatinib-resistant clones.;Data from this study suggested that administration of the clinically available HDAC inhibitor valproate may be a powerful strategy to enhance cytotoxic effects of imatinib in those patient resistant to imatinib or in which complete cytogenetic remission has been not reached.",
        "Doc_title":"Valproate enhances imatinib-induced growth arrest and apoptosis in chronic myeloid leukemia cells.",
        "Journal":"Cancer",
        "Do_id":"16444746",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Enzyme Inhibitors;Piperazines;Pyrimidines;Valproic Acid;Imatinib Mesylate",
        "Doc_meshdescriptors":"Antineoplastic Agents;Apoptosis;Benzamides;Drug Interactions;Drug Resistance, Neoplasm;Enzyme Inhibitors;Gene Expression Regulation, Neoplastic;Genes, abl;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Piperazines;Pyrimidines;Tumor Cells, Cultured;Valproic Acid",
        "Doc_meshqualifiers":"pharmacology;drug effects;pharmacology;drug effects;pathology;pharmacology;pharmacology;pharmacology",
        "_version_":1605809597339140096},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) is a stem cell disease in which BCR/ABL promotes the survival of leukemic cells. Heme oxygenase-1 (HO-1) is an inducible stress protein that catalyzes the degradation of heme and has recently been implicated in the regulation of growth and survival of various neoplastic cells. In the present study, we analyzed the expression and role of HO-1 in CML cells. As assessed by Northern and Western blot analysis as well as immunostaining, primary CML cells were found to express HO-1 mRNA and the HO-1 protein in a constitutive manner. Exposure of these cells to the BCR/ABL tyrosine kinase inhibitor STI571 resulted in decreased expression of HO-1 mRNA and protein. In addition, BCR/ABL was found to up-regulate HO-1 promoter activity, mRNA levels, and protein levels in Ba/F3 cells. To investigate the role of HO-1 for survival of primary CML cells, the HO-1 inducer hemin was used. Hemin-induced expression of HO-1 was found to protect CML cells from STI571-induced cell death. In addition, inhibition of HO-1 by zinc-(II)-deuteroporphyrin-IX-2,4-bisethyleneglycol resulted in a substantial decrease of cell viability. Furthermore, overexpression of HO-1 in the CML-derived cell line K562 was found to counteract STI571-induced apoptosis. Together, our data identify HO-1 as a novel BCR/ABL-driven survival molecule and potential target in leukemic cells in patients with CML. The pathogenetic and clinical implications of this observation remain to be elucidated.",
        "Doc_title":"Identification of heme oxygenase-1 as a novel BCR/ABL-dependent survival factor in chronic myeloid leukemia.",
        "Journal":"Cancer research",
        "Do_id":"15126353",
        "Doc_ChemicalList":"Benzamides;Membrane Proteins;Piperazines;Pyrimidines;RNA, Messenger;Carbon Monoxide;Imatinib Mesylate;Iron;HMOX1 protein, human;Heme Oxygenase (Decyclizing);Heme Oxygenase-1;Fusion Proteins, bcr-abl;Biliverdine",
        "Doc_meshdescriptors":"Apoptosis;Benzamides;Biliverdine;Carbon Monoxide;Cell Line, Transformed;Fusion Proteins, bcr-abl;Gene Expression Regulation, Enzymologic;Gene Expression Regulation, Leukemic;Heme Oxygenase (Decyclizing);Heme Oxygenase-1;Humans;Imatinib Mesylate;Iron;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Membrane Proteins;Piperazines;Pyrimidines;RNA, Messenger;Transcriptional Activation",
        "Doc_meshqualifiers":"drug effects;physiology;metabolism;pharmacology;metabolism;pharmacology;genetics;physiology;biosynthesis;genetics;physiology;metabolism;pharmacology;enzymology;genetics;pathology;pharmacology;pharmacology;biosynthesis;genetics",
        "_version_":1605876044071436288},
      {
        "Doc_abstract":"The clinical progression of chronic myeloid leukemia (CML) from chronic phase to blast crisis is characterized by the increasing failure of myeloid precursors to differentiate into mature granulocytes. This study was undertaken to investigate the influence of Bcr-Abl and of the small molecule Abl tyrosine-kinase inhibitor imatinib mesylate on granulocyte colony-stimulating factor (G-CSF)-induced neutrophilic differentiation. We show that differentiation of 32Dcl3 cells into mature granulocytes is accompanied by the increased expression of the antigens macrophage adhesion molecule-1 (Mac-1) and Gr-1, of the G-CSF receptor (G-CSFR), of myeloid transcription factors (CCAAT/enhancer-binding protein-alpha [C/EBPalpha], C/EBPepsilon, and PU.1), and of the cyclin-dependent kinase inhibitor p27(Kip1). In 32Dcl3 cells transfected with the bcr-abl gene (32D(Bcr-Abl)), G-CSF did not trigger either granulocytic differentiation or the up-regulation of C/EBPalpha, C/EBPepsilon, and the G-CSFR. This could be correlated to a defect in c-Myc down-regulation. In contrast, the up-regulation of PU.1 and p27(Kip1) by G-CSF was not affected by Bcr-Abl. Importantly, incubation of 32D(Bcr-Ablwt) cells with the kinase inhibitor imatinib mesylate prior to G-CSF stimulation completely neutralized the effects of Bcr-Abl on granulocytic differentiation and on C/EBPalpha and C/EBPepsilon expression. Taken together, the results suggest that the Bcr-Abl kinase induces a reversible block of the granulocytic differentiation program in myeloid cells by disturbing regulation of hematopoietic transcription factors such as C/EBPalpha and C/EBPepsilon.",
        "Doc_title":"The effects of Bcr-Abl on C/EBP transcription-factor regulation and neutrophilic differentiation are reversed by the Abl kinase inhibitor imatinib mesylate.",
        "Journal":"Blood",
        "Do_id":"12393654",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;CCAAT-Enhancer-Binding Proteins;CDKN1B protein, human;Carrier Proteins;Cdkn1a protein, mouse;Cyclin-Dependent Kinase Inhibitor p21;Cyclins;Enzyme Inhibitors;Intracellular Signaling Peptides and Proteins;Piperazines;Proto-Oncogene Proteins;Pyrimidines;Trans-Activators;proto-oncogene protein Spi-1;Granulocyte Colony-Stimulating Factor;Cyclin-Dependent Kinase Inhibitor p27;Imatinib Mesylate;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Animals;Antineoplastic Agents;Benzamides;CCAAT-Enhancer-Binding Proteins;Carrier Proteins;Cell Differentiation;Cell Line;Cyclin-Dependent Kinase Inhibitor p21;Cyclin-Dependent Kinase Inhibitor p27;Cyclins;Drug Antagonism;Enzyme Inhibitors;Fusion Proteins, bcr-abl;Gene Expression Regulation, Neoplastic;Granulocyte Colony-Stimulating Factor;Granulocytes;Imatinib Mesylate;Intracellular Signaling Peptides and Proteins;Mice;Neutrophils;Piperazines;Protein-Tyrosine Kinases;Proto-Oncogene Proteins;Pyrimidines;Trans-Activators",
        "Doc_meshqualifiers":"pharmacology;drug effects;metabolism;metabolism;drug effects;metabolism;pharmacology;drug effects;pharmacology;pharmacology;cytology;drug effects;cytology;drug effects;pharmacology;antagonists & inhibitors;metabolism;pharmacology;metabolism",
        "_version_":1605746414325858306},
      {
        "Doc_abstract":"To study the possibility of curing chronic myeloid leukemia with autogeneic hemopoietic stem cell transplantation in patients with negative Philadelphia (Ph) chromosome induced by imatinib mesylate (STI 571) treatment.;Two patients with chronic myeloid leukemia in chronic phase, who had 90% Ph chromosome-positive cells and bcr/abl fusion gene-positive cells as shown by interphase fluorescence in situ hybridization (I-FISH), failed to respond favorably to interferon-alpha therapy in the treatment courses of 7 and 8 months, respectively. Treatment with STI 571 at a daily dose of 300 to 400 mg for 5 months to 8 months was subsequently implemented, after which the Ph chromosome and bcr/abl fusion genes became normal in detection for 3 times. Peripheral blood haemopoietic stem cell mobilization was then initiated by intravenous injection of cytarabine (2.0 g/d) for 3 days, etoposide (0.2 g/d) for 3 d and cyclophosphamide (1.0 g/d) for one day. When the white blood cell was below 1.0x10(9)/L, the G-CSF (300 microg/d) was administered subcutaneously for 5 or 6 d, and the peripheral blood mononuclear cells were collected by CS3000 Plus blood cell separator. The percentage of bcr/abl fusion gene-positive cells among CD34(9) cells enriched by MiniMAC ranged from 11% to 14%. After 3 or 4 weeks, the patients received total body irradiation at 9 Gy given in 2 fractions, with intravenous injection of cyclophosphamide (60 mg/kg daily) and etoposide (300 mg/d) for 2 d. On the day of transplantation, the collected mononuclear cells were 4.17x10(8)/kg and 3.9x10(8)/kg, with CD34(+)/ cells reaching 4.89x10(6)/kg.b.w and 4.89x10(6)/kg. CsA was also used since day -1 to day +13 of the transplantation for prevention of graft-versus-host disease. G-CSF was administrated daily at the dose of 300 microg subcutaneously from day +3 to +12.;After the transplantation, the absolute neutrophil count (ANC) took a mean of 11 d to exceed 0.5x10(9)/L in these two patients, and 19 and 21 d, respectively, were needed for the platelet count to exceed 20x10(9)/L. The two patients showed cytogenetic relapse at 120 and 300 d after the transplantation, respectively.;Autogeneic peripheral blood stem cells transplantation after Ph chromosome is negative in patients with chronic myeloid leukemia, who receive STI 571 treatment, may also relapse, and more radical elimination of Ph chromosome-positive cells is needed.",
        "Doc_title":"[Autogeneic peripheral blood hemopoietic stem cell transplantation for chronic myeloid leukemia with imatinib mesylate-induced negative Philadelphia chromosome].",
        "Journal":"Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA",
        "Do_id":"14678896",
        "Doc_ChemicalList":"Antigens, CD34;Benzamides;Piperazines;Pyrimidines;Imatinib Mesylate",
        "Doc_meshdescriptors":"Adult;Antigens, CD34;Benzamides;Follow-Up Studies;Hematopoiesis;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Peripheral Blood Stem Cell Transplantation;Philadelphia Chromosome;Piperazines;Pyrimidines;Transplantation, Autologous",
        "Doc_meshqualifiers":"analysis;genetics;therapy;therapeutic use;therapeutic use",
        "_version_":1605742650689847296},
      {
        "Doc_abstract":"To determine the association of JAK2V617F mutation along with BCR-ABL translocation or Philadelphia chromosome in chronic myeloid leukemia with early disease progression to advanced stages (accelerated phase or blast crisis) and poor outcome.;Case series.;National Institute of Blood Diseases and Bone Marrow Transplantation, Karachi, from February 2008 to August 2009.;All the newly diagnosed cases of BCR-ABL or Philadelphia positive CML were tested for JAK2V617F mutation by Nested PCR. Demographic data, spleen size, hemoglobin levels, white blood cell and platelet counts were recorded. Independent sample t-test was used for age, haemoglobin level and spleen size. Fisher's exact test was applied to compare disease progression in JAK2V617F mutation positive and negative cases.;Out of 45 newly diagnosed cases of CML, 40 were in chronic phase, 01 in accelerated phase and 04 in blast crisis. JAK2V617F mutation was detected in 12 (26.7%) patients; 09 (22.5%) in chronic phase, none in accelerated phase and 03 (75%) in blast crisis. During a mean follow-up of 8 months, 03 patients in chronic phase transformed in blast crisis and 02 into accelerated phase. Overall 08 out 0f 11 (73%) JAK2V617F positive patients either had advanced disease or showed disease progression. Only 2 of 20 (10%) available patients, negative for the mutation, showed disease progression by transforming into blast crisis (p < 0.001). No statistically significant difference was seen in the age, spleen size, haemoglobin levels, white blood cells and platelets counts in JAK2V617F positive patients.;JAK2V617F mutation was detected in 26.7% cases of chronic myeloid leukemia. A significant proportion of them showed early disease progression.",
        "Doc_title":"JAK2V617F mutation in chronic myeloid leukemia predicts early disease progression.",
        "Journal":"Journal of the College of Physicians and Surgeons--Pakistan : JCPSP",
        "Do_id":"21798133",
        "Doc_ChemicalList":"Hemoglobins;JAK2 protein, human;Janus Kinase 2",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Blast Crisis;Child;Confidence Intervals;Disease Progression;Female;Hemoglobins;Humans;Janus Kinase 2;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Mutation;Philadelphia Chromosome;Prognosis;Risk Assessment;Statistics, Nonparametric;Time Factors;Young Adult",
        "Doc_meshqualifiers":"analysis;genetics;genetics;pathology",
        "_version_":1605893848676958208},
      {
        "Doc_abstract":"We encountered a 44-year-old woman with suspected chronic myelocytic leukemia (CML) in the acute phase that was difficult to be differentiate from Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL). At disease onset, her bone marrow showed an increase in blasts that were negative for myeloperoxydase (MPO) and Positive for CD10, 19, 34, and HLA.DR. Standard type Ph was detected by chromosome analysis, and both major and minor BCR/ABL m-RNA were detected by reverse-transcriptase polymerase chain reaction (RT-PCR) methods. Neutrophil alkaliphosphatase (NAP) score was normal, and neither eosinophilia nor basophilia was observed in peripheral blood. Under a presumptive diagnosis of Ph-positive ALL (L2), the patient was given AdVP (doxorubicin, vincristine, and prednisolone) therapy followed by a regimen of LMVP (L-asparaginase, mitoxantrone, and VP), and obtained a complete remission 2 months later. At that time, FISH analyses of her bone marrow and blood cells no longer detected bone marrow Ph or BCR/ABL fusion gene. A month later, however, the leukemia relapsed with an increase in MPO-positive blasts in bone marrow, and the patient died soon thereafter. We finally concluded that her leukemia was not Ph-positive ALL, but CML in the acute phase at disease onset.",
        "Doc_title":"[Blast crisis of chronic myelocytic leukemia that was difficult to differentiate from Ph+ acute lymphoblastic leukemia].",
        "Journal":"[Rinsho ketsueki] The Japanese journal of clinical hematology",
        "Do_id":"10624128",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adult;Blast Crisis;Diagnosis, Differential;Female;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Precursor Cell Lymphoblastic Leukemia-Lymphoma",
        "Doc_meshqualifiers":"pathology;diagnosis;pathology",
        "_version_":1605792117135769600},
      {
        "Doc_abstract":"To find new kinase inhibitors that overcome the imatinib resistance in treatment of chronic myeloid leukemia (CML), we synthesized C817, a novel derivative of curcumin, and tested its activities against wild-type (WT) and imatinib-resistant mutant Abl kinases, as well as in imatinib-sensitive and resistant CML cells in vitro.;32D cells harboring WT or mutant Abl kinases (nucleotide binding P-loop mutants Q252H, Y253F, and imatinib contact residue mutant T315I), as well as K562/G01 cells (with whole Bcr-Abl gene amplication) were tested. Kinase activity was measured using Kinase-Glo Luminescent Kinase Assay Platform in recombinant WT and mutant (Q252H, Y253F, and T315I) Abl kinases. Cell proliferation and apoptosis were examined using MTT assay and flow cytometry, respectively. The phosphorylation levels of Bcr-Abl initiated signaling proteins were analyzed using Western blotting. Colony forming units (CFU) growth and long term culture-initiating cells (LTC-ICs) were used to test the effects of C817 on human leukemia progenitor/stem cells.;C817 potently inhibited both WT and mutant (Q252H, Y253F, and T315I) Abl kinase activities in a non-ATP competitive manner with the values of IC at low nanomole levels. In consistent with above results, C817 suppressed the growth of both imatinib-sensitive and resistant CML cells, including wild-type K562, K562/G01, 32D-T315I, 32D-Q252H, and 32D-Y253F cells with the values of IC at low micromole levels. C817 (0.5 or 1 mol/L) dose-dependently inhibited the phosphorylation of Bcr-Abl and downstream proteins STAT-5 and CrkL in imatinib-resistant K562/G01 cells. Furthermore, C817 significantly suppressed CFU growth and LTC-ICs, implicating that C817 could eradiate human leukemia progenitor/stem cells.;C817 is a promising compound for treatment of CML patients with Bcr-Abl kinase domain mutations that confer imatinib resistance.",
        "Doc_title":"Curcumin derivative C817 inhibits proliferation of imatinib-resistant chronic myeloid leukemia cells with wild-type or mutant Bcr-Abl in vitro.",
        "Journal":"Acta pharmacologica Sinica",
        "Do_id":"24487968",
        "Doc_ChemicalList":"Antineoplastic Agents, Phytogenic;BCR-ABL1 fusion protein, human;Benzamides;C817 curcumin derivative;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Imatinib Mesylate;Fusion Proteins, bcr-abl;Curcumin",
        "Doc_meshdescriptors":"Antineoplastic Agents, Phytogenic;Apoptosis;Benzamides;Cell Proliferation;Curcumin;Dose-Response Relationship, Drug;Drug Resistance, Neoplasm;Fusion Proteins, bcr-abl;Genetic Predisposition to Disease;Humans;Imatinib Mesylate;K562 Cells;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mutation;Neoplastic Stem Cells;Phenotype;Phosphorylation;Piperazines;Protein Kinase Inhibitors;Pyrimidines",
        "Doc_meshqualifiers":"pharmacology;drug effects;pharmacology;drug effects;analogs & derivatives;pharmacology;genetics;antagonists & inhibitors;genetics;metabolism;enzymology;genetics;pathology;drug effects;enzymology;pathology;pharmacology;pharmacology;pharmacology",
        "_version_":1605746413757530112},
      {
        "Doc_abstract":"Philadelphia (Ph1) chromosome breakpoints in acute lymphoblastic leukemia (ALL) are of two kinds: those within the breakpoint cluster region (bcr+), as in chronic myeloid leukemia (CML), and those outside it (bcr-). These encode different c-abl messenger RNAs (mRNAs), p210 and p190, respectively. It has been suggested that one class of Ph+ ALL (bcr+) may be a variant of CML arising in a multipotent stem cell, the other (bcr-) de novo ALL initiated in a lymphoid-committed progenitor. Thirty-two cases of ALL (12 Ph1+, ten chromosomally normal, and ten non-mitotic cases) were investigated for bcr involvement. Breakpoints were found within five Ph1+ and in one normal case. There was no difference in clinical features, common ALL antigen (CALLA) positivity, cytogenetics, or response to treatment between the 6 bcr+ and 7 Ph1+ bcr- patients. Myeloid antigen expression was found in 2 bcr+ cases. Bcr rearrangement appeared to be restricted to the lymphoblastic component of marrow or blood in at least four bcr+ cases. In one case, separated myeloid and lymphoid cell fractions were both bcr+. Potential heterogeneity of the Ph1+ target cell, as seen in this study, may be more important in determining disease outcome than the precise location of the Ph breakpoint.",
        "Doc_title":"Variable Philadelphia breakpoints and potential lineage restriction of bcr rearrangement in acute lymphoblastic leukemia.",
        "Journal":"Blood",
        "Do_id":"3165301",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Genes, Immunoglobulin;Humans;Leukemia, Lymphoid;Multigene Family;Philadelphia Chromosome;Recombination, Genetic",
        "Doc_meshqualifiers":"genetics;immunology",
        "_version_":1605755182398832640},
      {
        "Doc_abstract":"Abl interactor (Abi) 1 was first identified as the downstream target of Abl tyrosine kinases and was found to be dysregulated in leukemic cells expressing oncogenic Bcr-Abl and v-Abl. Although the accumulating evidence supports a role of Abi1 in actin cytoskeleton remodeling and growth factor/receptor signaling, it is not clear how it contributes to Bcr-Abl-induced leukemogenesis. We show here that Abi1 gene silencing by short hairpin RNA attenuated the Bcr-Abl-induced abnormal actin remodeling, membrane-type 1 metalloproteinase clustering and inhibited cell adhesion and migration on fibronectin-coated surfaces. Although the knock down of Abi1 expression did not affect growth factor-independent growth of Bcr-Abl-transformed Ba/F3 cells in vitro, it impeded competitive expansion of these cells in non obese diabetic (NOD)/ severe combined immuno-deficiency (SCID) mice. Remarkably, the knock down of Abi1 expression in Bcr-Abl-transformed Ba/F3 cells impaired the leukemogenic potential of these cells in NOD/SCID mice. Abi1 contributes to Bcr-Abl-induced leukemogenesis in part through Src family kinases, as the knock down of Abi1 expression attenuates Bcr-Abl-stimulated activation of Lyn. Together, these data provide for the first time the direct evidence that supports a critical role of Abi1 pathway in the pathogenesis of Bcr-Abl-induced leukemia.",
        "Doc_title":"Abi1 gene silencing by short hairpin RNA impairs Bcr-Abl-induced cell adhesion and migration in vitro and leukemogenesis in vivo.",
        "Journal":"Carcinogenesis",
        "Do_id":"18453543",
        "Doc_ChemicalList":"Abi1 protein, mouse;Adaptor Proteins, Signal Transducing;Cytoskeletal Proteins;Mmp14 protein, mouse;RNA, Messenger;RNA, Small Interfering;Tyrosine;Fusion Proteins, bcr-abl;lyn protein-tyrosine kinase;src-Family Kinases;Matrix Metalloproteinase 14",
        "Doc_meshdescriptors":"Adaptor Proteins, Signal Transducing;Animals;Blotting, Western;Cell Adhesion;Cell Movement;Cell Transformation, Neoplastic;Cytoskeletal Proteins;Female;Flow Cytometry;Fusion Proteins, bcr-abl;Gene Silencing;Immunoprecipitation;Leukemia;Matrix Metalloproteinase 14;Mice;Mice, Inbred NOD;Mice, SCID;Microscopy, Fluorescence;Phosphorylation;Precursor Cells, B-Lymphoid;RNA, Messenger;RNA, Small Interfering;Retroviridae;Reverse Transcriptase Polymerase Chain Reaction;Survival Rate;Tyrosine;src-Family Kinases",
        "Doc_meshqualifiers":"antagonists & inhibitors;genetics;metabolism;physiology;physiology;antagonists & inhibitors;genetics;metabolism;physiology;genetics;pathology;metabolism;pathology;genetics;metabolism;pharmacology;genetics;metabolism;metabolism",
        "_version_":1605784995848257536},
      {
        "Doc_abstract":"Sialic acids as terminal residues of oligosaccharide chains play crucial roles in several cellular recognition events. Exploiting the selective affinity of Achatinin-H toward N-acetyl-9-O-acetylneuraminic acid-alpha2-6-GalNAc, we have demonstrated the presence of 9-O-acetylated sialoglycoproteins (Neu5,9Ac(2)-GPs) on lymphoblasts of 70 children with acute lymphoblastic leukemia (ALL) and on leukemic cell lines by fluorimetric HPLC and flow cytometric analysis. This study aims to assess the structural aspect of the glycotope of Neu5,9Ac(2)-GPs(ALL) and to evaluate whether these disease-specific molecules can be used to monitor the clinical outcome of ALL. The Neu5,9Ac(2)-GPs(ALL) were affinity-purified, and three distinct leukemia-specific molecular determinants (135, 120, and 90 kDa) were demonstrated by SDS-PAGE, western blotting, and isoelectric focusing. The carbohydrate epitope of Neu5,9Ac(2)-GPs(ALL) was confirmed by using synthetic sialic acid analogs. The enhanced presence of anti-Neu5,9Ac(2)-GP(ALL) antibody in ALL patients prompted us to develop an antigen-ELISA using purified Neu5,9Ac(2)-GPs(ALL) as coating antigens. Purified antigen was able to detect leukemia-specific antibodies at presentation of disease, which gradually decreased with treatment. Longitudinal monitoring of 18 patients revealed that in the early phase of the treatment patients with lower anti-Neu5,9Ac(2)-GPs showed a better prognosis. Minimal cross-reactivity was observed in other hematological disorders (n = 50) like chronic myeloid leukemia, acute myelogenous leukemia, chronic lymphocytic leukemia, and non-Hodgkin's lymphoma as well as normal healthy individuals (n = 21). This study demonstrated the potential of purified Neu5,9Ac(2)-GPs(ALL) as an alternate tool for detection of anti-Neu5,9Ac(2)-GP antibodies to be helpful for diagnosis and monitoring of childhood ALL patients.",
        "Doc_title":"Purification and characterization of 9-O-acetylated sialoglycoproteins from leukemic cells and their potential as immunological tool for monitoring childhood acute lymphoblastic leukemia.",
        "Journal":"Glycobiology",
        "Do_id":"15190007",
        "Doc_ChemicalList":"Sialic Acids;Sialoglycoproteins",
        "Doc_meshdescriptors":"Adolescent;Child;Child, Preschool;Disease Progression;Enzyme-Linked Immunosorbent Assay;Female;Humans;Infant;Leukocytes;Male;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Predictive Value of Tests;Prognosis;Sialic Acids;Sialoglycoproteins",
        "Doc_meshqualifiers":"chemistry;diagnosis;immunology;pathology;chemical synthesis;pharmacology;antagonists & inhibitors;chemistry;isolation & purification",
        "_version_":1605742792379727873},
      {
        "Doc_abstract":"The discovery of BCR/ABL as a driver oncogene in chronic myeloid leukemia (CML) resulted in the development of Imatinib, which, in fact, demonstrated the potential of targeting the kinase in cancers by effectively treating the CML patients. This observation revolutionized drug development to target the oncogenic kinases implicated in various other malignancies, such as, EGFR, B-RAF, KIT and PDGFRs. However, one major drawback of anti-kinase therapies is the emergence of drug resistance mutations rendering the target to have reduced or lost affinity for the drug. Understanding the mechanisms employed by resistant variants not only helps in developing the next generation inhibitors but also gives impetus to clinical management using personalized medicine. We reported a retroviral vector based screening strategy to identify the spectrum of resistance conferring mutations in BCR/ABL, which has helped in developing the next generation BCR/ABL inhibitors. Using Ruxolitinib and JAK2 as a drug target pair, here we describe in vitro screening methods that utilizes the mouse BAF3 cells expressing the random mutation library of JAK2 kinase. ",
        "Doc_title":"A method for screening and validation of resistant mutations against kinase inhibitors.",
        "Journal":"Journal of visualized experiments : JoVE",
        "Do_id":"25549138",
        "Doc_ChemicalList":"INCB018424;Protein Kinase Inhibitors;Pyrazoles;Imatinib Mesylate;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Animals;DNA Mutational Analysis;Drug Resistance, Neoplasm;Fusion Proteins, bcr-abl;Genetic Testing;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mice;Mutation;Protein Kinase Inhibitors;Pyrazoles",
        "Doc_meshqualifiers":"methods;genetics;genetics;methods;pharmacology;genetics;pharmacology;pharmacology",
        "_version_":1605800470578724864},
      {
        "Doc_abstract":"The emergence of resistance to imatinib mediated by mutations in the BCR-ABL has become a major challenge in the treatment of chronic myeloid leukemia (CML). Alternative therapeutic strategies to override imatinib-resistant CML are urgently needed. In this study, we investigated the effect of AKI603, a novel small molecule inhibitor of Aurora kinase A (AurA) to overcome resistance mediated by BCR-ABL-T315I mutation. Our results showed that AKI603 exhibited strong anti-proliferative activity in leukemic cells. AKI603 inhibited cell proliferation and colony formation capacities in imatinib-resistant CML cells by inducing cell cycle arrest with polyploidy accumulation. Surprisingly, inhibition of AurA by AKI603 induced leukemia cell senescence in both BCR-ABL wild type and T315I mutation cells. Furthermore, the induction of senescence was associated with enhancing reactive oxygen species (ROS) level. Moreover, the anti-tumor effect of AKI603 was proved in the BALB/c nude mice KBM5-T315I xenograft model. Taken together, our data demonstrate that the small molecule AurA inhibitor AKI603 may be used to overcome drug resistance induced by BCR-ABL-T315I mutation in CML.",
        "Doc_title":"Aurora A Kinase Inhibitor AKI603 Induces Cellular Senescence in Chronic Myeloid Leukemia Cells Harboring T315I Mutation.",
        "Journal":"Scientific reports",
        "Do_id":"27824120",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605891305770057728},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) is a clonal multilineage myeloproliferative disease of stem cell origin characterized by the presence of the Bcr/Abl oncoprotein, a constitutively active tyrosine kinase. The actual treatment of CML patients in chronic phase is the specific abl kinase inhibitor imatinib mesylate that induces 90% of cytogenetic responses in early-phase patients. However, resistance in long-term treated patients occurs and the allogeneic stem cell transplantation remains the only curative treatment in resistant patients. Despite recent reports outlining the role of allogeneic natural killer (NK) cells as potent antileukemic effectors, the mechanisms controlling the leukemic target recognition and lysis by activated NK cells have not been well identified. The authors' experimental data obtained on appropriate cellular models identify diverse mechanisms that could explain the increased NK-cell susceptibility of Bcr/Abl targets to NK-mediated lysis. They further delineate unexpected effects of the inhibition of the tyrosine kinase activity on the cross-talk between NK and CML leukemic cells. The consequences of such discoveries are discussed in the context of combined treatments with antikinases as well as adoptive cellular therapy approaches in myeloid leukemia patients.",
        "Doc_title":"Chronic myeloid leukemia and allogeneic natural killer cells: a surprising dialogue.",
        "Journal":"Expert review of clinical immunology",
        "Do_id":"20477618",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605800457692774400},
      {
        "Doc_abstract":"To review the pharmacology, pharmacokinetics, clinical trials, adverse effects, and formulary considerations of ponatinib, a pan-tyrosine kinase inhibitor (TKI).;A literature search of articles published between January 1966 and June 2013 was performed using PubMed with the following search terms: ponatinib, AP24534, and Iclusig. ARIAD Pharmaceuticals, Inc, was contacted for unpublished information. Other sources included American Society of Hematology abstracts, the Food and Drug Administration Center for Drug Evaluation and Research Web site, and clinicaltrials.gov.;Included articles and abstracts were published in English and contain information about ponatinib, particularly in the treatment of chronic myeloid leukemia (CML) or Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).;Following the phase II PACE trial, ponatinib was approved for the treatment of patients with chronic-phase (CP), accelerated-phase (AP), or blast-phase (BP) CML or Ph+ ALL who have become intolerant or resistant to previous therapy. Unlike other BCR-ABL TKIs, ponatinib was designed to overcome the T315I mutation. At 15.3 months, 46% of patients with CP-CML achieved a complete cytogenetic response, and 34% achieved a major molecular response. Complete hematologic responses occurred in 47% of patients with AP-CML, 21% with BP-CML, and 34% with Ph+ ALL after 1 year. Severe toxicities included myelosuppression, hepatotoxicity, pancreatitis, and arterial thrombosis.;Ponatinib is a potent TKI that can overcome several resistance mechanisms in previously treated patients with CML and Ph+ ALL. Ponatinib should be reserved for patients who have failed first-line therapy, have the T315I mutation, or have progressed.",
        "Doc_title":"Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.",
        "Journal":"The Annals of pharmacotherapy",
        "Do_id":"24265264",
        "Doc_ChemicalList":"Antineoplastic Agents;Imidazoles;Protein Kinase Inhibitors;Pyridazines;ponatinib;Protein-Tyrosine Kinases",
        "Doc_meshdescriptors":"Antineoplastic Agents;Clinical Trials as Topic;Disease-Free Survival;Dose-Response Relationship, Drug;Drug Resistance, Neoplasm;Humans;Imidazoles;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Protein Kinase Inhibitors;Protein-Tyrosine Kinases;Pyridazines",
        "Doc_meshqualifiers":"adverse effects;pharmacokinetics;therapeutic use;drug effects;adverse effects;pharmacokinetics;therapeutic use;drug therapy;enzymology;genetics;mortality;drug therapy;enzymology;genetics;mortality;adverse effects;pharmacokinetics;therapeutic use;antagonists & inhibitors;adverse effects;pharmacokinetics;therapeutic use",
        "_version_":1605825051218673664},
      {
        "Doc_abstract":"A \"masked\" Philadelphia chromosome (Ph), t(1;22;9)(p32;q11;q34), was found in the bone marrow and peripheral blood cells of a patient with chronic myeloid leukemia (CML) during the chronic and blastic phases of the disease. As an additional change, a reciprocal translocation t(12;13)(p13;q14) was observed in the blastic phase. Southern blot analysis showed a rearrangement of the breakpoint cluster region (bcr). Northern blot analysis with a c-abl probe showed an abnormal 8.5 kb c-abl RNA transcript in addition to the normal 6- and 7-kilobase (kb) c-abl species. Thus, the results demonstrate the presence of a c-abl/bcr rearrangement in the masked Ph corresponding to that observed in the standard Ph translocation t(9;22)(q34;q11) of CML.",
        "Doc_title":"Cytogenetic and molecular analysis of a \"masked\" Philadelphia chromosome in chronic and blastic phases of chronic myeloid leukemia.",
        "Journal":"Cancer genetics and cytogenetics",
        "Do_id":"2357696",
        "Doc_ChemicalList":"DNA, Neoplasm;RNA, Neoplasm",
        "Doc_meshdescriptors":"Blast Crisis;Blotting, Northern;Blotting, Southern;DNA, Neoplasm;Female;Humans;Karyotyping;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Middle Aged;Philadelphia Chromosome;RNA, Neoplasm;Restriction Mapping",
        "Doc_meshqualifiers":"genetics;pathology;genetics;genetics;pathology;genetics",
        "_version_":1605747523440345090},
      {
        "Doc_abstract":"JunB is a component of the activator protein 1 transcription factors and has been identified to be important in hematopoiesis. Transgenic mice lacking JunB expression develop myeloproliferative disease resembling human chronic myeloid leukemia (CML). JunB expression was significantly decreased in CML patients. We used real-time quantitative reverse transcription-polymerase chain reaction analysis to monitor both JunB and BCR-ABL expression during imatinib therapy. Nineteen patients were evaluated every 2 to 4 weeks, and their levels of JunB expression before therapy were significantly decreased compared with those of healthy individuals. After imatinib therapy, an increase in JunB expression was found in 5 patients, all of whom achieved a complete cytogenetic response (CCR) and molecular response (MR), with a decrease in BCR-ABL expression. JunB expression decreased to a very low level in 2 patients, both of whom showed progression to blast crisis. Variable JunB expression was found in the other 12 patients, and their outcomes were mostly driven by BCR-ABL levels. The patients with an increase in JunB expression were statistically more likely to achieve a major cytogenetic response (P = .045), CCR (P = .033), and MR (P = .033) than the group with no increase in JunB expression, and a durable response was observed. This study revealed that an increase in JunB expression is a good prognostic marker for predicting clinical response in CML patients treated with imatinib when such data are combined with an evaluation of BCR-ABL expression.",
        "Doc_title":"Usefulness of quantitative assessment of JunB gene expression as a marker for monitoring chronic myeloid leukemia patients undergoing imatinib therapy.",
        "Journal":"International journal of hematology",
        "Do_id":"17189224",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Biomarkers, Tumor;Piperazines;Proto-Oncogene Proteins c-jun;Pyrimidines;Imatinib Mesylate;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Antineoplastic Agents;Benzamides;Biomarkers, Tumor;Female;Fusion Proteins, bcr-abl;Gene Expression Regulation, Leukemic;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Monitoring, Physiologic;Piperazines;Predictive Value of Tests;Proto-Oncogene Proteins c-jun;Pyrimidines;Reverse Transcriptase Polymerase Chain Reaction;Treatment Outcome",
        "Doc_meshqualifiers":"administration & dosage;biosynthesis;genetics;biosynthesis;genetics;drug therapy;genetics;metabolism;administration & dosage;biosynthesis;genetics;administration & dosage",
        "_version_":1605792593754456064},
      {
        "Doc_abstract":"The Philadelphia chromosome generates a chimeric oncogene in which the BCR and c-ABL genes are fused. The product of this oncogene, BCR/ABL, has elevated ABL tyrosine kinase activity, relocates to the cytoskeleton, and phosphorylates multiple cellular substrates. BCR/ABL transforms hematopoietic cells and exerts a wide variety of biological effects, including reduction in growth factor dependence, enhanced viability, and altered adhesion of chronic myelocytic leukemia (CML) cells. Elevated tyrosine kinase activity of BCR/ABL is critical for activating downstream signal transduction and for all aspects of transformation. This review will describe mechanisms of transformation by the BCR/ABL oncogene and opportunities for clinical intervention with specific signal transduction inhibitors such as STI-571 in CML.",
        "Doc_title":"Mechanisms of transformation by the BCR/ABL oncogene.",
        "Journal":"International journal of hematology",
        "Do_id":"11345193",
        "Doc_ChemicalList":"Benzamides;Enzyme Inhibitors;Oncogene Proteins, Fusion;Piperazines;Pyrimidines;Reactive Oxygen Species;Imatinib Mesylate;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Benzamides;Cell Transformation, Neoplastic;Cytoskeleton;Enzyme Activation;Enzyme Inhibitors;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Models, Biological;Oncogene Proteins, Fusion;Philadelphia Chromosome;Phosphorylation;Piperazines;Protein Processing, Post-Translational;Protein Structure, Tertiary;Protein Transport;Pyrimidines;Reactive Oxygen Species;Signal Transduction",
        "Doc_meshqualifiers":"genetics;metabolism;pharmacology;therapeutic use;antagonists & inhibitors;chemistry;genetics;physiology;drug therapy;enzymology;genetics;genetics;physiology;pharmacology;therapeutic use;pharmacology;therapeutic use;physiology",
        "_version_":1605799593956605952},
      {
        "Doc_abstract":"The past decade has brought new technologies to the study of minimal residual disease (MRD) in leukemia. Each of them has limitations and is far from being accurate. Recently, a new multiparametric cell scanning system (Duet) was introduced to the field of MRD detection. This system has the advantage of automatically scanning large numbers of cells and performing combined analysis of morphology and fluorescence in situ hybridization (FISH) on the same cell. We used this system to characterize the lineage and degree of maturation of the cells carrying the minor m-BCR/ABL fusion, in a follow-up of an 8-year-old boy with Philadelphia-positive (Ph(+)) acute lymphoblastic leukemia (ALL). The boy was treated using a high-risk protocol and was closely monitored with FISH analysis for cells carrying the m-BCR/ABL fusion. Consecutive analysis along 2.5 years from remission showed 0.2-4.5% m-BCR/ALB(+) cells in the peripheral blood (PB), which is within the accepted background range for this method. The combined analysis found that all the m-BCR/ABL(+) cells were mature lymphocytes. Because mature lymphocytes have a long life span in the circulation, this finding supports the fact that the patient is in remission. Moreover, since mature differentiated cells have a low proliferative capacity, there is a low risk for relapse.",
        "Doc_title":"Combined analysis of morphology and fluorescence in situ hybridization in follow-up of minimal residual disease in a child with Philadelphia-positive acute lymphoblastic leukemia.",
        "Journal":"Cancer genetics and cytogenetics",
        "Do_id":"12419587",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Cell Division;Cell Lineage;Cell Size;Child;Child, Preschool;Follow-Up Studies;Fusion Proteins, bcr-abl;Humans;In Situ Hybridization, Fluorescence;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Neoplasm, Residual;Precursor Cell Lymphoblastic Leukemia-Lymphoma",
        "Doc_meshqualifiers":"analysis;genetics;pathology;genetics;pathology;genetics;pathology",
        "_version_":1605839341065601024},
      {
        "Doc_abstract":"The advent of imatinib, a selective inhibitor of the ABL tyrosine kinase, has revolutionized the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Combined with chemotherapy, imatinib exerts remarkable efficacy in patients with newly diagnosed disease with a complete remission (CR) rate of 95% and a survival rate of 55% at 3 years. Profound eradication of leukemia cells not only provides patients with a better chance for receiving allogeneic hematopoietic stem cell transplantation during first CR but also contributes to durable CR even without transplantation. Despite such improvement, however, relapse does occur, mainly owing to acquisition of resistance. Growing comprehension of the molecular mechanisms of resistance to imatinib has led to the development of novel BCR-ABL inhibitors that yield higher affinity for BCR-ABL and/or potent inhibitory activity against other target molecules such as SRC family kinases. The second-generation ABL kinase inhibitors, namely dasatinib and nilotinib, are already showing clinical activity in patients with imatinib-resistant Ph+ ALL, and other novel agents are undergoing preclinical and early clinical evaluation. Further improvement in treatment results will be achieved by identifying each patient's disease profile based on information obtained before and during treatment and by optimizing subsequent treatment accordingly.",
        "Doc_title":"Recent advances in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.",
        "Journal":"International journal of hematology",
        "Do_id":"19093166",
        "Doc_ChemicalList":"Protein Kinase Inhibitors;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Combined Modality Therapy;Fusion Proteins, bcr-abl;Humans;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Protein Kinase Inhibitors;Remission Induction",
        "Doc_meshqualifiers":"trends;antagonists & inhibitors;mortality;therapy;therapeutic use;methods",
        "_version_":1605876699510079488},
      {
        "Doc_abstract":"Chronic myeloid leukemia is a disease marked by expanded clonal hematopoiesis; it is incurable by chemotherapy or radiation but is cured in a majority of patients receiving bone marrow transplantation from nonidentical sibling donors, an outcome generally attributed to a T cell-mediated graft-versus-leukemia effect. In this report, we examine the effect of the P210BCR-ABL fusion protein of the BCR-ABL oncogene, the molecular hallmark of chronic myelogenous leukemia, on the sensitivity of mouse cell lines to apoptosis induced by chemotherapy, radiation, or activated cytotoxic T lymphocytes (CTLs). We find that, although cells expressing P210BCR-ABL by gene transfer are more resistant than their normal counterparts to apoptosis induced by chemotherapy or radiation, they are equally susceptible to apoptosis induced by alloreactive CTLs. These results show that CTLs overcome BCR-ABL-mediated resistance to apoptosis and, therefore, provide a biological correlation for the success of allogeneic bone marrow transplantation in chronic myelogenous leukemia.",
        "Doc_title":"Cytotoxic T cells overcome BCR-ABL-mediated resistance to apoptosis.",
        "Journal":"Cancer research",
        "Do_id":"7834607",
        "Doc_ChemicalList":"Etoposide;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Animals;Apoptosis;Cell Line;Cell Nucleus;Cell Survival;Cells, Cultured;Cytotoxicity, Immunologic;DNA Damage;Etoposide;Fusion Proteins, bcr-abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mice;Mice, Inbred C57BL;Spleen;T-Lymphocytes, Cytotoxic;Transfection",
        "Doc_meshqualifiers":"physiology;ultrastructure;drug effects;radiation effects;pharmacology;biosynthesis;physiology;immunology;immunology",
        "_version_":1605897839656828928},
      {
        "Doc_abstract":"The treatment of chronic myeloid leukemia (CML) has considerably evolved since imatinib mesylate has been introduced as a new therapeutic weapon for this disease. The 5-year updated results of the IRIS study confirmed that imatinib mesylate is the best first line therapy for chronic phase CML with an overall survival of 90%. Responses improve with time and complete cytogenetic and major molecular levels reach 87 and 70% respectively at 5 years. However, despite these remarkable improvements, new problems arise as sub-optimal responses, imatinib-resistances with recently identified BCR-ABL protein point mutations, responsible for a variety of therapeutic consequences : imatinib dose increase, alternative treatments with second generation tyrosine kinase inhibitors (TKIs : dastinib, nilotinib) or allogeneic stem cell transplantation. The treatment of accelerated and blastic phases relies on imatinib +/- conventional chemotherapy, ideally followed by allogeneic stem cell transplantation, as newly developed TKIs are currently evaluated within this frame. Finally, BCR-ABL(T315I) mutations remain a new therapeutic critical challenge as none of the three TKIs (imatinib, nilotinib, dasatinib) can efficiently control such diseases.",
        "Doc_title":"[Treatment of chronic myeloid leukemia in 2007].",
        "Journal":"Bulletin du cancer",
        "Do_id":"17964980",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Pyrimidines;Imatinib Mesylate",
        "Doc_meshdescriptors":"Antineoplastic Agents;Benzamides;Drug Resistance, Neoplasm;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Leukemia, Myeloid, Chronic-Phase;Piperazines;Pyrimidines",
        "Doc_meshqualifiers":"therapeutic use;drug therapy;drug therapy;therapeutic use;therapeutic use",
        "_version_":1605751323771273216},
      {
        "Doc_abstract":"To investigate the effect of real-time quantitative reverse transcriptase polymerase chain reaction (RT-PCR) approach in chronic myeloid leukemia (CML) for detecting the minimal residual disease (MRD) or monitoring the treatment response and predicting the prognosis.;Fifty-six CML patients, 39 males and 17 females, aged 39 (16 approximately 66), with disease history and frozen RNA specimens were studied, 31 of which were in the incipient chronic phase, 7 in the accelerated phase, and 17 in the rapidly progressing phase. Three or more frozen RNA specimens collected before and after treatment were preserved in 11 of the patients. Breakpoint cluster region-Abelson murine leukemia viral oncogene (BCR-ABL) of the patients in different CML stages was analyzed by RT-PCR approach.;The BCR-ABL transcript of those patients remaining in chronic period after treatment decreased to 1/3 that of the baseline level six months after the initiation of treatment and then remained at that level. The BCR-ABL transcript of those in which progressing change occurred increased when such change occurred. After allogeneic transplantation of peripheral blood stem cells the BCR-ABL level decreased significantly. The median DoseN in the 17 progressing patients was 10 492, significantly higher than those of the 31 patients in chronic phase (5920) and in the 7 patients in accelerated phase (4444, both P < 0.05). The minimal residual disease and the treatment response were closely associated with the level and its variation of BCR-ABL transcripts, the transcripts level in blastic crisis was significantly higher than that in chronic phase or accelerated phase.;Real-time quantitative RT-PCR is reliable and can be used to detect the minimal residual disease, monitor the treatment outcome, and predicting blastic crisis.",
        "Doc_title":"[Detection and quantification of BCR-ABL transcripts in patients with chronic myeloid leukemia by real-time quantitative reverse transcriptase polymerase chain reaction].",
        "Journal":"Zhonghua yi xue za zhi",
        "Do_id":"15854550",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Pyrimidines;Imatinib Mesylate;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Antineoplastic Agents;Benzamides;Female;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Piperazines;Prognosis;Pyrimidines;Reverse Transcriptase Polymerase Chain Reaction",
        "Doc_meshqualifiers":"therapeutic use;biosynthesis;genetics;drug therapy;genetics;therapeutic use;therapeutic use;methods",
        "_version_":1605755837682286592},
      {
        "Doc_abstract":"Imatinib mesylate is a potent and specific tyrosine kinase inhibitor against c-ABL, BCR-ABL, and c-KIT, and has been demonstrated to be highly active in chronic myeloid leukemia and gastrointestinal stromal tumors. We examined the antifibrotic effects of imatinib using a bleomycin-induced lung fibrosis model in mice because imatinib also inhibits tyrosine kinase of platelet-derived growth factor receptors (PDGFRs). Imatinib inhibited the growth of primary murine lung fibroblasts and the autophosphorylation of PDGFR-beta induced by PDGF. Administration of imatinib significantly prevented bleomycin-induced pulmonary fibrosis in mice, partly by reducing the number of mesenchymal cells incorporating bromodeoxyuridine. Analysis of bronchoalveolar lavage cells demonstrated that imatinib did not suppress early inflammation on Days 7 and 14 caused by bleomycin. These results suggest that imatinib has the potential to prevent pulmonary fibrosis by inhibiting the proliferation of mesenchymal cells, and that imatinib might be useful for the treatment of pulmonary fibrosis in humans.",
        "Doc_title":"Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice.",
        "Journal":"American journal of respiratory and critical care medicine",
        "Do_id":"15735062",
        "Doc_ChemicalList":"Benzamides;Intracellular Signaling Peptides and Proteins;Piperazines;Pyrimidines;protein kinase modulator;Bleomycin;Imatinib Mesylate",
        "Doc_meshdescriptors":"Animals;Benzamides;Bleomycin;Bronchoalveolar Lavage Fluid;Disease Models, Animal;Female;Fibroblasts;Imatinib Mesylate;Intracellular Signaling Peptides and Proteins;Mice;Mice, Inbred C57BL;Piperazines;Pulmonary Fibrosis;Pyrimidines;Reference Values;Treatment Outcome",
        "Doc_meshqualifiers":"drug effects;therapeutic use;therapeutic use;chemically induced;drug therapy;pathology;therapeutic use",
        "_version_":1605818655677874178},
      {
        "Doc_abstract":"The Philadelphia chromosome translocation generates a chimeric oncogene, BCR/ABL, which causes chronic myelogenous leukemia (CML). In primary leukemic neutrophils from patients with CML, the major tyrosine phosphorylated protein is CRKL, an SH2-SH3-SH3 adapter protein which has an overall homology of 60% to CRK, the human homologue of the v-crk oncogene. In cell lines transformed by BCR/ABL, CRKL was tyrosine phosphorylated, while CRK was not. We looked for changes in CRK- and CRKL-binding proteins in Ba/F3 hematopoietic cell lines which were transformed by BCR/ABL. Anti-CRK II or anti-CRKL immunoprecipitates were probed by far Western blotting with CRK II- or CRKL-GST fusion proteins to display CRK- and CRKL-coprecipitating proteins. There was a striking qualitative difference in the proteins coprecipitating with CRKL and CRK II. In untransformed cells, three major proteins coprecipitated with CRKL, identified as C3G, SOS and c-ABL. Each of these proteins was found to interact with the CRKL-SH3 domains, but not the SH2 domain. After BCR/ABL transformation, the CRKL SH3-domain binding proteins did not change, with the exception that BCR/ABL now coprecipitated with CRKL. Compared to CRKL, very few proteins coprecipitated with CRK II in untransformed, quiescent cells. After BCR/ABL transformation, both the CRKL- and CRK-SH2 domains bound to a new complex of proteins of approximate molecular weight 105-120 kDa. The major protein in this complex was identified as p120CBL. Thus, in these hematopoietic cell lines, CRKL is involved to a greater extent than CRK II in normal signaling pathways that involve c-ABL, C3G and SOS. In BCR/ABL-transformed cells, CRKL but not CRK II, appears to form complexes which potentially link BCR/ABL, c-ABL, C3G, and SOS to the protooncoprotein, p120CBL.",
        "Doc_title":"The BCR/ABL oncogene alters interaction of the adapter proteins CRKL and CRK with cellular proteins.",
        "Journal":"Leukemia",
        "Do_id":"9067577",
        "Doc_ChemicalList":"Adaptor Proteins, Signal Transducing;Antibodies, Monoclonal;CRKL protein;Membrane Proteins;Nuclear Proteins;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-crk;Son of Sevenless Proteins;Proto-Oncogene Proteins c-cbl;Ubiquitin-Protein Ligases;Fusion Proteins, bcr-abl;CBL protein, human;Cbl protein, mouse",
        "Doc_meshdescriptors":"Adaptor Proteins, Signal Transducing;Animals;Antibodies, Monoclonal;Antibody Specificity;Cell Line, Transformed;Fusion Proteins, bcr-abl;Genes, abl;Hematopoietic Stem Cells;Humans;Membrane Proteins;Mice;Nuclear Proteins;Precipitin Tests;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-cbl;Proto-Oncogene Proteins c-crk;Son of Sevenless Proteins;Ubiquitin-Protein Ligases;src Homology Domains",
        "Doc_meshqualifiers":"genetics;metabolism;physiology;metabolism;metabolism;metabolism;physiology",
        "_version_":1605902063460417536},
      {
        "Doc_abstract":"The effect of post-transplant maintenance tyrosine kinase inhibitors (TKIs) on the outcomes of allogeneic hematopoietic stem cell transplantation in high-risk Philadelphia chromosome-positive (Ph(+)) leukemia remains unknown.;A retrospective analysis that included allograft recipients with accelerated phase and blast phase chronic myeloid leukemia or Ph(+) acute lymphoblastic leukemia who had received post-transplant maintenance TKI therapy from 2004 to2014.;A total of 26 patients, 9 with accelerated phase/blast phase CML and 17 with Ph(+) acute lymphoblastic leukemia, received maintenance post-transplant therapy with imatinib, dasatinib, nilotinib, or ponatinib. The TKI was selected according to the pretransplantation TKI response, anticipated toxicities, and ABL1 domain mutations, when present. Newer generation TKIs were initiated at a 50% dose reduction from the standard pretransplantation dosing to limit the toxicities and avoid therapy interruptions. TKIs were started a median of 100 days (range, 28-238 days) after transplantation and were administered for a median of 16 months (range, 8 days to 105 months). Eight patients discontinued therapy because of adverse events. With a median follow-up of 3.6 years (range, 4 months to 8.7 years), the 5-year relapse-free survival rate was 61%. All 3 patients who developed a relapse underwent successful salvage treatment and remained disease-free. The 5-year overall survival rate was 78%.;Maintenance TKI therapy after transplantation is feasible and might reduce the incidence of relapses and improve outcomes after allogeneic hematopoietic stem cell transplantation for patients with high-risk Ph(+) leukemia.",
        "Doc_title":"Does Post-Transplant Maintenance Therapy With Tyrosine Kinase Inhibitors Improve Outcomes of Patients With High-Risk Philadelphia Chromosome-Positive Leukemia?",
        "Journal":"Clinical lymphoma, myeloma & leukemia",
        "Do_id":"27297665",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605899234870034432},
      {
        "Doc_abstract":"Obesity is associated with an increased incidence of many cancers, including leukemia, although it is unknown whether leukemia incidence is increased directly by obesity or rather by associated genetic, lifestyle, health, or socioeconomic factors. We developed animal models of obesity and leukemia to test whether obesity could directly accelerate acute lymphoblastic leukemia (ALL) using BCR/ABL transgenic and AKR/J mice weaned onto a high-fat diet. Mice were observed until development of progressive ALL. Although obese and control BCR/ABL mice had similar median survival, older obese mice had accelerated ALL onset, implying a time-dependent effect of obesity on ALL. Obese AKR mice developed ALL significantly earlier than controls. The effect of obesity was not explained by WBC count, thymus/spleen weight, or ALL phenotype. However, obese AKR mice had higher leptin, insulin, and interleukin-6 levels than controls, and these obesity-related hormones all have potential roles in leukemia pathogenesis. In conclusion, obesity directly accelerates presentation of ALL, likely by increasing the risk of an early event in leukemogenesis. This is the first study to show that obesity can directly accelerate the progression of ALL. Thus, the observed associations between obesity and leukemia incidence are likely to be directly related to biological effects of obesity.",
        "Doc_title":"Diet-induced obesity accelerates acute lymphoblastic leukemia progression in two murine models.",
        "Journal":"Cancer prevention research (Philadelphia, Pa.)",
        "Do_id":"20823291",
        "Doc_ChemicalList":"Adiponectin;Insulin;Interleukin-6;Leptin",
        "Doc_meshdescriptors":"Adiponectin;Age of Onset;Animals;Diet;Disease Models, Animal;Disease Progression;Genes, abl;Humans;Insulin;Interleukin-6;Leptin;Mice;Mice, Inbred AKR;Mice, Transgenic;Obesity;Precursor Cell Lymphoblastic Leukemia-Lymphoma",
        "Doc_meshqualifiers":"blood;genetics;blood;blood;blood;blood;complications;complications;genetics",
        "_version_":1605742778900283394},
      {
        "Doc_abstract":"The mechanism that is responsible for mature neutrophil overproduction in the chronic phase (CP) of chronic myeloid leukemia (CML), a neoplastic disease of hematopoietic stem cells carrying a constitutively active tyrosine kinase BCR-ABL, remains obscure. In this study, microarray analysis revealed that c-Jun, a monopoiesis-promoting transcription factor, was downregulated in CML neutrophils. BCR-ABL directly inhibited c-Jun expression, as c-Jun downregulation in primary CML neutrophils and in the CML blast cell lines, KCL22 and K562, was reversed by the tyrosine kinase inhibitor imatinib. We established a myeloid differentiation model in KCL22 cells using zinc-inducible CCAAT/enhancer-binding protein (C/EBP)alpha (KCL22/alpha). Myeloid differentiation was observed in C/EBP-induced KCL22/alpha cells. Imatinib-induced c-Jun upregulation promoted the monocytic differentiation of KCL22/alpha cells. c-Jun knockdown in KCL22/alpha cells by a short interfering RNA redirected their differentiation from the monocytic to the neutrophilic lineage, even after imatinib treatment. A blockade of PI3K-Akt signaling with an Akt inhibitor upregulated c-Jun and induced the monocytic differentiation of KCL22, K562, and C/EBP-induced KCL22/alpha cells. Thus, BCR-ABL downregulates c-Jun expression by activating the PI3K-Akt pathway during CML-CP, thereby allowing C/EBPs to promote neutrophil differentiation.",
        "Doc_title":"BCR-ABL promotes neutrophil differentiation in the chronic phase of chronic myeloid leukemia by downregulating c-Jun expression.",
        "Journal":"Leukemia",
        "Do_id":"19357699",
        "Doc_ChemicalList":"Benzamides;CCAAT-Enhancer-Binding Protein-alpha;Piperazines;Proto-Oncogene Proteins c-jun;Pyrimidines;Imatinib Mesylate;Phosphatidylinositol 3-Kinases;Fusion Proteins, bcr-abl;Proto-Oncogene Proteins c-akt",
        "Doc_meshdescriptors":"Benzamides;CCAAT-Enhancer-Binding Protein-alpha;Cell Differentiation;Down-Regulation;Fusion Proteins, bcr-abl;Gene Expression Profiling;Humans;Imatinib Mesylate;Leukemia, Myeloid, Chronic-Phase;Neutrophils;Phosphatidylinositol 3-Kinases;Piperazines;Proto-Oncogene Proteins c-akt;Proto-Oncogene Proteins c-jun;Pyrimidines",
        "Doc_meshqualifiers":"genetics;physiology;physiology;pathology;cytology;metabolism;physiology;pharmacology;physiology;antagonists & inhibitors;pharmacology",
        "_version_":1605902232228724736},
      {
        "Doc_abstract":"The FMS-like tyrosine kinase 3 (FLT3) is highly expressed in acute myeloid leukemia (AML). Internal tandem duplications (ITD) of the juxtamembrane domain lead to the constitutive activation of the FLT3 kinase inducing the activation of multiple genes, which may result in the expression of leukemia-associated antigens (LAAs). We analyzed the regulation of LAA in FLT3-wild-type (WT)- and FLT3-ITD(+) myeloid cells to identify potential targets for antigen-specific immunotherapy for AML patients. Antigens, such as PR-3, RHAMM, Survivin, WT-1 and PRAME, were upregulated by constitutively active FLT3-ITD as well as FLT3-WT activated by FLT3 ligand (FL). Cytotoxic T-cell (CTL) clones against PR-3, RHAMM, Survivin and an AML-directed CTL clone recognized AML cell lines and primary AML blasts expressing FLT3-ITD, as well as FLT3-WT(+) myeloid dendritic cells in the presence of FL. Downregulation of FLT3 led to the abolishment of CTL recognition. Comparing our findings concerning LAA upregulation by the FLT3 kinase with those already made for the Bcr-Abl kinase, we found analogies in the LAA expression pattern. Antigens upregulated by both FLT3 and Bcr-Abl may be promising targets for the development of immunotherapeutical approaches against myeloid leukemia of different origin.",
        "Doc_title":"FLT3-regulated antigens as targets for leukemia-reactive cytotoxic T lymphocytes.",
        "Journal":"Blood cancer journal",
        "Do_id":"22829124",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605763745829617664},
      {
        "Doc_abstract":"We describe a pediatric case of acute promyelocytic leukemia with an i(17q) after treatment of BCR/ABL positive chronic myeloid leukemia (CML) for 3.5 years. The patient was treated with Busulphan, alpha-2a interferon, hydroxyurea, and cytosine arabinoside at various times in the course of the chronic phase of CML, because he had no HLA-identical donor for bone marrow transplantation. Hematologic remission was achieved for a short time, but cytogenetic remission was never possible. When promyelocytic blast crisis was diagnosed according to the French-American-British classification, cytogenetic studies revealed an i(17q) as a new feature in our patient. The promyelocytic transformation was associated with the appearance of an i(17q) preceding CML are discussed in the light of recent literature.",
        "Doc_title":"Development of acute promyelocytic leukemia with isochromosome 17q after BCR/ABL positive chronic myeloid leukemia.",
        "Journal":"Cancer genetics and cytogenetics",
        "Do_id":"10087949",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Bone Marrow;Child, Preschool;Chromosomes, Human, Pair 17;Fusion Proteins, bcr-abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Leukemia, Promyelocytic, Acute;Male;Philadelphia Chromosome",
        "Doc_meshqualifiers":"pathology;genetics;drug therapy;genetics;pathology;drug therapy;genetics;pathology",
        "_version_":1605852192704561152},
      {
        "Doc_abstract":"The constitutively activated BCR-ABL tyrosine kinase of chronic myeloid leukemia (CML) is localized exclusively to the cytoplasm despite the three nuclear localization signals (NLS) in the ABL portion of this fusion protein. The NLS function of BCR-ABL is re-activated by a kinase inhibitor, imatinib, and in a kinase-defective BCR-ABL mutant. The mechanism of this kinase-dependent inhibition of the NLS function is not understood.;By examining the subcellular localization of mutant BCR-ABL proteins under conditions of imatinib and/or leptomycin B treatment to inhibit nuclear export, we have found that mutations of three specific tyrosines (Y232, Y253, Y257, according to ABL-1a numbering) in the kinase domain can inhibit the NLS function of kinase-proficient and kinase-defective BCR-ABL. Interestingly, binding of imatinib to the kinase-defective tyrosine-mutant restored the NLS function, suggesting that the kinase domain conformation induced by imatinib-binding is critical to the re-activation of the NLS function. The C-terminal region of ABL contains an F-actin binding domain (FABD). We examined the subcellular localization of several FABD-mutants and found that this domain is also required for the activated kinase to inhibit the NLS function; however, the binding to F-actin per se is not important. Furthermore, we found that some of the C-terminal deletions reduced the kinase sensitivity to imatinib.;Results from this study suggest that an autophosphorylation-dependent kinase conformation together with the C-terminal region including the FABD imposes a blockade of the BCR-ABL NLS function. Conversely, conformation of the C-terminal region including the FABD can influence the binding affinity of imatinib for the kinase domain. Elucidating the structural interactions among the kinase domain, the NLS region and the FABD may therefore provide insights on the design of next generation BCR-ABL inhibitors for the treatment of CML.",
        "Doc_title":"Interplay between kinase domain autophosphorylation and F-actin binding domain in regulating imatinib sensitivity and nuclear import of BCR-ABL.",
        "Journal":"PloS one",
        "Do_id":"21347248",
        "Doc_ChemicalList":"Actins;Benzamides;Nuclear Localization Signals;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Tyrosine;Imatinib Mesylate;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Actins;Active Transport, Cell Nucleus;Animals;Benzamides;COS Cells;Cell Nucleus;Cercopithecus aethiops;Cytoplasm;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Models, Molecular;Mutagenesis;Mutation;Nuclear Localization Signals;Phosphorylation;Piperazines;Protein Folding;Protein Kinase Inhibitors;Protein Structure, Tertiary;Pyrimidines;Tyrosine",
        "Doc_meshqualifiers":"metabolism;drug effects;drug effects;metabolism;drug effects;metabolism;antagonists & inhibitors;chemistry;genetics;metabolism;chemistry;metabolism;drug effects;pharmacology;drug effects;pharmacology;pharmacology;metabolism",
        "_version_":1605746307436118018},
      {
        "Doc_abstract":"Eight cases of Philadelphia positive acute leukemia (Ph+AL) were compared with 13 cases of Ph+ chronic myelogenous leukemia in blast crisis (BC) and 10 cases of Ph negative acute lymphoblastic leukemia (Ph-ALL) based on the clinical and molecular biological findings. Distinguishing clinical features were a high leukocyte count (median; 147.9 x 10(3)/microliters) for Ph+AL, and a high incidence of tumor formation and basophilia for BC. A cytogenetic study demonstrated the disappearance or marked reduction of Ph+ metaphases in Ph+AL in remission, while Ph+ cells persisted in BC. The major bcr gene was not rearranged in 4 Ph+AL cases, whereas it was found rearranged in 4 other cases of Ph+ AL and 6 cases of BC. Reverse transcriptase polymerase chain reaction technique demonstrated the presence of minor bcr/abl mRNA in the former three cases, and major bcr/abl mRNA in the latter 4 cases. Remission rates were 63% for Ph+AL, 38% for BC, and 100% for Ph-ALL, and the 50% survival were 12, 5 and 29 months, respectively. It was concluded that Ph+AL can be differentiated from BC by a marked reduction of Ph+ cells at remission, and that the prognosis of Ph+AL is better than BC, but worse than Ph-ALL.",
        "Doc_title":"[Clinical and molecular biological study of Ph positive acute leukemia: comparison with blast crisis of chronic myelogenous leukemia and Ph negative acute lymphoblastic leukemia].",
        "Journal":"[Rinsho ketsueki] The Japanese journal of clinical hematology",
        "Do_id":"1630016",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Blast Crisis;Female;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Philadelphia Chromosome;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Prognosis",
        "Doc_meshqualifiers":"genetics;pathology;genetics;pathology;genetics;pathology",
        "_version_":1605766247361806336},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) is a hematological malignancy, 95% of which is due to translocation between chromosomes 9 and 22 and the resulting bcr-abl fusion protein. Imatinib specifically binds to the bcr-abl and inhibits cancer cells. However, a subpopulation of the CML cells named leukemia stem cells are resistant to the imatinib therapy, leading to the relapse. In this study, we identified a subpopulation of CD34+ cells in K562 were much more resistant to imatinib than the bulk cells. Simvastatin single also had little pro-apoptotic effect on the CD34+ cells. In contrast, combination of simvastatin and imatinib induced a significant cell death in the subpopulation, which is dependent on the induced ROS by simvastatin as the effect was blocked by ROS scavenger N-acetyl-L: -cysteine (NAC). Our data here point out that combination of simvastatin and imatinib could be a therapeutic option for the resistant CML.",
        "Doc_title":"Combination of simvastatin and imatinib sensitizes the CD34+ cells in K562 to cell death.",
        "Journal":"Medical oncology (Northwood, London, England)",
        "Do_id":"20354828",
        "Doc_ChemicalList":"Antigens, CD34;Benzamides;Piperazines;Pyrimidines;Reactive Oxygen Species;Imatinib Mesylate;Simvastatin",
        "Doc_meshdescriptors":"Antigens, CD34;Antineoplastic Combined Chemotherapy Protocols;Benzamides;Cell Death;Cell Line, Tumor;Cell Separation;Drug Resistance, Neoplasm;Drug Synergism;Flow Cytometry;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Neoplastic Stem Cells;Piperazines;Pyrimidines;Reactive Oxygen Species;Simvastatin",
        "Doc_meshqualifiers":"metabolism;pharmacology;drug effects;drug effects;metabolism;pathology;drug effects;metabolism;administration & dosage;administration & dosage;administration & dosage",
        "_version_":1605891517667344384},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) relapse after allogeneic stem cell transplantation (SCT) is a relatively frequent situation, which is correlated to disease status, time from diagnosis to transplant and T-cell depletion. We evaluated the potential for early minimal residual disease (MRD) BCR-ABL quantification to predict relapse of CML patients receiving allogeneic SCT. Minimal residual disease was analyzed by real-time quantitative reverse transcriptase-polymerase chain reaction (RQ-PCR) at day 100 (d100) in 38 patients with >1 year follow-up after conventional non-T-cell-depleted SCT. Normal ABL control values from 1724 follow-up blood samples were used to define an RQ-PCR amplifiability index and the limits of reliable use of BCR-ABL ratios. We then compared the 14 patients with a high-level d100 BCR-ABL/ABL ratio (> or = 10(-4)) to that of the 24 patients with a negative/low-level ratio (<10(-4)). Despite being comparable for all classical parameters, the incidence of relapse was significantly higher in the high MRD group (11/14 (79%)) compared to that of the low/negative MRD group (7/24 (29%)) (P = 0.009), with d100 MRD values representing an independent risk factor of relapse and disease-free survival, but not of overall survival, in multivariate analysis. These data should facilitate risk-adapted post-transplant immunosuppression and/or tyrosine kinase inhibitor therapy based on an early evaluation of MRD.",
        "Doc_title":"Prediction of relapse by day 100 BCR-ABL quantification after allogeneic stem cell transplantation for chronic myeloid leukemia.",
        "Journal":"Leukemia",
        "Do_id":"16541140",
        "Doc_ChemicalList":"DNA, Complementary;RNA;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adolescent;Adult;DNA, Complementary;Female;Follow-Up Studies;Fusion Proteins, bcr-abl;Humans;K562 Cells;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Predictive Value of Tests;RNA;Recurrence;Reverse Transcriptase Polymerase Chain Reaction;Risk Factors;Sensitivity and Specificity;Stem Cell Transplantation;Survival Rate;Transplantation, Homologous;Treatment Outcome",
        "Doc_meshqualifiers":"genetics;genetics;diagnosis;genetics;therapy;genetics;methods;adverse effects",
        "_version_":1605903036174041088},
      {
        "Doc_abstract":"The chimeric bcr-abl gene formed by the Philadelphia translocation is thought to initiate chronic myeloid leukemia. Engraftment of mice with bone marrow cells infected with a bcr-abl retrovirus has been shown to elicit multiple hematopoietic disorders, including a clonal but nontransplantable hyperproliferation of erythroid and/or mast cells. Culture of spleen and bone marrow cells from such mice usually yielded mast cell lines, even when erythroid disease dominated the primary animal. The mast cells, which carried the same proviral insert as the primary disease, generally grew slowly and were neither transplantable nor clonogenic in agar until they had been cultured for several months. Unexpectedly, several bcr-abl-induced lines switched in vitro from mast cell to megakaryocytic and/or erythroid character, and one became myeloid. The dramatic phenotypic shifts seem likely to involve changes occurring within progenitor cells maintaining the clone, rather than mutation of mature mast cells. The variant lines exhibited substantial spontaneous differentiation, despite being readily transplantable and therefore fully transformed. The production of hematopoietic growth factors by the mast cell lines and their phenotypic variants may implicate an autocrine loop in their evolution. These novel bcr-abl cell lines should aid in the study of genetic events in the progression from chronic to acute leukemia and facilitate analysis of hematopoietic lineage commitment.",
        "Doc_title":"bcr-abl-Induced cell lines can switch from mast cell to erythroid or myeloid differentiation in vitro.",
        "Journal":"Blood",
        "Do_id":"1536951",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Animals;Bone Marrow;Bone Marrow Transplantation;Cell Differentiation;Cell Line;Erythrocytes;Fusion Proteins, bcr-abl;Gene Expression;Genes, p53;Granulocytes;Immunophenotyping;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mast Cells;Mice;Mice, Inbred BALB C;Mice, Inbred C57BL;Mice, Inbred DBA;Spleen;Transfection",
        "Doc_meshqualifiers":"pathology;pathology;genetics;pathology;genetics;pathology;pathology;pathology",
        "_version_":1605841928683782144},
      {
        "Doc_abstract":"This review focuses on the role of the chimeric BCR/ABL gene in leukemia development. First, we discuss and update knowledge regarding the molecular biology of BCR/ABL. We then review data regarding transforming activity of BCR/ABL. Third, we discuss the complex interactions between BCR/ABL and leukemia phenotype. We conclude with a brief discussion of possible therapeutic implications of these data.",
        "Doc_title":"BCR/ABL and leukemia.",
        "Journal":"Leukemia research",
        "Do_id":"8709625",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Animals;Fusion Proteins, bcr-abl;Humans;Leukemia",
        "Doc_meshqualifiers":"genetics;genetics",
        "_version_":1605757839573254144},
      {
        "Doc_abstract":"In the present study, we describe unrelated umbilical cord blood transplantation (CBT) in a 7-year-old Taiwanese boy with atypical chronic myeloid leukemia (BCR-ABL 1 negative). Physical examination was notable for splenomegaly. Cytogenetic analyses from the bone marrow revealed a t(3;5)(p21;q31) translocation. The patient then underwent CBT from an HLA-mismatched (two loci by serotype, three loci by genotype) unrelated donor of Caucasian origin. Times to neutrophil and platelet engraftment were 21 and 62days post-transplant, respectively. Acute graft-versus-host disease following transplantation was minimal. The patient remains in continuing hematological remission with full donor chimerism 28months after transplantation.",
        "Doc_title":"Successful transplantation of ethnically mismatched cord blood in a boy with atypical chronic myeloid leukemia.",
        "Journal":"International journal of hematology",
        "Do_id":"23264127",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Child;Cord Blood Stem Cell Transplantation;Humans;Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative;Male;Remission Induction;Transplantation Conditioning;Transplantation, Homologous;Treatment Outcome",
        "Doc_meshqualifiers":"diagnosis;therapy",
        "_version_":1605824249646284800},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by a reciprocal translocation between chromosomes 9 and 22. Imatinib mesylate is a potent and selective inhibitory of the BCR/ABL tyrosine kinase. Imatinib is a first choice of treatment of chronic phase CML. It has also shown activity in patients with CML in accelerated or blastic phases. However, the penetration of the drug and its active metabolites into the central nervous system (CNS) is poor. Therefore, the CNS is sanctuary site for malignant cells in patients treated with imatinib. Herein, we report a patient with CML in accelerated phase that developed central nervous system disease while on imatinib mesylate therapy.",
        "Doc_title":"Central nervous system blastic crisis in chronic myeloid leukemia on imatinib mesylate therapy: a case report.",
        "Journal":"Journal of neuro-oncology",
        "Do_id":"17318411",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Pyrimidines;Cytarabine;Dexamethasone;Imatinib Mesylate;Protein-Tyrosine Kinases;Methotrexate",
        "Doc_meshdescriptors":"Adult;Antineoplastic Agents;Antineoplastic Combined Chemotherapy Protocols;Benzamides;Blast Crisis;Blood-Brain Barrier;Central Nervous System Neoplasms;Cytarabine;Dexamethasone;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Magnetic Resonance Imaging;Male;Methotrexate;Piperazines;Protein-Tyrosine Kinases;Pyrimidines;Sarcoma, Myeloid;Treatment Outcome",
        "Doc_meshqualifiers":"pharmacokinetics;therapeutic use;therapeutic use;drug therapy;pathology;radiotherapy;drug effects;metabolism;drug therapy;radiotherapy;secondary;administration & dosage;administration & dosage;drug therapy;pathology;administration & dosage;pharmacokinetics;therapeutic use;antagonists & inhibitors;pharmacokinetics;therapeutic use;drug therapy;pathology;radiotherapy",
        "_version_":1605764839594000384},
      {
        "Doc_abstract":"The so-called Philadelphia (Ph) chromosome is present in more than 90% of chronic myeloid leukemia (CML) patients. Around 5-10% of these patients show complex translocations involving other chromosomes in addition to and/or besides chromosomes 9 and 22. CML cases with fusion transcripts, such as e13a3, in which ABL exon 3 rather than exon 2 has fused to BCR, are extremely rare. Such reported cases with the e13a3 transcript showed the Ph chromosome on karyotype analysis. This study reported a rare Ph chromosome-positive CML case with new complex chromosomal aberrations and an e13a3 BCR-ABL transcript that has yet to be established. A four-chromosome translocation involving chromosomal regions 12p11.2, 19q13.3, 9q34.1 and 22q11.2, besides a trisomy 8 and a derivative chromosome 12, were identified using high resolution multicolor banding. Reverse transcription polymerase chain reaction products showed the presence of BCR-ABL fusion transcript e13a3, and this signifies the major BCR breakpoint. The significance of the observed rearrangements and their possible role in the progression of CML was investigated.",
        "Doc_title":"A rare chronic myeloid leukemia case with Philadelphia chromosome, BCR-ABL e13a3 transcript and complex translocation involving four different chromosomes.",
        "Journal":"Oncology letters",
        "Do_id":"22966382",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605822175382601728},
      {
        "Doc_abstract":"The specific genetic events that distinguish the blast crisis from the chronic phase cells of chronic myelogenous leukemia (CML) are unknown. The most common karyotypic change that occurs as CML evolves from chronic phase to blast crisis is the development of multiple Philadelphia (Ph1) chromosomes, each of which is presumably harboring a translocated c-abl oncogene. We describe here a patient with CML who presented in lymphoid blast crisis with three Ph1 chromosomes/metaphase associated with an amplified, rearranged c-abl oncogene fragment and high levels of the aberrant 8-kilobase bcr-abl transcript. This rearranged c-abl fragment was amplified to a similar degree in both the patient's blast crisis cells and in his terminally differentiated granulocytes, but the level of the aberrant CML-specific bcr-abl transcript was some eight- to 16-fold higher in the blast crisis cells v the granulocytes. This analysis indicates that genomic amplification of a translocated c-abl oncogene, although perhaps important in the evolution of CML, nevertheless cannot, by itself, be the sole genetic event giving rise to blast crisis.",
        "Doc_title":"Chronic myelogenous leukemia: amplification of a rearranged c-abl oncogene in both chronic phase and blast crisis.",
        "Journal":"Blood",
        "Do_id":"3545323",
        "Doc_ChemicalList":"Proto-Oncogene Proteins;RNA, Messenger;RNA, Neoplasm;Proto-Oncogene Proteins c-abl",
        "Doc_meshdescriptors":"Adult;Blast Crisis;Gene Amplification;Humans;Leukemia, Myeloid;Male;Philadelphia Chromosome;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-abl;RNA, Messenger;RNA, Neoplasm",
        "Doc_meshqualifiers":"genetics;genetics;pathology;genetics;analysis;analysis",
        "_version_":1605897487327952896},
      {
        "Doc_abstract":"Constitutive tyrosine kinase activity of Bcr-Abl promotes proliferation and survival of chronic myelogenous leukemia (CML) cells. Inhibition of Bcr-Abl tyrosine kinase activity or signaling proteins activated by Bcr-Abl in CML cells blocks proliferation and causes apoptotic cell death. The selective Abl kinase inhibitor, STI-571 (marketed as Gleevec), is toxic to CML cells in culture, causes regression of CML tumors in nude mice, and is currently used to treat CML patients. Here we describe a p.o. active, dual Src/Abl kinase inhibitor with potent antiproliferative activity against CML cells in culture. This 4-anilino-3-quinolinecarbonitrile (SKI-606) ablates tyrosine phosphorylation of Bcr-Abl in CML cells and of v-Abl expressed in fibroblasts. SKI-606 inhibits phosphorylation of cellular proteins, including STAT5, at concentrations that inhibit proliferation in CML cells. Phosphorylation of the autoactivation site of the Src family kinases Lyn and/or Hck is also reduced by treatment with SKI-606. Once daily oral administration of this compound at 100 mg/kg for 5 days causes complete regression of large K562 xenografts in nude mice.",
        "Doc_title":"SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice.",
        "Journal":"Cancer research",
        "Do_id":"12543790",
        "Doc_ChemicalList":"Aniline Compounds;Antineoplastic Agents;DNA-Binding Proteins;Enzyme Inhibitors;Milk Proteins;Nitriles;Quinolines;STAT5 Transcription Factor;Trans-Activators;bosutinib;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl;Proto-Oncogene Proteins c-abl;src-Family Kinases",
        "Doc_meshdescriptors":"Aniline Compounds;Animals;Antineoplastic Agents;Cell Division;Cell Survival;DNA-Binding Proteins;Enzyme Inhibitors;Female;Fusion Proteins, bcr-abl;Humans;K562 Cells;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mice;Milk Proteins;Nitriles;Phosphorylation;Protein-Tyrosine Kinases;Proto-Oncogene Proteins c-abl;Quinolines;STAT5 Transcription Factor;Trans-Activators;Xenograft Model Antitumor Assays;src-Family Kinases",
        "Doc_meshqualifiers":"pharmacology;pharmacology;drug effects;drug effects;metabolism;pharmacology;drug therapy;enzymology;pathology;pharmacology;drug effects;antagonists & inhibitors;metabolism;antagonists & inhibitors;pharmacology;metabolism;antagonists & inhibitors;metabolism",
        "_version_":1605879947649351680},
      {
        "Doc_abstract":"The treatment of chronic myeloid leukemia (CML) has been revolutionized by the small molecule selective kinase inhibitor imatinib mesylate. Imanitib was the first BCR-ABL targeted agent approved for the treatment of CML patients and confers significant response in most patients; however, a substantial number of patients are initially refractory to the drug or may develop resistance during the course of treatment. Point mutations in the kinase domain (KD) of BCR-ABL that impact drug binding have been identified as one of the major mechanisms of resistance. We present here an overview of the current practice in monitoring for such mutations, including the methods used, criteria for investigating and guidelines for reporting the mutations. We further present and discuss the experience of our own laboratory in studying the KD mutations in Indian CML patients on imatinib treatment. ",
        "Doc_title":"Imatinib mesylate resistance and mutations: An Indian experience.",
        "Journal":"Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology",
        "Do_id":"24516315",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605755147616518144},
      {
        "Doc_abstract":"Essential thrombocythemia, polycythemia vera, and myelofibrosis with myeloid metaplasia constitute the \"classic\" bcr/abl-negative myeloproliferative disorders (MPDs). Each of these MPDs represents a stem cell-derived clonal myeloproliferation with the respective features of thrombocytosis, erythrocytosis, and bone marrow fibrosis. Unlike with cases of chronic myeloid leukemia, in which the bcr/abl mutation is invariably detected, current diagnosis of essential thrombocythemia, polycythemia vera, and myelofibrosis with myeloid metaplasia is based on a consensus-driven set of clinical and laboratory criteria that have undergone substantial modification in recent times. The recent discovery of a recurrent activating Janus tyrosine kinase (JAK2) mutation (JAK2VG17F) in all 3 classic MPDs offers another opportunity for refining current diagnoses and disease classifications. In this article, we outline contemporary diagnostic algorithms for each of these disorders and provide an evidence-based approach to management.",
        "Doc_title":"bcr/abl-negative, classic myeloproliferative disorders: diagnosis and treatment.",
        "Journal":"Mayo Clinic proceedings",
        "Do_id":"16178503",
        "Doc_ChemicalList":"Erythropoietin",
        "Doc_meshdescriptors":"Erythropoietin;Genes, abl;Humans;Myeloproliferative Disorders;Prognosis",
        "Doc_meshqualifiers":"blood;genetics;diagnosis;genetics;therapy",
        "_version_":1605904346531233792},
      {
        "Doc_abstract":"Recently, clinical studies of new drugs development to target specific forms of cancer were reported. Herceptin, a monoclonal antibody against the Her2/neu receptor tyrosine kinase, prolonged the survival of women with Her2/neu positive metastatic breast cancer. STI571, a small molecule inhibitor of the BCR/ABL, c-Kit and platelet derived growth factor receptor tyrosine kinase, produced pronounced clinical responses in patients with BCR/ABL positive chronic myeloid leukemia and c-Kit positive gastrointestial stromal tumors. In order to consider the use of the inhibitor of tyrosine kinases activity as anticancer drug, their mechanisms of the oncogenic activation and their impact on tumor transformation should be studied. The treatment with tyrosine kinase inhibitors such as STI571 or herceptin was a spectacular clinical success which stimulated research on the structure and function of both kinases and their inhibitors.",
        "Doc_title":"[Tyrosine kinases. New target of anticancer therapy].",
        "Journal":"Postepy biochemii",
        "Do_id":"16381169",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Benzamides;Piperazines;Pyrimidines;Imatinib Mesylate;Protein-Tyrosine Kinases;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshdescriptors":"Animals;Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Benzamides;Breast Neoplasms;Female;Gastrointestinal Neoplasms;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Lymphatic Metastasis;Piperazines;Protein-Tyrosine Kinases;Pyrimidines;Receptor, ErbB-2;Trastuzumab",
        "Doc_meshqualifiers":"pharmacology;therapeutic use;pharmacology;therapeutic use;drug therapy;mortality;drug therapy;drug therapy;pharmacology;therapeutic use;antagonists & inhibitors;pharmacology;therapeutic use;antagonists & inhibitors",
        "_version_":1605903098286440448},
      {
        "Doc_abstract":"Leukemic cells from two patients with Philadelphia-negative chronic myeloid leukemia (CML) were investigated: 1) Cytogenetics showed a normal 46,XY karyotype in both cases, 2) molecular studies revealed rearrangement of the M-BCR region and formation of BCR-ABL fusion mRNA with b2a2 (patient 1) or b3a2 (patient 2) configuration, and 3) fluorescence in situ hybridization (FISH) demonstrated relocation of the 5' BCR sequences from one chromosome 22 to one chromosome 9. The ABL probe hybridized to both chromosomes 9 at band q34, while two other probes which map centromeric and telomeric of BCR on 22q11 hybridized solely with chromosome 22. For the first time, a BCR-ABL rearrangement is shown to take place on 9q34 instead of in the usual location on 22q11. A rearrangement in the latter site is found in all Ph-positive CML and in almost all investigated CML with variant Ph or Ph-negative, BCR-positive cases. The few aberrant chromosomal localizations of BCR-ABL recombinant genes found previously were apparently the result of complex and successive changes. Furthermore in patient 2, both chromosomes 9 showed positive FISH signals with both ABL and BCR probes. Restriction fragment length polymorphism (RFLP) analysis indicated that mitotic recombination had occurred on the long arm of chromosome 9 and that the rearranged chromosome 9 was of paternal origin. The leukemic cells of this patient showed a duplication of the BCR-ABL gene, analogous to duplication of the Ph chromosome in classic CML. In addition they had lost the maternal alleles of the 9q34 chromosomal region.(ABSTRACT TRUNCATED AT 250 WORDS)",
        "Doc_title":"Translocation of BCR to chromosome 9: a new cytogenetic variant detected by FISH in two Ph-negative, BCR-positive patients with chronic myeloid leukemia.",
        "Journal":"Genes, chromosomes & cancer",
        "Do_id":"7512367",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adult;Blotting, Southern;Chromosomes, Human, Pair 22;Chromosomes, Human, Pair 9;Fatal Outcome;Fusion Proteins, bcr-abl;Gene Rearrangement;Humans;In Situ Hybridization, Fluorescence;Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative;Male;Middle Aged;Mitosis;Oncogenes;Polymorphism, Restriction Fragment Length;Recombination, Genetic;Translocation, Genetic",
        "Doc_meshqualifiers":"ultrastructure;ultrastructure;genetics;genetics;pathology",
        "_version_":1605840938526048256},
      {
        "Doc_abstract":"The standard RT-PCR method performed on RNA of a chronic myeloid leukemia patient resulted in a product of unusual size. Hybridisation to a probe containing the a2 sequences yielded a very faint band. Rehybridisation of the same blot to b3 sequences has given a firm signal. Based on the size of the product and on results of hybridisation tests, a translocation, resulting in a b3a3 juxtaposition, was supposed. The direct sequencing of the RT-PCR product has proven this hypothesis. We concluded, that double hybridisation of RT-PCR products of standard methods is a useful tool in detection of rare bcr-abl chimeras.",
        "Doc_title":"Detection of a b3a3 type chimera in chronic myeloid leukemia by double hybridisation of RT-PCR products.",
        "Journal":"Haematologia",
        "Do_id":"11128110",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Female;Fusion Proteins, bcr-abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Middle Aged;Reverse Transcriptase Polymerase Chain Reaction;Translocation, Genetic",
        "Doc_meshqualifiers":"genetics;genetics",
        "_version_":1605750751609487360},
      {
        "Doc_abstract":"Imatinib is broadly used in the frontline treatment of chronic myeloid leukemia (CML). Although long-term safety and efficacy have been established, some patients will not respond to imatinib. Nilotinib and dasatinib successfully recapture responses for most patients with imatinib-refractory or -intolerant disease. These drugs have different safety profiles, which are likely associated with their divergent inhibitory targets. The presence of Bcr-Abl mutations and safety profiles of available therapies in relation to patient history should be considered when choosing a second-line agent. This review evaluates the safety and tolerability of agents approved for CML treatment and briefly discusses newer third-line agents.",
        "Doc_title":"Optimizing outcomes in patients with chronic myeloid leukemia in chronic phase: comparative safety profiles of newer agents.",
        "Journal":"Leukemia & lymphoma",
        "Do_id":"20528247",
        "Doc_ChemicalList":"Antineoplastic Agents;Protein Kinase Inhibitors",
        "Doc_meshdescriptors":"Antineoplastic Agents;Clinical Trials as Topic;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Protein Kinase Inhibitors;Treatment Outcome",
        "Doc_meshqualifiers":"therapeutic use;drug therapy;therapeutic use",
        "_version_":1605873763405004800},
      {
        "Doc_abstract":"The major mechanism of imatinib resistance for patients with chronic myeloid leukemia (CML) is clonal expansion of leukemic cells with mutations in the Bcr-Abl fusion tyrosine kinase that reduce the capacity of imatinib to inhibit kinase activity. The early detection of such mutations may allow timely treatment intervention to prevent or overcome resistance. Direct sequencing of the BCR-ABL kinase domain is relatively rapid and allows detection of emerging mutations at a sensitivity of approx 20%. Mutations have been detected over a range of 242 amino acids, which spans the entire kinase domain. For optimal sensitivity, the kinase domain of the abnormal gene should be isolated by reverse-transcription (RT) polymerase chain reaction (PCR) amplification using primers that hybridize to the BCR and ABL genes. The quality of the RNA is assessed by real-time quantitative PCR prior to analysis, and BCR-ABL levels are determined. Only RNA of adequate quality is used to ensure accurate and reproducible mutation analysis. Depending on the level of BCR-ABL transcripts, a one- or two-step PCR is required to amplify the kinase domain. Direct sequencing with dye terminator chemistry is performed using PCR-purified products. The sequence is compared to an ABL kinase domain reference sequence using sequencing analysis software, which aligns the sequences and highlights single or multiple mutations.",
        "Doc_title":"Detection of BCR-ABL mutations and resistance to imatinib mesylate.",
        "Journal":"Methods in molecular medicine",
        "Do_id":"16502579",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Pyrimidines;Imatinib Mesylate;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Amino Acid Substitution;Antineoplastic Agents;Benzamides;DNA Mutational Analysis;Drug Resistance, Neoplasm;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mutation;Mutation, Missense;Piperazines;Polymerase Chain Reaction;Pyrimidines",
        "Doc_meshqualifiers":"pharmacology;methods;genetics;drug therapy;genetics;pharmacology;methods;pharmacology",
        "_version_":1605824077355810816},
      {
        "Doc_abstract":"A significant proportion of chronic myeloid leukemia (CML) patients achieve a major cytogenetic remission (MCR) to imatinib therapy after failing interferon (IFN) alpha-based protocols. We sought to determine levels of residual disease in patients with MCR using various molecular methods and to establish a relation between residual BCR-ABL transcript levels and rate of relapse in complete cytogenetic remission (CCR). Response was measured by conventional cytogenetic analysis, hypermetaphase and interphase fluorescence in situ hybridization (HM-FISH, IP-FISH) of bone marrow (BM) cells, qualitative nested and quantitative reverse transcriptase polymerase chain reaction (RT-PCR) for BCR-ABL transcripts. We investigated 323 peripheral blood (PB) and BM samples from 48 CML patients who achieved a complete (Ph+ 0%; n=41) or partial (Ph+ 1-34%; n=7) cytogenetic remission after 3-20 months of imatinib therapy. Prior to imatinib, 35 patients were in chronic phase (CP), eight in accelerated phase (AP), four in myeloid and one in lymphoid blast crisis. HM-FISH results correlated with ratios BCR-ABL/ABL in PB and BM. In patients with CCR, residual disease was detectable by HM-FISH (31%), IP-FISH (18%), and RT-PCR (100%). During follow-up, BCR-ABL became undetectable in two patients (one CP, one AP) by both nested and quantitative RT-PCR. CCR is ongoing in 30 evaluable patients, 11 patients have relapsed. At the time of best response, median ratios BCR-ABL/ABL were 2.1% (range 0.82-7.8) in patients with subsequent relapse and 0.075% (range 0-3.9) in patients with ongoing remission (P=0.0011). All 16 CP patients, who achieved ratios BCR-ABL/ABL <0.1% as best molecular response are in continuous remission, while 6/13 patients (46%) with ratios >/=0.1% have relapsed (P=0.0036). We conclude that: (i) in patients with CCR to imatinib, HM-FISH and RT-PCR usually reveal residual BCR-ABL+ cells; (ii) RT-PCR results derived from PB and BM are comparable in CP CML; and (iii) low levels of residual disease with ratios BCR-ABL/ABL &<0.1% are associated with continuous remission.",
        "Doc_title":"Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.",
        "Journal":"Leukemia",
        "Do_id":"12970765",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Interferon-alpha;Piperazines;Pyrimidines;RNA, Messenger;RNA, Neoplasm;Imatinib Mesylate;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adult;Aged;Antineoplastic Agents;Benzamides;Bone Marrow;Drug Resistance, Neoplasm;Female;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;In Situ Hybridization, Fluorescence;Interferon-alpha;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Neoplasm Recurrence, Local;Neoplasm, Residual;Piperazines;Prognosis;Protein-Tyrosine Kinases;Pyrimidines;RNA, Messenger;RNA, Neoplasm;Remission Induction;Reverse Transcriptase Polymerase Chain Reaction;Sensitivity and Specificity;Survival Rate",
        "Doc_meshqualifiers":"therapeutic use;metabolism;pathology;genetics;metabolism;therapeutic use;drug therapy;genetics;pathology;drug therapy;genetics;pathology;diagnosis;therapeutic use;antagonists & inhibitors;therapeutic use;analysis;genetics",
        "_version_":1605836292919132160},
      {
        "Doc_abstract":"An unusual cytogenetic rearrangement, described as ins(22;9)(q11;q34q21), was detected in a 49-year-old male patient diagnosed with chronic myeloid leukemia (CML). Reverse transcriptase polymerase chain reaction (RT-PCR) revealed a b3a2 fusion transcript. In order to confirm the cytogenetic findings and fully characterize the inverted insertion, we performed fluorescence in situ hybridization (FISH) assays using locus-specific and whole chromosome painting probes. Our FISH analysis showed the presence of the BCR/ABL fusion gene, verified the insertion and determined that the breakpoint on chromosome 22 where the insertion took place was located proximal to the BCR gene and distal to the TUPLE1 gene on 22q11.",
        "Doc_title":"Insertion (22;9)(q11;q34q21) in a patient with chronic myeloid leukemia characterized by fluorescence in situ hybridization.",
        "Journal":"Cancer genetics and cytogenetics",
        "Do_id":"11369063",
        "Doc_ChemicalList":"Biomarkers, Tumor;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Bone Marrow;Chromosome Banding;Chromosome Breakage;Chromosome Inversion;Chromosome Painting;Chromosomes, Human, Pair 22;Chromosomes, Human, Pair 9;Clone Cells;Fusion Proteins, bcr-abl;Humans;Karyotyping;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Models, Genetic;Mutagenesis, Insertional;Reverse Transcriptase Polymerase Chain Reaction;Translocation, Genetic",
        "Doc_meshqualifiers":"analysis;genetics;pathology;genetics;ultrastructure;genetics;ultrastructure;pathology;analysis;genetics;genetics;metabolism;pathology",
        "_version_":1605827536308142080},
      {
        "Doc_abstract":"Remission marrow from patients with BCR-ABL+ acute lymphoblastic leukemia (ALL) achieving clinical remission (CR) after induction or consolidation chemotherapy according to the German multicenter adult ALL (GMALL) protocol showed high titers of residual BCR-ABL+ cells. Therefore, we initiated a pilot study to monitor circulating BCR-ABL+ cells and to collect, purge, and autograft peripheral blood stem cells (PBSC) in these patients. After GMALL 05/93 high-risk phase II of induction chemotherapy (high-dose AraC 3 g/m2 x 8 does and mitoxantrone 10 mg/m2 x 3 doses), patients received 5-10 micrograms/kg subcutaneous recombinant human granulocyte colony-stimulating factor (rhG-CSF) daily. Mobilized CD34+ cells peaked between 20 and 26 days after starting chemotherapy at 4.8-75.6 (median 10.8) x 10(4)/mL peripheral blood (PB) (n = 5). Patients treated with additional chemotherapy cycles failed to mobilize adequate numbers of CD34+ cells. PB stem cells (PBSC) were purged using a cocktail of CD10, CD19, and AB4 monoclonal antibodies (mAbs) coupled to immunomagnetic beads (IMB). The median recoveries of total nucleated cells (TNC) and CD34+ cells after mAb/IMB purging were 84 and 81%. The peak numbers of CD34+ cells collected in a single leukapheresis were median 8.6 x 10(6)/kg pre- and 5.2 x 10(6)/kg postpurge (n = 4). The absolute prepurge CD19+ cells were as low as median 2.7 (range 1.4-19) x 10(6) per leukapheresis. Residual BCR-ABL+ cells in unpurged leukapheresis products were assessed by limiting-log10-dilution nested reverse-transcriptase polymerase chain reaction (RT-PCR) as one in 10(5) to one in 10(6) normal cells and were consistently undetectable in all purged PBSC autografts. We conclude that sufficient numbers of CD34+ cells for PBSCT can be collected after phase II but not at later stages of the GMALL 05/93 high risk protocol; PBSC grafts are 3 log less contaminated with residual BCR-ABL+ cells compared to an historical series of 13 autologous BM grafts; and purging of PBSC with mAb/IMB is feasible with minor loss of CD34+ cells and abolished BCR-ABL signals in the grafts.",
        "Doc_title":"Purging of peripheral blood stem cells yields BCR-ABL-negative autografts in patients with BCR-ABL-positive acute lymphoblastic leukemia.",
        "Journal":"Experimental hematology",
        "Do_id":"8542955",
        "Doc_ChemicalList":"Antigens, CD19;Antigens, CD34;DNA;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adult;Antigens, CD19;Antigens, CD34;DNA;Female;Fusion Proteins, bcr-abl;Hematopoietic Stem Cell Transplantation;Hematopoietic Stem Cells;Humans;Immunomagnetic Separation;Male;Middle Aged;Philadelphia Chromosome;Pilot Projects;Polymerase Chain Reaction;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Time Factors;Transplantation, Autologous",
        "Doc_meshqualifiers":"analysis;analysis;analysis;genetics;chemistry;cytology;drug therapy;genetics;therapy",
        "_version_":1605819365003886592},
      {
        "Doc_abstract":"Rare but serious cardiovascular and pulmonary adverse events (AEs) have been reported in patients with chronic myeloid leukemia treated with BCR-ABL inhibitors. Clinical trial data may not reflect the full AE profile of BCR-ABL inhibitors because of stringent study entry criteria, relatively small sample size, and limited duration of follow-up. To determine the utility of the FDA AE Reporting System (FAERS) surveillance database for identifying AEs possibly associated with the BCR-ABL inhibitors imatinib, dasatinib, and nilotinib in the postmarketing patient population, we conducted Multi-Item Gamma Poisson Shrinker disproportionality analyses of FAERS reports on AEs in relevant system organ classes. Signals consistent with the known safety profiles of these agents as well as signals for less well-described AEs were detected. Bone marrow necrosis, conjunctival hemorrhage, and peritoneal fluid retention events were uniquely associated with imatinib. AEs that most commonly reached the threshold for dasatinib consisted of terms relating to hemorrhage and fluid retention, including pleural effusion and pericardial effusion. Most terms that reached the threshold solely with nilotinib were related to peripheral and cardiac vascular events. Although this type of analysis cannot determine AE incidence or establish causality, these findings elucidate the AEs reported in patients treated with BCR-ABL inhibitors across multiple clinical trials and in the community setting for all approved and nonapproved indications, suggesting drug-AE associations warrant further investigation. These findings emphasize the need to consider patient comorbidities when selecting amongst BCR-ABL inhibitors.",
        "Doc_title":"Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: Data from the FDA Adverse Event Reporting System.",
        "Journal":"American journal of hematology",
        "Do_id":"25580915",
        "Doc_ChemicalList":"4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide;Antineoplastic Agents;Benzamides;Piperazines;Pyrimidines;Thiazoles;Imatinib Mesylate;Fusion Proteins, bcr-abl;Dasatinib",
        "Doc_meshdescriptors":"Adolescent;Adult;Adverse Drug Reaction Reporting Systems;Aged;Antineoplastic Agents;Benzamides;Cardiovascular Diseases;Dasatinib;Databases, Factual;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Logistic Models;Lung Diseases;Middle Aged;Piperazines;Product Surveillance, Postmarketing;Pyrimidines;Thiazoles;United States;United States Food and Drug Administration;Young Adult",
        "Doc_meshqualifiers":"administration & dosage;adverse effects;therapeutic use;administration & dosage;adverse effects;therapeutic use;chemically induced;epidemiology;antagonists & inhibitors;drug therapy;metabolism;chemically induced;epidemiology;administration & dosage;adverse effects;therapeutic use;administration & dosage;adverse effects;therapeutic use;administration & dosage;adverse effects;therapeutic use",
        "_version_":1605874754342879232},
      {
        "Doc_abstract":"The Philadelphia chromosome, arising as a consequence of the t(9;22) translocation, is one of the most frequent and certainly the most known cytogenetic abnormality present in human hematological malignancies. Unlike the vast majority of the other translocations, its presence is not restricted to a specific leukemia phenotype, but is found associated with chronic myelogenous leukemia as well as with a large percentage of acute lymphoblastic leukemias, particularly in elderly patients. Although its molecular counterpart is always represented by a rearrangement between the BCR and the ABL genes, this shows a certain degree of molecular variability. The pathogenetic relationship with the different leukemia phenotypes which have been found to be associated still awaits to be fully elucidated. However, a number of old and more recent observations seem to suggest that not only qualitative differences in the type of BCR/ABL proteins expressed, but also quantitative variations in their total level within the cells may have an important role in determining the leukemia phenotype.",
        "Doc_title":"BCR/ABL transcripts and leukemia phenotype: an unsolved puzzle.",
        "Journal":"Leukemia & lymphoma",
        "Do_id":"9322890",
        "Doc_ChemicalList":"RNA, Messenger;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Animals;Fusion Proteins, bcr-abl;Humans;Leukemia;Phenotype;Philadelphia Chromosome;RNA, Messenger",
        "Doc_meshqualifiers":"biosynthesis;genetics;genetics;metabolism;genetics;metabolism",
        "_version_":1605747097033768961},
      {
        "Doc_abstract":"The classical BCR-ABL negative myeloproliferative neoplasms (MPN) polycythemia vera, essential thrombocythemia, and primary myelofibrosis are clonal hematopoietic disorders characterized by excessive production of terminally differentiated myeloid cells. In MPN patients, the disease can progress to secondary myelofibrosis or acute myeloid leukemia. Clonal hematopoiesis, disease phenotype, and progression are caused by somatically acquired genetic lesions of genes involved in cytokine signaling, RNA splicing, as well as epigenetic regulation. This review provides an overview of point mutations and cytogenetic lesions associated with MPN and addresses the role of these somatic lesions in MPN disease progression.",
        "Doc_title":"Genetic and epigenetic alterations of myeloproliferative disorders.",
        "Journal":"International journal of hematology",
        "Do_id":"23233154",
        "Doc_ChemicalList":"ASXL1 protein, human;DNA-Binding Proteins;LNK protein, human;Proteins;Proto-Oncogene Proteins;Receptors, Thrombopoietin;Repressor Proteins;TET2 protein, human;Isocitrate Dehydrogenase;DNA (Cytosine-5-)-Methyltransferase;DNA methyltransferase 3A;Polycomb Repressive Complex 2;Proto-Oncogene Proteins c-cbl;Janus Kinase 2",
        "Doc_meshdescriptors":"Chromosome Aberrations;DNA (Cytosine-5-)-Methyltransferase;DNA-Binding Proteins;Disease Progression;Epigenesis, Genetic;Humans;Isocitrate Dehydrogenase;Janus Kinase 2;Mutation;Myeloproliferative Disorders;Polycomb Repressive Complex 2;Proteins;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-cbl;RNA Splicing;Receptors, Thrombopoietin;Repressor Proteins",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;genetics;genetics;genetics;genetics;genetics;genetics;genetics",
        "_version_":1605905538579693568},
      {
        "Doc_abstract":"Cellular or proto-oncogenes are normal cellular genes important in normal cell growth and development. In some instances abnormal expression of these genes is associated with altered cell growth or with malignant transformation. Abnormalities of cellular oncogenes are common in human leukemias. These arise by multiple mechanisms such as mutation, translocation, amplification, and others. Sometimes more than one abnormality is present within a single oncogene. In other instances, a leukemia cell may contain abnormalities of several different oncogenes. Some oncogene abnormalities are relatively specific for certain leukemias and occur in almost all cases; examples include ABL in chronic myelogenous leukemia or MYC in Burkitt leukemia/lymphoma. Other abnormalities are also relatively specific but occur in only some cases such as NRAS in acute myelogenous leukemia or BCL2 in B-cell acute lymphoblastic leukemia. In other leukemias, such as most cases of acute lymphoblastic leukemia and chronic lymphocytic leukemia, oncogene abnormalities are uncommon. The precise role of oncogenes in the pathogenesis of human leukemia is unknown. Retrovirus transduced versions of some of the oncogenes modified in human leukemias cause leukemia in animals. Other oncogenes, modified or unmodified, transform animal and human hematopoietic cells in vitro. Some oncogene products are hematopoietic growth factors or growth factor receptors while others regulate cell proliferation or differentiation by diverse mechanisms. Disruption of the balance between these processes seems the most likely mechanism of oncogene related leukemogenesis. If the role of oncogenes in human leukemias can be defined, innovative diagnostic and therapeutic strategies may be forthcoming.",
        "Doc_title":"Oncogenes and leukemia.",
        "Journal":"Leukemia",
        "Do_id":"2406517",
        "Doc_ChemicalList":"Proto-Oncogene Proteins",
        "Doc_meshdescriptors":"Animals;Humans;Leukemia;Leukemia, Experimental;Proto-Oncogene Proteins;Proto-Oncogenes",
        "Doc_meshqualifiers":"genetics;genetics;analysis",
        "_version_":1605851748614799360},
      {
        "Doc_abstract":"Chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphatic leukemia (Ph + ALL) are caused by the t(9;22), which fuses BCR to ABL resulting in deregulated ABL-tyrosine kinase activity. The constitutively activated BCR/ABL-kinase \"escapes\" the auto-inhibition mechanisms of c-ABL, such as allosteric inhibition. The ABL-kinase inhibitors (AKIs) Imatinib, Nilotinib or Dasatinib, which target the ATP-binding site, are effective in Ph + leukemia. Another molecular therapy approach targeting BCR/ABL restores allosteric inhibition. Given the fact that all AKIs fail to inhibit BCR/ABL harboring the 'gatekeeper' mutation T315I, we investigated the effects of AKIs in combination with the allosteric inhibitor GNF2 in Ph + leukemia.;The efficacy of this approach on the leukemogenic potential of BCR/ABL was studied in Ba/F3 cells, primary murine bone marrow cells, and untransformed Rat-1 fibroblasts expressing BCR/ABL or BCR/ABL-T315I as well as in patient-derived long-term cultures (PDLTC) from Ph + ALL-patients.;Here, we show that GNF-2 increased the effects of AKIs on unmutated BCR/ABL. Interestingly, the combination of Dasatinib and GNF-2 overcame resistance of BCR/ABL-T315I in all models used in a synergistic manner.;Our observations establish a new approach for the molecular targeting of BCR/ABL and its resistant mutants using a combination of AKIs and allosteric inhibitors.",
        "Doc_title":"Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I.",
        "Journal":"BMC cancer",
        "Do_id":"22985168",
        "Doc_ChemicalList":"Antineoplastic Agents;GNF-2 compound;Protein Kinase Inhibitors;Pyrimidines;Thiazoles;Fusion Proteins, bcr-abl;Dasatinib",
        "Doc_meshdescriptors":"Allosteric Regulation;Animals;Antineoplastic Agents;Cell Line, Tumor;Cell Proliferation;Cell Transformation, Neoplastic;Cells, Cultured;Colony-Forming Units Assay;Dasatinib;Female;Fusion Proteins, bcr-abl;Gene Expression;Hematopoietic Stem Cells;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mice;Mutation;Protein Kinase Inhibitors;Pyrimidines;Thiazoles",
        "Doc_meshqualifiers":"drug effects;pharmacology;drug effects;drug effects;genetics;antagonists & inhibitors;genetics;metabolism;genetics;pharmacology;pharmacology;pharmacology",
        "_version_":1605836123232272384},
      {
        "Doc_abstract":"Apoptosis is the major form of cell death associated with the action of chemotherapeutic agents on tumor cells, and therefore the expression of genes that interfere with apoptosis can have important consequences for the efficacy of therapeutic approaches. Here we show that K562, a chronic myelogenous leukemia (CML) cell line expressing the BCR-ABL fusion protein, are resistant to the induction of apoptosis by a number of agents and conditions. Antisense oligodeoxynucleotides corresponding to the translation start of bcr downregulate bcr-abl protein in these cells and render them susceptible to induction of apoptosis by chemotherapeutic agents or serum deprivation. Expression of a temperature sensitive v-Abl protein reverses the effects of the antisense oligonucleotides, such that the cells remain resistant to apoptosis at the permissive temperature. These data indicate that bcr-abl acts as an anti-apoptosis gene in CML cells and suggests that the effect is dependent on the abl kinase activity in this chimeric protein. Inhibition of bcr-abl to render CML cells susceptible to apoptosis can be combined with therapeutic drugs and/or treatment capable of inducing apoptosis to provide an effective strategy for elimination of these cells.",
        "Doc_title":"BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death.",
        "Journal":"Blood",
        "Do_id":"8118022",
        "Doc_ChemicalList":"DNA Primers;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl;Proto-Oncogene Proteins c-abl",
        "Doc_meshdescriptors":"Apoptosis;Base Sequence;DNA Primers;Fusion Proteins, bcr-abl;Humans;In Vitro Techniques;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Molecular Sequence Data;Protein-Tyrosine Kinases;Proto-Oncogene Proteins c-abl;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"chemistry;physiology;genetics;pathology;metabolism;metabolism",
        "_version_":1605774293526904832},
      {
        "Doc_abstract":"Antineoplasic agent-induced pulmonary toxicity is an important cause of respiratory failure. These novel antineoplastic agents include imatinib mesylate, a protein tyrosine kinase inhibitor that is encoded by the Bcr-Abl gen created by the Philadelphia chromosome abnormality in chronic myeloid leukemia. Pulmonary toxicity of imatinib is directly related to the dose used. The more severe pulmonary manifestations include pleural effusion by water retention and interstitial pneumonitis. We report the first case published in Mexico ofimatinib-induced pulmonary toxicity and its management in the intensive care unit of the Medica Sur Clinic Foundation.",
        "Doc_title":"[Imatinib-induced pulmonary toxicity].",
        "Journal":"Gaceta medica de Mexico",
        "Do_id":"20073450",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Pyrimidines;Imatinib Mesylate",
        "Doc_meshdescriptors":"Antineoplastic Agents;Benzamides;Female;Humans;Imatinib Mesylate;Lung Diseases;Middle Aged;Piperazines;Pyrimidines",
        "Doc_meshqualifiers":"adverse effects;chemically induced;adverse effects;adverse effects",
        "_version_":1605742758447808512},
      {
        "Doc_abstract":"We report a case of imatinib- and nilotinib-resistant Ph-positive chronic myeloid leukemia (CML) in blast crisis in which successful pretreatment with dasatinib with cord blood transplantation resulted in molecular remission. Before dasatinib therapy, the patient was found to have a F359V BCR-ABL mutation. He was treated with dasatinib for just 16, 19 days before allogeneic stem cell transplantation. This successful case indicates that reduction of tumor burden by second-generation tyrosine kinase inhibitors, in combination with stem cell transplantation, might be effective to treat CML, even in the advanced phase.",
        "Doc_title":"Successful prior treatment with dasatinib followed by stem cell transplantation in a patient with CML in blastic crisis with a BCR-ABL mutation.",
        "Journal":"International journal of hematology",
        "Do_id":"20047099",
        "Doc_ChemicalList":"Protein Kinase Inhibitors;Pyrimidines;Thiazoles;Fusion Proteins, bcr-abl;Dasatinib",
        "Doc_meshdescriptors":"Blast Crisis;Cord Blood Stem Cell Transplantation;Dasatinib;Fusion Proteins, bcr-abl;Hematopoietic Stem Cell Transplantation;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Protein Kinase Inhibitors;Pyrimidines;Thiazoles",
        "Doc_meshqualifiers":"drug therapy;genetics;pathology;genetics;drug therapy;genetics;pathology;administration & dosage;administration & dosage;administration & dosage",
        "_version_":1605792014638514176},
      {
        "Doc_abstract":"The v-abl gene in Abelson virus induces pre-B-cell lymphoma in mice while the BCR/ABL oncogene is associated with chronic myelogenous leukemia and some cases of acute lymphocytic leukemia in humans. Understanding the mechanisms by which these oncogenes affect various cell types has been hampered by a paucity of experimental systems that reproduce the range of biological effects associated with them. We have developed an experimental system in which murine hematopoietic stem cell populations are infected with either v-abl or BCR/ABL retroviruses and are used to reconstitute lethally irradiated mice. Irrespective of the form of activated abl, greater than 90% of the animals reconstituted with such cells develop tumors. About 50% of them develop a myeloproliferative syndrome that shares several features with the chronic phase of chronic myelogenous leukemia; the remaining animals succumb to pre-B-cell lymphomas. The myeloproliferative syndrome is characterized by large numbers of clonally derived, infected myeloid cells. This model will allow study of the mechanism by which activated abl genes affect hematopoietic precursors in chronic myelogenous leukemia. Furthermore, our results demonstrate that introduction of an activated abl gene into the appropriate target cell, not the structure of the gene, is the major determinant in myeloid cell specificity.",
        "Doc_title":"Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL.",
        "Journal":"Proceedings of the National Academy of Sciences of the United States of America",
        "Do_id":"2204061",
        "Doc_ChemicalList":"Viral Proteins;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Abelson murine leukemia virus;Animals;Fusion Proteins, bcr-abl;Hematopoietic Stem Cells;Leukemia, Experimental;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mice;Mice, Inbred BALB C;Moloney murine leukemia virus;Oncogenes;Retroviridae;Viral Proteins",
        "Doc_meshqualifiers":"genetics;genetics;cytology;genetics;microbiology;pathology;genetics;microbiology;pathology;genetics;genetics;genetics",
        "_version_":1605798358783361024},
      {
        "Doc_abstract":"The introduction of imatinib in the treatment of chronic myeloid leukemia (CML) represents the most successful example of targeted therapy in human cancer. However, leukemic stem cells are insensitive to tyrosine kinase inhibitors (TKIs) and contribute to the persistence of disease by representing a reservoir of selfrenewing cells that replenish the disease after drug discontinuation. This finding has refocused the interest of scientists toward drug combinations, ie, treating with TKIs and simultaneously targeting alternative survival mechanisms. One candidate target mechanism is autophagy, a cellular recycling process that acts as a cytoprotective shield in CML cells in response to TKI-induced stress and in other cancer cells surviving in an inhospitable microenvironment. On that basis, inhibition of autophagy has now become an exciting option for combination treatment in cancer, and clinical trials have been initiated in solid and hemopoietic tumors such as CML, chronic lymphocytic leukemia, and multiple myeloma. This review describes the biology of CML and elucidates how the molecular driver BCR-ABL led to the development of TKIs. We then discuss the molecular regulation of autophagy and the potential for autophagy inhibition as the next step in our attempt to tackle the problem of CML persistence to offer a curative option.",
        "Doc_title":"Kill one bird with two stones: potential efficacy of BCR-ABL and autophagy inhibition in CML.",
        "Journal":"Blood",
        "Do_id":"21693757",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Protein Kinase Inhibitors;Pyrimidines;STAT Transcription Factors;Imatinib Mesylate;Phosphatidylinositol 3-Kinases;Fusion Proteins, bcr-abl;Janus Kinases;Proto-Oncogene Proteins c-akt;ras Proteins",
        "Doc_meshdescriptors":"Animals;Antineoplastic Agents;Autophagy;Benzamides;Drug Resistance, Neoplasm;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Janus Kinases;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;MAP Kinase Signaling System;Mice;Models, Biological;Neoplastic Stem Cells;Phosphatidylinositol 3-Kinases;Piperazines;Protein Kinase Inhibitors;Proto-Oncogene Proteins c-akt;Pyrimidines;STAT Transcription Factors;Signal Transduction;ras Proteins",
        "Doc_meshqualifiers":"therapeutic use;drug effects;physiology;antagonists & inhibitors;metabolism;metabolism;drug therapy;genetics;metabolism;pathology;drug effects;metabolism;therapeutic use;therapeutic use;metabolism;therapeutic use;metabolism;metabolism",
        "_version_":1605760924960948224},
      {
        "Doc_abstract":"In response to deregulated oncogene activation, mammalian cells activate disposal programs such as programmed cell death. To investigate the mechanisms behind this oncogenic stress response we used Bcr-Abl over-expressing cells cultivated in presence of imatinib. Imatinib deprivation led to rapid induction of Bcr-Abl activity and over-stimulation of PI3K/Akt-, Ras/MAPK-, and JAK/STAT pathways. This resulted in a delayed necrosis-like cell death starting not before 48 hours after imatinib withdrawal. Cell death was preceded by enhanced glycolysis, glutaminolysis, and amino acid metabolism leading to elevated ATP and protein levels. This enhanced metabolism could be linked to induction of cell death as inhibition of glycolysis or glutaminolysis was sufficient to sustain cell viability. Therefore, these data provide first evidence that metabolic changes induced by Bcr-Abl hyper-activation are important mediators of oncogenic stress-induced cell death.During the first 30 hours after imatinib deprivation, Bcr-Abl hyper-activation did not affect proliferation but resulted in cellular swelling, vacuolization, and induction of eIF2 phosphorylation, CHOP expression, as well as alternative splicing of XPB, indicating endoplasmic reticulum stress response. Cell death was dependent on p38 and RIP1 signaling, whereas classical death effectors of ER stress, namely CHOP-BIM were antagonized by concomitant up-regulation of Bcl-xL.Screening of 1,120 compounds for their potential effects on oncogenic stress-induced cell death uncovered that corticosteroids antagonize cell death upon Bcr-Abl hyper-activation by normalizing cellular metabolism. This protective effect is further demonstrated by the finding that corticosteroids rendered lymphocytes permissive to the transforming activity of Bcr-Abl. As corticosteroids are used together with imatinib for treatment of Bcr-Abl positive acute lymphoblastic leukemia these data could have important implications for the design of combination therapy protocols.In conclusion, excessive induction of Warburg type metabolic alterations can cause cell death. Our data indicate that these metabolic changes are major mediators of oncogenic stress induced by Bcr-Abl.",
        "Doc_title":"Oncogenic stress induced by acute hyper-activation of Bcr-Abl leads to cell death upon induction of excessive aerobic glycolysis.",
        "Journal":"PloS one",
        "Do_id":"21949869",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Glucocorticoids;Piperazines;Pyrimidines;RNA, Small Interfering;Imatinib Mesylate;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Animals;Antineoplastic Agents;Apoptosis;Benzamides;Blotting, Western;Cell Cycle;Cell Proliferation;Cell Transformation, Neoplastic;Cells, Cultured;Drug Resistance, Neoplasm;Endoplasmic Reticulum Stress;Fusion Proteins, bcr-abl;Gas Chromatography-Mass Spectrometry;Glucocorticoids;Glycolysis;Imatinib Mesylate;Metabolomics;Mice;Necrosis;Piperazines;Precursor Cells, B-Lymphoid;Pyrimidines;RNA, Small Interfering;Up-Regulation",
        "Doc_meshqualifiers":"pharmacology;drug effects;drug effects;drug effects;drug effects;pathology;antagonists & inhibitors;genetics;metabolism;pharmacology;pharmacology;drug effects;metabolism;pathology;pharmacology;genetics",
        "_version_":1605742792622997505},
      {
        "Doc_abstract":"To investigate the comparability of bcr-abl (P210) transcript levels detected in different hospitals.;Ten hospitals in China took part in the four times of sample exchange and comparisons from April, 2010 to August, 2011. The exchange samples were prepared by Peking University People's Hospital. Firstly, the BCR-ABL (P210)(+) cells from a newly diagnosed chronic myeloid leukemia patient were 10-fold serially diluted by BCR-ABL (P210)(-) cells and they covered 4 magnitudes. Then, TRIzol reagents were thoroughly mixed with cells in each tube. Every 12 samples (three samples per magnitude) were sent to the other 9 hospitals. The cell number of each sample was 810(6). The detection of bcr-abl transcript levels by real-time quantitative PCR were performed in every hospital according to their own protocols. Conversion factors (CF) were calculated using regression equation.;Differences in bcr-abl transcript levels did exist among results of 10 hospitals in each comparison. In general, the results of the most of hospitals were in line with the dilutions of cells. CF of every hospital fluctuated. Three hospitals had relatively stable CF, and their ranges were 2.8 - 5.2, 1.2 - 2.8 and 2.2 - 6.8, respectively; two hospitals had unstable CF with ranges 0.76 - 7.0 and 2.1 - 18.7; three hospitals couldn't be calculated CF one or two times because of the significant deviation of the results from the actually bcr-abl transcript levels, and their ranges of CF which could be calculated were 1.9 - 19.2, 3.6 - 7.6 and 0.18 - 14.7; One hospital only had two CF (3.3 and 5.0) because of the replacement of an important reagent during the period of comparisons.;Comparability of bcr-abl (P210) transcript levels between different hospitals could be achieved through CF which acquired by sample exchange and comparison. The stable and reliable detection system is the premise to acquire correct CF.",
        "Doc_title":"[A multicenter comparison study on the quantitative detection of bcr-abl (P210) transcript levels in China].",
        "Journal":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi",
        "Do_id":"23611214",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Bone Marrow Cells;China;Fusion Proteins, bcr-abl;Hospitals;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Reverse Transcriptase Polymerase Chain Reaction",
        "Doc_meshqualifiers":"genetics;isolation & purification;diagnosis;genetics",
        "_version_":1605809787375714304},
      {
        "Doc_abstract":"To investigate the incidence of Philadelphia chromosome (Ph) in adult B-lineage acute lymphoblastic leukemia (B-ALL).;One hundred and twelve adult patients with previously untreated B-ALL were prospectively investigated by interphase dual-color dual-fusion fluorescence in situ hybridization (DD-FISH) with two-color break apart probe BCR-ABL and the results were compared with that of conventional cytogenetics (CC).;The incidence of Ph chromosome was 17.98% (16/89) and 31.25% (35/112) by CC and DD-FISH, respectively. The mean positive rate of Ph+cells by FISH was 66.23% (ranging 18.5%-99%). Of the 35 Ph+ALL patients by FISH, 25 were successfully karyotyped by CC which included 5 normal karyotypes, 20 abnormal karyotypes including 16 Ph chromosome and 13 complex abnormalities.;The incidence of Ph chromosome was 31.25% in adult with B-ALL. DD-FISH with BCR-ABL probe provides a powerful technique for the diagnosis of Ph+B-ALL. It is an important supplement to the CC analysis. DD-FISH technique should be used as a routine method for the diagnosis for adult acute B-ALL.",
        "Doc_title":"[Detection of the Philadelphia chromosome in adult B-lineage acute lymphoblastic leukemia using dual-color dual-fusion interphase fluorescence in situ hybridization].",
        "Journal":"Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics",
        "Do_id":"19199258",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;B-Lymphocytes;Chromosome Aberrations;Color;Female;Humans;In Situ Hybridization, Fluorescence;Interphase;Karyotyping;Male;Middle Aged;Philadelphia Chromosome;Precursor Cell Lymphoblastic Leukemia-Lymphoma",
        "Doc_meshqualifiers":"metabolism;pathology;methods;genetics;pathology",
        "_version_":1605751208515993600},
      {
        "Doc_abstract":"T315I is a genetic mutation of the Bcr-Abl tyrosine kinase, the pathogenetic abnormality in chronic myeloid leukemia (CML). It accounts for 10 ? 15% of clinically relevant CML mutations. Licensed tyrosine kinase inhibitors are ineffective against this mutation and its development reduces life expectancy of CML in chronic phase from 10 years to just 22 months. Extensive work is ongoing to establish the most effective therapy to overcome this mutation, including the development of novel specific agents and also re-examination of established therapies.;This review examines the agents in development, dividing them into Bcr-Abl-dependant and -independent groups. It looks at the progress of this research, updating the reader on the status of agents previously reported and introducing emerging therapeutic possibilities only recently announced.;Development of the T315I mutation is a devastating event for some patients with CML. There are potential therapeutic agents at all stages of the drug development cycle to target this patient subpopulation. Clinical activity has been demonstrated and a number of agents are on the cusp of being licensed and available for use.",
        "Doc_title":"Current status of agents active against the T315I chronic myeloid leukemia phenotype.",
        "Journal":"Expert opinion on emerging drugs",
        "Do_id":"21352071",
        "Doc_ChemicalList":"Antineoplastic Agents;Protein Kinase Inhibitors;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Antineoplastic Agents;Apoptosis;Clinical Trials as Topic;Drug Discovery;Fusion Proteins, bcr-abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Protein Kinase Inhibitors;Treatment Outcome",
        "Doc_meshqualifiers":"administration & dosage;adverse effects;therapeutic use;drug effects;methods;genetics;drug therapy;enzymology;administration & dosage;adverse effects;therapeutic use",
        "_version_":1605754278331285504},
      {
        "Doc_abstract":"Although imatinib induces marked responses in patients with chronic myeloid leukemia (CML), resistance is increasingly problematic, and treatment options for imatinib-resistant or -intolerant CML are limited. Dasatinib, a novel, highly potent, oral, multitargeted kinase inhibitor of BCR-ABL and SRC family kinases, induced cytogenetic responses in a phase 1 study in imatinib-resistant or -intolerant CML and was well tolerated. Initial results are presented from a phase 2 study of 186 patients with imatinib-resistant or -intolerant chronic-phase CML (CML-CP) designed to further establish the efficacy and safety of dasatinib (70 mg twice daily). At 8-months' follow-up, dasatinib induced notable responses, with 90% and 52% of patients achieving complete hematologic and major cytogenetic responses (MCyR), respectively. Responses were long lasting: only 2% of patients achieving MCyR progressed or died. Importantly, comparable responses were achieved by patients carrying BCR-ABL mutations conferring imatinib resistance. Dasatinib also induced molecular responses, reducing BCR-ABL/ABL transcript ratios from 66% at baseline to 2.6% at 9 months. Nonhematologic adverse events were generally mild to moderate, and most cytopenias were effectively managed with dose modifications. Cross-intolerance with imatinib was not evident. To conclude, dasatinib induces notable responses in imatinib-resistant or -intolerant CML-CP, is well tolerated, and represents a promising therapeutic option for these patients. This trial was registered at www.clinicaltrials.gov as CA180013.",
        "Doc_title":"Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy.",
        "Journal":"Blood",
        "Do_id":"17138817",
        "Doc_ChemicalList":"Benzamides;Piperazines;Pyrimidines;Thiazoles;Imatinib Mesylate;Fusion Proteins, bcr-abl;Dasatinib",
        "Doc_meshdescriptors":"Adult;Aged;Benzamides;Dasatinib;Drug Resistance, Neoplasm;Drug-Related Side Effects and Adverse Reactions;Female;Follow-Up Studies;Fusion Proteins, bcr-abl;Hematology;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Mutation;Piperazines;Pyrimidines;Thiazoles;Treatment Failure",
        "Doc_meshqualifiers":"drug effects;genetics;drug therapy;genetics;pathology;genetics;therapeutic use;adverse effects;therapeutic use;adverse effects;therapeutic use",
        "_version_":1605826189621985280},
      {
        "Doc_abstract":"Icsbp/Irf8 is an interferon regulatory transcription factor that functions as a suppressor of myeloid leukemias. Consistent with this activity, Icsbp represses a set of genes encoding proteins that promote cell proliferation/survival. One such gene encodes Gas2, a calpain inhibitor. We previously found that increased Gas2-expression in Bcr-abl+ cells stabilized catenin; a Calpain substrate. This was of interest, because catenin contributes to disease progression in chronic myeloid leukemia (CML). Calpain has additional substrates implicated in leukemogenesis, including Stat5. In the current study, we hypothesized that Stat5 activity in CML is regulated by Gas2/Calpain. We found that Bcr-abl-induced, Shp2-dependent dephosphorylation of Icsbp impaired repression of GAS2 by this transcription factor. The consequent decrease in Calpain activity stabilized Stat5 protein; increasing the absolute abundance of both phospho and total Stat5. This enhanced repression of the IRF8 promoter by Stat5 in a manner dependent on Icsbp, Gas2 and Calpain, but not Stat5 tyrosine phosphorylation. During normal myelopoiesis, increased expression and phosphorylation of Icsbp inhibits Calpain. In contrast, constitutive activation of Shp2 in Bcr-abl+ cells impairs regulation of Gas2/Calpain by Icsbp, aberrantly stabilizing Stat5 and enhancing IRF8 repression. This novel feedback mechanism enhances leukemogenesis by increasing Stat5 and decreasing Icsbp. Bcr-abl targeted tyrosine kinase inhibitors (TKIs) provide long term disease control, but CML is not cured by these agents. Our studies suggest targeting Calpain might be a rational therapeutic approach to decrease persistent leukemia stem cells (LSCs) during TKI-treatment.",
        "Doc_title":"Bcr-abl regulates Stat5 through Shp2, the interferon consensus sequence binding protein (Icsbp/Irf8), growth arrest specific 2 (Gas2) and calpain.",
        "Journal":"Oncotarget",
        "Do_id":"27769062",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605874989205028864},
      {
        "Doc_abstract":"The constitutively active tyrosine kinase BCR-ABL is the underlying cause of chronic myeloid leukemia (CML). Current CML treatments rely on the long-term use of tyrosine kinase inhibitors (TKIs), which target the ATP binding site of BCR-ABL. Over the course of treatment, 20-30% of CML patients develop TKI resistance, which is commonly attributed to point mutations in the drug-binding region. We design a new class of peptide inhibitors that target the substrate-binding site of BCR-ABL by grafting sequences derived from abltide, the optimal substrate of Abl kinase, onto a cell-penetrating cyclotide MCoTI-II. Three grafted cyclotides show significant Abl kinase inhibition in vitro in the low micromolar range using a novel kinase inhibition assay. Our work also demonstrates that a reengineered MCoTI-II with abltide sequences grafted in both loop 1 and 6 inhibits the activity of [T315I]Abl in vitro, a mutant Abl kinase harboring the \"gatekeeper\" mutation which is notorious for being multidrug resistant. Results from serum stability and cell internalization studies confirm that the MCoTI-II scaffold provides enzymatic stability and cell-penetrating properties to the lead molecules. Taken together, our study highlights that reengineered cyclotides incorporating abltide-derived sequences are promising substrate-competitive inhibitors for Abl kinase and the T315I mutant. ",
        "Doc_title":"Design of substrate-based BCR-ABL kinase inhibitors using the cyclotide scaffold.",
        "Journal":"Scientific reports",
        "Do_id":"26264857",
        "Doc_ChemicalList":"Protein Kinase Inhibitors;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Amino Acid Sequence;Fusion Proteins, bcr-abl;Humans;K562 Cells;Molecular Sequence Data;Protein Kinase Inhibitors;Sequence Homology, Amino Acid;Substrate Specificity",
        "Doc_meshqualifiers":"antagonists & inhibitors;chemistry;chemistry;pharmacology",
        "_version_":1605742739080609792},
      {
        "Doc_abstract":"Molecular breakpoint of the BCR-ABL fusion gene has been characterized for 122 chronic myeloid leukemia patients. Out of 122 cases, 33 b2a2, 69 b3a2, 2 e1a2, and 2 e19a2 cases have been detected. Six coexpressed both b2a2 and b3a2 transcripts. All the coexpressing samples had an A>G polymorphism at the putative splice branchpoint in intron 13. The T>C polymorphism in exon 13, reported to be linked to coexpression, was not present in all the coexpressing patients. No correlation of transcript type with platelet count was detected. Those expressing b2a2 transcript were diagnosed at relatively younger age and with higher white blood cell count, in agreement with other reports. However, the correlation was not statistically significant.",
        "Doc_title":"Molecular profiling of chronic myeloid leukemia in eastern India.",
        "Journal":"American journal of hematology",
        "Do_id":"16888785",
        "Doc_ChemicalList":"DNA Primers;DNA, Neoplasm;RNA, Neoplasm;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adult;Base Sequence;DNA Primers;DNA, Neoplasm;Female;Fusion Proteins, bcr-abl;Gene Expression Profiling;Genotype;Humans;India;Introns;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Polymorphism, Genetic;RNA, Neoplasm;Reverse Transcriptase Polymerase Chain Reaction;Transcription, Genetic",
        "Doc_meshqualifiers":"genetics;isolation & purification;genetics;genetics;genetics;isolation & purification",
        "_version_":1605805137692983296},
      {
        "Doc_abstract":"The presence of the BCR/ABL chimeric gene is the hallmark of defined types of human leukemia. To increase our knowledge of the oncogenic processes and to develop a model for this type of leukemia we generated a BCR/ABL (P190) transgenic mouse line. Over 95% of mice of this line die of leukemia or leukemia/lymphoma within 35-200 days of age. Karyotypically visible genetic alterations were absent from the early stages of BCR/ABL generated leukemia. A high frequency of aneuploidy was found in advanced leukemia indicating a primary and pivotal role for BCR/ABL in leukemogenesis. Moreover, the data suggest that BCR/ABL has a destabilizing effect on the regulation of the cell cycle. BCR/ABL expression was also found in tissues other than hematopoietic cells. However, this did not result in the development of solid tumors, strongly suggesting that the oncogenicity of BCR/ABL is limited to the hematopoietic lineage.",
        "Doc_title":"Ph-positive leukemia: a transgenic mouse model.",
        "Journal":"Leukemia & lymphoma",
        "Do_id":"8251894",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Animals;Bone Marrow Transplantation;Disease Models, Animal;Fusion Proteins, bcr-abl;Gene Expression Regulation, Leukemic;Genes, abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mice;Mice, Transgenic",
        "Doc_meshqualifiers":"genetics;physiology;genetics",
        "_version_":1605897511881408512},
      {
        "Doc_abstract":"To evaluate the sensitivity and specificity of dual-color and dual-fusion interphase fluorescence in situ hybridization (D-FISH) in determining the tumor load in patients with chronic myeloid leukemia (CML) receiving imatinib therapy.;The BCR-ABL fusion gene was detected by FISH in 24 cases of chronic myeloid leukemia treated with imatinib. The sensitivity and specificity of D-FISH were compared with those of single-fusion FISH (S-FISH) and RT-PCR.;D-FISH was more sensitive and specific than S-FISH. In normal control subjects, the cutoff rates of D-FISH and S-FISH were 0.73% and 6.24%, respectively, showing a significant difference between them. In 24 CML cases receiving imatinib treatment, the positivity rates of S-FISH and D-FISH were 7/24 (29.2%) and 13/24 (54.2%), respectively. The results of D-FISH had a high correlation to that of RT-PCR.;With lower false positive and false negative results, D-FISH can be used as a sensitive and specific method for monitoring the changes of the tumor load in CML patients during imatinib treatment.",
        "Doc_title":"[Dual-color/dual-fusion interphase fluorescence in situ hybridization probe for monitoring tumor load during imatinib therapy for chronic myeloid leukemia].",
        "Journal":"Nan fang yi ke da xue xue bao = Journal of Southern Medical University",
        "Do_id":"20118001",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Pyrimidines;Imatinib Mesylate;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adolescent;Adult;Antineoplastic Agents;Benzamides;Child;Female;Fusion Proteins, bcr-abl;Genes, abl;Humans;Imatinib Mesylate;In Situ Hybridization, Fluorescence;Interphase;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Piperazines;Pyrimidines;Sensitivity and Specificity;Tumor Burden;Young Adult",
        "Doc_meshqualifiers":"therapeutic use;genetics;genetics;methods;drug therapy;genetics;pathology;therapeutic use;therapeutic use;drug effects",
        "_version_":1605875719451181056},
      {
        "Doc_abstract":"Chronic Myeloid Leukemia was always referred as a unique cancer due to the apparent independence from tumor suppressors' deletions/mutations in the early stages of the disease. However, it is now well documented that even genetically wild-type tumor suppressors can be involved in tumorigenesis, when functionally inactivated. In particular, tumor suppressors' functions can be impaired by subtle variations of protein levels, changes in cellular compartmentalization and post-transcriptional/post-translational modifications, such as phosphorylation, acetylation, ubiquitination and sumoylation. Notably, tumor suppressors inactivation offers challenging therapeutic opportunities. The reactivation of an inactive and genetically wild-type tumor suppressor could indeed promote selective apoptosis of cancer cells without affecting normal cells.;Chronic Myeloid Leukemia (CML) could be considered as the paradigm for non-genomic loss of function of tumor suppressors due to the ability of BCR-ABL to directly promote functionally inactivation of several tumor suppressors.;In this review we will describe new insights on the role of FoxO, PP2A, p27, BLK, PTEN and other tumor suppressors in CML pathogenesis. Finally, we will describe strategies to promote tumor suppressors reactivation in CML.",
        "Doc_title":"The non-genomic loss of function of tumor suppressors: an essential role in the pathogenesis of chronic myeloid leukemia chronic phase.",
        "Journal":"BMC cancer",
        "Do_id":"27184141",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605879552469368832},
      {
        "Doc_abstract":"MicroRNAs (miRNAs) are small noncoding RNAs that participate in many biological processes by posttranscriptionally regulating gene expression. Dysregulation of miRNA expression has been shown to be typical of many neoplasms. Chronic myeloid leukemia (CML) is a disorder of hematopoietic stem cells carrying the Philadelphia (Ph) chromosome and an oncogenic BCR-ABL tyrosine kinase fusion gene. While the development of tyrosine kinase inhibitors (TKIs) like imatinib has revolutionized treatment of CML, it has become increasingly clear in recent years that TKI treatment alone will not be curative in many cases. Thus, further dissection of the regulatory networks that drive BCR-ABL-induced malignant transformation may help to identify other novel therapeutic approaches that complement TKI treatment. In this study we demonstrate that the expression of miR-424 is markedly low in CML cell lines and patient samples at time of diagnosis. With the aid of bioinformatics analysis we revealed a conserved target site for miR-424 in the 3'-untranslated region (UTR) of the ABL gene. Via luciferase assays, we showed that miR-424 directly targets BCR-ABL. Overexpression of miR-424 was shown to suppress proliferation and induce apoptosis of K562 cells as well as sensitize these cells to imatinib treatment. These findings strongly suggest that miR-424 acts as a tumor suppressor by downregulating BCR-ABL expression. Up-regulation of miR-424 in CML cells may therefore have a therapeutic effect against this disease. ",
        "Doc_title":"Restoration of miR-424 suppresses BCR-ABL activity and sensitizes CML cells to imatinib treatment.",
        "Journal":"Cancer letters",
        "Do_id":"25697481",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;MIRN424 microrna, human;MicroRNAs;Piperazines;Pyrimidines;Imatinib Mesylate;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Antineoplastic Agents;Apoptosis;Base Sequence;Benzamides;Cell Growth Processes;Combined Modality Therapy;Down-Regulation;Fusion Proteins, bcr-abl;HL-60 Cells;HeLa Cells;Humans;Imatinib Mesylate;K562 Cells;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;MicroRNAs;Piperazines;Pyrimidines;Transfection",
        "Doc_meshqualifiers":"pharmacology;drug effects;genetics;pharmacology;drug effects;genetics;antagonists & inhibitors;biosynthesis;genetics;metabolism;drug therapy;enzymology;genetics;therapy;administration & dosage;biosynthesis;genetics;pharmacology;pharmacology",
        "_version_":1605758405481332736},
      {
        "Doc_abstract":"Tyrosine kinase activity is associated with the transforming potential of several oncogenes. Human chronic myeloid leukemia (CML) cells and cell lines have been shown to contain an active bcr-c-abl p210 tyrosine kinase as a consequence of the Philadelphia chromosomal translocation. In the present work the activity of the c-abl and c-src oncogene-encoded tyrosine kinase was investigated during phorbol diester (TPA) induced differentiation of the K562 CML cells. The high tyrosine kinase activity of p210bcr-c-abl is strongly reduced during the initial 24 h of TPA treatment. In contrast, the activity of the c-src tyrosine kinase is not changed. No change occurs in the expression of the c-abl-specific RNAs during this period. Following the reduction of bcr-c-abl kinase activity, cell proliferation is arrested and megakaryoblastic antigens appear on the cells. Sodium butyrate caused a slight decrease in growth rate and of bcr-c-abl kinase activity during erythroid differentiation whereas no changes in c-src or c-abl tyrosine kinase activities were seen in DMSO-treated control cells.",
        "Doc_title":"The bcr-c-abl tyrosine kinase activity is extinguished by TPA in K562 leukemia cells.",
        "Journal":"FEBS letters",
        "Do_id":"3477472",
        "Doc_ChemicalList":"Protein-Tyrosine Kinases;Tetradecanoylphorbol Acetate",
        "Doc_meshdescriptors":"Cell Differentiation;Cell Line;Humans;Immunoelectrophoresis;Kinetics;Leukemia, Myeloid;Oncogenes;Protein-Tyrosine Kinases;Tetradecanoylphorbol Acetate",
        "Doc_meshqualifiers":"drug effects;enzymology;drug effects;antagonists & inhibitors;genetics;pharmacology",
        "_version_":1605910138196066304},
      {
        "Doc_abstract":"BCR-ABL is a constitutively activated tyrosine kinase that causes chronic myeloid leukemia (CML). Since tyrosine kinase activity is essential to the transforming function of BCR-ABL, an inhibitor of the kinase could be an effective treatment for CML.;We conducted a phase 1, dose-escalating trial of STI571 (formerly known as CGP 57148B), a specific inhibitor of the BCR-ABL tyrosine kinase. STI571 was administered orally to 83 patients with CML in the chronic phase in whom treatment with interferon alfa had failed. Patients were successively assigned to 1 of 14 doses ranging from 25 to 1000 mg per day.;Adverse effects of STI571 were minimal; the most common were nausea, myalgias, edema, and diarrhea. A maximal tolerated dose was not identified. Complete hematologic responses were observed in 53 of 54 patients treated with daily doses of 300 mg or more and typically occurred in the first four weeks of therapy. Of the 54 patients treated with doses of 300 mg or more, cytogenetic responses occurred in 29, including 17 (31 percent of the 54 patients who received this dose) with major responses (0 to 35 percent of cells in metaphase positive for the Philadelphia chromosome); 7 of these patients had complete cytogenetic remissions.;STI571 is well tolerated and has significant antileukemic activity in patients with CML in whom treatment with interferon alfa had failed. Our results provide evidence of the essential role of BCR-ABL tyrosine kinase activity in CML and demonstrate the potential for the development of anticancer drugs based on the specific molecular abnormality present in a human cancer.",
        "Doc_title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.",
        "Journal":"The New England journal of medicine",
        "Do_id":"11287972",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Enzyme Inhibitors;Interferon-alpha;Piperazines;Pyrimidines;Imatinib Mesylate;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adult;Aged;Antineoplastic Agents;Benzamides;Blood Cell Count;Dose-Response Relationship, Drug;Enzyme Inhibitors;Female;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Interferon-alpha;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Phosphorylation;Piperazines;Protein-Tyrosine Kinases;Pyrimidines;Recurrence;Remission Induction",
        "Doc_meshqualifiers":"administration & dosage;adverse effects;pharmacokinetics;administration & dosage;adverse effects;pharmacokinetics;antagonists & inhibitors;metabolism;therapeutic use;blood;drug therapy;enzymology;pathology;administration & dosage;adverse effects;pharmacokinetics;antagonists & inhibitors;metabolism;administration & dosage;adverse effects;pharmacokinetics;methods",
        "_version_":1605783461435539456},
      {
        "Doc_abstract":"Dasatanib, which has been approved for rescue therapy for patients with imatinib-resistant chronic myelogenous leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia, is a novel, orally available multitargeted kinase inhibitor of BCR-ABL and SRC family kinases (Quintas-Cardama et al, J Clin Oncol 2007;25:3908-14). It binds to both active and inactive conformations of the ABL gene and is 325 times more potent than imatinib in inhibiting the growth of BCR/ABL cells in vitro (Morelock and Sahn, Chest 1999;116:212-21; Huggins and Sahn, Clin Chest Med 2004;25:141-53). Although dasatinib is a generally well-tolerated drug in the treatment of Philadelphia chromosome positive hematopoetic malignancies, pleural effusions have been frequently noted and have been reported in up to 35% of patients (Sahn SA. Drug-induced pleural disease. In: Camus P, Rosenow E, editors. Drug-induced iatrogenic lung disease. London: Hodder Arnold; 2009). Although there have been numerous reports of effusions, none have provided complete pleural fluid analysis; therefore, we report 2 patients with dasatinib-induced pleural effusion with complete pleural fluid analysis.",
        "Doc_title":"Dasatinib-induced pleural effusions: a lymphatic network disorder?",
        "Journal":"The American journal of the medical sciences",
        "Do_id":"19838099",
        "Doc_ChemicalList":"Protein Kinase Inhibitors;Pyrimidines;Thiazoles;Dasatinib",
        "Doc_meshdescriptors":"Adult;Aged;Dasatinib;Female;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Pleural Effusion;Protein Kinase Inhibitors;Pyrimidines;Thiazoles",
        "Doc_meshqualifiers":"drug therapy;enzymology;chemically induced;diagnosis;administration & dosage;adverse effects;therapeutic use;administration & dosage;adverse effects;therapeutic use;administration & dosage;adverse effects;therapeutic use",
        "_version_":1605753049458933760},
      {
        "Doc_abstract":"The clonal and immunophenotypic characteristics of blood leukemic cells from BCR/ABL p190 transgenic mice were investigated. All cell populations evaluated in vivo and in vitro had B-lymphocyte progenitor immunophenotypes. Immunoglobulin (JH) rearrangement patterns provided evidence for clonal diversification at different sites in vivo. Multiple clones were established in vitro from two of these mice (nos. 730 and 753). These cells expressed BCR/ABL p190 protein tyrosine kinase (PTK) and were highly malignant on transfer to secondary recipients. Cells independently cloned in vitro shared identical immunophenotypes and clonal IgH rearrangements, but these were distinct from those of the dominant clones in the mouse from which they were derived. Nevertheless, in vitro clones from mouse no. 753 had an abnormal karyotype (chromosome 14 trisomy) in common with the dominant clone in blood, providing evidence for a hierarchy or clonal selection in vivo and in vitro. Two sets of in vitro clones proliferated independently of exogenous growth factors and stroma and released autocrine interleukin 7 growth factor activity. These data provide evidence for rapid divergent clonal evolution and selection of B-cell progenitors initiated by BCR/ABL p190, followed by other, secondary genetic events mirroring similar changes in the equivalent, highly malignant human leukemia Philadelphia (Ph)-positive/B-precursor acute lymphoblastic leukemia (ALL).",
        "Doc_title":"Clonal characteristics of acute lymphoblastic cells derived from BCR/ABL p190 transgenic mice.",
        "Journal":"Oncogene",
        "Do_id":"1377812",
        "Doc_ChemicalList":"Antigens, Surface;Fusion Proteins, bcr-abl;Antigens, CD45",
        "Doc_meshdescriptors":"Animals;Antigens, CD45;Antigens, Surface;Base Sequence;Cell Division;Female;Fusion Proteins, bcr-abl;Gene Rearrangement, B-Lymphocyte, Heavy Chain;Karyotyping;Mice;Mice, Inbred C57BL;Mice, Transgenic;Molecular Sequence Data;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"analysis;genetics;genetics;pathology",
        "_version_":1605809429477851136},
      {
        "Doc_abstract":"To quantify bone marrow bcr/abl mRNA levels in imatinib mesylate treated Ph chromosome positive chronic myeloid leukemia (CML) patients.;Serial monitoring of bcr/abl mRNA levels by real-time quantitative RT-PCR technique (RQ-PCR) was performed in 34 cases (120 samples) of CML treated with imatinib mesylate. All the patients were IFNalpha based treatment failure before enrolled in this study and the percentage of Ph(+) bone marrow cells were over 95%.;The sensitivity of RQ-PCR was 10 pg RNA, with both coefficients of interassay and intraassay variation below 5% for standard samples. The median bcr/abl mRNA level of 10 patients' samples pre imatinib treatment was 5.79% with marked variation (0.24%-60.90%). In 72 samples post imatinib treatment, which the rates of Ph(+) cells [Ph(+)%] were between 0 and 94%, the mRNA level well correlated with Ph(+)% (r = 0.82, P < 0.001). The mRNA levels of 7 patients who achieved complete cytogenetic response (CCyR) within 12 months decreased markedly, the levels of 6 analysable patients decreased by 65.9% - 98.8% after 3 months'treatment accordingly. The level further decreased to 0 after achieving CCyR. For 4 patients who achieved major cytogenetic response (Ph(+) cells < 35%) later than 12 months, the mRNA levels decreased slowly. The levels of 3 analysable patients on 3 month therapy decreased by 2.5%, 18.5% and 61.6% compared with that before treatment. Out of 5 patients in chronic phase without cytogenetic response, 1 decreased, 2 increased gradually and 2 had no change. In 4 disease progression patients, the levels increased stepwise.;Serial quantifications of bcr/abl mRNA levels are necessary for imatinib treated patients, and are more informative than a single detection. A sharp decline of bcr/abl mRNA levels after the treatment implies a promise of CCyR.",
        "Doc_title":"[Monitoring bcr/abl mRNA levels in imatinib mesylate treated chronic myeloid leukemia patients by real-time quantitative RT-PCR].",
        "Journal":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi",
        "Do_id":"15946498",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Pyrimidines;RNA, Messenger;Imatinib Mesylate;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Antineoplastic Agents;Benzamides;Bone Marrow;Disease Progression;Female;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Piperazines;Pyrimidines;RNA, Messenger;Reverse Transcriptase Polymerase Chain Reaction;Young Adult",
        "Doc_meshqualifiers":"therapeutic use;metabolism;genetics;drug therapy;genetics;pathology;therapeutic use;therapeutic use;genetics;metabolism;methods",
        "_version_":1605795580483731456},
      {
        "Doc_abstract":"PURPOSE Dasatinib is an orally available tyrosine kinase inhibitor with low nanomolar activity against SRC family kinases, BCR-ABL, c-KIT, EPHA2, and the PDGF- receptor. Dasatinib was found to have selective activity in several tumor models in the Pediatric Preclinical Testing Program. PATIENTS AND METHODS A phase I study of dasatinib in pediatric patients with refractory solid tumors or imatinib-refractory, Philadelphia chromosome-positive leukemia was performed. Dose levels of 50, 65, 85, and 110 mg/m/dose, administered orally twice daily for 28 days, with courses repeated without interruption, were studied. Pharmacokinetic studies were performed with the initial dose.;A total of 39 patients (solid tumors, n = 28; chronic myeloid leukemia [CML], n = 9; acute lymphoblastic leukemia, n = 2) were enrolled. No dose-limiting toxicities (DLTs) were observed at the 50, 65, and 85 mg/m dose levels. At 110 mg/m, two of six patients experienced DLT including grade 2 diarrhea and headache. In children with leukemia, grade 4 hypokalemia (50 mg/m), grade 3 diarrhea (85 mg/m), and grade 2 creatinine elevation (50 mg/m) were observed. DLT in later courses included pleural effusions, hemangiomatosis, and GI hemorrhage. There were three complete cytogenetic responses, three partial cytogenetic responses, and two partial/minimal cytogenetic responses observed in evaluable patients with CML. CONCLUSION Overall, drug disposition and tolerability of dasatinib were similar to those observed in adult patients.",
        "Doc_title":"Pediatric phase I trial and pharmacokinetic study of dasatinib: a report from the children's oncology group phase I consortium.",
        "Journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
        "Do_id":"21263099",
        "Doc_ChemicalList":"Pyrimidines;Thiazoles;Dasatinib",
        "Doc_meshdescriptors":"Administration, Oral;Adolescent;Child;Child, Preschool;Dasatinib;Dose-Response Relationship, Drug;Drug Administration Schedule;Female;Follow-Up Studies;Hematologic Neoplasms;Hospitals, Pediatric;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Maximum Tolerated Dose;Neoplasms;Patient Selection;Pediatrics;Philadelphia;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Pyrimidines;Risk Assessment;Thiazoles;Treatment Outcome;Young Adult",
        "Doc_meshqualifiers":"diagnosis;drug therapy;diagnosis;drug therapy;drug therapy;pathology;diagnosis;drug therapy;administration & dosage;adverse effects;pharmacokinetics;administration & dosage;adverse effects;pharmacokinetics",
        "_version_":1605761620162641920},
      {
        "Doc_abstract":"The Philadelphia (Ph1) chromosome in chronic myelogenous leukemia (CML) involves reciprocal translocation of the bcr gene and the c-abl oncogene. The fused bcr/abl gene is transcribed into two types of chimeric mRNA. By means of a combined method of S1 nuclease protection and polymerase chain reaction, we amplified sequences representative of the chimeric bcr/abl transcripts. Only 5 micrograms of total cellular RNA is needed and the chimeric bcr/abl message can be detected at a dilution of 1:100,000. We also detected residual chimeric bcr/abl transcripts in the remission samples from two Ph1-positive CML patients. This technique has the potential to identify a subpopulation of Ph1-positive CML patients in remission who are at high risk of relapse.",
        "Doc_title":"Detection of minimal residual bcr/abl transcripts by a modified polymerase chain reaction.",
        "Journal":"Blood",
        "Do_id":"2458151",
        "Doc_ChemicalList":"Neoplasm Proteins;Proto-Oncogene Proteins;RNA;Fusion Proteins, bcr-abl;DNA-Directed DNA Polymerase",
        "Doc_meshdescriptors":"Base Sequence;DNA-Directed DNA Polymerase;Fusion Proteins, bcr-abl;Humans;Leukemia, Myeloid;Molecular Sequence Data;Neoplasm Proteins;Nucleic Acid Hybridization;Philadelphia Chromosome;Proto-Oncogene Proteins;RNA;Transcription, Genetic",
        "Doc_meshqualifiers":"metabolism;enzymology;genetics;isolation & purification;isolation & purification;isolation & purification",
        "_version_":1605895483183595520},
      {
        "Doc_abstract":"In individuals with chronic myeloid leukemia (CML) treated by autologous hematopoietic stem cell (HSC) transplantation, malignant progenitors in the graft contribute to leukemic relapse, but the mechanisms of homing and engraftment of leukemic CML stem cells are unknown. Here we show that CD44 expression is increased on mouse stem-progenitor cells expressing BCR-ABL and that CD44 contributes functional E-selectin ligands. In a mouse retroviral transplantation model of CML, BCR-ABL1-transduced progenitors from CD44-mutant donors are defective in homing to recipient marrow, resulting in decreased engraftment and impaired induction of CML-like myeloproliferative disease. By contrast, CD44-deficient stem cells transduced with empty retrovirus engraft as efficiently as do wild-type HSCs. CD44 is dispensable for induction of acute B-lymphoblastic leukemia by BCR-ABL, indicating that CD44 is specifically required on leukemic cells that initiate CML. The requirement for donor CD44 is bypassed by direct intrafemoral injection of BCR-ABL1-transduced CD44-deficient stem cells or by coexpression of human CD44. Antibody to CD44 attenuates induction of CML-like leukemia in recipients. These results show that BCR-ABL-expressing leukemic stem cells depend to a greater extent on CD44 for homing and engraftment than do normal HSCs, and argue that CD44 blockade may be beneficial in autologous transplantation in CML.",
        "Doc_title":"Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells.",
        "Journal":"Nature medicine",
        "Do_id":"16998483",
        "Doc_ChemicalList":"Antigens, CD44;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Animals;Antigens, CD44;Bone Marrow Cells;Cell Line, Tumor;Cohort Studies;Fusion Proteins, bcr-abl;Hematopoietic Stem Cells;Humans;Leukemia;Mice;Retroviridae;Stem Cell Transplantation;Stem Cells;Transplantation, Autologous",
        "Doc_meshqualifiers":"biosynthesis;cytology;chemistry;physiology;cytology;metabolism;pathology;genetics;methods;cytology;metabolism",
        "_version_":1605845084406808576},
      {
        "Doc_abstract":"Targeting kinases is central to drug-based cancer therapy but remains challenging because the drugs often lack specificity, which may cause toxic side effects. Modulating side effects is difficult because kinases are evolutionarily and hence structurally related. The lack of specificity of the anticancer drug imatinib enables it to be used to treat chronic myeloid leukemia, where its target is the Bcr-Abl kinase, as well as a proportion of gastrointestinal stromal tumors (GISTs), where its target is the C-Kit kinase. However, imatinib also has cardiotoxic effects traceable to its impact on the C-Abl kinase. Motivated by this finding, we made a modification to imatinib that hampers Bcr-Abl inhibition; refocuses the impact on the C-Kit kinase; and promotes inhibition of an additional target, JNK, a change that is required to reinforce prevention of cardiotoxicity. We established the molecular blueprint for target discrimination in vitro using spectrophotometric and colorimetric assays and through a phage-displayed kinase screening library. We demonstrated controlled inhibitory impact on C-Kit kinase in human cell lines and established the therapeutic impact of the engineered compound in a novel GIST mouse model, revealing a marked reduction of cardiotoxicity. These findings identify the reengineered imatinib as an agent to treat GISTs with curbed side effects and reveal a bottom-up approach to control drug specificity.",
        "Doc_title":"An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic.",
        "Journal":"The Journal of clinical investigation",
        "Do_id":"18060038",
        "Doc_ChemicalList":"Benzamides;Cardiotoxins;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Imatinib Mesylate;Protein-Tyrosine Kinases;Proto-Oncogene Proteins c-kit;Fusion Proteins, bcr-abl;MAP Kinase Kinase 4",
        "Doc_meshdescriptors":"Animals;Benzamides;Cardiotoxins;Drug Screening Assays, Antitumor;Fusion Proteins, bcr-abl;Gastrointestinal Stromal Tumors;Heart Diseases;Humans;Imatinib Mesylate;K562 Cells;MAP Kinase Kinase 4;Neoplasms, Experimental;Piperazines;Protein Kinase Inhibitors;Protein-Tyrosine Kinases;Proto-Oncogene Proteins c-kit;Pyrimidines;Rats;Rats, Sprague-Dawley",
        "Doc_meshqualifiers":"chemistry;pharmacology;drug therapy;enzymology;chemically induced;enzymology;antagonists & inhibitors;metabolism;drug therapy;enzymology;adverse effects;chemistry;pharmacology;adverse effects;chemistry;pharmacology;antagonists & inhibitors;metabolism;metabolism;adverse effects;chemistry;pharmacology",
        "_version_":1605804146425856000},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) is a hematological malignancy that arises from the transformation of stem hematopoietic cells by the fusion oncogene BCR/ABL and subsequent clonal expansion of BCR/ABL-positive progenitor leukemic cells. The BCR/ABL protein displays a constitutively increased tyrosine kinase activity that alters many regulatory pathways, leading to uncontrolled growth, impaired differentiation and increased resistance to apoptosis featured by leukemic cells. Current CML therapy is based on tyrosine kinase inhibitors (TKIs), primarily imatinib, which induce apoptosis in leukemic cells. However, some patients show primary resistance to TKIs while others develop it in the course of therapy. In both cases, resistance may be underlined by perturbations in apoptotic signaling in leukemic cells. As mitochondria may play an important role in such signaling, alteration in mitochondrial metabolism may change resistance to pro-apoptotic action of TKIs in BCR/ABL-positive cells. Because BCR/ABL may induce reactive oxygen species and unfaithful DNA repair, it may affect the stability of mitochondrial DNA, influencing mitochondrial apoptotic signaling and in this way change the sensitivity of CML cells to TKIs. Moreover, cancer cells, including BCR/ABL-positive cells, show an increased level of glucose metabolism, resulting from the shift from oxidative phosphorylation to glycolysis to supply ATP for extensive proliferation. Enhanced level of glycolysis may be associated with TKI resistance and requires change in the expression of several genes regulated mostly by hypoxia-inducible factor-1, HIF-1. Such regulation may be associated with the impaired mitochondrial respiratory system in CML cells. In summary, mitochondria and mitochondria-associated molecules and pathways may be attractive targets to overcome TKI resistance in CML.",
        "Doc_title":"The role of mitochondrial DNA damage and repair in the resistance of BCR/ABL-expressing cells to tyrosine kinase inhibitors.",
        "Journal":"International journal of molecular sciences",
        "Do_id":"23965958",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;DNA, Mitochondrial;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Imatinib Mesylate;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Antineoplastic Agents;Apoptosis;Benzamides;DNA Damage;DNA Repair;DNA, Mitochondrial;Drug Resistance, Neoplasm;Fusion Proteins, bcr-abl;Genome, Mitochondrial;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Piperazines;Protein Kinase Inhibitors;Pyrimidines",
        "Doc_meshqualifiers":"pharmacology;pharmacology;genetics;metabolism;drug therapy;pharmacology;pharmacology;pharmacology",
        "_version_":1605806180097064960},
      {
        "Doc_abstract":"Because imatinib (IM) resistance in chronic myeloid leukemia is primarily caused by the re-establishment of Abl kinase, new inhibitors may be efficacious. We evaluated 3 new agents against 2 new K562 variants, IM-R1 and IM-R2 cells, which were developed having 7- and 27-fold greater IM resistance, respectively, than the parental K562 cells. Both variants possessed BCR-ABL gene amplification along with elevated levels of its transcript and protein. Greater BCR-ABL gene amplification was observed in IM-R2 cells than in IM-R1 cells, which was consistent with the higher mRNA and protein levels of Bcr-Abl, and ultimately correlated with the greater IM resistance in IM-R2 cells. No mutation in the Abl kinase domain was detected in either variant. Despite the absence of Lyn overexpression, the Src kinase inhibitor CGP76030 showed positive cooperability with IM in inhibiting cell growth of not only K562 cells but also these 2 variants. This might be because of the augmented inhibition of Erk1/2 phosphorylation. The new Abl kinase inhibitor nilotinib was 10-fold more potent than IM in inhibiting the growth of K562 cells. Nilotinib inhibited the growth of IM-R1 and IM-R2 cells as potently as K562 cells. The combination of nilotinib with CGP76030 showed little additivity, because the potency of nilotinib masked the efficacy of CGP76030. The new dual Abl/Lyn inhibitor INNO-406 (formerly NS-187) was slightly more potent than nilotinib in inhibiting the growth of all 3 cell lines. Because BCR-ABL gene amplification occurs in blast crisis, these inhibitors might overcome IM resistance in such patients' leukemia.",
        "Doc_title":"Overcoming imatinib resistance using Src inhibitor CGP76030, Abl inhibitor nilotinib and Abl/Lyn inhibitor INNO-406 in newly established K562 variants with BCR-ABL gene amplification.",
        "Journal":"International journal of cancer",
        "Do_id":"18338755",
        "Doc_ChemicalList":"4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide;Antineoplastic Agents;Benzamides;CGP 76030;P-Glycoprotein;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Pyrroles;abl-bcr fusion protein, human;bafetinib;Imatinib Mesylate;Fusion Proteins, bcr-abl;lyn protein-tyrosine kinase;src-Family Kinases",
        "Doc_meshdescriptors":"Antineoplastic Agents;Apoptosis;Benzamides;Blotting, Western;Cell Proliferation;Drug Resistance, Neoplasm;Flow Cytometry;Fusion Proteins, bcr-abl;Gene Amplification;Genes, abl;Humans;Imatinib Mesylate;In Situ Hybridization, Fluorescence;K562 Cells;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mutation;P-Glycoprotein;Phosphorylation;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Pyrroles;Reverse Transcriptase Polymerase Chain Reaction;src-Family Kinases",
        "Doc_meshqualifiers":"pharmacology;drug effects;drug effects;genetics;drug therapy;isolation & purification;pharmacology;pharmacology;pharmacology;pharmacology;antagonists & inhibitors",
        "_version_":1605893617912643584},
      {
        "Doc_abstract":"A variety of normal human tissues have been reported to harbor small cell populations carrying potentially oncogenic gene rearrangements. This backdrop of mutant cells may be present in the majority of healthy individuals and is apparently weakly selected against. This may provide empirical support for the concept of global neutrality, or near-neutrality (very weak selection), of many somatic mutations. Many healthy individuals, as well as patients with chronic myeloid leukemia, manifest the BCR-ABL fusion gene in blood cells. The presumed neutrality of the BCR-ABL rearrangement-carrying pluripotential hematopoietic stem cells and the relative uniformity of the incidence rate of CML worldwide were used to estimate the extent of the background of BCR-ABL-positive stem cells and the numerical size of the human pluripotential hematopoietic stem cell pool. Three different approaches (molecular-epidemiological, statistical, and population genetical) were employed. Each resulted in very similar estimates of the size of the stem cells carrying the BCR-ABL allele fusions (1.4 x 10(4) cells) and the size of the total human stem cell pool (1.6 x 10(9) cells per individual). The implication of these estimates in the context of the hierarchical nature of the stem cell pool is also considered. The presumptive smaller-sized population of CD34(-) stem cells could not be characterized by any of the approaches used as a \"founding\" population, representing an ultimate source of all hematopoietic progenitors, or as a subset of stem cells comprising a deeper \"kinetic\" segment of the total (10(9)-sized) stem cell compartment.",
        "Doc_title":"The fundamental prevalence of chronic myeloid leukemia-generating clonogenic cells in the light of the neutrality theory of evolution.",
        "Journal":"Blood cells, molecules & diseases",
        "Do_id":"11783955",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Cell Survival;Cell Transformation, Neoplastic;Clone Cells;Evolution, Molecular;Fusion Proteins, bcr-abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Models, Genetic;Mutation;Neoplastic Stem Cells;Poisson Distribution;Prevalence",
        "Doc_meshqualifiers":"genetics;pathology;genetics;etiology;genetics;pathology;cytology;pathology",
        "_version_":1605839529685549056},
      {
        "Doc_abstract":"The Philadelphia chromosome (Ph) derives from the balanced translocation between chromosomes 9 and 22. This chromosomal translocation results in the fusion between the 5' part of the BCR gene, normally located on chromosome 22, and the 3' part of the ABL gene on chromosome 9 giving origin to a BCR-ABL fusion gene which is transcribed and then translated into a hybrid protein. In general, three breakpoint cluster regions in the BCR gene have been described: major (M-BCR), minor (m-BCR) and micro (-BCR). Three main variants of the BCR-ABL gene have been described depending on the length of the sequence of the BCR gene included that encode for the P190, P210, P230 proteins. Most patients (95 %) were found to have P210 protein that resulted from rearrangement in the M-BCR region in the BCR gene and thus gives rise to b2a2 or b3a2 variants. The incidence of one or other rearrangement in chronic myeloid leukemia (CML) patients varies in different reported series. These two variants are associated with distinct clinical types of human leukemias. In this study, we report the frequencies of M-BCR-ABL fusion transcripts in 44 CML patients and we review the data on the correlations between the type of M-BCR/ABL variant and the corresponding sex, age and biological features. Forty-four untreated chronic phase CML patients were studied. The type of BCR-ABL fusion transcripts was determined by reverse transcriptase polymerase chain reaction (RT-PCR). More than half of them showed b3a2 fusion transcript (64 %), while (36 %) showed b2a2 transcript. No patients coexpressed b3a2/b2a2. Correlation between biological data demonstrated that: (a) M-BCR rearrangements were not associated with the sex of the patients. (b) Patients with b3a2 rearrangements were older than patients with b2a2 transcripts. (c) M-BCR rearrangements were influenced neither by the white blood count (WBC) nor with hemoglobin levels. However, platelet level is more elevated in patients with b3a2 transcript (681.2/L vs. 207/L; P = 0.001). In conclusion, we observed significant correlations between age, platelet level and M-BCR-ABL transcript, these observations deserve further investigations.",
        "Doc_title":"Analysis of the clinico-hematological relevance of the breakpoint location within M-BCR in chronic myeloid leukemia.",
        "Journal":"Medical oncology (Northwood, London, England)",
        "Do_id":"23269583",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adult;Chromosome Breakpoints;Female;Fusion Proteins, bcr-abl;Genes, abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Multiplex Polymerase Chain Reaction;Reverse Transcriptase Polymerase Chain Reaction",
        "Doc_meshqualifiers":"genetics;genetics;genetics",
        "_version_":1605873958874251264},
      {
        "Doc_abstract":"The Src-family protein-tyrosine kinase (PTK) Lyn is the most important Src-family kinase in B cells, having both inhibitory and stimulatory activity that is dependent on the receptor, ligand, and developmental context of the B cell. An important role for Lyn has been reported in acute myeloid leukemia and chronic myeloid leukemia, as well as certain solid tumors. Although several Src-family inhibitors are available, the development of Lyn-specific inhibitors, or inhibitors with reduced off-target activity to Lyn, has been hampered by the lack of structural data on the Lyn kinase. Here we report the crystal structure of the non-liganded form of Lyn kinase domain, as well as in complex with three different inhibitors: the ATP analogue AMP-PNP; the pan Src kinase inhibitor PP2; and the BCR-Abl/Src-family inhibitor Dasatinib. The Lyn kinase domain was determined in its \"active\" conformation, but in the unphosphorylated state. All three inhibitors are bound at the ATP-binding site, with PP2 and Dasatinib extending into a hydrophobic pocket deep in the substrate cleft, thereby providing a basis for the Src-specific inhibition. Analysis of sequence and structural differences around the active site region of the Src-family PTKs were evident. Accordingly, our data provide valuable information for the further development of therapeutics targeting Lyn and the important Src-family of kinases.",
        "Doc_title":"Crystal structures of the Lyn protein tyrosine kinase domain in its Apo- and inhibitor-bound state.",
        "Journal":"The Journal of biological chemistry",
        "Do_id":"18984583",
        "Doc_ChemicalList":"AG 1879;Apoenzymes;Protein Kinase Inhibitors;Pyrimidines;Thiazoles;Adenylyl Imidodiphosphate;lyn protein-tyrosine kinase;src-Family Kinases;Dasatinib",
        "Doc_meshdescriptors":"Adenylyl Imidodiphosphate;Animals;Apoenzymes;B-Lymphocytes;Catalytic Domain;Crystallography, X-Ray;Dasatinib;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Leukemia, Myeloid, Acute;Mice;Protein Kinase Inhibitors;Protein Structure, Tertiary;Pyrimidines;Thiazoles;src-Family Kinases",
        "Doc_meshqualifiers":"chemistry;therapeutic use;antagonists & inhibitors;chemistry;metabolism;enzymology;drug therapy;enzymology;drug therapy;enzymology;chemistry;therapeutic use;chemistry;therapeutic use;chemistry;therapeutic use;antagonists & inhibitors;chemistry;metabolism",
        "_version_":1605844352364445697},
      {
        "Doc_abstract":"The purpose of study was to evaluate the effect of stopping use of cyclosporine A (CsA) in reversion of donor chimeras of chronic myeloid leukemia (CML) patients relapsed after transplantation. Two CML patients were transplanted with allogeneic peripheral blood stem cells, and relapsed after transplantation, their bcr/abl gene and/or ph1 chromosome showed positive, donor chimeras decreased. For these two CML patients relapsed after transplantation, the use of CsA was stopped immediately, and the patient's body temperature, skin rash, blood picture, liver function and chimeras were planed to observe carefully. The results indicated that acute graft versus host disease (aGVHD) appeared in both patients. A hundred percent (100%) of donor chimeras were then found with bcr/abl gene and/or ph1 chromosome turning to negative in both patients. In conclusion, to stop using of CsA might be effective in the treatment of some CML patients relapsed after transplantation by reversing of donor chimeras and inducing graft-versus-leukemia (GVL) effect accompanied by GVHD.",
        "Doc_title":"[Reversing of donor chimeras by stopping use of CsA in 2 CML patients relapsed after transplantation].",
        "Journal":"Zhongguo shi yan xue ye xue za zhi",
        "Do_id":"17605884",
        "Doc_ChemicalList":"Cyclosporine",
        "Doc_meshdescriptors":"Adult;Antineoplastic Combined Chemotherapy Protocols;Cyclosporine;Graft vs Leukemia Effect;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Neoplasm Recurrence, Local;Peripheral Blood Stem Cell Transplantation;Transplantation Chimera",
        "Doc_meshqualifiers":"therapeutic use;therapeutic use;immunology;drug therapy;genetics;therapy;genetics;adverse effects;immunology",
        "_version_":1605746998650077184},
      {
        "Doc_abstract":"The interferon consensus sequence binding protein (Icsbp) is a transcription factor that influences multiple aspects of myelopoiesis. Expression of Icsbp is decreased in the bone marrow of human subjects with chronic myeloid leukemia (CML), and studies in murine models suggest that Icsbp functions as an anti-oncogene for CML. We previously identified a set of Icsbp target genes that may contribute to this anti-oncogene effect. The set includes PTPN13, the gene encoding Fas-associated phosphatase 1 (Fap1, a Fas antagonist). We previously demonstrated that myeloid progenitor cells from Icsbp-knockout mice exhibit Fap1-dependent Fas resistance. In the present study, we determined that the Fas resistance of Bcr-abl+cells is Icsbp- and Fap1-dependent. We also found that treatment of Bcr-abl bone marrow cells with a Fap1-blocking peptide prevents in vitro selection of a tyrosine kinase inhibitor (TKI)-resistant population. Therefore, these results have implications for therapeutic targeting of the Fas-resistant leukemia stem cell population and addressing TKI resistance in CML.",
        "Doc_title":"Fas-associated phosphatase 1 mediates Fas resistance in myeloid progenitor cells expressing the Bcr-abl oncogene.",
        "Journal":"Leukemia & lymphoma",
        "Do_id":"22891763",
        "Doc_ChemicalList":"Antigens, CD95;Benzamides;Interferon Regulatory Factors;Piperazines;Protein Kinase Inhibitors;Pyrimidines;interferon regulatory factor-8;Imatinib Mesylate;Fusion Proteins, bcr-abl;Protein Tyrosine Phosphatase, Non-Receptor Type 13;Ptpn13 protein, mouse",
        "Doc_meshdescriptors":"Animals;Antigens, CD95;Benzamides;Blotting, Western;Bone Marrow Cells;Cell Line, Tumor;Cells, Cultured;Drug Resistance, Neoplasm;Fusion Proteins, bcr-abl;Gene Expression;Humans;Imatinib Mesylate;Interferon Regulatory Factors;Mice;Mice, Inbred C57BL;Mice, Knockout;Myeloid Progenitor Cells;Piperazines;Promoter Regions, Genetic;Protein Binding;Protein Kinase Inhibitors;Protein Tyrosine Phosphatase, Non-Receptor Type 13;Pyrimidines;Reverse Transcriptase Polymerase Chain Reaction;U937 Cells",
        "Doc_meshqualifiers":"metabolism;pharmacology;drug effects;metabolism;genetics;metabolism;genetics;metabolism;metabolism;pharmacology;genetics;pharmacology;genetics;metabolism;pharmacology",
        "_version_":1605840170632871936},
      {
        "Doc_abstract":"The molecular characterization of childhood leukemias directly affects our treatment strategies. Acute lymphoblastic leukemia patients with the TEL-AML1 fusion have a favorable prognosis, whereas those with the E2A-PBX1 fusion require more intensive therapy to obtain a good outcome. Acute lymphoblastic leukemia patients whose leukemic lymphoblasts contain the MLL-AF4 or the BCR-ABL fusion are often candidates for allogeneic hematopoietic stem cell transplantation during first remission. Among acute myeloid leukemia patients, AML1-ETO and CBFbeta-MYH11 fusions are associated with a favorable response, especially when the chemotherapy regimen includes high-dose cytarabine. Patients with acute promyelocytic leukemia who carry the PML-RAR alpha fusion respond to all-trans retinoic acid and have an excellent outcome after treatment with all-trans retinoic acid in combination with anthracyclines. Several novel therapeutic agents targeted to molecular lesions of leukemic cells are under investigation.",
        "Doc_title":"Molecular diagnostics in the treatment of leukemia.",
        "Journal":"Current opinion in hematology",
        "Do_id":"10400371",
        "Doc_ChemicalList":"Neoplasm Proteins;Oncogene Proteins, Fusion",
        "Doc_meshdescriptors":"Humans;Leukemia;Neoplasm Proteins;Oncogene Proteins, Fusion;Translocation, Genetic",
        "Doc_meshqualifiers":"diagnosis;genetics;therapy;genetics;genetics",
        "_version_":1605891091219873792},
      {
        "Doc_abstract":"Human leukemia cell lines are of great value in leukemia research. In this study, we established and described the biological characteristics of a rare atypical chronic myeloid (aCML) leukemia cell line (NT-1). Mononuclear cells were isolated from the bone marrow of a patient with atypical chronic myeloid leukemia (Ph(-)/bcr(-)/abl(-)), and were passaged by liquid culture. Cells were maintained without any cytokines for over 1 year, and named NT-1. This cell line was extensively characterized using morphological assays, flow cytometry, cytogenetic analysis, clonogenic culture, quantitative fluorescent PCR, short tandem repeating sequence PCR (STR-PCR) and array-CGH. Its tumorigenic capacity was also examined in nude mice. The NT-1 cell line had morphological features of chronic myeloid leukemia and major myeloid markers (CD13, CD33, CD11b). Additionally, NT-1 expressed progenitor cells and natural killer cell-related antigens such as CD34, CD117, CD56. Cytogenetic analysis initially demonstrated two abnormalities: 47, xx, +8 and 47, xx, +8 accompanied by t(5;12)(q31;p13) translocation. The one-year passage process did not alter the karyotype. NT-1 cells maintained the same morphology, immunophenotyping and cytogenetic features as primary leukemia cells, which was strongly supported by STR-PCR results. Neither Epstein-Barr virus nor mycoplasma was detected in the NT-1 line. In addition, NT-1 cells showed high tumorigenic capacity in nude mice. NT-1 is a new atypical chronic myeloid leukemia cell line with the +8 and t(5,12) translocation, and exhibits high tumorigenicity in nude mice. This new cell line provides a useful tool for the study of leukemogenesis. ",
        "Doc_title":"Establishment and characterization of a rare atypical chronic myeloid leukemia cell line NT-1.",
        "Journal":"Leukemia research",
        "Do_id":"25012564",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Aged;Animals;Cell Line, Tumor;Cytogenetic Analysis;Female;Heterografts;Humans;Immunophenotyping;Karyotyping;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mice;Mice, Inbred BALB C;Mice, Nude;Neoplasm Transplantation;Primary Cell Culture",
        "Doc_meshqualifiers":"genetics;pathology",
        "_version_":1605820787489505280},
      {
        "Doc_abstract":"We present a 28-year-old patient with chronic myeloid leukemia (CML) in chronic phase complicated with nephrotic syndrome. The bone marrow cells revealed the presence of Philadelphia chromosome, the cytogenetic hallmark of CML, that results from a balanced, reciprocal translocation between the long arms of chromosomes 9 and 22, t(9;22)(q34;q11). This reciprocal translocation leads to the formation of the BCR/ABL fusion gene, the presence of which was confirmed using the highly sensitive fluorescence in situ hybridization technique. The renal biopsy was compatible with minimal change nephrotic syndrome. To the best of our knowledge, this is the first case of minimal change nephrotic syndrome associated with CML before the administration of any therapy.",
        "Doc_title":"A case of chronic myeloid leukemia complicated with minimal change nephrotic syndrome.",
        "Journal":"Acta haematologica",
        "Do_id":"12624495",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adult;Biopsy;Chromosomes, Human, Pair 22;Chromosomes, Human, Pair 9;Fusion Proteins, bcr-abl;Humans;In Situ Hybridization, Fluorescence;Kidney;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Nephrosis, Lipoid;Proteinuria;Translocation, Genetic;Ultrasonography",
        "Doc_meshqualifiers":"genetics;pathology;complications;diagnosis;genetics;complications;diagnosis",
        "_version_":1605795732287127552},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) results from malignant transformation of hematopoietic stem cells induced by the BCR-ABL oncogene. Transformation from chronic to blastic phase is the lethal step in CML. Leukemic stem cells (LSCs) are the basic reason for blastic transformation. It has been shown that Wnt/-catenin signaling contributes to the self-renewal capacity and proliferation of LSCs in CML. However, the role of Wnt/-catenin signaling in blastic transformation of CML is still obscure. Here, we explored the relationship between BCR-ABL and -catenin signaling in vitro and in vivo. We found that BCR-ABL stimulated -catenin via activation of PI3K/AKT signaling in blastic phase CML cells. Inhibition of the kinase activity of BCR-ABL, PI3K, or AKT decreased the level of -catenin in both K562 cells and a CML mouse model and suppressed the transcription of downstream target genes (c-myc and cyclin D1). In addition, inhibition of the BCR-ABL/PI3K/AKT pathway delayed the disease progression in the CML mouse model. To further explore the role of -catenin in the self-renewal and survival of CML LSCs, we established a secondary transplantation CML mouse model. Our data revealed that inhibition of the BCR-ABL/PI3K/AKT pathway reduced the tumor-initiating ability of K562 cells, decreased leukemia cell infiltration into peripheral blood and bone marrow, and prolonged the survival of mice. In conclusion, our data indicate a close relationship between -catenin and BCR-ABL/PI3K/AKT in blastic phase CML. -Catenin inhibition may be of therapeutic value by targeting LSCs in combination with a tyrosine kinase inhibitor, which may delay blastic transformation of CML.",
        "Doc_title":"Potential role of Wnt/-catenin signaling in blastic transformation of chronic myeloid leukemia: cross talk between -catenin and BCR-ABL.",
        "Journal":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine",
        "Do_id":"27817074",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605897447053197312},
      {
        "Doc_abstract":"Fanconi anemia (FA) is an autosomal recessive disorder with a high risk of malignancies including acute myeloid leukemia and squamous cell carcinoma. There is a constant search out of new potential therapeutic molecule to combat this disorder. In most cases, patients with FA develop haematological malignancies with acute myeloid leukemia and acute lymphoblastic leukemia. Identifying drugs which can efficiently block the pathways of both these disorders can be an ideal and novel strategy to treat FA. The curcumin, a natural compound obtained from turmeric is an interesting therapeutic molecule as it has been reported in the literature to combat both FA as well as leukemia. However, its complete mechanism is not elucidated. Herein, a systems biology approach for elucidating the therapeutic potential of curcumin against FA and leukemia is investigated by analyzing the computational molecular interactions of curcumin ligand with FANC G of FA and seven other key disease targets of leukemia. The proteins namely DOT1L, farnesyl transferase (FDPS), histone decetylase (EP3000), Polo-like kinase (PLK-2), aurora-like kinase (AUKRB), tyrosine kinase (ABL1), and retinoic acid receptor alpha (RARA) were chosen as disease targets for leukemia and modeled structure of FANC G protein as the disease target for FA. The docking investigations showed that curcumin had a very high binding affinity of -8.1kcal/mol with FANC G protein. The key disease targets of leukemia namely tyrosine kinase (ABL1), aurora-like kinase (AUKRB), and polo-like kinase (PLK-2) showed that they had the comparable binding affinities of -9.7 k cal/mol, -8.7 k cal/mol, and -8.6 k cal/mol, respectively with curcumin. Further, the percentage similarity scores obtained from PAM50 using EMBOSS MATCHER was shown to provide a clue to understand the structural relationships to an extent and to predict the binding affinity. This investigation shows that curcumin effectively interacts with the disease targets of both FA and leukemia.",
        "Doc_title":"A systems biology approach for elucidating the interaction of curcumin with Fanconi anemia FANC G protein and the key disease targets of leukemia.",
        "Journal":"Journal of receptor and signal transduction research",
        "Do_id":"27608133",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605903482299088896},
      {
        "Doc_abstract":"Imatinib is highly effective in newly diagnosed, but not in relapsed, Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). BCR-ABL tyrosine kinase domain (TKD) mutations are associated with acquired imatinib resistance, but their role in primary resistance is uncertain. Using highly sensitive ligation-PCR and denaturing high-performance liquid chromatography (DHPLC), we identified baseline TKD mutations in 21% and 42% of imatinib-nave patients with newly diagnosed (n=26) or recurrent (n=65) Ph+ ALL, respectively (P=ns). Within 4 weeks of starting the imatinib treatment, absolute levels of mutant bcr-abl transcripts increased significantly in patients with advanced, but not with de novo, Ph+ ALL. The net expansion of pre-existing mutant clones during imatinib treatment resulted in the rapid appearance of initially undetectable TKD mutations, which after 4 weeks were detectable in 70% of patients with advanced disease. There was a high degree of concordance between the type of mutations detected at relapse and during initial imatinib treatment. The profoundly different outgrowth dynamics of leukemic clones with bcr-abl mutations in imatinib-treated patients who differ in their disease history, provides clinical-translational evidence for a contributory role of non-mutational resistance mechanisms, possibly induced by prior chemotherapy. Moreover, the prevalence of pre-existing, clinically relevant TKD may have been underestimated in tyrosine kinase inhibitor-nave patients with Ph+ ALL.",
        "Doc_title":"Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia.",
        "Journal":"Leukemia",
        "Do_id":"22230800",
        "Doc_ChemicalList":"Benzamides;Piperazines;Protein Kinase Inhibitors;Pyrimidines;RNA, Messenger;Imatinib Mesylate;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Benzamides;Clinical Trials, Phase II as Topic;Drug Resistance, Neoplasm;Female;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Male;Middle Aged;Mutation;Neoplasm Recurrence, Local;Philadelphia Chromosome;Piperazines;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Prevalence;Prognosis;Prospective Studies;Protein Kinase Inhibitors;Pyrimidines;RNA, Messenger;Randomized Controlled Trials as Topic;Real-Time Polymerase Chain Reaction;Remission Induction;Reverse Transcriptase Polymerase Chain Reaction;Young Adult",
        "Doc_meshqualifiers":"genetics;antagonists & inhibitors;genetics;genetics;diagnosis;drug therapy;epidemiology;genetics;therapeutic use;diagnosis;drug therapy;epidemiology;genetics;therapeutic use;therapeutic use;genetics",
        "_version_":1605837354671538176},
      {
        "Doc_abstract":"The BCR-ABL tyrosine kinase inhibitor imatinib represents the current frontline therapy in chronic myeloid leukemia. Because many patients develop imatinib resistance, 2 second-generation drugs, nilotinib and dasatinib, displaying increased potency against BCR-ABL were developed. To predict potential side effects and novel medical uses, we generated comprehensive drug-protein interaction profiles by chemical proteomics for all 3 drugs. Our studies yielded 4 major findings: (1) The interaction profiles of the 3 drugs displayed strong differences and only a small overlap covering the ABL kinases. (2) Dasatinib bound in excess of 30 Tyr and Ser/Thr kinases, including major regulators of the immune system, suggesting that dasatinib might have a particular impact on immune function. (3) Despite the high specificity of nilotinib, the receptor tyrosine kinase DDR1 was identified and validated as an additional major target. (4) The oxidoreductase NQO2 was bound and inhibited by imatinib and nilotinib at physiologically relevant drug concentrations, representing the first nonkinase target of these drugs.",
        "Doc_title":"Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets.",
        "Journal":"Blood",
        "Do_id":"17720881",
        "Doc_ChemicalList":"4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide;Benzamides;Neoplasm Proteins;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Thiazoles;Imatinib Mesylate;NRH - quinone oxidoreductase2;Quinone Reductases;DDR1 protein, human;Discoidin Domain Receptor 1;Protein-Tyrosine Kinases;Receptor Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl;Protein-Serine-Threonine Kinases;Dasatinib",
        "Doc_meshdescriptors":"Benzamides;Dasatinib;Discoidin Domain Receptor 1;Dose-Response Relationship, Drug;Drug Resistance, Neoplasm;Drug Screening Assays, Antitumor;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;K562 Cells;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Neoplasm Proteins;Piperazines;Protein Kinase Inhibitors;Protein-Serine-Threonine Kinases;Protein-Tyrosine Kinases;Proteomics;Pyrimidines;Quinone Reductases;Receptor Protein-Tyrosine Kinases;Thiazoles",
        "Doc_meshqualifiers":"drug therapy;enzymology;antagonists & inhibitors;metabolism;chemistry;pharmacology;therapeutic use;chemistry;pharmacology;therapeutic use;antagonists & inhibitors;metabolism;antagonists & inhibitors;metabolism;chemistry;pharmacology;therapeutic use;antagonists & inhibitors;metabolism;antagonists & inhibitors;metabolism;chemistry;pharmacology;therapeutic use",
        "_version_":1605747021148323841},
      {
        "Doc_abstract":"The successful introduction of the tyrosine kinase inhibitors has initiated a new era in the management of chronic myeloid leukemia (CML). Imatinib mesilate therapy has significantly improved the prognosis of CML. A minority of patients in chronic-phase CML--and more patients in advanced phases--are resistant to imatinib, or develop resistance during treatment. This is attributed, in 40-50% of cases, to the development of mutations in the Bcr-Abl tyrosine kinase domain that impair imatinib binding. Nilotinib (Tasigna) is a novel potent selective oral kinase inhibitor. Preclinical and clinical investigations demonstrate that nilotinib effectively overcomes imatinib resistance, and has induced high rates of hematologic and cytogenetic responses in CML post imatinib failure.",
        "Doc_title":"Nilotinib: a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of leukemias.",
        "Journal":"Expert opinion on investigational drugs",
        "Do_id":"18549348",
        "Doc_ChemicalList":"4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide;Protein Kinase Inhibitors;Pyrimidines;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Animals;Clinical Trials as Topic;Drug Resistance, Neoplasm;Fusion Proteins, bcr-abl;Humans;Leukemia;Protein Kinase Inhibitors;Protein-Tyrosine Kinases;Pyrimidines",
        "Doc_meshqualifiers":"drug effects;drug therapy;enzymology;therapeutic use;antagonists & inhibitors;metabolism;chemistry;therapeutic use",
        "_version_":1605775113190375424},
      {
        "Doc_abstract":"To analyze the correlation between clinical features and cytogenetic finding of 45 adult patients with acute lymphoblastic leukemia (ALL), and to assess the value of chromosomal examination for the diagnosis and prognosis.;Fluorescence in situ hybridization (FISH) was utilized for detecting the BCR/ABL fusion gene and P53 gene. Median survival time (MST) of patients was compared using Log-rank test.;Respectively, the MST of patients with white blood cell count (WBC) 30  10(9)/L, normal karyotype, or without a Philadelphia chromosome were significantly greater than those with WBC > 30  10(9)/L, abnormal karyotype or Philadelphia chromosome (P< 0.05).;WBC, karyotype abnormalities and presence of Philadelphia chromosome are independent factors for the prognosis of ALL in adult patients.",
        "Doc_title":"[Clinical and cytogenetic analyses of 45 adult patients with acute lymphoblastic leukemia].",
        "Journal":"Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics",
        "Do_id":"22678807",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Abnormal Karyotype;Adult;Aged;Cytogenetic Analysis;Female;Fusion Proteins, bcr-abl;Genes, p53;Humans;Male;Middle Aged;Philadelphia Chromosome;Precursor Cell Lymphoblastic Leukemia-Lymphoma",
        "Doc_meshqualifiers":"methods;genetics;diagnosis;genetics",
        "_version_":1605747069010575360},
      {
        "Doc_abstract":"Several clinical observations demonstrate that immunologic effects are important in chronic myeloid leukemia (CML). The characteristic BCR-ABL fusion protein is a leukemia-specific antigen, and it has therefore received much immunologic attention, especially regarding the amino acid sequences that span the e14a2 junction. Other attractive targets are the Wilms' tumor 1 antigen and the PR1 epitope from proteinase 3, a granule protein overexpressed in CML. Imatinib may modulate several components of the immune response, although the clinical relevance of this effect is uncertain. In clinical trials, peptide vaccination appears safe and undoubtedly produces clinical effects, but randomized trials are now required to see if these are distinct from the effects of other concurrent therapy. These trials will be difficult to orchestrate in the competitive environment of novel therapies for CML.",
        "Doc_title":"Immunotherapeutic strategies in chronic myeloid leukemia.",
        "Journal":"Current hematologic malignancy reports",
        "Do_id":"20425356",
        "Doc_ChemicalList":"Antigens, Neoplasm;Benzamides;Cancer Vaccines;Epitopes;Neoplasm Proteins;Peptide Fragments;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Vaccines, Subunit;WT1 Proteins;Imatinib Mesylate;Fusion Proteins, bcr-abl;Myeloblastin",
        "Doc_meshdescriptors":"Antigens, Neoplasm;Benzamides;Cancer Vaccines;Clinical Trials as Topic;Clonal Anergy;Dendritic Cells;Epitopes;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Immunotherapy;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Myeloblastin;Neoplasm Proteins;Peptide Fragments;Piperazines;Protein Kinase Inhibitors;Pyrimidines;T-Lymphocyte Subsets;Vaccination;Vaccines, Subunit;WT1 Proteins",
        "Doc_meshqualifiers":"chemistry;immunology;immunology;therapeutic use;drug effects;immunology;chemistry;immunology;chemistry;genetics;immunology;methods;genetics;immunology;therapy;chemistry;immunology;chemistry;genetics;immunology;chemistry;immunology;pharmacology;therapeutic use;pharmacology;therapeutic use;pharmacology;therapeutic use;immunology;immunology;therapeutic use;chemistry;immunology",
        "_version_":1605741962540875777},
      {
        "Doc_abstract":"Chronic myelogenous leukemia (CML) is a myeloproliferative disorder characterized at the molecular level by the expression of Bcr-abl, a 210-kDa fusion protein with deregulated tyrosine kinase activity. Encouraged by the clinical validation of Bcr-abl as the target for the treatment of CML by imatinib, we sought to identify pharmacological agents that could target this kinase by a distinct mechanism. We report the discovery of a new class of Bcr-abl inhibitors using an unbiased differential cytotoxicity screen of a combinatorial kinase-directed heterocycle library. Compounds in this class (exemplified by GNF-2) show exclusive antiproliferative activity toward Bcr-abl-transformed cells, with potencies similar to imatinib, while showing no inhibition of the kinase activity of full-length or catalytic domain of c-abl. We propose that this new class of compounds inhibits Bcr-abl kinase activity through an allosteric non-ATP competitive mechanism.",
        "Doc_title":"Allosteric inhibitors of Bcr-abl-dependent cell proliferation.",
        "Journal":"Nature chemical biology",
        "Do_id":"16415863",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;GNF-2 compound;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Imatinib Mesylate;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Animals;Antineoplastic Agents;Apoptosis;Benzamides;Cell Line;Cell Line, Transformed;Cell Proliferation;Drug Resistance, Neoplasm;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mice;Piperazines;Protein Binding;Protein Conformation;Protein Kinase Inhibitors;Protein-Tyrosine Kinases;Pyrimidines",
        "Doc_meshqualifiers":"pharmacology;drug effects;antagonists & inhibitors;chemistry;metabolism;drug therapy;pharmacology;pharmacology;antagonists & inhibitors;pharmacology",
        "_version_":1605882884252499968},
      {
        "Doc_abstract":"Undetectable BCR-ABL transcripts in patients with chronic myeloid leukemia (CML) should not be regarded as indicative of a cure, due to the sensitivity limit of current real-time quantitative polymerase chain reaction (RQ-PCR) technology. To demonstrate the feasibility of more sensitive approaches, 62 samples from 43 patients with CML were screened by conventional RQ-PCR, replicate RQ-PCR (rRQ-PCR), and/or nanofluidic digital PCR (dPCR). First, we confirmed the correlation of dPCR to conventional RQ-PCR using 30 patient samples with various minimal residual disease (MRD) levels. When the sensitivity limits were determined using cell line and patient sample dilutions, rRQ-PCR and dPCR with pre-amplification showed 2-3 log improvement compared to conventional RQ-PCR, and 24 of 32 PCR negative samples as assayed by conventional RQ-PCR showed detectable BCR-ABL in rRQ-PCR and/or dPCR. More important, using dPCR in conjunction with a pre-amplification step, a continuous decline in MRD level could be precisely monitored even after it became undetectable by conventional RQ-PCR. In this study, both rRQ-PCR and dPCR demonstrated successful detection of BCR-ABL transcripts not detectable in conventional RQ-PCR, and these data show the potential feasibility of highly sensitive PCR approaches for molecular monitoring and clinical relevance in future CML management by allowing further characterization of patients who achieve PCR negativity in a conventional RQ-PCR assay.",
        "Doc_title":"Sensitive quantitation of minimal residual disease in chronic myeloid leukemia using nanofluidic digital polymerase chain reaction assay.",
        "Journal":"Leukemia & lymphoma",
        "Do_id":"21338281",
        "Doc_ChemicalList":"RNA, Messenger;RNA, Neoplasm;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Feasibility Studies;Fusion Proteins, bcr-abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Molecular Diagnostic Techniques;Nanotechnology;Neoplasm, Residual;Polymerase Chain Reaction;RNA, Messenger;RNA, Neoplasm;Sensitivity and Specificity",
        "Doc_meshqualifiers":"genetics;diagnosis;standards;instrumentation;methods;diagnosis;instrumentation;methods;standards;analysis;analysis",
        "_version_":1605748552706818048},
      {
        "Doc_abstract":"Basophil numbers are typically elevated in chronic myeloid leukemia (CML) and increase during disease progression. Histamine is an essential mediator and marker of basophils and is highly up-regulated in CML. We examined the biochemical basis of histamine synthesis in CML cells. The CML-specific oncoprotein BCR/ABL was found to promote expression of histidine decarboxylase (HDC) and synthesis of histamine in Ba/F3 cells. Moreover, the BCR/ABL tyrosine kinase inhibitors imatinib (STI571) and nilotinib (AMN107) decreased histamine levels and HDC mRNA expression in BCR/ABL-transformed Ba/F3 cells, in the CML-derived basophil cell line KU812, and in primary CML cells. Synthesis of histamine was found to be restricted to the basophil compartment of the CML clone and to depend on signaling through the PI3-kinase pathway. CML cells also expressed histamine receptors (HRs), including HR-1, HR-2, HR-4, and histamine-binding CYP450 isoenzymes which also serve as targets of HR antagonists. The HR-1 antagonists loratadine and terfenadine, which bind to CYP450, were found to counteract proliferation of CML cells, whereas no growth inhibition was observed with the HR-1 antagonist fexofenadine which is not targeted or metabolized by CYP450. Moreover, DPPE, an inhibitor of histamine-binding CYP450 isoenzymes, produced growth inhibition in CML cells. Together, these data show that BCR/ABL promotes histamine production in CML cells and that certain HR-targeting drugs exert antileukemic effects on CML cells.",
        "Doc_title":"The CML-related oncoprotein BCR/ABL induces expression of histidine decarboxylase (HDC) and the synthesis of histamine in leukemic cells.",
        "Journal":"Blood",
        "Do_id":"16849647",
        "Doc_ChemicalList":"Antineoplastic Agents;Histamine Antagonists;Oncogene Proteins;Receptors, Histamine;Histamine;Phosphatidylinositol 3-Kinases;Fusion Proteins, bcr-abl;Histidine Decarboxylase",
        "Doc_meshdescriptors":"Animals;Antineoplastic Agents;Cell Line;Fusion Proteins, bcr-abl;Gene Expression Regulation, Leukemic;Histamine;Histamine Antagonists;Histidine Decarboxylase;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mice;Oncogene Proteins;Phosphatidylinositol 3-Kinases;Receptors, Histamine;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"pharmacology;physiology;biosynthesis;pharmacology;genetics;drug therapy;enzymology;metabolism;pathology;metabolism;analysis",
        "_version_":1605851725656227840},
      {
        "Doc_abstract":"In this study, we investigated the expression of survivin (SVV) in 44 patients with typical Ph-positive chronic myeloid leukemia (CML) in different phases of the disease as well as in 20 matched healthy donors. We found a very high SVV expression in a predominant percentage of CML patients. We also observed a significantly increased SVV expression in patients in accelerated/blastic phase of the disease compared to patients in chronic phase. Moreover, SVV expression levels correlated in all CML patients with % of Ph-chromosome positive cells, with Bcr-Abl expression levels and with WBC-count. Based on this finding we suggest that SVV detection and monitoring in CML could represent both a useful biomarker and attractive candidate for devising new targeted and combined therapies in CML.",
        "Doc_title":"Survivin expression in chronic myeloid leukemia.",
        "Journal":"Cancer letters",
        "Do_id":"15922862",
        "Doc_ChemicalList":"BIRC5 protein, human;Biomarkers, Tumor;Inhibitor of Apoptosis Proteins;Microtubule-Associated Proteins;Neoplasm Proteins",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Aged, 80 and over;Biomarkers, Tumor;Case-Control Studies;Female;Gene Expression Profiling;Humans;Inhibitor of Apoptosis Proteins;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Microtubule-Associated Proteins;Middle Aged;Neoplasm Proteins;Polymerase Chain Reaction",
        "Doc_meshqualifiers":"blood;genetics;biosynthesis;blood",
        "_version_":1605741967861350401},
      {
        "Doc_abstract":"State of the art management of chronic myeloid leukemia (CML) patients with the selection of best available treatment options requires systematic cytogenetic and molecular monitoring. The choice of the first-line tyrosine kinase inhibitor depends on integration of comorbidities and individual treatment goals. Clinical prognostic scores should be used for cohort comparison and for stratification in randomized trials. Their relevance for individual treatment decisions has not yet been established. Essential for therapeutic decision-making is the achievement of predefined cytogenetic and molecular milestones in the course of the disease. In cases of treatment resistance or relapse the analysis of potential causes is required. After exclusion of compliance issues bone marrow analysis for the accurate characterization of the hematologic disease state and exclusion of clonal evolution is recommended. In parallel, BCR-ABL mutation analysis should be performed. The choice of second-line treatment depends on the predicted sensitivity of any BCR-ABL mutation detected and the clinical history of the patient. Most important is prevention of disease progression as treatment results in advanced disease are still not satisfying. Therefore, allogeneic stem cell transplantation should be considered early in resistant disease, when high-risk parameters (e.g. multiresistant mutations) have been detected.",
        "Doc_title":"[Tailored management of chronic myeloid leukemia].",
        "Journal":"Der Internist",
        "Do_id":"23371258",
        "Doc_ChemicalList":"Genetic Markers",
        "Doc_meshdescriptors":"Genetic Markers;Genetic Testing;Genetic Therapy;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Molecular Targeted Therapy;Precision Medicine;Stem Cell Transplantation",
        "Doc_meshqualifiers":"genetics;methods;trends;diagnosis;genetics;therapy;trends;methods;trends",
        "_version_":1605884151081205760},
      {
        "Doc_abstract":"A cancer dogma states that inactivation of oncogene(s) can cause cancer remission, implying that oncogenes are the Achilles' heel of cancers. This current \"hands on\" model of cancer has kept oncogenes firmly in focus as therapeutic targets and is in agreement with the fact that in human cancers all cancerous cells, with independence of the cellular heterogeneity existing within the tumor, carry the same oncogenic genetic lesions. This rule has now been broken in a study of the effect of the BCR-ABL oncogene in cancer development in a mouse model in which oncogene expression is restricted to the stem cell compartment. BCR-ABL is linked to chronic myeloid leukemia (CML) disease in humans, and this study shows that by limiting the oncogene expression to Sca1(+) cells CML arises, indicating that maintenance of oncogene expression is not critical for the generation of differentiated tumor cells and showing a \"hands off\" role for BCR-ABL in regulating cancer formation. Here we provide an update on the use of this system for modeling human cancer and its potential application for therapeutic targeting of cancer stem cells (CSCs) and the hands-off function of oncogenes.",
        "Doc_title":"Stem-cell driven cancer: \"hands-off\" regulation of cancer development.",
        "Journal":"Cell cycle (Georgetown, Tex.)",
        "Do_id":"19279406",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Animals;Fusion Proteins, bcr-abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mice;Neoplastic Stem Cells;Precancerous Conditions",
        "Doc_meshqualifiers":"metabolism;pathology;pathology;pathology",
        "_version_":1605897061997215744},
      {
        "Doc_abstract":"This study was aimed to investigate the JAK2V617F mutation in myeloproliferative disorders (MPD) and to evaluate the significance of JAK2V617F in diagnosis and therapy of MPD. The bcr/abl fusion gene in 70 MPD patients was detected by reverse transcription polymerase chain reaction (PT-PCR). The JAK2V617F mutation was detected by allele-specific polymerase chain reaction (AS-PCR) and the results were confirmed by sequence analysis. The results indicated that the bcr/abl fusion gene could be detected in 38 patients with chronic myeloid leukemia (CML), but not in the 32 none-CML patients. The JAK2V617F mutation was detected in 12 out of 16 (75%) patients with polycythemia vera (PV), 3 out of 10 (30%) patients with essential thrombocythemia (ET), 3 out of 6 (50%) patients with idiopathic myelofibrosis (IMF), but not in any of the CML patients. The JAK2V617F mutation frequencies between CML and bcr/abl negative MPD patients were statistically significant (p < 0.05). It is concluded that the JAK2V617F may be a characteristic molecular event in PV, ET and IMF patients which may serve as an important molecular marker for the diagnosis and classification of the three diseases.",
        "Doc_title":"[Tyrosine kinase JAK2V617F mutation in human myeloproliferative disorders].",
        "Journal":"Zhongguo shi yan xue ye xue za zhi",
        "Do_id":"19549360",
        "Doc_ChemicalList":"JAK2 protein, human;Janus Kinase 2",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Female;Humans;Janus Kinase 2;Male;Middle Aged;Myeloproliferative Disorders;Point Mutation;Polymerase Chain Reaction",
        "Doc_meshqualifiers":"genetics;genetics;methods",
        "_version_":1605897446035030016},
      {
        "Doc_abstract":"Point mutations in the kinase domain of BCR-ABL are the most common mechanism of drug resistance in chronic myeloid leukemia (CML) patients treated with ABL kinase inhibitors, including imatinib. It has also been shown in vitro that mutations outside the kinase domain in the neighboring linker, SH2, SH3, and Cap domains can confer imatinib resistance. In the context of ABL, these domains have an autoinhibitory effect on kinase activity, and mutations in this region can activate the enzyme. To determine the frequency and relevance to resistance of regulatory domain mutations in CML patients on imatinib, we screened for such mutations in a cohort of consecutive CML patients with various levels of response. Regulatory domain mutations were detected in 7 of 98 patients, whereas kinase domain mutations were detected in 29. One mutation (T212R) conferred in vitro tyrosine kinase inhibitor resistance and was associated with relapse, whereas most other mutations did not affect drug sensitivity. Mechanistic studies showed that T212R increased the activity of ABL and BCR-ABL and that T212R-induced resistance may be partially the result of stabilization of an active kinase conformation. Regulatory domain mutations are uncommon but may explain resistance in some patients without mutations in the kinase domain.",
        "Doc_title":"BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib.",
        "Journal":"Blood",
        "Do_id":"20519627",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Imatinib Mesylate;Protein Kinases;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Antineoplastic Agents;Benzamides;Cell Line;Cohort Studies;Drug Resistance, Neoplasm;Female;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Models, Molecular;Mutation;Piperazines;Protein Kinase Inhibitors;Protein Kinases;Pyrimidines;Young Adult;src Homology Domains",
        "Doc_meshqualifiers":"pharmacology;therapeutic use;chemistry;genetics;drug therapy;genetics;therapeutic use;pharmacology;therapeutic use;metabolism;therapeutic use",
        "_version_":1605812249031606272},
      {
        "Doc_abstract":"During the Vietnam War, southern Vietnam was exposed to a large amount of dioxin, a strong human carcinogen. Although we have observed much shorter survival in southern Vietnamese chronic myeloid leukemia (CML) patients, the cause remains to be clarified. Here, we report cytogenetic and molecular findings for 47 CML patients. Cytogenetically, the Philadelphia (Ph) chromosome was found in 44 patients (93.6%); of the remaining 3 patients with Ph-negative CML, 2 exhibited BCR/ABL transcripts but no BCR/ABL FISH fusion signals, suggesting the existence of two clones, with and without the BCR/ABL fusion gene. Surprisingly, in 17 patients (36.2%) (4 at diagnosis, 11 during chronic phase, and 2 in accelerated phase), we found several unique secondary chromosome abnormalities including trisomy 13, partial trisomy 13, and abnormalities of 1p, 3p, 6p, 7p, 10p, and 11p, which are different from the so-called additional chromosome abnormalities (extra Ph, +8, i(17q), +19, and +21) observed in blastic phase CML. FISH analysis revealed the Ph translocation with der(9) deletion in 11 patients (23.4%). Of these, 2 had two clones, with and without der(9) deletion, suggesting that der(9) deletion would occur in a subset of patients during disease progression. These observations point to preexisting genetic instability that induces various secondary chromosome abnormalities and multiple clones, resulting in shorter survival.",
        "Doc_title":"Unique secondary chromosomal abnormalities are frequently found in the chronic phase of chronic myeloid leukemia in southern Vietnam.",
        "Journal":"Cancer genetics and cytogenetics",
        "Do_id":"16772122",
        "Doc_ChemicalList":"RNA, Messenger;abl-bcr fusion protein, human;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Aged, 80 and over;Chromosome Aberrations;Chromosomes, Human, Pair 13;Female;Fusion Proteins, bcr-abl;Gene Deletion;Humans;In Situ Hybridization, Fluorescence;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative;Male;Middle Aged;Philadelphia Chromosome;RNA, Messenger;Translocation, Genetic;Trisomy;Vietnam",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;analysis;genetics;genetics",
        "_version_":1605775242896080896},
      {
        "Doc_abstract":"During therapy for chronic myeloid leukemia (CML), decline of the number of BCR-ABL transcripts has been shown to follow a biphasic pattern, with a fast phase followed by a slower phase. Hence, sustained remission requires a long phase of therapy. Data indicate that a combination of different available targeted drugs might prevent treatment failure due to drug resistance, especially at advanced stages of the disease. However, for long-term multiple-drug treatments, complications can arise from side effects. We investigate whether and how the number of drugs could be reduced during long-term therapy. Using computational models, we show that one or more drugs can be removed once the number of tumor cells is reduced significantly, without compromising the chances of sustained tumor suppression. Which drug to remove first depends on the number of mutations in the BCR-ABL gene that confer resistance to the drugs, as well as on how effectively the drugs inhibit Bcr-Abl protein tyrosine kinase activity and inhibit tumor growth. We further show that the number of CML cells at which the number of drugs can be reduced does not correlate with the two phases of decline of the BCR-ABL transcript numbers. Neither does it depend much on kinetic parameters of CML growth, except for the mutation rates at which resistance is generated. This is a significant finding because even without any information on most parameters, and using only the data on the number of cancer cells and the rate at which resistant mutants are generated, it is possible to predict at which stage of treatment the number of drugs can be reduced.",
        "Doc_title":"Combination therapies against chronic myeloid leukemia: short-term versus long-term strategies.",
        "Journal":"Cancer research",
        "Do_id":"19458080",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Antineoplastic Combined Chemotherapy Protocols;Genes, abl;Humans;Kinetics;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Models, Biological;Mutation;Substrate Specificity;Time Factors;Treatment Outcome;Tumor Burden",
        "Doc_meshqualifiers":"administration & dosage;therapeutic use;drug effects;genetics;drug therapy;genetics;pathology;physiology;drug effects;physiology",
        "_version_":1605822034777997312},
      {
        "Doc_abstract":"Imatinib mesylate is the initial therapy of choice for chronic myeloid leukemia in chronic phase (CML-CP), but in some patients, the disease becomes resistant to imatinib. Autologous stem cell transplantation using cells collected while in complete cytogenetic response (CCyR) may represent a therapeutic option for these patients. We mobilized and collected autologous CD34(+) stem cells from 20 CML-CP patients in CCyR, 19 of whom were taking imatinib, and measured BCR-ABL expression in the apheresis products, blood and bone marrow using real-time quantitative PCR (RQ-PCR). Stem cells were mobilized with G-CSF 10 microg/kg daily for 5 days. In patients whose initial collection was <2x10(6) CD34(+) cells/kg, G-CSF dose was increased to 10 microg/kg twice daily on the second attempt, and imatinib was held for 14 days if a third attempt was necessary. All 20 patients successfully mobilized the target yield of 2 to 5x10(6) CD34(+) cells/kg; 16 reached target yield with the first mobilization. The median number of CD34(+) cells collected was 4.4 (range, 2.0 - 8.4)x10(6)/kg in a median of 3 (range, 2 - 6) apheresis days. Of 17 patients whose stem cell products were evaluable by RQ-PCR, 11 (65%) had >or=1 daily product with undetectable BCR-ABL; 4 of these (24%) had no detectable BCR-ABL in any apheresis products. BCR-ABL expression in apheresis products was correlated with levels of expression in the blood and marrow prior to mobilization. No patient has yet required transplantation. With median follow-up of 18 months, all patients remain in CCyR and 9 of 16 (54%) have undetectable BCR-ABL in the most recent blood and marrow sample.",
        "Doc_title":"Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products.",
        "Journal":"Leukemia & lymphoma",
        "Do_id":"18297531",
        "Doc_ChemicalList":"Antigens, CD34;Benzamides;Piperazines;Pyrimidines;Recombinant Proteins;Granulocyte Colony-Stimulating Factor;Imatinib Mesylate;Fusion Proteins, bcr-abl;Filgrastim",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Antigens, CD34;Benzamides;Blood Component Removal;Bone Marrow;Cytogenetic Analysis;Female;Filgrastim;Fusion Proteins, bcr-abl;Granulocyte Colony-Stimulating Factor;Hematopoietic Stem Cell Mobilization;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Piperazines;Pyrimidines;Recombinant Proteins;Remission Induction;Transplantation, Autologous;Treatment Outcome",
        "Doc_meshqualifiers":"analysis;methods;chemistry;analysis;blood;administration & dosage;diagnosis;therapy;administration & dosage;administration & dosage",
        "_version_":1605763487052595200},
      {
        "Doc_abstract":"The BCR/ABL oncogene causes chronic myelogenous leukemia, a myeloproliferative disorder characterized by clonal expansion of hematopoietic progenitor cells and myeloid cells. It is shown here that transformation of the hematopoietic cell lines Ba/F3, 32Dcl3, and MO7e with BCR/ABL results in an increase in reactive oxygen species (ROS) compared with quiescent, untransformed cells. The increase in ROS was directly due to BCR/ABL because it was blocked by the ABL-specific tyrosine kinase inhibitor STI571. Oxidative stress through ROS is believed to have many biochemical effects, including the potential ability to inhibit protein-tyrosine phosphatases (PTPases). To understand the significance of increased production of ROS, a model system was established in which hydrogen peroxide (H(2)O(2)) was added to untransformed cells to mimic the increase in ROS induced constitutively by BCR/ABL. H(2)O(2) substantially reduced total cellular PTPase activity to a degree approximately equivalent to that of pervanadate, a well known PTPase inhibitor. Further, stimulation of untransformed cells with H(2)O(2) or pervanadate increased tyrosine phosphorylation of each of the most prominent known substrates of BCR/ABL, including c-ABL, c-CBL, SHC, and SHP-2. Treatment of the BCR/ABL-expressing cell line MO7/p210 with the reducing agents pyrrolidine dithiocarbamate or N-acetylcysteine reduced the accumulation of ROS and also decreased tyrosine phosphorylation of cellular proteins. Further, treatment of MO7e cells with H(2)O(2) or pervanadate increased the tyrosine kinase activity of c-ABL. Drugs that alter ROS metabolism or reactivate PTPases may antagonize BCR/ABL transformation.",
        "Doc_title":"The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells.",
        "Journal":"The Journal of biological chemistry",
        "Do_id":"10833515",
        "Doc_ChemicalList":"Reactive Oxygen Species;pervanadate;Rotenone;Vanadates;Hydrogen Peroxide;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl;Protein Tyrosine Phosphatases",
        "Doc_meshdescriptors":"Animals;Cell Line;Cell Transformation, Neoplastic;Fusion Proteins, bcr-abl;Hematopoietic Stem Cells;Humans;Hydrogen Peroxide;Megakaryocytes;Mice;Protein Tyrosine Phosphatases;Protein-Tyrosine Kinases;Reactive Oxygen Species;Rotenone;Signal Transduction;Vanadates",
        "Doc_meshqualifiers":"metabolism;metabolism;pharmacology;metabolism;metabolism;metabolism;metabolism;pharmacology;pharmacology",
        "_version_":1605791465604120576},
      {
        "Doc_abstract":"We describe the case of a 23-year-old man with acute lymphoblastic leukemia in whom the Philadelphia chromosome was first detected in the late stage of the disease. At diagnosis, the patient's leukocyte count was 39,400/microliter and leukemic cells were positive for CD10, 19, 20, 33, 34 and HLA-DR. Karyotypic analysis at diagnosis revealed 46,XY. Complete remission was achieved after the first induction therapy, but the disease recurred after 9 months. The patient underwent allogeneic peripheral blood stem cell transplantation from his HLA identical mother, but relapse occurred on day 80. The proportion of bone marrow lymphoblasts decreased transiently after donor lymphocyte infusion but later increased, and the patient died on day 362. The Philadelphia chromosome was first detected by karyotypic analysis on day 256. p190-type bcr/abl mRNA transcripts were negative following RT-PCR at the initial diagnosis, but became positive from the first relapse through the late stage. Generally, the product of the bcr/abl fusion gene has been thought to play an important role in leukemogenesis, however the present case suggests that this gene product is also related to disease progression.",
        "Doc_title":"[Acute lymphoblastic leukemia with p190 type bcr/abl chimeric mRNA at relapse].",
        "Journal":"[Rinsho ketsueki] The Japanese journal of clinical hematology",
        "Do_id":"12412288",
        "Doc_ChemicalList":"RNA, Messenger;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adult;Disease Progression;Fatal Outcome;Fusion Proteins, bcr-abl;Humans;Male;Neoplasm Recurrence, Local;Peripheral Blood Stem Cell Transplantation;Philadelphia Chromosome;Precursor Cell Lymphoblastic Leukemia-Lymphoma;RNA, Messenger;Transplantation Chimera",
        "Doc_meshqualifiers":"genetics;genetics;genetics;therapy;genetics;genetics",
        "_version_":1605750314350149632},
      {
        "Doc_abstract":"Imatinib (Glivec or Gleevec) potently inhibits the tyrosine kinase activity of BCR-ABL, a constitutively activated kinase, which causes chronic myelogenous leukemia (CML). Here we report the first almost complete backbone assignment of c-ABL kinase domain in complex with imatinib.",
        "Doc_title":"Backbone NMR resonance assignment of the Abelson kinase domain in complex with imatinib.",
        "Journal":"Biomolecular NMR assignments",
        "Do_id":"19636920",
        "Doc_ChemicalList":"Benzamides;Carbon Isotopes;Nitrogen Isotopes;Piperazines;Protein Kinase Inhibitors;Protons;Pyrimidines;Imatinib Mesylate;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Amino Acid Sequence;Benzamides;Binding Sites;Carbon Isotopes;Fusion Proteins, bcr-abl;Imatinib Mesylate;Magnetic Resonance Spectroscopy;Molecular Sequence Data;Molecular Weight;Nitrogen Isotopes;Piperazines;Protein Binding;Protein Kinase Inhibitors;Protons;Pyrimidines",
        "Doc_meshqualifiers":"chemistry;antagonists & inhibitors;methods;chemistry;chemistry;chemistry;chemistry",
        "_version_":1605832485550161920},
      {
        "Doc_abstract":"The Bcr-Abl fusion protein drives leukemogenesis and can render leukemia cells resistant to conventional chemotherapy. Geldanamycin (GA), a drug which destabilizes Hsp90-associated proteins, depletes cells of Bcr-Abl, an Hsp90 client, but not of Abl. Both HL60 cells transfected with Bcr-Abl and naturally Ph1-positive K562 leukemia cells are resistant to most cytotoxic drugs, but were found to be sensitive to GA. Furthermore, GA sensitized Bcr-Abl-expressing cells to doxorubicin (DOX) and paclitaxel (PTX). In contrast, in parental HL60 cells, 90 nM GA inhibited PARP cleavage, nuclear fragmentation, and cell death caused by 500 ng/ml DOX. Like GA, STI 571 (an inhibitor of the Abl kinase) sensitized Bcr-Abl-expressing cells to DOX. Unlike GA, STI 571 did not antagonize the cytotoxic effects of DOX in parental HL60 cells. These results indicate that sensitization of Bcr-Abl-expressing cells, but not desensitization of HL60 cells, depends on inhibition of Bcr-Abl. Thus, GA differentially affects leukemia cells depending on their Bcr-Abl expression and selectively increases apoptosis in Bcr-Abl-expressing cells.",
        "Doc_title":"The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy.",
        "Journal":"Leukemia",
        "Do_id":"11587211",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzoquinones;HSP90 Heat-Shock Proteins;Lactams, Macrocyclic;Quinones;Doxorubicin;Fusion Proteins, bcr-abl;Paclitaxel;geldanamycin",
        "Doc_meshdescriptors":"Antineoplastic Agents;Apoptosis;Benzoquinones;Doxorubicin;Drug Interactions;Drug Resistance;Fusion Proteins, bcr-abl;HSP90 Heat-Shock Proteins;Humans;Lactams, Macrocyclic;Leukemia;Paclitaxel;Quinones;Transfection;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"pharmacology;drug effects;pharmacology;biosynthesis;drug effects;antagonists & inhibitors;metabolism;pathology;pharmacology;pharmacology;drug effects",
        "_version_":1605873638601392128},
      {
        "Doc_abstract":"In chronic myeloid leukemia (CML), BCR/ABL-mediated oncogenic signaling can be targeted with the BCR/ABL-inhibitors Imatinib, Nilotinib and Dasatinib. However, these agents may also affect anti-tumor immunity. Here, we analyzed the effects of the 3 BCR/ABL-inhibitors on natural killer (NK) cell reactivity. Exposure of CML cells (K562, Meg-01) to pharmacological concentrations of Imatinib, Nilotinib and Dasatinib diminished expression of ligands for the activating immunoreceptor NKG2D to a similar extent. This resulted in comparably reduced NK cell cytotoxicity and IFN-gamma production. When direct effects on NK cell responses to K562 and primary CML cells as well as activating cytokines were studied, Dasatinib was found to abrogate NK cytotoxicity and cytokine production. Nilotinib did not alter cytotoxicity but, at high levels, impaired NK cytokine production, while Imatinib had no direct influence on NK cell reactivity. Of note, Nilotinib, but not the other BCR/ABL-inhibitors increased cell death within the preferentially cytokine-secreting CD56(bright)CD16(-) NK cell subset, which may, at least in part, serve to explain the effect of Nilotinib on NK cytokine production. Analysis of NK cell signaling revealed that Dasatinib inhibited proximal signaling events leading to decreased phosphorylation of PI3K and ERK that are crucial for NK cell reactivity. Imatinib and Nilotinib, in contrast, showed no relevant effect on NK cell PI3K or ERK activity. In light of the potential role of NK cells in the immunesurveillance of residual leukemia and for future combinatory immunotherapeutic approaches, our data indicate that choice and dosing of the most suitable BCR/ABL-inhibitor for a given patient require careful consideration.",
        "Doc_title":"The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity.",
        "Journal":"International journal of cancer",
        "Do_id":"20143399",
        "Doc_ChemicalList":"4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide;Aluminum Silicates;Antineoplastic Agents;Benzamides;Histocompatibility Antigens Class I;MICB antigen;Piperazines;Pyrimidines;Thiazoles;Interferon-gamma;Imatinib Mesylate;Fusion Proteins, bcr-abl;Dasatinib;mica",
        "Doc_meshdescriptors":"Aluminum Silicates;Antineoplastic Agents;Benzamides;Cell Line, Tumor;Cytotoxicity, Immunologic;Dasatinib;Down-Regulation;Fusion Proteins, bcr-abl;Histocompatibility Antigens Class I;Humans;Imatinib Mesylate;Interferon-gamma;K562 Cells;Killer Cells, Natural;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Piperazines;Pyrimidines;Thiazoles",
        "Doc_meshqualifiers":"metabolism;pharmacology;drug effects;antagonists & inhibitors;metabolism;metabolism;drug effects;immunology;drug therapy;embryology;immunology;pharmacology;pharmacology;pharmacology",
        "_version_":1605751606116089856},
      {
        "Doc_abstract":"Imatinib mesylate (IM) has become standard therapy for patients with chronic myeloid leukemia (CML), but CML stem cells are intrinsically resistant to IM and to second/third-generation tyrosine kinase inhibitors (TKIs), allowing the persistence of a 'reservoir' of BCR-ABL-expressing CML-initiating cells potentially responsible for disease progression. Although it is still controversial whether the 'insensitivity' of CML stem cells to treatment with TKIs is due to BCR-ABL-dependent or independent mechanisms, recent evidence indicates that treatment with IM suppresses BCR-ABL-dependent signaling in CML stem cells with no adverse effects on their survival. Treatment of CML cells with IM/TKIs induces autophagy, a genetically regulated process of adaptation to metabolic stress which may allow tumor cells to become metabolically inert, enabling their survival under conditions that may mimic growth factor/nutrient deprivation. Based on this hypothesis, TKI-induced autophagy may 'antagonize' TKI-induced cell death and inhibition of autophagy may eliminate this survival mechanism by restoring 'sensitivity' of CML stem cells to treatment with IM/TKIs. Consistent with this, recent evidence indicates that phenotypically and functionally defined CML-enriched stem cells that are insensitive to treatment with TKIs are efficiently eliminated by the combination of TKI and chloroquine, an inhibitor of late stage autophagy. Thus, inhibition of autophagy may 'sensitize' CML stem cells to treatment with TKIs, thus preserving the high specificity of TKI-based therapies.",
        "Doc_title":"Inhibition of autophagy: a new strategy to enhance sensitivity of chronic myeloid leukemia stem cells to tyrosine kinase inhibitors.",
        "Journal":"Leukemia & lymphoma",
        "Do_id":"21250825",
        "Doc_ChemicalList":"Protein Kinase Inhibitors;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Autophagy;Drug Resistance, Neoplasm;Fusion Proteins, bcr-abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Neoplastic Stem Cells;Protein Kinase Inhibitors",
        "Doc_meshqualifiers":"drug effects;drug effects;metabolism;drug therapy;drug effects;metabolism;pharmacology;therapeutic use",
        "_version_":1605746807232528384},
      {
        "Doc_abstract":"It has been suggested that type of chimeric mRNA is associated with differences in the clinical and hematologic characteristics of chronic myeloid leukemia (CML). However, prognostic value of type of chimeric mRNA bcr-xabl (b3a2 or b2a2) is still controversial.;We analyzed 97 cases of Philadelphia-positive CML to determine mRNA type by reverse-polymerase chain reaction (RT-PCR) and its relationship with clinical features.;We detected b3a2 bcr-abl transcripts in 27 (28%) cases, b2a2 in 57 (59%) cases, and 13 (13%) with both mRNA transcripts b3a2/b2a2. These frequencies were the total reverse of other reports. Age, sex, hemoglobin, and white-cell counts showed no significant difference for those with either b3a2 or b2a2 bcr-abl transcripts. However, platelet counts of b3a2 patients were significantly higher than those of b2a2 patients (743.3 vs 477.3 x 109/L; p = 0.01). In addition, in the subgroup of patients whose white-cell count at diagnosis was < 100 x 10(9)/L, those with b3a2 transcript had a significantly higher platelet count (679.1 vs. 352.2 x 10(9)/L; p = 0.001).;We observed reversed frequency of bcr-abl transcripts in this population, but agreement with other Latin-American reports. In addition, our data suggested that there is different CML biological behavior in our population and that there is a subpopulation of CML patients in whom b3a2 is associated witH higher thrombopoietic activity.",
        "Doc_title":"[Analysis of Bcr-abl type transcript and its relationship with platelet count in Mexican patients with chronic myeloid leukemia].",
        "Journal":"Gaceta medica de Mexico",
        "Do_id":"14723051",
        "Doc_ChemicalList":"Antigens, CD;Antigens, CD24;Antigens, Differentiation;BRCA2 Protein;CD24 protein, human;Membrane Glycoproteins;Transcription Factors;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Antigens, CD;Antigens, CD24;Antigens, Differentiation;BRCA2 Protein;Female;Fusion Proteins, bcr-abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Membrane Glycoproteins;Middle Aged;Platelet Count;Reverse Transcriptase Polymerase Chain Reaction;Transcription Factors",
        "Doc_meshqualifiers":"analysis;genetics;analysis;genetics;analysis;genetics;blood;genetics;pathology;chemistry;genetics",
        "_version_":1605818644432945154},
      {
        "Doc_abstract":"The Philadelphia chromosome translocation, which is present in 90-95% of chronic myelogenous leukemia patients, involves translocation of the c-abl protooncogene to chromosome 22 and is accompanied by activation of embryonic globin gene expression in the K562 chronic myelogenous leukemia cell line. To test directly if the protein products of the translocated c-abl protooncogene can activate embryonic globin gene expression, we transfected the v-abl oncogene (which shares the property of autophosphorylation with the translocated c-abl protooncogene) into mouse erythroleukemia cells. v-abl-transfected mouse erythroleukemia cells, which contained multiple copies of the v-abl transgenome, exhibited activation of mouse embryonic globin gene expression. These results suggest that the translocated c-abl protooncogene of the Philadelphia chromosome translocation is central to the pathogenesis of chronic myelogenous leukemia and that it may result in the activation of embryonic globin genes in some chronic myelogenous leukemia cell lines.",
        "Doc_title":"v-abl activates embryonic globin gene expression in mouse erythroleukemia cells.",
        "Journal":"Proceedings of the National Academy of Sciences of the United States of America",
        "Do_id":"3008148",
        "Doc_ChemicalList":"Globins;Adenine Phosphoribosyltransferase;Endonucleases;Single-Strand Specific DNA and RNA Endonucleases",
        "Doc_meshdescriptors":"Abelson murine leukemia virus;Adenine Phosphoribosyltransferase;Animals;Cell Line;Cell Transformation, Viral;Endonucleases;Gene Expression Regulation;Globins;Leukemia, Erythroblastic, Acute;Mice;Nucleic Acid Hybridization;Oncogenes;Single-Strand Specific DNA and RNA Endonucleases;Transfection",
        "Doc_meshqualifiers":"genetics;genetics;genetics",
        "_version_":1605853300692877312},
      {
        "Doc_abstract":"The Ph chromosome has been genetically linked to CML and ALL. Its chimeric fusion gene product, BCR-ABL, can generate leukemia in mice. This review will discuss selected model systems developed to study BCR-ABL induced leukemia and focuses on what we have learned about the human disease from these models. Five main experimental approaches will be discussed including: (i) Reconstitution of mice with bone marrow cells retrovirally transduced with BCR-ABL; (ii) Transgenic mice expressing BCR-ABL; (iii) Knock-in mice with BCR-ABL expression driven from the endogenous bcr locus; (iv) Development of CML-like disease in mice with loss of function mutations in heterologous genes; and (v) ES in vitro hematopoietic differentiation coupled with regulated BCR-ABL expression.",
        "Doc_title":"Modeling Philadelphia chromosome positive leukemias.",
        "Journal":"Oncogene",
        "Do_id":"11607816",
        "Doc_ChemicalList":"Oncogene Proteins, Fusion;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Animals;Bone Marrow Cells;Cell Differentiation;Fusion Proteins, bcr-abl;Genetic Linkage;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mice;Mice, Knockout;Mice, Transgenic;Models, Genetic;Oncogene Proteins, Fusion;Phenotype;Promoter Regions, Genetic;Protein Structure, Tertiary;Retroviridae;Transduction, Genetic",
        "Doc_meshqualifiers":"metabolism;genetics;metabolism;genetics;physiopathology;metabolism;genetics",
        "_version_":1605901613159940096},
      {
        "Doc_abstract":"Expression of oncogenic Bcr-Abl inhibits cell differentiation of hematopoietic stem/progenitor cells in chronic myeloid leukemia (CML). Differentiation therapy is considered to be a new strategy for treating this type of leukemia. Aclacinomycin A (ACM) is an antitumor antibiotic. Previous studies have shown that ACM induced erythroid differentiation of CML cells. In this study, we investigate the effect of ACM on the sensitivity of human CML cell line K562 to Bcr-Abl specific inhibitor imatinib (STI571, Gleevec). We first determined the optimal concentration of ACM for erythroid differentiation but not growth inhibition and apoptosis in K562 cells. Then, pretreatment with this optimal concentration of ACM followed by a minimally toxic concentration of imatinib strongly induced growth inhibition and apoptosis compared to that with simultaneous co-treatment, indicating that ACM-induced erythroid differentiation sensitizes K562 cells to imatinib. Sequential treatment with ACM and imatinib induced Bcr-Abl down-regulation, cytochrome c release into the cytosol, and caspase-3 activation, as well as decreased Mcl-1 and Bcl-xL expressions, but did not affect Fas ligand/Fas death receptor and procaspase-8 expressions. ACM/imatinib sequential treatment-induced apoptosis was suppressed by a caspase-9 inhibitor and a caspase-3 inhibitor, indicating that the caspase cascade is involved in this apoptosis. Furthermore, we demonstrated that ACM induced erythroid differentiation through the p38 mitogen-activated protein kinase (MAPK) pathway. The inhibition of erythroid differentiation by p38MAPK inhibitor SB202190, p38MAPK dominant negative mutant or p38MAPK shRNA knockdown, reduced the ACM/imatinib sequential treatment-mediated growth inhibition and apoptosis. These results suggest that differentiated K562 cells induced by ACM-mediated p38MAPK pathway become more sensitive to imatinib and result in down-regulations of Bcr-Abl and anti-apoptotic proteins, growth inhibition and apoptosis. These results provided a potential management by which ACM might have a crucial impact on increasing sensitivity of CML cells to imatinib in the differentiation therapeutic approaches.",
        "Doc_title":"Aclacinomycin A sensitizes K562 chronic myeloid leukemia cells to imatinib through p38MAPK-mediated erythroid differentiation.",
        "Journal":"PloS one",
        "Do_id":"23613979",
        "Doc_ChemicalList":"Antigens, CD95;Benzamides;Myeloid Cell Leukemia Sequence 1 Protein;Piperazines;Proto-Oncogene Proteins c-bcl-2;Pyrimidines;bcl-X Protein;Aclarubicin;Imatinib Mesylate;Fusion Proteins, bcr-abl;p38 Mitogen-Activated Protein Kinases;Caspase 3",
        "Doc_meshdescriptors":"Aclarubicin;Antigens, CD95;Apoptosis;Benzamides;Caspase 3;Cell Differentiation;Cell Proliferation;Down-Regulation;Drug Screening Assays, Antitumor;Enzyme Activation;Erythroid Cells;Fusion Proteins, bcr-abl;Gene Knockdown Techniques;Humans;Imatinib Mesylate;K562 Cells;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;MAP Kinase Signaling System;Myeloid Cell Leukemia Sequence 1 Protein;Piperazines;Proto-Oncogene Proteins c-bcl-2;Pyrimidines;bcl-X Protein;p38 Mitogen-Activated Protein Kinases",
        "Doc_meshqualifiers":"pharmacology;therapeutic use;metabolism;drug effects;pharmacology;therapeutic use;metabolism;drug effects;drug effects;drug effects;genetics;drug effects;drug effects;enzymology;pathology;metabolism;drug therapy;enzymology;pathology;drug effects;pharmacology;therapeutic use;metabolism;pharmacology;therapeutic use;metabolism;metabolism",
        "_version_":1605876950438510592},
      {
        "Doc_abstract":"The occurrence of acute bilineage leukemia is thought to be the malignant transformation of a myeloid or lymphoid leukemic progenitor with the potential to differentiate into the other lineages; however, the mechanisms of this lineage switch are not well understood. Here, we report on the extremely rare case of adult Philadelphia chromosome-positive acute bilineage leukemia, which is characterized by T-cell acute lymphoblastic leukemia and acute myelomonocytic leukemia. Chromosome analysis showed 46,XY,del(7)(p11.2),t(9;22)(q34;q11.2) in all metaphases and a minor BCR/ABL chimeric gene was detected in these leukemic cells by PT-PCR. When the CD5+ and CD5- cells were sorted, a fusion gene of BCR/ABL and the same clonally rearranged band of a T-cell receptor (TCR) gene were detected in both populations. Nucleotide sequencing of the TCR-gamma gene revealed the clonal rearrangement of the V8-JGT2 complex in both populations. Overexpression of PU.1, which plays a fundamental role in myelomonocyte development, was found in the sorted CD34+CD7+ and CD5-, but not CD5+ cells. These results suggest that leukemic progenitor cells in the T-lineage with the del(7) and t(9;22) have the potential to differentiate into myeloid lineage, and that enforced PU.1 expression may contribute in part of this phenomenon.",
        "Doc_title":"Molecular and phenotypic analysis of Philadelphia chromosome-positive bilineage leukemia: possibility of a lineage switch from T-lymphoid leukemic progenitor to myeloid cells.",
        "Journal":"Cancer genetics and cytogenetics",
        "Do_id":"16434313",
        "Doc_ChemicalList":"Receptors, Antigen, T-Cell, gamma-delta;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Cell Lineage;Fusion Proteins, bcr-abl;Gene Rearrangement;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Leukemia, Myeloid, Acute;Leukemia-Lymphoma, Adult T-Cell;Lymphocyte Subsets;Male;Middle Aged;Myeloid Progenitor Cells;Philadelphia Chromosome;Receptors, Antigen, T-Cell, gamma-delta;Translocation, Genetic;Treatment Failure",
        "Doc_meshqualifiers":"genetics;genetics;drug therapy;genetics;pathology;drug therapy;genetics;pathology;pathology;genetics",
        "_version_":1605903036994027520},
      {
        "Doc_abstract":"The t(9;22)(q34;q1 1) between the abl and bcr genes plays a pivotal role in the diagnosis and pathogenesis of chronic myelogenous leukemia (CML). Its detection is routinely accomplished by Southern blot analysis and karyotyping. Interphase fluorescence in situ hybridization (FISH) and reverse transcriptase-polymerase chain reaction (RT-PCR) are emerging molecular techniques that offer viable alternatives. We analyzed 40 samples of peripheral blood and bone marrow (CML, 16; acute myelogenous leukemia, 6; acute lymphoblastic leukemia [ALL], 1; chronic lymphoblastic leukemia, 2; myelodysplasias, 4; myeloproliferative disorders, unclassified, 3; nonleukemic hematologic malignancies, 3; hypercellular bone marrow, 1; normal control samples, 2; and K562 cell line samples, 2) for the presence of bcr-abl fusion gene and its messenger RNA (mRNA) transcript by FISH and RT-PCR, respectively. We compared the results with results of Southern blot analysis and karyotyping when available. Cost analysis was performed. Thirty-three samples were evaluable by FISH; 14 of 14 evaluable CML samples and one ALL sample were positive for bcr-abl by FISH (100%). The other 15 evaluable samples were negative; 16 of 16 (100%) and 13 of 16 (81%) of CML cases were positive for bcr-abl mRNA by RT-PCR (chemiluminescent blot method) and RT-PCR (colorimetric method), respectively. The ALL sample was positive by both RT-PCR methods. All other samples were negative by RT-PCR (chemiluminescent blot method), and all but 1 case of myeloproliferative disorder tested negative by RT-PCR (colorimetric method). We conclude the utility of FISH and RT-PCR is associated with certain limitations, such as insufficient RNA for RT-PCR and the occasional absence of internal positive FISH control signals. However, each procedure offers (with a high concordance rate) a specific and cost-effective alternative to Southern blot analysis and karyotyping and improved turnaround time for the detection of bcr-abl fusion gene or its mRNA transcript.",
        "Doc_title":"Comparative analysis of interphase FISH and RT-PCR to detect bcr-abl translocation in chronic myelogenous leukemia and related disorders.",
        "Journal":"American journal of clinical pathology",
        "Do_id":"9426513",
        "Doc_ChemicalList":"Fluorescent Dyes;Oncogene Proteins;Proto-Oncogene Proteins;RNA, Messenger;RNA, Neoplasm;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl;BCR protein, human;Proto-Oncogene Proteins c-bcr",
        "Doc_meshdescriptors":"Blotting, Southern;Bone Marrow;Chromosomes, Human, Pair 22;Chromosomes, Human, Pair 9;Colorimetry;Fluorescent Dyes;Fusion Proteins, bcr-abl;Genes, abl;Humans;In Situ Hybridization, Fluorescence;Karyotyping;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Leukocytes;Oncogene Proteins;Polymerase Chain Reaction;Protein-Tyrosine Kinases;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-bcr;RNA, Messenger;RNA, Neoplasm;Transcription, Genetic;Translocation, Genetic",
        "Doc_meshqualifiers":"economics;chemistry;analysis;genetics;genetics;economics;genetics;chemistry;genetics;economics;analysis;analysis",
        "_version_":1605756898104049664},
      {
        "Doc_abstract":"We explored the impact of early molecular response (EMR; BCR-ABL 10% on the international scale [BCR-ABL(IS)] at 3 or 6 months) on outcomes in patients with newly diagnosed chronic myeloid leukemia in chronic phase treated with nilotinib or imatinib based on 4 years of follow up in Evaluating Nilotinib Efficacy and Safety in Clinical Trials-Newly Diagnosed Patients. Patients (n = 846) received nilotinib 300 mg twice daily, nilotinib 400 mg twice daily, or imatinib 400 mg once daily. At 3 months, more patients had EMR failure (ie, BCR-ABL(IS) >10%) on imatinib (33%) than on nilotinib (9%-11%); similarly at 6 months, 16% of patients in the imatinib arm vs 3% and 7% in the nilotinib arms had EMR failure. In all arms, EMR failure was associated with lower rates of molecular response, an increased risk of progression, and lower overall survival compared with EMR achievement. We also analyzed patient and treatment characteristics associated with EMR and found distinct patterns in the nilotinib arms vs the imatinib arm. High Sokal risk score was associated with a high rate of EMR failure on imatinib, but not on nilotinib. In contrast, reduced dose intensity and dose interruptions were strongly associated with EMR failure in nilotinib-treated, but not imatinib-treated, patients. This study is registered at www.clinicaltrials.gov as #NCT00471497. ",
        "Doc_title":"Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib.",
        "Journal":"Blood",
        "Do_id":"24335106",
        "Doc_ChemicalList":"4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide;Antineoplastic Agents;Benzamides;Biomarkers, Tumor;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Imatinib Mesylate;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Antineoplastic Agents;Benzamides;Biomarkers, Tumor;Down-Regulation;Follow-Up Studies;Fusion Proteins, bcr-abl;Gene Expression Regulation, Neoplastic;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Neoadjuvant Therapy;Piperazines;Prognosis;Protein Kinase Inhibitors;Pyrimidines;Time Factors;Treatment Outcome",
        "Doc_meshqualifiers":"adverse effects;therapeutic use;adverse effects;therapeutic use;genetics;drug effects;genetics;genetics;drug effects;diagnosis;drug therapy;mortality;adverse effects;therapeutic use;adverse effects;therapeutic use;adverse effects;therapeutic use",
        "_version_":1605882727040548864},
      {
        "Doc_abstract":"Constitutively activated mutants of the non-receptor tyrosine kinases (TK) ABL1 (Abelson murine leukemia viral (v-abl) homolog (1) protein) and JAK2 (JAnus Kinase 2 or Just Another Kinase 2) play a central role in the pathogenesis of clinically and morphologically distinct chronic myeloproliferative disorders but are also found in some cases of de novo acute leukemia and lymphoma. Ligand-independent activation occurs as a consequence of point mutations or insertions/deletions within functionally relevant regulatory domains (JAK2) or the creation of TK fusion proteins by balanced reciprocal translocations, insertions or episomal amplification (ABL1 and JAK2). Specific abnormalities are correlated with clinical phenotype, although some are broad and encompass several World Health Organization-defined entities. TKs are excellent drug targets as exemplified by the activity of imatinib in BCR-ABL1-positive disease, particularly chronic myeloid leukemia. Resistance to imatinib is seen in a minority of cases and is often associated with the appearance of secondary point mutations within the TK domain of BCR-ABL1. These mutations are highly variable in their sensitivity to increased doses of imatinib or alternative TK inhibitors such as nilotinib or dasatinib. Selective and non-selective inhibitors of JAK2 are currently being developed, and encouraging data from pre-clinical experiments and initial phase-I studies regarding efficacy and potential toxicity of these compounds have already been reported.",
        "Doc_title":"Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders.",
        "Journal":"Leukemia",
        "Do_id":"18528425",
        "Doc_ChemicalList":"Autoantigens;Cell Cycle Proteins;PCM1 protein, human;Protein Kinase Inhibitors;JAK2 protein, human;Janus Kinase 2;Proto-Oncogene Proteins c-abl",
        "Doc_meshdescriptors":"Animals;Autoantigens;Cell Cycle Proteins;Genes, abl;Humans;Janus Kinase 2;Mutation;Myeloproliferative Disorders;Polycythemia Vera;Primary Myelofibrosis;Protein Kinase Inhibitors;Proto-Oncogene Proteins c-abl",
        "Doc_meshqualifiers":"genetics;genetics;antagonists & inhibitors;chemistry;genetics;drug therapy;genetics;pathology;genetics;genetics;therapeutic use;antagonists & inhibitors;chemistry;genetics",
        "_version_":1605742089786621952},
      {
        "Doc_abstract":"In Ph-positive (Ph(+)) leukemia, the quiescent cell state is one of the reasons for resistance to the BCR-ABL-kinase inhibitor, imatinib. In order to examine the mechanisms of resistance due to quiescence and the effect of the mammalian target of rapamycin inhibitor, everolimus, for such a resistant population, we used Ph(+) acute lymphoblastic leukemia patient cells serially xenotransplanted into NOD/SCID/IL2r(null) (NOG) mice. Spleen cells from leukemic mice showed a higher percentage of slow-cycling G(0) cells in the CD34(+)CD38(-) population compared with the CD34(+)CD38(+) and CD34(-) populations. After ex vivo imatinib treatment, more residual cells were observed in the CD34(+)CD38(-) population than in the other populations. Although slow-cycling G(0) cells were insensitive to imatinib in spite of BCR-ABL and CrkL dephosphorylation, combination treatment with everolimus induced substantial cell death, including that of the CD34(+)CD38(-) population, with p70-S6K dephosphorylation and decrease of MCL-1 expression. The leukemic non-obese diabetic/severe combined immunodeficiency (NOD/SCID) mouse system with the in vivo combination treatment with imatinib and everolimus showed a decrease of tumor burden including CD34(+) cells. These results imply that treatment with everolimus can overcome resistance to imatinib in Ph(+) leukemia due to quiescence.",
        "Doc_title":"The mTOR inhibitor, everolimus (RAD001), overcomes resistance to imatinib in quiescent Ph-positive acute lymphoblastic leukemia cells.",
        "Journal":"Blood cancer journal",
        "Do_id":"22829152",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605801962755850240},
      {
        "Doc_abstract":"Diagnosis of chronic myeloid leukemia (CML) is based on the detection of BCR-ABL gene or Philadelphia chromosome (Ph chromosome), and fusion proteins with different sizes are encoded depending on the breakpoint in the BCR gene. In general, 3 breakpoint cluster regions in the BCR gene have been described: major (M-bcr), minor (m-bcr), and micro (mu-bcr). This study was designed to determine the frequency of BCR-ABL transcripts using one-step multiplex reverse transcription polymerase chain reaction (RT-PCR). Bone marrow (BM) or peripheral blood (PB) samples at diagnosis from 548 patients were obtained with a referring diagnosis of Ph-positive (Ph+) CML, and multistep RT-PCR and newly developed one-step multiplex RT-PCR were applied on each sample. Compared with the previous multistep RT-PCR, one-step multiplex RT-PCR with the primers is the more rapid and accurate method to identify the BCR-ABL breakpoints. Most patients (538/548, 98.18%) were found to have b3a2 or b2a2, and total frequency of occurrence of c3a2, e1a2, b2a3, b1a1, and e1a3 or coexpression of b2a2 and b3a2 was less than 2.00%. No differences were observed between women and men. As the multiplex RT-PCR technique distinguishes BCR-ABL transcripts in all samples with high sensitivity and specificity, it easily could be applied at early stages of diagnosis. The incidence of one or the other rearrangement in CML patients varies in different reported series, and the frequency in each type of BCR-ABL transcript in Korean CML patients seems to be different from those of Western countries.",
        "Doc_title":"Comprehensive analysis of BCR-ABL transcript types in Korean CML patients using a newly developed multiplex RT-PCR.",
        "Journal":"Translational research : the journal of laboratory and clinical medicine",
        "Do_id":"17145570",
        "Doc_ChemicalList":"DNA, Complementary;RNA, Neoplasm;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Base Sequence;DNA, Complementary;Fusion Proteins, bcr-abl;Humans;Korea;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;RNA, Neoplasm;Reverse Transcriptase Polymerase Chain Reaction;Transcription, Genetic",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;isolation & purification;methods",
        "_version_":1605882861504692224},
      {
        "Doc_abstract":"To explore the efficacy and therapeutic outcome of imatinib combined with chemotherapy or allogeneic hematopoietic stem cell transplantation (allo-HSCT) for Philadelphia chromosome positive acute lymphoblastic leukemia (ALL).;Thirty patients from Jan 2006 to Mar 2009 were enrolled in this study. All patients received CDOLP induction chemotherapy regimen. Sixteen patients insensitive to chemotherapy were given imatinib simultaneously. Eleven of 30 patients underwent HSCT. The other 19 cases received consolidation therapy including HD-Ara-C, HD-MTX and HD-CTX. Maintenance therapy regimens were VP combined with imatinib.;The white blood cell (WBC) count in 17 patients was higher than 30 x 10(9)/L. Of 30 patients, 29 were B cell phenotype and 1 T cell phenotype, 24 had additional chromosomal abnormalities. The overall complete remission (CR) rate was 96.7%. The median CR duration was 9 (2 - 20) months. The 1-year and 3-year overall survival (OS) rates were (64.7 +/- 9.8)% and (30.0 +/- 12.4)%, and the event free survival (EFS) rates were (28.8 +/- 9.5)% and (19.2 +/- 10.1)%, respectively. The bcr-abl transcripts in 13 of 30 patients were continuous negative. The OS rate in patients with negative bcr-abl transcripts was higher than that with positive bcr-abl (70.7% vs 61.3%) (P = 0.189). The EFS rate of patients with continuous negative bcr-abl transcripts was significantly higher than that of patients with continuous positive bcr-abl transcripts (P = 0.01). The median overall survival duration of higher WBC count group and normal WBC count group were 10 (4 - 18) and 29(5 - 36) months, respectively. The patients of higher WBC count had lower OS and EFS rates than that of normal WBC count (46.9% and 15.5% vs 83.5% and 50.8%, respectively) (P = 0.003 and 0.009, respectively).;Imatinib can significantly improve molecular CR rate and CR duration for Ph(+) ALL patients. Imatinib combined with allo-HSCT is expectable to improve the curative ratio of these patients.",
        "Doc_title":"[Clinical study of imatinib for treatment of Philadelphia chromosome positive acute lymphoblastic leukemia.].",
        "Journal":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi",
        "Do_id":"20510109",
        "Doc_ChemicalList":"Imatinib Mesylate;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Fusion Proteins, bcr-abl;Hematopoietic Stem Cell Transplantation;Humans;Imatinib Mesylate;Philadelphia Chromosome;Precursor Cell Lymphoblastic Leukemia-Lymphoma",
        "Doc_meshqualifiers":"genetics;genetics",
        "_version_":1605804161603993600},
      {
        "Doc_abstract":"The Fifteenth International Symposium of the Foundation for Promotion of Cancer Research entitled 'New Horizons in the Diagnosis and Treatment of Hematological Malignancies Based on Molecular Genetic Features' was held in Tokyo on January 15-17, 2002. Twenty-nine invited speakers, including 12 from abroad and 17 from Japan, presented the updated results of their research. After an overview of the classification of hematological malignancies, new findings on some disease entities based on novel immunophenotypic and molecular genetic features were presented. The results of gene expression profiling and BCL6 and C-MYC gene rearrangement in diffuse large B-cell lymphoma were presented and oncogenic mechanism of acute myeloid leukemia was discussed. In the treatment of non-Hodgkin's lymphoma and acute leukemia, the present consensus and future directions were discussed based on the results of multicenter trials in the USA and Japan. As a molecular targeting therapy, the remarkable effect of a BCR-ABL tyrosine kinase inhibitor, STI571, in chronic myeloid leukemia and gastrointestinal stromal tumor was presented. Thereafter, promising results of active immunotherapy, chimeric anti-CD20 monoclonal antibody, anti-CD20 radioimmunoconjugate and anti-CD22 immunotoxin for B-cell lymphoma were presented. Finally, recent advances in allogeneic hematopoietic stem cell transplantation were discussed, focusing on reduced-intensity preparative regimens. The recent advances in basic and clinical research on hematological malignancies would lead to further improvement in the prognosis and quality of life of patients suffering from leukemia or lymphoma.",
        "Doc_title":"Report of the fifteenth international symposium of the foundation for promotion of cancer research: new horizons in the diagnosis and treatment of hematological malignancies based on molecular genetic features.",
        "Journal":"Japanese journal of clinical oncology",
        "Do_id":"12417606",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Biomedical Research;Hematologic Neoplasms;Humans;Medical Oncology;Molecular Biology;Stem Cell Transplantation",
        "Doc_meshqualifiers":"diagnosis;therapy",
        "_version_":1605795085857849344},
      {
        "Doc_abstract":"Imatinib mesylate is a tyrosine kinase inhibitor which targets Bcr-Abl-protein, c-Kit, and platelet-derived growth factor receptor. The drug was originally developed for treatment of chronic myeloid leukemia but is also regarded as first-line treatment of patients with metastatic gastrointestinal stromal tumours (GIST). Dermatologic side effects are common, with superficial edema and rash as the most frequent. In addition, imatinib mesylate treatment is often associated with hypopigmentation. Intraoral side effects are very rare. The present paper demonstrates 1 patient with GIST and 2 patients with chronic myeloid leukemia treated with imatinib mesylate for 5-6 years. All 3 patients presented with diffuse solitary bluish-brown pigmentations in the hard palate. The lesions persisted at follow-ups. There were no other pigmentations in the oral mucosa. The histopathologic examination showed depositions of melanin pigment in the lamina propria. The possible relationship between the observed melanotic maculae and imatinib mesylate treatment is discussed.",
        "Doc_title":"Oral pigmentation in the hard palate associated with imatinib mesylate therapy: a report of three cases.",
        "Journal":"Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics",
        "Do_id":"21330162",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Pyrimidines;Imatinib Mesylate",
        "Doc_meshdescriptors":"Aged;Antineoplastic Agents;Benzamides;Female;Gastrointestinal Stromal Tumors;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Melanosis;Middle Aged;Palate, Hard;Piperazines;Pyrimidines",
        "Doc_meshqualifiers":"adverse effects;drug therapy;drug therapy;chemically induced;drug effects;adverse effects;adverse effects",
        "_version_":1605747539162693633},
      {
        "Doc_abstract":"Imatinib mesylate is a drug that has been recently approved for the treatment for chronic myeloid leukemia. It acts as a potent and selective inhibitor of BCR-ABL tyrosine kinase. It also inhibits both c-kit and platelet-derived growth factor receptor tyrosine kinases. Hypopigmentation of the skin in patients receiving this drug has been recently reported. We report a 17-year-old Caucasian patient affected by chronic myeloid leukemia in therapy with imatinib mesylate who developed hypopigmented vitiligo-like patches and generalized lightening of the skin. In order to evaluate the lightening observed clinically, we measured the progressive skin color hypopigmentation by using a colorimeter over several months. The colorimetric evaluation confirmed the generalized and gradual lightening of patient's skin over treatment with imatinib mesylate. We believe that this is the first reported instance of vitiligo-like lesions in a pediatric patient treated with imatinib mesylate, and the second in a Caucasian patient.",
        "Doc_title":"Vitiligo-like lesions and diffuse lightening of the skin in a pediatric patient treated with imatinib mesylate: a noninvasive colorimetric assessment.",
        "Journal":"Pediatric dermatology",
        "Do_id":"16650231",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Pyrimidines;Imatinib Mesylate",
        "Doc_meshdescriptors":"Adolescent;Antineoplastic Agents;Benzamides;Colorimetry;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Piperazines;Pyrimidines;Skin Pigmentation;Vitiligo",
        "Doc_meshqualifiers":"adverse effects;drug therapy;adverse effects;adverse effects;drug effects;chemically induced",
        "_version_":1605895774109958144},
      {
        "Doc_abstract":"Second-generation tyrosine kinase inhibitors (second TKIs) such as nilotinib and dasatinib control the activity of most ABL kinase domain mutations observed in patients with imatinib resistance. Although in vitro data show that both agents can inhibit all mutations except T315I, some discrepancies have been observed in a small subset of mutation clones. Cytogenetic clonal evolution is the important resistance mechanism of chronic myeloid leukemia (CML). Accordingly, we observed the clinical significance of coexisting with clonal evolution and BCR-ABL mutant in CML patients treated with second TKIs.;We monitored BCR-ABL transcript kinetics, interrelationship of clones expressing non-mutated and mutant transcripts and clonal aberrations within Philadelphia (Ph) positive and negative clones, respectively, in eight patients with CML receiving dasatinib or nilotinib for 3~41 months.;Clinical responses were correlated with in vitro sensitivity of the BCR-ABL mutants to the second TKIs in four patients. Four patients showed resistance to the second TKIs as compared to in vitro observations; three of them developed chromosomal abnormalities in the Ph chromosome positive or negative metaphases. Another patient lost the original mutation but acquired a more resistant new mutation and became resistant to the second TKI.;Cytogenetic clonal evolution is an independent poor prognostic factor in CML, which could explain the onset of mechanisms for second TKIs resistance to ABL kinase domain mutations. The results indicate that an additional evaluation of chromosomal abnormalities is warranted when BCR-ABL mutants are more resistant than indicated by in vitro data.",
        "Doc_title":"Coexisting with clonal evolution and BCR-ABL mutant in CML patients treated with second-generation tyrosine kinase inhibitors predict the discrepancy of in vitro drug sensitivity.",
        "Journal":"Cancer research and treatment : official journal of Korean Cancer Association",
        "Do_id":"20369050",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605901606952370176},
      {
        "Doc_abstract":"Dasatinib is a highly potent BCR-ABL inhibitor with established efficacy and safety in imatinib-resistant/-intolerant patients with chronic myeloid leukemia (CML). In the phase 3 DASISION trial, patients with newly diagnosed chronic-phase (CP) CML were randomized to receive dasatinib 100 mg (n = 259) or imatinib 400 mg (n = 260) once daily. Primary data showed superior efficacy for dasatinib compared with imatinib after 12 months, including significantly higher rates of complete cytogenetic response (CCyR), confirmed CCyR (primary end point), and major molecular response (MMR). Here, 24-month data are presented. Cumulative response rates by 24 months in dasatinib and imatinib arms were: CCyR in 86% versus 82%, MMR in 64% versus 46%, and BCR-ABL reduction to  0.0032% (4.5-log reduction) in 17% versus 8%. Transformation to accelerated-/ blast-phase CML on study occurred in 2.3% with dasatinib versus 5.0% with imatinib. BCR-ABL mutations, assessed after discontinuation, were detected in 10 patients in each arm. In safety analyses, fluid retention, superficial edema, myalgia, vomiting, and rash were less frequent with dasatinib compared with imatinib, whereas pleural effusion and grade 3/4 thrombocytopenia were more frequent with dasatinib. Overall, dasatinib continues to show faster and deeper responses compared with imatinib, supporting first-line use of dasatinib in patients with newly diagnosed CML-CP. This study was registered at ClinicalTrials.gov: NCT00481247.",
        "Doc_title":"Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).",
        "Journal":"Blood",
        "Do_id":"22160483",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Pyrimidines;Thiazoles;Imatinib Mesylate;Fusion Proteins, bcr-abl;Dasatinib",
        "Doc_meshdescriptors":"Age of Onset;Algorithms;Antineoplastic Agents;Benzamides;Cytogenetic Analysis;DNA Mutational Analysis;Dasatinib;Follow-Up Studies;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Leukemia, Myeloid, Chronic-Phase;Middle Aged;Neoadjuvant Therapy;Piperazines;Pyrimidines;Thiazoles;Time Factors;Treatment Outcome",
        "Doc_meshqualifiers":"adverse effects;therapeutic use;genetics;diagnosis;drug therapy;epidemiology;genetics;adverse effects;therapeutic use;adverse effects;therapeutic use;adverse effects;therapeutic use",
        "_version_":1605757905858985984},
      {
        "Doc_abstract":"Idelalisib is a novel, highly selective, small-molecule, tyrosine kinase inhibitor with potent activity against phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform (PI3K). Given the highly selective inhibition of this compound, studies have shown that idelalisib is able to achieve significantly increased apoptotic activity in B-cell acute lymphoblastic leukemia (B-ALL) and chronic lymphocytic leukemia (CLL) cell lines, without significant increase in apoptosis among normal T and natural killer cells. Recent studies have suggested potential clinical benefit with idelalisib as either a single agent or in combination with established chemotherapeutic compounds including bendamustine and rituximab in relapsed/refractory CLL. This review will focus on the preclinical pharmacology, pharmacokinetics and clinical utility of idelalisib in the treatment of various indolent forms of non-Hodgkin's lymphoma. ",
        "Doc_title":"Idelalisib for the treatment of indolent non-Hodgkin's lymphoma.",
        "Journal":"Drugs of today (Barcelona, Spain : 1998)",
        "Do_id":"24619588",
        "Doc_ChemicalList":"Purines;Quinazolinones;Class Ia Phosphatidylinositol 3-Kinase;idelalisib",
        "Doc_meshdescriptors":"Animals;Class Ia Phosphatidylinositol 3-Kinase;Clinical Trials, Phase I as Topic;Clinical Trials, Phase II as Topic;Clinical Trials, Phase III as Topic;Humans;Lymphoma, Non-Hodgkin;Purines;Quinazolinones",
        "Doc_meshqualifiers":"pharmacokinetics;pharmacology;therapeutic use;drug therapy;metabolism;pharmacokinetics;pharmacology;therapeutic use;metabolism;pharmacokinetics;pharmacology;therapeutic use",
        "_version_":1605804203188420608},
      {
        "Doc_abstract":"The bcr-abl chimeric gene of Philadelphia chromosome positive chronic myelogenous leukemias is only weakly transforming. This transformation activity is greatly enhanced by a Lys-for-Glu substitution at position 832 in the c-abl gene, as occurs in the highly transforming v-abl genes. It has been suggested that this mutation results in a significant structural change in the encoded protein product. Using conformational energy analysis, we have determined the allowed low-energy conformations for residues 828-836 of this protein with Lys and Glu at position 832. In both cases, the overwhelmingly preferred conformation for this region is a bend-helix motif. The helix terminates at residue 836, and there are no discernible differences in conformation between the Lys- and Glu-containing sequences. These results suggest that the activating amino acid substitution at position 832 in the c-abl protein product does not produce its effect via a local conformational change.",
        "Doc_title":"An activating amino acid substitution in the c-abl oncogene protein fails to produce a local conformational change.",
        "Journal":"Journal of protein chemistry",
        "Do_id":"1838257",
        "Doc_ChemicalList":"Glutamates;Oncogene Proteins;Lysine",
        "Doc_meshdescriptors":"Amino Acid Sequence;Cell Transformation, Neoplastic;Genes, abl;Glutamates;Humans;Lysine;Models, Molecular;Molecular Sequence Data;Mutation;Oncogene Proteins;Philadelphia Chromosome;Protein Conformation;Software",
        "Doc_meshqualifiers":"genetics;chemistry;genetics",
        "_version_":1605883449310183424},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) is a stem cell-driven disorder caused by the BCR/Abl oncoprotein, a constitutively active tyrosine kinase (TK). Chronic-phase CML patients are treated with impressive efficacy with TK inhibitors (TKi) such as imatinib mesylate (IM). However, rather than definitively curing CML, TKi induces a state of minimal residual disease, due to the persistence of leukemia stem cells (LSC) which are insensitive to this class of drugs. LSC persistence may be due to different reasons, including the suppression of BCR/Abl oncoprotein. It has been shown that this suppression follows incubation in low oxygen under appropriate culture conditions and incubation times.Here we describe the culture repopulation ability (CRA) assay, a non-clonogenic assay capable - together with incubation in low oxygen - to reveal in vitro stem cells endowed with marrow repopulation ability (MRA) in vivo. The CRA assay can be used, before moving to animal tests, as a simple and reliable method for the prescreening of drugs potentially active on CML and other leukemias with respect to their activity on the more immature leukemia cell subsets. ",
        "Doc_title":"The Culture Repopulation Ability (CRA) Assay and Incubation in Low Oxygen to Test Antileukemic Drugs on Imatinib-Resistant CML Stem-Like Cells.",
        "Journal":"Methods in molecular biology (Clifton, N.J.)",
        "Do_id":"27581140",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605837580883984384},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) is associated with overexpression of BCR-ABL1, a nonreceptor tyrosine kinase critical for malignant transformation. We investigated whether non-coding microRNAs (miRNAs) targeting BCR-ABL1 mRNA contribute to the pathogenesis of CML. Indeed, miR-30a targeted BCR-ABL1 and was underexpressed in bone marrow from CML patients. In K562 leukemia cells, overexpression of miR-30a reduced ABL1 and BCR-ABL1 protein expression, decreased proliferation, and arrested cell cycle progression between G1 and S. These findings strongly suggest that miR-30a acts as a tumor suppressor by downregulating ABL1 and BCR-ABL1 expression. Upregulation of miR-30a in hematopoietic cells may have therapeutic efficacy against CML.",
        "Doc_title":"Decreased microRNA-30a levels are associated with enhanced ABL1 and BCR-ABL1 expression in chronic myeloid leukemia.",
        "Journal":"Leukemia research",
        "Do_id":"23287430",
        "Doc_ChemicalList":"MIRN30 microRNA, human;MicroRNAs;RNA, Small Interfering;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Case-Control Studies;Cells, Cultured;Down-Regulation;Fusion Proteins, bcr-abl;Gene Expression Regulation, Leukemic;Genes, Tumor Suppressor;Genes, abl;Humans;K562 Cells;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;MicroRNAs;RNA, Small Interfering;Up-Regulation",
        "Doc_meshqualifiers":"drug effects;genetics;genetics;drug effects;physiology;genetics;genetics;genetics;pharmacology;drug effects;genetics",
        "_version_":1605906699859787776},
      {
        "Doc_abstract":"Real-time quantitative polymerase chain reaction (RQ-PCR) has been accepted as integral part of the management of patients with hematologic malignancies. Whereas standardization efforts of RQ-PCR, initiated by Europe Against Cancer (EAC) group, have been gradually widespread in the world, Japanese laboratories use their individual protocol for RQ-PCR analysis. Therefore, we assessed the variability of quantitative results obtained from 4 different laboratories in Japan, including 3 companies and Tohoku University Hospital, using identical peripheral blood or bone marrow samples of patients in chronic myeloid leukemia (CML; n = 11) and acute myeloid leukemia (AML; n = 2). RQ-PCR was designed to quantify the copy numbers of disease-specific fusion chimeras; BCR-ABL (CML) and AML1-ETO (AML). In 5 out of 13 samples, the quantitative results from 4 laboratories varied more than 10 times (up to 712 times). Thus, we next sought to determine factors affecting the variability of RQ-PCR results across laboratories, by sending back RNA and cDNA samples from each company to Tohoku University, and they were further proceed to yield quantitative data. The main difference between companies and Tohoku University was probably due to the difference of blood separation method (Blood lysis or Ficoll-Hypaque). On the other hand, the variability among 4 laboratories was the most noticeable in the PCR step, mainly attributable to the difference of primer/probe sequence among laboratories. In conclusion, our analyses indicate the importance to limit both preanalytical (sample processing) and analytical (RQ-PCR) interlaboratory variability for RQ-PCR protocol, and the need of further efforts on standardization program in Japan.",
        "Doc_title":"Interlaboratory comparison of quantitative RT-PCR based detection for minimal residual disease in leukemias: a standardization approach in Japan.",
        "Journal":"The Tohoku journal of experimental medicine",
        "Do_id":"18285666",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Humans;Japan;Leukemia;Neoplasm, Residual;Reference Standards;Reproducibility of Results;Reverse Transcriptase Polymerase Chain Reaction",
        "Doc_meshqualifiers":"diagnosis;genetics;diagnosis;genetics;methods;standards",
        "_version_":1605796450371895296},
      {
        "Doc_abstract":"The SCID mouse represents a valuable tool for assessing growth characteristics and drug sensitivity of human leukemic cells. We have examined differences in the engraftment patterns in SCID mice of primary human leukemic cells isolated from children (< 21 years old) with either t(1;19)+/E2A-PBX1+ or t(9;22)+/BCR-ABL+ acute lymphoblastic leukemia. Leukemic cells from 13/24 t(1;19)+/E2A-PBX1+ patients caused overt leukemia in SCID mice. Macroscopic lesions were evident in 6/13 cases, with multiple sites involved in some mice: hepatomegaly,(3) splenomegaly(4), thymic enlargement; liver tumors(1), kidney tumors(1), abdominal tumors(1). Microscopic lesions in SCID mouse organs were present in all 13 cases and involved the bone marrow, brain, heart, gut, liver, kidney, lung, ovary, pancreas, skeletal muscle, spleen, and thymus. Leukemic cells from 5/20 t(9;22)+/BCR-ABL+ patients caused overt leukemia in SCID mice. Notably, macroscopic lesions (splenomegaly; leukemic bones; hepatic tumors) were observed in only 1 case. In all 5 cases, microscopic lesions were found in the mouse bone marrow. Additional microscopic lesions were restricted to skeletal muscle, spleen, and mesentery (1 case) or thymus (1 case). These findings differ markedly from those of t(1;19)+/E2A-PBX1+ leukemic cells due to the lack of involvement of major organs such as liver, pancreas, kidney, skin, or brain. These data illustrate the biological heterogeneity of childhood ALL and suggest that the differential risks associated with t(1;19)+/E2A-PBX1+ and t(9;22)+/BCR-ABL ALL might arise from unique engraftment and proliferation capabilities of the respective leukemic cell populations.",
        "Doc_title":"Distinct in vivo engraftment and growth patterns of t(1;19)+/E2A-PBX1+ and t(9;22)+/BCR-ABL+ human leukemia cells in SCID mice.",
        "Journal":"Leukemia & lymphoma",
        "Do_id":"10037003",
        "Doc_ChemicalList":"Homeodomain Proteins;Oncogene Proteins, Fusion;E2A-Pbx1 fusion protein;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adolescent;Adult;Animals;Cell Division;Child;Child, Preschool;Female;Fusion Proteins, bcr-abl;Homeodomain Proteins;Humans;Infant;Leukemia, Experimental;Male;Mice;Mice, SCID;Neoplasm Invasiveness;Neoplasm Transplantation;Oncogene Proteins, Fusion;Polymerase Chain Reaction;Predictive Value of Tests;Survival Rate;Translocation, Genetic",
        "Doc_meshqualifiers":"physiology;genetics;genetics;diagnosis;genetics;mortality;pathology;genetics;genetics",
        "_version_":1605818571294769152},
      {
        "Doc_abstract":"Due to the high efficacy of BCR-ABL tyrosine kinase inhibition (TKI) in chronic phase (CP) chronic myeloid leukemia (CML), the frequency of blast crisis (BC) is greatly reduced compared to the pre-TKI era. However, TKI treatment of BC has only marginally improved the number of favorable responses, including remissions, which for the most part have only been transitory. Occasionally, they provide a therapeutic window to perform an allogeneic stem cell transplantation (allo-SCT). The challenge remains to improve management of BC with the limited options available. We review and summarize articles pertaining to the treatment of BC CML published after 2002. Additionally, we will discuss whether there is a need for a new definition of BC and/or treatment failure. ",
        "Doc_title":"Management of chronic myeloid leukemia in blast crisis.",
        "Journal":"Annals of hematology",
        "Do_id":"25814082",
        "Doc_ChemicalList":"Antineoplastic Agents;BCR-ABL1 fusion protein, human;Protein Kinase Inhibitors;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Antineoplastic Agents;Blast Crisis;Combined Modality Therapy;Disease Progression;Fusion Proteins, bcr-abl;Hematopoietic Stem Cell Transplantation;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Practice Guidelines as Topic;Precision Medicine;Prognosis;Protein Kinase Inhibitors;Recurrence;Transplantation, Homologous",
        "Doc_meshqualifiers":"therapeutic use;diagnosis;etiology;prevention & control;antagonists & inhibitors;drug therapy;enzymology;physiopathology;therapy;therapeutic use",
        "_version_":1605879756580978688},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) comprises a simple and effective paradigm for generating new insights into the cellular origin, pathogenesis, and treatment of many types of human cancer. In particular, mouse models of CML have greatly facilitated the understanding of the underlying molecular mechanisms and pathogenesis of this disease and have led to the identification of new drug targets that in some cases offer the possibility of functional cure. There are currently three established CML mouse models: the BCR-ABL transgenic model, the BCR-ABL retroviral transduction/transplantation model, and the xenotransplant immunodeficient model. Each has its own unique advantages and disadvantages. Depending on the question of interest, some models may be more appropriate than others. In this chapter, we describe a newly developed xenotransplant mouse model to determine the efficacy of novel therapeutic agents, either alone or in combination. The model facilitates the evaluation of the frequency of leukemic stem cells with long-term leukemia-initiating activity, a critical subcellular population that causes disease relapse and progression, through the utilization of primary CD34(+) CML stem/progenitor cells obtained from CML patients at diagnosis and prior to drug treatment. We have also investigated the effectiveness of new combination treatment strategies designed to prevent the development of leukemia in vivo using BCR-ABL (+) blast crisis cells as a model system. These types of in vivo studies are important for the prediction of individual patient responses to drug therapy, and have the potential to facilitate the design of personalized combination therapy strategies. ",
        "Doc_title":"New Mouse Models to Investigate the Efficacy of Drug Combinations in Human Chronic Myeloid Leukemia.",
        "Journal":"Methods in molecular biology (Clifton, N.J.)",
        "Do_id":"27581149",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605892376503517184},
      {
        "Doc_abstract":"In recent years, the prognosis of chronic myeloid leukemia (CML) has been greatly improved either with interferon-alpha (IFN-alpha) therapy or allogeneic bone marrow transplantation (BMT). In the present study, minimal residual disease was evaluated in 21 patients in complete cytogenetic response (CCR) after such treatments. Samples from bone marrow aspirates or peripheral blood or both were analyzed by conventional cytogenetics, Southern blot, interphase fluorescent in situ hybridization (FISH), and quantitative reverse transcription-polymerase chain reaction (Q-RT-PCR). In all patients, FISH detected 1% to 12% nuclei with a BCR-ABL fusion gene, whereas Q-RT-PCR experiments were negative or weakly positive. Based on these results, we hypothesize that the BCR-ABL genomic rearrangement persists unexpressed in nonproliferating cells whatever the treatment (IFN-alpha or BMT). These data point to the need for follow-up of CML patients in CCR over an extensive period at the DNA level (FISH) to evaluate the residual disease and at the RNA level (Q-RT-PCR) to estimate the risk of relapse. (Blood. 2000;95:404-408)",
        "Doc_title":"Persistence of BCR-ABL genomic rearrangement in chronic myeloid leukemia patients in complete and sustained cytogenetic remission after interferon-alpha therapy or allogeneic bone marrow transplantation.",
        "Journal":"Blood",
        "Do_id":"10627442",
        "Doc_ChemicalList":"Antineoplastic Agents;Interferon-alpha;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adult;Aged;Antineoplastic Agents;Blotting, Southern;Bone Marrow Transplantation;Chromosomes, Human, Pair 22;Chromosomes, Human, Pair 9;Disease-Free Survival;Female;Follow-Up Studies;Fusion Proteins, bcr-abl;Gene Rearrangement;Humans;Immunosuppression;In Situ Hybridization, Fluorescence;Interferon-alpha;Karyotyping;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Time Factors;Translocation, Genetic",
        "Doc_meshqualifiers":"therapeutic use;genetics;therapeutic use;genetics;therapy",
        "_version_":1605928214766551040},
      {
        "Doc_abstract":"Imatinib is a tyrosine kinase inhibitor that suppresses the growth of bcr-abl-expressing chronic myeloid leukemia (CML) progenitor cells by blockade of the adenosine triphosphate (ATP)-binding site of the kinase domain of bcr-abl. Imatinib also inhibits the c-abl, platelet-derived growth factor (PDGF) receptor, abl-related gene (ARG) and stem-cell factor (SCF) receptor tyrosine kinases, and has been used clinically to inhibit the growth of malignant cells in patients with CML and gastrointestinal stromal tumors (GISTs). Although initially considered to have minimal effects of normal hematopoiesis, recent studies show that imatinib also inhibits the growth of some nonmalignant hematopoietic cells, including monocyte/macrophages. This inhibition could not be attributed to the known activity profile of imatinib. Here, we demonstrate for the first time that imatinib targets the macrophage colony-stimulating factor (M-CSF) receptor c-fms. Phosphorylation of c-fms was inhibited by therapeutic concentrations of imatinib, and this was not due to down-regulation in c-fms expression. Imatinib was also found to inhibit M-CSF-induced proliferation of a cytokine-dependent cell line, further supporting the hypothesis that imatinib affects the growth and development of monocyte and/or macrophages through inhibition of c-fms signaling. Importantly, these results identify an additional biologic target to those already defined for imatinib. Imatinib should now be assessed for activity in diseases where c-fms activation is implicated, including breast and ovarian cancer and inflammatory conditions.",
        "Doc_title":"Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib.",
        "Journal":"Blood",
        "Do_id":"15637141",
        "Doc_ChemicalList":"Antibodies;Benzamides;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Imatinib Mesylate;Proto-Oncogene Proteins c-kit;Receptor, Macrophage Colony-Stimulating Factor",
        "Doc_meshdescriptors":"Antibodies;Benzamides;Bone Marrow Cells;Cell Division;Humans;Imatinib Mesylate;In Vitro Techniques;Macrophages;Monocytes;Phosphorylation;Piperazines;Protein Kinase Inhibitors;Proto-Oncogene Proteins c-kit;Pyrimidines;Receptor, Macrophage Colony-Stimulating Factor;Signal Transduction",
        "Doc_meshqualifiers":"pharmacology;drug effects;metabolism;drug effects;immunology;cytology;cytology;drug effects;pharmacology;pharmacology;immunology;pharmacology;immunology;metabolism;drug effects",
        "_version_":1605742695371767808},
      {
        "Doc_abstract":"The use of imatinib in the treatment of BCR-ABL-positive chronic myeloid leukemia and gastrointestinal stromal tumors has significantly improved survival outcomes in patients afflicted by these malignancies. However, a substantial proportion of imatinib-treated patients still experience treatment failure. Suboptimal concentrations of imatinib have been postulated to contribute at least partially to the development of resistance against imatinib. Indeed, variations in the genes encoding drug transporters have been reported to markedly influence imatinib disposition and treatment outcomes in various populations. This review aims to consolidate and critically assess the studies conducted to date which have investigated the influence of pharmacogenetic variants in drug transporters on the disposition of imatinib and treatment outcomes in Asians and other populations.",
        "Doc_title":"Pharmacogenetics of drug transporters in modulating imatinib disposition and treatment outcomes in chronic myeloid leukemia & gastrointestinal stromal tumor patients.",
        "Journal":"Pharmacogenomics",
        "Do_id":"27804783",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605843912399781888},
      {
        "Doc_abstract":"Chronic myeloid leukemia, a disorder of hematopoietic stem cells, is currently treated using targeted molecular therapy with imatinib. We compare two models that describe the treatment of CML, a multi-scale model (Model 1) and a simple cell competition model (Model 2). Both models describe the competition of leukemic and normal cells, however Model 1 also describes the dynamics of BCR-ABL, the oncogene targeted by imatinib, at the sub-cellular level. Using clinical data, we analyze the differences in estimated parameters between the models and the capacity for each model to predict drug resistance. We found that while both models fit the data well, Model 1 is more biologically relevant. The estimated parameter ranges for Model 2 are unrealistic, whereas the parameter ranges for Model 1 are close to values found in literature. We also found that Model 1 predicts long-term drug resistance from patient data, which is exhibited by both an increase in the proportion of leukemic cells as well as an increase in BCR-ABL/ABL Model 2, however, is not able to predict resistance and accurately model the clinical data. These results suggest that including sub-cellular mechanisms in a mathematical model of CML can increase the accuracy of parameter estimation and may help to predict long-term drug resistance. ",
        "Doc_title":"Data and implication based comparison of two chronic myeloid leukemia models.",
        "Journal":"Mathematical biosciences and engineering : MBE",
        "Do_id":"24245631",
        "Doc_ChemicalList":"Benzamides;Piperazines;Pyrimidines;Imatinib Mesylate;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Algorithms;Benzamides;Computer Simulation;Drug Resistance, Neoplasm;Fusion Proteins, bcr-abl;Hematopoietic Stem Cells;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Models, Biological;Mutation;Piperazines;Pyrimidines;Randomized Controlled Trials as Topic;Time Factors;Treatment Outcome",
        "Doc_meshqualifiers":"administration & dosage;metabolism;metabolism;epidemiology;physiopathology;administration & dosage;administration & dosage",
        "_version_":1605806877477699584},
      {
        "Doc_abstract":"The outlook for newly diagnosed patients with chronic myeloid leukemia (CML) in the imatinib era is excellent for most patients. However, imatinib failure is observed in around 25%-30% of patients. With the availability of second-line tyrosine kinase inhibitor therapy and/or allogeneic transplantation, many of these patients with imatinib failure can still achieve durable cytogenetic and molecular responses. Early evidence of imatinib resistance, when the biology of the emerging leukemia might still be relatively favorable, is the best time to switch to second-line therapy. Close cytogenetic and molecular monitoring will facilitate early intervention in appropriate cases. However, caution should be used when interpreting minimal residual disease data, and the danger of inappropriate changes in therapy based on assay fluctuations should be recognized. A significant increase in the level of BCR-ABL to a level > 0.1% on the international scale (major molecular response) should prompt a repeat BCR-ABL assay, a mutation screen, and possibly marrow cytogenetics. What constitutes a significant increase depends on the laboratory-specific measurement reliability. The possibilities of poor compliance or drug interactions should be considered. If the repeat BCR-ABL assay, fluorescence in situ hybridization assay, or cytogenetics confirms loss of complete cytogenetic response or if a mutation is identified, a dose increase or a switch in therapy to a second-line kinase inhibitor might be indicated. At least until complete molecular response is achieved, regular real-time polymerase chain reaction monitoring reinforces the fact that leukemia is still present and that compliance is a challenge that requires ongoing vigilance from the patient and the clinician.",
        "Doc_title":"Measuring minimal residual disease in chronic myeloid leukemia: fluorescence in situ hybridization and polymerase chain reaction.",
        "Journal":"Clinical lymphoma & myeloma",
        "Do_id":"19778851",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Bone Marrow Cells;Clinical Trials as Topic;Cytogenetics;DNA Mutational Analysis;Fusion Proteins, bcr-abl;Humans;In Situ Hybridization;In Situ Hybridization, Fluorescence;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Medical Oncology;Neoplasm, Residual;Polymerase Chain Reaction;Time Factors;Treatment Outcome",
        "Doc_meshqualifiers":"metabolism;genetics;methods;diagnosis;genetics;therapy;methods;diagnosis;genetics;methods",
        "_version_":1605914321340071936},
      {
        "Doc_abstract":"Aging is associated with the functional decline of cells, tissues, and organs. At the same time, age is the single most important prognostic factor in the development of most human cancers, including chronic myelogenous and acute lymphoblastic leukemias initiated by Bcr-Abl oncogenic translocations. Prevailing paradigms attribute the association between aging and cancers to the accumulation of oncogenic mutations over time, because the accrual of oncogenic events is thought to be the rate-limiting step in initiation and progression of cancers. Conversely, aging-associated functional decline caused by both cell-autonomous and non-cell-autonomous mechanisms is likely to reduce the fitness of stem and progenitor cell populations. This reduction in fitness should be conducive for increased selection of oncogenic mutations that can at least partially alleviate fitness defects, thereby promoting the initiation of cancers. We tested this hypothesis using mouse hematopoietic models. Our studies indicate that the dramatic decline in the fitness of aged B-lymphopoiesis coincides with altered receptor-associated kinase signaling. We further show that Bcr-Abl provides a much greater competitive advantage to old B-lymphoid progenitors compared with young progenitors, coinciding with restored kinase signaling pathways, and that this enhanced competitive advantage translates into increased promotion of Bcr-Abl-driven leukemias. Moreover, impairing IL-7-mediated signaling is sufficient to promote selection for Bcr-Abl-expressing B progenitors. These studies support an unappreciated causative link between aging and cancer: increased selection of oncogenic mutations as a result of age-dependent alterations of the fitness landscape.",
        "Doc_title":"Declining lymphoid progenitor fitness promotes aging-associated leukemogenesis.",
        "Journal":"Proceedings of the National Academy of Sciences of the United States of America",
        "Do_id":"21098275",
        "Doc_ChemicalList":"Interleukin-7;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Aging;Animals;Bone Marrow Transplantation;Female;Fusion Proteins, bcr-abl;Genetic Fitness;Hematopoietic Stem Cells;Humans;Interleukin-7;Leukemia;Lymphopoiesis;Mice;Mice, Inbred BALB C;Mice, Transgenic;Signal Transduction;Stem Cells",
        "Doc_meshqualifiers":"physiology;genetics;metabolism;cytology;physiology;metabolism;physiopathology;physiology;physiology;physiology",
        "_version_":1605875074464743424},
      {
        "Doc_abstract":"Patients with chronic myeloid leukemia who fail to achieve timely treatment responses have a worse prognosis. Although many patients respond well to first-line treatment with imatinib, a significant proportion relapse or experience an inadequate response. Since effective alternative Bcr-Abl inhibitors are available (i.e., dasatinib or nilotinib), several regional groups have proposed milestones for imatinib failure or suboptimal response based on the achievement of specified levels of response within a defined treatment duration. A suboptimal response indicates that, although patients may continue to receive a benefit from continuing imatinib treatment at the assigned dose, long-term outcome may be better with an alternative strategy. The underlying mechanisms behind suboptimal responses are multifactorial and may differ from those causing relapse.",
        "Doc_title":"Suboptimal responses in chronic myeloid leukemia: milestones and mechanisms.",
        "Journal":"Expert review of hematology",
        "Do_id":"21082997",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Pyrimidines;Imatinib Mesylate",
        "Doc_meshdescriptors":"Antineoplastic Agents;Benzamides;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Piperazines;Prognosis;Pyrimidines;Treatment Outcome",
        "Doc_meshqualifiers":"therapeutic use;drug therapy;therapeutic use;therapeutic use",
        "_version_":1605742022881181697},
      {
        "Doc_abstract":"Dasatinib, which is an inhibitor of BCR-ABL and SRC family tyrosine kinases, is used for the treatment of patients with Philadelphia chromosome (Ph) positive leukemia, especially for those who develop resistance or who are intolerant to imatinib. The most common adverse effects attributed to its use are: myelosuppression, nausea, diarrhea, and peripheral edema. Hemorrhage, which could be gastrointestinal, genitourinary or central nervous system, is a less frequent adverse effect. In this case, we report a patient affected by precursor B-cell acute lymphoblastic leukemia (ALL) positive for the Ph chromosome translocation treated with the tyrosine kinase inhibitor (TKI) dasatinib. During the treatment with dasatinib the patient developed subdural hematoma (SDH). She did not have any head trauma, thrombocytopenia, coagulopathy or meningeal involvement, making dasatinib-induced platelet dysfunction the most likely cause of SDH. ",
        "Doc_title":"Spontaneous subdural hematoma in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia with normal platelet count after dasatinib treatment.",
        "Journal":"Platelets",
        "Do_id":"25025538",
        "Doc_ChemicalList":"Antineoplastic Agents;Protein Kinase Inhibitors;Dasatinib",
        "Doc_meshdescriptors":"Antineoplastic Agents;Brain;Dasatinib;Female;Hematoma, Subdural;Humans;Philadelphia Chromosome;Platelet Count;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Protein Kinase Inhibitors;Treatment Outcome",
        "Doc_meshqualifiers":"therapeutic use;pathology;therapeutic use;diagnosis;etiology;therapy;blood;complications;drug therapy;therapeutic use",
        "_version_":1605808936324169728},
      {
        "Doc_abstract":"Mathematical models of chronic myeloid leukemia (CML) cell population dynamics are being developed to improve CML understanding and treatment. We review such models in light of relevant findings from radiobiology, emphasizing 3 points. First, the CML models almost all assert that the latency time, from CML initiation to diagnosis, is at most 10 years. Meanwhile, current radiobiologic estimates, based on Japanese atomic bomb survivor data, indicate a substantially higher maximum, suggesting longer-term relapses and extra resistance mutations. Second, different CML models assume different numbers, between 400 and 10(6), of normal HSCs. Radiobiologic estimates favor values>10(6) for the number of normal cells (often assumed to be the HSCs) that are at risk for a CML-initiating BCR-ABL translocation. Moreover, there is some evidence for an HSC dead-band hypothesis, consistent with HSC numbers being very different across different healthy adults. Third, radiobiologists have found that sporadic (background, age-driven) chromosome translocation incidence increases with age during adulthood. BCR-ABL translocation incidence increasing with age would provide a hitherto underanalyzed contribution to observed background adult-onset CML incidence acceleration with age, and would cast some doubt on stage-number inferences from multistage carcinogenesis models in general.",
        "Doc_title":"Quantitative modeling of chronic myeloid leukemia: insights from radiobiology.",
        "Journal":"Blood",
        "Do_id":"22353999",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adult;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Models, Biological;Models, Theoretical;Nuclear Weapons;Radiation, Ionizing;Radiobiology;Recurrence;Survivors;Time Factors",
        "Doc_meshqualifiers":"diagnosis;epidemiology;etiology;therapy;methods;statistics & numerical data",
        "_version_":1605809534112104448},
      {
        "Doc_abstract":"As a better understanding of the molecular basis of carcinogenesis has emerged, oncogene-specific cell-signaling pathways have been successfully targeted to treat human malignances. Despite impressive advances in oncogene-directed therapeutics, genetic instability in cancer cells often manifest acquired resistance. This is particularly noted in the use of tyrosine kinase inhibitors therapies and not more evident than for chronic myeloid leukemia. Therefore, it is of great importance to understand the molecular mechanisms affecting cancer cell sensitivity and resistance to tyrosine kinase inhibitors.;In this study, we used continuous exposure to stepwise increasing concentrations of imatinib (0.6-1 M) to select imatinib-resistant K562 cells.;Expression of BCR-ABL increased both at RNA and protein levels in imatinib-resistant cell lines. Furthermore, expression levels of sphingosine kinase 1 (SphK1) were increased significantly in resistant cells, channeling sphingoid bases to the SphK1 pathway and activating sphingosine-1-phosphate-dependent tyrosine phosphorylation pathways that include the adaptor protein Crk. The partial inhibition of SphK1 activity by N,N-dimethylsphingosine or expression by small interfering RNA increased sensitivity to imatinib-induced apoptosis in resistant cells and returned BCR-ABL to baseline levels. To determine the resistance mechanism-induced SphK1 upregulation, we used pharmacological inhibitors of the phosphoinositide 3-kinase/AKT/mammalian target of rapamycin signaling pathway and observed robust downmodulation of SphK1 expression and activity when AKT2, but not AKT1 or AKT3, was suppressed.;These results demonstrate that SphK1 is upregulated in imatinib-resistant K562 cells by a pathway contingent on a phosphoinositide 3-kinase/AKT2/mammalian target of rapamycin signaling pathway. We propose that SphK1 plays an important role in development of acquired resistance to imatinib in chronic myeloid leukemia cell lines.",
        "Doc_title":"Sphingosine kinase 1 overexpression is regulated by signaling through PI3K, AKT2, and mTOR in imatinib-resistant chronic myeloid leukemia cells.",
        "Journal":"Experimental hematology",
        "Do_id":"21392556",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;DNA Primers;Piperazines;Pyrimidines;Imatinib Mesylate;Phosphatidylinositol 3-Kinases;Phosphotransferases (Alcohol Group Acceptor);sphingosine kinase;MTOR protein, human;TOR Serine-Threonine Kinases;Proto-Oncogene Proteins c-akt",
        "Doc_meshdescriptors":"Antineoplastic Agents;Apoptosis;Base Sequence;Benzamides;Blotting, Northern;Blotting, Western;DNA Primers;Drug Resistance, Neoplasm;Humans;Imatinib Mesylate;K562 Cells;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Phosphatidylinositol 3-Kinases;Phosphotransferases (Alcohol Group Acceptor);Piperazines;Proto-Oncogene Proteins c-akt;Pyrimidines;Reverse Transcriptase Polymerase Chain Reaction;Signal Transduction;TOR Serine-Threonine Kinases;Up-Regulation",
        "Doc_meshqualifiers":"pharmacology;enzymology;metabolism;pathology;metabolism;metabolism;pharmacology;metabolism;pharmacology;metabolism",
        "_version_":1605759002211254272},
      {
        "Doc_abstract":"Mutations in the kinase domain (KD) of BCR-ABL are the most prevalent mechanism of acquired imatinib resistance in patients with chronic myeloid leukemia (CML). Here we examine predisposing factors underlying acquisition of KD mutations, evidence for acquisition of mutations before and during therapy, and whether the detection of a KD mutation universally implies resistance. We also provide a perspective on how the second-line Abl inhibitors dasatinib and nilotinib are faring in the treatment of imatinib-resistant CML, especially in relation to specific KD mutations. We discuss the growing importance of the multi-inhibitor-resistant 315T>I mutant and the therapeutic potential that a 315T>I inhibitor would have. Last, we assess the potential of Abl kinase inhibitor combinations to induce stable responses even in advanced CML and interpret the emerging data in the context of CML pathogenesis.",
        "Doc_title":"Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia.",
        "Journal":"Blood",
        "Do_id":"17496200",
        "Doc_ChemicalList":"4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide;Benzamides;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Imatinib Mesylate;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Animals;Benzamides;Cell Proliferation;Drug Resistance, Neoplasm;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Models, Molecular;Mutation;Piperazines;Point Mutation;Protein Kinase Inhibitors;Protein Structure, Tertiary;Pyrimidines;Recurrence;Risk Factors",
        "Doc_meshqualifiers":"drug effects;genetics;antagonists & inhibitors;genetics;metabolism;drug therapy;enzymology;genetics;pathology;genetics;chemistry;therapeutic use;genetics;therapeutic use;chemistry;therapeutic use",
        "_version_":1605750863002861568},
      {
        "Doc_abstract":"The potential efficacy of prodrug activation of a transduced suicide gene in a cancer cell may be impaired or enhanced by oncoproteins produced by that cell. In the context of a gene therapy protocol for chronic myeloid leukemia (CML) we examined whether the Bcr-Abl fusion protein would have either of these effects. Thus, the mechanism of cell killing by transfer of herpes simplex virus thymidine kinase (HSV-tk) and subsequent ganciclovir (GCV) treatment was examined in pre-B (TonB210.1) cells and myeloid cells (32D) and in their BCR-ABL-expressing counterparts. HSV-tk-transduced cell lines, either in the presence or in the absence of BCR-ABL expression, became susceptible to GCV at concentrations which were nontoxic to the nontransduced cells. This susceptibility was represented by apoptotic cell death in all cases. Apoptosis was observed after 24 h of treatment with GCV in the tk-transduced parental cells and in the BCR-ABL-expressing TonB210.1 cells but only after a delay of more than 24 h in the 32Dp210 cells compared to 32D. Cell death in the BCR-ABL-expressing clones was preceded by S- and G2/M-phase cell cycle arrest. Activation of FAS/APO-1 and caspase-8 was observed in all the tk-transduced cell lines after GCV treatment. However, the caspase-8 inhibitor Z-IETD-FMK only partially abrogated tk/GCV-induced apoptosis. A possible role for inhibition of Bcl-2 or Bcl-x(L) expression in the apoptosis induced by GCV was observed in the tk-transduced TonB210.1 cells but not in the 32D or 32Dp210 cells. The data demonstrate that expression of the Bcr-Abl oncoprotein does not block the apoptosis induced by the HSV-tk/GCV system, suggesting that this suicide gene therapy strategy could be considered for the treatment of CML in blast crisis.",
        "Doc_title":"BCR-ABL-expressing cells transduced with the HSV-tk gene die by apoptosis upon treatment with ganciclovir.",
        "Journal":"Molecular therapy : the journal of the American Society of Gene Therapy",
        "Do_id":"11356068",
        "Doc_ChemicalList":"Annexin A5;Antigens, CD95;Antiviral Agents;Enzyme Precursors;Fas Ligand Protein;Fasl protein, mouse;Membrane Glycoproteins;Thymidine Kinase;Fusion Proteins, bcr-abl;Casp8 protein, mouse;Casp9 protein, mouse;Caspase 8;Caspase 9;Caspases;Ganciclovir",
        "Doc_meshdescriptors":"Animals;Annexin A5;Antigens, CD95;Antiviral Agents;Apoptosis;Blast Crisis;Blotting, Western;Caspase 8;Caspase 9;Caspases;Cell Line;Cell Separation;DNA Fragmentation;Dose-Response Relationship, Drug;Down-Regulation;Enzyme Activation;Enzyme Precursors;Fas Ligand Protein;Flow Cytometry;Fusion Proteins, bcr-abl;Ganciclovir;Gene Transfer Techniques;Genetic Vectors;Membrane Glycoproteins;Mice;Neoplasms;Simplexvirus;Thymidine Kinase;Time Factors;Transduction, Genetic",
        "Doc_meshqualifiers":"pharmacology;biosynthesis;pharmacology;drug therapy;biosynthesis;metabolism;biosynthesis;biosynthesis;pharmacology;biosynthesis;therapy;genetics;genetics",
        "_version_":1605762398493343744},
      {
        "Doc_abstract":"Chronic myelogenous leukemia is typified by constitutive activation of the c-abl kinase as a result of its fusion to the breakpoint cluster region (BCR). Because the truncated isoform of protein-tyrosine phosphatase receptor-type O (PTPROt) is specifically expressed in hematopoietic cells, we tested the possibility that it could potentially dephosphorylate and inactivate the fusion protein bcr/abl. Ectopic expression of PTPROt in the chronic myelogenous leukemia cell line K562 indeed resulted in hypophosphorylation of bcr/abl and reduced phosphorylation of its downstream targets CrkL and Stat5, confirming that PTPROt could inactivate the function of bcr/abl. Furthermore, the expression of catalytically active PTPROt in K562 cells caused reduced proliferation, delayed transition from G0/G1 to S phase, loss of anchorage independent growth, inhibition of ex vivo tumor growth, and increased their susceptibility to apoptosis, affirming that this tyrosine phosphatase can revert the transformation potential of bcr/abl. Additionally, the catalytically inactive PTPROt acted as a trapping mutant that was also able to inhibit anchorage independence and facilitate apoptosis of K562 cells. The inhibitory action of PTPROt on bcr/abl was also confirmed in a murine myeloid cell line overexpressing bcr/abl. PTPROt expression was suppressed in K562 cells and was relieved upon treatment of the cells with 5-azacytidine, an inhibitor of DNA methyltransferase, with concomitant hypomethylation of the PTPRO CpG island. These data demonstrate that suppression of PTPROt by promoter methylation could contribute to the augmented phosphorylation and constitutive activity of its substrate bcr/abl and provide a potentially significant molecular therapeutic target for bcr/abl-positive leukemia.",
        "Doc_title":"PTPROt inactivates the oncogenic fusion protein BCR/ABL and suppresses transformation of K562 cells.",
        "Journal":"The Journal of biological chemistry",
        "Do_id":"18997174",
        "Doc_ChemicalList":"Adaptor Proteins, Signal Transducing;CRKL protein;Enzyme Inhibitors;Isoenzymes;Nuclear Proteins;STAT5 Transcription Factor;DNA Modification Methylases;Fusion Proteins, bcr-abl;PTPRO protein, human;Ptpro protein, mouse;Receptor-Like Protein Tyrosine Phosphatases, Class 3;Azacitidine",
        "Doc_meshdescriptors":"Adaptor Proteins, Signal Transducing;Animals;Apoptosis;Azacitidine;Cell Transformation, Neoplastic;CpG Islands;DNA Methylation;DNA Modification Methylases;Enzyme Activation;Enzyme Inhibitors;Fusion Proteins, bcr-abl;Humans;Interphase;Isoenzymes;K562 Cells;Leukemia, Myeloid;Mice;Nuclear Proteins;Phosphorylation;Receptor-Like Protein Tyrosine Phosphatases, Class 3;STAT5 Transcription Factor",
        "Doc_meshqualifiers":"genetics;metabolism;drug effects;genetics;pharmacology;therapeutic use;drug effects;genetics;metabolism;genetics;drug effects;genetics;antagonists & inhibitors;genetics;metabolism;drug effects;genetics;pharmacology;therapeutic use;genetics;metabolism;drug effects;genetics;genetics;metabolism;drug therapy;enzymology;genetics;genetics;metabolism;drug effects;genetics;metabolism;genetics;metabolism",
        "_version_":1605742800193716226},
      {
        "Doc_abstract":"This article reviews to what extent molecular data can be used to rationalize therapeutic choices in the treatment of chronic myeloid leukemia. Two categories of data are discussed: markers that globally measure risk but do not provide a molecular rationale for therapy selection; and biomarkers with a causal link to a clinical phenotype, such as certain mutations of the BCR-ABL kinase domain. As therapy selection is still mainly based on clinical criteria, molecular biomarkers are discussed in the context of available clinical prognostication tools, focusing on biomarkers that do not reflect disease burden as a surrogate of responsiveness to treatment.",
        "Doc_title":"Selection of therapy: rational decisions based on molecular events.",
        "Journal":"Hematology/oncology clinics of North America",
        "Do_id":"22054732",
        "Doc_ChemicalList":"Biomarkers, Tumor",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Genes, abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mutation;Prognosis;Protein Structure, Tertiary",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;diagnosis;genetics;metabolism;therapy",
        "_version_":1605746406172131328},
      {
        "Doc_abstract":"A 14-year-old child presented with generalized lymphadenopathy and massive hepatosplenomegaly. Peripheral smear and bone marrow examination were suggestive of Ph' positive chronic myeloid leukemia (CML) in chronic phase. However, lymph node biopsy showed extramedullary blast crisis with evidence of myeloid and T cell markers in blasts. Reverse transcriptase-polymerase chain reaction from lymph node aspirate revealed transcript for bcr-abl p210. Thus, we present here a unique case of childhood CML with extramedullary biphenotypic blast crisis (myeloid/T cell type) at initial presentation with bone marrow remaining in chronic phase. This case provides further evidence to the highly heterogeneous presentation of CML.",
        "Doc_title":"Biphenotypic extramedullary blast crisis as a presenting manifestation of Philadelphia chromosome-positive CML in a child.",
        "Journal":"Pediatric hematology and oncology",
        "Do_id":"17454789",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adolescent;Blast Crisis;Fusion Proteins, bcr-abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Lymph Nodes;Male;Myeloid Cells;Reverse Transcriptase Polymerase Chain Reaction;T-Lymphocytes",
        "Doc_meshqualifiers":"diagnosis;genetics;metabolism;diagnosis;therapy;pathology;pathology;pathology",
        "_version_":1605823858925895680},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) is a rare disease in childhood which is almost exclusively associated with bcr-abl p210 (M-bcr) rearrangements. It has been suggested that co-expression of p190 and p210 may be a pathway of CML progression in adult patients. We report two cases of pediatric patients with a diagnosis of CML who presented co-expression of the p210 and p190 transcripts during progression to the blastic phase. The present data suggest that p190 may be a secondary event in at least some cases of childhood CML, suggesting an association with progression to a blastic crisis in these patients.",
        "Doc_title":"Is p190 bcr-abl rearrangement necessary for acute transformation in some p210 CML of childhood?",
        "Journal":"Leukemia research",
        "Do_id":"18495245",
        "Doc_ChemicalList":"RNA, Neoplasm;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Blast Crisis;Cell Transformation, Neoplastic;Child, Preschool;Disease Progression;Female;Fusion Proteins, bcr-abl;Gene Rearrangement;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;RNA, Neoplasm",
        "Doc_meshqualifiers":"genetics;genetics;genetics;analysis",
        "_version_":1605902413700530176},
      {
        "Doc_abstract":"We report a case of leukemoid reaction (LR) complicating renal abscess caused by Morganella morganii infection in an 80-year-old man. On administration, laboratory tests revealed white blood cell count of 76160 /microL and C reactive protein 3.09 mg/dL. Although chronic myeloid leukemia was suspected, bcr/abl fusion transcript was not observed. Contrast enhanced computer tomography imaging of the abdomen showed abscess in the right kidney. M. morganii was detected repeatedly in material of liquid from the abscess and arterial blood culture. To our knowledge, this is the first case of M. morganii infection complicating LR.",
        "Doc_title":"Renal abscess with Morganella morganii complicating leukemoid reaction.",
        "Journal":"Internal medicine (Tokyo, Japan)",
        "Do_id":"18176006",
        "Doc_ChemicalList":"C-Reactive Protein",
        "Doc_meshdescriptors":"Abdominal Abscess;Aged, 80 and over;C-Reactive Protein;Humans;Kidney Diseases;Leukemoid Reaction;Leukocyte Count;Male;Morganella morganii;Radiography",
        "Doc_meshqualifiers":"blood;complications;diagnostic imaging;microbiology;blood;diagnostic imaging;microbiology;blood;microbiology;isolation & purification",
        "_version_":1605908398306492416},
      {
        "Doc_abstract":"Because a substantial number of patients with chronic myeloid leukemia acquire resistance to ABL tyrosine kinase inhibitors (TKIs), their management remains a challenge. Ponatinib, also known as AP24534, is an oral multi-targeted TKI. Ponatinib is currently being investigated in a pivotal phase 2 clinical trial. In the present study, we analyzed the molecular and functional consequences of ponatinib against imatinib- or nilotinib-resistant (R) K562 and Ba/F3 cells. The proliferation of imatinib- or nilotinib-resistant K562 cells did not decrease after treatment with imatinib or nilotinib. Src family kinase Lyn was activated. Point mutation Ba/F3 cells (E334V) were also highly resistant to imatinib and nilotinib. Treatment with ponatinib for 72h inhibited the growth of imatinib- and nilotinib-resistant cells. The phosphorylation of BCR-ABL, Lyn, and Crk-L was reduced. This study demonstrates that ponatinib has an anti-leukemia effect by reducing ABL and Lyn kinase activity and this information may be of therapeutic relevance.",
        "Doc_title":"Efficacy of ponatinib against ABL tyrosine kinase inhibitor-resistant leukemia cells.",
        "Journal":"Biochemical and biophysical research communications",
        "Do_id":"23684619",
        "Doc_ChemicalList":"Antineoplastic Agents;Imidazoles;Protein Kinase Inhibitors;Pyridazines;ponatinib;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Antineoplastic Agents;Cell Line, Tumor;Drug Resistance, Neoplasm;Fusion Proteins, bcr-abl;Humans;Imidazoles;K562 Cells;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Protein Kinase Inhibitors;Protein-Tyrosine Kinases;Pyridazines",
        "Doc_meshqualifiers":"pharmacology;genetics;antagonists & inhibitors;genetics;metabolism;pharmacology;drug therapy;enzymology;genetics;pharmacology;antagonists & inhibitors;genetics;metabolism;pharmacology",
        "_version_":1605811078472663040},
      {
        "Doc_abstract":"To explore the optimal time of allogeneic hematopoietic stem cell transplantation (allo-HSCT) applied in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), and the optimum order of donor selection.;From Mar 2000 to Jul 2004, 32 patients with Ph+ ALL were treated by Allo-HSCT, and the follow up ended at Dec 30.2004 with medium of 13 months. Of whom, 24 were male, and 8 were female. Twenty-three patients have been transplanted in CR1, 9 patients beyond CR1 (1 in CR2, 8 in refractory or relapse status). Twelve cases received HSCT from identical sibling donor, 4 unrelated Cord Blood Transplantation (CBT), 3 HSCT from matched unrelated donor (MUD), and 13 HSCT from mismatched related donor (MMRD), of which, 6 cases were M(BCR/ABL) subtype, and 20 m(BCR/ABL) subtype. The Kaplan-Meier method was used to estimate the probabilities of leukemia-free survival (LFS), overall survival (OS) and relapse incidence (RI), and the factors were compared by means of the Log-rank test. Simultaneous effect of multiple covariates were estimated with Cox model.;Of all the 32 cases engrafted, 4-year OS was 57.19%, LFS 37.09%, and RI 56.36%. In univariate prognostic analysis model, the OS was higher in CR1 group pre-HSCT than that in non-CR1 group (74.50% vs 22.22%, P=0.0046), LFS was higher (49.06% vs 11.11%, P=0.0057), RI was lower (44.80% vs 84.76%, P=0.0157); the OS was higher in M(BCR/ABL) group than that in m(BCR/ABL) group (100% vs 40.91%, P=0.0318), LFS was higher (75% vs 17.72%, P=0.0057), RI was lower (25% vs 77.88, P=0.0116); OS was similar in HLA MM RD group to that in HLA identical group (52.65% vs 55.56%, P=0.6247), LFS was similar (45.12% vs 30.00%, P=0.8315), and RI was also similar (50.77% vs 60.62%, P=0.8217). In multiple covariate analysis model, the BCR/ABL type was the risk factor of LFS [P=0.005, Exp(B)=9.971] and RI (P=0.006, Exp(B)=9.488), the status of disease pre-HSCT and BCR/ABL subtype was the risk factor of OS [P was 0.010 and 0.038, Exp(B) was 4.532 and 37.537 respectively].;We had better do HSCT in CR1 to treat Ph+ ALL, if patient is refractory to chemotherapy, we can try STI571, and HSCT should be done as soon as possible if the patients get CR. Mismatched related donor is considered as regular donor for Ph+ ALL patients without identical donors. We should pay more attention to monitoring and prophylaxis of relapse in m(BCR/ABL) patients after HSCT.",
        "Doc_title":"[Allogeneic hematopoietic stem cell transplantation for treatment of Philadelphia chromosome positive acute lymphoblastic leukemia].",
        "Journal":"Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences",
        "Do_id":"15968308",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adolescent;Adult;Child;Female;Follow-Up Studies;Fusion Proteins, bcr-abl;Hematopoietic Stem Cell Transplantation;Humans;Male;Middle Aged;Neoplasm Recurrence, Local;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Transplantation, Homologous",
        "Doc_meshqualifiers":"metabolism;metabolism;therapy",
        "_version_":1605741949691625472},
      {
        "Doc_abstract":"Coexistence of two specific chromosomal translocations in the same clone is an infrequent phenomenon and has only rarely been reported in hematological malignancies. We report a combination of t(16;16)(p13;q22), the Philadelphia translocation t(9;22)(q34;q11.2), and deletion of the long arm of chromosome 7 in a patient with chronic myeloid leukemia in blast phase. Monotherapy treatment with imatinib mesylate resulted in the disappearance of the Ph-positive clone, but with persistence of t(16;16) and del(7) in all of the metaphases examined. The case illustrates that, although imatinib mesylate can be an effective treatment in eradication of the BCR-ABL fusion gene cells, the occurrence of additional specific abnormalities in Philadelphia-positive leukemias may pose a significant therapeutic challenge.",
        "Doc_title":"Simultaneous occurrence of t(9;22)(q34;q11.2) and t(16;16)(p13;q22) in a patient with chronic myeloid leukemia in blastic phase.",
        "Journal":"Cancer genetics and cytogenetics",
        "Do_id":"18503829",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Pyrimidines;Imatinib Mesylate",
        "Doc_meshdescriptors":"Adult;Antineoplastic Agents;Benzamides;Chromosomes, Human, Pair 16;Chromosomes, Human, Pair 22;Chromosomes, Human, Pair 9;Humans;Imatinib Mesylate;In Situ Hybridization, Fluorescence;Karyotyping;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Piperazines;Pyrimidines;Translocation, Genetic",
        "Doc_meshqualifiers":"therapeutic use;drug therapy;genetics;therapeutic use;therapeutic use",
        "_version_":1605796592925802496},
      {
        "Doc_abstract":"Resistance to imatinib is one of the most important issues in treatment of chronic myeloid leukemia (CML) patients. The objective of the study was to analyze the ex vivo drug resistance profile to bortezomib and 22 other antileukemic drugs, including three tyrosine kinase inhibitors (TKIs), in CML in comparison to acute myeloid leukemia (AML).;A total of 82 patients entered the study, including 36 CML and 46 AML adults. Among CML patients, 19 had advanced disease, 16 were resistant to imatinib, and 6 had ABL-kinase domain mutations. The ex vivo drug resistance profile was studied by the MTT assay.;CML CELLS WERE MORE RESISTANT THAN AML BLASTS TO THE FOLLOWING DRUGS: prednisolone, vincristine, doxorubicin, etoposide, melphalan, cytarabine, fludarabine, thiotepa, 4-HOO-cyclophosphamide, thioguanine, bortezomib, topotecan, and clofarabine. CML cells were 2-fold more sensitive to busulfan than AML cells. CML patients with clinical imatinib resistance had higher ex vivo resistance to vincristine, daunorubicin, etoposide, and busulfan. No significant differences to all tested drugs, including TKIs, were observed between CML patients with non-advanced and advanced disease. CML patients with mutation had higher ex vivo resistance to vincristine, idarubicin, thiotepa, and busulfan.;CML cells are ex vivo more resistant to most drugs than acute myeloid leukemia blasts. Busulfan is more active in CML than AML cells. In comparison to AML cells, bortezomib has little ex vivo activity in CML cells. No differences between CML subgroups in sensitivity to 3 tested TKIs were detected.",
        "Doc_title":"Bortezomib has little ex vivo activity in chronic myeloid leukemia: individual tumor response testing comparative study in acute and chronic myeloid leukemia.",
        "Journal":"Contemporary oncology (Poznan, Poland)",
        "Do_id":"23788881",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605774718775853056},
      {
        "Doc_abstract":"A simple microfluidic fluorescence in situ hybridization (FISH) device allowing accurate analysis of interphase nuclei in 1 hr in narrow channels is presented. Photolithography and fluorosilicic acid etching were used to fabricate microfluidic channels (referred to as FISHing lines) that allowed analysis of 10 samples on a glass microscope slide 0.2 l of sample volume was used to fill a micro-channel, which resembled a 250-fold reduction compared to conventional FISH. FISH signals were comparable to conventional FISH, with 50-fold less probe consumption and 10-fold less time. Cells were immobilized in single file in channels just exceeding the diameter of the cells, and were used for minimal residual disease (MRD) analysis. To test the micro-channels for application in FISH, MRD was simulated by mixing K562 cells (an established chronic myeloid leukemia cell line) carrying the BCR/ABL fusion gene across 1:1 to 1:1,000 Jurkat cells (an established acute lymphoblastic leukemia cell line). The limit of detection was seen to be 1:100 cells and 1:1,000 cells for FISHing lines and conventional FISH, respectively; however, the conventional method seemed to over-score the presence of K562 cells. This may in part be attributed to FISHing lines practically eliminating the chance of duplicate screening of cells and hastened the time of screening, enhancing scoring of all cells within the channels. This was compared to 1 in 500 cells on the slide being analyzed with the conventional FISH.",
        "Doc_title":"Microfluidic channel-assisted screening of hematopoietic malignancies.",
        "Journal":"Genes, chromosomes & cancer",
        "Do_id":"24339206",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Cell Size;Hematologic Neoplasms;Humans;In Situ Hybridization, Fluorescence;Jurkat Cells;K562 Cells;Microfluidics;Neoplasm, Residual",
        "Doc_meshqualifiers":"diagnosis;pathology;methods",
        "_version_":1605818710563487747},
      {
        "Doc_abstract":"In the face of competing tyrosine kinase inhibitors (TKIs), identification of chronic myeloid leukemia (CML) patients expecting favorable response to second-line treatment is warranted. At the time of imatinib resistance, the investigation of multidrug-resistance protein 1 (MDR1) and BCR-ABL yielded the following results: (i) Patients with high MDR1 transcript levels showed superior response at 48 months as compared with low-level MDR1 patients: major molecular response (MMR) in 41% vs 16% (P=0.014), complete cytogenetic response (CCyR) in 58% vs 39% (P=0.044), and progression-free survival (PFS) in 67% vs 46% (P=0.032). (ii) Patients with BCR-ABL(IS) <28% achieved higher MMR rates (48% vs 21%, P=0.009). (iii) PFS at 48 months was associated with in vitro resistance of BCR-ABL kinase domain mutations: 63% (no mutation) vs 61% (sensitive, intermediately sensitive or unknown IC50 (median inhibitory concentration)) vs 23% (resistant, P=0.01). (iv) Single-nucleotide polymorphisms (SNPs) at positions 1236 and 2677 were associated with higher MDR1 expression in comparison to wild type. (v) Nilotinib was able to impede proliferation of MDR1-overexpressing imatinib-resistant cells. High MDR1 gene expression might identify patients whose mode of imatinib resistance is essentially determined by increased efflux activity of MDR1 and therefore can be overcome by second-line nilotinib treatment.",
        "Doc_title":"MDR1 expression predicts outcome of Ph+ chronic phase CML patients on second-line nilotinib therapy after imatinib failure.",
        "Journal":"Leukemia",
        "Do_id":"24472814",
        "Doc_ChemicalList":"4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide;Benzamides;P-Glycoprotein;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Imatinib Mesylate;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Benzamides;Female;Follow-Up Studies;Fusion Proteins, bcr-abl;Gene Expression;Gene Knockdown Techniques;Humans;Imatinib Mesylate;Leukemia, Myeloid, Chronic-Phase;Male;Middle Aged;Mutation;Neoplasm Staging;P-Glycoprotein;Piperazines;Prognosis;Protein Kinase Inhibitors;Pyrimidines;RNA Interference;Treatment Failure;Treatment Outcome",
        "Doc_meshqualifiers":"therapeutic use;genetics;drug therapy;genetics;mortality;genetics;therapeutic use;therapeutic use;therapeutic use",
        "_version_":1605804582971113472},
      {
        "Doc_abstract":"The success of Imatinib (IM) therapy in chronic myeloid leukemia (CML) is compromised by the development of IM resistance and by a limited IM effect on hematopoietic stem cells. Danusertib (formerly PHA-739358) is a potent pan-aurora and ABL kinase inhibitor with activity against known BCR-ABL mutations, including T315I. Here, the individual contribution of both signaling pathways to the therapeutic effect of Danusertib as well as mechanisms underlying the development of resistance and, as a consequence, strategies to overcome resistance to Danusertib were investigated. Starting at low concentrations, a dose-dependent inhibition of BCR-ABL activity was observed, whereas inhibition of aurora kinase activity required higher concentrations, pointing to a therapeutic window between the two effects. Interestingly, the emergence of resistant clones during Danusertib exposure in vitro occurred considerably less frequently than with comparable concentrations of IM. In addition, Danusertib-resistant clones had no mutations in BCR-ABL or aurora kinase domains and remained IM-sensitive. Overexpression of Abcg2 efflux transporter was identified and functionally validated as the predominant mechanism of acquired Danusertib resistance in vitro. Finally, the combined treatment with IM and Danusertib significantly reduced the emergence of drug resistance in vitro, raising hope that this drug combination may also achieve more durable disease control in vivo.",
        "Doc_title":"Abcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor Danusertib in BCR-ABL-positive cells in vitro.",
        "Journal":"PloS one",
        "Do_id":"21541334",
        "Doc_ChemicalList":"ABCG2 protein, human;ATP Binding Cassette Transporter, Sub-Family G, Member 2;Benzamides;Neoplasm Proteins;Piperazines;Protein Kinase Inhibitors;Pyrazoles;Pyrimidines;Imatinib Mesylate;Fusion Proteins, bcr-abl;Aurora Kinases;Protein-Serine-Threonine Kinases;danusertib",
        "Doc_meshdescriptors":"ATP Binding Cassette Transporter, Sub-Family G, Member 2;ATP-Binding Cassette Transporters;Apoptosis;Aurora Kinases;Benzamides;Cell Differentiation;Cell Line, Tumor;Cell Proliferation;Clone Cells;Drug Resistance, Neoplasm;Drug Synergism;Fusion Proteins, bcr-abl;Gene Expression Regulation, Leukemic;Hematopoietic Stem Cells;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mutation;Neoplasm Proteins;Oligonucleotide Array Sequence Analysis;Piperazines;Polyploidy;Protein Kinase Inhibitors;Protein-Serine-Threonine Kinases;Pyrazoles;Pyrimidines;Signal Transduction",
        "Doc_meshqualifiers":"antagonists & inhibitors;genetics;metabolism;drug effects;pharmacology;drug effects;drug effects;drug effects;genetics;antagonists & inhibitors;metabolism;drug effects;drug effects;pathology;enzymology;genetics;pathology;genetics;antagonists & inhibitors;genetics;metabolism;pharmacology;pharmacology;antagonists & inhibitors;metabolism;pharmacology;pharmacology;drug effects",
        "_version_":1605818678951018496},
      {
        "Doc_abstract":"The success of imatinib mesylate (STI571, Gleevec) in treating chronic myeloid leukemia (CML) is, to date, the crowning achievement of targeted molecular therapy in cancer. Nearly 90% of newly diagnosed patients treated with imatinib in the chronic phase of the disease achieve a complete cytogenetic response. However, more than 95% of these patients retain detectable levels of BCR-ABL mRNA and patients discontinuing imatinib therapy almost invariably relapse, demonstrating that an imatinib insensitive population of leukemia-initiating cells (LICs) persists in nearly all patients. These findings underscore the need for treatments specifically targeting the leukemia-initiating population of CML cells. While mounting evidence suggests that the LIC in the chronic phase of CML is the BCR-ABL positive hematopoietic stem cell, several recent publications suggest that during CML blast crisis, a granulocyte-macrophage progenitor (GMP) population also acquires LIC properties through activation of the beta-catenin pathway. Characterization of these cells and evaluation of their sensitivity to imatinib is critical to our understanding and treatment of CML blast crisis.",
        "Doc_title":"The CML stem cell: evolution of the progenitor.",
        "Journal":"Cell cycle (Georgetown, Tex.)",
        "Do_id":"19342894",
        "Doc_ChemicalList":"Benzamides;Piperazines;Pyrimidines;Imatinib Mesylate",
        "Doc_meshdescriptors":"Animals;Benzamides;Biological Evolution;Blast Crisis;Granulocyte-Macrophage Progenitor Cells;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mice;Models, Biological;Neoplastic Stem Cells;Piperazines;Pyrimidines",
        "Doc_meshqualifiers":"drug therapy;drug effects;pathology;drug therapy;pathology;drug effects;pathology;pharmacology;therapeutic use;pharmacology;therapeutic use",
        "_version_":1605893152034521088},
      {
        "Doc_abstract":"We report on the first Philadelphia chromosome (Ph) positive chronic myelogenous leukemia (CML) characterized by a rearrangement within the 5' part of the bcr gene on chromosome 22, but outside the restricted breakpoint cluster region. In situ hybridization studies revealed a translocation of the c-abl oncogene to the Ph chromosome and Northern blot analysis identified a chimeric 8 kb bcr/abl RNA transcript in leukemic cells. These data suggest that 1. less bcr coding sequences than previously assumed may be essential for the putative transforming activity of the rearranged bcr/abl gene and 2. the bcr probes currently used for diagnostic purposes could miss Ph-positive CML cases.",
        "Doc_title":"Philadelphia-positive chronic myelogenous leukemia with breakpoint 5' of the breakpoint cluster region but within the bcr gene.",
        "Journal":"Blut",
        "Do_id":"3480009",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adult;Humans;Leukemia, Myeloid;Male;Oncogenes;Philadelphia Chromosome",
        "Doc_meshqualifiers":"genetics",
        "_version_":1605844898393620480},
      {
        "Doc_abstract":"The Philadelphia chromosome is the most common cytogenetic abnormality found in adult patients diagnosed with acute lymphoblastic leukemia. The result of this abnormality is the BCR-ABL protein, a constitutively active kinase involved in cell signaling and survival. When managed with multiagent chemotherapy regimens alone, patients have traditionally had an inferior outcome in terms of remission duration and overall survival when compared with patients who are Philadelphia chromosome-negative. Small-molecule tyrosine kinase inhibitors, such as imatinib and dasatinib, directly inhibit the BCR-ABL kinase, offering a targeted approach as a therapeutic option. As a result of several clinical trials with adequate follow-up, imatinib combined with chemotherapy represents the current standard of care for patients with newly diagnosed disease. Allogeneic stem cell transplantation has previously been the only modality to offer the potential for a cure, and it still should be considered for all patients deemed able to tolerate such an intervention. Second-generation tyrosine kinase inhibitors, such as dasatinib, may further improve the outcome in these patients. The role of molecular monitoring and the use of tyrosine kinase inhibitors after stem cell transplantation are areas of active investigation, and the results of ongoing trials will help to clarify the optimal management of these patients.",
        "Doc_title":"Role of tyrosine kinase inhibitors in the management of Philadelphia chromosome-positive acute lymphoblastic leukemia.",
        "Journal":"Current hematologic malignancy reports",
        "Do_id":"21660654",
        "Doc_ChemicalList":"Benzamides;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Thiazoles;Imatinib Mesylate;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl;Dasatinib",
        "Doc_meshdescriptors":"Benzamides;Clinical Trials as Topic;Combined Modality Therapy;Dasatinib;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;Philadelphia Chromosome;Piperazines;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Protein Kinase Inhibitors;Protein-Tyrosine Kinases;Pyrimidines;Stem Cell Transplantation;Thiazoles;Transplantation, Homologous",
        "Doc_meshqualifiers":"antagonists & inhibitors;metabolism;therapeutic use;drug therapy;therapeutic use;antagonists & inhibitors;metabolism;therapeutic use;therapeutic use",
        "_version_":1605802242096496640},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML), a hematopoietic stem cell cancer representing 15-20% of adult leukemias, is discussed. Epidemiology, staging biology, and monitoring techniques are reviewed.;CML is a myeloproliferative disorder that affects all lineages of hematopoiesis. Final confirmation of CML comes with detection of the Philadelphia Chromosome (Ph) or BCR-ABL transcripts. The disease presents in one of three phases: chronic phase, accelerated phase, or blast crisis. Progression from chronic phase to accelerated phase usually involves the accumulation of additional cytogenetic aberrations and the arising of resistance to therapy. Although at one point mortality associated with CML was high, new kinase inhibitor therapies have markedly extended the life-span of these patients. These inhibitors were derived through the initial observation of the association of the Ph with CML and the eventual identification of the BCR-ABL oncogene which arises from this translocation. Analysis of the mechanism by which BCR-ABL transforms cells identified this protein as a tyrosine kinase and led to the targeting of this activity. The majority of patients present in chronic phase, which is where these kinase inhibitors have their greatest efficacy. Monitoring of disease progression is of critical importance as the prognosis drops significantly for patients with advanced disease. Blood counts, cytogenetics, and polymerase chain reaction (PCR) are currently used to assess disease. Blood counts are inexpensive but lack sensitivity. Cytogenetic karyotyping while requiring specialized training provides evidence of clonal evolution. Quantitative PCR is capable of tremendous sensitivity making it well suited for assessing response to therapy and the early detection of therapy failures.;Our understanding of BCR-ABL has allowed the development of therapies, which may keep patients with CML in chronic phase indefinitely. This has created a situation in which patient monitoring is essential for detecting changes in the status of CML. The tests described here provide a comprehensive assessment of disease status allowing for effective patient management.",
        "Doc_title":"Chronic myeloid leukemia in 2007.",
        "Journal":"American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists",
        "Do_id":"18056931",
        "Doc_ChemicalList":"Antineoplastic Agents",
        "Doc_meshdescriptors":"Antineoplastic Agents;Clinical Trials as Topic;Drug Resistance, Neoplasm;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Leukemia, Myeloid, Chronic-Phase;Neoplasm Staging",
        "Doc_meshqualifiers":"therapeutic use;diagnosis;epidemiology;genetics;therapy;diagnosis;genetics;therapy",
        "_version_":1605765468535128064},
      {
        "Doc_abstract":"Many clinically validated kinases, such as BCR-ABL, c-Kit, PDGFR, and EGFR, become resistant to adenosine triphosphate-competitive inhibitors through mutation of the so-called gatekeeper amino acid from a threonine to a large hydrophobic amino acid, such as an isoleucine or methionine. We have developed a new class of adenosine triphosphate competitive inhibitors, exemplified by HG-7-85-01, which is capable of inhibiting T315I- BCR-ABL (clinically observed in chronic myeloid leukemia), T670I-c-Kit (clinically observed in gastrointestinal stromal tumors), and T674I/M-PDGFRalpha (clinically observed in hypereosinophilic syndrome). HG-7-85-01 is unique among all currently reported kinase inhibitors in having the ability to accommodate either a gatekeeper threonine, present in the wild-type forms of these kinases, or a large hydrophobic amino acid without becoming a promiscuous kinase inhibitor. The distinctive ability of HG-7-85-01 to simultaneously inhibit both wild-type and mutant forms of several kinases of clinical relevance is an important step in the development of the next generation of tyrosine kinase inhibitors.",
        "Doc_title":"Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants.",
        "Journal":"Blood",
        "Do_id":"20299508",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;HG-7-85-01 compound;Mutant Proteins;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Thiazoles;Threonine;Imatinib Mesylate;Proto-Oncogene Proteins c-kit;Receptor, Platelet-Derived Growth Factor alpha;Fusion Proteins, bcr-abl;src-Family Kinases",
        "Doc_meshdescriptors":"Amino Acid Substitution;Animals;Antineoplastic Agents;Benzamides;Cell Line, Tumor;Drug Discovery;Drug Resistance, Neoplasm;Fusion Proteins, bcr-abl;Humans;Imatinib Mesylate;In Vitro Techniques;Molecular Structure;Mutant Proteins;Mutation, Missense;Piperazines;Protein Kinase Inhibitors;Proto-Oncogene Proteins c-kit;Pyrimidines;Receptor, Platelet-Derived Growth Factor alpha;Thiazoles;Threonine;src-Family Kinases",
        "Doc_meshqualifiers":"pharmacology;genetics;antagonists & inhibitors;antagonists & inhibitors;chemistry;pharmacology;chemistry;pharmacology;antagonists & inhibitors;pharmacology;antagonists & inhibitors;chemistry;pharmacology;genetics;antagonists & inhibitors",
        "_version_":1605742131491635202},
      {
        "Doc_abstract":"Nilotinib is a second-generation tyrosine kinase inhibitor, designed to specifically inhibit break-point cluster region (BCR)-Abelson (ABL) and developed to treat chronic myeloid leukemia (CML) in patients showing a resistance to imatinib. We previously demonstrated that nilotinib-induced apoptosis was reduced by stem cell factor (SCF) addition. Here, the SCF-activated survival pathway was investigated. BCR-ABL expression was accompanied by the activation of the SCF receptor: c-KIT. Nilotinib inhibited this activation that was restored by SCF binding. Parallel variations were observed for mammaliam target of rapamycin (mTOR) kinase and mTOR complex 1 substrate S6K. The inhibition of mTORC1 restored the response of BCR-ABL cell lines to nilotinib in the presence of SCF. PI3K inhibition restored nilotinib-induced apoptosis. On hematopoietic progenitors from CML patient's bone marrows, mTORC1 inhibition also restored nilotinib sensitivity in the presence of SCF, confirming its involvement in SCF-activated survival pathway. However, this pathway seems not to be involved in the nilotinib-induced resistance of the CML stem cell population. Conversely, PI3K inhibition sensitized both CML progenitors and stem cells to nilotinib, suggesting that, downstream PI3K, two different kinase pathways are activated in CML progenitor and stem cell populations. ",
        "Doc_title":"PI3K/mTOR pathway inhibitors sensitize chronic myeloid leukemia stem cells to nilotinib and restore the response of progenitors to nilotinib in the presence of stem cell factor.",
        "Journal":"Cell death & disease",
        "Do_id":"24091670",
        "Doc_ChemicalList":"4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide;Protein Kinase Inhibitors;Proto-Oncogene Proteins c-bcl-2;Pyrimidines;Stem Cell Factor;Phosphotyrosine;Phosphatidylinositol 3-Kinases;TOR Serine-Threonine Kinases;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Apoptosis;Cell Line, Tumor;Cell Survival;Drug Resistance, Neoplasm;Drug Screening Assays, Antitumor;Fusion Proteins, bcr-abl;Hematopoietic Stem Cells;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Models, Biological;Neoplastic Stem Cells;Phosphatidylinositol 3-Kinases;Phosphorylation;Phosphotyrosine;Protein Kinase Inhibitors;Proto-Oncogene Proteins c-bcl-2;Pyrimidines;Signal Transduction;Stem Cell Factor;TOR Serine-Threonine Kinases",
        "Doc_meshqualifiers":"drug effects;drug effects;drug effects;metabolism;drug effects;pathology;pathology;pathology;antagonists & inhibitors;metabolism;drug effects;metabolism;pharmacology;metabolism;pharmacology;drug effects;pharmacology;antagonists & inhibitors;metabolism",
        "_version_":1605893373970874368},
      {
        "Doc_abstract":"A new flow cytometric (FC) BCR-ABL immunobead assay has been developed recently. Here we present the laboratory evaluation of the commercially available kit.;Mononuclear cells were isolated, lysed and processed according to the instructions of the manufacturer. Anti-BCR antibodies adsorbed to capture beads bind the BCR-ABL fusion proteins of the lysed cells, a phycoerythrin (PE)-conjugated anti-ABL antibody is the detector reagent and mean fluorescence intensity (MFI) signals were recorded by flow cytometry. Detection of t(9;22)(q34;q11) translocation was carried out with a quantitative PCR assay.;MFI results of 20 normal peripheral blood samples were 888 (meanSD), CV 9%. K562 cells were used as positive control. Within-batch imprecision was excellent (3.7% in the normal and 10% in the pathological range). Cut-off was chosen at MFI 112, where both sensitivity and specificity were 100%. Altogether 17 chronic myeloid leukemia (CML) and 16 acute leukemia samples were analyzed. All PCR positive samples (n=14) were positive with the FC method and negative results were also concordant (n=15). Frozen cell lysates can be stored up to 4 weeks without significant decrease of MFI signal.;The FC BCR-ABL assay is a fast, reproducible and reliable method that may be incorporated into standard flow cytometric protocols to help clinical decision-making.",
        "Doc_title":"Laboratory evaluation of a flow cytometric BCR-ABL immunobead assay.",
        "Journal":"Clinical chemistry and laboratory medicine",
        "Do_id":"22505532",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Flow Cytometry;Fusion Proteins, bcr-abl;Humans;Immunoassay;Laboratories;Leukemia;Microspheres;Polymerase Chain Reaction;Reference Standards",
        "Doc_meshqualifiers":"methods;standards;blood;genetics;methods;standards;blood",
        "_version_":1605818682141835264},
      {
        "Doc_abstract":"p210bcr/abl is detected in almost all chronic myelogenous leukemia (CML) patients and a significant number of acute lymphoblastic leukemia (ALL) cases. It is generated by a reciprocal chromosomal translocation, t(9;22) (q34;q11), and the enhanced kinase activity of the protein is believed to be implicated in the pathogenesis of the diseases. To examine its oncogenicity in vivo and to create an animal model for BCR/ABL-positive leukemias, we generated transgenic mice expressing p210bcr/abl driven by the promoter of the mouse tec gene, a cytoplasmic tyrosine kinase preferentially expressed in early hematopoietic progenitors. While the founder mice showed excessive proliferation of lymphoblasts shortly after birth and were diagnosed as ALL, the transgenic progeny reproducibly exhibited marked granulocyte hyperplasia with thrombocytosis after a long latent period, which closely resembles the clinical course of human CML. In addition, to investigate whether loss of p53 would play a role in the transition from chronic phase to blast crisis of CML, we crossmated p210bcr/abl transgenic (BCR/ABLtg/-) mice with p53 heterozygous (p53+/-) mice and generated p210bcr/abl transgenic, p53 heterozygous (BCR/ABLtg/- p53+/-) mice, in which a somatic alteration in the residual p53 allele directly abrogates p53 function. The BCR/ABLtg/- p53+/- mice exhibited rapid proliferation of blast cells and died in a short period compared with their wild-type (BCR/ABL-/- p53+/+), p53 heterozygous (BCR/ABL-/- p53+/-), and p210bcr/abl transgenic (BCR/ABLtg/- p53+/+) littermates. Interestingly, the normal p53 allele was frequently and preferentially lost in the tumor tissues, providing in vivo evidence that acquired loss of p53 contributes to the blastic transformation of p210bcr/abl-expressing hematopoietic cells. Our transgenic mice will be a useful model for investigating oncogenic properties of p210bcr/abl in vivo and will provide insights into the molecular mechanism(s) underlying the progression from chronic phase to blast crisis of CML.",
        "Doc_title":"Model mice for BCR/ABL-positive leukemias.",
        "Journal":"Blood cells, molecules & diseases",
        "Do_id":"11358387",
        "Doc_ChemicalList":"Tumor Suppressor Protein p53;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Animals;Disease Models, Animal;Female;Fusion Proteins, bcr-abl;Genotype;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Lymphocyte Activation;Male;Mice;Mice, Transgenic;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Promoter Regions, Genetic;Survival Rate;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"genetics;etiology;genetics;pathology;genetics;etiology;genetics;pathology;genetics",
        "_version_":1605883829716779008},
      {
        "Doc_abstract":"BCR-ABL fusion gene typically causes a type of acute lymphoblastic leukemia (ALL), known as Ph+ ALL. Although imatinib (IM) treatment induced high rates of complete response (CR), serious acute and late complications are frequent, whereas more vexatiously resistance to chemotherapy and clinical relapse develops. Therefore, the efficacy of treatment in Ph+ ALL is still to be determined. In this study, we focused our attention on the potential benefit of rapamycin (RAPA), an mammalian target of rapamycin (mTOR) inhibitor, in combination with IM on a Ph+ ALL cell line SUP-B15 and a primary Ph+ ALL sample in vitro. Analysis of cell proliferation showed that RAPA (50nm) plus IM exerted good synergistic effect on Ph+ ALL cells. Notably, we found that IM treatment induced the abnormal activation of the components of mTOR signaling pathway and p-BCR-ABL, whereas RAPA potently eliminated this deleterious side effect induced by IM and might overcome the resistance to IM. The synergistic effect was also associated with the increase in autophagy, which seemed to have an opposite role with apoptosis in Ph+ ALL cells, and cell cycle arrest in G1 phase. Altogether, our results suggested that IM in combination with RAPA was more effective for Ph+ ALL cells than IM alone. ",
        "Doc_title":"Mammalian target of rapamycin inhibitor rapamycin enhances anti-leukemia effect of imatinib on Ph+ acute lymphoblastic leukemia cells.",
        "Journal":"European journal of haematology",
        "Do_id":"24112092",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Imatinib Mesylate;TOR Serine-Threonine Kinases;Sirolimus",
        "Doc_meshdescriptors":"Antineoplastic Agents;Apoptosis;Benzamides;Cell Line, Tumor;Cell Proliferation;Dose-Response Relationship, Drug;Drug Synergism;G1 Phase Cell Cycle Checkpoints;Humans;Imatinib Mesylate;Piperazines;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Protein Kinase Inhibitors;Pyrimidines;Signal Transduction;Sirolimus;TOR Serine-Threonine Kinases",
        "Doc_meshqualifiers":"pharmacology;therapeutic use;drug effects;pharmacology;therapeutic use;drug effects;drug effects;pharmacology;therapeutic use;drug therapy;genetics;metabolism;pharmacology;therapeutic use;pharmacology;therapeutic use;drug effects;pharmacology;therapeutic use;antagonists & inhibitors;metabolism",
        "_version_":1605879850550165504},
      {
        "Doc_abstract":"Poor outcomes of some chronic myeloid leukemia ((CML) patients have been associated with submicroscopic der(9q) deletions, particularly the 5'ABL region. Deletion profiles of 120 BCR/ABL+ CML patients were studied using the dual-fusion fluorescence in situ hybridization probe. Poor prognosis was associated with 5'ABL deletion but not with 3'BCR deletion. Overall survival (OS) and chronic phase duration (CPD) were significantly shorter for 5'ABL deletion than for those without deletions (OS time: 27 vs. 61 months, P = 0.02; CPD: 17 vs. 56 months, P = 0.02). In addition, when isolated 5'ABL deletion patients were compared to those without it, a greater impact on prognosis was detected (OS time: 18 vs. 59 months, P = 0.0008; CPD: 7 vs. 54 months, P = 0.0003). Isolated 5'ABL deletion seems to have a greater impact on survival than does concomitant 5'ABL and 3'BCR deletion, although the difference was not statistically significant in this aspect (OS time: 18 vs. 28 months, P = 0.08).",
        "Doc_title":"Clinical implications of der(9q) deletions detected through dual-fusion fluorescence in situ hybridization in patients with chronic myeloid leukemia.",
        "Journal":"Cancer genetics and cytogenetics",
        "Do_id":"17889708",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adult;Chromosome Aberrations;Chromosomes, Human, Pair 9;Female;Gene Deletion;Humans;In Situ Hybridization, Fluorescence;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Male;Middle Aged;Nucleic Acid Hybridization;Risk Factors;Time Factors;Translocation, Genetic;Treatment Outcome",
        "Doc_meshqualifiers":"methods;genetics",
        "_version_":1605818741066563585},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) is driven by the expression of the BCR-ABL oncoprotein. STAT5 is a BCR-ABL substrate and persistently activated by tyrosine phosphorylation in CML cells. Activated STAT5 (pSTAT5) drives proliferation and survival of leukemic cells and contributes to initial transformation and maintenance of the disease. In cytokine-induced STAT5 signaling, phosphorylation of STAT5A on Y694 leads to nuclear accumulation of the transcription factor, followed by DNA-binding and gene induction. However, Src-family kinases (SFK) mediate cytoplasmic retention of pSTAT5A leading to attenuated target gene expression and colony formation in CML cells.;In this study we show that autophosphorylation of Y416 in the highly conserved activation loop of SFK generates a potent recruitment site for the SH2 domain of STAT5A. Binding of the SH2 domain to the activation loop is required for STAT5A(Y694) phosphorylation by SFK, but at the same time promotes the persistent cytoplasmic localization of the transcription factor as found in BCR-ABL(+) leukemia. As a consequence of the complex formation between tyrosine-phosphorylated SFK and the SH2 domain of STAT5A, the dimerization of STAT5A is impaired. We further demonstrate that constitutively active STAT5A(S710F) escapes from SFK-mediated cytoplasmic retention by enhancing STAT5A dimer stability.;Our results reveal important structural aspects of cytoplasmic pSTAT5A found in myeloid leukemias and will contribute to the understanding of STAT5A mediated cytoplasmic signaling.",
        "Doc_title":"Src family kinases interfere with dimerization of STAT5A through a phosphotyrosine-SH2 domain interaction.",
        "Journal":"Cell communication and signaling : CCS",
        "Do_id":"25885255",
        "Doc_ChemicalList":"STAT5 Transcription Factor;STAT5A protein, human;Stat5a protein, mouse;Tumor Suppressor Proteins;Fusion Proteins, bcr-abl;src-Family Kinases",
        "Doc_meshdescriptors":"Animals;Fusion Proteins, bcr-abl;HeLa Cells;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mice;Phosphorylation;Protein Multimerization;Protein Transport;STAT5 Transcription Factor;Signal Transduction;Tumor Suppressor Proteins;src Homology Domains;src-Family Kinases",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;metabolism;genetics;genetics;genetics;metabolism;genetics;metabolism;genetics;metabolism",
        "_version_":1605764025824575488},
      {
        "Doc_abstract":"Bcr/Abl is a chimeric oncogene that can cause both acute and chronic human leukemias. Bcr/Abl-encoded proteins exhibit elevated kinase activity compared to c-Abl, but the mechanisms of transformation are largely unknown. Some of the biological effects of Bcr/Abl overlap with those of hematopoietic cytokines, particularly interleukin 3 (IL-3). Such effects include mitogenesis, enhanced survival, and enhanced basophilic differentiation. Therefore, it has been suggested that p210Bcr/Abl and the IL-3 receptor may activate some common signal transduction pathways. An important pathway for IL-3 signaling involves activation of the Janus family kinases (JAKs) and subsequent tyrosyl phosphorylation of STAT proteins (signal transducers and activators of transcription). This pathway directly links growth factor receptors to gene transcription. We analyzed JAK activation, STAT protein phosphorylation, and the formation of specific DNA-binding complexes containing STAT proteins, in a series of leukemia cell lines transformed by Bcr/Abl or other oncogenes. We also examined these events in cell lines transformed by a temperature sensitive (ts) mutant of Bcr/Abl, where the kinase activity of Abl could be regulated. STAT1 and STAT5 were found to be constitutively phosphorylated in 32D, Ba/F3, and TF-1 cells transformed by Bcr/Abl, but not in the untransformed parental cell lines in the absence of IL-3. Phosphorylation of STAT1 and STAT5 was also observed in the human leukemia cell lines K562 and BV173, which express the Bcr/Abl oncogene, but not in several Bcr/Abl-negative leukemia cell lines. Phosphorylation of STAT1 and STAT5 was directly due to the tyrosine kinase activity of Bcr/Abl since it could be activated or deactivated by temperature shifting of cells expressing the Bcr/Abl ts mutant. DNA-STAT complexes were detected in all Bcr/Abl-transformed cell lines and they were supershifted by antibodies against STAT1 and STAT5. DNA-STAT complexes in 32Dp210Bcr/Abl cells were similar, but not identical, to those formed after IL-3 stimulation. It is interesting to note that JAK kinases (JAK1, JAK2, JAK3, and Tyk2) were not consistently activated in Bcr/Abl-positive cells. These data suggest that STATs can be activated directly by Bcr/Abl, possibly bypassing JAK family kinase activation. Overall, our results suggest a novel mechanism that could contribute to some of the major biological effects of Bcr/Abl transformation.",
        "Doc_title":"Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl.",
        "Journal":"The Journal of experimental medicine",
        "Do_id":"8642285",
        "Doc_ChemicalList":"Cytokines;DNA-Binding Proteins;Milk Proteins;Oligodeoxyribonucleotides;Recombinant Proteins;STAT1 Transcription Factor;STAT1 protein, human;STAT5 Transcription Factor;Trans-Activators;Phosphotyrosine;Tyrosine;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Base Sequence;Binding Sites;Cell Line;Cell Line, Transformed;Cell Nucleus;Cell Transformation, Neoplastic;Cytokines;DNA-Binding Proteins;Enzyme Activation;Fusion Proteins, bcr-abl;HL-60 Cells;Hematopoietic Stem Cells;Humans;Milk Proteins;Molecular Sequence Data;Oligodeoxyribonucleotides;Phosphorylation;Phosphotyrosine;Protein-Tyrosine Kinases;Recombinant Proteins;STAT1 Transcription Factor;STAT5 Transcription Factor;Signal Transduction;Trans-Activators;Transfection;Tumor Cells, Cultured;Tyrosine",
        "Doc_meshqualifiers":"metabolism;pharmacology;metabolism;biosynthesis;metabolism;analysis;metabolism;metabolism;biosynthesis;metabolism;metabolism;metabolism",
        "_version_":1605818616240930817},
      {
        "Doc_abstract":"Hypermethylation of the calcitonin gene has been described in various hematologic malignancies. In order to assess its frequency and potential usefulness as a marker for leukemic cells and to detect potential clinical correlations, 180 adult patients (aged > 15 years) with newly diagnosed acute leukemia including 133 cases of acute myeloid leukemia (AML) and 47 cases of acute lymphoblastic leukemia (ALL) were tested for its presence in leukemic blasts at diagnosis by Southern blot technique and polymerase chain reaction (PCR) using 3 sets of primers (P550, P566, P1400), amplifying the most frequent sites of hypermethylation upstream or within the gene. In AML, 92 patients (69%) had hypermethylation detected by Southern blot at diagnosis. This hypermethylation could be confirmed by PCR in 18 of 36 tested cases (50%). Hypermethylation was not significantly associated to any clinical or hematological characteristic of the disease. In ALL, 44 patients (94%) had hypermethylation detected by Southern blot at diagnosis. This hypermethylation could be confirmed by PCR in 33 of the 43 tested cases (77%). Sensitivity of PCR assessed by dilution was 1 to 0.1%. Hypermethylation was not either significantly related to any clinical or hematologic characteristics of the disease. Seven ALL cases which were positive by PCR at diagnosis and achieved cytological CR could be tested during CR. Five cases were negative and did not relapse after 3 to 27 months in CR. One case was positive at the beginning of CR and became negative after autologous transplant. However, he relapsed after 9 months in CR, 3 months after the last negative test. PCR for Bcr/Abl was also negative at this time. We conclude that hypermethylation of the calcitonine gene is frequent at diagnosis in adult acute leukemia, particularly in ALL.",
        "Doc_title":"Hypermethylation of calcitonin gene in adult acute leukemia at diagnosis and during complete remission.",
        "Journal":"Hematology and cell therapy",
        "Do_id":"10193642",
        "Doc_ChemicalList":"Calcitonin",
        "Doc_meshdescriptors":"Acute Disease;Adolescent;Adult;Aged;Aged, 80 and over;Blotting, Southern;Calcitonin;DNA Methylation;Female;Gene Expression Regulation, Neoplastic;Humans;Leukemia, Myeloid;Male;Middle Aged;Polymerase Chain Reaction;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Remission Induction",
        "Doc_meshqualifiers":"genetics;diagnosis;genetics;pathology;diagnosis;genetics;pathology",
        "_version_":1605810257805705216},
      {
        "Doc_abstract":"The characteristic expression of the constitutively active oncoprotein, BCR-ABL tyrosine kinase, inchronic myeloid leukemia (CML) was the basis for the development of BCR-ABL tyrosine kinase inhibitors for treatment. Three BCR-ABL inhibitors, imatinib, nilotinib, and dasatinib, have been approved by the US Food and Drug Administration for first-line treatment of patients with newly diagnosed CML in chronic phase (CML-CP).;This article reviews the key phase III clinical trials supporting the use of first-line imatinib, nilotinib, and dasatinib in patients with CML-CP, as well as findings of supportive phase II studies.;At the time of its approval in 2001,imatinib induced unprecedented response rates in patients with CML-CP; however, resistance and intolerance to imatinib prevent 20% to 30% of patients from deriving full therapeutic benefit. Nilotinib and dasatinib, both approved in 2010 for first-line CML-CP treatment, are more potent than imatinib and less susceptible to imatinib resistance mechanisms. Comparative clinical trials of each agent with imatinib have shown that they are associated withsignificantly deeper and more rapid responses than standard-dose imatinib, without compromising safety.;Given that evidence suggests achievement of an early response is predictive of improved long-term outcomes, earlier use of these compounds may lead to more rapid, deeper responses corresponding with improvements in patient outcome. Although future studies will benefit from more uniform definitions of end points and methods ofanalysis, data from published studies of first-line BCR-ABL inhibitor treatment for patients with newly diagnosed CML-CP support the use of dasatinib or nilotinib in place of imatinib.",
        "Doc_title":"A critical review of trials of first-line BCR-ABL inhibitor treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase.",
        "Journal":"Clinical lymphoma, myeloma & leukemia",
        "Do_id":"24095296",
        "Doc_ChemicalList":"4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide;Antineoplastic Agents;Protein Kinase Inhibitors;Pyrimidines;Thiazoles;Fusion Proteins, bcr-abl;Dasatinib",
        "Doc_meshdescriptors":"Antineoplastic Agents;Clinical Trials, Phase II as Topic;Clinical Trials, Phase III as Topic;Dasatinib;Fusion Proteins, bcr-abl;Humans;Leukemia, Myeloid, Chronic-Phase;Protein Kinase Inhibitors;Pyrimidines;Research Design;Thiazoles;Treatment Outcome",
        "Doc_meshqualifiers":"administration & dosage;adverse effects;therapeutic use;antagonists & inhibitors;drug therapy;metabolism;administration & dosage;adverse effects;therapeutic use;adverse effects;therapeutic use;adverse effects;therapeutic use",
        "_version_":1605762865882464256},
      {
        "Doc_abstract":"The therapeutic armamentarium of chronic myeloid leukemia (CML) has been considerably improved after the introduction of first- and second-generation tyrosine-kinase inhibitors (TKIs). Accordingly, the natural history of the diseases has changed, and patients in complete molecular response now have the same life expectancy of their healthy coetaneous. Notwithstanding these results,  20 - 30% of patients do not respond optimally to TKIs therapy, and most of these patients are potential candidates to progress toward the accelerated or blastic phase of the disease. Unfortunately, patients who become resistant to both first- and second-generation TKIs develop BCR-ABL kinase domain mutations, against which TKIs have extremely low cross-activity. In particular, none of the TKIs, with the exception of ponatinib, has significant activity against T315 mutation, which is estimated to be present in  15 - 20% of patients carrying BCR-ABL mutations. The use of omacetaxine mepesuccinate/homoharringtonine for the treatment of TKI-resistant CML patients regained interest due to its mechanism of action independent of binding to the ATP-binding pocket. Therefore, the activity of this compound is independent from the presence of BCR-ABL1 mutations, which makes it an attractive option for the treatment of CML patients after TKI failure. ",
        "Doc_title":"Resistant chronic myeloid leukemia beyond tyrosine-kinase inhibitor therapy: which role for omacetaxine?",
        "Journal":"Expert opinion on pharmacotherapy",
        "Do_id":"24152096",
        "Doc_ChemicalList":"Angiogenesis Inhibitors;Antineoplastic Agents, Phytogenic;Harringtonines;Protein Kinase Inhibitors;homoharringtonine;Protein-Tyrosine Kinases",
        "Doc_meshdescriptors":"Angiogenesis Inhibitors;Antineoplastic Agents, Phytogenic;Drug Resistance, Neoplasm;Harringtonines;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Protein Kinase Inhibitors;Protein-Tyrosine Kinases",
        "Doc_meshqualifiers":"therapeutic use;therapeutic use;therapeutic use;drug therapy;therapeutic use;antagonists & inhibitors",
        "_version_":1605742756277256194},
      {
        "Doc_abstract":"Bosutinib is an orally bioavailable SRC/ABL tyrosine kinase inhibitor with activity against all phases of resistant chronic myeloid leukemia that do not express the T315I or V299L ABL kinase domain mutations. Bosutinib has a unique toxicity profile that is manageable. This paper provides an overview of bosutinib, covering pharmacodynamics and pharmacokinetic properties, results of treatment in newly diagnosed and previously treated chronic myeloid leukemia patients, as well as common side effects. ",
        "Doc_title":"Bosutinib in the treatment of patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia: an overview.",
        "Journal":"Therapeutic advances in hematology",
        "Do_id":"24490020",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605853439903924224},
      {
        "Doc_abstract":"BCR-ABL is a chimeric oncogene generated by translocation of sequences from the c-ABLgene on chromosome 9 into the BCR gene on chromosome 22. Alternative chimeric proteins, BCR-ABLp190 and BCR-ABLp210, are produced that are characteristic of chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (Ph1-ALL) respectively. In CML, it is evident that the transformation occurs at the level of pluripotent stem cells. However, Ph1-ALL has been thought to affect progenitor cells with lymphoid differentiation. Recently, it has been demonstrated that normal primitive cells, rather than committed progenitor cells, are the target for leukemic transformation in Ph1-ALL. In this review, we discuss what is known about the relationship between the specific BCR-ABLp190 oncogene, the target cell and the characteristics of the subsequent disease process it causes. We also discuss how this information may be applied to the establishment of new directions in therapy.",
        "Doc_title":"Philadelphia-positive B-cell acute lymphoblastic leukemia is initiated in an uncommitted progenitor cell.",
        "Journal":"Leukemia & lymphoma",
        "Do_id":"11697484",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Animals;Burkitt Lymphoma;Cell Differentiation;Cell Transformation, Neoplastic;Fusion Proteins, bcr-abl;Hematopoietic Stem Cells;Humans;Philadelphia Chromosome;Precursor Cell Lymphoblastic Leukemia-Lymphoma",
        "Doc_meshqualifiers":"etiology;pathology;genetics;pathology;genetics;pathology;etiology;genetics;pathology",
        "_version_":1605795742988894208},
      {
        "Doc_abstract":"Cancer stem cells (CSCs) are responsible for the initiation and maintenance of some types of cancer, suggesting that inhibition of these cells may limit disease progression and relapse. Unfortunately, few CSC-specific genes have been identified. Here, we determined that the gene encoding arachidonate 15-lipoxygenase (Alox15/15-LO) is essential for the survival of leukemia stem cells (LSCs) in a murine model of BCR-ABL-induced chronic myeloid leukemia (CML). In the absence of Alox15, BCR-ABL was unable to induce CML in mice. Furthermore, Alox15 deletion impaired LSC function by affecting cell division and apoptosis, leading to an eventual depletion of LSCs. Moreover, chemical inhibition of 15-LO function impaired LSC function and attenuated CML in mice. The defective CML phenotype in Alox15-deficient animals was rescued by depleting the gene encoding P-selectin, which is upregulated in Alox15-deficient animals. Both deletion and overexpression of P-selectin affected the survival of LSCs. In human CML cell lines and CD34+ cells, knockdown of Alox15 or inhibition of 15-LO dramatically reduced survival. Loss of Alox15 altered expression of PTEN, PI3K/AKT, and the transcription factor ICSBP, which are known mediators of cancer pathogenesis. These results suggest that ALOX15 has potential as a therapeutic target for eradicating LSCs in CML. ",
        "Doc_title":"Arachidonate 15-lipoxygenase is required for chronic myeloid leukemia stem cell survival.",
        "Journal":"The Journal of clinical investigation",
        "Do_id":"25105362",
        "Doc_ChemicalList":"6,11-dihydro-5-thia-11-aza-benzo(a)-fluorene;Fluorenes;Lipoxygenase Inhibitors;P-Selectin;Arachidonate 15-Lipoxygenase;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Animals;Apoptosis;Arachidonate 15-Lipoxygenase;Cell Line, Tumor;Cells, Cultured;Fluorenes;Fusion Proteins, bcr-abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Lipoxygenase Inhibitors;Mice;Mice, Inbred C57BL;Neoplastic Stem Cells;P-Selectin",
        "Doc_meshqualifiers":"genetics;physiology;pharmacology;physiology;etiology;pathology;pharmacology;physiology;physiology",
        "_version_":1605876441730252800},
      {
        "Doc_abstract":"In chronic myeloid leukemia (CML), resistance to imatinib is diverse. In addition to BCR-ABL-dependent mechanisms, BCR-ABL-independent mechanisms have been proposed. Here we established and characterized novel CML cell lines, an imatinib-sensitive cell line, MYL, and an imatinib-resistant subline, MYL-R. Treatment with imatinib inhibited phosphorylation of BCR-ABL and CrkL in both MYL and MYL-R, even though imatinib-induced apoptosis was preferentially observed in MYL than MYL-R, indicating that the resistance is based on a BCR-ABL-independent mechanism. MYL-R showed elevated expressions of Lyn mRNA, Lyn protein, phosphorylated Lyn, and phosphorylated STAT5. Silencing of Lyn by short-interfering RNA (siRNA) in MYL-R, but not in MYL, induced significant growth-inhibition, increased caspase-3 activity, and induced partial recovery from imatinib-resistance. Expression of Bcl-2, previously reported to be associated with Lyn-mediated resistance, was not elevated in MYL-R. Expression of Bim, which plays an important role in imatinib-induced cell-killing, was not suppressed in MYL-R. These results imply that diverse mechanisms of resistance exist among cell types. Treatment of MYL-R cells with various reagents known to have anti-leukemic activity revealed that zoledronic acid and the farnesyl transferase inhibitor (SCH 66336) showed strong synergism with imatinib; interferon alpha, PP2, CGP76030, and FK228 (depsipeptide) showed synergism; whereas soluble TRAIL and As2O3 showed additivity or antagonism, and 17-AAG and radicicol showed antagonism. Treatment with either PP2 or zoledronic acid induced greater growth-reduction in MYL-R than MYL. Taken together, Lyn may play an important role in imatinib-resistance in MYL-R. Some novel reagents, including siRNA targeting Lyn, may have good potential to overcome this resistance.",
        "Doc_title":"Establishment and characterization of a novel imatinib-sensitive chronic myeloid leukemia cell line MYL, and an imatinib-resistant subline MYL-R showing overexpression of Lyn.",
        "Journal":"European journal of haematology",
        "Do_id":"17432977",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;DNA Primers;Piperazines;Pyrimidines;RNA, Small Interfering;Imatinib Mesylate;lyn protein-tyrosine kinase;src-Family Kinases",
        "Doc_meshdescriptors":"Adult;Antineoplastic Agents;Apoptosis;Base Sequence;Benzamides;Cell Line, Tumor;DNA Primers;Drug Resistance, Neoplasm;Female;Genes, abl;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Oligonucleotide Array Sequence Analysis;Phosphorylation;Piperazines;Pyrimidines;RNA, Small Interfering;Reverse Transcriptase Polymerase Chain Reaction;src-Family Kinases",
        "Doc_meshqualifiers":"pharmacology;genetics;pathology;pharmacology;pharmacology;genetics",
        "_version_":1605801388366888960},
      {
        "Doc_abstract":"Aside from bone marrow transplantation, a definitive cure for Philadelphia (Ph) chromosome-positive chronic myeloid leukemia (CML) has yet to be developed. Although Imatinib, the first molecularly targeted drug developed for CML has achieved a remarkable success, the emergence of resistance to this agent mitigates the prospect of a cure for this leukemia. Though a variety of resistance mechanisms can arise, in the majority of patients resistance coincides with reactivation of the tyrosine kinase activity of the BCR-ABL fusion oncoprotein. This can result from gene amplification and, more importantly, point mutations that disrupt the bind of imatinib to BCR-ABL itself. In this review, we aim to define and illuminate mechanisms of resistance and describe how drug resistance is shedding new light on kinase domain regulation.;In light of recent studies and publications, it is now clear that Imatinib exerts its inhibitory action by stabilizing the inactive non ATP-binding conformation of BCR-ABL and that mutations even outside the kinase domain can lead to enhanced autophosphorylation of the kinase, thereby stabilizing the active conformation that resists imatinib binding. So far, 25 different substitutions of 21 amino acid residues of BCR-ABL have been detected in CML patients. In addition, it has been recently illustrated that mutations preexist the onset of treatment and that some confer a more aggressive disease phenotype. Finally it has been shown that molecular remission is almost never reached through Imatinib therapy.;The most common mechanism of relapse for CML patients treated with Imatinib is the appearance of point mutations in the BCR-ABL oncogene that confer resistance to this drug. Insights into the emerging problem of resistance should promote the rational development of alternative, synergistic, and potentially curative treatment strategies.",
        "Doc_title":"Mechanisms and implications of imatinib resistance mutations in BCR-ABL.",
        "Journal":"Current opinion in hematology",
        "Do_id":"14676625",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Pyrimidines;Imatinib Mesylate;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Antineoplastic Agents;Benzamides;Drug Resistance, Neoplasm;Fusion Proteins, bcr-abl;Genes, abl;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Piperazines;Point Mutation;Protein-Tyrosine Kinases;Pyrimidines;Signal Transduction",
        "Doc_meshqualifiers":"therapeutic use;genetics;drug therapy;genetics;metabolism;pharmacology;therapeutic use;genetics;metabolism;metabolism;pharmacology;therapeutic use",
        "_version_":1605818600604565504},
      {
        "Doc_abstract":"Chronic myeloid leukemia (CML) is amyeloproliferative disorder of hematopoietic stem cells carrying Philadelphia (Ph) chromosome and the oncogenic BCR-ABL1 fusion gene. microRNAs (miRNAs) belong to hematopoiesis transcription regulators and their deregulated expression associates with pathogenesis of CML. The current study assesses and validates expression profiles of selected oncogenic and tumor suppressing miRNAs that are associated with different imatinib mesylate (IM) response in CML patients carrying rare BCR-ABL variants. Microarray analysis has identified different expression of 70 miRNAs (46 up- and 24 down-regulated) when compared IM-resistant with IM-responsive patients carrying Ph chromosome. Significantly up-regulated expression of oncogenic miRNAs (miR-17, miR-18a, miR-20a, miR-21, miR-27a and miR-155) and significantly down-regulated expression of tumor supressing mRNAs (let-7d, miR-205, miR-320, miR-451 and miR-574) in IM-resistant compared to IM-responsive patients was confirmed and validated by qRT-PCR. This study confirms the involvement of the selected oncogenic and tumor suppressing miRNAs in CML pathogenesis and IM response and suggests that these miRNAs could be suitable biomarkers for differential diagnosis of CML patients carrying rare BCR-ABL transcripts, as well as for prediction of their IM response and therapy outcome. ",
        "Doc_title":"microRNA expression profiling as supportive diagnostic and therapy prediction tool in chronic myeloid leukemia.",
        "Journal":"Neoplasma",
        "Do_id":"26458312",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605808704696877056},
      {
        "Doc_abstract":"We describe a method of spectrophotometric detection of BCR/ABL chimeric sequences amplified by multiplex reverse transcriptase-polymerase chain reaction (RT-PCR), enabling the use of archival hematologic slides as RNA sources. Multiplex PCR amplified b3a2, b2a2, and e1a2 break points of the BCR/ABL translocation and the normal ABL gene product. Assessment of sensitivity, performed on K562 cells, showed that the threshold approximated radioactive methods of detection (i.e., 1 positive cell in 1 x 10(6) negative cells for single round PCR and lower than 1 positive cell in 1 x 10(7) negative cells for nested PCR). Then, we assayed 38 different archival hematologic slides from 18 patients, including 11 cases of chronic myelogenous leukemia or chronic myelogenous leukemia-like disease, such as a case of myelofibrosis and a case of chronic neutrophilic leukemia, 6 cases of acute lymphoblastic leukemia, and 1 case of acute myelogenous leukemia. Amplification and spectrophotometric detection of BCR/ABL fusion messenger RNAs gave an unambiguous positive result in 24 (89%) of 27 expected positive slides, among which 17 (63%) were positive after a single PCR round. Concordant unambiguous results were obtained from 35 (92%) of 38 slides, as verified through parallel analyses of corresponding cryopreserved cells. Retrospective analysis on archival hematologic slides yielded identification of the presence or absence of the t(9;22) translocation and break point in 14 previously uncharacterized cases. The application of this method can help define the diagnosis of cases lacking other appropriate material and assist in the retrospective analysis of large patient series for which only smears are available.",
        "Doc_title":"Spectrophotometric detection of RT-PCR-amplified BCR/ABL fusion transcripts. A survey performed on archival hematologic slides.",
        "Journal":"American journal of clinical pathology",
        "Do_id":"9322590",
        "Doc_ChemicalList":"Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Cell Line;Fusion Proteins, bcr-abl;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Leukemia, Myeloid, Acute;Polymerase Chain Reaction;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Retrospective Studies;Sensitivity and Specificity;Spectrophotometry;Translocation, Genetic;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"genetics;diagnosis;genetics;diagnosis;genetics;methods;diagnosis;genetics;methods",
        "_version_":1605746808575754240},
      {
        "Doc_abstract":"Chronic myeloid leukemias and 5% to 20% of acute lymphoid leukemias are characterized by the Philadelphia chromosome, a reciprocal chromosomal translocation, t(9;22)(q34;q11), generating BCR-ABL and ABL-BCR fusion genes. Cytogenetic studies have recently shown a preferential involvement of the paternally derived chromosome 9 and the maternally derived chromosome 22 in this translocation, indicating that imprinting might be involved in the formation or selection of the translocation. In this study, we have identified a BamHI polymorphism in the coding region of BCR exon 1, allowing us to investigate whether both BCR alleles are transcribed. By using a reverse transcriptase-polymerase chain reaction assay, we show that both BCR alleles are expressed in the peripheral blood cells of normal individuals.",
        "Doc_title":"No evidence for genomic imprinting of the human BCR gene.",
        "Journal":"Blood",
        "Do_id":"8204871",
        "Doc_ChemicalList":"Oncogene Proteins;Proto-Oncogene Proteins;Protein-Tyrosine Kinases;Fusion Proteins, bcr-abl;BCR protein, human;Proto-Oncogene Proteins c-bcr",
        "Doc_meshdescriptors":"Alleles;Base Sequence;Fusion Proteins, bcr-abl;Gene Expression;Humans;Molecular Sequence Data;Oncogene Proteins;Oncogenes;Polymerase Chain Reaction;Polymorphism, Genetic;Protein-Tyrosine Kinases;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-bcr",
        "Doc_meshqualifiers":"genetics;genetics",
        "_version_":1605756807264862208},
      {
        "Doc_abstract":"The phenylaminopyrimidine-derivate Imatinib mesylate has been developed for targeted inhibition of the Abelson kinase (c-ABL), which is constitutively activated when translocated to the genetic locus of the breakpoint cluster region (leading to the BCR/ABL fusion gene), thereby forming the causative pathogenetic event for the development of chronic myeloid leukemia (CML). Of note, due to its physico-chemical properties, kinase specificity of Imatinib is limited. Despite of its well documented clinical efficacy mediated by inhibition of constitutively activated tyrosine kinases such as BCR/ABL in CML, PDGF-RA in HES and mutated c-kit in GIST patients, other tyrosine kinases such as Flt-3, Lck and mitogen-activated kinases (MAPK) are affected as well. Accordingly, it has recently been shown that therapeutic doses of Imatinib also target a variety of immune cells, e.g. by modulating the differentiation of dendritic cells (DC) as well as by impeding proper T-cell and macrophage function. In contrast, combining Imatinib with Interleukin 2 (IL-2) potently activates NK-cells and led to the description of a new subclass of DC, so-called IK-DC. The latter mediate Imatinib/IL-2-induced regression of tumors in pre-clinical animal models via production of high amounts of IFN-gamma and the death receptor ligand TRAIL. Thus, Imatinib exerts potent immuno-modulatory effects in vitro and in vivo, which will be discussed together with their clinical relevance in detail throughout this review.",
        "Doc_title":"The kinase inhibitor imatinib--an immunosuppressive drug?",
        "Journal":"Current cancer drug targets",
        "Do_id":"17504122",
        "Doc_ChemicalList":"Benzamides;Immunosuppressive Agents;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Imatinib Mesylate",
        "Doc_meshdescriptors":"Animals;Benzamides;Humans;Imatinib Mesylate;Immunosuppressive Agents;Piperazines;Protein Kinase Inhibitors;Pyrimidines",
        "Doc_meshqualifiers":"pharmacology;therapeutic use;pharmacology;therapeutic use;pharmacology;therapeutic use;pharmacology;therapeutic use",
        "_version_":1605789313501495296}]
  }}
